{"meta":{"query_hash":"1a36a5363d3f","filters":{"venue":"Journal of Thoracic Oncology"},"cohort_total":1243,"direct_labels_cover":7,"predictions_cover":1243,"exported":1243,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/1a36a5363d3f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Thoracic+Oncology"},"results":[{"id":"W1138370978","doi":"10.1097/jto.0000000000000652","title":"Refining Prognosis in Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Institutes of Health","keywords":"Medicine; Lung cancer; Population; Disease; Cancer; Oncology; Identification (biology); Medical physics; Intensive care medicine; Personalized medicine; Internal medicine; Bioinformatics","score_opus":0.09822665380393408,"score_gpt":0.5511675105923424,"score_spread":0.4529408567884083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1138370978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9420449,0.012039216,0.000026016469,0.03313338,0.00081700704,0.00016552465,0.000001473713,0.00001149778,0.011760969],"genre_scores_gemma":[0.9941265,0.00052114157,0.0032248963,0.00045902608,0.00067222514,0.000027966818,4.010442e-7,0.000013985953,0.0009538617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986475,0.0001589647,0.0004265236,0.00010161695,0.00040192858,0.00026342986],"domain_scores_gemma":[0.99879193,0.00012654404,0.00027421457,0.00008225703,0.000500055,0.00022502038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001505988,0.000083299936,0.0005052605,0.0002970194,0.00002141729,0.000007501453,0.00011282043,0.000088774206,0.00005306939],"category_scores_gemma":[0.0008257452,0.00005957822,0.00007258367,0.00029255723,0.00007663041,0.00011103856,0.00007274744,0.00055778073,0.000005262048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031634402,0.0003116351,0.7814902,0.00022159136,0.0002770908,0.002117709,0.0019709545,0.000062258085,0.0006967177,0.000014353737,0.045482177,0.16419187],"study_design_scores_gemma":[0.01068011,0.014442503,0.4992847,0.0037855508,0.0012337612,0.0048956326,0.0046076514,0.00094187405,0.0058600362,0.00041740024,0.453361,0.0004897803],"about_ca_topic_score_codex":0.00011100304,"about_ca_topic_score_gemma":0.00023300655,"teacher_disagreement_score":0.40787882,"about_ca_system_score_codex":0.0016512019,"about_ca_system_score_gemma":0.0017218232,"threshold_uncertainty_score":0.43178353},"labels":[],"label_agreement":null},{"id":"W1491879437","doi":"10.1097/jto.0000000000000141","title":"Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Merck KGaA","keywords":"Cetuximab; T790M; Medicine; Vinorelbine; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Chemotherapy; Immunohistochemistry; Exon; Cisplatin; Cancer research; Cancer; Gefitinib; Colorectal cancer; Biology; Gene","score_opus":0.014516855675895071,"score_gpt":0.4043220095751472,"score_spread":0.38980515389925213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1491879437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964327,0.0004837771,0.00058477983,0.0009371424,0.00011646719,0.0010980604,0.0000057117504,0.000004833645,0.00033648417],"genre_scores_gemma":[0.9972276,0.000048684808,0.0023198728,0.00013602985,0.00010101278,0.000037989823,0.000010732817,0.000019142752,0.00009893869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861425,0.00027377883,0.0005532903,0.00014603011,0.00024529177,0.00016737301],"domain_scores_gemma":[0.9978778,0.00078345626,0.0007671939,0.00015638578,0.00030164805,0.00011351747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047935394,0.00013111324,0.000554454,0.00017457225,0.00007659818,0.000009083679,0.00007730943,0.00007690841,0.000017681858],"category_scores_gemma":[0.00018801616,0.00007396574,0.000051295076,0.00021019326,0.00008979738,0.00011959227,0.000018135337,0.00028029326,3.972258e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005261471,0.0009497796,0.94878495,0.00008011478,0.00014573958,0.000008161985,0.0091255475,0.0005730733,0.000048761172,0.000006969845,0.000048978218,0.03496644],"study_design_scores_gemma":[0.03639958,0.002777007,0.9576047,0.00021667291,0.0008563064,0.0000056628805,0.0013988529,0.000103050384,0.00026398667,0.0000636365,0.00023856615,0.000071992195],"about_ca_topic_score_codex":0.00008423995,"about_ca_topic_score_gemma":0.000069983646,"teacher_disagreement_score":0.034894448,"about_ca_system_score_codex":0.00046672006,"about_ca_system_score_gemma":0.00055736187,"threshold_uncertainty_score":0.30162355},"labels":[],"label_agreement":null},{"id":"W1505708219","doi":"10.1097/jto.0b013e3181914506","title":"Detection and Localization of Intraepithelial Neoplasia and Invasive Carcinoma Using Fluorescence-Reflectance Bronchoscopy: An International, Multicenter Clinical Trial","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Bronchoscopy; Radiology; Carcinoma in situ; Stage (stratigraphy); Dysplasia; Intraepithelial neoplasia; Lung cancer; Atypia; Sputum; Autofluorescence; Pathology; Carcinoma; Cancer; Internal medicine","score_opus":0.06132612809831663,"score_gpt":0.4872373348481143,"score_spread":0.4259112067497977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1505708219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967377,0.00025455153,0.0016174088,0.00043023188,0.0005944986,0.0003238811,0.0000028702066,0.0000051141496,0.000033711058],"genre_scores_gemma":[0.9945018,0.001329512,0.0033351819,0.00018692634,0.00063036225,0.000001219078,0.0000010315754,0.000007825448,0.0000060909942],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984061,0.00033289817,0.00069871184,0.00016157706,0.00025689646,0.00014378635],"domain_scores_gemma":[0.998525,0.00023952292,0.0005717284,0.000086529624,0.0004332518,0.00014392186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091420236,0.00010397499,0.00050732726,0.00021534813,0.00005453654,0.00001397128,0.00009141922,0.0001433128,0.000008139557],"category_scores_gemma":[0.0009458657,0.00008232246,0.00006857563,0.00010366774,0.00023445542,0.00024561802,0.00003110444,0.00035390406,2.2229615e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17899758,0.00092539215,0.030137409,0.000065124295,0.00025522674,0.00014004148,0.0013035904,0.00003160806,0.41885912,0.0000065875042,0.000022497345,0.36925584],"study_design_scores_gemma":[0.11495246,0.11499599,0.50998694,0.0011903988,0.0012787527,0.003195523,0.0029387097,0.08649181,0.16172858,0.0013439502,0.0013668517,0.0005300309],"about_ca_topic_score_codex":0.000015637106,"about_ca_topic_score_gemma":0.000059124093,"teacher_disagreement_score":0.47984952,"about_ca_system_score_codex":0.0002010466,"about_ca_system_score_gemma":0.00024915198,"threshold_uncertainty_score":0.33570126},"labels":[],"label_agreement":null},{"id":"W1963894850","doi":"10.1097/jto.0b013e3182862e7e","title":"Influence of Postoperative Infectious Complications on Long-Term Survival of Lung Cancer Patients: A Population-Based Cohort Study","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Hazard ratio; Surgery; Complication; Lung cancer; Proportional hazards model; Confidence interval; Population; Cohort; Internal medicine","score_opus":0.015581393106313056,"score_gpt":0.4122598667495245,"score_spread":0.3966784736432114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963894850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700713,0.00008289307,0.000014932823,0.0012546423,0.00019329244,0.0012255547,0.00001544941,0.000004951378,0.00020118005],"genre_scores_gemma":[0.9993762,0.00003683942,0.000077445584,0.00031175968,0.000039700553,0.00012113576,0.00001141995,0.00001066122,0.000014872904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860156,0.00018137082,0.0006621666,0.00013008942,0.00031409395,0.00011069831],"domain_scores_gemma":[0.9972088,0.00028228815,0.0008679362,0.00018599232,0.001361884,0.00009310004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020320152,0.00011625335,0.0006008082,0.000187851,0.000043797358,0.000005408346,0.0000825485,0.00006498322,0.00010656157],"category_scores_gemma":[0.00011573683,0.0000831589,0.00010288765,0.00017552279,0.000051559025,0.00009461332,0.000016555941,0.00016735666,0.0000027262004],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031812096,0.005240852,0.9873767,0.000069687856,0.00052411354,0.000009005602,0.00027185277,0.002706408,0.00011186892,0.000009937041,0.00011755635,0.0032438922],"study_design_scores_gemma":[0.0018007099,0.0063955197,0.9903334,0.0003238795,0.00060402224,0.000007713212,0.000034937115,0.000045428642,0.0003773222,0.000008259701,0.000010246324,0.00005856572],"about_ca_topic_score_codex":0.0011535356,"about_ca_topic_score_gemma":0.00046549996,"teacher_disagreement_score":0.0031853265,"about_ca_system_score_codex":0.00093899155,"about_ca_system_score_gemma":0.00037468466,"threshold_uncertainty_score":0.33911216},"labels":[],"label_agreement":null},{"id":"W1964932776","doi":"10.1097/jto.0b013e3181c814e7","title":"Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":252,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre","funders":"Institut Gustave-Roussy","keywords":"Vinorelbine; Medicine; Hazard ratio; Lung cancer; Internal medicine; Regimen; Oncology; Subgroup analysis; Cisplatin; Adjuvant; Chemotherapy; Confidence interval","score_opus":0.025767383261174625,"score_gpt":0.4158649491972392,"score_spread":0.3900975659360646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964932776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909072,0.0030566081,0.00037096534,0.0032004188,0.00090140617,0.0011780247,0.000083947794,0.0000057113534,0.00029572484],"genre_scores_gemma":[0.995312,0.00041349948,0.0034857765,0.00021744354,0.0003232942,0.00009544058,0.000031685915,0.00002363538,0.000097274424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776715,0.00021809754,0.00095851655,0.00026621882,0.00050974597,0.00028025912],"domain_scores_gemma":[0.99626255,0.0007136003,0.0014561759,0.00035507602,0.0010320359,0.00018054046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016488025,0.00021376649,0.0011597926,0.0004069453,0.00012404038,0.00001661122,0.00019575498,0.0002100393,0.00024029089],"category_scores_gemma":[0.00025221944,0.0001331363,0.00042305057,0.0005564389,0.0001157454,0.00007345957,0.00006975624,0.0004990998,4.0595887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042161914,0.0013523012,0.8050725,0.0008535701,0.005021853,0.000060590824,0.0017168375,0.001297904,0.070708826,0.00004615307,0.007870254,0.10178303],"study_design_scores_gemma":[0.004968238,0.0021780727,0.853548,0.00037321288,0.029750561,0.0001006641,0.00016996085,0.09524222,0.012316351,0.00005749821,0.001135662,0.00015954542],"about_ca_topic_score_codex":0.00026069488,"about_ca_topic_score_gemma":0.0026910636,"teacher_disagreement_score":0.10162348,"about_ca_system_score_codex":0.00065235124,"about_ca_system_score_gemma":0.00084447436,"threshold_uncertainty_score":0.5429141},"labels":[],"label_agreement":null},{"id":"W1965355592","doi":"10.1097/jto.0b013e31826910ff","title":"Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Battle; Biomarker; Internal medicine; Oncology; Clinical trial; Ancient history; Genetics","score_opus":0.0532146545083367,"score_gpt":0.49037195425966423,"score_spread":0.43715729975132755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965355592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945267,0.00077271956,0.000024603007,0.0017470444,0.0018633935,0.00032120856,0.000028648252,0.0000038298995,0.00071187975],"genre_scores_gemma":[0.99768937,0.000085886015,0.0015041817,0.00016059054,0.00038627873,0.000005879776,0.000012749456,0.000008482376,0.00014655878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878,0.00024091991,0.0006127591,0.000072599905,0.00016774381,0.00012596899],"domain_scores_gemma":[0.99773365,0.001254737,0.00057739613,0.00012261156,0.00018737702,0.00012424654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049703056,0.00008407936,0.00046409498,0.00005103862,0.000037623282,0.0000052307482,0.00006217489,0.00011846691,0.000110088054],"category_scores_gemma":[0.00068883586,0.000041370797,0.00015532543,0.00006666164,0.00011693239,0.00009599472,0.000023958644,0.0001651242,0.0000039083207],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011968307,0.0011169205,0.78318614,0.000007901109,0.000719669,0.0000060066864,0.00038550064,4.982167e-8,0.00003150802,0.000004598351,0.0025173454,0.20005605],"study_design_scores_gemma":[0.017975848,0.0038391324,0.96814907,0.0000581109,0.0014018627,0.00002072132,0.0001959745,0.0000019652819,0.00008266859,0.000035431345,0.008200822,0.00003841329],"about_ca_topic_score_codex":0.000038849244,"about_ca_topic_score_gemma":0.0000064301635,"teacher_disagreement_score":0.20001763,"about_ca_system_score_codex":0.000070760136,"about_ca_system_score_gemma":0.00021406516,"threshold_uncertainty_score":0.16870521},"labels":[],"label_agreement":null},{"id":"W1965816195","doi":"10.1097/jto.0b013e31824cbafa","title":"Vascular Image Patterns of Lymph Nodes for the Prediction of Metastatic Disease During EBUS-TBNA for Mediastinal Staging of Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Radiology; Hilum (anatomy); Metastasis; Lymph; Blood flow; Lung; Lung cancer; Cancer; Ultrasound; Nuclear medicine; Pathology; Internal medicine","score_opus":0.0281737362456996,"score_gpt":0.41588724602113464,"score_spread":0.38771350977543506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965816195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803902,0.0064618224,0.0103756925,0.0012068681,0.0006119602,0.00060742017,0.00033365755,0.0000031874285,0.000009202826],"genre_scores_gemma":[0.9946806,0.0012056114,0.0034560964,0.00004134479,0.00044907094,0.00012372836,0.000007190107,0.000018494278,0.000017868144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986996,0.000077474484,0.0006511504,0.0000888963,0.0002745932,0.00020829141],"domain_scores_gemma":[0.99767965,0.00061286875,0.00096556125,0.00015253911,0.00044860787,0.00014074355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070583087,0.00011164135,0.0005761023,0.00012568285,0.00004340686,0.0000028523793,0.00009174171,0.00003099729,0.00005349454],"category_scores_gemma":[0.00020592153,0.00006858028,0.00035824272,0.000068246205,0.000070012946,0.00013386166,0.000024001285,0.00007864275,6.929699e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004278392,0.0015627923,0.9555515,0.0064067035,0.0029885669,0.000019485235,0.0013009212,0.00040284192,0.0067248256,0.000029994344,0.00024923115,0.020484716],"study_design_scores_gemma":[0.0050842105,0.0009317516,0.94172114,0.0015810512,0.01156446,0.00006511857,0.0007847953,0.0016804871,0.036142677,0.000046120193,0.00032165612,0.00007655852],"about_ca_topic_score_codex":0.000052903775,"about_ca_topic_score_gemma":0.0000068235445,"teacher_disagreement_score":0.029417852,"about_ca_system_score_codex":0.00040375887,"about_ca_system_score_gemma":0.00037712773,"threshold_uncertainty_score":0.27966228},"labels":[],"label_agreement":null},{"id":"W1965852911","doi":"10.1097/jto.0b013e31818dda9d","title":"The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chemokine receptor; CXCR4; Stromal cell; Medicine; Chemokine; Cancer research; Lung cancer; Immunology; Stromal cell-derived factor 1; Chemokine receptor CCR5; Chemotaxis; Proinflammatory cytokine; Receptor; Inflammation; Oncology; Internal medicine","score_opus":0.04991087899817811,"score_gpt":0.4309868280111587,"score_spread":0.3810759490129806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965852911","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012538406,0.9905738,0.0013439811,0.002338086,0.0031769373,0.0016886488,0.000034306562,0.00001969006,0.0006991566],"genre_scores_gemma":[0.000018289875,0.97523797,0.0072538517,0.0004454825,0.008289034,0.00011518639,0.000038563532,0.00016229511,0.008439357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961178,0.00026259816,0.0020382425,0.00040720336,0.00045626253,0.00071789406],"domain_scores_gemma":[0.9940752,0.0013572187,0.0030308329,0.00044343603,0.00060673844,0.00048660184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011666312,0.00067880243,0.0040218583,0.0003154296,0.00026056753,0.00004516649,0.0006657701,0.0009245322,0.0004622268],"category_scores_gemma":[0.00021604566,0.0003872214,0.0022212404,0.00044049433,0.00012455788,0.00006989552,0.000092508635,0.0018229899,0.00001381428],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005687605,0.00021738387,0.00001898853,0.006866378,0.0011053137,0.00007268386,0.00020745714,0.0000031425304,0.00009230141,0.00000254979,0.10690983,0.8839352],"study_design_scores_gemma":[0.0011963006,0.0012144077,0.000001978002,0.008361498,0.0043514473,0.0019275851,0.000067936046,0.000053397125,0.000459498,0.000032411237,0.9819756,0.00035791905],"about_ca_topic_score_codex":0.000017937382,"about_ca_topic_score_gemma":0.00000871591,"teacher_disagreement_score":0.8835773,"about_ca_system_score_codex":0.0014126735,"about_ca_system_score_gemma":0.007442715,"threshold_uncertainty_score":0.99985796},"labels":[],"label_agreement":null},{"id":"W1966162777","doi":"10.1097/jto.0b013e3181f49c22","title":"Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Gemcitabine; Placebo; Clinical endpoint; Hazard ratio; Internal medicine; Lung cancer; Oncology; Phases of clinical research; Chemotherapy; Surgery; Gastroenterology; Randomized controlled trial; Confidence interval; Pathology","score_opus":0.014081198314610735,"score_gpt":0.42025279930545734,"score_spread":0.4061716009908466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966162777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961955,0.000580608,0.000049171893,0.0006836304,0.0003009368,0.0020167243,0.000017287985,0.000003028911,0.00015310146],"genre_scores_gemma":[0.998489,0.0002159676,0.0009622349,0.00014976902,0.000058758775,0.00007235934,0.0000058341598,0.00001563253,0.000030423113],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859744,0.00016863135,0.0006181585,0.00016981587,0.00024983656,0.00019610126],"domain_scores_gemma":[0.99860835,0.00028979642,0.0005676858,0.0001957444,0.00024686265,0.000091552836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004738527,0.00016252385,0.00055704056,0.00022893275,0.000051558036,0.000008463531,0.00013201173,0.00008532453,0.00006355106],"category_scores_gemma":[0.000040610223,0.0000835495,0.000050465875,0.00028117915,0.0000724786,0.00007777233,0.000012284681,0.000547061,2.5923768e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07959852,0.018595088,0.18945009,0.00008964241,0.000202159,0.00031843415,0.01025279,0.0002129226,0.0009011179,9.141043e-7,0.00006856485,0.70030975],"study_design_scores_gemma":[0.16812222,0.07529889,0.74823135,0.0005028188,0.0010024569,0.00006487092,0.0032939361,0.00021084746,0.00078257045,0.000005544552,0.0022711493,0.00021333095],"about_ca_topic_score_codex":0.000111930036,"about_ca_topic_score_gemma":0.0024399967,"teacher_disagreement_score":0.7000964,"about_ca_system_score_codex":0.0002372814,"about_ca_system_score_gemma":0.0010341525,"threshold_uncertainty_score":0.34070498},"labels":[],"label_agreement":null},{"id":"W1969546651","doi":"10.1097/01.jto.0000283422.51520.02","title":"PD5-1-4: Differences in pattern of practice in radiation therapy for patients with non-small cell lung cancer between physicians from the United States and Other Countries","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Radiation oncologist; Radiation oncology; Radiation therapy; Regimen; Radiosurgery; Family medicine; Dose fractionation; Internal medicine; Medical physics; Oncology; Nuclear medicine","score_opus":0.01348141752030314,"score_gpt":0.4046035537501839,"score_spread":0.3911221362298808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969546651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946446,0.0027031961,0.004913339,0.0021938812,0.0001918985,0.00046053395,0.00003957118,0.0000019070073,0.00003122558],"genre_scores_gemma":[0.98992175,0.004887536,0.0020284858,0.0027588364,0.0003559953,0.0000096782305,0.000011266499,0.000013964343,0.000012464036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990285,0.00016514612,0.00042020777,0.000099830475,0.0001279231,0.00015839108],"domain_scores_gemma":[0.9954231,0.0034735687,0.0008032602,0.00007356149,0.00019544468,0.000031078023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006548402,0.0001036357,0.00045265976,0.00014830867,0.00003408103,0.00000444179,0.0000919293,0.00012327993,0.000010695756],"category_scores_gemma":[0.00005871392,0.000058868736,0.000029747443,0.00016016071,0.0001548375,0.000101651174,0.0000066145944,0.00028336875,6.83389e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004563445,0.00036818936,0.8577948,0.000026068396,0.00012684359,0.000009956028,0.008140646,0.00004809772,0.000045440516,9.4977247e-7,0.00008167766,0.12879387],"study_design_scores_gemma":[0.0048999507,0.0031994116,0.97432506,0.00022625332,0.00015985998,0.0000042344177,0.0020134088,0.00012428117,0.0004755945,0.000076971155,0.0144199245,0.00007506853],"about_ca_topic_score_codex":0.0004370847,"about_ca_topic_score_gemma":0.00067416567,"teacher_disagreement_score":0.1287188,"about_ca_system_score_codex":0.0001651923,"about_ca_system_score_gemma":0.00015336493,"threshold_uncertainty_score":0.24005975},"labels":[],"label_agreement":null},{"id":"W1969687889","doi":"10.1097/jto.0b013e3182106d48","title":"Routinely Obtained Diagnostic Material as a Source of RNA for Personalized Medicine in Lung Cancer Patients","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Response Biomedical (Canada)","funders":"Cancer Research UK","keywords":"Medicine; Lung cancer; Personalized medicine; Medical physics; Oncology; Internal medicine; Intensive care medicine; Bioinformatics","score_opus":0.01621553423817874,"score_gpt":0.3820832228284975,"score_spread":0.36586768859031876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969687889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901562,0.0004790831,0.007725741,0.00048317164,0.00020889923,0.00035060244,0.000017964641,0.0000033683648,0.0005749799],"genre_scores_gemma":[0.99492365,0.00036136934,0.0038547392,0.00033267512,0.00022801443,0.00008129431,0.000034257573,0.000015919552,0.00016807583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989601,0.00011872695,0.000523954,0.00015096291,0.0000781451,0.00016811906],"domain_scores_gemma":[0.9988834,0.00005964837,0.00058898446,0.0001269874,0.0002768882,0.00006404829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040169002,0.00011321959,0.00034568564,0.00009100214,0.000026257618,0.0000017274309,0.00022011185,0.00021757542,0.00009730204],"category_scores_gemma":[0.00044559155,0.00008942875,0.000107903375,0.00007318794,0.00014917892,0.000003208441,0.00005363613,0.0000960768,2.9165216e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006669468,0.0011209939,0.035989154,0.00017802075,0.0003198138,0.000022383609,0.0010024399,0.000014759651,0.9067226,0.00071243534,0.007044575,0.040203333],"study_design_scores_gemma":[0.0064104395,0.01567192,0.038462814,0.00040749108,0.0006907938,0.00017342965,0.0004563322,0.00011172416,0.82865185,0.0021355713,0.10627536,0.00055231265],"about_ca_topic_score_codex":0.000119503755,"about_ca_topic_score_gemma":0.000026992835,"teacher_disagreement_score":0.09923078,"about_ca_system_score_codex":0.00004365196,"about_ca_system_score_gemma":0.0001585875,"threshold_uncertainty_score":0.36467984},"labels":[],"label_agreement":null},{"id":"W1970017653","doi":"10.1097/01.jto.0000283712.18087.57","title":"P1-097: 18Fluorodeoxyglucose Positron Emission Tomography and co-registered computed tomography for radiation treatment planning in lung cancer: a systematic review","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario; McMaster University; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Positron emission tomography; Nuclear medicine; Radiation treatment planning; Lung cancer; Radiation therapy; PET-CT; Radiology; Tomography; Medical physics; Oncology","score_opus":0.07459570965364852,"score_gpt":0.521934951972629,"score_spread":0.4473392423189804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970017653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000065271386,0.98998994,0.0033985681,0.001000485,0.00015509441,0.005266093,0.00003768589,0.000034147142,0.000052747437],"genre_scores_gemma":[0.0000620097,0.98760325,0.010820452,0.00043838602,0.00027523775,0.0005813402,0.0001262211,0.000041707437,0.000051378083],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9964892,0.00040390764,0.0021788997,0.00032158336,0.00029113435,0.00031521835],"domain_scores_gemma":[0.99575907,0.0007366549,0.0026400182,0.00034238526,0.00018422632,0.00033767475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019148551,0.000395043,0.0043544667,0.0010203668,0.00007397811,0.000021624728,0.00020524605,0.00040807162,0.000008926697],"category_scores_gemma":[0.00018825452,0.00026069803,0.00079940417,0.0006180054,0.00008173102,0.00006287111,0.000027953287,0.00057831727,3.6533413e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009435816,0.00025273845,0.00005118936,0.48958114,0.0003799103,0.00009567797,0.00005366129,1.6541462e-7,0.0000090617405,0.0000046323908,0.0048485035,0.50462896],"study_design_scores_gemma":[0.0005764988,0.0010147237,0.000023879396,0.58645433,0.009257909,0.0013214138,0.000011051408,0.00014586904,0.000014758103,0.000011375777,0.4009919,0.0001762826],"about_ca_topic_score_codex":0.000014889367,"about_ca_topic_score_gemma":0.000002176168,"teacher_disagreement_score":0.5044527,"about_ca_system_score_codex":0.0008659616,"about_ca_system_score_gemma":0.0005795945,"threshold_uncertainty_score":0.9999845},"labels":[],"label_agreement":null},{"id":"W1970053179","doi":"10.1097/jto.0b013e3182a4dd8e","title":"Whole-Genome Sequencing Analysis Identifies a Distinctive Mutational Spectrum in an Arsenic-Related Lung Tumor","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Arsenic contamination and mitigation","field":"Environmental Science","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Lung cancer; Arsenic; Genome; Genetics; Biology; Lung; Arsenic toxicity; Cancer research; Carcinogen; Medicine; Gene; Pathology; Internal medicine; Chemistry","score_opus":0.011567965542635244,"score_gpt":0.3281408009680893,"score_spread":0.31657283542545406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970053179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941549,0.000025045427,0.0019204463,0.0017378603,0.00016347542,0.00014444628,0.0000046547757,0.000008763863,0.0018404663],"genre_scores_gemma":[0.9979098,0.0000026409361,0.0010937157,0.00016043642,0.00004340121,0.0000076016518,0.00001960852,0.000006964501,0.00075583335],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984118,0.00029250394,0.0006280379,0.00017699978,0.00028367658,0.00020701824],"domain_scores_gemma":[0.99897766,0.00011798526,0.0006218793,0.000105973566,0.00004902294,0.00012747383],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007965631,0.000102765116,0.00029323786,0.0003170312,0.00007889011,0.000038824834,0.00018356183,0.00007170744,0.0043484974],"category_scores_gemma":[0.00010217967,0.00009248178,0.00012277087,0.0005523821,0.00012894579,0.00082078984,0.000057962698,0.00026811587,0.00014843217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004206575,0.001157816,0.2991541,0.000036383306,0.0010486784,0.001707688,0.03026229,0.104308896,0.48651934,0.0004911743,0.0010031421,0.07388985],"study_design_scores_gemma":[0.00033572208,0.0002053899,0.96019745,0.000012592635,0.0002821165,0.00024743486,0.0034647745,0.03034,0.00054569216,0.0037221708,0.0004932373,0.00015341716],"about_ca_topic_score_codex":0.00016008863,"about_ca_topic_score_gemma":0.0022547957,"teacher_disagreement_score":0.66104335,"about_ca_system_score_codex":0.0014560221,"about_ca_system_score_gemma":0.0001030208,"threshold_uncertainty_score":0.99656165},"labels":[],"label_agreement":null},{"id":"W1970409562","doi":"10.1097/jto.0b013e3181c3f4f1","title":"Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"Medicine; Lambert-Eaton myasthenic syndrome; Subclinical infection; Ataxia; Lung cancer; Incidence (geometry); Cerebellar ataxia; Internal medicine; Cancer; Prospective cohort study; Gastroenterology; Antibody titer; Antibody; Myasthenia gravis; Titer; Immunology","score_opus":0.012151490934625126,"score_gpt":0.38011049620090026,"score_spread":0.3679590052662751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970409562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948716,0.00077807205,0.000016871423,0.002204276,0.0006315438,0.00067474524,0.0000011153041,0.000005154185,0.0008166207],"genre_scores_gemma":[0.99821895,0.00007001709,0.0008477292,0.00014123782,0.00017914407,0.000026549953,2.484907e-7,0.000019648494,0.0004964718],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982939,0.0002449513,0.00076598756,0.0001764439,0.00028654435,0.00023219004],"domain_scores_gemma":[0.99823004,0.00023773858,0.0007416657,0.00030309713,0.0003670167,0.000120467186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016935905,0.00015696812,0.0007269119,0.00024649806,0.000049289647,0.000009232571,0.00032479793,0.00015669699,0.00018053252],"category_scores_gemma":[0.00016878634,0.000093682225,0.00014529076,0.00034948578,0.00013627492,0.0000835019,0.00009383222,0.0012177277,0.0000045349716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018245272,0.0017969115,0.9471428,0.00012349643,0.00016923265,0.0015444413,0.013541535,0.000015030717,0.017954549,0.000084712585,0.00010436439,0.015698427],"study_design_scores_gemma":[0.002058412,0.0056562065,0.9791545,0.0002545065,0.0005011814,0.0030690888,0.0028840937,0.00012814498,0.004440115,0.00073552376,0.000986328,0.00013185233],"about_ca_topic_score_codex":0.00061739626,"about_ca_topic_score_gemma":0.0047566844,"teacher_disagreement_score":0.032011773,"about_ca_system_score_codex":0.00023535326,"about_ca_system_score_gemma":0.00069488084,"threshold_uncertainty_score":0.52904886},"labels":[],"label_agreement":null},{"id":"W1970582321","doi":"10.1097/01.jto.0000283411.38367.97","title":"PD3-3-1: A phase Ib/randomized phase II, non-comparative, open label trial of paclitaxel and carboplatin with or without the anti-IGF-IR antibody CP-751,871 as first-line treatment for advanced non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Paclitaxel; Gastroenterology; Phases of clinical research; Pharmacokinetics; Oncology; Interim analysis; Clinical endpoint; Toxicity; Clinical trial; Chemotherapy","score_opus":0.05195269812214726,"score_gpt":0.49867693263420454,"score_spread":0.4467242345120573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970582321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826094,0.0012943511,0.009716748,0.0007329097,0.0002035059,0.0045414586,0.00006897761,0.0000030140634,0.0008296243],"genre_scores_gemma":[0.9888336,0.0010543985,0.0077465046,0.00013696599,0.0003482035,0.00021982095,0.000042058753,0.000029861269,0.0015886027],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997796,0.0002856547,0.00092067424,0.00034392133,0.0002509549,0.0004027903],"domain_scores_gemma":[0.99733746,0.00041652942,0.0011288739,0.00030569397,0.00059518864,0.0002162658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019652864,0.0003061641,0.0012961329,0.00014896554,0.00024879538,0.000042911728,0.00038798907,0.00021599558,0.000047746664],"category_scores_gemma":[0.00021182015,0.0001672638,0.0001818444,0.00019381492,0.00027021818,0.000026241452,0.00013845522,0.00023888821,5.236318e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7016843,0.003400515,0.00011981829,0.00007061725,0.00048341797,0.000049744653,0.0007391292,0.000117994,0.27417335,0.0000029845241,0.00018930915,0.018968834],"study_design_scores_gemma":[0.60601616,0.052904386,0.000028748198,0.00012683698,0.0004425434,0.00010472008,0.00046217462,0.002063407,0.32735106,0.000012822946,0.010266305,0.00022084804],"about_ca_topic_score_codex":0.00017276713,"about_ca_topic_score_gemma":0.0009585776,"teacher_disagreement_score":0.09566812,"about_ca_system_score_codex":0.000104779574,"about_ca_system_score_gemma":0.001253471,"threshold_uncertainty_score":0.682082},"labels":[],"label_agreement":null},{"id":"W1971195877","doi":"10.1097/jto.0000000000000446","title":"Mitosis Trumps T Stage and Proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification for Prognostic Value in Resected Stage 1 Lung Adenocarcinoma","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Stage (stratigraphy); Adenocarcinoma; Lung cancer; Pathology; Mitotic index; Concordance; Cancer; Univariate analysis; Oncology; Internal medicine; Multivariate analysis; Biology","score_opus":0.046746440416169224,"score_gpt":0.4350243769316102,"score_spread":0.388277936515441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971195877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98854303,0.00102355,0.00083320413,0.006591406,0.00041895593,0.0024615696,0.000053605683,0.000011341823,0.000063303894],"genre_scores_gemma":[0.99633604,0.0003652643,0.0020422204,0.00036652404,0.00046720772,0.000205523,0.000009745259,0.000033938348,0.00017351241],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770266,0.00056548073,0.00079434883,0.00027526947,0.00041990422,0.00024234579],"domain_scores_gemma":[0.99534523,0.001972662,0.001730451,0.00019216651,0.0006733568,0.00008615164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028254509,0.00016672825,0.00056695775,0.00011621563,0.00013411487,0.00003190168,0.00018968807,0.00009898041,0.000007443581],"category_scores_gemma":[0.0007451752,0.00011594255,0.00025970768,0.00023535031,0.00009206591,0.000115134295,0.00004587599,0.00031432358,1.2933712e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021916109,0.0015612198,0.92955434,0.0004651884,0.0014601965,0.000005611658,0.00465296,0.00016382262,0.0021935874,0.000036302725,0.003158078,0.054557092],"study_design_scores_gemma":[0.0045983023,0.005990351,0.9574878,0.0002934425,0.0016347527,0.0000056868716,0.005922371,0.018015869,0.0009087745,0.000011597427,0.0050096824,0.00012132879],"about_ca_topic_score_codex":0.00009456867,"about_ca_topic_score_gemma":0.00020429585,"teacher_disagreement_score":0.054435764,"about_ca_system_score_codex":0.0022380247,"about_ca_system_score_gemma":0.0004333778,"threshold_uncertainty_score":0.5852357},"labels":[],"label_agreement":null},{"id":"W1971535810","doi":"10.1097/jto.0b013e31819518fc","title":"Prevention and Management of Bone Metastases in Lung Cancer: A Review","year":2009,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Intensive care medicine; Lung; Internal medicine","score_opus":0.07383239960164495,"score_gpt":0.5407166464370329,"score_spread":0.46688424683538793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971535810","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054042885,0.9971991,0.000005956391,0.00085682626,0.00016828423,0.00132183,0.000010149903,0.0000025045504,0.00038129697],"genre_scores_gemma":[0.000010561851,0.9962802,0.002951364,0.00021228685,0.00005096682,0.00004647619,0.00001406785,0.000013858035,0.00042025026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974066,0.000422895,0.0016208183,0.00015163596,0.00021214322,0.00018590443],"domain_scores_gemma":[0.9973918,0.000077059005,0.002129633,0.00015287552,0.00009393267,0.00015465198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011888536,0.00020400186,0.0035503833,0.00036903954,0.0000144136775,0.0000021822405,0.00006023798,0.00016889532,0.000054368007],"category_scores_gemma":[0.000034711018,0.00013743134,0.00038640812,0.00029845737,0.000029373927,0.00004913696,0.000029561994,0.00039839998,0.0000014130076],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012356455,0.0003824773,0.000027521295,0.22025044,0.0004917897,0.001074701,0.0000053481463,3.9758543e-8,2.6078434e-8,0.000007448022,0.0012274097,0.7764092],"study_design_scores_gemma":[0.00053643406,0.0010704446,0.00018873966,0.27749947,0.012840202,0.0019811736,0.000004028861,3.2912934e-7,2.0442856e-7,0.000021293718,0.70580083,0.00005686555],"about_ca_topic_score_codex":0.00001906407,"about_ca_topic_score_gemma":0.000023213704,"teacher_disagreement_score":0.77635235,"about_ca_system_score_codex":0.0005048742,"about_ca_system_score_gemma":0.0008196601,"threshold_uncertainty_score":0.56042874},"labels":[],"label_agreement":null},{"id":"W1971623971","doi":"10.1097/jto.0b013e3182a46c0c","title":"CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Institute of Environmental Health Sciences; National Institutes of Health; National Cancer Institute; National Human Genome Research Institute; University of Texas Southwestern Medical Center; Canary Foundation","keywords":"CDKN2A; KRAS; Cancer research; Methylation; DNA methylation; Point mutation; Lung cancer; Mutation; Carcinogenesis; Biology; Gene; Medicine; Molecular biology; Genetics; Gene expression; Oncology","score_opus":0.035855057782011625,"score_gpt":0.39492850899086474,"score_spread":0.3590734512088531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971623971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032346107,0.9617241,0.0023543683,0.0009765902,0.00053680415,0.0016592579,0.0000142834015,0.000010987527,0.0003774964],"genre_scores_gemma":[0.015048389,0.9779749,0.0057100346,0.00047638462,0.0002592274,0.00016552539,0.000017347815,0.00009533634,0.0002528453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976296,0.00046744512,0.00098427,0.0003719031,0.00023350051,0.0003133097],"domain_scores_gemma":[0.9976728,0.00032378506,0.001141607,0.00028289686,0.00026849547,0.00031041293],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082293665,0.00043168454,0.0020141238,0.0009573468,0.000057627367,0.00003640383,0.00016390142,0.0010015925,0.000033308792],"category_scores_gemma":[0.0002845015,0.00031922112,0.00025726133,0.00047770268,0.000048905396,0.00010184526,0.000114538816,0.0018286015,0.0000026019247],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023806104,0.00014653687,0.00012683045,0.00714267,0.0003344355,0.00048625315,0.00067434774,0.00002576901,0.0040124287,0.000071199545,0.00076494296,0.9859765],"study_design_scores_gemma":[0.006023471,0.009269335,0.0067467005,0.09595175,0.013395961,0.017405823,0.0014440283,0.00014361838,0.0070521957,0.0018066729,0.8384969,0.0022635185],"about_ca_topic_score_codex":0.00007649359,"about_ca_topic_score_gemma":0.000074178286,"teacher_disagreement_score":0.98371303,"about_ca_system_score_codex":0.0011684477,"about_ca_system_score_gemma":0.0012222161,"threshold_uncertainty_score":0.999926},"labels":[],"label_agreement":null},{"id":"W1971811999","doi":"10.1097/jto.0000000000000356","title":"Forty Years of the International Association for Study of Lung Cancer Pathology Committee","year":2014,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Lung cancer; Multidisciplinary approach; Adenocarcinoma; Clinical Practice; Pathology; Cancer; Clinical Oncology; Family medicine; Oncology; Internal medicine","score_opus":0.04240405601126869,"score_gpt":0.5292521534044129,"score_spread":0.4868480973931442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971811999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016638951,0.97366387,0.00007511516,0.0010183626,0.0051848902,0.0022421535,0.00018307597,0.000004542791,0.000989022],"genre_scores_gemma":[0.015846543,0.97999173,0.00072859274,0.00018196808,0.0010511302,0.00017752392,0.000029112574,0.000043183954,0.0019501919],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998228,0.00025803907,0.0009988333,0.000106765954,0.00029739397,0.000110974644],"domain_scores_gemma":[0.9948898,0.00056572503,0.003731595,0.00017475401,0.00060004106,0.00003810787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008568418,0.00012131296,0.0015699336,0.00018451353,0.000026723732,0.0000036509098,0.00025446486,0.00023773924,0.00003503337],"category_scores_gemma":[0.00037140024,0.000074058706,0.00053574605,0.00012427678,0.000031811203,0.000030937572,0.00005225356,0.00031386648,4.2643518e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016648958,0.0010266887,0.008403119,0.0027692395,0.0037990487,0.000019541627,0.0006831936,0.000007527174,0.0000036036517,0.000015169275,0.007321502,0.9757849],"study_design_scores_gemma":[0.0015088989,0.0018518702,0.0059303734,0.002922469,0.015652612,0.0001563482,0.000177386,0.0000060202906,0.000003948079,0.000046532627,0.9716764,0.00006713417],"about_ca_topic_score_codex":0.00002845451,"about_ca_topic_score_gemma":0.000088982364,"teacher_disagreement_score":0.9757177,"about_ca_system_score_codex":0.0012896227,"about_ca_system_score_gemma":0.0012634302,"threshold_uncertainty_score":0.33723184},"labels":[],"label_agreement":null},{"id":"W1973594634","doi":"10.1097/jto.0b013e31816de276","title":"Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centracare","funders":"National Cancer Institute","keywords":"Medicine; Carboplatin; Regimen; Internal medicine; Bortezomib; Cancer; Gastroenterology; Esophagus; Surgery; Oncology; Chemotherapy; Multiple myeloma","score_opus":0.03312363589053794,"score_gpt":0.38729129038000304,"score_spread":0.3541676544894651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973594634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741393,0.017303385,0.00008066073,0.005287336,0.00016703963,0.0014892776,0.001495997,0.000012533311,0.000024508621],"genre_scores_gemma":[0.9858048,0.008594728,0.0040168595,0.00034914652,0.00058064034,0.00019413968,0.00016283285,0.00003873328,0.000258113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748194,0.00019687747,0.0007390709,0.0004204137,0.0005185156,0.0006432095],"domain_scores_gemma":[0.9972939,0.00068524707,0.000766861,0.00026489532,0.00031567898,0.0006734022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027177506,0.00036637118,0.00097287947,0.0001670254,0.00046510383,0.000025446367,0.00013129707,0.00008148281,0.000049857463],"category_scores_gemma":[0.0001655392,0.00020224634,0.00014919597,0.00023993362,0.00031181,0.00017878521,0.00005976219,0.00035391733,6.242185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12868881,0.007019766,0.5143051,0.00014652056,0.0038636844,0.0059451954,0.0052731917,0.00016006996,0.000027272381,0.0000085972115,0.0034553458,0.33110642],"study_design_scores_gemma":[0.09633607,0.18039115,0.70870805,0.00040265784,0.0040490674,0.0014152628,0.00035970754,0.00037446682,0.0003366468,0.000113727416,0.0071883444,0.00032487942],"about_ca_topic_score_codex":0.0021870113,"about_ca_topic_score_gemma":0.0031369794,"teacher_disagreement_score":0.33078152,"about_ca_system_score_codex":0.0010159863,"about_ca_system_score_gemma":0.001064672,"threshold_uncertainty_score":0.82473665},"labels":[],"label_agreement":null},{"id":"W1974050574","doi":"10.1097/jto.0b013e31823f459c","title":"Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Regional Health Centre; Sunnybrook Health Science Centre; Centre hospitalier de l'Université Laval; Ottawa Regional Cancer Foundation; Baker Hughes (Canada); Thames Valley Children's Centre; Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Regimen; Carboplatin; Lung cancer; Gastroenterology; Phases of clinical research; Oncology; Population; Chemotherapy; Cisplatin; Surgery; Randomized controlled trial","score_opus":0.016719970619575104,"score_gpt":0.3516007821071582,"score_spread":0.33488081148758314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974050574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977351,0.00013896995,0.00007615083,0.00010890493,0.00017840476,0.0014865255,0.000016428185,0.0000055004643,0.00025405159],"genre_scores_gemma":[0.99463,0.000043640026,0.005104758,0.000037004855,0.0000556755,0.0000383728,0.000014306208,0.000028782088,0.00004750596],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99801517,0.00027027013,0.0009925282,0.00023340715,0.00023716717,0.00025145678],"domain_scores_gemma":[0.9976335,0.00008803337,0.0014167469,0.00022484572,0.00047004237,0.00016684228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005173394,0.00020182,0.0010184256,0.0005176728,0.000020079939,0.0000026021742,0.00011879284,0.0001810163,0.000041111893],"category_scores_gemma":[0.00008843691,0.00014979314,0.00004493299,0.0002975024,0.00017043861,0.00019294694,0.00007828136,0.0003292172,1.5023608e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6291787,0.018623896,0.30719817,0.0008536305,0.0001335236,0.00051872694,0.008325843,0.00013583976,0.004357134,0.0000020903337,0.00003935819,0.030633114],"study_design_scores_gemma":[0.45575306,0.20703933,0.3241241,0.0021869855,0.0010496764,0.00020933406,0.0011007856,0.0010243047,0.0071144872,0.00003176739,0.00004016748,0.00032598685],"about_ca_topic_score_codex":0.00010395189,"about_ca_topic_score_gemma":0.00047881482,"teacher_disagreement_score":0.18841544,"about_ca_system_score_codex":0.0002896034,"about_ca_system_score_gemma":0.0004996345,"threshold_uncertainty_score":0.61083865},"labels":[],"label_agreement":null},{"id":"W1975313529","doi":"10.1016/s1556-0864(15)31641-5","title":"Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline","year":2006,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Cancer Care Ontario; Juravinski Cancer Centre; Sudbury Regional Hospital","funders":"","keywords":"Docetaxel; Medicine; Internal medicine; Erlotinib; Pemetrexed; Oncology; Lung cancer; Gefitinib; Topotecan; Febrile neutropenia; Afatinib; Guideline; Regimen; Vinorelbine; Chemotherapy; Cancer; Neutropenia; Epidermal growth factor receptor; Pathology; Cisplatin","score_opus":0.07230581937056216,"score_gpt":0.5353964829965041,"score_spread":0.463090663625942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975313529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008691919,0.9814305,0.0003518629,0.0017824206,0.0009206916,0.015041496,0.00022997103,0.00001554891,0.00021887582],"genre_scores_gemma":[0.000003987959,0.98267263,0.008943558,0.0013873,0.0009018483,0.0027927202,0.00013281022,0.000094199364,0.0030709608],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99443895,0.0008489375,0.0036046451,0.0004089928,0.00031952752,0.0003789766],"domain_scores_gemma":[0.9880402,0.0015629163,0.0079310015,0.00039445877,0.001802269,0.00026915356],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022292626,0.0006034217,0.0066122087,0.00031200718,0.000100673205,0.000041587173,0.00025559159,0.00039625424,0.00014510777],"category_scores_gemma":[0.00081764115,0.0002934233,0.0007236836,0.00034886936,0.00005458268,0.0001347419,0.000042034324,0.00061534287,0.000003131368],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012414299,0.00056379486,5.6559566e-7,0.7338839,0.0025303194,0.0008437986,0.000109849316,7.597903e-7,7.5965636e-7,0.0000011736323,0.017047979,0.24377565],"study_design_scores_gemma":[0.0012150727,0.0040644924,1.1619049e-7,0.39509773,0.065458104,0.016483705,0.000085136875,0.000009157357,0.0000013219103,0.0000011226745,0.5174077,0.0001763329],"about_ca_topic_score_codex":0.000012434657,"about_ca_topic_score_gemma":0.000041500432,"teacher_disagreement_score":0.5003597,"about_ca_system_score_codex":0.0022651134,"about_ca_system_score_gemma":0.008210871,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W1975382050","doi":"10.1097/jto.0b013e318298762f","title":"EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"EZH2; Cell cycle; Carcinogenesis; Cancer research; Apoptosis; Propidium iodide; Cell; Biology; Viability assay; Cell sorting; Programmed cell death; Cancer; Epigenetics; Genetics","score_opus":0.014014484821083764,"score_gpt":0.33164893344429164,"score_spread":0.3176344486232079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975382050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055904,0.000986318,0.0070416653,0.00039986765,0.00020349219,0.00017469499,0.0000027493725,0.0000027046162,0.0006294713],"genre_scores_gemma":[0.9800663,0.00054544,0.018963931,0.000029936784,0.00024631427,0.0000053550725,0.000013138876,0.000014710382,0.00011484398],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889594,0.00016713365,0.0004969474,0.00015503423,0.00014993278,0.00013501034],"domain_scores_gemma":[0.9986516,0.000039585237,0.0006906194,0.0001570151,0.00039684598,0.00006428944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032537943,0.00011051489,0.0002560971,0.000078616315,0.000053043495,0.000015522939,0.0001045828,0.00019951063,0.000035834215],"category_scores_gemma":[0.000088138906,0.00009681319,0.000087584915,0.00009058552,0.00007359156,0.000024658157,0.000052628868,0.00008437275,0.0000025290035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000872932,0.00010479934,0.0035727709,0.00004046639,0.000035458834,4.986379e-7,0.00015084639,0.0011911849,0.95756567,0.00001527908,0.00013127556,0.037104465],"study_design_scores_gemma":[0.0003092149,0.0012810326,0.051957376,0.000023960214,0.00006844857,0.000013900121,0.00010439735,0.0012193331,0.94059753,0.0028930432,0.0014181227,0.00011363252],"about_ca_topic_score_codex":0.000028013568,"about_ca_topic_score_gemma":0.000005411129,"teacher_disagreement_score":0.048384603,"about_ca_system_score_codex":0.000030353,"about_ca_system_score_gemma":0.000089437846,"threshold_uncertainty_score":0.39479277},"labels":[],"label_agreement":null},{"id":"W1975807921","doi":"10.1097/jto.0b013e31827ce554","title":"A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"Universitair Ziekenhuis Gent; International Association for the Study of Lung Cancer; Amgen","keywords":"Medicine; Carboplatin; Neutropenia; Hazard ratio; Internal medicine; Lung cancer; Clinical endpoint; Confidence interval; Anemia; Paclitaxel; Placebo; Adverse effect; Performance status; Randomized controlled trial; Gastroenterology; Chemotherapy; Surgery; Cisplatin; Pathology","score_opus":0.025710527713149682,"score_gpt":0.45832775688968086,"score_spread":0.43261722917653117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975807921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915731,0.002439974,0.00056063954,0.00075775926,0.00014312302,0.0042999717,0.00002844217,0.000004224488,0.00019279627],"genre_scores_gemma":[0.9901414,0.00062514766,0.007658935,0.00004401118,0.00008901131,0.0005689587,0.0000050235612,0.00002160124,0.0008459259],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987014,0.00009569091,0.0007371833,0.00015134327,0.00015482023,0.00015957102],"domain_scores_gemma":[0.9974974,0.0005229542,0.001092448,0.00014149002,0.0006094135,0.00013629207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021701069,0.00017916186,0.0015622164,0.0001547348,0.000046123994,0.0000053848116,0.000047791695,0.00007167759,0.000072945935],"category_scores_gemma":[0.00006199999,0.00009273736,0.0001300365,0.00010629998,0.00009908178,0.00007896396,0.000009994154,0.00008289581,1.563743e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73945034,0.01982268,0.020563118,0.0010015514,0.006655908,0.00017969895,0.023232426,0.000557388,0.0037735004,0.000005267533,0.00017354047,0.1845846],"study_design_scores_gemma":[0.88360095,0.08563158,0.0016697708,0.0004738073,0.012822243,0.00022422375,0.0076704007,0.0030339968,0.0041263434,0.00003620854,0.0005539408,0.00015655473],"about_ca_topic_score_codex":0.0004115571,"about_ca_topic_score_gemma":0.00055260235,"teacher_disagreement_score":0.18442805,"about_ca_system_score_codex":0.00029545213,"about_ca_system_score_gemma":0.0007487634,"threshold_uncertainty_score":0.37817198},"labels":[],"label_agreement":null},{"id":"W1977486624","doi":"10.1097/jto.0b013e3182641d4f","title":"Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; International Association for the Study of Lung Cancer","keywords":"PTEN; Tensin; Cancer research; Hazard ratio; Tissue microarray; Immunohistochemistry; Lung cancer; Medicine; Pathology; Adenocarcinoma; Biology; Cancer; Internal medicine; PI3K/AKT/mTOR pathway; Confidence interval; Signal transduction; Genetics","score_opus":0.01674984007972901,"score_gpt":0.3494437762652105,"score_spread":0.3326939361854815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977486624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848877,0.013997577,0.00018602225,0.00029302746,0.00029608753,0.00026795542,0.000019856687,0.0000024391163,0.00004931547],"genre_scores_gemma":[0.9957581,0.00010552058,0.0034625607,0.00022404635,0.00034007803,0.0000139022495,0.000010033712,0.0000218619,0.00006387387],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983509,0.0003511108,0.00055241014,0.00021308659,0.00020888414,0.00032357554],"domain_scores_gemma":[0.9987484,0.00005155235,0.00059349043,0.00022171417,0.00019208645,0.00019276043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001130583,0.00016445748,0.00037325354,0.00013396367,0.000032298303,0.000009533289,0.00022473847,0.00034534,0.00005556498],"category_scores_gemma":[0.00026878173,0.00013757452,0.00007552034,0.00009197605,0.00014879882,0.000029926145,0.00014257812,0.00030899764,0.0000012110125],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020905153,0.00052705343,0.38692796,0.00011368514,0.0000661672,0.00015208968,0.00031077449,0.000010207697,0.5997042,0.000006687444,0.0010743039,0.009016344],"study_design_scores_gemma":[0.0010384821,0.002445972,0.1707775,0.00023117446,0.000102261016,0.0011507244,0.00023457457,0.000042357857,0.8210101,0.00008361988,0.0026619066,0.00022129665],"about_ca_topic_score_codex":0.000015277537,"about_ca_topic_score_gemma":0.00001057387,"teacher_disagreement_score":0.22130592,"about_ca_system_score_codex":0.000086637236,"about_ca_system_score_gemma":0.00025458547,"threshold_uncertainty_score":0.56101257},"labels":[],"label_agreement":null},{"id":"W1978236936","doi":"10.1097/jto.0b013e318290868f","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Lung cancer; Tyrosine kinase; Oncology; Internal medicine; Cancer; Selection (genetic algorithm); Pathology; Receptor","score_opus":0.014683227863495754,"score_gpt":0.41812177314189347,"score_spread":0.40343854527839773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978236936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972452,0.0016146568,0.011540494,0.008826332,0.0005759196,0.0036443446,0.0013328211,0.000004647952,0.000008775725],"genre_scores_gemma":[0.97791916,0.00015768253,0.020193081,0.00044509166,0.00033166193,0.00078916486,0.000095083684,0.000023064847,0.00004599239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981847,0.00011695636,0.0011053482,0.00017751592,0.00024609096,0.00016938378],"domain_scores_gemma":[0.99088764,0.0016093815,0.0030492996,0.00008657191,0.004324454,0.00004263028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011015566,0.00013352587,0.0005602887,0.00010431618,0.00010150998,0.000008736016,0.00009426556,0.000113856564,0.0000036729036],"category_scores_gemma":[0.0029163975,0.000087523294,0.00012346593,0.00016331291,0.00005512157,0.00008579626,0.00003139375,0.00010293632,8.633668e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032963392,0.0021903547,0.7534816,0.00031214757,0.004239749,0.000003853183,0.0019461736,0.0019673328,0.07527795,0.00006530039,0.03613245,0.121086754],"study_design_scores_gemma":[0.06831558,0.051397335,0.5245193,0.0013550363,0.037798185,0.000063887775,0.010729671,0.2072919,0.065834895,0.0024158726,0.029385237,0.000893111],"about_ca_topic_score_codex":0.00094210665,"about_ca_topic_score_gemma":0.0002941427,"teacher_disagreement_score":0.2289623,"about_ca_system_score_codex":0.00087489554,"about_ca_system_score_gemma":0.00035081067,"threshold_uncertainty_score":0.35690963},"labels":[],"label_agreement":null},{"id":"W1978523409","doi":"10.1097/01.jto.0000284044.79081.8e","title":"P3-068: An economic analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, a randomized trial of erlotinib versus best supportive care after cisplatin based chemotherapy in advanced non-small-cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Clinical trial; Randomized controlled trial; Erlotinib Hydrochloride; Quality of life (healthcare); Pharmacoeconomics; Internal medicine; Cost effectiveness; Oncology; Cost-effectiveness analysis; Intensive care medicine; Cancer; Epidermal growth factor receptor; Nursing","score_opus":0.05899033882409777,"score_gpt":0.4328327356971707,"score_spread":0.3738423968730729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978523409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886077,0.0020567302,0.00068910944,0.00043885424,0.004556483,0.0010645519,0.0007670076,0.0000018931001,0.0018176563],"genre_scores_gemma":[0.99712026,0.0007648878,0.0010147919,0.00033278507,0.0005873063,0.000063361826,0.000011417189,0.000026474563,0.00007870096],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9930276,0.0003888965,0.00567216,0.0003733646,0.00015019081,0.00038778037],"domain_scores_gemma":[0.9880299,0.0018410627,0.009242685,0.000282195,0.00042548118,0.00017865917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011127686,0.00027807464,0.0039861677,0.0007820134,0.00004617439,0.000013275783,0.00052304025,0.00035582372,0.00051216385],"category_scores_gemma":[0.0012319725,0.0002417857,0.0012256649,0.0004964426,0.0003100223,0.00033333065,0.000043936532,0.0004604901,6.479873e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8712723,0.0007535641,0.07885866,0.00013732575,0.0024872536,0.000010900843,0.0011362451,0.025180418,0.00009284577,0.00027209925,0.00020106888,0.01959727],"study_design_scores_gemma":[0.8105288,0.0036667236,0.15810503,0.00038919438,0.003068536,0.0000031193592,0.00094331946,0.01398817,0.0022943516,0.00041549906,0.0057662046,0.00083100476],"about_ca_topic_score_codex":0.04079503,"about_ca_topic_score_gemma":0.3970023,"teacher_disagreement_score":0.35620728,"about_ca_system_score_codex":0.002084612,"about_ca_system_score_gemma":0.005535105,"threshold_uncertainty_score":0.9859735},"labels":[],"label_agreement":null},{"id":"W1979699724","doi":"10.1097/jto.0b013e3181c8cbf5","title":"Surgery for Limited Stage Small Cell Lung Cancer: Time to Fish or Cut Bait","year":2010,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fish <Actinopterygii>; Stage (stratigraphy); Lung cancer; Surgery; Oncology; Fishery; Biology","score_opus":0.05446420084354163,"score_gpt":0.4431004005296949,"score_spread":0.38863619968615326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979699724","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012865949,0.001488969,0.00012615454,0.9773979,0.0034306115,0.0018806315,0.0005335929,0.000042432504,0.0022337297],"genre_scores_gemma":[0.00013493471,0.001767147,0.004952203,0.68008333,0.027176198,0.0003420924,0.00012478176,0.00023351827,0.28518578],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603295,0.00034739132,0.001273576,0.00047479387,0.00081652956,0.0010547575],"domain_scores_gemma":[0.9920591,0.0038463299,0.0014407822,0.0005174006,0.001679557,0.000456793],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0019018304,0.0004949775,0.00261021,0.0011050052,0.0001380959,0.000052153602,0.00056214863,0.0019025801,0.0028928649],"category_scores_gemma":[0.002057996,0.0003506684,0.00076295825,0.00038933457,0.00015791734,0.00009752421,0.00023213144,0.006622655,0.000066267654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00558004,0.00016048572,0.00045527818,0.003201133,0.0009643948,0.00576494,0.00018263822,0.000004585839,0.00089404854,6.163097e-8,0.9618732,0.020919211],"study_design_scores_gemma":[0.00091934466,0.0025501458,0.0002524496,0.0010388545,0.0014466803,0.0005649663,0.00003481774,0.000044947352,0.0010779903,0.000005010633,0.9917262,0.00033860237],"about_ca_topic_score_codex":0.000070397036,"about_ca_topic_score_gemma":0.00033119452,"teacher_disagreement_score":0.2973146,"about_ca_system_score_codex":0.0020345633,"about_ca_system_score_gemma":0.006273783,"threshold_uncertainty_score":0.99989456},"labels":[],"label_agreement":null},{"id":"W1979701357","doi":"10.1097/jto.0b013e31827d5237","title":"Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; Lung cancer; Protein expression; Cancer; Cancer research; Internal medicine; Gene; Genetics","score_opus":0.008888721747690374,"score_gpt":0.3042185138192221,"score_spread":0.2953297920715317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979701357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99714416,0.0016346169,0.00055506866,0.00019731335,0.0000833342,0.00027906863,0.0000050367153,0.0000013882674,0.000099998106],"genre_scores_gemma":[0.9961974,0.00059140543,0.0026382713,0.000055800152,0.000052984753,0.000024307386,0.0000042606457,0.000011351418,0.00042419895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916315,0.000082379454,0.0003291765,0.00015515965,0.00011392518,0.00015618422],"domain_scores_gemma":[0.99890804,0.000014521679,0.0006374436,0.000100071666,0.0002770629,0.00006284265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026239772,0.00010720487,0.00026416962,0.0000735217,0.000026015105,0.000007691698,0.00010584288,0.00019638178,0.00003798151],"category_scores_gemma":[0.000034845016,0.00007956365,0.000037005426,0.00012561148,0.00005670363,0.000010445255,0.000035163743,0.00014781117,1.914183e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003484455,0.000074047624,0.0024697562,0.00006746713,0.000024612846,0.0000080872815,0.00012513656,0.000096251904,0.98742604,0.0000012432179,0.00045083775,0.008908093],"study_design_scores_gemma":[0.0007713499,0.0007452682,0.013764473,0.00047211855,0.00003701112,0.000017908413,0.00010504484,0.00050923834,0.98299855,0.0000712105,0.00038971126,0.000118120035],"about_ca_topic_score_codex":0.00011824072,"about_ca_topic_score_gemma":0.00022753814,"teacher_disagreement_score":0.011294717,"about_ca_system_score_codex":0.00011079261,"about_ca_system_score_gemma":0.00028858453,"threshold_uncertainty_score":0.32445115},"labels":[],"label_agreement":null},{"id":"W1980343318","doi":"10.1097/01.jto.0000283478.00088.2c","title":"P2-036: Novel mechanism of collagen-tumor cell interaction by integrin alpha-11 expression by cancer associated fibroblasts in non-small cell lung cancer cells","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"A549 cell; Cancer research; Stromal cell; Small hairpin RNA; Fibroblast; Cell culture; Molecular biology; Downregulation and upregulation; Lung cancer; Biology; Medicine; Pathology; Gene; Gene knockdown","score_opus":0.0184295028745918,"score_gpt":0.39543347408038415,"score_spread":0.3770039712057924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980343318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909771,0.0011921049,0.0043788096,0.0005297535,0.0010428668,0.00064889534,0.000065128326,0.000011750049,0.0011535693],"genre_scores_gemma":[0.9918261,0.0007010043,0.002759543,0.00037145388,0.00019409064,0.000023248685,0.000018028697,0.00006791093,0.0040386305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964269,0.00031301603,0.0014595021,0.0003666265,0.00076976034,0.0006641917],"domain_scores_gemma":[0.996238,0.0005850257,0.001751907,0.00024082631,0.0007645779,0.0004196726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001949432,0.00031509323,0.001038694,0.0006855053,0.000057470566,0.000017607723,0.0003663646,0.0004652711,0.00072665606],"category_scores_gemma":[0.00017730052,0.00026873665,0.00024101857,0.0006005309,0.00007616463,0.00015851295,0.00017190109,0.0011421901,0.000007604972],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027176267,0.0019422419,0.0018181825,0.00037052436,0.000063200685,0.00035298316,0.00061529805,0.00014795431,0.9452274,5.1255415e-7,0.04369909,0.0030450195],"study_design_scores_gemma":[0.003130805,0.0015992203,0.001079851,0.0011424591,0.00016740938,0.000072915944,0.0010369223,0.0016811572,0.9825246,0.0000062063777,0.0073480126,0.00021047195],"about_ca_topic_score_codex":0.0011623738,"about_ca_topic_score_gemma":0.0011899236,"teacher_disagreement_score":0.0372972,"about_ca_system_score_codex":0.0026448525,"about_ca_system_score_gemma":0.0009143258,"threshold_uncertainty_score":0.99997646},"labels":[],"label_agreement":null},{"id":"W1980548940","doi":"10.1097/jto.0b013e318158d488","title":"Detection of Lung Cancer by Automated Sputum Cytometry","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Seoul National University Hospital; Universität Innsbruck; Seoul National University","keywords":"Medicine; Lung cancer; Sputum; Stage (stratigraphy); Receiver operating characteristic; Cancer; Papanicolaou stain; Internal medicine; Cytology; Lung; Pathology; Oncology; Gastroenterology; Tuberculosis; Cervical cancer; Biology","score_opus":0.01334182497883783,"score_gpt":0.4425441588071337,"score_spread":0.42920233382829587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980548940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903628,0.0048793955,0.0009485589,0.0015365008,0.0011291901,0.00014943109,0.000006705126,0.000027797842,0.00095960044],"genre_scores_gemma":[0.9977476,0.00066229864,0.00080310705,0.00025991807,0.00034264027,0.0000038757953,0.0000016425388,0.000013342259,0.00016556637],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886477,0.000051210536,0.00054954214,0.00009658031,0.0002502236,0.00018766052],"domain_scores_gemma":[0.99866194,0.00014566474,0.0006411408,0.000104082756,0.00029976666,0.00014738817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006682743,0.0000970011,0.00047762127,0.00027357848,0.00002826451,0.0000036265365,0.000061872284,0.00015047833,0.00011817509],"category_scores_gemma":[0.00006240701,0.00007115613,0.00014405156,0.00030186996,0.000046943125,0.00006429072,0.000015240049,0.00022402505,0.0000025681675],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050718402,0.002268909,0.22431695,0.0005625222,0.0017368137,0.00093827944,0.0004341867,0.000030510768,0.19162536,0.000007791125,0.039850906,0.5331559],"study_design_scores_gemma":[0.0032248416,0.006484901,0.35578498,0.0006823675,0.0021506487,0.0016615578,0.00023536345,0.00058991945,0.5892819,0.000024646937,0.039712373,0.0001664846],"about_ca_topic_score_codex":0.00007927737,"about_ca_topic_score_gemma":0.000065751825,"teacher_disagreement_score":0.53298944,"about_ca_system_score_codex":0.001453194,"about_ca_system_score_gemma":0.00029053946,"threshold_uncertainty_score":0.38000518},"labels":[],"label_agreement":null},{"id":"W1980640527","doi":"10.1097/01.jto.0000283725.33126.12","title":"P1-110: The dosimetric effects of changes in thoracic cavity fluid levels during adjuvant hemithoracic intensity modulated radiotherapy following extrapleural pneumonectomy for mesotheliomas","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Radiation therapy; Nuclear medicine; Pneumonectomy; Lung; Radiology; Internal medicine","score_opus":0.01689947741757448,"score_gpt":0.38449964888362775,"score_spread":0.3676001714660533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980640527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.894347,0.002904444,0.100696556,0.00037050078,0.00068861153,0.000898426,0.000015757096,0.000037765636,0.000040933195],"genre_scores_gemma":[0.97533,0.00010436159,0.023761205,0.000096537275,0.0005497968,0.000033750275,0.0000033541505,0.00007344932,0.000047563073],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970812,0.00038986895,0.0011070214,0.0003433633,0.00038923035,0.00068930874],"domain_scores_gemma":[0.9963893,0.0013932094,0.0013580031,0.00040692583,0.00029903496,0.00015347415],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00273411,0.00040449534,0.0013721235,0.0009797591,0.00017544847,0.000026182914,0.0005973547,0.00022846101,0.00002374508],"category_scores_gemma":[0.00013366451,0.0002970657,0.0005717795,0.0011491306,0.00015924712,0.00030922765,0.00006733077,0.0007134918,2.5317985e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002094656,0.000350569,0.022057971,0.00016079062,0.00049930386,0.00015631132,0.0011067501,0.00017909914,0.75213116,0.000025957186,0.000028628721,0.22120878],"study_design_scores_gemma":[0.001564186,0.0013548619,0.05433665,0.00033780118,0.00022268915,0.000176629,0.00027714123,0.0007285365,0.9388883,0.0008721974,0.00084557594,0.00039544504],"about_ca_topic_score_codex":0.00005157471,"about_ca_topic_score_gemma":0.000029158191,"teacher_disagreement_score":0.22081333,"about_ca_system_score_codex":0.0005375452,"about_ca_system_score_gemma":0.00015322199,"threshold_uncertainty_score":0.99994814},"labels":[],"label_agreement":null},{"id":"W1980709802","doi":"10.1097/jto.0b013e3181f77a6a","title":"Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Akaike information criterion; Quality of life (healthcare); EQ-5D; Cancer; Lung cancer; Physical therapy; Sample size determination; Clinical trial; Disease; Health related quality of life; Statistics; Internal medicine","score_opus":0.4687690010008675,"score_gpt":0.5908531953729299,"score_spread":0.12208419437206242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980709802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892739,0.0037429112,0.0005680016,0.005105207,0.0005483123,0.0004283151,0.0002524507,0.0000037348698,0.00007717184],"genre_scores_gemma":[0.9962261,0.0010524623,0.0022061695,0.0001028681,0.0003437001,0.00001269914,0.000012968439,0.000018352208,0.000024709365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99477845,0.0008686736,0.0038456225,0.00022353313,0.000116946736,0.00016675133],"domain_scores_gemma":[0.99264777,0.0013936572,0.0047503207,0.00022534997,0.0008853007,0.00009758298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017021747,0.00010200591,0.0011023832,0.00037991794,0.000073070456,0.000010650062,0.00017463914,0.00015978307,0.0002078859],"category_scores_gemma":[0.006331585,0.0001067887,0.00007190146,0.00022776949,0.00020303804,0.00023273462,0.000032701922,0.00017688854,0.000001792693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029581625,0.00045594532,0.9814731,0.00056927686,0.00013154512,3.5484325e-7,0.0047160946,0.00013298227,0.0013302912,0.001808331,0.0004170076,0.00866927],"study_design_scores_gemma":[0.00093134603,0.00046737483,0.9818506,0.0001952543,0.000025725622,0.0000010358866,0.0008050276,0.0012310935,0.0010299997,0.013009433,0.00036662334,0.000086488144],"about_ca_topic_score_codex":0.0063165682,"about_ca_topic_score_gemma":0.0024828175,"teacher_disagreement_score":0.011201101,"about_ca_system_score_codex":0.00058807904,"about_ca_system_score_gemma":0.00059641426,"threshold_uncertainty_score":0.95488036},"labels":[],"label_agreement":null},{"id":"W1981058663","doi":"10.1097/jto.0000000000000258","title":"Lung Cancer Screening Using Low-Dose Computed Tomography—Keeping Participants Out of Harm’s Way","year":2014,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Lung cancer screening; Computed tomography; Harm; Lung cancer; Do no harm; Radiology; Nuclear medicine; Medical physics; Oncology; Psychiatry","score_opus":0.05012599741904356,"score_gpt":0.4648178656712029,"score_spread":0.41469186825215937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981058663","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.084226646,0.011712918,0.0024103574,0.0011395148,0.8994606,0.00065189536,0.000110087734,0.000029074215,0.00025889865],"genre_scores_gemma":[0.2815089,0.0017158316,0.009264715,0.00031089477,0.706877,0.00003249571,0.000052866842,0.00012556244,0.00011173825],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958856,0.0004046135,0.00165817,0.00038765167,0.0010356101,0.0006283293],"domain_scores_gemma":[0.993498,0.0011013352,0.0032229475,0.00037368987,0.0013738265,0.00043019344],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014150257,0.0004417707,0.0025388945,0.0006214332,0.000102433354,0.000029735076,0.00030765723,0.0009071114,0.0001354872],"category_scores_gemma":[0.00043354637,0.0003527989,0.00074697717,0.00027459484,0.00016232699,0.00012300187,0.000121572244,0.0013850675,0.0000019051752],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004921392,0.0014554427,0.014778664,0.0033584875,0.0067412523,0.0011581139,0.0010182508,0.0016303358,0.00072113716,0.0000025920824,0.87670034,0.087513976],"study_design_scores_gemma":[0.015456542,0.008211312,0.015344582,0.050951917,0.03488311,0.00029648794,0.00034433338,0.01016464,0.0050723036,0.000049164286,0.85786027,0.0013653566],"about_ca_topic_score_codex":0.00023401609,"about_ca_topic_score_gemma":0.00013912829,"teacher_disagreement_score":0.19728224,"about_ca_system_score_codex":0.0016969849,"about_ca_system_score_gemma":0.0020880993,"threshold_uncertainty_score":0.9998924},"labels":[],"label_agreement":null},{"id":"W1982375306","doi":"10.1097/01.jto.0000283409.92625.b0","title":"PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Juravinski Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Bevacizumab; Chemotherapy; Vascular endothelial growth factor; Lung cancer; Oncology; Angiogenesis; Lung; Cancer research; Internal medicine; Pathology; VEGF receptors","score_opus":0.06686320572958923,"score_gpt":0.5102595416486647,"score_spread":0.44339633591907546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982375306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898686,0.00025998888,0.0032756878,0.0021485612,0.00047779994,0.0024963073,0.0014489831,0.0000025083543,0.000021564281],"genre_scores_gemma":[0.99445456,0.00014786074,0.0046860497,0.00018298136,0.00013007871,0.00019643804,0.0001646126,0.000020206084,0.000017208149],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9915557,0.0027905898,0.004579386,0.00024448827,0.0006306793,0.00019918793],"domain_scores_gemma":[0.98037624,0.010327132,0.0073181367,0.00016371738,0.0017037807,0.00011100582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022510016,0.00020312374,0.0026921397,0.00090094353,0.000045361125,0.0000052682176,0.00015946705,0.00018921008,0.000052728887],"category_scores_gemma":[0.005377063,0.00013205664,0.0005015955,0.0009405465,0.00012407487,0.00014074052,0.000006781803,0.00027632824,1.3483941e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08238554,0.004771713,0.08973543,0.0003242954,0.0044205706,0.000004472451,0.0015897887,0.010869062,0.78265285,0.00009975796,0.00046921129,0.022677327],"study_design_scores_gemma":[0.05102656,0.00808685,0.68345827,0.00082747923,0.0064391885,0.0000023922237,0.0011816074,0.0011894442,0.24699071,0.00006453269,0.0005017947,0.00023115957],"about_ca_topic_score_codex":0.014700284,"about_ca_topic_score_gemma":0.064777955,"teacher_disagreement_score":0.5937229,"about_ca_system_score_codex":0.0019742413,"about_ca_system_score_gemma":0.009874929,"threshold_uncertainty_score":0.99573815},"labels":[],"label_agreement":null},{"id":"W1982989334","doi":"10.1097/jto.0b013e3182333df5","title":"Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Sunitinib; Tolerability; Internal medicine; Cohort; Oncology; Pemetrexed; Mesothelioma; Progression-free survival; Surgery; Chemotherapy; Cancer; Adverse effect; Cisplatin; Pathology","score_opus":0.23668982645893433,"score_gpt":0.5433903831258738,"score_spread":0.3067005566669395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982989334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971246,0.0003593557,0.000015676787,0.0007166092,0.00047840155,0.000497004,0.000010297398,0.000004584551,0.0007934674],"genre_scores_gemma":[0.9985969,0.000075992844,0.00041611263,0.00036204467,0.0003237932,0.000010532756,0.000006224808,0.000012577669,0.00019584114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951501,0.0016473641,0.0024825437,0.00015865391,0.00039127338,0.00017005717],"domain_scores_gemma":[0.9967567,0.00082422263,0.0019054654,0.0002501982,0.00009017333,0.00017325004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007825497,0.00012841941,0.0010618793,0.00018734772,0.000055100667,0.000003435315,0.00017915526,0.00011076393,0.0005044189],"category_scores_gemma":[0.0016899813,0.00007120868,0.0003421903,0.00017109652,0.00019553669,0.000088753004,0.000086091764,0.00037007558,0.000004593717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06789097,0.06796884,0.6529203,0.00007711515,0.0010261248,0.017398281,0.0041376306,0.0000071131703,0.0041791806,0.00009165036,0.0022495054,0.18205325],"study_design_scores_gemma":[0.00978474,0.046568714,0.9286067,0.00015023533,0.0013737496,0.004176535,0.0043493453,0.000024131145,0.000583741,0.00048431635,0.0037870104,0.00011076476],"about_ca_topic_score_codex":0.00006735218,"about_ca_topic_score_gemma":0.000067686626,"teacher_disagreement_score":0.27568638,"about_ca_system_score_codex":0.00009446254,"about_ca_system_score_gemma":0.00022762029,"threshold_uncertainty_score":0.5523034},"labels":[],"label_agreement":null},{"id":"W1983722062","doi":"10.1097/jto.0b013e318217b6e0","title":"Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Chemotherapy; Odds ratio; Toxicity; Proportional hazards model; Confidence interval; Retrospective cohort study; Oncology; Gastroenterology; Surgery","score_opus":0.02202072324844074,"score_gpt":0.36501205374136464,"score_spread":0.3429913304929239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983722062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963272,0.0010881367,0.000059525293,0.00006310659,0.0002484793,0.0003553161,0.0000019079816,0.00000437366,0.0018519503],"genre_scores_gemma":[0.99811137,0.0016513454,0.00008747188,0.00005339341,0.00004190789,0.0000060668212,3.4631137e-7,0.00001160641,0.00003651782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989321,0.00012243818,0.00049673783,0.00013638883,0.00014527953,0.00016704516],"domain_scores_gemma":[0.99912226,0.000041838604,0.0005548896,0.0000811145,0.00013442892,0.00006549084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008462273,0.00011614959,0.00062215584,0.00021878215,0.00004759896,0.000005343976,0.00005183832,0.00012309867,0.000048413836],"category_scores_gemma":[0.000037085923,0.0000968679,0.00005493235,0.00018289257,0.000075769836,0.00006796105,0.000025637457,0.00030352923,1.6076719e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010363472,0.0014385529,0.9635688,0.00010126371,0.0001103063,0.000044002074,0.0024107161,0.000010725446,0.026877064,0.0000013114806,0.000030309453,0.004370601],"study_design_scores_gemma":[0.0036729332,0.0045835474,0.98678917,0.00008953445,0.00031504018,0.00004077973,0.00092533993,0.00009656331,0.0033597543,0.00002629739,0.000017501718,0.0000835643],"about_ca_topic_score_codex":0.0026321034,"about_ca_topic_score_gemma":0.0020395007,"teacher_disagreement_score":0.02351731,"about_ca_system_score_codex":0.00018510027,"about_ca_system_score_gemma":0.00023822287,"threshold_uncertainty_score":0.39789703},"labels":[],"label_agreement":null},{"id":"W1983889550","doi":"10.1097/jto.0b013e31828cb548","title":"Improving the Quality of Lung Cancer Care in Ontario: The Lung Cancer Disease Pathway Initiative","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Cancer Care Ontario; Juravinski Hospital; McMaster University; University of Toronto; Hamilton Health Sciences; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"Cancer Care Ontario","keywords":"Medicine; Multidisciplinary approach; Quality management; Cancer; Lung cancer; Health care; Disease; Family medicine; Survivorship curve; Nursing; Oncology; Internal medicine; Operations management","score_opus":0.03409029978613142,"score_gpt":0.43411762458108644,"score_spread":0.400027324794955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983889550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9660978,0.018597066,0.000012661836,0.013251591,0.0007043875,0.0007589322,0.000025799645,0.0000036327554,0.0005481803],"genre_scores_gemma":[0.99716425,0.0006259447,0.00009247602,0.0014132427,0.00027185876,0.0002685656,0.0000024781655,0.000013646603,0.0001475337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820197,0.00038431655,0.0006923614,0.00015148417,0.00033279607,0.00023709671],"domain_scores_gemma":[0.9976694,0.00047018018,0.000917023,0.00024906444,0.00054732384,0.00014702979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006031899,0.0001509249,0.0005604967,0.00007924129,0.000081510574,0.000015772948,0.00018800679,0.00008361499,0.0005966956],"category_scores_gemma":[0.00013572176,0.00007212347,0.00021241947,0.0001417639,0.00012446089,0.0001416348,0.00006486796,0.0005706049,0.0000011038939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011143445,0.00034037064,0.9392035,0.00034795038,0.0004489027,0.00009247508,0.009440749,0.00014070554,0.0001964312,0.000034886958,0.0023791704,0.046260495],"study_design_scores_gemma":[0.0012999063,0.00045797235,0.9916178,0.00064280647,0.0007677337,0.000014905191,0.0025429248,0.00016233769,0.0005852415,0.000057495763,0.0017630451,0.00008781285],"about_ca_topic_score_codex":0.10895023,"about_ca_topic_score_gemma":0.23896483,"teacher_disagreement_score":0.1300146,"about_ca_system_score_codex":0.004172984,"about_ca_system_score_gemma":0.0038409696,"threshold_uncertainty_score":0.9996498},"labels":[],"label_agreement":null},{"id":"W1984238071","doi":"10.1097/01.jto.0000283088.78970.9b","title":"PRS-03: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Gemcitabine; Tolerability; Internal medicine; Hazard ratio; Lung cancer; Clinical endpoint; Cisplatin; Oncology; Randomization; Performance status; Chemotherapy; Randomized controlled trial; Confidence interval; Adverse effect","score_opus":0.023517749746730113,"score_gpt":0.43480362599452227,"score_spread":0.41128587624779217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984238071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935104,0.00053868996,0.0017815075,0.00018441753,0.0005873206,0.0021769989,0.000028752318,0.000009991504,0.0011818842],"genre_scores_gemma":[0.9883548,0.000056294753,0.010738577,0.00012098309,0.00010786502,0.000063006424,0.000023807514,0.00004593891,0.00048871664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99715704,0.00011975807,0.0013560334,0.00031407442,0.0005974911,0.00045560673],"domain_scores_gemma":[0.9965446,0.0005192467,0.0015563484,0.00025778072,0.0008421397,0.00027991054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064380077,0.0003266309,0.0013216186,0.00059279334,0.000072987335,0.000010236171,0.00018539952,0.000115367984,0.00018605568],"category_scores_gemma":[0.00014570364,0.00021862198,0.0001215542,0.00075513753,0.00008329116,0.00019842281,0.000052522624,0.000507241,0.0000022225554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5361421,0.030895572,0.08139877,0.0010993502,0.0046879533,0.0063361456,0.034141444,0.010464619,0.002686276,0.000005520121,0.0006752381,0.29146698],"study_design_scores_gemma":[0.6241478,0.13171944,0.1797606,0.0023069098,0.014872135,0.00022489783,0.035124213,0.0040472583,0.005821493,0.000013138156,0.0010261033,0.0009359967],"about_ca_topic_score_codex":0.00030714323,"about_ca_topic_score_gemma":0.0029737402,"teacher_disagreement_score":0.290531,"about_ca_system_score_codex":0.0021754545,"about_ca_system_score_gemma":0.002437041,"threshold_uncertainty_score":0.89151454},"labels":[],"label_agreement":null},{"id":"W1984408971","doi":"10.1097/jto.0000000000000037","title":"Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Eli Lilly and Company","keywords":"Gemcitabine; Medicine; Placebo; Internal medicine; Lung cancer; Nausea; Cisplatin; Clinical endpoint; Randomization; Phases of clinical research; Performance status; Gastroenterology; Oncology; Chemotherapy; Randomized controlled trial; Pathology","score_opus":0.058801172210615704,"score_gpt":0.4491317996074688,"score_spread":0.3903306273968531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984408971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724293,0.0018866075,0.0008323154,0.008617159,0.0037640466,0.0056288727,0.000024397836,0.000029903953,0.0067874356],"genre_scores_gemma":[0.9909654,0.0006141544,0.001906443,0.0003103009,0.0020192123,0.0008620486,0.00006227268,0.00007032088,0.0031897984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958211,0.0004127854,0.0020470868,0.00042775253,0.0005757013,0.00071553857],"domain_scores_gemma":[0.9954586,0.0015206574,0.0016597011,0.00043986348,0.00053662725,0.00038453253],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019251618,0.0005076421,0.0022788383,0.00050396647,0.00048652478,0.00010911278,0.00042750474,0.00036650064,0.0007250297],"category_scores_gemma":[0.00025976167,0.00032723337,0.0005545328,0.00053374056,0.00026473438,0.00037437686,0.00017645571,0.001295099,0.00004512936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9742282,0.0016732641,0.00028076416,0.00018919843,0.0011079442,0.00034029692,0.0032612479,0.0072295438,0.00039304545,0.000026441943,0.0036128198,0.0076572387],"study_design_scores_gemma":[0.95073026,0.004289713,0.000056769484,0.00038438436,0.0038889742,0.00022374693,0.00097339205,0.035339672,0.00046692597,0.000030160903,0.0033026424,0.0003133291],"about_ca_topic_score_codex":0.0015138119,"about_ca_topic_score_gemma":0.0016791109,"teacher_disagreement_score":0.028110126,"about_ca_system_score_codex":0.002536749,"about_ca_system_score_gemma":0.0023595518,"threshold_uncertainty_score":0.999918},"labels":[],"label_agreement":null},{"id":"W1984886683","doi":"10.1097/jto.0b013e318299243b","title":"Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; EQ-5D; Quality of life (healthcare); Lung cancer; Visual analogue scale; Cross-sectional study; Internal medicine; Prospective cohort study; Disease; Health related quality of life; Physical therapy; Pathology","score_opus":0.029199908234222638,"score_gpt":0.41507218381378624,"score_spread":0.3858722755795636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984886683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969922,0.0006904007,0.0000039427036,0.0005968726,0.00018571549,0.0012571284,0.000033615815,0.0000043601217,0.00023579795],"genre_scores_gemma":[0.9988194,0.00017796968,0.00071137905,0.00014175329,0.000022693901,0.000081078986,0.00001115682,0.000013282455,0.00002124912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972578,0.00051651313,0.0014079823,0.00025716666,0.00029521398,0.00026530868],"domain_scores_gemma":[0.997036,0.00039771042,0.0015594616,0.00013438897,0.00066968123,0.00020279983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013837046,0.00015709334,0.00095270225,0.00024592192,0.00004183932,0.000010346074,0.00005595633,0.0001018968,0.000051986637],"category_scores_gemma":[0.00015739388,0.000114353905,0.00006398289,0.00036852743,0.00008809215,0.00014246201,0.000038753693,0.0004344936,4.6361887e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005860743,0.0021111686,0.9745457,0.00035363957,0.00013915704,0.0000121296835,0.0011000421,0.00014173634,0.0000074915065,0.0000014673981,0.000056829093,0.015669858],"study_design_scores_gemma":[0.006751915,0.0032483551,0.98918825,0.00040369254,0.000030233346,0.000005588483,0.00010859017,0.00009008878,0.000053870208,0.000026230056,0.0000065492777,0.00008661102],"about_ca_topic_score_codex":0.01827206,"about_ca_topic_score_gemma":0.026762677,"teacher_disagreement_score":0.015583246,"about_ca_system_score_codex":0.0022105032,"about_ca_system_score_gemma":0.0013479722,"threshold_uncertainty_score":0.99099636},"labels":[],"label_agreement":null},{"id":"W1986983880","doi":"10.1016/s1556-0864(15)31598-7","title":"Management of Unresected Stage III Non-small Cell Lung Cancer: A Systematic Review","year":2006,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Sunnybrook Health Science Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"World Health Organization","keywords":"Medicine; Radiation therapy; Lung cancer; Oncology; Regimen; Performance status; Meta-analysis; Stage (stratigraphy); Randomized controlled trial; Internal medicine; Chemoradiotherapy; Chemotherapy; Surgery","score_opus":0.034295420713152495,"score_gpt":0.44854236008149667,"score_spread":0.41424693936834417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986983880","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000036067162,0.9906776,0.000046011493,0.00025247998,0.00071077415,0.0049920497,0.000054196014,0.000010230657,0.0032205975],"genre_scores_gemma":[0.00003883666,0.9933616,0.0010261715,0.00014664169,0.00027015596,0.0005406604,0.000035629942,0.0000676002,0.004512732],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99496424,0.0005658712,0.0032232602,0.00032331116,0.00056061265,0.00036271973],"domain_scores_gemma":[0.9922915,0.00033517677,0.0060628834,0.00062542927,0.00046726,0.00021776088],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012997545,0.0005292265,0.0087012835,0.0004153456,0.00003819028,0.000011915077,0.0004179067,0.00034739246,0.00017489215],"category_scores_gemma":[0.000029320487,0.00032619873,0.0015727357,0.00054566213,0.000050203722,0.000044463482,0.000112519854,0.0006631723,0.000009622066],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006872343,0.0008113479,0.000019011513,0.8718581,0.003717876,0.0026628976,0.000023638733,0.0000020094467,1.4465114e-7,0.0000061842393,0.010392553,0.11043747],"study_design_scores_gemma":[0.00071846833,0.0007867868,0.000009846697,0.66490155,0.074410796,0.0004370094,0.000023006816,0.0000023444215,0.000004133778,0.0000010794819,0.25854912,0.00015586994],"about_ca_topic_score_codex":0.00008019919,"about_ca_topic_score_gemma":0.000031740277,"teacher_disagreement_score":0.24815658,"about_ca_system_score_codex":0.0033859406,"about_ca_system_score_gemma":0.0016887502,"threshold_uncertainty_score":0.999919},"labels":[],"label_agreement":null},{"id":"W1987517287","doi":"10.1016/s1556-0864(15)30359-2","title":"Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Lung cancer; White blood cell; Adverse effect; Odds ratio; Oncology; Chemotherapy; Logistic regression; Performance status; Stage (stratigraphy)","score_opus":0.023967493516016833,"score_gpt":0.4100761805325731,"score_spread":0.38610868701655626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987517287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582314,0.0014699781,0.00008880957,0.00007550721,0.00045474895,0.0011471153,0.00078209495,0.00001010326,0.00014849768],"genre_scores_gemma":[0.99753135,0.0008568064,0.0010081178,0.000023825125,0.00018810731,0.0000707259,0.00007276569,0.000033168835,0.0002150995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621814,0.00057272095,0.0019178112,0.0003028249,0.0005092564,0.00047926288],"domain_scores_gemma":[0.99479795,0.0004307237,0.0036388405,0.00035341896,0.00044839512,0.00033066256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005838318,0.0004151286,0.0025936603,0.0009565558,0.00004835323,0.0000034102761,0.0001842929,0.00018982362,0.00059054093],"category_scores_gemma":[0.000109319546,0.00026727526,0.00223293,0.00073832704,0.00008593184,0.0001113563,0.00003097643,0.00019842229,5.8161885e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018663825,0.004391304,0.9162067,0.00023026955,0.020709531,0.00023561656,0.0004563405,0.01756284,0.005913998,7.1568974e-7,0.00011437493,0.015514487],"study_design_scores_gemma":[0.005626434,0.0059241173,0.93390805,0.0002841047,0.03654642,0.000004805032,0.00016470338,0.0005432217,0.016716829,0.0000021286835,0.000104197235,0.0001749924],"about_ca_topic_score_codex":0.0012660644,"about_ca_topic_score_gemma":0.001617235,"teacher_disagreement_score":0.01770135,"about_ca_system_score_codex":0.0048968974,"about_ca_system_score_gemma":0.0015172948,"threshold_uncertainty_score":0.99997795},"labels":[],"label_agreement":null},{"id":"W1988111472","doi":"10.1097/jto.0000000000000060","title":"The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Cancer Care Ontario; International Association for the Study of Lung Cancer","keywords":"Medicine; Lung cancer; Lung cancer screening; Guideline; Family medicine; Scopus; Task force; Cancer; MEDLINE; Internal medicine; Pathology","score_opus":0.04299329443059084,"score_gpt":0.45288545786890394,"score_spread":0.4098921634383131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988111472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6526742,0.0003677959,0.00027542264,0.34330723,0.001879035,0.00043451635,0.0000084687235,0.000009563249,0.0010437658],"genre_scores_gemma":[0.99375266,0.00029163936,0.000712399,0.0025234288,0.0010051895,0.000088330184,0.0000030961903,0.000014751777,0.0016084949],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976346,0.0010015293,0.00054418197,0.00013638347,0.0004767703,0.00020653439],"domain_scores_gemma":[0.99618495,0.0022488607,0.0007033957,0.00022851331,0.00051533134,0.00011896937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048636026,0.000118135016,0.00030698846,0.00012332392,0.0003314592,0.00007684265,0.00030559965,0.00007498078,0.00013325152],"category_scores_gemma":[0.000664968,0.0000639667,0.00013439842,0.00017797448,0.000023681774,0.0000876902,0.00007166453,0.00044694825,0.000011803903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010063328,0.0018713914,0.48858973,0.000017097844,0.0029796946,0.00007608939,0.0039021566,0.00091940956,0.0002007864,0.00015259262,0.23724028,0.25398743],"study_design_scores_gemma":[0.0025323764,0.004043193,0.4574616,0.00022835135,0.0011802126,0.00008707651,0.005948812,0.0010564496,0.00008777451,0.00015789417,0.52709275,0.00012352892],"about_ca_topic_score_codex":0.000085606516,"about_ca_topic_score_gemma":0.00095587084,"teacher_disagreement_score":0.34107846,"about_ca_system_score_codex":0.0022255671,"about_ca_system_score_gemma":0.0004258455,"threshold_uncertainty_score":0.581978},"labels":[],"label_agreement":null},{"id":"W1988197453","doi":"10.1097/jto.0b013e318220c912","title":"Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Toronto General Hospital; McMaster University; London Health Sciences Centre; University of Toronto; Western University; University of Ottawa; Hamilton Health Sciences; University Health Network; Ottawa Hospital","funders":"","keywords":"Mediastinoscopy; Medicine; Mediastinum; Radiology; Positron emission tomography; Thoracotomy; Lung cancer; Mediastinal lymph node; Lung cancer staging; Stage (stratigraphy); Nuclear medicine; Cancer; Metastasis; Surgery; Oncology; Internal medicine","score_opus":0.02098465753425711,"score_gpt":0.33826102349993153,"score_spread":0.31727636596567443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988197453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289966,0.0025893224,0.0002066173,0.0011341628,0.0007187394,0.0016342881,0.000042598393,0.00002029779,0.0007543266],"genre_scores_gemma":[0.9943087,0.00039862152,0.0044827363,0.00017618379,0.00045888295,0.00008665809,0.00003150655,0.00004486553,0.000011818008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99507594,0.0008167651,0.0018465895,0.0005555133,0.00096439564,0.00074078585],"domain_scores_gemma":[0.99560285,0.00094599137,0.0020688085,0.00042536593,0.00053825154,0.00041876113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020272662,0.0005112765,0.0015020723,0.0018591445,0.00012999383,0.00003718406,0.0005487832,0.00027221566,0.000028987497],"category_scores_gemma":[0.00008954107,0.00032947812,0.00047266687,0.0017038152,0.00021301451,0.00026397358,0.00010189982,0.0012526,2.985104e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13003089,0.0034058527,0.83375406,0.000620386,0.00050418294,0.0018724496,0.017982224,0.00012940587,0.0046709054,0.0000025268585,0.0009706171,0.0060565243],"study_design_scores_gemma":[0.060505714,0.015544946,0.878346,0.008214503,0.0020377606,0.00029734056,0.0034328518,0.0005204044,0.03053547,0.000047240377,0.000063220155,0.00045449904],"about_ca_topic_score_codex":0.0019392279,"about_ca_topic_score_gemma":0.00077140506,"teacher_disagreement_score":0.06952517,"about_ca_system_score_codex":0.0007503654,"about_ca_system_score_gemma":0.0011273549,"threshold_uncertainty_score":0.9999157},"labels":[],"label_agreement":null},{"id":"W1988450487","doi":"10.1097/01.jto.0000283290.04435.f2","title":"D6-06: Detection of circulating tumour cells from peripheral blood samples by a novel cell concentration method and immunohistochemistry (IHC) compared with reverse transcriptase-polymerase chain reaction (RT-PCR) in Stage III/IV Non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Medicine; Immunohistochemistry; Lung cancer; Malignancy; Circulating tumor cell; Pathology; Stage (stratigraphy); Antibody; Lung; Cancer; Metastasis; Immunology; Internal medicine; Biology","score_opus":0.01105964327983354,"score_gpt":0.30762633921400845,"score_spread":0.2965666959341749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988450487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9227438,0.003801778,0.0726913,0.000046856836,0.00023496512,0.00022462323,0.00017160174,0.0000028362983,0.000082233964],"genre_scores_gemma":[0.98952657,0.0006048619,0.009342976,0.000103498714,0.00022674534,0.000008230219,0.00007796137,0.000026428668,0.00008272379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850804,0.00009700987,0.000702129,0.0002896911,0.00014090167,0.00026225153],"domain_scores_gemma":[0.9984878,0.00011234685,0.0009474312,0.000154744,0.00017328854,0.00012444844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006113099,0.00021009501,0.00043826792,0.00006656264,0.00006702168,0.000018161309,0.0001212977,0.00025324215,0.000010130665],"category_scores_gemma":[0.000026195983,0.00021287544,0.000098176504,0.000104275205,0.000075557684,0.000015804606,0.000024982317,0.00031694726,6.4006585e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020314245,0.00036123945,0.0018990232,0.000100281024,0.00008748425,0.000032485223,0.00069764775,0.001006082,0.99162203,4.918884e-7,0.000074364645,0.002087435],"study_design_scores_gemma":[0.0034431503,0.00060998934,0.0015963125,0.00010002108,0.0002898081,0.00006143725,0.0012621311,0.0009504495,0.9906723,0.000002715138,0.0007914412,0.00022023288],"about_ca_topic_score_codex":0.0022235147,"about_ca_topic_score_gemma":0.00066947157,"teacher_disagreement_score":0.066782765,"about_ca_system_score_codex":0.0002418552,"about_ca_system_score_gemma":0.0004029464,"threshold_uncertainty_score":0.86808085},"labels":[],"label_agreement":null},{"id":"W1990194589","doi":"10.1097/jto.0000000000000447","title":"Validation of a Multiprotein Plasma Classifier to Identify Benign Lung Nodules","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Medicine; Lung; Classifier (UML); Etiology; Radiology; Internal medicine; Pathology; Gastroenterology; Artificial intelligence; Computer science","score_opus":0.05853476112028652,"score_gpt":0.46342442445723653,"score_spread":0.40488966333695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990194589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98960704,0.0003284262,0.0005569145,0.00716418,0.00074444135,0.00032568848,0.000005372248,0.000006790215,0.0012611477],"genre_scores_gemma":[0.986894,0.000042330732,0.012146096,0.00022517654,0.0003752658,0.000016429309,0.0000036430074,0.000013749133,0.00028329692],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986476,0.00013775853,0.0005731838,0.00012577104,0.0003630241,0.00015269648],"domain_scores_gemma":[0.9983161,0.000118711374,0.00052520836,0.0001687802,0.0005833038,0.00028787984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075532583,0.00010587815,0.0005208918,0.0002356298,0.000020970952,0.000010228839,0.000098001496,0.00012514154,0.00006799554],"category_scores_gemma":[0.0003382066,0.000077325894,0.00014290675,0.00016015753,0.000036475645,0.00010745551,0.00003655736,0.00017748348,0.000024854058],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019253619,0.0068530003,0.2828572,0.00087513076,0.0027028928,0.0023505194,0.008293554,0.0017401461,0.07330386,0.00034142128,0.12861075,0.4728179],"study_design_scores_gemma":[0.012799179,0.021451604,0.19143029,0.0021357697,0.003462075,0.0025411446,0.0028130773,0.0007368912,0.66539973,0.00083819096,0.09594042,0.00045166575],"about_ca_topic_score_codex":0.00003227569,"about_ca_topic_score_gemma":0.000020457566,"teacher_disagreement_score":0.59209585,"about_ca_system_score_codex":0.0009146347,"about_ca_system_score_gemma":0.0005173513,"threshold_uncertainty_score":0.31532586},"labels":[],"label_agreement":null},{"id":"W1991039961","doi":"10.1097/01.jto.0000283406.00250.d4","title":"PD3-2-4: Third-line erlotinib therapy versus best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC), Canada. Is it cost effective?","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Oncology; Cost effectiveness; Internal medicine; Docetaxel; Clinical endpoint; Life expectancy; Cancer; Epidermal growth factor receptor; Randomized controlled trial","score_opus":0.024791435808955087,"score_gpt":0.3453572376271947,"score_spread":0.3205658018182396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991039961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685448,0.013273308,0.0012161229,0.0011546249,0.0043071955,0.0017297708,0.00073959,0.0000063583825,0.009028222],"genre_scores_gemma":[0.98978865,0.0039106878,0.0012381923,0.0019131409,0.0008527904,0.00015129936,0.000014194061,0.00006351156,0.0020675356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971915,0.00003401409,0.0015378555,0.00042316056,0.000069187445,0.0007442875],"domain_scores_gemma":[0.99669456,0.0005145683,0.0018949552,0.0002074626,0.00041860947,0.00026986512],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012624005,0.00023170366,0.001254689,0.00020375894,0.00015497104,0.00010035313,0.00041002827,0.0003374773,0.00039721798],"category_scores_gemma":[0.00020952764,0.0003521589,0.00026220005,0.00024207993,0.00008626315,0.0003480234,0.000044974266,0.0005749893,0.000009705112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067998725,0.0006457622,0.26601213,0.00036946774,0.00039711478,0.00040016006,0.004082609,0.0008983784,0.00010184484,0.000050454422,0.05621162,0.6640306],"study_design_scores_gemma":[0.015174282,0.0047636265,0.19828302,0.0004156668,0.00011190514,0.00005974622,0.0045816493,0.0003066716,0.0016927124,0.0003830972,0.7732354,0.0009922262],"about_ca_topic_score_codex":0.40881765,"about_ca_topic_score_gemma":0.96719176,"teacher_disagreement_score":0.7170238,"about_ca_system_score_codex":0.0032292455,"about_ca_system_score_gemma":0.0018650756,"threshold_uncertainty_score":0.99989307},"labels":[],"label_agreement":null},{"id":"W1991069433","doi":"10.1097/jto.0b013e3181a4b8e0","title":"The Management of Thymoma: A Systematic Review and Practice Guideline","year":2009,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":285,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; McMaster University; Cancer Care Ontario; London Health Sciences Centre; Toronto General Hospital; Hamilton Health Sciences; McMaster University Medical Centre; Ottawa Hospital; Kingston General Hospital","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Medicine; Stage (stratigraphy); Radiation therapy; Guideline; Thymoma; Chemoradiotherapy; Surgery; Disease; Chemotherapy; Internal medicine; Pathology","score_opus":0.053665753710472774,"score_gpt":0.5036216847042131,"score_spread":0.4499559309937403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991069433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.0005089e-7,0.986524,0.00007058616,0.0064682295,0.00023002361,0.0019933917,0.0000036036215,0.0000048420093,0.0047050514],"genre_scores_gemma":[9.5292023e-7,0.9894807,0.00804056,0.0012535971,0.00018756547,0.00002500627,0.000003927109,0.000027178638,0.0009805553],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942092,0.0013613831,0.0035607473,0.00017609612,0.0004708377,0.00022178616],"domain_scores_gemma":[0.9913254,0.0012322328,0.0060488773,0.00054507283,0.00068786286,0.00016055642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007854145,0.00031707343,0.0055300505,0.00017085478,0.000064508946,0.000017437858,0.00036622366,0.00023337176,0.000022316392],"category_scores_gemma":[0.00093824737,0.00014852216,0.0007221401,0.0003076711,0.00009265624,0.00006819105,0.00009948395,0.0006709741,0.000011811739],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007281061,0.000110147696,1.8698078e-8,0.50267917,0.0012976467,0.00067384704,0.000010092813,7.482037e-9,4.4360192e-8,0.00017185802,0.004249854,0.4907345],"study_design_scores_gemma":[0.0001247594,0.0007862063,3.0711615e-7,0.36332247,0.048734367,0.026305376,0.00007100384,3.190517e-7,4.3854968e-8,0.00005270074,0.5605405,0.00006195009],"about_ca_topic_score_codex":0.0000010058183,"about_ca_topic_score_gemma":4.962665e-7,"teacher_disagreement_score":0.5562906,"about_ca_system_score_codex":0.00020346978,"about_ca_system_score_gemma":0.00044791336,"threshold_uncertainty_score":0.6056558},"labels":[],"label_agreement":null},{"id":"W1992624894","doi":"10.1097/jto.0000000000000318","title":"Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Crizotinib; Pemetrexed; Docetaxel; Lung cancer; Internal medicine; Quality of life (healthcare); Oncology; Performance status; ALK inhibitor; Chemotherapy; Physical therapy; Nursing","score_opus":0.015420929267800036,"score_gpt":0.4012637173132929,"score_spread":0.3858427880454929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992624894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532443,0.00022372008,0.00011151679,0.00034455612,0.00009250532,0.0033515762,0.000015838908,0.00000431503,0.0005315471],"genre_scores_gemma":[0.9965681,0.00007389647,0.0029629837,0.00014144515,0.000021693373,0.00013596074,0.00001888113,0.000019128856,0.00005792946],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973916,0.0005249351,0.0014350192,0.0001848785,0.0002782519,0.0001853563],"domain_scores_gemma":[0.99622834,0.00052336906,0.0024121983,0.00014752596,0.00056735607,0.00012119558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007099682,0.00019097983,0.0021112435,0.0002529893,0.00001924605,0.0000042104984,0.000053345433,0.000095231706,0.000022162536],"category_scores_gemma":[0.00024853298,0.000110875466,0.00011581923,0.00023371386,0.00013574102,0.000087846776,0.000012162902,0.00019199,6.5933726e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53983086,0.0020281372,0.4468692,0.00016061019,0.00061152823,0.000011441318,0.0026030804,0.00007579625,0.00015813131,0.0000011613117,0.000007126069,0.007642932],"study_design_scores_gemma":[0.6572297,0.007018707,0.33272207,0.0005827067,0.0008780273,0.000005594972,0.0003544817,0.00012622034,0.0009684865,0.0000045224056,0.00001421545,0.00009522573],"about_ca_topic_score_codex":0.0007054671,"about_ca_topic_score_gemma":0.000554603,"teacher_disagreement_score":0.117398895,"about_ca_system_score_codex":0.00027106405,"about_ca_system_score_gemma":0.00080682605,"threshold_uncertainty_score":0.45213702},"labels":[],"label_agreement":null},{"id":"W1992665509","doi":"10.1097/01.jto.0000268669.64625.bb","title":"The Rationale for Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Carboplatin; Oncology; Chemotherapy; Lung cancer; Internal medicine; Stage (stratigraphy); Adjuvant; Randomized controlled trial; Clinical trial; Cancer; Adjuvant therapy; Surgery; Cisplatin","score_opus":0.02160218549280023,"score_gpt":0.4239702123905741,"score_spread":0.40236802689777385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992665509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97245276,0.006435479,0.0013669176,0.016715454,0.0007964434,0.0007278821,0.0000069175867,0.0000033869721,0.0014947376],"genre_scores_gemma":[0.9859712,0.0035894671,0.0043164,0.0019378869,0.000861226,0.000073776464,0.0000027565857,0.000021294783,0.003226005],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990592,0.00003110012,0.00044528666,0.00009682388,0.00014411725,0.00022344677],"domain_scores_gemma":[0.99871635,0.0005164174,0.00036836643,0.00010478248,0.00020164212,0.00009245387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010960354,0.000090983,0.00032478568,0.00008986396,0.00006124676,0.000009600231,0.0000881454,0.00008440006,0.00006443069],"category_scores_gemma":[0.00003169911,0.00005344269,0.0001323122,0.000092596834,0.000032825246,0.000038128856,0.0000096612375,0.00018842127,0.0000012641412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015185191,0.0030966145,0.29108542,0.0006012131,0.00074542785,0.0007779628,0.0046687904,0.00038352294,0.0058881394,0.00019184884,0.045707494,0.6316684],"study_design_scores_gemma":[0.013039541,0.0049689226,0.3094767,0.0005287039,0.0006391806,0.00019314062,0.0021440596,0.00073928456,0.05339657,0.00022541909,0.6144277,0.00022077245],"about_ca_topic_score_codex":0.000034526543,"about_ca_topic_score_gemma":0.0008743377,"teacher_disagreement_score":0.6314476,"about_ca_system_score_codex":0.0011648466,"about_ca_system_score_gemma":0.00069581886,"threshold_uncertainty_score":0.30460334},"labels":[],"label_agreement":null},{"id":"W1992981649","doi":"10.1097/01.jto.0000284357.56037.37","title":"P1-259: Patient and caregiver perceptions of symptom severity: a needs assessment in persons diagnosed with primary and metastatic brain tumours and their caregivers","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Disease; Lung cancer; Brain tumor; Family medicine; Psychiatry; Internal medicine","score_opus":0.012067099301342712,"score_gpt":0.34815082136144926,"score_spread":0.33608372206010656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992981649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313605,0.0014308918,0.0005492994,0.0038611249,0.0000810458,0.0004033392,0.000023399298,0.000005686314,0.0005091501],"genre_scores_gemma":[0.9973581,0.0007569032,0.0013150467,0.00046308717,0.000037187936,0.0000075147163,0.0000027719443,0.000014174316,0.000045242778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988237,0.00017652404,0.0004001315,0.00015284099,0.00021738147,0.00022943006],"domain_scores_gemma":[0.99849105,0.00066217495,0.0003941103,0.00007626021,0.0001971148,0.0001792989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062136847,0.00017600025,0.0007089522,0.0005496816,0.00007209687,0.000008639791,0.000035718353,0.00007461623,0.00001693824],"category_scores_gemma":[0.00008504865,0.00012574626,0.000059397607,0.00025196184,0.0004595683,0.00012815314,0.000064583146,0.00044364936,9.847872e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004167183,0.0011034517,0.5066495,0.0005820136,0.0013158463,0.0018458155,0.14674301,0.00001936937,0.0035976507,0.000014683506,0.0010925134,0.332869],"study_design_scores_gemma":[0.0030867842,0.006323072,0.781953,0.0006197086,0.0006461718,0.0021653732,0.20448007,0.000034594144,0.000099595825,0.0000183392,0.0004494671,0.00012387973],"about_ca_topic_score_codex":0.0001155614,"about_ca_topic_score_gemma":0.0003683906,"teacher_disagreement_score":0.3327451,"about_ca_system_score_codex":0.00054821954,"about_ca_system_score_gemma":0.0003827693,"threshold_uncertainty_score":0.5127784},"labels":[],"label_agreement":null},{"id":"W1994149481","doi":"10.1097/jto.0b013e3182519d4d","title":"Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Lymphoma; Medicine; Pathology; Immunohistochemistry; In situ hybridization; Lung cancer; Lung; Cancer research; Biology; Internal medicine; Gene; Gene expression","score_opus":0.018185451420730765,"score_gpt":0.3533658169457758,"score_spread":0.33518036552504504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994149481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963893,0.00155988,0.00017184344,0.00043118012,0.000288524,0.00026544364,0.0000060887874,0.000004320005,0.0008833811],"genre_scores_gemma":[0.9969395,0.00040706588,0.0020820578,0.00030273033,0.00013155722,0.000017627235,0.000023174636,0.000015798894,0.00008049903],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987751,0.00008461963,0.00059783907,0.000098460885,0.00018270442,0.00026123077],"domain_scores_gemma":[0.998747,0.00006230914,0.0007920736,0.00010473878,0.00020433131,0.00008956609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039745113,0.00013611904,0.000579307,0.00025632678,0.000038172133,0.0000056039976,0.00008050996,0.0001103692,0.00003421863],"category_scores_gemma":[0.000008314006,0.000094427414,0.000072271076,0.00020013686,0.000034197088,0.00012117809,0.00003295029,0.00012225057,0.0000018241199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012546412,0.0016768962,0.58015513,0.0003837951,0.0001750802,0.00020985499,0.0016116597,0.00000919062,0.39851028,0.00001634799,0.00003898561,0.01595811],"study_design_scores_gemma":[0.0025705632,0.0007584197,0.86278564,0.000756335,0.00039906587,0.0008464512,0.0001631919,0.000016982793,0.13058853,0.0000013689506,0.0010175969,0.00009584919],"about_ca_topic_score_codex":0.000093263785,"about_ca_topic_score_gemma":0.000031582906,"teacher_disagreement_score":0.2826305,"about_ca_system_score_codex":0.0014988381,"about_ca_system_score_gemma":0.00083009404,"threshold_uncertainty_score":0.39194095},"labels":[],"label_agreement":null},{"id":"W1996192566","doi":"10.1097/jto.0b013e3181ffe909","title":"Pharmacogenetic and Germline Prognostic Markers of Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Toronto; Cancer Care Ontario","keywords":"Pharmacogenetics; Medicine; Lung cancer; Candidate gene; Oncology; Population; Bioinformatics; Internal medicine; Genotype; Genetics; Biology; Gene","score_opus":0.03054511726158285,"score_gpt":0.4697045928526449,"score_spread":0.43915947559106205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996192566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880493,0.007282738,0.000110151654,0.0010207753,0.0003848512,0.00020802021,0.000006857755,0.000003851451,0.0029334133],"genre_scores_gemma":[0.9934802,0.0010742954,0.004728803,0.00024201209,0.0001388685,0.000008872313,0.0000010086287,0.000009604336,0.00031633908],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993477,0.000047995043,0.00032456417,0.0000696957,0.00010408017,0.00010596531],"domain_scores_gemma":[0.9992138,0.000055772467,0.00034363312,0.000057634115,0.00021051939,0.00011863659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016964946,0.00007020799,0.00029755096,0.00011686852,0.000020229585,0.0000017308327,0.00004131671,0.000050626328,0.0003829028],"category_scores_gemma":[0.000038475875,0.0000494147,0.00006373461,0.00008408113,0.00007344704,0.00004528242,0.000014538964,0.00011543247,7.3598903e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050607715,0.001141219,0.47830698,0.00058123755,0.002228832,0.00076915155,0.002780275,0.000010637471,0.011620438,0.00002075432,0.003996105,0.4934836],"study_design_scores_gemma":[0.0057233176,0.00851926,0.9302594,0.00086807436,0.013587094,0.0035256871,0.0006642324,0.00045196412,0.017360112,0.00024732781,0.018577164,0.00021636291],"about_ca_topic_score_codex":0.000027346985,"about_ca_topic_score_gemma":0.000007576836,"teacher_disagreement_score":0.49326724,"about_ca_system_score_codex":0.00011772092,"about_ca_system_score_gemma":0.0004725414,"threshold_uncertainty_score":0.4192517},"labels":[],"label_agreement":null},{"id":"W1997036848","doi":"10.1097/jto.0b013e31820d782d","title":"Selecting Patients with Extensive-Stage Small Cell Lung Cancer for Prophylactic Cranial Irradiation by Predicting Brain Metastases","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Stage (stratigraphy); Lung cancer; Radiology; Lung; Oncology; Brain metastasis; Cancer; Internal medicine; Metastasis","score_opus":0.03521243200563374,"score_gpt":0.4076535004350479,"score_spread":0.37244106842941416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997036848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935594,0.0013644184,0.0017265729,0.0012152141,0.0004202165,0.0011568759,0.000057921057,0.000019413563,0.00047994833],"genre_scores_gemma":[0.9877897,0.000055560824,0.010533812,0.00043170518,0.0004808456,0.00007542271,0.00000903332,0.000041365816,0.00058255595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826956,0.00021837177,0.00050621765,0.000214603,0.00038278487,0.00040849292],"domain_scores_gemma":[0.99686664,0.0004801618,0.0009359613,0.0001164282,0.0014128741,0.00018792797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089271605,0.00017557378,0.0005751144,0.00020114385,0.00016981953,0.000015775751,0.00011899523,0.00009319988,0.000065141954],"category_scores_gemma":[0.0010706369,0.000122017715,0.00010999121,0.00020819079,0.00007925538,0.00020586458,0.00003930945,0.00047178112,7.589098e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038531844,0.002559235,0.8055092,0.0035853875,0.0022467112,0.00036057227,0.010276657,0.000109268214,0.018069156,0.000007476567,0.0220943,0.0966502],"study_design_scores_gemma":[0.044726554,0.10753964,0.6993203,0.002369396,0.012433001,0.00065442314,0.0086216545,0.0047280174,0.07616723,0.0001675232,0.04160187,0.0016703599],"about_ca_topic_score_codex":0.00014263764,"about_ca_topic_score_gemma":0.00010994654,"teacher_disagreement_score":0.10618887,"about_ca_system_score_codex":0.0008182323,"about_ca_system_score_gemma":0.0010088622,"threshold_uncertainty_score":0.4975738},"labels":[],"label_agreement":null},{"id":"W1997170706","doi":"10.1097/01.jto.0000284095.28451.43","title":"P3-120: Response rates of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) in clinical practice","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Erlotinib; Gefitinib; Oncology; Internal medicine; Lung cancer; Chemotherapy; Erlotinib Hydrochloride; Progression-free survival; Cancer; Epidermal growth factor receptor","score_opus":0.0665285186272268,"score_gpt":0.555089055594481,"score_spread":0.48856053696725416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997170706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503155,0.0024768033,0.00029901986,0.0087726265,0.0007444861,0.0010456896,0.000012430394,0.0000072949665,0.001610075],"genre_scores_gemma":[0.9686876,0.0021203174,0.02514727,0.0028669038,0.0003148001,0.000037213602,0.0000049236614,0.000030745225,0.00079023716],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965133,0.0005794378,0.001945788,0.00026131605,0.0003112878,0.00038887895],"domain_scores_gemma":[0.994631,0.0027985717,0.0012975245,0.00023380117,0.0007322732,0.00030683872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004498798,0.00020762357,0.0010584608,0.0005277578,0.000033093424,0.000009809081,0.00018265039,0.00021038923,0.00015801715],"category_scores_gemma":[0.001270509,0.00014747729,0.00017400079,0.0006032555,0.00007536855,0.00016536507,0.000029001982,0.0006773714,0.0000070173714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51881355,0.009967258,0.16155216,0.00021918629,0.0006830278,0.0075724814,0.010425802,0.0018299826,0.028855471,0.000012931384,0.0012285665,0.2588396],"study_design_scores_gemma":[0.038153537,0.034875717,0.7900962,0.002090139,0.0010851069,0.0013986318,0.009535786,0.00031735055,0.034451503,0.000044514807,0.08748711,0.00046435912],"about_ca_topic_score_codex":0.00029310797,"about_ca_topic_score_gemma":0.0010902107,"teacher_disagreement_score":0.6285441,"about_ca_system_score_codex":0.00094911375,"about_ca_system_score_gemma":0.0036821414,"threshold_uncertainty_score":0.6531961},"labels":[],"label_agreement":null},{"id":"W1997931731","doi":"10.1016/s1556-0864(15)31530-6","title":"Association between Anemia Arising during Therapy and Outcomes of Chemoradiation for Limited Small-cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Anemia; Internal medicine; Hazard ratio; Lung cancer; Radiation therapy; Oncology; Univariate analysis; Hemoglobin; Proportional hazards model; Chemoradiotherapy; Cancer; Epoetin alfa; Multivariate analysis; Confidence interval","score_opus":0.023884234809759177,"score_gpt":0.376553467999584,"score_spread":0.35266923318982485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997931731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098414,0.00190727,0.00011156223,0.00639669,0.00015743659,0.00022795354,0.00000730081,0.0000069792773,0.00020065764],"genre_scores_gemma":[0.9908431,0.00072383386,0.0070651965,0.00009108377,0.00049515476,0.0000056274494,0.000009034681,0.000013492108,0.0007534465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911845,0.000053023166,0.00045861056,0.00008735443,0.00013925007,0.0001432936],"domain_scores_gemma":[0.9984391,0.00030089077,0.0009215945,0.000058000824,0.00022796738,0.00005245121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038051617,0.00009583342,0.00050217664,0.00012405,0.000050560026,0.000007679682,0.00003414755,0.00016591557,0.000015114571],"category_scores_gemma":[0.00006408154,0.0000728188,0.00011435257,0.00007584177,0.000019566429,0.0000499167,0.00000824793,0.00015236523,1.8066828e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042057823,0.00022889604,0.9539379,0.0002071251,0.0002475183,0.000013237447,0.00022494512,0.000020445761,0.021612221,0.000002314201,0.0005515987,0.022533251],"study_design_scores_gemma":[0.0037569301,0.0007161358,0.92215294,0.000102782535,0.0008243544,0.00003338455,0.00010840037,0.000056477,0.07129883,0.00006896836,0.00081000687,0.000070806454],"about_ca_topic_score_codex":0.00006036403,"about_ca_topic_score_gemma":0.000017001084,"teacher_disagreement_score":0.04968661,"about_ca_system_score_codex":0.00060106855,"about_ca_system_score_gemma":0.00015186248,"threshold_uncertainty_score":0.29694647},"labels":[],"label_agreement":null},{"id":"W1998814098","doi":"10.1097/jto.0b013e3181f8a298","title":"Exercise Capacity, Lung Function, and Quality of Life After Interventional Bronchoscopy","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Tracheal and airway disorders","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Medical Research Council; Health Research Board","keywords":"Medicine; Spirometry; Quality of life (healthcare); Lung cancer; Airway obstruction; Prospective cohort study; Cohort; Internal medicine; Airway; Physical therapy; Surgery; Asthma","score_opus":0.03081435813309142,"score_gpt":0.400684961662911,"score_spread":0.3698706035298196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998814098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379903,0.0013846569,0.00056098896,0.0027448952,0.0008593799,0.000093088755,0.0000061670603,0.000005948361,0.00054585346],"genre_scores_gemma":[0.9962926,0.00006998698,0.0028147376,0.0002865585,0.00027384577,0.0000033007657,0.000001599762,0.0000079827505,0.00024938773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988103,0.00008747035,0.00066962733,0.00009745552,0.00021269063,0.00012247378],"domain_scores_gemma":[0.9988164,0.00009201546,0.00048980786,0.00010369185,0.0002924892,0.00020560468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081636145,0.00008930418,0.00048365325,0.00013578818,0.00002625715,0.000005999529,0.00006310159,0.00016033545,0.00072432094],"category_scores_gemma":[0.00022940717,0.00006803049,0.00018461802,0.00007835704,0.00018824797,0.000115849914,0.00003022504,0.0005543332,0.00000421293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021195138,0.0030930361,0.7605045,0.0016099691,0.00043134863,0.000031204952,0.0007429142,0.0000037649352,0.045035247,0.0006561701,0.00509606,0.16160066],"study_design_scores_gemma":[0.0015602258,0.0017822513,0.98751307,0.00022852991,0.00031633858,0.00013668824,0.00024711541,0.000015335443,0.0007410934,0.001388541,0.005987744,0.00008309889],"about_ca_topic_score_codex":0.000031900778,"about_ca_topic_score_gemma":0.00010628829,"teacher_disagreement_score":0.22700855,"about_ca_system_score_codex":0.00003144145,"about_ca_system_score_gemma":0.00020437363,"threshold_uncertainty_score":0.7930806},"labels":[],"label_agreement":null},{"id":"W1999131323","doi":"10.1097/jto.0b013e318187220f","title":"Targeting Angiogenesis in the Treatment of Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bevacizumab; Sunitinib; Vandetanib; Sorafenib; Lung cancer; Angiogenesis; Oncology; Internal medicine; Cancer; Clinical trial; Vascular endothelial growth factor; Chemotherapy; Pharmacology; VEGF receptors","score_opus":0.06417265380548509,"score_gpt":0.4929776811005017,"score_spread":0.4288050272950166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999131323","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015070387,0.9971493,0.000012290515,0.00060674216,0.00009743252,0.00025146833,0.00001602499,0.0000024522535,0.0003572651],"genre_scores_gemma":[0.00030478652,0.99822104,0.00035649142,0.00013171663,0.00071042177,0.000024014798,0.0000156897,0.00001662926,0.00021922748],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977327,0.0005328492,0.0011850039,0.00012058727,0.00025938568,0.00016947692],"domain_scores_gemma":[0.9977672,0.00032009694,0.0015197168,0.00015776485,0.00016035241,0.000074856536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041237203,0.0002059685,0.0023903097,0.0005689921,0.00003360396,0.000003771699,0.00013594746,0.00024645525,0.00020703314],"category_scores_gemma":[0.00006523436,0.000104753584,0.0013676339,0.00051241834,0.00006581343,0.000029027497,0.00000920023,0.0002620176,0.0000034796867],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007753643,0.0008023019,0.00016275852,0.002090241,0.0007593993,0.0014474402,0.00040626066,0.000007344351,0.0000101608075,0.0000011068292,0.0035792908,0.99065614],"study_design_scores_gemma":[0.0003246522,0.00083282666,0.000041228705,0.010350692,0.0039210515,0.002343073,0.000126145,0.000013767532,0.000011715432,0.0000017148858,0.98195016,0.0000829479],"about_ca_topic_score_codex":0.00003437196,"about_ca_topic_score_gemma":0.000018215578,"teacher_disagreement_score":0.9905732,"about_ca_system_score_codex":0.00078610406,"about_ca_system_score_gemma":0.0010547749,"threshold_uncertainty_score":0.42717272},"labels":[],"label_agreement":null},{"id":"W1999718617","doi":"10.1097/jto.0b013e318074bba7","title":"Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; DLCO; Lung cancer; Thoracotomy; Spirometry; Surgery; Lung cancer surgery; Cardiorespiratory fitness; Prospective cohort study; Diffusing capacity; Internal medicine; Lung","score_opus":0.037018675416541004,"score_gpt":0.4508333146619192,"score_spread":0.4138146392453782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999718617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9087922,0.003965065,0.0015247463,0.005613564,0.0011905626,0.07657348,0.00007162209,0.000020848342,0.0022478977],"genre_scores_gemma":[0.9862736,0.00039047474,0.0033565424,0.0001307381,0.00051704847,0.009082775,0.0000037580419,0.00001933836,0.0002257122],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984578,0.00005933422,0.00074536155,0.0001735757,0.000356118,0.00020782925],"domain_scores_gemma":[0.9979804,0.0001488863,0.00073209754,0.00012083546,0.0008615511,0.00015623341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019658296,0.00013181499,0.0005496748,0.00017284759,0.000064245156,0.0000088428405,0.00005583643,0.0001312092,0.000016356225],"category_scores_gemma":[0.0001715231,0.00008945052,0.000108722525,0.0001218211,0.00006502782,0.000099013305,0.000020243326,0.00018865007,2.6526902e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23398949,0.0028677215,0.108801894,0.0037671437,0.002173866,0.00034888063,0.0052248402,0.00015140185,0.012599918,0.00006173694,0.04977091,0.5802422],"study_design_scores_gemma":[0.054114744,0.056258038,0.3324338,0.011989313,0.005780934,0.00065306586,0.0020326306,0.0007450266,0.41184327,0.00031440015,0.1232745,0.0005602992],"about_ca_topic_score_codex":0.00030840255,"about_ca_topic_score_gemma":0.002328951,"teacher_disagreement_score":0.5796819,"about_ca_system_score_codex":0.0034524107,"about_ca_system_score_gemma":0.00087712886,"threshold_uncertainty_score":0.9027934},"labels":[],"label_agreement":null},{"id":"W2000895546","doi":"10.1097/jto.0b013e3182199a99","title":"CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Tissue microarray; CXCR4; Oncology; Internal medicine; Stage (stratigraphy); Immunohistochemistry; Population; Cancer; Stromal cell; Pathology; Chemokine; Receptor; Biology","score_opus":0.04665558690820787,"score_gpt":0.38109939794316855,"score_spread":0.3344438110349607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000895546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964407,0.0004395853,0.00017161031,0.00050590874,0.00015906797,0.00027095832,0.000008549144,0.0000107583555,0.0019928368],"genre_scores_gemma":[0.9946562,0.00012494637,0.0027752216,0.0005895735,0.00019128936,0.000010897759,0.0000031958607,0.000038049282,0.0016106454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839383,0.00012162212,0.000634781,0.0001950292,0.00031936748,0.00033536492],"domain_scores_gemma":[0.99822044,0.00020874341,0.000938937,0.00014177413,0.00028089446,0.00020919336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006138035,0.0002126653,0.00087349786,0.0002370854,0.000045123816,0.000010455369,0.00014410348,0.00023291641,0.00076552597],"category_scores_gemma":[0.00008498242,0.00012962347,0.00011819296,0.00024344362,0.00006042511,0.00011505212,0.000038190206,0.00069806847,0.0000027833255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035180876,0.0008760004,0.9715443,0.00019863872,0.00018266405,0.0019098935,0.003126217,0.000039243085,0.015725717,7.9053484e-7,0.0008019117,0.0020764915],"study_design_scores_gemma":[0.012265448,0.0072597084,0.8297004,0.0054976987,0.001168701,0.00045858926,0.0031801888,0.0008426559,0.13630871,0.000014026475,0.0027219662,0.00058189227],"about_ca_topic_score_codex":0.00022112414,"about_ca_topic_score_gemma":0.00032228773,"teacher_disagreement_score":0.14184393,"about_ca_system_score_codex":0.00054908585,"about_ca_system_score_gemma":0.0005747041,"threshold_uncertainty_score":0.8381973},"labels":[],"label_agreement":null},{"id":"W2001086187","doi":"10.1097/jto.0000000000000453","title":"Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned","year":2014,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ablative case; Medicine; Radiation therapy; Lung cancer; Stage (stratigraphy); Radiology; SABR volatility model; Radiosurgery; Lung; Oncology; Internal medicine","score_opus":0.05489329028154382,"score_gpt":0.4625472785839474,"score_spread":0.40765398830240357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001086187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008430955,0.99030906,0.0006602224,0.0026735475,0.002152697,0.003098295,0.000047565183,0.0000178604,0.00019765634],"genre_scores_gemma":[0.00030336218,0.9917318,0.002107782,0.00048193807,0.0013995627,0.00031104323,0.00004216171,0.0001573329,0.0034650126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962756,0.00056655024,0.0016192952,0.0005098628,0.00037925458,0.0006494624],"domain_scores_gemma":[0.9938943,0.0010699877,0.003535979,0.00044204132,0.0005966951,0.0004609964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008958836,0.00068424264,0.004701956,0.00045170446,0.00010112717,0.00012815685,0.00036514725,0.0007255536,0.00025754966],"category_scores_gemma":[0.000056380642,0.00046610078,0.0014130714,0.00021505925,0.00009468672,0.00026298143,0.000041296425,0.0010933876,0.000009123452],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014584895,0.0008308964,0.00038664232,0.025082381,0.0064229732,0.00052791537,0.0008026863,0.000018343057,0.0000031729023,0.000003666597,0.0031064807,0.96135634],"study_design_scores_gemma":[0.0034889418,0.0065987147,0.00007256684,0.033575,0.014869382,0.00042449773,0.00016896424,0.00009563183,0.00003739026,0.000009757511,0.9402885,0.00037066496],"about_ca_topic_score_codex":0.00008527702,"about_ca_topic_score_gemma":0.00010637607,"teacher_disagreement_score":0.96098566,"about_ca_system_score_codex":0.005699938,"about_ca_system_score_gemma":0.0038481746,"threshold_uncertainty_score":0.99977905},"labels":[],"label_agreement":null},{"id":"W2001512292","doi":"10.1097/jto.0b013e3182049d8b","title":"Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Brock University; Juravinski Cancer Centre","funders":"U.S. Department of Veterans Affairs","keywords":"Lovastatin; Clonogenic assay; Cancer research; Protein kinase B; Radioresistance; AMPK; Medicine; Biology; Phosphorylation; Apoptosis; Cell biology; Protein kinase A; Endocrinology; Internal medicine; Biochemistry; Cholesterol; Radiation therapy","score_opus":0.014673293544814637,"score_gpt":0.3219560555189213,"score_spread":0.3072827619741067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001512292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98571545,0.0057999957,0.0058821538,0.00008968315,0.0022139389,0.00012679162,0.000026119316,0.0000016867157,0.0001441902],"genre_scores_gemma":[0.98670787,0.00085945555,0.011086618,0.00010291445,0.0011904704,0.0000034644024,0.0000034891057,0.0000133152025,0.00003238978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989543,0.00015118458,0.00047361845,0.00014568743,0.00014101129,0.00013417247],"domain_scores_gemma":[0.9988044,0.000023473078,0.0006448808,0.00014062987,0.00028910773,0.000097546756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037064907,0.00010447476,0.00035072217,0.00010608338,0.00002653653,0.000003925982,0.000098600955,0.00009703737,0.000018865972],"category_scores_gemma":[0.00007066923,0.00009468692,0.00009085052,0.00008943948,0.000064991036,0.000010918552,0.0000441423,0.000086002656,1.6470719e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009199361,0.000055579756,0.0006788088,0.000086707776,0.0000629791,0.000002864966,0.00068736146,0.00056010374,0.9692932,0.000027704038,0.0021508122,0.025473945],"study_design_scores_gemma":[0.0004704447,0.00047379808,0.012868143,0.00010200713,0.0001090137,0.000058257603,0.00020322955,0.00016125228,0.97683465,0.000068207526,0.008545349,0.00010562738],"about_ca_topic_score_codex":0.000031091542,"about_ca_topic_score_gemma":0.000018490156,"teacher_disagreement_score":0.025368318,"about_ca_system_score_codex":0.000035435427,"about_ca_system_score_gemma":0.00022759325,"threshold_uncertainty_score":0.38612205},"labels":[],"label_agreement":null},{"id":"W2002071677","doi":"10.1097/jto.0000000000000159","title":"Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Pneumonectomy; Pneumonitis; Confidence interval; Surgery; Hazard ratio; Population; Malignancy; Radiosurgery; Lung; Adverse effect; Radiation therapy; Radiology; Internal medicine","score_opus":0.008373289657794636,"score_gpt":0.3506350327415202,"score_spread":0.34226174308372553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002071677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954327,0.0006882928,0.000048919574,0.0028665792,0.00017295855,0.00030062193,9.990098e-7,0.00000523993,0.00048371663],"genre_scores_gemma":[0.9976757,0.00062946434,0.00097262365,0.0005049686,0.00014637237,0.0000035823325,0.0000016610174,0.000015696107,0.000049897255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990032,0.00016801392,0.0003654174,0.00012852148,0.00017826521,0.00015660214],"domain_scores_gemma":[0.99904734,0.0002416218,0.00033632864,0.00013567555,0.000103903665,0.00013515505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035385138,0.00011554832,0.00058821356,0.00013898715,0.00002496014,0.000009550485,0.00004999652,0.000072592135,0.0000332716],"category_scores_gemma":[0.000057445188,0.00007104277,0.00005338637,0.000093419345,0.000044117853,0.00007370655,0.000011744834,0.0002224512,0.0000018271672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008503211,0.0015934779,0.80240166,0.0000639188,0.00031756642,0.00012490898,0.00030171496,0.000010307614,0.000023552302,0.000011263374,0.00015296692,0.18649548],"study_design_scores_gemma":[0.009060211,0.01283544,0.95652056,0.00028748333,0.00030764216,0.00023519817,0.0000112148,0.000023617651,0.000047273552,0.0000116064675,0.020589398,0.000070331436],"about_ca_topic_score_codex":0.000009127562,"about_ca_topic_score_gemma":0.000016128271,"teacher_disagreement_score":0.18642515,"about_ca_system_score_codex":0.0006529538,"about_ca_system_score_gemma":0.00014572119,"threshold_uncertainty_score":0.289704},"labels":[],"label_agreement":null},{"id":"W2002302492","doi":"10.1097/jto.0b013e31822e28fc","title":"Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome","year":2011,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb","keywords":"Medicine; Immunotherapy; Oncology; Lung cancer; Immune system; Antigen; Immunology; Vaccine therapy; Internal medicine; Clinical trial","score_opus":0.11005115657962596,"score_gpt":0.39440373266210527,"score_spread":0.2843525760824793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002302492","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082586956,0.98433024,0.0032089623,0.00015841915,0.008135346,0.0027138921,0.00026573145,0.00002398987,0.00033757585],"genre_scores_gemma":[0.00014890936,0.9888525,0.0044429726,0.00038417714,0.00032240295,0.0006533175,0.00004596498,0.00018089988,0.0049688607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947395,0.0008045133,0.0029186069,0.00055051834,0.00007373511,0.00091315963],"domain_scores_gemma":[0.99390376,0.0010273926,0.0039698286,0.0006978881,0.00031382078,0.00008732982],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016290151,0.00089083606,0.0045415116,0.00085640646,0.00025488128,0.000036139303,0.0013859015,0.0017012564,0.00031307715],"category_scores_gemma":[0.000120228615,0.000647321,0.0020861982,0.00030019105,0.00017999926,0.00013241479,0.00019626935,0.0016275548,0.000082752726],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038750044,0.0009570432,0.000007851921,0.0042528203,0.0024189488,0.000011808628,0.0012560069,0.0000020769503,0.0046585756,0.000030754618,0.0020807865,0.9804483],"study_design_scores_gemma":[0.0015124421,0.004848412,0.000009813921,0.002567816,0.0019458566,0.00063058647,0.00017911076,8.4502017e-7,0.0031042183,0.000010784123,0.9845246,0.0006655071],"about_ca_topic_score_codex":0.000051375242,"about_ca_topic_score_gemma":0.0000086382015,"teacher_disagreement_score":0.9824438,"about_ca_system_score_codex":0.0008066668,"about_ca_system_score_gemma":0.0020689538,"threshold_uncertainty_score":0.9995978},"labels":[],"label_agreement":null},{"id":"W2002419738","doi":"10.1097/jto.0b013e3182208ee0","title":"Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T-Cell Depletion in a Murine Mesothelioma Model","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Mesothelioma Applied Research Foundation","keywords":"Cancer research; FOXP3; CD8; Cisplatin; Medicine; Flow cytometry; IL-2 receptor; Cytotoxic T cell; T cell; Regulatory T cell; Immunology; Biology; Chemotherapy; Immune system; Internal medicine","score_opus":0.026372478909632815,"score_gpt":0.34288822936882474,"score_spread":0.31651575045919195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002419738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978968,0.00032490536,0.00024106876,0.0003085259,0.000036963193,0.0001409774,0.000017281121,0.000006085683,0.0010274026],"genre_scores_gemma":[0.99451613,0.00005562714,0.004763336,0.00031760568,0.0000634765,0.0000025441398,0.000019616617,0.000018056327,0.00024357576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987363,0.000076386044,0.0006779836,0.00012513528,0.00026286303,0.000121299294],"domain_scores_gemma":[0.9989636,0.000033931097,0.0007092881,0.00012654437,0.00005772943,0.00010893367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000300709,0.00011038593,0.00039269176,0.00022898712,0.000018671415,0.0000017171999,0.00007134526,0.000104112136,0.00013762475],"category_scores_gemma":[0.000016716018,0.00009252383,0.00012290734,0.00012508276,0.000072888775,0.0001055867,0.000019310683,0.00015116856,0.0000045864667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036302127,0.0019024039,0.79866993,0.00017676438,0.000047739326,0.00007198828,0.0008491098,0.00011193087,0.18539667,0.0000051116476,0.0015786501,0.007559477],"study_design_scores_gemma":[0.0013726262,0.0010518235,0.7830961,0.000094625604,0.00015663539,0.000073246716,0.0001431305,0.00069738313,0.21227361,0.0008019511,0.00015347028,0.00008539573],"about_ca_topic_score_codex":0.00004127936,"about_ca_topic_score_gemma":0.000003242346,"teacher_disagreement_score":0.026876941,"about_ca_system_score_codex":0.0002271605,"about_ca_system_score_gemma":0.000099348916,"threshold_uncertainty_score":0.37730122},"labels":[],"label_agreement":null},{"id":"W2002999774","doi":"10.1097/jto.0b013e3181ccbaa9","title":"Persistent Confusion on the Clinical and Pathologic Nodal Staging in Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Lung cancer; Citation; Cancer staging; Oncology; Cancer; Internal medicine; Library science","score_opus":0.04759238100245223,"score_gpt":0.4761266340571598,"score_spread":0.4285342530547076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002999774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504209,0.0007427502,0.000002970242,0.046609607,0.001075944,0.00018274663,0.0000022722195,0.000003157749,0.0009596127],"genre_scores_gemma":[0.9952308,0.0013911503,0.00034948642,0.0025088668,0.00041562153,0.000010850747,4.378754e-7,0.0000067142437,0.00008605126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989977,0.00017551024,0.0004061807,0.00012598734,0.00015207783,0.00014253032],"domain_scores_gemma":[0.99896276,0.00044616815,0.00026726598,0.00012091021,0.00009575484,0.000107149295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001266054,0.00008594258,0.00037430707,0.000081146696,0.000048066577,0.000010015043,0.00006771728,0.00012886795,0.0001886174],"category_scores_gemma":[0.00017829298,0.000043799104,0.00013984382,0.000059840095,0.00013581205,0.000029659568,0.00003482142,0.0007952215,0.000002073372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011668958,0.000736282,0.847001,0.000040306284,0.0001336221,0.0011757757,0.0004974789,0.00000774482,0.0006859846,0.0001365749,0.0025501393,0.14586818],"study_design_scores_gemma":[0.0028415772,0.004841753,0.9651501,0.0004916997,0.0006704768,0.0012240682,0.00076629216,0.00038317658,0.0004219468,0.00013219443,0.02296975,0.000106936954],"about_ca_topic_score_codex":0.000030545056,"about_ca_topic_score_gemma":0.00014651385,"teacher_disagreement_score":0.14576125,"about_ca_system_score_codex":0.00021606527,"about_ca_system_score_gemma":0.0002886123,"threshold_uncertainty_score":0.34548858},"labels":[],"label_agreement":null},{"id":"W2003069503","doi":"10.1097/jto.0000000000000235","title":"Circulating Tumor Microemboli Diagnostics for Patients with Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"National Center for Research Resources; University of California, San Diego; National Cancer Institute; National Institutes of Health; Vetenskapsrådet; Université de Sherbrooke; Thailand Science Research and Innovation; National Center for Advancing Translational Sciences; Canary Foundation; LUNGevity Foundation","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Receiver operating characteristic; Cancer; Internal medicine; Circulating tumor cell; Cytokeratin; Phlebotomy; Oncology; Radiology; Area under the curve; Pathology; Metastasis; Immunohistochemistry","score_opus":0.01194024365796291,"score_gpt":0.3634783727508102,"score_spread":0.35153812909284726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003069503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99423796,0.0007932554,0.0012465826,0.0016421248,0.0007168375,0.00063916354,0.000014340837,0.000007603178,0.00070211967],"genre_scores_gemma":[0.9862794,0.00019210244,0.011409973,0.0011524836,0.0007631036,0.00007416123,0.00000788293,0.000034949066,0.00008592577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988502,0.000056479475,0.000453024,0.00016767965,0.00019475569,0.00027781655],"domain_scores_gemma":[0.99785006,0.0005286723,0.0006907664,0.00015262014,0.000582232,0.00019563593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002901234,0.00016324346,0.00061569037,0.000109501794,0.00007418603,0.000014710771,0.00009423102,0.0000830331,0.00003930545],"category_scores_gemma":[0.00016069318,0.000109043925,0.00014956378,0.00009264895,0.000038156897,0.000054865224,0.000023467712,0.00020799093,0.0000023244374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013572052,0.0019236065,0.931586,0.0007055294,0.0004755132,0.00017863922,0.00038882694,0.00017052358,0.00024275153,0.000012371913,0.008184149,0.054774832],"study_design_scores_gemma":[0.022475284,0.023038782,0.86680645,0.003211415,0.009260007,0.00060159323,0.00026043374,0.0018280174,0.008558589,0.00014216578,0.063229844,0.0005874441],"about_ca_topic_score_codex":0.000024222058,"about_ca_topic_score_gemma":0.00003943777,"teacher_disagreement_score":0.06477963,"about_ca_system_score_codex":0.0007908583,"about_ca_system_score_gemma":0.00048762443,"threshold_uncertainty_score":0.44466823},"labels":[],"label_agreement":null},{"id":"W2003360283","doi":"10.1097/jto.0000000000000196","title":"Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Royal Columbian Hospital; University Health Network","funders":"Ontario Ministry of Health and Long-Term Care; AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Histology; Population; Pathology; Mutation; Lung cancer; Cytology; Internal medicine; Adenocarcinoma; Mutation testing; Epidermal growth factor receptor; Oncology; Cancer; Biology; Gene; Genetics","score_opus":0.02377364564514958,"score_gpt":0.4344116558714719,"score_spread":0.41063801022632235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003360283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947882,0.00008796632,0.0014715561,0.0024635019,0.00014960062,0.00014926295,0.000005517598,0.000011077377,0.0008732629],"genre_scores_gemma":[0.98847324,0.0000013394248,0.010836228,0.0004198916,0.000120002966,0.0000061645173,0.00006194016,0.00001166969,0.000069532965],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991452,0.00015141086,0.00031402282,0.00008746678,0.00017031204,0.00013156043],"domain_scores_gemma":[0.9979776,0.0010731446,0.00047903095,0.000064713466,0.0003350149,0.00007045201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041800347,0.00008371741,0.00031141556,0.0002118748,0.000056121953,0.000014922139,0.000044202865,0.00008338514,0.000024003817],"category_scores_gemma":[0.0015791537,0.00005724302,0.00003959176,0.00029819275,0.000022595028,0.00009920104,0.0000041485214,0.00019455681,9.348158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005216623,0.00036078444,0.9322727,0.00003158501,0.000112188194,0.00013054846,0.00023006035,0.003848135,0.00016702827,0.00003570012,0.00011383336,0.06217581],"study_design_scores_gemma":[0.0018936485,0.0019292912,0.99244887,0.0002999318,0.00034336778,0.00014654214,0.00009991482,0.0017734801,0.0002861089,0.00045323154,0.00026237758,0.000063221465],"about_ca_topic_score_codex":0.00042173706,"about_ca_topic_score_gemma":0.00068037986,"teacher_disagreement_score":0.06211259,"about_ca_system_score_codex":0.000577702,"about_ca_system_score_gemma":0.00043320042,"threshold_uncertainty_score":0.23343027},"labels":[],"label_agreement":null},{"id":"W2003901423","doi":"10.1097/01.jto.0000283006.34791.31","title":"E05-06: Clinical staging of small cell lung cancer: report of the International Association for the Study of Lung Cancer Staging Initiative, Small Cell Lung Cancer Subcommittee","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; TNM staging system; Lung cancer; Stage (stratigraphy); Oncology; Internal medicine; Lung cancer staging; Pleural effusion; Cancer; Radiology; Neoplasm staging; Mediastinoscopy","score_opus":0.07672109753829616,"score_gpt":0.5107732582045514,"score_spread":0.4340521606662553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003901423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775502,0.007365985,0.0009345444,0.007836018,0.0030188665,0.0018633779,0.00009801618,0.000009402302,0.0013236107],"genre_scores_gemma":[0.9927139,0.0032267673,0.0007369764,0.00040281765,0.0012557639,0.00011546008,0.0000035451772,0.00004386836,0.0015008601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99470234,0.00057263346,0.002591894,0.00033370944,0.0012629365,0.00053646654],"domain_scores_gemma":[0.98608726,0.0038186233,0.005920211,0.00041354203,0.003617873,0.00014248755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009323629,0.000261948,0.0012969862,0.0003241042,0.00018320842,0.00001703529,0.0007582377,0.00020567767,0.000081125116],"category_scores_gemma":[0.0017074795,0.00016776474,0.000453438,0.00049200567,0.0002117316,0.00014104573,0.00038116556,0.0012705579,1.1208324e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021838346,0.0011519669,0.96832514,0.00093571504,0.0028600597,0.00010148001,0.0055127623,0.0008786487,0.0019098661,0.000004806671,0.010172703,0.005963044],"study_design_scores_gemma":[0.007477462,0.0018469443,0.9447403,0.0015150572,0.005374431,0.000040436877,0.011155444,0.0040606023,0.016216537,0.00002900458,0.007259143,0.00028465214],"about_ca_topic_score_codex":0.0019331431,"about_ca_topic_score_gemma":0.004260346,"teacher_disagreement_score":0.023584828,"about_ca_system_score_codex":0.0034116604,"about_ca_system_score_gemma":0.0035693836,"threshold_uncertainty_score":0.89213735},"labels":[],"label_agreement":null},{"id":"W2004997735","doi":"10.1097/jto.0b013e3181cbf465","title":"Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant Pleural Mesothelioma","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Mesothelioma; Radiology; Computed tomography; Multimodality; Tomography; Positron emission tomography; Pathology","score_opus":0.007713433901874678,"score_gpt":0.31568934847549046,"score_spread":0.3079759145736158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004997735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867046,0.00054880045,0.000025982892,0.0001672091,0.0002063226,0.00022848365,0.00009024312,0.0000064527653,0.00005603636],"genre_scores_gemma":[0.9978087,0.00006290721,0.001902445,0.00010014509,0.000046812173,0.00000502119,0.000055640434,0.000012562552,0.0000057489037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837697,0.00021930187,0.00075247785,0.00014849556,0.0003441744,0.0001585985],"domain_scores_gemma":[0.99870163,0.00009017783,0.0006344882,0.00016324983,0.00027012327,0.00014032029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041262142,0.00015148339,0.0005290681,0.0004412526,0.000019323821,0.0000036932922,0.000119049495,0.00016313978,0.00020206442],"category_scores_gemma":[0.00004930368,0.00010712777,0.00026780576,0.00036404846,0.000148078,0.00011469706,0.000029338764,0.00029777578,9.591108e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011557038,0.0023629235,0.75264114,0.00003925744,0.000076576114,0.000019543693,0.000116223695,0.0000077876875,0.18984658,0.0000019143338,0.00003679268,0.043294236],"study_design_scores_gemma":[0.0017143,0.0021288593,0.9451331,0.00015601378,0.000038976916,0.00003501136,0.0000609214,0.00016745039,0.050121512,0.0002193333,0.00013789171,0.00008661952],"about_ca_topic_score_codex":0.000050930063,"about_ca_topic_score_gemma":0.000016176837,"teacher_disagreement_score":0.19249198,"about_ca_system_score_codex":0.00007123363,"about_ca_system_score_gemma":0.00010685288,"threshold_uncertainty_score":0.4368544},"labels":[],"label_agreement":null},{"id":"W2005195171","doi":"10.1097/jto.0000000000000006","title":"Clinical Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Staging of Patients with Potentially Resectable Esophageal Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Juravinski Hospital; Institute for Clinical Evaluative Sciences; McMaster University Medical Centre","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Hamilton Health Sciences","keywords":"Medicine; Stage (stratigraphy); Positron emission tomography; Esophageal cancer; Radiology; Prospective cohort study; Cohort; Cancer staging; Cancer; Fluorodeoxyglucose; Nuclear medicine; Internal medicine","score_opus":0.023173699525757825,"score_gpt":0.4092050004425111,"score_spread":0.3860313009167533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005195171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936898,0.0039975843,0.00016713467,0.0009699816,0.00017502208,0.000722095,0.000018528735,0.000005255868,0.00025459385],"genre_scores_gemma":[0.9954775,0.00017833705,0.004026723,0.00013677179,0.00011788094,0.000016997274,0.00000954396,0.000013873877,0.000022387381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967144,0.0007869284,0.0010975052,0.00021575287,0.00082295714,0.00036243154],"domain_scores_gemma":[0.99719554,0.00037064555,0.0008806809,0.00031564786,0.0009939267,0.00024355842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016710946,0.00016949876,0.00084095786,0.00044537312,0.00005259287,0.000012564862,0.00030561205,0.00012618933,0.00021469008],"category_scores_gemma":[0.00010705673,0.000093934614,0.0003088619,0.0006905372,0.000262972,0.00019133017,0.00006986349,0.00074854196,8.368314e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070992988,0.002765086,0.86963284,0.00018191057,0.0003369222,0.00021199205,0.00022926644,0.000010775898,0.00023400545,0.0000035493708,0.0006658271,0.11862854],"study_design_scores_gemma":[0.0033563052,0.00872834,0.98418176,0.00035124552,0.00024619687,0.00003394007,0.00014681059,0.00008513671,0.0025295862,0.00017198527,0.000105419414,0.00006327647],"about_ca_topic_score_codex":0.00054203114,"about_ca_topic_score_gemma":0.00007965619,"teacher_disagreement_score":0.11856526,"about_ca_system_score_codex":0.00012138382,"about_ca_system_score_gemma":0.0007068269,"threshold_uncertainty_score":0.38305426},"labels":[],"label_agreement":null},{"id":"W2005842252","doi":"10.1097/jto.0000000000000230","title":"Comparison of the Yield of Different Diagnostic Procedures for Cellular Differentiation and Genetic Profiling of Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Biopsy; Bronchoalveolar lavage; Pathology; Epidermal growth factor receptor; Carcinoma; Lung; Cancer; Oncology; Internal medicine","score_opus":0.022712014938560135,"score_gpt":0.4126552338120417,"score_spread":0.3899432188734816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005842252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975194,0.0021931098,0.006630083,0.00046179676,0.00028464172,0.0006011217,0.000009109562,0.0000013682386,0.00006681991],"genre_scores_gemma":[0.997308,0.00016512688,0.0023026685,0.00002772575,0.00010780069,0.000028113778,0.0000023436369,0.000009493704,0.000048699418],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909693,0.000053583895,0.00054052525,0.00007863851,0.00013607765,0.000094269344],"domain_scores_gemma":[0.9980814,0.0004976031,0.0009955156,0.000098956516,0.00027919246,0.00004736696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001042024,0.00008570921,0.000508796,0.0000769945,0.000031754735,0.000002481474,0.00007189058,0.00007413048,0.000009707774],"category_scores_gemma":[0.000273914,0.00004981128,0.00010996469,0.00005674353,0.000056422094,0.000018537858,0.00002238993,0.00010226224,2.9339864e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039710908,0.00087863166,0.7492717,0.0026345106,0.00030510957,0.0000012113983,0.0013881074,0.00034618773,0.22995216,0.000021430864,0.00012732972,0.014676546],"study_design_scores_gemma":[0.0013906092,0.0021826376,0.45698977,0.0008695865,0.003204248,0.000013883462,0.00033889513,0.004181681,0.530619,0.00011529354,0.00003959476,0.000054783104],"about_ca_topic_score_codex":0.000018548726,"about_ca_topic_score_gemma":0.000047372556,"teacher_disagreement_score":0.30066687,"about_ca_system_score_codex":0.000077644094,"about_ca_system_score_gemma":0.0002652814,"threshold_uncertainty_score":0.2031245},"labels":[],"label_agreement":null},{"id":"W2006489296","doi":"10.1097/jto.0000000000000239","title":"Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval; Pfizer (Canada); Centre Hospitalier de l’Université de Montréal; McGill University; London Health Sciences Centre; Princess Margaret Cancer Centre; Health Sciences North; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; University Health Network; University of Alberta; Dalhousie University; University of Ottawa; McGill University Health Centre; Jewish General Hospital; Health Sciences Centre; University of Calgary; Ottawa Hospital; McMaster University Medical Centre; University of Alberta Hospital; University of Toronto; University of British Columbia; Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Immunohistochemistry; Lung cancer; Intraclass correlation; Fluorescence in situ hybridization; Crizotinib; Oncology; Internal medicine; Pathology; Biology","score_opus":0.021496453022647334,"score_gpt":0.42448151199295237,"score_spread":0.402985058970305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006489296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8478002,0.00027148405,0.15004393,0.0008903488,0.0001762835,0.0005983475,0.000027328977,0.000003149996,0.00018894892],"genre_scores_gemma":[0.96619296,0.000023088358,0.033535782,0.00011249841,0.000060166043,0.000020723579,0.0000045335078,0.000010253987,0.000040006296],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.999327,0.00005096727,0.00033011893,0.000083279745,0.00009236488,0.00011628865],"domain_scores_gemma":[0.9990304,0.00013483853,0.000269982,0.000051268515,0.00039870501,0.00011479774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002983346,0.00006550556,0.00027311125,0.00025838468,0.000041282376,0.00000673698,0.000027791055,0.000049959403,0.0000062588388],"category_scores_gemma":[0.0003456032,0.000053251806,0.000025469431,0.00012517009,0.00001749003,0.00008144066,0.000006563036,0.000045882585,3.2232812e-8],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014180633,0.0004555681,0.12463656,0.00018262384,0.00018529934,0.000033493256,0.0025918195,0.7524829,0.00013178439,0.000010479109,0.00010235639,0.11776905],"study_design_scores_gemma":[0.0039717997,0.0015755778,0.020683423,0.00021721555,0.0007020857,0.000028690103,0.00042021493,0.97212774,0.00003854606,0.000022275275,0.00016528092,0.00004715058],"about_ca_topic_score_codex":0.0029874132,"about_ca_topic_score_gemma":0.029704435,"teacher_disagreement_score":0.21964484,"about_ca_system_score_codex":0.0009334648,"about_ca_system_score_gemma":0.0011789411,"threshold_uncertainty_score":0.9880009},"labels":[],"label_agreement":null},{"id":"W2006813505","doi":"10.1097/jto.0b013e3181cee24f","title":"Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Neutropenia; Internal medicine; Interim analysis; Lung cancer; Febrile neutropenia; Phases of clinical research; Discontinuation; Adverse effect; Leukopenia; Combination therapy; Oncology; Surgery; Chemotherapy; Randomized controlled trial","score_opus":0.019319522764414274,"score_gpt":0.43457780159295745,"score_spread":0.41525827882854316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006813505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476457,0.0004905823,0.000050892646,0.00032725272,0.000697673,0.002663407,0.00001245925,0.000006852598,0.0009863172],"genre_scores_gemma":[0.99702626,0.00011990981,0.0017552712,0.00016538882,0.00015143558,0.00012617107,0.000009563619,0.000029807568,0.00061621406],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99814004,0.00014328699,0.0009228269,0.00021018213,0.0003379467,0.00024571584],"domain_scores_gemma":[0.9975639,0.00018170192,0.0011664736,0.00023661515,0.0006778568,0.00017347328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061187334,0.00022233759,0.0013402337,0.00045151912,0.00006399051,0.000008513489,0.00014842127,0.00013009801,0.00052964484],"category_scores_gemma":[0.00003974621,0.0001384559,0.0001542298,0.00031788545,0.000077227305,0.0001446125,0.00003120539,0.00060515077,9.257204e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8462779,0.028378123,0.031870503,0.00009575804,0.001318504,0.00021896878,0.0089878915,0.0003218963,0.0037045404,0.0000029788362,0.00009102639,0.078731924],"study_design_scores_gemma":[0.93642265,0.042618535,0.011713526,0.00014068093,0.0013610534,0.000033432225,0.0014183283,0.00009543911,0.005328716,0.000013605332,0.00069668976,0.00015733726],"about_ca_topic_score_codex":0.00018236546,"about_ca_topic_score_gemma":0.000984831,"teacher_disagreement_score":0.09014477,"about_ca_system_score_codex":0.00035649465,"about_ca_system_score_gemma":0.0014514124,"threshold_uncertainty_score":0.5799239},"labels":[],"label_agreement":null},{"id":"W2008263368","doi":"10.1097/jto.0b013e318208c7da","title":"Spontaneous Smoking Cessation Before Lung Cancer Diagnosis","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Cancer; Nicotine; Internal medicine; Prostate cancer; Pathology","score_opus":0.04655709024756718,"score_gpt":0.4157680065210333,"score_spread":0.36921091627346614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008263368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452096,0.0003118699,0.00017983002,0.0008942418,0.0014418645,0.00011538256,0.0000032670305,0.000017119348,0.0025154627],"genre_scores_gemma":[0.99816257,0.00018212237,0.0005317691,0.00031800236,0.00058375223,0.000024849072,0.0000035321043,0.000017219223,0.00017616976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989021,0.00008835459,0.00044082,0.000105586456,0.00029270558,0.00017045885],"domain_scores_gemma":[0.99884874,0.000057409412,0.0005472821,0.0001173725,0.00031262182,0.00011656715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000530798,0.00010142969,0.0003386532,0.00022002518,0.000059508697,0.000008479118,0.00009958117,0.00019686008,0.0014907387],"category_scores_gemma":[0.00009642962,0.00008010593,0.00012626073,0.00015358659,0.00004343639,0.00014790532,0.000014275286,0.00038153553,0.0000012433749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005785229,0.00025644345,0.7442325,0.00004851671,0.00010436797,0.002834909,0.0023906452,0.0000035789026,0.0002070115,0.000023641502,0.0012023846,0.2481175],"study_design_scores_gemma":[0.0006869193,0.0014526015,0.9746514,0.00031005565,0.0014855175,0.010112769,0.00046047906,0.000031660853,0.0056483424,0.0002198279,0.00483987,0.0001005739],"about_ca_topic_score_codex":0.000093974806,"about_ca_topic_score_gemma":0.000064094354,"teacher_disagreement_score":0.24801694,"about_ca_system_score_codex":0.00061091105,"about_ca_system_score_gemma":0.0002772765,"threshold_uncertainty_score":0.999422},"labels":[],"label_agreement":null},{"id":"W2008651273","doi":"10.1097/01.jto.0000283949.08894.3a","title":"P2-241: A retrospective study of the role of chemotherapy in non-small cell lung cancer (nsclc) patients with brain metastases treated in Alberta, Canada from 2000-2004","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Chemotherapy; Docetaxel; Radiation therapy; Oncology; Radiosurgery; Lung cancer; Brain metastasis; Internal medicine; Retrospective cohort study; Adenocarcinoma; Cancer; Metastasis","score_opus":0.006003622359283601,"score_gpt":0.3066969985081909,"score_spread":0.3006933761489073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008651273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972245,0.00086356694,0.000008862461,0.0005876089,0.00011269068,0.00086330227,0.0000642275,0.000001126058,0.00027410797],"genre_scores_gemma":[0.9990902,0.000020167314,0.00045604235,0.00025345807,0.000045663972,0.000010018173,0.000005926148,0.00002140408,0.000097147706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998032,0.00029449875,0.00081225106,0.00019154667,0.00040323826,0.0002664982],"domain_scores_gemma":[0.9980345,0.00036034296,0.0009860556,0.00023861557,0.00027346282,0.000107054955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061008736,0.00019785644,0.0009562939,0.0002178109,0.000023460396,0.0000028548602,0.00015796868,0.00008546999,0.00009947613],"category_scores_gemma":[0.00007001345,0.00011656933,0.00009909717,0.0005005444,0.000054977783,0.000045078425,0.00002560444,0.00035979788,1.2007064e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005908658,0.0049085817,0.9715845,0.000024850026,0.0005896339,0.00023484179,0.0029401574,0.00016819643,0.0004048106,8.465888e-7,0.00017171586,0.013063188],"study_design_scores_gemma":[0.010508676,0.004385114,0.9729696,0.00026465303,0.00056473055,0.00001326662,0.0028468687,0.00003062359,0.00802279,0.000016233438,0.00028462382,0.00009283906],"about_ca_topic_score_codex":0.698432,"about_ca_topic_score_gemma":0.93021005,"teacher_disagreement_score":0.23177803,"about_ca_system_score_codex":0.0017426936,"about_ca_system_score_gemma":0.0014654365,"threshold_uncertainty_score":0.47535592},"labels":[],"label_agreement":null},{"id":"W2010198077","doi":"10.1097/jto.0b013e31824c7bed","title":"Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Imclone; Presbyterian Historical Society; Bristol-Myers Squibb; U.S. Department of Health and Human Services","keywords":"Medicine; Cetuximab; Irinotecan; Cisplatin; Oncology; Internal medicine; Radiation therapy; Esophageal cancer; Phases of clinical research; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.05171227114998329,"score_gpt":0.48092212307836535,"score_spread":0.42920985192838207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010198077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95044476,0.04435461,0.00025808654,0.0017487025,0.0004421059,0.0022959576,0.00006018134,0.000011191428,0.00038440942],"genre_scores_gemma":[0.9937277,0.0022205373,0.0022085719,0.00025771704,0.00055093324,0.00026153892,0.0000038516496,0.000044051583,0.0007251295],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99741524,0.00039075187,0.0007395955,0.00026374112,0.0005555083,0.0006351677],"domain_scores_gemma":[0.99741846,0.0005349897,0.00078672235,0.00032204238,0.00049123017,0.00044654994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078585895,0.0003146023,0.0011612896,0.00023345562,0.00027998918,0.000015425576,0.00020732851,0.00015164768,0.00012024213],"category_scores_gemma":[0.00016879704,0.0001863019,0.00027072453,0.0003119936,0.00020033013,0.00022581303,0.000082360726,0.00040464549,0.0000016183487],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064111665,0.017337747,0.02132672,0.0002474151,0.0023545905,0.0004943085,0.0074699963,0.00017377498,0.0015741802,0.000081021615,0.00034404837,0.8844845],"study_design_scores_gemma":[0.13372153,0.7158362,0.038149342,0.0011146185,0.005509015,0.005375853,0.009997673,0.00064831454,0.068063535,0.00071880996,0.020146584,0.00071846717],"about_ca_topic_score_codex":0.00029227894,"about_ca_topic_score_gemma":0.00029016778,"teacher_disagreement_score":0.88376606,"about_ca_system_score_codex":0.0019393058,"about_ca_system_score_gemma":0.0018021155,"threshold_uncertainty_score":0.7597171},"labels":[],"label_agreement":null},{"id":"W2010465480","doi":"10.1097/jto.0b013e31824fe9e6","title":"A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Non–Small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Credit Valley Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; KRAS; Hazard ratio; Internal medicine; Oncology; Chemotherapy; Lung cancer; Confounding; Cancer; Proportional hazards model; Confidence interval; Colorectal cancer","score_opus":0.012510923849754602,"score_gpt":0.37922587982214323,"score_spread":0.3667149559723886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010465480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973711,0.0008407747,0.00007772625,0.0007171247,0.00025492607,0.00038269488,0.00009732737,0.0000025987422,0.00025573635],"genre_scores_gemma":[0.99855065,0.000036676505,0.0009801369,0.00025496757,0.00008809308,0.000031005937,0.000006369105,0.000014846694,0.00003727593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99874574,0.0002469956,0.00051678147,0.00011494199,0.00021696322,0.000158568],"domain_scores_gemma":[0.99722886,0.0014929986,0.0008485923,0.00015680252,0.00017173696,0.000101028534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043682178,0.00014391262,0.0008632175,0.00026898232,0.000037176145,0.0000035944854,0.00008146237,0.000079152334,0.000117062904],"category_scores_gemma":[0.00013906613,0.00008719379,0.00022203554,0.00049095356,0.00008499015,0.000068091635,0.000014192522,0.00022492601,3.5608653e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042695757,0.0009258257,0.9465492,0.0001477504,0.003462262,0.00003075104,0.007704873,0.005357081,0.021414764,0.00000328587,0.000036463964,0.010098206],"study_design_scores_gemma":[0.0058635334,0.0015140993,0.9048815,0.000325293,0.010115667,0.0000041932162,0.0008923549,0.0014760015,0.07479065,0.000017848077,0.00003390036,0.000084981024],"about_ca_topic_score_codex":0.00039068077,"about_ca_topic_score_gemma":0.0005259331,"teacher_disagreement_score":0.05337589,"about_ca_system_score_codex":0.0003930013,"about_ca_system_score_gemma":0.0004190122,"threshold_uncertainty_score":0.35556597},"labels":[],"label_agreement":null},{"id":"W2010840029","doi":"10.1097/jto.0b013e318220cb8e","title":"A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saint John Regional Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Oncology; Internal medicine; Randomized controlled trial; MEDLINE; non-small cell lung cancer (NSCLC); Pathology","score_opus":0.1074515341946355,"score_gpt":0.4733191048693627,"score_spread":0.3658675706747272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010840029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021642781,0.9918212,0.0000015299328,0.0036551799,0.0001871008,0.0033383274,0.00014906164,9.011298e-7,0.00063022214],"genre_scores_gemma":[0.00014030907,0.99847823,0.00040411705,0.00047107862,0.000032036,0.0002462774,0.000013113398,0.000016405169,0.00019842455],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976128,0.00078992674,0.0012307912,0.0001164084,0.00009809935,0.00015197859],"domain_scores_gemma":[0.99617136,0.0012989442,0.0019117031,0.00031277857,0.00019483444,0.000110400804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006401689,0.00021408056,0.0022787652,0.000342618,0.000046833193,0.000006638247,0.00013471708,0.00013666142,0.00006488068],"category_scores_gemma":[0.00013092482,0.000090369955,0.00035852563,0.00027968638,0.00008156058,0.000017688651,0.000007062318,0.00020658363,0.000001140564],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084232895,0.0010532343,0.00009502814,0.61883163,0.006768635,0.00024425532,0.0027150367,8.8572415e-7,4.2168463e-7,0.000034590394,0.009276576,0.36089545],"study_design_scores_gemma":[0.00045530693,0.0017883867,0.000045118974,0.34723058,0.05823923,0.0006687132,0.00036364837,0.0000038248436,0.0000012917255,0.0000033846661,0.591106,0.0000945274],"about_ca_topic_score_codex":0.008921047,"about_ca_topic_score_gemma":0.0134612825,"teacher_disagreement_score":0.5818294,"about_ca_system_score_codex":0.0011271264,"about_ca_system_score_gemma":0.0029826318,"threshold_uncertainty_score":0.99767864},"labels":[],"label_agreement":null},{"id":"W2010880842","doi":"10.1016/s1556-0864(15)31514-8","title":"Lung Cancer Screening Using Multi-Slice Thin-Section Computed Tomography and Autofluorescence Bronchoscopy","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Bronchoscopy; Radiology; Computed tomography; Autofluorescence; Tomography; Lung cancer screening; Section (typography); Lung; Nuclear medicine; Pathology; Internal medicine; Optics; Fluorescence","score_opus":0.03336827526393974,"score_gpt":0.44371570234867314,"score_spread":0.4103474270847334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010880842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650263,0.008378875,0.024446458,0.001179576,0.0005762776,0.00026160572,0.0000050204862,0.000028409355,0.00009745226],"genre_scores_gemma":[0.9367131,0.00052965013,0.061559062,0.00024211647,0.0008182235,0.0000043543396,0.0000016623304,0.000021566611,0.000110264235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998484,0.00021066848,0.00047362913,0.00018129456,0.00033319014,0.0003172072],"domain_scores_gemma":[0.9987085,0.0001833384,0.00045023856,0.00011346276,0.00040337667,0.00014112158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007201442,0.00015553948,0.00053976773,0.0004251983,0.00017695525,0.00002465733,0.00011266328,0.00014229557,0.000025087218],"category_scores_gemma":[0.000069183334,0.00012461796,0.00012334292,0.00038097036,0.00020855534,0.0001819049,0.000069567766,0.00065197144,2.3264586e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004768694,0.0007614959,0.2144761,0.0004140686,0.0010842008,0.00068537204,0.0011218896,0.00227875,0.6881309,0.0000129526015,0.0024707683,0.083794825],"study_design_scores_gemma":[0.0039429865,0.0019609593,0.79729164,0.0013144546,0.00068795524,0.0026215103,0.00048141173,0.17364883,0.012072036,0.000059821614,0.0056085316,0.00030986045],"about_ca_topic_score_codex":0.000743322,"about_ca_topic_score_gemma":0.00020047557,"teacher_disagreement_score":0.6760588,"about_ca_system_score_codex":0.00041392137,"about_ca_system_score_gemma":0.00027545696,"threshold_uncertainty_score":0.5081773},"labels":[],"label_agreement":null},{"id":"W2010995223","doi":"10.1097/jto.0b013e3181d35627","title":"Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients with Non-small Cell Lung Cancer in Nonoperable Patients Pursuing Radiotherapy as a Primary Treatment","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiology; Lymph node; Lung cancer; Lung cancer staging; Cancer staging; Radiation therapy; Mediastinum; Mediastinoscopy; Cancer; Oncology; Internal medicine","score_opus":0.009268921572571896,"score_gpt":0.3365860746532199,"score_spread":0.32731715308064796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010995223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957519,0.00027470995,0.00020142861,0.0005842888,0.0009460175,0.001710997,0.000033179258,0.00000778663,0.0004896949],"genre_scores_gemma":[0.9909888,0.00021715184,0.0074562253,0.0004972567,0.0004206571,0.00024853583,0.000045785353,0.0000475976,0.000077973666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981381,0.00009223857,0.00074753526,0.00029714947,0.00030092988,0.00042404633],"domain_scores_gemma":[0.9986887,0.0002027812,0.0005059086,0.00017766739,0.00025030965,0.00017463016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034354365,0.00028215192,0.00081340515,0.00033077077,0.00007139762,0.000031270596,0.00011681849,0.00018546701,0.00007321662],"category_scores_gemma":[0.000025956842,0.00020329152,0.0001601377,0.00018099764,0.000041569787,0.00022233516,0.00000839632,0.00031448598,7.2046817e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064928704,0.0047370754,0.93198335,0.00016743082,0.00021422288,0.00004099186,0.0025786778,0.0010516961,0.0025988112,0.0000017576514,0.00009783061,0.050035264],"study_design_scores_gemma":[0.041166663,0.009197046,0.9424524,0.0003971609,0.00053772115,0.000032926866,0.00008948304,0.00029948854,0.0047853948,0.000009312508,0.0008009177,0.00023151212],"about_ca_topic_score_codex":0.0007212561,"about_ca_topic_score_gemma":0.0011128982,"teacher_disagreement_score":0.049803752,"about_ca_system_score_codex":0.0046572615,"about_ca_system_score_gemma":0.0015151119,"threshold_uncertainty_score":0.9991637},"labels":[],"label_agreement":null},{"id":"W2011193838","doi":"10.1097/01.jto.0000284100.58945.65","title":"P3-125: Similar characteristics of responders treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) Gefitinib and Erlotinib for advanced non small cell lung cancer (NSCLC) in a single Canadian institution.","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Epidermal growth factor receptor; Internal medicine; Oncology; Lung cancer; Progressive disease; Erlotinib Hydrochloride; Tyrosine-kinase inhibitor; Performance status; Cancer; Disease","score_opus":0.018077672776778027,"score_gpt":0.3596085842959359,"score_spread":0.3415309115191579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011193838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177283,0.0008455711,0.00039688812,0.0052011637,0.00034039843,0.00088597235,0.00016603086,0.000006350769,0.00038479004],"genre_scores_gemma":[0.99535906,0.00016298982,0.0033859105,0.00056581566,0.00022942814,0.000028723096,0.000027728205,0.000027123475,0.00021319359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859685,0.00007681082,0.0006324816,0.0001799693,0.00015285012,0.00036104914],"domain_scores_gemma":[0.99810004,0.00030948408,0.00067024835,0.00011676712,0.00050892425,0.0002945557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045010843,0.00019430774,0.0005589995,0.00041063246,0.00011931678,0.00001271249,0.00008345743,0.00015876936,0.000027848366],"category_scores_gemma":[0.0001632065,0.00012644961,0.000086037915,0.0003056325,0.00015716387,0.0001319501,0.000012401648,0.00028530866,3.1749963e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049429398,0.0030179133,0.4882808,0.0016052735,0.0012673137,0.0017087959,0.014634362,0.00026970005,0.18211892,0.00011508264,0.0035350313,0.2540174],"study_design_scores_gemma":[0.029356893,0.021625677,0.71692616,0.003367869,0.0040411633,0.0007141486,0.008041114,0.00030352053,0.16226247,0.0000345562,0.052419268,0.00090716995],"about_ca_topic_score_codex":0.0032870113,"about_ca_topic_score_gemma":0.021327807,"teacher_disagreement_score":0.25311023,"about_ca_system_score_codex":0.0013572464,"about_ca_system_score_gemma":0.0019328169,"threshold_uncertainty_score":0.9965304},"labels":[],"label_agreement":null},{"id":"W2011445390","doi":"10.1097/jto.0000000000000128","title":"Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Weill Cornell Medical College; National Cancer Institute; University of Toronto; Universität Wien; lékařská fakulta Univerzity Karlovy; Università degli Studi del Piemonte Orientale; Medizinische Universität Wien; Università degli Studi di Parma; Alfaisal University; Imperial College London; Univerzita Karlova v Praze; Bursa Uludağ Üniversitesi; Aix-Marseille Université; Aristotle University of Thessaloniki; Society of Thoracic Surgeons","keywords":"Medicine; Thymic carcinoma; Incidence (geometry); Radiation therapy; Cumulative incidence; Surgery; Biopsy; Retrospective cohort study; Resection; Carcinoma; Stage (stratigraphy); Cohort; Internal medicine; Thymoma","score_opus":0.024792976974350185,"score_gpt":0.36053035360464103,"score_spread":0.33573737663029085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011445390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965856,0.00019728758,0.00019729398,0.00060833327,0.00044504268,0.000458873,0.000062996696,0.0000068176314,0.0014377673],"genre_scores_gemma":[0.998258,0.000051908784,0.00094907783,0.0002629106,0.00033849527,0.0000028485354,0.000030628624,0.00003132601,0.000074785145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962234,0.001581944,0.0011492872,0.00021551909,0.00059297035,0.00023687148],"domain_scores_gemma":[0.99643326,0.0006624065,0.0015054202,0.00061939936,0.00061419304,0.00016531278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036680708,0.00019126048,0.0010067436,0.00009771004,0.00008336756,0.000007901296,0.00039639082,0.000091133494,0.00011234448],"category_scores_gemma":[0.00032735537,0.000115296905,0.00035427907,0.00022766653,0.0001688002,0.000085852684,0.00017984472,0.0005600255,0.0000090243475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011538798,0.002659292,0.9539264,0.00007086729,0.00044783694,0.000057634814,0.0020579158,0.0000037748373,0.0013502234,0.0000069719645,0.0048529324,0.033412296],"study_design_scores_gemma":[0.0015043254,0.0037812805,0.9858666,0.00014031825,0.0011324058,0.00007434761,0.0016949206,0.00007935328,0.0005172475,0.00005685795,0.0050562397,0.00009606797],"about_ca_topic_score_codex":0.0003123828,"about_ca_topic_score_gemma":0.000083433835,"teacher_disagreement_score":0.03331623,"about_ca_system_score_codex":0.00008742149,"about_ca_system_score_gemma":0.00021420373,"threshold_uncertainty_score":0.47016713},"labels":[],"label_agreement":null},{"id":"W2013357857","doi":"10.1097/jto.0b013e318274a83e","title":"Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; BC Cancer Agency; Toronto General Hospital; University Health Network; University of British Columbia","funders":"","keywords":"Medicine; Immunohistochemistry; Antibody; Pathology; Identification (biology); Lung; Carcinoma; Cancer research; Immunology; Internal medicine; Biology","score_opus":0.020855329640578263,"score_gpt":0.42071270338615807,"score_spread":0.39985737374557984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013357857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909505,0.0038904073,0.002959847,0.0008835481,0.0002050028,0.00042666993,0.000014296255,0.000002295046,0.0006674013],"genre_scores_gemma":[0.9897503,0.0001875105,0.008551536,0.00014783522,0.00012601721,0.000023565424,0.0000128512975,0.000012109767,0.0011882522],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99898183,0.000019523688,0.0005729687,0.000106874875,0.00014223701,0.00017653998],"domain_scores_gemma":[0.9989547,0.000046685025,0.0005616212,0.00014261852,0.00021795541,0.00007637986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060138496,0.000090278,0.0003323024,0.00013556879,0.000043165397,0.0000076123783,0.000060438095,0.00009803952,0.000038684084],"category_scores_gemma":[0.000028551449,0.00007734833,0.000085620355,0.000083147,0.000027652053,0.00011504775,0.000023883755,0.0001348112,8.780026e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014391433,0.00095961493,0.3543754,0.00091073435,0.00032456647,0.000036951868,0.0052475645,0.0000121630555,0.6114092,0.0000052673704,0.0024903913,0.022789016],"study_design_scores_gemma":[0.008272803,0.0017528654,0.57495874,0.00065672083,0.0034734136,0.0007370162,0.00393752,0.0009000153,0.39780566,0.00006786938,0.0071723466,0.0002650277],"about_ca_topic_score_codex":0.00005194804,"about_ca_topic_score_gemma":0.0000012774808,"teacher_disagreement_score":0.22058335,"about_ca_system_score_codex":0.00033738377,"about_ca_system_score_gemma":0.0001959324,"threshold_uncertainty_score":0.31541735},"labels":[],"label_agreement":null},{"id":"W2014719020","doi":"10.1097/jto.0b013e3181f77b58","title":"Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Ministry of Health, Labour and Welfare; Ministry of Education, Culture, Sports, Science and Technology; Uehara Memorial Foundation","keywords":"Medicine; Mediastinal lymph node; Lung cancer; Carcinoembryonic antigen; Mediastinoscopy; Adenocarcinoma; Adenosquamous carcinoma; Gemcitabine; Pathology; Radiology; Cancer; Metastasis; Internal medicine","score_opus":0.01937904244433617,"score_gpt":0.41664265429161007,"score_spread":0.3972636118472739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014719020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949859,0.00038534723,0.0018862179,0.00029657813,0.0016337313,0.0005173427,0.000023274117,0.000013267419,0.00025835828],"genre_scores_gemma":[0.98654664,0.00007965185,0.011082084,0.00006616965,0.002084663,0.000036836063,0.000013866441,0.000028939423,0.00006115254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861836,0.00010484906,0.00058004906,0.00019017288,0.00029338658,0.00021320739],"domain_scores_gemma":[0.9986308,0.000052292995,0.0005733751,0.0001722105,0.00037389956,0.00019739823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015299694,0.00019865159,0.0005153662,0.00023163174,0.000111940266,0.000017045479,0.000052541825,0.00020080434,0.00015898312],"category_scores_gemma":[0.000019450856,0.00013420568,0.00016068212,0.00016837995,0.00009193909,0.0002901642,0.0000054064176,0.00023727895,6.505533e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008071309,0.0015500725,0.024060382,0.0000600822,0.0005121522,0.00016064067,0.0028660994,0.00040649148,0.8353621,0.0000029656944,0.000014773004,0.12693296],"study_design_scores_gemma":[0.016416244,0.04483467,0.12165745,0.00026610759,0.00937662,0.011137675,0.0008103069,0.0023514356,0.78771305,0.0000619844,0.004920008,0.00045444042],"about_ca_topic_score_codex":0.00052303285,"about_ca_topic_score_gemma":0.001643636,"teacher_disagreement_score":0.12647852,"about_ca_system_score_codex":0.00089841353,"about_ca_system_score_gemma":0.0010690289,"threshold_uncertainty_score":0.5472749},"labels":[],"label_agreement":null},{"id":"W2014945112","doi":"10.1016/s1556-0864(15)30389-0","title":"Inflammatory Myofibroblastic Tumor of the Left Main Stem Bronchus","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"IgG4-Related and Inflammatory Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Etiology; Inflammatory pseudotumor; Pathology; Lung; Lesion; Bronchus; Plasma cell granuloma; Mesenchymal stem cell; CD34; Stem cell; Respiratory disease; Internal medicine","score_opus":0.00860805674486874,"score_gpt":0.3085093681124095,"score_spread":0.2999013113675407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014945112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071425,0.0008426407,0.00005383633,0.0010258423,0.00077926955,0.0001927069,0.00000751374,0.000015006256,0.006368951],"genre_scores_gemma":[0.99702454,0.000014827593,0.00030455543,0.0002904742,0.0006249803,0.0000013219545,0.0000010998035,0.000022035023,0.0017161652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99794275,0.00027014545,0.0010229549,0.000114851064,0.00039133642,0.0002579852],"domain_scores_gemma":[0.9980309,0.00020796247,0.001079318,0.00025943588,0.00027863792,0.00014375035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005441318,0.00016022676,0.0005915388,0.00018856382,0.000070636095,0.000008419524,0.00024185432,0.00015946053,0.00019322002],"category_scores_gemma":[0.00013184069,0.000100025456,0.00035202634,0.00014507929,0.00024146489,0.00012542256,0.000058256737,0.00048210646,0.000020723654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015706552,0.003920702,0.3541051,0.0033739293,0.0015499594,0.010427163,0.0014278259,0.0042906436,0.40209427,0.005023686,0.13802123,0.06005895],"study_design_scores_gemma":[0.0041077714,0.003909295,0.78246385,0.0023260673,0.002136738,0.018189408,0.0010844677,0.00026883816,0.06691438,0.0021847717,0.11597865,0.00043577753],"about_ca_topic_score_codex":0.0000044334806,"about_ca_topic_score_gemma":0.000011258509,"teacher_disagreement_score":0.42835876,"about_ca_system_score_codex":0.0002781933,"about_ca_system_score_gemma":0.0011207351,"threshold_uncertainty_score":0.407892},"labels":[],"label_agreement":null},{"id":"W2015319412","doi":"10.1097/jto.0b013e3181a9a03b","title":"Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Cancer; Targeted therapy; Oncology; Internal medicine","score_opus":0.01405356603031655,"score_gpt":0.43465061647998,"score_spread":0.42059705044966345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015319412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963106,0.00723062,0.00008024368,0.027610218,0.00036218687,0.00034623794,0.0000721222,0.0000073083543,0.0011851015],"genre_scores_gemma":[0.9954595,0.0018971673,0.00091070804,0.0009866249,0.00032769947,0.000010721999,0.000025774576,0.00000829923,0.00037351603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899477,0.00016658856,0.00043128317,0.000088403474,0.00018004616,0.00013893397],"domain_scores_gemma":[0.9988126,0.00020982556,0.00037486598,0.000113071495,0.0004241998,0.00006541076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001639064,0.0000880743,0.00034178558,0.000121432975,0.000042372936,0.0000053882395,0.00010554159,0.000083138766,0.000117181036],"category_scores_gemma":[0.000050234445,0.00005259756,0.00008319464,0.00036639845,0.000045076184,0.00011264489,0.0000074944933,0.0002534301,5.6957515e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008063336,0.0037470337,0.56649643,0.000046190955,0.0024844746,0.00047809316,0.026049322,0.0013670722,0.074255556,0.00007528075,0.103833646,0.21310358],"study_design_scores_gemma":[0.0029417526,0.0022501978,0.9766435,0.00016565548,0.0006864162,0.00008094139,0.0012694289,0.00018591573,0.0046604527,0.00022863035,0.010809565,0.00007754636],"about_ca_topic_score_codex":0.0004220806,"about_ca_topic_score_gemma":0.00019255941,"teacher_disagreement_score":0.4101471,"about_ca_system_score_codex":0.0002574078,"about_ca_system_score_gemma":0.0010631459,"threshold_uncertainty_score":0.21448663},"labels":[],"label_agreement":null},{"id":"W2015378165","doi":"10.1097/01.jto.0000283154.03863.ae","title":"B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Regional Municipality of Durham; Ottawa Hospital","funders":"","keywords":"Medicine; Gefitinib; Chemotherapy; Lung cancer; Internal medicine; Oncology; Performance status; Placebo; Randomized controlled trial; Cancer; Epidermal growth factor receptor; Pathology","score_opus":0.021232777513109966,"score_gpt":0.41634247318091366,"score_spread":0.3951096956678037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015378165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913319,0.0021329902,0.0001114049,0.00012860371,0.0006348097,0.0047332775,0.00004126634,0.000009133399,0.0008766479],"genre_scores_gemma":[0.9960344,0.0011457151,0.0021540318,0.00009466882,0.00012794562,0.00019528398,0.00004788887,0.000046100064,0.00015396635],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973652,0.00012135551,0.0011705067,0.0003403669,0.00046698298,0.00053560437],"domain_scores_gemma":[0.99698824,0.00030647934,0.0014532284,0.00020486608,0.0007266511,0.00032055486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000533985,0.00035377764,0.0014673762,0.0004096249,0.00014031949,0.0000147693045,0.00013758152,0.00016402142,0.000043348293],"category_scores_gemma":[0.000039242033,0.0002517375,0.00013252768,0.00027177107,0.00016397613,0.00027601476,0.000059400332,0.0004950299,7.439644e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84991187,0.006290244,0.034369923,0.0003812425,0.0011336551,0.00027944002,0.031216132,0.0012373395,0.000077692945,5.135066e-7,0.0000205564,0.0750814],"study_design_scores_gemma":[0.9296368,0.029597668,0.009757265,0.00060922554,0.0026990592,0.000027367454,0.025835792,0.00052534224,0.0007998277,3.158418e-7,0.0002654146,0.0002459758],"about_ca_topic_score_codex":0.0005113757,"about_ca_topic_score_gemma":0.0016415108,"teacher_disagreement_score":0.07972489,"about_ca_system_score_codex":0.0017285581,"about_ca_system_score_gemma":0.0012163433,"threshold_uncertainty_score":0.9999935},"labels":[],"label_agreement":null},{"id":"W2016081804","doi":"10.1097/jto.0b013e318227816a","title":"Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Epidermal growth factor receptor; Oncology; Lung cancer; Internal medicine; T790M; Targeted therapy; Tyrosine-kinase inhibitor; Cancer; Gefitinib","score_opus":0.08567214479608881,"score_gpt":0.46499578844738887,"score_spread":0.37932364365130006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016081804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632085,0.000076253375,0.006183679,0.0005467235,0.000096923424,0.006279821,0.000053967826,0.000005417238,0.0004363585],"genre_scores_gemma":[0.92807025,0.0000141374885,0.07048291,0.00016755534,0.00006167846,0.0011565272,0.0000158257,0.000014509806,0.000016633272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783003,0.000350538,0.0012279085,0.0002280047,0.00016445386,0.00019907186],"domain_scores_gemma":[0.9971292,0.0006666654,0.0011766192,0.0001601211,0.00070203247,0.0001653742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009617759,0.00014485676,0.00094818196,0.00022297124,0.00006722141,0.000008554554,0.00013189873,0.00017111687,0.000021671125],"category_scores_gemma":[0.00060825725,0.00007997969,0.0002625101,0.0004862723,0.00024360478,0.000065247936,0.000033019907,0.00038328007,1.8121023e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002269805,0.0027479094,0.95222706,0.0001189545,0.0013235129,0.000036222602,0.0012167506,0.00003540231,0.000034470264,0.000009205969,0.000027528951,0.039953172],"study_design_scores_gemma":[0.0051102927,0.005867889,0.9811099,0.00013364959,0.005675821,0.000013393563,0.0005760415,0.0012973773,0.00005078898,0.000028131091,0.00005151141,0.0000851954],"about_ca_topic_score_codex":0.00003323827,"about_ca_topic_score_gemma":0.000028067185,"teacher_disagreement_score":0.06429923,"about_ca_system_score_codex":0.000099420846,"about_ca_system_score_gemma":0.0006076566,"threshold_uncertainty_score":0.3261477},"labels":[],"label_agreement":null},{"id":"W2017158584","doi":"10.1097/jto.0b013e31812d05d5","title":"The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":619,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"International Association for the Study of Lung Cancer; Eli Lilly and Company","keywords":"Medicine; Lung cancer staging; External validity; Stage (stratigraphy); Population; Proportional hazards model; Surveillance, Epidemiology, and End Results; Lung cancer; Epidemiology; Cancer registry; Medical physics; Statistics; Oncology; Surgery; Pathology; Environmental health","score_opus":0.0404194295711356,"score_gpt":0.42630256806134686,"score_spread":0.3858831384902113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017158584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860247,0.0015397547,0.0002874102,0.010075447,0.0003940218,0.0016235741,0.000020268513,0.0000010448474,0.000033828837],"genre_scores_gemma":[0.998567,0.0009559342,0.00024869567,0.00009541673,0.000078951336,0.000024001623,0.0000011319842,0.000008304929,0.000020581818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825686,0.00035787147,0.00079913135,0.0001041094,0.00034763687,0.00013436841],"domain_scores_gemma":[0.9969005,0.000602701,0.0019309865,0.00021244877,0.00033244494,0.000020929932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032683827,0.000096079,0.00033222875,0.00007594789,0.00012726696,0.000008775246,0.00016948549,0.00006526672,0.0000019018213],"category_scores_gemma":[0.0002806748,0.000035889894,0.00013285491,0.00021376454,0.00029016862,0.000079292244,0.000049394337,0.00017986304,5.380501e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024784657,0.0007584413,0.8393041,0.002095935,0.00035813573,0.000005299019,0.012981097,0.00007790864,0.055020455,0.001721566,0.0014419779,0.083756626],"study_design_scores_gemma":[0.001821938,0.0011644497,0.73534906,0.0044143214,0.0011920199,0.00010232625,0.010753949,0.00038418276,0.2426736,0.00049725507,0.0015679083,0.00007896859],"about_ca_topic_score_codex":0.00020354241,"about_ca_topic_score_gemma":0.00025517255,"teacher_disagreement_score":0.18765315,"about_ca_system_score_codex":0.00036845362,"about_ca_system_score_gemma":0.00043906816,"threshold_uncertainty_score":0.14635473},"labels":[],"label_agreement":null},{"id":"W2017377922","doi":"10.1016/s1556-0864(15)31635-x","title":"A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Lung cancer; Internal medicine; Paclitaxel; Chemotherapy; Oncology; Cancer; Gastroenterology; Pharmacokinetics; Cisplatin","score_opus":0.012420980461030769,"score_gpt":0.416144619225652,"score_spread":0.4037236387646212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017377922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701625,0.0006423416,0.000121619305,0.00083810237,0.000059182803,0.0007908054,0.000008512617,0.0000023227344,0.00052086],"genre_scores_gemma":[0.9974606,0.00007719934,0.0022352657,0.000079449725,0.00002563614,0.000038076516,0.00002256221,0.000014139739,0.00004709009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989721,0.00007658948,0.0004092657,0.00012113237,0.00029522364,0.0001256623],"domain_scores_gemma":[0.9987781,0.000058639744,0.00053187046,0.0000754533,0.0005073228,0.000048613958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037384123,0.00011090533,0.00038838715,0.00024379943,0.000020854033,0.00000449641,0.000031579715,0.00006992149,0.000030459454],"category_scores_gemma":[0.000023563876,0.00007612064,0.000024384635,0.0002354623,0.000039651113,0.00011375569,0.0000052643613,0.00014914776,1.4268753e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010567054,0.0071252175,0.8102529,0.00016780104,0.00013653515,0.000049738817,0.0019133331,0.004373184,0.00060302013,0.0000059407016,0.000044717333,0.16476053],"study_design_scores_gemma":[0.09015505,0.018838497,0.8817428,0.0007143983,0.0010018011,0.000028924453,0.00038836064,0.0045418185,0.0020855726,0.00015534642,0.00021282774,0.0001346422],"about_ca_topic_score_codex":0.00045222588,"about_ca_topic_score_gemma":0.0020928106,"teacher_disagreement_score":0.1646259,"about_ca_system_score_codex":0.000724463,"about_ca_system_score_gemma":0.0006846552,"threshold_uncertainty_score":0.31041098},"labels":[],"label_agreement":null},{"id":"W2017968348","doi":"10.1097/jto.0000000000000017","title":"The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Thymic carcinoma; Stage (stratigraphy); Lung cancer staging; Lung cancer; Cancer; Disease; Intensive care medicine; Oncology; Pathology; Internal medicine; Thymoma","score_opus":0.05803141444213014,"score_gpt":0.40521525899512806,"score_spread":0.3471838445529979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017968348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890821,0.0011267638,0.0031300862,0.0042377883,0.00049002573,0.0010608562,0.00000874917,0.000015680902,0.00084794784],"genre_scores_gemma":[0.9687803,0.00021017232,0.027071036,0.00025124746,0.00024777418,0.00011631728,0.000006705441,0.000032273274,0.0032841652],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976653,0.00015299021,0.0012131701,0.00017934474,0.0003933646,0.00039584356],"domain_scores_gemma":[0.9968524,0.0004223301,0.0013958629,0.00027400767,0.0009439368,0.00011148716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017633572,0.00019444144,0.0006364207,0.00025144636,0.00023465305,0.000042356092,0.00029700977,0.00015058869,0.00006265295],"category_scores_gemma":[0.00032937294,0.00011589084,0.00022182596,0.00021252758,0.00017787068,0.00017206985,0.00005977865,0.00028802964,0.000014652988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002835216,0.0008201781,0.010923052,0.0010295191,0.00067641924,0.00006286351,0.01188008,0.0000089465275,0.39308348,0.0036292984,0.010679126,0.5643718],"study_design_scores_gemma":[0.0039150314,0.006037639,0.2469311,0.0015839,0.00074661674,0.0012824114,0.039110694,0.0010726429,0.10317827,0.003249576,0.5922629,0.0006291826],"about_ca_topic_score_codex":0.000017917642,"about_ca_topic_score_gemma":0.000028413795,"teacher_disagreement_score":0.5815838,"about_ca_system_score_codex":0.00031279027,"about_ca_system_score_gemma":0.0016117409,"threshold_uncertainty_score":0.47258914},"labels":[],"label_agreement":null},{"id":"W2018754160","doi":"10.1097/jto.0b013e3181b27799","title":"The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Texas MD Anderson Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University; Institut Gustave-Roussy; International Association for the Study of Lung Cancer; Eli Lilly and Company","keywords":"Medicine; Lung cancer staging; Lung cancer; Stage (stratigraphy); TNM staging system; Oncology; Internal medicine; Population; Malignancy; Cancer; Survival analysis; Radiology; Neoplasm staging; Mediastinoscopy","score_opus":0.04987874132873191,"score_gpt":0.4713034335580689,"score_spread":0.421424692229337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018754160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90516055,0.027191343,0.0009109547,0.060297925,0.0009523501,0.0048053428,0.000064543245,0.000009088015,0.0006079361],"genre_scores_gemma":[0.9894455,0.008239009,0.00044649252,0.0005676538,0.00059576303,0.0005577613,0.000001855445,0.000024383535,0.00012156563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954409,0.00138431,0.0013997513,0.00028552246,0.00090410456,0.0005854],"domain_scores_gemma":[0.9938818,0.0023056942,0.0023881155,0.0005459217,0.0008412851,0.00003715084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007843881,0.00025246973,0.00078166946,0.00024580976,0.0003864239,0.00003293295,0.0009893158,0.00014294473,0.000007377295],"category_scores_gemma":[0.0011579609,0.00010462873,0.00029734737,0.0009005648,0.00041702847,0.00020757603,0.00011608383,0.0012164849,3.1434258e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009629119,0.0014434526,0.47568712,0.0069005624,0.0011204178,0.0001383616,0.10716237,0.010941934,0.07475107,0.0011143603,0.01894431,0.29216692],"study_design_scores_gemma":[0.010475121,0.0040911823,0.7007277,0.019528614,0.0048216344,0.00032704338,0.12421092,0.07518847,0.046360783,0.0029855433,0.010335271,0.00094771275],"about_ca_topic_score_codex":0.0006801299,"about_ca_topic_score_gemma":0.0022156588,"teacher_disagreement_score":0.2912192,"about_ca_system_score_codex":0.0014777427,"about_ca_system_score_gemma":0.0018246684,"threshold_uncertainty_score":0.5285089},"labels":[],"label_agreement":null},{"id":"W2019527474","doi":"10.1097/jto.0b013e3181aba89f","title":"A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Erlotinib; Bortezomib; Lung cancer; Oncology; Internal medicine; Phases of clinical research; Cancer; Clinical trial; Multiple myeloma; Epidermal growth factor receptor","score_opus":0.013298029746935674,"score_gpt":0.42461881121354794,"score_spread":0.4113207814666123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019527474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493176,0.0016803299,0.00007165972,0.00077922636,0.000058761427,0.0020523479,0.0000020634886,0.000004061555,0.0004197958],"genre_scores_gemma":[0.99812204,0.00046764655,0.0010912085,0.00009068978,0.000023577652,0.000060980405,0.0000042090037,0.0000095679725,0.0001300849],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99867815,0.00021702936,0.00068166805,0.0001335795,0.00014027773,0.00014931976],"domain_scores_gemma":[0.9988218,0.00014435651,0.0006557745,0.00008900926,0.000205945,0.0000831009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053445966,0.00012540893,0.0010494707,0.00036208247,0.000018776236,0.0000049524983,0.000045612527,0.00006648338,0.000012236339],"category_scores_gemma":[0.0000465104,0.00008351321,0.000051235103,0.00028412632,0.000037562502,0.00010079387,0.0000063845696,0.00020651608,9.992179e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62696004,0.030215697,0.14407142,0.00025777487,0.0007131838,0.0017346032,0.02224892,0.0009903206,0.00435683,0.0000042069537,0.00006585457,0.16838117],"study_design_scores_gemma":[0.8576227,0.02298817,0.11071878,0.00073583843,0.0024923265,0.00018241836,0.0024182717,0.0010378705,0.0015948587,0.00003828612,0.000045111894,0.00012540577],"about_ca_topic_score_codex":0.00020914194,"about_ca_topic_score_gemma":0.0006892485,"teacher_disagreement_score":0.23066263,"about_ca_system_score_codex":0.00035596688,"about_ca_system_score_gemma":0.00043201013,"threshold_uncertainty_score":0.34055698},"labels":[],"label_agreement":null},{"id":"W2020297058","doi":"10.1097/jto.0000000000000283","title":"Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Memorial University of Newfoundland; Foothills Medical Centre; Université Laval; Queen Elizabeth II Health Sciences Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Beatrice Hunter Cancer Research Institute; Juravinski Cancer Centre; St. Joseph’s Healthcare Hamilton; University of British Columbia; Dalhousie University; Ottawa Hospital; University Health Network; Cancer Care Ontario; Vancouver General Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; McMaster University; Brock University; Canadian Centre for Applied Research in Cancer Control","funders":"Canadian Cancer Society Research Institute; Terry Fox Research Institute; Pfizer; Princess Margaret Cancer Foundation; Partenariat Canadien Contre Le Cancer; Canadian Centre for Applied Research in Cancer Control; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Computed tomography; Lung cancer; Resource (disambiguation); Resource use; Lung cancer screening; Tomography; Radiology; Intensive care medicine; Medical physics; Environmental resource management; Oncology","score_opus":0.01821951918217701,"score_gpt":0.3698026707782277,"score_spread":0.3515831515960507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020297058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967976,0.0011072246,0.00011026039,0.0016020675,0.0000922454,0.00011853106,0.0000025998272,0.0000015656591,0.00016790497],"genre_scores_gemma":[0.99902767,0.00013095798,0.00046533014,0.00024964497,0.00011133723,0.000003941969,0.0000010925003,0.0000066002185,0.0000034159798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931794,0.00011225662,0.00023570478,0.00006802129,0.00016737082,0.00009869652],"domain_scores_gemma":[0.9993443,0.00016988169,0.00027228624,0.00006732491,0.00008718058,0.00005904763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022008269,0.000056375527,0.00026426555,0.00010170714,0.000025187268,0.0000039911,0.000044615324,0.000031275144,0.000008126931],"category_scores_gemma":[0.000020793073,0.000035976616,0.000024643501,0.00016911984,0.000043400345,0.00002991363,0.000016610524,0.0001474079,2.080118e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012288642,0.000066515655,0.7957426,0.0000829298,0.00017888358,0.00015672014,0.000279803,0.00045174477,0.000041162813,0.000009411298,0.00028700623,0.2014744],"study_design_scores_gemma":[0.0015299034,0.00054183195,0.99225724,0.0007666156,0.00020435125,0.00018585907,0.00023091679,0.00085578946,0.0006505451,0.0000028100073,0.002734429,0.000039708837],"about_ca_topic_score_codex":0.05781898,"about_ca_topic_score_gemma":0.36916274,"teacher_disagreement_score":0.31134376,"about_ca_system_score_codex":0.00060333766,"about_ca_system_score_gemma":0.0005099814,"threshold_uncertainty_score":0.9484551},"labels":[],"label_agreement":null},{"id":"W2020651197","doi":"10.1097/01.jto.0000283272.03542.5d","title":"D4-02: Aneusomy by FISH analysis and histology as predictors of invasive lung cancer in bronchial biopsies from high risk subjects","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Dysplasia; Pathology; Histology; Lung cancer; Biopsy; Carcinoma in situ; Bronchoscopy; Lung; Cancer; Abnormality; Carcinoma; Population; Internal medicine; Radiology","score_opus":0.01066083645246567,"score_gpt":0.35348438592816017,"score_spread":0.3428235494756945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020651197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98846096,0.008940419,0.000087326356,0.0012040222,0.0006357943,0.00015327056,0.00017112673,0.000004876427,0.0003422185],"genre_scores_gemma":[0.994581,0.003906845,0.00070545997,0.00030628484,0.00037370104,0.0000039448787,0.000014262796,0.000012558545,0.00009595951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978571,0.0003281842,0.0009797113,0.00023573019,0.00030417863,0.00029508007],"domain_scores_gemma":[0.9973262,0.0008228271,0.0012038266,0.00015840693,0.00029724234,0.0001914725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010747466,0.00018865019,0.0014573501,0.0007443763,0.000055035176,0.000005589711,0.000110187626,0.00020236784,0.00025804565],"category_scores_gemma":[0.0006154817,0.00014737077,0.00023142959,0.0005442672,0.00030296677,0.00008308872,0.0000713374,0.0004892656,5.8764874e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029969027,0.00026957053,0.95038766,0.000080290316,0.002855266,0.0011287932,0.0015053975,0.000011914973,0.0065850327,0.000004758624,0.0033563795,0.030818025],"study_design_scores_gemma":[0.0015833069,0.0016927407,0.9733619,0.00008394654,0.0064138556,0.00029249408,0.0013456858,0.00001937936,0.01324762,0.000052466297,0.001786231,0.000120361794],"about_ca_topic_score_codex":0.003915829,"about_ca_topic_score_gemma":0.011784868,"teacher_disagreement_score":0.030697662,"about_ca_system_score_codex":0.00035456047,"about_ca_system_score_gemma":0.00040464115,"threshold_uncertainty_score":0.6576233},"labels":[],"label_agreement":null},{"id":"W2021364039","doi":"10.1097/jto.0b013e31824165d7","title":"Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Diffusing capacity; Pulmonary function testing; Lung cancer; Nuclear medicine; Pneumonitis; Stage (stratigraphy); Lung volumes; Radiation therapy; Lung; Biopsy; Pulmonary toxicity; Radiology; Internal medicine; Lung function","score_opus":0.01789741283420605,"score_gpt":0.38101007632316536,"score_spread":0.3631126634889593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2021364039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97671604,0.01703342,0.0014071505,0.0011658118,0.00095806003,0.002322207,0.00005252424,0.000004841861,0.0003399237],"genre_scores_gemma":[0.9923413,0.0025135044,0.0029438105,0.00030814824,0.0006579123,0.0004333865,0.000002964747,0.000035313587,0.000763666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989462,0.000079775076,0.00039466482,0.00016816474,0.00013365247,0.00027755482],"domain_scores_gemma":[0.9981587,0.0006234476,0.00065141096,0.00014948566,0.00023583147,0.00018113252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000393689,0.00019049668,0.0006735485,0.00012058724,0.000057496814,0.000008776477,0.000051636078,0.00015709485,0.000088082685],"category_scores_gemma":[0.000020013193,0.00013101866,0.00027859988,0.000066202694,0.000039166793,0.00013459988,0.000013732962,0.00014129614,5.5189054e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02908018,0.0045010922,0.82043207,0.0020989247,0.0037818379,0.00006449317,0.0020708672,0.000012322857,0.0041840123,0.000009518698,0.0019046528,0.13186],"study_design_scores_gemma":[0.010312429,0.04267454,0.8788086,0.0008699897,0.0070533603,0.00023645503,0.0002949663,0.00052612514,0.028062372,0.000051590716,0.03086174,0.0002478181],"about_ca_topic_score_codex":0.00006258905,"about_ca_topic_score_gemma":0.000012634758,"teacher_disagreement_score":0.13161218,"about_ca_system_score_codex":0.0011883465,"about_ca_system_score_gemma":0.00022719227,"threshold_uncertainty_score":0.53427863},"labels":[],"label_agreement":null},{"id":"W2022146783","doi":"10.1097/jto.0b013e318060096b","title":"The Difficulties of a Randomized Study in Superior Vena Caval Obstruction","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Central Venous Catheters and Hemodialysis","field":"Health Professions","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mediastinum; Randomized controlled trial; Superior vena cava syndrome; Surgery; Complication; Radiology; Superior vena cava","score_opus":0.03682566662144529,"score_gpt":0.45829615242104477,"score_spread":0.42147048579959945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022146783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958057,0.00053020497,0.00011519201,0.00081698695,0.0016357186,0.00065950304,0.000001350289,0.0000041939434,0.0004311558],"genre_scores_gemma":[0.9987885,0.00022938274,0.0003400618,0.000052311218,0.00036018327,0.000010664206,4.3107116e-7,0.000008468555,0.00021001804],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99611735,0.0016479904,0.0015763826,0.000081878614,0.00024960726,0.00032678884],"domain_scores_gemma":[0.9956898,0.0026697002,0.001157024,0.00012914828,0.00027959887,0.000074718315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0087385075,0.00009154874,0.0009675722,0.00020276943,0.00026954277,0.00000467225,0.00017927954,0.00014665739,0.00004944491],"category_scores_gemma":[0.00073828455,0.000050687955,0.00027224186,0.00018681836,0.00014778755,0.00006136697,0.000044172488,0.00066408317,0.0000043284344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3697432,0.00323231,0.2031707,0.00017376446,0.0009206951,0.00034943924,0.15161896,0.00011754573,0.0049345866,0.0003227502,0.00092894165,0.2644871],"study_design_scores_gemma":[0.12808277,0.0037707454,0.60049754,0.00031918628,0.0012488122,0.00017261921,0.253369,0.00013219078,0.0005317035,0.0013989127,0.010190924,0.0002856153],"about_ca_topic_score_codex":0.00018939638,"about_ca_topic_score_gemma":0.0020673696,"teacher_disagreement_score":0.39732683,"about_ca_system_score_codex":0.00038921248,"about_ca_system_score_gemma":0.0003130098,"threshold_uncertainty_score":0.30286098},"labels":[],"label_agreement":null},{"id":"W2022463221","doi":"10.1097/jto.0b013e318186a272","title":"Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer?","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Performance status; Lung cancer; Internal medicine; Rating scale; Clinical trial; Cohen's kappa; Chemotherapy; Oncology","score_opus":0.04532789985795701,"score_gpt":0.447389640119803,"score_spread":0.402061740261846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022463221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949647,0.006518278,0.000014064755,0.0018001806,0.0007437497,0.00048468952,0.000011561913,0.000012841102,0.00091816235],"genre_scores_gemma":[0.9623876,0.03510035,0.0017547802,0.00032264864,0.00014670896,0.00008458963,0.000006376327,0.000020958449,0.00017597918],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983323,0.00012591394,0.0006399898,0.00020185485,0.00030902892,0.0003909204],"domain_scores_gemma":[0.9985517,0.00030049527,0.00044556006,0.00020178345,0.00022171176,0.00027873367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015463638,0.0002051958,0.0007759408,0.00030614858,0.00009031596,0.0000055281225,0.00007482424,0.00013522436,0.00013092108],"category_scores_gemma":[0.0000865672,0.0001358771,0.00018274675,0.00033677754,0.00006228417,0.00015340008,0.000023265255,0.00028921422,0.000007577144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003445012,0.0016966288,0.48709235,0.00002945818,0.00027715028,0.0020710402,0.0010827698,0.0012635855,0.0004060704,0.0000015432466,0.0016338864,0.5010005],"study_design_scores_gemma":[0.009245048,0.02429069,0.8973952,0.0012910358,0.00084211945,0.0024093143,0.00037387206,0.00093777553,0.013933761,0.0000111653335,0.04900419,0.00026583057],"about_ca_topic_score_codex":0.00011982251,"about_ca_topic_score_gemma":0.0002764058,"teacher_disagreement_score":0.5007347,"about_ca_system_score_codex":0.004931744,"about_ca_system_score_gemma":0.001379382,"threshold_uncertainty_score":0.99888813},"labels":[],"label_agreement":null},{"id":"W2022757670","doi":"10.1097/jto.0000000000000303","title":"The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Oncology; Pathology; Internal medicine","score_opus":0.039266554587099996,"score_gpt":0.387557472074915,"score_spread":0.348290917487815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022757670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9265706,0.0005764922,0.025103072,0.041559163,0.0021145097,0.0038385647,0.00006233369,0.0000111505915,0.00016414122],"genre_scores_gemma":[0.99683684,0.00009363457,0.001265968,0.0002544249,0.001219967,0.00012856473,0.0000046149175,0.00003068619,0.00016531764],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997391,0.00042831028,0.0012171026,0.00016402874,0.00047581954,0.0003237699],"domain_scores_gemma":[0.9934551,0.0029845724,0.0023438071,0.00047630994,0.0006848348,0.000055341174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005381632,0.00018221384,0.0006060571,0.00010660873,0.0005241447,0.000026399537,0.00058377086,0.00010411499,0.000006909278],"category_scores_gemma":[0.000912421,0.00006847558,0.00049169274,0.00018370188,0.00041207238,0.00007630177,0.000074782954,0.00039255279,6.55204e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015986525,0.0012191222,0.0078032473,0.0012936776,0.0012399735,0.000012480817,0.006842768,0.00036413077,0.26902792,0.02581523,0.00969876,0.66069615],"study_design_scores_gemma":[0.010770015,0.017621588,0.3086043,0.00433138,0.006006553,0.0030714162,0.032848902,0.09179547,0.21786569,0.025812251,0.28050095,0.00077149516],"about_ca_topic_score_codex":0.000039602855,"about_ca_topic_score_gemma":0.000048105485,"teacher_disagreement_score":0.6599247,"about_ca_system_score_codex":0.00015170345,"about_ca_system_score_gemma":0.0006106675,"threshold_uncertainty_score":0.403135},"labels":[],"label_agreement":null},{"id":"W2024360503","doi":"10.1097/jto.0b013e31827e2145","title":"Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Clinical trial; Oncology; Clinical Practice; Internal medicine; Family medicine","score_opus":0.08774807205020181,"score_gpt":0.544413237073292,"score_spread":0.45666516502309024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024360503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98102415,0.0016426743,0.00082228816,0.012017515,0.001258674,0.0024488312,0.000024032626,0.000014116179,0.0007477216],"genre_scores_gemma":[0.98847526,0.00042435163,0.009039668,0.0011203254,0.0005850636,0.00016400435,0.000028598739,0.000034210934,0.00012850916],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99153984,0.0038748141,0.0033752215,0.00032221532,0.0004668228,0.0004210875],"domain_scores_gemma":[0.9836458,0.010300686,0.0047475644,0.0003468381,0.00071110897,0.00024799388],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009334325,0.0002694051,0.0025931806,0.00046006154,0.00009164491,0.00004582189,0.0002075068,0.0002589035,0.00021102115],"category_scores_gemma":[0.0144907795,0.00014744155,0.00037063594,0.0004834023,0.00009825878,0.00072466163,0.00003722379,0.0009439597,0.00001592987],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0326933,0.0036752378,0.007888819,0.000017973201,0.0006987625,0.00035098434,0.0019061266,0.00008994317,0.00027337568,0.000006534944,0.0005360381,0.95186293],"study_design_scores_gemma":[0.46560815,0.10882545,0.22793071,0.0067777946,0.011886786,0.00046071943,0.07935001,0.00042811857,0.0007764186,0.0022838525,0.094416365,0.0012556189],"about_ca_topic_score_codex":0.00012794392,"about_ca_topic_score_gemma":0.0001927016,"teacher_disagreement_score":0.9506073,"about_ca_system_score_codex":0.0006076769,"about_ca_system_score_gemma":0.00093002134,"threshold_uncertainty_score":0.9938106},"labels":[],"label_agreement":null},{"id":"W2024593618","doi":"10.1097/01.jto.0000283140.60799.58","title":"B1-02: A Phase 1-2 study of the anti-sense oligonucleotide OGX-011 in combination with a platinum/gemcitabine regimen as first-line therapy for advanced non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ottawa Regional Cancer Foundation; Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Medicine; Carboplatin; Chemotherapy; Regimen; Docetaxel; Internal medicine; Oncology; Clusterin; Cisplatin; Apoptosis; Biology","score_opus":0.02335798420310963,"score_gpt":0.41573086604142884,"score_spread":0.3923728818383192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024593618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278826,0.0007373164,0.0009364036,0.0021261296,0.00050644117,0.002568721,0.000011377209,0.000010675691,0.00031465132],"genre_scores_gemma":[0.9962219,0.00019455382,0.002666359,0.00042986995,0.00019597447,0.00006481306,0.0000034652876,0.000047433987,0.00017560297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997755,0.0002073677,0.0010670411,0.000268003,0.00032619937,0.0003763988],"domain_scores_gemma":[0.99683106,0.00058640045,0.0014382154,0.00037774103,0.0006100974,0.00015648759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014355936,0.00024238681,0.00094433234,0.0003906718,0.000079517704,0.000006674723,0.0002296293,0.00015990551,0.00004680047],"category_scores_gemma":[0.00024552495,0.00016020794,0.00015648526,0.00044409448,0.00012809953,0.00009804685,0.00007239295,0.00047943718,7.9208974e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2559701,0.056010276,0.3133227,0.001527895,0.0013960421,0.006449478,0.027503284,0.0064778454,0.14586648,0.000030893712,0.0011728131,0.1842722],"study_design_scores_gemma":[0.19458663,0.13763367,0.5528321,0.0021591266,0.002734548,0.003885068,0.011834294,0.0039548688,0.08605863,0.00032611593,0.0032002467,0.0007946736],"about_ca_topic_score_codex":0.00006385879,"about_ca_topic_score_gemma":0.0006906343,"teacher_disagreement_score":0.23950943,"about_ca_system_score_codex":0.00043493675,"about_ca_system_score_gemma":0.0005354102,"threshold_uncertainty_score":0.65330905},"labels":[],"label_agreement":null},{"id":"W2024849736","doi":"10.1097/jto.0b013e3182a46bf1","title":"Transesophageal Ultrasonography for Lung Cancer Staging: Learning Curves of Pulmonologists","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Wilson Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pulmonologists; Radiology; Lung cancer; Ultrasonography; Lung; Endoscopic ultrasonography; Oncology; Internal medicine; Endoscopy; Intensive care medicine","score_opus":0.02281103423129477,"score_gpt":0.4295266803131937,"score_spread":0.4067156460818989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024849736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9551669,0.027665744,0.0010332641,0.014368101,0.0005391964,0.00071064924,0.000011008415,0.000014634071,0.00049050373],"genre_scores_gemma":[0.9872031,0.007925331,0.0038615065,0.00047218552,0.00023787914,0.00010349667,0.0000043577475,0.000016916296,0.00017523051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988268,0.00009643987,0.00054248556,0.00012919922,0.00017510678,0.00022998704],"domain_scores_gemma":[0.99835587,0.00033250704,0.0006209556,0.00010129861,0.000452967,0.00013643417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036585238,0.00012737748,0.0006600672,0.00018650161,0.000043145865,0.0000076270976,0.00009985244,0.00010875445,0.0002849143],"category_scores_gemma":[0.000097708966,0.000090312904,0.0003271383,0.00014849933,0.00009113451,0.00012028429,0.0000084789,0.0002798758,9.826468e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014401417,0.0013101472,0.7134626,0.0027034886,0.0017137999,0.000117376214,0.00080859265,0.00022332577,0.0046337238,0.000033422606,0.020213773,0.2533396],"study_design_scores_gemma":[0.008044192,0.021172293,0.8731989,0.006312765,0.006712683,0.00085769343,0.0013272179,0.000992094,0.04496259,0.00037888743,0.035563327,0.0004773539],"about_ca_topic_score_codex":0.00009537002,"about_ca_topic_score_gemma":0.000012347763,"teacher_disagreement_score":0.25286224,"about_ca_system_score_codex":0.00030861716,"about_ca_system_score_gemma":0.0003594346,"threshold_uncertainty_score":0.36828533},"labels":[],"label_agreement":null},{"id":"W2025756290","doi":"10.1097/jto.0b013e318200f972","title":"Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Anaplastic lymphoma kinase; Lung cancer; Epidermal growth factor receptor; Medicine; Cancer research; Cancer; Receptor tyrosine kinase; Oncology; Targeted therapy; Tyrosine kinase; Mesothelioma; Bioinformatics; Internal medicine; Biology; Pathology; Receptor","score_opus":0.054740956245108996,"score_gpt":0.500218743728637,"score_spread":0.44547778748352795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025756290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98386216,0.0009713517,0.00004255614,0.01210448,0.000673277,0.00035697166,0.00015019465,0.0000034285786,0.0018355541],"genre_scores_gemma":[0.9929322,0.0005386922,0.00546309,0.0008070099,0.00013012502,0.000011682953,0.000003454836,0.000012004537,0.00010171961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785763,0.0006054524,0.0010808728,0.0001520611,0.00015132049,0.0001526386],"domain_scores_gemma":[0.9957569,0.001397081,0.002125648,0.0002092877,0.000401824,0.00010920909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009086896,0.000107700784,0.00080078846,0.00007555142,0.00006217977,0.0000012873385,0.00018380112,0.00011596367,0.000050870854],"category_scores_gemma":[0.00037849194,0.000056648445,0.0002824238,0.0002814484,0.000737856,0.000040880008,0.00008300306,0.00033839472,3.360713e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004700778,0.0010965595,0.80257064,0.000045954384,0.0037905546,0.000022322176,0.008988836,0.00002520099,0.0052559646,0.00010302139,0.020345645,0.15305452],"study_design_scores_gemma":[0.0019217505,0.0058447546,0.97553235,0.00027155163,0.0022320629,0.00006835903,0.0067289704,0.00008326443,0.002840188,0.0004732724,0.0039318707,0.00007160212],"about_ca_topic_score_codex":0.0028954337,"about_ca_topic_score_gemma":0.00032051135,"teacher_disagreement_score":0.17296171,"about_ca_system_score_codex":0.00014043058,"about_ca_system_score_gemma":0.0011605168,"threshold_uncertainty_score":0.4377049},"labels":[],"label_agreement":null},{"id":"W2026531006","doi":"10.1097/01.jto.0000283130.99810.bc","title":"A6-06: Integrative genomic and gene expression analysis of NSCLC identifies subtype-specific signatures of pathway disruption","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"","keywords":"Transcriptome; Phenotype; Lung cancer; Gene; Gene expression profiling; Biology; Adenocarcinoma; Gene expression; Computational biology; Cancer; Cancer research; Medicine; Genetics; Pathology","score_opus":0.016705847861384848,"score_gpt":0.3565700237391123,"score_spread":0.33986417587772744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026531006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732721,0.0048863725,0.021212108,0.00009019069,0.00023475282,0.00007160857,0.000013696052,0.0000016773904,0.00021751937],"genre_scores_gemma":[0.9959208,0.0012413813,0.0023974073,0.000033829285,0.00016517502,0.0000016782833,0.000034436063,0.000008581183,0.00019675778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987371,0.00017215083,0.0006200811,0.00018194177,0.00016847486,0.00012024907],"domain_scores_gemma":[0.99821293,0.000055337292,0.0010754318,0.00019765362,0.00036992793,0.00008869946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000807661,0.0001147079,0.00039103217,0.000401626,0.000037721737,0.000007892111,0.0001673229,0.00023228662,0.000027485921],"category_scores_gemma":[0.00009798926,0.00008583539,0.00019175945,0.00026682334,0.00013667562,0.000010715276,0.00006258706,0.00015183726,4.4679305e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010584767,0.00011471681,0.0019767247,0.000015770001,0.00023106992,0.000004727511,0.00038584703,0.00011658493,0.9706527,0.000031070285,0.00091141026,0.0245009],"study_design_scores_gemma":[0.00023722691,0.00048682006,0.047695514,0.00003652606,0.0002079423,0.000014479774,0.0011769868,0.00001982957,0.94337314,0.0001076623,0.0065633547,0.00008051295],"about_ca_topic_score_codex":0.000003059822,"about_ca_topic_score_gemma":0.000024528748,"teacher_disagreement_score":0.04571879,"about_ca_system_score_codex":0.000044419936,"about_ca_system_score_gemma":0.0001282075,"threshold_uncertainty_score":0.35002655},"labels":[],"label_agreement":null},{"id":"W2026635246","doi":"10.1097/jto.0b013e3181c6f035","title":"First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review","year":2010,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Sunnybrook Health Science Centre; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Pemetrexed; Vinorelbine; Oncology; Bevacizumab; Carboplatin; Internal medicine; Docetaxel; Gemcitabine; Gefitinib; Irinotecan; Lung cancer; Chemotherapy; Randomized controlled trial; Cancer; Epidermal growth factor receptor; Cisplatin; Colorectal cancer","score_opus":0.028756584065757228,"score_gpt":0.4678776361280142,"score_spread":0.439121052062257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026635246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033990282,0.9912002,0.000028724111,0.0007814428,0.0006597432,0.006624772,0.000034393073,0.0000051969405,0.0003256166],"genre_scores_gemma":[0.0001638417,0.9970097,0.0006298131,0.0002689311,0.0003377585,0.0009907635,0.000018626197,0.00005002684,0.0005305704],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9964391,0.0004397565,0.0023422004,0.00022577186,0.0002989489,0.00025424745],"domain_scores_gemma":[0.99444264,0.0005970358,0.003981699,0.0005622697,0.0003027723,0.00011360466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083129783,0.00043871207,0.0061254916,0.0003102099,0.00004428278,0.000009004403,0.00034933886,0.0003543756,0.00004434566],"category_scores_gemma":[0.00006507886,0.0002082216,0.0010888703,0.0004271106,0.00004593933,0.00004368506,0.000010970253,0.00054654013,0.0000050235785],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006777446,0.0009992942,0.000013747398,0.6856844,0.0007794818,0.00025608108,0.0007765575,0.000005220661,0.0000017751596,0.0000011401582,0.00010687359,0.31130767],"study_design_scores_gemma":[0.0013651042,0.0025768757,0.000004659339,0.6512321,0.032296266,0.0025325124,0.00013434823,0.000006210575,0.000003812561,0.000002359271,0.30971676,0.00012896123],"about_ca_topic_score_codex":0.00003427316,"about_ca_topic_score_gemma":0.00008607267,"teacher_disagreement_score":0.3111787,"about_ca_system_score_codex":0.0019268594,"about_ca_system_score_gemma":0.0024736181,"threshold_uncertainty_score":0.84910303},"labels":[],"label_agreement":null},{"id":"W2027000221","doi":"10.1016/s1556-0864(15)30405-6","title":"Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefitsin an Orthotopic Human Non-small Cell Lung Cancer Model","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Princess Margaret Cancer Centre; QLT (Canada); Western University; Toronto General Hospital; University of Toronto; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Integrin-linked kinase; Metastasis; Cisplatin; Protein kinase B; In vivo; Kinase; Cancer; Lung cancer; Cancer research; Internal medicine; Pathology; Apoptosis; Chemotherapy; Biology; Cell cycle","score_opus":0.05637292678203847,"score_gpt":0.46730509626079947,"score_spread":0.410932169478761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027000221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913199,0.0009595095,0.0014544016,0.001527233,0.0005248237,0.0004689895,0.00000742695,0.0000243389,0.0037133826],"genre_scores_gemma":[0.977857,0.00029598622,0.01614667,0.00047721018,0.00192206,0.000017773566,0.00001543406,0.000056591434,0.0032113057],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99632376,0.00044704496,0.0017009,0.0004037424,0.00055709435,0.0005674567],"domain_scores_gemma":[0.9970824,0.0002715209,0.00080958667,0.00040403288,0.0008329361,0.0005995099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017497834,0.00028948413,0.0010503064,0.00045080393,0.00013801423,0.000043820044,0.000396161,0.0005771339,0.00031082504],"category_scores_gemma":[0.00013759811,0.0002300195,0.0004195265,0.00028267776,0.00023436159,0.00015291841,0.00013819219,0.001984597,0.0000190825],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036853896,0.006319147,0.27047712,0.0005959867,0.00023362628,0.005179224,0.00030588222,0.0053424616,0.5870528,0.000117694384,0.011558378,0.109132275],"study_design_scores_gemma":[0.020551054,0.02948344,0.38975376,0.0024236795,0.003704917,0.0030492328,0.001556809,0.2817031,0.24107371,0.002518014,0.022130556,0.0020517057],"about_ca_topic_score_codex":0.00018273269,"about_ca_topic_score_gemma":0.00065142056,"teacher_disagreement_score":0.3459791,"about_ca_system_score_codex":0.0005438874,"about_ca_system_score_gemma":0.0018915866,"threshold_uncertainty_score":0.9379923},"labels":[],"label_agreement":null},{"id":"W2027288404","doi":"10.1097/jto.0b013e31823f43af","title":"Adjuvant Chemotherapy for Non-small Cell Lung Cancer: Practice Patterns and Outcomes in the General Population of Ontario, Canada","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; Institute for Clinical Evaluative Sciences; University Health Network; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Carboplatin; Population; Cancer registry; Lung cancer; Internal medicine; Retrospective cohort study; Regimen; Cancer; Cohort; Chemotherapy regimen; Oncology; Proportional hazards model; Chemotherapy; Surgery; Cisplatin","score_opus":0.01818095820754486,"score_gpt":0.39392856071247634,"score_spread":0.3757476025049315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027288404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867097,0.0012043352,0.000035522844,0.0110346135,0.00048740656,0.00038199258,0.000009867154,7.171206e-7,0.00013584229],"genre_scores_gemma":[0.995045,0.0003877513,0.001967524,0.0021782443,0.00024899602,0.000029459407,0.000004128434,0.000008399629,0.00013051435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920684,0.00006761806,0.00035081056,0.00006545882,0.00015022629,0.00015901947],"domain_scores_gemma":[0.9989559,0.00028889507,0.0004943949,0.0000863208,0.00010460091,0.00006988774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048631118,0.000086240834,0.00040244422,0.000048926628,0.00002364125,0.0000042283655,0.00005456303,0.000056018685,0.000028638036],"category_scores_gemma":[0.00002838399,0.000050374456,0.000063220185,0.000035689452,0.000009013475,0.000083408966,0.000008157051,0.00015006156,3.599991e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053180475,0.00049925264,0.9777482,0.000119527,0.00015095065,0.000026188842,0.0022986955,0.000015878335,0.000041195042,0.000005683548,0.0015460629,0.017016541],"study_design_scores_gemma":[0.0017759568,0.0007055354,0.9840806,0.00008882528,0.0005629965,0.00012735641,0.00035720385,0.00003290526,0.0005356207,0.0000062124154,0.011678924,0.00004783822],"about_ca_topic_score_codex":0.69169486,"about_ca_topic_score_gemma":0.876542,"teacher_disagreement_score":0.18484715,"about_ca_system_score_codex":0.0020131532,"about_ca_system_score_gemma":0.0011564709,"threshold_uncertainty_score":0.5264326},"labels":[],"label_agreement":null},{"id":"W2027650328","doi":"10.1097/01.jto.0000283191.47168.f6","title":"C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Everolimus; Response Evaluation Criteria in Solid Tumors; Lung cancer; Internal medicine; Clinical endpoint; Oncology; Adverse effect; Progressive disease; Phases of clinical research; Pharmacodynamics; non-small cell lung cancer (NSCLC); Chemotherapy; Cancer; Urology; Pharmacokinetics; Clinical trial","score_opus":0.011632239800556256,"score_gpt":0.40016437341604594,"score_spread":0.38853213361548966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027650328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963412,0.0005883887,0.0005270136,0.00038996123,0.00023945047,0.0018049859,0.000010214353,0.000010754864,0.0000880064],"genre_scores_gemma":[0.9914892,0.00011992011,0.0076254914,0.00040941418,0.00014072807,0.000032918335,0.000004244494,0.0000483915,0.00012972909],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99803597,0.000079868325,0.00093167723,0.00027254096,0.0003436379,0.00033629645],"domain_scores_gemma":[0.9979777,0.00019904492,0.001065408,0.00019016006,0.00036572784,0.00020197482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047789278,0.0002668856,0.0008625577,0.00044308553,0.00010672882,0.000010289483,0.00010685243,0.00014522673,0.000063534215],"category_scores_gemma":[0.000029110724,0.00017806662,0.00008431613,0.00037818291,0.00006650751,0.0001603634,0.000019343022,0.00035800817,2.385207e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07305217,0.01580395,0.40256372,0.00023640603,0.0006147642,0.00031357427,0.016706767,0.0006312021,0.004030344,2.2495792e-7,0.00006319803,0.48598367],"study_design_scores_gemma":[0.29592305,0.13401136,0.52790904,0.0020930558,0.0022869904,0.000075803335,0.009507216,0.0008402653,0.02463003,0.0000070480155,0.0020538585,0.000662275],"about_ca_topic_score_codex":0.00011586435,"about_ca_topic_score_gemma":0.00055775174,"teacher_disagreement_score":0.4853214,"about_ca_system_score_codex":0.0008277712,"about_ca_system_score_gemma":0.0011266192,"threshold_uncertainty_score":0.7261346},"labels":[],"label_agreement":null},{"id":"W2027964418","doi":"10.1097/jto.0b013e31820b8a52","title":"Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Contouring; Lung cancer; Atelectasis; Radiology; Chemotherapy; Lung; Nuclear medicine; Oncology; Internal medicine","score_opus":0.01345648470153745,"score_gpt":0.3629034649018728,"score_spread":0.3494469802003354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027964418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831972,0.002104256,0.01336876,0.000447059,0.00019088369,0.00014787068,0.000006522867,0.000008864198,0.00052859896],"genre_scores_gemma":[0.90888643,0.00059027143,0.089436874,0.00017272255,0.0007363207,0.000023839997,0.0000010809132,0.000027058302,0.00012541233],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991772,0.00010352622,0.00028888645,0.00013277191,0.00009641913,0.00020116821],"domain_scores_gemma":[0.99931175,0.000050685318,0.00040971398,0.00008073994,0.00005240909,0.00009471349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022814669,0.00013183813,0.0003465013,0.00018729457,0.000052799463,0.0000079929005,0.00014140116,0.00006701869,0.00047613206],"category_scores_gemma":[0.0000018959753,0.00010372411,0.000060625025,0.000085368374,0.00007461191,0.000121215366,0.000024280956,0.0003673698,1.5939328e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026688376,0.0010266261,0.43105045,0.0001560115,0.00022288313,0.00049838383,0.0050436975,0.00005499521,0.3712007,0.00024350056,0.000777632,0.18705626],"study_design_scores_gemma":[0.006520833,0.0032581738,0.3873774,0.0016670369,0.00023043249,0.0010062132,0.0008844564,0.0018151393,0.5800657,0.0035580609,0.012523915,0.0010925989],"about_ca_topic_score_codex":0.0000444,"about_ca_topic_score_gemma":0.000011566126,"teacher_disagreement_score":0.20886499,"about_ca_system_score_codex":0.00019545782,"about_ca_system_score_gemma":0.00010913623,"threshold_uncertainty_score":0.5213312},"labels":[],"label_agreement":null},{"id":"W2028688785","doi":"10.1097/jto.0000000000000075","title":"Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Biomarker; Oncology; Lung cancer; Internal medicine; Drug development; Drug; Phases of clinical research; Targeted therapy; Cancer; Pharmacology","score_opus":0.032864315858611784,"score_gpt":0.4776749802075942,"score_spread":0.4448106643489824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028688785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888377,0.0035279884,0.00014624922,0.004010599,0.0018577193,0.0004321662,0.000006991257,0.000006351049,0.001174192],"genre_scores_gemma":[0.9861107,0.0037554665,0.007986802,0.00041562426,0.001128689,0.000024273637,0.0000036810204,0.000017910028,0.0005568505],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99839306,0.000441505,0.00070682773,0.00016022877,0.00012304909,0.00017531872],"domain_scores_gemma":[0.9985116,0.00039393667,0.00066501094,0.00011778369,0.00014455456,0.00016711724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014088649,0.00011529032,0.0005704988,0.00017744426,0.000050785828,0.000011458435,0.000072312665,0.0001837752,0.00012882293],"category_scores_gemma":[0.0002685003,0.000079719764,0.0001357086,0.00014006734,0.00009490453,0.00006530907,0.000019253388,0.00039756089,0.0000028552374],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072694525,0.0015722543,0.17358348,0.00010625151,0.0014199966,0.00009318129,0.0021080764,0.00001708817,0.0029381544,0.0000060610055,0.011714034,0.7337469],"study_design_scores_gemma":[0.22931042,0.030528624,0.47657362,0.00091869774,0.007508736,0.00035714864,0.0029723474,0.0015526527,0.0028713145,0.0003660405,0.24644473,0.00059566856],"about_ca_topic_score_codex":0.00012126056,"about_ca_topic_score_gemma":0.000082042956,"teacher_disagreement_score":0.73315126,"about_ca_system_score_codex":0.00024984512,"about_ca_system_score_gemma":0.0006206664,"threshold_uncertainty_score":0.32508776},"labels":[],"label_agreement":null},{"id":"W2028918452","doi":"10.1097/jto.0b013e318189f562","title":"Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Pneumonectomy; Internal medicine; Chemotherapy; Lung cancer; Oncology; Stage (stratigraphy); Wedge resection; Surgery","score_opus":0.022638358275795804,"score_gpt":0.3931895175014463,"score_spread":0.3705511592256505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028918452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98143995,0.0068726256,0.000047553767,0.007379235,0.0006779334,0.00026521969,0.0000027780604,0.00000617029,0.003308521],"genre_scores_gemma":[0.98347354,0.010452478,0.0027017072,0.0018128973,0.00056545687,0.000025644775,0.0000012493637,0.00002250849,0.00094451633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988328,0.00005316162,0.00052634045,0.00014703712,0.00019115102,0.00024951244],"domain_scores_gemma":[0.9990722,0.000076606804,0.00038281415,0.00014859032,0.0001521351,0.00016768379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028004052,0.0001418035,0.00066230615,0.00019017319,0.00003621025,0.000003953089,0.00010222421,0.00014046802,0.0003160302],"category_scores_gemma":[0.000014360017,0.00010174953,0.00017719735,0.00016756754,0.000047058922,0.000056011024,0.000016405036,0.0003538217,0.000008899855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027406092,0.003189741,0.74037987,0.00029293756,0.0004037276,0.0071012597,0.0033208798,0.00016836483,0.0023986767,0.0000040254645,0.035495523,0.2045044],"study_design_scores_gemma":[0.007221993,0.0031922867,0.9087427,0.00064106565,0.0004904589,0.0021586579,0.00023311804,0.00022082416,0.012050303,0.00002588719,0.064841226,0.00018142875],"about_ca_topic_score_codex":0.000107927604,"about_ca_topic_score_gemma":0.00016396036,"teacher_disagreement_score":0.20432296,"about_ca_system_score_codex":0.0014018406,"about_ca_system_score_gemma":0.00091850205,"threshold_uncertainty_score":0.41492257},"labels":[],"label_agreement":null},{"id":"W2029754918","doi":"10.1097/jto.0b013e31819f9a8a","title":"Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network; Robarts Clinical Trials","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Pooled analysis; Internal medicine; Randomized controlled trial; Oncology; Meta-analysis","score_opus":0.13531102536660117,"score_gpt":0.5512805536224024,"score_spread":0.4159695282558012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029754918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98597527,0.0027420814,0.00042974387,0.009390279,0.00069716567,0.00049948925,0.000007152702,0.0000033591073,0.00025546472],"genre_scores_gemma":[0.995285,0.002771349,0.0007679855,0.00065524474,0.00047468022,0.0000029409744,0.0000016801137,0.000006064036,0.000035052508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9940643,0.0020025056,0.0032873296,0.00013851031,0.0003639856,0.00014342267],"domain_scores_gemma":[0.9927466,0.00183728,0.004785679,0.0001964095,0.00032784222,0.00010619436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022579754,0.00011455738,0.0038439913,0.0004885246,0.000037442285,0.000008699062,0.00013611924,0.00018098213,0.0001460626],"category_scores_gemma":[0.004696565,0.00006483447,0.001078862,0.00059033796,0.0001000658,0.0000711883,0.00003922675,0.00024381552,1.3602155e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006893337,0.00472005,0.20191765,0.0003952118,0.03030295,0.000054157194,0.0012592844,0.0007327231,0.046604805,0.0013450074,0.009272216,0.6965026],"study_design_scores_gemma":[0.0021567785,0.0022715947,0.9223107,0.00034641995,0.067947306,0.000019729627,0.00018622885,0.0015756107,0.0015269929,0.00031597965,0.0012749777,0.00006767584],"about_ca_topic_score_codex":0.000031466465,"about_ca_topic_score_gemma":0.000029011391,"teacher_disagreement_score":0.72039306,"about_ca_system_score_codex":0.000100956575,"about_ca_system_score_gemma":0.00022165598,"threshold_uncertainty_score":0.7825737},"labels":[],"label_agreement":null},{"id":"W2030193153","doi":"10.1097/jto.0b013e31822f657a","title":"Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Canadian Centre for Applied Research in Cancer Control; University of British Columbia","funders":"","keywords":"Docetaxel; Erlotinib; Medicine; Oncology; Proportional hazards model; Internal medicine; Lung cancer; Hazard ratio; Population; Cost effectiveness; Survival analysis; Cancer; Epidermal growth factor receptor; Confidence interval","score_opus":0.06841015148918138,"score_gpt":0.4833870429544134,"score_spread":0.41497689146523203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030193153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98649305,0.0012333455,0.0037262726,0.00028800196,0.0005814041,0.0018937739,0.00017160056,0.000011324925,0.005601226],"genre_scores_gemma":[0.97986156,0.00075952004,0.01226973,0.00009251655,0.00030747522,0.00032926045,0.00002751115,0.000029161523,0.0063232803],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985526,0.00012849315,0.000717558,0.00020677893,0.00013770883,0.0002568438],"domain_scores_gemma":[0.9975902,0.000387913,0.0010050698,0.00022104521,0.00058822864,0.00020758857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036921276,0.0002046381,0.0012651981,0.0005909274,0.00006052769,0.000005730617,0.00010185666,0.000115042305,0.0006619479],"category_scores_gemma":[0.000025194742,0.00012891037,0.0005601968,0.0005679273,0.00005861648,0.00007516823,0.000013933987,0.000113033275,0.0000014245429],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06517847,0.018580755,0.39993963,0.002832448,0.04278303,0.0014555758,0.015042917,0.0011947852,0.011645142,0.00007475744,0.0015913195,0.43968117],"study_design_scores_gemma":[0.035023145,0.062944725,0.5109641,0.00083008443,0.14870317,0.00045197646,0.0019199231,0.0026948263,0.1905097,0.00020253747,0.045083947,0.00067184854],"about_ca_topic_score_codex":0.0008447842,"about_ca_topic_score_gemma":0.0037993435,"teacher_disagreement_score":0.4390093,"about_ca_system_score_codex":0.0012876075,"about_ca_system_score_gemma":0.0015017465,"threshold_uncertainty_score":0.7247865},"labels":[],"label_agreement":null},{"id":"W2030500811","doi":"10.1097/jto.0b013e318160c0cb","title":"Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Oncology; Lung cancer; Multivariate analysis; Disease; Cancer","score_opus":0.02656031899069337,"score_gpt":0.41168510553714527,"score_spread":0.3851247865464519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030500811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99375266,0.0015924269,0.000021385196,0.0032368482,0.0002342454,0.00039341106,0.000008310467,0.0000048666407,0.0007558181],"genre_scores_gemma":[0.99459827,0.00087164843,0.0020699608,0.00090564,0.000120477926,0.000010315478,0.0000015467342,0.000023739658,0.0013984053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984709,0.000116172385,0.0005962917,0.0001429717,0.00040111374,0.0002725542],"domain_scores_gemma":[0.9978772,0.00020560574,0.0006522955,0.00016900062,0.0009700301,0.00012586982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003462127,0.00014917625,0.00097162393,0.00030172852,0.00003515607,0.000001857858,0.00013359726,0.00010648955,0.00021052256],"category_scores_gemma":[0.0001442384,0.00009456389,0.00011523049,0.0002374433,0.00018151735,0.000075715645,0.000038839473,0.00052917405,0.0000013111119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084219435,0.00086968456,0.978605,0.00022671014,0.00042260104,0.00041354823,0.0016066044,0.000038060647,0.0007410927,7.6034155e-7,0.0029783677,0.0056756353],"study_design_scores_gemma":[0.008060859,0.0045846784,0.9813336,0.00021470009,0.00014605296,0.000075889955,0.00020208512,0.0000144024225,0.0034934941,0.0000099151,0.0017733605,0.00009096904],"about_ca_topic_score_codex":0.000053281427,"about_ca_topic_score_gemma":0.00019068256,"teacher_disagreement_score":0.005584666,"about_ca_system_score_codex":0.00064053753,"about_ca_system_score_gemma":0.0009269307,"threshold_uncertainty_score":0.38562036},"labels":[],"label_agreement":null},{"id":"W2030653110","doi":"10.1097/jto.0000000000000032","title":"Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"BODE index; Medicine; Body mass index; Hazard ratio; Proportional hazards model; Internal medicine; Confidence interval; Cardiology; COPD","score_opus":0.016008798924229576,"score_gpt":0.33838356777817974,"score_spread":0.32237476885395017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030653110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947897,0.0012288325,0.00017694183,0.0015037145,0.00052936474,0.0012480492,0.000009370081,0.0000064387896,0.0005075701],"genre_scores_gemma":[0.9981265,0.00032324053,0.00068829965,0.00006913808,0.00020922718,0.00007672524,0.0000025990973,0.000025926845,0.00047831205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977567,0.0003229263,0.0007807328,0.00025108343,0.0005097084,0.00037882576],"domain_scores_gemma":[0.99782133,0.0001746522,0.00062527467,0.00029106127,0.0008364461,0.00025121856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006862034,0.00019748832,0.00065288146,0.00036927065,0.00009057871,0.000026858736,0.00025281723,0.00025587447,0.00040926522],"category_scores_gemma":[0.00024918522,0.00014196304,0.00012289577,0.00048939424,0.00028784407,0.00034343827,0.000121739264,0.00093363284,0.0000040006307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006195253,0.00042011167,0.95671105,0.0009607646,0.0000889209,0.00006300978,0.00043228615,0.0007339239,0.017089715,0.000004448488,0.00034721327,0.022529045],"study_design_scores_gemma":[0.0016700921,0.0002497026,0.9748234,0.00062238256,0.00032648278,0.0002547943,0.0006682393,0.009993116,0.010624719,0.00047287933,0.00016165242,0.00013253248],"about_ca_topic_score_codex":0.000779339,"about_ca_topic_score_gemma":0.000088610206,"teacher_disagreement_score":0.022396514,"about_ca_system_score_codex":0.0010605532,"about_ca_system_score_gemma":0.0013309333,"threshold_uncertainty_score":0.5789085},"labels":[],"label_agreement":null},{"id":"W2030755679","doi":"10.1097/jto.0b013e31827ce361","title":"Patterns of Failure after Stereotactic Body Radiation Therapy or Lobar Resection for Clinical Stage I Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pneumonectomy; Lung cancer; Stage (stratigraphy); Radiation therapy; Chemotherapy; Surgery; Retrospective cohort study; Radiology; Internal medicine","score_opus":0.04244048711907311,"score_gpt":0.4616937628662159,"score_spread":0.4192532757471428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030755679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907005,0.0018362284,0.00030861012,0.004914262,0.0010402563,0.0011116513,0.000024036379,0.0000052281566,0.000059223745],"genre_scores_gemma":[0.989808,0.006481667,0.0008827563,0.0006227474,0.00093650696,0.0002376796,0.0000053176054,0.00002514291,0.0010001607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984149,0.00017847016,0.0008265755,0.00017613904,0.00019811302,0.00020580844],"domain_scores_gemma":[0.99780726,0.0003986602,0.0009525253,0.00018883348,0.0004926714,0.0001600429],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005591949,0.00014357611,0.0006350403,0.00014042562,0.000031912667,0.00001699419,0.000086535925,0.00021149039,0.0009631949],"category_scores_gemma":[0.00005736799,0.00008982357,0.00028060554,0.0000842686,0.000024602932,0.00016396274,0.000016955388,0.00028432236,0.0000047988406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012304934,0.0017343244,0.90438545,0.0007054706,0.00088670093,0.00010865573,0.00041837848,0.0000085816955,0.0005741488,0.0000012106008,0.010534845,0.06833733],"study_design_scores_gemma":[0.009282096,0.021947578,0.9234864,0.0006400739,0.0013353245,0.00012750505,0.0003077165,0.00030484205,0.0069082757,0.000015533227,0.035481583,0.00016305718],"about_ca_topic_score_codex":0.00015370251,"about_ca_topic_score_gemma":0.00027390817,"teacher_disagreement_score":0.06817427,"about_ca_system_score_codex":0.00069397606,"about_ca_system_score_gemma":0.0006199364,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W2030901022","doi":"10.1097/jto.0b013e3181729299","title":"A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Proportional hazards model; Erlotinib Hydrochloride; Lung cancer; Placebo; Oncology; Cancer; Epidermal growth factor receptor; Pathology","score_opus":0.13341071472068913,"score_gpt":0.5576453272849964,"score_spread":0.4242346125643073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030901022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958786,0.00011909396,0.00007149504,0.000804786,0.001051838,0.001770064,0.000056052733,0.0000037640693,0.00024430954],"genre_scores_gemma":[0.9974615,0.00008180519,0.0013346967,0.00029646544,0.00047688134,0.00010499726,0.000022145727,0.000014319924,0.00020720717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962853,0.0006088498,0.0022462208,0.00019155568,0.0004790822,0.00018899667],"domain_scores_gemma":[0.9953928,0.0015748802,0.0016080413,0.000095910735,0.001132152,0.00019620248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002693302,0.00013524157,0.0013244019,0.00018353866,0.00005960881,0.000003270359,0.00009515307,0.00013952768,0.000028152574],"category_scores_gemma":[0.0033282943,0.00008598931,0.00018585422,0.00024159178,0.00014017407,0.000102715334,0.00001543601,0.00033571813,2.6991214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010370325,0.0058743344,0.95066285,0.000033136035,0.0010644681,0.000293234,0.00021442767,0.000056505738,0.0000019150032,0.000004773096,0.0025659264,0.028858082],"study_design_scores_gemma":[0.017202891,0.01627116,0.9575813,0.00017599299,0.0010423046,0.00011066955,0.00016683222,0.00005682724,0.0000040662994,0.000018249571,0.007292854,0.000076880606],"about_ca_topic_score_codex":0.009727605,"about_ca_topic_score_gemma":0.12883975,"teacher_disagreement_score":0.11911214,"about_ca_system_score_codex":0.00076878647,"about_ca_system_score_gemma":0.010201621,"threshold_uncertainty_score":0.9968667},"labels":[],"label_agreement":null},{"id":"W2031403784","doi":"10.1097/jto.0b013e31815ba7d0","title":"Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of California, Davis","keywords":"Medicine; Pemetrexed; Internal medicine; Neutropenia; Tolerability; Lung cancer; Oncology; Progressive disease; Bortezomib; Toxicity; Gastroenterology; Surgery; Chemotherapy; Adverse effect; Multiple myeloma; Cisplatin","score_opus":0.01833055488774541,"score_gpt":0.4664682977449494,"score_spread":0.448137742857204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031403784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974478,0.0010824947,0.00025198612,0.00017136129,0.00015869876,0.0005428633,0.000008198367,0.000002791564,0.00033384134],"genre_scores_gemma":[0.997439,0.00018510729,0.0021594074,0.00005372423,0.00006466643,0.000013402647,0.000001784753,0.000015786658,0.000067118206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987173,0.00006176996,0.0006705068,0.00014448943,0.00022080715,0.00018512897],"domain_scores_gemma":[0.9985722,0.00014689604,0.00078281335,0.00013021573,0.00023538648,0.00013252777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031023758,0.00014688699,0.00078461034,0.0004247197,0.000025459158,0.0000027445471,0.0000659441,0.000049879007,0.00002249976],"category_scores_gemma":[0.000025468784,0.000094577204,0.00006012772,0.00021369896,0.000057636273,0.000054573116,0.000017772954,0.00021821538,1.0932292e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020619208,0.027037598,0.6371267,0.00041346913,0.000998387,0.00120729,0.007336375,0.0006861468,0.023707941,0.000009928621,0.000028683182,0.2808283],"study_design_scores_gemma":[0.06594608,0.07099912,0.74728197,0.0015342402,0.0034336636,0.00020705472,0.015843788,0.00027483096,0.09412642,0.000028488063,0.00009171684,0.0002326587],"about_ca_topic_score_codex":0.00012870709,"about_ca_topic_score_gemma":0.000996895,"teacher_disagreement_score":0.28059563,"about_ca_system_score_codex":0.00035991406,"about_ca_system_score_gemma":0.00036518925,"threshold_uncertainty_score":0.38567463},"labels":[],"label_agreement":null},{"id":"W2031569728","doi":"10.1097/jto.0b013e3181f1906d","title":"The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices: A Matter of Would, Could, and Should","year":2010,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Lung cancer staging; Stage (stratigraphy); Cancer staging; Scopus; Cancer; TNM staging system; Oncology; Radiology; Internal medicine; MEDLINE; Neoplasm staging","score_opus":0.028401619784447694,"score_gpt":0.40578993254737783,"score_spread":0.3773883127629301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031569728","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2292485,0.045433134,0.000026904778,0.72028315,0.0025034589,0.0012609032,0.000258633,0.000017379401,0.0009679603],"genre_scores_gemma":[0.46143726,0.050612763,0.0045254906,0.46014854,0.014248569,0.00093667454,0.00009054968,0.0004756473,0.007524503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748653,0.00027595024,0.0009697227,0.00034569707,0.0005101785,0.00041189732],"domain_scores_gemma":[0.99672174,0.0006428791,0.0017353231,0.0003911991,0.00032647303,0.00018235561],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006140241,0.0004392002,0.0016935886,0.0002562787,0.00015325133,0.000059241058,0.0001708375,0.0009387031,0.00010440998],"category_scores_gemma":[0.000024481353,0.00023372083,0.0003123879,0.00010811805,0.0002443402,0.00008653602,0.00007718553,0.002702914,0.000001735876],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024453627,0.0007684575,0.19468929,0.008408496,0.0148338955,0.007462237,0.0013016345,0.000013986214,0.00023184797,0.000011610212,0.6627423,0.10709085],"study_design_scores_gemma":[0.0027996772,0.0020072043,0.009499818,0.002867118,0.01369839,0.003939773,0.00042249417,0.00006250957,0.00084699725,0.00001076359,0.96356845,0.00027679908],"about_ca_topic_score_codex":0.0004353494,"about_ca_topic_score_gemma":0.00016839262,"teacher_disagreement_score":0.30082613,"about_ca_system_score_codex":0.0018524689,"about_ca_system_score_gemma":0.0007625944,"threshold_uncertainty_score":0.9995979},"labels":[],"label_agreement":null},{"id":"W2031570350","doi":"10.1097/jto.0b013e318283d958","title":"KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer","year":2013,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; KRAS; Lung cancer; Oncology; Internal medicine; Lung; Cancer; Cancer research; Pathology; Colorectal cancer","score_opus":0.026520790264676575,"score_gpt":0.464020375822829,"score_spread":0.43749958555815244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031570350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031029093,0.9896275,0.00007864499,0.00048251604,0.00062637014,0.002073016,0.000047886195,0.0000066515213,0.003954507],"genre_scores_gemma":[0.0008902767,0.9944238,0.001883811,0.000104760875,0.0003334584,0.00040735924,0.000041553598,0.00004362664,0.0018713293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982385,0.00022183101,0.0008736898,0.0002311783,0.00017971141,0.00025511443],"domain_scores_gemma":[0.9977897,0.00045720473,0.001087772,0.00013467307,0.00028651694,0.00024416702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028746563,0.00028475368,0.0016484542,0.0005346001,0.000052821106,0.000022255841,0.000108434884,0.00035293572,0.00020086067],"category_scores_gemma":[0.00011598389,0.00019576949,0.00026036607,0.00028954487,0.000090474714,0.00010779842,0.000031045558,0.0007450686,0.000014875881],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014794436,0.00038912764,0.0010515476,0.00893851,0.0010643628,0.0007578931,0.00069102313,0.000013455519,0.0000011669556,0.0000030761892,0.0015805719,0.98536134],"study_design_scores_gemma":[0.0020241768,0.0043088016,0.003474143,0.031448178,0.037633993,0.0035818282,0.0007673411,0.00013090632,0.0000029226649,0.00012524903,0.91614443,0.00035804493],"about_ca_topic_score_codex":0.0000984994,"about_ca_topic_score_gemma":0.00005370588,"teacher_disagreement_score":0.9850033,"about_ca_system_score_codex":0.0012591507,"about_ca_system_score_gemma":0.004292761,"threshold_uncertainty_score":0.7983248},"labels":[],"label_agreement":null},{"id":"W2031625514","doi":"10.1097/01.jto.0000269737.05962.a0","title":"Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Epidermal growth factor receptor; Gemcitabine; Internal medicine; ERCC1; Targeted therapy; Cancer research; KRAS; Tyrosine kinase; Cancer; Predictive marker; Chemotherapy; Erlotinib; Adjuvant therapy; DNA repair; Gene; Biology; Receptor","score_opus":0.052436483941243665,"score_gpt":0.5092956571945961,"score_spread":0.45685917325335246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031625514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055668666,0.98870623,0.0008276704,0.00012585621,0.0012286939,0.0025362417,0.00014294942,0.000006716363,0.0008587591],"genre_scores_gemma":[0.0004986199,0.9833153,0.014495483,0.00013087064,0.00056796684,0.00032142422,0.00012028981,0.00006862692,0.00048141772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978801,0.00011722786,0.0011545471,0.0002975044,0.00014328051,0.00040730985],"domain_scores_gemma":[0.99679977,0.0008978031,0.0014761576,0.00021271392,0.00038681936,0.00022673869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032810587,0.00038849603,0.0025222348,0.0007608512,0.000072684204,0.000010901541,0.00015500616,0.0003311373,0.000046388297],"category_scores_gemma":[0.000068506204,0.00021561125,0.0005167131,0.00031082454,0.000049165956,0.000054784603,0.00002587662,0.00041265687,0.0000034730867],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065515796,0.001570055,0.003995771,0.00190021,0.00090695015,0.00030400485,0.00021416252,0.0000055999503,3.875069e-7,0.0000039547876,0.0003192969,0.99012446],"study_design_scores_gemma":[0.004077719,0.0071562105,0.0005277505,0.010820568,0.010818346,0.00017619331,0.000055833214,0.000006904577,0.0000029119317,0.000015253177,0.9661451,0.0001972246],"about_ca_topic_score_codex":0.00006601129,"about_ca_topic_score_gemma":0.00019250812,"teacher_disagreement_score":0.98992723,"about_ca_system_score_codex":0.0039034968,"about_ca_system_score_gemma":0.0041724714,"threshold_uncertainty_score":0.99992037},"labels":[],"label_agreement":null},{"id":"W2031842367","doi":"10.1097/01.jto.0000283752.16093.92","title":"P1-138: A 15-year review of outcomes at The Ottawa Hospital Regional Cancer Centre [TOHRCC] of the treatment of malignant pleural mesothelioma [MPM], with a case-control analysis of the role of radical surgery","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Univariate analysis; Internal medicine; Stage (stratigraphy); Surgery; Extrapleural Pneumonectomy; Performance status; Mesothelioma; Multivariate analysis; Weight loss; Proportional hazards model; Cancer; Lung cancer; Pneumonectomy; Pathology","score_opus":0.027427253388476618,"score_gpt":0.38762110336902944,"score_spread":0.3601938499805528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031842367","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13051942,0.8662513,0.0000013860029,0.0014153323,0.00016037097,0.0008267742,0.00077415415,0.0000013756321,0.00004989302],"genre_scores_gemma":[0.08995088,0.90939766,0.00007194388,0.00016587821,0.000100243604,0.000020732472,0.000023580737,0.000027980941,0.00024109955],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99546933,0.00086547097,0.002228102,0.00021227718,0.0009915974,0.00023321618],"domain_scores_gemma":[0.9917377,0.0016691627,0.0056586023,0.0005502408,0.0002551495,0.00012911521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008922916,0.0003590165,0.004314391,0.00030326162,0.000051512892,0.0000016234906,0.00033419518,0.00019898606,0.00045084686],"category_scores_gemma":[0.0001789446,0.00013424206,0.0035575493,0.0007769852,0.0008336835,0.00003504281,0.00006527518,0.00023772764,6.991916e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032593792,0.00490389,0.5098296,0.02718695,0.029380415,0.0005529807,0.0003776687,0.00007054969,0.00004684676,0.00004279918,0.0019242398,0.42242473],"study_design_scores_gemma":[0.0025086324,0.0040719477,0.3243518,0.08050431,0.20705721,0.004139946,0.00071231066,0.000023276643,0.0004216581,0.000021892898,0.37572932,0.0004577051],"about_ca_topic_score_codex":0.00022788806,"about_ca_topic_score_gemma":0.00024031811,"teacher_disagreement_score":0.42196703,"about_ca_system_score_codex":0.0005843246,"about_ca_system_score_gemma":0.0010901779,"threshold_uncertainty_score":0.54742324},"labels":[],"label_agreement":null},{"id":"W2031964028","doi":"10.1097/jto.0b013e3181ba2f1d","title":"Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Pfizer","keywords":"Medicine; Carboplatin; Pharmacodynamics; Pharmacokinetics; Paclitaxel; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacology; Lung cancer; Oncology; Adverse effect; Area under the curve; Dosing; Gastroenterology; Cancer; Chemotherapy; Progressive disease; Cisplatin","score_opus":0.014821190921398584,"score_gpt":0.33412320526199674,"score_spread":0.31930201434059813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031964028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921616,0.0013692878,0.000042828524,0.0049553635,0.000652595,0.0003945984,0.000021096801,0.000010042393,0.00039263596],"genre_scores_gemma":[0.99594265,0.0019672026,0.0011470966,0.0006790489,0.00017497677,0.000001389252,0.0000074801565,0.000021754293,0.000058425],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980218,0.00023885179,0.00088825804,0.00020635933,0.0003845399,0.00026019602],"domain_scores_gemma":[0.9981279,0.00021524506,0.0007870435,0.0001460035,0.00052146637,0.00020235498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004974769,0.00023772045,0.00071401877,0.0002591054,0.000062256346,0.000015217492,0.00014755093,0.00020994981,0.000026577078],"category_scores_gemma":[0.0002581842,0.00015592911,0.00007953696,0.00047001478,0.00020657221,0.00022337103,0.000057998932,0.00084981415,0.0000010769005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03463383,0.003942919,0.2332698,0.00072037254,0.0006473299,0.00035897412,0.0069929752,0.00004007502,0.3247617,0.00035901504,0.0038412318,0.3904318],"study_design_scores_gemma":[0.017895749,0.020004075,0.8970708,0.00086060213,0.0008605348,0.0013089088,0.00092055835,0.0010424448,0.049160093,0.0008602532,0.009458207,0.0005577523],"about_ca_topic_score_codex":0.000020238702,"about_ca_topic_score_gemma":0.00001250782,"teacher_disagreement_score":0.663801,"about_ca_system_score_codex":0.0002453444,"about_ca_system_score_gemma":0.00033122682,"threshold_uncertainty_score":0.6358605},"labels":[],"label_agreement":null},{"id":"W2032454683","doi":"10.1097/01.jto.0000283193.48953.cd","title":"C1-06: BO17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placebo in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Royal Victoria Hospital","funders":"","keywords":"Medicine; Bevacizumab; Gemcitabine; Carboplatin; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Regimen; Placebo; Progression-free survival; Chemotherapy; Cisplatin; Phases of clinical research; Surgery; Randomized controlled trial; Pathology","score_opus":0.020225855283292567,"score_gpt":0.40939970616873156,"score_spread":0.389173850885439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032454683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568164,0.0007477594,0.00025994997,0.00033094635,0.00035077444,0.0023950315,0.00002173364,0.000008477526,0.00020366962],"genre_scores_gemma":[0.99696404,0.00029372223,0.0017985293,0.00012873694,0.00021688004,0.000071352464,0.000012558899,0.000042915548,0.0004712544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99758863,0.00011227677,0.0010974652,0.00034104686,0.00039000326,0.00047058158],"domain_scores_gemma":[0.9972708,0.0004936367,0.0012386316,0.00020349957,0.000488481,0.000304907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063270825,0.00035630807,0.0013373366,0.0005031859,0.00007495804,0.000007459958,0.00014461149,0.0001603484,0.00022982569],"category_scores_gemma":[0.000045735927,0.00020789061,0.00006532108,0.00050987897,0.00010438745,0.00013939313,0.000059138296,0.00062411744,7.5364596e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.570958,0.02292931,0.29619762,0.0005162242,0.0005490112,0.0025154117,0.0058996673,0.00034072317,0.00043330062,1.2457781e-7,0.0005123759,0.09914824],"study_design_scores_gemma":[0.40527537,0.3231502,0.25493762,0.0015358817,0.0045665395,0.0006665613,0.0035370828,0.0007676888,0.0026312543,0.000002244572,0.0023332569,0.00059631665],"about_ca_topic_score_codex":0.00013776652,"about_ca_topic_score_gemma":0.008781819,"teacher_disagreement_score":0.30022088,"about_ca_system_score_codex":0.0007636749,"about_ca_system_score_gemma":0.00082065345,"threshold_uncertainty_score":0.8477533},"labels":[],"label_agreement":null},{"id":"W2032604714","doi":"10.1097/jto.0b013e3181eaf30f","title":"Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Gemcitabine; Cisplatin; Lung cancer; Oncology; Internal medicine; Phases of clinical research; Chemotherapy; Histology","score_opus":0.014013495300058607,"score_gpt":0.37180322837231183,"score_spread":0.3577897330722532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032604714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99090225,0.0024843344,0.0005310694,0.0009151082,0.0008429835,0.0030752714,0.00025862284,0.000010236236,0.0009801557],"genre_scores_gemma":[0.99639934,0.00052502076,0.0018992429,0.0001702719,0.00016779857,0.00014222936,0.0001783068,0.000047846985,0.00046991714],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996931,0.0003490308,0.0014945501,0.00045047395,0.00040909435,0.00036581192],"domain_scores_gemma":[0.9951413,0.0014883919,0.0022205445,0.0003704079,0.00057319104,0.00020613821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008907812,0.00036684168,0.0016557397,0.00024990176,0.00016235794,0.000016167023,0.00023411661,0.00025592212,0.00008737202],"category_scores_gemma":[0.0002771495,0.00023651999,0.00012965222,0.00040921933,0.0001902859,0.00013605296,0.00007979578,0.00083653897,3.6603217e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8838141,0.0039301543,0.04083653,0.00020014374,0.0013362666,0.00014688463,0.029826146,0.0030548233,0.003961487,0.0000012761773,0.0022563345,0.030635865],"study_design_scores_gemma":[0.93441695,0.004898246,0.031459633,0.0004942966,0.00690885,0.000013115473,0.004763562,0.012667207,0.0018616444,0.0000036340878,0.0021461814,0.00036670692],"about_ca_topic_score_codex":0.002668731,"about_ca_topic_score_gemma":0.0064894403,"teacher_disagreement_score":0.050602835,"about_ca_system_score_codex":0.001168949,"about_ca_system_score_gemma":0.0012763843,"threshold_uncertainty_score":0.96450055},"labels":[],"label_agreement":null},{"id":"W2032713794","doi":"10.1097/01.jto.0000283530.57729.23","title":"P2-066: Analysis of EGFR gene copy number, EGFR mutations, KRAS mutations and EGFR expression in a cohort of non-small cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors at a North American institution.","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"KRAS; Erlotinib; CISH; Gefitinib; Medicine; Lung cancer; Epidermal growth factor receptor; Chromogenic in situ hybridization; Cancer research; Population; Tyrosine kinase; Fluorescence in situ hybridization; Neuroblastoma RAS viral oncogene homolog; Gene duplication; EGFR inhibitors; Oncology; Cancer; Internal medicine; Gene; Biology; Gene expression; In situ hybridization; Genetics; Receptor","score_opus":0.009157552079469352,"score_gpt":0.3628220872885492,"score_spread":0.35366453520907987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032713794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99728626,0.0004155757,0.0010080545,0.00016764329,0.00010829508,0.000600617,0.00020220251,0.000007867802,0.00020346825],"genre_scores_gemma":[0.9934862,0.00031817926,0.005730176,0.00008015175,0.000057635716,0.00003246969,0.00020958706,0.000021219284,0.000064339685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978954,0.00012664229,0.0010961308,0.00025343176,0.00035700752,0.00027135416],"domain_scores_gemma":[0.9969024,0.00022607052,0.0015742584,0.00015346907,0.00088898314,0.00025480104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022697277,0.00022904859,0.0010129089,0.00091931707,0.00010558596,0.0000074720133,0.000079774516,0.000103133614,0.00005158271],"category_scores_gemma":[0.000079609075,0.00017061968,0.00016274561,0.0016072588,0.00030727955,0.0001849969,0.000034491197,0.0002274764,6.532062e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017829163,0.001559227,0.9823024,0.00012795565,0.0012333508,0.00019797769,0.0019178408,0.0011290584,0.0051254476,0.0000012353273,0.00006792051,0.004554656],"study_design_scores_gemma":[0.0033030608,0.0014218944,0.9502577,0.0002083922,0.005598659,0.000048672457,0.00042400183,0.00023890902,0.038302176,0.0000013245548,0.000056534955,0.00013867546],"about_ca_topic_score_codex":0.002060781,"about_ca_topic_score_gemma":0.004547068,"teacher_disagreement_score":0.033176728,"about_ca_system_score_codex":0.0013356776,"about_ca_system_score_gemma":0.00070544495,"threshold_uncertainty_score":0.6957668},"labels":[],"label_agreement":null},{"id":"W2033630804","doi":"10.1016/s1556-0864(15)31590-2","title":"Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montfort Hospital","funders":"Bristol-Myers Squibb","keywords":"Medicine; Carboplatin; Lung cancer; Neutropenia; Internal medicine; Confidence interval; Regimen; Performance status; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Febrile neutropenia; Surgery; Oncology; Progressive disease; Cisplatin","score_opus":0.007400073066617246,"score_gpt":0.3712792204894756,"score_spread":0.3638791474228584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033630804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547267,0.00039690794,0.0000678918,0.0007762383,0.00022404142,0.0016099622,0.00002962595,0.000011053515,0.0014116158],"genre_scores_gemma":[0.99484295,0.000012184988,0.0042210254,0.0001265093,0.000101075646,0.00009811961,0.000022898661,0.00003379274,0.0005414553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984285,0.00009992297,0.00062343664,0.00022866594,0.00031066115,0.00030877496],"domain_scores_gemma":[0.99845755,0.00007287667,0.00068442634,0.00018448666,0.00044961183,0.00015102615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016512071,0.00023032208,0.0006900217,0.0002553527,0.00009245464,0.000013402725,0.00009906395,0.00008289872,0.00003112625],"category_scores_gemma":[0.000012327805,0.00014653265,0.00006988294,0.00026101625,0.00004574915,0.00016279341,0.000023476981,0.00036097775,9.1234614e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038958274,0.03131944,0.87277937,0.00013435722,0.00059053075,0.0014721544,0.004704362,0.0017647537,0.00042576715,0.0000011384074,0.00054288126,0.04730698],"study_design_scores_gemma":[0.11252378,0.20102093,0.675242,0.00073418487,0.0031303521,0.000037719834,0.004567396,0.0006251961,0.0005030371,0.000009583216,0.0012751278,0.00033068607],"about_ca_topic_score_codex":0.00061219407,"about_ca_topic_score_gemma":0.002870652,"teacher_disagreement_score":0.19753735,"about_ca_system_score_codex":0.0008016165,"about_ca_system_score_gemma":0.00072039943,"threshold_uncertainty_score":0.5975428},"labels":[],"label_agreement":null},{"id":"W2034304549","doi":"10.1097/jto.0b013e3182572ead","title":"Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Chemotherapy; Perioperative; Surgery; Hazard ratio; Radiation therapy; Lung cancer; Small-cell carcinoma; Retrospective cohort study; Carcinoma; Internal medicine; Confidence interval","score_opus":0.0170289900780441,"score_gpt":0.3991541811091218,"score_spread":0.3821251910310777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034304549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99643564,0.0008716733,0.000009667265,0.0007516078,0.0002447566,0.00056966406,0.000004738046,0.0000065369586,0.0011057054],"genre_scores_gemma":[0.9982842,0.00014414033,0.00052592135,0.00018873537,0.00023365986,0.00001010795,0.0000025753848,0.000031071748,0.0005795609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781096,0.00055880053,0.0005161172,0.00012987187,0.00045178496,0.00053247693],"domain_scores_gemma":[0.9981715,0.00053352385,0.0004932377,0.00021586586,0.00036329636,0.00022255219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009822701,0.00017551267,0.0008730231,0.0003644805,0.000030202133,0.000003838077,0.00016797309,0.000059192524,0.00012229464],"category_scores_gemma":[0.000328149,0.00009845918,0.00010063687,0.00039276184,0.00009129693,0.000105198225,0.0000767269,0.0006250488,0.0000049858368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059091523,0.0026245697,0.92231256,0.0008354127,0.000114697286,0.00048084173,0.0004528429,0.0000018709911,0.0024355818,4.594713e-7,0.0019189025,0.009730732],"study_design_scores_gemma":[0.026006378,0.057874564,0.82833725,0.00021699347,0.00030080084,0.00028026119,0.00012789223,0.0000108406675,0.07882449,0.0000016669558,0.007889443,0.00012939719],"about_ca_topic_score_codex":0.00002368143,"about_ca_topic_score_gemma":0.00002519834,"teacher_disagreement_score":0.09397529,"about_ca_system_score_codex":0.00040287687,"about_ca_system_score_gemma":0.00035696905,"threshold_uncertainty_score":0.4015049},"labels":[],"label_agreement":null},{"id":"W2034323933","doi":"10.1097/jto.0b013e318217b623","title":"Treatment Delays in Non-small Cell Lung Cancer and Their Prognostic Implications","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Proportional hazards model; Lung cancer; Internal medicine; Chemotherapy; Survival analysis; Oncology; Surgery; Confidence interval","score_opus":0.03809232957842099,"score_gpt":0.37784570975236825,"score_spread":0.33975338017394724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034323933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887705,0.003791556,0.0002718394,0.001650219,0.00031706344,0.00027180996,0.0000075630765,0.000004994247,0.0049144872],"genre_scores_gemma":[0.99749374,0.0011660258,0.0006553176,0.00021791484,0.00017584195,0.00004693123,0.0000013613628,0.000011685222,0.00023116946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932826,0.000052228053,0.00030222288,0.00010847951,0.000046538353,0.000162256],"domain_scores_gemma":[0.99930644,0.00009530032,0.0002148281,0.000114821014,0.00013097543,0.00013762932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016236259,0.000104084545,0.0003518977,0.00014909753,0.00002679409,0.000004457674,0.00006439014,0.00010005313,0.000066434906],"category_scores_gemma":[0.000014948636,0.000069067406,0.00007929313,0.00012330327,0.000038655493,0.00004144966,0.000019136036,0.00018767138,0.0000014983789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009077426,0.0007744106,0.705086,0.00013654491,0.00012872346,0.00022730231,0.015365063,0.00000393849,0.0025757132,0.000022057442,0.00026845012,0.2745041],"study_design_scores_gemma":[0.0022519235,0.0052655037,0.9681075,0.00027822464,0.0008114526,0.0016897356,0.0040591937,0.00018767023,0.0065836622,0.00031997458,0.01025151,0.00019363174],"about_ca_topic_score_codex":0.00050380256,"about_ca_topic_score_gemma":0.0030772153,"teacher_disagreement_score":0.27431047,"about_ca_system_score_codex":0.00041007798,"about_ca_system_score_gemma":0.00045156127,"threshold_uncertainty_score":0.2816487},"labels":[],"label_agreement":null},{"id":"W2034593650","doi":"10.1097/jto.0b013e3182333a0b","title":"Quantitative Computed Tomography Analysis of Emphysema and Lung Cancer Risk","year":2011,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Lung; Lung cancer screening; Radiology; Hounsfield scale; Quantitative computed tomography; Computed tomography; Internal medicine","score_opus":0.032858766947101076,"score_gpt":0.42460349113524176,"score_spread":0.39174472418814066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034593650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81126916,0.056111623,0.0010153074,0.12569362,0.0015611852,0.0011171983,0.0011703152,0.000028951677,0.002032625],"genre_scores_gemma":[0.737307,0.025431398,0.04743722,0.16834638,0.015653623,0.00016670709,0.0010316657,0.0006569885,0.0039690332],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99620676,0.0009657582,0.0011534974,0.00041616813,0.0007970073,0.0004608354],"domain_scores_gemma":[0.9943891,0.0008442544,0.0025493498,0.00040949785,0.0015262645,0.00028152735],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00083407696,0.00036883305,0.0025579182,0.0031631165,0.000072067094,0.0000140204065,0.00034417427,0.0007822026,0.00074505486],"category_scores_gemma":[0.00019384181,0.0002950963,0.0010814697,0.0016059928,0.00067851925,0.00012302247,0.00015571089,0.002963592,0.0000022415197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008255327,0.0010537913,0.27620164,0.005220632,0.07975524,0.010494994,0.0018552716,0.00011331292,0.00043373264,0.00003280082,0.5381673,0.078415945],"study_design_scores_gemma":[0.0019368292,0.0036362268,0.8284261,0.0013820543,0.08433849,0.0007000138,0.0005334441,0.005057653,0.00021310632,0.0004299985,0.07275229,0.00059378595],"about_ca_topic_score_codex":0.000408816,"about_ca_topic_score_gemma":0.0000852834,"teacher_disagreement_score":0.55222446,"about_ca_system_score_codex":0.0006590947,"about_ca_system_score_gemma":0.0013605369,"threshold_uncertainty_score":0.9999501},"labels":[],"label_agreement":null},{"id":"W2034934674","doi":"10.1097/jto.0b013e318265b4df","title":"Endobronchial Ultrasound Doppler Image Features Correlate with mRNA Expression of hif1-α and vegf-c in Patients with Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Lymph; Lymph node; Vascularity; Pathology; Blood flow; Angiogenesis; Lung cancer; Messenger RNA; Lung; Internal medicine; Biology; Gene","score_opus":0.00665023826643339,"score_gpt":0.32943080131767094,"score_spread":0.32278056305123753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034934674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99528885,0.0026127195,0.000034439207,0.0003010188,0.00032841324,0.00038712527,0.000010843641,0.000003328935,0.0010332424],"genre_scores_gemma":[0.9952488,0.0005081324,0.0037362378,0.00011241388,0.00023095244,0.000018959325,0.000005002899,0.000021769109,0.00011770805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988831,0.00008558411,0.0003559008,0.00013865117,0.00026587115,0.00027083722],"domain_scores_gemma":[0.9987283,0.00015947751,0.0005915311,0.00013178054,0.0001867675,0.00020218035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022267361,0.00017286187,0.0005793369,0.00014292932,0.000033666915,0.000008330572,0.000065151304,0.00012192978,0.00008080426],"category_scores_gemma":[0.000018600711,0.000097590775,0.00005470727,0.00010653399,0.000094116105,0.00017821176,0.000026786323,0.00036896073,7.0300786e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006581434,0.0017411641,0.982088,0.00022738516,0.00017219652,0.00008616192,0.001405007,0.000028961509,0.0021566201,0.0000016026762,0.002120854,0.003390609],"study_design_scores_gemma":[0.007421261,0.0035011924,0.97185916,0.0009810083,0.0008652132,0.0002684776,0.00017100279,0.000003004875,0.014339871,0.0000037126892,0.00047487763,0.00011124693],"about_ca_topic_score_codex":0.000098116936,"about_ca_topic_score_gemma":0.00011193494,"teacher_disagreement_score":0.012183251,"about_ca_system_score_codex":0.0005052699,"about_ca_system_score_gemma":0.00028439244,"threshold_uncertainty_score":0.39796364},"labels":[],"label_agreement":null},{"id":"W2035196686","doi":"10.1097/jto.0000000000000314","title":"Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Steering committee; Medical physics; Oncology; Engineering management","score_opus":0.10711290547778558,"score_gpt":0.5311780178185476,"score_spread":0.424065112340762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035196686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9480658,0.0008999922,0.03726343,0.00594002,0.00050352054,0.007159129,0.000010416752,0.0000068731083,0.00015083165],"genre_scores_gemma":[0.9107126,0.000047203743,0.086631335,0.00019429198,0.00024242619,0.0019776616,0.0000034806947,0.0000248418,0.0001661843],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973189,0.00018560133,0.0018381112,0.00018958554,0.00025073043,0.00021705736],"domain_scores_gemma":[0.9963658,0.0007820064,0.0019132029,0.00018821035,0.0006625276,0.00008826152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002405615,0.00017875333,0.00092972594,0.00026105376,0.00007640672,0.000014658179,0.00013296101,0.00013824315,0.000014079419],"category_scores_gemma":[0.0005897294,0.000112215625,0.0002066628,0.00022337816,0.00011866797,0.000081430335,0.000036470476,0.00022589092,6.795327e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010291992,0.00060667744,0.08608917,0.0030475794,0.0021015743,0.00002385468,0.03903792,0.003671636,0.023601407,0.00016820974,0.0031774007,0.8281826],"study_design_scores_gemma":[0.029585242,0.02912818,0.36048326,0.112529196,0.008773548,0.0006724191,0.2025509,0.023709893,0.13868071,0.0029418047,0.08887785,0.0020670004],"about_ca_topic_score_codex":0.00016596414,"about_ca_topic_score_gemma":0.0019226111,"teacher_disagreement_score":0.82611555,"about_ca_system_score_codex":0.0006677389,"about_ca_system_score_gemma":0.0026829098,"threshold_uncertainty_score":0.47593668},"labels":[],"label_agreement":null},{"id":"W2036141953","doi":"10.1097/jto.0b013e31819e77ce","title":"Prediction of True Positive Lung Cancers in Individuals with Abnormal Suspicious Chest Radiographs—A Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; National Lung Screening Trial; Receiver operating characteristic; Body mass index; Colorectal cancer; Lung; Prospective cohort study; Radiography; Logistic regression; Prostate cancer; Lung cancer screening; Cancer; Oncology; Radiology","score_opus":0.016369751348168305,"score_gpt":0.36810957746838896,"score_spread":0.35173982612022064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036141953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993842,0.0019574857,0.000032702872,0.0016809318,0.00029559407,0.0019237639,0.0000461032,0.000009218747,0.00021219114],"genre_scores_gemma":[0.9976068,0.00074846006,0.001078528,0.00013974095,0.00030090244,0.000083660365,0.000008234373,0.000015687832,0.00001796246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99812895,0.00024405621,0.0007427168,0.00023271036,0.00037502378,0.0002765161],"domain_scores_gemma":[0.99851,0.00014107375,0.000816908,0.00011101617,0.00024788678,0.00017309285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008065513,0.00020338548,0.0009057146,0.000517032,0.000066935056,0.00001806668,0.000078423254,0.00014072607,0.00002115894],"category_scores_gemma":[0.00003698284,0.00014518532,0.00009866524,0.00046659802,0.00010576675,0.00019957667,0.000017771647,0.00041021997,5.82085e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06621233,0.0020281924,0.88997304,0.00006325371,0.0012527114,0.0005958562,0.004875499,0.00027824653,0.000096460564,0.000004253992,0.00038248918,0.034237657],"study_design_scores_gemma":[0.04780475,0.0446511,0.90230733,0.0006699872,0.0017095525,0.0004464907,0.001519263,0.00010431165,0.0005715628,0.000009081659,0.000103173195,0.0001034237],"about_ca_topic_score_codex":0.0007674205,"about_ca_topic_score_gemma":0.00086082506,"teacher_disagreement_score":0.04262291,"about_ca_system_score_codex":0.0012766952,"about_ca_system_score_gemma":0.00091832556,"threshold_uncertainty_score":0.5920485},"labels":[],"label_agreement":null},{"id":"W2036855640","doi":"10.1097/jto.0b013e318260e00d","title":"A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cone beam computed tomography; Lung cancer; Nuclear medicine; Radiation therapy; Stage (stratigraphy); Radiology; Internal medicine; Computed tomography","score_opus":0.030241822947970655,"score_gpt":0.4345624354750607,"score_spread":0.40432061252709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036855640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96990395,0.014697121,0.011456697,0.0014740423,0.0008932536,0.0012622989,0.00025621805,0.0000152060165,0.00004121325],"genre_scores_gemma":[0.9269346,0.0021025287,0.06893763,0.001078224,0.000610191,0.00005699194,0.000032321583,0.00006800521,0.00017952664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997314,0.0002698414,0.0012455094,0.00028043048,0.00037575336,0.0005144774],"domain_scores_gemma":[0.99544156,0.0006776407,0.0020513446,0.00034922437,0.001126823,0.00035340872],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007721585,0.00037532597,0.002313097,0.0011365662,0.00009936792,0.000033151482,0.0002057909,0.00022459017,0.00019385753],"category_scores_gemma":[0.000037854206,0.00027907584,0.0009286496,0.0014242526,0.00013792496,0.00028505927,0.000025869413,0.0003137066,1.8647425e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032193235,0.0034313665,0.9427308,0.0005267129,0.028319642,0.00008954313,0.003479684,0.0013756253,0.012648659,0.000004352917,0.0014640806,0.0027102428],"study_design_scores_gemma":[0.01716646,0.0045368094,0.89020383,0.0005629454,0.039013505,0.0001356173,0.0010706247,0.028591702,0.014143114,0.0000027981685,0.0040117973,0.00056081126],"about_ca_topic_score_codex":0.00028580555,"about_ca_topic_score_gemma":0.00011916141,"teacher_disagreement_score":0.05748093,"about_ca_system_score_codex":0.0019580948,"about_ca_system_score_gemma":0.000933151,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W2037177568","doi":"10.1097/jto.0b013e318275b327","title":"Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; Regional Municipality of Durham; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Erlotinib; Quality of life (healthcare); Internal medicine; Gemcitabine; Lung cancer; Oncology; Chemotherapy; Cancer; Epidermal growth factor receptor","score_opus":0.037281891279979544,"score_gpt":0.46244101102089336,"score_spread":0.4251591197409138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037177568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905233,0.0042621903,0.00126259,0.0011136129,0.0005581062,0.0012756576,0.00007411383,0.0000075623752,0.0009228895],"genre_scores_gemma":[0.98926306,0.00036751758,0.009050311,0.00030952596,0.00036742314,0.00007917777,0.000032758253,0.00002371635,0.00050649187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963925,0.00042147367,0.002328137,0.00018803177,0.00034109093,0.00032878213],"domain_scores_gemma":[0.9939023,0.0020045023,0.0030228796,0.00023197051,0.00058932824,0.00024902035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027837772,0.00023188874,0.0029854863,0.00053877407,0.000040273368,0.000004768516,0.00013811029,0.00019111203,0.000434134],"category_scores_gemma":[0.0014031604,0.00017046183,0.0006478801,0.0010297861,0.00009415568,0.00015308184,0.000025847203,0.0003278697,3.476128e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83002406,0.0045592403,0.10537179,0.00058370235,0.0072957305,0.000016198474,0.0034097608,0.0023012294,0.025305152,0.000006171037,0.0005598735,0.020567087],"study_design_scores_gemma":[0.9463391,0.0033915306,0.025697585,0.0003510341,0.012830207,0.000016662281,0.00052102795,0.003676062,0.0060531925,0.000020978272,0.0008365457,0.00026612266],"about_ca_topic_score_codex":0.0004990176,"about_ca_topic_score_gemma":0.00056778337,"teacher_disagreement_score":0.116314985,"about_ca_system_score_codex":0.00045587283,"about_ca_system_score_gemma":0.00094420544,"threshold_uncertainty_score":0.69512314},"labels":[],"label_agreement":null},{"id":"W2037745350","doi":"10.1097/01.jto.0000283402.21334.01","title":"PD3-1-8: Motexafin Gadolinium (MGd) is active as a single agent in advanced non-small-cell lung cancer (NSCLC) patients who failed platinum-based chemotherapy: preliminary results of a phase II trial","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metal complexes synthesis and properties","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Chemotherapy; Regimen; Gastroenterology; Adenocarcinoma; Chemotherapy regimen; Rash; Cancer","score_opus":0.04330509680022206,"score_gpt":0.399930743098755,"score_spread":0.35662564629853294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037745350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931262,0.000741081,0.0002583484,0.001265498,0.00065327313,0.001229932,0.000038705577,0.000008270357,0.002678654],"genre_scores_gemma":[0.9937342,0.00011938912,0.004071907,0.00093814445,0.00036486657,0.000019910287,0.000009171363,0.000042584008,0.00069983036],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966334,0.00032859005,0.0017772745,0.00031921145,0.00050845137,0.00043304043],"domain_scores_gemma":[0.9963688,0.0005806125,0.0020024462,0.00030132048,0.00051766576,0.00022910972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015921001,0.0003008467,0.0013568441,0.00049018266,0.000074780386,0.000009548378,0.00024028381,0.00029056403,0.0002572367],"category_scores_gemma":[0.00054236595,0.0002287454,0.0003524735,0.00032066993,0.000104581915,0.00013592461,0.000065138076,0.00059943355,0.0000030476533],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68703973,0.008683226,0.0005393432,0.00025305842,0.00019575452,0.00013648593,0.0051689977,0.000084624124,0.085860096,3.4722618e-7,0.0008931201,0.21114522],"study_design_scores_gemma":[0.18311922,0.111563265,0.0071950713,0.002116592,0.000603105,0.00003421014,0.001066514,0.0018419101,0.68366575,0.000028418885,0.008394674,0.0003712516],"about_ca_topic_score_codex":0.00009128829,"about_ca_topic_score_gemma":0.00005780838,"teacher_disagreement_score":0.5978057,"about_ca_system_score_codex":0.0005785741,"about_ca_system_score_gemma":0.00092869124,"threshold_uncertainty_score":0.93279666},"labels":[],"label_agreement":null},{"id":"W2038822008","doi":"10.1097/01.jto.0000284054.96114.bf","title":"P3-078: MO19390: an open-label safety study of bevacizumab in combination with chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Bevacizumab; Medicine; Carboplatin; Chemotherapy; Internal medicine; Oncology; Regimen; Chemotherapy regimen; Clinical endpoint; Lung cancer; Surgery; Clinical trial; Cisplatin","score_opus":0.023025813081603036,"score_gpt":0.4326784761061702,"score_spread":0.40965266302456715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038822008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995217,0.00033330184,0.0004545834,0.00036493764,0.00021085673,0.0029110066,0.000025423868,0.00000501874,0.00047784502],"genre_scores_gemma":[0.99389285,0.00043701872,0.005183056,0.00007250583,0.000053691198,0.00007151699,0.000032924698,0.00003837169,0.00021809257],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980681,0.00008647127,0.0009394672,0.0002621481,0.00037872748,0.0002650822],"domain_scores_gemma":[0.9973067,0.0001470155,0.0013328055,0.00026819855,0.0007680943,0.00017717048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032656698,0.0002585732,0.000988976,0.00031734622,0.00006989028,0.000008638644,0.00018302136,0.00010596732,0.000060734244],"category_scores_gemma":[0.000015516707,0.00015388112,0.000042464973,0.0004192951,0.000056473382,0.00021607798,0.000024566574,0.00018197995,4.3122483e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15887234,0.094226904,0.21709374,0.00024126041,0.00085052376,0.0003385466,0.014781334,0.0011248164,0.00028398097,0.00000202062,0.000025337195,0.5121592],"study_design_scores_gemma":[0.1504512,0.3837778,0.45359087,0.00082124746,0.0020702232,0.000065538465,0.0041258004,0.00043307382,0.0036264104,0.000010716966,0.0007509751,0.0002761682],"about_ca_topic_score_codex":0.0005792127,"about_ca_topic_score_gemma":0.0060428167,"teacher_disagreement_score":0.511883,"about_ca_system_score_codex":0.0018133011,"about_ca_system_score_gemma":0.0011874045,"threshold_uncertainty_score":0.627509},"labels":[],"label_agreement":null},{"id":"W2039529590","doi":"10.1097/jto.0b013e318168be93","title":"Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mutation; Exon; Adenocarcinoma; Mutation testing; Molecular biology; Medicine; Genetic heterogeneity; Tumor heterogeneity; Pathology; Cancer research; Gene; Genetics; Biology; Cancer; Phenotype","score_opus":0.03125366369807042,"score_gpt":0.4581790945065547,"score_spread":0.4269254308084843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039529590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942409,0.0023191294,0.00033041663,0.0013127939,0.00026355777,0.00015118654,0.0000031211864,0.0000035979635,0.0013752913],"genre_scores_gemma":[0.99559015,0.00014352301,0.0037718946,0.00013913798,0.00013087236,0.0000035407088,0.0000043180844,0.0000079051115,0.00020863315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911433,0.000081475046,0.00046076495,0.00007575453,0.0001576807,0.00011001384],"domain_scores_gemma":[0.99918574,0.00007998076,0.00037457855,0.00008976842,0.00019070612,0.0000792416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018826059,0.000068487534,0.00036892254,0.00022153236,0.000026670241,0.0000014635976,0.000051689443,0.000085314394,0.000060379607],"category_scores_gemma":[0.000077405464,0.000053770527,0.00007653623,0.00015777916,0.000059567952,0.00008761636,0.000011031715,0.0001539984,0.0000041389453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002238658,0.0017997568,0.8013106,0.00027975955,0.000543356,0.008234242,0.0057439697,0.00030285068,0.012760691,0.00005722802,0.0020898602,0.16463906],"study_design_scores_gemma":[0.002231532,0.0031962325,0.9494491,0.00013123683,0.0005082948,0.009283632,0.00037133484,0.00007276531,0.030983366,0.00008842758,0.0036128855,0.00007114584],"about_ca_topic_score_codex":0.00004532962,"about_ca_topic_score_gemma":0.000038376398,"teacher_disagreement_score":0.1645679,"about_ca_system_score_codex":0.00043422615,"about_ca_system_score_gemma":0.0005244629,"threshold_uncertainty_score":0.21926984},"labels":[],"label_agreement":null},{"id":"W2039850325","doi":"10.1097/jto.0b013e3181bf111d","title":"Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nelfinavir; Radiation therapy; Lung cancer; Regimen; Chemoradiotherapy; Positron emission tomography; Radiology; Nuclear medicine; Surgery; Oncology; Viral load; Human immunodeficiency virus (HIV); Immunology","score_opus":0.010244901750540433,"score_gpt":0.38195021972980064,"score_spread":0.3717053179792602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039850325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935084,0.002927879,0.00007015471,0.0026778036,0.00016860553,0.00034477442,0.00001545951,0.000007157941,0.00027978662],"genre_scores_gemma":[0.998565,0.00026953183,0.00038473404,0.00063133705,0.00008054705,0.0000145039685,0.0000034088314,0.000011991572,0.000038935013],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99866533,0.00018968427,0.00053254433,0.0001530786,0.00017549866,0.00028384844],"domain_scores_gemma":[0.9987531,0.00012058689,0.00080287486,0.0000760579,0.00014575578,0.0001016292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073512393,0.00012460507,0.00045338023,0.00032430913,0.00013449097,0.000016943484,0.00006086733,0.000104587074,0.00003623107],"category_scores_gemma":[0.00040702577,0.00011185326,0.00012045514,0.000215892,0.000039355295,0.0001600343,0.000019735411,0.00028821456,1.3952547e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071426906,0.0009586585,0.021870902,0.00013517436,0.00021822802,0.00065001426,0.0073670894,0.00076691824,0.44314033,0.000022621001,0.00046439652,0.4529788],"study_design_scores_gemma":[0.008076781,0.007978609,0.9613116,0.0006187105,0.00049305375,0.00044758953,0.0024527926,0.0017879858,0.015909912,0.00021519753,0.00043468154,0.00027312138],"about_ca_topic_score_codex":0.00008571804,"about_ca_topic_score_gemma":0.000050670646,"teacher_disagreement_score":0.93944067,"about_ca_system_score_codex":0.0013892768,"about_ca_system_score_gemma":0.00043146434,"threshold_uncertainty_score":0.45612437},"labels":[],"label_agreement":null},{"id":"W2040260890","doi":"10.1097/jto.0b013e3182a47501","title":"Radiotherapy for Intubated Patients with Malignant Airway Obstruction: Futile or Facilitating Extubation?","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Tracheal and airway disorders","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Airway obstruction; Radiation therapy; Intubation; Airway; Intensive care medicine; Surgery","score_opus":0.018315767526805086,"score_gpt":0.3568677985765,"score_spread":0.3385520310496949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040260890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882725,0.0002015903,0.0051083113,0.0049734795,0.00043953714,0.00068329467,0.000010510007,0.000020392514,0.0002903698],"genre_scores_gemma":[0.9500469,0.00004933774,0.047664754,0.00048420485,0.00032473865,0.000045759865,0.000018595922,0.000025755715,0.0013399669],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987928,0.000075330536,0.00054680643,0.00013661903,0.00022064429,0.00022780003],"domain_scores_gemma":[0.9982896,0.00023008036,0.00048236278,0.00010677432,0.0007344376,0.00015677756],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022558923,0.00013615574,0.00044920584,0.0001464983,0.00008841744,0.000016455697,0.0000844127,0.00012261036,0.0009795448],"category_scores_gemma":[0.00015836851,0.00007865701,0.000107628926,0.00017393884,0.00007808648,0.00023069253,0.000007916724,0.00022419875,0.000010659506],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060419175,0.0006255537,0.01178372,0.00015608592,0.0002285763,0.000014253288,0.001014319,0.00009071739,0.0010020394,0.000018696275,0.0041408176,0.9748833],"study_design_scores_gemma":[0.039025646,0.16114207,0.5258896,0.0013457143,0.0013950453,0.0023512498,0.019565834,0.0045528463,0.0054649715,0.0025033022,0.23547052,0.0012932619],"about_ca_topic_score_codex":0.000011875443,"about_ca_topic_score_gemma":0.000010739268,"teacher_disagreement_score":0.97359,"about_ca_system_score_codex":0.00020046257,"about_ca_system_score_gemma":0.0002830894,"threshold_uncertainty_score":0.9999337},"labels":[],"label_agreement":null},{"id":"W2040376006","doi":"10.1097/jto.0b013e3181d1273d","title":"Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Sanofi","keywords":"Pemetrexed; Medicine; Gemcitabine; Cisplatin; Oncology; Internal medicine; Lung cancer; Subgroup analysis; Exploratory analysis; Chemotherapy; Confidence interval","score_opus":0.017154949277299467,"score_gpt":0.4004389938961633,"score_spread":0.3832840446188638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040376006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973613,0.0002021218,0.00007251627,0.000215156,0.0003734784,0.0011181883,0.00024452302,0.0000043133964,0.00040841632],"genre_scores_gemma":[0.99606013,0.00016671437,0.0034309716,0.000010717109,0.0000968088,0.000034015375,0.00014300722,0.000021443248,0.000036199544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976208,0.00012634708,0.0014266823,0.0002689043,0.0003381979,0.00021907645],"domain_scores_gemma":[0.9964543,0.0003137108,0.002091248,0.00032254163,0.0005810758,0.00023709735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042425215,0.0002432514,0.0014926034,0.0008253475,0.000048680504,0.0000045244524,0.00011089377,0.00015931744,0.00005706517],"category_scores_gemma":[0.00014207113,0.00017140068,0.00018776077,0.0008793267,0.00013166074,0.0001748299,0.000025494104,0.00026152193,1.4860916e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.796162,0.013756622,0.024922328,0.00016466322,0.0038950765,0.00012837144,0.00849437,0.0015878634,0.004119245,0.000004621026,0.000009153643,0.1467557],"study_design_scores_gemma":[0.7477819,0.098639496,0.122124664,0.0004621454,0.020653524,0.000014331264,0.0024789653,0.0015503989,0.005726426,0.000005179415,0.00030050075,0.00026251626],"about_ca_topic_score_codex":0.0002831185,"about_ca_topic_score_gemma":0.0051816427,"teacher_disagreement_score":0.14649317,"about_ca_system_score_codex":0.00039907693,"about_ca_system_score_gemma":0.0008887914,"threshold_uncertainty_score":0.69895166},"labels":[],"label_agreement":null},{"id":"W2040581402","doi":"10.1097/jto.0b013e3181c0a313","title":"Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centracare","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Proportional hazards model; Internal medicine; Lung cancer; Oncology; Progression-free survival; Survival analysis; Confidence interval; Overall survival","score_opus":0.0454404424386616,"score_gpt":0.4894780537140975,"score_spread":0.44403761127543595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040581402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98702335,0.0014790306,0.00021734179,0.0066850153,0.0026784472,0.0009427175,0.000025559808,0.0000056833396,0.00094284123],"genre_scores_gemma":[0.9841765,0.00080603897,0.012445021,0.00064331415,0.0011264556,0.00018204747,0.000004804906,0.00002372931,0.0005920581],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835676,0.00010116302,0.00094476383,0.00017498393,0.00014858932,0.00027371518],"domain_scores_gemma":[0.9978824,0.0005781542,0.0009117321,0.00016847215,0.00025830977,0.00020088186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017046474,0.00015402271,0.0011417317,0.0002225566,0.00005272343,0.000007960808,0.00011568942,0.00018759342,0.00030990178],"category_scores_gemma":[0.00038163777,0.00010741404,0.00031306385,0.00011437229,0.00003274918,0.00008361416,0.000027971464,0.0004528495,0.0000022570164],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01797813,0.009078356,0.020815078,0.00060660054,0.0005623336,0.0008118297,0.0015846045,0.000073484705,0.15661262,0.000027110767,0.017198062,0.77465177],"study_design_scores_gemma":[0.09806533,0.03804508,0.015070815,0.001666712,0.0051989807,0.0008014745,0.0006260906,0.0007250692,0.53651047,0.00055428914,0.3021785,0.00055716763],"about_ca_topic_score_codex":0.000025228532,"about_ca_topic_score_gemma":0.0004126087,"teacher_disagreement_score":0.77409464,"about_ca_system_score_codex":0.00064961467,"about_ca_system_score_gemma":0.001039893,"threshold_uncertainty_score":0.43802175},"labels":[],"label_agreement":null},{"id":"W2040665303","doi":"10.1097/jto.0000000000000264","title":"Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Reproducibility; Pathology; Chromatography","score_opus":0.06282599643344805,"score_gpt":0.4364768087589718,"score_spread":0.3736508123255238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040665303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972234,0.00010638293,0.00002089697,0.0013338727,0.00067079504,0.00029721568,0.0000041519825,0.000009146918,0.00033416244],"genre_scores_gemma":[0.9983836,0.00005389853,0.001130087,0.00014121852,0.0002195841,0.000022615835,0.000008637835,0.000009754395,0.000030636926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974903,0.00072147127,0.0009047025,0.0004366905,0.0002974335,0.00014939191],"domain_scores_gemma":[0.998088,0.00029512204,0.0005800664,0.0005979467,0.00030898163,0.00012985936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002816443,0.00013345799,0.00076357386,0.0002426252,0.000021167376,0.0000067830188,0.00018777362,0.0001056077,0.00022227045],"category_scores_gemma":[0.0015555448,0.00008952853,0.00016337156,0.00013866418,0.000067785724,0.00012899066,0.0000564703,0.00029057323,0.0000036337285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002023015,0.017807223,0.9366269,0.000016411246,0.0001000814,0.00061714044,0.00058722915,0.000012276089,0.00016900018,0.000017890268,0.000060595357,0.04196224],"study_design_scores_gemma":[0.0028778042,0.011391763,0.9833737,0.00007806733,0.00025639212,0.00029671672,0.00025669608,0.00007066313,0.0008394431,0.00016755472,0.00032202137,0.00006919346],"about_ca_topic_score_codex":0.00010413196,"about_ca_topic_score_gemma":0.00012669885,"teacher_disagreement_score":0.046746787,"about_ca_system_score_codex":0.0002905652,"about_ca_system_score_gemma":0.00008255516,"threshold_uncertainty_score":0.36508673},"labels":[],"label_agreement":null},{"id":"W2041814933","doi":"10.1097/jto.0b013e3181a94b08","title":"Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Genentech; Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Erlotinib; Pharmacodynamics; Separation (statistics); Pharmacology; Oncology; Internal medicine; Pharmacokinetics; Cancer; Chemotherapy; Machine learning; Epidermal growth factor receptor; Cisplatin","score_opus":0.022437710646904255,"score_gpt":0.4925979184773803,"score_spread":0.4701602078304761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041814933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713998,0.00014430973,0.014395327,0.012224439,0.00025493256,0.00049501227,0.000002745928,0.000011353583,0.0010720827],"genre_scores_gemma":[0.9819745,0.000031259933,0.016579332,0.0010714468,0.00010589317,0.000010977002,0.000013964918,0.0000090369085,0.00020360714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901277,0.00011002332,0.00041326915,0.00011832,0.00019469015,0.00015094687],"domain_scores_gemma":[0.9991659,0.000053136544,0.0003103212,0.00008303514,0.00024598796,0.00014164406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032769926,0.000110691384,0.00034295363,0.00043903844,0.00003740672,0.000013433135,0.00006652451,0.0000600908,0.000039658495],"category_scores_gemma":[0.00004627574,0.00007920714,0.000060187667,0.00030686441,0.00002095869,0.0001752149,0.0000066933835,0.00020414038,0.00000846085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0144224465,0.005052467,0.0022132087,0.00002892227,0.00022317641,0.0007199576,0.0016772485,0.00062926905,0.026825428,0.00020794553,0.0005071173,0.94749284],"study_design_scores_gemma":[0.11405706,0.38634214,0.3874757,0.002856235,0.0072825346,0.006711388,0.007050634,0.014122368,0.041892856,0.0039825905,0.026944611,0.0012818945],"about_ca_topic_score_codex":0.0000059987487,"about_ca_topic_score_gemma":0.000027974456,"teacher_disagreement_score":0.9462109,"about_ca_system_score_codex":0.00071481924,"about_ca_system_score_gemma":0.0003941475,"threshold_uncertainty_score":0.32299733},"labels":[],"label_agreement":null},{"id":"W2042085637","doi":"10.1097/jto.0b013e3182288af9","title":"Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Decortication; Pleurectomy; Mesothelioma; Adjuvant chemotherapy; Extrapleural Pneumonectomy; Surgery; Pneumonectomy; Oncology; Internal medicine; Pathology; Lung; Cancer; Peritoneal mesothelioma; Breast cancer","score_opus":0.01229750446984872,"score_gpt":0.30299529283098336,"score_spread":0.29069778836113463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042085637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976587,0.00029768824,0.000042315874,0.0010047521,0.000100385325,0.00032830963,0.00002952859,0.000014099044,0.0005241926],"genre_scores_gemma":[0.99636084,0.00005508467,0.001998859,0.0010724971,0.00006415498,0.000011891886,0.000044280765,0.000038277616,0.00035413654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984249,0.00010481349,0.00055023597,0.00021327316,0.00042355125,0.0002832597],"domain_scores_gemma":[0.99892193,0.000053130974,0.00048775144,0.00018898051,0.00012288798,0.00022533843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001829454,0.00022265111,0.0005619444,0.000203728,0.000045346915,0.0000077171335,0.00015435624,0.00009662929,0.00047843475],"category_scores_gemma":[0.000025138957,0.00013391982,0.00009676209,0.0002088581,0.00014451987,0.0002005511,0.000020387157,0.00023043908,0.000022542603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038177457,0.0024953063,0.9441411,0.000035672827,0.00020224278,0.00027654972,0.00042197466,0.0000061343685,0.0027778244,0.000005740499,0.0012409771,0.010219027],"study_design_scores_gemma":[0.007644985,0.007333243,0.9795676,0.00014260376,0.00026992886,0.00028215713,0.0001541339,0.00002113475,0.0029099558,0.00003386449,0.0014598868,0.00018052534],"about_ca_topic_score_codex":0.000031873755,"about_ca_topic_score_gemma":0.000037483125,"teacher_disagreement_score":0.03542649,"about_ca_system_score_codex":0.0002873554,"about_ca_system_score_gemma":0.00019126556,"threshold_uncertainty_score":0.54610914},"labels":[],"label_agreement":null},{"id":"W2042091710","doi":"10.1097/01.jto.0000283284.66317.c1","title":"D5-07: Survival and zoledronic acid-induced normalization of bone marker levels in patients with non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University; McGill University Health Centre","funders":"","keywords":"Zoledronic acid; Medicine; Internal medicine; N-terminal telopeptide; Lung cancer; Oncology; Creatinine; Denosumab; Bisphosphonate; Urology; Surgery; Osteoporosis; Alkaline phosphatase; Osteocalcin","score_opus":0.020899653284414503,"score_gpt":0.3769631664567681,"score_spread":0.3560635131723536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042091710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718934,0.0006636534,0.00029550542,0.00030230422,0.00034398495,0.0003459776,0.0000049840855,0.0000031293637,0.000851145],"genre_scores_gemma":[0.9981525,0.000099293306,0.0013817995,0.00016352504,0.00006267797,0.0000032203445,0.000004136491,0.000017340062,0.00011551259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985454,0.00009793952,0.00068762596,0.0001227195,0.00024863516,0.00029767898],"domain_scores_gemma":[0.9985601,0.000087005035,0.0007150215,0.000101749465,0.00031919024,0.00021695143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086597825,0.00013089554,0.0005921821,0.00027808984,0.00003083186,0.0000032129851,0.00004263219,0.00017199278,0.000053244017],"category_scores_gemma":[0.00003619216,0.0000954223,0.000044934888,0.00019671995,0.00003502141,0.00010108208,0.000021423995,0.00030649168,0.0000013745183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005273028,0.00078817375,0.9619153,0.0002957215,0.00008413065,0.00019438112,0.00034187795,0.000008147926,0.0008450546,0.0000016914329,0.000038909824,0.03021354],"study_design_scores_gemma":[0.0065324437,0.0026516567,0.98693424,0.00028214566,0.00026867213,0.00007047444,0.000099947196,0.00005570023,0.002871899,0.0000047713816,0.00015260173,0.000075442484],"about_ca_topic_score_codex":0.00015716451,"about_ca_topic_score_gemma":0.00078639534,"teacher_disagreement_score":0.030138098,"about_ca_system_score_codex":0.0004304447,"about_ca_system_score_gemma":0.00070583087,"threshold_uncertainty_score":0.38912085},"labels":[],"label_agreement":null},{"id":"W2042211087","doi":"10.1097/jto.0b013e31821ea60c","title":"Radiation Therapy Definitions and Reporting Guidelines for Thymic Malignancies","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Workgroup; Medicine; Radiation oncology; Radiation therapy; Surgery","score_opus":0.32044237559725613,"score_gpt":0.4856161338466503,"score_spread":0.16517375824939418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042211087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98926175,0.0025568851,0.001581607,0.0043626404,0.000369363,0.0001895481,0.0000032668747,0.00000970008,0.0016652528],"genre_scores_gemma":[0.9311923,0.0017717739,0.06485839,0.0013959634,0.00057557126,0.00001040476,0.00000351624,0.000015191045,0.00017693774],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985436,0.000045225468,0.0011074134,0.000082797495,0.000096482734,0.00012444319],"domain_scores_gemma":[0.9972641,0.00010398424,0.0017670818,0.00008901476,0.00069077616,0.00008507831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332658,0.000077001896,0.0003973213,0.00013305547,0.0000654499,0.00000665759,0.00004283524,0.00009044188,0.00005864233],"category_scores_gemma":[0.001372361,0.00005284402,0.00013397906,0.00006280959,0.00004474773,0.00007523868,0.000009659709,0.00011309678,0.0000015807044],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027403494,0.00039169705,0.03775197,0.00010244884,0.00026786161,0.0003679678,0.0023010157,0.0000012047126,0.022829808,0.0027093,0.0093886405,0.92114776],"study_design_scores_gemma":[0.0060718195,0.018131146,0.53350264,0.00070000975,0.0011356901,0.035838105,0.0032020465,0.00030067988,0.035866775,0.068104155,0.29667538,0.00047152097],"about_ca_topic_score_codex":0.0000087529,"about_ca_topic_score_gemma":0.000003868856,"teacher_disagreement_score":0.92067623,"about_ca_system_score_codex":0.000038810984,"about_ca_system_score_gemma":0.00020371005,"threshold_uncertainty_score":0.21549167},"labels":[],"label_agreement":null},{"id":"W2042581859","doi":"10.1016/s1556-0864(15)30414-7","title":"Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University","funders":"","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Oncology; Internal medicine; Immunohistochemistry; Chemotherapy; EGFR inhibitors; Clinical trial; Cancer; Pathology","score_opus":0.02562727282986741,"score_gpt":0.43916000619585455,"score_spread":0.4135327333659871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042581859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767,0.0003234906,0.009113697,0.00035827584,0.00036674246,0.0017851093,0.0001432646,0.000008880759,0.00023052828],"genre_scores_gemma":[0.90661615,0.00005198201,0.09241743,0.000058935635,0.00034567673,0.00015503191,0.00004394104,0.00002993255,0.00028093296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984648,0.00008125757,0.0007845662,0.00022943717,0.0001742273,0.00026571736],"domain_scores_gemma":[0.9969113,0.00054064,0.0012501077,0.00012449376,0.0010348078,0.00013865685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002331272,0.00018946297,0.00080343866,0.00009165117,0.00009554154,0.0000057684274,0.00006580239,0.00013089082,0.00003414634],"category_scores_gemma":[0.000062031264,0.00010818561,0.000209279,0.00009949928,0.000057326804,0.00010978526,0.000009375894,0.00012303589,1.8746387e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019973472,0.003586719,0.8690908,0.00044001828,0.00048235504,0.00000795412,0.00048389166,0.000071184324,0.0022564703,0.0000015041247,0.00088762154,0.102718],"study_design_scores_gemma":[0.050858397,0.081017494,0.7497107,0.0014858403,0.0055763363,0.000046685927,0.0006511818,0.00054084347,0.09381529,0.00004759697,0.015815116,0.00043456352],"about_ca_topic_score_codex":0.000055506072,"about_ca_topic_score_gemma":0.00008646329,"teacher_disagreement_score":0.11938015,"about_ca_system_score_codex":0.00044684275,"about_ca_system_score_gemma":0.0011045556,"threshold_uncertainty_score":0.4411681},"labels":[],"label_agreement":null},{"id":"W2042846576","doi":"10.1097/jto.0b013e318168c815","title":"Second-Line Treatment of Advanced Non-small Cell Lung Cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Erlotinib; Gefitinib; Chemotherapy; Oncology; Lung cancer; Internal medicine; Performance status; Cancer; Intensive care medicine; Epidermal growth factor receptor; Cisplatin","score_opus":0.024784287049145974,"score_gpt":0.43600086396255666,"score_spread":0.4112165769134107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042846576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98390055,0.0063319406,0.00018930192,0.0012152635,0.0006367459,0.0003078806,0.000022088368,0.000006240485,0.0073899813],"genre_scores_gemma":[0.9804613,0.003091739,0.0080697285,0.00021754127,0.00039055463,0.0000232268,0.000006477821,0.000018381203,0.0077210437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990242,0.000039475846,0.00050854514,0.00011448137,0.00013846214,0.00017483695],"domain_scores_gemma":[0.9987217,0.000076215714,0.00058465864,0.00014428509,0.0003157338,0.00015738195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000758752,0.00013308981,0.00062550814,0.00015707072,0.000053448963,0.0000018129414,0.00006249623,0.0000953816,0.0004805805],"category_scores_gemma":[0.000011437938,0.00009089614,0.0002075205,0.00012874576,0.00005821501,0.00006608715,0.0000098004175,0.00011755486,0.00000416202],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009317824,0.013009887,0.1524763,0.0009929157,0.0041536167,0.006484267,0.020056393,0.002709481,0.106246226,0.000020287924,0.011372284,0.6731605],"study_design_scores_gemma":[0.03055368,0.05370718,0.19737364,0.00080780505,0.009640064,0.0072408346,0.0024895556,0.0005588374,0.32910523,0.000095104915,0.36785385,0.0005742321],"about_ca_topic_score_codex":0.000036841953,"about_ca_topic_score_gemma":0.00006218062,"teacher_disagreement_score":0.67258626,"about_ca_system_score_codex":0.0008292633,"about_ca_system_score_gemma":0.0014618859,"threshold_uncertainty_score":0.5262019},"labels":[],"label_agreement":null},{"id":"W2043014115","doi":"10.1097/01.jto.0000283353.30118.37","title":"PD2-1-7: Differences in the gene expression profiles of tumors from patients with and without COPD","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"COPD; Lung cancer; Medicine; Lung; Carcinogenesis; Inflammation; Confounding; Internal medicine; Cancer; Oncology; Immunology; Pathology","score_opus":0.018745053422091377,"score_gpt":0.3952673920409283,"score_spread":0.37652233861883694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043014115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982582,0.00040451504,0.00017925799,0.00042124806,0.000078075354,0.00019869336,0.000007941793,0.0000016315022,0.00045044435],"genre_scores_gemma":[0.9937654,0.00003052718,0.0059682513,0.000116209856,0.000075249925,0.0000030115784,0.0000056761537,0.0000047458643,0.000030903353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99928164,0.00006916663,0.00029305575,0.00006893804,0.00019552711,0.0000916616],"domain_scores_gemma":[0.9992608,0.00013328835,0.0003605968,0.00007288827,0.00012090883,0.000051531748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024894872,0.000066734116,0.00029013326,0.00009220959,0.000027075923,0.0000041917465,0.000057149864,0.000046858902,0.000019063229],"category_scores_gemma":[0.000036380992,0.000030343992,0.000024250141,0.00007711519,0.00007842424,0.00005650019,0.000010960374,0.00013568412,3.1197433e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016634463,0.0004698836,0.9764122,0.00001815118,0.00006517697,0.000054380474,0.0022148367,8.230366e-7,0.0023368888,0.0000043223317,0.000074879375,0.016685033],"study_design_scores_gemma":[0.0016561124,0.002076717,0.98798484,0.00025482642,0.00021583255,0.00006372106,0.0014157229,0.0000025478453,0.006005089,0.00009089372,0.00020073757,0.000032987497],"about_ca_topic_score_codex":0.000038941856,"about_ca_topic_score_gemma":0.00003938545,"teacher_disagreement_score":0.016652046,"about_ca_system_score_codex":0.00006647556,"about_ca_system_score_gemma":0.00014830627,"threshold_uncertainty_score":0.12373921},"labels":[],"label_agreement":null},{"id":"W2043150920","doi":"10.1097/01.jto.0000391377.17179.6b","title":"Targeting Vascular Endothelial Growth Factor in Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bevacizumab; Aflibercept; Lung cancer; Oncology; Internal medicine; Vascular endothelial growth factor; Erlotinib; Hazard ratio; Angiogenesis; Placental growth factor; Cancer; Chemotherapy; Epidermal growth factor receptor; Confidence interval; VEGF receptors","score_opus":0.013680175737415284,"score_gpt":0.42623934737230396,"score_spread":0.41255917163488864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043150920","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922968,0.0010345207,0.00016054677,0.0031100996,0.0017177985,0.00017619504,0.000011208003,0.0000075247544,0.0014852823],"genre_scores_gemma":[0.9942883,0.0003019267,0.0038617984,0.00035434114,0.00092820975,0.000011026336,0.000002360163,0.000014589915,0.00023743713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991325,0.000054474764,0.00036672124,0.00009553992,0.00017144163,0.00017929009],"domain_scores_gemma":[0.9992256,0.000097843724,0.00026459707,0.000078023986,0.00021249225,0.00012144109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025278152,0.000089756344,0.00034733163,0.0001817505,0.00003654492,0.000008079131,0.00007497326,0.00011811249,0.0005154639],"category_scores_gemma":[0.0002265964,0.00006381258,0.00011965608,0.00011810192,0.000035376044,0.00010483866,0.000015158375,0.00052355044,0.0000040439863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011244282,0.0012024981,0.66538584,0.00026635116,0.0011011274,0.0016047433,0.0040834695,0.00009172345,0.18789144,0.00019513367,0.0036267114,0.13342653],"study_design_scores_gemma":[0.013408805,0.0032915324,0.6817824,0.0006680649,0.0036201992,0.001985744,0.0013837061,0.0010901743,0.027930109,0.00080721604,0.26343077,0.0006012418],"about_ca_topic_score_codex":0.00012391707,"about_ca_topic_score_gemma":0.000109996276,"teacher_disagreement_score":0.25980407,"about_ca_system_score_codex":0.00034625398,"about_ca_system_score_gemma":0.00078502,"threshold_uncertainty_score":0.5643968},"labels":[],"label_agreement":null},{"id":"W2043379157","doi":"10.1097/jto.0b013e31819846fb","title":"Survival and Treatment Pattern of Non-small Cell Lung Cancer Over 20 Years","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.01949681175356983,"score_gpt":0.3966165715690093,"score_spread":0.3771197598154395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043379157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918899,0.0033348424,0.00004166275,0.0027392986,0.00042610016,0.00019302826,0.000011823684,0.0000032290889,0.00136014],"genre_scores_gemma":[0.9948225,0.003504524,0.0005618603,0.00033251735,0.00036994618,0.0000057977654,0.0000019157417,0.000010069481,0.0003908427],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99915427,0.0000537841,0.00035784277,0.00012125716,0.00015337775,0.00015947665],"domain_scores_gemma":[0.999191,0.00008306422,0.0003608522,0.000119462755,0.00009846734,0.00014716845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016307391,0.00012067817,0.0005747594,0.00010372178,0.00001687284,0.000005713804,0.00005077718,0.00009596827,0.00013151942],"category_scores_gemma":[0.000005223389,0.000084074716,0.0001398762,0.0000649335,0.00003094347,0.000038676215,0.000012520036,0.00012183597,0.0000014164341],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008999839,0.0017219776,0.41736406,0.00009029843,0.000515582,0.00075494836,0.00094123336,0.000025601063,0.0023703943,0.0000024324215,0.003090709,0.57222277],"study_design_scores_gemma":[0.0043256725,0.009239983,0.96610373,0.0003025655,0.0016964378,0.00018205016,0.000164704,0.00009131913,0.0076578963,0.000017938828,0.010111336,0.00010635003],"about_ca_topic_score_codex":0.00018478686,"about_ca_topic_score_gemma":0.00021278288,"teacher_disagreement_score":0.57211643,"about_ca_system_score_codex":0.00071365637,"about_ca_system_score_gemma":0.00034785047,"threshold_uncertainty_score":0.34284675},"labels":[],"label_agreement":null},{"id":"W2043428486","doi":"10.1097/jto.0b013e3181952678","title":"Defining Genomic Alteration Boundaries for a Combined Small Cell and Non-small Cell Lung Carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Small Cell Lung Carcinoma; Lung; Small-cell carcinoma; Cell; Carcinoma; Cancer research; Pathology; Internal medicine; Genetics; Biology","score_opus":0.023514930183573268,"score_gpt":0.38241518063877733,"score_spread":0.3589002504552041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043428486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827439,0.0061968053,0.0023578228,0.0057570143,0.00041133576,0.0005955864,0.0000067933906,0.000010768699,0.0019199806],"genre_scores_gemma":[0.9797622,0.00026125443,0.018131336,0.0007909224,0.00041253775,0.000014312836,0.0000061336737,0.000018854265,0.0006024333],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99863136,0.00010333323,0.0005365228,0.00018834134,0.00017421583,0.0003662138],"domain_scores_gemma":[0.9984977,0.0003028139,0.00044509524,0.00014037936,0.00041718953,0.00019681841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008608386,0.00016712518,0.0006511301,0.0002394191,0.00026546678,0.0000862358,0.00012172633,0.00012725715,0.000011206759],"category_scores_gemma":[0.00016725763,0.00013621399,0.00013312556,0.00009480799,0.00013910477,0.00009504828,0.00005613785,0.00041085543,0.0000030662206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0507211,0.0031958614,0.24544965,0.0062700287,0.0011018746,0.0026842125,0.033347458,0.00022169811,0.37785637,0.0007396914,0.06785225,0.2105598],"study_design_scores_gemma":[0.035504393,0.10032382,0.60354394,0.001081409,0.0044739675,0.0032726733,0.0058008796,0.008703868,0.12252232,0.0041533657,0.109356016,0.0012633562],"about_ca_topic_score_codex":0.000019408142,"about_ca_topic_score_gemma":0.000040354036,"teacher_disagreement_score":0.35809427,"about_ca_system_score_codex":0.0005625993,"about_ca_system_score_gemma":0.0013062248,"threshold_uncertainty_score":0.5554645},"labels":[],"label_agreement":null},{"id":"W2043604340","doi":"10.1097/jto.0000000000000505","title":"Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Hazard ratio; Cohort; Internal medicine; Cluster (spacecraft); Proportional hazards model; Survival analysis; Stage (stratigraphy); Cancer; Oncology; Phenotype; Disease; Cohort study; Pathology; Confidence interval; Genetics; Biology; Gene","score_opus":0.02075688296798867,"score_gpt":0.41624481291248194,"score_spread":0.3954879299444933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043604340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130666,0.001006617,0.0039096223,0.00077956886,0.0003078661,0.0006708344,0.000009051777,0.0000065445784,0.0020032087],"genre_scores_gemma":[0.99397814,0.00006695716,0.004782892,0.00020160456,0.00016428699,0.00002544953,0.0000067927576,0.000016886348,0.00075696403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99849004,0.00016257694,0.0005865219,0.00017990783,0.00038334273,0.00019760874],"domain_scores_gemma":[0.9977227,0.000045801742,0.00081072457,0.00024825882,0.00091918325,0.00025337358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065290945,0.00014903344,0.00090261915,0.00033130334,0.000047707083,0.000011769347,0.00012905867,0.000085341424,0.00007197454],"category_scores_gemma":[0.000022779092,0.000097464326,0.00020071257,0.0004933424,0.000051897514,0.00010330379,0.000034845445,0.00021635185,0.0000021859887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027185974,0.002155276,0.9714715,0.00007146621,0.008815334,0.0002644393,0.0012480471,0.006277456,0.0002772535,6.306932e-7,0.00078676344,0.005913243],"study_design_scores_gemma":[0.010369362,0.014998951,0.8653082,0.00014850248,0.09888993,0.0004066071,0.0029824425,0.0017508098,0.0027538938,0.000017748514,0.0021094093,0.00026411013],"about_ca_topic_score_codex":0.0004804042,"about_ca_topic_score_gemma":0.0009783721,"teacher_disagreement_score":0.10616326,"about_ca_system_score_codex":0.0006169674,"about_ca_system_score_gemma":0.0015810695,"threshold_uncertainty_score":0.39744797},"labels":[],"label_agreement":null},{"id":"W2044332607","doi":"10.1097/jto.0b013e3181ae2962","title":"Chest Wall Pain and Rib Fracture after Stereotactic Radiotherapy for Peripheral Non-small Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Radiology; Lung cancer; Lung; Peripheral; Nuclear medicine; Oncology; Internal medicine","score_opus":0.011510147201337886,"score_gpt":0.3722549224660927,"score_spread":0.36074477526475485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044332607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9342466,0.019348266,0.0015323242,0.04366363,0.0003961815,0.00063506386,0.0000066358207,0.000008398595,0.00016290451],"genre_scores_gemma":[0.9707444,0.0024294304,0.008483843,0.01681259,0.0009267494,0.0000606915,0.000002344754,0.000023804932,0.0005161588],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99894655,0.000103410865,0.00037344478,0.00018036357,0.00013376636,0.00026246218],"domain_scores_gemma":[0.99892956,0.00020013642,0.0003601855,0.00013543604,0.00016256265,0.00021213865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004939829,0.0001869539,0.0006097636,0.000093514616,0.000047666206,0.000025580375,0.00007095098,0.00018440223,0.00019679309],"category_scores_gemma":[0.000021660171,0.00012790482,0.00019050506,0.00005916811,0.000031507978,0.00008820997,0.000006563888,0.00029300078,4.5341713e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015206686,0.0029494462,0.36390692,0.0011302036,0.0014425693,0.0015239172,0.005805279,0.000112580965,0.0023026133,0.0000041431886,0.033324663,0.57229096],"study_design_scores_gemma":[0.009307338,0.021149222,0.6720307,0.00085858477,0.002264922,0.00084788323,0.00022587294,0.0013658609,0.002114281,0.000114947696,0.28936154,0.0003588759],"about_ca_topic_score_codex":0.000024305626,"about_ca_topic_score_gemma":0.00005288711,"teacher_disagreement_score":0.5719321,"about_ca_system_score_codex":0.0011230783,"about_ca_system_score_gemma":0.00038212212,"threshold_uncertainty_score":0.5215807},"labels":[],"label_agreement":null},{"id":"W2044741114","doi":"10.1097/jto.0b013e31824fea07","title":"Stage III Non–Small-Cell Lung Cancer: Population-Based Patterns of Treatment in British Columbia, Canada","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency","keywords":"Medicine; Population; Chemoradiotherapy; Chemotherapy; Adenocarcinoma; Internal medicine; Stage (stratigraphy); Radiation therapy; Lung cancer; Small-cell carcinoma; Cancer; Malignancy; Cohort; Hazard ratio; Cancer registry; Oncology; Surgery","score_opus":0.014931134895875376,"score_gpt":0.3537554385234399,"score_spread":0.3388243036275645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044741114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957599,0.0020919119,0.000019101295,0.00071751926,0.00072668144,0.00041484434,0.00008347752,0.0000029232763,0.00018363773],"genre_scores_gemma":[0.99760467,0.0004952687,0.00033135753,0.0003540673,0.0002754998,0.000047579553,0.000018811837,0.000017665734,0.00085505453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864906,0.00009389783,0.0006322363,0.00011699197,0.00021360703,0.0002942105],"domain_scores_gemma":[0.9987187,0.00014965187,0.0006153668,0.00014300137,0.0001405611,0.000232729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023606351,0.00010672871,0.0006928688,0.0000651021,0.000034745502,0.000012523543,0.00007085071,0.00009836092,0.00048995536],"category_scores_gemma":[0.00001493486,0.00011970758,0.00012932645,0.00010893435,0.000012983187,0.00006124573,0.000012730706,0.00015432737,3.216798e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015921435,0.0013112684,0.9690769,0.0002448607,0.00017924752,0.00043082493,0.00016149007,0.00023919897,0.00004584293,2.8740845e-7,0.0010806426,0.027070248],"study_design_scores_gemma":[0.003562316,0.0013935535,0.9888685,0.0005265791,0.0006288425,0.00008965971,0.00026587836,0.000104065635,0.00073028804,0.0000010253257,0.0037338622,0.00009546247],"about_ca_topic_score_codex":0.96169454,"about_ca_topic_score_gemma":0.9930084,"teacher_disagreement_score":0.031313863,"about_ca_system_score_codex":0.0076930663,"about_ca_system_score_gemma":0.0035085164,"threshold_uncertainty_score":0.9961162},"labels":[],"label_agreement":null},{"id":"W2045626426","doi":"10.1097/jto.0b013e31824166c1","title":"Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Pharmacogenetics; Odds ratio; Placebo; Epidermal growth factor receptor; Confidence interval; Gastroenterology; Genotype; Cancer; Pathology; Biology; Genetics","score_opus":0.03442907352970298,"score_gpt":0.5197147873300292,"score_spread":0.4852857138003262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045626426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849046,0.0052745542,0.0008415948,0.00046060182,0.0013702398,0.0024167267,0.000020365424,0.0000037999453,0.001121665],"genre_scores_gemma":[0.9940505,0.0016306889,0.0031043724,0.00017430584,0.0004919288,0.0001554875,0.000008716531,0.000017156703,0.00036683062],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956968,0.00089089014,0.0026704837,0.00016098809,0.00028609863,0.0002947707],"domain_scores_gemma":[0.9945978,0.0017160513,0.002843822,0.00018432939,0.00039757363,0.00026045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036214753,0.00018662693,0.003823628,0.00075400475,0.000023881968,0.0000033212832,0.00013154393,0.00017737075,0.0003447166],"category_scores_gemma":[0.0004409779,0.00012734509,0.0013163153,0.00058012304,0.00012738358,0.00009065287,0.000024568932,0.00035366265,7.9068866e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93711007,0.006345086,0.0094525665,0.00009459784,0.009521814,0.00004700425,0.0014040975,0.00087581825,0.0042619715,0.0000017013735,0.00014268626,0.030742574],"study_design_scores_gemma":[0.93496174,0.0027831045,0.0012770545,0.00012368822,0.054859564,0.000017307124,0.00027430846,0.0028649603,0.0023150092,0.00000491275,0.00042411682,0.000094210925],"about_ca_topic_score_codex":0.000060862283,"about_ca_topic_score_gemma":0.000051484676,"teacher_disagreement_score":0.04533775,"about_ca_system_score_codex":0.00029784534,"about_ca_system_score_gemma":0.0013287325,"threshold_uncertainty_score":0.5192982},"labels":[],"label_agreement":null},{"id":"W2045709376","doi":"10.1097/jto.0b013e3181c6e330","title":"RBM5 as a Putative Tumor Suppressor Gene for Lung Cancer","year":2010,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University; Sudbury Regional Hospital; University of Ottawa","funders":"","keywords":"Medicine; Suppressor; Lung cancer; Cancer research; Tumor suppressor gene; Gene; Cancer; Oncology; Internal medicine; Genetics; Carcinogenesis; Biology","score_opus":0.02482729537096977,"score_gpt":0.4664462881572129,"score_spread":0.4416189927862431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045709376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013728016,0.9927414,0.001278044,0.0002806626,0.0029923886,0.00093556254,0.00021897478,0.0000054514885,0.00017473419],"genre_scores_gemma":[0.00011361308,0.98929304,0.0046436503,0.00012280853,0.00416453,0.00020912023,0.00020246021,0.00010041194,0.0011503901],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976653,0.00031467702,0.0010603687,0.00039194414,0.0002061887,0.00036151637],"domain_scores_gemma":[0.9963084,0.00014127651,0.0024512091,0.0003163358,0.000602172,0.00018060805],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000686975,0.00039694502,0.0015957371,0.00023123206,0.000083004204,0.000026884087,0.0004612049,0.0010840022,0.00007359704],"category_scores_gemma":[0.00032575487,0.00032408047,0.0009530699,0.00015480354,0.00011769105,0.000008819226,0.000111504145,0.00075316645,0.0000046292107],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005255485,0.00009235439,0.0000012599087,0.0021970298,0.0008946724,0.000037264977,0.000040579132,0.00010272228,0.008146677,0.000006232674,0.008706517,0.9792491],"study_design_scores_gemma":[0.0003915375,0.0010641664,0.00000218111,0.0011319409,0.0024746037,0.0018580541,0.000011413961,0.0000380482,0.007617505,0.00005234184,0.9850447,0.00031347605],"about_ca_topic_score_codex":0.000008773709,"about_ca_topic_score_gemma":0.00004221812,"teacher_disagreement_score":0.97893566,"about_ca_system_score_codex":0.00037654687,"about_ca_system_score_gemma":0.0033557627,"threshold_uncertainty_score":0.99992114},"labels":[],"label_agreement":null},{"id":"W2046020180","doi":"10.1097/jto.0b013e3181a949b2","title":"A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metal-Catalyzed Oxygenation Mechanisms","field":"Chemistry","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Mount Sinai Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute","keywords":"Docetaxel; Medicine; Internal medicine; Febrile neutropenia; Lung cancer; Oncology; Neutropenia; Cancer; Chemotherapy","score_opus":0.028310411868452744,"score_gpt":0.40873044256894625,"score_spread":0.3804200307004935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046020180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621004,0.00069604936,0.000047981004,0.00028464716,0.00044608972,0.0012192964,0.000066873705,0.000011923196,0.001017109],"genre_scores_gemma":[0.997164,0.00007821536,0.0005251987,0.00008962755,0.00014993899,0.00007438754,0.000005746263,0.000030003916,0.0018828813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962069,0.00035784408,0.0020862382,0.00039334493,0.00056576147,0.00038994802],"domain_scores_gemma":[0.9952601,0.00019906208,0.003215977,0.00066141895,0.00046981228,0.00019360507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008798151,0.00038792525,0.0015069515,0.0003475277,0.00016016832,0.000012028109,0.00070570986,0.00020430294,0.00085125945],"category_scores_gemma":[0.00013921267,0.00028107557,0.00028154126,0.00047695293,0.000057995487,0.0001691703,0.00016373623,0.00059985026,0.000001539255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009605526,0.1470227,0.0005346544,0.00018607243,0.0008127117,0.00068785954,0.027362932,0.0033462544,0.7408828,0.000007493209,0.00011242397,0.06943859],"study_design_scores_gemma":[0.08788428,0.094046734,0.0002888496,0.000193488,0.0017986721,0.00024297569,0.02669076,0.0015280324,0.7858202,0.0001248866,0.0009739341,0.00040717397],"about_ca_topic_score_codex":0.00014090989,"about_ca_topic_score_gemma":0.0012582691,"teacher_disagreement_score":0.07827875,"about_ca_system_score_codex":0.0010268528,"about_ca_system_score_gemma":0.0012904053,"threshold_uncertainty_score":0.9999641},"labels":[],"label_agreement":null},{"id":"W2047213739","doi":"10.1097/01.jto.0000263708.08332.76","title":"Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer?","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Asymptomatic; Stage (stratigraphy); Randomized controlled trial; Cancer; Internal medicine; Surgery","score_opus":0.016433774239267823,"score_gpt":0.4023726481106881,"score_spread":0.3859388738714203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047213739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935267,0.0003868965,0.00024207796,0.0023977193,0.0023453133,0.00029744618,0.0000063649777,0.0000072663656,0.00079022767],"genre_scores_gemma":[0.9924207,0.00007469079,0.002325298,0.0041389433,0.0002745766,0.0000040902682,0.000005192124,0.00002107925,0.0007354449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837357,0.000061929044,0.00077399425,0.00016438775,0.00029354583,0.00033256318],"domain_scores_gemma":[0.9981523,0.00015648892,0.000593222,0.00015371633,0.0007459599,0.00019831007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005586054,0.00015625464,0.0007313498,0.00032819342,0.00003076516,0.000005635215,0.00012011199,0.00012977386,0.00025835854],"category_scores_gemma":[0.00018357181,0.00008340332,0.00012263049,0.00018513243,0.00007534411,0.00021481504,0.000030582505,0.00060615427,0.0000024246335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01857063,0.00014101458,0.78338873,0.00008217208,0.00015237562,0.00051495165,0.0007082212,0.00003283263,0.00041429198,0.000002560633,0.0006832651,0.19530894],"study_design_scores_gemma":[0.009812409,0.003323992,0.9667764,0.00031729855,0.0002746079,0.00009470711,0.0010342762,0.000031309784,0.0011517543,0.00001748785,0.016990926,0.00017488905],"about_ca_topic_score_codex":0.00003064456,"about_ca_topic_score_gemma":0.0003893141,"teacher_disagreement_score":0.19513404,"about_ca_system_score_codex":0.0011711331,"about_ca_system_score_gemma":0.00049595186,"threshold_uncertainty_score":0.34010887},"labels":[],"label_agreement":null},{"id":"W2047671914","doi":"10.1097/jto.0b013e3181f20d9a","title":"The Multidisciplinary Approach to Thymoma: Combining Molecular and Clinical Approaches","year":2010,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Thymoma; Disease; Stage (stratigraphy); Clinical trial; Thymic carcinoma; Oncology; Internal medicine; Pathology","score_opus":0.13286609729591572,"score_gpt":0.4940038296430064,"score_spread":0.3611377323470907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047671914","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021952472,0.9886294,0.00035677076,0.0012109672,0.001184191,0.0009653933,0.0000049507953,0.000012587437,0.0054404764],"genre_scores_gemma":[0.00059550995,0.97670203,0.020896308,0.00012865632,0.0011312389,0.000032899123,0.000010893394,0.000083198145,0.00041928084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99575263,0.0009979727,0.0020362057,0.00040261072,0.00040161159,0.0004089654],"domain_scores_gemma":[0.9957827,0.0012193562,0.0016368668,0.00057223043,0.00019604042,0.0005928426],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004838119,0.00043009603,0.003442373,0.00027720572,0.00020959275,0.000057719164,0.00053670455,0.0010154418,0.0000055572214],"category_scores_gemma":[0.00067751826,0.00022473357,0.0010873537,0.00026926145,0.00037351353,0.00004881269,0.0003891665,0.0033651814,0.000017019627],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003214541,0.0006135024,0.000052071377,0.0017688775,0.0005272389,0.000485574,0.00011497884,2.4977737e-7,0.0000016620825,0.0004643579,0.00041835653,0.9952317],"study_design_scores_gemma":[0.0005050793,0.0024712195,0.00015542924,0.0026344552,0.0034821348,0.015533027,0.00023417824,0.00003337257,0.0000010085799,0.00020767412,0.9745209,0.0002215224],"about_ca_topic_score_codex":0.0000012799517,"about_ca_topic_score_gemma":0.0000020825746,"teacher_disagreement_score":0.99501014,"about_ca_system_score_codex":0.00012214591,"about_ca_system_score_gemma":0.0010451004,"threshold_uncertainty_score":0.9989341},"labels":[],"label_agreement":null},{"id":"W2048477728","doi":"10.1097/jto.0000000000000055","title":"PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"PTEN; Medicine; PI3K/AKT/mTOR pathway; Tissue microarray; Tensin; Chemotherapy; Oncology; Cancer research; Induction chemotherapy; Immunohistochemistry; Mesothelioma; Internal medicine; Pathology; Apoptosis; Biology","score_opus":0.010387389753284192,"score_gpt":0.32476105907970226,"score_spread":0.3143736693264181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048477728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979193,0.000095338815,0.000044956127,0.0013314427,0.00010725688,0.00015555463,0.000005349125,0.000009411902,0.00033136204],"genre_scores_gemma":[0.99829704,0.000022054417,0.0007980573,0.00048098702,0.00013113275,0.000005589967,0.000025053585,0.000019541047,0.00022053828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989162,0.00013060613,0.00037590563,0.00012951772,0.0002862396,0.00016155186],"domain_scores_gemma":[0.9993113,0.00006372369,0.0003276778,0.00009126137,0.00006700645,0.00013902086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022116242,0.00012944435,0.00037360805,0.00018600204,0.000033441775,0.000007151396,0.00007865789,0.00009824773,0.00012823663],"category_scores_gemma":[0.000053298256,0.00008905592,0.000089947476,0.00016388122,0.000057565925,0.00013333386,0.000011164682,0.00019472772,0.000007760023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008259777,0.0015012795,0.85004544,0.000030492934,0.00010997436,0.000055146775,0.00010085818,0.000027584203,0.091619216,0.0000019149863,0.0018570728,0.04639123],"study_design_scores_gemma":[0.0043904977,0.0070033097,0.9668198,0.00014124044,0.00019542864,0.00018352467,0.000093250455,0.00007866861,0.0152377905,0.000055074255,0.005661424,0.00013998602],"about_ca_topic_score_codex":0.000013443369,"about_ca_topic_score_gemma":0.000004768305,"teacher_disagreement_score":0.11677435,"about_ca_system_score_codex":0.0002866609,"about_ca_system_score_gemma":0.000060671427,"threshold_uncertainty_score":0.36315948},"labels":[],"label_agreement":null},{"id":"W2048594374","doi":"10.1097/01.jto.0000284084.26665.47","title":"P3-108: Correlative genomics in a phase II clinical trial of first-line therapy of erlotinib for clinically selected patients with advanced non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Genome British Columbia; BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Oncology; Internal medicine; Lung cancer; Adenocarcinoma; Population; KRAS; Cancer; Epidermal growth factor receptor; Colorectal cancer","score_opus":0.03825366415585448,"score_gpt":0.5004756711090539,"score_spread":0.4622220069531994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048594374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912523,0.00038363587,0.0046259942,0.0003745783,0.0008068623,0.002274385,0.000044645032,0.0000040669274,0.00023351272],"genre_scores_gemma":[0.97652376,0.0008116992,0.02194017,0.00016444035,0.00034680395,0.000036422483,0.000026477876,0.000027886994,0.00012233855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970974,0.00011002884,0.0021510974,0.00019377319,0.00020143559,0.0002463041],"domain_scores_gemma":[0.99448097,0.0012066929,0.002595766,0.00015070352,0.0014072241,0.00015863393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012780157,0.00016562664,0.0011532755,0.00020928432,0.000045825498,0.0000020810232,0.00011891549,0.0002324009,0.000027141288],"category_scores_gemma":[0.00035934846,0.00011366357,0.00023917198,0.00030548667,0.000113669485,0.000068583635,0.000019747235,0.00041524885,1.5447644e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56615734,0.017846657,0.18422185,0.00009793993,0.0007959914,0.000036695037,0.0019510478,0.00031454893,0.00036716307,0.0000021973992,0.00012004289,0.22808851],"study_design_scores_gemma":[0.5707919,0.2869312,0.12943238,0.0006043926,0.0018899787,0.000018354625,0.00042228607,0.00090068276,0.0023809962,0.00004212355,0.006353205,0.00023252612],"about_ca_topic_score_codex":0.000018767092,"about_ca_topic_score_gemma":0.00020659162,"teacher_disagreement_score":0.2690845,"about_ca_system_score_codex":0.00040249934,"about_ca_system_score_gemma":0.0019087588,"threshold_uncertainty_score":0.46350658},"labels":[],"label_agreement":null},{"id":"W2049112489","doi":"10.1097/01.jto.0000283711.18087.8c","title":"P1-096: 18Fluorodeoxyglucose Positron Emission Tomography in the diagnosis and staging of lung cancer: a systematic review and practitioner guideline in Ontario, Canada","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Hamilton Health Sciences; University of Toronto; McMaster University; Cancer Care Ontario; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Guideline; Positron emission tomography; Systematic review; Randomized controlled trial; Lung cancer; Medical physics; MEDLINE; Radiology; Surgery; Oncology; Pathology","score_opus":0.034876352231110554,"score_gpt":0.4483372942133111,"score_spread":0.4134609419822005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049112489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015908239,0.9930128,0.0000029556163,0.0028530976,0.00017984235,0.0022458073,0.000019670324,0.0000016917274,0.00009329924],"genre_scores_gemma":[0.0009641662,0.9972142,0.00034596797,0.0010667546,0.0000721503,0.00027228854,0.00001678971,0.000021044563,0.00002666112],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99610215,0.0006796061,0.0023174428,0.00023888289,0.0004173775,0.00024454048],"domain_scores_gemma":[0.99603367,0.0009889917,0.0023626948,0.00025713682,0.0002089425,0.00014855067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027279053,0.00031713088,0.0038925356,0.00046602596,0.00003661367,0.000012757312,0.00015003348,0.00019563177,0.000053339638],"category_scores_gemma":[0.00023559202,0.00017508009,0.0002458423,0.00042850125,0.000046306286,0.00008785842,0.000047120695,0.0008579552,6.6824505e-8],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010105572,0.0005386032,0.014337537,0.7660206,0.0008868231,0.0013191549,0.00033723185,9.325381e-7,2.4036126e-7,0.0000047668696,0.007421423,0.20903161],"study_design_scores_gemma":[0.0005854224,0.0005770426,0.0015137382,0.73292446,0.019855145,0.0017374804,0.00013092713,0.000002082351,0.0000021102876,0.0000056356375,0.24249648,0.00016947146],"about_ca_topic_score_codex":0.34959942,"about_ca_topic_score_gemma":0.77684265,"teacher_disagreement_score":0.4272432,"about_ca_system_score_codex":0.003984784,"about_ca_system_score_gemma":0.003925997,"threshold_uncertainty_score":0.99983877},"labels":[],"label_agreement":null},{"id":"W2049681888","doi":"10.1097/jto.0b013e31818b1771","title":"Practical Considerations Arising from the Implementation of Lung Stereotactic Body Radiation Therapy (SBRT) at a Comprehensive Cancer Center","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Medical physics; Radiation treatment planning; Lung; Radiation therapy; Radiosurgery; Clinical Practice; Radiology; Radiation oncologist; Radiation oncology; Oncology; Internal medicine","score_opus":0.06987239469980837,"score_gpt":0.49186368593933577,"score_spread":0.4219912912395274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049681888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96669775,0.0019459483,0.000059935395,0.030302549,0.00050773384,0.0003655593,0.000027734466,0.0000041887324,0.000088592285],"genre_scores_gemma":[0.99165815,0.0048340973,0.00092466816,0.0021153553,0.0004045056,0.000019033,0.000015878768,0.000010833888,0.000017467015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987035,0.00027315918,0.0005273575,0.000110495406,0.0002562987,0.00012922642],"domain_scores_gemma":[0.99761605,0.0009708042,0.0008302893,0.00013200911,0.00037504375,0.000075793774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014726394,0.00010209449,0.00038090532,0.000065174674,0.00014357452,0.000009936302,0.000029903846,0.00006678917,0.00072989723],"category_scores_gemma":[0.0000501032,0.000063120475,0.00013154313,0.00007598256,0.000076437704,0.00014734923,0.000019406452,0.00020398738,0.0000036406077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016115438,0.000925682,0.92379224,0.000025557356,0.0017236749,0.00054587284,0.0044638608,0.000013281649,0.0029465451,0.0000399495,0.051342394,0.012569373],"study_design_scores_gemma":[0.0039999005,0.0013896449,0.9642142,0.00010036497,0.00078727753,0.0022232912,0.00062565744,0.00006146795,0.009214929,0.00007115299,0.017240083,0.00007200682],"about_ca_topic_score_codex":0.0003108698,"about_ca_topic_score_gemma":0.00022518984,"teacher_disagreement_score":0.04042196,"about_ca_system_score_codex":0.0012401126,"about_ca_system_score_gemma":0.0007880583,"threshold_uncertainty_score":0.7991863},"labels":[],"label_agreement":null},{"id":"W2049978627","doi":"10.1097/jto.0b013e31817c6094","title":"Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"University of Toronto","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Univariate analysis; Immunohistochemistry; Radiation therapy; Internal medicine; Oncology; Cancer; MAPK/ERK pathway; Prospective cohort study; Epidermal growth factor; Pathology; Cancer research; Receptor; Kinase; Biology; Multivariate analysis","score_opus":0.016138289761563358,"score_gpt":0.3563431171994241,"score_spread":0.34020482743786074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049978627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688673,0.00046277125,0.00040627457,0.0009061822,0.00016169384,0.0008355346,0.00002517759,0.000012690244,0.00030291616],"genre_scores_gemma":[0.9917831,0.0008868435,0.006295343,0.00013943376,0.00012809348,0.000026351161,0.0000115431285,0.000068768466,0.0006605339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713296,0.0003828307,0.0007604532,0.00026896317,0.0009460052,0.00050880696],"domain_scores_gemma":[0.99622047,0.00030126478,0.0012799276,0.00019143439,0.0017448855,0.00026202743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060602045,0.00026727465,0.0011583387,0.00036004887,0.00005464418,0.0000072180546,0.00019426011,0.00026490248,0.00026374924],"category_scores_gemma":[0.00009639851,0.0001711601,0.00008254107,0.0007379702,0.00014190961,0.0001807691,0.000016939746,0.00088210043,0.0000015615469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037832912,0.0010623392,0.9474027,0.00019608818,0.0005293721,0.00031192877,0.0009231668,0.00048317152,0.0028587438,1.9897841e-7,0.0005492754,0.007850072],"study_design_scores_gemma":[0.016515104,0.018284759,0.93965596,0.00086028787,0.00022111642,0.000075061296,0.00014645564,0.00017628804,0.023061585,5.8965975e-7,0.0007559658,0.00024684993],"about_ca_topic_score_codex":0.00036609793,"about_ca_topic_score_gemma":0.00044551748,"teacher_disagreement_score":0.021317806,"about_ca_system_score_codex":0.0029965346,"about_ca_system_score_gemma":0.0026005183,"threshold_uncertainty_score":0.78358334},"labels":[],"label_agreement":null},{"id":"W2050271614","doi":"10.1097/jto.0b013e31829f6a43","title":"Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; William Osler Health System; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Gefitinib; Epidermal growth factor receptor; Internal medicine; Adenocarcinoma; Oncology; Lung cancer; Turnaround time; Clinical trial; Cancer","score_opus":0.08133866460632966,"score_gpt":0.4917260507136124,"score_spread":0.41038738610728276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050271614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881868,0.0018547821,0.0003261745,0.007043556,0.0003428435,0.0017084089,0.00007530196,0.000011043481,0.0004510893],"genre_scores_gemma":[0.98477656,0.000090274014,0.014360778,0.00021978389,0.00027650283,0.00020831496,0.000016326188,0.000021009111,0.000030433828],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984869,0.00014113949,0.00075667066,0.00017613565,0.00015086537,0.0002882871],"domain_scores_gemma":[0.99777603,0.00015177258,0.00077846786,0.00010682351,0.0009273446,0.00025956475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034022986,0.00012874622,0.0005628796,0.0002937608,0.00005439334,0.00001656107,0.00009321448,0.00008478835,0.00005836532],"category_scores_gemma":[0.000048666,0.000101564874,0.00007499249,0.00017268972,0.000012607617,0.00023602536,0.000016160173,0.00014397319,0.0000011979455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049581815,0.0004782962,0.053822305,0.003823337,0.00029161526,0.000024485722,0.017154852,0.00017115672,0.00390822,0.00005689298,0.00072782306,0.9190452],"study_design_scores_gemma":[0.01116036,0.03128369,0.6762389,0.0020315319,0.0009818247,0.00033259243,0.26346576,0.0010903222,0.011696612,0.000049781054,0.0012291295,0.00043950425],"about_ca_topic_score_codex":0.003622016,"about_ca_topic_score_gemma":0.0054375185,"teacher_disagreement_score":0.9186057,"about_ca_system_score_codex":0.0017308044,"about_ca_system_score_gemma":0.0017011779,"threshold_uncertainty_score":0.54754287},"labels":[],"label_agreement":null},{"id":"W2050320070","doi":"10.1097/jto.0b013e31823e0667","title":"Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Thoracentesis; Thoracoscopy; Parietal Pleura; Pleural effusion; Mesothelioma; Malignancy; Pleural disease; Pathology; Malignant pleural effusion; Cytology; Radiology; Respiratory disease; Lung; Internal medicine","score_opus":0.023523567747455728,"score_gpt":0.33506129588667566,"score_spread":0.3115377281392199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050320070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973856,0.0005872941,0.000013569942,0.0013286362,0.00022939664,0.00020856896,0.00001646387,0.000009011533,0.00022143577],"genre_scores_gemma":[0.99782234,0.000061298764,0.0008783706,0.00085221906,0.00024593715,0.0000047692024,0.00001810893,0.00001720216,0.00009974294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984328,0.00013122977,0.0005163686,0.00015830698,0.00039425594,0.0003670296],"domain_scores_gemma":[0.9990056,0.00016848218,0.0002970304,0.0001114795,0.000059341743,0.00035807013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003247316,0.00019716095,0.0005336475,0.0002226154,0.000058829995,0.000010703917,0.000094977586,0.00014304132,0.0002501114],"category_scores_gemma":[0.00012424677,0.000115536954,0.00010182884,0.00013027902,0.00017245149,0.00031185977,0.00007960438,0.0003218823,0.000018278337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102995215,0.0012323699,0.9747448,0.000043895387,0.000061840634,0.0001970763,0.00016929058,0.000012925219,0.0035042476,0.000019324318,0.0003877094,0.009326986],"study_design_scores_gemma":[0.001907072,0.004702006,0.99028116,0.00015372288,0.0001723603,0.0007714049,0.00016419649,0.000025843568,0.00097645336,0.000053148557,0.0006524198,0.00014021753],"about_ca_topic_score_codex":0.000012980506,"about_ca_topic_score_gemma":0.000009587571,"teacher_disagreement_score":0.015536342,"about_ca_system_score_codex":0.00023730041,"about_ca_system_score_gemma":0.000079380545,"threshold_uncertainty_score":0.47114602},"labels":[],"label_agreement":null},{"id":"W2051096017","doi":"10.1097/jto.0b013e31826c1155","title":"Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Lung cancer; Internal medicine; Clinical trial; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology; Alternative medicine; Epidermal growth factor receptor","score_opus":0.031063588858787277,"score_gpt":0.44058916429867845,"score_spread":0.40952557543989115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051096017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955895,0.00041702436,0.000010347466,0.00033275672,0.0002586691,0.0030877837,0.000041021052,0.000003009274,0.000259918],"genre_scores_gemma":[0.998831,0.000091626964,0.00051226176,0.000083535684,0.00023812159,0.00016059812,0.000007611096,0.000016715114,0.00005857575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975062,0.0008423096,0.0009841463,0.0001499618,0.00027502817,0.00024235243],"domain_scores_gemma":[0.9960364,0.00231625,0.0012051002,0.00015207955,0.00017416239,0.00011599984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018192265,0.00016768418,0.00086111185,0.00010632933,0.00004798723,0.0000094305915,0.00012048691,0.00014030424,0.000018389874],"category_scores_gemma":[0.0008479134,0.0000670549,0.000088680914,0.00029903487,0.00014458805,0.00013579376,0.000020375732,0.000465305,2.4653934e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18294461,0.003275987,0.798827,0.000049441183,0.00024397759,0.000029135528,0.0016738222,0.000049288894,0.00004633163,7.1956754e-7,0.00004329353,0.012816386],"study_design_scores_gemma":[0.085026324,0.022605581,0.88710916,0.00053126394,0.0024435748,0.0000742858,0.0016759046,0.00011500127,0.00013534454,0.0000028728264,0.00020164289,0.00007906491],"about_ca_topic_score_codex":0.000044345103,"about_ca_topic_score_gemma":0.00040406315,"teacher_disagreement_score":0.09791828,"about_ca_system_score_codex":0.00028296083,"about_ca_system_score_gemma":0.0009422334,"threshold_uncertainty_score":0.27344194},"labels":[],"label_agreement":null},{"id":"W2051503841","doi":"10.1097/jto.0b013e3181e15d74","title":"Prospective Study of Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer","year":2010,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Lambert-Eaton myasthenic syndrome; Medicine; Lung cancer; Autoantibody; Cancer; Internal medicine; Antibody; Oncology; Pathology; Immunology","score_opus":0.018199363740046784,"score_gpt":0.37574629642307084,"score_spread":0.35754693268302407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051503841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9095711,0.0013545435,0.000005559839,0.08473979,0.0015680119,0.0012829129,0.000015996797,0.000009583907,0.0014524829],"genre_scores_gemma":[0.9625043,0.0001965598,0.0007098692,0.028421694,0.0026754816,0.00007854233,0.000010621375,0.00013236994,0.0052705156],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964292,0.0004816762,0.0016075594,0.00040792584,0.00055835146,0.00051528966],"domain_scores_gemma":[0.99617004,0.00028084044,0.002288957,0.0005046163,0.00060000556,0.00015551051],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0010401828,0.00044938928,0.0024834385,0.00096908264,0.000038194466,0.000014425464,0.0004619456,0.0019164268,0.00048643528],"category_scores_gemma":[0.000085478714,0.0003380787,0.0004063351,0.00038580212,0.000116198884,0.000073590054,0.000115277246,0.009006425,0.000008620288],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009253177,0.012807752,0.5204773,0.005026318,0.0033523296,0.1375864,0.012871072,0.00003158241,0.004104266,0.000012914054,0.2712096,0.023267293],"study_design_scores_gemma":[0.020721486,0.05887798,0.40049788,0.005423695,0.010936582,0.042547043,0.0026902335,0.000101097125,0.002103837,0.00078789477,0.45358893,0.00172333],"about_ca_topic_score_codex":0.0003762845,"about_ca_topic_score_gemma":0.0009553391,"teacher_disagreement_score":0.18237934,"about_ca_system_score_codex":0.0007234586,"about_ca_system_score_gemma":0.0012881844,"threshold_uncertainty_score":0.99990714},"labels":[],"label_agreement":null},{"id":"W2051616527","doi":"10.1097/jto.0b013e3182435f3e","title":"Tumor Vasculature as a Therapeutic Target in Non-small Cell Lung Cancer","year":2012,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Angiogenesis; Clinical trial; Vasculogenesis; Cancer; Oncology; Bioinformatics; Cancer research; Internal medicine; Stem cell; Progenitor cell","score_opus":0.028898553325629434,"score_gpt":0.4094536583498998,"score_spread":0.38055510502427037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051616527","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016445827,0.995259,0.00014532912,0.000071219234,0.0015023766,0.00039275517,0.000022741911,0.0000024525825,0.00095957733],"genre_scores_gemma":[0.0018337892,0.9930332,0.00088817615,0.0005272656,0.0026493245,0.0000730532,0.000027166376,0.00008376197,0.00088429527],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763733,0.00043369498,0.000931285,0.00032679748,0.00018501111,0.00048587666],"domain_scores_gemma":[0.99784285,0.000051865645,0.0013873278,0.00034259303,0.0001901916,0.00018514504],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008646424,0.0004407365,0.0017179349,0.0002257834,0.000043211487,0.000019702198,0.0005731173,0.00092967006,0.0002126644],"category_scores_gemma":[0.000021947697,0.00032026047,0.0011295537,0.00021492933,0.00006475496,0.000007593993,0.00013915083,0.00073795347,0.000014323068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017242848,0.0003127287,0.00040615824,0.0053260177,0.00075694965,0.00015823489,0.000076728706,0.000029524734,0.0005418627,0.00000404543,0.003089126,0.9891262],"study_design_scores_gemma":[0.00024467098,0.00039518814,0.0000831179,0.0016954299,0.001728921,0.00059454935,0.000026678774,0.000003103631,0.00033819786,0.000012173315,0.99453485,0.00034311827],"about_ca_topic_score_codex":0.000024988549,"about_ca_topic_score_gemma":0.000038838065,"teacher_disagreement_score":0.9914457,"about_ca_system_score_codex":0.00032383605,"about_ca_system_score_gemma":0.0019313125,"threshold_uncertainty_score":0.99992496},"labels":[],"label_agreement":null},{"id":"W2051780629","doi":"10.1097/01.jto.0000268668.64625.f2","title":"Should Mutational Analyses of Tumor Samples Bypass Histopathology?","year":2007,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Histopathology; Pathology","score_opus":0.11166283347676562,"score_gpt":0.5254802178010496,"score_spread":0.41381738432428394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051780629","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05004582,0.008709155,0.0034817087,0.9180235,0.0040340223,0.00066429237,0.00032186566,0.000034335233,0.014685256],"genre_scores_gemma":[0.06992231,0.00029809045,0.07002492,0.8371755,0.013028224,0.000029850544,0.00077410415,0.00015418876,0.008592818],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997429,0.00021191583,0.0012281061,0.00022386729,0.0006051951,0.00030187896],"domain_scores_gemma":[0.99598217,0.0006109105,0.0020928816,0.00024262747,0.0009526489,0.000118754295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056178204,0.0002694849,0.001394986,0.000938817,0.000055557874,0.000007719886,0.0001978929,0.00065220275,0.0004879969],"category_scores_gemma":[0.00029904532,0.00019789446,0.0005374849,0.00024502573,0.00027460617,0.000079143945,0.000031408767,0.0016039145,0.000012134276],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009587043,0.0005085364,0.0017057514,0.0004566289,0.001580329,0.025011735,0.00039581727,0.000039245293,0.0018723017,0.000017417764,0.94784456,0.019608991],"study_design_scores_gemma":[0.0011248962,0.002620178,0.009696593,0.0003073045,0.0070103756,0.014253923,0.0001881273,0.0000049876085,0.0012615249,0.00041295466,0.96293986,0.00017930359],"about_ca_topic_score_codex":0.000053008476,"about_ca_topic_score_gemma":0.0000123091595,"teacher_disagreement_score":0.08084805,"about_ca_system_score_codex":0.0010292459,"about_ca_system_score_gemma":0.002188295,"threshold_uncertainty_score":0.8069902},"labels":[],"label_agreement":null},{"id":"W2051893611","doi":"10.1097/01.jto.0000391364.18141.9d","title":"Fibroblast Growth Factor Inhibitors","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Fibroblast growth factor receptor; Cancer research; Fibroblast growth factor; Fibroblast growth factor receptor 1; Medicine; Gefitinib; Epidermal growth factor receptor; Cabozantinib; Receptor tyrosine kinase; Tyrosine kinase; Cancer; Internal medicine; Receptor","score_opus":0.01380360927404905,"score_gpt":0.3729134639243062,"score_spread":0.35910985465025713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051893611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957185,0.00006814678,0.0002756597,0.0010297265,0.00084659795,0.00010242694,0.000012923019,0.0000068999598,0.0019391412],"genre_scores_gemma":[0.99406254,0.000025117759,0.0036466154,0.00013547966,0.0015737922,0.0000026969526,0.00000676148,0.00003209504,0.00051488465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845356,0.0001723659,0.00049147324,0.00021186822,0.00030916047,0.0003615916],"domain_scores_gemma":[0.9985226,0.000058537626,0.00039272718,0.00026299985,0.0004886762,0.0002744786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005043283,0.0001723175,0.00029671393,0.00019240212,0.00006796211,0.000030774838,0.00047588887,0.00041447702,0.00021748312],"category_scores_gemma":[0.000685089,0.00014177962,0.0002171627,0.0001450159,0.0001980113,0.000015338685,0.00018743076,0.00082264194,0.000042669555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041945692,0.00012821815,0.0034201648,0.000030459356,0.00006298989,0.00004928671,0.000052995474,0.0000027824317,0.9761555,0.000033390013,0.008704127,0.010940603],"study_design_scores_gemma":[0.00043305525,0.0028508576,0.012135625,0.000038203896,0.000017056725,0.0009144462,0.00006827117,0.000006517251,0.8818205,0.00019287977,0.10132129,0.00020132215],"about_ca_topic_score_codex":0.0000060511843,"about_ca_topic_score_gemma":0.00004871984,"teacher_disagreement_score":0.09433505,"about_ca_system_score_codex":0.000045124554,"about_ca_system_score_gemma":0.00048561895,"threshold_uncertainty_score":0.57816046},"labels":[],"label_agreement":null},{"id":"W2052267217","doi":"10.1097/jto.0b013e31820c2f2e","title":"Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer screening; Retrospective cohort study; Lung cancer; Radiation therapy; Cancer; Computed tomographic; Interim; Computed tomography; Disease; Interim analysis; Radiology; Clinical trial; Internal medicine","score_opus":0.04729657512002468,"score_gpt":0.40958893375337474,"score_spread":0.3622923586333501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052267217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946595,0.0035142393,0.000050526578,0.0004907654,0.00048530014,0.0006929678,0.00001595726,0.000013187129,0.000077585144],"genre_scores_gemma":[0.99469894,0.00226336,0.002645427,0.00011571634,0.00014950946,0.000058919417,0.0000035825244,0.000029504132,0.000035023095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978408,0.00019907209,0.0008810671,0.00022437,0.00038846157,0.000466204],"domain_scores_gemma":[0.9979695,0.00018393392,0.00087973615,0.0001494912,0.0005782444,0.0002391125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005574096,0.000221827,0.0010847346,0.0005390174,0.000070821785,0.000011962585,0.0001819747,0.00012231943,0.000036295165],"category_scores_gemma":[0.0001398047,0.00017314001,0.00014981501,0.0003884302,0.00021691683,0.0001246291,0.00016471402,0.0006464188,1.3094743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002153968,0.00076123665,0.9616409,0.0010242813,0.00056637096,0.00035123256,0.0029356102,0.0000104542105,0.00029591675,9.1885215e-7,0.000065049615,0.030194089],"study_design_scores_gemma":[0.0039750035,0.0011031843,0.99125236,0.0012190901,0.0005108319,0.000023804896,0.0002841943,0.000406012,0.0010175405,0.0000042890633,0.000058888472,0.00014477271],"about_ca_topic_score_codex":0.0012847832,"about_ca_topic_score_gemma":0.0007885345,"teacher_disagreement_score":0.030049317,"about_ca_system_score_codex":0.0005045865,"about_ca_system_score_gemma":0.0003627501,"threshold_uncertainty_score":0.7060445},"labels":[],"label_agreement":null},{"id":"W2052653411","doi":"10.1097/jto.0000000000000293","title":"The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Hyogo College of Medicine; KU Leuven; Seoul National University; Samsung; Imperial College London; Cleveland Clinic; Memorial Sloan-Kettering Cancer Center; Gentofte Hospital; Cancer Research Institute","keywords":"Medicine; Lymph node; Pathology; Oncology","score_opus":0.02638520375604361,"score_gpt":0.3571935872077797,"score_spread":0.33080838345173613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052653411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98466974,0.00014225909,0.0015454172,0.01057792,0.0010017281,0.0016856766,0.000049257516,0.000011254668,0.00031673408],"genre_scores_gemma":[0.99690384,0.000044093744,0.0013500478,0.0003655469,0.001080216,0.000065454486,0.0000099420295,0.000046114812,0.00013476746],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9954821,0.0010886611,0.0018485738,0.0002885364,0.000767151,0.00052498514],"domain_scores_gemma":[0.99479854,0.0011141804,0.0028789947,0.0005896608,0.00053058454,0.00008805138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006179644,0.00029946436,0.0009715392,0.00034841156,0.00030034286,0.000034404,0.00079151726,0.0001866243,0.000012510755],"category_scores_gemma":[0.000944412,0.00014355274,0.0004980667,0.00042909986,0.00044454366,0.00015353419,0.00008791751,0.00063712173,0.0000030023145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027473256,0.0034693968,0.07560789,0.0029626673,0.00070463936,0.00023790864,0.02118998,0.00037879654,0.6140103,0.01522141,0.0029667441,0.23577704],"study_design_scores_gemma":[0.015027062,0.01116927,0.7112181,0.007758266,0.001972295,0.004877334,0.0323175,0.018443618,0.15114513,0.021706138,0.023368524,0.0009967687],"about_ca_topic_score_codex":0.00009967858,"about_ca_topic_score_gemma":0.00008403214,"teacher_disagreement_score":0.6356102,"about_ca_system_score_codex":0.00034302665,"about_ca_system_score_gemma":0.0012944438,"threshold_uncertainty_score":0.5853911},"labels":[],"label_agreement":null},{"id":"W2052731636","doi":"10.1097/jto.0000000000000215","title":"Prognostic Factors for Cure, Recurrence and Long-Term Survival After Surgical Resection of Thymoma","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Thymoma; Thymectomy; Stage (stratigraphy); Surgery; Multivariate analysis; Myasthenia gravis; Radiation therapy; Chemoradiotherapy; Internal medicine","score_opus":0.03451030894162865,"score_gpt":0.4062984901962493,"score_spread":0.37178818125462065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052731636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99644035,0.00062310364,0.0008782944,0.0007269037,0.0007662141,0.00025838483,0.000006303751,0.0000054038014,0.00029505606],"genre_scores_gemma":[0.9984585,0.00013304887,0.0007147079,0.000026215364,0.0005025614,0.000007130516,0.0000041566977,0.000013901453,0.00013978181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986709,0.0002157888,0.000543919,0.00014266465,0.00023138987,0.00019533366],"domain_scores_gemma":[0.99812937,0.00074428413,0.00046579668,0.0001238117,0.00036146678,0.00017530032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010149544,0.0001238963,0.0006182113,0.00017267917,0.000035434805,0.00000942966,0.00008022512,0.00017316666,0.000055012308],"category_scores_gemma":[0.00053932896,0.000084000654,0.00016375561,0.0001038159,0.00012365793,0.00008130836,0.000030455729,0.00028337943,0.0000011986102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009576691,0.00046101748,0.8999939,0.0004868115,0.0001366415,0.0002168062,0.00030671185,6.697485e-7,0.00070795714,0.00025101073,0.00012275823,0.08773905],"study_design_scores_gemma":[0.0018666299,0.014024332,0.9696748,0.0004905012,0.000458664,0.0025247617,0.000083238876,0.00004765043,0.0013775842,0.0006759259,0.0086534675,0.00012240779],"about_ca_topic_score_codex":0.0000029184348,"about_ca_topic_score_gemma":0.00002054256,"teacher_disagreement_score":0.08761664,"about_ca_system_score_codex":0.000050643994,"about_ca_system_score_gemma":0.00012303052,"threshold_uncertainty_score":0.3425447},"labels":[],"label_agreement":null},{"id":"W2053090237","doi":"10.1016/s1556-0864(15)30401-9","title":"Immune-Modulating Vaccines in Non-small Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Immune system; Immunology; Chemotherapy; Cancer; Antigen; Targeted therapy; Oncology; Internal medicine","score_opus":0.010219783417475125,"score_gpt":0.3380810902113118,"score_spread":0.3278613067938366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053090237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94087,0.054192193,0.0002578636,0.0006782393,0.0021027955,0.00017397576,0.0000037905459,0.000013094458,0.0017080748],"genre_scores_gemma":[0.99378604,0.0007417997,0.00058522733,0.0001467354,0.00019217162,0.000012363587,0.0000057112416,0.000026982216,0.004502993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761134,0.0005937532,0.0011175437,0.00017142156,0.00004430325,0.0004616618],"domain_scores_gemma":[0.9982478,0.00040878763,0.00094347907,0.00020315315,0.0001808157,0.000015979002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010373944,0.00022089102,0.0007254978,0.00043896455,0.00012814328,0.000015985177,0.00038906638,0.00041142697,0.00048822205],"category_scores_gemma":[0.000059730093,0.00018235875,0.00023379912,0.00026127117,0.000081942846,0.00016737424,0.00006885263,0.0007811591,0.00003229927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027585777,0.00049336266,0.024047084,0.000061607854,0.00014146612,0.00010912193,0.00064060924,0.0005574587,0.9141572,0.000018378314,0.0018879973,0.0551271],"study_design_scores_gemma":[0.0054684756,0.0015252156,0.3354403,0.00048209738,0.00025390694,0.0013374975,0.0009823544,0.00010859294,0.5850311,0.00025389993,0.06857212,0.00054446596],"about_ca_topic_score_codex":0.00063371554,"about_ca_topic_score_gemma":0.00015037949,"teacher_disagreement_score":0.32912615,"about_ca_system_score_codex":0.00027620804,"about_ca_system_score_gemma":0.0003739812,"threshold_uncertainty_score":0.74363744},"labels":[],"label_agreement":null},{"id":"W2053394601","doi":"10.1097/jto.0b013e31822ae061","title":"Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Docetaxel; Febrile neutropenia; Rash; Neutropenia; Internal medicine; Oncology; Mucositis; Chemotherapy; Pharmacodynamics; Epidermal growth factor receptor; Pharmacology; Surgery; Pharmacokinetics; Cancer","score_opus":0.06447132353536798,"score_gpt":0.5097804440297722,"score_spread":0.4453091204944042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053394601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98764324,0.00019925648,0.004476517,0.0022670934,0.0010300368,0.0006858624,0.000027116213,0.000016137588,0.0036547526],"genre_scores_gemma":[0.96600723,0.000034312183,0.03283564,0.00031020312,0.0003502478,0.000013192515,0.000013928314,0.00001680721,0.00041842947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982107,0.00020325676,0.0010195681,0.00015927415,0.00021515244,0.00019204234],"domain_scores_gemma":[0.9981795,0.00011164494,0.0008578963,0.00015563561,0.00046542505,0.00022987646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006705151,0.00014757054,0.00061242335,0.00033978742,0.00008140588,0.0000073529554,0.0001248213,0.00011992977,0.0001454977],"category_scores_gemma":[0.00022695334,0.00011038344,0.00019033306,0.00028119062,0.000067405264,0.0001651566,0.000035760822,0.0002555287,0.000009997902],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6597646,0.008497758,0.000059609203,0.00006759615,0.0014524626,0.00049185095,0.010330667,0.00007046885,0.07996083,0.00008339574,0.0016517877,0.237569],"study_design_scores_gemma":[0.4961859,0.32221487,0.0017109758,0.0015447375,0.01127509,0.0028252297,0.003379798,0.0023244836,0.1348216,0.0009534958,0.022103557,0.0006602603],"about_ca_topic_score_codex":0.000025575711,"about_ca_topic_score_gemma":0.000013235532,"teacher_disagreement_score":0.31371713,"about_ca_system_score_codex":0.00033077315,"about_ca_system_score_gemma":0.0007854382,"threshold_uncertainty_score":0.45013058},"labels":[],"label_agreement":null},{"id":"W2054266161","doi":"10.1097/jto.0b013e3182370e02","title":"Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Bevacizumab; Internal medicine; Lung cancer; Adverse effect; Surgery; Clinical endpoint; Chemotherapy; Proteinuria; Oncology; Randomized controlled trial","score_opus":0.017857850082036206,"score_gpt":0.37348717613681515,"score_spread":0.3556293260547789,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054266161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954147,0.0012980727,0.00041450295,0.00033937863,0.00039379296,0.0015984912,0.000039163355,0.0000040701325,0.00049784296],"genre_scores_gemma":[0.9927973,0.0018990015,0.0050208666,0.000042213636,0.00008530901,0.000026943891,0.0000114123295,0.000025850937,0.000091089074],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99797565,0.00011385776,0.0012104247,0.00021310875,0.00023518718,0.00025176187],"domain_scores_gemma":[0.9979133,0.0002712979,0.0011881635,0.00017452949,0.00031779447,0.00013494176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037602716,0.0002076903,0.0010705448,0.0003273789,0.000034648736,0.0000027274605,0.000117578165,0.00014817975,0.0001181855],"category_scores_gemma":[0.00008630545,0.0001396884,0.000099802055,0.00031900435,0.000089628404,0.00009984572,0.00002684594,0.00034911121,2.2190169e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6015515,0.0046102437,0.089129694,0.00057997974,0.00031349238,0.00014162716,0.0076816212,0.0005460498,0.00007244798,0.0000020582072,0.00004212504,0.29532918],"study_design_scores_gemma":[0.44752795,0.055984013,0.48583588,0.003227203,0.0017677847,0.0000969849,0.00081555103,0.0009894441,0.00186036,0.00001531587,0.0015098149,0.00036972328],"about_ca_topic_score_codex":0.00023120698,"about_ca_topic_score_gemma":0.0015125755,"teacher_disagreement_score":0.39670616,"about_ca_system_score_codex":0.00096785795,"about_ca_system_score_gemma":0.0012426579,"threshold_uncertainty_score":0.56963277},"labels":[],"label_agreement":null},{"id":"W2054724578","doi":"10.1097/jto.0b013e318200e509","title":"Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"Sunesis","keywords":"Medicine; Refractory (planetary science); Chemotherapy; Lung cancer; Oncology; Internal medicine; Multicenter study; Randomized controlled trial","score_opus":0.07526664195801742,"score_gpt":0.48279497794253895,"score_spread":0.40752833598452154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054724578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915674,0.0023297423,0.00003258494,0.0017439799,0.00080334477,0.00095227675,0.000014187301,0.0000080478,0.0025484394],"genre_scores_gemma":[0.987945,0.005871072,0.001841032,0.001130844,0.0007968421,0.0000315496,0.0000015739108,0.00003694982,0.0023451203],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977077,0.0003856151,0.0009567382,0.00021476983,0.00036182956,0.00037331478],"domain_scores_gemma":[0.9976763,0.00032998784,0.0009435184,0.00022047765,0.00063981453,0.00018986319],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013033594,0.00021308669,0.0010818515,0.00040406839,0.000047241418,0.0000039642596,0.00019429982,0.00020702569,0.0016221892],"category_scores_gemma":[0.00028239176,0.00013875897,0.00022467757,0.00023592942,0.00020742408,0.00011579014,0.00007162611,0.00082687545,0.0000032805608],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74399966,0.011525019,0.0012789508,0.00025869874,0.00085554435,0.0014570705,0.014833481,0.0000015653659,0.06006774,0.0000016914888,0.0024802084,0.16324034],"study_design_scores_gemma":[0.36232018,0.17043795,0.005788382,0.00092764007,0.00053493143,0.00032588057,0.0031013435,0.000186604,0.4207559,0.000061158586,0.035186272,0.0003737687],"about_ca_topic_score_codex":0.00021143956,"about_ca_topic_score_gemma":0.00041309395,"teacher_disagreement_score":0.3816795,"about_ca_system_score_codex":0.0007514933,"about_ca_system_score_gemma":0.0015932441,"threshold_uncertainty_score":0.99929047},"labels":[],"label_agreement":null},{"id":"W2055219877","doi":"10.1097/jto.0b013e318292bdcd","title":"Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genetics, Bioinformatics, and Biomedical Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Disease; Oncology; Internal medicine; Identification (biology); Stage (stratigraphy); Biostatistics; Bioinformatics; Epidemiology","score_opus":0.02192992709996171,"score_gpt":0.392681153750278,"score_spread":0.3707512266503163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055219877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870943,0.0016923667,0.0062182955,0.003162881,0.0010032511,0.0004186981,0.00003327913,0.0000044179155,0.0003725259],"genre_scores_gemma":[0.97829485,0.004393439,0.015104758,0.0010390952,0.000620941,0.000009858933,0.000035822457,0.00002055486,0.0004806688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99826807,0.00016704432,0.0006768758,0.00019095381,0.00031878095,0.0003782846],"domain_scores_gemma":[0.99809194,0.0002099391,0.00035450945,0.00019309681,0.0005910464,0.0005594478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006326003,0.000172981,0.000361963,0.00017473455,0.00007258999,0.0000963559,0.0003042696,0.00030538917,0.000055934503],"category_scores_gemma":[0.0017171794,0.00012711658,0.00009785252,0.00012443538,0.0002691904,0.000026759635,0.00023692659,0.00029811467,0.00003970524],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008530902,0.0005545515,0.020601887,0.00016900449,0.00040946683,0.00005072469,0.001473154,0.000022120706,0.063434824,0.000015708252,0.061083913,0.85133153],"study_design_scores_gemma":[0.0018242918,0.04125034,0.16610555,0.0004786261,0.0004358696,0.00057424,0.013977533,0.0008306121,0.07902101,0.0014315353,0.6931244,0.00094597065],"about_ca_topic_score_codex":0.000008935235,"about_ca_topic_score_gemma":0.000018108649,"teacher_disagreement_score":0.8503856,"about_ca_system_score_codex":0.000049544586,"about_ca_system_score_gemma":0.00034722095,"threshold_uncertainty_score":0.5183664},"labels":[],"label_agreement":null},{"id":"W2056230207","doi":"10.1097/jto.0b013e3182289479","title":"Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"NF-κB Signaling Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Vancouver General Hospital","funders":"National Cancer Institute; National Institute of Dental and Craniofacial Research; Canadian Institutes of Health Research","keywords":"Gene knockdown; Ubiquitin ligase; DNA ligase; Gene; Biology; Gene expression; Signal transduction; Ubiquitin; Medicine; Cell biology; Molecular biology; Genetics","score_opus":0.050262513797039506,"score_gpt":0.3687357483992173,"score_spread":0.3184732346021778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056230207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930694,0.00031806607,0.005633034,0.00015367128,0.00025382836,0.00020832707,0.000037313614,0.000003304504,0.00032306457],"genre_scores_gemma":[0.99340075,0.00015080055,0.0060047763,0.00017383888,0.00017935627,0.0000110881965,0.000017471695,0.000024710982,0.000037203314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809784,0.00029436147,0.0009055565,0.00021809086,0.00024598133,0.00023815566],"domain_scores_gemma":[0.99793,0.00003495653,0.0013502344,0.00023347634,0.00035595358,0.00009538501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058357127,0.00017454631,0.0005073234,0.00021799991,0.00003096654,0.0000044955536,0.00029650077,0.00028354386,0.00012207996],"category_scores_gemma":[0.00007183727,0.0001671879,0.0001734753,0.00014732305,0.00009866233,0.000013540043,0.0001039865,0.00022131827,0.0000013235808],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010736746,0.00048040354,0.0029074987,0.00013535151,0.00011502112,0.000023972816,0.00097119494,0.00008627541,0.9869403,0.00009128377,0.00017841347,0.00699659],"study_design_scores_gemma":[0.0008134386,0.0013254025,0.018404488,0.00019680953,0.000083611136,0.00006624567,0.00018850589,0.00039457314,0.9772765,0.0005703107,0.00052945706,0.00015067316],"about_ca_topic_score_codex":0.00014579452,"about_ca_topic_score_gemma":0.000078958015,"teacher_disagreement_score":0.015496989,"about_ca_system_score_codex":0.00013031476,"about_ca_system_score_gemma":0.0003001104,"threshold_uncertainty_score":0.6817725},"labels":[],"label_agreement":null},{"id":"W2057618618","doi":"10.1097/jto.0b013e318199e03a","title":"BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Lung cancer; Biomarker; Internal medicine; Tissue microarray; Immunohistochemistry; Chromogranin A; Multivariate analysis; Univariate analysis; Cancer; Population; Pathology; Biology","score_opus":0.019581209392830187,"score_gpt":0.43774782563849296,"score_spread":0.41816661624566276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057618618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771606,0.002655789,0.002505989,0.0130422,0.0010885044,0.001125642,0.000021081878,0.00000992938,0.0023902783],"genre_scores_gemma":[0.98654205,0.00029963715,0.010142465,0.0010967845,0.00048906973,0.000046220055,0.000006125729,0.000015051491,0.001362626],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99906045,0.000044570945,0.000433195,0.00013561726,0.00010091762,0.00022523313],"domain_scores_gemma":[0.9990284,0.000130383,0.00037045474,0.0001018589,0.00023923321,0.00012971407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027081274,0.00011578382,0.0004406098,0.00016297355,0.000042720094,0.000009510162,0.00008055295,0.00012965886,0.00005386827],"category_scores_gemma":[0.00005714706,0.00008194163,0.0001309649,0.00011919988,0.00001620302,0.00008019036,0.000010623721,0.00021952408,0.0000012342042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007814307,0.00466428,0.083197124,0.0007427247,0.00041738327,0.0005481217,0.0066124643,0.00016946338,0.21576889,0.000014922431,0.023164062,0.6568863],"study_design_scores_gemma":[0.044114653,0.03687595,0.623853,0.0047386494,0.008636854,0.00087337074,0.0036461481,0.0088936845,0.13851693,0.0016915802,0.12703554,0.0011236122],"about_ca_topic_score_codex":0.000023806151,"about_ca_topic_score_gemma":0.00003677154,"teacher_disagreement_score":0.6557627,"about_ca_system_score_codex":0.0005026173,"about_ca_system_score_gemma":0.0007721002,"threshold_uncertainty_score":0.3341483},"labels":[],"label_agreement":null},{"id":"W2057886846","doi":"10.1097/01.jto.0000283106.85632.e3","title":"A3-03: Pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC): Results from a randomized phase III dose finding trial in patients who progressed following platinum-containing chemotherapy","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Docetaxel; Chemotherapy; Oncology; Interim analysis; Performance status; Phases of clinical research; Toxicity; Randomized controlled trial; Gastroenterology; Surgery; Cisplatin","score_opus":0.02359953387203726,"score_gpt":0.44636421540173876,"score_spread":0.4227646815297015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057886846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891998,0.0024323594,0.0012122556,0.00059138564,0.0011920647,0.0049953666,0.000057764224,0.0000075394832,0.0003114315],"genre_scores_gemma":[0.990348,0.00039953305,0.0081114285,0.000109816596,0.0004824271,0.00025517025,0.0000472545,0.000032784224,0.00021360767],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974891,0.00014050372,0.0015087625,0.00023797361,0.00027643115,0.00034722523],"domain_scores_gemma":[0.9950688,0.0026150655,0.0017466685,0.00019302072,0.0002517268,0.00012470118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013908179,0.00024140374,0.0015576365,0.00029408143,0.00010929356,0.000015125317,0.00012248335,0.00015309431,0.000020937412],"category_scores_gemma":[0.00027560885,0.00014453393,0.0005965357,0.00024793655,0.00005329909,0.0001063818,0.000010369908,0.00018402025,2.2646084e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.707431,0.0028511991,0.0025156692,0.000023926457,0.001352871,0.00006726915,0.01118576,0.00009978716,0.00068946654,6.6394836e-7,0.000044732355,0.27373764],"study_design_scores_gemma":[0.9702351,0.01317801,0.0035659387,0.00056117825,0.0030509557,0.0000028873505,0.0013659013,0.0009117837,0.0060180645,0.000020497424,0.00096049503,0.0001291632],"about_ca_topic_score_codex":0.00019782418,"about_ca_topic_score_gemma":0.0001721499,"teacher_disagreement_score":0.27360848,"about_ca_system_score_codex":0.001203315,"about_ca_system_score_gemma":0.00077455427,"threshold_uncertainty_score":0.58939224},"labels":[],"label_agreement":null},{"id":"W2059213354","doi":"10.1016/s1556-0864(15)31507-0","title":"Practitioner Feedback on Lung Cancer Practice Guidelines in Ontario","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Ottawa Hospital; McMaster University Medical Centre; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Specialty; Lung cancer; Family medicine; Clinical Practice; Radiation therapy; Oncology; Surgery; Pathology","score_opus":0.17482442973993437,"score_gpt":0.5920633798591426,"score_spread":0.4172389501192082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059213354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6392548,0.00065747387,0.0011475058,0.33380142,0.0024388991,0.0005376212,0.000004944424,0.00001866656,0.02213863],"genre_scores_gemma":[0.8021255,0.00062783755,0.12823062,0.054878134,0.005016103,0.00003654386,0.000035513578,0.00006920397,0.008980525],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962181,0.0003684572,0.0024088514,0.00020087493,0.0005523353,0.00025137205],"domain_scores_gemma":[0.99300754,0.0021858444,0.0022384508,0.0001941041,0.0022530968,0.000120966695],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003543909,0.00015893398,0.00056821224,0.00032215458,0.00004477674,0.000022747978,0.00010900336,0.00020201593,0.0010781995],"category_scores_gemma":[0.01084746,0.00012865233,0.00015262679,0.00025167377,0.00004606914,0.00067255733,0.00003397607,0.0012054455,0.00003424278],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024800733,0.0041469247,0.08589018,0.00010535064,0.00042146552,0.0034283518,0.00043648048,0.007248493,0.004081431,0.00032142323,0.62490225,0.24421692],"study_design_scores_gemma":[0.003106969,0.0019591372,0.11860609,0.00035097304,0.00090832054,0.002531401,0.0006808749,0.00039259318,0.0003689321,0.00038319713,0.87055033,0.0001611815],"about_ca_topic_score_codex":0.046330135,"about_ca_topic_score_gemma":0.13030152,"teacher_disagreement_score":0.2789233,"about_ca_system_score_codex":0.0023161753,"about_ca_system_score_gemma":0.0029118392,"threshold_uncertainty_score":0.99983495},"labels":[],"label_agreement":null},{"id":"W2059355012","doi":"10.1097/jto.0b013e318282707b","title":"A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Etoposide; Neutropenia; Pomalidomide; Internal medicine; Adverse effect; Regimen; Chemotherapy; Gastroenterology; Surgery; Thalidomide; Multiple myeloma","score_opus":0.022202202067033938,"score_gpt":0.42377374883985286,"score_spread":0.4015715467728189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059355012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967365,0.0004954403,0.000020315347,0.0009692841,0.000056132463,0.0015157051,0.0000033047604,0.0000031769794,0.00020008514],"genre_scores_gemma":[0.99884516,0.00008941745,0.00069943216,0.00011257564,0.00002812925,0.00006154047,0.000001386666,0.000017302527,0.00014505582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983399,0.00026178907,0.0005703879,0.00017346234,0.00040815666,0.0002463256],"domain_scores_gemma":[0.9980951,0.00022041211,0.0005956513,0.00013172504,0.00083957013,0.00011753651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005210539,0.00014595449,0.0007310202,0.000472659,0.00002989265,0.0000104907285,0.00008759453,0.000066767265,0.000029132945],"category_scores_gemma":[0.00013968501,0.00009403698,0.000024297811,0.0003221629,0.00011013524,0.00018065574,0.000060546503,0.00046670932,4.459706e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012486373,0.014326448,0.9549568,0.0003142588,0.00021948024,0.00046162304,0.00436922,0.000065178654,0.00068343966,0.0000018248485,0.00016212076,0.011953223],"study_design_scores_gemma":[0.07411508,0.033381093,0.8858215,0.00064279797,0.00025862345,0.000035762103,0.0046285875,0.00033532368,0.0006157806,0.000013622595,0.000038872662,0.00011294115],"about_ca_topic_score_codex":0.0011639864,"about_ca_topic_score_gemma":0.0025047683,"teacher_disagreement_score":0.0691353,"about_ca_system_score_codex":0.0005522358,"about_ca_system_score_gemma":0.0003957458,"threshold_uncertainty_score":0.38347167},"labels":[],"label_agreement":null},{"id":"W2061026641","doi":"10.1097/jto.0000000000000011","title":"Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non–Small-Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Celgene","keywords":"Medicine; Carboplatin; Internal medicine; Taxane; Peripheral neuropathy; Neutropenia; Lung cancer; Peripheral edema; Paclitaxel; Gastroenterology; Cancer; Oncology; Toxicity; Surgery; Chemotherapy; Breast cancer; Adverse effect; Cisplatin; Diabetes mellitus","score_opus":0.02962712005654688,"score_gpt":0.41083622599818354,"score_spread":0.38120910594163665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061026641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905979,0.002009516,0.000084392144,0.0010914775,0.0025761502,0.0032643264,0.000084977626,0.000018772404,0.0002725056],"genre_scores_gemma":[0.9974371,0.00019766245,0.0009857138,0.00031535764,0.0003270676,0.00043724602,0.000043540684,0.000056220826,0.00020007078],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965269,0.00038159275,0.0017543476,0.00039161553,0.00036139277,0.00058414496],"domain_scores_gemma":[0.99501884,0.0010726284,0.0026568894,0.00023571224,0.0006614865,0.00035445942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065555185,0.0003877012,0.0016931924,0.0004840965,0.000076053366,0.000017155526,0.0001372606,0.00037287665,0.00013660024],"category_scores_gemma":[0.0005140685,0.00033681528,0.00035765668,0.00038326185,0.00014455261,0.0001557934,0.00005129961,0.0006171976,9.877174e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.657944,0.0090907235,0.007632244,0.0008808471,0.0019765364,0.0016414089,0.0041676005,0.0020964593,0.20318945,0.0000035838495,0.0026712439,0.10870586],"study_design_scores_gemma":[0.82497597,0.09739049,0.0044789333,0.0008066253,0.006132826,0.00018807786,0.0018113579,0.032899935,0.02903883,0.000041415642,0.0015105229,0.00072499743],"about_ca_topic_score_codex":0.00068739284,"about_ca_topic_score_gemma":0.000563554,"teacher_disagreement_score":0.17415063,"about_ca_system_score_codex":0.0016688604,"about_ca_system_score_gemma":0.002620727,"threshold_uncertainty_score":0.9999084},"labels":[],"label_agreement":null},{"id":"W2062944510","doi":"10.1097/jto.0000000000000078","title":"A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"Princess Margaret Hospital Foundation","keywords":"Medicine; Mesothelioma; Extrapleural Pneumonectomy; Radiation therapy; Perioperative; Clinical endpoint; Surgery; Oncology; Internal medicine; Pneumonectomy; Lung cancer; Randomized controlled trial; Pathology","score_opus":0.0848180178626301,"score_gpt":0.44137001164294903,"score_spread":0.35655199378031893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062944510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99271685,0.00093912275,0.002315074,0.0016973763,0.00030293467,0.0018757276,0.000030699928,0.000010250795,0.00011198996],"genre_scores_gemma":[0.99406326,0.00002508199,0.0040006293,0.00067074416,0.0006459125,0.00032235155,0.00002195102,0.000027605265,0.00022249286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977934,0.00061101624,0.0006774096,0.00022559216,0.000427237,0.0002653653],"domain_scores_gemma":[0.99727005,0.0015899322,0.0005580275,0.00024650773,0.00020876278,0.00012670472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004860733,0.00016156441,0.0005467461,0.00016329155,0.0001682255,0.000024775421,0.00013294032,0.000088735964,0.00006598724],"category_scores_gemma":[0.0008774169,0.000092416834,0.00038783866,0.00014254404,0.0000827357,0.00013045064,0.000028108103,0.00014050255,0.0000024084325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06666555,0.005182381,0.719015,0.00029050946,0.00061391806,0.000018261348,0.00094647397,0.0002480767,0.0051141903,0.000023761748,0.003308767,0.19857311],"study_design_scores_gemma":[0.0038623833,0.0111406315,0.96971416,0.000055707143,0.0007622725,0.00023450653,0.0009161481,0.0068908697,0.0010412409,0.0010371064,0.004170224,0.00017473786],"about_ca_topic_score_codex":0.000009519878,"about_ca_topic_score_gemma":0.000006019905,"teacher_disagreement_score":0.2506992,"about_ca_system_score_codex":0.00026551014,"about_ca_system_score_gemma":0.00025464455,"threshold_uncertainty_score":0.3768649},"labels":[],"label_agreement":null},{"id":"W2063431127","doi":"10.1097/jto.0b013e31819f2e0e","title":"Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Auto Workers; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Asbestos; Mesothelioma; Lung cancer; Radiology; Nodule (geology); Peritoneal mesothelioma; Lung cancer screening; Pleural disease; Lung; Pathology; Respiratory disease; Internal medicine","score_opus":0.024162284551502815,"score_gpt":0.3762817615259019,"score_spread":0.3521194769743991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063431127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901027,0.007908891,0.00012557716,0.001348808,0.00006446238,0.00018321458,0.000019515754,0.000002281596,0.00024455928],"genre_scores_gemma":[0.99340457,0.00012202199,0.005610592,0.00045640298,0.00008781167,0.0000065672325,0.0000030254396,0.0000059862473,0.00030303834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992802,0.000047949572,0.00031285174,0.00008039109,0.00016946718,0.00010915386],"domain_scores_gemma":[0.9994223,0.00007875076,0.00032221313,0.000048014346,0.0000404252,0.00008829577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025573562,0.00007621404,0.0003315045,0.00016395733,0.00001378137,0.0000015862308,0.00004245274,0.000058279813,0.000055497494],"category_scores_gemma":[0.000029437599,0.000052519994,0.000055216515,0.00004835657,0.00006980857,0.00007997752,0.00000867305,0.00011639552,9.1372094e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050898865,0.00045727822,0.9031403,0.0001587273,0.00015011666,0.00014472917,0.00054775376,0.0001825417,0.0074030003,0.00003450253,0.0015334138,0.08115777],"study_design_scores_gemma":[0.0016698666,0.0041671777,0.989623,0.00039080734,0.00039956652,0.00040091452,0.00017504694,0.00014690656,0.0004523728,0.000080756094,0.0024275915,0.00006595558],"about_ca_topic_score_codex":0.000011392405,"about_ca_topic_score_gemma":0.000013171496,"teacher_disagreement_score":0.086482756,"about_ca_system_score_codex":0.0002956593,"about_ca_system_score_gemma":0.0002499225,"threshold_uncertainty_score":0.21417032},"labels":[],"label_agreement":null},{"id":"W2064508141","doi":"10.1097/jto.0000000000000058","title":"NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Queen's University; McMaster University; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Leukopenia; Etoposide; Internal medicine; Gastroenterology; Cancer; Anemia; Surgery; Chemotherapy","score_opus":0.03256486841170175,"score_gpt":0.46006590205995973,"score_spread":0.427501033648258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064508141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346125,0.0015213094,0.00024081497,0.0027231965,0.00025728784,0.00075907906,0.0000051449,0.000004723626,0.001027191],"genre_scores_gemma":[0.997427,0.00070039043,0.0011167392,0.0002088782,0.00019180101,0.00003179606,0.0000021897401,0.000019779298,0.0003014602],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978322,0.0004581874,0.00078484026,0.00019949542,0.00042382945,0.00030148987],"domain_scores_gemma":[0.99794614,0.0005700963,0.0007063141,0.00016164001,0.0004771764,0.00013862122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001878797,0.00016231801,0.0009804992,0.0006139757,0.000035937243,0.0000100472125,0.00012268232,0.00014807971,0.000035822894],"category_scores_gemma":[0.0006704291,0.00012001388,0.00006311698,0.00035211953,0.00018624832,0.00013289726,0.00007246568,0.00072796334,5.789348e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5284383,0.007525648,0.15915217,0.0030522244,0.0006780461,0.0027854347,0.009799444,0.00062674674,0.03470246,0.0002364868,0.0016922825,0.25131074],"study_design_scores_gemma":[0.65447414,0.099341825,0.18342021,0.0049994504,0.0015706419,0.0009154162,0.004740201,0.01030837,0.030660871,0.00077629363,0.007995257,0.000797332],"about_ca_topic_score_codex":0.0003272572,"about_ca_topic_score_gemma":0.0014447146,"teacher_disagreement_score":0.2505134,"about_ca_system_score_codex":0.0008901423,"about_ca_system_score_gemma":0.0009813479,"threshold_uncertainty_score":0.48940238},"labels":[],"label_agreement":null},{"id":"W2064926421","doi":"10.1097/jto.0b013e3181e2f7fb","title":"A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi","keywords":"Medicine; Internal medicine; Erlotinib; Adenocarcinoma; Gastroenterology; Surgery; Lung cancer; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.016228669322148195,"score_gpt":0.35978506222365086,"score_spread":0.3435563929015027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064926421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979687,0.0011732305,0.00003674908,0.000079546924,0.00039535816,0.00026674208,0.00003080872,9.437556e-7,0.000047922993],"genre_scores_gemma":[0.9991819,0.00012925304,0.00039692456,0.000045202127,0.00020066506,0.0000051831494,0.0000011369262,0.000014864709,0.000024825977],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986442,0.00023305014,0.0006213214,0.00016345091,0.00018246808,0.000155508],"domain_scores_gemma":[0.9988385,0.000066341,0.0006382973,0.00021577929,0.00017587963,0.00006519877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043492677,0.00013069672,0.00039720806,0.00008797271,0.000034060755,0.000005400456,0.0002779034,0.00017243809,0.00003385979],"category_scores_gemma":[0.00015094847,0.000088243396,0.00019306227,0.00008966849,0.00013753152,0.000007320681,0.00009296186,0.0002368411,1.2088837e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025703607,0.0014669591,0.10679079,0.000052134455,0.00019660262,0.00001675628,0.0011196655,0.000005864695,0.87980705,0.000006280865,0.00010951271,0.007858039],"study_design_scores_gemma":[0.010062973,0.009984783,0.5924201,0.000083631385,0.0003918629,0.00012897007,0.0028817062,0.0000827979,0.3805045,0.000027586864,0.003179778,0.0002512977],"about_ca_topic_score_codex":0.000060814255,"about_ca_topic_score_gemma":0.00025147232,"teacher_disagreement_score":0.49930254,"about_ca_system_score_codex":0.00002242519,"about_ca_system_score_gemma":0.00017267151,"threshold_uncertainty_score":0.35984614},"labels":[],"label_agreement":null},{"id":"W2064946261","doi":"10.1097/jto.0b013e31802baff6","title":"Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Cancer; Adjuvant therapy; Oncology; Clinical trial; Randomized controlled trial; Surgery","score_opus":0.026571725191385873,"score_gpt":0.4032838127953759,"score_spread":0.37671208760399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064946261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995445,0.0004081581,0.0006895631,0.0019414647,0.00040306317,0.0007641968,0.000021629097,0.0000057876728,0.00032110765],"genre_scores_gemma":[0.99456066,0.00017378807,0.0037295176,0.0010190079,0.0003272757,0.000031642092,0.000015177489,0.00003043595,0.00011252068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986854,0.000042188014,0.0005345963,0.0001707421,0.0002274648,0.00033957456],"domain_scores_gemma":[0.9986359,0.0001635564,0.0004923859,0.00014335224,0.00039989158,0.00016489738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044591102,0.0001568713,0.0006197239,0.00021822209,0.00003359988,0.0000074377167,0.00010092045,0.00012518303,0.000080818914],"category_scores_gemma":[0.000015035883,0.0001031975,0.00011217666,0.00014083787,0.000028010878,0.000054412176,0.000014393313,0.00028438086,8.4514386e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013711025,0.00172497,0.9267332,0.00023057497,0.00022042554,0.0001837168,0.0005285217,0.000019131356,0.00017120932,0.0000012475267,0.0021665662,0.054309443],"study_design_scores_gemma":[0.012272001,0.008535733,0.97056866,0.0005818286,0.00032002694,0.000029549783,0.000112231435,0.00005061683,0.0030646047,0.000006930441,0.0043469914,0.0001108342],"about_ca_topic_score_codex":0.00013296654,"about_ca_topic_score_gemma":0.0012545722,"teacher_disagreement_score":0.054198608,"about_ca_system_score_codex":0.00152567,"about_ca_system_score_gemma":0.00038958856,"threshold_uncertainty_score":0.42082718},"labels":[],"label_agreement":null},{"id":"W2065028684","doi":"10.1097/jto.0b013e3181fd83a4","title":"Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Vinorelbine; Epidermal growth factor receptor; Oncology; Hazard ratio; Internal medicine; Chemotherapy; Lung cancer; Fluorescence in situ hybridization; Copy-number variation; Mutation; Cancer research; Cisplatin; Cancer; Confidence interval; Gene; Biology; Genetics","score_opus":0.00959289005364907,"score_gpt":0.3787633561425244,"score_spread":0.3691704660888753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065028684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946255,0.0010017956,0.0016977435,0.0012093639,0.00039970403,0.0008354753,0.00016443181,0.0000037283398,0.00006227341],"genre_scores_gemma":[0.96901834,0.00062240404,0.02985252,0.00015200122,0.00021515832,0.000057561243,0.000023694449,0.000020605527,0.00003769076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990468,0.000059962997,0.00043132156,0.00014992547,0.00011373494,0.00019825027],"domain_scores_gemma":[0.99867266,0.0003053431,0.0004635435,0.0000638076,0.00033293728,0.00016172037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022800009,0.00012939108,0.00046600975,0.00012715207,0.000037830345,0.000007828039,0.00003524123,0.00013336199,0.00005328535],"category_scores_gemma":[0.000112829075,0.000098185745,0.000055645854,0.00009630713,0.00009250352,0.00010402585,0.000011918704,0.00023268993,2.433143e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057059648,0.0010341281,0.85375893,0.0006243038,0.0003663673,0.00009799662,0.008862526,0.000035350462,0.089715905,0.000039516173,0.0003434125,0.039415598],"study_design_scores_gemma":[0.010298823,0.003019719,0.9236854,0.0003047974,0.0009483221,0.0002725908,0.000762968,0.00074227614,0.05875707,0.00042607283,0.00063064665,0.00015135772],"about_ca_topic_score_codex":0.000100398596,"about_ca_topic_score_gemma":0.000081822,"teacher_disagreement_score":0.06992642,"about_ca_system_score_codex":0.00022580885,"about_ca_system_score_gemma":0.0005493242,"threshold_uncertainty_score":0.40038985},"labels":[],"label_agreement":null},{"id":"W2065188377","doi":"10.1097/jto.0b013e31815bdc0d","title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; TNM staging system; Lung cancer; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer staging; Cancer; Radiology; Neoplasm staging; Mediastinoscopy","score_opus":0.08743869756397145,"score_gpt":0.5345343729513192,"score_spread":0.4470956753873478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065188377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9278429,0.01468297,0.00456825,0.03844688,0.0044858786,0.0094485795,0.0002976914,0.000011669545,0.0002151563],"genre_scores_gemma":[0.9916513,0.0039524985,0.00040704754,0.00036657232,0.001715688,0.0015750002,0.0000037853677,0.000045499666,0.00028260602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994358,0.0010207952,0.0022121214,0.0003473572,0.0014516247,0.00061010313],"domain_scores_gemma":[0.9856891,0.006765809,0.004591869,0.0004451213,0.002450157,0.000057937257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018128235,0.00027180483,0.0009175928,0.0002716052,0.0006018018,0.000055863136,0.0010565232,0.00013773711,0.000017323096],"category_scores_gemma":[0.002129544,0.00012359684,0.00049783714,0.0006764766,0.00026238943,0.00024094035,0.00022741749,0.0011092466,2.0859401e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047902223,0.0007581795,0.9167002,0.0013408045,0.0040609506,0.000006144891,0.013840146,0.0033722068,0.0023753154,0.000075370896,0.011988404,0.040692072],"study_design_scores_gemma":[0.013076812,0.0017739381,0.69148844,0.0053310515,0.014627916,0.000028471,0.08578396,0.16220851,0.01341223,0.00015253866,0.011545762,0.0005703658],"about_ca_topic_score_codex":0.0025226092,"about_ca_topic_score_gemma":0.012910472,"teacher_disagreement_score":0.22521174,"about_ca_system_score_codex":0.0038355954,"about_ca_system_score_gemma":0.002892151,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W2065276159","doi":"10.1097/01.jto.0000283329.83483.2b","title":"PD6-1-7: A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C).","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"","keywords":"Topotecan; Medicine; Oncology; Internal medicine; Apoptosis; Chemotherapy; Cell cycle checkpoint; Pharmacology; Cancer; Cell cycle","score_opus":0.016519547986206362,"score_gpt":0.4052030107723295,"score_spread":0.38868346278612315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065276159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948684,0.00015364285,0.000020497704,0.0007831941,0.00022202492,0.0036201803,0.000011570302,0.000006066559,0.00031439812],"genre_scores_gemma":[0.99955094,0.000029011322,0.00013133971,0.00005648315,0.000053260213,0.000049276638,0.000002090799,0.0000279101,0.00009968424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966187,0.00048859627,0.001163398,0.00031166547,0.0009922052,0.00042546907],"domain_scores_gemma":[0.99642426,0.000248711,0.0016297689,0.0003156979,0.0012388059,0.00014277699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017892031,0.0002562434,0.0011538725,0.00052814104,0.00012362994,0.000006223133,0.00027707193,0.000111560585,0.000018481947],"category_scores_gemma":[0.00025409638,0.00015822977,0.000069805676,0.0009355714,0.00027988118,0.00014209464,0.00024021055,0.00093637157,9.4840395e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054770976,0.115165204,0.758235,0.00027619113,0.00073599676,0.0010389219,0.055345852,0.0001009655,0.0008021466,0.0000017443248,0.00012242788,0.013404581],"study_design_scores_gemma":[0.10566846,0.26841226,0.5777964,0.000885186,0.0007078221,0.000036509267,0.040276356,0.00008583515,0.005867152,0.000006342032,0.000053902706,0.00020374515],"about_ca_topic_score_codex":0.0007330445,"about_ca_topic_score_gemma":0.008556366,"teacher_disagreement_score":0.18043858,"about_ca_system_score_codex":0.001445817,"about_ca_system_score_gemma":0.001034646,"threshold_uncertainty_score":0.6452423},"labels":[],"label_agreement":null},{"id":"W2066369833","doi":"10.1097/jto.0b013e31823529fc","title":"Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Uniklinikum Giessen und Marburg; Universitair Medisch Centrum Groningen; Paul Scherrer Institut; Massachusetts General Hospital","keywords":"Medicine; Nuclear medicine; Radiation therapy; Lung cancer; Proton therapy; Radiation treatment planning; Radiology; Cancer; Oncology; Internal medicine","score_opus":0.07913867718996968,"score_gpt":0.4621745659316453,"score_spread":0.3830358887416756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066369833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435693,0.0009215338,0.0011332704,0.00031771508,0.00032097936,0.002534705,0.000005924178,0.0000044269573,0.00040449516],"genre_scores_gemma":[0.97697794,0.0005779604,0.02166684,0.00021528469,0.00036279066,0.00008874267,0.0000010615269,0.000017209957,0.00009214777],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99820447,0.000208017,0.0011118068,0.00016003389,0.00012357223,0.00019208703],"domain_scores_gemma":[0.9978112,0.00059522945,0.0011179097,0.00013283663,0.00018303705,0.00015977018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016196991,0.00011741687,0.0008503638,0.00029560988,0.000028951825,0.000004790058,0.00010172522,0.00018560464,0.000024713243],"category_scores_gemma":[0.00015835969,0.00008311552,0.00013602452,0.0002021525,0.000103097926,0.00006513941,0.000010298193,0.00038204424,1.5871353e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.678079,0.003458387,0.2660829,0.00033784084,0.0003888761,0.00009726628,0.0042110337,0.00006391246,0.003488824,0.000004618629,0.00043712056,0.043350227],"study_design_scores_gemma":[0.57581985,0.063119285,0.27153307,0.0011986623,0.0016278909,0.00046116346,0.0012639149,0.03158178,0.04227971,0.000046357894,0.010588868,0.00047942778],"about_ca_topic_score_codex":0.0000650623,"about_ca_topic_score_gemma":0.00007517386,"teacher_disagreement_score":0.10225912,"about_ca_system_score_codex":0.00014378036,"about_ca_system_score_gemma":0.0006662941,"threshold_uncertainty_score":0.33893526},"labels":[],"label_agreement":null},{"id":"W2066815258","doi":"10.1097/jto.0b013e31821b10ab","title":"Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":104,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Biostatistics; Primer (cosmetics); Hazard; Hazard ratio; Medical physics; Internal medicine; Epidemiology; Confidence interval","score_opus":0.5000480710161161,"score_gpt":0.6300492098192128,"score_spread":0.1300011388030966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066815258","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04518644,0.000575672,0.91614085,0.009258149,0.016635528,0.0012867089,0.00007894095,0.00009025863,0.010747438],"genre_scores_gemma":[0.011676288,0.00033904237,0.98419803,0.001965819,0.0012539024,0.000011714424,4.2562039e-7,0.000051055387,0.0005036919],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9934827,0.0023972273,0.0028546257,0.00030305109,0.0005066216,0.00045578327],"domain_scores_gemma":[0.963823,0.032328524,0.0019742977,0.00050305726,0.00082010153,0.0005509748],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008971442,0.00026537987,0.001538774,0.00027184596,0.00008298503,0.00006461742,0.00067717675,0.00041784017,0.0010260611],"category_scores_gemma":[0.104607716,0.00020897527,0.00032364877,0.00034163104,0.00022388711,0.00027552314,0.00018538638,0.0008430241,0.00023151746],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030723584,0.0015037879,0.00047959344,0.00013779382,0.0003679365,0.0007879913,0.0019509018,0.0000015529428,0.0005053036,0.035262886,0.06031378,0.8956161],"study_design_scores_gemma":[0.0008791065,0.005572874,0.00088903884,0.00044471284,0.0007280694,0.00031084087,0.00089930464,0.0000357256,0.004700632,0.9163087,0.068881705,0.00034930283],"about_ca_topic_score_codex":0.0000029243388,"about_ca_topic_score_gemma":0.000024381654,"teacher_disagreement_score":0.89526683,"about_ca_system_score_codex":0.00021668604,"about_ca_system_score_gemma":0.0005270483,"threshold_uncertainty_score":0.9998871},"labels":[],"label_agreement":null},{"id":"W2066898096","doi":"10.1097/jto.0b013e3181d86e8b","title":"Maintenance Therapy in Advanced Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; Maintenance therapy; Internal medicine; Intensive care medicine; Chemotherapy","score_opus":0.030570816910562584,"score_gpt":0.4891913458128282,"score_spread":0.4586205289022656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066898096","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001989733,0.99004364,0.0000528425,0.0005559737,0.0020389524,0.0010539958,0.0000211728,0.0000072018242,0.0042364975],"genre_scores_gemma":[0.00017688477,0.99172807,0.0038675747,0.00031079684,0.0006939612,0.00014401993,0.000012750386,0.00005978993,0.00300618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980436,0.00013735707,0.0010454167,0.00024616133,0.00018508732,0.00034238608],"domain_scores_gemma":[0.9975209,0.0001820051,0.0015428617,0.00027114578,0.00029257356,0.00019046728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040451455,0.00033710126,0.0024087927,0.00043210844,0.00003826639,0.000011953927,0.00024004486,0.00053435226,0.0001732449],"category_scores_gemma":[0.000044260625,0.00021148639,0.0005705528,0.00031694066,0.00005441024,0.00007822704,0.000028822084,0.0015476975,0.000010588426],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021930491,0.00042906508,0.00022727535,0.0034019384,0.0002964785,0.0008122552,0.0002424453,0.0000045493703,0.000017798664,0.0000024679214,0.001125584,0.99322087],"study_design_scores_gemma":[0.0016405489,0.0010780992,0.00020478957,0.011751931,0.00222712,0.00082839787,0.00005741419,0.000004341672,0.000014807449,0.0000140913,0.9820073,0.00017115718],"about_ca_topic_score_codex":0.00003363077,"about_ca_topic_score_gemma":0.00010602135,"teacher_disagreement_score":0.9930497,"about_ca_system_score_codex":0.0014323593,"about_ca_system_score_gemma":0.0049719056,"threshold_uncertainty_score":0.8819947},"labels":[],"label_agreement":null},{"id":"W2067040443","doi":"10.1097/jto.0b013e318160f36b","title":"Systemic Inflammation, Cardiorespiratory Fitness, and Quality of Life in Patients with Advanced Non-small Cell Lung Cancer","year":2008,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Cardiorespiratory fitness; Lung cancer; Systemic inflammation; Quality of life (healthcare); Inflammation; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.019931132665895475,"score_gpt":0.35751258644551515,"score_spread":0.3375814537796197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067040443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97755975,0.010071567,0.000027572685,0.010453813,0.00040398157,0.0010854969,0.00008947335,0.000006191329,0.00030216103],"genre_scores_gemma":[0.9815951,0.0017960578,0.00063709787,0.012288991,0.0030123414,0.00009108079,0.000084239604,0.00012075434,0.000374311],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590266,0.0007638573,0.0015903,0.00035728377,0.0009611328,0.0004247946],"domain_scores_gemma":[0.99515325,0.0003390664,0.0022921728,0.0003943535,0.0015690028,0.00025216278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007733984,0.00034312363,0.0020370968,0.0006615888,0.000047210244,0.000008196241,0.0002588587,0.00070356566,0.000048339585],"category_scores_gemma":[0.00024133356,0.00027121673,0.0002087718,0.0003027839,0.00031169076,0.00016954684,0.00010175989,0.0022676757,0.0000015309449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048790146,0.00022382005,0.94326043,0.014465982,0.00044424407,0.0012839496,0.0003713712,0.00024683485,0.00023758365,3.258063e-7,0.023205275,0.011381187],"study_design_scores_gemma":[0.006360265,0.0010478835,0.9711889,0.002832302,0.0005481506,0.00014794154,0.00017425255,0.00003485911,0.00011328456,0.0000040723103,0.017225042,0.00032306212],"about_ca_topic_score_codex":0.00011041683,"about_ca_topic_score_gemma":0.000046524932,"teacher_disagreement_score":0.027928473,"about_ca_system_score_codex":0.0019521837,"about_ca_system_score_gemma":0.005257404,"threshold_uncertainty_score":0.999974},"labels":[],"label_agreement":null},{"id":"W2067553383","doi":"10.1097/01.jto.0000283429.66767.d1","title":"PD5-2-3: Translating research into routine clinical practice: image-guided lung stereotactic radiation therapy for unresectable patients with early stage lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Stage (stratigraphy); Radiation treatment planning; Radiology; Clinical Practice; Nuclear medicine; Medical physics; Oncology","score_opus":0.07306407232495013,"score_gpt":0.560690254948064,"score_spread":0.48762618262311386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067553383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822163,0.0031650122,0.0017350578,0.00960075,0.0007459399,0.0016550411,0.000011417192,0.000013873723,0.00085658586],"genre_scores_gemma":[0.9771178,0.0012460367,0.019351093,0.0005414052,0.0013445655,0.000069072754,0.000012530706,0.00005110366,0.000266413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99652237,0.0005930915,0.0012060497,0.00030733697,0.00082640996,0.00054476835],"domain_scores_gemma":[0.99316883,0.0027764284,0.0011155608,0.00024490358,0.0023773154,0.0003169436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073580267,0.00019492349,0.00071703794,0.00032518475,0.00021066063,0.00005681675,0.00014827728,0.00021788647,0.000113333794],"category_scores_gemma":[0.0010175228,0.000131994,0.00019933043,0.00038973644,0.00011423298,0.0005651467,0.000022422846,0.0008756331,0.0000019572924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027061654,0.0023591162,0.74540883,0.00025798831,0.0011923271,0.00025977657,0.0019219192,0.00001859201,0.00013424816,0.000017149368,0.0046545737,0.21671382],"study_design_scores_gemma":[0.028845634,0.027724726,0.89359945,0.0009532562,0.0017546705,0.00012866467,0.0009055877,0.0005596112,0.0020734896,0.00006497459,0.043076254,0.00031369494],"about_ca_topic_score_codex":0.00037326114,"about_ca_topic_score_gemma":0.0002145315,"teacher_disagreement_score":0.21640012,"about_ca_system_score_codex":0.002217964,"about_ca_system_score_gemma":0.0013446634,"threshold_uncertainty_score":0.5799899},"labels":[],"label_agreement":null},{"id":"W2067996554","doi":"10.1097/jto.0b013e3181fc7687","title":"Positron Emission Tomography with 18Fluorodeoxyglucose in Radiation Treatment Planning for Non-small Cell Lung Cancer: A Systematic Review","year":2010,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Positron emission tomography; Lung cancer; Radiation treatment planning; Nuclear medicine; Radiation therapy; Cancer; Medical physics; Radiology; Oncology; Internal medicine","score_opus":0.017043344678340087,"score_gpt":0.4208654524553222,"score_spread":0.40382210777698213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067996554","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008063106,0.97467285,0.020510891,0.000045878245,0.00021502645,0.0043384028,0.000036849724,0.000012300735,0.000087170694],"genre_scores_gemma":[0.00002465702,0.9754943,0.022560392,0.000034452056,0.00043921804,0.0012327196,0.00003709196,0.00007448696,0.000102679056],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99749666,0.00035976118,0.0014231288,0.00027519133,0.0001329816,0.00031226675],"domain_scores_gemma":[0.99520564,0.00040161572,0.0038143108,0.00030160934,0.00014796988,0.00012885027],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069039233,0.00048253578,0.003873524,0.00044961125,0.00006615191,0.000023571547,0.0003343083,0.00026827893,0.000014676151],"category_scores_gemma":[0.000010393404,0.00029810192,0.0007487376,0.00029806868,0.000025167445,0.00012826188,0.000016911687,0.00067065854,1.9773745e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007611989,0.0002425476,0.00012126018,0.29031417,0.00037023,0.000018633782,0.00012307621,0.000011556093,0.0000168118,0.000004104449,0.00012465831,0.70857686],"study_design_scores_gemma":[0.00062187895,0.0018414666,0.000002248462,0.6214957,0.0077554327,0.00011428117,0.000024245035,0.000056523946,0.00020837368,0.000032923635,0.36741704,0.0004298526],"about_ca_topic_score_codex":0.000015536674,"about_ca_topic_score_gemma":0.0000035936332,"teacher_disagreement_score":0.708147,"about_ca_system_score_codex":0.0008413697,"about_ca_system_score_gemma":0.0009738626,"threshold_uncertainty_score":0.99994713},"labels":[],"label_agreement":null},{"id":"W2069157431","doi":"10.1097/jto.0b013e318174e9a7","title":"Immunotherapy for Lung Cancer","year":2008,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":88,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Immunotherapy; Cancer; Melanoma; Clinical trial; Vaccine therapy; Immunology; Oncology; Randomized controlled trial; Immune system; Cancer vaccine; Cancer immunotherapy; Internal medicine; Cancer research","score_opus":0.044594059901639414,"score_gpt":0.4588411893239707,"score_spread":0.41424712942233133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069157431","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049952447,0.9905728,0.00047764918,0.00019325828,0.0074428055,0.00091377407,0.000104680716,0.000025028157,0.00022003496],"genre_scores_gemma":[0.0000053634667,0.99047035,0.0005872397,0.00020144964,0.000485926,0.0001748216,0.00005070337,0.00011582858,0.007908322],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954871,0.0014811459,0.0020388137,0.00030194057,0.00007301088,0.00061802124],"domain_scores_gemma":[0.9939626,0.0018229921,0.0033404536,0.0004296783,0.00040903816,0.00003522829],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00092947023,0.0006071411,0.004183867,0.00070198503,0.00030008366,0.000018949331,0.001005531,0.0016234198,0.00086582935],"category_scores_gemma":[0.00018171238,0.0004323796,0.0022910947,0.0002772701,0.00034288684,0.00015271123,0.000065344044,0.0014413545,0.00005129249],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024275421,0.0002626846,0.0000011744859,0.0019801804,0.004021878,0.000047279624,0.00024784307,9.0936396e-7,0.0005129257,0.000018751589,0.04012514,0.9503537],"study_design_scores_gemma":[0.0010807852,0.0014279236,0.0000026882421,0.004836091,0.0013057684,0.0077988147,0.000034623714,3.5498485e-7,0.00027929666,0.000015674155,0.9828118,0.00040618578],"about_ca_topic_score_codex":0.000013809961,"about_ca_topic_score_gemma":0.0000024132694,"teacher_disagreement_score":0.94994754,"about_ca_system_score_codex":0.00069106824,"about_ca_system_score_gemma":0.0032667688,"threshold_uncertainty_score":0.9998128},"labels":[],"label_agreement":null},{"id":"W2069381074","doi":"10.1016/s1556-0864(15)31538-0","title":"Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Randomized controlled trial; Adjuvant therapy; Breast cancer; Clinical trial; Adjuvant; Disease; Internal medicine; Stage (stratigraphy); Adjuvant chemotherapy; Surgery","score_opus":0.01681397994361417,"score_gpt":0.4042033111193032,"score_spread":0.387389331175689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069381074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748561,0.0064504077,0.0007852744,0.013175364,0.0009331894,0.00064012833,0.000015511168,0.000012317593,0.0031317296],"genre_scores_gemma":[0.984076,0.0012084835,0.009061304,0.0012287446,0.0018841507,0.00008891801,0.000008417168,0.000035792666,0.002408154],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989053,0.000042302592,0.00047697208,0.0001509539,0.00016436937,0.00026012267],"domain_scores_gemma":[0.9986996,0.00016553554,0.0004849514,0.00014498756,0.00038439606,0.0001205009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030318173,0.0001401777,0.00059079204,0.00013592279,0.000050405244,0.000010626885,0.000096162636,0.00014609584,0.00016745088],"category_scores_gemma":[0.000017141936,0.000098143806,0.00024596468,0.000119820725,0.00003291241,0.000044160126,0.000012363124,0.0002040662,0.0000028693862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012598745,0.005563998,0.21405917,0.0013867586,0.001255999,0.0010680533,0.00081695046,0.00033609563,0.033392835,0.00004967357,0.48656324,0.24290846],"study_design_scores_gemma":[0.022511102,0.0135164475,0.3228663,0.0013083795,0.0037894852,0.0008492988,0.00025038276,0.0010988717,0.20848137,0.00054189557,0.4243254,0.0004610914],"about_ca_topic_score_codex":0.00015101503,"about_ca_topic_score_gemma":0.00021119344,"teacher_disagreement_score":0.24244738,"about_ca_system_score_codex":0.0011500845,"about_ca_system_score_gemma":0.0007506945,"threshold_uncertainty_score":0.4002188},"labels":[],"label_agreement":null},{"id":"W2069422280","doi":"10.1097/jto.0b013e318189f551","title":"The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review","year":2008,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; Histology; Lung cancer; Internal medicine; Oncology; Clinical trial; Pathology","score_opus":0.012812267287756213,"score_gpt":0.43091978674002324,"score_spread":0.41810751945226704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069422280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003045026,0.99608064,0.0000077189,0.00054088933,0.00040230234,0.0017290855,0.00004807829,0.0000030845558,0.0008836766],"genre_scores_gemma":[0.00011166822,0.9982937,0.000679864,0.00012067861,0.00017270964,0.00021977813,0.000023471015,0.000027137416,0.00035099845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794585,0.00033456137,0.0011303406,0.00020576023,0.00015637222,0.00022714908],"domain_scores_gemma":[0.9968317,0.0005630208,0.0018958914,0.00020150497,0.00038587872,0.00012199338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029341812,0.00026888636,0.0024523747,0.00024385542,0.000060724735,0.000005270577,0.00016728361,0.0003124121,0.000008185671],"category_scores_gemma":[0.00019234112,0.00014798225,0.00035091653,0.0003735138,0.00012940899,0.00005598978,0.00004411413,0.00088125735,6.011592e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020368087,0.00023578135,0.00050993555,0.03751618,0.00048952276,0.00065136125,0.00059982063,0.0000018072022,0.0000014758283,0.0000029544183,0.0012092602,0.9585782],"study_design_scores_gemma":[0.0005810568,0.0014784773,0.00031319488,0.13097857,0.006778922,0.004722219,0.000064823245,0.00000673391,0.0000012275062,0.000014963331,0.85496503,0.00009475967],"about_ca_topic_score_codex":0.0000071404866,"about_ca_topic_score_gemma":0.00002655222,"teacher_disagreement_score":0.95848346,"about_ca_system_score_codex":0.00085156,"about_ca_system_score_gemma":0.0030632338,"threshold_uncertainty_score":0.6034541},"labels":[],"label_agreement":null},{"id":"W2070403142","doi":"10.1097/jto.0000000000000435","title":"Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist","year":2015,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; London Health Sciences Centre","funders":"American Association for Thoracic Surgery","keywords":"Medicine; SABR volatility model; Radiation oncologist; Radiation therapy; Radiology; Lung cancer; Context (archaeology); Radiation treatment planning; Stage (stratigraphy); Surgery; Oncology","score_opus":0.05953560582904216,"score_gpt":0.48417808954590824,"score_spread":0.4246424837168661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070403142","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059914764,0.98958397,0.00026242615,0.0010567035,0.0038284843,0.004337558,0.00028180098,0.000004622527,0.000045316716],"genre_scores_gemma":[0.0023875337,0.9925724,0.0010039441,0.00019104718,0.0015424318,0.0018571392,0.000107496904,0.000052778054,0.00028521748],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977355,0.00021784537,0.0012585233,0.00021589131,0.00032733916,0.00024488542],"domain_scores_gemma":[0.9937538,0.0014310954,0.0033127363,0.00025647174,0.0011049855,0.00014089207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010649276,0.00028625596,0.0022418054,0.00022703905,0.000055220302,0.000014996177,0.0001800141,0.00038322338,0.000038620758],"category_scores_gemma":[0.00039614888,0.00015870587,0.0010085739,0.00016322879,0.000058180936,0.00010258751,0.000028643926,0.00028575773,0.0000012309793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002732093,0.0006176604,0.0024841174,0.009621892,0.0024217968,0.00000853694,0.0001920439,0.000004220994,5.6319532e-8,0.0000044638778,0.019571403,0.9623417],"study_design_scores_gemma":[0.003544975,0.004877055,0.0012701188,0.0040030326,0.02605987,0.00002919022,0.000019792096,0.00004370547,0.0000036691865,0.000014584318,0.96000487,0.00012913879],"about_ca_topic_score_codex":0.000026491321,"about_ca_topic_score_gemma":0.000052917538,"teacher_disagreement_score":0.96221256,"about_ca_system_score_codex":0.00462447,"about_ca_system_score_gemma":0.0035284583,"threshold_uncertainty_score":0.9991966},"labels":[],"label_agreement":null},{"id":"W2071539936","doi":"10.1097/jto.0b013e3182773fce","title":"Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Afatinib; Lung cancer; Placebo; Internal medicine; Gefitinib; Erlotinib; Adverse effect; Quality of life (healthcare); Randomized controlled trial; Chest pain; Gastroenterology; Cancer; Pathology; Epidermal growth factor receptor","score_opus":0.02487591600355954,"score_gpt":0.4309749554100554,"score_spread":0.4060990394064959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071539936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993539,0.001240774,0.000047071284,0.0003093805,0.0001805775,0.003945069,0.000108877684,0.000006429278,0.00062286644],"genre_scores_gemma":[0.9958334,0.0006886799,0.0026675,0.00006925342,0.000090186855,0.0002022363,0.000032181375,0.000026140593,0.00039044232],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99592835,0.00043862336,0.002741538,0.0002452894,0.00037937262,0.00026682884],"domain_scores_gemma":[0.99293745,0.0011974587,0.004200728,0.00022287526,0.0012070151,0.00023446292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012250392,0.00024684,0.0026447992,0.00033523087,0.000032327753,0.0000071075083,0.00011969425,0.00017717641,0.0001075445],"category_scores_gemma":[0.0008524854,0.00014922257,0.00024055952,0.0003284842,0.00018931294,0.00017416247,0.000032805805,0.00025345926,2.5739385e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93821925,0.004813289,0.030189184,0.0008515783,0.0013104291,0.000020307656,0.0042662555,0.00014590287,0.001930093,0.000005453517,0.00012623363,0.01812201],"study_design_scores_gemma":[0.95566875,0.01345652,0.020898674,0.0015985362,0.003155379,0.000015586023,0.00081877987,0.00036202837,0.003808229,0.000011194121,0.000044162618,0.0001621645],"about_ca_topic_score_codex":0.0014708621,"about_ca_topic_score_gemma":0.00037880402,"teacher_disagreement_score":0.017959846,"about_ca_system_score_codex":0.0002638459,"about_ca_system_score_gemma":0.0013499433,"threshold_uncertainty_score":0.608512},"labels":[],"label_agreement":null},{"id":"W2072514736","doi":"10.1097/jto.0b013e318208c7c1","title":"Thoracoscopic Assessment of Pleural Tumor Burden in Patients with Malignant Pleural Effusion: Prognostic and Therapeutic Implications","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Pleural and Pulmonary Diseases","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Thoracoscopy; Pleural effusion; Malignant pleural effusion; Lung cancer; Pleural disease; Cancer; Surgery; Radiology; Internal medicine; Lung; Respiratory disease","score_opus":0.03453432268948158,"score_gpt":0.3753903741857457,"score_spread":0.34085605149626413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072514736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974275,0.00042171538,0.00002301173,0.0011763757,0.00009950836,0.00041094987,0.0000166254,0.000006812824,0.00041750743],"genre_scores_gemma":[0.9970615,0.00003445314,0.002549755,0.00020053363,0.00007373739,0.000012587339,0.000007735326,0.000013147908,0.000046552123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869084,0.0001682099,0.0005645463,0.00014609206,0.00022665905,0.00020363338],"domain_scores_gemma":[0.998718,0.000131607,0.00052855245,0.00014782454,0.00029607528,0.00017794217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024381278,0.00014122545,0.00052120094,0.00020427244,0.000039325634,0.0000051536804,0.00012532159,0.000059331098,0.000089843605],"category_scores_gemma":[0.000049905073,0.00008640721,0.000068318295,0.00019105646,0.00012629066,0.00010041604,0.000047417805,0.00025055045,0.000001204842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021186639,0.0010120859,0.96905607,0.00012646517,0.000080037586,0.00019769404,0.0002532282,0.0000034593033,0.0011019708,0.0000479493,0.000027938013,0.025974426],"study_design_scores_gemma":[0.0012807872,0.006195724,0.9903828,0.00030288144,0.00037670063,0.00046371596,0.00020608347,0.00006621901,0.00013546235,0.00031069113,0.00019043701,0.000088494045],"about_ca_topic_score_codex":0.00001896418,"about_ca_topic_score_gemma":0.000014363704,"teacher_disagreement_score":0.025885932,"about_ca_system_score_codex":0.000097459815,"about_ca_system_score_gemma":0.0003820776,"threshold_uncertainty_score":0.3523584},"labels":[],"label_agreement":null},{"id":"W2073971978","doi":"10.1097/01.jto.0000283169.58362.02","title":"B5-03: Dose-effect correlation for radiotherapy induced fibrosis using Monte Carlo dose calculations and a novel fibrosis image segmentation technique.","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Radiation therapy; Gemcitabine; Lung cancer; Fibrosis; Radiology; Nuclear medicine; Radiation treatment planning; Carboplatin; Correlation; Lung; Cancer; Chemotherapy; Oncology; Internal medicine; Cisplatin","score_opus":0.02341608584834115,"score_gpt":0.4196134288692935,"score_spread":0.39619734302095233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073971978","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34863743,0.00011573575,0.65023804,0.00009083978,0.00014422744,0.0006868856,0.000018511688,0.000022192417,0.00004611773],"genre_scores_gemma":[0.46688962,0.000011097581,0.5326335,0.000035503475,0.0003346174,0.00003574989,0.000005857053,0.00003217131,0.000021891894],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986268,0.0001198889,0.00063056697,0.00019640253,0.00016121894,0.00026512108],"domain_scores_gemma":[0.9981233,0.00048551665,0.00091235037,0.00014336153,0.00022822089,0.00010728616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010243009,0.00021369397,0.00046774466,0.00031859984,0.00019127909,0.000042327865,0.0001145003,0.00017470424,0.000029103743],"category_scores_gemma":[0.000025542224,0.00019191652,0.00019287484,0.00023549687,0.000071723254,0.0005235876,0.000018708866,0.00030107854,1.6244172e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094295276,0.00013741174,0.005401708,0.00002626592,0.00013702476,0.0000025402255,0.0003549103,0.0008267208,0.88323283,0.000103188366,0.00007624378,0.108758174],"study_design_scores_gemma":[0.007233928,0.009274326,0.02420836,0.00050294807,0.00088868634,0.0004242326,0.0007424612,0.039757956,0.9072551,0.0019936098,0.006592716,0.0011256894],"about_ca_topic_score_codex":0.00007042494,"about_ca_topic_score_gemma":0.000004971048,"teacher_disagreement_score":0.118252166,"about_ca_system_score_codex":0.0004842114,"about_ca_system_score_gemma":0.000113904964,"threshold_uncertainty_score":0.78261286},"labels":[],"label_agreement":null},{"id":"W2074096030","doi":"10.1097/jto.0000000000000119","title":"The Impact of Peer Review of Volume Delineation in Stereotactic Body Radiation Therapy Planning for Primary Lung Cancer: A Multicenter Quality Assurance Study","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of British Columbia; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Quality assurance; Lung cancer; Medical physics; Radiation therapy; Radiation treatment planning; Oncology; Radiology; Pathology","score_opus":0.02774789013151986,"score_gpt":0.49566578155538416,"score_spread":0.4679178914238643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074096030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87833184,0.008960185,0.1107208,0.00076615287,0.00015756417,0.0009829843,0.00001770396,0.000004359163,0.00005839287],"genre_scores_gemma":[0.99390316,0.0014878039,0.004216596,0.00006133925,0.00021775902,0.000052055715,0.0000046052123,0.0000133141775,0.000043385015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980587,0.00059668155,0.0009030298,0.00009064727,0.00021957429,0.00013138405],"domain_scores_gemma":[0.9964518,0.0006481988,0.0019904906,0.00015313823,0.000728956,0.000027442471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031627857,0.00010499369,0.0005519997,0.000071903276,0.000038928378,0.000007751863,0.00017759806,0.000036637,0.000018884342],"category_scores_gemma":[0.00017991533,0.000067384106,0.00018459847,0.00010479572,0.000028898909,0.00019033668,0.000010301664,0.00019367985,3.4546108e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012202684,0.0004380884,0.7478939,0.0002783208,0.0002730288,3.6063034e-7,0.00062257546,0.0005660675,0.0016038893,0.000010404426,0.0005827148,0.24651037],"study_design_scores_gemma":[0.0025816543,0.003031098,0.9764812,0.0016499498,0.00013268279,0.0000031722047,0.0001685526,0.007019753,0.00099582,0.00017496003,0.00759723,0.00016392063],"about_ca_topic_score_codex":0.00012451113,"about_ca_topic_score_gemma":0.000004908455,"teacher_disagreement_score":0.24634646,"about_ca_system_score_codex":0.0002762103,"about_ca_system_score_gemma":0.00021713685,"threshold_uncertainty_score":0.27478442},"labels":[{"model":"gemma","categories":["metaresearch"],"domain":"evaluation","study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W2075619734","doi":"10.1097/01.jto.0000283794.35361.e0","title":"P3-037: A novel trans-lymphatic drug delivery system of gelatin sponge impregnated with PLGA-Paclitaxel microspheres for the control of lymphatic metastasis in lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; PLGA; Paclitaxel; Lymphatic system; Lung cancer; Lymph; Metastasis; Drug delivery; Pharmacology; Cancer; Pathology; Internal medicine; In vitro; Chemistry","score_opus":0.016384442382596513,"score_gpt":0.3575556532277692,"score_spread":0.3411712108451727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075619734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96172446,0.01308287,0.022804344,0.0006771556,0.0003656241,0.0010772103,0.000060906736,0.000009070251,0.00019837392],"genre_scores_gemma":[0.9960889,0.0001123784,0.0031721808,0.0003124804,0.00013749234,0.000021361438,0.0000018603952,0.000030012856,0.00012329269],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99735826,0.0002405721,0.0015003476,0.00016042976,0.00039617403,0.0003442017],"domain_scores_gemma":[0.995718,0.0014886223,0.0015655349,0.00020188042,0.0008922421,0.00013369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002847098,0.00021090909,0.0011460215,0.00034776513,0.00006339117,0.000007138721,0.00020275754,0.0001744297,0.00005306429],"category_scores_gemma":[0.00012210573,0.00012467016,0.00030776317,0.0003973835,0.00021779317,0.00013097936,0.000013213767,0.00021528496,4.453139e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11687382,0.0043082978,0.052250165,0.013721471,0.009419485,0.0012506335,0.013125395,0.01294676,0.5262528,0.0003408236,0.0011187007,0.24839166],"study_design_scores_gemma":[0.14895989,0.01891258,0.13489823,0.028848717,0.037878353,0.008504681,0.07918612,0.15814014,0.37425265,0.000054797736,0.00826778,0.002096056],"about_ca_topic_score_codex":0.00017119116,"about_ca_topic_score_gemma":0.00045896496,"teacher_disagreement_score":0.2462956,"about_ca_system_score_codex":0.0006636031,"about_ca_system_score_gemma":0.0010847951,"threshold_uncertainty_score":0.5083901},"labels":[],"label_agreement":null},{"id":"W2075624292","doi":"10.1097/jto.0b013e3181b05713","title":"New Endobronchial Ultrasound Imaging for Differentiating Metastatic Site Within a Mediastinal Lymph Node","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Radiology; Ultrasound; Lymph node; Mediastinal lymph node; Endobronchial ultrasound; Lung cancer; Metastasis; Cancer; Pathology; Bronchoscopy; Internal medicine","score_opus":0.021882618797219353,"score_gpt":0.398967567942469,"score_spread":0.37708494914524965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075624292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95943904,0.0018086379,0.023968063,0.012000223,0.0014782317,0.00044797326,0.000016144368,0.000025105712,0.00081657997],"genre_scores_gemma":[0.8973298,0.00006830732,0.099759884,0.0013503446,0.0013062477,0.000008169422,0.000011171027,0.000017859289,0.0001481963],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99837357,0.00010097983,0.0007176921,0.00018622023,0.00030884737,0.00031268102],"domain_scores_gemma":[0.9978721,0.0006586055,0.0008076318,0.00013916829,0.0002051384,0.00031731342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053677824,0.00019160596,0.00072610035,0.00017248747,0.00008406036,0.000032396485,0.0001045894,0.000053552765,0.00012579293],"category_scores_gemma":[0.00044721202,0.0001372636,0.00029523674,0.000111068475,0.000032898384,0.00013495814,0.000013826975,0.00023274032,0.000005701298],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008620381,0.0025710734,0.14499037,0.00037610624,0.001401078,0.0017131538,0.0050785625,0.00023289256,0.02523349,0.00025540922,0.013419456,0.796108],"study_design_scores_gemma":[0.04180484,0.019357476,0.80551267,0.0033759968,0.01875167,0.039392013,0.0021497032,0.0027611097,0.038342156,0.0123966,0.015049911,0.0011058395],"about_ca_topic_score_codex":0.000024261233,"about_ca_topic_score_gemma":0.000018539698,"teacher_disagreement_score":0.79500216,"about_ca_system_score_codex":0.00082058326,"about_ca_system_score_gemma":0.0008732935,"threshold_uncertainty_score":0.5597448},"labels":[],"label_agreement":null},{"id":"W2075924209","doi":"10.1097/jto.0b013e31820b8b9b","title":"Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Chemotherapy; Lung cancer; Univariate analysis; Performance status; Surgery; Retrospective cohort study; Multivariate analysis; Palliative care; Cancer; Internal medicine","score_opus":0.029698361430186407,"score_gpt":0.38161006946885856,"score_spread":0.35191170803867217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075924209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910993,0.0017752072,0.00001847254,0.005160494,0.00021709071,0.0013611474,0.000026263988,0.0000031616657,0.00033888678],"genre_scores_gemma":[0.9950873,0.0031152524,0.00033793814,0.000247641,0.00015165494,0.00013958715,7.797724e-7,0.000015961945,0.00090388267],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989308,0.00012264453,0.00044552772,0.00015271026,0.00016969522,0.00017861764],"domain_scores_gemma":[0.9982765,0.0004004825,0.0007880817,0.00026545222,0.00020107783,0.0000684449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018960358,0.00018517961,0.000529927,0.00005817162,0.00011655872,0.0000070510578,0.00013520638,0.00009914553,0.000041490468],"category_scores_gemma":[0.000015269934,0.000069495225,0.0002784844,0.000097191645,0.00011340247,0.000036661077,0.000018234843,0.00012429566,3.7811216e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02255944,0.018396884,0.3074003,0.00094956585,0.0076176887,0.00019223595,0.11624529,0.0016339362,0.012688636,0.00021148917,0.006507761,0.50559676],"study_design_scores_gemma":[0.017659532,0.100292504,0.59048516,0.0009803972,0.01019,0.00024338106,0.0019707622,0.0002454114,0.22729118,0.00020982623,0.050181966,0.00024985473],"about_ca_topic_score_codex":0.00088579766,"about_ca_topic_score_gemma":0.00065249484,"teacher_disagreement_score":0.5053469,"about_ca_system_score_codex":0.0009303396,"about_ca_system_score_gemma":0.00039012128,"threshold_uncertainty_score":0.2833933},"labels":[],"label_agreement":null},{"id":"W2076004515","doi":"10.1097/jto.0b013e318200f496","title":"How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Endobronchial ultrasound; Radiology; Nuclear medicine; Medical physics; Bronchoscopy","score_opus":0.09090996493359627,"score_gpt":0.4587642079172075,"score_spread":0.36785424298361125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076004515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96425587,0.00024088159,0.025928162,0.0067407275,0.0019833597,0.0004302837,0.00009367518,0.000011688988,0.00031538153],"genre_scores_gemma":[0.82854325,0.00007692145,0.16982408,0.00021336495,0.0011457282,0.000035883862,0.00004362445,0.00001631487,0.00010080623],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980712,0.00029649946,0.0008091518,0.00024143077,0.00032199672,0.00025974997],"domain_scores_gemma":[0.9957784,0.0022077397,0.0009375744,0.00020148582,0.000694761,0.00018008475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014966023,0.00019354382,0.0012336697,0.000622947,0.00008706344,0.000023025437,0.00013143836,0.00030645137,0.0002297903],"category_scores_gemma":[0.0010656031,0.00014785204,0.0008772704,0.00037993747,0.00016583558,0.00014828319,0.000012490773,0.00040453553,7.2611556e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017144157,0.005556622,0.14898804,0.00037812904,0.023333846,0.00010296864,0.004097267,0.003065624,0.5298464,0.002165045,0.011470206,0.25385174],"study_design_scores_gemma":[0.017133983,0.028352557,0.4503633,0.00016425611,0.06308854,0.0046980777,0.0026758204,0.0014800858,0.3144949,0.0012912691,0.11552908,0.0007281053],"about_ca_topic_score_codex":0.00008069877,"about_ca_topic_score_gemma":0.00072650326,"teacher_disagreement_score":0.30137527,"about_ca_system_score_codex":0.00035022668,"about_ca_system_score_gemma":0.0006449083,"threshold_uncertainty_score":0.6029231},"labels":[],"label_agreement":null},{"id":"W2077751179","doi":"10.1097/jto.0b013e318160f37d","title":"Factors Contributing to Adjuvant Therapy Decisions","year":2008,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Vinorelbine; Lung cancer; Internal medicine; Oncology; Adjuvant therapy; Clinical trial; Cancer; Randomized controlled trial; Stage (stratigraphy); Adjuvant; Chemotherapy; Cisplatin","score_opus":0.08230328733744029,"score_gpt":0.4538163507761621,"score_spread":0.3715130634387218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077751179","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19238357,0.004797048,0.0001484906,0.79825073,0.0028316139,0.0005742639,0.000055500997,0.000018950817,0.00093979324],"genre_scores_gemma":[0.1277122,0.008679644,0.0022830623,0.84746695,0.011900389,0.00003313472,0.000095716256,0.00011117626,0.001717709],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729645,0.00022183031,0.0009681993,0.00027867244,0.00063565065,0.00059916737],"domain_scores_gemma":[0.99627084,0.0014178652,0.0010155336,0.00035089618,0.0006382526,0.00030663956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004841116,0.00036469955,0.0018118166,0.0004480031,0.00013574708,0.000018706953,0.0002535184,0.00083143666,0.00027529566],"category_scores_gemma":[0.0005096105,0.00021809324,0.00067495863,0.00020559192,0.0000617252,0.000052252664,0.000069595015,0.0020030814,0.000045884753],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005795645,0.00032806778,0.007877868,0.000022548296,0.0008168305,0.009483611,0.00030137232,0.0000038077908,0.000027594355,5.824954e-7,0.8816291,0.09892904],"study_design_scores_gemma":[0.0013752644,0.005398909,0.02149489,0.0007644463,0.0006036542,0.002248585,0.00006291573,7.557373e-7,0.00064708537,0.000032786706,0.9671922,0.00017851783],"about_ca_topic_score_codex":0.000020676962,"about_ca_topic_score_gemma":0.000008273566,"teacher_disagreement_score":0.098750524,"about_ca_system_score_codex":0.0021953403,"about_ca_system_score_gemma":0.0013026071,"threshold_uncertainty_score":0.8893584},"labels":[],"label_agreement":null},{"id":"W2077755081","doi":"10.1097/jto.0b013e318070ccbf","title":"Constrictive Pericarditis After Left Extrapleural Pneumonectomy and Radiotherapy for Malignant Mesothelioma","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Constrictive pericarditis; Decortication; Surgery; Radiation therapy; Mesothelioma; Pneumonectomy; Chylothorax; Complication; Pericardium; Pericardiectomy; Pneumopericardium; Radiology; Lung; Internal medicine","score_opus":0.012990832649745541,"score_gpt":0.3780772831355347,"score_spread":0.36508645048578914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077755081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897292,0.004635713,0.0033163836,0.0013474118,0.00025056186,0.00022710129,0.000033588098,0.0000064438805,0.00045359507],"genre_scores_gemma":[0.9885856,0.00036648262,0.009647417,0.00084128114,0.0003583883,0.000005112498,0.0000037909786,0.000014058472,0.00017785982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991493,0.000054985045,0.00033047856,0.000112439804,0.00017473553,0.00017802007],"domain_scores_gemma":[0.9991625,0.00029957428,0.00020494718,0.00006221876,0.00007522896,0.00019556544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039499573,0.000104954335,0.0003595357,0.00015390643,0.000049178405,0.000007201644,0.000040370047,0.00008157355,0.00015323427],"category_scores_gemma":[0.000049076018,0.00007627398,0.000170459,0.00005181992,0.00016682176,0.0000815431,0.000012139464,0.00013252786,0.0000021305593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024933761,0.0007806708,0.6364451,0.000118677235,0.00059770455,0.001539767,0.0006270368,0.000007695583,0.044053026,0.00007561501,0.0015195839,0.28930137],"study_design_scores_gemma":[0.0013190473,0.0033905366,0.9564615,0.000053590335,0.00033970768,0.005534715,0.00038148108,0.000021826581,0.0021077446,0.00023991366,0.03005145,0.00009852333],"about_ca_topic_score_codex":0.0000021746937,"about_ca_topic_score_gemma":0.0000017930267,"teacher_disagreement_score":0.32001635,"about_ca_system_score_codex":0.00020451493,"about_ca_system_score_gemma":0.00009179298,"threshold_uncertainty_score":0.31103626},"labels":[],"label_agreement":null},{"id":"W2077921146","doi":"10.1097/01.jto.0000283754.00846.9c","title":"P1-140: Outcomes with a platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Gemcitabine; Internal medicine; Mesothelioma; Systemic therapy; Cohort; Cisplatin; Oncology; Chemotherapy; Surgery; Cancer; Pathology","score_opus":0.061645445156598096,"score_gpt":0.442747503969435,"score_spread":0.38110205881283693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077921146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004858902,0.98943925,0.00004872493,0.00086105004,0.00025585576,0.004123473,0.00023691735,0.0000124213975,0.00016338393],"genre_scores_gemma":[0.0007868682,0.99197906,0.0033809172,0.001405962,0.00024296522,0.00019916742,0.0001213833,0.00008782264,0.0017958356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952037,0.0005243057,0.0026938473,0.0003827329,0.00078993075,0.00040551243],"domain_scores_gemma":[0.9914734,0.0033898954,0.004180156,0.00031003056,0.0003907262,0.00025583693],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022198048,0.00040406958,0.0047340537,0.00033942802,0.00007305239,0.00003205713,0.0003129114,0.0003594726,0.0003333607],"category_scores_gemma":[0.0026641253,0.0003058736,0.0008236655,0.00050589006,0.00016530605,0.00021055678,0.000064334294,0.0006704969,0.000007637403],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007789052,0.0018671984,0.005165985,0.18562625,0.0013983905,0.0050794953,0.000034396224,0.000004423416,0.0000013197623,0.0000018100671,0.002529385,0.7905023],"study_design_scores_gemma":[0.0038307237,0.010373738,0.003475157,0.28991714,0.0053505073,0.029094322,0.00015741444,0.0000037782418,0.0000010966075,0.00001315598,0.6574409,0.00034206084],"about_ca_topic_score_codex":0.00057684927,"about_ca_topic_score_gemma":0.0036418354,"teacher_disagreement_score":0.79016024,"about_ca_system_score_codex":0.0013978735,"about_ca_system_score_gemma":0.0032606267,"threshold_uncertainty_score":0.9999393},"labels":[],"label_agreement":null},{"id":"W2078708232","doi":"10.1097/jto.0b013e318276241c","title":"Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Thymoma; Thymic carcinoma; Population; Radiation therapy; Cancer; Cohort; Stage (stratigraphy); Cancer registry; Thymectomy; Internal medicine; Adjuvant therapy; Disease; Surgery; Oncology; Myasthenia gravis","score_opus":0.01958322546633727,"score_gpt":0.36709829922835424,"score_spread":0.34751507376201696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078708232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970563,0.00041514647,0.00011094103,0.0010503251,0.0003252855,0.00092209724,0.000008869716,0.000002047053,0.00010896363],"genre_scores_gemma":[0.9974233,0.000008546237,0.0013142071,0.00018220504,0.000087145956,0.000013279406,4.6147017e-7,0.000008763827,0.0009621278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989707,0.00011478283,0.0004899282,0.00006252026,0.00023513242,0.00012695987],"domain_scores_gemma":[0.9987051,0.00028666953,0.0006328221,0.00017839698,0.0001448658,0.00005217691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000885096,0.000055250115,0.00040519767,0.000036415444,0.00006554668,0.000009835413,0.00013349116,0.00004665066,0.000022072176],"category_scores_gemma":[0.000079610625,0.000037681166,0.00012515123,0.00008164571,0.000049295475,0.00004354318,0.00004503601,0.000119851764,1.2634976e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031299156,0.0012270379,0.94014704,0.0001698404,0.00028312876,0.000016026781,0.00017737599,0.0000068251834,0.000024590878,0.000024491119,0.0010398357,0.05657082],"study_design_scores_gemma":[0.0015824399,0.0015373701,0.9921524,0.00009439152,0.00078640867,0.00013776169,0.001028373,0.000034396893,0.000013798618,0.00011462588,0.0024837605,0.000034286277],"about_ca_topic_score_codex":0.0005902936,"about_ca_topic_score_gemma":0.0030351118,"teacher_disagreement_score":0.056536537,"about_ca_system_score_codex":0.00004984282,"about_ca_system_score_gemma":0.00007593941,"threshold_uncertainty_score":0.16936636},"labels":[],"label_agreement":null},{"id":"W2078929954","doi":"10.1097/jto.0b013e318158d4b6","title":"Time to Treat: A System Redesign Focusing on Decreasing the Time from Suspicion of Lung Cancer to Diagnosis","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto East General Hospital; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Referral; Cancer; Lung cancer screening; Lung; Surgery; Radiology; Internal medicine","score_opus":0.020008500398463254,"score_gpt":0.4068119878619122,"score_spread":0.38680348746344895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078929954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97797984,0.001342285,0.00027779018,0.016807036,0.00036182362,0.00065444584,0.000016961701,0.000015496496,0.0025443106],"genre_scores_gemma":[0.993985,0.000086367465,0.003162089,0.0012879235,0.0010419259,0.00003873596,0.0000021768346,0.000032067226,0.00036369413],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817204,0.0002084708,0.0007099339,0.00020800447,0.0004031195,0.0002984517],"domain_scores_gemma":[0.9973647,0.0011985179,0.0005454318,0.00026823595,0.0002953102,0.00032778402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001164102,0.0001855675,0.000783424,0.0002869505,0.00008880518,0.000015475094,0.00015743986,0.00013601403,0.00033061847],"category_scores_gemma":[0.00018820779,0.0001129449,0.00020996349,0.00030433966,0.00003855536,0.000053456577,0.0000398506,0.00020896962,0.00006853795],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025398795,0.0028165078,0.049711917,0.00043152645,0.0020791765,0.002742612,0.0055140094,0.0010484266,0.03387914,0.0000595884,0.06518979,0.8111285],"study_design_scores_gemma":[0.009853,0.03827451,0.26918215,0.033652384,0.015904095,0.0019794812,0.0028143816,0.0009738073,0.5572034,0.00010700583,0.06894565,0.0011101225],"about_ca_topic_score_codex":0.0004383199,"about_ca_topic_score_gemma":0.00006884086,"teacher_disagreement_score":0.81001836,"about_ca_system_score_codex":0.003256262,"about_ca_system_score_gemma":0.00037034278,"threshold_uncertainty_score":0.85150117},"labels":[],"label_agreement":null},{"id":"W2079025929","doi":"10.1097/jto.0b013e31811ea275","title":"High Risk of Deep Vein Thrombosis in Patients with Non-small Cell Lung Cancer: A Cohort Study of 493 Patients","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Deep vein; Lung cancer; Cohort; Incidence (geometry); Retrospective cohort study; Confidence interval; Stage (stratigraphy); Thrombosis; Cancer; Surgery","score_opus":0.008315502292973682,"score_gpt":0.33156845580615124,"score_spread":0.32325295351317757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079025929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711764,0.000117613956,0.00015203789,0.000060073948,0.0004981072,0.0014681899,0.000008631934,0.0000041101025,0.00057359337],"genre_scores_gemma":[0.9979628,0.00026306312,0.0015297249,0.000096337826,0.00008373912,0.000017512195,0.0000047858057,0.000027671496,0.000014388469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973893,0.000187208,0.0012581542,0.0002169345,0.0006191289,0.00032925582],"domain_scores_gemma":[0.9966405,0.00016435022,0.0020180957,0.00027625504,0.0007478931,0.00015291716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013426035,0.00020146837,0.0014943044,0.00051652495,0.000037603437,0.000004382387,0.00021407704,0.00013689372,0.00007902168],"category_scores_gemma":[0.0000741831,0.0001482948,0.00012042816,0.0003929505,0.00006554348,0.000088993205,0.00009037141,0.00040702845,0.0000011020092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018140697,0.021008968,0.9565393,0.00024712802,0.0008404846,0.000045799767,0.0024402882,0.00042911983,0.00003355215,0.0000016736252,0.00035268956,0.016246952],"study_design_scores_gemma":[0.006939121,0.017960705,0.97045374,0.00027715944,0.002364053,0.0000012682336,0.001192355,0.000027073567,0.00058717735,0.0000069804473,0.00007124399,0.00011909635],"about_ca_topic_score_codex":0.0014972887,"about_ca_topic_score_gemma":0.0018907604,"teacher_disagreement_score":0.016127856,"about_ca_system_score_codex":0.0005013018,"about_ca_system_score_gemma":0.0001776256,"threshold_uncertainty_score":0.60472864},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2079289956","doi":"10.1097/jto.0b013e3182a46fe9","title":"Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Squamous-cell carcinoma of the lung; Lymph node; Concordance; Lung cancer; Oncology; Gene duplication; Fluorescence in situ hybridization; Tissue microarray; Pathology; Carcinoma; Lung; Internal medicine; Cancer research; Stage (stratigraphy); Cancer; Gene; Chromosome; Biology","score_opus":0.014343941253574325,"score_gpt":0.3303836450165069,"score_spread":0.3160397037629326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079289956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975949,0.0004888362,0.0005772958,0.00037599256,0.00018682897,0.0005003211,0.000025674255,0.0000049100995,0.00024523397],"genre_scores_gemma":[0.99629813,0.000038280134,0.003134826,0.00002956899,0.00024759618,0.000023559454,0.000035776084,0.00003783261,0.0001544511],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974621,0.0005852792,0.00086781674,0.00029759662,0.0003533131,0.00043392525],"domain_scores_gemma":[0.9977379,0.00017375569,0.00070795947,0.00031404442,0.0008634189,0.00020293266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046784527,0.00020684574,0.0004347636,0.00035922884,0.00004022167,0.000023860155,0.0004985548,0.000389603,0.0001683718],"category_scores_gemma":[0.00085211906,0.00018236855,0.00015328034,0.00033248708,0.00015110648,0.000026901884,0.00015864926,0.00045747924,0.000026336198],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005928555,0.00035502668,0.04079969,0.00021144676,0.000025288837,0.000016279057,0.00017486457,0.00006818951,0.9543904,0.0000069927523,0.0021069893,0.0012519914],"study_design_scores_gemma":[0.0007184218,0.003179072,0.16775991,0.000047981128,0.000021816433,0.000092560236,0.00011147241,0.00015273274,0.8273337,0.00007794144,0.00033240992,0.00017197439],"about_ca_topic_score_codex":0.00011508659,"about_ca_topic_score_gemma":0.000027853384,"teacher_disagreement_score":0.12705669,"about_ca_system_score_codex":0.00021019684,"about_ca_system_score_gemma":0.0005678751,"threshold_uncertainty_score":0.7436773},"labels":[],"label_agreement":null},{"id":"W2079997250","doi":"10.1097/jto.0b013e31827ce38e","title":"Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Research Resources","keywords":"Medicine; Lung cancer; Trastuzumab; Lapatinib; Cancer research; Pemetrexed; T790M; Oncology; Erlotinib; Bevacizumab; Internal medicine; Afatinib; Carboplatin; Crizotinib; Tyrosine-kinase inhibitor; Cancer; Epidermal growth factor receptor; Gefitinib; Breast cancer; Chemotherapy; Cisplatin","score_opus":0.01443599740957417,"score_gpt":0.3844427298241555,"score_spread":0.3700067324145813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079997250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895674,0.0009967983,0.00043096114,0.006687006,0.00017618993,0.00073983095,0.0000054024126,0.000013519997,0.0013828903],"genre_scores_gemma":[0.9936994,0.00042331073,0.0036490313,0.0002456763,0.0002065575,0.00009161776,0.0000314534,0.000023762339,0.0016292364],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99902195,0.00006901547,0.00032909916,0.00017789053,0.00022502219,0.00017701906],"domain_scores_gemma":[0.9986675,0.00005164165,0.0005462266,0.00010642042,0.00045616587,0.00017209201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010815405,0.00018241556,0.00042589384,0.00017294541,0.00011986693,0.000033110595,0.000024975749,0.000112651695,0.00013120913],"category_scores_gemma":[0.000005251553,0.000101716294,0.000048523718,0.0001604549,0.00007341944,0.00028427556,0.000010432769,0.00016847251,0.0000033833003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0091977995,0.011133892,0.37736598,0.0014278372,0.0036594416,0.007783586,0.019687869,0.0014926826,0.033885933,0.000070836606,0.011538606,0.5227555],"study_design_scores_gemma":[0.06876984,0.09919054,0.64960384,0.007709047,0.017633948,0.025294116,0.01608625,0.0064449604,0.09432682,0.00036673763,0.013206536,0.0013673645],"about_ca_topic_score_codex":0.00025656074,"about_ca_topic_score_gemma":0.00020758614,"teacher_disagreement_score":0.5213882,"about_ca_system_score_codex":0.0007660054,"about_ca_system_score_gemma":0.00065477076,"threshold_uncertainty_score":0.41478702},"labels":[],"label_agreement":null},{"id":"W2080346361","doi":"10.1097/jto.0b013e318060d2f1","title":"Patterns of Radiotherapy Re-Treatment in Patients with Lung Cancer: A Retrospective, Longitudinal Study","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes","funders":"","keywords":"Medicine; Radiation therapy; Retrospective cohort study; Lung cancer; Cancer; Oncology; Radiology; Internal medicine","score_opus":0.018556525020702576,"score_gpt":0.42112214880165577,"score_spread":0.4025656237809532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080346361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713916,0.0009621727,0.000096355805,0.0006063054,0.0002859634,0.0007643049,0.000009090308,0.0000041902845,0.00013244025],"genre_scores_gemma":[0.9983883,0.00043417208,0.00082943693,0.00006663597,0.00018597832,0.000020270132,0.0000018075465,0.000017990273,0.000055409393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854994,0.00008441923,0.0005902162,0.00018036056,0.00036722774,0.00022782858],"domain_scores_gemma":[0.9986608,0.00009383477,0.00063256297,0.00017932586,0.00031102187,0.00012245224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044471855,0.00016173323,0.00082507054,0.0002838035,0.000024067016,0.0000046250693,0.00007237706,0.000073346375,0.00012823612],"category_scores_gemma":[0.000013586757,0.00009870996,0.00010941795,0.00020642306,0.000028752633,0.00006882416,0.000011735919,0.00018704338,2.8577497e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009014759,0.010023306,0.94556856,0.000050088485,0.001166524,0.0008519622,0.001321664,0.000020353596,0.00001100216,0.0000024832582,0.00008855518,0.031880736],"study_design_scores_gemma":[0.009508415,0.0344311,0.95396847,0.00034176992,0.0006805584,0.00004261861,0.00035776928,0.0000034578175,0.0003298023,0.0000032353103,0.00025828063,0.00007454555],"about_ca_topic_score_codex":0.0005895334,"about_ca_topic_score_gemma":0.003435875,"teacher_disagreement_score":0.03180619,"about_ca_system_score_codex":0.0051421127,"about_ca_system_score_gemma":0.0003609225,"threshold_uncertainty_score":0.99867696},"labels":[],"label_agreement":null},{"id":"W2080577190","doi":"10.1097/jto.0000000000000148","title":"Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Enzyme function and inhibition","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute","keywords":"Medicine; Hazard ratio; Internal medicine; Immunohistochemistry; Pathology; Oncology; Confidence interval","score_opus":0.008483269016617832,"score_gpt":0.3233833252648511,"score_spread":0.31490005624823325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080577190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560434,0.0012688887,0.0006017564,0.00033829157,0.00045149127,0.00011676728,0.000008166599,0.0000042305883,0.0016060884],"genre_scores_gemma":[0.9949537,0.0019493821,0.0008268194,0.00028788619,0.00041374343,0.000008398137,0.000011464311,0.000016938886,0.0015317007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868363,0.0003938116,0.0004033576,0.00020744659,0.00011240548,0.00019934449],"domain_scores_gemma":[0.9990414,0.00004345825,0.00048003803,0.0001727931,0.00013576589,0.00012655639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083743525,0.00012922761,0.00026368853,0.0001446418,0.00008542081,0.000011504786,0.0001055591,0.00029451857,0.00006953185],"category_scores_gemma":[0.00020332447,0.00010882486,0.00007168573,0.0001031976,0.000052882722,0.000012157143,0.00009462674,0.00040827497,9.3200225e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010734248,0.00016026456,0.0047293548,0.000055045257,0.000020179485,0.000023868452,0.00015711803,0.00048688226,0.98641634,0.0000023224582,0.003548232,0.0033269557],"study_design_scores_gemma":[0.0023646252,0.0025029718,0.003709049,0.00015758383,0.00009874431,0.00008790707,0.00019810768,0.0014833611,0.94657063,0.000022619603,0.042593684,0.00021070967],"about_ca_topic_score_codex":0.000063381645,"about_ca_topic_score_gemma":0.00039106476,"teacher_disagreement_score":0.039845716,"about_ca_system_score_codex":0.00007805441,"about_ca_system_score_gemma":0.00017938319,"threshold_uncertainty_score":0.44377488},"labels":[],"label_agreement":null},{"id":"W2080647562","doi":"10.1097/jto.0000000000000288","title":"Practice Makes Perfect Protocols: The Canadian Anaplastic Lymphoma Kinase Study","year":2014,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anaplastic lymphoma kinase; Lymphoma; Anaplastic large-cell lymphoma; Cancer research; Oncology; Internal medicine","score_opus":0.0381527367887229,"score_gpt":0.4712579935456024,"score_spread":0.4331052567568795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080647562","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032830543,0.00037404962,0.000025055075,0.96674985,0.0012786416,0.0122019155,0.000020088579,0.000015139267,0.016052224],"genre_scores_gemma":[0.10299602,0.000026304378,0.0014007982,0.874111,0.012486677,0.0033737943,0.00004826314,0.00012119479,0.0054359464],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689984,0.0010682119,0.0007278184,0.00025510462,0.0006132485,0.0004357689],"domain_scores_gemma":[0.99602115,0.0010897489,0.0012816058,0.0004716482,0.0008636339,0.00027219558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012515907,0.0003146271,0.00091238675,0.00045471813,0.00033343438,0.0000942356,0.0003344168,0.0005598354,0.00017056543],"category_scores_gemma":[0.0010973982,0.00017896741,0.0002588545,0.00022375735,0.00013063276,0.00012231478,0.000028908851,0.0016718362,0.00006712816],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011347112,0.00079635385,0.00068819494,0.0001849632,0.0018550705,0.026214661,0.0012622603,0.000010111229,0.000002363896,0.000003939004,0.90140176,0.06644564],"study_design_scores_gemma":[0.0018146047,0.012797422,0.0021711092,0.00029918234,0.005605272,0.0112645,0.00096464175,0.000010242641,0.000004399692,0.000026358057,0.9648911,0.00015118653],"about_ca_topic_score_codex":0.010137205,"about_ca_topic_score_gemma":0.035368983,"teacher_disagreement_score":0.09971297,"about_ca_system_score_codex":0.0032071655,"about_ca_system_score_gemma":0.00871308,"threshold_uncertainty_score":0.9969066},"labels":[],"label_agreement":null},{"id":"W2080916956","doi":"10.1097/01.jto.0000283609.87888.34","title":"P2-145: Reduction of non small cell lung cancer (NSCLC) cell line migration in vitro by inhibition of the CXCR4/SDF-1 axis; a novel approach to preventing dissemination of early stage NSCLC.","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Stromal cell; CXCR4; Cancer research; Medicine; Metastasis; Homing (biology); Cell migration; Lung cancer; Cell culture; Chemokine; Pathology; Cancer; Receptor; Internal medicine; Biology","score_opus":0.016138536959134614,"score_gpt":0.35572244930392904,"score_spread":0.33958391234479446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080916956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755548,0.00038267195,0.022430856,0.00031865088,0.00026036167,0.00050131767,0.000018836587,0.0000030292724,0.0005294243],"genre_scores_gemma":[0.99161345,0.00006291904,0.0075002816,0.000019447203,0.00026209676,0.000006183224,0.00001472583,0.000019056939,0.00050182187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797565,0.00010319359,0.0012034243,0.00016039377,0.0003622583,0.00019509639],"domain_scores_gemma":[0.9973418,0.00013032726,0.0018161042,0.00013500956,0.00049668615,0.00008006199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018696293,0.00013808596,0.0005508861,0.00035791815,0.000029669229,0.0000050057033,0.00010140289,0.00020788478,0.000016167882],"category_scores_gemma":[0.00012554422,0.00010717736,0.0001880913,0.0005255435,0.0000473091,0.000118070166,0.00003752947,0.00040672594,1.0676682e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019193182,0.001338323,0.003455142,0.0006657592,0.000028718516,0.0000019531565,0.0031253686,0.0004919446,0.9737204,0.0000013509268,0.00018929841,0.015062452],"study_design_scores_gemma":[0.00092109403,0.0007841327,0.00617675,0.0009849132,0.00021648325,0.000028548477,0.0014461032,0.0016574052,0.98760116,0.0000031776926,0.000098086035,0.00008211845],"about_ca_topic_score_codex":0.00027516196,"about_ca_topic_score_gemma":0.000053715168,"teacher_disagreement_score":0.016058614,"about_ca_system_score_codex":0.00038861472,"about_ca_system_score_gemma":0.00025685068,"threshold_uncertainty_score":0.43705657},"labels":[],"label_agreement":null},{"id":"W2081042531","doi":"10.1097/jto.0b013e31820c2f18","title":"Treatment of Cardiac Angiosarcoma with Radiation and Docetaxel: A Case Report with Partial Response and Prolonged Stable Disease","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Pericardial effusion; Docetaxel; Internal medicine; Pericardium; Radiology; Surgery; Cardiology; Cancer","score_opus":0.023639472024194818,"score_gpt":0.35157700708587347,"score_spread":0.32793753506167866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081042531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640894,0.002294495,0.00002413511,0.00067301706,0.000087522494,0.0003453236,0.000012577951,0.0000059939603,0.00014800548],"genre_scores_gemma":[0.9976443,0.00015392553,0.0019290787,0.000019277888,0.00012432499,0.00001191077,0.0000023835453,0.000014066091,0.00010071752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897027,0.00023898602,0.0003407987,0.0001441141,0.00015998833,0.0001458566],"domain_scores_gemma":[0.99875826,0.000100210505,0.0004968057,0.00017281095,0.00017355119,0.00029834668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005426195,0.00011976177,0.0006342574,0.00013260164,0.000043912536,0.0000066523453,0.000016422407,0.000053167823,0.000011302781],"category_scores_gemma":[0.000076683566,0.00007173753,0.00008534267,0.00009412583,0.00015990078,0.000099901634,0.000011390947,0.000090501526,2.0576708e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16055264,0.0011729423,0.5091391,0.00011220262,0.0009797665,0.28199282,0.0035510436,0.0000032662992,0.00097426854,0.000016166416,0.000105918225,0.041399837],"study_design_scores_gemma":[0.0030927383,0.024889339,0.69827396,0.00008930481,0.0028423553,0.26125818,0.0007016137,0.000024602447,0.0036271417,0.00002664187,0.0050562886,0.00011782326],"about_ca_topic_score_codex":0.00008324871,"about_ca_topic_score_gemma":0.000014753285,"teacher_disagreement_score":0.18913485,"about_ca_system_score_codex":0.00011365046,"about_ca_system_score_gemma":0.0005538278,"threshold_uncertainty_score":0.29253715},"labels":[],"label_agreement":null},{"id":"W2081213854","doi":"10.1097/01.jto.0000283780.87833.c2","title":"P3-023: Preliminary results of an escalating dose phase I /II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Newfoundland and Labrador Centre for Applied Health Research; University of Calgary","funders":"","keywords":"Nimotuzumab; Medicine; Radiation therapy; Oncology; Internal medicine; Toxicity; Phases of clinical research; Epidermal growth factor receptor; Chemotherapy; Progressive disease; Lung cancer; Clinical trial; Gastroenterology; Cancer; Surgery","score_opus":0.041263050625945694,"score_gpt":0.4926962457130592,"score_spread":0.4514331950871135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081213854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950679,0.00016763115,0.0017698277,0.00049692276,0.00033329977,0.002059524,0.00003078826,0.0000048252746,0.00006925919],"genre_scores_gemma":[0.98785096,0.0001483081,0.011518887,0.00011631614,0.00020222989,0.000018092494,0.000030137668,0.000026557107,0.00008850359],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99694735,0.00036566737,0.0016812206,0.00023442999,0.0004840371,0.00028727925],"domain_scores_gemma":[0.996598,0.00094058056,0.0017430336,0.00021456035,0.0003669984,0.00013680711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024468647,0.00018538118,0.00092174084,0.000308543,0.00008066281,0.000008323723,0.00017843327,0.00019671248,0.000014659079],"category_scores_gemma":[0.00025904956,0.00009954503,0.00014996581,0.0003785613,0.00023662727,0.00023469543,0.000019944137,0.00042353873,5.1811e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6924311,0.022337534,0.05502298,0.000039388142,0.00025315315,0.00021257834,0.0016254857,0.00016443254,0.0007772152,0.000009769239,0.000024605622,0.22710174],"study_design_scores_gemma":[0.43120444,0.22545819,0.33937514,0.0006076667,0.00022239673,0.00007605061,0.0004998411,0.0009365713,0.0011630504,0.000023267377,0.00032695994,0.000106432904],"about_ca_topic_score_codex":0.00011250805,"about_ca_topic_score_gemma":0.0001417875,"teacher_disagreement_score":0.28435215,"about_ca_system_score_codex":0.0004403337,"about_ca_system_score_gemma":0.0012750186,"threshold_uncertainty_score":0.40593284},"labels":[],"label_agreement":null},{"id":"W2082112511","doi":"10.1097/jto.0b013e318180210c","title":"Waiting Times in Early-Stage Non-small Cell Lung Cancer (NSCLC)","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Cancer Care Nova Scotia","funders":"","keywords":"Medicine; Referral; Stage (stratigraphy); Chemotherapy; Lung cancer; Cancer; Retrospective cohort study; Medical record; General surgery; Surgery; Internal medicine; Family medicine","score_opus":0.06351269186827833,"score_gpt":0.4224498155052145,"score_spread":0.35893712363693614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082112511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777361,0.0025543654,0.00019224185,0.0015059854,0.00043231668,0.00015654574,0.0000024884814,0.000009389095,0.01741054],"genre_scores_gemma":[0.99151766,0.0006347827,0.0037232658,0.0009796803,0.00067424774,0.0000056319336,7.7355384e-7,0.000017768085,0.0024461937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840516,0.00010218323,0.0006543915,0.00015828563,0.00030815174,0.00037184314],"domain_scores_gemma":[0.99875027,0.00012299488,0.00053608883,0.00013401179,0.00025392545,0.00020268119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006891992,0.00014442703,0.00060722645,0.00025414265,0.000072825496,0.000009008433,0.00018157222,0.0001804791,0.00028633137],"category_scores_gemma":[0.00009883447,0.00012007478,0.00016465825,0.0002661354,0.00007199242,0.00016906018,0.000050757764,0.00073372916,0.000014262952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002651938,0.00031736834,0.92061085,0.00024192377,0.0001225375,0.0133584775,0.004137272,0.00093111716,0.00821851,0.000015777128,0.009357526,0.0400367],"study_design_scores_gemma":[0.0074579734,0.006586293,0.86901957,0.003629872,0.00089419907,0.009619444,0.0047477116,0.008245354,0.03108709,0.00009199497,0.05779423,0.00082628976],"about_ca_topic_score_codex":0.00057091267,"about_ca_topic_score_gemma":0.00017185962,"teacher_disagreement_score":0.0515913,"about_ca_system_score_codex":0.0005725522,"about_ca_system_score_gemma":0.0011048327,"threshold_uncertainty_score":0.48965073},"labels":[],"label_agreement":null},{"id":"W2082195351","doi":"10.1097/jto.0b013e3181560b92","title":"Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Hôpital Notre-Dame; McGill University Health Centre","funders":"Eli Lilly Canada","keywords":"Gemcitabine; Medicine; Carboplatin; Regimen; Neutropenia; Internal medicine; Chemotherapy; Concomitant; Lung cancer; Gastroenterology; Induction chemotherapy; Surgery; Chemotherapy regimen; Vinorelbine; Oncology; Cisplatin","score_opus":0.01212658411202245,"score_gpt":0.3781482938194433,"score_spread":0.3660217097074209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082195351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715234,0.005733032,0.0015319183,0.0031176095,0.00032822968,0.0020309086,0.000059299127,0.0000105932095,0.000036076053],"genre_scores_gemma":[0.9851027,0.0029849424,0.00988283,0.00076006685,0.0005308942,0.000080260295,0.000011765923,0.00005749242,0.00058901514],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99844974,0.0000652759,0.0005795345,0.00033600494,0.00021315669,0.00035629666],"domain_scores_gemma":[0.9982635,0.00030959913,0.00070209993,0.00014919946,0.00025034996,0.0003252936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006951702,0.00031105915,0.0009227295,0.00017475548,0.00014134694,0.00003885042,0.000049775328,0.00019152251,0.000027188109],"category_scores_gemma":[0.000024166078,0.0001988677,0.00007857718,0.00012097353,0.0001688795,0.00021436068,0.000017081162,0.00030082202,4.1179973e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6977631,0.0075301994,0.096818484,0.0008252226,0.0026421493,0.00052027416,0.0049056765,0.000012346919,0.062902845,0.000006091471,0.0037722068,0.122301415],"study_design_scores_gemma":[0.7711226,0.13847888,0.03246943,0.0011203693,0.003408078,0.0007232683,0.0012873707,0.0010199326,0.03068542,0.000006127032,0.019018454,0.0006600997],"about_ca_topic_score_codex":0.00012425912,"about_ca_topic_score_gemma":0.000308064,"teacher_disagreement_score":0.13094868,"about_ca_system_score_codex":0.0005807035,"about_ca_system_score_gemma":0.00029430233,"threshold_uncertainty_score":0.8109589},"labels":[],"label_agreement":null},{"id":"W2082906715","doi":"10.1016/s1556-0864(15)30360-9","title":"Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer?","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Amgen Canada","keywords":"Medicine; Internal medicine; Neutropenia; Carboplatin; Lung cancer; Chemotherapy; Febrile neutropenia; Performance status; Regimen; Granulocyte colony-stimulating factor; Hazard ratio; Gastroenterology; Surgery; Chemotherapy regimen; Oncology; Cisplatin; Confidence interval","score_opus":0.00630827182617636,"score_gpt":0.3047303130474068,"score_spread":0.2984220412212304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082906715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963046,0.00068966066,0.0002703287,0.00018232499,0.0017164769,0.00038711066,0.000010603684,0.0000128959455,0.000426018],"genre_scores_gemma":[0.9987511,0.00004696755,0.0004573713,0.00003309789,0.000090529305,0.0000125371225,0.000023333863,0.000020524083,0.00056453235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807376,0.00058636145,0.00070199266,0.00017845046,0.0000753335,0.00038411983],"domain_scores_gemma":[0.9982322,0.00042766653,0.00091446633,0.00014279094,0.00025959892,0.000023271428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000523849,0.00020702711,0.00063421734,0.00028524024,0.000111691945,0.000012907164,0.00020882658,0.0002993265,0.00011965339],"category_scores_gemma":[0.000059172846,0.00012544179,0.00010768899,0.00018498686,0.00008048675,0.00021916385,0.00004310203,0.0005590802,0.000012651229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010664545,0.000518884,0.7961944,0.00010356719,0.00012848037,0.000057136403,0.0005080138,0.0024073566,0.15512933,0.0000057878738,0.00020438607,0.034078147],"study_design_scores_gemma":[0.0049513173,0.002240269,0.90413994,0.00020427388,0.000116749296,0.00001640093,0.00013082691,0.000050137794,0.0849889,0.00001788194,0.0029062168,0.00023710189],"about_ca_topic_score_codex":0.00014554596,"about_ca_topic_score_gemma":0.00039356726,"teacher_disagreement_score":0.107945554,"about_ca_system_score_codex":0.00038524327,"about_ca_system_score_gemma":0.00032091243,"threshold_uncertainty_score":0.5115368},"labels":[],"label_agreement":null},{"id":"W2083429682","doi":"10.1097/jto.0b013e3181e77a92","title":"Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Cetuximab; Internal medicine; Oncology; Phases of clinical research; Regimen; Gastroenterology; Progression-free survival; Epidermal growth factor receptor; Adenocarcinoma; Chemotherapy; Colorectal cancer; Cancer","score_opus":0.030234436750549345,"score_gpt":0.4276358738198085,"score_spread":0.3974014370692592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083429682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949131,0.0015323091,0.000015998085,0.0010614832,0.0004614606,0.0015526965,0.000026741987,0.000016309472,0.00041991012],"genre_scores_gemma":[0.99624187,0.000038292193,0.0024248085,0.0005196677,0.00036113773,0.000072892326,0.000026585072,0.00004817062,0.00026659563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966809,0.0005559257,0.0010006191,0.00038746378,0.00075882464,0.00061624445],"domain_scores_gemma":[0.997445,0.00031533727,0.0007294267,0.00039873793,0.00052500935,0.00058648724],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014329096,0.0003424857,0.0013698285,0.0006681552,0.00013874755,0.000023212453,0.00030270108,0.0001853396,0.001205639],"category_scores_gemma":[0.00017544883,0.00022194345,0.00018472501,0.00044379223,0.00022015997,0.0002415904,0.00009477185,0.001796882,0.000033000055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08436464,0.07997296,0.5739529,0.000074681775,0.0014096668,0.024580894,0.0038290273,0.0000041902754,0.00040429068,0.000028894694,0.00023969052,0.23113818],"study_design_scores_gemma":[0.07128747,0.40331975,0.51986116,0.00004397756,0.00052107207,0.0014897133,0.0011149552,0.00001193599,0.00054761686,0.00017231308,0.0014468868,0.0001831716],"about_ca_topic_score_codex":0.00014394814,"about_ca_topic_score_gemma":0.0019414333,"teacher_disagreement_score":0.3233468,"about_ca_system_score_codex":0.00074495835,"about_ca_system_score_gemma":0.0017142876,"threshold_uncertainty_score":0.9997074},"labels":[],"label_agreement":null},{"id":"W2083547960","doi":"10.1097/01.jto.0000283087.71346.19","title":"PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Docetaxel; Gefitinib; Lung cancer; Internal medicine; Oncology; Tolerability; Hazard ratio; Population; Clinical endpoint; Randomized controlled trial; Performance status; Chemotherapy; Cancer; Epidermal growth factor receptor; Adverse effect; Confidence interval","score_opus":0.033084413309192914,"score_gpt":0.45279197386248055,"score_spread":0.4197075605532876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083547960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892774,0.00028763965,0.0027551015,0.00040816827,0.00021493227,0.0063336487,0.000025391675,0.000017173059,0.00068052835],"genre_scores_gemma":[0.9843129,0.00003779197,0.014088084,0.00044933675,0.00006994978,0.00030156152,0.0000280416,0.00006555468,0.0006467641],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99728876,0.00027099886,0.0011564712,0.0003691488,0.0004440911,0.00047054514],"domain_scores_gemma":[0.9965464,0.0007078135,0.001453449,0.0002839726,0.0007116934,0.00029670433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010500733,0.00039350186,0.001753666,0.00038879918,0.000097528835,0.000046794874,0.00027832392,0.00010078085,0.00016723921],"category_scores_gemma":[0.00009353247,0.00021850287,0.00009145599,0.00053316547,0.00013943162,0.00026990726,0.000039307088,0.00047234155,0.0000013660068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.894408,0.021498602,0.02477028,0.00015275921,0.0027338895,0.0017651668,0.0020041105,0.0005131624,0.00013256042,0.0000010059472,0.000097000855,0.05192347],"study_design_scores_gemma":[0.93453854,0.046023972,0.009231718,0.001103358,0.0053473767,0.00006102274,0.0013310909,0.00079622935,0.0011081055,0.0000024615251,0.0001735318,0.00028257357],"about_ca_topic_score_codex":0.00028126375,"about_ca_topic_score_gemma":0.002623875,"teacher_disagreement_score":0.051640894,"about_ca_system_score_codex":0.001111801,"about_ca_system_score_gemma":0.0022724818,"threshold_uncertainty_score":0.8910288},"labels":[],"label_agreement":null},{"id":"W2084415993","doi":"10.1097/jto.0b013e318220c93e","title":"Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Adverse effect; Lung cancer; Progression-free survival; Clinical endpoint; Internal medicine; Nausea; Surgery; Phases of clinical research; Urology; Gastroenterology; Oncology; Clinical trial; Chemotherapy","score_opus":0.022733172148207265,"score_gpt":0.434747771304466,"score_spread":0.41201459915625877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084415993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400395,0.00033780432,0.00013247824,0.00015855693,0.0006919655,0.0006870578,0.000014012977,0.0000037106627,0.003970449],"genre_scores_gemma":[0.99102557,0.00012667793,0.008275488,0.000119158045,0.00015791475,0.00002574094,0.000005787812,0.00001769503,0.00024597405],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99887806,0.000060115653,0.000585905,0.000118475495,0.00018231763,0.00017515168],"domain_scores_gemma":[0.9985585,0.00005183725,0.0007666201,0.0001322569,0.00036521206,0.00012554771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019476585,0.00011880823,0.00055646163,0.0002112814,0.000021029762,0.000002307007,0.00008709533,0.0000988319,0.00015121339],"category_scores_gemma":[0.000029963383,0.0000794456,0.00009464939,0.00017111999,0.000045465935,0.00010426973,0.000014458619,0.00023941648,0.0000015271586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4537165,0.029779183,0.19641133,0.00036807993,0.0008807276,0.0005294904,0.008499881,0.000082730534,0.001060867,0.0000101420355,0.00060976396,0.30805132],"study_design_scores_gemma":[0.63457304,0.1254346,0.21515343,0.0011807986,0.004519114,0.00006428395,0.001188278,0.00008200039,0.011689822,0.00007321598,0.005685679,0.0003557474],"about_ca_topic_score_codex":0.00006925489,"about_ca_topic_score_gemma":0.00007301908,"teacher_disagreement_score":0.30769557,"about_ca_system_score_codex":0.00035170093,"about_ca_system_score_gemma":0.0010269858,"threshold_uncertainty_score":0.32396975},"labels":[],"label_agreement":null},{"id":"W2084437976","doi":"10.1016/s1556-0864(15)31597-5","title":"Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review","year":2006,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Cancer Care Ontario; Juravinski Cancer Centre","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Lung cancer; Oncology; Internal medicine; Epidermal growth factor receptor; Erlotinib Hydrochloride; Placebo; Chemotherapy; Cancer; Pathology","score_opus":0.05388417740941101,"score_gpt":0.4443536176957201,"score_spread":0.39046944028630914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084437976","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004984137,0.9887902,0.000003254473,0.0007377385,0.00047351207,0.004729391,0.00016462913,0.0000025235363,0.00011460272],"genre_scores_gemma":[0.0006360602,0.9979334,0.0003951135,0.00015470298,0.00023619198,0.00027283927,0.000016447852,0.0000329683,0.00032228796],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99582815,0.0010816082,0.0023528223,0.00019651839,0.00031877196,0.0002221286],"domain_scores_gemma":[0.99383783,0.0011731051,0.0042502806,0.00035750042,0.00029551095,0.00008576523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058409193,0.00037329234,0.0043178014,0.00023375422,0.00004721096,0.000011552402,0.00022430762,0.00024423096,0.000022748578],"category_scores_gemma":[0.00018179655,0.000157003,0.0009252366,0.0003983935,0.000109038636,0.000067119065,0.00002797431,0.0003735915,8.5049254e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006699878,0.0013360912,0.0011035978,0.85898197,0.0012016913,0.00009022637,0.0011845496,0.0000014931018,0.000004879119,0.0000040691093,0.0019607185,0.1340637],"study_design_scores_gemma":[0.0012053964,0.0026132588,0.00054889196,0.712906,0.0479866,0.0009229283,0.0001870146,0.0000032898,0.000041823478,0.0000031493007,0.23336768,0.0002139612],"about_ca_topic_score_codex":0.0002650874,"about_ca_topic_score_gemma":0.00008711922,"teacher_disagreement_score":0.23140696,"about_ca_system_score_codex":0.0009623329,"about_ca_system_score_gemma":0.0017443254,"threshold_uncertainty_score":0.64023966},"labels":[],"label_agreement":null},{"id":"W2084850747","doi":"10.1097/jto.0b013e3182217d81","title":"miR-101 DNA Copy Loss is a Prominent Subtype Specific Event in Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Lung cancer; Event (particle physics); Computational biology; Oncology; Biology","score_opus":0.02290697913244613,"score_gpt":0.3695693286423679,"score_spread":0.3466623495099218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084850747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931012,0.0046966313,0.00036024067,0.0006132493,0.0005683097,0.00019215785,0.000010401902,0.0000024847448,0.00045533918],"genre_scores_gemma":[0.9969904,0.0006844843,0.0014202232,0.00020078555,0.00042775046,0.00001236162,0.0000073927577,0.000019053476,0.00023757153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987833,0.0001525399,0.0005037272,0.000194197,0.00014063415,0.00022561739],"domain_scores_gemma":[0.9989761,0.000010353836,0.000500584,0.0002026216,0.00019311521,0.00011718715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004183291,0.00013346627,0.00026583968,0.00011900038,0.000025022855,0.000007133927,0.00022344601,0.00020804905,0.00046522229],"category_scores_gemma":[0.00003100171,0.00011805832,0.0001383797,0.0001093103,0.00006909887,0.000008511929,0.0000673227,0.0001660226,0.000008095927],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036259391,0.0006528086,0.046473455,0.000113890965,0.00022709122,0.00028711927,0.0008021557,0.000041537758,0.905659,0.000021017058,0.02721158,0.014884359],"study_design_scores_gemma":[0.0011795338,0.0011320742,0.113927916,0.00015662744,0.00013501245,0.00042071383,0.000119202814,0.00007938196,0.7596965,0.00022700142,0.12262549,0.00030055692],"about_ca_topic_score_codex":0.0000189075,"about_ca_topic_score_gemma":0.00006652716,"teacher_disagreement_score":0.14596257,"about_ca_system_score_codex":0.00023492512,"about_ca_system_score_gemma":0.00040388477,"threshold_uncertainty_score":0.50938576},"labels":[],"label_agreement":null},{"id":"W2084920067","doi":"10.1097/01.jto.0000284067.45483.01","title":"P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Tolerability; Regimen; Lung cancer; Oncology; Internal medicine; Pharmacology; Combination therapy; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.013891774908671052,"score_gpt":0.39219524273297685,"score_spread":0.3783034678243058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084920067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550223,0.0007934819,0.00012360669,0.00029156427,0.000113077316,0.0026746981,0.000019522904,0.0000092914825,0.00047250287],"genre_scores_gemma":[0.99774855,0.00004755578,0.0010423451,0.000100952144,0.00010795667,0.000106619504,0.000011602919,0.00004181695,0.00079261145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982632,0.00016343774,0.00060555566,0.00023842456,0.00037145457,0.00035795502],"domain_scores_gemma":[0.9979525,0.00012778281,0.00092163635,0.00024484898,0.0005650456,0.00018813822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003903191,0.00028779602,0.0009085832,0.00040711532,0.000069279144,0.000012493562,0.00010712847,0.000089221794,0.000050253882],"category_scores_gemma":[0.000009927669,0.00012873892,0.00009197793,0.00070187787,0.00009485229,0.00009951516,0.000014532389,0.00023738862,5.509253e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04650705,0.024745127,0.83078265,0.000074805874,0.0017897565,0.0018142166,0.012496766,0.000096223004,0.00034953872,2.474718e-7,0.0003079687,0.08103566],"study_design_scores_gemma":[0.16778478,0.35060114,0.4364209,0.001004398,0.014616759,0.00028405513,0.018353181,0.00008472283,0.0070424653,0.0000011532479,0.0033351514,0.000471291],"about_ca_topic_score_codex":0.001276453,"about_ca_topic_score_gemma":0.0073517733,"teacher_disagreement_score":0.39436173,"about_ca_system_score_codex":0.0009838204,"about_ca_system_score_gemma":0.00084822933,"threshold_uncertainty_score":0.5249821},"labels":[],"label_agreement":null},{"id":"W2085040748","doi":"10.1097/jto.0b013e31819ccf26","title":"Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Cancer registry; Internal medicine; Cancer; Referral; Medical record; General surgery; Oncology; Family medicine","score_opus":0.01677002134510748,"score_gpt":0.3512280738886697,"score_spread":0.33445805254356226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085040748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957989,0.00018200265,0.0000034479,0.003332918,0.00016126898,0.000379963,0.000017560731,0.0000014070336,0.00012253382],"genre_scores_gemma":[0.9985394,0.0002836858,0.00044321406,0.0006044247,0.00005455686,0.000010193597,0.000007422708,0.00000890273,0.000048205526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988848,0.00007944428,0.0005416091,0.00012928876,0.00017741167,0.00018745313],"domain_scores_gemma":[0.9985989,0.00050810823,0.00047713894,0.00009573663,0.00018508657,0.00013508287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034328867,0.00011326282,0.00072122103,0.00016545864,0.00001385064,0.000003955387,0.00004895408,0.00009089589,0.000008971345],"category_scores_gemma":[0.00011125111,0.00007656968,0.00004401291,0.000121099736,0.000059944003,0.00007994963,0.0000045998295,0.00014845342,4.4460762e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007070596,0.0014119878,0.9406575,0.00005162705,0.000084593456,0.00019508795,0.0004064665,0.0000131478855,0.000011117446,0.000006311123,0.00066647824,0.04942507],"study_design_scores_gemma":[0.004815121,0.011148771,0.98055154,0.00028696406,0.00009564033,0.00003950383,0.0001603212,0.0000145368285,0.00042297802,0.000017871833,0.0023791203,0.000067601504],"about_ca_topic_score_codex":0.09718726,"about_ca_topic_score_gemma":0.59635365,"teacher_disagreement_score":0.49916637,"about_ca_system_score_codex":0.0010118481,"about_ca_system_score_gemma":0.0018376821,"threshold_uncertainty_score":0.9088246},"labels":[],"label_agreement":null},{"id":"W2086326785","doi":"10.1097/01.jto.0000437419.31348.a4","title":"Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Surgery; Vertebrectomy; Lung cancer; Univariate analysis; Intensive care unit; Etoposide; Lung; Pneumonectomy; Chemotherapy; Internal medicine; Resection; Multivariate analysis","score_opus":0.020092052772940402,"score_gpt":0.39518671777022024,"score_spread":0.37509466499727984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086326785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94660676,0.0482887,0.000032585056,0.0039197775,0.00040571223,0.0004450695,0.0000015590941,0.0000036053348,0.0002962617],"genre_scores_gemma":[0.97966486,0.018772827,0.00041610096,0.00026866602,0.00040929258,0.000081145045,7.5444774e-7,0.00001591689,0.00037042462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988676,0.0001234813,0.0005419106,0.00012957535,0.00015758486,0.00017985971],"domain_scores_gemma":[0.9989069,0.00016316782,0.00047162676,0.00015709709,0.00017910471,0.0001221112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041793316,0.00013139177,0.00055064965,0.00014707421,0.000043289998,0.000014101462,0.00009146103,0.00012068019,0.00022817326],"category_scores_gemma":[0.00003083234,0.00007295966,0.0001407469,0.000118078766,0.00006789714,0.0001060164,0.000061031304,0.0003118272,0.000004144215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005252128,0.00042459604,0.8239675,0.0009479415,0.00029826062,0.00044568308,0.0004187165,0.000008071268,0.001809608,0.0000010743464,0.00019604954,0.17095728],"study_design_scores_gemma":[0.001105745,0.0020404467,0.98840755,0.00091770274,0.0018450484,0.0013791879,0.00013941118,0.00012127725,0.0030339914,0.000019476016,0.00089246687,0.00009772108],"about_ca_topic_score_codex":0.00013388129,"about_ca_topic_score_gemma":0.00011839152,"teacher_disagreement_score":0.17085956,"about_ca_system_score_codex":0.00055874034,"about_ca_system_score_gemma":0.00019405293,"threshold_uncertainty_score":0.29752085},"labels":[],"label_agreement":null},{"id":"W2087586265","doi":"10.1097/01.jto.0000407566.37523.c5","title":"Targeting the Phosphatidylinosital 3-Kinase, Akt, and Mammalian Target of Rapamycin Pathway in Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Protein kinase B; PI3K/AKT/mTOR pathway; Cancer research; Lung cancer; Kinase; Cell biology; Signal transduction; Oncology; Biology","score_opus":0.01400728450804022,"score_gpt":0.31091862346867133,"score_spread":0.2969113389606311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087586265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830846,0.013957828,0.0006862536,0.00020019464,0.00068759837,0.0001861565,0.000020027372,0.000002202802,0.0011751015],"genre_scores_gemma":[0.9935114,0.00048781818,0.005160342,0.0002425944,0.00040165408,0.000013421132,0.000004484768,0.000025584886,0.00015269955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845845,0.00022823048,0.00064379704,0.00022016952,0.00014538865,0.00030396815],"domain_scores_gemma":[0.99864924,0.00006173082,0.00078195817,0.00019410759,0.00021338084,0.00009957686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010780557,0.00018236622,0.00038838573,0.000094034905,0.000054059074,0.000009586071,0.0003710365,0.00025665888,0.000089356894],"category_scores_gemma":[0.000082150065,0.00013609526,0.00012165217,0.00012629948,0.00015053952,0.000011715091,0.00010680523,0.00035416518,7.61056e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014006561,0.00039483813,0.112522,0.00019378183,0.00015388096,0.00015231414,0.0019746153,0.0005162228,0.8689016,0.000009853953,0.002490562,0.011289641],"study_design_scores_gemma":[0.00080325204,0.0015532447,0.00940449,0.00010491383,0.000079731515,0.000077237986,0.00059758,0.00014277124,0.979935,0.00008186881,0.0070146676,0.00020527974],"about_ca_topic_score_codex":0.00010108084,"about_ca_topic_score_gemma":0.000091958194,"teacher_disagreement_score":0.11103333,"about_ca_system_score_codex":0.00008252507,"about_ca_system_score_gemma":0.00043070674,"threshold_uncertainty_score":0.5549804},"labels":[],"label_agreement":null},{"id":"W2087769940","doi":"10.1097/jto.0b013e31826aec2b","title":"Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":340,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Pfizer; Eli Lilly and Company; Amgen","keywords":"Denosumab; Medicine; Zoledronic acid; Hazard ratio; Internal medicine; Lung cancer; Oncology; Adverse effect; Multiple myeloma; Urology; Surgery; Osteoporosis; Confidence interval","score_opus":0.01981952497666678,"score_gpt":0.40054476409922946,"score_spread":0.3807252391225627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087769940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947955,0.0034221602,0.00005357284,0.00019591824,0.0001887026,0.0012659971,0.000045144272,0.000007816504,0.000025165704],"genre_scores_gemma":[0.99879956,0.00016287499,0.00071181485,0.000082007355,0.000068651934,0.000072867384,0.00005196266,0.000021039104,0.000029202247],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976343,0.00051239884,0.0007652171,0.00021484638,0.00044739945,0.0004258326],"domain_scores_gemma":[0.99802345,0.00033771349,0.0008363657,0.00018515607,0.00020942422,0.00040789598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000925711,0.0002552992,0.0020083033,0.00046932825,0.000059129514,0.000013455621,0.000054357268,0.000087347915,0.00010945705],"category_scores_gemma":[0.000062021376,0.00014591489,0.00013821472,0.00040123155,0.0000780596,0.00022355099,0.000026681295,0.00031851602,8.1303244e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4250855,0.0059095956,0.54964846,0.000020340356,0.007487965,0.00020684102,0.0004333424,0.0000066446164,0.000015522046,5.1360735e-7,0.00000780424,0.01117747],"study_design_scores_gemma":[0.48690984,0.013870425,0.47362173,0.000059375358,0.024897315,0.000012917018,0.00031173447,0.000077839846,0.000089722416,0.000001360818,0.000027035694,0.00012072505],"about_ca_topic_score_codex":0.0028541782,"about_ca_topic_score_gemma":0.0033274214,"teacher_disagreement_score":0.07602671,"about_ca_system_score_codex":0.00079397816,"about_ca_system_score_gemma":0.00036138977,"threshold_uncertainty_score":0.59502363},"labels":[],"label_agreement":null},{"id":"W2087775197","doi":"10.1097/01.jto.0000284173.03442.81","title":"P3-198: An audit of elective mediastinal lymph node irradiation in stage III non-small cell lung cancer patients entered onto a prospective randomized phase III study","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Lymph node; Radiation therapy; Mediastinal lymph node; Mediastinum; Lymph; Stage (stratigraphy); Radiology; Population; Cancer; Nuclear medicine; Surgery; Oncology; Internal medicine; Metastasis; Pathology","score_opus":0.014305130098893375,"score_gpt":0.40081198919634353,"score_spread":0.38650685909745014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087775197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945988,0.00054379005,0.0005346085,0.00018813745,0.0006957268,0.0027708202,0.000021277718,0.000007814363,0.00063900603],"genre_scores_gemma":[0.99812424,0.00020555721,0.0008433048,0.00013372827,0.0003565458,0.00017416182,0.000012543694,0.00002718116,0.00012275124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969801,0.0004289381,0.0013990605,0.0003172125,0.00049761037,0.00037712583],"domain_scores_gemma":[0.9964012,0.00049547304,0.0018595371,0.00018316743,0.0007944473,0.00026618456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019418317,0.00026233474,0.0016530019,0.0005172885,0.000054354176,0.000010612286,0.00014421818,0.00015207783,0.000116145304],"category_scores_gemma":[0.00016937096,0.0001972357,0.00024248565,0.00031810583,0.00008215954,0.00019250819,0.000035793455,0.0003664144,9.698224e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35991243,0.024420371,0.5840461,0.0001341829,0.000965942,0.00046869414,0.017048545,0.00010128683,0.0009168093,0.0000023660261,0.00009152391,0.011891748],"study_design_scores_gemma":[0.4765547,0.012560488,0.4992285,0.00040791524,0.0020061226,0.000028829329,0.003002579,0.0005619001,0.0054334765,0.000017464648,0.000028244609,0.00016978117],"about_ca_topic_score_codex":0.0013799224,"about_ca_topic_score_gemma":0.0033454113,"teacher_disagreement_score":0.11664226,"about_ca_system_score_codex":0.00488612,"about_ca_system_score_gemma":0.0010321488,"threshold_uncertainty_score":0.998934},"labels":[],"label_agreement":null},{"id":"W2088333572","doi":"10.1097/jto.0b013e31829fd3d5","title":"Screening High-Risk Populations for Lung Cancer: Guideline Recommendations","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; Sunnybrook Health Science Centre; Health Sciences Centre; Mount Sinai Hospital; Occupational Cancer Research Centre; McMaster University; Cancer Care Ontario; Women's College Hospital; Health Sciences North; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Guideline; Lung cancer screening; Lung cancer; National Lung Screening Trial; Randomized controlled trial; Systematic review; Population; Intensive care medicine; Cancer; Health care; Family medicine; MEDLINE; Internal medicine; Pathology; Environmental health","score_opus":0.05040346496039893,"score_gpt":0.4831314318398169,"score_spread":0.43272796687941795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088333572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57877535,0.0040938673,0.08286577,0.3280032,0.0036955215,0.0017562489,0.0001481423,0.000042114756,0.00061981374],"genre_scores_gemma":[0.657709,0.0011738229,0.33739224,0.001465745,0.0013908554,0.00019950428,0.00005982452,0.00002511265,0.00058391277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987648,0.00007781429,0.00071698206,0.00011881956,0.00013500643,0.00018655078],"domain_scores_gemma":[0.9981109,0.00021520429,0.0007307098,0.00013955212,0.00063653657,0.00016708455],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004142206,0.000106160885,0.0004255371,0.0001674217,0.0001357926,0.000017605105,0.00007596439,0.00009467908,0.0009366539],"category_scores_gemma":[0.00016611398,0.00007821639,0.00018631265,0.00012427843,0.000023435268,0.00015880463,0.000020392567,0.00020623287,0.0000046209793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023484754,0.0003571993,0.07494016,0.00004000388,0.00047269755,0.000009791307,0.00011041217,0.0005754461,0.00006965364,0.0001338005,0.37837,0.544686],"study_design_scores_gemma":[0.009559507,0.007326519,0.31475165,0.0013067484,0.009134486,0.0007281681,0.00086613203,0.01953694,0.001483059,0.0041670743,0.63066584,0.0004738562],"about_ca_topic_score_codex":0.000796279,"about_ca_topic_score_gemma":0.00027203633,"teacher_disagreement_score":0.54421216,"about_ca_system_score_codex":0.00071779493,"about_ca_system_score_gemma":0.00030585233,"threshold_uncertainty_score":0.99997663},"labels":[],"label_agreement":null},{"id":"W2088357532","doi":"10.1016/s1556-0864(15)31605-1","title":"Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients","year":2006,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation","funders":"","keywords":"Vinorelbine; Medicine; Gefitinib; Oncology; Lung cancer; Cisplatin; Chemotherapy; Vinblastine; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.012515906492385633,"score_gpt":0.39447117709965124,"score_spread":0.3819552706072656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088357532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989565,0.00065876264,0.0017999407,0.0028501714,0.0005344747,0.0011181228,0.00007860408,0.000016266542,0.0033786467],"genre_scores_gemma":[0.97360176,0.00015954861,0.018671699,0.0010494983,0.001080357,0.0001301047,0.000062572806,0.00005608021,0.005188376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984994,0.000040577273,0.0006285295,0.00021954621,0.00026369232,0.00034824098],"domain_scores_gemma":[0.9978151,0.00018966079,0.0008855515,0.00015733947,0.00078380713,0.00016856825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017157517,0.00023933248,0.0006637122,0.00019107189,0.00011224099,0.000019338759,0.000124619,0.00016430207,0.00021989665],"category_scores_gemma":[0.000027508035,0.00014499649,0.00016956328,0.00020217635,0.000069173766,0.00010938249,0.000017454811,0.00025324308,0.0000029544099],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04568083,0.01004504,0.5963774,0.0016669403,0.0025944072,0.0009815472,0.0037668657,0.0012569312,0.0058033466,0.00005737905,0.10222052,0.2295488],"study_design_scores_gemma":[0.071028925,0.0516562,0.6353717,0.0022770306,0.012356667,0.0011489663,0.0010275332,0.002052679,0.031799473,0.00031747867,0.18977492,0.0011884288],"about_ca_topic_score_codex":0.0001985278,"about_ca_topic_score_gemma":0.000258963,"teacher_disagreement_score":0.22836037,"about_ca_system_score_codex":0.00074111833,"about_ca_system_score_gemma":0.0012076675,"threshold_uncertainty_score":0.5912785},"labels":[],"label_agreement":null},{"id":"W2088720324","doi":"10.1097/jto.0b013e31812f3c1a","title":"The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3678,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Eli Lilly and Company","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Lung cancer staging; Cancer; TNM staging system; Malignant pleural effusion; Radiology; Oncology; Internal medicine; Neoplasm staging","score_opus":0.03745429011440165,"score_gpt":0.4494347467826887,"score_spread":0.41198045666828703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088720324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9498389,0.0036185489,0.0010378909,0.04120264,0.0011237975,0.0029590093,0.000030075416,0.0000032713658,0.0001858907],"genre_scores_gemma":[0.9974553,0.0014823723,0.0002715747,0.00027889246,0.0003466555,0.00006246244,0.0000016647156,0.000015962534,0.00008509994],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99757487,0.00039405792,0.001067076,0.0001395462,0.00057382527,0.00025065726],"domain_scores_gemma":[0.9953243,0.0014742871,0.0023183383,0.00040851923,0.00044605695,0.00002846127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053539257,0.00013952385,0.00044023688,0.00009842474,0.00023050004,0.000013886847,0.00045410305,0.00009272962,0.000007825027],"category_scores_gemma":[0.00036669147,0.000048021906,0.00032362988,0.00038106262,0.0002399797,0.000096047144,0.00006559983,0.00036931635,6.9438535e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068240897,0.0024631799,0.41048047,0.0026689295,0.001138502,0.00003575435,0.022741612,0.00045725718,0.019179143,0.0042206133,0.013195914,0.5165945],"study_design_scores_gemma":[0.0031116966,0.0024082016,0.8691292,0.006480676,0.0026147491,0.00017967861,0.02433922,0.0016939905,0.066645324,0.00066205714,0.02255696,0.0001782704],"about_ca_topic_score_codex":0.00025134126,"about_ca_topic_score_gemma":0.00061598426,"teacher_disagreement_score":0.51641625,"about_ca_system_score_codex":0.00069080316,"about_ca_system_score_gemma":0.0007146676,"threshold_uncertainty_score":0.19582765},"labels":[],"label_agreement":null},{"id":"W2088824540","doi":"10.1097/jto.0b013e31819e77e8","title":"Prognostic Value of the Six-Minute Walk in Advanced Non-small Cell Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":152,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Sanofi","keywords":"Medicine; Confidence interval; Lung cancer; Chemotherapy; Internal medicine; Proportional hazards model; Surgery","score_opus":0.013196545751807646,"score_gpt":0.3683823666056061,"score_spread":0.35518582085379846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088824540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98648787,0.0034617998,0.00008948951,0.005286925,0.0014181309,0.00034873898,0.000003934691,0.000004624547,0.0028984745],"genre_scores_gemma":[0.99692255,0.00032403998,0.0006958457,0.0010978976,0.00033883456,0.000008022388,6.0298964e-7,0.000012536232,0.00059966283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985914,0.00015612484,0.00060225883,0.000131126,0.0002688839,0.0002501994],"domain_scores_gemma":[0.99863815,0.00015671753,0.0006150519,0.00020928636,0.00026870347,0.00011209258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005164259,0.00013272633,0.0005829277,0.00015818622,0.00003976215,0.000003916317,0.00023500327,0.00015409643,0.000054965098],"category_scores_gemma":[0.000119827346,0.00008715578,0.00021452583,0.0003559881,0.000052297273,0.000064920976,0.000045912555,0.00058548525,9.772547e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054843836,0.0016423768,0.5198429,0.00097235496,0.00017746081,0.00094624626,0.011992321,0.0020402276,0.059307836,0.00006365314,0.0026161785,0.39491403],"study_design_scores_gemma":[0.0035276818,0.004694749,0.9276933,0.0022855492,0.0010685651,0.0006392489,0.0019000644,0.0006935795,0.037310075,0.0003728215,0.019538116,0.00027623234],"about_ca_topic_score_codex":0.00010790466,"about_ca_topic_score_gemma":0.00093324104,"teacher_disagreement_score":0.40785038,"about_ca_system_score_codex":0.0004427036,"about_ca_system_score_gemma":0.0010011873,"threshold_uncertainty_score":0.35541096},"labels":[],"label_agreement":null},{"id":"W2089494879","doi":"10.1097/01.jto.0000283139.22682.5e","title":"B1-01: A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thames Valley Children's Centre; Juravinski Cancer Centre; Université Laval; Centre Hospitalier de l’Université de Montréal; BC Cancer Agency; Ottawa Hospital; CancerCare Manitoba; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Population; Randomized controlled trial; Randomization; Stage (stratigraphy); Malignant pleural effusion; Pleural effusion; Surgery; Radiation therapy; Lung cancer; Chemotherapy; Gastroenterology; Oncology","score_opus":0.01961926060097893,"score_gpt":0.3901935571364993,"score_spread":0.3705742965355204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089494879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95513034,0.023223318,0.01541974,0.00018834644,0.0020051894,0.00385143,0.000103203376,0.000018558432,0.000059864607],"genre_scores_gemma":[0.9919097,0.003743705,0.0012874069,0.0000776515,0.00012616834,0.00007973805,0.000044842003,0.00006316442,0.0026676152],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9916626,0.0032663685,0.0037294966,0.00042479308,0.000177321,0.00073941675],"domain_scores_gemma":[0.9871303,0.0055166245,0.0053313766,0.0005430633,0.0014087103,0.000069945054],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0064336355,0.0005870219,0.0065058325,0.0016191679,0.00021036057,0.000017890561,0.0007748052,0.00061774766,0.0013924272],"category_scores_gemma":[0.00037520935,0.00039346036,0.0019143141,0.0010154162,0.00028869446,0.00018851242,0.00007765721,0.00079364347,0.0000034539805],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5682683,0.008477141,0.00041215666,0.000041214607,0.021953775,0.00004163141,0.004105386,0.00012289737,0.37278324,0.0000024346891,0.00019087427,0.02360091],"study_design_scores_gemma":[0.74084,0.008354505,0.002650269,0.0001458543,0.009299592,0.000059944792,0.009639956,0.00020204703,0.22590569,0.0000054369625,0.0024788447,0.0004178178],"about_ca_topic_score_codex":0.00022133635,"about_ca_topic_score_gemma":0.0003363617,"teacher_disagreement_score":0.17257172,"about_ca_system_score_codex":0.00030462627,"about_ca_system_score_gemma":0.00082026183,"threshold_uncertainty_score":0.9998517},"labels":[],"label_agreement":null},{"id":"W2091246083","doi":"10.1097/jto.0000000000000220","title":"Future Directions in Palliative Radiotherapy for Malignant Airway Obstruction Requiring Mechanical Ventilation","year":2014,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Radiation therapy; Guideline; Palliative care; Lung cancer; Scopus; Radiation oncologist; MEDLINE; Oncology; Internal medicine; Pathology; Nursing","score_opus":0.032982294402515634,"score_gpt":0.40889190886354226,"score_spread":0.3759096144610266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091246083","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014822962,0.004399354,0.0049703377,0.9655649,0.008846555,0.0011438712,0.000019939836,0.000022927457,0.00020912156],"genre_scores_gemma":[0.11335937,0.03150124,0.11395466,0.55676985,0.17910372,0.0010082794,0.00057660916,0.00049709954,0.0032291806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99817634,0.0002746524,0.00076173357,0.00025414236,0.00027482235,0.00025831012],"domain_scores_gemma":[0.998028,0.0003748993,0.0010693574,0.00017824564,0.00027782194,0.00007168782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063406146,0.0002230369,0.0009679044,0.0003880794,0.00007012273,0.000015980157,0.00009300778,0.0008631343,0.00007395815],"category_scores_gemma":[0.0000725536,0.00016816401,0.00041077763,0.00014673312,0.000035194396,0.000079852354,0.000010611127,0.0013363026,0.0000024040978],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00528549,0.0006745896,0.0019067195,0.00097356085,0.001712278,0.0012639283,0.00070601667,0.000061265586,0.00056103425,0.000095416384,0.6471786,0.3395811],"study_design_scores_gemma":[0.0017827218,0.003362156,0.0026417032,0.00091835525,0.000870802,0.00072042254,0.00006200311,0.000087853274,0.00094373355,0.0005199518,0.987947,0.00014331716],"about_ca_topic_score_codex":0.0000104758565,"about_ca_topic_score_gemma":0.000039953462,"teacher_disagreement_score":0.4087951,"about_ca_system_score_codex":0.003304808,"about_ca_system_score_gemma":0.00033733636,"threshold_uncertainty_score":0.86419576},"labels":[],"label_agreement":null},{"id":"W2091596054","doi":"10.1097/jto.0000000000000042","title":"Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":404,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Proportional hazards model; Gene signature; Lung cancer; Confidence interval; Stage (stratigraphy); Survival analysis; Adenocarcinoma; Log-rank test; Carcinoma; Cancer; Gene expression; Gene; Biology","score_opus":0.026061796208071118,"score_gpt":0.3939454826504968,"score_spread":0.36788368644242564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091596054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933112,0.001800149,0.00062072143,0.0012608527,0.0009450362,0.0016674199,0.00004595509,0.000007989188,0.00034062465],"genre_scores_gemma":[0.99290943,0.00029681888,0.004651883,0.00024052843,0.00025764832,0.00023502645,0.00002658169,0.000030951476,0.001351137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983147,0.00010667043,0.0007469837,0.0002234004,0.00031210526,0.00029618767],"domain_scores_gemma":[0.9970524,0.00027271826,0.0013091924,0.00017536941,0.00100672,0.00018361655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037877593,0.00019269716,0.00071502855,0.00023516153,0.00007011899,0.000013993778,0.00013837808,0.0002680188,0.00033567948],"category_scores_gemma":[0.00013020886,0.00014501796,0.00022745306,0.00012940986,0.000048505957,0.00014433845,0.00005876228,0.00033980468,0.000004674845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016415068,0.0029651888,0.93599623,0.0015328549,0.000933001,0.00012813431,0.0012184803,0.0003694544,0.014502659,0.000007355953,0.007300922,0.03340423],"study_design_scores_gemma":[0.012187544,0.013745468,0.7360354,0.0012672319,0.00465993,0.00008470304,0.00038542395,0.00057505484,0.22351582,0.00009477069,0.0070246663,0.00042400972],"about_ca_topic_score_codex":0.0002049909,"about_ca_topic_score_gemma":0.00006224559,"teacher_disagreement_score":0.20901316,"about_ca_system_score_codex":0.0015839452,"about_ca_system_score_gemma":0.00067678955,"threshold_uncertainty_score":0.59136605},"labels":[],"label_agreement":null},{"id":"W2092137529","doi":"10.1097/jto.0b013e3181d40a1b","title":"The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University; University Health Network","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Lung cancer; Cancer; Adverse effect; Confidence interval; Clinical trial; Chemotherapy; Oncology","score_opus":0.08061870314447525,"score_gpt":0.5216139087608775,"score_spread":0.44099520561640226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092137529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962169,0.00087492756,0.000007865936,0.001132185,0.0007879426,0.00070385245,0.0001413166,9.299407e-7,0.00013408042],"genre_scores_gemma":[0.99560225,0.0032969501,0.000552049,0.00018546672,0.00022002478,0.000026857913,0.0000035462951,0.000008079013,0.00010477801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960063,0.00076585653,0.0026133172,0.00013477544,0.00034722683,0.00013248762],"domain_scores_gemma":[0.992224,0.00332477,0.003597047,0.0001510226,0.0005756646,0.00012752543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005787267,0.0001343657,0.0016452182,0.00012562018,0.000034086213,0.0000012380167,0.0001171284,0.00014979093,0.00003642633],"category_scores_gemma":[0.001610912,0.0000786562,0.00025983062,0.00013533734,0.00018089176,0.000057808265,0.000016169397,0.00024479756,4.157682e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036892723,0.0045711375,0.73703533,0.0007007952,0.0048154704,0.000028357883,0.0024346223,0.0071064974,0.056521807,0.000110110035,0.0009431286,0.14884003],"study_design_scores_gemma":[0.020345304,0.0033871937,0.9583279,0.00047277563,0.0012241419,0.000009742382,0.00040751984,0.000109730754,0.0111819,0.000059173875,0.0043602968,0.00011430998],"about_ca_topic_score_codex":0.07211282,"about_ca_topic_score_gemma":0.15932341,"teacher_disagreement_score":0.22129259,"about_ca_system_score_codex":0.00064900547,"about_ca_system_score_gemma":0.0114496425,"threshold_uncertainty_score":0.9941545},"labels":[],"label_agreement":null},{"id":"W2093581148","doi":"10.1097/jto.0b013e3182178ef7","title":"Using Laser Raman Spectroscopy to Reduce False Positives of Autofluorescence Bronchoscopies: A Pilot Study","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Autofluorescence; Medicine; False positive paradox; Raman spectroscopy; Bronchoscopy; Pathology; Nuclear medicine; Radiology; Optics; Fluorescence; Artificial intelligence","score_opus":0.10355623787526433,"score_gpt":0.48341742685445255,"score_spread":0.3798611889791882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093581148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649435,0.0003718774,0.00041827423,0.00048230728,0.00033988451,0.00073823595,0.000006257644,0.00001385583,0.0011349443],"genre_scores_gemma":[0.97248214,0.00010304609,0.026778912,0.00017285894,0.0001984146,0.000007608763,2.911716e-7,0.000024812818,0.0002319338],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977385,0.0004192047,0.00074886996,0.0002182359,0.0004861413,0.00038908783],"domain_scores_gemma":[0.99811876,0.00019301461,0.00054721354,0.0002964188,0.00055952894,0.00028503823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012383449,0.00019146451,0.0009480206,0.00040721873,0.000092319635,0.0000106883645,0.00031594417,0.000058312646,0.00015377812],"category_scores_gemma":[0.00050406856,0.00014577605,0.000113178845,0.00036663905,0.00024563586,0.00013885793,0.0001498492,0.00050799845,0.000006533093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021892438,0.0051199743,0.006935528,0.00009227433,0.00073110656,0.0008887869,0.00961593,0.000007644159,0.9500017,0.000007787448,0.0005138775,0.0041929106],"study_design_scores_gemma":[0.0035096863,0.14283721,0.21005148,0.0009460461,0.0007068802,0.001217326,0.012233303,0.000052990647,0.6274048,0.00039013982,0.0003674226,0.00028270547],"about_ca_topic_score_codex":0.00023908357,"about_ca_topic_score_gemma":0.000068775706,"teacher_disagreement_score":0.32259694,"about_ca_system_score_codex":0.00050895393,"about_ca_system_score_gemma":0.0006362672,"threshold_uncertainty_score":0.5944575},"labels":[],"label_agreement":null},{"id":"W2093742457","doi":"10.1097/jto.0000000000000524","title":"Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non–Small-Cell Lung Cancer: CEPO Review and Recommendations","year":2015,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Montreal General Hospital; Hôpital Maisonneuve-Rosemont; Hôpital Notre-Dame; Institut National d'Excellence en Santé et en Services Sociaux; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; SABR volatility model; Radiation therapy; Lung cancer; Stage (stratigraphy); Guideline; Cancer; Ablative case; Surgery; Oncology; Internal medicine","score_opus":0.0915831223192649,"score_gpt":0.5009766301833591,"score_spread":0.40939350786409423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093742457","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021740359,0.9905348,0.000031489883,0.004231395,0.00058357103,0.004105445,0.0001487074,0.0000034821132,0.00014373419],"genre_scores_gemma":[0.0000765078,0.99717164,0.00055175123,0.00021490095,0.00037609416,0.00074729056,0.000038832575,0.000037258444,0.0007856952],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808437,0.00032977227,0.0010428304,0.00020453623,0.00015805435,0.00018043237],"domain_scores_gemma":[0.99535406,0.0011056542,0.0026759575,0.00027135262,0.00044436543,0.00014861148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007031128,0.00031115653,0.0026389412,0.00015950885,0.000072421164,0.0000140606,0.00011665563,0.00018804154,0.000101326754],"category_scores_gemma":[0.00003594204,0.00015782457,0.0005928742,0.00018020993,0.00005091812,0.00006862244,0.000014172561,0.0002292332,0.0000013145883],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022058071,0.00080776453,0.00026947237,0.013584172,0.0031910948,0.000017889077,0.0004738513,6.8306497e-7,1.3607269e-7,0.000002455745,0.00510634,0.9763256],"study_design_scores_gemma":[0.0017110142,0.007674121,0.00016392519,0.0119985165,0.027097534,0.00011961013,0.000045999233,0.000006275854,0.000007453569,0.0000048602883,0.9510603,0.00011037425],"about_ca_topic_score_codex":0.0000784165,"about_ca_topic_score_gemma":0.000033649838,"teacher_disagreement_score":0.9762152,"about_ca_system_score_codex":0.002361712,"about_ca_system_score_gemma":0.0019907795,"threshold_uncertainty_score":0.6435899},"labels":[],"label_agreement":null},{"id":"W2094875114","doi":"10.1097/jto.0b013e3181a52c3f","title":"Spontaneous Pneumothorax and Lung Carcinoma: Should One Consider Synchronous Malignant Pleural Mesothelioma?","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Hydropneumothorax; Mesothelioma; Pneumothorax; Lung; Asbestos; Carcinoma; Radiology; Concomitant; Lung cancer; Asbestosis; Pathology; Internal medicine","score_opus":0.0285180404540852,"score_gpt":0.3684911453810118,"score_spread":0.3399731049269266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094875114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825865,0.0041162455,0.000049678543,0.011312039,0.00019879483,0.00017613854,0.000013620789,0.000013939166,0.0015330327],"genre_scores_gemma":[0.9930989,0.00018295924,0.002669128,0.0033524083,0.00028085866,0.0000015301764,0.0000068385493,0.0000151220365,0.00039225598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986289,0.000109420864,0.0005014809,0.00017489369,0.00033472554,0.000250546],"domain_scores_gemma":[0.99896187,0.00018981184,0.00030529665,0.00013568717,0.00007667542,0.0003306703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002704099,0.0001702466,0.0005611193,0.00017649098,0.00007398641,0.000014717311,0.00008043138,0.00013809634,0.0002907026],"category_scores_gemma":[0.0001031678,0.00013119288,0.00014166442,0.00008249682,0.00014058966,0.00010919787,0.00003198379,0.0002845219,0.000015424514],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029898828,0.0073047024,0.23777051,0.0006301672,0.001168555,0.15509485,0.0013159825,0.00016976686,0.16664289,0.00090956764,0.017139537,0.38195464],"study_design_scores_gemma":[0.0015502757,0.006890341,0.86111677,0.00021636089,0.0013177928,0.11936745,0.00029209265,0.00029157224,0.0029070869,0.001223722,0.004570493,0.00025605038],"about_ca_topic_score_codex":0.000009765474,"about_ca_topic_score_gemma":0.000005347852,"teacher_disagreement_score":0.62334627,"about_ca_system_score_codex":0.00035717746,"about_ca_system_score_gemma":0.00023505234,"threshold_uncertainty_score":0.53498906},"labels":[],"label_agreement":null},{"id":"W2100911552","doi":"10.1097/jto.0000000000000290","title":"The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Stage (stratigraphy); Pathology","score_opus":0.07762067339217371,"score_gpt":0.4031608989327712,"score_spread":0.32554022554059747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100911552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9244877,0.00024394914,0.056638908,0.013119624,0.0014930756,0.0038295083,0.000073475436,0.000020406205,0.00009335319],"genre_scores_gemma":[0.99529433,0.000026619951,0.003266009,0.00009145553,0.0009927383,0.00018472908,0.000010541436,0.000035581645,0.00009799385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967372,0.00074556016,0.0014208634,0.00023148843,0.00055119727,0.00031372264],"domain_scores_gemma":[0.99277437,0.0021288856,0.003334128,0.00056004536,0.0011216394,0.00008093732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068293624,0.00019627457,0.00062831596,0.00018138746,0.00042517218,0.00003709686,0.0005329825,0.0001467688,0.0000030077833],"category_scores_gemma":[0.0012489713,0.000091546404,0.00039701542,0.00024711184,0.00031216393,0.00021493991,0.00003350942,0.00033644852,4.780943e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02302514,0.0010454383,0.01308608,0.0045555113,0.00044473194,0.000007862894,0.0031275074,0.00046408773,0.61487085,0.049679123,0.0013783836,0.28831527],"study_design_scores_gemma":[0.008586822,0.027820382,0.23664166,0.012376905,0.003885171,0.00093750947,0.052245464,0.2982362,0.33243865,0.0042355685,0.02186088,0.0007348149],"about_ca_topic_score_codex":0.00003855931,"about_ca_topic_score_gemma":0.00006541935,"teacher_disagreement_score":0.29777208,"about_ca_system_score_codex":0.00035750025,"about_ca_system_score_gemma":0.0018111657,"threshold_uncertainty_score":0.3733154},"labels":[],"label_agreement":null},{"id":"W2100917720","doi":"10.1097/jto.0b013e31825cca1c","title":"Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Erlotinib; Medicine; Sunitinib; Internal medicine; Adverse effect; Lung cancer; Rash; Pharmacokinetics; Oncology; Pharmacology; Cmax; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.0495951457264359,"score_gpt":0.4846970472410096,"score_spread":0.4351019015145737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100917720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825653,0.011562173,0.00047308358,0.001471054,0.0008736537,0.0023582615,0.000025883248,0.0000047602266,0.0006658657],"genre_scores_gemma":[0.991742,0.0012265356,0.0047852006,0.00013068103,0.00036439736,0.00033861093,0.0000039722154,0.00002345213,0.001385145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986813,0.00011472167,0.0006286584,0.00010765725,0.00016513583,0.00030250443],"domain_scores_gemma":[0.99820894,0.0006187427,0.00062831165,0.00018085702,0.0002389354,0.00012421705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045487258,0.00015773471,0.00070102455,0.00017878869,0.00006828435,0.000005499658,0.0001018699,0.0000490771,0.00005514073],"category_scores_gemma":[0.0000451915,0.000090237234,0.00019815545,0.00018624833,0.000048724578,0.000093735616,0.000011330644,0.0001348166,0.0000016090135],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009750026,0.025542151,0.1767325,0.0006029936,0.0034149978,0.0003164474,0.05747361,0.0024995178,0.0018205228,0.000026145335,0.0012389631,0.7205821],"study_design_scores_gemma":[0.10508416,0.12864353,0.3805861,0.0013427988,0.050084945,0.0015370041,0.16389798,0.0033665835,0.014605731,0.00014234443,0.1498417,0.0008671628],"about_ca_topic_score_codex":0.00012820092,"about_ca_topic_score_gemma":0.00028752442,"teacher_disagreement_score":0.71971494,"about_ca_system_score_codex":0.0010540393,"about_ca_system_score_gemma":0.0009457974,"threshold_uncertainty_score":0.36797678},"labels":[],"label_agreement":null},{"id":"W2120170192","doi":"10.1097/jto.0b013e3181d8fe80","title":"Primary Sarcoma of the Mediastinum: A Report of 16 Cases Referred to the British Columbia Cancer Agency","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Mediastinum; Sarcoma; Cohort; Surgery; Cancer; Localized disease; Stage (stratigraphy); Cancer registry; Internal medicine; Pathology","score_opus":0.03361500099042513,"score_gpt":0.393201025165745,"score_spread":0.3595860241753199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120170192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98452955,0.0019433688,0.000003772972,0.009509898,0.0015924575,0.00037957265,0.000027571305,0.000004095911,0.002009725],"genre_scores_gemma":[0.9962146,0.00028712914,0.0011140159,0.0008431218,0.0004763904,0.000028774475,0.0000023545206,0.000015472675,0.0010181145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998201,0.00016349177,0.0008822792,0.00013588606,0.00043420983,0.00018310535],"domain_scores_gemma":[0.9973058,0.00047925196,0.0011363712,0.00040445026,0.00053156685,0.00014254307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008752503,0.00009156231,0.000652367,0.00004839652,0.00010954773,0.000023109067,0.0002618356,0.0001265051,0.0004932957],"category_scores_gemma":[0.0010536751,0.00006330093,0.0002795538,0.00024159238,0.00017522278,0.00004133173,0.00010192309,0.00043135617,0.0000016857223],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005157456,0.0015484745,0.40969032,0.00009216396,0.00038180177,0.0063291667,0.0004695,0.0000023964274,0.0069390084,0.0000025001727,0.1009133,0.47311562],"study_design_scores_gemma":[0.00063562015,0.0010639935,0.8950095,0.0003507362,0.000650309,0.037540972,0.00016122956,9.5355756e-7,0.0023783597,0.00009858214,0.062051553,0.000058165864],"about_ca_topic_score_codex":0.007417708,"about_ca_topic_score_gemma":0.07265463,"teacher_disagreement_score":0.4853192,"about_ca_system_score_codex":0.0002176135,"about_ca_system_score_gemma":0.0010948174,"threshold_uncertainty_score":0.999192},"labels":[],"label_agreement":null},{"id":"W2120326191","doi":"10.1097/jto.0000000000000115","title":"An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Anaplastic lymphoma kinase; Immunohistochemistry; Medicine; Concordance; Fluorescence in situ hybridization; Crizotinib; Lung cancer; Fish <Actinopterygii>; Pathology; Companion diagnostic; Cancer; Oncology; Internal medicine; Biology; Gene","score_opus":0.022543182242455412,"score_gpt":0.4662150926820093,"score_spread":0.4436719104395539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120326191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085003,0.000098549914,0.0063893083,0.0017336621,0.00032079875,0.00039908115,0.000018837698,0.00001031413,0.00017943178],"genre_scores_gemma":[0.9973381,0.000066356595,0.0017126271,0.0002488621,0.00058760785,0.0000046189,0.000014521819,0.000014960984,0.000012327385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851084,0.00044795912,0.00044582842,0.00021623012,0.00023813339,0.00014100465],"domain_scores_gemma":[0.9984347,0.00045252807,0.00051186455,0.00010791234,0.00034809954,0.00014486017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092110294,0.00015273363,0.0004481084,0.00017430611,0.0001795176,0.00006606301,0.00006542813,0.00009900881,0.0000046772325],"category_scores_gemma":[0.0001552813,0.0001060165,0.00004065774,0.00010266551,0.00018330352,0.0003611511,0.00003812412,0.00028062452,3.5094746e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006670067,0.00019022322,0.5694793,0.000028412403,0.0011023415,0.000057669648,0.003889807,0.000035671972,0.006709842,0.0000128318425,0.00001659256,0.41781035],"study_design_scores_gemma":[0.0024407334,0.0057660104,0.97645706,0.00015568896,0.0029541224,0.0008536696,0.0045463974,0.0037407621,0.0019012188,0.00037256855,0.0006745546,0.00013720519],"about_ca_topic_score_codex":0.00016342232,"about_ca_topic_score_gemma":0.00012690134,"teacher_disagreement_score":0.41767314,"about_ca_system_score_codex":0.00022418109,"about_ca_system_score_gemma":0.00018479677,"threshold_uncertainty_score":0.43232277},"labels":[],"label_agreement":null},{"id":"W2122190388","doi":"10.1097/jto.0000000000000667","title":"The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials","year":2015,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Oncology; Lung cancer; Clinical trial; Internal medicine; Chemotherapy; Performance status; Overall survival; Cisplatin","score_opus":0.09060818567827861,"score_gpt":0.5530540261727904,"score_spread":0.4624458404945118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122190388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0750095,0.91986173,0.000059587426,0.00083796895,0.0019489765,0.0018916948,0.000042844098,0.0000031978232,0.00034451068],"genre_scores_gemma":[0.018294469,0.98024726,0.00032259506,0.00006564575,0.0005820952,0.00006460397,0.0000030979884,0.000035304936,0.0003849115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944754,0.0015486006,0.0031339042,0.00021059714,0.0004041502,0.00022733286],"domain_scores_gemma":[0.9896361,0.0027432689,0.0063588326,0.0004212306,0.0007232115,0.000117326665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076286034,0.0002676385,0.0033679802,0.00019520757,0.00006314388,0.000006978665,0.00040581182,0.00040781233,0.000009976246],"category_scores_gemma":[0.0016156975,0.00012380882,0.00089533394,0.00039887134,0.00016309197,0.000060468068,0.000054739336,0.00095902133,8.057354e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014663052,0.0006026217,0.002631014,0.0035882113,0.0006790421,0.000016368816,0.00020857622,0.00050360645,0.000018030465,0.0000071383542,0.00016096854,0.99011815],"study_design_scores_gemma":[0.013171445,0.009185555,0.013273549,0.048360206,0.017898615,0.00017625009,0.0007383993,0.00020191178,0.00006764485,0.00013231022,0.89637303,0.0004210937],"about_ca_topic_score_codex":0.00018353738,"about_ca_topic_score_gemma":0.00037365913,"teacher_disagreement_score":0.98969704,"about_ca_system_score_codex":0.0022905068,"about_ca_system_score_gemma":0.0075665032,"threshold_uncertainty_score":0.9980597},"labels":[],"label_agreement":null},{"id":"W2129527916","doi":"10.1097/01.jto.0000263720.15062.51","title":"Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Hamilton Health Sciences; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Topotecan; Carboplatin; Internal medicine; Randomized controlled trial; Vincristine; Oncology; Lung cancer; Guideline; Chemotherapy; Cyclophosphamide; Surgery; Cisplatin; Pathology","score_opus":0.10232241946579926,"score_gpt":0.576323181801895,"score_spread":0.4740007623360958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129527916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.0434256e-7,0.9789378,0.00073633384,0.011595373,0.00048154488,0.007164213,0.000025952424,0.000014160058,0.0010443219],"genre_scores_gemma":[9.8034725e-8,0.96984667,0.020853622,0.0058874995,0.00095765805,0.00040196817,0.000009937261,0.000090882444,0.001951668],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99446815,0.0010198936,0.0031820214,0.00034007846,0.0005059899,0.0004838463],"domain_scores_gemma":[0.98759633,0.0044746706,0.005103148,0.0004266282,0.002070161,0.00032903036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010550305,0.0004766721,0.008196913,0.00044489995,0.000085291,0.000021998121,0.00035141406,0.00045204093,0.000049169463],"category_scores_gemma":[0.0070799333,0.0002943296,0.00088537496,0.00041543352,0.00011382481,0.00010330454,0.00009723024,0.0012410249,0.000003885267],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041937962,0.00013649091,4.198086e-7,0.6843728,0.0018835863,0.00023809074,0.000064551576,5.4039454e-8,7.756171e-7,0.0000019179233,0.054999802,0.25788215],"study_design_scores_gemma":[0.0006136263,0.001093159,8.7032404e-8,0.35914844,0.040667705,0.004102558,0.000053060336,0.0000022979305,9.169513e-7,0.0000032561134,0.59418166,0.00013322063],"about_ca_topic_score_codex":0.000013053214,"about_ca_topic_score_gemma":0.000009774541,"teacher_disagreement_score":0.5391819,"about_ca_system_score_codex":0.0020842922,"about_ca_system_score_gemma":0.0036568407,"threshold_uncertainty_score":0.9999509},"labels":[],"label_agreement":null},{"id":"W2136132386","doi":"10.1097/jto.0b013e3181d6e052","title":"Stage I Non-small Cell Lung Cancer (NSCLC) in Patients Aged 75 Years and Older: Does Age Determine Survival After Radical Treatment?","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Stage (stratigraphy); Proportional hazards model; Internal medicine; Multivariate analysis; Radiation therapy; Lung cancer; Population; Oncology; Cancer; Disease; Performance status; Surgery","score_opus":0.011030344497568453,"score_gpt":0.3543189988032303,"score_spread":0.34328865430566186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136132386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967029,0.0005771475,0.000004174931,0.0006578376,0.0012854099,0.0004496185,0.000025960504,0.0000060442003,0.000290874],"genre_scores_gemma":[0.9964681,0.00091773656,0.0010742081,0.0002476599,0.000397742,0.000053852727,0.000005791486,0.000026875703,0.0008080108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866444,0.00011424322,0.00048710834,0.0002274195,0.00021206711,0.00029473344],"domain_scores_gemma":[0.9989947,0.00016130482,0.00031138468,0.00018387726,0.00007431201,0.0002744003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002781675,0.00020000707,0.00069502887,0.00016453113,0.000029342344,0.000020667718,0.0000832655,0.00017504318,0.0003002754],"category_scores_gemma":[0.000026107373,0.00012621042,0.00014258828,0.00009019872,0.00009810443,0.00008252213,0.000040141804,0.0004393193,0.0000027360165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018270285,0.0018513815,0.9257097,0.000114109906,0.0001664902,0.0032528827,0.0010015005,0.00000118918,0.0007628504,5.4008905e-7,0.00019192311,0.065120384],"study_design_scores_gemma":[0.0076956847,0.002318338,0.98249245,0.00022287054,0.00057292986,0.000042657754,0.00006810337,0.000013986443,0.001703048,0.0000052485207,0.0047393935,0.00012531996],"about_ca_topic_score_codex":0.00025284776,"about_ca_topic_score_gemma":0.0032529954,"teacher_disagreement_score":0.06499506,"about_ca_system_score_codex":0.000691771,"about_ca_system_score_gemma":0.00032519223,"threshold_uncertainty_score":0.51467115},"labels":[],"label_agreement":null},{"id":"W2140508852","doi":"10.1097/jto.0000000000000225","title":"Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Pemetrexed; Medicine; Docetaxel; Erlotinib; Lung cancer; Internal medicine; Chemotherapy; Oncology; Population; Retrospective cohort study; Cancer; Erlotinib Hydrochloride; Performance status; Surgery; Epidermal growth factor receptor; Cisplatin","score_opus":0.014809590185107559,"score_gpt":0.4152750910974777,"score_spread":0.4004655009123701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140508852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540443,0.00830596,0.0002646541,0.0043475092,0.00022978189,0.00067778816,0.000013428974,0.000006543172,0.0007499183],"genre_scores_gemma":[0.9800171,0.0077194492,0.010157013,0.0014523694,0.00019731456,0.00003198915,0.00001328332,0.000032396718,0.00037905734],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99844825,0.00008804146,0.0009024032,0.00016988147,0.00021605044,0.00017536551],"domain_scores_gemma":[0.9977997,0.00010237642,0.0013042524,0.00021049881,0.0004952638,0.00008791723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005030432,0.0001648041,0.0010414782,0.00020086413,0.000019282455,0.0000031394318,0.00012487061,0.00012398891,0.00009582283],"category_scores_gemma":[0.00009768616,0.00012561984,0.00021409805,0.00027654663,0.000041700565,0.00007057044,0.000008400244,0.0002017822,8.041347e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068675634,0.0033400827,0.21698122,0.0067438595,0.0011114542,0.000040717165,0.0015347892,0.00065415393,0.09471821,0.000048114252,0.0017410215,0.6662188],"study_design_scores_gemma":[0.021907568,0.010161903,0.8806522,0.010683144,0.0026258007,0.000068994734,0.00074089406,0.0019050795,0.05816352,0.0002761503,0.012369177,0.00044556064],"about_ca_topic_score_codex":0.00019221327,"about_ca_topic_score_gemma":0.00014777198,"teacher_disagreement_score":0.6657733,"about_ca_system_score_codex":0.00058977783,"about_ca_system_score_gemma":0.00068720896,"threshold_uncertainty_score":0.5122628},"labels":[],"label_agreement":null},{"id":"W2143450809","doi":"10.1097/jto.0b013e3181a52370","title":"The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project","year":2009,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"International Association for the Study of Lung Cancer; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Cancer; Lung cancer staging; Prospective cohort study; Cancer staging; Oncology; Internal medicine; Radiology","score_opus":0.1319517946465685,"score_gpt":0.5728973128518954,"score_spread":0.4409455182053269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143450809","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000072171633,0.9862427,0.000066387336,0.004316159,0.0015569379,0.0070465854,0.00022775457,0.000012112222,0.00052412646],"genre_scores_gemma":[0.000020481415,0.9937019,0.0013094993,0.00029588552,0.0024837053,0.001110456,0.00005545281,0.000057672343,0.00096499594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689776,0.00034309202,0.001342822,0.00043292344,0.0004918146,0.0004915769],"domain_scores_gemma":[0.99444586,0.0015504407,0.0025239943,0.00091826584,0.00047803836,0.00008342719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024756717,0.00041955945,0.002076852,0.00019697963,0.00037525815,0.000088161854,0.0009825688,0.00023593205,0.000017978795],"category_scores_gemma":[0.00035433832,0.00017132082,0.0006212036,0.00036980567,0.00010827105,0.0001349591,0.00020150692,0.0009358463,0.0000018524481],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004456411,0.00033853686,0.00022102075,0.004072095,0.003660371,0.0000977628,0.00018583599,4.1429513e-7,4.6656755e-8,0.000020869373,0.08841703,0.9025404],"study_design_scores_gemma":[0.0008573803,0.0016828958,0.00009467435,0.011567855,0.018434778,0.0005257432,0.00020274974,0.000049969898,0.0000013325184,0.000027324131,0.9663994,0.00015591593],"about_ca_topic_score_codex":0.00008261482,"about_ca_topic_score_gemma":0.00019490176,"teacher_disagreement_score":0.90238446,"about_ca_system_score_codex":0.0037417,"about_ca_system_score_gemma":0.0081775235,"threshold_uncertainty_score":0.99744517},"labels":[],"label_agreement":null},{"id":"W2149783480","doi":"10.1097/jto.0b013e3181651c0e","title":"Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University; Hamilton Regional Laboratory Medicine Program; McGill University Health Centre","funders":"Cancer Research UK","keywords":"Medicine; Zoledronic acid; Internal medicine; Lung cancer; Placebo; Oncology; Creatinine; Bone metastasis; Relative risk; Proportional hazards model; Gastroenterology; Cancer; Surgery; Prostate cancer; Pathology; Confidence interval","score_opus":0.017692576209447343,"score_gpt":0.3649551179157881,"score_spread":0.34726254170634074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149783480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968694,0.001921508,0.000012429523,0.0007549798,0.00011194272,0.00026585237,0.000041340372,0.0000027898877,0.000019786501],"genre_scores_gemma":[0.9987549,0.0005229097,0.00056879077,0.00008028413,0.000018407545,0.0000054542384,0.000006477821,0.000011427008,0.000031316667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989352,0.00017932599,0.00035025965,0.00012754604,0.00022012835,0.00018749823],"domain_scores_gemma":[0.9988778,0.00013735353,0.00044944583,0.00008825015,0.00012593792,0.00032121319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020490673,0.00011778295,0.00063154596,0.00014945716,0.000035651698,0.0000021461203,0.000026451433,0.00005343903,0.000029186542],"category_scores_gemma":[0.000065374734,0.000082096754,0.00003400991,0.00012358661,0.00012295118,0.000117868105,0.000020569114,0.00024884363,2.8406762e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029727317,0.0007485067,0.94855285,0.00015233541,0.00026456875,0.0006207116,0.00016933412,0.000003713168,0.00015316613,2.9929072e-7,0.000034081706,0.019573122],"study_design_scores_gemma":[0.007185749,0.0021912458,0.98929876,0.00022487511,0.00059604726,0.00007748164,0.00004191551,0.00010346393,0.00017080958,0.000010597585,0.000039364902,0.000059705417],"about_ca_topic_score_codex":0.00029884608,"about_ca_topic_score_gemma":0.0003544374,"teacher_disagreement_score":0.040745903,"about_ca_system_score_codex":0.00024265432,"about_ca_system_score_gemma":0.00071886386,"threshold_uncertainty_score":0.33478084},"labels":[],"label_agreement":null},{"id":"W2156728903","doi":"10.1097/jto.0b013e3181f7c6d4","title":"Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Pemetrexed; Medicine; Histology; Gemcitabine; Internal medicine; Lung cancer; Oncology; Docetaxel; Chemotherapy; Hazard ratio; Proportional hazards model; Cisplatin; Confidence interval","score_opus":0.0683959621102853,"score_gpt":0.5275235590163642,"score_spread":0.45912759690607885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156728903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926476,0.0025486199,0.0003214367,0.0015775394,0.0013287471,0.0006062406,0.000040015013,0.0000050652097,0.0009247318],"genre_scores_gemma":[0.9970431,0.0005713814,0.0017352311,0.00007665789,0.00023333795,0.000053451415,0.000018778393,0.000016319795,0.00025173964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978505,0.00027242748,0.001287214,0.000199734,0.00014843685,0.00024169189],"domain_scores_gemma":[0.9978722,0.0005081821,0.0010647983,0.00018607493,0.00023152312,0.0001372265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066662556,0.00019442322,0.0015685734,0.0007345411,0.000032977452,0.0000071126137,0.00010720049,0.00024683593,0.00039011711],"category_scores_gemma":[0.00022765047,0.00013968119,0.00028454076,0.00034631634,0.00008559942,0.00014248087,0.00001726668,0.0005084901,0.000001464319],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01419927,0.009389041,0.20492463,0.00016853574,0.001000504,0.0010984418,0.003787937,0.00013684442,0.5287613,0.000006509619,0.00076100294,0.23576598],"study_design_scores_gemma":[0.2182502,0.049915664,0.26143888,0.0011273652,0.028206913,0.003729186,0.010094949,0.008759389,0.38501233,0.0003327249,0.03182441,0.0013079806],"about_ca_topic_score_codex":0.0034765068,"about_ca_topic_score_gemma":0.023345979,"teacher_disagreement_score":0.234458,"about_ca_system_score_codex":0.0012768331,"about_ca_system_score_gemma":0.0013051754,"threshold_uncertainty_score":0.9944754},"labels":[],"label_agreement":null},{"id":"W2166070477","doi":"10.1097/jto.0b013e31827ed0ff","title":"Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012","year":2013,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cetuximab; Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Chemotherapy; Cancer; Internal medicine; Targeted therapy; Tyrosine kinase; Cancer research; Receptor; Colorectal cancer","score_opus":0.04816229289077918,"score_gpt":0.4939762288443586,"score_spread":0.44581393595357943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166070477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010750702,0.9938644,0.00003766349,0.0011647359,0.0017725581,0.0010267813,0.00012900266,0.000011368962,0.0009184268],"genre_scores_gemma":[0.00016787167,0.9954448,0.0015564893,0.00018151643,0.0010274439,0.00014344382,0.00009550943,0.000052170628,0.0013307641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99734354,0.00038310105,0.0013468128,0.00022499064,0.00027786713,0.00042366696],"domain_scores_gemma":[0.9971871,0.00025348781,0.0016913773,0.00015841346,0.00037934812,0.0003303107],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002858787,0.0003361088,0.0024289833,0.00066983927,0.00004454043,0.00001947355,0.000080840015,0.0005003737,0.0016899946],"category_scores_gemma":[0.00013639267,0.00022562906,0.0005114521,0.00033094385,0.00005946382,0.0003236521,0.000037286634,0.0009845785,0.0000612232],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009895425,0.00034102818,0.00032594064,0.007558758,0.00069396436,0.00037956,0.00022618964,8.8092736e-7,0.000005725283,0.000011307403,0.01893767,0.97142005],"study_design_scores_gemma":[0.00079495553,0.0007032085,0.00033461608,0.0129251825,0.0037714317,0.0009147392,0.00005310065,0.0000021190742,0.0000095625355,0.00002156673,0.9802884,0.00018115607],"about_ca_topic_score_codex":0.00017007916,"about_ca_topic_score_gemma":0.000051733296,"teacher_disagreement_score":0.97123885,"about_ca_system_score_codex":0.004016426,"about_ca_system_score_gemma":0.004107997,"threshold_uncertainty_score":0.999807},"labels":[],"label_agreement":null},{"id":"W2199876520","doi":"10.1097/01.jto.0000282945.52286.f4","title":"M06-04: Genomic signatures of prognosis in early stage non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Internal medicine; Oncology; Cancer; Population; non-small cell lung cancer (NSCLC); Disease","score_opus":0.01715326802040467,"score_gpt":0.38859351971222217,"score_spread":0.3714402516918175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199876520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964906,0.006385452,0.000068809,0.0011967341,0.0005402884,0.00044700943,0.00001000029,0.000004902824,0.0016977254],"genre_scores_gemma":[0.9951324,0.0012062044,0.002608068,0.0002836543,0.00036320713,0.000018546205,0.0000015209217,0.000023265247,0.0003631721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984351,0.0000717968,0.0007668159,0.00016786031,0.00023797686,0.00032048815],"domain_scores_gemma":[0.9984696,0.00022291324,0.0007538745,0.00013741381,0.00023845438,0.00017778258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084957696,0.0001594013,0.000711634,0.00037041144,0.000023344368,0.0000071167356,0.000143351,0.00021841803,0.000116737894],"category_scores_gemma":[0.000027922784,0.000119226024,0.0002008025,0.00021828513,0.00005607193,0.00006444745,0.000038003724,0.00047794942,0.0000026729417],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022438136,0.0016599883,0.9485109,0.0005093282,0.0003292397,0.0016923759,0.0016398743,0.00020149315,0.012349875,0.000008345539,0.001324245,0.029530564],"study_design_scores_gemma":[0.0024986956,0.0034911737,0.91992664,0.00058074837,0.0006893108,0.00007889476,0.000314457,0.000041144525,0.06799545,0.000013932156,0.004247636,0.000121931625],"about_ca_topic_score_codex":0.0003887616,"about_ca_topic_score_gemma":0.00081780105,"teacher_disagreement_score":0.055645574,"about_ca_system_score_codex":0.0013906608,"about_ca_system_score_gemma":0.0007464309,"threshold_uncertainty_score":0.48618963},"labels":[],"label_agreement":null},{"id":"W2200511737","doi":"10.1097/jto.0000000000000587","title":"Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Fluid-attenuated inversion recovery; Radiosurgery; Progressive disease; Asymptomatic; Radiology; Pathology; Oncology; Radiation therapy; Internal medicine; Magnetic resonance imaging; Chemotherapy","score_opus":0.026399545738224468,"score_gpt":0.3635849369765484,"score_spread":0.337185391238324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2200511737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958096,0.0008285339,0.00008355275,0.0017428882,0.00036456969,0.00035271002,0.0000037935363,0.00001697625,0.00079738506],"genre_scores_gemma":[0.99227417,0.000015129013,0.007224034,0.000119393335,0.00027206494,0.000010783503,0.000005926129,0.000018898005,0.000059608246],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982248,0.0002933879,0.0006467994,0.00015115744,0.00037405101,0.0003098013],"domain_scores_gemma":[0.99850446,0.000046775567,0.00057397364,0.00015806199,0.00027360854,0.00044309138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058115594,0.00016568703,0.0006717583,0.00022124029,0.000024525267,0.000011395855,0.000061831866,0.00012783644,0.000017438262],"category_scores_gemma":[0.00006417976,0.00009371758,0.00011894998,0.00022940132,0.000055021246,0.0000793104,0.000028506316,0.00032864374,0.000007843576],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050722465,0.007004041,0.13866812,0.0005284806,0.0008204525,0.09276198,0.003661106,0.0006424151,0.0015084406,0.00006960877,0.004563956,0.69904894],"study_design_scores_gemma":[0.05603025,0.2364146,0.29887637,0.0133557385,0.0051407665,0.2246797,0.03722858,0.0028850595,0.053489298,0.00015028904,0.0704155,0.001333855],"about_ca_topic_score_codex":0.000052224725,"about_ca_topic_score_gemma":0.000026453152,"teacher_disagreement_score":0.69771504,"about_ca_system_score_codex":0.0013366265,"about_ca_system_score_gemma":0.0006017772,"threshold_uncertainty_score":0.3821692},"labels":[],"label_agreement":null},{"id":"W2212041110","doi":"10.1016/s1556-0864(15)31579-3","title":"A Review of First-Line Treatment for Small-cell Lung Cancer","year":2006,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Etoposide; Prophylactic cranial irradiation; Radiation therapy; Chemotherapy; Oncology; Regimen; Lung cancer; Cisplatin; Clinical trial; Internal medicine","score_opus":0.13951046375844217,"score_gpt":0.5695194519831677,"score_spread":0.4300089882247255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2212041110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000604434,0.9923308,0.00009200376,0.0025161393,0.00063057226,0.0031363824,0.00015441218,0.0000075219386,0.0011261208],"genre_scores_gemma":[9.797693e-7,0.9921924,0.0020976893,0.00024431612,0.0016619163,0.00053317787,0.000036494792,0.00006427842,0.0031687843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99665546,0.00029934003,0.0019995472,0.00027229343,0.00035476172,0.00041862228],"domain_scores_gemma":[0.99443275,0.0009589219,0.0029840963,0.00035997518,0.0010641043,0.00020014464],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001221893,0.00043884656,0.006084387,0.00038985183,0.00005872221,0.0000055084333,0.0002940028,0.00032336713,0.0001316669],"category_scores_gemma":[0.0004078037,0.0002591662,0.001854806,0.00034763652,0.00011290219,0.000035090354,0.000084108004,0.0005550744,0.0000029808511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021874205,0.00043388933,0.000018297436,0.36826625,0.0012198153,0.00012409853,0.000018301169,7.462153e-7,3.7967163e-7,7.662206e-7,0.047850586,0.58184814],"study_design_scores_gemma":[0.00086075475,0.0038343717,0.0000019721913,0.23398978,0.016122708,0.00043278476,0.000005293032,0.000003163156,0.000008310053,0.00000549399,0.74461114,0.00012421956],"about_ca_topic_score_codex":0.00008433912,"about_ca_topic_score_gemma":0.00017023203,"teacher_disagreement_score":0.6967606,"about_ca_system_score_codex":0.003819098,"about_ca_system_score_gemma":0.004654768,"threshold_uncertainty_score":0.99998605},"labels":[],"label_agreement":null},{"id":"W2217340753","doi":"10.1097/jto.0000000000000584","title":"Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Apoptosis; Mdm2; Medicine; Cancer research; Cell cycle checkpoint; Cell growth; Cell culture; Cell cycle; Growth inhibition; Cancer; Pharmacology; Chemistry; Internal medicine; Biology; Biochemistry","score_opus":0.031859427551261504,"score_gpt":0.364442301453854,"score_spread":0.33258287390259245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2217340753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889546,0.002304135,0.0022631516,0.0013847272,0.0015375662,0.0004135665,0.000007247964,0.000021420092,0.003113571],"genre_scores_gemma":[0.9944725,0.00022373046,0.004125474,0.000629384,0.0004275658,0.000026316706,0.0000062298814,0.000048463444,0.000040346993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977802,0.00025450028,0.00095413486,0.000243024,0.00036820088,0.00039992624],"domain_scores_gemma":[0.9975739,0.000123133,0.0010228663,0.0001556697,0.00077664136,0.00034775128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005887984,0.00022556607,0.0007128867,0.00055353204,0.000039672093,0.00002412088,0.00014843138,0.00021774138,0.000052287418],"category_scores_gemma":[0.00027299084,0.00020199345,0.0001831226,0.00034477928,0.00005975241,0.00034578345,0.000100829486,0.0010935533,0.000006446863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01245544,0.002444007,0.008489303,0.0010488833,0.00047899346,0.011663584,0.018096533,0.03484684,0.8264014,0.000016455724,0.013971665,0.070086874],"study_design_scores_gemma":[0.00870949,0.0067797992,0.0009806277,0.0031186934,0.001246662,0.007147863,0.007981259,0.03331767,0.9242628,0.00051158294,0.0052903597,0.00065318873],"about_ca_topic_score_codex":0.00029873138,"about_ca_topic_score_gemma":0.00023189129,"teacher_disagreement_score":0.09786138,"about_ca_system_score_codex":0.0015455454,"about_ca_system_score_gemma":0.0014833338,"threshold_uncertainty_score":0.8237054},"labels":[],"label_agreement":null},{"id":"W2217745328","doi":"10.1097/jto.0b013e31824c98b9","title":"KRAS Mutation Spectrum Notably Diverges between Non-small Cell Lung and Colorectal Carcinomas: In Response","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"KRAS; Colorectal cancer; Medicine; Oncology; Lung cancer; Biomarker; Context (archaeology); Epidermal growth factor receptor; Cetuximab; Internal medicine; Cancer research; Cancer; Mutation; Biology; Gene; Genetics","score_opus":0.01722374543797107,"score_gpt":0.3880828342954637,"score_spread":0.37085908885749264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2217745328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937201,0.001677838,0.0001803373,0.0027084178,0.0004027155,0.0002554355,0.000008918266,0.0000058995365,0.001040297],"genre_scores_gemma":[0.9967317,0.00009480639,0.0022727572,0.00011242572,0.0004368686,0.000006980334,0.000006086529,0.000013954663,0.0003244291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989201,0.0001951599,0.00038772356,0.00010153215,0.00013762106,0.00025790348],"domain_scores_gemma":[0.9989819,0.00034362983,0.00031328484,0.00007360651,0.000082753686,0.00020483976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007424815,0.000114102884,0.00040745593,0.00030304134,0.00005441886,0.0000097995835,0.000050997696,0.00012502483,0.000038401457],"category_scores_gemma":[0.000074317446,0.000089911344,0.000068532245,0.00015730724,0.000049650003,0.00017548644,0.000023520879,0.00026767072,0.0000066377625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034599379,0.0004036201,0.97234446,0.00007558032,0.00014929584,0.0005054868,0.0071245837,0.000011638412,0.0044033336,0.000007375122,0.00032872346,0.0111859515],"study_design_scores_gemma":[0.0018733788,0.0021365737,0.9865539,0.00007124569,0.0007753457,0.00065568695,0.0010083632,0.000027987591,0.004962958,0.000063547086,0.0017872681,0.00008372594],"about_ca_topic_score_codex":0.000056552348,"about_ca_topic_score_gemma":0.000045358294,"teacher_disagreement_score":0.0142094465,"about_ca_system_score_codex":0.0005912952,"about_ca_system_score_gemma":0.000504174,"threshold_uncertainty_score":0.3666478},"labels":[],"label_agreement":null},{"id":"W2220506303","doi":"10.1097/jto.0000000000000526","title":"Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?","year":2015,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Immunohistochemistry; Medicine; Biomarker; Lung cancer; Companion diagnostic; Monoclonal antibody; Cancer; Oncology; Antibody; clone (Java method); Immunotherapy; Internal medicine; Pathology; Immunology; Biology","score_opus":0.049017193594614844,"score_gpt":0.4799286196516864,"score_spread":0.43091142605707156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2220506303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025815065,0.9932495,0.0000018332926,0.001113483,0.0013781067,0.0009027026,0.000020416925,0.000009018929,0.0007434838],"genre_scores_gemma":[0.00006298845,0.9957381,0.00028833846,0.0003202287,0.00034870458,0.000098844816,0.000016958838,0.000057081103,0.0030687577],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99638826,0.0003277153,0.002044401,0.00031602677,0.00043663033,0.0004869811],"domain_scores_gemma":[0.9969886,0.0001833924,0.0019811213,0.00034630919,0.0002869179,0.00021365979],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022753845,0.0004395776,0.0034298117,0.0006325469,0.000025216446,0.000053952783,0.00036504006,0.00072600297,0.00035160757],"category_scores_gemma":[0.0000949063,0.00032916892,0.00069067697,0.00063357066,0.00013484707,0.00023119748,0.00006375289,0.0017470318,0.000010760562],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032074566,0.0003306052,0.00013706253,0.009139209,0.000595442,0.0013918502,0.00055467756,4.216558e-7,0.00008430732,1.0428017e-7,0.008648841,0.97591],"study_design_scores_gemma":[0.001845413,0.0007492665,0.00003949075,0.043039817,0.0011091263,0.0024538708,0.00012730526,0.000004252807,0.00006566185,0.000018435014,0.9502733,0.000274108],"about_ca_topic_score_codex":0.00012488777,"about_ca_topic_score_gemma":0.000071736606,"teacher_disagreement_score":0.9756359,"about_ca_system_score_codex":0.005593837,"about_ca_system_score_gemma":0.006441243,"threshold_uncertainty_score":0.999916},"labels":[],"label_agreement":null},{"id":"W2222860631","doi":"10.1016/j.jtho.2015.09.006","title":"Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Cancer; Internal medicine; Biopsy; Informed consent; Oncology; Pathology; Alternative medicine","score_opus":0.10706431643290101,"score_gpt":0.5944875724242861,"score_spread":0.48742325599138503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222860631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908027,0.00032221517,0.00029296553,0.0067894207,0.0005109469,0.00081149355,0.000021260405,0.0000048364354,0.0004441359],"genre_scores_gemma":[0.99585307,0.0002240981,0.0025066717,0.0003163826,0.00031614146,0.00010667436,0.0000020051089,0.000016607466,0.0006583822],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735904,0.000814612,0.0010107268,0.00018834599,0.00033062266,0.00029664286],"domain_scores_gemma":[0.996857,0.0010692886,0.00065778085,0.00016305057,0.00093703426,0.00031588387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032906102,0.00010558549,0.00072726206,0.00035993697,0.00005444594,0.0000104358105,0.0000931414,0.0001264501,0.00010890118],"category_scores_gemma":[0.0017409857,0.00005416744,0.00010945873,0.00031415277,0.00007354797,0.00012827326,0.000030833355,0.00030582014,0.000010103056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069180666,0.00096138543,0.69429713,0.00004700086,0.00014418736,0.00011322321,0.00074173283,0.00004444341,0.000648164,0.0000019052792,0.0013375849,0.29474518],"study_design_scores_gemma":[0.0091489265,0.0073836325,0.9657853,0.0010822687,0.00060124556,0.0000103099665,0.0005740267,0.000022905086,0.001463817,0.00003243884,0.013792856,0.000102246915],"about_ca_topic_score_codex":0.000028222885,"about_ca_topic_score_gemma":0.00030227532,"teacher_disagreement_score":0.29464293,"about_ca_system_score_codex":0.000859803,"about_ca_system_score_gemma":0.0012535747,"threshold_uncertainty_score":0.2248355},"labels":[],"label_agreement":null},{"id":"W2223006975","doi":"10.1016/j.jtho.2015.09.008","title":"Radiotherapeutic Management of Non–Small Cell Lung Cancer in the Minimal Resource Setting","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Queen's University; London Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Scope (computer science); Narrative review; Health care; Intensive care medicine; Disease; Radiation therapy; Oncology; Pathology; Economic growth; Surgery","score_opus":0.03180434624076132,"score_gpt":0.49055018503854214,"score_spread":0.4587458387977808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223006975","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019326196,0.9907647,0.0011802143,0.0012048837,0.0009805282,0.00096868083,0.0000121216,0.0000049410583,0.004690682],"genre_scores_gemma":[0.000041330804,0.98517716,0.010358703,0.00073093025,0.0014388975,0.000050392526,0.0000020827601,0.000054131055,0.0021463986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964462,0.0009934312,0.0016106333,0.0002620175,0.0002913589,0.00039638876],"domain_scores_gemma":[0.99552715,0.0012283883,0.0026660415,0.00039253323,0.00009708784,0.00008880331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024985734,0.0003596448,0.0027000129,0.0004450355,0.000056900353,0.0000074785303,0.0006855497,0.0006081959,0.00016516441],"category_scores_gemma":[0.000027502556,0.00018335826,0.00067119143,0.0003569818,0.00024672868,0.00006985111,0.000055291177,0.0012761744,0.000003252061],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005933023,0.0003404215,0.000116968135,0.015760733,0.0008812636,0.0014696083,0.00050860754,0.000006601911,0.000009636373,0.000017261416,0.0016545171,0.9786411],"study_design_scores_gemma":[0.0011027167,0.0011713001,0.00008347833,0.026900264,0.0031780151,0.0024376367,0.0003430043,0.000009527875,0.0000056394574,0.000017891198,0.9645843,0.0001662108],"about_ca_topic_score_codex":0.0000014132089,"about_ca_topic_score_gemma":0.0000033692852,"teacher_disagreement_score":0.97847486,"about_ca_system_score_codex":0.0010868569,"about_ca_system_score_gemma":0.0010405761,"threshold_uncertainty_score":0.7477133},"labels":[],"label_agreement":null},{"id":"W2228221433","doi":"10.1016/j.jtho.2015.09.009","title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4643,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Samsung; Hyogo College of Medicine; Universidade de São Paulo; Seoul National University; Imperial College London; International Association for the Study of Lung Cancer; Keio University; Yale University; Peter MacCallum Cancer Centre; National Cancer Institute; Cleveland Clinic; Memorial Sloan-Kettering Cancer Center; Gentofte Hospital; Cancer Research Institute","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Lung cancer staging; Biostatistics; Globe; Cancer; Oncology; Medical physics; Internal medicine; Epidemiology","score_opus":0.041670162273424745,"score_gpt":0.46258132740242325,"score_spread":0.4209111651289985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2228221433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8664412,0.0059289606,0.0032237326,0.115367055,0.00232675,0.0063818092,0.00015553582,0.000007277884,0.00016768387],"genre_scores_gemma":[0.99500275,0.0025228143,0.00055226294,0.0004211058,0.0007077874,0.00049759744,0.000002052241,0.00002305442,0.00027057758],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979812,0.00031177295,0.0008551722,0.00017758169,0.00041039186,0.000263873],"domain_scores_gemma":[0.9960194,0.0012484943,0.0017967054,0.00035113932,0.00055115635,0.000033105076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022328256,0.00015081004,0.0004600703,0.00009076257,0.00024672755,0.000017830078,0.00036539385,0.00011272864,0.000013867073],"category_scores_gemma":[0.00037230473,0.000050711624,0.0003219666,0.0002455389,0.00015987043,0.00016006012,0.000051126724,0.00022561812,5.2679326e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006301425,0.001191007,0.2906546,0.0036193558,0.0011645517,0.000008428549,0.00919845,0.00009650613,0.019896453,0.0031797152,0.050384086,0.61430544],"study_design_scores_gemma":[0.019039063,0.0064756484,0.46889934,0.03522175,0.008999148,0.00019638799,0.011937694,0.010216995,0.1339432,0.0025444461,0.30178472,0.00074157625],"about_ca_topic_score_codex":0.00017880008,"about_ca_topic_score_gemma":0.00058835157,"teacher_disagreement_score":0.61356384,"about_ca_system_score_codex":0.0013936068,"about_ca_system_score_gemma":0.0010903792,"threshold_uncertainty_score":0.36442333},"labels":[],"label_agreement":null},{"id":"W2229481660","doi":"10.1097/jto.0000000000000588","title":"Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; Genentech; AstraZeneca; Celgene; Merck KGaA; Sanofi; Eli Lilly and Company","keywords":"Cabazitaxel; Topotecan; Taxane; Medicine; Hazard ratio; Internal medicine; Oncology; Chemotherapy; Lung cancer; Confidence interval; Surgery; Cancer; Prostate cancer; Breast cancer","score_opus":0.0301059198192701,"score_gpt":0.4078467590959927,"score_spread":0.37774083927672264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2229481660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284464,0.0015985541,0.000043176853,0.0043445923,0.00020272727,0.00082552206,0.000016720802,0.000012657159,0.000111431546],"genre_scores_gemma":[0.99644697,0.00007231443,0.0024351003,0.00025987896,0.00032864715,0.00014027793,0.0000037153404,0.000041583353,0.0002714981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982466,0.00010283436,0.0003884193,0.0002261496,0.00062218384,0.00041378767],"domain_scores_gemma":[0.9979564,0.00012825422,0.00044992013,0.00020526235,0.000770399,0.00048978935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026725436,0.0002187015,0.0005951359,0.0002566988,0.00005193142,0.000015958716,0.00014170093,0.00008282612,0.0001145393],"category_scores_gemma":[0.00016684626,0.00012533559,0.00006166164,0.00031135223,0.00016219488,0.0001231013,0.0000464015,0.0005107243,0.0000013634946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31774282,0.0009738254,0.67054015,0.0004971049,0.00026065548,0.0031051214,0.0008329707,0.0007443022,0.000009187271,9.416292e-8,0.00026651882,0.0050272187],"study_design_scores_gemma":[0.059179045,0.019204773,0.91561425,0.0021334963,0.0006735714,0.00004578558,0.0004402838,0.0002941474,0.0007626607,0.0000043066957,0.0013312647,0.0003164229],"about_ca_topic_score_codex":0.000045723697,"about_ca_topic_score_gemma":0.0011601496,"teacher_disagreement_score":0.2585638,"about_ca_system_score_codex":0.0018924375,"about_ca_system_score_gemma":0.0027046546,"threshold_uncertainty_score":0.5111037},"labels":[],"label_agreement":null},{"id":"W2240664420","doi":"10.1097/01.jto.0000282977.65747.30","title":"M17-03: Stimuvax (L-BLP25): a peptide vaccine strategy in non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"MUC1; Transmembrane protein; Antigen; Medicine; Glycoprotein; Transmembrane domain; Immunotherapy; Cytoplasm; Lung cancer; Mucin; Cancer immunotherapy; Cancer research; Extracellular; Cell biology; Immune system; Molecular biology; Immunology; Biology; Pathology; Receptor; Internal medicine","score_opus":0.015219611323218203,"score_gpt":0.3612262481349707,"score_spread":0.3460066368117525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240664420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9582197,0.034902055,0.0005984698,0.0006430794,0.0018594473,0.000272333,0.00000785395,0.000016561942,0.003480508],"genre_scores_gemma":[0.9891956,0.002093036,0.00047955813,0.0004949649,0.00019961859,0.000009398639,0.0000068779636,0.000036909394,0.0074840495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970625,0.0005650804,0.0013028879,0.00024315024,0.00006980149,0.00075655145],"domain_scores_gemma":[0.99780345,0.0006533879,0.0009598433,0.0002713235,0.0002548912,0.000057085515],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002529461,0.00030289975,0.00089758466,0.00066850835,0.0001286595,0.000018020175,0.0005422802,0.00062663056,0.001307913],"category_scores_gemma":[0.000096286,0.0002509327,0.00025527654,0.00036917778,0.0001121307,0.00020432282,0.000080511876,0.0013417185,0.000102296566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017278014,0.0010011989,0.011617189,0.00010251136,0.00044245282,0.0007227868,0.0015521129,0.00033772617,0.81658566,0.000026053256,0.008183043,0.14215124],"study_design_scores_gemma":[0.011003344,0.0067141852,0.28725493,0.00064525445,0.0004946181,0.003529828,0.003665909,0.00004818096,0.44013843,0.00015947006,0.24546532,0.0008805363],"about_ca_topic_score_codex":0.00023967955,"about_ca_topic_score_gemma":0.00048216624,"teacher_disagreement_score":0.37644726,"about_ca_system_score_codex":0.00047077786,"about_ca_system_score_gemma":0.0007814716,"threshold_uncertainty_score":0.9999943},"labels":[],"label_agreement":null},{"id":"W2246298227","doi":"10.1097/01.jto.0000282986.26736.42","title":"M20-01: The cost of care for patients with lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Intensive care medicine; Cancer; General surgery; Oncology; Internal medicine","score_opus":0.014359814039029103,"score_gpt":0.428540137494496,"score_spread":0.4141803234554669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2246298227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894273,0.0038734907,0.00037747464,0.003701623,0.0006889703,0.00085695833,0.00002754356,0.000003256698,0.0010433274],"genre_scores_gemma":[0.99745554,0.00023667658,0.0014179958,0.0004464946,0.00032587643,0.000027489123,0.000004758787,0.000012573342,0.00007258253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991806,0.000028247976,0.00033698548,0.00007718371,0.00021297419,0.00016399576],"domain_scores_gemma":[0.99838483,0.00027229704,0.0004953982,0.00011744781,0.00064131257,0.000088714194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029461615,0.000084203464,0.0003846616,0.00006940679,0.000048625345,0.0000033428948,0.000078548095,0.00006710194,0.00004826326],"category_scores_gemma":[0.000041158328,0.000041066865,0.00011730562,0.000091405134,0.00006104461,0.000037212554,0.000012441717,0.00013700027,3.9519855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009174642,0.00087246415,0.70327353,0.00039276757,0.0007153804,0.000078685116,0.0015449119,0.000043618566,0.000027273445,0.000032013584,0.007097859,0.27674684],"study_design_scores_gemma":[0.0071649733,0.014230816,0.8299477,0.0009896698,0.0030515615,0.000117867516,0.0015368633,0.000015894351,0.004294188,0.00002415876,0.13850799,0.00011830513],"about_ca_topic_score_codex":0.000032994743,"about_ca_topic_score_gemma":0.00038599252,"teacher_disagreement_score":0.27662852,"about_ca_system_score_codex":0.0008785978,"about_ca_system_score_gemma":0.00041231368,"threshold_uncertainty_score":0.22975026},"labels":[],"label_agreement":null},{"id":"W2247489063","doi":"10.1016/j.jtho.2015.10.006","title":"Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemoradiotherapy; Esophagitis; Lung cancer; Oncology; Internal medicine; Radiation therapy; Radiology; Nuclear medicine; Disease","score_opus":0.03245355939307582,"score_gpt":0.43435984596082555,"score_spread":0.40190628656774974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2247489063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97198397,0.022145553,0.002974336,0.0011560968,0.0006770073,0.00079897203,0.000016899112,0.000017629123,0.00022951358],"genre_scores_gemma":[0.97217333,0.00085529377,0.024784846,0.00023220055,0.001467878,0.00005349169,0.0000061554856,0.000047103695,0.00037968426],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833095,0.00009584433,0.0005548083,0.00021055185,0.00037345363,0.00043440514],"domain_scores_gemma":[0.99796844,0.00012455658,0.0006277768,0.00015463728,0.00062976993,0.0004948124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006660346,0.00018317193,0.00065930653,0.00023301352,0.000105127925,0.000024495026,0.00013351352,0.00008665247,0.000047358222],"category_scores_gemma":[0.00014812069,0.00015349552,0.00018709102,0.00018451146,0.000048564136,0.00021217263,0.00002738899,0.00037281789,0.0000014759502],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043256503,0.0021238509,0.4687323,0.00287971,0.0018289725,0.011614594,0.0041124322,0.018553138,0.051615816,0.000008005922,0.0020697485,0.39320496],"study_design_scores_gemma":[0.107397944,0.044146728,0.112051144,0.003631452,0.004548867,0.023617174,0.0036132662,0.1245468,0.56746435,0.00042573136,0.007171902,0.0013846159],"about_ca_topic_score_codex":0.00008013849,"about_ca_topic_score_gemma":0.000039569368,"teacher_disagreement_score":0.5158486,"about_ca_system_score_codex":0.0026843452,"about_ca_system_score_gemma":0.0024059333,"threshold_uncertainty_score":0.701947},"labels":[],"label_agreement":null},{"id":"W2251194141","doi":"10.1016/j.jtho.2015.09.012","title":"Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Congenital Diaphragmatic Hernia Studies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Somatic cell; Germline; Germline mutation; Adenocarcinoma; Mutation; Cancer research; Genetics; Internal medicine; Cancer; Gene; Biology","score_opus":0.0321020733021252,"score_gpt":0.3898176019386864,"score_spread":0.3577155286365612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2251194141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065924,0.002675054,0.00006909474,0.005171165,0.0002645602,0.00023063515,0.0000029321852,0.0000043966747,0.000922947],"genre_scores_gemma":[0.99861634,0.00003116399,0.0009057318,0.00012492745,0.00007448301,0.000004080997,0.0000010423634,0.000009506064,0.00023273553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861205,0.00022852496,0.0006845425,0.0000777745,0.00025686427,0.00014023599],"domain_scores_gemma":[0.99872065,0.00027252446,0.00048544697,0.00012691358,0.00027158888,0.00012289658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055350055,0.000099430705,0.0005567041,0.00019758749,0.000027179636,0.0000054432176,0.00009930885,0.00008444713,0.000042174168],"category_scores_gemma":[0.0008110366,0.00006114961,0.00009677743,0.00023411287,0.00015853852,0.00008205931,0.000085842825,0.00029273913,0.000004153009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001323138,0.0010420716,0.94976085,0.0006225869,0.000612335,0.00055649475,0.01071963,0.00003624865,0.00444303,0.000042381558,0.0017352852,0.02910595],"study_design_scores_gemma":[0.0022878782,0.00075481244,0.98772204,0.00032675554,0.00076331495,0.0016632557,0.0029579876,0.0022121344,0.00037563322,0.0005946294,0.0002696704,0.00007187673],"about_ca_topic_score_codex":0.00001995922,"about_ca_topic_score_gemma":0.00008967338,"teacher_disagreement_score":0.037961204,"about_ca_system_score_codex":0.00017276485,"about_ca_system_score_gemma":0.00036658288,"threshold_uncertainty_score":0.24936084},"labels":[],"label_agreement":null},{"id":"W2251438188","doi":"10.1097/jto.0000000000000630","title":"The 2015 World Health Organization Classification of Lung Tumors","year":2015,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":4546,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphangioleiomyomatosis; Pathology; Lung cancer; Hamartoma; Adenocarcinoma; Lung; Immunohistochemistry; Cancer; Large cell; Tuberous sclerosis; Internal medicine","score_opus":0.039780734554397894,"score_gpt":0.4732321122120633,"score_spread":0.4334513776576654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2251438188","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090768293,0.018289613,0.00052682776,0.07815316,0.8995167,0.00035211214,0.000026473404,0.000024646082,0.0022027786],"genre_scores_gemma":[0.010003811,0.0052145645,0.0026584137,0.0007611123,0.96986,0.000007908829,0.00020204783,0.00008879201,0.011203318],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965181,0.0007514553,0.0013524689,0.00017034271,0.00094467646,0.00026297473],"domain_scores_gemma":[0.99080753,0.0019052563,0.0032779663,0.00029290048,0.0034448036,0.00027156138],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0054624258,0.0001905159,0.0012510794,0.00032132296,0.00014500656,0.000011340326,0.0002826738,0.00043667376,0.000023903942],"category_scores_gemma":[0.012786495,0.00011460851,0.00012341709,0.000457486,0.0004404141,0.000048863385,0.00006850958,0.0017989757,0.000010043698],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038944016,0.00014568203,0.0012466128,0.00025753802,0.00019681988,0.00007554094,0.00042485874,8.8533125e-7,0.000037106114,0.000014805743,0.9785274,0.018683266],"study_design_scores_gemma":[0.000583161,0.0015170603,0.001960393,0.00067945424,0.00050288957,0.00026816412,0.0004130167,0.00001789775,0.000020855821,0.0001375321,0.99381757,0.000082006816],"about_ca_topic_score_codex":0.000013741522,"about_ca_topic_score_gemma":0.00004648996,"teacher_disagreement_score":0.07739206,"about_ca_system_score_codex":0.00080229883,"about_ca_system_score_gemma":0.0062531233,"threshold_uncertainty_score":0.9993805},"labels":[],"label_agreement":null},{"id":"W2259595058","doi":"10.1016/s1556-0864(16)30011-9","title":"MINI ORAL SESSIONS","year":2015,"lang":"de","type":"article","venue":"Journal of Thoracic Oncology","topic":"Diverse Scientific and Economic Studies","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dominican University College","funders":"","keywords":"Medicine; Medical physics","score_opus":0.12173533371317494,"score_gpt":0.3780329174382404,"score_spread":0.2562975837250655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259595058","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17500846,0.073675014,0.0009819278,0.01582416,0.17811453,0.00035566822,0.0007345393,0.000026895954,0.5552788],"genre_scores_gemma":[0.44443008,0.0062396037,0.014684921,0.0020407315,0.0060612704,0.0000074066256,0.000013116066,0.000078203186,0.5264447],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973277,0.0001142401,0.0016598001,0.00033733528,0.00008641594,0.00047455006],"domain_scores_gemma":[0.9963217,0.0001625231,0.0024239863,0.0003038384,0.0002934699,0.00049448974],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0038954818,0.00022225778,0.0013045386,0.000560441,0.00014239753,0.00010943511,0.0005787516,0.00029677837,0.004393422],"category_scores_gemma":[0.000720471,0.00022348286,0.00037987984,0.00029580708,0.0003001693,0.0004361806,0.0002741498,0.00048695522,0.020477558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003646176,0.00046816422,0.0056891916,0.000024868767,0.00061128574,0.00020263698,0.002466676,0.00015717979,0.0000022022207,0.004020824,0.96744084,0.018551528],"study_design_scores_gemma":[0.0008365311,0.0008040886,0.00079634035,0.000048560174,0.000170617,0.00009800203,0.004740077,0.000301966,0.000013705353,0.0042033554,0.98775023,0.00023654864],"about_ca_topic_score_codex":0.000033157776,"about_ca_topic_score_gemma":0.000010053726,"teacher_disagreement_score":0.26942164,"about_ca_system_score_codex":0.00077894016,"about_ca_system_score_gemma":0.0005396741,"threshold_uncertainty_score":0.9965167},"labels":[],"label_agreement":null},{"id":"W2268267848","doi":"10.1016/j.jtho.2015.11.014","title":"First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":356,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Lung cancer; Oncology; Internal medicine; Pemetrexed; Epidermal growth factor receptor; Adenocarcinoma; Chemotherapy; Hazard ratio; Cisplatin; Erlotinib; Cancer; Confidence interval","score_opus":0.01940608127207443,"score_gpt":0.3866569509001219,"score_spread":0.3672508696280475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268267848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675233,0.00067198096,0.00029144363,0.011522865,0.00020454924,0.0003649797,0.00010591247,0.0000050597178,0.000080905396],"genre_scores_gemma":[0.99268925,0.0005505451,0.006026604,0.00040218938,0.00011665595,0.000021198915,0.000014128308,0.000019472549,0.0001599553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914455,0.00007332077,0.0003433982,0.00014257221,0.00012740854,0.00016875521],"domain_scores_gemma":[0.998802,0.00042368393,0.0003510541,0.00007710081,0.00019424487,0.00015188102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013567701,0.00013598424,0.00041669444,0.00015985713,0.000059521473,0.000009526331,0.00004250028,0.00007208869,0.00010459694],"category_scores_gemma":[0.00006364108,0.00007819427,0.000039461578,0.00010593667,0.00008267796,0.00013732085,0.000015452764,0.00012382417,7.7836876e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007654377,0.0009353783,0.85719454,0.00013856296,0.0005987595,0.00007847694,0.0016013248,0.000021096053,0.0011671478,0.000005875288,0.00066710176,0.12993734],"study_design_scores_gemma":[0.029308137,0.006627078,0.95410967,0.00037301859,0.0009390177,0.000052679115,0.00019084454,0.000041523697,0.0048733214,0.000034261833,0.0032677108,0.00018276715],"about_ca_topic_score_codex":0.00010279066,"about_ca_topic_score_gemma":0.0003862753,"teacher_disagreement_score":0.12975456,"about_ca_system_score_codex":0.0003243034,"about_ca_system_score_gemma":0.0002858175,"threshold_uncertainty_score":0.318867},"labels":[],"label_agreement":null},{"id":"W2271051170","doi":"10.1016/j.jtho.2015.11.010","title":"Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Queen's University; University of Ottawa; Princess Margaret Cancer Centre","funders":"Cancer Research UK","keywords":"KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Epidermal growth factor receptor; Placebo; Transversion; Cancer research; Cancer; Mutation; Confidence interval; Pathology; Biology; Genetics; Colorectal cancer","score_opus":0.009590676305780855,"score_gpt":0.329713282366593,"score_spread":0.3201226060608121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2271051170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983259,0.0005014361,0.0001348078,0.00022192445,0.00006877883,0.00062550296,0.00008392003,0.0000025944787,0.00003513088],"genre_scores_gemma":[0.9989492,0.000038785944,0.0008703335,0.000026669448,0.000024194758,0.000015449274,0.00004411593,0.000012033988,0.000019199135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891084,0.0001604598,0.00042261108,0.00013201953,0.00024284908,0.00013120212],"domain_scores_gemma":[0.9979382,0.0001274595,0.00086377416,0.000072328796,0.00086801685,0.00013018264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015142573,0.00012267132,0.0004946887,0.0003573153,0.000026877453,0.000005849427,0.000031392647,0.00007421874,0.0000066056273],"category_scores_gemma":[0.000121572186,0.00006810601,0.000042752148,0.00062834873,0.0001122242,0.0001328334,0.000013387188,0.00013697158,4.637426e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043521193,0.0005584096,0.9848468,0.00011679534,0.0013356955,0.000023957573,0.0039809905,0.001643635,0.0003383185,0.0000013361735,0.000013498214,0.0027884583],"study_design_scores_gemma":[0.0048498223,0.005195856,0.97378224,0.00026962959,0.010033601,0.000011106059,0.0007884811,0.0011356774,0.0038622417,0.0000058495502,0.0000034348338,0.00006204909],"about_ca_topic_score_codex":0.00048654238,"about_ca_topic_score_gemma":0.00026426802,"teacher_disagreement_score":0.011064534,"about_ca_system_score_codex":0.0004037242,"about_ca_system_score_gemma":0.0007252447,"threshold_uncertainty_score":0.27772826},"labels":[],"label_agreement":null},{"id":"W2278015318","doi":"10.1016/j.jtho.2015.12.095","title":"Contrasting Management of Small Cell Lung Cancer and Non–Small Cell Lung Cancer: Emerging Data for Low-Dose Computed Tomography Screening","year":2016,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Computed tomography; Lung; Cancer; Lung cancer screening; Radiology; Oncology; Internal medicine","score_opus":0.04530686336755013,"score_gpt":0.422963664208508,"score_spread":0.3776568008409579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278015318","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09222891,0.18554042,0.070272736,0.627729,0.0075775366,0.009951178,0.0033973926,0.00011515778,0.0031876985],"genre_scores_gemma":[0.104847886,0.11432704,0.434016,0.24215633,0.08330979,0.0018376389,0.0015996061,0.0016853627,0.016220357],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955976,0.00024657577,0.0015304693,0.000767482,0.00074945856,0.0011084],"domain_scores_gemma":[0.99424636,0.0009961234,0.0026622803,0.0007330308,0.0010838062,0.00027842043],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018945591,0.0005850532,0.0022370103,0.00090338785,0.00021257793,0.000045116594,0.0010353366,0.00055164745,0.00005349923],"category_scores_gemma":[0.00007778911,0.0004473006,0.00038840986,0.00036958823,0.00026787093,0.00017875023,0.0010290577,0.0020648162,3.9250295e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032185032,0.00021077943,0.018754566,0.0414721,0.006897377,0.0031877293,0.00055253936,0.00011920994,0.0015319621,9.576339e-7,0.7599258,0.1641285],"study_design_scores_gemma":[0.021823527,0.0035963485,0.009715971,0.054141074,0.024543228,0.0004473326,0.0011996505,0.020893604,0.0027548806,0.00003931898,0.8591091,0.001735977],"about_ca_topic_score_codex":0.00022239248,"about_ca_topic_score_gemma":0.00009601765,"teacher_disagreement_score":0.38557264,"about_ca_system_score_codex":0.0007990999,"about_ca_system_score_gemma":0.0010532619,"threshold_uncertainty_score":0.9997979},"labels":[],"label_agreement":null},{"id":"W2278644320","doi":"10.1016/j.jtho.2016.02.006","title":"Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Biomarker; Internal medicine; Oncology; Osteopontin; Cohort; Mesothelin; Mesothelioma; Cancer; Pathology","score_opus":0.05428266177662308,"score_gpt":0.45195162177274356,"score_spread":0.3976689599961205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2278644320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572235,0.00036875697,0.000021903426,0.0027563742,0.00036556373,0.0001480311,0.0000118809785,0.000003597809,0.0006015447],"genre_scores_gemma":[0.9980507,0.00020975692,0.0011505524,0.00018562272,0.00014395943,0.000004163506,0.000002202637,0.000008756031,0.00024431007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981022,0.00021720132,0.00106987,0.00012453245,0.0003235767,0.00016265738],"domain_scores_gemma":[0.99830055,0.0006364277,0.00073201786,0.0000987717,0.000057783698,0.0001744332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085188355,0.00009933115,0.00053890696,0.00023659097,0.000013321986,0.000002222388,0.00010693164,0.00011985512,0.00032700796],"category_scores_gemma":[0.00042724772,0.00005315223,0.00019185874,0.00011535379,0.00018599023,0.000093194096,0.000047261372,0.00012448903,0.000027862663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005038041,0.0013149249,0.82165164,0.00004778828,0.00012332745,0.00048630688,0.000040357332,0.0000017492445,0.0069633923,0.00001881595,0.0004986416,0.16381504],"study_design_scores_gemma":[0.0018988972,0.002999934,0.9880695,0.00039732095,0.00020388103,0.00047862765,0.00008640925,0.000021822741,0.0017995839,0.00020926022,0.0037719202,0.00006289451],"about_ca_topic_score_codex":0.000005015358,"about_ca_topic_score_gemma":0.00000779198,"teacher_disagreement_score":0.16641782,"about_ca_system_score_codex":0.00014165278,"about_ca_system_score_gemma":0.00026019823,"threshold_uncertainty_score":0.3580508},"labels":[],"label_agreement":null},{"id":"W2281252038","doi":"10.1016/j.jtho.2015.12.083","title":"OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)∗","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Metformin; Internal medicine; Oncology; Lung cancer; Radiation therapy; non-small cell lung cancer (NSCLC); Chemotherapy; Clinical trial; PI3K/AKT/mTOR pathway; Apoptosis; Insulin; A549 cell","score_opus":0.01477428131028496,"score_gpt":0.36994427933914054,"score_spread":0.35516999802885557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281252038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644491,0.03307996,0.0007951781,0.00048386084,0.0004906499,0.0005485885,0.00001832116,0.0000017001835,0.00013260744],"genre_scores_gemma":[0.9874701,0.008352716,0.0032455886,0.00033769265,0.00046129592,0.000059672722,0.0000012595356,0.000015314952,0.000056361936],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980946,0.00041291158,0.00076938444,0.00027291183,0.00016673641,0.00028343563],"domain_scores_gemma":[0.99842227,0.00018990148,0.00071822316,0.0002476814,0.00024838484,0.0001735666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002009859,0.0001781807,0.00055783254,0.000076010285,0.00005566911,0.000008464851,0.00026727348,0.00018764763,0.000017536791],"category_scores_gemma":[0.0006278218,0.00010995884,0.00013472646,0.00014505247,0.00020199496,0.000015477865,0.00014521873,0.00023157435,2.7198953e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00518431,0.00028625698,0.00024004115,0.000068127556,0.000043194104,0.0000059655576,0.0003898908,0.000031656935,0.42765963,0.0000026373893,0.000294893,0.5657934],"study_design_scores_gemma":[0.025079926,0.0066275964,0.001272169,0.00067927537,0.0002467468,0.00007292388,0.00029767316,0.00010622674,0.9181369,0.00027442316,0.046856552,0.0003496052],"about_ca_topic_score_codex":0.000015378917,"about_ca_topic_score_gemma":0.00007792879,"teacher_disagreement_score":0.56544375,"about_ca_system_score_codex":0.00010265838,"about_ca_system_score_gemma":0.00088607456,"threshold_uncertainty_score":0.44839913},"labels":[],"label_agreement":null},{"id":"W2284382116","doi":"10.1097/jto.0000000000000403","title":"Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Asymptomatic; Adenocarcinoma; Radiology; Brain metastasis; Magnetic resonance imaging; Radiation therapy; Alectinib; Brain tumor; Pathology; Cancer; Internal medicine; Metastasis","score_opus":0.038139767453974266,"score_gpt":0.45984445410499986,"score_spread":0.42170468665102556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284382116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846261,0.00034472518,0.00006173319,0.0103791235,0.00052455324,0.00023611895,0.000017331233,0.000008068022,0.0038022597],"genre_scores_gemma":[0.9932731,0.0000170426,0.0033848982,0.0028907396,0.00019280538,0.0000064960313,0.00002402275,0.000014107865,0.00019682612],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99870855,0.00030275132,0.00041937648,0.00013174624,0.0002663894,0.00017120237],"domain_scores_gemma":[0.99878776,0.00016413284,0.00032980164,0.00013412676,0.00028858645,0.00029557763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039263477,0.00011775991,0.00041304316,0.0002838978,0.000032420478,0.00001101227,0.0000642058,0.00008028686,0.000054658416],"category_scores_gemma":[0.0002448143,0.00008025044,0.000085832085,0.00015597936,0.000040167222,0.00014632731,0.00002199706,0.0002588837,0.000015022084],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0119113475,0.011978581,0.009163547,0.000044429453,0.0003479064,0.00863423,0.011825733,0.00031342093,0.004447831,0.00018390376,0.012268352,0.9288807],"study_design_scores_gemma":[0.063514754,0.36302054,0.21487871,0.0024538874,0.006493202,0.019888617,0.04911417,0.0014214676,0.039764978,0.0052569443,0.2327436,0.001449111],"about_ca_topic_score_codex":0.000038080383,"about_ca_topic_score_gemma":0.000062589,"teacher_disagreement_score":0.9274316,"about_ca_system_score_codex":0.00071849365,"about_ca_system_score_gemma":0.00059543725,"threshold_uncertainty_score":0.3272518},"labels":[],"label_agreement":null},{"id":"W2284650234","doi":"10.1016/j.jtho.2015.11.004","title":"Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Human Genome Research Institute; National Key Research and Development Program of China; National Cancer Institute; National Institutes of Health; Genentech; National Natural Science Foundation of China; Canary Foundation","keywords":"DNA methylation; Methylation; Lung cancer; Medicine; Cancer research; Bisulfite sequencing; Biomarker; Pathology; Adenocarcinoma; Oncology; Cancer; Biology; Internal medicine; Gene expression; Gene","score_opus":0.0448204245942699,"score_gpt":0.4352873108975545,"score_spread":0.39046688630328463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2284650234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95142007,0.0027686737,0.043089613,0.00041201862,0.00066727854,0.00017480885,0.000007780486,0.00000183833,0.0014579222],"genre_scores_gemma":[0.9868781,0.0002059606,0.012324746,0.000049519917,0.00030584965,0.000006567818,0.000033879594,0.0000133715175,0.00018200585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989377,0.00019333333,0.00046494562,0.00011871771,0.00016385055,0.00012139807],"domain_scores_gemma":[0.9982248,0.00006363632,0.000731728,0.00012609355,0.0007538611,0.00009986554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015622029,0.00008714596,0.00022833879,0.00011762153,0.000026872192,0.000008423944,0.000120774,0.0001923205,0.000009513353],"category_scores_gemma":[0.00062908046,0.00007767499,0.00012818012,0.00009551957,0.00004493709,0.000009837214,0.000028506123,0.00006409281,7.015555e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018695195,0.000078950434,0.0022582,0.00004190839,0.00016166376,0.0000026755915,0.00017651336,0.0027041566,0.91822165,0.00004069579,0.001892094,0.07255198],"study_design_scores_gemma":[0.0008264044,0.0023390688,0.0011692664,0.000023968085,0.00015326317,0.00002524178,0.0001730907,0.00083264324,0.94786733,0.0015493003,0.044928838,0.00011157882],"about_ca_topic_score_codex":0.000021188958,"about_ca_topic_score_gemma":0.000013715399,"teacher_disagreement_score":0.0724404,"about_ca_system_score_codex":0.00013190103,"about_ca_system_score_gemma":0.0006916204,"threshold_uncertainty_score":0.3167494},"labels":[],"label_agreement":null},{"id":"W2285783448","doi":"10.1097/01.jto.0000283345.76753.da","title":"PD6-3-7: Bone metastases from non-small cell lung cancer (NSCLC) result in meaningful skeletal morbidity within a patient’s lifetime","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Waterloo; McGill University Health Centre","funders":"","keywords":"Medicine; Zoledronic acid; Lung cancer; Spinal cord compression; Concomitant; Pathologic fracture; Internal medicine; Surgery; Placebo; Malignancy; Radiation therapy; Cancer; Oncology; Pathology","score_opus":0.02607441248168963,"score_gpt":0.3938486741580384,"score_spread":0.3677742616763488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2285783448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902104,0.0043403194,0.00024574346,0.00155351,0.0012506401,0.000458581,0.00005721845,0.000014909682,0.0018686458],"genre_scores_gemma":[0.98231626,0.00028367434,0.015311947,0.0012840398,0.0004205212,0.000011467968,0.000021668011,0.00003373975,0.00031669458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970014,0.00026795806,0.0014533957,0.00028355804,0.0004359164,0.00055778463],"domain_scores_gemma":[0.9971769,0.0004026541,0.0012950675,0.00024325983,0.00029723914,0.00058492064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001522861,0.00025901207,0.0010666904,0.00041843517,0.00007276942,0.000011439966,0.00012671131,0.0002863678,0.00018376247],"category_scores_gemma":[0.0002552578,0.00020163454,0.0002111106,0.00031777754,0.00007588668,0.00013544387,0.000058052992,0.0009649289,0.000022798029],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046262622,0.011986888,0.5419851,0.00085933297,0.0017639727,0.049585696,0.014576664,0.00035173245,0.015498127,0.000019827015,0.021883365,0.2952267],"study_design_scores_gemma":[0.034392387,0.021419445,0.80496895,0.00345351,0.00600525,0.0041798446,0.003988472,0.0017913523,0.07106379,0.0004312842,0.047047555,0.0012581486],"about_ca_topic_score_codex":0.0032135237,"about_ca_topic_score_gemma":0.003895952,"teacher_disagreement_score":0.29396856,"about_ca_system_score_codex":0.0009264241,"about_ca_system_score_gemma":0.0014455012,"threshold_uncertainty_score":0.8222418},"labels":[],"label_agreement":null},{"id":"W2286863291","doi":"10.1097/jto.0000000000000624","title":"PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Erlotinib; Hazard ratio; Oncology; Internal medicine; Lung cancer; Anaplastic lymphoma kinase; Predictive marker; Confidence interval; Proportional hazards model; Cancer; Epidermal growth factor receptor","score_opus":0.021082067881831982,"score_gpt":0.42347044043921617,"score_spread":0.4023883725573842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286863291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832196,0.0016836955,0.0027092458,0.002264787,0.0005995607,0.0015510299,0.00002497558,0.000010169381,0.0028345985],"genre_scores_gemma":[0.98653716,0.00016370129,0.010484458,0.00019028598,0.000481471,0.000323753,0.000014000435,0.000028330885,0.0017768668],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989164,0.00006316279,0.0003848769,0.00017882006,0.00020832173,0.0002484376],"domain_scores_gemma":[0.99864984,0.000106178755,0.00040859316,0.00011104894,0.00045289632,0.0002714186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024335479,0.00016641074,0.0005045118,0.00018979779,0.00004518492,0.000012250945,0.00006634507,0.0001273468,0.000047200585],"category_scores_gemma":[0.000045789646,0.00010071285,0.00011083202,0.00012346826,0.000042274925,0.00010482458,0.000017098966,0.00013506204,0.0000025107267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.111976534,0.012863611,0.55630845,0.00063658814,0.0031920245,0.007072377,0.021601167,0.00405199,0.014346483,0.000012718784,0.01301587,0.25492218],"study_design_scores_gemma":[0.16609214,0.26363268,0.32277718,0.007354413,0.032813806,0.009609132,0.031111473,0.01445226,0.05640706,0.0007702869,0.093419105,0.0015604295],"about_ca_topic_score_codex":0.000120131066,"about_ca_topic_score_gemma":0.00009701368,"teacher_disagreement_score":0.25336176,"about_ca_system_score_codex":0.0014001335,"about_ca_system_score_gemma":0.0024740037,"threshold_uncertainty_score":0.43887764},"labels":[],"label_agreement":null},{"id":"W2287191467","doi":"10.1016/j.jtho.2015.11.005","title":"The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pathology; Radiology","score_opus":0.04946298198283544,"score_gpt":0.4468200165736084,"score_spread":0.397357034590773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2287191467","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002854885,0.97932124,0.000084214604,0.01873223,0.00060307595,0.00062980026,0.000051689458,0.0000045006655,0.00028774736],"genre_scores_gemma":[0.013959712,0.9846003,0.00012612231,0.00015525975,0.00028080415,0.000011924614,0.000030431405,0.000025668205,0.00080977933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970319,0.000740059,0.0014064648,0.00014664326,0.0005203596,0.00015455081],"domain_scores_gemma":[0.9932412,0.0009239142,0.005033228,0.00040092602,0.00031396828,0.00008674883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010497398,0.00018411492,0.0009302163,0.0001219145,0.00018854749,0.000008137715,0.00045460882,0.00011317652,0.000044381453],"category_scores_gemma":[0.0005561245,0.00006934372,0.00031689357,0.0005339364,0.00046837595,0.000107953994,0.00005985573,0.00036605028,0.000013358345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019847437,0.00025348537,0.0015841317,0.0020832312,0.00013222173,0.0000014423047,0.000041911077,0.000004096554,0.00004531672,0.0008781842,0.005105945,0.9896716],"study_design_scores_gemma":[0.000160469,0.00037166825,0.05236988,0.006152121,0.00070433907,0.00016249546,0.00015440628,0.000004673498,0.00002110164,0.00029201707,0.9395352,0.000071646165],"about_ca_topic_score_codex":0.0000035238545,"about_ca_topic_score_gemma":0.000019928786,"teacher_disagreement_score":0.98959994,"about_ca_system_score_codex":0.0007536682,"about_ca_system_score_gemma":0.0017914586,"threshold_uncertainty_score":0.31779706},"labels":[],"label_agreement":null},{"id":"W2293003343","doi":"10.1016/j.jtho.2015.12.038","title":"Translational application of microRNA profiling for early detection of lung cancer: A comparison of sputum and blood","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA and protein synthesis mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Sputum; Medicine; Lung cancer; microRNA; Oncology; Internal medicine; KRAS; Microarray; Carcinogenesis; Stage (stratigraphy); Cancer; Bioinformatics; Pathology; Gene; Gene expression; Colorectal cancer; Biology; Tuberculosis","score_opus":0.014578570392970476,"score_gpt":0.3684975315138957,"score_spread":0.3539189611209252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2293003343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86365354,0.0015990618,0.13428256,0.00016608562,0.000077643555,0.00018580575,0.00002120118,6.7125364e-7,0.000013445558],"genre_scores_gemma":[0.9888039,0.00013778354,0.0109095,0.0000049223613,0.000110167595,0.00001378292,0.0000013961654,0.0000067609703,0.000011785369],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992445,0.00006706094,0.0004521118,0.00008706312,0.00007835612,0.00007091439],"domain_scores_gemma":[0.9987414,0.0000626646,0.00084010797,0.00006978385,0.00025839236,0.000027638269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038116085,0.000058838115,0.00026047745,0.00005859076,0.000017651091,0.0000012400902,0.0000794471,0.00013579986,0.0000026142457],"category_scores_gemma":[0.000045732348,0.000043683427,0.000086252076,0.00003553771,0.00005440853,0.0000057564976,0.000010792458,0.000036024034,3.106361e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009475338,0.000080978156,0.008133825,0.00010682638,0.00009255146,1.1173548e-7,0.00005378665,0.000008010085,0.8418983,0.000029861449,0.000003848665,0.14864434],"study_design_scores_gemma":[0.0005024809,0.0014548803,0.0023619994,0.000060518887,0.00015353414,0.000017844706,0.000025734718,0.000074953336,0.99453205,0.00030384609,0.00046824137,0.000043939996],"about_ca_topic_score_codex":0.0000073613805,"about_ca_topic_score_gemma":0.000013061231,"teacher_disagreement_score":0.1526337,"about_ca_system_score_codex":0.000009175894,"about_ca_system_score_gemma":0.00010202719,"threshold_uncertainty_score":0.17813584},"labels":[],"label_agreement":null},{"id":"W2298541750","doi":"10.1016/j.jtho.2016.01.021","title":"Computer Vision Tool and Technician as First Reader of Lung Cancer Screening CT Scans","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary; University of Ottawa; Juravinski Hospital; Memorial University of Newfoundland; Vancouver Coastal Health; Institut universitaire de cardiologie et de pneumologie de Québec; University Health Network; Ottawa Hospital; Dalhousie University; Brock University; Toronto General Hospital","funders":"Partenariat Canadien Contre Le Cancer; Terry Fox Research Institute","keywords":"Technician; Medicine; Lung cancer; Radiology; Lung cancer screening; Confidence interval; Computed tomography; Medical physics; Nuclear medicine; Internal medicine","score_opus":0.01801706518436059,"score_gpt":0.41952486429711655,"score_spread":0.40150779911275597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2298541750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96216995,0.002403624,0.0018195842,0.032350086,0.00043752347,0.0002395799,0.000009625624,0.000010400126,0.0005596556],"genre_scores_gemma":[0.9907296,0.0019860177,0.006037421,0.00056163943,0.00044221262,0.000008155705,5.5668096e-7,0.000014518688,0.00021992026],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990219,0.000051945783,0.00042364735,0.00013468409,0.00020797638,0.0001598483],"domain_scores_gemma":[0.99891984,0.00020666294,0.00043158865,0.0001335587,0.00019535105,0.000113003596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031627144,0.000109175715,0.0004908327,0.00014955296,0.000044281613,0.00000640789,0.00006886094,0.00007423228,0.000167591],"category_scores_gemma":[0.000036929003,0.00006044283,0.00009867699,0.000096096264,0.000095566524,0.0001053711,0.00004654506,0.0001337616,0.0000018859859],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001304857,0.00038720306,0.1565624,0.00017866645,0.00047606067,0.00064774795,0.00016466505,0.00001681893,0.0014474997,0.000041743922,0.014550869,0.82422143],"study_design_scores_gemma":[0.009800841,0.02132981,0.678687,0.01607062,0.00346088,0.008707527,0.000222517,0.0005846494,0.0226131,0.0002234058,0.23783937,0.00046029958],"about_ca_topic_score_codex":0.00009980451,"about_ca_topic_score_gemma":0.00010190575,"teacher_disagreement_score":0.82376117,"about_ca_system_score_codex":0.00046975125,"about_ca_system_score_gemma":0.00025401957,"threshold_uncertainty_score":0.2464787},"labels":[],"label_agreement":null},{"id":"W2299138773","doi":"10.1016/j.jtho.2015.12.081","title":"NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC)","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Metformin; AMPK; Oncology; Internal medicine; Lung cancer; non-small cell lung cancer (NSCLC); Cetuximab; Cancer; Cancer research; Kinase; Protein kinase A; A549 cell","score_opus":0.014830705867023095,"score_gpt":0.3703083138532801,"score_spread":0.355477607986257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299138773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95136404,0.044925407,0.00081081805,0.00031493232,0.0013485145,0.00041384282,0.000016238057,0.000006105355,0.00080013217],"genre_scores_gemma":[0.9697607,0.017221853,0.006973929,0.0018768375,0.002862089,0.000094530675,0.000008738233,0.00007041558,0.0011308794],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975459,0.00028387422,0.0009726146,0.0003810465,0.00025798767,0.00055857573],"domain_scores_gemma":[0.99800706,0.000090797206,0.00096353545,0.00029832072,0.00032422578,0.00031603826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012434274,0.00029720087,0.0007831993,0.00018375732,0.000085681924,0.000017580214,0.00037131403,0.00040918417,0.00013275571],"category_scores_gemma":[0.0004434359,0.0002166047,0.00027617966,0.00019475461,0.000153242,0.000028630564,0.00011684439,0.00036208387,0.0000055706487],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010184169,0.0003961632,0.00013795837,0.000040519564,0.00009501215,0.00008323107,0.00027957323,0.000038308925,0.46643573,0.0000043046884,0.00166122,0.52064383],"study_design_scores_gemma":[0.06373168,0.0064850315,0.00007562473,0.00044606623,0.00030546662,0.0001978405,0.000266347,0.00015656477,0.72663546,0.00015881848,0.20100088,0.0005402163],"about_ca_topic_score_codex":0.000028780652,"about_ca_topic_score_gemma":0.00012443603,"teacher_disagreement_score":0.52010363,"about_ca_system_score_codex":0.00024933723,"about_ca_system_score_gemma":0.0019288918,"threshold_uncertainty_score":0.8832883},"labels":[],"label_agreement":null},{"id":"W2304288722","doi":"10.1016/j.jtho.2016.03.007","title":"The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Windsor Regional Hospital","funders":"Cancer Care Ontario; Ontario Ministry of Health and Long-Term Care; Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Internal medicine; Oncology; Docetaxel; Hazard ratio; Maintenance therapy; Lung cancer; Randomized controlled trial; Chemotherapy; Gemcitabine; Confidence interval; Cisplatin","score_opus":0.0387747819572843,"score_gpt":0.4359392451606983,"score_spread":0.39716446320341403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304288722","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042739947,0.9931328,0.000030074396,0.0003138262,0.00025194706,0.0056442176,0.00009389294,0.0000018077168,0.00010401309],"genre_scores_gemma":[0.0006817456,0.9977611,0.00017690951,0.00009067335,0.00006483972,0.00055132125,0.0000084240855,0.000029136081,0.0006358674],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99631894,0.000890953,0.0020488668,0.00015914152,0.0003539182,0.00022820181],"domain_scores_gemma":[0.992265,0.0012668236,0.0052749403,0.0005270362,0.00059538387,0.0000708132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080589904,0.00031301254,0.003941465,0.00016628613,0.000044560114,0.000009201145,0.0003176935,0.00014216885,0.000008626531],"category_scores_gemma":[0.00015796197,0.00009682086,0.0005738438,0.00029789316,0.0000932372,0.000056333552,0.000022511194,0.00025489577,0.0000019042617],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020348854,0.0006085061,0.00038008468,0.7949,0.0018544212,0.0001270374,0.0004710537,0.000001923077,2.2699892e-7,0.000006186849,0.00066236116,0.2007847],"study_design_scores_gemma":[0.0010515562,0.0020017584,0.0000617612,0.8422822,0.031250585,0.00047697782,0.00012047353,0.0000012798184,6.1535764e-7,0.0000011443284,0.122661896,0.00008977714],"about_ca_topic_score_codex":0.00005693577,"about_ca_topic_score_gemma":0.000061524996,"teacher_disagreement_score":0.20069493,"about_ca_system_score_codex":0.0018314238,"about_ca_system_score_gemma":0.0028441383,"threshold_uncertainty_score":0.50453794},"labels":[],"label_agreement":null},{"id":"W2304373741","doi":"10.1097/jto.0000000000000693","title":"Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Hazard ratio; Placebo; Lung cancer; Gastroenterology; Clinical endpoint; Oncology; Progression-free survival; Confidence interval; Randomized controlled trial; Hepatocellular carcinoma; Chemotherapy; Pathology","score_opus":0.02768786980656785,"score_gpt":0.4436823993396465,"score_spread":0.41599452953307864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304373741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961455,0.00032003142,0.00019925568,0.0010817365,0.00044436584,0.0005062238,0.0000052688233,0.0000026119415,0.0012950114],"genre_scores_gemma":[0.99629766,0.00004136895,0.0028812746,0.00012890289,0.00019534558,0.000010439724,0.000006938835,0.000011686958,0.0004264073],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990809,0.000068214686,0.000445427,0.00008530686,0.00020985029,0.00011033301],"domain_scores_gemma":[0.9987568,0.00003666882,0.00058392884,0.00008844231,0.00038922936,0.00014492338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022705359,0.000087329965,0.0003822892,0.00015166975,0.000015072469,0.0000046380787,0.00005501093,0.000090118,0.00005033309],"category_scores_gemma":[0.000026256179,0.000056244404,0.000057482044,0.00013341292,0.000026856827,0.00008730152,0.0000060639936,0.00015502852,8.296863e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48146716,0.007507493,0.39459252,0.00018445686,0.0005484626,0.00029998913,0.0047489093,0.00060301693,0.00059300155,0.000008625774,0.00309119,0.10635516],"study_design_scores_gemma":[0.4659157,0.10359108,0.3869406,0.0012132043,0.0036689304,0.0001486514,0.0020495155,0.0004692186,0.012542907,0.00018273851,0.022824936,0.00045249885],"about_ca_topic_score_codex":0.000041866348,"about_ca_topic_score_gemma":0.00005471852,"teacher_disagreement_score":0.10590266,"about_ca_system_score_codex":0.00047309033,"about_ca_system_score_gemma":0.0024487055,"threshold_uncertainty_score":0.43438983},"labels":[],"label_agreement":null},{"id":"W2310252196","doi":"10.1016/j.jtho.2016.03.012","title":"Scientific Advances in Lung Cancer 2015","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":282,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; Ignyta; Chugai Pharmaceutical; Genentech; Astellas Pharma; KWF Kankerbestrijding; Clovis Oncology; Les Laboratories Pierre Fabre; Vertex Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Teva Pharmaceutical Industries; International Association for the Study of Lung Cancer; Cancer Care Ontario; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Intensive care medicine; Medical physics; Oncology","score_opus":0.04438451963432331,"score_gpt":0.5351431034609488,"score_spread":0.4907585838266255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2310252196","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004750344,0.9920766,0.000007636562,0.0018160649,0.0042314534,0.0005047992,0.000029059758,0.0000058460078,0.0012810605],"genre_scores_gemma":[0.000049381182,0.9966513,0.00030618708,0.00007520832,0.0011192312,0.00009104455,0.00000599683,0.00003335767,0.0016683178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99765515,0.0002514478,0.0011138727,0.0002966668,0.000359812,0.00032306713],"domain_scores_gemma":[0.9973953,0.00033088724,0.0014868515,0.00027280848,0.00030317082,0.00021101486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009568277,0.00028353318,0.0026844032,0.0006856255,0.000043670934,0.000025641382,0.00022486532,0.00032234803,0.00048623868],"category_scores_gemma":[0.0001062475,0.00015106682,0.0005927355,0.00037839997,0.00013890413,0.00020259782,0.00005240477,0.00054147094,0.000040987226],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011766473,0.00033033808,0.00043080223,0.010140583,0.0003148695,0.0008476857,0.00003619899,5.449746e-7,2.8720865e-7,0.000010645332,0.017195348,0.97057503],"study_design_scores_gemma":[0.0005483277,0.0005174509,0.00005109988,0.068404354,0.0024437173,0.00084844977,0.000008786142,5.65196e-7,0.0000029026194,0.000036314697,0.9270121,0.00012593807],"about_ca_topic_score_codex":0.0000066151915,"about_ca_topic_score_gemma":0.000104726016,"teacher_disagreement_score":0.9704491,"about_ca_system_score_codex":0.0046279714,"about_ca_system_score_gemma":0.0041704616,"threshold_uncertainty_score":0.9991931},"labels":[],"label_agreement":null},{"id":"W2322184086","doi":"10.1016/j.jtho.2015.12.057","title":"Unique roles for Akt isoforms in lung cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"AKT1; AKT2; Protein kinase B; Carcinogenesis; Lung cancer; Cancer research; Gene isoform; Cancer; Biology; Medicine; Signal transduction; Internal medicine; Cell biology; Gene; Biochemistry","score_opus":0.015044496829734352,"score_gpt":0.414492276531218,"score_spread":0.39944777970148365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322184086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766969,0.003957452,0.013369103,0.0042803176,0.0010384356,0.00020645719,0.000031367883,0.0000047911863,0.00041517912],"genre_scores_gemma":[0.99315065,0.0009114821,0.0031851353,0.00061382307,0.0011356848,0.000045113364,0.0000028929278,0.000027625045,0.0009275729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884987,0.00010465482,0.0004604954,0.00018166678,0.00011123774,0.0002920949],"domain_scores_gemma":[0.99896514,0.00009286799,0.000435407,0.00016681827,0.0002477769,0.000091989874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007503365,0.00013251479,0.0003087943,0.00011444872,0.000032976368,0.0000082574115,0.00029711312,0.00029001743,0.000059848102],"category_scores_gemma":[0.00021047026,0.00008628115,0.0001514905,0.00007353031,0.00007931189,0.000011653297,0.00005833332,0.0001241725,0.0000012439391],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018157742,0.00011097381,0.009486942,0.00005272957,0.00013683838,0.000026361908,0.00008163017,0.00015111841,0.8175067,0.000049249,0.014776681,0.155805],"study_design_scores_gemma":[0.0016678504,0.00226374,0.0018148958,0.00028366,0.000091069,0.0001836647,0.00007812458,0.000060709714,0.6392409,0.0009977994,0.35304582,0.00027175524],"about_ca_topic_score_codex":0.000010130498,"about_ca_topic_score_gemma":0.00029934398,"teacher_disagreement_score":0.33826914,"about_ca_system_score_codex":0.0002792953,"about_ca_system_score_gemma":0.0006620788,"threshold_uncertainty_score":0.3518443},"labels":[],"label_agreement":null},{"id":"W2330471016","doi":"10.1016/j.jtho.2015.12.082","title":"Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC)","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute; NRG Oncology","keywords":"AMPK; Metformin; Medicine; Cancer research; PI3K/AKT/mTOR pathway; Internal medicine; Pharmacology; Apoptosis; Protein kinase A; Kinase; Biology; Insulin; Cell biology; Biochemistry","score_opus":0.007576943788998205,"score_gpt":0.31959634941016596,"score_spread":0.31201940562116776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330471016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.924787,0.06930195,0.0028918441,0.0004460991,0.0020213695,0.00023183235,0.000028508173,0.0000039285565,0.00028749547],"genre_scores_gemma":[0.9818676,0.0105868615,0.003157602,0.0013800336,0.0025694577,0.000031771066,0.0000021285073,0.000039273466,0.0003652508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980372,0.00032069074,0.00062442437,0.00033982622,0.00017548614,0.000502375],"domain_scores_gemma":[0.99858683,0.000068607755,0.0005524556,0.00024228997,0.00029904098,0.00025078814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015158914,0.0002269439,0.0006274927,0.00016995044,0.00004644061,0.00001635866,0.0002651214,0.00021200723,0.00006748999],"category_scores_gemma":[0.00022969786,0.00016145277,0.00019612747,0.00014836372,0.000059384187,0.000016021639,0.00013267546,0.0002556913,0.000008223262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005461902,0.00010720559,0.0022543208,0.00003828868,0.000062527484,0.000075640484,0.00012550307,0.00009375791,0.7767806,0.000003360933,0.0040309117,0.2158817],"study_design_scores_gemma":[0.001657226,0.00047351673,0.0069924654,0.00011986773,0.00017202969,0.00006176967,0.00013315339,0.000056455523,0.7086532,0.000040338055,0.28127727,0.00036268678],"about_ca_topic_score_codex":0.00005123906,"about_ca_topic_score_gemma":0.00017023139,"teacher_disagreement_score":0.27724636,"about_ca_system_score_codex":0.00016360515,"about_ca_system_score_gemma":0.00061992503,"threshold_uncertainty_score":0.6583853},"labels":[],"label_agreement":null},{"id":"W2331944835","doi":"10.1016/j.jtho.2016.03.016","title":"Prediction of Early Death in Patients with Early-Stage NSCLC—Can We Select Patients without a Potential Benefit of SBRT as a Curative Treatment Approach?","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Comorbidity; Stage (stratigraphy); Logistic regression; Performance status; Internal medicine; Lung cancer; Proportional hazards model; Multivariate analysis; Radiosurgery; Oncology; Surgery; Cancer; Radiation therapy","score_opus":0.019983203402410575,"score_gpt":0.33355743918762953,"score_spread":0.313574235785219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331944835","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977888,0.000102775775,0.00013844948,0.00043871795,0.00016113522,0.00081437174,0.00011805559,0.0000063976972,0.0004312993],"genre_scores_gemma":[0.9981241,0.0001957471,0.0012860699,0.000026752647,0.0000738183,0.000039686314,0.000014065469,0.00002517851,0.00021455224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806195,0.00014946306,0.00077225536,0.00023907784,0.00052097545,0.0002562598],"domain_scores_gemma":[0.997761,0.00008065519,0.0011503048,0.00020001024,0.00063798483,0.0001700415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017814423,0.00023038324,0.00089712854,0.00033724387,0.00003011149,0.000005750894,0.000094070645,0.00015016951,0.000040284867],"category_scores_gemma":[0.000037137866,0.00012222985,0.00017526984,0.00020307032,0.00009463203,0.00017485983,0.000024808729,0.0001502597,0.0000021135377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013283923,0.0061838357,0.9340982,0.000058358357,0.0008157448,0.000041666626,0.0014416273,0.000020111314,0.000118817996,0.000018290297,0.000022034515,0.043897387],"study_design_scores_gemma":[0.01362162,0.05808118,0.923276,0.0008102104,0.0008106215,0.000026726328,0.00008940776,0.000008674156,0.002966249,0.00006058368,0.00015672483,0.000091966576],"about_ca_topic_score_codex":0.00024245035,"about_ca_topic_score_gemma":0.000071274066,"teacher_disagreement_score":0.051897347,"about_ca_system_score_codex":0.0017458539,"about_ca_system_score_gemma":0.0005246442,"threshold_uncertainty_score":0.49843884},"labels":[],"label_agreement":null},{"id":"W2335999692","doi":"10.1016/s1556-0864(16)30197-6","title":"84P Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"AMPK; Metformin; Medicine; PI3K/AKT/mTOR pathway; Cancer research; Lung cancer; Protein kinase B; Internal medicine; AMP-activated protein kinase; Pharmacology; Oncology; Apoptosis; Protein kinase A; Kinase; Insulin; Biology; Cell biology","score_opus":0.01620514229648225,"score_gpt":0.37664538737047476,"score_spread":0.3604402450739925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2335999692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80091816,0.19075407,0.0035510988,0.0023228074,0.0019246659,0.0002966216,0.00012128378,0.000005610781,0.00010565523],"genre_scores_gemma":[0.82815725,0.11324368,0.02783628,0.019788451,0.008673573,0.00013141909,0.000008236812,0.0001197477,0.0020413431],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978855,0.00026727372,0.0006255479,0.00044299735,0.0002520225,0.00052663515],"domain_scores_gemma":[0.99811417,0.000097677665,0.00028476634,0.00040900317,0.00057998154,0.00051440485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005702822,0.000303973,0.00089823577,0.00020229095,0.00007518391,0.00002524246,0.000455005,0.00022880262,0.00012609195],"category_scores_gemma":[0.00017303122,0.00021162714,0.00022966815,0.0001965095,0.000052005624,0.0000117357395,0.00019286052,0.00016518742,0.00001980186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000783187,0.000099020544,0.001634155,0.000025230109,0.00060417195,0.000036396264,0.0010348579,0.00048775694,0.59159863,0.0000026833554,0.024737583,0.37895632],"study_design_scores_gemma":[0.0007413462,0.000794013,0.0031858745,0.00015262606,0.00028172965,0.000013799727,0.00036608058,0.000004739088,0.5263816,0.000022976606,0.46775326,0.00030196377],"about_ca_topic_score_codex":0.00011658322,"about_ca_topic_score_gemma":0.00094035733,"teacher_disagreement_score":0.4430157,"about_ca_system_score_codex":0.00018352242,"about_ca_system_score_gemma":0.0005027539,"threshold_uncertainty_score":0.86299044},"labels":[],"label_agreement":null},{"id":"W2336234029","doi":"10.1016/s1556-0864(16)30212-x","title":"99PD: Modelling of pulmonary function test changes after stereotactic body radiotherapy for stage I NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; DLCO; Pulmonary function testing; Nuclear medicine; Lung; Radiation therapy; Stage (stratigraphy); Lung volumes; Radiology; Internal medicine; Lung function; Diffusing capacity","score_opus":0.024285938769643165,"score_gpt":0.36439272015875973,"score_spread":0.34010678138911654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336234029","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.088079885,0.00073722843,0.9095513,0.0008098987,0.00029953787,0.0002536891,0.000043296874,0.0000150210335,0.00021012794],"genre_scores_gemma":[0.9499427,0.00022545316,0.047426406,0.000111289584,0.0010404856,0.0000459097,0.0000014670981,0.00004237156,0.0011639203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989701,0.000082077604,0.00044442306,0.00014643845,0.00013308461,0.00022389484],"domain_scores_gemma":[0.9981913,0.00048181938,0.0008609373,0.00017375148,0.00022136573,0.00007085572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038481067,0.00015612209,0.0004464144,0.00017948919,0.00003999556,0.000008651173,0.00016160945,0.00009042235,0.00030597296],"category_scores_gemma":[0.000010074365,0.000104814426,0.00017413554,0.00007783741,0.00006747099,0.0002843518,0.000014333542,0.0001519328,5.734504e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044807447,0.0006375687,0.01397228,0.0000655801,0.0003756181,0.000017533968,0.00020292253,0.00019856343,0.18749785,0.0002631839,0.00021161951,0.7920765],"study_design_scores_gemma":[0.0065742293,0.02577314,0.0051733823,0.0014298784,0.0009727145,0.00031572126,0.00069600204,0.01709131,0.20708421,0.024593858,0.70866716,0.0016283932],"about_ca_topic_score_codex":0.0000036756305,"about_ca_topic_score_gemma":8.922955e-7,"teacher_disagreement_score":0.8621249,"about_ca_system_score_codex":0.00016346673,"about_ca_system_score_gemma":0.000101001395,"threshold_uncertainty_score":0.42742082},"labels":[],"label_agreement":null},{"id":"W2336729059","doi":"10.1016/s1556-0864(16)30288-x","title":"178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; EMD Serono; Pfizer; Daiichi-Sankyo; Novartis Pharma; Ariad Pharmaceuticals; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Ceritinib; Medicine; Internal medicine; Crizotinib; Oncology; Hazard ratio; Confidence interval; Lung cancer","score_opus":0.017134398721657618,"score_gpt":0.43364449810355965,"score_spread":0.41651009938190203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336729059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98334974,0.000662317,0.00009756456,0.013605633,0.00027794935,0.0005911477,0.000045472112,0.000012859371,0.0013573099],"genre_scores_gemma":[0.9981169,0.00007047028,0.0010968811,0.00015795197,0.00012290697,0.000027460324,0.000026399408,0.000019953255,0.00036108997],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983056,0.00026461523,0.0006008444,0.00016680971,0.00044481634,0.00021730067],"domain_scores_gemma":[0.9975809,0.00020817724,0.001022772,0.00014172056,0.00084544683,0.00020097186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061735464,0.00014073106,0.00054854125,0.00023226648,0.000045024506,0.0000075972384,0.000080830374,0.00013976522,0.000105375766],"category_scores_gemma":[0.00049785123,0.0000740521,0.00010491705,0.00021720423,0.00012306728,0.00020141569,0.000023764882,0.00018204696,0.0000029057535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018314904,0.003111941,0.2339559,0.00010135192,0.0004556962,0.0009729318,0.0013826075,0.0000024449694,0.013051588,0.00002963137,0.0006039481,0.72801703],"study_design_scores_gemma":[0.01698147,0.017157877,0.94322217,0.0065687117,0.0018548279,0.00026350282,0.0008923395,0.000049995666,0.008294142,0.00040842663,0.0040472643,0.00025926044],"about_ca_topic_score_codex":0.000006849511,"about_ca_topic_score_gemma":0.000047195772,"teacher_disagreement_score":0.7277578,"about_ca_system_score_codex":0.0004310522,"about_ca_system_score_gemma":0.0009952115,"threshold_uncertainty_score":0.3019757},"labels":[],"label_agreement":null},{"id":"W2336760376","doi":"10.1016/s1556-0864(16)30314-8","title":"206TiP: METIS: A phase III study of radiosurgery with TTFields for 1–10 brain metastases from NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurocognitive; Clinical endpoint; Oncology; Internal medicine; Radiosurgery; Population; Clinical trial; Radiation therapy; Cognition","score_opus":0.03876438262449277,"score_gpt":0.42214168159018606,"score_spread":0.3833772989656933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336760376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891012,0.0007927783,0.0014207265,0.0075799436,0.00027875436,0.0005990408,0.0000652849,0.0000080372565,0.00015428266],"genre_scores_gemma":[0.9944086,0.00005777649,0.0046915216,0.00027578085,0.0002896297,0.000051792405,0.0000053967524,0.000020781512,0.00019873606],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982871,0.00024555018,0.00076272886,0.00018555092,0.00030307064,0.00021599003],"domain_scores_gemma":[0.9960844,0.0021752282,0.0008999652,0.00024891747,0.00039512798,0.00019637153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008125286,0.0001739567,0.0011571693,0.00024208904,0.000039930917,0.000007292182,0.000110206376,0.000108149165,0.00061056437],"category_scores_gemma":[0.000427256,0.000087414,0.00024514223,0.00015436564,0.00007192476,0.00011162914,0.000024142731,0.000117120915,0.0000047062294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053906303,0.03277376,0.023367692,0.00007095154,0.0074768146,0.0041031446,0.0011730867,0.000004700405,0.03213272,0.00004424065,0.07918183,0.7657648],"study_design_scores_gemma":[0.27736592,0.25748867,0.036297623,0.0028045324,0.026752602,0.0050178226,0.009866607,0.000046246852,0.18749143,0.0012713324,0.19463472,0.0009624828],"about_ca_topic_score_codex":0.000046191148,"about_ca_topic_score_gemma":0.00007140549,"teacher_disagreement_score":0.7648023,"about_ca_system_score_codex":0.00013528169,"about_ca_system_score_gemma":0.00032362272,"threshold_uncertainty_score":0.66852516},"labels":[],"label_agreement":null},{"id":"W2337227118","doi":"10.1016/s1556-0864(16)30250-7","title":"140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Gefitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Erlotinib; Adverse effect; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.03421572737096714,"score_gpt":0.4650041278192836,"score_spread":0.43078840044831646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337227118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98465234,0.0004617484,0.0042851996,0.0024422817,0.00073860475,0.005310241,0.00030096192,0.000016072743,0.0017925429],"genre_scores_gemma":[0.97654057,0.0005067028,0.020508727,0.00016566571,0.00049194286,0.0009842148,0.00004515057,0.000052486437,0.0007045544],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975719,0.0001238376,0.0012030517,0.00034934925,0.000324258,0.00042764415],"domain_scores_gemma":[0.99553436,0.00083727424,0.00214055,0.00026222694,0.00092006475,0.00030554723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003799158,0.00034280858,0.0012229328,0.00018028784,0.00024503615,0.000033712127,0.00022840156,0.0001517855,0.00011564572],"category_scores_gemma":[0.00034818795,0.00020385135,0.00023201427,0.000245093,0.000086427404,0.00037789711,0.00005382135,0.00014891376,0.0000018947633],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57449734,0.015753685,0.0040407637,0.00036584574,0.0021833153,0.00012320968,0.0014732402,0.0002985719,0.0027886312,0.000018425757,0.00041621,0.39804074],"study_design_scores_gemma":[0.9206968,0.055147454,0.0006299465,0.0021743097,0.004793668,0.00008264826,0.00040526918,0.00046208492,0.010029478,0.000069062204,0.0052058357,0.00030345004],"about_ca_topic_score_codex":0.00013725559,"about_ca_topic_score_gemma":0.0001296738,"teacher_disagreement_score":0.3977373,"about_ca_system_score_codex":0.0023655503,"about_ca_system_score_gemma":0.0025453349,"threshold_uncertainty_score":0.83128166},"labels":[],"label_agreement":null},{"id":"W2337379543","doi":"10.1016/s1556-0864(16)30306-9","title":"197PD: Identifying dosimetric predictors of toxicity in multiple lung tumors treated with stereotactic ablative radiotherapy (SABR)","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; SABR volatility model; Lung; Radiosurgery; Radiation therapy; Toxicity; Pneumonitis; Radiology; Ablative case; Lung cancer; Retrospective cohort study; Nuclear medicine; Surgery; Internal medicine","score_opus":0.025277421461060906,"score_gpt":0.3804336748127833,"score_spread":0.3551562533517224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337379543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965678,0.0013162208,0.0003255338,0.0009297496,0.00020972997,0.00038312294,0.000009610629,0.000009934244,0.00024830885],"genre_scores_gemma":[0.99776477,0.0006311505,0.0011524197,0.00008359224,0.000145399,0.000013642557,0.0000012103457,0.000023546076,0.00018424833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982477,0.00023651794,0.0007338843,0.00019262794,0.00033823287,0.00025107802],"domain_scores_gemma":[0.997691,0.0007659047,0.0009587171,0.00018595965,0.0002336753,0.00016478155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005152955,0.0001819049,0.0008876907,0.00067358516,0.000031209463,0.000007729001,0.00011090189,0.00011540402,0.00012066529],"category_scores_gemma":[0.00018458981,0.000096759046,0.00015083177,0.0005761645,0.00012327751,0.00020841135,0.000017978302,0.0002159122,0.0000016650306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052821054,0.0012218696,0.96355915,0.00011496908,0.0010548111,0.0008160091,0.00061738386,0.000015728136,0.006228691,0.000003499607,0.00025011878,0.020835686],"study_design_scores_gemma":[0.008331963,0.007944935,0.9345375,0.0017562214,0.0007111736,0.0007652932,0.00017374866,0.000071587085,0.045076028,0.00001533291,0.00048205367,0.00013419679],"about_ca_topic_score_codex":0.00009985987,"about_ca_topic_score_gemma":0.00012340577,"teacher_disagreement_score":0.038847335,"about_ca_system_score_codex":0.0022856442,"about_ca_system_score_gemma":0.0003930895,"threshold_uncertainty_score":0.59768796},"labels":[],"label_agreement":null},{"id":"W2339638771","doi":"10.1016/j.jtho.2016.02.002","title":"Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University; University Health Network","funders":"World Health Organization","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Confidence interval; Adjuvant therapy; Randomized controlled trial; Adjuvant; Proportional hazards model; Clinical trial; Cancer","score_opus":0.012577229196344153,"score_gpt":0.3953484298414588,"score_spread":0.38277120064511466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339638771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904407,0.0017300716,0.0048571504,0.0006815625,0.0001261161,0.0019328578,0.00014992342,0.000004898766,0.00007667826],"genre_scores_gemma":[0.99769545,0.00018986945,0.0017226548,0.000062908846,0.0000667581,0.00016955228,0.000035228877,0.000015337811,0.00004226976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974164,0.0011146086,0.00088994077,0.00018197286,0.00024090086,0.00015621915],"domain_scores_gemma":[0.99336874,0.004613707,0.0013684524,0.00012429597,0.0004031099,0.000121698235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013039211,0.00017750698,0.002066076,0.0004950334,0.00003354358,0.000007776814,0.00005948322,0.00011089151,0.00010344911],"category_scores_gemma":[0.00068747177,0.00008136713,0.0003050735,0.0003659427,0.00011995269,0.00008475482,0.000009643356,0.00014396028,3.7255927e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23367389,0.00079145376,0.68743485,0.00006553471,0.0075182104,0.000048643422,0.0011062464,0.0004339313,0.00065630703,3.3859405e-7,0.0000286266,0.06824195],"study_design_scores_gemma":[0.317693,0.007751678,0.5918048,0.0008202236,0.07674114,0.000003659338,0.000097795084,0.0020700372,0.0028447101,0.000029206627,0.000022223614,0.000121504825],"about_ca_topic_score_codex":0.00014341313,"about_ca_topic_score_gemma":0.00011271193,"teacher_disagreement_score":0.095630035,"about_ca_system_score_codex":0.00033680734,"about_ca_system_score_gemma":0.0006912313,"threshold_uncertainty_score":0.33180553},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2340723773","doi":"10.1016/s1556-0864(16)30286-6","title":"176P: ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Chemotherapy; Incidence (geometry); Retrospective cohort study; Cohort; Medical record; Population; Cancer; Stage (stratigraphy); Oncology; Disease; Anaplastic lymphoma kinase","score_opus":0.014809282303309438,"score_gpt":0.3853893853732345,"score_spread":0.3705801030699251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2340723773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877564,0.001097634,0.00027470556,0.006766502,0.00050788414,0.00030490258,0.000063398555,0.000010164855,0.0032184368],"genre_scores_gemma":[0.99509436,0.0004886434,0.0010608179,0.00073733676,0.00025364966,0.000014917913,0.000004216852,0.000029055554,0.0023170207],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99883807,0.000119761404,0.00045643278,0.00014523264,0.0001892797,0.0002512152],"domain_scores_gemma":[0.99798316,0.00019448077,0.00089923036,0.00016218264,0.0006016264,0.00015932419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032508344,0.0001527478,0.0008413093,0.0001567567,0.00005478823,0.0000059544127,0.000107232445,0.00015224038,0.00032414417],"category_scores_gemma":[0.000054840722,0.00008283023,0.00013432557,0.00018316876,0.000091253874,0.000091594025,0.000018508481,0.00019783854,0.000005576629],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013922676,0.013070239,0.11618319,0.0009648192,0.019724853,0.005314123,0.025904972,0.00015817859,0.37846556,0.00009309665,0.0637525,0.3624458],"study_design_scores_gemma":[0.035542272,0.0271152,0.7179687,0.006456987,0.024034638,0.0012274929,0.0012359364,0.000082535415,0.15512708,0.00073356536,0.029675443,0.0008001771],"about_ca_topic_score_codex":0.00023858827,"about_ca_topic_score_gemma":0.0001322435,"teacher_disagreement_score":0.6017855,"about_ca_system_score_codex":0.00071788504,"about_ca_system_score_gemma":0.0014730504,"threshold_uncertainty_score":0.35491514},"labels":[],"label_agreement":null},{"id":"W2341741235","doi":"10.1016/s1556-0864(16)30248-9","title":"138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Tolerability; Lung cancer; Internal medicine; Adverse effect; Pharmacokinetics; Oncology; Urology; Incidence (geometry); Pharmacology; Gastroenterology; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.012401138771057037,"score_gpt":0.41622696611177845,"score_spread":0.4038258273407214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341741235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950089,0.0025267112,0.00016559052,0.0006847998,0.00011058668,0.00088635937,0.00015382613,0.0000026664163,0.0004606008],"genre_scores_gemma":[0.9977585,0.0010170933,0.0009668302,0.00008968992,0.000048092024,0.00001641942,0.000012580028,0.000020235431,0.00007057316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982949,0.00019672514,0.0008045387,0.00020013099,0.00029090032,0.00021282655],"domain_scores_gemma":[0.9968172,0.00077419146,0.0013863619,0.00018302744,0.0007034607,0.0001358023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029768373,0.00021548201,0.0007930037,0.00029866587,0.00004883906,0.0000045492616,0.000090614034,0.00009737586,0.000067137735],"category_scores_gemma":[0.00010929503,0.0001055799,0.00014404197,0.0002415902,0.00017292019,0.00014304662,0.000034083037,0.00018372448,2.3653377e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080456175,0.0056697424,0.50481427,0.00090139534,0.005288552,0.00017484048,0.014967546,0.0037563846,0.035371788,0.00004467444,0.00029235147,0.3482623],"study_design_scores_gemma":[0.014290294,0.013507677,0.9576671,0.001977651,0.0022966517,0.00003667995,0.000907953,0.00023812825,0.008926313,0.000008630956,0.000017098126,0.00012583735],"about_ca_topic_score_codex":0.00021849567,"about_ca_topic_score_gemma":0.000085043735,"teacher_disagreement_score":0.45285285,"about_ca_system_score_codex":0.00076998665,"about_ca_system_score_gemma":0.0008429845,"threshold_uncertainty_score":0.43054232},"labels":[],"label_agreement":null},{"id":"W2388964360","doi":"10.1016/j.jtho.2016.04.027","title":"North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; National Institutes of Health; International Association for the Study of Lung Cancer; Mesothelioma Applied Research Foundation","keywords":"Medicine; Concordance; Pathological; Radiology; Mesothelioma; Stage (stratigraphy); Nuclear medicine; Internal medicine; Pathology","score_opus":0.10290907217497236,"score_gpt":0.5065885224324851,"score_spread":0.40367945025751273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2388964360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972151,0.00023740267,0.0012610623,0.00031825135,0.00018662444,0.0006911456,0.000080978745,0.0000037425043,0.0000057114516],"genre_scores_gemma":[0.9947017,0.000057774763,0.00508454,0.000054627573,0.00006122388,0.0000052521623,0.0000017297074,0.000012246612,0.000020915837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977996,0.00043380493,0.0011042578,0.00020015016,0.0002970632,0.00016517106],"domain_scores_gemma":[0.99648035,0.0016280238,0.0013442703,0.00014075698,0.0002693985,0.00013720848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014890644,0.00012322584,0.00076408737,0.00022974337,0.00004116994,0.0000040144023,0.00009612613,0.000014151963,0.000009694528],"category_scores_gemma":[0.0017109057,0.000074430776,0.00015999957,0.00018487065,0.00038954426,0.00009215826,0.00008381589,0.000122123,6.031416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006737634,0.0046954006,0.92469877,0.00008314788,0.00030344978,0.000103681996,0.00047781254,0.0000058454275,0.00024173065,0.0000012889114,0.000048024405,0.062603205],"study_design_scores_gemma":[0.0035765688,0.012281076,0.9735666,0.00007981849,0.0008826771,0.000044356315,0.009112917,0.0002711148,0.000068887915,0.000019340712,0.000025818004,0.000070831054],"about_ca_topic_score_codex":0.00003983903,"about_ca_topic_score_gemma":0.000057504923,"teacher_disagreement_score":0.06253237,"about_ca_system_score_codex":0.00016484807,"about_ca_system_score_gemma":0.00013271859,"threshold_uncertainty_score":0.3035199},"labels":[],"label_agreement":null},{"id":"W2402010036","doi":"10.1016/j.jtho.2016.05.010","title":"ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genetic Syndromes and Imprinting","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Methylation; Gene; DNA methylation; Lung cancer; Gene expression; Cancer research; Lung; Genetics; Pathology; Internal medicine; Biology","score_opus":0.010288991759806392,"score_gpt":0.3360287557402515,"score_spread":0.3257397639804451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402010036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611443,0.0028602362,0.00038403037,0.00032032508,0.00015489347,0.00009027005,0.000002953399,0.0000019397432,0.00007091256],"genre_scores_gemma":[0.994622,0.00085390505,0.0040539615,0.00010625276,0.00017307531,0.00000406936,0.0000012558194,0.000016145792,0.0001693433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999017,0.00021518373,0.00031257625,0.00019593896,0.00008601933,0.00017328367],"domain_scores_gemma":[0.9993298,0.000094859926,0.0002694169,0.00012728275,0.000070207374,0.00010844711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005220039,0.00011016767,0.0002103049,0.000084689396,0.000037122238,0.000017695495,0.00009000949,0.0001733315,0.000026656622],"category_scores_gemma":[0.00024024185,0.00007633449,0.000035233563,0.00004140668,0.00006641505,0.000017105978,0.00007960494,0.00007455663,6.333151e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118770855,0.000024040948,0.12673984,0.000012159421,0.00002733379,0.000012070871,0.00009759455,0.0000139725435,0.8404329,0.0000016177033,0.00003429516,0.03248542],"study_design_scores_gemma":[0.0006071422,0.0010440467,0.47627556,0.00009528726,0.000037088448,0.00038709122,0.00008764905,0.000038664835,0.51965165,0.00022260536,0.0014318774,0.000121310666],"about_ca_topic_score_codex":0.000052443283,"about_ca_topic_score_gemma":0.00003689491,"teacher_disagreement_score":0.34953573,"about_ca_system_score_codex":0.000044634853,"about_ca_system_score_gemma":0.00009186012,"threshold_uncertainty_score":0.311283},"labels":[],"label_agreement":null},{"id":"W2403654892","doi":"10.1016/j.jtho.2016.05.008","title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Pfizer Canada; Chugai Pharmaceutical; Eisai; National Comprehensive Cancer Network; Ariad Pharmaceuticals; Genentech; AstraZeneca Canada; EMD Serono; International Association for the Study of Lung Cancer; Gilead Sciences; GlaxoSmithKline; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Osimertinib; Epidermal growth factor receptor; Oncology; Internal medicine; Erlotinib; Targeted therapy; Tyrosine kinase; Cancer; Receptor","score_opus":0.03320840595427421,"score_gpt":0.4896282325833793,"score_spread":0.4564198266291051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2403654892","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003583349,0.9835849,0.00028207563,0.0029303632,0.0024990735,0.005433189,0.00046922223,0.0000038747876,0.0012139828],"genre_scores_gemma":[0.0041208426,0.99143296,0.000686978,0.00005471497,0.00023122448,0.000739895,0.000019787529,0.0000326213,0.00268098],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997203,0.00029422145,0.0015243673,0.00020624841,0.0004942234,0.00027797688],"domain_scores_gemma":[0.9927451,0.0020453902,0.004118617,0.00018659452,0.00083788147,0.00006640367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013028738,0.00023979931,0.0011395379,0.00027639538,0.000109915956,0.000018487219,0.00025293906,0.00013018491,0.000032417083],"category_scores_gemma":[0.00006837044,0.00011891222,0.00031280288,0.00017822994,0.000044348322,0.000042229,0.000060265746,0.00031272802,6.0148733e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012945391,0.0012547084,0.00095267396,0.003704236,0.011309783,0.00010735767,0.002123248,0.0009761073,0.000003164729,0.00003476341,0.0047902823,0.9734491],"study_design_scores_gemma":[0.015524501,0.006369264,0.0036848458,0.058912415,0.048909117,0.000052502615,0.011488894,0.00073178316,0.0000905084,0.000046812005,0.8537201,0.00046920902],"about_ca_topic_score_codex":0.00032225158,"about_ca_topic_score_gemma":0.0003509795,"teacher_disagreement_score":0.9729799,"about_ca_system_score_codex":0.007290891,"about_ca_system_score_gemma":0.0024491304,"threshold_uncertainty_score":0.9965199},"labels":[],"label_agreement":null},{"id":"W2415409512","doi":"10.1016/j.jtho.2016.05.029","title":"Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma; PharmaMar; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer; Eli Lilly and Company","keywords":"Crizotinib; Medicine; Ceritinib; Oncology; Alectinib; ALK inhibitor; Internal medicine; Targeted therapy; Lung cancer; Cancer","score_opus":0.03761913424189329,"score_gpt":0.46634445798500007,"score_spread":0.4287253237431068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2415409512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946908,0.002127876,0.00026298905,0.0010616991,0.00009822232,0.00062753505,0.000015876289,0.0000128427655,0.0011021626],"genre_scores_gemma":[0.99594975,0.00015277983,0.0035261451,0.00012860715,0.000109419234,0.000019040577,0.0000073180977,0.000016865044,0.00009009784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983066,0.00033273958,0.00073879585,0.00017910782,0.0002174868,0.00022532506],"domain_scores_gemma":[0.9980362,0.00043379143,0.00080019725,0.00013376477,0.00040801862,0.00018801096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024984006,0.00018486749,0.0010976786,0.00022779123,0.000040714534,0.000009944689,0.00008607163,0.00010574497,0.00009850662],"category_scores_gemma":[0.000086927044,0.0001023535,0.000074698975,0.00015265918,0.0002299418,0.00024014078,0.000013286816,0.00020693387,0.0000018686862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09656645,0.0051137195,0.11340683,0.00010673229,0.0016665464,0.0009303276,0.016680509,0.00006903925,0.12703906,0.00012186397,0.00008961281,0.6382093],"study_design_scores_gemma":[0.05622262,0.054980118,0.83230186,0.0025754063,0.0018917181,0.0020698209,0.0062661357,0.00008353543,0.040813666,0.00019054505,0.002283904,0.00032065512],"about_ca_topic_score_codex":0.00005585101,"about_ca_topic_score_gemma":0.00013649832,"teacher_disagreement_score":0.718895,"about_ca_system_score_codex":0.00020462205,"about_ca_system_score_gemma":0.000491214,"threshold_uncertainty_score":0.41738546},"labels":[],"label_agreement":null},{"id":"W2461519976","doi":"10.1097/01.jto.0000283447.32702.66","title":"P2-005: Expression networks regulated by gene dosage in lung adenocarcinoma","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Gene; Gene dosage; Copy-number variation; Gene expression profiling; Biology; Gene expression; Adenocarcinoma; Cancer research; Ingenuity; Cancer; Computational biology; Genetics; Genome","score_opus":0.009911158304949826,"score_gpt":0.3538790412009094,"score_spread":0.3439678828959596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2461519976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96642953,0.012311909,0.019839022,0.0003672869,0.00041412545,0.000095013704,0.0000035614066,0.000003315086,0.0005362112],"genre_scores_gemma":[0.9959917,0.00074030284,0.0019402698,0.00024568426,0.00051466486,0.0000032408013,0.000024925757,0.000016776428,0.00052241265],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998752,0.00013725199,0.00053521694,0.00018138718,0.00012374457,0.00027038707],"domain_scores_gemma":[0.99909765,0.00003342635,0.00041874484,0.00022165917,0.000110090485,0.00011843085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097302895,0.00011736198,0.000234786,0.00010646699,0.0000493478,0.000011553639,0.00023795877,0.0003384344,0.00003992336],"category_scores_gemma":[0.00004845604,0.000100823665,0.00009393572,0.00014751987,0.000058517675,0.000008808149,0.000057086196,0.00027079703,0.0000013483248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000951091,0.00016588217,0.007832907,0.000008054765,0.000034286808,0.00008389202,0.00004989659,0.00062946224,0.9344986,0.0000046053724,0.018313143,0.037428167],"study_design_scores_gemma":[0.0014607407,0.001350608,0.08876856,0.00008620811,0.000081096616,0.000691293,0.0002616693,0.0006273673,0.79520786,0.00006277869,0.111049876,0.0003519312],"about_ca_topic_score_codex":0.0000068229106,"about_ca_topic_score_gemma":0.000021190452,"teacher_disagreement_score":0.13929074,"about_ca_system_score_codex":0.00012318851,"about_ca_system_score_gemma":0.00012373933,"threshold_uncertainty_score":0.41114697},"labels":[],"label_agreement":null},{"id":"W2465504588","doi":"10.1097/01.jto.0000283289.96811.23","title":"D6-05: Genomic profile of invasion in lung adenocarcinoma with bronchioloalveolar features (AWBF)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Comparative genomic hybridization; In silico; Adenocarcinoma; Biology; Fluorescence in situ hybridization; Chromosome instability; Candidate gene; Bacterial artificial chromosome; Genome; Pathology; Gene; Cancer; Genetics; Medicine; Chromosome","score_opus":0.010897251297456235,"score_gpt":0.35250421728643644,"score_spread":0.3416069659889802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465504588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985141,0.005847512,0.007180213,0.0002686018,0.00025407097,0.0003030585,0.0000067858064,0.0000032284318,0.0009955763],"genre_scores_gemma":[0.9922649,0.0003387804,0.0066413865,0.00014534392,0.00027415453,0.0000046346677,0.000015479776,0.00003344016,0.00028187624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981792,0.0002441393,0.00059997453,0.00026201358,0.00031119195,0.0004034936],"domain_scores_gemma":[0.99865395,0.00005296754,0.00054276147,0.000291777,0.0003057061,0.00015286764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014996177,0.00017503765,0.00042009022,0.00036680777,0.000039934712,0.000009515228,0.000385473,0.00042566718,0.00004994007],"category_scores_gemma":[0.00014952276,0.00014331461,0.00014385472,0.00025414303,0.00012854525,0.000010121931,0.00015633329,0.00061556936,0.0000025489953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050519155,0.00019543705,0.0025356885,0.000080305545,0.00013825847,0.00043037735,0.00014134523,0.0003093485,0.9717266,0.000024454197,0.0016095781,0.01775667],"study_design_scores_gemma":[0.0014862143,0.005649732,0.040923294,0.00013006724,0.000082456376,0.0019781184,0.00035451745,0.000036932706,0.94268686,0.00006417828,0.00640086,0.00020674682],"about_ca_topic_score_codex":0.000033815057,"about_ca_topic_score_gemma":0.00032048358,"teacher_disagreement_score":0.038387608,"about_ca_system_score_codex":0.00024842971,"about_ca_system_score_gemma":0.0007775988,"threshold_uncertainty_score":0.58442},"labels":[],"label_agreement":null},{"id":"W2466985514","doi":"10.1097/01.jto.0000283361.52989.e3","title":"PD2-2-7: Two wrongs make a right: the use of whole genome amplification for pair-wise genome-wide copy number analysis of limited patient material","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genomic variations and chromosomal abnormalities","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"Genome; Copy number analysis; Gene duplication; Copy-number variation; Computational biology; Multiple displacement amplification; Gene dosage; Biology; SNP array; Polymerase chain reaction; Human genome; Genetics; Molecular biology; Gene; Single-nucleotide polymorphism; DNA extraction","score_opus":0.02352908507514999,"score_gpt":0.3282995411410309,"score_spread":0.3047704560658809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2466985514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98553014,0.00010380693,0.013093148,0.0003923073,0.0002455909,0.00022916177,0.00032296914,0.0000023017128,0.00008058871],"genre_scores_gemma":[0.99111235,0.00004330804,0.007924722,0.00019138187,0.0002154335,0.000009851383,0.00027160204,0.000014615932,0.00021671026],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832076,0.00016549994,0.0009788469,0.00015894738,0.0001539739,0.0002219714],"domain_scores_gemma":[0.997551,0.00014650257,0.0013177497,0.0003001143,0.0006118471,0.00007276979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079691026,0.00013667089,0.00044297447,0.0001703773,0.00007837574,0.000019640813,0.00023497088,0.00016243634,0.00009458363],"category_scores_gemma":[0.00011085227,0.00009947389,0.0003383098,0.00023911687,0.00012264347,0.000011682781,0.00006883262,0.00008991105,0.0000016266418],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041842246,0.00077749445,0.029743806,0.00008422169,0.002953798,0.000013467659,0.0015961624,0.0060912073,0.94610983,0.00021766913,0.0007970674,0.0074310466],"study_design_scores_gemma":[0.0013838006,0.0033932629,0.12983635,0.000025413085,0.003505078,0.00017342798,0.0017789844,0.00023349046,0.28259897,0.00031274534,0.5763618,0.0003966872],"about_ca_topic_score_codex":0.000037510476,"about_ca_topic_score_gemma":0.00011594813,"teacher_disagreement_score":0.66351086,"about_ca_system_score_codex":0.00008051487,"about_ca_system_score_gemma":0.00015653204,"threshold_uncertainty_score":0.40564275},"labels":[],"label_agreement":null},{"id":"W2468391810","doi":"10.1097/01.jto.0000283371.17597.ce","title":"PD4-1-1: The impact of systemic therapy versus surgery on outcomes in multifocal bronchioloalveolar carcinoma","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Carcinoma; Stage (stratigraphy); Disease; Systemic therapy; Cancer; Medical record; Internal medicine; Surgery","score_opus":0.05058374150316422,"score_gpt":0.45600523914919244,"score_spread":0.4054214976460282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468391810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942391,0.002759972,0.000010488116,0.0013598226,0.0009471088,0.00027498702,0.0000044183494,0.0000045972783,0.00039951995],"genre_scores_gemma":[0.99875575,0.0007005798,0.00008582182,0.00015444269,0.0002555719,0.0000052681817,0.0000014931011,0.0000149189245,0.00002616409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982771,0.00024165685,0.0008025572,0.00012406416,0.0002795466,0.00027505137],"domain_scores_gemma":[0.99612683,0.0026838756,0.00066551374,0.00024140121,0.00015881329,0.00012354273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017912503,0.00016686655,0.0009507303,0.00030970207,0.000029991983,0.000004981352,0.00012457444,0.00015590318,0.00004933018],"category_scores_gemma":[0.00022764903,0.00008009718,0.00059772696,0.00018083479,0.000082482235,0.00004749352,0.000016499744,0.0003935383,0.0000055348514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015526034,0.0014054385,0.89788204,0.000034936464,0.0006368455,0.0007750534,0.0005765198,0.00010109846,0.00058534846,0.000007780386,0.00083987694,0.08162902],"study_design_scores_gemma":[0.0036723237,0.0075129983,0.98489225,0.00027639003,0.00014865713,0.000532967,0.00048704483,0.000014496711,0.0021589727,0.000012500995,0.00022280189,0.00006861402],"about_ca_topic_score_codex":0.0003060224,"about_ca_topic_score_gemma":0.000093250645,"teacher_disagreement_score":0.08701018,"about_ca_system_score_codex":0.0017746508,"about_ca_system_score_gemma":0.00066679216,"threshold_uncertainty_score":0.464065},"labels":[],"label_agreement":null},{"id":"W2471286646","doi":"10.1016/j.jtho.2016.06.003","title":"Comprehensive Clinical Staging for Resectable Lung Cancer: Clinicopathological Correlations and the Role of Brain MRI","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Lung cancer; Positron emission tomography; Stage (stratigraphy); Magnetic resonance imaging; Radiology; Asymptomatic; Cancer; Brain metastasis; Lung cancer staging; Population; Cancer staging; Retrospective cohort study; Pathological; Metastasis; Nuclear medicine; Surgery; Internal medicine","score_opus":0.045078287820327856,"score_gpt":0.49513978719571966,"score_spread":0.4500614993753918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471286646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91508275,0.011131491,0.0014942108,0.070276536,0.00079052756,0.00066661794,0.000032808293,0.0000068374306,0.0005182324],"genre_scores_gemma":[0.98993886,0.0052749165,0.0030078678,0.00096339034,0.0005217043,0.000041243646,0.0000010318403,0.000010218773,0.00024079363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983578,0.00038862802,0.000806302,0.00014232456,0.00014286891,0.0001621213],"domain_scores_gemma":[0.99237144,0.0061967443,0.0007498893,0.00014602715,0.00042483167,0.00011109399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015356232,0.00009049148,0.0007383378,0.000065234635,0.000070674956,0.0000055293476,0.000086081855,0.00013231461,0.000055676188],"category_scores_gemma":[0.000695262,0.00004008812,0.00024289459,0.00006764372,0.00035254957,0.00005858103,0.000047719765,0.0002252382,8.3176116e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011361041,0.0006161703,0.67715126,0.00009796473,0.0004889013,0.000060200346,0.00041477985,0.000020223408,0.00047219137,0.001053842,0.012192453,0.29607096],"study_design_scores_gemma":[0.038796544,0.01595147,0.60599524,0.0022374392,0.004561151,0.0011464495,0.0019342547,0.0019996488,0.0018227343,0.009973787,0.31530675,0.000274555],"about_ca_topic_score_codex":0.00001445041,"about_ca_topic_score_gemma":0.000018717308,"teacher_disagreement_score":0.3031143,"about_ca_system_score_codex":0.00021688636,"about_ca_system_score_gemma":0.0004160418,"threshold_uncertainty_score":0.1634746},"labels":[],"label_agreement":null},{"id":"W2474670944","doi":"10.1097/01.jto.0000283407.07873.7c","title":"PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Gefitinib; Medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Internal medicine; Epidermal growth factor receptor; Clinical endpoint; Adenocarcinoma; Cancer; Progressive disease; Chemotherapy; Clinical trial","score_opus":0.050427726566217516,"score_gpt":0.5477697998901098,"score_spread":0.49734207332389224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2474670944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562201,0.0005724154,0.00080013415,0.003228283,0.0008152148,0.00023553922,0.0000048565507,0.000007134787,0.038116332],"genre_scores_gemma":[0.98676354,0.00013476955,0.00821653,0.0011742216,0.0006071707,0.0000027055992,0.0000034821917,0.000011223394,0.0030863355],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843556,0.00014797559,0.0009183633,0.00011645403,0.00017616215,0.00020550172],"domain_scores_gemma":[0.99863917,0.00039563558,0.00041805295,0.00011067971,0.00024815366,0.00018831357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018512034,0.000090846,0.00048545667,0.00020432488,0.00003137449,0.0000067839514,0.00007042219,0.00015541991,0.00023200596],"category_scores_gemma":[0.00028137316,0.00006369534,0.00014884886,0.00016638768,0.00008244827,0.00010444155,0.000019111805,0.0005055435,0.000020861038],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00623457,0.0029015495,0.29626358,0.00006017822,0.00056040304,0.0063933157,0.0031604436,0.000032776843,0.0005907255,0.0004635045,0.0032691122,0.68006986],"study_design_scores_gemma":[0.0051975357,0.008113564,0.82789946,0.00024963703,0.0005789991,0.0013044922,0.0032129514,0.000026469535,0.0009983514,0.00017104422,0.15211785,0.00012962313],"about_ca_topic_score_codex":0.000016386992,"about_ca_topic_score_gemma":0.00013145599,"teacher_disagreement_score":0.6799402,"about_ca_system_score_codex":0.00044115848,"about_ca_system_score_gemma":0.00086671254,"threshold_uncertainty_score":0.25974205},"labels":[],"label_agreement":null},{"id":"W2480501096","doi":"10.1016/j.jtho.2016.04.019","title":"Staging, Tumor Profile, and Prognostic Groups in Lung Cancer or the New Tower of Babel","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Tower of Babel; Tower; Oncology; Cancer; Internal medicine; Archaeology","score_opus":0.0201661556378863,"score_gpt":0.4099912908275508,"score_spread":0.3898251351896645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2480501096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9564283,0.003919305,0.00005071992,0.03837806,0.00040134724,0.00044761293,0.0000059826607,0.0000038167254,0.00036485953],"genre_scores_gemma":[0.9951842,0.0015159869,0.00087828864,0.0005439266,0.00032170862,0.000032130265,2.51078e-7,0.000012187964,0.0015113534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989993,0.00008341999,0.00043653755,0.00011610522,0.00018415325,0.00018051575],"domain_scores_gemma":[0.99879515,0.00040480812,0.00042435605,0.00012118196,0.00013053203,0.00012398294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004034409,0.000103360675,0.00044819087,0.000108948494,0.00002062989,0.0000056376307,0.000085390624,0.00005414195,0.00045548286],"category_scores_gemma":[0.00020024675,0.000037413836,0.00006368226,0.00012741864,0.00008692706,0.00008288254,0.000036901853,0.00015902509,0.0000011351216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027315568,0.000578981,0.7247876,0.00021840456,0.00031370975,0.0006610842,0.00082300947,0.0000018949717,0.0008894199,0.00004864018,0.020597668,0.24834801],"study_design_scores_gemma":[0.007140114,0.006334696,0.9410597,0.004152635,0.0014675556,0.0013462092,0.00043378246,0.00004987699,0.007091978,0.00033505447,0.030420128,0.00016824358],"about_ca_topic_score_codex":0.00009452695,"about_ca_topic_score_gemma":0.00027681093,"teacher_disagreement_score":0.24817978,"about_ca_system_score_codex":0.00051639834,"about_ca_system_score_gemma":0.0010605818,"threshold_uncertainty_score":0.4987218},"labels":[],"label_agreement":null},{"id":"W2491258584","doi":"10.1016/j.jtho.2016.07.023","title":"A 10-Gene Yin Yang Expression Ratio Signature for Stage IA and IB Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"University of Toronto; CancerCare Manitoba Foundation; Manitoba Medical Service Foundation","keywords":"Gene signature; Lung cancer; Medicine; Malignancy; Adenocarcinoma; Stage (stratigraphy); Gene expression; Oncology; Microarray analysis techniques; Gene expression profiling; Cancer; Gene; Microarray; Bioinformatics; Internal medicine; Biology; Genetics","score_opus":0.0228435743461157,"score_gpt":0.39072228181819346,"score_spread":0.36787870747207774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2491258584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723331,0.010255044,0.00546455,0.00997352,0.0005888003,0.0005811638,0.00004889877,0.000010949377,0.00074401736],"genre_scores_gemma":[0.963819,0.0014044306,0.008744983,0.0008352711,0.0011571293,0.000085563704,0.0000033297183,0.000037443268,0.023912838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888265,0.00008582804,0.00042259594,0.00019015676,0.00017501852,0.00024377595],"domain_scores_gemma":[0.998633,0.00018667433,0.0005142698,0.00013303294,0.00033265885,0.00020035973],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050881365,0.00014732362,0.00050925714,0.00012479829,0.000069488226,0.000014495084,0.00009962437,0.00024562277,0.0013380698],"category_scores_gemma":[0.00007919104,0.0000844993,0.00014665592,0.000075762655,0.000051667903,0.00011894449,0.000044385735,0.00023260835,0.0000036821475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040760683,0.0002128736,0.0030949947,0.0003664675,0.00009620908,0.0000641957,0.0003015071,0.00001029582,0.7929324,0.000002437728,0.043795634,0.15504691],"study_design_scores_gemma":[0.0040545813,0.004140837,0.0035801602,0.0010826528,0.0006692947,0.0001241265,0.00024382502,0.00016362057,0.7628232,0.000024927225,0.2228923,0.00020044581],"about_ca_topic_score_codex":0.0000071635204,"about_ca_topic_score_gemma":0.000028230905,"teacher_disagreement_score":0.17909667,"about_ca_system_score_codex":0.00027577346,"about_ca_system_score_gemma":0.0004981184,"threshold_uncertainty_score":0.99957484},"labels":[],"label_agreement":null},{"id":"W2491676082","doi":"10.1016/j.jtho.2016.06.024","title":"A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Hamilton Health Sciences; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Alberta Cancer Foundation; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Chemotherapy; Mesothelioma; Open label; Stage (stratigraphy); Clinical trial; Pathology","score_opus":0.018291046721890525,"score_gpt":0.3917271278468672,"score_spread":0.37343608112497667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2491676082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984564,0.00007248386,0.000012637538,0.00048387088,0.000234019,0.0006092563,0.000024397395,0.000004185853,0.00010272834],"genre_scores_gemma":[0.99924433,0.000014454351,0.00035730223,0.00008482386,0.000112712754,0.000012057944,0.000004369061,0.000014257092,0.00015566494],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983688,0.00015755638,0.0006851098,0.00014579191,0.00046374855,0.00017898338],"domain_scores_gemma":[0.99884355,0.000119190634,0.00063645665,0.0001427967,0.00010464681,0.0001533318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028154146,0.0001348604,0.00056916784,0.00026013234,0.000034030752,0.0000021665167,0.00010822411,0.00006790732,0.00016692042],"category_scores_gemma":[0.000113836526,0.000070593866,0.000089893976,0.00015328676,0.00008706209,0.00016167935,0.000051827432,0.00013110982,0.0000050364756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5086618,0.04312659,0.2955589,0.00003139039,0.00021492342,0.00030507692,0.00046907458,0.000014179917,0.0026269227,0.0000047374274,0.00014957074,0.14883682],"study_design_scores_gemma":[0.207784,0.19084021,0.59836805,0.00029716012,0.0003770215,0.000054230095,0.00052490475,0.0000031138047,0.0009160188,0.00007487975,0.0006397667,0.00012064266],"about_ca_topic_score_codex":0.000006189532,"about_ca_topic_score_gemma":0.000015941829,"teacher_disagreement_score":0.30280915,"about_ca_system_score_codex":0.00026038635,"about_ca_system_score_gemma":0.00018309029,"threshold_uncertainty_score":0.28787342},"labels":[],"label_agreement":null},{"id":"W2492095263","doi":"10.1016/j.jtho.2016.06.028","title":"The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Lung cancer staging; Cancer; Classification scheme; Metastasis; Oncology; Radiology; Medical physics; Internal medicine; Machine learning; Mediastinoscopy; Computer science","score_opus":0.12764680975784382,"score_gpt":0.4954103306432486,"score_spread":0.36776352088540476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2492095263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795481,0.0012373595,0.0025623464,0.014134012,0.00032038745,0.0021207735,0.000030410507,0.0000012721343,0.00004534233],"genre_scores_gemma":[0.99654484,0.0010622792,0.002048132,0.000048062706,0.00008711101,0.00017607454,0.0000028315806,0.000010454663,0.000020199182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965328,0.0013787566,0.0013358336,0.0001513201,0.00044667782,0.0001546425],"domain_scores_gemma":[0.99381775,0.0023687603,0.0029489743,0.00031998893,0.00052808545,0.0000164252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058543235,0.0001221916,0.0005226102,0.00015501768,0.000095976204,0.0000057026123,0.00030529505,0.00011608097,0.00000675314],"category_scores_gemma":[0.00055382424,0.000043514534,0.00013435597,0.00035653994,0.00022986757,0.00011480362,0.00004342088,0.00018849756,1.4193698e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024771942,0.0007835218,0.5457164,0.001919136,0.0004333936,0.000001008008,0.025348688,0.000061739294,0.13884927,0.0016281839,0.000632034,0.2821494],"study_design_scores_gemma":[0.0022740925,0.00057014864,0.8041191,0.003639221,0.00079290854,0.000012237546,0.006506762,0.0006486591,0.17972803,0.00032273124,0.0013076215,0.00007847667],"about_ca_topic_score_codex":0.00015339183,"about_ca_topic_score_gemma":0.00091054244,"teacher_disagreement_score":0.28207093,"about_ca_system_score_codex":0.0006195255,"about_ca_system_score_gemma":0.001226654,"threshold_uncertainty_score":0.21760315},"labels":[],"label_agreement":null},{"id":"W2500721338","doi":"10.1016/j.jtho.2016.04.028","title":"Consensus Report of the 2015 Weinman International Conference on Mesothelioma","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"U.S. Bureau of Land Management; National Cancer Institute; National Institutes of Health; International Association for the Study of Lung Cancer; Tower Cancer Research Foundation; Mesothelioma Applied Research Foundation; University of Hawaiʻi Foundation; U.S. Department of the Interior; U.S. Department of Defense","keywords":"Medicine; Mesothelioma; Consensus conference; General surgery; Library science; Pathology; Internal medicine","score_opus":0.03761093013155992,"score_gpt":0.4244572881720094,"score_spread":0.3868463580404495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2500721338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9365915,0.00006274782,0.000023831992,0.0479579,0.0008004192,0.00006970225,0.000019990552,0.0000029957782,0.014470898],"genre_scores_gemma":[0.9958364,0.00004441035,0.0004639159,0.0004213776,0.0001846831,0.0000010426861,0.0000012702225,0.0000052038095,0.0030417293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905574,0.00007150137,0.0003932613,0.00007346981,0.0003332953,0.000072750285],"domain_scores_gemma":[0.9989516,0.000120691875,0.00056282844,0.00013706274,0.00014896838,0.00007884052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026877745,0.00006251593,0.00020443505,0.00007280901,0.000019364797,0.0000019963163,0.00012513279,0.00005419333,0.0007217154],"category_scores_gemma":[0.00024085147,0.0000287129,0.00012962274,0.0000399873,0.00019003011,0.000026887363,0.000038026847,0.000093108574,0.000022803644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015108964,0.0027464614,0.4755079,0.00007705318,0.000870229,0.003875891,0.00018067138,0.000018317718,0.24957736,0.0045006247,0.07976461,0.16777194],"study_design_scores_gemma":[0.0014473128,0.0020845938,0.89622945,0.00053510757,0.0002828041,0.010089156,0.00015965046,0.00001891249,0.024324123,0.003708406,0.06102682,0.00009365353],"about_ca_topic_score_codex":0.000002795137,"about_ca_topic_score_gemma":0.0000021622077,"teacher_disagreement_score":0.4207216,"about_ca_system_score_codex":0.00015940079,"about_ca_system_score_gemma":0.00024597454,"threshold_uncertainty_score":0.7902278},"labels":[],"label_agreement":null},{"id":"W2511007688","doi":"10.1097/01.jto.0000283014.32112.e8","title":"E08-01: Autofluorescence bronchoscopy and optical coherence tomography","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Optical Coherence Tomography Applications","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Autofluorescence; Medicine; Pathology; Optical coherence tomography; Bronchoscopy; Dysplasia; Biomedical engineering; Fluorescence; Radiology; Materials science; Optics","score_opus":0.014463648652648138,"score_gpt":0.34647497916486947,"score_spread":0.3320113305122213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511007688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9117376,0.0019683822,0.06694298,0.0006305377,0.0006626831,0.00023531183,0.0000046464215,0.0001349715,0.017682834],"genre_scores_gemma":[0.92536956,0.00013204782,0.07420468,0.00007636556,0.00017718127,0.000005016288,5.664747e-7,0.000018136112,0.00001645793],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986159,0.00003836416,0.00058689323,0.00014341559,0.00024060842,0.0003748072],"domain_scores_gemma":[0.99874926,0.00042205138,0.00014557388,0.00018976616,0.00014968945,0.00034367177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008725002,0.00016160108,0.00035178033,0.0003161871,0.000059058642,0.000033438067,0.00030126574,0.00021198895,0.000078955905],"category_scores_gemma":[0.00008079729,0.00014565131,0.00011123094,0.000546685,0.0003052754,0.00019895434,0.000039260565,0.00062886404,0.000017749846],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048925035,0.00046707716,0.01848829,0.00020509197,0.00028527316,0.00039044206,0.0006158865,0.00047124128,0.10527305,0.0063011954,0.004410514,0.8626027],"study_design_scores_gemma":[0.0022923264,0.0066047334,0.6757577,0.0006570472,0.0009555028,0.004433606,0.0016688203,0.005571959,0.14751728,0.021665646,0.1307967,0.0020786598],"about_ca_topic_score_codex":0.000002247858,"about_ca_topic_score_gemma":0.000014926465,"teacher_disagreement_score":0.860524,"about_ca_system_score_codex":0.00009521011,"about_ca_system_score_gemma":0.00006372142,"threshold_uncertainty_score":0.59394884},"labels":[],"label_agreement":null},{"id":"W2512042252","doi":"10.1016/j.jtho.2016.08.139","title":"An Anaplastic Lymphoma Kinase Immunohistochemistry–Negative but Fluorescence In Situ Hybridization–Positive Lung Adenocarcinoma Is Resistant to Crizotinib","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Canadian Cancer Society Research Institute","keywords":"Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Fluorescence in situ hybridization; Cancer research; Lung cancer; Immunohistochemistry; Fusion gene; Medicine; Adenocarcinoma; Tyrosine-kinase inhibitor; Molecular biology; In situ hybridization; Cancer; Biology; Pathology; Gene expression; Gene; Internal medicine","score_opus":0.01211312311629011,"score_gpt":0.39674905284954265,"score_spread":0.38463592973325256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512042252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022466,0.00052137347,0.0018111952,0.00545128,0.00027681657,0.00033423692,0.00006245251,0.000012297161,0.0013056975],"genre_scores_gemma":[0.9922651,0.000051378196,0.006279159,0.00053566037,0.0002109571,0.000019811909,0.000007671845,0.000022619506,0.0006076213],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984073,0.0001496164,0.0006112246,0.0002680243,0.00028168893,0.00028211382],"domain_scores_gemma":[0.99813616,0.00027560457,0.00042215397,0.00024628677,0.00059867854,0.000321116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026219327,0.0001821471,0.00048642748,0.0002882275,0.00008474078,0.000016969661,0.00016585129,0.000110828194,0.00011177018],"category_scores_gemma":[0.00043903495,0.0001257485,0.000102049264,0.00030167546,0.00010806711,0.00021516327,0.00003234393,0.00013079305,0.000016204389],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0116109755,0.00128625,0.00972642,0.00008979217,0.00035830023,0.0035746729,0.004350069,0.000014561401,0.86370915,0.00006331765,0.0020502375,0.10316627],"study_design_scores_gemma":[0.007528913,0.010274504,0.4472361,0.002081059,0.0012614358,0.0020176254,0.002547554,0.0000877218,0.52517545,0.00028314794,0.0010878227,0.00041869795],"about_ca_topic_score_codex":0.000055975826,"about_ca_topic_score_gemma":0.00003128809,"teacher_disagreement_score":0.43750966,"about_ca_system_score_codex":0.0024032453,"about_ca_system_score_gemma":0.0012871758,"threshold_uncertainty_score":0.6284403},"labels":[],"label_agreement":null},{"id":"W2513159858","doi":"10.1097/01.jto.0000283346.53882.24","title":"PD6-3-8: Skeletal morbidity and zoledronic acid benefits in patients with bone metastases from non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McGill University Health Centre","funders":"","keywords":"Medicine; Zoledronic acid; Spinal cord compression; Concomitant; Pathologic fracture; Placebo; Lung cancer; Internal medicine; Malignancy; Surgery; Bisphosphonate; Oncology; Osteoporosis; Pathology","score_opus":0.016917680127284583,"score_gpt":0.3633484159635222,"score_spread":0.3464307358362376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513159858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140805,0.007061615,0.00008935013,0.00050551514,0.0003242072,0.00034747648,0.00004269366,0.00000566023,0.0002154129],"genre_scores_gemma":[0.99427265,0.00047454354,0.0045956317,0.0004177594,0.00013714193,0.0000057755637,0.000018032315,0.00002023418,0.000058231508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984759,0.00008053048,0.00059865,0.00018877411,0.00025980707,0.00039635526],"domain_scores_gemma":[0.9986186,0.00012990605,0.0005476572,0.0001331748,0.0001854835,0.0003851648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051126897,0.00018048432,0.0007063743,0.0002399145,0.00004975344,0.000006906587,0.0000611339,0.00015784611,0.00007417124],"category_scores_gemma":[0.00002668688,0.00012688816,0.000069365415,0.0001616685,0.000056826957,0.00011687374,0.000033493427,0.00049185514,0.0000037311772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045263567,0.0013193855,0.88603055,0.00011376675,0.00017121846,0.0008034569,0.00021505413,0.0000147106,0.00014748109,8.2975095e-7,0.00020361127,0.10645359],"study_design_scores_gemma":[0.007059253,0.003149877,0.985693,0.00025307623,0.00070391997,0.0001164986,0.000071247734,0.00003439349,0.0019021323,0.000012025401,0.00089378114,0.00011084686],"about_ca_topic_score_codex":0.0007183196,"about_ca_topic_score_gemma":0.0028414477,"teacher_disagreement_score":0.10634274,"about_ca_system_score_codex":0.00050475413,"about_ca_system_score_gemma":0.00056560105,"threshold_uncertainty_score":0.5174349},"labels":[],"label_agreement":null},{"id":"W2518871594","doi":"10.1097/01.jto.0000283046.50283.51","title":"MTP4-01: Small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Oncology","score_opus":0.040807048020115894,"score_gpt":0.498526565168928,"score_spread":0.4577195171488121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518871594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92929745,0.01759718,0.0012153686,0.013157039,0.0017010508,0.00033575128,0.000003881055,0.00002150993,0.036670774],"genre_scores_gemma":[0.98145294,0.0022636077,0.0062364163,0.0015442737,0.0023951319,0.0000075640073,8.1046096e-7,0.00003056849,0.0060686865],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982948,0.00009941052,0.0005699269,0.00014076463,0.0004250878,0.00047002087],"domain_scores_gemma":[0.9982118,0.000332121,0.00043750595,0.00016768069,0.0005263011,0.00032456475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019233822,0.00013372634,0.0005908646,0.00030577776,0.00007334271,0.00000915196,0.00018774245,0.00014709977,0.00037132457],"category_scores_gemma":[0.00025776413,0.00009637413,0.00018360057,0.00025365778,0.00012543835,0.000073380725,0.00009018218,0.00077815884,0.000016282816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0134989945,0.0014629532,0.21793753,0.0016673589,0.0014968449,0.010342039,0.003647222,0.00005867917,0.052509703,0.00005636848,0.19111039,0.50621194],"study_design_scores_gemma":[0.004995213,0.0069508287,0.19343497,0.00089657557,0.0018236814,0.0031133671,0.0022936456,0.00011748026,0.062255573,0.00023763315,0.72347224,0.0004087747],"about_ca_topic_score_codex":0.00006287563,"about_ca_topic_score_gemma":0.00021948921,"teacher_disagreement_score":0.53236187,"about_ca_system_score_codex":0.001321021,"about_ca_system_score_gemma":0.0011229956,"threshold_uncertainty_score":0.40657437},"labels":[],"label_agreement":null},{"id":"W2519194501","doi":"10.1097/01.jto.0000283823.54863.21","title":"P2-165: A phase I/II study of concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; University of Ottawa; Eli Lilly (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Pemetrexed; Carboplatin; Regimen; Internal medicine; Lung cancer; Cisplatin; Premedication; Oncology; Phases of clinical research; Chemotherapy; Urology; Gastroenterology; Surgery","score_opus":0.027489787078774534,"score_gpt":0.4922198396536212,"score_spread":0.4647300525748467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519194501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935021,0.0019067149,0.0008466917,0.00033710082,0.0009188607,0.000770452,0.000020499585,0.000005606138,0.0016920031],"genre_scores_gemma":[0.9978661,0.00019011827,0.00073242944,0.000114043054,0.00028160974,0.000017433742,0.000007853886,0.000017225717,0.00077317335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982335,0.00009573647,0.00096121366,0.00016188441,0.00029387965,0.00025380292],"domain_scores_gemma":[0.9981703,0.00016708838,0.0010247282,0.00014229026,0.00032167914,0.00017391058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083248084,0.00015243357,0.00063646113,0.0005329284,0.00006065604,0.000005987987,0.00009850265,0.000110543755,0.00018962429],"category_scores_gemma":[0.000059024605,0.00012049127,0.00011160323,0.0003827378,0.000036223253,0.00010710244,0.000032479467,0.0003633236,0.0000013785639],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041367793,0.024629131,0.24860989,0.000433262,0.0008314442,0.0015790127,0.028112836,0.0007612776,0.0070397407,0.000017830438,0.0013834317,0.6824654],"study_design_scores_gemma":[0.11205768,0.12335424,0.6494945,0.0014197459,0.010026874,0.0004683703,0.03894923,0.0039150845,0.02459724,0.000048124235,0.03486727,0.00080159033],"about_ca_topic_score_codex":0.000309422,"about_ca_topic_score_gemma":0.00084481563,"teacher_disagreement_score":0.68166375,"about_ca_system_score_codex":0.0010489041,"about_ca_system_score_gemma":0.0009243994,"threshold_uncertainty_score":0.49134913},"labels":[],"label_agreement":null},{"id":"W2519502486","doi":"10.1097/01.jto.0000284174.03442.4f","title":"P3-199: CT, FDG PET and pathology: validating imaging to improve radiation targeting in non–small cell lung cancer (NSCLC)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; PET-CT; Positron emission tomography; Radiology; Nuclear medicine; Pathology","score_opus":0.007196511881390643,"score_gpt":0.37959060255778004,"score_spread":0.3723940906763894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519502486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97329223,0.0019832638,0.014848296,0.00737275,0.001063653,0.0002718155,0.0000014823024,0.000013435902,0.0011530994],"genre_scores_gemma":[0.9541017,0.0002360886,0.041859392,0.0026524987,0.0009922369,0.0000053581884,0.0000030647923,0.000032734493,0.000116953524],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980088,0.00017912524,0.00086293684,0.00025679974,0.00021837548,0.00047397366],"domain_scores_gemma":[0.998309,0.0004139975,0.00066847756,0.00011601357,0.00015357857,0.00033890668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046653626,0.00017174694,0.0005914569,0.0005045682,0.00008729386,0.000028810864,0.00013188997,0.00006494672,0.000031950774],"category_scores_gemma":[0.0010260908,0.00014937452,0.00008821217,0.00024737202,0.0000636935,0.00012877137,0.00008434126,0.0011797661,0.0000020194518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048804082,0.00014161174,0.22208342,0.00023097155,0.00003684903,0.005911057,0.001894392,0.0003613355,0.13970798,0.0000048358047,0.0015252408,0.62761426],"study_design_scores_gemma":[0.018173551,0.0047958596,0.5826325,0.00416812,0.0022197526,0.027483145,0.0115276575,0.2443454,0.04787909,0.00045124817,0.054452296,0.0018714169],"about_ca_topic_score_codex":0.000118171825,"about_ca_topic_score_gemma":0.000017153536,"teacher_disagreement_score":0.62574285,"about_ca_system_score_codex":0.0004711147,"about_ca_system_score_gemma":0.00030901426,"threshold_uncertainty_score":0.60913163},"labels":[],"label_agreement":null},{"id":"W2519559032","doi":"10.1097/01.jto.0000284347.51092.70","title":"P1-249: Anemia rates in completely resected non-small cell lung cancer (NSCLC) patients receiving adjuvant chemotherapy; An interim analysis","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Essar Steel Algoma (Canada); Lakeridge Health; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Anemia; Internal medicine; Chemotherapy; Interim analysis; Oncology; Lung cancer; Cancer; Surgery; Randomized controlled trial","score_opus":0.026870102349707478,"score_gpt":0.41629490382433976,"score_spread":0.38942480147463227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519559032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947348,0.00088189787,0.00039358065,0.0013207288,0.00041951958,0.00030288947,0.000006326678,0.000015013671,0.0019252084],"genre_scores_gemma":[0.99049985,0.0005186579,0.007584014,0.00070340774,0.0003262508,0.000005513844,0.000028452723,0.000033855235,0.0002999944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976293,0.000233113,0.0010616488,0.00028800408,0.00031589062,0.00047203925],"domain_scores_gemma":[0.9978832,0.00025307716,0.0008490341,0.00025496117,0.00043844135,0.0003212598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011754833,0.00025508084,0.0010912026,0.00080601545,0.00006818314,0.000019877489,0.0002118557,0.0002514781,0.0004338646],"category_scores_gemma":[0.00007955109,0.00019552361,0.0002723941,0.0008206512,0.00009514479,0.00011548394,0.000045161305,0.0006794205,0.0000038482426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004867907,0.0026823299,0.8393306,0.00019039947,0.00062470615,0.0010529312,0.003375201,0.000091080256,0.021994757,5.800807e-7,0.001329249,0.12446027],"study_design_scores_gemma":[0.005151868,0.005073002,0.9612229,0.00059945026,0.0015714545,0.00012863685,0.0016830601,0.0007333743,0.022076296,0.00000930581,0.0014964445,0.00025424958],"about_ca_topic_score_codex":0.00031472286,"about_ca_topic_score_gemma":0.0020150973,"teacher_disagreement_score":0.12420602,"about_ca_system_score_codex":0.0012188464,"about_ca_system_score_gemma":0.00040099953,"threshold_uncertainty_score":0.7973221},"labels":[],"label_agreement":null},{"id":"W2519959729","doi":"10.1097/01.jto.0000283821.09121.0c","title":"P2-163: Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC): A Single Institution Canadian Experience","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Carboplatin; Regimen; Radiation therapy; Lung cancer; Stage (stratigraphy); Etoposide; Chemotherapy; Adenocarcinoma; Surgery; Cisplatin; Nuclear medicine; Oncology; Internal medicine; Cancer","score_opus":0.028421123536006804,"score_gpt":0.4409167984616368,"score_spread":0.41249567492563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2519959729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96601915,0.0018372998,0.01893832,0.0016303397,0.0023406057,0.00078389345,0.0000392219,0.000010017926,0.008401175],"genre_scores_gemma":[0.99390405,0.00009916246,0.0030158663,0.00064178865,0.00058130315,0.000041675972,0.000019095423,0.000014160803,0.0016829119],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989039,0.000020486985,0.0004641876,0.00014302887,0.00015032195,0.00031813292],"domain_scores_gemma":[0.9985942,0.00006915588,0.0004605359,0.00009950793,0.00039687072,0.00037972693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035052697,0.00012390841,0.00033317643,0.00026682453,0.0001368958,0.000016304275,0.00008175651,0.00013316864,0.00013690321],"category_scores_gemma":[0.000051470994,0.00010378067,0.000117052645,0.00016705143,0.000057655176,0.00014800264,0.000008803048,0.00017821841,0.000002823208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038351351,0.002498175,0.045993872,0.00088740163,0.0008296499,0.001244039,0.03420136,0.0005914937,0.05126237,0.00022281698,0.014732147,0.84370154],"study_design_scores_gemma":[0.020099362,0.008673585,0.06632033,0.0011770262,0.0040326444,0.0008181365,0.016346427,0.0022959176,0.12886646,0.000045679804,0.75052464,0.00079976895],"about_ca_topic_score_codex":0.005200145,"about_ca_topic_score_gemma":0.021601902,"teacher_disagreement_score":0.84290177,"about_ca_system_score_codex":0.0032816045,"about_ca_system_score_gemma":0.0032529496,"threshold_uncertainty_score":0.9962513},"labels":[],"label_agreement":null},{"id":"W2520313415","doi":"10.1097/01.jto.0000283732.04417.60","title":"P1-117: The development of a practice guideline for the management of malignant thymoma through a formal consensus process.","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre; Kingston General Hospital; Ottawa Hospital; University of Ottawa; Queen's University; London Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Guideline; Thymoma; Delphi method; Family medicine; Evidence-based medicine; Lung cancer; Surgery; Alternative medicine; Pathology; Statistics","score_opus":0.045002804620090646,"score_gpt":0.4575041500782334,"score_spread":0.41250134545814277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520313415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74326956,0.0053483583,0.16207017,0.06540599,0.0013630044,0.003013461,0.00001729469,0.000018188752,0.019493954],"genre_scores_gemma":[0.73775613,0.00014946592,0.26016647,0.0014095214,0.00025459423,0.000017069035,0.0000022516342,0.000020489524,0.00022400181],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99696124,0.00009293288,0.0019373271,0.00012660674,0.0005357638,0.0003461124],"domain_scores_gemma":[0.9953153,0.0009948491,0.0021414887,0.000267899,0.0012020966,0.000078373014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068350765,0.00015998472,0.0005907726,0.00009589231,0.00014158526,0.0000065595277,0.0003139537,0.00011194747,0.00004065376],"category_scores_gemma":[0.00032527736,0.00007640046,0.00021461702,0.00023971451,0.00018687749,0.00009083181,0.00008531102,0.0002790092,0.0000016750716],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031057455,0.002176908,0.00032844272,0.0015246556,0.0040431954,0.00087193644,0.015720416,0.00008798553,0.0034053216,0.0063694348,0.010002654,0.9244116],"study_design_scores_gemma":[0.0037039262,0.0044535995,0.0046455897,0.0007554861,0.0028135595,0.006872673,0.040642325,0.00020075047,0.02811863,0.0016696858,0.9059408,0.00018299134],"about_ca_topic_score_codex":0.0000068562094,"about_ca_topic_score_gemma":0.000019389097,"teacher_disagreement_score":0.9242286,"about_ca_system_score_codex":0.00011732332,"about_ca_system_score_gemma":0.00067262864,"threshold_uncertainty_score":0.31155202},"labels":[],"label_agreement":null},{"id":"W2520338817","doi":"10.1097/01.jto.0000282978.73370.61","title":"M17-04: TLR9 agonists","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"TLR9; Toll-Like Receptor 9; Innate immune system; CpG Oligodeoxynucleotide; CpG site; Toll-like receptor; Immune system; Proinflammatory cytokine; Biology; Receptor; Immunology; Gene; Cancer research; Genetics; Inflammation; DNA methylation; Gene expression","score_opus":0.016522163634744052,"score_gpt":0.38079443214208913,"score_spread":0.36427226850734507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520338817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97773343,0.0034558557,0.0019560743,0.0020001363,0.003463274,0.000091353,0.0000011504766,0.000020848289,0.011277859],"genre_scores_gemma":[0.99439484,0.00014545067,0.0008124774,0.000364372,0.00024929852,8.8291887e-7,0.000007131011,0.00001217436,0.0040133963],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983286,0.00037085955,0.0007934504,0.000102831116,0.00005509419,0.00034916608],"domain_scores_gemma":[0.99837685,0.00042037267,0.0007355014,0.00016736254,0.00026371464,0.000036205667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027290676,0.000126025,0.00041396596,0.00032296876,0.00012522108,0.000010100886,0.000267735,0.00040260315,0.0006152776],"category_scores_gemma":[0.00029471266,0.00010096621,0.00017926717,0.00015007461,0.00015353254,0.00017979169,0.000049107675,0.0005796142,0.0005824339],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036532208,0.00017917565,0.00037246005,0.000012967247,0.00019437564,0.0002433968,0.0006186304,0.000004097751,0.6273741,0.0003459154,0.01007822,0.3569234],"study_design_scores_gemma":[0.0006240978,0.0011169666,0.012003491,0.000031752083,0.00008038521,0.0034555737,0.0004011106,7.0875416e-7,0.337066,0.00034054441,0.6447719,0.00010749743],"about_ca_topic_score_codex":0.0000076986635,"about_ca_topic_score_gemma":0.000013713228,"teacher_disagreement_score":0.6346936,"about_ca_system_score_codex":0.00019118046,"about_ca_system_score_gemma":0.00027222882,"threshold_uncertainty_score":0.7486204},"labels":[],"label_agreement":null},{"id":"W2520638260","doi":"10.1097/01.jto.0000284346.73963.c2","title":"P1-248: Lung cancer guideline development in ontario: impact on policy and practice","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Guideline; Radiation therapy; Lung cancer; Cancer; Multidisciplinary approach; Family medicine; Clinical Practice; Population; Intensive care medicine; Internal medicine; Pathology","score_opus":0.16168413329253387,"score_gpt":0.629639598305419,"score_spread":0.4679554650128852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520638260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95017,0.00038793488,0.0015148311,0.04352352,0.00051518716,0.00031595127,0.0000015955615,0.000007240195,0.0035637761],"genre_scores_gemma":[0.91625345,0.00024254157,0.068001054,0.014037515,0.0010091685,0.000003837672,0.000007854977,0.000023212751,0.00042139186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964488,0.00026520703,0.0023217914,0.00017764565,0.00044656615,0.00033995794],"domain_scores_gemma":[0.99355334,0.0037735035,0.0015369018,0.00014184239,0.0006849263,0.00030945792],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.009889077,0.00016726805,0.0005691884,0.00057320687,0.000045069457,0.0000151733075,0.00009021107,0.00017774421,0.00037789912],"category_scores_gemma":[0.012264641,0.00012413581,0.00009172734,0.00027810287,0.000047678106,0.00033562758,0.000055893765,0.0009564569,0.000005864563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.026541602,0.0011904631,0.092270754,0.000042678443,0.00040079775,0.001654674,0.002125786,0.00023917528,0.0021312367,0.00004188101,0.013045505,0.86031544],"study_design_scores_gemma":[0.0036592276,0.003341038,0.48081848,0.00028437513,0.00049987034,0.004690884,0.0013974685,0.0001250094,0.000692034,0.000095351825,0.5042081,0.00018814381],"about_ca_topic_score_codex":0.02512671,"about_ca_topic_score_gemma":0.09128686,"teacher_disagreement_score":0.86012733,"about_ca_system_score_codex":0.004921252,"about_ca_system_score_gemma":0.006435105,"threshold_uncertainty_score":0.9991975},"labels":[],"label_agreement":null},{"id":"W2520655071","doi":"10.1097/01.jto.0000284375.51392.90","title":"P1-277: Regional Cancer Centre (RCC) and Community Hospital (CH) Collaboration: A New Paradigm For Lung Cancer Service Organization?","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; Toronto East General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lung cancer; Multidisciplinary approach; Cancer; Service (business); Health care; Family medicine; Radiation therapy; Oncology; Internal medicine; General surgery","score_opus":0.1173161469449394,"score_gpt":0.5508817497040199,"score_spread":0.4335656027590805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520655071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6968383,0.0010013141,0.006984513,0.2934843,0.0010539737,0.0005435319,0.000026974009,0.00001419077,0.000052874057],"genre_scores_gemma":[0.9480795,0.0012640827,0.02339814,0.022588423,0.003931796,0.000009074639,0.00010183571,0.000057126083,0.0005699962],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980002,0.0002638351,0.0011084185,0.00013062207,0.00027617486,0.00022071523],"domain_scores_gemma":[0.9944863,0.0018988985,0.0012400977,0.00015692566,0.0019166184,0.0003011831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020326152,0.00013531148,0.0004412612,0.000120842255,0.00022203512,0.000029452382,0.00012643386,0.00018162564,0.0003774409],"category_scores_gemma":[0.002074461,0.000119955876,0.00005764696,0.0005326909,0.00005399789,0.0003567348,0.000049135884,0.0006111717,0.000001546025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010224568,0.0021207717,0.2382884,0.00070536905,0.0012332534,0.0001467144,0.014636465,0.00037857785,0.0024802864,0.00041935587,0.5222034,0.20716284],"study_design_scores_gemma":[0.015753167,0.0055693146,0.27450848,0.00086898636,0.0050434005,0.0014968642,0.030364012,0.0019895681,0.0017868674,0.0016011728,0.66034937,0.0006687967],"about_ca_topic_score_codex":0.001004526,"about_ca_topic_score_gemma":0.008833487,"teacher_disagreement_score":0.2708959,"about_ca_system_score_codex":0.0006918261,"about_ca_system_score_gemma":0.0025083355,"threshold_uncertainty_score":0.4929293},"labels":[],"label_agreement":null},{"id":"W2520703434","doi":"10.1097/01.jto.0000284321.19705.61","title":"P1-223: Costs associated with intravenous chemotherapy administration in patients with lung cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Etoposide; Carboplatin; Chemotherapy; Irinotecan; Lung cancer; Cisplatin; Oncology; Internal medicine; Topotecan; Route of administration; Cancer; Colorectal cancer","score_opus":0.012162735568057003,"score_gpt":0.4152775145712979,"score_spread":0.4031147790032409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520703434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959205,0.00026887853,0.000081758066,0.0018674426,0.0002835534,0.00036091017,0.0000048152065,0.000008050718,0.0012041414],"genre_scores_gemma":[0.99808896,0.0000848967,0.00044178872,0.00089454325,0.00022834963,0.000006343586,0.000014856657,0.000018427801,0.00022183324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989226,0.00007620506,0.00038835953,0.00011598497,0.00024189822,0.0002549632],"domain_scores_gemma":[0.99883693,0.00013058478,0.00054339826,0.00006543952,0.00028566006,0.00013798059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046055033,0.0001306178,0.0004571688,0.0001932507,0.000031551823,0.0000060445564,0.000059086848,0.0001481708,0.0002092847],"category_scores_gemma":[0.00002327087,0.000087309294,0.000042702275,0.00025930227,0.00006651787,0.000082483464,0.0000051879774,0.00036200482,8.148499e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042544153,0.004607381,0.80767554,0.000026397238,0.0006104476,0.000892605,0.0006280571,0.000014346314,0.00035735188,0.0000036281347,0.0009860285,0.14165404],"study_design_scores_gemma":[0.012031337,0.019045899,0.96361685,0.00025012955,0.000493164,0.00016450055,0.00008736668,0.00001624134,0.0021325368,0.0000057518914,0.0020479227,0.00010827694],"about_ca_topic_score_codex":0.000044124197,"about_ca_topic_score_gemma":0.0018455774,"teacher_disagreement_score":0.15594132,"about_ca_system_score_codex":0.0019034058,"about_ca_system_score_gemma":0.0008150508,"threshold_uncertainty_score":0.497734},"labels":[],"label_agreement":null},{"id":"W2520823875","doi":"10.1097/01.jto.0000283753.93221.8b","title":"P1-139: A survey of Canadian practice in management of malignant pleural mesothelioma (MPM)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Pleural and Pulmonary Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Sunnybrook Health Science Centre; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Mesothelioma; Thoracoscopy; Mediastinoscopy; Extrapleural Pneumonectomy; Radiation therapy; Thoracotomy; General surgery; Pneumonectomy; Lung cancer; Surgery; Biopsy; Radiology; Internal medicine; Pathology","score_opus":0.04979523341599644,"score_gpt":0.4211742061444005,"score_spread":0.37137897272840403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520823875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857124,0.0015870859,0.000018127916,0.0032992617,0.0003266652,0.00018435981,0.000049617396,0.0000026843795,0.008819782],"genre_scores_gemma":[0.9961192,0.0006389623,0.0022807848,0.00038416247,0.00006748917,9.890961e-7,0.000008613961,0.000011336315,0.00048848696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799824,0.00032153446,0.0009404937,0.00011297142,0.00032286323,0.00030391017],"domain_scores_gemma":[0.99775887,0.00054557045,0.0007906473,0.00015783707,0.00039342872,0.00035364472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029827175,0.00011500594,0.0005960194,0.0011479016,0.000019553328,0.0000028191282,0.00017537549,0.00010926506,0.00013662089],"category_scores_gemma":[0.00044006374,0.00008778696,0.00011899569,0.0008512288,0.00008510324,0.00012907757,0.00003403106,0.00023796913,0.000005540075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04597217,0.0048513487,0.41669166,0.0018476822,0.0015745249,0.09162161,0.0015039821,0.00013801904,0.011428479,0.0003999287,0.011208407,0.4127622],"study_design_scores_gemma":[0.0008293809,0.0016279093,0.9670099,0.000413971,0.00033624063,0.0027815616,0.0012108637,0.000016254602,0.0016191355,0.00005844314,0.024010459,0.00008585987],"about_ca_topic_score_codex":0.028672572,"about_ca_topic_score_gemma":0.07078075,"teacher_disagreement_score":0.55031824,"about_ca_system_score_codex":0.0002449088,"about_ca_system_score_gemma":0.00067052164,"threshold_uncertainty_score":0.9777956},"labels":[],"label_agreement":null},{"id":"W2521027990","doi":"10.1097/01.jto.0000283138.22682.17","title":"A7-07: The usefulness of positron emission tomography (PET) in an early lung cancer detection program","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Positron emission tomography; Lung cancer; Radiology; Malignancy; Nuclear medicine; Computed tomography; PET-CT; Internal medicine","score_opus":0.02086476602195136,"score_gpt":0.42715156223588063,"score_spread":0.40628679621392927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521027990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956223,0.0015395427,0.00011002609,0.0014855075,0.0005686528,0.0004476391,0.0000014990517,0.000010551445,0.00021428356],"genre_scores_gemma":[0.998621,0.00020203114,0.0006471258,0.000121464254,0.00032404446,0.00003388113,0.0000010224104,0.000014033675,0.000035435245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866503,0.00014974544,0.0005510197,0.000130063,0.0002761393,0.00022798846],"domain_scores_gemma":[0.9987695,0.0001345018,0.00052889925,0.00016470882,0.00025881696,0.00014354796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009563439,0.00011678151,0.00041447367,0.00028526026,0.000050830662,0.000012006967,0.0001173796,0.00010972994,0.000040163006],"category_scores_gemma":[0.000028436025,0.00006873588,0.00016242512,0.00036597557,0.00007011307,0.00013779057,0.00001996279,0.00036940922,5.3325215e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029446525,0.0014610736,0.5264424,0.00009785532,0.00017357487,0.0003193069,0.00065952796,0.000020573676,0.005445765,0.000004495423,0.00013422394,0.46229655],"study_design_scores_gemma":[0.0014035506,0.0069404277,0.92704505,0.0005136215,0.0006294214,0.00038617713,0.00037569788,0.00009389832,0.06069105,0.000041553532,0.0017989237,0.00008061031],"about_ca_topic_score_codex":0.00026274886,"about_ca_topic_score_gemma":0.00093267043,"teacher_disagreement_score":0.46221593,"about_ca_system_score_codex":0.0007715827,"about_ca_system_score_gemma":0.00023582081,"threshold_uncertainty_score":0.28029677},"labels":[],"label_agreement":null},{"id":"W2521916949","doi":"10.1016/j.jtho.2016.08.056","title":"P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Oncology; Adverse effect; Adenocarcinoma; Randomized controlled trial; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.014894614685271545,"score_gpt":0.39925166213243707,"score_spread":0.38435704744716553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521916949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696454,0.00065101776,0.00709421,0.016453281,0.001622601,0.0028625412,0.00020262368,0.000015501757,0.0014528566],"genre_scores_gemma":[0.9915508,0.00026468432,0.003915262,0.00085266464,0.0014317915,0.00031156966,0.000039006773,0.00004356404,0.0015906673],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983857,0.000105756306,0.000664514,0.0002169903,0.00030704925,0.00031998917],"domain_scores_gemma":[0.99668956,0.0009802452,0.00102916,0.0001913189,0.00092951,0.00018020121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037357718,0.00021416474,0.0005772602,0.00013983356,0.00023886365,0.000022385007,0.00015838422,0.00013835652,0.00013811693],"category_scores_gemma":[0.00015284843,0.00010088,0.0002120778,0.00016013678,0.00010043982,0.00016450735,0.000025857378,0.00021748325,0.0000044723297],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38977855,0.007914764,0.09209402,0.00080316176,0.006132156,0.00056430866,0.008917222,0.0005211851,0.00047423394,0.00014954494,0.038333498,0.45431733],"study_design_scores_gemma":[0.58261764,0.109609365,0.14474577,0.005013545,0.029764064,0.00078109524,0.0024235973,0.0014664311,0.007046106,0.00058669207,0.11461832,0.0013273724],"about_ca_topic_score_codex":0.000049454404,"about_ca_topic_score_gemma":0.00013227703,"teacher_disagreement_score":0.45298997,"about_ca_system_score_codex":0.0010322172,"about_ca_system_score_gemma":0.0012779882,"threshold_uncertainty_score":0.4113767},"labels":[],"label_agreement":null},{"id":"W2522615762","doi":"10.1016/j.jtho.2016.08.027","title":"P1.05: An International Epidemiological Analysis of Young Patients Diagnosed With NSCLC (ADUJOV-CLICaP)","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Adenocarcinoma; Lung cancer; Population; Stage (stratigraphy); Retrospective cohort study; Cancer; Cancer registry; Oncology","score_opus":0.029275830899180573,"score_gpt":0.46054303011625375,"score_spread":0.4312671992170732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522615762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925512,0.0000695456,0.001558264,0.0028585773,0.00039434555,0.00013887078,0.000032179836,0.000007819887,0.0023891828],"genre_scores_gemma":[0.9942092,0.00015359664,0.0048094844,0.00035527372,0.00018151644,0.0000085010915,0.00002181636,0.000008984997,0.00025165832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855286,0.00018508498,0.0006532976,0.00015973735,0.0002893917,0.00015962878],"domain_scores_gemma":[0.99779344,0.00040345913,0.0008400037,0.00017601332,0.0006035254,0.00018357212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045717804,0.00011585378,0.000740281,0.00041408904,0.000031240237,0.0000047085437,0.0001510949,0.000113569615,0.0003508292],"category_scores_gemma":[0.00046479554,0.000054555207,0.00023640391,0.0002818191,0.00012288257,0.00019923039,0.000023431943,0.00013046824,0.000003713375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017454799,0.0013363467,0.84780663,0.0000064394517,0.0034046804,0.00019171633,0.0003132041,0.000029416613,0.0004364927,0.00007994218,0.0005066321,0.14414302],"study_design_scores_gemma":[0.0024573773,0.0053864922,0.9810065,0.000099086355,0.0046023624,0.000097068056,0.0001634077,0.000036046407,0.0001687641,0.00007923034,0.0058380235,0.00006564683],"about_ca_topic_score_codex":0.000033201424,"about_ca_topic_score_gemma":0.000057936828,"teacher_disagreement_score":0.14407736,"about_ca_system_score_codex":0.00038655518,"about_ca_system_score_gemma":0.0002400004,"threshold_uncertainty_score":0.3841334},"labels":[],"label_agreement":null},{"id":"W2523018303","doi":"10.1016/j.jtho.2016.08.130","title":"Response to Yamamoto et al.","year":2016,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Medicine; Mutation; Cancer research; Lung cancer; Tyrosine kinase; Oncology; Phenotype; Cancer; Internal medicine; Gene; Biology; Genetics; Colorectal cancer; Receptor","score_opus":0.027093633624768382,"score_gpt":0.48318756875809393,"score_spread":0.4560939351333255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523018303","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042818687,0.00038190986,0.00027801102,0.98569536,0.0019916487,0.00035255976,0.00004987593,0.000014576439,0.0069541777],"genre_scores_gemma":[0.0007620417,0.00012782046,0.0041984417,0.9576855,0.003016724,0.000020675983,0.000015480557,0.000051281266,0.034122057],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979555,0.00050441996,0.00059644715,0.00020827596,0.00042587167,0.00030950934],"domain_scores_gemma":[0.99774855,0.0006043267,0.0006351212,0.00030984732,0.0004895715,0.0002126022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010550782,0.00021787021,0.00081631663,0.000559857,0.000041209,0.000017880202,0.00019384419,0.00047439782,0.0004930597],"category_scores_gemma":[0.00039558593,0.00013263896,0.00029633366,0.00013285092,0.000051702584,0.0000816984,0.000048523674,0.0012545292,0.00023156543],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047188145,0.0000806041,0.000044211345,0.000032057615,0.00051152334,0.008947855,0.00023758248,6.8038054e-7,0.0011566442,0.0000017720018,0.9280064,0.056261823],"study_design_scores_gemma":[0.0010068188,0.0046221116,0.00059657195,0.00055942254,0.000871869,0.0039353017,0.000032346445,1.777488e-7,0.00016545935,0.00008660326,0.98799896,0.00012435783],"about_ca_topic_score_codex":0.0000058357386,"about_ca_topic_score_gemma":0.0000027280014,"teacher_disagreement_score":0.05999253,"about_ca_system_score_codex":0.0012671134,"about_ca_system_score_gemma":0.0025081476,"threshold_uncertainty_score":0.5450375},"labels":[],"label_agreement":null},{"id":"W2524206199","doi":"10.1097/01.jto.0000283072.85701.98","title":"WS-07: Designs for vaccine and immunotherapy trials","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immune system; Medicine; Immunotherapy; Immunology; Cancer; Innate immune system; Mechanism (biology); Acquired immune system; Cancer immunotherapy; Cancer vaccine; Internal medicine","score_opus":0.10621394388018486,"score_gpt":0.4933764924582765,"score_spread":0.3871625485780917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524206199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46888956,0.06868,0.42082494,0.02662929,0.010020409,0.0015270062,0.00006441665,0.000056683784,0.0033076655],"genre_scores_gemma":[0.8155305,0.0025421553,0.17149732,0.0047629518,0.0012288777,0.000010269221,0.0000069830476,0.000052362793,0.00436859],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975217,0.0008135921,0.0011352855,0.00014956946,0.00003657265,0.00034329234],"domain_scores_gemma":[0.9949498,0.0037629544,0.00086082995,0.00012552766,0.00024321991,0.000057660527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01318796,0.00015324833,0.0010481176,0.000204806,0.000107191314,0.000012019669,0.00019589913,0.00052056863,0.00052134844],"category_scores_gemma":[0.0012539398,0.0000994417,0.00029475644,0.00010313633,0.000128237,0.00006631856,0.000030969048,0.00039457704,0.000009278198],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008377924,0.00020554973,0.000317913,0.000018441558,0.00051313,0.000023480436,0.0001022008,2.8573444e-7,0.3800425,0.00038968932,0.009195562,0.6008133],"study_design_scores_gemma":[0.0037073418,0.005951333,0.005032046,0.000045204728,0.0005135611,0.0015279108,0.00031758595,0.0000032803898,0.21187072,0.005180155,0.7656489,0.00020196436],"about_ca_topic_score_codex":0.0000026055827,"about_ca_topic_score_gemma":0.0000072317175,"teacher_disagreement_score":0.75645334,"about_ca_system_score_codex":0.00007193635,"about_ca_system_score_gemma":0.00011865108,"threshold_uncertainty_score":0.57084},"labels":[],"label_agreement":null},{"id":"W2524433904","doi":"10.1016/j.jtho.2016.08.055","title":"P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Pemetrexed; Gemcitabine; Chemotherapy; Oncology; Lung cancer; Cisplatin; Adenocarcinoma; Gefitinib; Gastroenterology; Cancer; Epidermal growth factor receptor","score_opus":0.018030987761416553,"score_gpt":0.4345742131105186,"score_spread":0.41654322534910204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524433904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197525,0.00018615558,0.0044574235,0.0014337703,0.00061110704,0.0004252844,0.00013525764,0.000007895344,0.00076783384],"genre_scores_gemma":[0.99344033,0.00007850968,0.0055508884,0.00023630293,0.00019096148,0.000019495896,0.000055090895,0.000019160369,0.00040923845],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987554,0.000094382674,0.0005723642,0.0001469475,0.00025154516,0.00017938075],"domain_scores_gemma":[0.997711,0.00060807937,0.000837621,0.00014482124,0.00057889405,0.00011958598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029120885,0.000120659526,0.0006244558,0.0004300425,0.000045108816,0.000006928205,0.00009028937,0.00011559283,0.00019200794],"category_scores_gemma":[0.00019649122,0.00007988401,0.0003751447,0.00037170868,0.00007423431,0.0001369371,0.000010936946,0.00009393337,0.0000030057042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028285298,0.003019108,0.08412419,0.00011727425,0.025228715,0.0001807988,0.007307309,0.00008041764,0.006703153,0.00015199994,0.004878888,0.83992285],"study_design_scores_gemma":[0.026654935,0.01120891,0.9280864,0.00033177817,0.020803869,0.000036493468,0.0008909829,0.00015646513,0.005647918,0.00018468942,0.0057739746,0.00022359345],"about_ca_topic_score_codex":0.000017886434,"about_ca_topic_score_gemma":0.000032982032,"teacher_disagreement_score":0.8439622,"about_ca_system_score_codex":0.0006454206,"about_ca_system_score_gemma":0.00036188812,"threshold_uncertainty_score":0.32575753},"labels":[],"label_agreement":null},{"id":"W2524899570","doi":"10.1097/01.jto.0000283123.90401.9f","title":"A5-06: Heat shock protein 27 - a novel target for non-small cell lung cancer and possible marker of metastasis","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Hsp27; In vivo; Transfection; A549 cell; Cancer research; Cell growth; Cell cycle; In vitro; Biology; Cell; Medicine; Lung cancer; Heat shock protein; Molecular biology; Cell culture; Pathology; Cancer; Internal medicine; Hsp70; Gene","score_opus":0.017842256751102414,"score_gpt":0.3582211975212432,"score_spread":0.3403789407701408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524899570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9453783,0.006199057,0.04658788,0.00057031336,0.00022960774,0.0003781631,0.00006436295,0.0000015230689,0.0005907966],"genre_scores_gemma":[0.93790925,0.0005657628,0.05875778,0.00016868628,0.00038335583,0.000035893187,0.000012324507,0.00002418956,0.0021427742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989605,0.000037603593,0.000485892,0.00018022499,0.00009954851,0.00023624218],"domain_scores_gemma":[0.9989351,0.00003300782,0.00039271408,0.00016604536,0.00036010603,0.000113009264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092643936,0.0001284352,0.0003233172,0.00010303879,0.000053683565,0.000011166947,0.00016875165,0.00018922669,0.000027508408],"category_scores_gemma":[0.00004164483,0.00010632916,0.00014538284,0.00009268532,0.000070199574,0.000008442816,0.00004984569,0.00013014051,3.0032484e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012284173,0.00027458987,0.0026688708,0.00017722335,0.00018124482,0.0000049602895,0.00007339788,0.00011321712,0.97453445,0.0000131445195,0.0031843425,0.017546114],"study_design_scores_gemma":[0.0013864316,0.0017325707,0.0044265147,0.00007580518,0.00027063373,0.00009877045,0.00026102332,0.00033404448,0.8530115,0.00006583628,0.13813047,0.000206439],"about_ca_topic_score_codex":0.000024368172,"about_ca_topic_score_gemma":0.000059037673,"teacher_disagreement_score":0.13494612,"about_ca_system_score_codex":0.00006739258,"about_ca_system_score_gemma":0.00041104876,"threshold_uncertainty_score":0.4335977},"labels":[],"label_agreement":null},{"id":"W2526038812","doi":"10.1097/01.jto.0000284287.47197.e2","title":"P1-189: Quantitative Image Analysis for Intra-epithelial Neoplasia","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Dysplasia; Autofluorescence; Biopsy; Bronchoscopy; Vascularity; Carcinoma in situ; Lung cancer; Radiology; Lesion; Pathology; Carcinoma","score_opus":0.030271310106212035,"score_gpt":0.46049845611820056,"score_spread":0.4302271460119885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526038812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94953674,0.00082861754,0.036674757,0.008649422,0.0009788118,0.00039595427,0.000030242923,0.000013730381,0.0028917517],"genre_scores_gemma":[0.9195358,0.0002023461,0.07864819,0.00066999334,0.0006520576,0.000010322281,0.000009980645,0.000017210947,0.00025407015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986031,0.000060736736,0.0006581461,0.00016147186,0.00023430315,0.00028224557],"domain_scores_gemma":[0.9978346,0.00068445416,0.0006159592,0.00014919683,0.00049153186,0.00022420692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012893337,0.0001411728,0.0008250198,0.00048439912,0.000060514478,0.0000140537795,0.000096774645,0.00013616892,0.00013261111],"category_scores_gemma":[0.0002254802,0.000099292854,0.00054922927,0.0004249394,0.00008867039,0.00010019979,0.00001683031,0.00022993847,0.0000137498555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053307198,0.007873884,0.22583675,0.000582599,0.033079855,0.0066891857,0.0061071,0.00022473389,0.021090453,0.0035625263,0.028800692,0.612845],"study_design_scores_gemma":[0.012345272,0.043969028,0.573304,0.00042788908,0.04383044,0.002617964,0.004853396,0.0005729504,0.101887,0.0023803927,0.21319434,0.0006173215],"about_ca_topic_score_codex":0.000021599246,"about_ca_topic_score_gemma":0.0002495989,"teacher_disagreement_score":0.6122277,"about_ca_system_score_codex":0.0008220826,"about_ca_system_score_gemma":0.0003799508,"threshold_uncertainty_score":0.4049045},"labels":[],"label_agreement":null},{"id":"W2528885621","doi":"10.1016/j.jtho.2016.08.075","title":"P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Nintedanib; Medicine; Pemetrexed; Internal medicine; Bevacizumab; Oncology; Vascular endothelial growth factor; Docetaxel; Chemotherapy; Cisplatin; Idiopathic pulmonary fibrosis; Lung","score_opus":0.016399167234283907,"score_gpt":0.37042164148596113,"score_spread":0.3540224742516772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528885621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984894,0.00010444617,0.000029967792,0.00055351935,0.0001615806,0.00036995864,0.00002738806,0.0000058823807,0.0002578943],"genre_scores_gemma":[0.9988306,0.000015033749,0.00048109647,0.00011591214,0.0000802762,0.0000061234496,0.000006839268,0.000018596254,0.00044549347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981373,0.0001523697,0.0007667068,0.00017359614,0.0005560236,0.00021401516],"domain_scores_gemma":[0.99868786,0.00013786688,0.0006838676,0.0001711093,0.00013503077,0.00018425121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034160574,0.0001669057,0.0006175293,0.0003546254,0.000042009247,0.0000034508398,0.00013708232,0.000075408025,0.0005437892],"category_scores_gemma":[0.0000975846,0.00008942726,0.00010411437,0.00021254746,0.000113338414,0.00016444885,0.000069944916,0.00015944359,0.000008049385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031329285,0.01760471,0.87761533,0.00003246092,0.0002489903,0.00037692185,0.0005206021,0.000012043296,0.00343419,0.0000056366553,0.0006326664,0.06818716],"study_design_scores_gemma":[0.019911654,0.048131905,0.9284717,0.00034547132,0.00040205073,0.00010875697,0.00079339155,0.000013790222,0.0010603409,0.000040033716,0.00060114753,0.00011977343],"about_ca_topic_score_codex":0.00002602291,"about_ca_topic_score_gemma":0.000039644037,"teacher_disagreement_score":0.06806739,"about_ca_system_score_codex":0.00030901303,"about_ca_system_score_gemma":0.00015214733,"threshold_uncertainty_score":0.59541106},"labels":[],"label_agreement":null},{"id":"W2529745477","doi":"10.1016/j.jtho.2016.08.026","title":"P1.04: Defining the Genetic Architecture of Lung Cancer Etiology","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Nutrition, Genetics, and Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Etiology; Lung cancer; Cancer; Genetic architecture; Architecture; Oncology; Pathology; Internal medicine; Environmental health","score_opus":0.00904725411354365,"score_gpt":0.35923072432527914,"score_spread":0.3501834702117355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529745477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971543,0.018765302,0.004396172,0.004066673,0.0006973831,0.00010975909,0.000040878123,0.0000029169287,0.00037787535],"genre_scores_gemma":[0.99221665,0.0034196458,0.0026296724,0.00063545123,0.0008416374,0.00001055337,0.0000037602467,0.000017567081,0.00022507297],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99866474,0.00032328308,0.00047566637,0.00016903221,0.00013369448,0.00023356974],"domain_scores_gemma":[0.99871445,0.000109606226,0.00053443835,0.00025493113,0.00027026978,0.00011630607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003654352,0.00013120078,0.00028525334,0.00008193198,0.00006106248,0.0000054892275,0.000334685,0.00020914496,0.00009714842],"category_scores_gemma":[0.00021213794,0.000073848554,0.0001954683,0.00006845568,0.00027165053,0.0000031200475,0.00008480368,0.00013737501,0.0000020327072],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025744059,0.0002985566,0.0427309,0.00011352633,0.00041005926,0.00004946539,0.00022806278,0.0004506461,0.70072246,0.00013628081,0.020538542,0.23174708],"study_design_scores_gemma":[0.0051552574,0.0069076493,0.16139054,0.000502558,0.0013390089,0.002220768,0.0004365093,0.000042902386,0.37814537,0.0076214946,0.43541652,0.00082143786],"about_ca_topic_score_codex":0.0000069850835,"about_ca_topic_score_gemma":0.000040269297,"teacher_disagreement_score":0.41487798,"about_ca_system_score_codex":0.000041545278,"about_ca_system_score_gemma":0.00045969192,"threshold_uncertainty_score":0.30114567},"labels":[],"label_agreement":null},{"id":"W2538228736","doi":"10.1016/j.jtho.2016.08.128","title":"Trimodality Approach to Stage IIIA-N2 NSCLC: As Good as It Gets?","year":2016,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Internal medicine","score_opus":0.03994339609854078,"score_gpt":0.42952247980569763,"score_spread":0.3895790837071569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538228736","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007066495,0.0011583286,0.00020737456,0.8550695,0.0022239638,0.00094194786,0.00008469722,0.000027677113,0.13321997],"genre_scores_gemma":[0.02010905,0.0014680153,0.0035902006,0.8859842,0.021267477,0.00015025714,0.00007532443,0.00015337624,0.0672021],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956957,0.00056487625,0.0013343085,0.0006141315,0.0010276252,0.0007633337],"domain_scores_gemma":[0.9959734,0.00057692436,0.0015658541,0.00076897553,0.0005777806,0.00053704047],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013163473,0.0005717916,0.0023397359,0.0005141286,0.00009503082,0.000046028577,0.0004970079,0.001440293,0.0010121207],"category_scores_gemma":[0.00032449237,0.0003596069,0.0008332924,0.00017303089,0.00012751839,0.00013204936,0.00015129935,0.0024580094,0.0005768587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002120257,0.0010313493,0.00047459707,0.0004626792,0.0016867017,0.009087719,0.00035102866,0.0000018106975,0.000043600347,0.00005500191,0.9135863,0.07109893],"study_design_scores_gemma":[0.002540357,0.007201195,0.00074075593,0.0009653885,0.0020868394,0.003246313,0.000111598594,9.604461e-7,0.00042953942,0.0003389286,0.9819996,0.00033854507],"about_ca_topic_score_codex":0.00014293207,"about_ca_topic_score_gemma":0.000015615005,"teacher_disagreement_score":0.070760384,"about_ca_system_score_codex":0.004025936,"about_ca_system_score_gemma":0.0029890353,"threshold_uncertainty_score":0.9999011},"labels":[],"label_agreement":null},{"id":"W2539531174","doi":"10.1016/j.jtho.2016.09.008","title":"ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Clinical trial; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Immunotherapy; Cancer","score_opus":0.027884889969543695,"score_gpt":0.41439323166111675,"score_spread":0.38650834169157305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539531174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98759264,0.0019857776,0.00012732705,0.008086385,0.00017961777,0.00030830887,0.0000060363486,0.000007747373,0.0017061542],"genre_scores_gemma":[0.9897314,0.0061651682,0.0015309503,0.00010150496,0.00019297839,0.0000025205102,9.516737e-7,0.000025737188,0.0022488046],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981191,0.00021755556,0.0008279185,0.000202603,0.00031265093,0.00032016385],"domain_scores_gemma":[0.9980001,0.00080045784,0.00046236027,0.0002278444,0.00027423952,0.00023502193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014464845,0.00015564496,0.0009004789,0.00037634556,0.00003816622,0.000006433583,0.00013195496,0.00019065395,0.00055047544],"category_scores_gemma":[0.0006094051,0.00010095897,0.00010045245,0.00023483983,0.0002965205,0.00015191313,0.000102626414,0.00041431648,0.0000057601474],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033117868,0.0004605737,0.010538361,0.00015319834,0.00010974069,0.00030974764,0.0003783386,0.000006364424,0.12936978,0.000015620457,0.00012736162,0.82541305],"study_design_scores_gemma":[0.09355594,0.033790816,0.5080074,0.0043339087,0.00061604375,0.008782637,0.0010084645,0.00041368962,0.08208799,0.0014552174,0.26522136,0.00072649156],"about_ca_topic_score_codex":0.000015628166,"about_ca_topic_score_gemma":0.00010871148,"teacher_disagreement_score":0.8246865,"about_ca_system_score_codex":0.00034448196,"about_ca_system_score_gemma":0.0002746604,"threshold_uncertainty_score":0.602732},"labels":[],"label_agreement":null},{"id":"W2541763324","doi":"10.1016/j.jtho.2016.09.011","title":"ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Everolimus; Gastroenterology; Neuroendocrine tumors; Placebo; Subgroup analysis; Adverse effect; Lung; Surgery; Urology; Confidence interval; Pathology","score_opus":0.014482590116125231,"score_gpt":0.384324659602508,"score_spread":0.36984206948638276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2541763324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99012035,0.0015705508,0.00005981436,0.007306701,0.00021647086,0.00046603865,0.000017253558,0.000006149427,0.00023666877],"genre_scores_gemma":[0.9977284,0.0006526159,0.0009557439,0.00012444955,0.0001203183,0.000008149788,0.0000012523644,0.00002034127,0.00038869324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99700445,0.00050336024,0.001162547,0.0002618736,0.00065548904,0.00041228565],"domain_scores_gemma":[0.99676096,0.00095257483,0.0012441286,0.0003540063,0.0004449676,0.00024336262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044192182,0.00019672888,0.0011180273,0.00080424774,0.000043889973,0.0000049297373,0.00031933442,0.000019706586,0.00020739854],"category_scores_gemma":[0.001507459,0.000106820546,0.00029731737,0.0011317297,0.000537304,0.0002346067,0.00016266796,0.00050284073,0.0000014203292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042248365,0.0020343666,0.7498377,0.00049960206,0.0012339987,0.011907737,0.00012161021,0.0008197352,0.04579411,0.00016169006,0.0010193122,0.14432177],"study_design_scores_gemma":[0.007689905,0.0053742738,0.9491914,0.0006454289,0.0010208822,0.011909918,0.00011988294,0.00013753262,0.017375868,0.00020346785,0.0061780848,0.00015338817],"about_ca_topic_score_codex":0.000012496967,"about_ca_topic_score_gemma":0.00004664098,"teacher_disagreement_score":0.19935367,"about_ca_system_score_codex":0.00020882324,"about_ca_system_score_gemma":0.00051172904,"threshold_uncertainty_score":0.43560153},"labels":[],"label_agreement":null},{"id":"W2551446562","doi":"10.1016/j.jtho.2016.08.067","title":"P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Medicine; Tolerability; Internal medicine; Lung cancer; Adverse effect; Post-hoc analysis; Incidence (geometry); Oncology; Pharmacokinetics; Erlotinib; Cancer; Epidermal growth factor receptor","score_opus":0.026308255957970872,"score_gpt":0.49145907067676575,"score_spread":0.4651508147187949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551446562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946989,0.001410648,0.00015239947,0.0018823876,0.00014744618,0.00033052635,0.00007228588,0.0000034020316,0.0013020204],"genre_scores_gemma":[0.9979613,0.00049646903,0.0011808845,0.000105636886,0.00009587401,0.000003577658,0.000010091145,0.000011880468,0.00013432],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854875,0.00018993343,0.00074528746,0.00013308293,0.00022371268,0.00015923628],"domain_scores_gemma":[0.99780685,0.00067850674,0.0008415704,0.00013134746,0.0004027405,0.00013896415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033163797,0.0001388972,0.000672259,0.0004078249,0.000026075515,0.0000029771227,0.00006082742,0.00010092134,0.00014034816],"category_scores_gemma":[0.00022803368,0.00007680614,0.00020685514,0.00019999893,0.000108581364,0.000116789095,0.000019131321,0.00014187468,0.0000019721497],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043941304,0.004452445,0.017191384,0.00015351309,0.0033487373,0.00063815666,0.0051487326,0.0007391122,0.06118518,0.000138377,0.00039231122,0.8626707],"study_design_scores_gemma":[0.00958803,0.022421304,0.9558233,0.0011073677,0.0016400298,0.00044121605,0.00071586366,0.000052492764,0.007937462,0.000065479355,0.00010443373,0.00010304724],"about_ca_topic_score_codex":0.00011007497,"about_ca_topic_score_gemma":0.000027865366,"teacher_disagreement_score":0.9386319,"about_ca_system_score_codex":0.00089207856,"about_ca_system_score_gemma":0.00077075016,"threshold_uncertainty_score":0.31320634},"labels":[],"label_agreement":null},{"id":"W2552086545","doi":"10.1016/j.jtho.2016.08.110","title":"P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Antibody; Oncology; Gastroenterology; Immunotherapy; Cancer; Immunology","score_opus":0.017608884163936512,"score_gpt":0.3861327224011434,"score_spread":0.36852383823720686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552086545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633217,0.00026081217,0.000119237855,0.0015579754,0.00031949446,0.0012009311,0.000006380728,0.0000038843914,0.00019911757],"genre_scores_gemma":[0.9989718,0.00009502652,0.0002810015,0.00031989906,0.00013078922,0.00003618212,0.0000018698539,0.000016983267,0.00014645768],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983497,0.00023592003,0.00071047706,0.00013739096,0.00034498915,0.000221472],"domain_scores_gemma":[0.9980542,0.00048392123,0.0008131987,0.00023888393,0.00035232527,0.000057490564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007898043,0.0001408538,0.00062350405,0.0002114236,0.000040708914,0.0000054668603,0.00023033733,0.00009706165,0.00007771624],"category_scores_gemma":[0.00013061058,0.0000619267,0.0001385209,0.00018480931,0.00009617655,0.000111456124,0.000018888308,0.00018105589,0.0000011978776],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26004365,0.006754052,0.20152828,0.00007928085,0.00047509008,0.0001309768,0.0013436863,0.0000022815593,0.004235454,0.000001683675,0.00035597713,0.52504957],"study_design_scores_gemma":[0.06319991,0.048326984,0.8841898,0.00039557263,0.00032463338,0.0001908065,0.0007531274,0.0000015137374,0.0004651378,0.000025245858,0.0020196917,0.00010762256],"about_ca_topic_score_codex":0.0000071598506,"about_ca_topic_score_gemma":0.00011167462,"teacher_disagreement_score":0.6826615,"about_ca_system_score_codex":0.00025550948,"about_ca_system_score_gemma":0.00028158084,"threshold_uncertainty_score":0.25252977},"labels":[],"label_agreement":null},{"id":"W2556521065","doi":"10.1016/j.jtho.2016.11.2218","title":"A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Trametinib; Pemetrexed; Medicine; KRAS; Docetaxel; Internal medicine; Oncology; Lung cancer; Tolerability; Rash; MEK inhibitor; Chemotherapy; Cancer; Adverse effect; Colorectal cancer; MAPK/ERK pathway; Cisplatin; Biology","score_opus":0.034283906387632686,"score_gpt":0.49569798246561175,"score_spread":0.4614140760779791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556521065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962198,0.000470425,0.0003134494,0.00073317834,0.00037721207,0.0013829191,0.000017747758,0.000009126132,0.00047615706],"genre_scores_gemma":[0.99141294,0.00006818547,0.0070965,0.00017784475,0.00014265622,0.00009792258,0.0000028342763,0.000029321141,0.0009717892],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981958,0.0001923521,0.0006844558,0.00023316823,0.000393275,0.00030092348],"domain_scores_gemma":[0.9980473,0.00026244408,0.0007766707,0.00018550639,0.0005406047,0.00018745594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000552664,0.00019291576,0.0007140245,0.00031579915,0.000055751985,0.000009654863,0.000118662014,0.00008021169,0.0002421599],"category_scores_gemma":[0.00019233856,0.00009500319,0.00008669524,0.0003357819,0.000041277664,0.00016926891,0.000025358006,0.00024942032,0.0000033661083],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029237827,0.018407568,0.21380389,0.00011903951,0.00062028,0.0005839381,0.0044226474,0.000120942204,0.0013166249,3.8061415e-7,0.00021301222,0.73115385],"study_design_scores_gemma":[0.34467804,0.16647306,0.46845448,0.0022637865,0.007533922,0.00016146616,0.006295744,0.00046331732,0.001593128,0.000017538598,0.0015387435,0.0005267926],"about_ca_topic_score_codex":0.000041211897,"about_ca_topic_score_gemma":0.00023207665,"teacher_disagreement_score":0.73062706,"about_ca_system_score_codex":0.0014597487,"about_ca_system_score_gemma":0.0020048155,"threshold_uncertainty_score":0.38741177},"labels":[],"label_agreement":null},{"id":"W2556818341","doi":"10.1016/j.jtho.2016.08.069","title":"P1.47: ABOUND.sqm QoL by Response: Interim Analysis of Squamous NSCLC Pts Treated With nab-Paclitaxel/Carboplatin Induction Therapy","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Carboplatin; Clinical endpoint; Interim analysis; Induction chemotherapy; non-small cell lung cancer (NSCLC); Oncology; Paclitaxel; Lung cancer; Quality of life (healthcare); Maintenance therapy; Response Evaluation Criteria in Solid Tumors; Interim; Randomized controlled trial; Progressive disease; Chemotherapy","score_opus":0.024417823025486642,"score_gpt":0.4399750097691598,"score_spread":0.4155571867436732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556818341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924047,0.00096383196,0.0005717321,0.0048731402,0.00020057378,0.0002435324,0.00004403992,0.000015865635,0.0006825593],"genre_scores_gemma":[0.99649954,0.00018595929,0.00089210976,0.00020615247,0.00012458902,0.0000138680225,0.000013789704,0.000023082375,0.0020408838],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99824214,0.0003786743,0.0006696227,0.00019129612,0.00030906603,0.00020920149],"domain_scores_gemma":[0.9977821,0.00038421026,0.00094822113,0.00024900114,0.00047503444,0.00016143199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005645602,0.00018083538,0.00082765805,0.00069824565,0.00005330214,0.000011579139,0.00010403543,0.00017732612,0.0003210472],"category_scores_gemma":[0.00015461001,0.0000956244,0.00024183972,0.0007300412,0.00016464393,0.0001717066,0.000012595102,0.00019521904,0.0000041927824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05991302,0.0019447423,0.03164313,0.00002918412,0.009816018,0.00037473708,0.0022467065,0.000029130699,0.36222196,0.000014019995,0.0033264237,0.52844095],"study_design_scores_gemma":[0.025263356,0.07608886,0.62947124,0.0010023727,0.028318465,0.002343496,0.0039734375,0.000071056034,0.14786011,0.00018807694,0.08471372,0.0007058022],"about_ca_topic_score_codex":0.00009028447,"about_ca_topic_score_gemma":0.000045686793,"teacher_disagreement_score":0.5978281,"about_ca_system_score_codex":0.0007960511,"about_ca_system_score_gemma":0.00063881744,"threshold_uncertainty_score":0.38994497},"labels":[],"label_agreement":null},{"id":"W2557730509","doi":"10.1016/j.jtho.2016.11.2228","title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Celgene; AstraZeneca","keywords":"Immunohistochemistry; Medicine; Staining; Pathology; Companion diagnostic; Lung cancer; Cancer; Internal medicine","score_opus":0.04763398284113613,"score_gpt":0.4766245741671307,"score_spread":0.4289905913259946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557730509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754738,0.0051530064,0.0024160375,0.01213288,0.0020428288,0.00079400704,0.00048330918,0.000017796925,0.0014863295],"genre_scores_gemma":[0.99434125,0.0006373579,0.0024448233,0.00033520063,0.0007932545,0.000038251164,0.000012569775,0.000028816272,0.0013684682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99734616,0.00027103224,0.0014247353,0.00025440456,0.00039634242,0.0003073234],"domain_scores_gemma":[0.99579066,0.00089122594,0.0021821302,0.0004969638,0.0005418003,0.00009718961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001990494,0.00021644759,0.00090896635,0.00011603514,0.000099906065,0.00001195515,0.00043784108,0.0002972332,0.00017589894],"category_scores_gemma":[0.0007369761,0.00011717488,0.00056731206,0.00019102753,0.0002837927,0.00009176498,0.0000745008,0.0004326063,0.0000010569928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081707664,0.00080026407,0.0016284583,0.0001162794,0.0008706921,0.000022050785,0.00071745226,0.000004053292,0.702617,0.000003878523,0.03067177,0.18084048],"study_design_scores_gemma":[0.02984146,0.0040932093,0.009651,0.0027053899,0.0016976614,0.00040397287,0.0008791973,0.00043880657,0.74564284,0.00014455392,0.2041421,0.00035982195],"about_ca_topic_score_codex":0.00030711349,"about_ca_topic_score_gemma":0.000048282753,"teacher_disagreement_score":0.18048064,"about_ca_system_score_codex":0.0012575729,"about_ca_system_score_gemma":0.0017692336,"threshold_uncertainty_score":0.47782528},"labels":[],"label_agreement":null},{"id":"W2564674425","doi":"10.1016/j.jtho.2016.12.004","title":"The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; H&E stain; Pathology; Immunohistochemistry; Biopsy; Lung cancer; Differential diagnosis; Carcinoma; Medical diagnosis; Radiology","score_opus":0.09684801767149295,"score_gpt":0.481293159134783,"score_spread":0.38444514146329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564674425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916368,0.004570368,0.000005034473,0.0029469174,0.00027736725,0.00050990516,0.000039582515,0.0000018168176,0.000012211079],"genre_scores_gemma":[0.99342275,0.0061569056,0.000060422608,0.0000140133725,0.0001735602,0.00009743024,4.6463487e-7,0.000008617818,0.000065863314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810797,0.00034371484,0.0007992812,0.0002485564,0.00033543448,0.00016505811],"domain_scores_gemma":[0.99539244,0.0025993763,0.0009273829,0.000434896,0.00058722787,0.000058692483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019089243,0.000110194036,0.0005552282,0.000103879334,0.000056894893,0.00000810251,0.0002777609,0.00005985448,0.000026281787],"category_scores_gemma":[0.0043913275,0.00005086175,0.000097890545,0.000108126646,0.00030785246,0.00013213564,0.000234759,0.00025381782,3.730507e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003217495,0.0009689347,0.8963239,0.00030825316,0.00048086705,0.000060233044,0.0021035864,0.000005526054,0.069102496,0.00000223983,0.00023812518,0.027188348],"study_design_scores_gemma":[0.002035347,0.0029370547,0.8480885,0.00072054396,0.000549589,0.000089771915,0.0017423945,0.00006414278,0.1433513,0.000025550235,0.000316481,0.0000793396],"about_ca_topic_score_codex":0.00040012843,"about_ca_topic_score_gemma":0.00047125464,"teacher_disagreement_score":0.074248806,"about_ca_system_score_codex":0.000397531,"about_ca_system_score_gemma":0.00033918896,"threshold_uncertainty_score":0.52571464},"labels":[],"label_agreement":null},{"id":"W2566524736","doi":"10.1016/j.jtho.2016.11.2207","title":"P3.07-016 Ontario's Episode-Based Funding Model Reveals Practice Variation in Adjuvant NSCLC Chemotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Vinorelbine; Carboplatin; Regimen; Etoposide; Chemotherapy; Internal medicine; Guideline; Chemotherapy regimen; Oncology; Cisplatin","score_opus":0.04592004504252597,"score_gpt":0.4418636756049424,"score_spread":0.39594363056241644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566524736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9216329,0.00061522634,0.005247884,0.06089652,0.0009992627,0.0005529255,0.0000045035777,0.0000151229015,0.010035649],"genre_scores_gemma":[0.96827507,0.00030998202,0.02766964,0.002593416,0.00035049237,0.00002054609,0.000002304348,0.00002292015,0.0007556578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983546,0.00016487131,0.0006619903,0.00020815311,0.0003342122,0.0002761854],"domain_scores_gemma":[0.9971361,0.00036406552,0.001600584,0.00040732758,0.00031911005,0.00017282012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017819459,0.00016686662,0.0007117479,0.00019813563,0.00013804887,0.000052152875,0.0002012515,0.00020045819,0.00019229086],"category_scores_gemma":[0.0005302234,0.00012804224,0.00017533104,0.000053940767,0.000050320617,0.0004301647,0.000028573962,0.00049779576,0.00001677538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026752928,0.0076496336,0.55429864,0.0002956435,0.0012661407,0.0035245123,0.005620845,0.004661981,0.004364971,0.00041822795,0.008640324,0.38250616],"study_design_scores_gemma":[0.0156809,0.0076083974,0.91844165,0.0021157938,0.0018872143,0.0013929277,0.00022799996,0.0074099796,0.0014568256,0.0025390459,0.040831916,0.0004073746],"about_ca_topic_score_codex":0.0023611228,"about_ca_topic_score_gemma":0.005621126,"teacher_disagreement_score":0.3820988,"about_ca_system_score_codex":0.004427241,"about_ca_system_score_gemma":0.0015548817,"threshold_uncertainty_score":0.9993946},"labels":[],"label_agreement":null},{"id":"W2567727441","doi":"10.1016/j.jtho.2016.11.845","title":"P1.05-060 Adherence to Surveillance Guidelines in Resected NSCLC: Physician Compliance and Impact on Outcomes","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Guideline; Lung cancer; Pneumonectomy; Stage (stratigraphy); Internal medicine; Lung cancer screening; Population; Multivariate analysis; Retrospective cohort study","score_opus":0.1526843750495054,"score_gpt":0.5464006768220669,"score_spread":0.39371630177256156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567727441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97052413,0.0008257063,0.000024228813,0.024190145,0.0006411982,0.00019207929,0.000007915578,0.000008118219,0.0035865046],"genre_scores_gemma":[0.9951504,0.00034428263,0.001363859,0.002232964,0.0004000076,0.000005181049,3.7800976e-7,0.000013134731,0.0004897898],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99855196,0.00011674346,0.0006035355,0.00018939147,0.00024620967,0.00029218447],"domain_scores_gemma":[0.9981726,0.000263515,0.00056926225,0.0003337407,0.0004584962,0.00020241267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083389215,0.00017579015,0.0011443552,0.00017449152,0.00013837258,0.000028084285,0.00023661915,0.00009257043,0.000014650838],"category_scores_gemma":[0.0015495498,0.000114021524,0.0001189521,0.00011095737,0.00011870025,0.000110467765,0.00008951153,0.000383781,0.0000117115915],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004247412,0.00022691238,0.4074973,0.00007544694,0.00013902021,0.0006014287,0.00036611757,0.000024365181,0.0034122553,0.000010310106,0.01622181,0.56717765],"study_design_scores_gemma":[0.0012951114,0.006286795,0.9815119,0.0008449214,0.00002629978,0.00014955718,0.00012126632,0.000047588615,0.00032971066,0.00009754616,0.009175362,0.000113933944],"about_ca_topic_score_codex":0.0002246458,"about_ca_topic_score_gemma":0.0007694523,"teacher_disagreement_score":0.5740146,"about_ca_system_score_codex":0.00025208725,"about_ca_system_score_gemma":0.00028822833,"threshold_uncertainty_score":0.4649663},"labels":[],"label_agreement":null},{"id":"W2567730437","doi":"10.1016/j.jtho.2016.11.355","title":"OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Nintedanib; Medicine; Placebo; Pemetrexed; Internal medicine; Bevacizumab; Clinical endpoint; Adverse effect; Neutropenia; Oncology; Pazopanib; Cisplatin; Gastroenterology; Urology; Surgery; Chemotherapy; Randomized controlled trial; Pathology; Cancer; Idiopathic pulmonary fibrosis; Sunitinib","score_opus":0.01993698530407767,"score_gpt":0.38331797979049326,"score_spread":0.3633809944864156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567730437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938361,0.00014574097,0.0000209315,0.0035191267,0.00064046006,0.0008262556,0.00004445896,0.0000060733705,0.0009608731],"genre_scores_gemma":[0.99761176,0.000018707578,0.00058995327,0.0004810933,0.000490548,0.000019399107,0.000036914425,0.000018764875,0.00073287316],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99816376,0.00018581556,0.00067713053,0.00019024758,0.00054665416,0.00023641737],"domain_scores_gemma":[0.9979781,0.00045704967,0.0009676286,0.00031264435,0.000097840246,0.00018677201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063853245,0.00019317109,0.00082146976,0.00012523792,0.00031377742,0.000040771523,0.00033132435,0.00013194086,0.000627088],"category_scores_gemma":[0.0008437333,0.000106660984,0.00021908448,0.000061665225,0.00020112382,0.00023505716,0.00010936604,0.0004780576,0.000025561201],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7506578,0.002886724,0.22145276,0.000009985197,0.00033962054,0.00019572252,0.00031780513,0.00002876333,0.00011641994,0.000007689826,0.0032883114,0.020698415],"study_design_scores_gemma":[0.3274827,0.015890323,0.6523208,0.00020453507,0.0008345624,0.000029379773,0.00018612355,0.00019770116,0.00007562907,0.0001201681,0.0025258362,0.00013222391],"about_ca_topic_score_codex":0.00007093923,"about_ca_topic_score_gemma":0.00006301872,"teacher_disagreement_score":0.43086806,"about_ca_system_score_codex":0.00045873265,"about_ca_system_score_gemma":0.00033328534,"threshold_uncertainty_score":0.6866174},"labels":[],"label_agreement":null},{"id":"W2567738349","doi":"10.1016/j.jtho.2016.11.1090","title":"P2.01-038 Discrimination of NSCLC Cases from Cancer-Free Controls and Adenocarcinoma from Squamous Cell Carcinoma Using Plasma Metabolomics Profiles","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Metabolomics; Lung cancer; Adenocarcinoma; Oncology; Cancer; Carcinoma; Internal medicine; Stage (stratigraphy); Pathology; Bioinformatics; Biology","score_opus":0.04565949370275341,"score_gpt":0.3891603804902915,"score_spread":0.3435008867875381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567738349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97692215,0.018434811,0.000046781595,0.002806653,0.00084059057,0.0003596871,0.00040071097,0.0000054031693,0.00018318395],"genre_scores_gemma":[0.99302554,0.00065971795,0.005328041,0.00011050635,0.0007755563,0.000016352406,0.000017080447,0.000027001268,0.00004021326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839723,0.0001531727,0.0006741256,0.00025649645,0.0002921027,0.00022684966],"domain_scores_gemma":[0.99663836,0.0006174434,0.001759019,0.0004895608,0.0002973787,0.00019826926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025567022,0.00022031844,0.001077112,0.00013785642,0.00016773865,0.000044303575,0.00026932044,0.00019873,0.00007947474],"category_scores_gemma":[0.00034654822,0.00016444536,0.00018846076,0.000035357367,0.00021451993,0.0002389624,0.00012519225,0.00026655424,0.0000010328895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046600983,0.00092850067,0.9317423,0.00021459894,0.00049602374,0.001575144,0.0012313137,0.00002940531,0.018510163,0.000027106333,0.00093619403,0.03964916],"study_design_scores_gemma":[0.007964421,0.0024072127,0.8772295,0.00037551307,0.005463206,0.0004009086,0.00094157015,0.0006933841,0.10352827,0.0003923337,0.00042288267,0.00018075852],"about_ca_topic_score_codex":0.006964809,"about_ca_topic_score_gemma":0.0015813677,"teacher_disagreement_score":0.08501811,"about_ca_system_score_codex":0.00061836845,"about_ca_system_score_gemma":0.0006297365,"threshold_uncertainty_score":0.9996479},"labels":[],"label_agreement":null},{"id":"W2567743054","doi":"10.1016/j.jtho.2016.11.010","title":"PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Pemetrexed; Lung cancer; Internal medicine; Oncology; Chemotherapy; Quality of life (healthcare); Adverse effect; Progression-free survival; Tolerability; Cancer; Immunotherapy; Cisplatin","score_opus":0.09413103862692979,"score_gpt":0.4769493827011173,"score_spread":0.3828183440741875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567743054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96669096,0.0042056795,0.00067860534,0.026536485,0.0007067902,0.0006160159,0.00013740623,0.00001171438,0.00041632497],"genre_scores_gemma":[0.98681396,0.0014586006,0.00890156,0.0021696822,0.00032764603,0.000009503526,0.000054594304,0.000040880434,0.00022357206],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99696743,0.0002900033,0.0016974326,0.00033344055,0.0003546727,0.00035701293],"domain_scores_gemma":[0.99451625,0.0004679611,0.0034453517,0.0011235293,0.00022873742,0.00021817921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002575378,0.00022461517,0.0016039237,0.00019692948,0.00013332773,0.000023683224,0.0007732805,0.00027844557,0.0001952757],"category_scores_gemma":[0.0005612611,0.00016606873,0.00020949267,0.00011728021,0.0002965241,0.0003384152,0.000079938305,0.000537931,0.0000023981727],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82329047,0.00094658055,0.007538228,0.00028304086,0.00095959235,0.00006841699,0.0008703334,0.000012329134,0.012613795,0.000009941185,0.0042039603,0.14920335],"study_design_scores_gemma":[0.041103307,0.010863257,0.89854574,0.0011813256,0.00021123952,0.00030733112,0.00096380763,0.00023241834,0.0023953991,0.00051950914,0.0433749,0.00030174394],"about_ca_topic_score_codex":0.0017160311,"about_ca_topic_score_gemma":0.0010998141,"teacher_disagreement_score":0.89100754,"about_ca_system_score_codex":0.00045428856,"about_ca_system_score_gemma":0.0021408915,"threshold_uncertainty_score":0.6772086},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2567796156","doi":"10.1016/j.jtho.2016.11.790","title":"P1.05-006 Identification of miRNAs and mRNAs Associated with Metastasis in Early-Stage Non-Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"microRNA; Medicine; Metastasis; Lung cancer; Adenocarcinoma; Cancer; Stage (stratigraphy); Oncology; Cancer research; Gene; Internal medicine; Biology; Genetics","score_opus":0.018999540439072447,"score_gpt":0.3638715356350836,"score_spread":0.3448719951960112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567796156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996047,0.0018692564,0.0008394722,0.0004262641,0.00019341524,0.00014133376,0.00002755369,0.0000012069163,0.00045445928],"genre_scores_gemma":[0.9970103,0.0011928885,0.00051102345,0.000036633613,0.00009179956,0.000015373329,0.0000052216365,0.000014907564,0.0011218498],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989365,0.00010302663,0.0004922849,0.00017994107,0.0001251065,0.00016316544],"domain_scores_gemma":[0.9977473,0.000023257075,0.0015566768,0.00031176605,0.00029139468,0.00006959747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007527179,0.00011450426,0.00031849806,0.00010507374,0.00009973482,0.000040526153,0.00030108407,0.00016853996,0.000010365538],"category_scores_gemma":[0.00009348258,0.00009443115,0.00007431355,0.000063752006,0.00013136002,0.000020591837,0.000060452847,0.00017436453,3.271023e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076936797,0.00038031873,0.16970219,0.00009293785,0.0003228846,0.000042041305,0.00040142372,0.00031185022,0.79752463,0.000015341162,0.00074398547,0.029693052],"study_design_scores_gemma":[0.0014193637,0.00086305954,0.6399021,0.0001378131,0.00031061497,0.000029642708,0.0002831043,0.0001461126,0.35109246,0.000026301568,0.0055895397,0.00019988572],"about_ca_topic_score_codex":0.00018918514,"about_ca_topic_score_gemma":0.00070503796,"teacher_disagreement_score":0.4701999,"about_ca_system_score_codex":0.00008340718,"about_ca_system_score_gemma":0.00033979877,"threshold_uncertainty_score":0.38507906},"labels":[],"label_agreement":null},{"id":"W2567822129","doi":"10.1016/j.jtho.2016.11.2090","title":"PUB119 Lanreotide in Patients with Lung Neuroendocrine Tumors: The Randomized Double-Blind Placebo-Controlled International Phase 3 SPINET Study","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Lanreotide; Medicine; Neuroendocrine tumors; Clinical endpoint; Internal medicine; Oncology; Placebo; Phases of clinical research; Lung cancer; Lung; Chemotherapy; Randomized controlled trial; Gastroenterology; Surgery; Pathology","score_opus":0.03275642882209268,"score_gpt":0.4543495624240792,"score_spread":0.4215931336019865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567822129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97930485,0.000082542225,0.000019872694,0.013592186,0.00075243565,0.0043127006,0.000004315275,0.0000120549485,0.0019190133],"genre_scores_gemma":[0.99783844,0.000042782674,0.0003170536,0.00025394082,0.00052768167,0.00014904609,0.000005180565,0.000032634987,0.0008332682],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99619085,0.0008753362,0.001190679,0.00027907445,0.0010068836,0.00045719644],"domain_scores_gemma":[0.99594915,0.00080681965,0.0017913211,0.00057441625,0.0006417465,0.00023654377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001805385,0.0002638308,0.0017161019,0.0005223473,0.00017736203,0.00013894546,0.00090976816,0.00001146169,0.00015155855],"category_scores_gemma":[0.0031913186,0.00013658105,0.00024532547,0.00012961058,0.00033958242,0.000513931,0.00023046628,0.0011192771,0.00000825973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9000601,0.0039449045,0.07168197,0.000023549197,0.00056468917,0.019274496,0.000090168585,0.00006495365,0.000030993215,0.000011256892,0.00045107948,0.0038018348],"study_design_scores_gemma":[0.95541644,0.00738775,0.03173064,0.0001312675,0.0004888583,0.0028359024,0.00024369256,0.00038412987,0.00010715542,0.000044984674,0.0011097441,0.000119415796],"about_ca_topic_score_codex":0.000051079936,"about_ca_topic_score_gemma":0.00014122672,"teacher_disagreement_score":0.05535635,"about_ca_system_score_codex":0.00024538825,"about_ca_system_score_gemma":0.00041437495,"threshold_uncertainty_score":0.55696136},"labels":[],"label_agreement":null},{"id":"W2567823689","doi":"10.1016/j.jtho.2016.11.2024","title":"PUB054 Preferences for the Provision of Smoking Cessation Education among Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Cancer; Malignancy; Family medicine; Internal medicine","score_opus":0.10852932397313263,"score_gpt":0.5002840624089512,"score_spread":0.39175473843581854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567823689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389815,0.0005593074,0.00031816273,0.002569163,0.0012874343,0.0003093299,0.000003133809,0.0000020721673,0.0010532436],"genre_scores_gemma":[0.99829096,0.00017855344,0.0007558691,0.00016724567,0.0004556851,0.000020662108,0.000002152019,0.00000494011,0.0001239313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991367,0.00004376084,0.00037324292,0.00007664602,0.0002651755,0.00010448059],"domain_scores_gemma":[0.99719894,0.00012503841,0.0015489681,0.00015645873,0.00091873814,0.00005188197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068605103,0.00006137914,0.00023855697,0.000066455825,0.00018627006,0.00002854915,0.00023172035,0.000085867585,0.000026246236],"category_scores_gemma":[0.00067298755,0.00003620681,0.00008804489,0.00003824443,0.00009525011,0.00033587986,0.00003157486,0.00016211931,2.2671551e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005437448,0.000087860106,0.44522873,0.000050838433,0.00004243282,6.248445e-7,0.00026336362,0.000015947644,0.0001592103,0.000012381431,0.0015814826,0.5520134],"study_design_scores_gemma":[0.00045794336,0.00131107,0.9886025,0.00046176,0.00032552224,0.000011014635,0.00065453217,0.00009923401,0.0021275722,0.00044638567,0.005462659,0.000039759943],"about_ca_topic_score_codex":0.00034693838,"about_ca_topic_score_gemma":0.0002694012,"teacher_disagreement_score":0.55197364,"about_ca_system_score_codex":0.000187939,"about_ca_system_score_gemma":0.0007642193,"threshold_uncertainty_score":0.14764708},"labels":[],"label_agreement":null},{"id":"W2567850999","doi":"10.1016/j.jtho.2016.11.1666","title":"P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Ceritinib; Medicine; Crizotinib; Anaplastic lymphoma kinase; Pharmacokinetics; Internal medicine; ALK inhibitor; non-small cell lung cancer (NSCLC); Clinical endpoint; Gastroenterology; Oncology; Lung cancer; Randomized controlled trial","score_opus":0.06544336920317444,"score_gpt":0.515530127097982,"score_spread":0.4500867578948075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567850999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99508905,0.00018791943,0.000076113225,0.0013305248,0.00051453756,0.0009333719,0.00003536059,0.000007948324,0.0018251896],"genre_scores_gemma":[0.9966663,0.00008233944,0.0024410835,0.00009381163,0.00012234416,0.00004434194,0.000010378799,0.000031475574,0.00050793163],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976323,0.0003186746,0.001002616,0.00024566293,0.00043325574,0.0003674805],"domain_scores_gemma":[0.9974126,0.00032003783,0.0013183295,0.00039289152,0.0003366882,0.00021943571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066324463,0.00023582905,0.0011587341,0.000477683,0.000100318925,0.000032610114,0.00025701986,0.000082402614,0.00015435796],"category_scores_gemma":[0.00034060172,0.00015399823,0.00009999791,0.00025689704,0.00015385401,0.00031220462,0.000056925597,0.00047562656,0.0000058109413],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3255551,0.044131324,0.04800464,0.00070163916,0.006071458,0.043017626,0.04313437,0.00070825586,0.006411243,0.00002279555,0.0011619382,0.4810796],"study_design_scores_gemma":[0.43522698,0.23813905,0.22152059,0.003919047,0.010912477,0.0034662485,0.07295062,0.0010571212,0.0021137712,0.0003406305,0.009296681,0.0010567774],"about_ca_topic_score_codex":0.0006527132,"about_ca_topic_score_gemma":0.0081065865,"teacher_disagreement_score":0.48002285,"about_ca_system_score_codex":0.0006703431,"about_ca_system_score_gemma":0.001142608,"threshold_uncertainty_score":0.62798655},"labels":[],"label_agreement":null},{"id":"W2567867817","doi":"10.1016/j.jtho.2016.11.539","title":"P1.01-015 Polyphenols-Rich Fruit Extracts Prevent Tobacco Specific Nitrosamine-Induced DNA Damage in Lung Epithelial Cells","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Beatrice Hunter Cancer Research Institute; Dalhousie University","funders":"","keywords":"Polyphenol; DNA damage; Biochemistry; Molecular biology; Chemistry; DNA; Biology; Antioxidant","score_opus":0.025351663147141743,"score_gpt":0.3587700349845739,"score_spread":0.3334183718374321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567867817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935393,0.00083186536,0.00023294214,0.00054227206,0.0014015731,0.0002640999,0.00003996282,0.0000040593254,0.0031439222],"genre_scores_gemma":[0.99512714,0.00035636366,0.0019273988,0.00013975521,0.001726515,0.000008170114,0.000023917366,0.000037875532,0.0006528852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977782,0.00030240766,0.00080388185,0.00040156767,0.00021640437,0.00049758295],"domain_scores_gemma":[0.9975454,0.00007300253,0.0012297329,0.00071689824,0.00020535702,0.00022955955],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009310474,0.00029467585,0.00062039314,0.00014484751,0.00015587982,0.000085113556,0.0010003925,0.0004356245,0.000072504816],"category_scores_gemma":[0.00026481252,0.0002730809,0.0002266928,0.000057822104,0.00016756257,0.000031536772,0.00032197256,0.00054990745,0.000017827322],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009817928,0.00056467694,0.0017375329,0.0000326787,0.000101078746,0.00018704789,0.00014100363,0.000020770533,0.98314226,0.0000114001905,0.002555933,0.010523818],"study_design_scores_gemma":[0.0010331966,0.0009076948,0.02160173,0.000063405394,0.000067038935,0.000105018575,0.00023901627,0.0000073188,0.9597933,0.00034756915,0.015541334,0.000293336],"about_ca_topic_score_codex":0.000023598343,"about_ca_topic_score_gemma":0.00013189384,"teacher_disagreement_score":0.023348924,"about_ca_system_score_codex":0.00017746631,"about_ca_system_score_gemma":0.0003465482,"threshold_uncertainty_score":0.99997216},"labels":[],"label_agreement":null},{"id":"W2567890599","doi":"10.1016/j.jtho.2016.11.1903","title":"P3.03-004 Genome-Wide Copy Number Aberrations in Mesothelioma and Its Correlation with Tumor Microenvironment including PD-L1 Expression","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Tissue microarray; Medicine; Histology; Immune system; CD8; Pathology; Immune checkpoint; Correlation; FOXP3; Tumor microenvironment; Immunohistochemistry; Cancer research; Immunology; Immunotherapy","score_opus":0.02424887390676265,"score_gpt":0.3738862406909474,"score_spread":0.3496373667841847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567890599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956928,0.00038349532,0.00017917417,0.0018789255,0.0001257555,0.00019889827,0.0000082195575,0.000004116885,0.0015286219],"genre_scores_gemma":[0.9950735,0.00019311064,0.003753052,0.00034328224,0.00012070822,0.000008302096,0.000009713665,0.000014689687,0.00048366393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901986,0.00007398409,0.0003696677,0.00014646216,0.00024168,0.00014832494],"domain_scores_gemma":[0.99898654,0.00009448207,0.00058892963,0.00014425682,0.000025205549,0.00016059338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024779592,0.000121764235,0.00030647268,0.00010972676,0.00021894525,0.000022107028,0.0000945178,0.00007295702,0.0002753276],"category_scores_gemma":[0.000088067034,0.00008960535,0.000050446255,0.000036734906,0.00011257771,0.00029792628,0.00008141914,0.00022618409,0.000035945264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003609774,0.000546856,0.9472663,0.000058166952,0.000054340937,0.0004461902,0.00029317936,0.00022692127,0.044555455,0.000010913788,0.00032036347,0.0026115798],"study_design_scores_gemma":[0.0012446413,0.0007862798,0.98789203,0.00029597353,0.00015891495,0.00083094876,0.00017861063,0.0001530362,0.005496523,0.00014715554,0.0027185543,0.00009734061],"about_ca_topic_score_codex":0.000007923029,"about_ca_topic_score_gemma":0.000018709892,"teacher_disagreement_score":0.040625762,"about_ca_system_score_codex":0.00035241677,"about_ca_system_score_gemma":0.00009618185,"threshold_uncertainty_score":0.36540002},"labels":[],"label_agreement":null},{"id":"W2567930116","doi":"10.1016/j.jtho.2016.11.657","title":"P1.02-073 Characterizing the Genomes of Lung Adenocarcinomas from Never Smokers Reveals SHPRH as a Novel Candidate Tumor Suppressor Gene","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"KRAS; Gene; ROS1; Carcinogenesis; Biology; Cancer research; Mutation; Genetics; CDKN2A; Candidate gene; Tumor suppressor gene; Mutant; Cancer; Adenocarcinoma","score_opus":0.02381025962629285,"score_gpt":0.36580579042063144,"score_spread":0.3419955307943386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567930116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899358,0.00405492,0.00033033197,0.0043304316,0.000626406,0.00015742911,0.00011591925,0.0000021463209,0.00044659723],"genre_scores_gemma":[0.9954144,0.00072590227,0.0013355789,0.0011572625,0.00084182195,0.000013198213,0.000024535297,0.000023201566,0.00046409373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986406,0.00012924375,0.00056971685,0.00022888489,0.00018292916,0.0002486196],"domain_scores_gemma":[0.99732125,0.00004429672,0.0015547501,0.00072214747,0.00024565682,0.00011187574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005824206,0.00016413283,0.0004087208,0.000060006143,0.0002528382,0.00005934433,0.00085024594,0.00016270501,0.00009390551],"category_scores_gemma":[0.00015079585,0.00011696039,0.00020668654,0.00003738319,0.00022110422,0.000031499243,0.00019338235,0.00024222597,0.000003922247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006273085,0.00009175251,0.0052012634,0.000016602013,0.00027925117,0.000032856737,0.00017393468,0.0000135922655,0.9857626,0.0000248299,0.0022864714,0.005489558],"study_design_scores_gemma":[0.0010676477,0.0007446961,0.30276012,0.0000757724,0.0003994372,0.00047907225,0.00029135795,0.00006485121,0.56430423,0.00018592982,0.12935296,0.0002739154],"about_ca_topic_score_codex":0.00016807516,"about_ca_topic_score_gemma":0.000028638602,"teacher_disagreement_score":0.42145833,"about_ca_system_score_codex":0.0000767789,"about_ca_system_score_gemma":0.00041974045,"threshold_uncertainty_score":0.47695065},"labels":[],"label_agreement":null},{"id":"W2567996140","doi":"10.1016/j.jtho.2016.11.1279","title":"P2.03a-069 Effectiveness of Adjuvant Carboplatin-Based Chemotherapy Compared to Cisplatin in Resected Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Carboplatin; Vinorelbine; Medicine; Cisplatin; Regimen; Lung cancer; Internal medicine; Oncology; Chemotherapy; Adjuvant","score_opus":0.021799149197732324,"score_gpt":0.4554990417687556,"score_spread":0.43369989257102326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567996140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939732,0.0004210617,0.0005148179,0.0014028737,0.00056078675,0.0007427483,0.000019974188,0.0000056167905,0.002358947],"genre_scores_gemma":[0.99628526,0.00003778383,0.0030842952,0.0002043824,0.00015211447,0.000042887605,0.0000061736428,0.000024810095,0.000162275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986082,0.0001964332,0.0005613471,0.0001780042,0.0002210457,0.00023496897],"domain_scores_gemma":[0.9978774,0.0003281911,0.00085059326,0.0003279267,0.0004385753,0.00017730397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006543786,0.00016292914,0.00088956946,0.0002982034,0.00008574173,0.000014925658,0.00021576359,0.00013859323,0.000074168485],"category_scores_gemma":[0.00012965804,0.00012635624,0.00013860482,0.00015352771,0.000066367385,0.00006581476,0.000028313216,0.00030194176,0.0000017798301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015437326,0.0018196801,0.7435649,0.0012686253,0.0006156211,0.0008094576,0.003371765,0.005142504,0.18369804,0.000005072577,0.00069223763,0.043574788],"study_design_scores_gemma":[0.008407048,0.0019404312,0.91392,0.0015591802,0.0005493684,0.000040179984,0.00019693092,0.0018609178,0.07090598,0.00002076785,0.00047282322,0.00012637519],"about_ca_topic_score_codex":0.0007977785,"about_ca_topic_score_gemma":0.0006614582,"teacher_disagreement_score":0.17035511,"about_ca_system_score_codex":0.0008699268,"about_ca_system_score_gemma":0.0014754899,"threshold_uncertainty_score":0.5152658},"labels":[],"label_agreement":null},{"id":"W2568071671","doi":"10.1016/j.jtho.2016.11.410","title":"MA05.06 Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; McMaster University; Ontario Clinical Oncology Group; Juravinski Cancer Centre","funders":"","keywords":"Medicine; COPD; Lung cancer; Spirometry; Population; Cohort; Cancer; Cancer registry; Internal medicine; Lung cancer screening; Physical therapy; Asthma","score_opus":0.02990465353831891,"score_gpt":0.4350520368945017,"score_spread":0.40514738335618283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568071671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148506,0.003881778,0.000017760854,0.002651699,0.000530992,0.001064738,0.000061933024,0.000007955886,0.00029806828],"genre_scores_gemma":[0.99862546,0.0001643024,0.00022027364,0.00004478817,0.00060885673,0.00012367153,0.000013890462,0.000036549747,0.00016222442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712914,0.000468659,0.00090313284,0.0003388256,0.00074645696,0.00041380955],"domain_scores_gemma":[0.99681044,0.00027341553,0.001318706,0.0006522919,0.0005033617,0.0004417975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007982953,0.00023159165,0.0009173635,0.0005962854,0.00016198444,0.0000249474,0.00046364006,0.00014639659,0.00052561064],"category_scores_gemma":[0.00072601374,0.00020136088,0.0002801636,0.000220252,0.00020194425,0.00041348892,0.00017584718,0.00068413623,0.0000034490517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041582296,0.0031438405,0.9079976,0.00082097575,0.00018594747,0.003538373,0.00013405932,0.0005826176,0.00019852263,0.0000088956185,0.0000930015,0.079137914],"study_design_scores_gemma":[0.002075291,0.000729716,0.98920023,0.0006228595,0.0007184388,0.00005627011,0.00028893884,0.005587114,0.00011219921,0.0002103414,0.00024648255,0.00015214137],"about_ca_topic_score_codex":0.0008790611,"about_ca_topic_score_gemma":0.00045767665,"teacher_disagreement_score":0.08120258,"about_ca_system_score_codex":0.0039783227,"about_ca_system_score_gemma":0.0027041305,"threshold_uncertainty_score":0.9998452},"labels":[],"label_agreement":null},{"id":"W2568109935","doi":"10.1016/j.jtho.2016.11.1499","title":"P2.06-006 Phase I/II Dose Escalation Study of L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Medicine; Lung cancer; Cancer; Toxicity; Internal medicine; Gastroenterology; Adverse effect; Antibody; Oncology; Immunology","score_opus":0.018547209788640433,"score_gpt":0.4213723223146117,"score_spread":0.40282511252597125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568109935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976879,0.00020700527,0.00017484833,0.00020783643,0.0002642936,0.0006894372,0.000011087494,0.0000015318108,0.00075609586],"genre_scores_gemma":[0.9985936,0.00014647406,0.00028447242,0.00006883444,0.00020391714,0.00003160576,0.000012094473,0.000021107175,0.0006378848],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99840933,0.0001962315,0.0006349291,0.00022855419,0.00028024465,0.00025068322],"domain_scores_gemma":[0.99798375,0.000027190837,0.0010041666,0.00036688568,0.0004940768,0.00012392411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006369064,0.0001580108,0.00039543986,0.00021118096,0.00016688461,0.000029317114,0.00045635458,0.00023857522,0.00005559211],"category_scores_gemma":[0.0001646738,0.00013666655,0.0001115138,0.00008833647,0.00006508848,0.000021363625,0.00015073984,0.00030554616,0.0000028093718],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010475794,0.016743584,0.2703901,0.00012955404,0.00019754523,0.00013573865,0.0027849367,0.0010124892,0.544495,0.0000012300919,0.0017647761,0.15186925],"study_design_scores_gemma":[0.05159015,0.06348944,0.5023667,0.00019721554,0.00022632052,0.00004843146,0.0013941427,0.004140956,0.36220753,0.00006968821,0.013554784,0.0007146413],"about_ca_topic_score_codex":0.00036648972,"about_ca_topic_score_gemma":0.0007649148,"teacher_disagreement_score":0.2319766,"about_ca_system_score_codex":0.00011390162,"about_ca_system_score_gemma":0.00036613306,"threshold_uncertainty_score":0.55731},"labels":[],"label_agreement":null},{"id":"W2568140973","doi":"10.1016/j.jtho.2016.11.962","title":"P1.07-050 Patterns of Relapse in Small Cell Lung Cancer (SCLC): A Retrospective Analysis of Outcomes from a Single Canadian Center","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Conventional PCI; Carboplatin; Etoposide; Retrospective cohort study; Chemotherapy; Internal medicine; Single Center; Lung cancer; Radiation therapy; Stage (stratigraphy); Oncology; Surgery; Cisplatin","score_opus":0.04123785998035705,"score_gpt":0.44019176793862125,"score_spread":0.3989539079582642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568140973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907341,0.0010222895,0.000030966054,0.0051199137,0.00042302615,0.00023233617,0.0002778361,0.0000025119598,0.0021570006],"genre_scores_gemma":[0.99789625,0.0006523067,0.00062380766,0.0001907081,0.00014583267,0.000008356261,0.0000054875054,0.000017248492,0.00045998135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804276,0.00018717397,0.0008091752,0.0002147349,0.0003673171,0.00037883324],"domain_scores_gemma":[0.99703836,0.00021506383,0.0013938296,0.00047388548,0.0005967984,0.00028208192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071362895,0.0001638912,0.0015685047,0.0010226911,0.00007598255,0.000015466057,0.00039512504,0.00016269326,0.00042789234],"category_scores_gemma":[0.00066204974,0.00012518291,0.0003943518,0.00024561622,0.00016474494,0.0001213688,0.0001307783,0.0005804607,0.0000013243796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077573163,0.0004021869,0.9872435,0.0001300599,0.0030693256,0.00059455977,0.0021369874,0.000026057092,0.0015914548,0.0000024016404,0.0005282444,0.0034995133],"study_design_scores_gemma":[0.0017104285,0.00082594884,0.99163055,0.00043357056,0.0023962,0.00001059751,0.00060974853,0.00011700744,0.0016753401,0.00003416383,0.00046413695,0.00009229526],"about_ca_topic_score_codex":0.2197961,"about_ca_topic_score_gemma":0.68279874,"teacher_disagreement_score":0.46300265,"about_ca_system_score_codex":0.002784447,"about_ca_system_score_gemma":0.0012599793,"threshold_uncertainty_score":0.7853993},"labels":[],"label_agreement":null},{"id":"W2568149294","doi":"10.1016/j.jtho.2016.11.445","title":"MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa; University of Calgary; Hôpital Notre-Dame; Queen's University; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Pemetrexed; Durvalumab; Medicine; Carboplatin; Tremelimumab; Tolerability; Internal medicine; Cisplatin; Oncology; Gemcitabine; Chemotherapy; Pembrolizumab; Cancer; Immunotherapy; Adverse effect; Ipilimumab","score_opus":0.0332512173496041,"score_gpt":0.4461936429016305,"score_spread":0.41294242555202637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568149294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926324,0.00065982126,0.00010068544,0.0020876238,0.0009123633,0.0009224851,0.000006393691,0.000016031341,0.0026621867],"genre_scores_gemma":[0.99672097,0.00014642665,0.0018135818,0.0003641946,0.0003578521,0.000028245948,0.0000035156338,0.00004844738,0.0005167409],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971091,0.00027666698,0.0011664693,0.00034901546,0.00061298657,0.00048573597],"domain_scores_gemma":[0.9966156,0.00024260503,0.0018264814,0.00073309796,0.00034581352,0.0002363979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015906291,0.0003332798,0.0012876183,0.0005709634,0.00024422116,0.000064029366,0.0005061686,0.00023628905,0.00022406956],"category_scores_gemma":[0.00034537714,0.00023974768,0.0002460571,0.00030125224,0.00023981143,0.00039780655,0.000079392456,0.0008616819,0.000013096796],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1567167,0.008930001,0.03665657,0.00010200515,0.0007105273,0.006816308,0.0026976578,0.000018479026,0.031244531,0.0000022220172,0.00068715785,0.7554178],"study_design_scores_gemma":[0.20089889,0.15944889,0.5860558,0.0017279516,0.0017876289,0.006785071,0.014671609,0.000307817,0.011240032,0.00010733798,0.01599329,0.0009756884],"about_ca_topic_score_codex":0.00015419802,"about_ca_topic_score_gemma":0.0011472135,"teacher_disagreement_score":0.75444216,"about_ca_system_score_codex":0.0008031,"about_ca_system_score_gemma":0.0010192699,"threshold_uncertainty_score":0.9776627},"labels":[],"label_agreement":null},{"id":"W2568171230","doi":"10.1016/j.jtho.2018.09.027","title":"Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"Sirtex Medical; European Organisation for Research and Treatment of Cancer; Cancer Research UK; Ministère des Affaires Sociales et de la Santé; Canadian Cancer Society Research Institute; National Institute for Health and Care Research; National Cancer Research Institute; Cancer Research Institute","keywords":"Medicine; Outcome (game theory); Compliance (psychology); Radiation therapy; Patient compliance; Surgery; Emergency medicine","score_opus":0.13159369692412945,"score_gpt":0.5185113461987123,"score_spread":0.38691764927458283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568171230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111897,0.0017865822,0.000030357614,0.004082397,0.0013850493,0.00067291013,0.000008131306,0.000005665299,0.000909925],"genre_scores_gemma":[0.9979533,0.00059733656,0.00028971134,0.00039093016,0.00064178,0.000012321291,0.0000016800665,0.000013314631,0.00009963778],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976902,0.0004941494,0.0008315271,0.00016907546,0.0005207679,0.0002943031],"domain_scores_gemma":[0.9976964,0.00075320515,0.000657738,0.00020502864,0.0005702155,0.00011741028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011425321,0.00016134341,0.0008707533,0.00020791504,0.000065216715,0.000013074462,0.0002592227,0.00011639939,0.00006812359],"category_scores_gemma":[0.0005572291,0.000096526324,0.00013184187,0.0002747041,0.0006010304,0.00010649578,0.000044673976,0.0005041809,0.0000046524356],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3351057,0.0018560988,0.29820833,0.00026829867,0.0008475768,0.00021697566,0.0053465716,9.123458e-7,0.0007178816,0.000035867863,0.009181209,0.3482146],"study_design_scores_gemma":[0.23532702,0.17005941,0.50076014,0.00068355876,0.0006950725,0.00021406102,0.0018399669,0.00015446648,0.00084108824,0.00007344783,0.08903209,0.00031968314],"about_ca_topic_score_codex":0.00010038929,"about_ca_topic_score_gemma":0.00017266968,"teacher_disagreement_score":0.3478949,"about_ca_system_score_codex":0.0005154329,"about_ca_system_score_gemma":0.00026077114,"threshold_uncertainty_score":0.39362293},"labels":[],"label_agreement":null},{"id":"W2568171831","doi":"10.1016/j.jtho.2016.11.712","title":"P1.03-041 Do Several Rounds of Negative Screening Low Dose CT Scans Influence the Risk to Develop Lung Cancer?","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Malignancy; Population; Cohort; Referral; Interim; Cancer; Radiology; Internal medicine; Family medicine","score_opus":0.023756288426426492,"score_gpt":0.43408569019935855,"score_spread":0.4103294017729321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568171831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508453,0.0008558113,0.0003394123,0.011652816,0.0006072252,0.0003896849,0.000028865083,0.000006346227,0.0010352854],"genre_scores_gemma":[0.99184734,0.001174351,0.0054843314,0.0007232529,0.00046003074,0.00003622538,6.5633236e-7,0.000019366393,0.00025447292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830115,0.00020459013,0.00057956483,0.00020192245,0.000406009,0.00030677827],"domain_scores_gemma":[0.99654067,0.0003811185,0.0015425961,0.0004463687,0.00084725034,0.00024199083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009287784,0.00019474937,0.00072047726,0.00013444589,0.0003632566,0.000060039933,0.00044328827,0.00008482407,0.00007699304],"category_scores_gemma":[0.0008031631,0.000116772986,0.00015661384,0.00022781995,0.00020128825,0.00025801707,0.00014773464,0.00050371856,0.0000048817433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036474243,0.00042050896,0.6399723,0.00014529644,0.0015659382,0.00070664193,0.003084284,0.0044315993,0.000314334,0.000035293677,0.0060416977,0.33963463],"study_design_scores_gemma":[0.0021535433,0.0017252725,0.98407197,0.0014240806,0.001204416,0.000455692,0.00037594428,0.0003858246,0.0037545173,0.00009952628,0.0042003337,0.00014887463],"about_ca_topic_score_codex":0.0020339566,"about_ca_topic_score_gemma":0.0011170851,"teacher_disagreement_score":0.3440996,"about_ca_system_score_codex":0.0012106181,"about_ca_system_score_gemma":0.0016371779,"threshold_uncertainty_score":0.4761864},"labels":[],"label_agreement":null},{"id":"W2568216745","doi":"10.1016/j.jtho.2016.11.1074","title":"P2.01-022 A PIWI-Interacting RNAs Co-Expression Networks as a Prognostic Factor in Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Piwi-interacting RNA; Transcriptome; Biology; microRNA; Epigenetics; Gene; Gene expression; Computational biology; Psychological repression; RNA; Metastasis; Lung cancer; Cancer; Cancer research; Genetics; Medicine; RNA interference; Pathology","score_opus":0.018714022953925977,"score_gpt":0.4255995260276653,"score_spread":0.40688550307373933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568216745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457204,0.0019505764,0.0012409517,0.0005851557,0.0008816947,0.00021521769,0.0000069292705,0.0000039919223,0.00054346764],"genre_scores_gemma":[0.99778754,0.0002692721,0.0006540639,0.00011812744,0.0009534986,0.000014951937,0.000011269295,0.000024207566,0.00016706705],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986189,0.00022719383,0.0004965805,0.0002189146,0.00015878494,0.0002796275],"domain_scores_gemma":[0.99801296,0.000075258504,0.0012847655,0.00031692922,0.0001698897,0.0001402203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042682744,0.00015860584,0.0003149532,0.00009917732,0.00016990323,0.00006635387,0.0004066312,0.0002782003,0.00013801522],"category_scores_gemma":[0.0007468532,0.00013761381,0.00014407697,0.000035747496,0.00007221642,0.000029786544,0.00015287897,0.00036318856,0.0000031425395],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019035629,0.00028769072,0.16336124,0.00008284425,0.00014816115,0.00026781837,0.00018790213,0.00198436,0.78237206,0.0000030110243,0.004571657,0.044829726],"study_design_scores_gemma":[0.00298882,0.0020718274,0.5416741,0.0018239897,0.00034315875,0.0011674383,0.0003412075,0.00741771,0.36754963,0.00013270925,0.07368108,0.00080835173],"about_ca_topic_score_codex":0.00003277643,"about_ca_topic_score_gemma":0.00009602653,"teacher_disagreement_score":0.4148224,"about_ca_system_score_codex":0.00019491214,"about_ca_system_score_gemma":0.00039127568,"threshold_uncertainty_score":0.56117284},"labels":[],"label_agreement":null},{"id":"W2568332508","doi":"10.1016/j.jtho.2016.11.853","title":"P1.05-068 Elderly Patients with Resected Stage II Non-small Cell Lung Cancer Are Less Likely to Have a Consultation with a Medical Oncologist","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Cancer Care Ontario; University of Toronto","funders":"","keywords":"Medicine; Guideline; Stage (stratigraphy); Socioeconomic status; Internal medicine; Lung cancer; Cancer registry; Cancer; Chemotherapy; Medical record; Logistic regression; Radiation therapy; Population","score_opus":0.025805666113714962,"score_gpt":0.4044331437281841,"score_spread":0.37862747761446913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568332508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827034,0.0002711673,0.0002431021,0.013965683,0.00049974304,0.0009919071,0.000039778875,0.000013691259,0.0012715324],"genre_scores_gemma":[0.9942913,0.00020106642,0.002729013,0.0010139012,0.0003721926,0.00013219242,0.000011226145,0.000037325903,0.0012117613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774295,0.00013871105,0.0005948589,0.00033768438,0.0007862439,0.0003995235],"domain_scores_gemma":[0.9957287,0.0002967711,0.0016666313,0.00041212834,0.0012870139,0.00060878176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005073343,0.00026671635,0.00094109296,0.00020304864,0.00037456932,0.000059974434,0.00033284823,0.00027421306,0.00012546907],"category_scores_gemma":[0.00046006404,0.0001606991,0.000100315796,0.00012000945,0.00021789076,0.00015970395,0.00010566593,0.00061761006,0.0000034639281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014606359,0.0029879645,0.8987951,0.00032240996,0.00071124086,0.0037818842,0.002000368,0.00007788097,0.000056719342,0.0000033394203,0.008438589,0.06821811],"study_design_scores_gemma":[0.016922114,0.035304002,0.9264679,0.0035683615,0.0015582963,0.00022905029,0.0015403169,0.00008841188,0.0013615055,0.000004192661,0.012663211,0.00029263017],"about_ca_topic_score_codex":0.0008157267,"about_ca_topic_score_gemma":0.010996047,"teacher_disagreement_score":0.06792548,"about_ca_system_score_codex":0.0017453318,"about_ca_system_score_gemma":0.002488282,"threshold_uncertainty_score":0.6553119},"labels":[],"label_agreement":null},{"id":"W2568379852","doi":"10.1016/j.jtho.2016.11.258","title":"OA06.03 Transcriptome Analysis of ATM-Deficient NSCLC","year":2017,"lang":"fr","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Lethbridge; University of Calgary","funders":"","keywords":"Synthetic lethality; Medicine; Transcriptome; Cancer research; Lung cancer; Cancer; Targeted therapy; Epigenetics; Oncology; Bioinformatics; DNA repair; Internal medicine; Biology; Gene; Gene expression; Genetics","score_opus":0.03592268970109802,"score_gpt":0.4830086538398027,"score_spread":0.44708596413870466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568379852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8589834,0.048740733,0.0019320922,0.03487551,0.011823101,0.00035597023,0.00019004148,0.000008144804,0.043091025],"genre_scores_gemma":[0.98476917,0.0020454673,0.002361378,0.000295506,0.00085068715,0.0000042845577,0.000010242299,0.00002101428,0.009642275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99758494,0.00022879291,0.0011218395,0.00020725415,0.00044846398,0.00040868687],"domain_scores_gemma":[0.9959875,0.00019735048,0.0021851433,0.0005885969,0.0007006946,0.00034072867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010259354,0.00021551897,0.0014708969,0.00067700446,0.00024855338,0.000041575728,0.0004019671,0.0002910021,0.0013658382],"category_scores_gemma":[0.00027241497,0.00017062576,0.0009613842,0.00039444037,0.00046309317,0.00026898738,0.000042221887,0.0004391561,0.00004623772],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026805107,0.005119565,0.04310106,0.00052520557,0.036115244,0.0025646375,0.00861557,0.0015042006,0.008981148,0.0014855141,0.0060343225,0.883273],"study_design_scores_gemma":[0.005200489,0.009333003,0.42017418,0.0014496499,0.17275056,0.0010961425,0.0037688934,0.0014234141,0.0026410993,0.0004837256,0.38130197,0.00037688098],"about_ca_topic_score_codex":0.00025939115,"about_ca_topic_score_gemma":0.0001617918,"teacher_disagreement_score":0.8828961,"about_ca_system_score_codex":0.0010070283,"about_ca_system_score_gemma":0.001395097,"threshold_uncertainty_score":0.99954706},"labels":[],"label_agreement":null},{"id":"W2568400966","doi":"10.1016/j.jtho.2016.11.903","title":"P1.06-039 Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Transplantation: Methods and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Chemotherapy; Oncology; Population; Cancer; Vinorelbine; Discontinuation; Incidence (geometry); Univariate analysis; Surgery; Multivariate analysis","score_opus":0.054939316111110754,"score_gpt":0.4716355989883079,"score_spread":0.4166962828771972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568400966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416244,0.0004514944,0.00087150454,0.0029737158,0.0010591538,0.00033003482,0.000014958036,0.000005932459,0.00013076043],"genre_scores_gemma":[0.9937957,0.0002703771,0.005316015,0.0002564585,0.0001344939,0.0000054410484,6.7875715e-7,0.000015213214,0.00020563795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984127,0.00028576443,0.0005525097,0.00017195844,0.00040195393,0.00017509157],"domain_scores_gemma":[0.9981407,0.00035089513,0.0009578099,0.00029594993,0.00015112554,0.00010350216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009315848,0.00015888402,0.0009514433,0.00009054332,0.0002670125,0.00002864437,0.00032484948,0.0001211797,0.000031294745],"category_scores_gemma":[0.0002826639,0.000090378846,0.00018232017,0.0000688682,0.00010296084,0.00020549328,0.00005110954,0.00044680282,3.118386e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006284088,0.00016895206,0.9762047,0.000045541306,0.0007336297,0.00040513914,0.011203377,0.0000025736595,0.0032299664,0.0000074336835,0.000018760275,0.0073515275],"study_design_scores_gemma":[0.0023113077,0.0004743271,0.98915005,0.00045310665,0.0018125856,0.00019751674,0.0019438498,0.000021673397,0.003380238,0.00011645297,0.00004624445,0.00009263135],"about_ca_topic_score_codex":0.0003410756,"about_ca_topic_score_gemma":0.0013559291,"teacher_disagreement_score":0.0129453745,"about_ca_system_score_codex":0.00018204554,"about_ca_system_score_gemma":0.00040793585,"threshold_uncertainty_score":0.36855423},"labels":[],"label_agreement":null},{"id":"W2568433485","doi":"10.1016/j.jtho.2016.11.1617","title":"P3.01-051 Analysis of Molecular Aberrations Associated with COPD in Patients with Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"COPD; Medicine; Lung cancer; microRNA; Lung; Cancer; Internal medicine; Disease; Oncology; Treatment of lung cancer; Bioinformatics; Gene; Biology","score_opus":0.010510878449957234,"score_gpt":0.3835928403627835,"score_spread":0.3730819619128263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568433485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260294,0.00042794104,0.0057361787,0.00039781188,0.00010643131,0.00021238728,0.00003756598,0.0000019141698,0.00047685346],"genre_scores_gemma":[0.9988649,0.000088545705,0.0006991764,0.00009178008,0.000035604175,0.00001327244,0.00004858375,0.00002328466,0.00013488608],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99845177,0.00021918843,0.00042915178,0.00022256187,0.00040845585,0.0002688629],"domain_scores_gemma":[0.9975596,0.000024387946,0.0010928786,0.00043810694,0.00077357184,0.0001114482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049486343,0.00014978307,0.00052007637,0.0003695831,0.000097409684,0.000028977038,0.0004191248,0.0002550635,0.000054933727],"category_scores_gemma":[0.00025216074,0.000118168056,0.00015198062,0.00035986866,0.00015938097,0.000016221045,0.00009712431,0.00032325764,2.9230935e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022045674,0.0037338368,0.34846482,0.00013548617,0.029983025,0.00069702003,0.00081242836,0.08972928,0.46781036,0.0000995149,0.0025599594,0.033928603],"study_design_scores_gemma":[0.009404896,0.012495731,0.68469924,0.0005618671,0.0075141033,0.000035394936,0.00025934106,0.0038806128,0.277637,0.000060006278,0.0025868008,0.00086499896],"about_ca_topic_score_codex":0.000106024054,"about_ca_topic_score_gemma":0.0024487418,"teacher_disagreement_score":0.33623442,"about_ca_system_score_codex":0.00023486669,"about_ca_system_score_gemma":0.00072307704,"threshold_uncertainty_score":0.48187536},"labels":[],"label_agreement":null},{"id":"W2568438117","doi":"10.1016/j.jtho.2016.11.1587","title":"P3.01-021 Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumor Nodules","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pathology; Pleomorphism (cytology); Concordance; Grading (engineering); Cytopathology; Kappa; Adenocarcinoma; Cancer; Cytology; Internal medicine; Immunohistochemistry","score_opus":0.08495526198753471,"score_gpt":0.4807525175736771,"score_spread":0.39579725558614237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568438117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154043,0.0029080524,0.000030454485,0.0041126804,0.0005348965,0.00017942682,0.000009023875,0.0000046447367,0.0006803663],"genre_scores_gemma":[0.9800797,0.0003601343,0.019291336,0.00014402793,0.00007663607,0.0000083503965,0.0000022676395,0.00000957404,0.000027953054],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979178,0.00029007837,0.0009766648,0.0004135506,0.00020817365,0.0001937696],"domain_scores_gemma":[0.99615926,0.00044758318,0.0020759017,0.00083386485,0.00038913847,0.00009427971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016812634,0.00015242644,0.0012534289,0.00019102907,0.000080937876,0.000009697453,0.00017446153,0.00010025061,0.0000502614],"category_scores_gemma":[0.0009031125,0.00011241886,0.0001360427,0.00005163729,0.00036354375,0.00011761211,0.00013646838,0.0003206499,4.0519637e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001775495,0.0012152406,0.93771887,0.00054999656,0.00016304987,0.0008962621,0.00043183836,0.000016180184,0.012230812,0.000034832414,0.00033119234,0.044636223],"study_design_scores_gemma":[0.0021102799,0.0034560612,0.98593867,0.00062021246,0.0003042179,0.00049348676,0.00062683254,0.00012149018,0.0041407826,0.0002062011,0.001893384,0.00008838397],"about_ca_topic_score_codex":0.00027855954,"about_ca_topic_score_gemma":0.00014982554,"teacher_disagreement_score":0.04821979,"about_ca_system_score_codex":0.0010441617,"about_ca_system_score_gemma":0.0004113174,"threshold_uncertainty_score":0.4584308},"labels":[],"label_agreement":null},{"id":"W2568485502","doi":"10.1016/j.jtho.2016.11.594","title":"P1.02-011 Comparison of EGFR and KRAS Mutations in Archival Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Concordance; KRAS; Medicine; T790M; Genotyping; COLD-PCR; Oncology; Internal medicine; Multiplex; Multiplex polymerase chain reaction; Circulating tumor DNA; Mutation; Cancer; Genotype; Polymerase chain reaction; Gene; Point mutation; Bioinformatics; Genetics; Biology; Colorectal cancer","score_opus":0.03164669369310644,"score_gpt":0.4361099790840248,"score_spread":0.40446328539091836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568485502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817914,0.0010167962,0.00014343575,0.00020519322,0.000106926265,0.00009700613,0.000027840912,4.65123e-7,0.00022316982],"genre_scores_gemma":[0.9987989,0.00011258406,0.0009184982,0.000025224686,0.00012865216,0.000001688569,0.0000032042428,0.000007843778,0.000003383866],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991492,0.00009922729,0.00044629353,0.00010853157,0.00007063586,0.00012608059],"domain_scores_gemma":[0.99858963,0.0001286435,0.0009202596,0.00020018997,0.00009501135,0.00006623775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041730815,0.00009096664,0.00035259602,0.000056086254,0.00008930187,0.000019920448,0.00018465237,0.00005022303,0.0000029606292],"category_scores_gemma":[0.00041349255,0.00006712445,0.00008021647,0.000024309144,0.0002710393,0.0000068954732,0.00013643548,0.00014291158,1.2073284e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051998266,0.00025590256,0.3110508,0.00006225317,0.00015249851,0.000043206874,0.0005995187,0.0013128403,0.6443738,0.000045550667,0.00013894742,0.04144469],"study_design_scores_gemma":[0.00070491864,0.0023249264,0.8114242,0.000058948528,0.00009743017,0.0005930644,0.00031992455,0.0005890037,0.18279156,0.0005885959,0.00039766182,0.00010979979],"about_ca_topic_score_codex":0.00018753375,"about_ca_topic_score_gemma":0.0003243337,"teacher_disagreement_score":0.50037336,"about_ca_system_score_codex":0.000034108016,"about_ca_system_score_gemma":0.00024288791,"threshold_uncertainty_score":0.27372554},"labels":[],"label_agreement":null},{"id":"W2568516571","doi":"10.1016/j.jtho.2016.11.366","title":"OA24.01 Radiotherapy Quality Assurance of Concurrent Chemoradiotherapy in PROCLAIM Phase III Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Trillium Health Centre","funders":"","keywords":"Medicine; Chemoradiotherapy; Radiation therapy; Adverse effect; Quality assurance; Hazard ratio; Nuclear medicine; Internal medicine; Oncology; Confidence interval","score_opus":0.13801966123474138,"score_gpt":0.49039477370912093,"score_spread":0.3523751124743796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568516571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892367,0.0036911366,0.0004111865,0.0044164574,0.0010251566,0.0008170317,0.0000071791574,0.000008482334,0.0006996971],"genre_scores_gemma":[0.99507654,0.0011910258,0.0025300118,0.00015351987,0.00082879397,0.000020747062,0.0000039186657,0.0000229745,0.00017246234],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975785,0.00038423704,0.0012151712,0.00019313188,0.00036521524,0.00026371964],"domain_scores_gemma":[0.99688524,0.0002496226,0.0020370653,0.00040585615,0.00023867612,0.00018351921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002098427,0.00019765885,0.0015786587,0.00021075686,0.00007778957,0.000023067936,0.00030119225,0.00023882034,0.00020358668],"category_scores_gemma":[0.00031010102,0.00014972065,0.0003956223,0.0001011705,0.00021772123,0.00018282776,0.000018805902,0.0004253652,0.0000019754448],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18654689,0.0056557725,0.18612187,0.0002703514,0.0005939527,0.0011869379,0.0011032948,9.903493e-7,0.028026734,0.000049660383,0.0009699499,0.5894736],"study_design_scores_gemma":[0.6737481,0.049005497,0.077593155,0.001084635,0.0009883624,0.0013250161,0.0003643718,0.0009632573,0.1079988,0.00032984393,0.0859373,0.00066167355],"about_ca_topic_score_codex":0.0000534546,"about_ca_topic_score_gemma":0.000033190285,"teacher_disagreement_score":0.58881193,"about_ca_system_score_codex":0.0003842766,"about_ca_system_score_gemma":0.00085013534,"threshold_uncertainty_score":0.6105431},"labels":[],"label_agreement":null},{"id":"W2568529746","doi":"10.1016/j.jtho.2016.11.1872","title":"P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutrophil to lymphocyte ratio; Lung cancer; Oncology; Chemotherapy; Cancer; Clinical trial; Lymphocyte; Gastroenterology; Cohort; Progressive disease","score_opus":0.02389154745672809,"score_gpt":0.43475354475530664,"score_spread":0.41086199729857853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568529746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245894,0.001007875,0.0002922124,0.003547788,0.0016434996,0.00048201316,0.000014978987,0.000009262055,0.0005434472],"genre_scores_gemma":[0.9898295,0.00024953773,0.0086318925,0.00035391853,0.00079939177,0.000026168771,0.0000046180953,0.000029231758,0.000075779164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997412,0.00018185061,0.0014920887,0.00026313568,0.00039861933,0.00025230393],"domain_scores_gemma":[0.99617314,0.00023301084,0.002234179,0.00045867375,0.0005879416,0.0003130601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011079978,0.00019334687,0.0009288266,0.00026825324,0.00009475458,0.000021287842,0.00029699018,0.00027939462,0.00010886569],"category_scores_gemma":[0.0006676468,0.00015268059,0.00022473447,0.00013303517,0.00020817925,0.00029556925,0.000109834284,0.00044840775,0.0000051198526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029532468,0.0004455746,0.780656,0.00010384063,0.00030251473,0.00061538856,0.00036716933,0.0010071163,0.0049353815,0.000010686859,0.00046735205,0.18155652],"study_design_scores_gemma":[0.005129614,0.002082194,0.97825795,0.0013884132,0.00068819145,0.000098607365,0.00017684279,0.001737106,0.008320413,0.00009567802,0.0018446082,0.00018035641],"about_ca_topic_score_codex":0.00010456627,"about_ca_topic_score_gemma":0.00028076564,"teacher_disagreement_score":0.19760199,"about_ca_system_score_codex":0.00089330086,"about_ca_system_score_gemma":0.0012490278,"threshold_uncertainty_score":0.6226134},"labels":[],"label_agreement":null},{"id":"W2568608113","doi":"10.1016/j.jtho.2016.11.034","title":"ED06.03 Pain Management","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Referred pain; Cancer pain; Chronic pain; Palliative care; Nociceptor; Visceral pain; Hyperalgesia; Neuropathic pain; Disease; Cancer; Nociception; Anesthesia; Physical therapy; Internal medicine","score_opus":0.04628104484605768,"score_gpt":0.49795082124000295,"score_spread":0.4516697763939453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568608113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7066799,0.0016238893,0.00047296353,0.058926668,0.0045291865,0.00044824855,0.0000035175574,0.000022655495,0.22729301],"genre_scores_gemma":[0.9799075,0.00064629834,0.0048591522,0.002241983,0.0012356763,0.0000069739162,0.0000016024009,0.000013429279,0.011087387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990808,0.00014736116,0.00032586313,0.00009996961,0.00015675563,0.00018928111],"domain_scores_gemma":[0.9987848,0.00009537426,0.0005940664,0.00025130544,0.000116716015,0.00015775736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011425042,0.000098024524,0.00041564647,0.00013639606,0.000140033,0.000018953928,0.0002119096,0.00009853244,0.0007012804],"category_scores_gemma":[0.00007878721,0.000073011826,0.0001664475,0.00003174858,0.00010133393,0.0000927654,0.00006401493,0.000258629,0.00006430879],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032543992,0.0010476444,0.012461612,0.00011368008,0.00076428085,0.0053779786,0.00017432969,0.0000029053808,0.001482454,0.00015022306,0.110105,0.8650655],"study_design_scores_gemma":[0.0028846313,0.005599323,0.068034336,0.00011790491,0.001195048,0.0016253573,0.00017597809,0.00003182805,0.0013756021,0.0008809909,0.9179787,0.00010028501],"about_ca_topic_score_codex":0.000008252238,"about_ca_topic_score_gemma":0.000013066278,"teacher_disagreement_score":0.8649652,"about_ca_system_score_codex":0.0002893415,"about_ca_system_score_gemma":0.0001587383,"threshold_uncertainty_score":0.7678529},"labels":[],"label_agreement":null},{"id":"W2568650842","doi":"10.1016/j.jtho.2016.11.1117","title":"P2.01-065 Quantification of Tumor-Immune Cell Spatial Relationships in the Lung Tumor Microenvironment Using Single Cell Profiling","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"KRAS; Tumor microenvironment; Immunohistochemistry; CD8; Medicine; Immune system; Pathology; Adenocarcinoma; T cell; Cancer research; Immunology; Internal medicine; Cancer","score_opus":0.06269955750267579,"score_gpt":0.37652949442402606,"score_spread":0.31382993692135025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568650842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333066,0.0023499867,0.0011450504,0.0015866093,0.0004991263,0.00035380662,0.0000036648407,0.0000027740462,0.00072830875],"genre_scores_gemma":[0.99394405,0.000097155826,0.0055381022,0.00011517284,0.0002008963,0.000003335468,0.0000038386643,0.000015525144,0.000081906495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981306,0.00038303685,0.00090724544,0.00013245687,0.0002628716,0.00018376095],"domain_scores_gemma":[0.99721277,0.0001861501,0.0020716416,0.00040628284,0.00008061155,0.000042547752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023394013,0.00012060528,0.00040967425,0.00016948354,0.00022069395,0.00002864198,0.00030011553,0.00009261486,0.000042637446],"category_scores_gemma":[0.00014004463,0.00008697219,0.00017284519,0.00008084471,0.00019493393,0.00014078297,0.000037503414,0.0005232043,0.000002776128],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003731926,0.0008960716,0.035828788,0.00017211233,0.000041913336,0.0001412885,0.00086674193,0.00014212278,0.95357305,0.000004677078,0.00011629433,0.004485004],"study_design_scores_gemma":[0.003162945,0.001864595,0.350822,0.0005375007,0.0004973971,0.0011019562,0.0030580915,0.0019251992,0.6329221,0.00006661809,0.0038561942,0.00018539374],"about_ca_topic_score_codex":0.00013401601,"about_ca_topic_score_gemma":0.000036118254,"teacher_disagreement_score":0.32065094,"about_ca_system_score_codex":0.00045009365,"about_ca_system_score_gemma":0.0002897414,"threshold_uncertainty_score":0.3546623},"labels":[],"label_agreement":null},{"id":"W2568673175","doi":"10.1016/j.jtho.2016.11.1985","title":"PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Immunohistochemistry; Pathology; Biopsy; Immunostaining; Lung cancer; Carcinoma; Not Otherwise Specified; Cancer; Kappa; Internal medicine","score_opus":0.21427963595774463,"score_gpt":0.5570368561241257,"score_spread":0.34275722016638105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568673175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932124,0.0005347205,0.0000027414103,0.0052653244,0.00026396022,0.0005198019,0.000018114053,0.0000013226655,0.00018164041],"genre_scores_gemma":[0.99907607,0.0003067988,0.00030734824,0.00002956891,0.00017547785,0.000028497328,7.9968925e-7,0.000006841945,0.00006857208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798715,0.0003956481,0.0008278754,0.00022515738,0.00042912402,0.00013506624],"domain_scores_gemma":[0.9950245,0.0011167958,0.0017135465,0.0013253376,0.0007748826,0.000044953573],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0061130635,0.0000902338,0.00062120723,0.0001006347,0.000110518544,0.000025170852,0.000947629,0.000054477052,0.00002323179],"category_scores_gemma":[0.016819514,0.000047563342,0.0001139112,0.00008795594,0.00065175066,0.00031685256,0.00056790956,0.00040450273,9.9073105e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004905233,0.0016787789,0.9335998,0.00019259372,0.0006964776,0.00018829097,0.004632493,0.000017742685,0.021789724,0.0000068606982,0.000749685,0.031542297],"study_design_scores_gemma":[0.0012793457,0.0037306496,0.96339154,0.000346008,0.0002999823,0.0003065577,0.005548831,0.000035541052,0.02408613,0.00012933773,0.00079336803,0.000052684776],"about_ca_topic_score_codex":0.0011984614,"about_ca_topic_score_gemma":0.00037917003,"teacher_disagreement_score":0.03148961,"about_ca_system_score_codex":0.00034863967,"about_ca_system_score_gemma":0.00051401823,"threshold_uncertainty_score":0.99146223},"labels":[],"label_agreement":null},{"id":"W2568802220","doi":"10.1016/j.jtho.2016.11.238","title":"OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Tolerability; Internal medicine; Adverse effect; Oncology; Ipilimumab; Docetaxel; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Population; Progression-free survival; Chemotherapy; Phases of clinical research; Immunotherapy; Clinical trial; Cancer","score_opus":0.025470528182510967,"score_gpt":0.3758445914173529,"score_spread":0.35037406323484194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568802220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311185,0.0018376788,0.00011320874,0.0034378283,0.0007208258,0.0004654133,0.000019003292,0.000015653366,0.00027855625],"genre_scores_gemma":[0.99565876,0.0014480845,0.0016593437,0.00057615456,0.00020004869,0.000010087248,0.000011911195,0.000045883986,0.00038975058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801016,0.00009966563,0.00081899355,0.00029742758,0.0003728842,0.0004008828],"domain_scores_gemma":[0.99757606,0.00013885844,0.0013396904,0.00054100045,0.00020881782,0.00019558276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047049476,0.00029802235,0.0011319036,0.00023029283,0.00021131434,0.00006205908,0.00033845552,0.00024661154,0.00024168448],"category_scores_gemma":[0.00009727414,0.00021268062,0.00018127132,0.000083708466,0.00030224095,0.0004377896,0.00006927422,0.0004945139,0.00000630651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06417533,0.0005825894,0.5662152,0.00005126884,0.00043811853,0.00024257046,0.0005036115,0.000008499941,0.0003744178,5.830633e-7,0.000073633615,0.3673342],"study_design_scores_gemma":[0.03685613,0.0053264364,0.954313,0.0005762531,0.0002068209,0.000101167374,0.00009371878,0.000040302148,0.00041052327,0.000041793526,0.0018044058,0.00022948925],"about_ca_topic_score_codex":0.00023816702,"about_ca_topic_score_gemma":0.0013755801,"teacher_disagreement_score":0.38809776,"about_ca_system_score_codex":0.00075975223,"about_ca_system_score_gemma":0.0003871152,"threshold_uncertainty_score":0.8672864},"labels":[],"label_agreement":null},{"id":"W2568848478","doi":"10.1016/j.jtho.2016.11.1181","title":"P2.02-034 Both Induction and Adjuvant Treatment Improve Outcomes of Surgically-Resected IIIA(N2) NSCLC When Compared to Definitive Chemoradiotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Chemoradiotherapy; Lung cancer; Stage (stratigraphy); Surgery; Proportional hazards model; Pneumonectomy; Internal medicine; Oncology; Radiation therapy","score_opus":0.045084847057202206,"score_gpt":0.4310796189836252,"score_spread":0.38599477192642295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568848478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98281,0.00094093935,0.000048241636,0.013756002,0.0006494423,0.0005294984,0.000025432275,0.000009594307,0.0012308008],"genre_scores_gemma":[0.9942146,0.0010655252,0.0035888166,0.0003461179,0.00029937964,0.000030070058,0.0000050790136,0.000022021677,0.00042837398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985274,0.00011703619,0.00061511516,0.00023356164,0.00026644603,0.00024044192],"domain_scores_gemma":[0.99776655,0.00023227537,0.0010057295,0.0003616574,0.00033813066,0.0002956743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034186724,0.0002251633,0.0013838393,0.00018880416,0.00012971082,0.00003150946,0.00013820466,0.00015638479,0.00010923223],"category_scores_gemma":[0.00014360751,0.00014435372,0.00022324687,0.000049204315,0.00014997563,0.00013124167,0.00004420861,0.0001899673,0.000003715324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012399764,0.004171803,0.36251712,0.00010741468,0.0033568628,0.0009281508,0.00358018,0.000007980119,0.01383028,0.0000736,0.0016443314,0.59738255],"study_design_scores_gemma":[0.011534277,0.017140064,0.9333297,0.00034362724,0.0013143885,0.00066718843,0.00046249214,0.000023511337,0.024915341,0.00025579223,0.00981102,0.00020256423],"about_ca_topic_score_codex":0.0003412412,"about_ca_topic_score_gemma":0.0002625488,"teacher_disagreement_score":0.59717995,"about_ca_system_score_codex":0.0011303998,"about_ca_system_score_gemma":0.00043598242,"threshold_uncertainty_score":0.5886574},"labels":[],"label_agreement":null},{"id":"W2568885197","doi":"10.1016/j.jtho.2016.11.1825","title":"P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"David Geffen School of Medicine, University of California, Los Angeles; Deutsches Zentrum für Lungenforschung; Tel Aviv University","keywords":"Pembrolizumab; Medicine; Dosing; Pharmacokinetics; Lung cancer; non-small cell lung cancer (NSCLC); Population; Internal medicine; Area under the curve; Oncology; Adverse effect; Urology; Gastroenterology; Cancer; Immunotherapy","score_opus":0.049424323586636905,"score_gpt":0.42637060500342583,"score_spread":0.37694628141678893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568885197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862554,0.0090872515,0.0003072186,0.0021934907,0.0009251789,0.00085560064,0.00006774627,0.0000028156064,0.0003052608],"genre_scores_gemma":[0.9840283,0.009761493,0.004051896,0.00014790331,0.00029841452,0.000042569656,0.0000022411798,0.000025704287,0.001641494],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984308,0.00008161929,0.00089856866,0.00013986614,0.000214595,0.00023453316],"domain_scores_gemma":[0.995789,0.0005007104,0.0025751786,0.00051723147,0.0005322318,0.00008566453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043202628,0.00017914783,0.0009656297,0.0001401325,0.00010203931,0.0000097306,0.0002958684,0.00016314091,0.00011574837],"category_scores_gemma":[0.00010017181,0.00010686331,0.00056209473,0.00007698383,0.00027170192,0.00011587841,0.000027177668,0.00014388075,2.9732163e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12770607,0.0021644665,0.009583107,0.00065904495,0.0018190201,0.000063203115,0.00215756,0.00018392278,0.32346398,0.0000042862175,0.0028161653,0.5293792],"study_design_scores_gemma":[0.053039838,0.04970056,0.19960701,0.0020072744,0.0065669655,0.00043952637,0.0016551155,0.0016292142,0.4657739,0.00005103783,0.2191063,0.00042325506],"about_ca_topic_score_codex":0.0003909002,"about_ca_topic_score_gemma":0.00026885123,"teacher_disagreement_score":0.52895594,"about_ca_system_score_codex":0.00039978043,"about_ca_system_score_gemma":0.0010278556,"threshold_uncertainty_score":0.4357759},"labels":[],"label_agreement":null},{"id":"W2569046072","doi":"10.1016/j.jtho.2016.11.362","title":"OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Afatinib; Medicine; Internal medicine; Erlotinib; Lung cancer; Oncology; Adenocarcinoma; Post-hoc analysis; Gastroenterology; Lung; Refractory (planetary science); Surgery; Cancer; Epidermal growth factor receptor","score_opus":0.04173091787525284,"score_gpt":0.4870332160086389,"score_spread":0.44530229813338607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569046072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927368,0.00078673556,0.00029047803,0.0024813192,0.0007318385,0.0013108948,0.00008297106,0.0000024511364,0.001576501],"genre_scores_gemma":[0.99793226,0.000025770792,0.0006667678,0.00020435645,0.00026027573,0.000045862016,0.000021676939,0.000016411179,0.0008266031],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978076,0.0003090458,0.0011308489,0.00018159444,0.00033539083,0.00023551036],"domain_scores_gemma":[0.9954242,0.000783746,0.00265792,0.00064375176,0.00040210845,0.000088287845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012552927,0.00017126345,0.0010289267,0.00039567013,0.00017965806,0.000017390263,0.0004879376,0.00014807018,0.00015436434],"category_scores_gemma":[0.0005442197,0.00009554078,0.00064579677,0.00033023438,0.00019563005,0.00014293386,0.000047564572,0.00032438088,3.239147e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6140586,0.016903715,0.1921354,0.001593848,0.00784268,0.0009076803,0.029053863,0.0020083797,0.0275221,0.00017840425,0.00561116,0.10218413],"study_design_scores_gemma":[0.37543702,0.028617637,0.5038912,0.00039806648,0.047077384,0.0002731885,0.0061690654,0.0029644205,0.03188825,0.00021354813,0.0026261618,0.00044402262],"about_ca_topic_score_codex":0.000031877764,"about_ca_topic_score_gemma":0.000302823,"teacher_disagreement_score":0.31175584,"about_ca_system_score_codex":0.00030137377,"about_ca_system_score_gemma":0.00095089833,"threshold_uncertainty_score":0.389604},"labels":[],"label_agreement":null},{"id":"W2569092380","doi":"10.1016/j.jtho.2016.11.1643","title":"P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Internal medicine; Nausea; Adverse effect; Refractory (planetary science); Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Randomized controlled trial; Gastroenterology; Clinical trial; Lung cancer","score_opus":0.03058263829566181,"score_gpt":0.507547969852704,"score_spread":0.4769653315570422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569092380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850425,0.0009108894,0.00026111357,0.0066416985,0.002208729,0.00095332635,0.000036446836,0.0000095774685,0.0039357343],"genre_scores_gemma":[0.99126315,0.00042843077,0.0064566378,0.00037327473,0.0011060148,0.000035644094,0.00003632694,0.000020366688,0.00028012847],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978215,0.00039954053,0.0009485284,0.00022577643,0.00029362887,0.00031101823],"domain_scores_gemma":[0.9973173,0.00059861806,0.0013396567,0.00027576042,0.00016517038,0.0003034658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097346894,0.00020120553,0.0013366073,0.00017267841,0.00017378807,0.00008475221,0.00016820787,0.00017647712,0.00034359726],"category_scores_gemma":[0.0005178881,0.00014197158,0.00026060586,0.000042651805,0.0002748327,0.00032464103,0.000055409233,0.00052855775,0.000004855345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73726636,0.0039217537,0.0044329776,0.000036983958,0.0013971409,0.0015050789,0.0016862542,0.000004215516,0.0017386253,0.00008970605,0.0017011345,0.24621975],"study_design_scores_gemma":[0.94898504,0.006071749,0.026586695,0.00032557678,0.0024603384,0.00032539514,0.0006043371,0.000375105,0.00034310785,0.0009968509,0.012737978,0.00018781508],"about_ca_topic_score_codex":0.00040761984,"about_ca_topic_score_gemma":0.00011738625,"teacher_disagreement_score":0.24603194,"about_ca_system_score_codex":0.0004839529,"about_ca_system_score_gemma":0.001385702,"threshold_uncertainty_score":0.5789433},"labels":[],"label_agreement":null},{"id":"W2569156879","doi":"10.1016/j.jtho.2016.11.811","title":"P1.05-027 Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cohort; Gene signature; Oncology; Internal medicine; Proportional hazards model; Cancer; Gene; Gene expression; Biology","score_opus":0.02062930364676682,"score_gpt":0.37024134485358956,"score_spread":0.34961204120682277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569156879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467994,0.0061232434,0.0063994913,0.0008327989,0.00081228063,0.0007639011,0.000040775198,0.0000033640206,0.00034419104],"genre_scores_gemma":[0.9964667,0.00006934357,0.001413369,0.00015177202,0.0007867324,0.000080266014,0.000011699161,0.000024788993,0.000995335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872285,0.00013237445,0.00045347982,0.00025787402,0.00017566224,0.00025778433],"domain_scores_gemma":[0.99790627,0.000101469785,0.0010148593,0.0005596679,0.0003172432,0.00010049905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069553277,0.00016988553,0.0002972522,0.000044185508,0.0004769348,0.000080233534,0.0007082724,0.00021417251,0.000012200469],"category_scores_gemma":[0.0002946763,0.00011273479,0.00016994066,0.00003036295,0.00013389673,0.000013716818,0.00014100298,0.00026565974,6.4173474e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007545239,0.00090166414,0.012300065,0.0000374709,0.00006540048,0.000021347249,0.00017760963,0.00010378604,0.9365128,0.0000048262013,0.04655156,0.0025689092],"study_design_scores_gemma":[0.004403397,0.0054622097,0.04849365,0.000038214293,0.00087118236,0.0003656906,0.0015303321,0.00052585074,0.8454413,0.00005603594,0.09232899,0.000483158],"about_ca_topic_score_codex":0.000012531195,"about_ca_topic_score_gemma":0.000015977339,"teacher_disagreement_score":0.091071546,"about_ca_system_score_codex":0.00007383565,"about_ca_system_score_gemma":0.00033140162,"threshold_uncertainty_score":0.45971915},"labels":[],"label_agreement":null},{"id":"W2569188319","doi":"10.1016/j.jtho.2016.11.363","title":"OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"","keywords":"Afatinib; Medicine; Gefitinib; Internal medicine; Clinical endpoint; Rash; Lung cancer; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.039474801036027844,"score_gpt":0.48193392923488265,"score_spread":0.4424591281988548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569188319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98200494,0.00048224189,0.0002007458,0.005294404,0.0014561755,0.00024565074,0.00004893469,0.000009513821,0.010257398],"genre_scores_gemma":[0.99574625,0.00035899965,0.0027816924,0.00012658667,0.00023122402,0.0000076997585,0.00006368859,0.000018349343,0.00066547806],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99817723,0.00011680912,0.0009008288,0.00020077397,0.00033326136,0.00027111985],"domain_scores_gemma":[0.99707824,0.00028856323,0.0015579986,0.000443056,0.00045832162,0.00017383571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000571688,0.00017720326,0.0011504061,0.0005773844,0.00012761613,0.000020682022,0.00025328397,0.00016982004,0.0003939943],"category_scores_gemma":[0.00048772196,0.00014011978,0.00035789574,0.00032238598,0.00011902635,0.0002492418,0.00006204209,0.00034844206,0.0000045123306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07455573,0.006811038,0.35054612,0.00043263094,0.03129372,0.005100636,0.004903699,0.015827846,0.005398794,0.00070939894,0.0050424,0.499378],"study_design_scores_gemma":[0.02631385,0.006558881,0.9077413,0.00046907229,0.019748498,0.0001550692,0.00085199747,0.00319818,0.0012041205,0.00018707984,0.03321952,0.00035243103],"about_ca_topic_score_codex":0.00016960567,"about_ca_topic_score_gemma":0.0011004293,"teacher_disagreement_score":0.5571952,"about_ca_system_score_codex":0.00056998595,"about_ca_system_score_gemma":0.00055726146,"threshold_uncertainty_score":0.5713919},"labels":[],"label_agreement":null},{"id":"W2569249229","doi":"10.1016/j.jtho.2016.11.2022","title":"PUB052 Proteome Signatures and New Cancer Drivers","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Proteome; Tissue microarray; Medicine; Proteomics; Lung cancer; Stable isotope labeling by amino acids in cell culture; Cancer research; Cancer; Quantitative proteomics; In vivo; Oncology; Bioinformatics; Biology; Internal medicine; Gene","score_opus":0.021621944053964375,"score_gpt":0.3912528929463201,"score_spread":0.3696309488923557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569249229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96170646,0.012944281,0.00041450272,0.006672438,0.015750783,0.00020022079,0.000012459978,0.0000043262567,0.0022945045],"genre_scores_gemma":[0.92670894,0.009544342,0.004935237,0.0011252074,0.04999091,0.000010625017,0.0000036674212,0.000032077933,0.0076490175],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992591,0.000059244143,0.00022439074,0.00015609903,0.00011448226,0.00018667888],"domain_scores_gemma":[0.99887234,0.000010440993,0.0005482674,0.00023888845,0.00013961138,0.00019042422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029090676,0.000112670146,0.00028102836,0.00005521163,0.0001452032,0.000048412592,0.00031592627,0.00022883445,0.000046082987],"category_scores_gemma":[0.00017810237,0.00009151801,0.00010277281,0.000018404475,0.00015073326,0.000015576044,0.00011700798,0.00022687727,0.0000014617592],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000927986,0.000059722148,0.0027247611,0.000030318773,0.00019670707,0.000005377436,0.00017631763,0.00003162795,0.45848617,0.000050914765,0.18095686,0.35635325],"study_design_scores_gemma":[0.0006095173,0.00049626955,0.018976113,0.000025832327,0.00009329859,0.0001280142,0.000057338828,0.0000030992594,0.020779656,0.00026720145,0.95844924,0.00011440319],"about_ca_topic_score_codex":0.00008795597,"about_ca_topic_score_gemma":0.00025290012,"teacher_disagreement_score":0.7774924,"about_ca_system_score_codex":0.000037951733,"about_ca_system_score_gemma":0.00063653284,"threshold_uncertainty_score":0.3731996},"labels":[],"label_agreement":null},{"id":"W2569251433","doi":"10.1016/j.jtho.2016.11.415","title":"MA06.01 Overall Survival Characterization of Incidental N2 Non-Small Cell Lung Cancer over 14 Years at a Single Canadian Institution","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Oncology; Institution; Internal medicine","score_opus":0.02048787871871421,"score_gpt":0.391425412883193,"score_spread":0.3709375341644788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569251433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99178207,0.00013935207,0.000089256595,0.0010735393,0.0020205823,0.00023016974,0.00006232775,0.0000036767142,0.0045990436],"genre_scores_gemma":[0.99705434,0.0001563811,0.00030805005,0.00024275444,0.00041981708,0.000006184225,0.00003278619,0.000015286061,0.001764428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990896,0.000043118333,0.00036819762,0.000116283045,0.00018961683,0.00019315816],"domain_scores_gemma":[0.9985359,0.000018509212,0.0008272706,0.00018632534,0.00020782738,0.00022419842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019223156,0.00010550292,0.0003656435,0.00019150267,0.00015559327,0.000024213354,0.0001275151,0.00014204616,0.00024501764],"category_scores_gemma":[0.000041246574,0.00009278435,0.00011129224,0.00004796673,0.00007659969,0.00023397809,0.000040424315,0.00016753959,0.00000469569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015369474,0.00077706965,0.68880546,0.00025549385,0.0005963615,0.0011590245,0.002583849,0.00007344097,0.2709107,0.00003562378,0.0015712037,0.031694826],"study_design_scores_gemma":[0.002048491,0.0006803348,0.9747613,0.00024110051,0.00076050457,0.00017878167,0.000057215002,0.00012784498,0.0065012784,0.000010468077,0.014532913,0.00009977016],"about_ca_topic_score_codex":0.017035937,"about_ca_topic_score_gemma":0.047985334,"teacher_disagreement_score":0.28595585,"about_ca_system_score_codex":0.002598071,"about_ca_system_score_gemma":0.0017648604,"threshold_uncertainty_score":0.9895097},"labels":[],"label_agreement":null},{"id":"W2569392255","doi":"10.1016/j.jtho.2016.11.279","title":"OA09.05 Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (FAZA) to Assess Tumor Hypoxia in Non-Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Tumor hypoxia; Nuclear medicine; Lung cancer; Positron emission tomography; Hypoxia (environmental); Primary tumor; Standardized uptake value; Radiation therapy; Cancer; Radiology; Metastasis; Internal medicine; Oxygen; Chemistry","score_opus":0.013967177242285151,"score_gpt":0.3448850767404128,"score_spread":0.33091789949812767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569392255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893129,0.004168538,0.0008085474,0.0011305753,0.0021984226,0.00039263445,0.000017779292,0.000006028362,0.0019645793],"genre_scores_gemma":[0.9880089,0.001039527,0.0068408065,0.00081479544,0.0023116474,0.00004632829,0.0000071151576,0.00005264558,0.00087823515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978835,0.00019615822,0.00062751374,0.0004526727,0.00027982963,0.0005603377],"domain_scores_gemma":[0.99758774,0.000036433503,0.0010084517,0.00062184833,0.00034121,0.0004043375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00077157427,0.000331752,0.00071772706,0.00029742668,0.00020716518,0.00009997297,0.0008348308,0.00018545717,0.000026211814],"category_scores_gemma":[0.00009514999,0.00027018398,0.00025005513,0.00015410094,0.00011224016,0.000035430698,0.00022697968,0.0005120823,0.0000025258555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030093072,0.00037129442,0.03539632,0.00010898405,0.00013407764,0.00035656328,0.00015795595,0.00025848948,0.9187497,0.0000031917116,0.013705283,0.027748834],"study_design_scores_gemma":[0.0034654704,0.003120835,0.19708733,0.00060054177,0.00049422064,0.0014200092,0.00028430801,0.00007593311,0.64129674,0.00004342679,0.1513417,0.0007694951],"about_ca_topic_score_codex":0.00023631465,"about_ca_topic_score_gemma":0.0010028547,"teacher_disagreement_score":0.27745298,"about_ca_system_score_codex":0.0001653432,"about_ca_system_score_gemma":0.0010025194,"threshold_uncertainty_score":0.999975},"labels":[],"label_agreement":null},{"id":"W2569456079","doi":"10.1016/j.jtho.2016.11.463","title":"MA11.03 INSM1 is a Novel Biomarker and a Crucial Regulator of the Neuroendocrine Differentiation Pathway in Neuroendocrine Tumors of the Lung","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Neuroendocrine differentiation; Chromogranin A; Synaptophysin; Gene knockdown; Lung cancer; Cancer research; Immunohistochemistry; Pathology; Neuroendocrine tumors; Adenocarcinoma; Biology; Medicine; Cancer; Cell culture; Internal medicine; Prostate cancer; Genetics","score_opus":0.03276922568384346,"score_gpt":0.39845632722336116,"score_spread":0.3656871015395177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569456079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969246,0.000253498,0.000006654419,0.018479563,0.0007464259,0.0005153135,0.0000209644,0.000004176796,0.00028095648],"genre_scores_gemma":[0.998708,0.00014085468,0.00024324127,0.00031103057,0.00016418396,0.000006937606,4.2032136e-7,0.000027087854,0.00039826246],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99741113,0.00034168494,0.0009966128,0.0002353555,0.0006507503,0.00036443627],"domain_scores_gemma":[0.9966793,0.00022297559,0.0019258538,0.0007384226,0.0002892509,0.00014417026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002904774,0.00020179222,0.00078062544,0.00029005404,0.0001457424,0.00002444421,0.000700645,0.000013989888,0.00004000929],"category_scores_gemma":[0.0020864103,0.000113817754,0.00026022087,0.0002538602,0.0005709507,0.0002402019,0.00060789735,0.00070028065,5.492481e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069667986,0.0016690226,0.33376068,0.00088327535,0.0002096972,0.0036518225,0.00032324798,0.000015778996,0.6143279,0.00024401846,0.0019581378,0.03598962],"study_design_scores_gemma":[0.0027979212,0.0009299373,0.85876954,0.00043432403,0.00012218564,0.010733623,0.00009404786,0.00036965066,0.120773844,0.00028280477,0.0046041063,0.00008803711],"about_ca_topic_score_codex":0.000055570938,"about_ca_topic_score_gemma":0.00010825538,"teacher_disagreement_score":0.52500886,"about_ca_system_score_codex":0.00011464105,"about_ca_system_score_gemma":0.00043542907,"threshold_uncertainty_score":0.46413532},"labels":[],"label_agreement":null},{"id":"W2569458236","doi":"10.1016/j.jtho.2016.11.040","title":"ED08.03 Adjuvant Chemotherapy of Completely Resected","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Regimen; Internal medicine; Lung cancer; Randomized controlled trial; Adjuvant; Chemotherapy; Oncology; Adjuvant therapy; Stage (stratigraphy); Surgery; Clinical trial; Confidence interval","score_opus":0.060770610564019716,"score_gpt":0.4546556931179764,"score_spread":0.39388508255395666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569458236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95830745,0.00042747645,0.00021520085,0.020286238,0.0010917861,0.00018501875,0.000002851677,0.000009049761,0.01947492],"genre_scores_gemma":[0.99232084,0.00031008452,0.0039933384,0.0007075449,0.0005713571,0.0000011017405,0.0000012667552,0.000013230652,0.0020812128],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988346,0.00006136867,0.00053731666,0.00009547774,0.00028992005,0.00018131731],"domain_scores_gemma":[0.9978367,0.00009163404,0.0012791898,0.00036768828,0.00031442576,0.000110337234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064008636,0.00010154191,0.0007246506,0.00020332584,0.00008129581,0.000015858717,0.0003319458,0.000091180525,0.00039659697],"category_scores_gemma":[0.00028001418,0.000074588956,0.00020830387,0.00007139201,0.00015688273,0.00010670841,0.00006930604,0.0002845399,0.0000109725825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007937044,0.0006299769,0.114071585,0.00028274645,0.0007554445,0.000934332,0.00043187442,0.000006348916,0.014599129,0.00016888794,0.06690999,0.7932726],"study_design_scores_gemma":[0.0033545434,0.0036884148,0.7951581,0.00017942645,0.00036019523,0.0005248204,0.00021128301,0.000049300717,0.003894585,0.00040072514,0.19209081,0.0000877889],"about_ca_topic_score_codex":0.000031212177,"about_ca_topic_score_gemma":0.000023705696,"teacher_disagreement_score":0.7931849,"about_ca_system_score_codex":0.00013972385,"about_ca_system_score_gemma":0.0002210077,"threshold_uncertainty_score":0.43424588},"labels":[],"label_agreement":null},{"id":"W2569500944","doi":"10.1016/j.jtho.2016.11.107","title":"SC19.02 Invasive Staging of Lung Cancer: EBUS, EUS and Beyond","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Mediastinoscopy; Endoscopic ultrasound; Radiology; Lung cancer; Lung cancer staging; Cancer staging; Mediastinal lymph node; Fine-needle aspiration; Lymph node; Esophagus; Mediastinum; Cancer; Biopsy; Surgery; Metastasis; Oncology; Pathology; Internal medicine","score_opus":0.024265760785740935,"score_gpt":0.4441604884712086,"score_spread":0.41989472768546765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569500944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705739,0.0071773673,0.0000147283345,0.017549243,0.0007428441,0.00017642508,0.00001194127,0.0000035949633,0.003749944],"genre_scores_gemma":[0.99029344,0.0072674383,0.0012944661,0.0004223295,0.0003970674,0.000007752424,8.945142e-7,0.000012610095,0.00030398238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990344,0.000055098284,0.00039884288,0.00012537805,0.000201308,0.00018496503],"domain_scores_gemma":[0.99810785,0.00016913637,0.001047753,0.00023973366,0.00025505715,0.00018048532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004061643,0.000111138375,0.0006192707,0.00012256949,0.00012174059,0.00002202488,0.00013731043,0.000092785274,0.00010798448],"category_scores_gemma":[0.00016683296,0.000080392376,0.000107906526,0.000029719933,0.00015711504,0.00015195002,0.00007555286,0.00022368626,0.0000011047532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010848899,0.0004690449,0.7937691,0.0005181898,0.0010131543,0.0010729519,0.0009081334,0.000009628197,0.0019128558,0.000098095086,0.010621945,0.18852198],"study_design_scores_gemma":[0.005739757,0.0045795236,0.9180727,0.00243877,0.003778938,0.001433116,0.0007270401,0.00008452211,0.037433587,0.0005734341,0.02489491,0.00024371815],"about_ca_topic_score_codex":0.00016180791,"about_ca_topic_score_gemma":0.00028082277,"teacher_disagreement_score":0.18827826,"about_ca_system_score_codex":0.0005633616,"about_ca_system_score_gemma":0.00081904593,"threshold_uncertainty_score":0.32783058},"labels":[],"label_agreement":null},{"id":"W2569547003","doi":"10.1016/j.jtho.2016.11.058","title":"ED14.05 Immunotherapy of Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Immunotherapy; Lung cancer; Cancer immunotherapy; Targeted therapy; Cancer research; Cancer; Clinical trial; Oncology; Immune system; Immunology; Internal medicine","score_opus":0.04548576438345652,"score_gpt":0.5014252161603496,"score_spread":0.4559394517768931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569547003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9488307,0.019142354,0.00020495307,0.016393231,0.001571305,0.00031209196,0.000008704321,0.000007594509,0.013529063],"genre_scores_gemma":[0.98197985,0.008795677,0.0036152257,0.00042475815,0.001005557,0.000012206068,4.0118383e-7,0.000025847417,0.004140481],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99862736,0.00012308561,0.0005139304,0.00011659987,0.00034251166,0.0002765011],"domain_scores_gemma":[0.9974617,0.00016606471,0.0011830025,0.00040822258,0.00064595026,0.00013510908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009819616,0.000121512836,0.0007480784,0.00016668299,0.00014693633,0.000017165014,0.00042235618,0.0001201937,0.00026205837],"category_scores_gemma":[0.00029432125,0.00008585776,0.00021794367,0.000056478897,0.00026932397,0.00011042245,0.00011739587,0.0005143512,0.0000037618413],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012580729,0.0012581438,0.22164723,0.0016406744,0.002404506,0.0015803053,0.0031185339,0.000041677118,0.15327695,0.000044114382,0.08590667,0.5165005],"study_design_scores_gemma":[0.010555654,0.011652662,0.47885147,0.0020154922,0.0015995515,0.0012873877,0.001112601,0.00026267563,0.12821601,0.0004993321,0.3635094,0.0004377726],"about_ca_topic_score_codex":0.00018813649,"about_ca_topic_score_gemma":0.00009220147,"teacher_disagreement_score":0.5160627,"about_ca_system_score_codex":0.0005252532,"about_ca_system_score_gemma":0.0011757041,"threshold_uncertainty_score":0.35011777},"labels":[],"label_agreement":null},{"id":"W2569615651","doi":"10.1016/j.jtho.2016.11.244","title":"OA04.01 Educational and Wealth Inequalities in Tobacco Use among Men and Women in 54 Low-And-Middle-Income Countries","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Inequality; Medicine; Low and middle income countries; Developing country; Index (typography); Population; Demography; Distribution (mathematics); Environmental health; Economics; Economic growth; Mathematics","score_opus":0.053450870909389527,"score_gpt":0.39907405499963294,"score_spread":0.3456231840902434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569615651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93855196,0.00030478436,0.000001733149,0.0581201,0.00041404922,0.00012838465,0.0000034558495,0.0000047972826,0.002470731],"genre_scores_gemma":[0.99230677,0.0007915848,0.00013924959,0.005731808,0.00078524795,0.000011001263,0.0000015887344,0.000009996017,0.00022274873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981376,0.00019578273,0.0008261179,0.00017067685,0.0001292324,0.0005405953],"domain_scores_gemma":[0.99770844,0.00077626994,0.0011326657,0.0001500894,0.00014338287,0.00008916026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005376214,0.00014721208,0.0006547833,0.00043587087,0.0002811877,0.00027605388,0.00021493399,0.00017512374,0.000047213423],"category_scores_gemma":[0.0028990998,0.00012327642,0.000025227308,0.00009297438,0.00034560356,0.0018232856,0.00027446917,0.0004478765,0.0000037626671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024052768,0.000053910953,0.985509,0.00045575,0.000017089435,0.000025509036,0.0009416946,0.000017036191,9.546442e-7,0.008079687,0.0023746288,0.0022842558],"study_design_scores_gemma":[0.00056462124,0.00007876421,0.93324083,0.00027481822,0.000010987963,0.00004420216,0.002351753,0.00026142158,1.719418e-7,0.007989172,0.055072643,0.00011058711],"about_ca_topic_score_codex":0.010099714,"about_ca_topic_score_gemma":0.0028240257,"teacher_disagreement_score":0.053754814,"about_ca_system_score_codex":0.00027507922,"about_ca_system_score_gemma":0.00024851406,"threshold_uncertainty_score":0.99649215},"labels":[],"label_agreement":null},{"id":"W2569660087","doi":"10.1016/j.jtho.2016.11.1670","title":"P3.02b-003 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Lung cancer; Internal medicine; Oncology; Immunohistochemistry; Lung; Adenocarcinoma; Carcinoma; Epidermal growth factor receptor; Cancer","score_opus":0.017297589953040496,"score_gpt":0.393243893855291,"score_spread":0.37594630390225053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569660087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99629366,0.00045067523,0.000062967345,0.0006281375,0.00047764208,0.0005554331,0.00019226882,0.0000024556368,0.0013367329],"genre_scores_gemma":[0.9974321,0.000008193124,0.0021327857,0.000063998305,0.0000735225,0.000010024301,0.000014399991,0.000017041779,0.00024795122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987606,0.00008010631,0.0005776496,0.00015584826,0.00024018543,0.00018564449],"domain_scores_gemma":[0.99677306,0.00029659586,0.0019251347,0.00035787935,0.000526455,0.000120852346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003157787,0.0001468303,0.00072985963,0.00024697764,0.00016636077,0.000012921319,0.0001883943,0.000081320126,0.00007868991],"category_scores_gemma":[0.00018759466,0.00008667277,0.0002616423,0.00018928084,0.00019857816,0.000113778064,0.000050691167,0.00014301825,1.4601721e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012055562,0.0010632743,0.9717925,0.00047136808,0.003923374,0.000041111947,0.0009784553,0.00007507677,0.0004782824,0.000012939355,0.00096641015,0.008141652],"study_design_scores_gemma":[0.011227564,0.006814596,0.95888275,0.000087383894,0.017873824,0.000028025828,0.00064817275,0.0008907056,0.0027777364,0.00001161503,0.00065441127,0.00010319988],"about_ca_topic_score_codex":0.00004375707,"about_ca_topic_score_gemma":0.00013392139,"teacher_disagreement_score":0.0139504485,"about_ca_system_score_codex":0.00020288325,"about_ca_system_score_gemma":0.00051298254,"threshold_uncertainty_score":0.3534413},"labels":[],"label_agreement":null},{"id":"W2569692561","doi":"10.1016/j.jtho.2016.11.1359","title":"P2.03b-077 EGFR/ALK+ Patient-Derived Xenografts from Advanced NSCLC for TKI Drug Selection &amp; Resistance Development: The REAL-PDX Study","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; T790M; Cancer; Epidermal growth factor receptor; Gefitinib","score_opus":0.02683265940397953,"score_gpt":0.4207443422632279,"score_spread":0.3939116828592483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569692561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995567,0.0010432465,0.0004320286,0.0009307528,0.0005171293,0.00064529467,0.000027431408,0.000006059009,0.00083103596],"genre_scores_gemma":[0.9919413,0.00034844578,0.006038394,0.00009013454,0.00046832053,0.0001009762,0.000036292025,0.000026258927,0.0009498957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983844,0.00023926818,0.0004689175,0.00029966095,0.0002682263,0.0003395095],"domain_scores_gemma":[0.9980839,0.000076651886,0.0008847526,0.0003926837,0.0004176042,0.00014441725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051146274,0.00018662393,0.0003305862,0.000063562475,0.0006980112,0.00008482485,0.0005260651,0.00012077512,0.000015895912],"category_scores_gemma":[0.0002606967,0.00013328425,0.00014782384,0.00005502705,0.00013413942,0.00002561402,0.00015759248,0.00022213053,0.0000063929915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025277404,0.0022065418,0.020605251,0.000050182756,0.0021164063,0.00010250292,0.0034491667,0.000047233865,0.39051104,0.000011757562,0.020521915,0.5351006],"study_design_scores_gemma":[0.005528614,0.0042458368,0.07542316,0.00010423043,0.00026587825,0.000047126137,0.0012426102,0.000004816324,0.19930096,0.00078783906,0.71265316,0.00039578616],"about_ca_topic_score_codex":0.00016313969,"about_ca_topic_score_gemma":0.014064076,"teacher_disagreement_score":0.6921312,"about_ca_system_score_codex":0.00023279314,"about_ca_system_score_gemma":0.0006027722,"threshold_uncertainty_score":0.78480846},"labels":[],"label_agreement":null},{"id":"W2569810001","doi":"10.1016/j.jtho.2016.11.1089","title":"P2.01-037 Molecular Biology Underlying COPD and Lung Cancer Converge on FOXM1 Network","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; FOXM1; COPD; Cell cycle; Adenocarcinoma; Gene; Gene regulatory network; Medicine; Lung; Transcription factor; Disease; Biology; Gene expression; Bioinformatics; Cancer research; Computational biology; Cancer; Oncology; Internal medicine; Genetics","score_opus":0.052204142471280385,"score_gpt":0.47035147604030936,"score_spread":0.418147333569029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569810001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601769,0.010469084,0.0008485764,0.021466032,0.0023043037,0.00025412114,0.0000050324875,0.000012893048,0.004463077],"genre_scores_gemma":[0.9920355,0.0023174062,0.0014670624,0.003183512,0.00076542137,0.000013892297,0.0000014428927,0.000023657029,0.00019208122],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986998,0.00015337538,0.00043990035,0.00020428024,0.00016344538,0.0003392203],"domain_scores_gemma":[0.9983612,0.00011751859,0.00082685193,0.00028769908,0.0001849193,0.0002218546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006437407,0.00016517538,0.0007084865,0.000098770426,0.00024215161,0.000037049605,0.0002104493,0.00025071815,0.00023572489],"category_scores_gemma":[0.000136652,0.00012574473,0.00015263329,0.00005548364,0.00021752401,0.000093041584,0.00008632859,0.0005112191,0.0000039647352],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007956496,0.00056598894,0.33937812,0.00045202053,0.0019784912,0.0014029407,0.0004561105,0.00022494627,0.021543745,0.0029663169,0.041595705,0.58147913],"study_design_scores_gemma":[0.012975598,0.029413728,0.496139,0.0043476257,0.0061470554,0.003487043,0.0007588647,0.0035511623,0.01831805,0.0066765537,0.4168334,0.0013519217],"about_ca_topic_score_codex":0.000060500417,"about_ca_topic_score_gemma":0.00004077293,"teacher_disagreement_score":0.5801272,"about_ca_system_score_codex":0.00027120224,"about_ca_system_score_gemma":0.00035248432,"threshold_uncertainty_score":0.51277214},"labels":[],"label_agreement":null},{"id":"W2569849089","doi":"10.1016/j.jtho.2016.11.090","title":"SC13.02 Increased Risk for Lung Cancer in COPD","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; COPD; Lung cancer; Pulmonary function testing; Vital capacity; Internal medicine; Diffusing capacity; Lung cancer screening; Lung volumes; Air trapping; Lung; Cancer; Physical therapy; Lung function","score_opus":0.030849104552158522,"score_gpt":0.4633472364825672,"score_spread":0.4324981319304087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569849089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841646,0.004145365,0.00021004456,0.006608651,0.00087279564,0.00071859657,0.00010074405,0.000008386446,0.0031708018],"genre_scores_gemma":[0.9947342,0.0006779205,0.0020863942,0.0002163276,0.0012280524,0.000050532908,0.0000043784025,0.00003365509,0.0009684983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980431,0.00026208756,0.0006048159,0.00023249997,0.0003966537,0.0004607948],"domain_scores_gemma":[0.9971762,0.00039780498,0.001004437,0.00045565976,0.0005632721,0.0004026485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015585753,0.00016536123,0.0007549392,0.00034023938,0.00022823623,0.00003669387,0.000434065,0.00021037445,0.00061337266],"category_scores_gemma":[0.0015779645,0.00013608628,0.00026440062,0.000100716825,0.00027892992,0.00025236327,0.00012648907,0.00079132913,0.000007404364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0109422505,0.00076597906,0.6234341,0.0007083347,0.00039753746,0.0017694368,0.000200919,0.00006813695,0.0021522413,0.000049914153,0.0094294315,0.3500817],"study_design_scores_gemma":[0.005123291,0.0008364377,0.9649357,0.00047876782,0.00062316534,0.0004678976,0.00022260186,0.0053041554,0.0008431232,0.0005653045,0.020438034,0.0001615067],"about_ca_topic_score_codex":0.00044838924,"about_ca_topic_score_gemma":0.0005221772,"teacher_disagreement_score":0.34992018,"about_ca_system_score_codex":0.0018514508,"about_ca_system_score_gemma":0.002443063,"threshold_uncertainty_score":0.67160004},"labels":[],"label_agreement":null},{"id":"W2569849644","doi":"10.1016/j.jtho.2016.11.1504","title":"P2.06-011 Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cancer; Oncology; Chemotherapy; Monoclonal antibody; Neuregulin; Lung cancer; In situ hybridization; Phases of clinical research; Cancer research; Pathology; Antibody; Receptor; Messenger RNA; Immunology","score_opus":0.06833756263630814,"score_gpt":0.51890546857189,"score_spread":0.4505679059355819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569849644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857592,0.00074637606,0.0006805836,0.009618375,0.00042378,0.0017097002,0.000012501593,0.000014000374,0.0010354605],"genre_scores_gemma":[0.9870903,0.0010514022,0.008827129,0.0011206523,0.0003726153,0.000043445034,0.0000034209756,0.00008504688,0.0014060121],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957663,0.0006188401,0.001556677,0.0004096418,0.0010264708,0.0006221043],"domain_scores_gemma":[0.995547,0.00048843364,0.0017942362,0.0009098345,0.0008588186,0.00040170382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002734733,0.00035430072,0.0021410405,0.00055232213,0.00014523084,0.000044986697,0.00087592023,0.00021742843,0.0007426347],"category_scores_gemma":[0.0007231589,0.0002632805,0.00024811452,0.00035260274,0.00042603532,0.0003162094,0.00010904112,0.0011783636,0.000018159337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12817235,0.014177874,0.005218819,0.00039688224,0.0011814394,0.007006118,0.0055046487,0.0001036808,0.022408247,0.000006723576,0.0019847476,0.8138385],"study_design_scores_gemma":[0.3428176,0.27576616,0.16184908,0.0056412085,0.001820442,0.0079727955,0.018563746,0.0025906565,0.12370665,0.0007968313,0.056779984,0.0016948399],"about_ca_topic_score_codex":0.00017225475,"about_ca_topic_score_gemma":0.0005092581,"teacher_disagreement_score":0.8121436,"about_ca_system_score_codex":0.0011400321,"about_ca_system_score_gemma":0.0026279045,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W2569870964","doi":"10.1016/j.jtho.2016.11.388","title":"MA02.09 Long Non-Coding RNA Expression from Pseudogene Loci as a Novel Mechanism of Cancer Gene Regulation","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pseudogene; Gene; Genetics; Biology; Long non-coding RNA; Carcinogenesis; RNA; Coding region; Gene expression; Computational biology; Genome","score_opus":0.026546132942395977,"score_gpt":0.4051533481713211,"score_spread":0.3786072152289251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569870964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7471395,0.0011106736,0.24937718,0.0005905229,0.0008886861,0.00022016712,0.000036316644,0.0000036954068,0.0006332274],"genre_scores_gemma":[0.9866811,0.00103131,0.010733516,0.00010353548,0.00091984624,0.000013346907,0.00002687594,0.000043384345,0.0004470664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812895,0.00013292163,0.00061887456,0.00033646062,0.00045602833,0.00032675988],"domain_scores_gemma":[0.99707425,0.00002879633,0.0014962825,0.00065089087,0.0005640941,0.00018569797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000710372,0.00020424029,0.00047506535,0.00016080652,0.0002112562,0.000045534336,0.0007072342,0.000531302,0.00018145655],"category_scores_gemma":[0.000279026,0.00018913213,0.000247372,0.00006801812,0.00011583425,0.000025411206,0.00037670153,0.00037350573,0.000006012582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001271782,0.00013021677,0.000036589347,0.000027704014,0.00021401806,0.00007194163,0.00007209736,0.00043836466,0.96392965,0.000036582598,0.00034145458,0.03342962],"study_design_scores_gemma":[0.0011334713,0.00088718906,0.001167731,0.00017553981,0.00013784204,0.00015870365,0.000053139604,0.0005319635,0.99356955,0.0007310991,0.0012751095,0.00017864257],"about_ca_topic_score_codex":0.00025748627,"about_ca_topic_score_gemma":0.00013048443,"teacher_disagreement_score":0.23954159,"about_ca_system_score_codex":0.00020151261,"about_ca_system_score_gemma":0.0006841036,"threshold_uncertainty_score":0.7712585},"labels":[],"label_agreement":null},{"id":"W2569936242","doi":"10.1016/j.jtho.2016.11.1531","title":"P2.06-038 An RCT of the Detection of Autoantibodies to Tumor Antigens in Lung Cancer Using the EarlyCDT-Lung Test in Scotland (ECLS) in 12 208 Study Subjects","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Stage (stratigraphy); Randomized controlled trial; National Lung Screening Trial; Internal medicine; Cancer; Lung; Incidence (geometry); Disease; Oncology","score_opus":0.027097108231497094,"score_gpt":0.4499857429287151,"score_spread":0.42288863469721805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569936242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959274,0.00049180683,0.000083623134,0.0023645936,0.00058277714,0.00046423983,0.0000016932514,0.000002559539,0.00008130991],"genre_scores_gemma":[0.9990868,0.00008136002,0.00041437446,0.00015287605,0.00021581353,0.0000039679207,1.6724746e-7,0.000016351743,0.00002831161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806404,0.0004435093,0.0007660477,0.00015631052,0.0003166981,0.00025339992],"domain_scores_gemma":[0.99818915,0.0003116577,0.0009550181,0.00032412913,0.0001359637,0.000084065134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028842944,0.00012686536,0.0006748113,0.0003926091,0.00011821032,0.000023381119,0.00037990705,0.00007722788,0.000008613909],"category_scores_gemma":[0.0022173282,0.000075299715,0.00008262796,0.00023676235,0.0001889307,0.00015333887,0.00011564937,0.0009497061,1.5979994e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004456283,0.00048044132,0.93088657,0.00009284723,0.000041377756,0.00023259014,0.004113104,0.0013592489,0.051497713,7.889842e-7,0.000016185599,0.010833481],"study_design_scores_gemma":[0.001314809,0.0008624136,0.9715405,0.0009793505,0.00013508237,0.00023536723,0.0015188641,0.021271007,0.001978453,0.000019318679,0.00007503009,0.00006982232],"about_ca_topic_score_codex":0.00368191,"about_ca_topic_score_gemma":0.010659523,"teacher_disagreement_score":0.04951926,"about_ca_system_score_codex":0.0003237708,"about_ca_system_score_gemma":0.0004920029,"threshold_uncertainty_score":0.59482646},"labels":[],"label_agreement":null},{"id":"W2569944120","doi":"10.1016/j.jtho.2016.11.2061","title":"PUB091 Metabolic and Epigenetic Changes Associated with Lung Cancer Using a CRISPR/Cas9 Mouse Model","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"KRAS; Epigenetics; Lung cancer; Cancer research; CRISPR; Cancer; Biology; Medicine; Lung; Bioinformatics; Pathology; Gene; Genetics; Internal medicine; Colorectal cancer","score_opus":0.026648645429924105,"score_gpt":0.431932467222229,"score_spread":0.4052838217923049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569944120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739258,0.008095001,0.01692931,0.0006168315,0.00021246297,0.00010007951,0.000015411038,0.0000038795324,0.00010121118],"genre_scores_gemma":[0.9923812,0.0022321998,0.004496815,0.00013327382,0.0003236982,0.000006228746,0.0000022433646,0.000029131816,0.00039519274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991362,0.00006191871,0.00022818563,0.00018027126,0.00013158991,0.00026181276],"domain_scores_gemma":[0.9988967,0.0000153348,0.000484079,0.00025749952,0.000209007,0.00013738318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037862564,0.00016052158,0.00035985402,0.000081300626,0.00017180174,0.000052069467,0.00024441426,0.00019132673,0.000006654449],"category_scores_gemma":[0.0001558608,0.00013033424,0.000063479696,0.0000313413,0.00010541297,0.000010312528,0.00011607967,0.0001818658,1.3174815e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043196295,0.00012240057,0.010636943,0.000058659265,0.0006755211,0.00005202728,0.0002945755,0.027950522,0.9287428,0.000009135888,0.00039636964,0.030629085],"study_design_scores_gemma":[0.0022261776,0.0017816749,0.026835341,0.00024104665,0.0015971316,0.000600333,0.0002467773,0.081376456,0.8763885,0.00008389329,0.00783623,0.0007864504],"about_ca_topic_score_codex":0.000026987731,"about_ca_topic_score_gemma":0.00038275053,"teacher_disagreement_score":0.053425934,"about_ca_system_score_codex":0.000044495504,"about_ca_system_score_gemma":0.00022527513,"threshold_uncertainty_score":0.5314876},"labels":[],"label_agreement":null},{"id":"W2569966395","doi":"10.1016/j.jtho.2016.11.1551","title":"P2.08-001 Giving a Voice to Patients and Caregivers through the Lung Cancer Canada ‘Faces of Lung Cancer’ Survey","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Family Support in Illness","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Feeling; Lung cancer; Demographics; Stressor; Depression (economics); Loneliness; Cancer; Family medicine; Quality of life (healthcare); Family caregivers; Emotional support; Social support; Physical therapy; Internal medicine; Clinical psychology; Psychiatry; Nursing; Psychology; Demography","score_opus":0.03409008943621182,"score_gpt":0.42941818223125044,"score_spread":0.3953280927950386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569966395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981978,0.0011373522,0.000010835058,0.008659784,0.0043657827,0.00025916166,0.00013245511,0.0000036215174,0.0034530114],"genre_scores_gemma":[0.9976505,0.0006920387,0.00009916809,0.0005196516,0.00029353116,0.000010277928,0.0000010170234,0.000010910395,0.00072287646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765307,0.0006816288,0.00045447316,0.00017574336,0.0006442239,0.00039083432],"domain_scores_gemma":[0.99660224,0.00080105785,0.0013579999,0.00023329305,0.0008176503,0.00018776486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017478876,0.00013670757,0.00047526447,0.000055270684,0.0010202205,0.000079843296,0.00093997706,0.00012935423,0.0001538511],"category_scores_gemma":[0.0014026398,0.00010127741,0.00005527413,0.00015420537,0.00042914017,0.00044354732,0.00018730402,0.0003136287,3.9191562e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018054045,0.00004836124,0.89966625,0.000058914087,0.00015383579,0.000031403426,0.01762447,0.00016902397,0.000016314256,0.00003298509,0.06602371,0.015994215],"study_design_scores_gemma":[0.0003793653,0.000111705405,0.8322436,0.00017960339,0.00014884194,0.0000043903638,0.0069292425,0.00004201995,0.000055953253,0.000032635227,0.1596935,0.0001791364],"about_ca_topic_score_codex":0.97190243,"about_ca_topic_score_gemma":0.9907148,"teacher_disagreement_score":0.09366978,"about_ca_system_score_codex":0.0013711833,"about_ca_system_score_gemma":0.004013493,"threshold_uncertainty_score":0.78468144},"labels":[],"label_agreement":null},{"id":"W2569983671","doi":"10.1016/j.jtho.2016.11.337","title":"OA19.01 A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Cohort; Gene signature; Pathology; Gene expression; Gene","score_opus":0.014401480905708022,"score_gpt":0.3816849195196446,"score_spread":0.3672834386139366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569983671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97960734,0.003372763,0.010448561,0.0052141035,0.0005022831,0.00048033637,0.00001352742,0.00000572566,0.00035534456],"genre_scores_gemma":[0.99114203,0.00010219856,0.007962986,0.00019197873,0.00039037876,0.0000075457538,0.0000070247957,0.000018780333,0.00017708122],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99869657,0.00018962577,0.0005007492,0.0001383273,0.0002856558,0.00018910554],"domain_scores_gemma":[0.9974057,0.0007366165,0.0012195192,0.00022444593,0.00027247216,0.00014124038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015639572,0.00011917015,0.00051540625,0.00008331306,0.00024068622,0.000043276363,0.00020679459,0.00013811117,0.000024691117],"category_scores_gemma":[0.0022254796,0.00007259218,0.00012484998,0.00002944219,0.00023904625,0.00009641294,0.000063523934,0.0005202529,1.480623e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005362176,0.00043114874,0.118406065,0.0009274624,0.00014722187,0.0002477517,0.0011998147,0.00012992838,0.80105436,0.000025166184,0.03911855,0.032950375],"study_design_scores_gemma":[0.014815437,0.0054962435,0.08136827,0.0008456622,0.0036264944,0.0023386762,0.00086520356,0.024853395,0.83691466,0.00070285646,0.027750589,0.0004225345],"about_ca_topic_score_codex":0.000009535473,"about_ca_topic_score_gemma":5.7361655e-7,"teacher_disagreement_score":0.037037805,"about_ca_system_score_codex":0.00009370375,"about_ca_system_score_gemma":0.0002796686,"threshold_uncertainty_score":0.29602233},"labels":[],"label_agreement":null},{"id":"W2570114477","doi":"10.1016/j.jtho.2016.11.1785","title":"P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; T790M; non-small cell lung cancer (NSCLC); Internal medicine; Oncology; Osimertinib; Lung cancer; Erlotinib; EGFR inhibitors; Acquired resistance; Phases of clinical research; Resistance mutation; Cancer; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Gefitinib; Clinical trial; A549 cell","score_opus":0.02240743886775497,"score_gpt":0.4393268700468884,"score_spread":0.41691943117913344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570114477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946009,0.00024137188,0.000045246023,0.0007808891,0.0005416485,0.0010134178,0.00017562907,0.0000056270337,0.0025952586],"genre_scores_gemma":[0.99749863,0.000057289224,0.0017595382,0.00010448291,0.00023215004,0.000030355774,0.000020745214,0.000027793229,0.0002690065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793166,0.00013587113,0.0009952324,0.00026418845,0.0004014676,0.00027158568],"domain_scores_gemma":[0.99645036,0.00014899249,0.002147524,0.00051436323,0.00053537125,0.00020336416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040235117,0.00021451159,0.0008744185,0.0002325072,0.00014570823,0.00002783531,0.00028417874,0.00013025657,0.000069826536],"category_scores_gemma":[0.00013316153,0.00014379286,0.00009922935,0.00010950096,0.00008439871,0.00019718103,0.00006607702,0.00040513984,0.0000029764785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045350887,0.025730435,0.80658334,0.00019273518,0.0017440809,0.0017601167,0.026339946,0.0002624432,0.0018406115,0.0000015544517,0.0011598736,0.08903395],"study_design_scores_gemma":[0.09801031,0.026720114,0.8616194,0.001469776,0.0037077002,0.000037291164,0.004253164,0.00042431167,0.0022949865,0.000027034237,0.0011506312,0.00028528256],"about_ca_topic_score_codex":0.0021097523,"about_ca_topic_score_gemma":0.0018331067,"teacher_disagreement_score":0.08874866,"about_ca_system_score_codex":0.0007158697,"about_ca_system_score_gemma":0.0012534065,"threshold_uncertainty_score":0.5863703},"labels":[],"label_agreement":null},{"id":"W2570151487","doi":"10.1016/j.jtho.2016.11.045","title":"ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; ROS1; Lung cancer; Oncogene; Liquid biopsy; Personalized medicine; Cancer research; Crizotinib; Cancer; Fusion gene; Targeted therapy; Tyrosine kinase; KRAS; Mutation; Precision medicine; Gene; Oncology; Bioinformatics; Internal medicine; Adenocarcinoma; Pathology; Biology; Genetics; Cell cycle","score_opus":0.036203383191534697,"score_gpt":0.49293769551190125,"score_spread":0.45673431232036654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570151487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708937,0.0038112458,0.002069523,0.010536946,0.0025667623,0.00094759045,0.000027393306,0.000018546345,0.009128288],"genre_scores_gemma":[0.9854453,0.000817617,0.0105552,0.0004764731,0.00089584483,0.00004062309,0.000006031506,0.000023444425,0.0017394607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907726,0.000046504625,0.00040499296,0.00012548178,0.00015413288,0.0001916212],"domain_scores_gemma":[0.99812305,0.00010845347,0.00092607253,0.0003084161,0.0003848176,0.00014918909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002693845,0.00011665412,0.0005183028,0.00010037697,0.00023351135,0.000026235313,0.00019989604,0.00011914559,0.000056794248],"category_scores_gemma":[0.00014368785,0.00007988923,0.00023262823,0.000029712539,0.00006723315,0.00016256254,0.000019502506,0.00015517467,0.000009715974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005218315,0.00054179376,0.0049401964,0.000104572144,0.00089586317,0.00029805646,0.00064258964,0.00005606527,0.029859524,0.000087715685,0.0040094717,0.95334584],"study_design_scores_gemma":[0.03276442,0.027152648,0.043711327,0.0018840147,0.0036907685,0.0102399625,0.0024361694,0.00026663265,0.023686346,0.001427225,0.8522087,0.0005318264],"about_ca_topic_score_codex":0.000006894759,"about_ca_topic_score_gemma":0.0000111145155,"teacher_disagreement_score":0.952814,"about_ca_system_score_codex":0.00044728644,"about_ca_system_score_gemma":0.00084661733,"threshold_uncertainty_score":0.3257788},"labels":[],"label_agreement":null},{"id":"W2570179087","doi":"10.1016/j.jtho.2016.11.519","title":"MA17.06 Landscape of Somatic Mutations Involving Lung Cancer Associated Genes in Non-Small Cell Lung Cancer (NSCLC) Patient-Derived Xenografts","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Lung cancer; Exome sequencing; Cancer; Gene; Exome; Adenocarcinoma; Somatic cell; Cancer research; Mutation; Genetics; Biology; Medicine; Pathology","score_opus":0.012531813921234891,"score_gpt":0.34197982700495466,"score_spread":0.3294480130837198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570179087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847943,0.013092316,0.0001650157,0.00035703552,0.0009097485,0.0002254675,0.000077235876,0.0000023074867,0.00037654582],"genre_scores_gemma":[0.99327326,0.0051409877,0.0009274388,0.00014768999,0.0003594936,0.00003240422,0.000024068873,0.000027259392,0.0000674105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985935,0.00011010754,0.00066549075,0.00019412306,0.00014118226,0.00029558584],"domain_scores_gemma":[0.9975596,0.000091357695,0.0015984181,0.00028184353,0.00035616301,0.00011261282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003301044,0.0001731777,0.00046605984,0.00014530035,0.00014410216,0.000043150372,0.0003780359,0.00025753854,0.000038925733],"category_scores_gemma":[0.00024409503,0.00016532635,0.0001631552,0.00007005463,0.00008410834,0.00001574276,0.00016613682,0.00021812545,6.50485e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028216958,0.0004077981,0.34656742,0.00023235285,0.0003361419,0.0000714459,0.0011820071,0.0052398653,0.629018,0.0000024684332,0.002302335,0.01435795],"study_design_scores_gemma":[0.0056454195,0.0020581065,0.38090622,0.0013571744,0.0013711688,0.00007064442,0.001963963,0.012089412,0.58958334,0.00014268514,0.0038308066,0.0009810656],"about_ca_topic_score_codex":0.00042765317,"about_ca_topic_score_gemma":0.0035932842,"teacher_disagreement_score":0.03943471,"about_ca_system_score_codex":0.00020433163,"about_ca_system_score_gemma":0.00092051906,"threshold_uncertainty_score":0.6741813},"labels":[],"label_agreement":null},{"id":"W2570179707","doi":"10.1016/j.jtho.2016.11.1695","title":"P3.02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Erlotinib; Cancer research; Epigenomics; Epidermal growth factor receptor; Biology; Population; Medicine; Cancer; Internal medicine; DNA methylation; Genetics; Gene expression; Gene","score_opus":0.04549280924966785,"score_gpt":0.4478053006809738,"score_spread":0.40231249143130593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570179707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98733765,0.00036378414,0.00017149237,0.008752044,0.0013613194,0.0003928816,0.000012702494,0.000021039272,0.0015870703],"genre_scores_gemma":[0.99299157,0.00006981965,0.004385354,0.001031441,0.0012718946,0.0000066295197,0.00003676378,0.000033040058,0.00017349812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982887,0.00019892026,0.00068818446,0.00018333858,0.00033924473,0.00030160448],"domain_scores_gemma":[0.9974541,0.000112986425,0.0015398388,0.00038591953,0.0003457984,0.00016132474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062932004,0.0001910527,0.0005961703,0.0001759321,0.00067421707,0.0001340027,0.00024298693,0.0001612286,0.000044180575],"category_scores_gemma":[0.00016995786,0.0001224073,0.00018093962,0.00009264946,0.00014462056,0.00042182434,0.00007488681,0.00044674912,0.000009386624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009362077,0.0018325954,0.16263731,0.0003470504,0.0029041045,0.0033882966,0.008776649,0.00033396823,0.30648622,0.00006145286,0.0018959582,0.50197434],"study_design_scores_gemma":[0.0027724726,0.0013281264,0.9812991,0.0005892614,0.0017873546,0.0027055456,0.0006233225,0.00020100894,0.0020369808,0.000094009105,0.006388082,0.00017473933],"about_ca_topic_score_codex":0.00011139968,"about_ca_topic_score_gemma":0.000040874096,"teacher_disagreement_score":0.8186618,"about_ca_system_score_codex":0.0007122805,"about_ca_system_score_gemma":0.0006756492,"threshold_uncertainty_score":0.5185601},"labels":[],"label_agreement":null},{"id":"W2570187446","doi":"10.1016/j.jtho.2016.11.1615","title":"P3.01-049 ELF3 Overexpression Leads to Oncogenic Reprogramming of Protein Interactions Exposing Therapeutically Actionable Targets","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Carcinogenesis; Cancer research; Biology; Transcription factor; Oncogene; Gene; Computational biology; Genetics; Cell cycle","score_opus":0.05345729772459745,"score_gpt":0.4500703081552784,"score_spread":0.3966130104306809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570187446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256695,0.0005256834,0.0019619176,0.010299742,0.0006892604,0.0004709513,0.0000031989302,0.000016218712,0.0034660515],"genre_scores_gemma":[0.97155774,0.000083186336,0.026808834,0.00036948104,0.00058189256,0.000033764005,0.0000012675073,0.00002640352,0.00053744786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982313,0.000120176985,0.0007608701,0.00022084171,0.00037934486,0.00028747504],"domain_scores_gemma":[0.9974371,0.000090860936,0.0012433882,0.00046798855,0.0005204353,0.00024022645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008145883,0.00015663766,0.0006329018,0.00021438678,0.00027668002,0.000053470736,0.00028791084,0.00016306264,0.00033100398],"category_scores_gemma":[0.00041210628,0.00012084796,0.0002992182,0.00010158167,0.00010907371,0.0003518666,0.00011603663,0.0005672533,0.000023876653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003342299,0.00062541506,0.0038833527,0.000089053094,0.00016290812,0.00004567662,0.00029146724,0.000013546593,0.60653156,0.000024193618,0.0008291359,0.38416138],"study_design_scores_gemma":[0.0014295345,0.008329457,0.023362659,0.0024863859,0.00054195046,0.0009669956,0.00067780947,0.000084534455,0.70495546,0.00032551828,0.25659648,0.00024324586],"about_ca_topic_score_codex":0.00002674578,"about_ca_topic_score_gemma":0.000013150318,"teacher_disagreement_score":0.38391814,"about_ca_system_score_codex":0.00040272856,"about_ca_system_score_gemma":0.0004448771,"threshold_uncertainty_score":0.49280366},"labels":[],"label_agreement":null},{"id":"W2570225271","doi":"10.1016/j.jtho.2016.11.1690","title":"P3.02b-023 Physician Patterns of Care in Patients with EGFR Mutation+ NSCLC: An International Survey into Testing and Treatment Choice","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; China; Family medicine; Internal medicine","score_opus":0.03218217973167105,"score_gpt":0.4488049454194688,"score_spread":0.41662276568779777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570225271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982389,0.000058955015,0.000030420002,0.00034499107,0.00021017909,0.00021026404,0.000042184136,0.000003128407,0.00086097966],"genre_scores_gemma":[0.9970542,0.000017017452,0.0025983849,0.000071931,0.00014238668,0.0000066862444,0.000054996326,0.000012092813,0.0000422562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991827,0.00008741397,0.00031492184,0.00012630055,0.00018421984,0.00010446921],"domain_scores_gemma":[0.9982587,0.0001597416,0.0006981114,0.00016568702,0.0006278369,0.00008992851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014565616,0.000105469764,0.00034443277,0.00014568456,0.00008871884,0.000023727822,0.00010399519,0.000052881565,0.0000081808885],"category_scores_gemma":[0.00020310875,0.00007292426,0.00003397913,0.000047324713,0.0000557854,0.00030020668,0.000022021326,0.00010220838,5.948402e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008582819,0.0005129939,0.69898045,0.00002167862,0.00015817185,0.00005212087,0.0014317076,0.000026531647,0.000024197647,0.0000018935377,0.0000024843948,0.29792947],"study_design_scores_gemma":[0.0039774384,0.008552818,0.9859351,0.0002448196,0.00024561523,0.000024818677,0.0005769006,0.000037002144,0.00011539481,0.000020762856,0.00021000992,0.000059357928],"about_ca_topic_score_codex":0.0016840209,"about_ca_topic_score_gemma":0.0040238067,"teacher_disagreement_score":0.29787013,"about_ca_system_score_codex":0.00060536305,"about_ca_system_score_gemma":0.00033719005,"threshold_uncertainty_score":0.2973765},"labels":[],"label_agreement":null},{"id":"W2570273251","doi":"10.1016/j.jtho.2016.11.436","title":"MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Pemetrexed; Osimertinib; Internal medicine; T790M; Oncology; Hazard ratio; Population; Carboplatin; Gastroenterology; Chemotherapy; Cisplatin; Confidence interval; Cancer; Gefitinib; Epidermal growth factor receptor; Erlotinib","score_opus":0.022921898595448742,"score_gpt":0.4647339912339375,"score_spread":0.44181209263848875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570273251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97201896,0.00030202235,0.0066899173,0.010472251,0.0012384048,0.0007792074,0.00011409472,0.000021789836,0.008363329],"genre_scores_gemma":[0.9697655,0.00004458944,0.027096912,0.00037529718,0.00037636323,0.000037577258,0.000081906794,0.000025179943,0.002196679],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984423,0.000088628265,0.0006819439,0.0002297853,0.00027857372,0.00027876472],"domain_scores_gemma":[0.99675184,0.00039576594,0.0015925253,0.00032781274,0.0007189911,0.00021304266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042390698,0.00018966626,0.0008473347,0.0004569258,0.0003768783,0.00005511549,0.00019451893,0.00015034105,0.00013547942],"category_scores_gemma":[0.0006417709,0.0001466146,0.00048449414,0.00022051127,0.00010177698,0.00035498367,0.00003154949,0.00024366395,0.000019335963],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018220086,0.0011638382,0.019837357,0.00011635335,0.011137792,0.00085274706,0.002222885,0.0011123432,0.0054414007,0.00016756335,0.0034770898,0.93625057],"study_design_scores_gemma":[0.02566758,0.021821002,0.80499476,0.0007119502,0.05439338,0.001890296,0.0027854934,0.0069051892,0.03430331,0.0018036838,0.043932125,0.00079120405],"about_ca_topic_score_codex":0.00003170824,"about_ca_topic_score_gemma":0.000094179246,"teacher_disagreement_score":0.9354593,"about_ca_system_score_codex":0.0005778864,"about_ca_system_score_gemma":0.00054289366,"threshold_uncertainty_score":0.597877},"labels":[],"label_agreement":null},{"id":"W2570293420","doi":"10.1016/j.jtho.2016.11.1352","title":"P2.03b-071 Therapeutic Targeting of the Phosphatidylinositol-3 Kinase Pathway in Lung Squamous Cell Carcinoma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"PTEN; Medicine; Cancer research; PI3K/AKT/mTOR pathway; Copy-number variation; Immunohistochemistry; Kinase; Fluorescence in situ hybridization; Cancer; Pathology; Internal medicine; Biology; Gene; Signal transduction; Genetics","score_opus":0.015417419255110308,"score_gpt":0.3449588059130113,"score_spread":0.329541386657901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570293420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886606,0.0074814996,0.00016996292,0.0007111853,0.0015285026,0.00015518384,0.000009060919,0.0000022036804,0.0012818126],"genre_scores_gemma":[0.99820286,0.000060582544,0.0006582404,0.000262985,0.00056393945,0.0000054222282,0.000002179283,0.000027246495,0.00021655508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982719,0.0003234687,0.0006560082,0.00021815153,0.00023439295,0.00029607926],"domain_scores_gemma":[0.9974678,0.000085140586,0.001544335,0.00056952605,0.00025008264,0.00008307765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010147898,0.00018167998,0.0004002273,0.00006810894,0.000166586,0.000028198907,0.0009881883,0.0002989498,0.000025552858],"category_scores_gemma":[0.0003060968,0.00013341632,0.00024757072,0.00006673957,0.00021200707,0.000014366559,0.00022878934,0.00042014,0.000001528632],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070330116,0.00028223524,0.09819363,0.000105080646,0.00004172631,0.000101954116,0.00029895367,0.00037659306,0.8857869,0.000017208027,0.0010687753,0.013023624],"study_design_scores_gemma":[0.00091863563,0.0009839264,0.036974408,0.00005339558,0.0000698046,0.00008307842,0.00014652949,0.00014465836,0.94946474,0.00017216142,0.010818242,0.00017042142],"about_ca_topic_score_codex":0.00004889302,"about_ca_topic_score_gemma":0.00004933696,"teacher_disagreement_score":0.063677825,"about_ca_system_score_codex":0.0001425883,"about_ca_system_score_gemma":0.0006410862,"threshold_uncertainty_score":0.544056},"labels":[],"label_agreement":null},{"id":"W2570295968","doi":"10.1016/j.jtho.2016.11.852","title":"P1.05-067 Consultation with Medical Oncology Less Common in Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Guideline; Stage (stratigraphy); Internal medicine; Lung cancer; Socioeconomic status; Chemotherapy; Cancer; Medical record; Cancer registry; Radiation therapy; Logistic regression; Population","score_opus":0.022489493043828485,"score_gpt":0.4190126798632871,"score_spread":0.39652318681945864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570295968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98405373,0.00048519712,0.000037991274,0.011304935,0.0005137828,0.0006125458,0.000017615048,0.0000094765555,0.0029647483],"genre_scores_gemma":[0.99716604,0.00048931374,0.0010503094,0.00051338994,0.00021337761,0.000063918014,0.000014496971,0.000028878118,0.0004603074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997794,0.00026848944,0.0006732481,0.00025491416,0.0006528125,0.00035657914],"domain_scores_gemma":[0.9968088,0.00044498887,0.0014422234,0.0003364293,0.0006221791,0.00034533162],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006508214,0.00021648072,0.0009650726,0.00023324504,0.00023355095,0.00002727347,0.0002806439,0.00032146415,0.00020447622],"category_scores_gemma":[0.00023462929,0.00013419421,0.00007212903,0.0001294789,0.00027419953,0.0001999056,0.00007910231,0.00079827936,0.0000018844346],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012868223,0.0036040465,0.846236,0.0002016466,0.00039350576,0.0036640181,0.0013430793,0.000047423244,0.000048151873,0.000015234949,0.0023597332,0.12921892],"study_design_scores_gemma":[0.026495762,0.031772017,0.9188585,0.002191724,0.0010577742,0.00035057098,0.0006622528,0.00014450913,0.001036345,0.000012967183,0.017175047,0.00024251416],"about_ca_topic_score_codex":0.0010109164,"about_ca_topic_score_gemma":0.017851373,"teacher_disagreement_score":0.1289764,"about_ca_system_score_codex":0.002060431,"about_ca_system_score_gemma":0.002877799,"threshold_uncertainty_score":0.9961485},"labels":[],"label_agreement":null},{"id":"W2570352564","doi":"10.1016/j.jtho.2016.11.325","title":"OA17.02 Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University of Ottawa; Canadian Partnership Against Cancer; Juravinski Cancer Centre; Cancer Care Ontario","funders":"","keywords":"Medicine; Smoking cessation; Demography; False positive paradox; Lung cancer screening; Population; Lung cancer; Incidence (geometry); Environmental health; Statistics; Internal medicine; Pathology","score_opus":0.07946529963686563,"score_gpt":0.4566048709058,"score_spread":0.3771395712689344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570352564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798955,0.002204173,0.00013643513,0.01676333,0.0006038578,0.00011948154,0.000021750351,0.0000018877462,0.00025360272],"genre_scores_gemma":[0.9959147,0.0011700336,0.0016237742,0.0010295954,0.00020979463,0.0000014972915,0.0000018334275,0.000008195359,0.0000405924],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985968,0.000116774405,0.0007063399,0.00013077009,0.00020274005,0.00024660322],"domain_scores_gemma":[0.9978312,0.00008351512,0.0014664899,0.00015924631,0.00014964608,0.0003098697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008403137,0.00010480316,0.00077767996,0.00011200694,0.00012302546,0.000018630511,0.00020365475,0.00007580435,0.00015358513],"category_scores_gemma":[0.00026527265,0.00008986768,0.00005088544,0.000035374207,0.00019262033,0.0001557784,0.00006006607,0.0003398917,2.4628685e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004438801,0.00003751545,0.8732002,0.0002660101,0.00023514427,0.002475947,0.00037231072,0.00027837892,0.0017472925,0.00006973568,0.004579235,0.11229946],"study_design_scores_gemma":[0.006072468,0.003957579,0.957783,0.0035991243,0.00066272786,0.0089039495,0.00693944,0.004513455,0.0020626169,0.00034122923,0.00473092,0.0004335321],"about_ca_topic_score_codex":0.6713452,"about_ca_topic_score_gemma":0.6654139,"teacher_disagreement_score":0.11186592,"about_ca_system_score_codex":0.0011654767,"about_ca_system_score_gemma":0.016467456,"threshold_uncertainty_score":0.98910826},"labels":[],"label_agreement":null},{"id":"W2570400106","doi":"10.1016/j.jtho.2016.11.1952","title":"P3.03-053 Malignant Mesothelioma in Iranian Patients: A Study from National Institute of Tuberculosis and Lung Disease","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Cape Breton University","funders":"","keywords":"Medicine; Mesothelioma; Asbestos; Tuberculosis; Stage (stratigraphy); Lung cancer; Pathological; Internal medicine; Lung; Retrospective cohort study; Gastroenterology; Surgery; Pathology","score_opus":0.020840570374060157,"score_gpt":0.3872166204876649,"score_spread":0.36637605011360475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570400106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971162,0.00039548543,0.000005036831,0.0013785021,0.00024907972,0.00023539213,0.000098131546,0.0000021726762,0.00051998487],"genre_scores_gemma":[0.9991018,0.00007317994,0.00042840006,0.00020214861,0.00012241284,0.000005781588,0.00001631701,0.0000082679035,0.000041690117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878883,0.000081009326,0.00046634037,0.00013669887,0.00042310267,0.00010403488],"domain_scores_gemma":[0.99899596,0.00006442951,0.00047952752,0.00014630491,0.000114759394,0.0001990078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002643661,0.00010359349,0.00036737375,0.00017600678,0.00007811623,0.000013492035,0.00012831346,0.000052284267,0.00008958686],"category_scores_gemma":[0.00030255815,0.000078510246,0.00008589448,0.00004300036,0.00015563844,0.00027879656,0.00008236084,0.00012607475,0.0000043095442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004096721,0.0031239232,0.9806875,0.000053118998,0.00017838251,0.00029268942,0.0001989653,0.000016712913,0.00034928284,0.00002452669,0.00015370801,0.01082447],"study_design_scores_gemma":[0.0022444543,0.0009897522,0.994672,0.00020196273,0.0004113989,0.00001772272,0.0001487079,0.00014699718,0.00005458489,0.0006068285,0.00043614613,0.00006946881],"about_ca_topic_score_codex":0.000093538176,"about_ca_topic_score_gemma":0.000067582616,"teacher_disagreement_score":0.013984476,"about_ca_system_score_codex":0.00023177081,"about_ca_system_score_gemma":0.00020298276,"threshold_uncertainty_score":0.3201555},"labels":[],"label_agreement":null},{"id":"W2570478176","doi":"10.1016/j.jtho.2016.11.382","title":"MA02.01 Extracellular Vescicle miRNAs Regulate Gene Expression in Local Lung Adenocarcinoma Endothelial Cells","year":2017,"lang":"it","type":"article","venue":"Journal of Thoracic Oncology","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Microvesicles; Extracellular; Extracellular vesicle; Cell biology; microRNA; Biology; Vesicle; Angiogenesis; Cancer research; Biochemistry; Gene","score_opus":0.014949999274855588,"score_gpt":0.3417391614588079,"score_spread":0.3267891621839523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570478176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9559218,0.031619854,0.0065643336,0.0012202595,0.0033224374,0.00045517064,0.00010247343,0.0000079249385,0.00078572537],"genre_scores_gemma":[0.98395896,0.0019695533,0.0077883215,0.00014894192,0.002277922,0.000009520483,0.000020981937,0.00011641801,0.0037093584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99459845,0.001117424,0.0018051292,0.0008304698,0.00062824314,0.0010202901],"domain_scores_gemma":[0.9941172,0.0000998125,0.0029664622,0.0017761199,0.00033651007,0.00070392055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002251618,0.0006140779,0.0011037755,0.00029737005,0.00043735877,0.00020183605,0.0021318984,0.0012570567,0.00026762413],"category_scores_gemma":[0.00037950327,0.0006057333,0.0006769379,0.00010862059,0.00094028795,0.00008575656,0.0009019827,0.0011868984,0.000059711474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049934764,0.0010927905,0.00605031,0.00017986071,0.00018742052,0.005839602,0.00026097166,0.00067123637,0.94957197,0.000014203715,0.003562116,0.027576037],"study_design_scores_gemma":[0.0028199677,0.0016490784,0.009896728,0.000404165,0.0003774833,0.0011161014,0.00032541095,0.0010342541,0.94849133,0.00027488652,0.03300066,0.00060991384],"about_ca_topic_score_codex":0.00002991394,"about_ca_topic_score_gemma":0.000043834418,"teacher_disagreement_score":0.029650303,"about_ca_system_score_codex":0.00049733574,"about_ca_system_score_gemma":0.0011556108,"threshold_uncertainty_score":0.9996394},"labels":[],"label_agreement":null},{"id":"W2570509192","doi":"10.1016/j.jtho.2016.11.384","title":"MA02.03 Expression of Oncofetal miRNAs Inactivates NFIB, a Developmental Transcription Factor Linked to Tumor Aggressiveness in Lung Adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of British Columbia; Vancouver General Hospital; Princess Margaret Cancer Centre; Occupational Cancer Research Centre","funders":"","keywords":"microRNA; Adenocarcinoma; Cancer research; Lung cancer; Biology; Medicine; Transcription factor; Context (archaeology); Cancer; Oncofetal antigen; Pathology; Gene; Genetics; Immunotherapy","score_opus":0.022431444496714557,"score_gpt":0.3647797494040955,"score_spread":0.34234830490738094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570509192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978051,0.0007892101,0.00033922307,0.00027854464,0.0004013272,0.00023822357,0.000018777873,0.000002555642,0.00012703701],"genre_scores_gemma":[0.99625415,0.000043287106,0.003338541,0.000048615137,0.00022413752,0.000009727335,0.000012841802,0.000020201176,0.00004851052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855673,0.00020198629,0.0006066495,0.0002206246,0.00019755217,0.00021648184],"domain_scores_gemma":[0.99832886,0.00003083057,0.001057803,0.000240774,0.00019602945,0.00014568161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033226926,0.00016794702,0.0003939801,0.00019103184,0.000095462725,0.000024648798,0.00042233485,0.00021742794,0.000040916846],"category_scores_gemma":[0.00031892562,0.00014996243,0.0001467708,0.00005751672,0.00009152554,0.000036084937,0.000100650745,0.00018467059,0.0000028291158],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023282554,0.00021938296,0.041526843,0.00008553377,0.000044276432,0.00009516208,0.00029169765,0.00003706291,0.94575226,0.0000015632895,0.00016869867,0.009449267],"study_design_scores_gemma":[0.0005932222,0.00041800554,0.39343926,0.00025861993,0.000026121188,0.00014427122,0.00015583845,0.0000105990175,0.60369295,0.000019867295,0.0011309693,0.000110286186],"about_ca_topic_score_codex":0.000015094915,"about_ca_topic_score_gemma":0.000040008836,"teacher_disagreement_score":0.3519124,"about_ca_system_score_codex":0.00025987948,"about_ca_system_score_gemma":0.00045228284,"threshold_uncertainty_score":0.61152905},"labels":[],"label_agreement":null},{"id":"W2570636359","doi":"10.1016/j.jtho.2016.11.1253","title":"P2.03a-044 Severe Adverse Events Impact Overall Survival (OS) and Costs in Elderly Patients with Advanced NSCLC on Second-Line Therapy","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Anemia; Cancer; Lung cancer; Confounding","score_opus":0.02613751416812625,"score_gpt":0.3458345473447551,"score_spread":0.31969703317662884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570636359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98613375,0.0005715089,0.000045107987,0.00069468346,0.0010056038,0.00026601655,0.0001284896,0.0000049333858,0.011149919],"genre_scores_gemma":[0.9977231,0.0009055687,0.00035639052,0.0003833225,0.00021801866,0.0000049563687,0.000005203483,0.000032267093,0.0003711491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832207,0.000050542418,0.0008590847,0.00030286668,0.00006917536,0.00039624886],"domain_scores_gemma":[0.9969994,0.00011829328,0.0021828997,0.00036872143,0.00012356995,0.00020713366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082956976,0.0002567957,0.00096686074,0.00030021928,0.00014682113,0.00004422161,0.00040015765,0.00021994847,0.0003217378],"category_scores_gemma":[0.00020808064,0.00022077176,0.00015624518,0.000054942622,0.00009986684,0.0010327848,0.00005518192,0.00048700435,0.00003528168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009206681,0.0005874361,0.7578257,0.000016432388,0.00018567815,0.000056940735,0.00027728136,0.00030084504,0.000010897717,0.0007875332,0.00037953866,0.2303651],"study_design_scores_gemma":[0.0065636835,0.005775387,0.9718091,0.000109614244,0.00000992105,0.000023323886,0.000036956593,0.000040823215,0.000019714798,0.002811111,0.012512745,0.0002876475],"about_ca_topic_score_codex":0.00011714212,"about_ca_topic_score_gemma":0.00037808705,"teacher_disagreement_score":0.23007745,"about_ca_system_score_codex":0.00076038606,"about_ca_system_score_gemma":0.00018927593,"threshold_uncertainty_score":0.90028113},"labels":[],"label_agreement":null},{"id":"W2570652997","doi":"10.1016/j.jtho.2016.11.886","title":"P1.06-022 Clinical Characteristics of Survival Outliers in Stage IV Adenocarcinoma Lung Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adenocarcinoma; Lung cancer; Internal medicine; Stage (stratigraphy); Survival analysis; Survival rate; Overdiagnosis; Cancer; Oncology; Disease; Carcinoma","score_opus":0.048994167802714636,"score_gpt":0.5144322426180289,"score_spread":0.46543807481531424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570652997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368405,0.0003870927,0.000030669926,0.0015984064,0.0022634864,0.00024484296,0.00006332311,0.0000032997275,0.0017247999],"genre_scores_gemma":[0.99708575,0.0004178021,0.00055281783,0.00017352888,0.00044028184,0.0000068247914,0.000013285838,0.000017159944,0.0012925446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982045,0.00016223323,0.0010105468,0.00014444238,0.0002722013,0.00020606222],"domain_scores_gemma":[0.9972772,0.00014838249,0.0017367224,0.00027309934,0.00038424338,0.00018034111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006969685,0.000121562036,0.00084360107,0.00015006882,0.000083160885,0.000014785745,0.00020881376,0.0001666675,0.00011817157],"category_scores_gemma":[0.00046781776,0.00009340068,0.00018056176,0.000052849307,0.00016335827,0.00014248614,0.00006158083,0.00042539847,0.0000027982792],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011717529,0.0009576406,0.9379323,0.00009521519,0.00032706966,0.00028153587,0.00053977745,0.0000027931505,0.00003672544,0.00001698874,0.0005792614,0.058058936],"study_design_scores_gemma":[0.003076521,0.0015379523,0.9864159,0.00019304571,0.0007013167,0.000018849289,0.00020465012,0.000060851387,0.00003885755,0.00001489263,0.0076645156,0.00007262482],"about_ca_topic_score_codex":0.000109897075,"about_ca_topic_score_gemma":0.00010612514,"teacher_disagreement_score":0.05798631,"about_ca_system_score_codex":0.00054551626,"about_ca_system_score_gemma":0.0010237665,"threshold_uncertainty_score":0.3808769},"labels":[],"label_agreement":null},{"id":"W2570763243","doi":"10.1016/j.jtho.2016.11.1067","title":"P2.01-015 Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"microRNA; Gene; Epigenetics; Copy-number variation; Adenocarcinoma; Biology; Gene expression; Genetics; Gene expression profiling; Cancer research; Cancer; Genome","score_opus":0.015068465715322882,"score_gpt":0.376349046602108,"score_spread":0.3612805808867851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570763243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891834,0.0026078601,0.0066096,0.00027742435,0.0005472598,0.00036201157,0.000010681961,0.0000020520151,0.00039970042],"genre_scores_gemma":[0.9969541,0.0005147353,0.002069756,0.000038898754,0.00018381569,0.000017668302,0.000011532393,0.000027094566,0.0001824243],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823093,0.000340439,0.00065115106,0.00022167953,0.0002798884,0.00027593726],"domain_scores_gemma":[0.99787384,0.00008858477,0.0010094132,0.00048704154,0.00042040698,0.00012068731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044921716,0.00016592209,0.00051384413,0.0001607057,0.00007592591,0.000023111796,0.00062187406,0.0003147218,0.00005062799],"category_scores_gemma":[0.00069615076,0.0001540909,0.00020143461,0.000080463775,0.00021383505,0.000015432603,0.00025552424,0.00032829653,0.000002282281],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008712599,0.00034773076,0.015079997,0.00028292867,0.00024092617,0.00012289666,0.00010898932,0.000060068876,0.97596025,0.000022630824,0.0010460439,0.0058562714],"study_design_scores_gemma":[0.001268276,0.0010771443,0.031224007,0.0002213421,0.0001759814,0.00014402723,0.0000418053,0.00011323265,0.96446145,0.00017639344,0.0009642779,0.00013208602],"about_ca_topic_score_codex":0.000057113626,"about_ca_topic_score_gemma":0.0001668579,"teacher_disagreement_score":0.016144011,"about_ca_system_score_codex":0.00007786288,"about_ca_system_score_gemma":0.0006757646,"threshold_uncertainty_score":0.62836444},"labels":[],"label_agreement":null},{"id":"W2570785609","doi":"10.1016/j.jtho.2016.11.006","title":"PL03.03: Randomized Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Pemetrexed; Medicine; T790M; Internal medicine; Oncology; Carboplatin; Erlotinib; Chemotherapy; Cisplatin; Epidermal growth factor receptor; Gefitinib; Cancer","score_opus":0.029999989005579823,"score_gpt":0.4933886263280734,"score_spread":0.4633886373224936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570785609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876845,0.00057808764,0.0018799008,0.0021169821,0.0009706836,0.0027141252,0.00004405407,0.000011919548,0.003999739],"genre_scores_gemma":[0.99143326,0.00007375437,0.0068165096,0.00017925719,0.00034151736,0.000116227784,0.000015811962,0.000028008923,0.0009956763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978847,0.00019251934,0.0011438356,0.00021103933,0.00031033478,0.00025758863],"domain_scores_gemma":[0.9950496,0.00093334354,0.0026293187,0.00037633235,0.000817871,0.00019356649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010505283,0.0002113068,0.0018155251,0.000247087,0.00028123704,0.000022417938,0.00023688666,0.00012923259,0.000094390954],"category_scores_gemma":[0.0012411398,0.00014567353,0.00042193398,0.000087203254,0.0001890947,0.00023943643,0.000047584155,0.00026584254,0.0000038489147],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71741366,0.009915855,0.0013078171,0.0001025065,0.004622793,0.00039388385,0.006906625,0.000057378587,0.0054373224,0.00007631085,0.0012827528,0.2524831],"study_design_scores_gemma":[0.9342951,0.029905919,0.004333382,0.00051513733,0.009234229,0.00033036742,0.0048507815,0.00031467056,0.011131761,0.00048495448,0.0043639694,0.000239686],"about_ca_topic_score_codex":0.000056086392,"about_ca_topic_score_gemma":0.000041210027,"teacher_disagreement_score":0.25224343,"about_ca_system_score_codex":0.00032113437,"about_ca_system_score_gemma":0.0005968966,"threshold_uncertainty_score":0.59403944},"labels":[],"label_agreement":null},{"id":"W2570847733","doi":"10.1016/j.jtho.2016.11.619","title":"P1.02-036 An EGFR Tyrosine Kinase Inhibitor Sensitive Patient-Derived Lung Cancer Xenograft Model without Classical Sensitizing Mutations","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; T790M; Cancer research; Exon; Medicine; Lung cancer; Tyrosine kinase; Molecular biology; Erlotinib Hydrochloride; Point mutation; Tyrosine-kinase inhibitor; Wild type; Osimertinib; Protein kinase domain; Gefitinib; Mutant; Epidermal growth factor receptor; Cancer; Oncology; Biology; Gene; Internal medicine; Genetics; Receptor","score_opus":0.029850153302110067,"score_gpt":0.4542525652315685,"score_spread":0.42440241192945843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570847733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831302,0.00034577667,0.0017061492,0.012007145,0.00095359486,0.00040915585,0.00007129047,0.000028608985,0.0013480646],"genre_scores_gemma":[0.9825724,0.00008611781,0.015111922,0.0008783002,0.00087572454,0.000020540461,0.000033924134,0.000041620762,0.0003794892],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982925,0.00015661902,0.0005994762,0.0002622531,0.0003434385,0.00034571768],"domain_scores_gemma":[0.9972649,0.00008457067,0.0010099167,0.00036352518,0.00084054173,0.00043651005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023563842,0.00023334601,0.0006832044,0.00021523099,0.00056557363,0.000082605184,0.00011438477,0.00020219687,0.000030606505],"category_scores_gemma":[0.00018183867,0.00018286439,0.00020407086,0.00008339573,0.00027024595,0.0005260676,0.000063493724,0.00050084625,0.0000048675324],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008354775,0.0042932644,0.020075219,0.00030124237,0.00322806,0.009196325,0.023425464,0.008062514,0.40068537,0.00028487644,0.006832033,0.5152609],"study_design_scores_gemma":[0.03344087,0.025262058,0.21613686,0.0054632286,0.031619336,0.017197674,0.021026358,0.37383252,0.25114763,0.0015225186,0.020589959,0.0027609554],"about_ca_topic_score_codex":0.000118371,"about_ca_topic_score_gemma":0.00025316575,"teacher_disagreement_score":0.5124999,"about_ca_system_score_codex":0.0010273636,"about_ca_system_score_gemma":0.0013219606,"threshold_uncertainty_score":0.74569935},"labels":[],"label_agreement":null},{"id":"W2570860829","doi":"10.1016/j.jtho.2016.11.1289","title":"P2.03b-008 The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Cohort; Internal medicine; Brain metastasis; Disease; Quality of life (healthcare); Cancer; Stage (stratigraphy); Metastasis","score_opus":0.034841824826755526,"score_gpt":0.5079073517794082,"score_spread":0.47306552695265264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570860829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99114615,0.002807983,0.000015245838,0.0051914398,0.00011312494,0.000393255,0.0001371594,0.0000013126039,0.00019434752],"genre_scores_gemma":[0.9990772,0.00057736074,0.00012615012,0.00014773493,0.000029314711,0.000009586301,0.000006425944,0.000007908477,0.000018334722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895567,0.00023840633,0.00043359536,0.0001006597,0.00013058778,0.00014106419],"domain_scores_gemma":[0.9983236,0.00018559616,0.0009976557,0.00023904334,0.00015415669,0.00009990296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041814323,0.00012081306,0.00060600834,0.00011651403,0.000077624274,0.0000071085105,0.000094742085,0.000045726836,0.00002411331],"category_scores_gemma":[0.00015412373,0.000056689496,0.00016569809,0.00005211831,0.0001481459,0.00006465882,0.000022338849,0.00011513003,1.1664999e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028456468,0.0028656337,0.6601196,0.00012275943,0.0015801986,0.00007182161,0.004150922,0.00010943508,0.000884524,0.000025517145,0.0010112914,0.32621264],"study_design_scores_gemma":[0.0029203235,0.0083600925,0.9833046,0.00031822946,0.00031987278,0.000036775567,0.0001775979,0.00008718794,0.0039944565,0.00018494851,0.0002513851,0.00004452218],"about_ca_topic_score_codex":0.002608082,"about_ca_topic_score_gemma":0.0005608027,"teacher_disagreement_score":0.32616812,"about_ca_system_score_codex":0.0006265863,"about_ca_system_score_gemma":0.0010318799,"threshold_uncertainty_score":0.39426574},"labels":[],"label_agreement":null},{"id":"W2570887191","doi":"10.1016/j.jtho.2016.11.1593","title":"P3.01-027 3D Telomere Nuclear Organization to Distinguish Multiple Synchronous Lung Adenocarcinoma from Metastatic Lung Adenocarcinoma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Lung; Telomere; Adenocarcinoma; Lung cancer; Lesion; Cancer; Fluorescence in situ hybridization; Genome instability; Oncology; Pathology; Radiology; Internal medicine; Gene; DNA damage; Biology","score_opus":0.016472427107066208,"score_gpt":0.34888109180419935,"score_spread":0.33240866469713315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570887191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883039,0.0027051326,0.0058746967,0.0013839677,0.00088390836,0.00024661017,0.000057297366,0.0000111075715,0.000533372],"genre_scores_gemma":[0.9859818,0.00015794701,0.011986917,0.00036942726,0.0011195383,0.000007819569,0.00004924984,0.000060555376,0.00026669676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983208,0.0001786476,0.00059431,0.00036867568,0.00022248815,0.0003150824],"domain_scores_gemma":[0.9974309,0.00006460582,0.0009896648,0.00073012034,0.0005340947,0.00025058066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037685246,0.00022256917,0.0004457445,0.00010801954,0.0004650224,0.00014571322,0.0008092271,0.00020765243,0.00022325045],"category_scores_gemma":[0.0012657671,0.0002058108,0.00013365441,0.000103483355,0.00011907133,0.000030595438,0.00025678644,0.00026253422,0.00003238261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018825473,0.00082941586,0.4587457,0.00017494602,0.0012878011,0.0005375113,0.0017054012,0.00071093405,0.38364384,0.00009712759,0.042986024,0.10739876],"study_design_scores_gemma":[0.002138831,0.0023923384,0.8959908,0.0001866517,0.0011419741,0.00084506866,0.001190082,0.0022823985,0.028360667,0.00010670155,0.06449851,0.00086598773],"about_ca_topic_score_codex":0.000117041614,"about_ca_topic_score_gemma":0.00009183865,"teacher_disagreement_score":0.4372451,"about_ca_system_score_codex":0.00023663157,"about_ca_system_score_gemma":0.00035888745,"threshold_uncertainty_score":0.8392721},"labels":[],"label_agreement":null},{"id":"W2570930368","doi":"10.1016/j.jtho.2016.11.318","title":"OA16.01 The Role of Patient Groups in Integrating the Patient Voice into Drug Funding Decisions","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Medicine; Outreach; Government (linguistics); Agency (philosophy); Family medicine; Clinical trial; Focus group; Health care; Public health; Audit; Public relations; Nursing; Business; Political science; Internal medicine; Marketing","score_opus":0.03229709152736573,"score_gpt":0.3413315963126943,"score_spread":0.30903450478532857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570930368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97338885,0.0043896395,0.00028327986,0.0044274125,0.001454837,0.00016194415,0.000012792327,0.0000023629707,0.015878903],"genre_scores_gemma":[0.99779654,0.00055678625,0.0009789842,0.0003634914,0.00023626859,0.000008108032,4.2698647e-7,0.000014261928,0.00004512843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802786,0.000078335615,0.0014020321,0.00016161098,0.000060178852,0.00026996565],"domain_scores_gemma":[0.9952553,0.0005844045,0.003515512,0.00046139376,0.0001039899,0.0000794315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019789538,0.00013525151,0.0005983844,0.00020145996,0.00037280231,0.00009566546,0.0008395268,0.000111896225,0.00006334939],"category_scores_gemma":[0.0019576638,0.000088311164,0.00021184489,0.00009671714,0.00021221802,0.00045854523,0.00022025402,0.0005632685,0.000030814466],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037466962,0.00025351418,0.09329057,0.000011234173,0.00009335086,0.00002049966,0.016320847,0.0004185073,0.000085750486,0.034750674,0.0012767573,0.85310364],"study_design_scores_gemma":[0.00084506586,0.0015461957,0.14959107,0.0004003096,0.000054075896,0.0001140484,0.01815846,0.0017861576,0.000984338,0.36812046,0.45799118,0.0004086149],"about_ca_topic_score_codex":0.0007653858,"about_ca_topic_score_gemma":0.0013880441,"teacher_disagreement_score":0.852695,"about_ca_system_score_codex":0.00043118795,"about_ca_system_score_gemma":0.00014208736,"threshold_uncertainty_score":0.3601225},"labels":[],"label_agreement":null},{"id":"W2570953391","doi":"10.1016/j.jtho.2016.11.1193","title":"P2.02-046 Prognostic Value of Early Tumor Regression during Chemo-Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Adenocarcinoma; Radiation therapy; Lung cancer; Stage (stratigraphy); Proportional hazards model; Retrospective cohort study; Survival analysis; Cancer; Radiology; Internal medicine; Oncology; Surgery","score_opus":0.013673639511436743,"score_gpt":0.39736532481851156,"score_spread":0.3836916853070748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570953391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99051195,0.0049777813,0.0000527763,0.0025284793,0.0007177543,0.00057756255,0.000004271412,0.0000064898036,0.0006229138],"genre_scores_gemma":[0.99197954,0.0022976217,0.0047798627,0.0001552024,0.00042360366,0.000049877686,8.022925e-7,0.000034626788,0.0002788534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983464,0.00008810808,0.00071675587,0.00023347621,0.000291834,0.00032344388],"domain_scores_gemma":[0.9974857,0.00013147549,0.0015440546,0.00038411908,0.0002618943,0.00019274678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041173378,0.00021175774,0.0009381595,0.00020476762,0.000098028824,0.000020742093,0.0002837412,0.00014647019,0.000066811204],"category_scores_gemma":[0.00010750603,0.00014955434,0.00020322212,0.00008982779,0.0000984079,0.0001663006,0.00005711967,0.00043744524,0.000001673352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050894385,0.0014003342,0.91797024,0.0009657737,0.0002622461,0.0021464722,0.0010109902,0.00035338706,0.028825514,0.0000037656835,0.00023516307,0.04173667],"study_design_scores_gemma":[0.0068079196,0.00347257,0.90565854,0.0049290396,0.00045544934,0.0003134747,0.00009943971,0.00031892653,0.07734638,0.000024318779,0.0004199024,0.00015404071],"about_ca_topic_score_codex":0.00018777644,"about_ca_topic_score_gemma":0.00013411214,"teacher_disagreement_score":0.048520863,"about_ca_system_score_codex":0.0014311546,"about_ca_system_score_gemma":0.0009789682,"threshold_uncertainty_score":0.6098649},"labels":[],"label_agreement":null},{"id":"W2570957508","doi":"10.1016/j.jtho.2016.11.1868","title":"P3.02c-073 Evidence Suggesting a Dichotomous “Present vs absent” Determinant of PDL1 Inhibitor Efficacy in Non-Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Cancer","score_opus":0.03564783153842322,"score_gpt":0.4638598057751654,"score_spread":0.4282119742367422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570957508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990091,0.00348141,0.00008892759,0.0034096038,0.00106614,0.0005913284,0.000007692011,0.000006698209,0.001257185],"genre_scores_gemma":[0.9949533,0.0008818589,0.0024928947,0.00012816874,0.0007247355,0.000031910684,0.0000012023863,0.000025738076,0.0007602089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809253,0.00011456886,0.0008848643,0.00023170943,0.00032563254,0.00035071617],"domain_scores_gemma":[0.9969013,0.0004296383,0.0016383526,0.000406912,0.00039156762,0.00023228159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006360991,0.00019726543,0.0008114318,0.00026553601,0.00013073266,0.000033653527,0.0003240056,0.0001660199,0.00006300948],"category_scores_gemma":[0.00046796165,0.00014710524,0.00021031516,0.000113759,0.00013905445,0.00023206793,0.00011599459,0.00047571294,0.000004488677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067597465,0.0037111451,0.4605598,0.0017239618,0.0005689251,0.0075242915,0.008668416,0.0006213302,0.057448953,0.0000035460464,0.0025407975,0.4498691],"study_design_scores_gemma":[0.009896319,0.0067404527,0.9040656,0.012920679,0.0032786096,0.0015028734,0.00079038506,0.0022548637,0.052060757,0.000031135296,0.0060175974,0.00044069096],"about_ca_topic_score_codex":0.0008528662,"about_ca_topic_score_gemma":0.0003747158,"teacher_disagreement_score":0.4494284,"about_ca_system_score_codex":0.00081287674,"about_ca_system_score_gemma":0.0014924266,"threshold_uncertainty_score":0.5998777},"labels":[],"label_agreement":null},{"id":"W2571040977","doi":"10.1016/j.jtho.2016.11.785","title":"P1.05-001 Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); microRNA; Oncology; Cancer; Pathology; Internal medicine; Computational biology; Cancer research; Biology; Gene","score_opus":0.011157043869860784,"score_gpt":0.33764397219544046,"score_spread":0.3264869283255797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571040977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335027,0.004111276,0.0010858537,0.0004876556,0.00027475556,0.0004356638,0.000027463757,0.000001994129,0.00022504108],"genre_scores_gemma":[0.9986943,0.00005382793,0.0006016343,0.000032744,0.00031100138,0.000011418987,0.000031679985,0.00001529656,0.00024812593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99901366,0.00015027978,0.00040929238,0.0001518006,0.00012747102,0.00014747877],"domain_scores_gemma":[0.99795073,0.00012350142,0.001268258,0.0002477057,0.00034129072,0.00006851091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000540392,0.00011512883,0.00022774472,0.00005180594,0.0001734648,0.000048095313,0.00024198047,0.00021183217,0.0000083518],"category_scores_gemma":[0.0004465046,0.00008760383,0.00010072156,0.000022979953,0.00016692361,0.000019631627,0.0000612056,0.00011760718,2.1777423e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009281894,0.00019746929,0.053617835,0.00018065373,0.000072576746,0.000007548664,0.000108060565,0.00007391922,0.92852384,0.000017721744,0.011913614,0.0043585477],"study_design_scores_gemma":[0.001459526,0.0015019391,0.19733617,0.000039131373,0.0005959763,0.00012170327,0.000082189275,0.00040787266,0.7904455,0.00018521711,0.007655713,0.00016907515],"about_ca_topic_score_codex":0.000015130408,"about_ca_topic_score_gemma":0.000005299952,"teacher_disagreement_score":0.14371833,"about_ca_system_score_codex":0.00004782858,"about_ca_system_score_gemma":0.00016750347,"threshold_uncertainty_score":0.35723808},"labels":[],"label_agreement":null},{"id":"W2571057783","doi":"10.1016/j.jtho.2016.11.846","title":"P1.05-061 Increased Treatment-Related Toxicity in Patients with Early-Stage Non-Small Cell Lung Cancer and Co-Existing Interstitial Lung Disease","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; London Health Sciences Centre","funders":"","keywords":"Medicine; SABR volatility model; Lung cancer; Radiation therapy; Stage (stratigraphy); Pulmonary toxicity; Interstitial lung disease; Toxicity; Surgery; Lung; Internal medicine","score_opus":0.01455867567338129,"score_gpt":0.35681372514236515,"score_spread":0.34225504946898383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571057783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961627,0.00059599377,0.000057387846,0.00048252844,0.00047773504,0.0005233179,0.00010711492,0.00001067873,0.001582552],"genre_scores_gemma":[0.9985484,0.00013651793,0.00024335319,0.00014052368,0.00030437036,0.000015195965,0.000018273031,0.00003227393,0.00056109804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983655,0.00013289796,0.00060988485,0.0002786855,0.00025073843,0.00036227633],"domain_scores_gemma":[0.9979014,0.00008704714,0.00095310295,0.0002870821,0.00021813548,0.00055327895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002948543,0.0002685746,0.00073885015,0.00022861378,0.00023955519,0.00006697149,0.0001968952,0.00016724848,0.00008630831],"category_scores_gemma":[0.00011496645,0.00019890691,0.0001777006,0.0000635123,0.00021612283,0.00029517958,0.00007724571,0.00042381327,0.0000017748542],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043927785,0.0013243576,0.9427725,0.00040698267,0.00024027843,0.0027092784,0.00048921886,0.000022127924,0.0004883225,0.0000064873307,0.00019477501,0.007417861],"study_design_scores_gemma":[0.0078765815,0.010367161,0.9751414,0.0018043746,0.0014148366,0.000056674366,0.0001424389,0.0020944725,0.00027142742,0.000009756344,0.0005602916,0.00026055556],"about_ca_topic_score_codex":0.0008585868,"about_ca_topic_score_gemma":0.00011186723,"teacher_disagreement_score":0.036051203,"about_ca_system_score_codex":0.00091331196,"about_ca_system_score_gemma":0.0007558556,"threshold_uncertainty_score":0.81111884},"labels":[],"label_agreement":null},{"id":"W2571097605","doi":"10.1016/j.jtho.2016.11.514","title":"MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Osimertinib; Medicine; Internal medicine; Oncology; T790M; Clinical trial; Population; Target lesion; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.05776611874330057,"score_gpt":0.5222276652436241,"score_spread":0.4644615465003235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571097605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98687124,0.00016864476,0.00028734846,0.010234066,0.00056960917,0.0008197533,0.0005043456,0.000007602154,0.00053738675],"genre_scores_gemma":[0.98909205,0.000015757272,0.009276417,0.0007103119,0.00031631606,0.000014242209,0.00014382135,0.000024347963,0.0004067155],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977234,0.0005652809,0.00084100245,0.00029323343,0.00032236663,0.00025470916],"domain_scores_gemma":[0.99653035,0.0006465358,0.0013538044,0.00080230494,0.00037848947,0.00028850176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015780613,0.00018365543,0.0010335719,0.0002510878,0.00022100066,0.000035827674,0.00042776385,0.000096308635,0.00015238998],"category_scores_gemma":[0.0025956386,0.00012183708,0.00009441668,0.00010450324,0.000075931835,0.00043923143,0.00017880012,0.00027206537,0.000015381947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3685036,0.0068544983,0.053621016,0.000014721155,0.001651141,0.0015350438,0.0026831925,0.000049515504,0.006279214,0.000006224175,0.002716638,0.5560852],"study_design_scores_gemma":[0.107977234,0.037601672,0.8071068,0.0012730706,0.004706888,0.00009568881,0.0006557446,0.0000560562,0.0037523198,0.00014497762,0.036292467,0.0003370735],"about_ca_topic_score_codex":0.00013336824,"about_ca_topic_score_gemma":0.00024152105,"teacher_disagreement_score":0.7534858,"about_ca_system_score_codex":0.00050729024,"about_ca_system_score_gemma":0.0010188252,"threshold_uncertainty_score":0.4968372},"labels":[{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"grok","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"opus","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2571125375","doi":"10.1016/j.jtho.2016.11.146","title":"MTE12.01 Clinically Relevant Signal Transduction Pathways","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"DNA damage; DNA repair; Cancer research; Autocrine signalling; Cell cycle; Cancer; Cancer cell; Cell cycle checkpoint; Medicine; Signal transduction; Lung cancer; Cell growth; Biology; Cell biology; DNA; Pathology; Cell culture; Genetics; Internal medicine","score_opus":0.051937804890367874,"score_gpt":0.4824144023932271,"score_spread":0.4304765975028592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571125375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392686,0.00056130276,0.0026893553,0.02808927,0.0026338005,0.0002849917,0.000011276619,0.000021137443,0.026440263],"genre_scores_gemma":[0.9884411,0.00033941338,0.008640549,0.0004459064,0.0011433322,0.0000041741014,0.0000032781145,0.0000140773045,0.0009681767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881166,0.00007953324,0.0006120674,0.00012094694,0.00021370998,0.00016210912],"domain_scores_gemma":[0.9983109,0.00010061131,0.00087998837,0.0002507111,0.00027115727,0.00018663528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063466525,0.00009696317,0.00043579523,0.00009095889,0.00021115228,0.000027904734,0.00014692095,0.00014895869,0.00039193442],"category_scores_gemma":[0.00021156209,0.000067634566,0.00023358133,0.000031472733,0.00012196287,0.00018623621,0.000016639202,0.00036289336,0.000027743648],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041589714,0.0011999409,0.008747465,0.00006941758,0.0006702589,0.0017014855,0.0011491189,0.000020563513,0.012780242,0.0001515188,0.0043757283,0.9649753],"study_design_scores_gemma":[0.013281146,0.037166588,0.33176455,0.0009740482,0.007962397,0.014441703,0.0019571928,0.00026850763,0.011271357,0.008507528,0.571893,0.0005120143],"about_ca_topic_score_codex":0.000011156326,"about_ca_topic_score_gemma":0.000009953657,"teacher_disagreement_score":0.9644633,"about_ca_system_score_codex":0.00027439705,"about_ca_system_score_gemma":0.00084602274,"threshold_uncertainty_score":0.4291407},"labels":[],"label_agreement":null},{"id":"W2571163914","doi":"10.1016/j.jtho.2016.11.340","title":"OA19.05 High Oncofetal Chondroitin Sulfate Expression is an Independent Prognostic Factor of Poor Survival in Early-Stage NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Oncofetal antigen; Medicine; Immunohistochemistry; Stage (stratigraphy); Cancer; Tissue microarray; Cancer research; Oncology; Internal medicine; Pathology; Biology; Immunotherapy","score_opus":0.03829389505454253,"score_gpt":0.4056784001397854,"score_spread":0.3673845050852429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571163914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745977,0.000097754004,0.0003238812,0.00067897,0.00052541256,0.00026903616,0.0000509911,0.0000030338317,0.00059112685],"genre_scores_gemma":[0.9973779,0.0000805627,0.0010707477,0.000053120828,0.00030755365,0.0000074741965,0.000016297829,0.000023018167,0.0010633318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782056,0.00041358548,0.0006694523,0.00027932337,0.00047843906,0.00033863372],"domain_scores_gemma":[0.9978837,0.000046524314,0.0009797715,0.00047845388,0.00039251745,0.0002190303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009591817,0.00017617496,0.00045638112,0.00021041786,0.00012015947,0.0000584115,0.0006971799,0.00037833824,0.0002140472],"category_scores_gemma":[0.00061333575,0.00014757045,0.00015183493,0.000063820524,0.00015908461,0.000046623023,0.00025679052,0.00047360908,0.000009368692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002905765,0.00066341844,0.07040077,0.000059054742,0.0000643014,0.000302096,0.00027912811,0.000030230565,0.89478266,0.000020677473,0.00024036791,0.030251538],"study_design_scores_gemma":[0.0018963545,0.0037293492,0.3928724,0.00010241706,0.000021530544,0.00009322839,0.00021709903,0.000056380937,0.5934003,0.00009033864,0.0073186755,0.00020191607],"about_ca_topic_score_codex":0.00019048982,"about_ca_topic_score_gemma":0.0003585496,"teacher_disagreement_score":0.32247162,"about_ca_system_score_codex":0.000076638156,"about_ca_system_score_gemma":0.00043853113,"threshold_uncertainty_score":0.6017748},"labels":[],"label_agreement":null},{"id":"W2571231086","doi":"10.1016/j.jtho.2016.11.1527","title":"P2.06-034 METIS: A Phase 3 Study of Radiosurgery with TTFields for 1-10 Brain Metastases from NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiosurgery; Neurocognitive; Internal medicine; Oncology; Lung cancer; Clinical endpoint; Adverse effect; Clinical trial; Radiation therapy","score_opus":0.05523166883416413,"score_gpt":0.4564823163951067,"score_spread":0.4012506475609426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571231086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908595,0.00069239264,0.0002800725,0.006863113,0.00032919392,0.0006129531,0.00006612999,0.0000065575664,0.000290095],"genre_scores_gemma":[0.993598,0.0000394383,0.005515011,0.00024263114,0.0003719258,0.000045661323,0.000012745815,0.000022328768,0.0001522887],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983645,0.00020634473,0.00069516647,0.00019659458,0.00031653245,0.00022086782],"domain_scores_gemma":[0.99619544,0.0011727214,0.0015369594,0.00048220716,0.0004072111,0.00020546338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009495074,0.00018743468,0.0012397816,0.00019924442,0.00014059329,0.00003123417,0.00021597258,0.0001220307,0.00028109265],"category_scores_gemma":[0.0008191308,0.000118704265,0.0002748374,0.00007064889,0.00010349916,0.00015833498,0.00004407758,0.00020351274,0.0000049952937],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04380213,0.0582108,0.14289561,0.00021130801,0.01320856,0.01158453,0.0027733508,0.000027274562,0.012198222,0.000054633656,0.10329872,0.61173487],"study_design_scores_gemma":[0.16727483,0.2373794,0.24612297,0.002321994,0.036180288,0.0055618268,0.015721278,0.00026307622,0.09335333,0.0011971834,0.19348675,0.001137081],"about_ca_topic_score_codex":0.00010614429,"about_ca_topic_score_gemma":0.00012427631,"teacher_disagreement_score":0.6105978,"about_ca_system_score_codex":0.00010767512,"about_ca_system_score_gemma":0.00034002351,"threshold_uncertainty_score":0.48406196},"labels":[],"label_agreement":null},{"id":"W2571237858","doi":"10.1016/j.jtho.2016.11.1687","title":"P3.02b-020 Gender and Ethnicity Influence on Outcome in EGFRmut+ NSCLC Patients Treated at a Single Canadian Institution","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Red Cross Society; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Ethnic group; Demography; Cohort; Statistical significance; Oncology; Retrospective cohort study; Adenocarcinoma; Cancer","score_opus":0.05802074750904134,"score_gpt":0.45492069164079807,"score_spread":0.3968999441317567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571237858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98725075,0.00009703949,0.0000043202854,0.0016491467,0.00029663317,0.00020841295,0.000013104137,0.0000041399944,0.010476478],"genre_scores_gemma":[0.99856967,0.00003304687,0.00023211657,0.0008257461,0.00007069828,0.00000441306,0.0000063400466,0.00000804423,0.000249953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991015,0.000063502084,0.00036014497,0.0001298584,0.00014927234,0.00019570584],"domain_scores_gemma":[0.9989176,0.00004176787,0.00040109418,0.00017773549,0.0001878119,0.00027400962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019346629,0.00010776514,0.00033220058,0.00024697784,0.0002127044,0.00002088964,0.000085947635,0.00014061312,0.000039582177],"category_scores_gemma":[0.0003331937,0.000080378486,0.000052330543,0.00005862,0.00010981131,0.00017709877,0.00002703278,0.00023756755,0.000013226272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082052447,0.000406506,0.95944357,0.000025650048,0.00008734292,0.00052033924,0.00064015476,0.000036741396,0.0004258809,0.000032201777,0.00019479982,0.037366316],"study_design_scores_gemma":[0.0021476166,0.0017786378,0.9906671,0.00010980895,0.00021266895,0.00015354832,0.000051386694,0.00001615845,0.00022069704,0.00005463835,0.0045180772,0.000069655376],"about_ca_topic_score_codex":0.009473124,"about_ca_topic_score_gemma":0.028936082,"teacher_disagreement_score":0.03729666,"about_ca_system_score_codex":0.002832914,"about_ca_system_score_gemma":0.0005387514,"threshold_uncertainty_score":0.9971229},"labels":[],"label_agreement":null},{"id":"W2571282285","doi":"10.1016/j.jtho.2016.11.1802","title":"P3.02c-007 Assessment of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Delmar (Canada)","funders":"","keywords":"Cisplatin; Medicine; Propidium iodide; Carboplatin; Oxaliplatin; Cytotoxicity; Cancer research; Lung cancer; Oncology; MTT assay; Context (archaeology); Chemotherapy; Cancer; Pharmacology; Apoptosis; Internal medicine; In vitro; Programmed cell death; Chemistry; Colorectal cancer; Biology; Biochemistry","score_opus":0.03400603725908536,"score_gpt":0.4911374968613661,"score_spread":0.45713145960228074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571282285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98328245,0.0011001108,0.000078328136,0.0027459972,0.00073014403,0.0005303356,0.000016780592,0.0000022203108,0.011513639],"genre_scores_gemma":[0.99304014,0.0029201526,0.002593005,0.0001001225,0.00026555939,0.00004098019,0.000003011382,0.000014105175,0.0010229084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870235,0.00013155663,0.0006227218,0.00012211896,0.00024527783,0.00017599195],"domain_scores_gemma":[0.9975325,0.00025639893,0.001505115,0.00040419897,0.00021330273,0.00008852678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039586824,0.00013835145,0.0006652207,0.00018619695,0.000086789485,0.00001092437,0.00021551731,0.0001283334,0.00013457272],"category_scores_gemma":[0.000043117798,0.000073149706,0.00019181284,0.00008469416,0.000100044075,0.000112413196,0.00001665734,0.00022524192,9.233421e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006139655,0.015648095,0.64980674,0.00076339615,0.002009971,0.0025468136,0.014466418,0.0002663861,0.011145484,0.000033326956,0.002740024,0.29443368],"study_design_scores_gemma":[0.012497415,0.027017953,0.8840544,0.00085294043,0.00497962,0.00033847534,0.0033392424,0.00051661883,0.009090002,0.000039688948,0.0570777,0.0001959389],"about_ca_topic_score_codex":0.0006895914,"about_ca_topic_score_gemma":0.0007152502,"teacher_disagreement_score":0.29423776,"about_ca_system_score_codex":0.00109836,"about_ca_system_score_gemma":0.0019655193,"threshold_uncertainty_score":0.34867468},"labels":[],"label_agreement":null},{"id":"W2571288365","doi":"10.1016/j.jtho.2016.11.854","title":"P1.05-069 Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Chemoradiotherapy; Proportional hazards model; Hazard ratio; Multivariate analysis; Logistic regression; Surgery; Performance status; Radiation therapy; Internal medicine; Chemotherapy; Confidence interval","score_opus":0.07498363541413251,"score_gpt":0.4377366872946163,"score_spread":0.3627530518804838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571288365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98834264,0.0002330375,0.00033512586,0.0043810233,0.0003553063,0.00037785637,0.000008003934,0.000010629369,0.0059563713],"genre_scores_gemma":[0.99025875,0.00012944665,0.0066985968,0.000053881628,0.00019515294,0.000019700607,0.0000052458836,0.000016371981,0.0026228502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984043,0.00006696296,0.00075244583,0.00021205949,0.0003499576,0.00021422522],"domain_scores_gemma":[0.9970996,0.000077553705,0.0018334183,0.0005151456,0.0002708931,0.00020338666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006540097,0.00019086822,0.0010691932,0.00015044458,0.00019718416,0.00001766746,0.00017010017,0.00018463118,0.000043602424],"category_scores_gemma":[0.00014226363,0.00010942897,0.00026698757,0.0000633239,0.00026719808,0.00018042685,0.00006328412,0.0002981133,0.0000027481199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004936544,0.0051096207,0.8967177,0.00023313578,0.0017048157,0.033418097,0.0005395863,0.00006133758,0.00021177782,0.000085017215,0.0005935762,0.05638877],"study_design_scores_gemma":[0.015754892,0.014031692,0.9003029,0.0010467225,0.0028163667,0.020059768,0.00046873867,0.00016881009,0.008308297,0.00001312174,0.036764916,0.00026378594],"about_ca_topic_score_codex":0.00013791372,"about_ca_topic_score_gemma":0.00009092462,"teacher_disagreement_score":0.056124985,"about_ca_system_score_codex":0.0006324382,"about_ca_system_score_gemma":0.00070567394,"threshold_uncertainty_score":0.4462384},"labels":[],"label_agreement":null},{"id":"W2571308635","doi":"10.1016/j.jtho.2016.11.927","title":"P1.07-016 Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Stage (stratigraphy); Contraindication; Cancer; Logistic regression; Lung cancer; Medicaid; Pneumonectomy; Demographics; Surgery; Internal medicine; Pathology; Health care","score_opus":0.10757032847245042,"score_gpt":0.508546255502176,"score_spread":0.4009759270297256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571308635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98112464,0.0057342174,0.000013219098,0.0111767445,0.00023361937,0.00019149153,0.000026514468,0.0000017166005,0.0014978554],"genre_scores_gemma":[0.97806907,0.020486705,0.00022686324,0.00011534795,0.00021350992,0.000014048597,6.5458363e-7,0.000011425147,0.00086237356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984001,0.00037932844,0.00053789455,0.00012290975,0.00033280978,0.00022698582],"domain_scores_gemma":[0.9965473,0.0014536879,0.0013213649,0.0003280155,0.0002614507,0.00008820249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012885482,0.000122024656,0.0007384607,0.0002543706,0.000074324766,0.000018295048,0.0001822607,0.00008367444,0.000061109335],"category_scores_gemma":[0.00038571842,0.00007008045,0.00014012241,0.00007629403,0.00019339575,0.00016608162,0.00005120174,0.00026778347,4.7186012e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004485733,0.0015983462,0.8586938,0.0005655252,0.0006370639,0.0013368417,0.0074411305,0.000006094395,0.00069590076,0.0000073772217,0.0013455284,0.12318666],"study_design_scores_gemma":[0.0020834936,0.004550343,0.9694652,0.00043838006,0.000842967,0.00018129512,0.0030854186,0.000015335007,0.0024011675,0.000014685945,0.016837757,0.00008397596],"about_ca_topic_score_codex":0.0032467558,"about_ca_topic_score_gemma":0.0018131267,"teacher_disagreement_score":0.12310269,"about_ca_system_score_codex":0.0004658715,"about_ca_system_score_gemma":0.0006862588,"threshold_uncertainty_score":0.4908145},"labels":[],"label_agreement":null},{"id":"W2571316201","doi":"10.1016/j.jtho.2016.11.2056","title":"PUB086 Concurrent Loss of Tumour Suppressors LKB1 and BRG1 Contribute to Epigenetic Dysregulation in NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Epigenetics; Cancer research; ARID1A; Chromatin remodeling; Lung cancer; Cancer; Acetylation; Histone; Suppressor; Stathmin; Tumor suppressor gene; Biology; Medicine; Genetics; Phosphorylation; Gene; Mutation; Carcinogenesis; Oncology","score_opus":0.018111969190220463,"score_gpt":0.389723865352014,"score_spread":0.3716118961617935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571316201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463195,0.0015400108,0.0018190156,0.0012702076,0.00043877919,0.00011162837,0.000014067609,0.0000011871298,0.0001731417],"genre_scores_gemma":[0.9985653,0.00032539864,0.000695946,0.00007533077,0.0002338013,0.0000029420526,0.0000046290043,0.000009215326,0.00008742578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989788,0.00011181466,0.0004660296,0.0001481937,0.00012531554,0.00016987334],"domain_scores_gemma":[0.9987991,0.00002924974,0.00062879705,0.00021031623,0.0002269878,0.000105565414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006160149,0.00010061647,0.000335583,0.00007539506,0.000056573062,0.000021244172,0.00023977582,0.00015074335,0.000010377198],"category_scores_gemma":[0.00032624582,0.00008932031,0.00007437284,0.000028695189,0.000108604276,0.0000084239855,0.0001103973,0.00012404061,9.422406e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096579955,0.0002083393,0.02196764,0.000097523756,0.00010075298,0.000050692473,0.00029320104,0.0019754579,0.7886839,0.00004062025,0.0011588966,0.18445717],"study_design_scores_gemma":[0.003492238,0.0032217433,0.39085877,0.0004661763,0.00017307718,0.0005371953,0.00022866856,0.0013611024,0.5784157,0.00075188815,0.020087795,0.0004056701],"about_ca_topic_score_codex":0.000023581582,"about_ca_topic_score_gemma":0.00010879945,"teacher_disagreement_score":0.36889112,"about_ca_system_score_codex":0.000050107432,"about_ca_system_score_gemma":0.0001794212,"threshold_uncertainty_score":0.36423764},"labels":[],"label_agreement":null},{"id":"W2571360934","doi":"10.1016/j.jtho.2016.11.389","title":"MA03.01 Gender Disparities in Non-Small Cell Lung Cancer: A Systematic Review","year":2017,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Systematic review; MEDLINE; Incidence (geometry); Cochrane Library; Epidemiology; Etiology; Meta-analysis; Cancer; Disease; Demography; Internal medicine","score_opus":0.05211150806487626,"score_gpt":0.4291973350105136,"score_spread":0.37708582694563736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571360934","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011541524,0.9968324,0.00012359295,0.00015362953,0.00094135443,0.0012720088,0.00006350427,0.0000027539725,0.000495349],"genre_scores_gemma":[0.00021452198,0.9973227,0.00036163762,0.00037189305,0.0005202961,0.00018062971,0.000042820157,0.000063743035,0.0009217858],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964099,0.00073004095,0.0018969987,0.00033713423,0.00020942971,0.0004165213],"domain_scores_gemma":[0.9966079,0.0000890379,0.0023185017,0.00064564485,0.00015823582,0.00018069723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014071744,0.0004919397,0.0041790833,0.00020492231,0.00008060909,0.000041644384,0.00093300204,0.00070996425,0.000046030087],"category_scores_gemma":[0.0001289197,0.0003562551,0.0011660871,0.00009589212,0.00008058904,0.000008861135,0.00012041505,0.00077529356,0.0000090704125],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044500608,0.00013863355,0.00002348823,0.93007064,0.0004586662,0.00040989878,0.000028522632,0.000002284449,0.000033840897,0.0000021020878,0.002887493,0.06589993],"study_design_scores_gemma":[0.00029727403,0.00044245008,0.000010869613,0.43800345,0.008212809,0.0017158221,0.000015584526,0.0000041688954,0.000021947775,0.0000071324953,0.55079013,0.00047836112],"about_ca_topic_score_codex":0.000045589997,"about_ca_topic_score_gemma":0.00012048395,"teacher_disagreement_score":0.54790264,"about_ca_system_score_codex":0.00019762352,"about_ca_system_score_gemma":0.0015203217,"threshold_uncertainty_score":0.99988896},"labels":[],"label_agreement":null},{"id":"W2571380519","doi":"10.1016/j.jtho.2016.11.1142","title":"P2.01-090 Platin Induced Phosphorylation of ATM and ATM-Deficiency as a Predictive Marker of Platin Sensitivity in Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cisplatin; Cancer research; DNA damage; Clonogenic assay; Cell culture; Apoptosis; Cell cycle; Molecular biology; Cell growth; Carboplatin; Medicine; Biology; DNA; Genetics; Chemotherapy; Internal medicine","score_opus":0.017551223096460792,"score_gpt":0.3606120441978442,"score_spread":0.3430608211013834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571380519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931828,0.0009849998,0.00051857217,0.00049781677,0.0004154926,0.00050776335,0.00002072758,0.0000049952564,0.003866843],"genre_scores_gemma":[0.9979888,0.00026579577,0.0014583559,0.000055935867,0.000114516886,0.000007086651,0.0000024021672,0.000024927504,0.000082175735],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813163,0.00017200298,0.0008531586,0.00023543912,0.00035399597,0.00025376634],"domain_scores_gemma":[0.9967029,0.00024892087,0.0021732398,0.0003163414,0.00041215273,0.0001464283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014105865,0.00019007677,0.0008727169,0.00027148527,0.00007496509,0.0000099544195,0.00012510868,0.00038682047,0.00005524409],"category_scores_gemma":[0.0005470037,0.00017180205,0.0001408861,0.00015362675,0.00018321633,0.00015112714,0.000110008106,0.0007500139,0.0000010796828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012163551,0.00090180436,0.23395748,0.00063729374,0.00027386227,0.00110152,0.0046889484,0.001165624,0.68560785,0.0000146569,0.00028112557,0.05920629],"study_design_scores_gemma":[0.003962133,0.0036113616,0.80776215,0.0012601131,0.0006228089,0.0005646913,0.0005849594,0.00945785,0.17182611,0.000087790104,0.000081299244,0.00017872282],"about_ca_topic_score_codex":0.00077585824,"about_ca_topic_score_gemma":0.00065705355,"teacher_disagreement_score":0.5738047,"about_ca_system_score_codex":0.00053036865,"about_ca_system_score_gemma":0.0011516998,"threshold_uncertainty_score":0.70058846},"labels":[],"label_agreement":null},{"id":"W2571417207","doi":"10.1016/j.jtho.2016.11.245","title":"OA04.02 Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Smoking cessation; Lung cancer screening; Internal medicine; Stage (stratigraphy); Cancer; Clinical endpoint; Clinical trial; Pathology","score_opus":0.02356426324017958,"score_gpt":0.4274010001882532,"score_spread":0.40383673694807365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571417207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948934,0.0001798142,0.000051662955,0.00051054655,0.0015593402,0.0008466198,0.000045670276,0.0000070724786,0.0019059068],"genre_scores_gemma":[0.99589384,0.00004827518,0.002037449,0.00009062516,0.00054296287,0.000068448375,0.000019563158,0.000029453366,0.0012693652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984409,0.00006572712,0.00069078954,0.00022797362,0.0003098225,0.00026474532],"domain_scores_gemma":[0.99744874,0.00005877388,0.0016187441,0.00039336953,0.00029308157,0.00018730389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030692888,0.00017165231,0.00065122946,0.0001785352,0.00014481602,0.00005428536,0.00019423808,0.00015706384,0.00017079852],"category_scores_gemma":[0.00007089525,0.00012414876,0.00013044344,0.000060765466,0.00006146528,0.00023562575,0.000051468156,0.00045254818,0.0000021946366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021175643,0.0013367464,0.94425935,0.00003199214,0.00026752512,0.0046646046,0.0008398328,0.000013559456,0.00008526104,3.8902542e-7,0.0002574448,0.027067674],"study_design_scores_gemma":[0.03851936,0.0041468055,0.95172864,0.0002542707,0.0018532679,0.00006333529,0.00015029436,0.000010336001,0.00033355493,0.000005581201,0.0028078612,0.00012666582],"about_ca_topic_score_codex":0.0026014156,"about_ca_topic_score_gemma":0.0010670733,"teacher_disagreement_score":0.026941009,"about_ca_system_score_codex":0.0009579619,"about_ca_system_score_gemma":0.0013166469,"threshold_uncertainty_score":0.5062639},"labels":[],"label_agreement":null},{"id":"W2571455092","doi":"10.1016/j.jtho.2016.11.568","title":"P1.01-044 Accelerometer-Determined Physical Activity and Sedentary Time among Lung Cancer Survivors","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Athabasca University; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Physical activity; Physical therapy; Cancer; Sedentary behavior; Gerontology; Internal medicine","score_opus":0.028933761931366785,"score_gpt":0.4230642367906355,"score_spread":0.3941304748592687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571455092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935486,0.00034131782,0.000028990118,0.0027653095,0.0014592775,0.00018320773,0.000015972852,0.000015204128,0.0016421743],"genre_scores_gemma":[0.99660057,0.00019428537,0.000096257274,0.00020944723,0.0014524492,0.000009044488,0.0000017427077,0.00002802497,0.0014081582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99866587,0.00017704451,0.0002887131,0.00022834181,0.00033867703,0.00030135177],"domain_scores_gemma":[0.9981283,0.00019385181,0.0008147379,0.00037843257,0.00016481659,0.00031988678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005067194,0.0002045775,0.0008648344,0.0001599333,0.00020424448,0.000070887334,0.0002854908,0.00018566265,0.00024738512],"category_scores_gemma":[0.00010534912,0.00016265361,0.00023998246,0.000070244234,0.0002766819,0.00046396715,0.00016314103,0.00061263156,0.0000049466244],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004638535,0.0007002839,0.36672786,0.00034472917,0.0006663914,0.0014237189,0.0019242073,0.0000040038767,0.03750614,0.000002081924,0.0028645531,0.5831975],"study_design_scores_gemma":[0.0013339343,0.0015042227,0.9808845,0.00031806107,0.0010084393,0.000630581,0.00021695583,0.00091899873,0.008655392,0.000047312733,0.004231711,0.00024989212],"about_ca_topic_score_codex":0.0022523752,"about_ca_topic_score_gemma":0.004026208,"teacher_disagreement_score":0.61415666,"about_ca_system_score_codex":0.00034269414,"about_ca_system_score_gemma":0.00030681226,"threshold_uncertainty_score":0.66328216},"labels":[],"label_agreement":null},{"id":"W2571472318","doi":"10.1016/j.jtho.2016.11.823","title":"P1.05-039 Recurrence and Survival Outcome after Segmentectomy for Non-Small Cell Lung Cancer: A Long-Term Follow-Up Study at a Single Institute","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Lymphovascular invasion; Adenosquamous carcinoma; Stage (stratigraphy); Internal medicine; Multivariate analysis; Lung cancer; Oncology; T-stage; Proportional hazards model; Overall survival; Cancer; Gastroenterology; Adenocarcinoma; Metastasis","score_opus":0.05049541740277671,"score_gpt":0.42965758773486706,"score_spread":0.3791621703320904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571472318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896312,0.0022348645,0.00016514062,0.002042849,0.004287599,0.0013226536,0.000022673808,0.000008414759,0.00028461913],"genre_scores_gemma":[0.99635154,0.00044892656,0.00092399283,0.00019122098,0.0006003115,0.00024020621,0.0000025252664,0.000027174765,0.0012141258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983419,0.00007802626,0.0006464342,0.00032693334,0.00025781296,0.00034888566],"domain_scores_gemma":[0.997931,0.00014433837,0.00096977135,0.00040616243,0.00027034717,0.00027836158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062379515,0.00025323223,0.000967307,0.00013948977,0.00026290346,0.00007227414,0.00023453638,0.00013448468,0.000043780023],"category_scores_gemma":[0.000095304975,0.00018533938,0.00024504872,0.00004820758,0.00011776798,0.00021381005,0.00018805824,0.00027015174,0.000002568299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004654787,0.001590078,0.953925,0.00055609265,0.00051160855,0.0014229467,0.00085495785,0.0000021108797,0.00028148724,5.8585584e-7,0.0005965384,0.035603803],"study_design_scores_gemma":[0.013181554,0.009229055,0.96706164,0.0007637761,0.0032716321,0.0003842517,0.00014755594,0.000024506424,0.0017288832,0.0000082084225,0.0039596325,0.00023929506],"about_ca_topic_score_codex":0.00012056257,"about_ca_topic_score_gemma":0.0038704735,"teacher_disagreement_score":0.035364505,"about_ca_system_score_codex":0.0019092454,"about_ca_system_score_gemma":0.00049866125,"threshold_uncertainty_score":0.755792},"labels":[],"label_agreement":null},{"id":"W2580626787","doi":"10.1016/j.jtho.2017.01.002","title":"The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Thymoma; Thymic carcinoma; Hazard ratio; Proportional hazards model; Stage (stratigraphy); Propensity score matching; Radiation therapy; Cancer; Surgery; Internal medicine; Multivariate analysis; Oncology; Confidence interval","score_opus":0.030464027211737906,"score_gpt":0.46083251723872104,"score_spread":0.43036849002698313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580626787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863893,0.0029428492,0.00016774384,0.009077772,0.00027857965,0.00029203435,0.000009755059,0.0000020440334,0.0008399407],"genre_scores_gemma":[0.9967079,0.00044926928,0.0019660525,0.00013445155,0.00030680888,0.000003912854,6.349061e-7,0.000015022501,0.00041592726],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990892,0.0000986041,0.0004086924,0.00009299468,0.00012562296,0.00018489704],"domain_scores_gemma":[0.9980407,0.00032180807,0.00083825353,0.00030058585,0.0003715814,0.0001270719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008575697,0.00011728799,0.000568223,0.000075502525,0.0002987473,0.00003815241,0.00022492667,0.00010714757,0.000026145324],"category_scores_gemma":[0.0002943149,0.000058032758,0.00028757958,0.00002567641,0.0002844891,0.0001005877,0.000030219839,0.00021506487,5.423025e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02402965,0.00051041355,0.1541371,0.00008119844,0.001476178,0.0003432732,0.002976249,0.0000070333167,0.08623378,0.0012464622,0.009124581,0.7198341],"study_design_scores_gemma":[0.004285053,0.02573941,0.9308323,0.00012490316,0.0003000062,0.0061050607,0.0005385669,0.000536481,0.0057253493,0.0020020555,0.023674939,0.00013587608],"about_ca_topic_score_codex":0.00004882356,"about_ca_topic_score_gemma":0.000014484712,"teacher_disagreement_score":0.7766952,"about_ca_system_score_codex":0.0001346087,"about_ca_system_score_gemma":0.00045116464,"threshold_uncertainty_score":0.23665072},"labels":[],"label_agreement":null},{"id":"W2586885021","doi":"10.1016/j.jtho.2016.01.012","title":"Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Cancer Research UK","keywords":"Cancer research; Targeted therapy; Aurora kinase; Medicine; Wnt signaling pathway; Receptor tyrosine kinase; Tyrosine kinase; Biology; Kinase; Bioinformatics; Cancer; Signal transduction; Cell cycle; Receptor; Internal medicine; Genetics","score_opus":0.047730748269638766,"score_gpt":0.530468196576259,"score_spread":0.48273744830662024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586885021","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00075899175,0.98551506,0.00018413052,0.010797636,0.0010779493,0.0012664475,0.00008162415,0.000015110734,0.00030306462],"genre_scores_gemma":[0.00018394912,0.9973048,0.0013550553,0.0005000396,0.00028998865,0.00014709237,0.000018987337,0.0000643403,0.00013573845],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956285,0.0011821734,0.0017095874,0.0005522681,0.0001755576,0.0007519611],"domain_scores_gemma":[0.99652684,0.00078844326,0.0015509662,0.0003315389,0.00044384788,0.00035835968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013244773,0.0005776187,0.0048842244,0.0009841401,0.000060810256,0.00000998082,0.0004289555,0.00087559427,0.00008827462],"category_scores_gemma":[0.0004857642,0.00033782312,0.00048717827,0.00044587193,0.00044819008,0.000071299255,0.00017799174,0.0016034383,0.0000016406633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046248897,0.00015119245,0.0013453823,0.010721236,0.0008608386,0.00044828648,0.00023010418,2.0373987e-7,0.0004262871,0.00001721265,0.0001383547,0.98519844],"study_design_scores_gemma":[0.001733014,0.0023120507,0.00003383023,0.0067738523,0.0017255427,0.00036425388,0.000038830938,0.000002678539,0.000067509434,0.0003167372,0.9863257,0.00030599974],"about_ca_topic_score_codex":0.00014626834,"about_ca_topic_score_gemma":0.0009951605,"teacher_disagreement_score":0.98618734,"about_ca_system_score_codex":0.002356047,"about_ca_system_score_gemma":0.0035819847,"threshold_uncertainty_score":0.9999074},"labels":[],"label_agreement":null},{"id":"W2587904625","doi":"10.1016/j.jtho.2017.01.001","title":"Response to Screening for Brain Metastases in Resectable Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Magnetic resonance imaging; Stage (stratigraphy); Lung cancer; Disease; Radiology; Oncology; Internal medicine","score_opus":0.05940973779735049,"score_gpt":0.4515554000288349,"score_spread":0.3921456622314844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587904625","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061746996,0.003697943,0.0031061012,0.92760205,0.0012821517,0.0017423526,0.00037145885,0.000009774784,0.00044114483],"genre_scores_gemma":[0.00937487,0.00028865662,0.20800877,0.73133785,0.010288405,0.000526815,0.00018147359,0.00028197296,0.039711174],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623847,0.0010853973,0.0010494884,0.0004401953,0.000441783,0.00074466685],"domain_scores_gemma":[0.9945657,0.0025401672,0.0015175947,0.00061539095,0.0004785728,0.00028254563],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005450709,0.00042679167,0.0019645358,0.0010691648,0.00014794206,0.00006281685,0.0004728182,0.0007406908,0.00020532534],"category_scores_gemma":[0.0015580447,0.00032966494,0.00060362805,0.00017835623,0.00007060439,0.00010871506,0.00012918083,0.0020469024,0.00000692517],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020429302,0.00026688914,0.00051292824,0.00068398233,0.0006677031,0.018068971,0.00022790057,0.00011135239,0.0011193086,4.1798847e-7,0.927612,0.030299226],"study_design_scores_gemma":[0.0037650785,0.005716253,0.0009970235,0.0016240828,0.0019968364,0.0012442513,0.00010140593,0.00007082666,0.0014714237,0.000026345648,0.9827123,0.0002741547],"about_ca_topic_score_codex":0.0002677063,"about_ca_topic_score_gemma":0.0002447375,"teacher_disagreement_score":0.20490266,"about_ca_system_score_codex":0.0010492111,"about_ca_system_score_gemma":0.00217937,"threshold_uncertainty_score":0.99991554},"labels":[],"label_agreement":null},{"id":"W2588914509","doi":"10.1016/j.jtho.2017.01.007","title":"HER2 Transmembrane Domain Mutations: Rare New Target for Non–Small Cell Lung Cancer Therapy","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Medicine; Lung cancer; Breast cancer; ErbB; Targeted therapy; Cancer; Cancer research; Oncology; Internal medicine; Epidermal growth factor receptor; Receptor tyrosine kinase; Receptor","score_opus":0.06442857875986661,"score_gpt":0.4781557608819319,"score_spread":0.4137271821220653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588914509","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007298348,0.020065144,0.0047940137,0.95594954,0.004271838,0.002947325,0.00023176901,0.000027946253,0.0044140867],"genre_scores_gemma":[0.0026508302,0.019973364,0.13180517,0.59618264,0.10487252,0.0009956968,0.00053820835,0.0008795276,0.14210205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959605,0.00045397176,0.0012597854,0.00049998215,0.0008990397,0.00092673296],"domain_scores_gemma":[0.99519175,0.00084512227,0.0017503322,0.0007276857,0.001039347,0.00044577883],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0017001345,0.00052064256,0.002019822,0.0006487025,0.00023950885,0.0000968983,0.0010566706,0.0017971778,0.001823763],"category_scores_gemma":[0.00019970088,0.000410659,0.0008911458,0.00017199162,0.00023357166,0.00015651845,0.000044057986,0.0047457465,0.00001959259],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027622427,0.00018714556,0.00022240412,0.0023082055,0.0006921437,0.005115024,0.0009658137,0.000029628485,0.0015579757,5.7794983e-7,0.8937351,0.09242374],"study_design_scores_gemma":[0.0045732576,0.0038524,0.00013453972,0.001348351,0.0006916506,0.0013169555,0.000107947024,0.00006699116,0.0027533686,0.0006010367,0.9841975,0.0003560197],"about_ca_topic_score_codex":0.00021216272,"about_ca_topic_score_gemma":0.0000913812,"teacher_disagreement_score":0.3597669,"about_ca_system_score_codex":0.0015778571,"about_ca_system_score_gemma":0.011993536,"threshold_uncertainty_score":0.99983454},"labels":[],"label_agreement":null},{"id":"W2592847908","doi":"10.1016/j.jtho.2017.02.013","title":"The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"Cancer Council Victoria; State Government of Victoria; National Health and Medical Research Council; Canadian Institutes of Health Research; Medical Research Council; Terry Fox Research Institute","keywords":"Medicine; Mesothelioma; Genome; Immune system; Copy-number variation; Tumor microenvironment; Computational biology; Cancer research; Immunology; Genetics; Biology; Pathology; Gene","score_opus":0.017023625101576664,"score_gpt":0.37243603378706197,"score_spread":0.3554124086854853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592847908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844847,0.0019643272,0.000014762923,0.009966378,0.00026544623,0.000108237415,0.000005865985,0.0000019644694,0.0031883554],"genre_scores_gemma":[0.99579793,0.0019219388,0.0005474265,0.00023929006,0.00013288402,0.0000037070822,0.0000037361458,0.000009321205,0.0013437641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999132,0.00009595297,0.0003685451,0.00008883163,0.00017405364,0.000140668],"domain_scores_gemma":[0.99907315,0.00018246629,0.0004185144,0.00020453893,0.000019566827,0.0001017735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005086491,0.000085751395,0.0002582158,0.00004107484,0.00026546276,0.000032652944,0.0001476606,0.00006193018,0.0001593563],"category_scores_gemma":[0.0001548939,0.00005554608,0.00007509627,0.000020955571,0.00028452443,0.00012418647,0.00007684948,0.00019320284,0.000037174763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014055483,0.0002720028,0.9771098,0.000016527227,0.000082308245,0.00017751711,0.0000806969,0.000005707922,0.004770559,0.00005485921,0.0004088549,0.01561562],"study_design_scores_gemma":[0.0006550486,0.0002786717,0.95753944,0.00003280151,0.00009357906,0.00033409114,0.00018646634,0.0000060394163,0.00055658777,0.0004703862,0.03979589,0.000051014187],"about_ca_topic_score_codex":0.000017728822,"about_ca_topic_score_gemma":0.000036645273,"teacher_disagreement_score":0.039387032,"about_ca_system_score_codex":0.00017435582,"about_ca_system_score_gemma":0.00007565998,"threshold_uncertainty_score":0.22651035},"labels":[],"label_agreement":null},{"id":"W2602174837","doi":"10.1016/j.jtho.2017.02.016","title":"Correlation, Causation and Confounding—What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Breast cancer; Radiation therapy; Oncology; Internal medicine; Cancer; Mastectomy; Lung cancer; Population","score_opus":0.011949280404888598,"score_gpt":0.37988901460977886,"score_spread":0.3679397342048903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602174837","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21424265,0.13301335,0.00072333874,0.6430243,0.00793729,0.00053514366,0.00037141837,0.000005720273,0.00014678467],"genre_scores_gemma":[0.57607967,0.24257572,0.00087115745,0.15099838,0.025958428,0.00018428157,0.00012227567,0.00021295194,0.002997104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998374,0.00032219524,0.0005275564,0.00027197492,0.0002645464,0.00023976166],"domain_scores_gemma":[0.9966628,0.00015586887,0.0024206033,0.00035303354,0.0003627801,0.000044934877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051442825,0.00028680815,0.0006932977,0.00009829369,0.00027691422,0.00006688152,0.00032211968,0.0006502052,0.000050791958],"category_scores_gemma":[0.000055090968,0.00019478524,0.00031678996,0.000048951104,0.0002651178,0.000031697393,0.000076433396,0.0007251896,2.2843844e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011990519,0.00007288075,0.15158859,0.00024116278,0.009639739,0.0001472584,0.0019017096,0.00020718094,0.0015375844,0.000001913017,0.66790485,0.16555807],"study_design_scores_gemma":[0.0025170282,0.00062051887,0.10890509,0.001356216,0.0065508825,0.001551301,0.00042339938,0.00019713228,0.0014055446,0.00010226001,0.8757432,0.0006274408],"about_ca_topic_score_codex":0.0005305171,"about_ca_topic_score_gemma":0.00016770292,"teacher_disagreement_score":0.4920259,"about_ca_system_score_codex":0.00033816474,"about_ca_system_score_gemma":0.00060749485,"threshold_uncertainty_score":0.79431117},"labels":[],"label_agreement":null},{"id":"W2607454228","doi":"10.1016/j.jtho.2017.04.003","title":"Plasma ctDNA Analysis for Detection of the EGFR  T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Chugai Pharmaceutical; Pfizer; AstraZeneca; Ono Pharmaceutical; Bristol-Myers Squibb; Eli Lilly and Company; Astellas Pharma","keywords":"T790M; Osimertinib; Medicine; Lung cancer; Internal medicine; Oncology; Mutation; Cancer; Pathology; Adenocarcinoma; Biology; Gene; ROS1; Genetics","score_opus":0.011154955999801906,"score_gpt":0.40021180272298307,"score_spread":0.38905684672318114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607454228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611926,0.000088950816,0.001979987,0.00057352957,0.00039833807,0.0005122651,0.000016153766,0.0000017460354,0.0003097738],"genre_scores_gemma":[0.9974263,0.000021900547,0.0021751218,0.000047666847,0.00006243046,0.00003562615,0.0000045690017,0.0000093710005,0.00021703918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927425,0.000037926915,0.00033052824,0.0000973606,0.00014610839,0.00011382836],"domain_scores_gemma":[0.9981572,0.000062714695,0.0011303807,0.00018227437,0.00041999394,0.00004744554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015955832,0.00008080254,0.00035870296,0.00019032204,0.00011511453,0.000009202663,0.000104818486,0.00007083864,0.000012151292],"category_scores_gemma":[0.00006892292,0.000047611342,0.00014440423,0.00015901659,0.000043197444,0.00012241385,0.0000143161715,0.00013101682,2.0842155e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033760273,0.0005352523,0.8443789,0.00012977695,0.0010192133,0.000012507516,0.0009411701,0.004755001,0.0015742774,0.0000014268453,0.000023454255,0.14325298],"study_design_scores_gemma":[0.0047525708,0.0018039753,0.9759082,0.00013266332,0.004494605,0.0000072253074,0.00019522167,0.0012944704,0.011054495,0.0000171947,0.00028654616,0.00005279549],"about_ca_topic_score_codex":0.0001037835,"about_ca_topic_score_gemma":0.0012215992,"teacher_disagreement_score":0.14320019,"about_ca_system_score_codex":0.0005216429,"about_ca_system_score_gemma":0.0003911453,"threshold_uncertainty_score":0.19415341},"labels":[],"label_agreement":null},{"id":"W2607668193","doi":"10.1016/j.jtho.2017.04.010","title":"Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ABB (Canada); Centre Hospitalier de l’Université de Montréal","funders":"Eli Lilly and Company","keywords":"Veliparib; Medicine; Hazard ratio; Internal medicine; Carboplatin; Oncology; PARP inhibitor; Lung cancer; Confidence interval; Poly ADP ribose polymerase; Chemotherapy; Genetics; Cisplatin; Biology","score_opus":0.021952441980889303,"score_gpt":0.3739411683643788,"score_spread":0.3519887263834895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607668193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99216574,0.00052657205,0.0004503069,0.001966767,0.002410988,0.00055445434,0.000013505563,0.000012572399,0.0018990927],"genre_scores_gemma":[0.99389195,0.00008757853,0.003474066,0.0014162337,0.0007718063,0.000031018197,0.0000028050542,0.000037777423,0.0002867332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99814427,0.00017377692,0.00060421904,0.0002673822,0.00043452758,0.00037585341],"domain_scores_gemma":[0.9973349,0.000117173215,0.0012328654,0.00041422006,0.00057952123,0.0003213178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000846946,0.00021253103,0.00075637636,0.00030038913,0.00010991064,0.000016292955,0.00018034113,0.00020070949,0.00008596666],"category_scores_gemma":[0.000171263,0.0001770226,0.00010043784,0.00008531004,0.00012188539,0.000279636,0.000072304814,0.00072767696,0.0000040279165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01471882,0.0010750045,0.8770108,0.00025539624,0.0001664648,0.0009804838,0.002144313,0.0008875728,0.010991273,0.000001712062,0.010265827,0.08150231],"study_design_scores_gemma":[0.009812286,0.0038206724,0.93532836,0.0018597607,0.00029735273,0.00010423667,0.00010878551,0.00014766149,0.010551973,0.0000094677425,0.037675813,0.00028361863],"about_ca_topic_score_codex":0.00007862602,"about_ca_topic_score_gemma":0.00026638928,"teacher_disagreement_score":0.08121869,"about_ca_system_score_codex":0.003925778,"about_ca_system_score_gemma":0.001389529,"threshold_uncertainty_score":0.99989796},"labels":[],"label_agreement":null},{"id":"W2609444947","doi":"10.1016/j.jtho.2017.04.011","title":"The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":507,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Stage (stratigraphy); TNM staging system; Lung cancer; Lung cancer staging; Oncology; Cancer; Radiology; Neoplasm staging; Internal medicine; Mediastinoscopy","score_opus":0.04161483914917415,"score_gpt":0.45957928251022584,"score_spread":0.4179644433610517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609444947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97531676,0.002496535,0.00007784645,0.019183839,0.0014061792,0.0010791764,0.000037190857,0.0000017642641,0.00040071513],"genre_scores_gemma":[0.9961634,0.0030087833,0.0000747008,0.00015341556,0.00040622096,0.000044580232,0.0000012252394,0.000013568517,0.00013405501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972827,0.0006673556,0.0009589241,0.00015238536,0.0007581012,0.00018052787],"domain_scores_gemma":[0.9939137,0.00040865646,0.004352551,0.00074790535,0.00055021775,0.000026957281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021921478,0.00014571779,0.00047530443,0.0000816033,0.0003061408,0.000024972403,0.000770215,0.0001125512,0.000034200108],"category_scores_gemma":[0.00032733934,0.000054524207,0.00029521054,0.00023805912,0.00035640018,0.00019300723,0.0001282476,0.00045650124,9.12267e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013367096,0.00077532604,0.90473735,0.0011217457,0.0004807532,0.00000622233,0.0075807027,0.00032948484,0.018848754,0.00075553794,0.0043638917,0.05966354],"study_design_scores_gemma":[0.0012031784,0.00035594482,0.938072,0.0044542425,0.0010754928,0.000026405807,0.0012101848,0.0008063828,0.0500402,0.00015266129,0.0025356116,0.00006768294],"about_ca_topic_score_codex":0.001175148,"about_ca_topic_score_gemma":0.0005708301,"teacher_disagreement_score":0.05959586,"about_ca_system_score_codex":0.0008652828,"about_ca_system_score_gemma":0.00093935366,"threshold_uncertainty_score":0.23546185},"labels":[],"label_agreement":null},{"id":"W2612382972","doi":"10.1016/j.jtho.2017.04.021","title":"The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Université Laval; Sinai Health System; Women's College Hospital; University of British Columbia; Memorial University of Newfoundland; Foothills Medical Centre; Queen Elizabeth II Health Sciences Centre; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; Trillium Health Centre; Beatrice Hunter Cancer Research Institute; Juravinski Cancer Centre; Dalhousie University; Ottawa Hospital; University Health Network; Brock University; McMaster University; Cancer Care Ontario; BC Cancer Agency; Simon Fraser University; Canadian Centre for Applied Research in Cancer Control","funders":"National Cancer Institute; Prevent Cancer Foundation","keywords":"Medicine; Lung cancer screening; Lung cancer; Cost effectiveness; Oncology; Risk analysis (engineering)","score_opus":0.027790681457577224,"score_gpt":0.4610000758514565,"score_spread":0.4332093943938793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612382972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940402,0.0031512307,0.00018744377,0.0013117598,0.00044899856,0.00060331647,0.000008451729,0.000003266543,0.00024535172],"genre_scores_gemma":[0.99506366,0.0034176172,0.0013376627,0.000012267909,0.00010352,0.000037122947,4.4871882e-7,0.000007843849,0.000019833904],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990294,0.00019057062,0.0003284068,0.00010069362,0.00020506336,0.00014587333],"domain_scores_gemma":[0.9975531,0.00056734646,0.0012427381,0.00021857368,0.00033068974,0.00008751764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093471806,0.00008884986,0.0005076513,0.00006190779,0.00019338202,0.000014734359,0.00015265874,0.000075685966,0.00000890537],"category_scores_gemma":[0.00022710128,0.00005027647,0.00011839319,0.000048491635,0.00033173704,0.000071606395,0.00005681637,0.00020299703,1.3540644e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015697207,0.00037158708,0.44969466,0.0001988063,0.0005110531,0.000044537497,0.00013308444,0.000077201265,0.00021529106,0.000048840822,0.00011068366,0.54702455],"study_design_scores_gemma":[0.0027661163,0.0043894653,0.97902817,0.0011400742,0.0015390588,0.0001044073,0.00020207628,0.00025536172,0.008296865,0.000074341646,0.0021479095,0.000056145338],"about_ca_topic_score_codex":0.00045641765,"about_ca_topic_score_gemma":0.00013475667,"teacher_disagreement_score":0.5469684,"about_ca_system_score_codex":0.00026876107,"about_ca_system_score_gemma":0.0002971561,"threshold_uncertainty_score":0.20502149},"labels":[],"label_agreement":null},{"id":"W2613587169","doi":"10.1016/j.jtho.2016.11.540","title":"P1.01-016 An International Epidemiological Analysis of Young Patients Diagnosed with NSCLC (AduJov - CLICaP)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Stage (stratigraphy); Adenocarcinoma; Population; Lung cancer; Retrospective cohort study; Cancer","score_opus":0.03913262411329611,"score_gpt":0.489806248689828,"score_spread":0.45067362457653193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613587169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897133,0.00006251632,0.0004593122,0.0020755935,0.00049410196,0.0001519439,0.000034757213,0.000006222316,0.00700224],"genre_scores_gemma":[0.99378014,0.00014271941,0.0052469857,0.00031720137,0.00024230938,0.000007734766,0.00005491754,0.00000931652,0.00019865533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986041,0.00014987774,0.0006183829,0.0001678382,0.00029684947,0.00016290566],"domain_scores_gemma":[0.9972335,0.0002146548,0.0014889505,0.00033815068,0.0005338474,0.00019090109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005298338,0.00012289658,0.00080518215,0.00031318312,0.00011364795,0.000018966515,0.0002882511,0.00012865891,0.00025306904],"category_scores_gemma":[0.00066672504,0.00007181987,0.00025332114,0.00011836684,0.00017990089,0.0002820057,0.000043011856,0.0002224898,0.000003252743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017155273,0.0014029028,0.91927457,0.000008899409,0.0037276556,0.00025489889,0.00039464404,0.000077420846,0.000087584835,0.00007678688,0.0004068869,0.072572224],"study_design_scores_gemma":[0.0020020718,0.003798274,0.98452055,0.00006749532,0.0052662236,0.00006550278,0.00019325347,0.0001996566,0.000058911453,0.00006900412,0.003694703,0.00006436438],"about_ca_topic_score_codex":0.0001129656,"about_ca_topic_score_gemma":0.0001621587,"teacher_disagreement_score":0.07250786,"about_ca_system_score_codex":0.00029467937,"about_ca_system_score_gemma":0.0002541003,"threshold_uncertainty_score":0.29287294},"labels":[],"label_agreement":null},{"id":"W2614942658","doi":"10.1016/j.jtho.2017.05.002","title":"EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; T790M; Afatinib; Gefitinib; Internal medicine; Oncology; Erlotinib; Sanger sequencing; Mutation; Genotyping; Cancer; Epidermal growth factor receptor; Genetics; Genotype; Gene; Biology","score_opus":0.052111973696244984,"score_gpt":0.5453192214811934,"score_spread":0.4932072477849484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614942658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937218,0.00029587984,0.0025515838,0.0022815203,0.00025938818,0.0004615687,0.000007904226,0.0000032679236,0.00041712646],"genre_scores_gemma":[0.99430114,0.000049007333,0.005244841,0.00003412664,0.000111325964,0.000036966383,0.0000078129915,0.0000051755865,0.00020958224],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991066,0.000050474784,0.0005222988,0.000100340585,0.00013264142,0.00008767072],"domain_scores_gemma":[0.9975925,0.00008095228,0.0014306919,0.00008810758,0.0007698384,0.000037909795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035265306,0.000069981856,0.0004470589,0.00029393972,0.00016414688,0.000007945892,0.000041097148,0.000040542338,0.000008604972],"category_scores_gemma":[0.00046619598,0.000048115377,0.00014577358,0.00016157792,0.000064037544,0.00017638344,0.000010405779,0.00009201469,2.1633798e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016552802,0.007564685,0.19386819,0.00027025808,0.012170352,0.00018533466,0.022987094,0.0043747267,0.017684832,0.0003099202,0.0009935078,0.7230383],"study_design_scores_gemma":[0.0451173,0.11451587,0.64378124,0.000833822,0.04198221,0.0007250519,0.016719686,0.009667905,0.1120221,0.0075152777,0.006653167,0.00046635003],"about_ca_topic_score_codex":0.000062456435,"about_ca_topic_score_gemma":0.00043573958,"teacher_disagreement_score":0.72257197,"about_ca_system_score_codex":0.00060338574,"about_ca_system_score_gemma":0.00032347778,"threshold_uncertainty_score":0.1962088},"labels":[],"label_agreement":null},{"id":"W2616513983","doi":"10.1016/j.jtho.2017.04.008","title":"Immune Signatures of Non–Small Cell Lung Cancer","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Pembrolizumab; Medicine; Nivolumab; Atezolizumab; Oncology; Lung cancer; Internal medicine; Immunotherapy; Chemotherapy; PD-L1; Cancer","score_opus":0.02078147109960025,"score_gpt":0.3932704617069904,"score_spread":0.37248899060739016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616513983","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.105836295,0.112392284,0.00012239849,0.7568349,0.011166942,0.0009202045,0.0001002245,0.000016984204,0.012609739],"genre_scores_gemma":[0.16275547,0.029174494,0.007650743,0.6707866,0.048197415,0.00007180255,0.00012744257,0.00041747672,0.08081854],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756444,0.0001896594,0.001195657,0.00022390546,0.00044814125,0.00037821737],"domain_scores_gemma":[0.9945427,0.00022537167,0.0040061474,0.000559292,0.000580652,0.000085803586],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00087120343,0.0003355041,0.0017542089,0.00044145132,0.00008130042,0.00002111167,0.00065005245,0.0016187656,0.00069755845],"category_scores_gemma":[0.00006924881,0.0002464677,0.00091016816,0.00009644735,0.0002633856,0.000074087104,0.000073009294,0.0033745859,0.0000033686617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060294406,0.00016781778,0.00033609438,0.0017010669,0.0013381875,0.0036953888,0.00025865194,0.000004381335,0.053768106,1.0166409e-7,0.8769546,0.055746134],"study_design_scores_gemma":[0.0021175852,0.0022215892,0.0034174423,0.0020614103,0.0022351881,0.0010616769,0.000046914927,0.000015079718,0.018190613,0.000013215429,0.9683695,0.00024981308],"about_ca_topic_score_codex":0.00021161581,"about_ca_topic_score_gemma":0.00002263732,"teacher_disagreement_score":0.09141484,"about_ca_system_score_codex":0.0006153788,"about_ca_system_score_gemma":0.002390979,"threshold_uncertainty_score":0.99999875},"labels":[],"label_agreement":null},{"id":"W2620097568","doi":"10.1016/j.jtho.2017.05.019","title":"Scientific Advances in Thoracic Oncology 2016","year":2017,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Foundation Medicine; Loxo Oncology; Pharmacyclics; Chugai Pharmaceutical; EMD Serono; Genentech; Medela; Astellas Pharma; Daiichi-Sankyo; Taiho Pharmaceutical; National Institutes of Health; Regeneron Pharmaceuticals; Meiji Seika Pharma; American Cancer Society; Shionogi; Helsinn; Mirati Therapeutics; Clovis Oncology; Varian Medical Systems; Ariad Pharmaceuticals; Cancer Research UK; Array BioPharma; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; G1 Therapeutics; Celgene; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb; Pfizer","keywords":"Medicine; Lung cancer; Targeted therapy; Immunotherapy; Oncology; Radiation therapy; Internal medicine; Radiation oncology; Medical physics; Cancer; Intensive care medicine","score_opus":0.09726148855054398,"score_gpt":0.5912693878452375,"score_spread":0.4940078992946936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620097568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004618203,0.9706821,0.000033983702,0.0011585277,0.0055169677,0.00078118395,0.000036017795,0.0000125214665,0.02173253],"genre_scores_gemma":[0.00007789357,0.9855449,0.002556884,0.00009569005,0.0010601156,0.00006053309,0.000052614072,0.00005116522,0.0105002085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639624,0.0005754029,0.0017016127,0.0004405417,0.00040466306,0.00048151604],"domain_scores_gemma":[0.99449295,0.00044802425,0.0035879111,0.00063798827,0.00051443494,0.0003186642],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019147306,0.000419483,0.003994627,0.0012933355,0.0002313369,0.00008167926,0.0005589751,0.0007366934,0.00022057489],"category_scores_gemma":[0.00048836553,0.00027204453,0.0008467315,0.000374101,0.0004395757,0.00046038162,0.00010798177,0.0013009381,0.00016035301],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002648219,0.00066624983,0.00003127014,0.0047401185,0.00039394328,0.00267764,0.00017280239,0.0000012359145,0.0000010592909,0.00002059106,0.0047185495,0.98631173],"study_design_scores_gemma":[0.00062142033,0.0019500148,0.00003614861,0.016661948,0.005202749,0.0052143238,0.00009200566,0.000001062578,0.0000019470797,0.00022606648,0.9697905,0.00020180835],"about_ca_topic_score_codex":0.0000092871,"about_ca_topic_score_gemma":0.00011476572,"teacher_disagreement_score":0.9861099,"about_ca_system_score_codex":0.0029916274,"about_ca_system_score_gemma":0.012674849,"threshold_uncertainty_score":0.9999732},"labels":[],"label_agreement":null},{"id":"W2642802273","doi":"10.1016/j.jtho.2017.06.015","title":"Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Prophylactic cranial irradiation; Medicine; Oncology; Randomized controlled trial; Radiation therapy; Internal medicine; Nuclear medicine; Conventional PCI","score_opus":0.05793151531993769,"score_gpt":0.4838327757027396,"score_spread":0.4259012603828019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2642802273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97203547,0.0018602235,0.001967847,0.011480494,0.0022651742,0.010034691,0.000056496745,0.000038259343,0.00026136724],"genre_scores_gemma":[0.9916867,0.0003536665,0.0034207036,0.00045232542,0.002834677,0.0009122318,0.000017470802,0.00007533093,0.00024691733],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994627,0.0014554575,0.0016188741,0.00071415317,0.00081827684,0.000766253],"domain_scores_gemma":[0.99190074,0.0014167789,0.0029691833,0.0005164054,0.002311837,0.0008850375],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0037109908,0.0005155262,0.0026680976,0.00070652895,0.0013622475,0.00019088414,0.00040238397,0.00027950713,0.00006623503],"category_scores_gemma":[0.0063319704,0.00042853292,0.00036729284,0.0002125227,0.000502468,0.00070427574,0.00022406258,0.00093870907,0.00000694397],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85995203,0.006858086,0.008399964,0.0013662182,0.0016644954,0.0011108022,0.012332632,0.0003678324,0.017842872,0.000020491765,0.0012952476,0.08878932],"study_design_scores_gemma":[0.6848668,0.050603308,0.20997904,0.0005204172,0.012976655,0.00043322975,0.0023480156,0.033848763,0.0007175225,0.000422633,0.002236765,0.001046875],"about_ca_topic_score_codex":0.00037020523,"about_ca_topic_score_gemma":0.0004279298,"teacher_disagreement_score":0.20157908,"about_ca_system_score_codex":0.002548647,"about_ca_system_score_gemma":0.0035759448,"threshold_uncertainty_score":0.99993783},"labels":[],"label_agreement":null},{"id":"W2734805455","doi":"10.1016/j.jtho.2017.07.005","title":"ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Merck Sharp and Dohme; Yuhan; Novartis Pharmaceuticals Corporation; AstraZeneca; Celgene; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ceritinib; Medicine; Crizotinib; Anaplastic lymphoma kinase; Gastroenterology; Tolerability; Pharmacokinetics; Internal medicine; Meal; Vomiting; Nausea; ALK inhibitor; Pharmacology; Adverse effect; Lung cancer","score_opus":0.02337236563680686,"score_gpt":0.4175437570014449,"score_spread":0.3941713913646381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734805455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548066,0.00024328308,0.00016194217,0.00022234945,0.00044808091,0.0028956116,0.0000852573,0.00000857362,0.00045426894],"genre_scores_gemma":[0.9977485,0.000075490585,0.0015779658,0.000055577293,0.00007411207,0.00021026375,0.000019711257,0.000052570354,0.00018581691],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99685824,0.0005713094,0.0011792919,0.0003481839,0.0005696551,0.00047334481],"domain_scores_gemma":[0.9961678,0.00059669936,0.0019618876,0.00040130314,0.00058300456,0.00028931908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007074098,0.00037156555,0.002052448,0.0005875684,0.00012770342,0.000042944157,0.00025992616,0.00009321922,0.00010847319],"category_scores_gemma":[0.00032206508,0.00022464822,0.00014204452,0.0003316752,0.00021168962,0.0002871018,0.000049874885,0.0003530442,0.0000015389128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8906046,0.015155401,0.047456004,0.00041044966,0.0024170782,0.004248999,0.009301348,0.0005119638,0.00027675543,4.8642937e-7,0.000056760455,0.02956015],"study_design_scores_gemma":[0.86091757,0.03574622,0.089706525,0.001671454,0.006316467,0.00007385867,0.0039731003,0.0009510965,0.00028790307,0.000004422656,0.000059568658,0.00029180848],"about_ca_topic_score_codex":0.0019262338,"about_ca_topic_score_gemma":0.0137277115,"teacher_disagreement_score":0.042250525,"about_ca_system_score_codex":0.001071289,"about_ca_system_score_gemma":0.0020478552,"threshold_uncertainty_score":0.9160888},"labels":[],"label_agreement":null},{"id":"W2754545205","doi":"10.1016/j.jtho.2017.08.013","title":"Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; McMaster University; Ontario Clinical Oncology Group","funders":"","keywords":"Medicine; Scopus; Cancer drugs; Health care; Cancer; Gross domestic product; MEDLINE; Family medicine; Economic growth; Internal medicine; Political science; Law","score_opus":0.1571983237497091,"score_gpt":0.4658715835707787,"score_spread":0.3086732598210696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754545205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46081847,0.041596897,0.00415326,0.4069488,0.046722297,0.0030194162,0.0017320353,0.000053726828,0.034955103],"genre_scores_gemma":[0.37795758,0.017532645,0.021440163,0.27882963,0.23996875,0.0005178209,0.0003797398,0.0012075033,0.06216616],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962813,0.00025943786,0.0022234353,0.000528102,0.00013635479,0.0005713695],"domain_scores_gemma":[0.98825896,0.0003457479,0.010093162,0.00070049235,0.0003901472,0.00021150119],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042674593,0.00041098343,0.0026896934,0.0005320835,0.00015015496,0.000120628596,0.0012093936,0.0010618602,0.0009449939],"category_scores_gemma":[0.0007898803,0.00043257858,0.0006162002,0.000095188494,0.00024760503,0.0008609702,0.00012607475,0.0019483413,0.000063988875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077852834,0.00017844261,0.0023537786,0.0005120001,0.00071580446,0.0002210592,0.0005969739,0.0005251435,0.000056263016,0.00039566692,0.7678434,0.22582293],"study_design_scores_gemma":[0.0010079732,0.0009606936,0.002525006,0.00045905614,0.00024383291,0.00010894977,0.000029290784,0.00013981048,0.000349107,0.014300298,0.9794113,0.00046469067],"about_ca_topic_score_codex":0.0010106349,"about_ca_topic_score_gemma":0.00011276405,"teacher_disagreement_score":0.22535823,"about_ca_system_score_codex":0.0009577524,"about_ca_system_score_gemma":0.0018914582,"threshold_uncertainty_score":0.9999683},"labels":[],"label_agreement":null},{"id":"W2765900584","doi":"10.1016/j.jtho.2016.11.731","title":"P1.03-059 Organized High Risk Lung Cancer Screening in Ontario, Canada: A Multi-Centre Prospective Evaluation","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Brock University","funders":"","keywords":"Medicine; Delphi method; Multidisciplinary approach; Lung cancer screening; Family medicine; Likert scale; Scale (ratio); Agency (philosophy); Medical education; Lung cancer; Artificial intelligence; Psychology; Pathology","score_opus":0.10827325767210508,"score_gpt":0.5305864022229722,"score_spread":0.4223131445508671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765900584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845337,0.0002260773,0.00030994698,0.010646434,0.0011297839,0.0008174067,0.000008025536,0.000018029648,0.0023105543],"genre_scores_gemma":[0.99067724,0.0001179707,0.0078100283,0.000060679617,0.00031327276,0.000024948788,6.9510924e-7,0.000018356079,0.0009768297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963324,0.0012860593,0.0005195603,0.00021208913,0.0011929175,0.00045697045],"domain_scores_gemma":[0.9966026,0.00035054475,0.0013278594,0.00024557696,0.0012790868,0.00019434205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075474293,0.00012158195,0.00042792704,0.00019959058,0.00076972554,0.00011377914,0.0008225352,0.00022637169,0.0008369731],"category_scores_gemma":[0.004508191,0.000111077985,0.000066761364,0.00019116666,0.00023409528,0.0004298023,0.00013939953,0.0011573414,0.0000024660615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00049106404,0.0001807833,0.8921018,0.000008281634,0.00011879642,0.0002579338,0.008076162,0.00016754288,0.00011631301,0.000072546834,0.006655455,0.09175327],"study_design_scores_gemma":[0.0015788114,0.00011897922,0.98311186,0.0001762952,0.00015923497,0.000014750994,0.0037214588,0.0011375033,0.00036699767,0.0008117797,0.008631984,0.00017035459],"about_ca_topic_score_codex":0.993163,"about_ca_topic_score_gemma":0.9997569,"teacher_disagreement_score":0.09158292,"about_ca_system_score_codex":0.010011543,"about_ca_system_score_gemma":0.01794711,"threshold_uncertainty_score":0.99378884},"labels":[],"label_agreement":null},{"id":"W2766164907","doi":"10.1016/j.jtho.2016.11.1329","title":"P2.03b-048 Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Biomarker; Lung cancer; Internal medicine; Oncology; Cancer; Adenocarcinoma","score_opus":0.03329229529869292,"score_gpt":0.4661179616146297,"score_spread":0.4328256663159368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766164907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98889744,0.00018637667,0.00019020849,0.0024003452,0.00059744145,0.0005264542,0.000008395513,0.000005830651,0.0071874955],"genre_scores_gemma":[0.98918194,0.000019635278,0.009707549,0.0005436019,0.00014103738,0.000032871932,0.0000027326548,0.000022507213,0.0003481555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900097,0.000035006862,0.00037123146,0.00016584902,0.00018849951,0.00023843805],"domain_scores_gemma":[0.9982784,0.00008021121,0.00071157375,0.00024557541,0.00048366326,0.00020060556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019359672,0.00013587192,0.00042662487,0.00021658228,0.00013404933,0.000049828086,0.0002491548,0.00007916524,0.000038574908],"category_scores_gemma":[0.00015903714,0.00009233518,0.00005134003,0.00014816519,0.000038569637,0.00030731925,0.00007740554,0.00022045361,0.0000032297094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014469051,0.00046827135,0.8190751,0.00007853946,0.00011788077,0.00021067534,0.000349002,0.00016624318,0.00039032503,4.6189874e-7,0.00056501705,0.1771316],"study_design_scores_gemma":[0.003868348,0.0017881817,0.9901946,0.0006382409,0.00045667906,0.00002742725,0.000067153764,0.00008485111,0.0004487483,0.000011370913,0.0023103433,0.000104008715],"about_ca_topic_score_codex":0.00015751811,"about_ca_topic_score_gemma":0.00027464252,"teacher_disagreement_score":0.17702758,"about_ca_system_score_codex":0.00068887597,"about_ca_system_score_gemma":0.0008666284,"threshold_uncertainty_score":0.37653196},"labels":[],"label_agreement":null},{"id":"W2766484950","doi":"10.1016/j.jtho.2017.09.072","title":"PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Nintedanib; Medicine; Pemetrexed; Internal medicine; Oncology; Placebo; Platelet-derived growth factor receptor; Hazard ratio; Progression-free survival; Gastroenterology; Urology; Pharmacology; Cisplatin; Chemotherapy; Pathology; Confidence interval; Receptor; Growth factor","score_opus":0.02231411731401505,"score_gpt":0.40432774178486103,"score_spread":0.38201362447084597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766484950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631816,0.00012721827,0.000012625756,0.0012612627,0.00032381405,0.0004787659,0.0000280691,0.0000091209395,0.0014409819],"genre_scores_gemma":[0.99770784,0.000017671495,0.0008214713,0.00028203634,0.00020742916,0.000011115415,0.000021010117,0.00002757141,0.0009038507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980211,0.00011657261,0.0007006084,0.0002484861,0.0006090854,0.00030409524],"domain_scores_gemma":[0.9981183,0.0000817081,0.0010054905,0.0003572225,0.00015636723,0.0002809281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004819801,0.00023370744,0.00071773713,0.00028811672,0.00023420833,0.000031128748,0.00030229503,0.000108477834,0.0005036965],"category_scores_gemma":[0.00020656952,0.00015754,0.0001485276,0.000109581284,0.00018562308,0.00031418662,0.00015225187,0.000374181,0.000026654634],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018482177,0.012543258,0.9118682,0.000039322218,0.00028292442,0.0014440558,0.0006202522,0.00001988416,0.00087041274,0.0000059221748,0.0014452718,0.0523783],"study_design_scores_gemma":[0.014684675,0.019771293,0.9611854,0.00023442211,0.0005125907,0.0002495445,0.0007324775,0.000095696254,0.0006646767,0.00006124111,0.0016262674,0.00018171227],"about_ca_topic_score_codex":0.0000635173,"about_ca_topic_score_gemma":0.00008258411,"teacher_disagreement_score":0.05219659,"about_ca_system_score_codex":0.00044417087,"about_ca_system_score_gemma":0.00023183445,"threshold_uncertainty_score":0.6424295},"labels":[],"label_agreement":null},{"id":"W2766758519","doi":"10.1016/j.jtho.2017.09.053","title":"PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Lung cancer; Internal medicine; Retrospective cohort study; Oncology; Cancer; Immunotherapy","score_opus":0.1576655767193353,"score_gpt":0.4429013988265487,"score_spread":0.28523582210721343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766758519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887583,0.0017482527,0.00047338766,0.00040165932,0.0012234484,0.00027271506,0.00013891942,0.0000030517867,0.006980216],"genre_scores_gemma":[0.9869831,0.0014723554,0.010754144,0.00011135021,0.00039980395,0.0000047073804,0.0000045190927,0.000033890083,0.0002361003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970207,0.00009890249,0.002032295,0.00037393605,0.000078198675,0.00039593113],"domain_scores_gemma":[0.9915105,0.00023193152,0.0068034143,0.0011188242,0.00021989214,0.00011540295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005376107,0.00020353058,0.0013185248,0.00039552248,0.00017538764,0.00006096038,0.0014553512,0.00014371678,0.00011965874],"category_scores_gemma":[0.0003671296,0.00018799804,0.00015350808,0.0001961871,0.00022883124,0.001094745,0.00027657297,0.00045230406,0.0000023989458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025017997,0.0006577132,0.6370533,0.0004327507,0.0003209539,0.00003644201,0.004451928,0.014932178,0.006192342,0.0012269095,0.00083743635,0.33135626],"study_design_scores_gemma":[0.0025328796,0.0010892112,0.92530876,0.00037608232,0.0001791779,0.000016791855,0.00090089365,0.0573024,0.0012539639,0.002242472,0.008375712,0.0004216375],"about_ca_topic_score_codex":0.012488959,"about_ca_topic_score_gemma":0.0063588778,"teacher_disagreement_score":0.3309346,"about_ca_system_score_codex":0.00046892333,"about_ca_system_score_gemma":0.00077789155,"threshold_uncertainty_score":0.994087},"labels":[],"label_agreement":null},{"id":"W2767212171","doi":"10.1016/j.jtho.2017.09.650","title":"MA 20.11 Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Dalhousie University; University of Calgary","funders":"","keywords":"Medicine; COPD; Spirometry; Lung cancer; Lung cancer screening; Obstructive lung disease; Population; Internal medicine; Wheeze; Asthma; Risk factor; Physical therapy; Bronchodilator; Environmental health","score_opus":0.03106835868313802,"score_gpt":0.4308351198996585,"score_spread":0.3997667612165205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767212171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98014414,0.011558455,0.00015574842,0.0057086884,0.0007247736,0.00065497024,0.00005661724,0.000014436968,0.0009821709],"genre_scores_gemma":[0.9953631,0.0006545385,0.0009499304,0.000076010685,0.0013334982,0.000043089145,0.000013629385,0.00004037299,0.0015257932],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725556,0.0003289421,0.0007477444,0.00039151043,0.00070996763,0.00056627486],"domain_scores_gemma":[0.9971182,0.00015181291,0.0010938288,0.000606038,0.00043415546,0.00059600803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078063837,0.00024654696,0.00069215964,0.0004531887,0.00027638208,0.000051389707,0.0005349839,0.00018904326,0.00064378453],"category_scores_gemma":[0.0006210752,0.00022069152,0.00026448094,0.00018038438,0.00032149642,0.0007893434,0.0002563134,0.0008809157,0.0000071485474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035371215,0.00031019317,0.78598315,0.001385106,0.00009995002,0.0045154667,0.000086350614,0.00045504273,0.000681778,0.000029778173,0.00018425418,0.20273182],"study_design_scores_gemma":[0.0010955037,0.00018027252,0.9837131,0.0013570716,0.00045383355,0.00061875395,0.00011990096,0.010297567,0.00006858905,0.00043947273,0.0014698877,0.00018604865],"about_ca_topic_score_codex":0.00031260095,"about_ca_topic_score_gemma":0.00028926856,"teacher_disagreement_score":0.20254576,"about_ca_system_score_codex":0.0036136608,"about_ca_system_score_gemma":0.0019132555,"threshold_uncertainty_score":0.94495976},"labels":[],"label_agreement":null},{"id":"W2767226828","doi":"10.1016/j.jtho.2017.09.1522","title":"P3.01-081 Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Mediastinoscopy; Pneumonectomy; Lung cancer; Surgery; Radiology; Oncology","score_opus":0.01989994853281816,"score_gpt":0.38961848470193605,"score_spread":0.3697185361691179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767226828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866803,0.0018788817,0.0004283734,0.004640225,0.0017483956,0.0004960352,0.000034130073,0.0000074787463,0.004086173],"genre_scores_gemma":[0.99021,0.0020459755,0.005880592,0.00054193794,0.00081092765,0.00005835321,0.0000027600681,0.000038386497,0.0004110658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978425,0.00015404634,0.0008140559,0.0002944334,0.0004753795,0.00041957613],"domain_scores_gemma":[0.9959694,0.0005357274,0.0019635628,0.000430191,0.0007636024,0.00033749145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000575531,0.00028877053,0.0011490114,0.00018269144,0.00012869011,0.000032592143,0.00033931722,0.00017961283,0.00036881742],"category_scores_gemma":[0.00028179507,0.00021808546,0.0003235877,0.00006848357,0.000218016,0.00027894185,0.00015085722,0.0005592414,0.000006503385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026107203,0.0026219434,0.80843884,0.0019357204,0.0022738443,0.0064629293,0.005889267,0.0006333373,0.008941813,0.000023844015,0.004210322,0.13246094],"study_design_scores_gemma":[0.015011355,0.008600294,0.9027993,0.0059868884,0.0034294594,0.00033049792,0.0013290804,0.00029905667,0.058748454,0.00023288483,0.002714065,0.00051868655],"about_ca_topic_score_codex":0.0002859736,"about_ca_topic_score_gemma":0.0008270863,"teacher_disagreement_score":0.13194224,"about_ca_system_score_codex":0.0012291046,"about_ca_system_score_gemma":0.0023288399,"threshold_uncertainty_score":0.88932675},"labels":[],"label_agreement":null},{"id":"W2767264551","doi":"10.1016/j.jtho.2017.09.332","title":"OA 02.06 Radioimmunotherapy Combining CTLA-4 Blockade or Low-Dose Cyclophosphamide with Local Radiation in Murine Malignant Mesothelioma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiation Therapy and Dosimetry","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Radioimmunotherapy; Mesothelioma; Cyclophosphamide; Oncology; Internal medicine; Cancer research; Immunology; Chemotherapy; Pathology; Antibody","score_opus":0.017677037131300075,"score_gpt":0.37999162719615287,"score_spread":0.3623145900648528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767264551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824614,0.0024945366,0.0015109921,0.005971918,0.0006407712,0.00034006507,0.0000032764024,0.000020546215,0.0007717592],"genre_scores_gemma":[0.9927941,0.001304516,0.003262426,0.0011656744,0.0005150211,0.000009472815,0.0000048149573,0.000046857713,0.00089713885],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99779207,0.00024691815,0.000940639,0.00022996719,0.00041821637,0.0003721883],"domain_scores_gemma":[0.99726087,0.00027393218,0.0015581942,0.0004924251,0.00019114917,0.0002234226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014174423,0.00024732522,0.0009358011,0.00052775437,0.00022367416,0.000059209153,0.000342,0.00027396157,0.00030930547],"category_scores_gemma":[0.00022989055,0.00016654414,0.00015586415,0.00026035405,0.0002698657,0.00035111164,0.000029155764,0.0006245067,0.000020923113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05818308,0.0022629201,0.1377221,0.00019453201,0.00090065214,0.0081226295,0.0024682777,0.0010038394,0.043978434,0.00010129998,0.001230737,0.7438315],"study_design_scores_gemma":[0.031628698,0.015506523,0.8218317,0.001445767,0.00049301726,0.01222695,0.0009452028,0.0036330482,0.07313306,0.0004739133,0.03801767,0.0006644436],"about_ca_topic_score_codex":0.00005883361,"about_ca_topic_score_gemma":0.000031699838,"teacher_disagreement_score":0.74316704,"about_ca_system_score_codex":0.00054540596,"about_ca_system_score_gemma":0.0007880012,"threshold_uncertainty_score":0.6791473},"labels":[],"label_agreement":null},{"id":"W2767305697","doi":"10.1016/j.jtho.2017.09.583","title":"MA 14.14 The First 100 Days: Early findings from the Lung Cancer Screening Pilot for People at High Risk in Ontario, Canada","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Cancer; Lung cancer screening; Environmental health; Oncology; Internal medicine","score_opus":0.06272549741094524,"score_gpt":0.3906640214714651,"score_spread":0.3279385240605199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767305697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629235,0.0012111224,0.00020115256,0.0333234,0.001465509,0.00039900548,0.000054398188,0.000004396587,0.00041750053],"genre_scores_gemma":[0.99447733,0.00014148568,0.0010166343,0.0025477048,0.00081203796,0.000033212604,0.0000047666595,0.000020276566,0.00094656163],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980996,0.00011450562,0.00060217583,0.00022033442,0.00051806413,0.0004452971],"domain_scores_gemma":[0.99712837,0.0008756448,0.0010708998,0.00046584732,0.00030302748,0.0001562164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013862719,0.0001908663,0.0006488503,0.0000553825,0.00097428,0.00008428058,0.0007816619,0.0001315882,0.00038915605],"category_scores_gemma":[0.00070860866,0.00011120095,0.00015173566,0.00008425481,0.0001157376,0.0002295161,0.00018618134,0.0010252654,0.0000018786984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043530283,0.000032142787,0.9086302,0.000014747916,0.00021928448,0.00020234041,0.001683027,0.00028299386,0.000041349733,0.000010353138,0.078064166,0.006466378],"study_design_scores_gemma":[0.0015963706,0.0009554006,0.9256747,0.00044832248,0.0005246316,0.00014683904,0.00047100201,0.00021772178,0.000111253474,0.00012410543,0.069610335,0.000119368626],"about_ca_topic_score_codex":0.9871343,"about_ca_topic_score_gemma":0.99929446,"teacher_disagreement_score":0.031553805,"about_ca_system_score_codex":0.0031856475,"about_ca_system_score_gemma":0.002463686,"threshold_uncertainty_score":0.83303577},"labels":[],"label_agreement":null},{"id":"W2767319519","doi":"10.1016/j.jtho.2017.09.621","title":"MA 18.01 Driving Improvements in Cancer Care Ontario's Smoking Cessation Initiative for Cancer Patients in Ontario, Canada","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Smoking cessation; Balanced scorecard; Cancer; Family medicine; General partnership; Cancer screening; Internal medicine","score_opus":0.07503777162174191,"score_gpt":0.45504164204481057,"score_spread":0.38000387042306866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767319519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927242,0.00013894697,0.000014242184,0.003171934,0.0021982398,0.0004724082,0.000013866628,0.000002113091,0.0012640626],"genre_scores_gemma":[0.99719536,0.00007193872,0.0005467671,0.0016655045,0.00021426071,0.00006938683,0.0000123078635,0.000013625438,0.00021081953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985253,0.00006322826,0.00067802874,0.00015320553,0.00026928514,0.0003109173],"domain_scores_gemma":[0.99814063,0.00008087143,0.0010694521,0.00011730177,0.00045452794,0.0001371978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003985605,0.00011960735,0.00049265096,0.00022571959,0.00017232916,0.000021635306,0.00014350103,0.0001266117,0.00040405546],"category_scores_gemma":[0.00012854021,0.00011207014,0.00005376259,0.00004950036,0.000028388999,0.00023578355,0.000039777893,0.00068956806,1.19182374e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006699928,0.00015209499,0.95071447,0.00017395141,0.000037553247,0.000082296865,0.0039309436,0.000025091607,0.00004813397,0.00000233609,0.0009702152,0.043192945],"study_design_scores_gemma":[0.0039595827,0.0005656681,0.96905553,0.0013094558,0.00007027848,0.0000070575848,0.00095866877,0.000026527918,0.00032759947,0.00010156065,0.023522114,0.00009592291],"about_ca_topic_score_codex":0.9854831,"about_ca_topic_score_gemma":0.9999327,"teacher_disagreement_score":0.043097023,"about_ca_system_score_codex":0.018016048,"about_ca_system_score_gemma":0.008999512,"threshold_uncertainty_score":0.99661857},"labels":[],"label_agreement":null},{"id":"W2767325000","doi":"10.1016/j.jtho.2017.09.598","title":"MA 16.03 Health Utility Scores in Patients with Thymic Malignancies Treated with Multimodality Therapy","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multimodality; Oncology; Linguistics","score_opus":0.26831073000815403,"score_gpt":0.49486147446489775,"score_spread":0.22655074445674372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767325000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738083,0.00091790996,0.00044526588,0.02252252,0.00034473094,0.0006801573,0.00010515873,0.000012274655,0.001163674],"genre_scores_gemma":[0.99319506,0.00020119213,0.0027644383,0.0035029624,0.0001601257,0.000019744895,0.000010229683,0.000027734102,0.0001184943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457234,0.00081540085,0.003559491,0.00039872184,0.00016636206,0.0004877002],"domain_scores_gemma":[0.98911977,0.0004568357,0.009202159,0.00071495253,0.00026142548,0.0002448329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015172029,0.00024130326,0.0018113316,0.00038143463,0.00035417013,0.00010198222,0.00056756963,0.00018518594,0.00017721562],"category_scores_gemma":[0.0010990249,0.00020099082,0.00011214103,0.00011606055,0.0002707586,0.00080182403,0.000047061883,0.00041028406,0.00007365973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014899083,0.0005972069,0.9872125,0.000106893036,0.00010136267,0.000007909748,0.000879046,0.00004852016,5.042441e-7,0.00035999934,0.0014834894,0.007712681],"study_design_scores_gemma":[0.0030626303,0.002259419,0.98700225,0.00021017887,0.000007246065,0.000013063573,0.00032115603,0.00013096127,0.000010439905,0.0020361524,0.004740799,0.00020571682],"about_ca_topic_score_codex":0.002621185,"about_ca_topic_score_gemma":0.0021978188,"teacher_disagreement_score":0.01938677,"about_ca_system_score_codex":0.0015459475,"about_ca_system_score_gemma":0.0008132922,"threshold_uncertainty_score":0.8196168},"labels":[],"label_agreement":null},{"id":"W2767414705","doi":"10.1016/j.jtho.2017.09.1521","title":"P3.01-080 Overall Survival (OS) of Pathological N2 Non-Small Cell Lung Cancer (NSCLC) After Surgical Resection","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Pneumonectomy; Lung cancer; Surgery; Adenocarcinoma; Univariate analysis; Cohort; Cancer; Oncology; Internal medicine; Multivariate analysis","score_opus":0.029349331792354577,"score_gpt":0.4168075862692782,"score_spread":0.3874582544769236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767414705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825047,0.002276057,0.00007642806,0.005058634,0.0019700357,0.00029811155,0.000016469494,0.000008140541,0.0077913837],"genre_scores_gemma":[0.9938791,0.002567569,0.0009951526,0.00019542429,0.0013652334,0.00003913592,0.0000027536457,0.000023056313,0.0009325939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804884,0.00023092466,0.0007169301,0.00026551195,0.00039602962,0.00034176707],"domain_scores_gemma":[0.99760276,0.00022948408,0.0011060679,0.00042530283,0.00037432372,0.0002620898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000941439,0.00021228292,0.0009821944,0.00014007691,0.000120853714,0.000030671465,0.00024146924,0.00033921446,0.00061401096],"category_scores_gemma":[0.00009424439,0.0001430642,0.00041117554,0.000055281533,0.00016743195,0.00013945461,0.000119135286,0.00057241984,0.000007884743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025159346,0.003289891,0.9099681,0.00064459175,0.0006801461,0.012112611,0.0005447016,0.00006064524,0.0020763113,0.00003818037,0.007386163,0.038039338],"study_design_scores_gemma":[0.008114238,0.008861063,0.9476624,0.0010648076,0.0018057766,0.0015525513,0.000108074455,0.00016399162,0.008161577,0.00012592187,0.022106275,0.00027330153],"about_ca_topic_score_codex":0.00018096864,"about_ca_topic_score_gemma":0.00025136102,"teacher_disagreement_score":0.03776604,"about_ca_system_score_codex":0.00082944264,"about_ca_system_score_gemma":0.0005696209,"threshold_uncertainty_score":0.6722989},"labels":[],"label_agreement":null},{"id":"W2767515241","doi":"10.1016/j.jtho.2017.09.748","title":"P1.02-016 Establishment of Lung Adenocarcinoma Organoid Cultures","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Organoid; Medicine; Adenocarcinoma; Lung; Pathology; Internal medicine; Cell biology; Cancer; Biology","score_opus":0.02089828376509513,"score_gpt":0.4626878867959317,"score_spread":0.4417896030308366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767515241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566175,0.004061028,0.00018642726,0.013128247,0.0013913475,0.00029617455,0.000015720016,0.000009730654,0.024293842],"genre_scores_gemma":[0.9931086,0.00024022274,0.003564752,0.0002517033,0.00047506453,0.0000040070786,0.000003944464,0.000012945798,0.0023387843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989709,0.000051944615,0.0004557329,0.00010854973,0.0002478595,0.00016498624],"domain_scores_gemma":[0.99808335,0.000050748302,0.001014204,0.00031266606,0.00038173422,0.00015729398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000275957,0.00010875613,0.0004927771,0.00012495808,0.00015117713,0.000026699323,0.00021280398,0.00011491408,0.00025469376],"category_scores_gemma":[0.00016245784,0.00007144662,0.00015515361,0.000049716782,0.00011997906,0.00019712096,0.000054116692,0.0002182727,0.0000070221026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049063833,0.0036362384,0.4958784,0.0007787576,0.004052385,0.0039471723,0.008130226,0.000039730505,0.033368163,0.0009116676,0.11657125,0.32777962],"study_design_scores_gemma":[0.004964467,0.0055713304,0.82504195,0.0005722466,0.0044520344,0.0033216714,0.0016573147,0.00003364778,0.029130725,0.0006276056,0.12440724,0.00021976704],"about_ca_topic_score_codex":0.000045330442,"about_ca_topic_score_gemma":0.00001666427,"teacher_disagreement_score":0.32916355,"about_ca_system_score_codex":0.00039685713,"about_ca_system_score_gemma":0.0006990172,"threshold_uncertainty_score":0.29135087},"labels":[],"label_agreement":null},{"id":"W2767533365","doi":"10.1016/j.jtho.2016.11.1711","title":"P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Subgroup analysis; Adverse effect; Oncology; Randomized controlled trial; Population; Gastroenterology; Confidence interval; Epidermal growth factor receptor; Cancer","score_opus":0.037671125392540354,"score_gpt":0.4715929215892605,"score_spread":0.43392179619672017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767533365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335927,0.0003075122,0.00061592436,0.0012561785,0.00083626574,0.00073215726,0.00027501388,0.0000092455875,0.0026084317],"genre_scores_gemma":[0.9944566,0.00014418007,0.003970794,0.00011444322,0.00030813192,0.00005266569,0.00029384726,0.000024234489,0.00063508464],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983745,0.00009189417,0.0007514654,0.00022230828,0.00031122827,0.00024856508],"domain_scores_gemma":[0.9964232,0.0005826514,0.0017181142,0.00034768935,0.0007350641,0.00019330354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002918056,0.00019843827,0.00094173977,0.00042303928,0.00024853996,0.000033128657,0.00016974409,0.00015716071,0.00017089967],"category_scores_gemma":[0.00047297432,0.00015449757,0.0005746478,0.00019713491,0.000117926036,0.00020415026,0.000030044856,0.00014408755,0.0000068127824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054903433,0.0110944165,0.17723365,0.00029344845,0.056470595,0.0014698479,0.015101679,0.0014966864,0.0005541727,0.00027777016,0.00246042,0.6786439],"study_design_scores_gemma":[0.030560542,0.03446758,0.87400675,0.00035794426,0.05022367,0.00008302068,0.0012164024,0.0009935311,0.001970416,0.00022154301,0.0055966307,0.0003019518],"about_ca_topic_score_codex":0.00019261244,"about_ca_topic_score_gemma":0.00031434384,"teacher_disagreement_score":0.6967731,"about_ca_system_score_codex":0.00107351,"about_ca_system_score_gemma":0.00048683045,"threshold_uncertainty_score":0.63002276},"labels":[],"label_agreement":null},{"id":"W2767552869","doi":"10.1016/j.jtho.2017.09.1471","title":"P3.01-030 CNS Metastases in EGFR Mutation Positive (EGFRm) NSCLC Patients: The Prognostic Relevance of Presenting Symptoms","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Relevance (law); Oncology; Internal medicine; Clinical significance","score_opus":0.01999370768669994,"score_gpt":0.4286620453183036,"score_spread":0.40866833763160365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767552869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99165237,0.00067261606,0.00020482799,0.0034284864,0.00045424738,0.0005256891,0.000023819633,0.000004626321,0.0030333125],"genre_scores_gemma":[0.997486,0.0000800863,0.0018696211,0.00017014578,0.00015249508,0.000017357923,0.000013586962,0.0000130427925,0.00019766019],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986536,0.00019700278,0.00057149946,0.00012297153,0.0002730874,0.00018185821],"domain_scores_gemma":[0.9973719,0.00054332305,0.0012750279,0.00023212277,0.00050805305,0.00006954728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004711863,0.000111272275,0.00042632385,0.00014421153,0.00016386413,0.000025562653,0.00018049114,0.00007082627,0.000023787548],"category_scores_gemma":[0.0015728081,0.00006894749,0.00012704064,0.00009747928,0.00016415874,0.00028513567,0.000047766716,0.00025678903,0.0000034233851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026385963,0.002906074,0.5046997,0.00022389021,0.0013896467,0.0009150049,0.0057816436,0.00031398376,0.0009375321,0.00025108672,0.0010343796,0.47890848],"study_design_scores_gemma":[0.0030507282,0.0035118598,0.9842641,0.00077672064,0.0018358727,0.00034780326,0.00097613194,0.00020722674,0.0020834426,0.0006849043,0.0021588898,0.00010232427],"about_ca_topic_score_codex":0.00009257465,"about_ca_topic_score_gemma":0.00008613115,"teacher_disagreement_score":0.47956443,"about_ca_system_score_codex":0.00029719318,"about_ca_system_score_gemma":0.00038133748,"threshold_uncertainty_score":0.28115973},"labels":[],"label_agreement":null},{"id":"W2767592913","doi":"10.1016/j.jtho.2017.09.847","title":"P1.03-043 30-Day Mortality Following Systemic Anti-Cancer Treatment for NSCLC at a Single Canadian Cancer Centre","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Cancer; Regimen; Logistic regression","score_opus":0.07523692787222827,"score_gpt":0.45004130643035706,"score_spread":0.37480437855812876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767592913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761503,0.009506592,0.000009711583,0.0070257997,0.0027277558,0.00071710744,0.00014867351,0.000011428941,0.0037026727],"genre_scores_gemma":[0.99293745,0.0012968034,0.0001278053,0.00029697476,0.0009309083,0.000094253075,0.00000635555,0.00003088817,0.0042785374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830806,0.00008940375,0.0005576753,0.00027321957,0.00024473076,0.0005269007],"domain_scores_gemma":[0.9979942,0.00011435919,0.0008426395,0.00033526903,0.00027788553,0.00043568498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039074093,0.0002686447,0.0011585992,0.00014174248,0.0006741438,0.000046609577,0.00018656059,0.000177561,0.00023636343],"category_scores_gemma":[0.0001313077,0.00018676168,0.00053526706,0.00005266032,0.00009337543,0.0001272448,0.000050989904,0.0001485607,0.000008905119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013649922,0.00071726006,0.5892561,0.00022403168,0.005353101,0.0017688349,0.0021904176,0.000032991185,0.005449123,0.000007882233,0.0057123834,0.38792285],"study_design_scores_gemma":[0.012886464,0.008818337,0.6488132,0.0023757021,0.01043222,0.00057113095,0.0017938764,0.00021159316,0.0106817875,0.00007086609,0.30260092,0.0007438933],"about_ca_topic_score_codex":0.025983686,"about_ca_topic_score_gemma":0.26563734,"teacher_disagreement_score":0.38717896,"about_ca_system_score_codex":0.008200322,"about_ca_system_score_gemma":0.0018390871,"threshold_uncertainty_score":0.995607},"labels":[],"label_agreement":null},{"id":"W2767633783","doi":"10.1016/j.jtho.2017.09.413","title":"OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Dalhousie University; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; National Lung Screening Trial; Lung cancer; Lung cancer screening; Stage (stratigraphy); Internal medicine; Population; Cancer; Oncology; Environmental health","score_opus":0.06523028321171212,"score_gpt":0.46511511806133976,"score_spread":0.39988483484962767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767633783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711292,0.002058453,0.00032477092,0.024522303,0.0006020412,0.0005648369,0.000021631056,0.000008169839,0.00076863443],"genre_scores_gemma":[0.9968713,0.00081034895,0.00048383072,0.0006287944,0.0005232256,0.000073743126,0.0000012134603,0.000020831381,0.0005867055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852604,0.00020138633,0.00043916638,0.00018171601,0.0002910559,0.00036065295],"domain_scores_gemma":[0.99808884,0.000104103536,0.00088237406,0.00034103022,0.0002409749,0.0003426867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010207673,0.00015342773,0.0005047688,0.0001024328,0.00063591666,0.00006962285,0.00025274698,0.000111789945,0.00014323794],"category_scores_gemma":[0.00017433881,0.00009035723,0.00015442727,0.00006811637,0.00008321431,0.00014748778,0.00003927717,0.0005128594,0.0000054633233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009190257,0.0010361229,0.7984423,0.000021137654,0.0017014527,0.0002215187,0.0014660785,0.0012319785,0.000084241394,0.0000071320096,0.06111311,0.13375589],"study_design_scores_gemma":[0.004534975,0.006450546,0.90052134,0.00029556837,0.010643386,0.00040903856,0.0016428308,0.036194976,0.0008968911,0.00014942864,0.037974697,0.0002863003],"about_ca_topic_score_codex":0.0387786,"about_ca_topic_score_gemma":0.14821297,"teacher_disagreement_score":0.1334696,"about_ca_system_score_codex":0.0012188802,"about_ca_system_score_gemma":0.0010219152,"threshold_uncertainty_score":0.9676223},"labels":[],"label_agreement":null},{"id":"W2767706435","doi":"10.1016/j.jtho.2017.10.019","title":"Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Pathology; Adenocarcinoma; Cytopathology; Lung; Lung cancer; Cancer; Cytology; Internal medicine","score_opus":0.03144488692909882,"score_gpt":0.4212168585437926,"score_spread":0.3897719716146938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767706435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962768,0.0009186248,0.000041914613,0.0017012486,0.00034948994,0.00017285346,0.000018456129,0.0000027620608,0.000517868],"genre_scores_gemma":[0.9958521,0.00028561192,0.0035514925,0.00012635736,0.00013616795,0.000010918599,0.000014392762,0.0000088963425,0.000014064207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985949,0.00022901161,0.0007194406,0.00016884546,0.00014475152,0.00014306729],"domain_scores_gemma":[0.9983931,0.00018615345,0.0010444057,0.00020610876,0.0000993111,0.00007092254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010105149,0.00011938957,0.000686623,0.00016344241,0.000037982598,0.000028010754,0.00012120653,0.00008640101,0.000038733164],"category_scores_gemma":[0.00038530116,0.00009122195,0.00006796573,0.00004819531,0.000102996666,0.0002259376,0.0001069569,0.00024542556,3.2582705e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015449497,0.0007662762,0.96576065,0.00022199885,0.000131753,0.0033639825,0.001183414,0.000016420403,0.0018573842,0.000010215199,0.00031158098,0.024831373],"study_design_scores_gemma":[0.0014245842,0.0008683547,0.99433696,0.0013179168,0.00024608764,0.00011067668,0.00012423658,0.0002166392,0.00086967007,0.00031373964,0.000104762,0.00006635907],"about_ca_topic_score_codex":0.000987902,"about_ca_topic_score_gemma":0.00070438354,"teacher_disagreement_score":0.028576322,"about_ca_system_score_codex":0.000644977,"about_ca_system_score_gemma":0.00014533034,"threshold_uncertainty_score":0.3719923},"labels":[],"label_agreement":null},{"id":"W2767730672","doi":"10.1016/j.jtho.2017.09.1460","title":"P3.01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T790M; Epidermal growth factor; Cancer research; Epidermal growth factor receptor; Oncology; Multicenter study; Pathology; Internal medicine; Cancer","score_opus":0.04505640761547724,"score_gpt":0.377962518376672,"score_spread":0.33290611076119475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767730672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976875,0.000055522676,0.00038946222,0.0003516822,0.0007675398,0.0003419274,0.00006734363,0.0000017643531,0.00033723598],"genre_scores_gemma":[0.9949222,0.000011125106,0.004174556,0.00013741925,0.0006846866,0.000009074436,0.000012899995,0.000023594435,0.000024442781],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987206,0.000089200556,0.00060003105,0.00019383756,0.00011839712,0.00027792927],"domain_scores_gemma":[0.99746376,0.0002208923,0.0012993353,0.00027274416,0.0005556556,0.00018760865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050687854,0.0001414319,0.00035487243,0.000111597474,0.00024414907,0.000052406493,0.00035830753,0.00012861073,0.000009557566],"category_scores_gemma":[0.0028539423,0.00013578692,0.00012229792,0.000031741172,0.000055655502,0.000016344473,0.00009250728,0.0001453717,0.0000010491481],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018223007,0.001106719,0.40242478,0.00022341976,0.00061944657,0.00026929763,0.0011405812,0.0016736743,0.51059765,0.000030231024,0.0017002114,0.07839172],"study_design_scores_gemma":[0.009904808,0.018921483,0.48334587,0.00029795166,0.00095329183,0.00090973475,0.003099081,0.005238477,0.461926,0.00036789585,0.013961489,0.0010738919],"about_ca_topic_score_codex":0.0029540735,"about_ca_topic_score_gemma":0.0113790305,"teacher_disagreement_score":0.080921106,"about_ca_system_score_codex":0.00013391869,"about_ca_system_score_gemma":0.00072117295,"threshold_uncertainty_score":0.6349766},"labels":[],"label_agreement":null},{"id":"W2767799213","doi":"10.1016/j.jtho.2016.11.1076","title":"P2.01-024 Expression of miR-106 Paralogs Improves Prognostic Value of Mesenchymal Signatures but Only miR-106b Promotes Invasiveness","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"microRNA; Cancer research; Epithelial–mesenchymal transition; Adenocarcinoma; Transfection; Biology; Lymph node; Lung cancer; Phenotype; Mesenchymal stem cell; Cancer; Downregulation and upregulation; Medicine; Gene; Pathology; Immunology; Cell biology; Genetics","score_opus":0.015118931058136794,"score_gpt":0.3523047076795823,"score_spread":0.3371857766214455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767799213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99572134,0.0025246402,0.00034387538,0.00034476205,0.0004733091,0.00036719776,0.000036374455,0.0000042428155,0.00018425827],"genre_scores_gemma":[0.99417657,0.000112787005,0.00512776,0.000034592384,0.00036997037,0.000008750646,0.000027522326,0.0000276601,0.00011440293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796647,0.00035390895,0.00081719,0.0002831023,0.00030457086,0.00027473908],"domain_scores_gemma":[0.996193,0.00011662379,0.002420593,0.0005588102,0.0005629785,0.00014801248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069335324,0.00023110324,0.0005981902,0.000138229,0.00012347977,0.000027244865,0.00071037427,0.0004895529,0.000022917973],"category_scores_gemma":[0.001211837,0.00018606363,0.0002974539,0.00005312133,0.0003924473,0.000034657565,0.0002664733,0.00026167498,0.0000014594806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013895544,0.00046248053,0.007125884,0.00030869042,0.00015523785,0.000047711572,0.00008540051,0.00008965376,0.9825937,0.000031599207,0.00065828906,0.007051784],"study_design_scores_gemma":[0.0006076975,0.001772347,0.105507426,0.00032155163,0.00019908948,0.00014833699,0.00008292976,0.000040909257,0.8894235,0.00054748077,0.0011816748,0.00016704766],"about_ca_topic_score_codex":0.000019490815,"about_ca_topic_score_gemma":0.000018817327,"teacher_disagreement_score":0.09838154,"about_ca_system_score_codex":0.00004860368,"about_ca_system_score_gemma":0.00084625307,"threshold_uncertainty_score":0.7587455},"labels":[],"label_agreement":null},{"id":"W2767853540","doi":"10.1016/j.jtho.2016.11.929","title":"P1.07-017 Indications for Adjuvant Mediastinal Radiation in Surgically Resected Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Proportional hazards model; Pneumonectomy; Resection margin; Hazard ratio; Radiation therapy; Lung cancer; Comorbidity; Survival analysis; Cancer; Stage (stratigraphy); Oncology; Internal medicine; Surgery; Resection; Confidence interval","score_opus":0.05568723844528266,"score_gpt":0.5043517592412755,"score_spread":0.44866452079599284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767853540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95635444,0.005570194,0.00061043026,0.03257706,0.0009976821,0.0009231168,0.00003334282,0.000011966174,0.0029217813],"genre_scores_gemma":[0.9915765,0.002771493,0.0031839197,0.00019105124,0.001180209,0.00012815358,0.000007966402,0.000021168064,0.00093955576],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982472,0.00018157226,0.0006352879,0.00018587486,0.00037374656,0.00037632298],"domain_scores_gemma":[0.99706066,0.0006446165,0.0011128476,0.00029462698,0.00065532234,0.00023194287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016660432,0.00012909537,0.00063781923,0.00037647277,0.00025670437,0.00003501668,0.00037534756,0.00016419015,0.00013010102],"category_scores_gemma":[0.002597822,0.00010010359,0.00014449356,0.00011484724,0.00020074804,0.00016658065,0.00010239577,0.0006371361,0.00000476906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013828091,0.0013870317,0.4947798,0.0013296728,0.0007051833,0.0014414807,0.0035953382,0.00012547147,0.012162916,0.00008788963,0.044630498,0.42592663],"study_design_scores_gemma":[0.0060279574,0.0026725866,0.94439834,0.0006516972,0.00056138524,0.00026701562,0.0003180507,0.0009822015,0.003077893,0.0002949715,0.040567394,0.00018052303],"about_ca_topic_score_codex":0.00015211814,"about_ca_topic_score_gemma":0.00088221993,"teacher_disagreement_score":0.44961852,"about_ca_system_score_codex":0.0011531332,"about_ca_system_score_gemma":0.0022710874,"threshold_uncertainty_score":0.4082106},"labels":[],"label_agreement":null},{"id":"W2767905976","doi":"10.1016/j.jtho.2017.09.429","title":"OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Pemetrexed; Carboplatin; Chemotherapy; Gemcitabine; Internal medicine; Oncology; Cisplatin; Neutropenia; Surgery; Cancer; Immunotherapy","score_opus":0.03107285707539334,"score_gpt":0.40509584104625496,"score_spread":0.37402298397086164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767905976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9126274,0.0017900005,0.0050261472,0.07169034,0.0029193615,0.0012814935,0.00006277881,0.000060426584,0.004542053],"genre_scores_gemma":[0.96656173,0.00087668316,0.0236187,0.0046838247,0.0014111297,0.000037968686,0.000025750835,0.00008124933,0.0027029433],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980126,0.00006175558,0.0008865733,0.00026495356,0.0003211966,0.0004529072],"domain_scores_gemma":[0.9968092,0.00017486232,0.0017675252,0.00060962245,0.0004290306,0.00020979774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012157528,0.00027476813,0.000988146,0.00020015075,0.0003677829,0.00006634211,0.0004836671,0.0003113854,0.0005933132],"category_scores_gemma":[0.00019339024,0.00021849992,0.00051159126,0.00009586113,0.00024657373,0.00026103342,0.000038517985,0.00043555736,0.000020002002],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26629928,0.00087990344,0.0012672741,0.00041953914,0.0010708509,0.0002829672,0.00041896204,0.00025695426,0.044499356,0.000032435546,0.027815651,0.6567568],"study_design_scores_gemma":[0.06113664,0.009733895,0.0069840318,0.0007760606,0.00056815235,0.00075357157,0.00021478298,0.0012722893,0.05726826,0.00041455936,0.86038023,0.0004975156],"about_ca_topic_score_codex":0.000022828648,"about_ca_topic_score_gemma":0.00008717061,"teacher_disagreement_score":0.8325646,"about_ca_system_score_codex":0.00066862995,"about_ca_system_score_gemma":0.00083016016,"threshold_uncertainty_score":0.89101684},"labels":[],"label_agreement":null},{"id":"W2767979847","doi":"10.1016/j.jtho.2017.09.414","title":"OA 15.02 Benefits, Harms, and Economic Efficiency of Low-Dose CT Lung Cancer Screening Strategies in a Population-Based Setting","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Partenariat Canadien Contre Le Cancer; Terry Fox Research Institute","keywords":"Medicine; Overdiagnosis; Lung cancer screening; Nodule (geology); Lung cancer; Population; Cost effectiveness; Radiology; Oncology; Environmental health; Risk analysis (engineering)","score_opus":0.0235858302666893,"score_gpt":0.41730641413511543,"score_spread":0.3937205838684261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767979847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154073,0.0037004433,0.000036743917,0.0039350064,0.00031785032,0.00019072482,0.000013504903,0.000003837467,0.00026114815],"genre_scores_gemma":[0.9976737,0.0004051231,0.0015653787,0.00011419105,0.00020411906,0.000010042593,0.0000031709194,0.000012145889,0.000012153382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989483,0.000058450052,0.00053777726,0.00015030437,0.00012454057,0.00018067863],"domain_scores_gemma":[0.99844474,0.00017752717,0.0010212954,0.00017836512,0.00008203747,0.000096045434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005041201,0.000120278775,0.0005405683,0.00018364638,0.000105132036,0.000041307692,0.000117288284,0.00006121439,0.000068198315],"category_scores_gemma":[0.000071571136,0.000095182215,0.00009354503,0.00003423617,0.00006162415,0.0002093979,0.00003334535,0.00020195117,5.4992586e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052821456,0.00021719262,0.9030354,0.0002497221,0.0001224202,0.0001611488,0.00017838867,0.0062675215,0.000111072586,0.0000488726,0.00011241533,0.08896761],"study_design_scores_gemma":[0.0024663105,0.0006753099,0.987645,0.0015032461,0.00027963903,0.00010401131,0.00023744321,0.005716718,0.0011270333,0.00004965422,0.00010428531,0.000091390735],"about_ca_topic_score_codex":0.0015404734,"about_ca_topic_score_gemma":0.001662336,"teacher_disagreement_score":0.08887622,"about_ca_system_score_codex":0.000656116,"about_ca_system_score_gemma":0.0006972811,"threshold_uncertainty_score":0.3881418},"labels":[],"label_agreement":null},{"id":"W2768024069","doi":"10.1016/j.jtho.2017.09.470","title":"MA 04.02 Assessing the Psychosocial Needs of Newly Diagnosed NSCLC Patients: Identifying the Population Most At-Risk","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Psychosocial; Oncology; Population; Internal medicine; Environmental health; Psychiatry","score_opus":0.036433115736729485,"score_gpt":0.43148478997891615,"score_spread":0.3950516742421867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768024069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855648,0.00055371085,0.00030249322,0.007016273,0.004058817,0.0002181894,0.000008358198,0.0000062522718,0.002271079],"genre_scores_gemma":[0.9975579,0.00022081833,0.00013264958,0.000512554,0.0013169575,0.0000048499683,0.000005810225,0.000019158228,0.00022932464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981725,0.00041797376,0.0006466568,0.00009457435,0.0004644506,0.00020381353],"domain_scores_gemma":[0.99620366,0.00042373542,0.0023844142,0.00042814988,0.00047297383,0.00008708505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014083083,0.00012768191,0.00045251555,0.00012358291,0.0006844684,0.0000938953,0.00040830462,0.00016997791,0.00008571791],"category_scores_gemma":[0.0009049432,0.00007259277,0.0002532162,0.00015791152,0.0001788453,0.00029327432,0.00010613204,0.0005688084,0.0000044002663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007685871,0.00016814539,0.6337384,0.00004532134,0.00014574247,0.000027385515,0.004183722,0.000011499494,0.0002631737,0.00002429072,0.0030139214,0.35760978],"study_design_scores_gemma":[0.0013392575,0.0005558725,0.9821552,0.00025739445,0.0005981823,0.000077415854,0.004313867,0.000030049172,0.00019083422,0.00038904115,0.01001101,0.00008185697],"about_ca_topic_score_codex":0.0009192987,"about_ca_topic_score_gemma":0.001443547,"teacher_disagreement_score":0.35752794,"about_ca_system_score_codex":0.000362718,"about_ca_system_score_gemma":0.00020448904,"threshold_uncertainty_score":0.5264447},"labels":[],"label_agreement":null},{"id":"W2768069700","doi":"10.1016/j.jtho.2017.09.1456","title":"P3.01-015 Differential Outcomes between First and Second Generation TKIs in Patients with Activating EGFR Mutations in NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Differential (mechanical device); Oncology; Internal medicine","score_opus":0.028821338462236397,"score_gpt":0.42280130659606613,"score_spread":0.39397996813382974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768069700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621916,0.000034630164,0.0001526351,0.002668317,0.00018126382,0.00023063652,0.00001174961,0.0000027481192,0.0004988641],"genre_scores_gemma":[0.99790365,0.000005949052,0.0016826421,0.00006706716,0.00016543822,0.000008315623,0.000024307687,0.000010424026,0.00013224078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99919647,0.000051491643,0.0003651358,0.000110685614,0.00014548999,0.00013070893],"domain_scores_gemma":[0.99908066,0.00010241078,0.00051033415,0.00011572071,0.00011100886,0.00007987492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013824357,0.00009769368,0.00038467287,0.0002063006,0.00015258713,0.000036559988,0.00006239993,0.00008374164,0.000055980683],"category_scores_gemma":[0.00012154122,0.00006769079,0.000036052705,0.00004914694,0.00005712968,0.00028187133,0.00002399595,0.0002213402,8.915257e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026634373,0.00027115535,0.9295073,0.000022119859,0.00014599627,0.0000405541,0.00093112746,0.000016667425,0.000062043146,0.0000057026655,0.000050173883,0.0686808],"study_design_scores_gemma":[0.0041542994,0.0010693715,0.9935928,0.000111008565,0.00023417077,0.000015194445,0.00016096041,0.000059663565,0.00010417763,0.0000364543,0.00039973177,0.0000621767],"about_ca_topic_score_codex":0.00006213154,"about_ca_topic_score_gemma":0.0014856255,"teacher_disagreement_score":0.068618625,"about_ca_system_score_codex":0.00032695231,"about_ca_system_score_gemma":0.00019761606,"threshold_uncertainty_score":0.276035},"labels":[],"label_agreement":null},{"id":"W2768085936","doi":"10.1016/j.jtho.2017.09.1148","title":"P2.01-046 Clinical Characteristics of Survival with De Novo Versus Relapsed Metastatic Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Histology; Performance status; Cancer; Proportional hazards model; Log-rank test; Stage (stratigraphy); Multivariate analysis; Retrospective cohort study; Survival analysis","score_opus":0.05919334601014433,"score_gpt":0.4998981719931777,"score_spread":0.4407048259830334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768085936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896947,0.00032864208,0.0010426828,0.0021438003,0.0021211717,0.00024583648,0.00003302851,0.0000051192064,0.004385013],"genre_scores_gemma":[0.9842302,0.00055876595,0.013488892,0.00015321755,0.0005683937,0.000009661806,0.0000062294757,0.00002541141,0.00095920265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998511,0.00014253307,0.0007413647,0.0001440426,0.0002250065,0.00023605293],"domain_scores_gemma":[0.99685204,0.0003733996,0.001765355,0.00032647347,0.00044533762,0.00023741889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079590775,0.00014459238,0.00089006877,0.00009621963,0.000116149255,0.000019650653,0.0002090117,0.00012180423,0.000102704726],"category_scores_gemma":[0.00027240659,0.00009860718,0.00018781036,0.00005418506,0.00018139614,0.00009775654,0.000038797458,0.00043437234,0.0000034944708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033216536,0.003280111,0.81911814,0.00083105895,0.0048976345,0.0046208673,0.0021102547,0.000059523896,0.002112166,0.000049870767,0.0020250923,0.12767877],"study_design_scores_gemma":[0.0214826,0.013124468,0.93262297,0.00077348854,0.014948061,0.0006756055,0.0008629479,0.00034361906,0.0015335116,0.00003737315,0.013330846,0.00026448307],"about_ca_topic_score_codex":0.00010006032,"about_ca_topic_score_gemma":0.00018330697,"teacher_disagreement_score":0.12741427,"about_ca_system_score_codex":0.0004063652,"about_ca_system_score_gemma":0.0025250486,"threshold_uncertainty_score":0.44793278},"labels":[],"label_agreement":null},{"id":"W2768204041","doi":"10.1016/j.jtho.2016.11.1585","title":"P3.01-019 Desmoplasia is Associated with Poor Prognosis and Carcinoma-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Desmoplasia; Medicine; Adenocarcinoma; Lung cancer; Pathology; Oncology; Internal medicine; Cancer; Carcinoma; Stroma; Immunohistochemistry","score_opus":0.020913697856810916,"score_gpt":0.3924394119058729,"score_spread":0.371525714049062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768204041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396497,0.00067697023,0.000018633596,0.0035153877,0.0001820846,0.00046624203,0.000040248557,0.000008683304,0.0011267806],"genre_scores_gemma":[0.99801487,0.0001335744,0.0007013922,0.0003931181,0.000094196184,0.000035118872,0.000009332133,0.000028229431,0.00059016043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869174,0.00010944878,0.00043954822,0.00021944303,0.00020987801,0.00032993426],"domain_scores_gemma":[0.998101,0.00010302929,0.0010976664,0.00016796353,0.00031961768,0.00021072241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035199118,0.00019756304,0.0006923087,0.00016731131,0.00021270638,0.000051998155,0.00014536618,0.00022998349,0.000042014217],"category_scores_gemma":[0.00010193084,0.00014394538,0.00010971663,0.000111240326,0.000107716536,0.00017631373,0.00005188941,0.00037248648,0.0000014059266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086951314,0.0007885321,0.98827124,0.00009971049,0.00074318465,0.00079780887,0.0011745386,0.000017784612,0.0013394085,5.137431e-7,0.0012568755,0.0046408796],"study_design_scores_gemma":[0.0049545467,0.0025108603,0.9828863,0.00079598074,0.0017373238,0.00022664046,0.00021275828,0.00042904622,0.0058524166,0.000010034257,0.00023152775,0.00015256039],"about_ca_topic_score_codex":0.00049925334,"about_ca_topic_score_gemma":0.0034028755,"teacher_disagreement_score":0.005384946,"about_ca_system_score_codex":0.0009561201,"about_ca_system_score_gemma":0.00091292034,"threshold_uncertainty_score":0.5869922},"labels":[],"label_agreement":null},{"id":"W2768218337","doi":"10.1016/j.jtho.2017.11.046","title":"P2.05-019 Overall Survival (OS) of Pathological T1N0 Non-Small Cell Lung Cancer (NSCLC) After Resection","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval","funders":"","keywords":"Medicine; Pathological; Lung cancer; Oncology; Resection; Internal medicine; Radiology; Surgery","score_opus":0.028320343359701267,"score_gpt":0.44581546228381236,"score_spread":0.41749511892411106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768218337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798725,0.0012343089,0.00046474108,0.0031993398,0.0021956016,0.0002826624,0.000025922614,0.000006767914,0.0127181355],"genre_scores_gemma":[0.99350023,0.0005886742,0.002116638,0.0002826192,0.0008199296,0.000024300656,0.0000040722744,0.000019083647,0.0026444308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986424,0.00012672902,0.0005396792,0.00018193337,0.00026322133,0.00024605112],"domain_scores_gemma":[0.9979924,0.00009560701,0.0009842115,0.0003268762,0.00042916875,0.00017176713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051396847,0.00015382528,0.00062669173,0.00014422665,0.00013491088,0.000024722052,0.0001863066,0.00023133683,0.00033019474],"category_scores_gemma":[0.00010887657,0.00010708835,0.0002443705,0.00005153294,0.000121003424,0.00016218568,0.00007009092,0.00041657937,0.0000067762658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019161364,0.003230587,0.825914,0.0008805618,0.001419072,0.005681579,0.0034875656,0.0002301566,0.023286961,0.00006210999,0.013200895,0.10344511],"study_design_scores_gemma":[0.004572226,0.004505956,0.9697054,0.0005053527,0.00209898,0.0006601944,0.00028698274,0.0001488448,0.005089451,0.00018672255,0.01205636,0.0001835123],"about_ca_topic_score_codex":0.00019619173,"about_ca_topic_score_gemma":0.0001974728,"teacher_disagreement_score":0.14379138,"about_ca_system_score_codex":0.00042729414,"about_ca_system_score_gemma":0.00078805804,"threshold_uncertainty_score":0.4366936},"labels":[],"label_agreement":null},{"id":"W2768218715","doi":"10.1016/j.jtho.2016.11.1611","title":"P3.01-045 Sex Differences in CXCR4-Dependent Motility of NSCLC Cells","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Stromal cell; Motility; Estrogen receptor; Cancer research; Lung cancer; Cytokine; Estrogen; CXCR4; Metastasis; Internal medicine; Receptor; Chemokine; Oncology; Immunology; Cancer; Biology; Cell biology; Breast cancer","score_opus":0.06156221202117612,"score_gpt":0.4305156784832454,"score_spread":0.3689534664620693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768218715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890096,0.00014989845,0.00028375743,0.0024260108,0.0011266216,0.00011914554,0.00000949784,0.000004912588,0.006870547],"genre_scores_gemma":[0.997698,0.0001067092,0.0010106561,0.00010625576,0.00035657137,0.0000017427492,7.8484425e-7,0.00000922397,0.000710037],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99846625,0.0001511079,0.00077594473,0.00013887834,0.00027932742,0.00018848239],"domain_scores_gemma":[0.99790275,0.00020995918,0.0011644453,0.00034942463,0.00023898017,0.00013445085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009518778,0.00011935439,0.00074701227,0.0002221145,0.00008283119,0.00002099959,0.00028845694,0.00015243949,0.0004715498],"category_scores_gemma":[0.0003840835,0.00008813047,0.00020709606,0.000048777292,0.00014702683,0.00015410643,0.0000747853,0.0006754294,0.00001059864],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004037616,0.0033983686,0.2059632,0.00028280026,0.00035340298,0.0012430084,0.0017322788,0.00004116033,0.5848676,0.000058509006,0.0028525556,0.19516952],"study_design_scores_gemma":[0.0027924308,0.00741396,0.6278347,0.0010215003,0.00046369704,0.0015696392,0.0017096612,0.00073531177,0.34544763,0.0009027129,0.009890271,0.00021850875],"about_ca_topic_score_codex":0.00016150998,"about_ca_topic_score_gemma":0.00013079791,"teacher_disagreement_score":0.4218715,"about_ca_system_score_codex":0.00017499753,"about_ca_system_score_gemma":0.0003747434,"threshold_uncertainty_score":0.51631397},"labels":[],"label_agreement":null},{"id":"W2768399638","doi":"10.1016/j.jtho.2017.07.033","title":"A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Adenocarcinoma; KRAS; ROS1; Lung cancer; Oncology; Cancer; Cancer research; Internal medicine; Colorectal cancer","score_opus":0.025807942625664194,"score_gpt":0.3868548193563452,"score_spread":0.361046876730681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768399638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75237346,0.0028229528,0.00011665202,0.23575075,0.0004800108,0.0025415097,0.0001426306,0.000025098296,0.005746925],"genre_scores_gemma":[0.9495079,0.00009927533,0.0150326295,0.025685139,0.0033296559,0.00014232787,0.00017929934,0.0001452374,0.005878547],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9977102,0.00024736213,0.0007893835,0.00035267966,0.0005183995,0.00038194572],"domain_scores_gemma":[0.9946803,0.0001833444,0.0032319173,0.00060454634,0.0011029891,0.0001969037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028082525,0.00041474332,0.0015169681,0.0005113119,0.0001806545,0.000023585719,0.00025081536,0.00070063956,0.00016122728],"category_scores_gemma":[0.00013529032,0.00024512157,0.00023457265,0.00016034553,0.00031415923,0.00016821758,0.00005916579,0.0018822612,0.000006149396],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0084985,0.0009200196,0.0030088166,0.0017800091,0.002668875,0.8793583,0.0017422779,0.0000096331505,0.0017153549,0.0000019608885,0.075561464,0.024734795],"study_design_scores_gemma":[0.0063113794,0.042476617,0.004833222,0.0064532445,0.011126722,0.7983918,0.0012398689,0.000016059847,0.0034526077,0.00011100595,0.12497682,0.0006106285],"about_ca_topic_score_codex":0.0002750843,"about_ca_topic_score_gemma":0.0001444481,"teacher_disagreement_score":0.2100656,"about_ca_system_score_codex":0.00066470075,"about_ca_system_score_gemma":0.0046731555,"threshold_uncertainty_score":0.99957675},"labels":[],"label_agreement":null},{"id":"W2768571810","doi":"10.1016/j.jtho.2017.11.023","title":"P2.04-010 Afatinib in Combination with Pembrolizumab in Patients with Stage IIIB/IV Squamous Cell Carcinoma (SCC) of the Lung","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Pembrolizumab; Stage (stratigraphy); Squamous-cell carcinoma of the lung; Basal cell; Oncology; Internal medicine; Lung; Cancer; Immunotherapy; Gefitinib","score_opus":0.011921780221711545,"score_gpt":0.37027959043291175,"score_spread":0.3583578102112002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768571810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936497,0.00010483463,0.000022680584,0.0011501919,0.00021711481,0.0005034894,0.000009278597,0.0000023433975,0.0043403357],"genre_scores_gemma":[0.9987165,0.0000052608525,0.00051373604,0.00007595478,0.000036589525,0.00000953692,0.000005018723,0.000015984979,0.0006214273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886113,0.00011295734,0.00042448158,0.000118572774,0.00031064684,0.000172192],"domain_scores_gemma":[0.9981641,0.00007573269,0.0010855887,0.00030068282,0.00030556475,0.000068313864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024215411,0.0001252445,0.00043761602,0.0001863761,0.00009067408,0.000013686129,0.00018747177,0.00009036743,0.000029124987],"category_scores_gemma":[0.00007716984,0.000065539316,0.000058607166,0.000118888296,0.00012223625,0.00017831178,0.0000363349,0.00033516495,8.4213565e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041770786,0.0016446655,0.986955,0.00011425045,0.000043229677,0.000157217,0.0015434265,0.00010860177,0.00006057524,0.000023978528,0.00010068728,0.005071281],"study_design_scores_gemma":[0.014745094,0.004834849,0.97849286,0.00017173187,0.00029297726,0.000036124708,0.00039002582,0.000084856336,0.0005295623,0.000027510221,0.00032772063,0.00006672049],"about_ca_topic_score_codex":0.0002091919,"about_ca_topic_score_gemma":0.00052560493,"teacher_disagreement_score":0.010568015,"about_ca_system_score_codex":0.0005975782,"about_ca_system_score_gemma":0.0007587492,"threshold_uncertainty_score":0.26726156},"labels":[],"label_agreement":null},{"id":"W2769169845","doi":"10.1016/j.jtho.2016.11.979","title":"P1.08-012 Characterizing Time to Care for Lung Cancer Surgical Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Referral; Lung cancer; Malignancy; Cancer; General surgery; Population; Retrospective cohort study; Health care; Emergency medicine; Surgery; Family medicine; Internal medicine","score_opus":0.05925147134889998,"score_gpt":0.48203623904904014,"score_spread":0.4227847677001402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769169845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871438,0.00079481245,0.000082347055,0.0070855725,0.0011400607,0.0003882067,0.00002966154,0.000008126254,0.0033273844],"genre_scores_gemma":[0.9923982,0.00006463112,0.002955849,0.0014326599,0.0020284436,0.000021980952,0.000008513682,0.000020229792,0.0010694751],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987462,0.000047445366,0.0004435881,0.0001535778,0.00029816185,0.00031099163],"domain_scores_gemma":[0.99799645,0.000079688594,0.0006677484,0.00022495714,0.000725459,0.00030570853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043115634,0.00012534203,0.0006029654,0.000104440194,0.00026182635,0.00004351935,0.00028240032,0.00015029787,0.00033832563],"category_scores_gemma":[0.00032256873,0.000098631346,0.00020423245,0.000045118202,0.000045308334,0.00024438355,0.00008472744,0.00026857472,0.000025608593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01158699,0.00021650863,0.17886701,0.00032807933,0.0002938065,0.0008051326,0.0016151323,0.000024728102,0.0042837267,0.00001097397,0.03116374,0.77080417],"study_design_scores_gemma":[0.0030689198,0.004409625,0.23906326,0.0012387286,0.0006782399,0.00052396697,0.00030517264,0.00017223464,0.002226025,0.00001434018,0.74805206,0.00024741076],"about_ca_topic_score_codex":0.00003448041,"about_ca_topic_score_gemma":0.000024339786,"teacher_disagreement_score":0.77055675,"about_ca_system_score_codex":0.0006247715,"about_ca_system_score_gemma":0.0004336357,"threshold_uncertainty_score":0.40220696},"labels":[],"label_agreement":null},{"id":"W2769646570","doi":"10.1016/j.jtho.2016.11.1351","title":"P2.03b-070 Establishment of Organoid Cell Lines from Lung Squamous Cell Carcinoma","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Organoid; Matrigel; Medicine; Cancer research; Cell culture; Cell; Pathology; Doubling time; Biology; Cell biology","score_opus":0.02406334417559696,"score_gpt":0.37480552016227703,"score_spread":0.35074217598668006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769646570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97995234,0.005152859,0.00022260776,0.0024094111,0.0021776329,0.0001958293,0.00003910118,0.0000070443343,0.009843204],"genre_scores_gemma":[0.98888844,0.00035285478,0.0071472316,0.0003195198,0.0014175238,0.0000025730747,0.000007021502,0.000032529915,0.0018323198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981115,0.00011879821,0.00086211204,0.00021481838,0.00040313983,0.00028962322],"domain_scores_gemma":[0.99643886,0.00019782806,0.0019100083,0.0006126986,0.00053313357,0.00030749998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006488122,0.00020227084,0.0010078038,0.00020123342,0.00012994386,0.000037078924,0.00042841866,0.0002099229,0.0006178269],"category_scores_gemma":[0.00019658536,0.00015755047,0.0003146361,0.00008262669,0.00014772298,0.00017786876,0.00014789718,0.0004904454,0.0000151612285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009402422,0.0041005,0.10146618,0.0015046461,0.0003060758,0.0038462454,0.0032674817,0.00006583767,0.64918566,0.000012998001,0.06708236,0.15975961],"study_design_scores_gemma":[0.0051012062,0.004629206,0.045709632,0.00015874785,0.002362585,0.00044426322,0.0010560382,0.00007720843,0.8495248,0.00016936366,0.09048909,0.00027788183],"about_ca_topic_score_codex":0.00044106148,"about_ca_topic_score_gemma":0.0000861279,"teacher_disagreement_score":0.20033914,"about_ca_system_score_codex":0.00031861587,"about_ca_system_score_gemma":0.0009134805,"threshold_uncertainty_score":0.6764771},"labels":[],"label_agreement":null},{"id":"W2770058948","doi":"10.1016/j.jtho.2016.11.670","title":"P1.02-086 ATM Mutations in Lung Cancer Correlate to Higher Mutation Rates","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Mutation; Oncology; Cancer research; Internal medicine; Genetics; Gene; Biology","score_opus":0.017995936452284367,"score_gpt":0.4207287440898827,"score_spread":0.40273280763759833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770058948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99047756,0.0015139028,0.00078693096,0.0038679575,0.001938574,0.00013660218,0.00002060918,0.0000017282412,0.0012561319],"genre_scores_gemma":[0.9960748,0.00045002435,0.0013376147,0.0007440471,0.00067264045,0.000016196604,0.000009731057,0.000015423057,0.0006795105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916816,0.000058064426,0.0003569818,0.0001510152,0.000086050415,0.00017971729],"domain_scores_gemma":[0.9989339,0.000051096107,0.00049427076,0.00021573176,0.00019520427,0.000109783316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030908766,0.00010093112,0.00022040703,0.00009149911,0.00011376353,0.0000499507,0.00025959074,0.00015888594,0.000060485774],"category_scores_gemma":[0.00027107444,0.00009524034,0.00007791402,0.000048282225,0.000057543697,0.000011407314,0.00009003325,0.00016081458,0.000006829141],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038357105,0.00085424125,0.1618809,0.00014502459,0.0006901804,0.001203921,0.0017309134,0.04562561,0.3245851,0.0005190714,0.070811264,0.38811806],"study_design_scores_gemma":[0.0028405853,0.0028053646,0.6175378,0.0002352962,0.0003948675,0.00029019912,0.00032034444,0.00091365346,0.06494211,0.0014222788,0.30766845,0.0006290844],"about_ca_topic_score_codex":0.00011522607,"about_ca_topic_score_gemma":0.00085737783,"teacher_disagreement_score":0.4556569,"about_ca_system_score_codex":0.00015844133,"about_ca_system_score_gemma":0.00040768966,"threshold_uncertainty_score":0.38837886},"labels":[],"label_agreement":null},{"id":"W2770677081","doi":"10.1016/j.jtho.2016.11.1371","title":"P2.03b-089 CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Immunohistochemistry; Dendritic cell; Cancer research; Adenocarcinoma; Immunosurveillance; Cancer; Lung cancer; Immune system; Myeloid; Immunology; Pathology; Internal medicine","score_opus":0.036107051764902164,"score_gpt":0.4116131324339759,"score_spread":0.37550608066907376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770677081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803393,0.007885798,0.00003778642,0.009430937,0.0006995937,0.0002032068,0.0000013632075,0.0000057597945,0.0013962421],"genre_scores_gemma":[0.996869,0.0006138254,0.0012942532,0.00035993507,0.0004391375,0.000005250567,8.811603e-7,0.000014726775,0.00040296227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988428,0.000103056016,0.00050615775,0.00014498703,0.00018666343,0.00021636221],"domain_scores_gemma":[0.99880636,0.000073671385,0.0006456393,0.0002355115,0.00011096134,0.00012787252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010280454,0.00012351366,0.0005208022,0.00020909727,0.000111907604,0.000040061484,0.00019678767,0.00018345937,0.000090045374],"category_scores_gemma":[0.00012290332,0.000094296855,0.00012994873,0.00007237961,0.00019794764,0.00017564284,0.00005190358,0.00041492327,0.0000032966586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009939398,0.0004507156,0.7308597,0.00024037488,0.00030150873,0.0027631528,0.0008658864,7.924178e-7,0.035035685,0.000026442596,0.003271434,0.21624492],"study_design_scores_gemma":[0.0047156685,0.0028946572,0.92188096,0.0004872325,0.0004033408,0.0026446574,0.00039360722,0.00011241795,0.012131973,0.00022558516,0.0539242,0.00018570916],"about_ca_topic_score_codex":0.00008443691,"about_ca_topic_score_gemma":0.00006377429,"teacher_disagreement_score":0.21605921,"about_ca_system_score_codex":0.00030215376,"about_ca_system_score_gemma":0.00036688402,"threshold_uncertainty_score":0.3845314},"labels":[],"label_agreement":null},{"id":"W2770837274","doi":"10.1016/j.jtho.2017.11.088","title":"P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Royal Victoria Hospital; Lakeridge Health; Richmond Hospital; Dr. Georges-L.-Dumont University Hospital Centre; Interior Health; Thunder Bay Regional Health Sciences Centre; CancerCare Manitoba; Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Hôpital Charles-Le Moyne; Cégep de Rimouski; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.023992013256225977,"score_gpt":0.39462491183558024,"score_spread":0.3706328985793543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770837274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238753,0.0009425256,0.0000072479825,0.0023017116,0.000531907,0.00028133587,0.000012642429,0.000004460633,0.0035306585],"genre_scores_gemma":[0.9980282,0.0007464367,0.00069756055,0.00015448092,0.00008912145,0.0000020621912,0.0000046407654,0.000017870083,0.00025961816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99844605,0.00010672583,0.0007506251,0.00015718311,0.00019872806,0.00034066447],"domain_scores_gemma":[0.9980825,0.00009670117,0.0010317707,0.0002748281,0.00024996052,0.00026420841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007716365,0.00014818525,0.0006596885,0.00036032553,0.00016662035,0.000020764663,0.0002159838,0.00019847832,0.00010700349],"category_scores_gemma":[0.0004440911,0.00012424987,0.00012381993,0.0001077939,0.00018748653,0.00021837409,0.00004093781,0.00033567575,0.0000026065811],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022412874,0.00033995288,0.17563225,0.00010760903,0.00024974832,0.00026416229,0.000913425,0.000005833131,0.0074723656,0.0000040837367,0.0003364928,0.7922612],"study_design_scores_gemma":[0.010083806,0.0044131675,0.96310407,0.00087697397,0.00015748687,0.00023481053,0.00021341887,0.00003853,0.002354184,0.00003457894,0.01834979,0.00013920404],"about_ca_topic_score_codex":0.014786519,"about_ca_topic_score_gemma":0.03980296,"teacher_disagreement_score":0.792122,"about_ca_system_score_codex":0.0008785733,"about_ca_system_score_gemma":0.0009566721,"threshold_uncertainty_score":0.9917741},"labels":[],"label_agreement":null},{"id":"W2784623697","doi":"10.1016/j.jtho.2017.12.001","title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Guideline; Medicine; KRAS; ROS1; Lung cancer; Context (archaeology); Targeted therapy; Companion diagnostic; Pathology; Oncology; Internal medicine; Medical physics; Adenocarcinoma; Cancer; Family medicine; Intensive care medicine","score_opus":0.019680333514212882,"score_gpt":0.43259753655044925,"score_spread":0.41291720303623636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2784623697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775223,0.0011348887,0.014739835,0.0039425856,0.0006854003,0.0017281133,0.00008019186,0.000012953448,0.00015374241],"genre_scores_gemma":[0.9600015,0.00002485233,0.038787887,0.0003336147,0.0005338405,0.000107999,0.000043717962,0.000022877139,0.00014371198],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99909264,0.000031157244,0.0004885342,0.00010594868,0.00012849597,0.00015322209],"domain_scores_gemma":[0.99687034,0.0001347073,0.0006693891,0.00007745054,0.0021812196,0.0000669185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018737884,0.00011179587,0.0003264164,0.000101958576,0.000110862675,0.000005605483,0.00004421736,0.00006190335,0.000024957953],"category_scores_gemma":[0.00012682739,0.000058577258,0.00009450291,0.00022366206,0.00006279778,0.000053864165,0.0000065638624,0.000047752226,1.7212233e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023118163,0.004399671,0.100331925,0.00029171468,0.006001273,0.000033912824,0.0015574052,0.0015791833,0.10888719,0.00003495806,0.050085407,0.7036792],"study_design_scores_gemma":[0.030751392,0.14127117,0.019880168,0.0008877107,0.021749875,0.00030497153,0.00056250737,0.026962467,0.51483744,0.00012810394,0.24225347,0.00041073552],"about_ca_topic_score_codex":0.000095147305,"about_ca_topic_score_gemma":0.000071069226,"teacher_disagreement_score":0.70326847,"about_ca_system_score_codex":0.00064728473,"about_ca_system_score_gemma":0.0007642954,"threshold_uncertainty_score":0.23887113},"labels":[],"label_agreement":null},{"id":"W2788517166","doi":"10.1016/j.jtho.2019.07.028","title":"Lung Cancer in Brazil","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Roche; AstraZeneca","keywords":"Medicine; Lung cancer; Cancer; Incidence (geometry); Adenocarcinoma; Population; National Lung Screening Trial; Lung cancer screening; Tuberculosis; Cause of death; Internal medicine; Oncology; Gynecology; Pathology; Environmental health; Disease","score_opus":0.02593907583967014,"score_gpt":0.4622634185972563,"score_spread":0.43632434275758614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788517166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8322989,0.0062956456,0.00004282711,0.15746039,0.00053201074,0.00015667513,0.0000038418316,0.000007047217,0.0032027052],"genre_scores_gemma":[0.99126816,0.0012822954,0.00072971155,0.005956106,0.0006498928,0.000008289229,5.51066e-7,0.000009708356,0.00009526884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999226,0.000056706423,0.00034179146,0.000092910195,0.000148309,0.00013427924],"domain_scores_gemma":[0.9993757,0.00006941244,0.00022057259,0.000060470767,0.00009224555,0.00018158407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016703818,0.000073843796,0.0004201525,0.00007755241,0.000012816081,0.0000048166426,0.0000641139,0.00007490292,0.000510516],"category_scores_gemma":[0.000062983156,0.00005260711,0.00010323054,0.00016126457,0.000023469936,0.000058229798,0.000019594048,0.00026652007,0.000008583438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033149607,0.0008212737,0.5761221,0.0003274669,0.000466882,0.0041636066,0.0018287783,0.00022597454,0.0012456727,0.000046272402,0.062184263,0.34925276],"study_design_scores_gemma":[0.008387589,0.008515737,0.63560075,0.0012792664,0.0018118019,0.0012718382,0.00054663717,0.0012562902,0.008227107,0.00014895391,0.33267778,0.0002762204],"about_ca_topic_score_codex":0.000026733964,"about_ca_topic_score_gemma":0.00006937504,"teacher_disagreement_score":0.34897652,"about_ca_system_score_codex":0.000810102,"about_ca_system_score_gemma":0.0005561561,"threshold_uncertainty_score":0.5589792},"labels":[],"label_agreement":null},{"id":"W2788520522","doi":"10.1016/j.jtho.2018.02.012","title":"The IASLC Lung Cancer Staging Project: A Renewed Call to Participation","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Colorado Denver; School of Medicine, New York University; Shanghai Chest Hospital; Hyogo College of Medicine; Technische Universität München; Universidade de São Paulo; Seoul National University; Ohio State University; University of Leicester; York University; Aix-Marseille Université; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Yale University; Brigham and Women's Hospital; University of Toronto; Memorial Sloan-Kettering Cancer Center; Ankara Universitesi","keywords":"Medicine; Lung cancer staging; Lung cancer; Electronic data capture; Ninth; Biostatistics; Cancer; Medical physics; Family medicine; Oncology; Epidemiology; Clinical trial; Pathology; Internal medicine","score_opus":0.03956983996992276,"score_gpt":0.5040590853241131,"score_spread":0.4644892453541904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788520522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95122135,0.0011607375,0.00025672195,0.043302253,0.0013977962,0.0004566863,0.0000031535,0.000011558701,0.002189769],"genre_scores_gemma":[0.99398696,0.00042538773,0.0014143742,0.0017406846,0.0014655007,0.0000814371,7.0880014e-7,0.000013655457,0.00087130145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988852,0.00011734406,0.00039794977,0.000118079224,0.00023651874,0.0002448723],"domain_scores_gemma":[0.99871516,0.00016938432,0.0003220807,0.00016404089,0.0004811221,0.0001482386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006159278,0.00009240576,0.00029635828,0.00009978279,0.00013814437,0.000022572103,0.00009418571,0.00006112893,0.000058213318],"category_scores_gemma":[0.00017270527,0.000051589534,0.00008811435,0.00019660087,0.00006327323,0.000059389487,0.00003193058,0.00015892532,0.000009506893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051906556,0.00074005837,0.12881382,0.000111343,0.0009395075,0.0003090407,0.0065709827,0.00005240903,0.0016394526,0.00007863618,0.1836584,0.6718957],"study_design_scores_gemma":[0.002867572,0.011616337,0.22303337,0.0011356367,0.002494537,0.00037001105,0.00080798916,0.00092328613,0.016938502,0.0001404187,0.73942596,0.00024640237],"about_ca_topic_score_codex":0.00020017142,"about_ca_topic_score_gemma":0.00093891344,"teacher_disagreement_score":0.6716493,"about_ca_system_score_codex":0.0012328521,"about_ca_system_score_gemma":0.00085419684,"threshold_uncertainty_score":0.32238653},"labels":[],"label_agreement":null},{"id":"W2789694417","doi":"10.1016/j.jtho.2018.02.023","title":"Brief Report on Radiological Changes following Stereotactic Ablative Radiotherapy (SABR) for Early-Stage Lung Tumors: A Pictorial Essay","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Ablative case; SABR volatility model; Radiological weapon; Radiology; Radiation therapy; Stage (stratigraphy); Stereotactic radiotherapy; Lung; Radiosurgery; Internal medicine","score_opus":0.034536007897679896,"score_gpt":0.434688407894272,"score_spread":0.4001523999965921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789694417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845693,0.00065344386,0.0010238338,0.006608251,0.004463841,0.000809152,0.000011358944,0.000024297118,0.0018365394],"genre_scores_gemma":[0.98591727,0.00012774339,0.0042951196,0.0011571322,0.0071216407,0.000063899075,0.0000070886344,0.000035954603,0.0012741621],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980943,0.00023101675,0.0006494526,0.00031410996,0.00034164454,0.0003694754],"domain_scores_gemma":[0.99754214,0.00073835114,0.0009160481,0.00026592234,0.0003040252,0.00023353596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011875414,0.00023297235,0.0010255529,0.00018957215,0.0001258525,0.00002949931,0.00013177899,0.00022600497,0.00018955131],"category_scores_gemma":[0.00043535948,0.00015511754,0.0004102197,0.00013720879,0.00012084471,0.0001125662,0.000021877397,0.0003412589,0.0000037266745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11998766,0.00984012,0.4986814,0.00074044726,0.021569947,0.0636119,0.019351216,0.000029263318,0.008685636,0.0011991363,0.055594515,0.20070875],"study_design_scores_gemma":[0.023441477,0.15734488,0.20289317,0.002145194,0.0040376075,0.011371491,0.00070402445,0.00023556953,0.014790302,0.0006180002,0.5816046,0.00081368274],"about_ca_topic_score_codex":0.000026423335,"about_ca_topic_score_gemma":0.000027566775,"teacher_disagreement_score":0.5260101,"about_ca_system_score_codex":0.0020800452,"about_ca_system_score_gemma":0.0005921004,"threshold_uncertainty_score":0.63255095},"labels":[],"label_agreement":null},{"id":"W2791989359","doi":"10.1016/j.jtho.2018.03.005","title":"Translation of Knowledge to Practice—Improving Awareness in NSCLC Molecular Testing","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Health Centre; University Health Network; Princess Margaret Cancer Centre; Ottawa Hospital; London Health Sciences Centre; McMaster University","funders":"","keywords":"Medicine; Specialty; Intervention (counseling); Lung cancer; Medical physics; Knowledge translation; Lung cancer screening; Family medicine; Oncology; Nursing","score_opus":0.04596574257182692,"score_gpt":0.5004211194500483,"score_spread":0.45445537687822135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2791989359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96256715,0.00089474453,0.014208517,0.0039831153,0.0006268316,0.00029417267,0.0000019603094,0.000007232715,0.017416246],"genre_scores_gemma":[0.92880857,0.0000046293944,0.0706939,0.00021640596,0.00020564179,0.0000040907416,9.094728e-7,0.000009609044,0.000056265046],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991288,0.00010755412,0.00043410913,0.00008752036,0.00012305086,0.00011896382],"domain_scores_gemma":[0.9984788,0.00026723332,0.00036215488,0.00008745465,0.0007173457,0.00008705423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053491944,0.00006724507,0.00029830413,0.00026550208,0.000028040606,0.0000043986615,0.000055424654,0.00007099739,0.00001637615],"category_scores_gemma":[0.00079939107,0.000054317512,0.0000499754,0.00036008446,0.000036967347,0.00013035077,0.000012084372,0.00013826325,0.0000054884226],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010266721,0.0006253485,0.0054228767,0.00008930274,0.00010543305,0.00022764041,0.0036246746,0.00007345699,0.06911832,0.000022542567,0.0000767369,0.919587],"study_design_scores_gemma":[0.024758069,0.08240451,0.24286485,0.007297871,0.010974545,0.011866334,0.01460816,0.0071830107,0.35077253,0.0017341895,0.24436368,0.0011722561],"about_ca_topic_score_codex":0.000064988715,"about_ca_topic_score_gemma":0.00007264938,"teacher_disagreement_score":0.9184147,"about_ca_system_score_codex":0.00028761738,"about_ca_system_score_gemma":0.0010439613,"threshold_uncertainty_score":0.22150038},"labels":[],"label_agreement":null},{"id":"W2796510657","doi":"10.1016/s1556-0864(18)30404-0","title":"130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Oncology; Immunohistochemistry; Stage (stratigraphy); Real world data","score_opus":0.02686796737099981,"score_gpt":0.428025967513239,"score_spread":0.4011580001422392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796510657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921598,0.003548102,0.000418364,0.0007576478,0.00089696504,0.0013306737,0.000016824692,0.000008355952,0.00086325424],"genre_scores_gemma":[0.99038583,0.002356007,0.0053543733,0.00038802094,0.00026505822,0.00004211193,6.233309e-7,0.000021464526,0.0011864817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972627,0.0005450526,0.0011489211,0.0002576072,0.00043419583,0.0003515029],"domain_scores_gemma":[0.9973411,0.00037222783,0.0012799948,0.00039733716,0.00047658038,0.00013273429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013029817,0.000228178,0.00077471265,0.00018270462,0.000077286684,0.000012761779,0.0004527758,0.00009232269,0.00046176554],"category_scores_gemma":[0.000119003285,0.00012858244,0.0001766534,0.0005480854,0.00024233929,0.0001539389,0.00010095325,0.00039531017,0.0000023079508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24764977,0.007967064,0.28133112,0.002849116,0.0010025217,0.001266916,0.015305712,0.00039263777,0.20185082,0.0000015816447,0.004715793,0.23566693],"study_design_scores_gemma":[0.037868533,0.02766993,0.745055,0.011480429,0.003857725,0.0005136716,0.022757381,0.0018469923,0.13435449,0.000044062086,0.013792342,0.0007594212],"about_ca_topic_score_codex":0.00033754358,"about_ca_topic_score_gemma":0.003120224,"teacher_disagreement_score":0.4637239,"about_ca_system_score_codex":0.00072385836,"about_ca_system_score_gemma":0.001159138,"threshold_uncertainty_score":0.52434397},"labels":[],"label_agreement":null},{"id":"W2796562992","doi":"10.1016/s1556-0864(18)30320-4","title":"40P Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Medicaid; Demography; Hazard ratio; Percentile; Population; Proportional hazards model; Lung cancer; Cancer; Health care; Survival analysis; Environmental health; Internal medicine; Confidence interval; Statistics","score_opus":0.051042875707591494,"score_gpt":0.4710203688380194,"score_spread":0.4199774931304279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796562992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982078,0.00020504059,0.000007143927,0.00085428427,0.0003378493,0.00023414599,0.00006283578,7.106424e-7,0.00009015498],"genre_scores_gemma":[0.9984376,0.0004697472,0.0003210287,0.0006553785,0.00009566969,0.0000020474956,0.000008050938,0.000005930609,0.0000045826405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833643,0.00029018265,0.00091514084,0.000099424884,0.00014690946,0.00021188],"domain_scores_gemma":[0.99846417,0.00041206175,0.00056790217,0.00008112993,0.00028216382,0.00019255988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011645819,0.00007775249,0.00067874865,0.00032594372,0.000022116106,0.00000522272,0.00008925028,0.00008586782,0.000011387171],"category_scores_gemma":[0.00048205582,0.000055588123,0.000026611815,0.00023312983,0.00016280623,0.000067321824,0.000027289088,0.00035171214,8.801696e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027855157,0.00015379598,0.933658,0.00012376455,0.00003163645,0.000025781801,0.002747172,0.00000914405,0.000082390805,0.0000023370765,0.00012769287,0.060252775],"study_design_scores_gemma":[0.0012263559,0.0018523324,0.9896238,0.00023674809,0.00003988724,0.000008370672,0.0012225754,0.001075173,0.000058882186,0.000004030842,0.0046033175,0.00004855919],"about_ca_topic_score_codex":0.04299426,"about_ca_topic_score_gemma":0.24493718,"teacher_disagreement_score":0.20194292,"about_ca_system_score_codex":0.0002515955,"about_ca_system_score_gemma":0.0014272721,"threshold_uncertainty_score":0.96337855},"labels":[],"label_agreement":null},{"id":"W2796627553","doi":"10.1016/j.jtho.2018.04.002","title":"Progress in the Management of Early-Stage Non–Small Cell Lung Cancer in 2017","year":2018,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Eli Lilly and Company; Canadian Asian Studies Association; Gilead Sciences; Novartis; Pfizer","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Oncology; Intensive care medicine","score_opus":0.05594716007412279,"score_gpt":0.48545508259680387,"score_spread":0.4295079225226811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796627553","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0084246155,0.9858973,0.00000272941,0.000548991,0.00070233934,0.0015895434,0.000018792634,0.0000021373062,0.0028135485],"genre_scores_gemma":[0.0027572918,0.99504316,0.0008434789,0.00007178757,0.0004008984,0.00026494978,0.00000438859,0.000029591243,0.0005844778],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752927,0.00034769266,0.0012435799,0.00023895374,0.00033220186,0.00030832918],"domain_scores_gemma":[0.9974543,0.00015837036,0.0017836546,0.00038577733,0.0001324261,0.000085500025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013611389,0.00029065847,0.0021469533,0.00042097588,0.000021735328,0.000013677724,0.00044561,0.00029780096,0.00009147865],"category_scores_gemma":[0.0000054720313,0.00015924436,0.00046942668,0.00035776323,0.00010447262,0.00004538825,0.00009063885,0.0006846546,0.0000072829143],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002959716,0.0015685956,0.010840435,0.04770558,0.00094491837,0.004798726,0.0006620536,0.0000018629081,4.3402235e-8,0.000009069884,0.0029150306,0.93025774],"study_design_scores_gemma":[0.0015004724,0.0023422318,0.012243966,0.069442235,0.007158055,0.00028699572,0.00020415714,0.0000045630964,0.0000051404386,0.000007314194,0.9066269,0.00017797315],"about_ca_topic_score_codex":0.00007113708,"about_ca_topic_score_gemma":0.0002248804,"teacher_disagreement_score":0.93007976,"about_ca_system_score_codex":0.0016456107,"about_ca_system_score_gemma":0.0009866952,"threshold_uncertainty_score":0.6493796},"labels":[],"label_agreement":null},{"id":"W2796881586","doi":"10.1016/s1556-0864(18)30400-3","title":"127TiP Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cyberknife; Radiation therapy; Adverse effect; Radiosurgery; Radiology; Lung cancer; Adjuvant radiotherapy; Oncology; Surgery; Internal medicine","score_opus":0.010545133972166509,"score_gpt":0.3932450260713897,"score_spread":0.3826998920992232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796881586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96589476,0.0002811483,0.030963175,0.00008184454,0.00030732816,0.0015796274,0.000011500041,0.00002570029,0.0008549102],"genre_scores_gemma":[0.976766,0.000029508645,0.022423679,0.000065151755,0.00040706326,0.000052661733,0.000004479566,0.00008192365,0.00016953742],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99614006,0.00088836235,0.0014659473,0.00043119138,0.00055752264,0.0005169249],"domain_scores_gemma":[0.99644214,0.00031574903,0.0016040616,0.00054799096,0.00091313093,0.00017695034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001262464,0.0003988792,0.0014459246,0.00046610154,0.0001377504,0.000043509874,0.00060466916,0.000119168966,0.00035709556],"category_scores_gemma":[0.00005125621,0.00030114118,0.0001213273,0.0006960635,0.00018570517,0.0006778017,0.000073195806,0.0008445665,0.0000016494088],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030503316,0.044363584,0.37107906,0.000037667927,0.0012163081,0.00025124257,0.006829359,0.0010081519,0.0031945454,0.000025842237,0.00021992163,0.54127103],"study_design_scores_gemma":[0.19821137,0.5432067,0.14396288,0.0017026934,0.001306929,0.0002276479,0.029078525,0.0065526105,0.008988023,0.0007935847,0.06290312,0.0030658946],"about_ca_topic_score_codex":0.00015229823,"about_ca_topic_score_gemma":0.00009083616,"teacher_disagreement_score":0.5382051,"about_ca_system_score_codex":0.00033105878,"about_ca_system_score_gemma":0.00056026696,"threshold_uncertainty_score":0.9999441},"labels":[],"label_agreement":null},{"id":"W2797129264","doi":"10.1016/s1556-0864(18)30473-8","title":"200PD High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"Medicine; Confidence interval; Cancer; Radiation therapy; Surgery; General surgery; Radiology; Internal medicine","score_opus":0.0881049473024208,"score_gpt":0.4701105662633723,"score_spread":0.3820056189609515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797129264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783624,0.0010511642,0.000008940313,0.0078748055,0.0012795303,0.0012626688,0.00064412935,0.000011469406,0.000031042124],"genre_scores_gemma":[0.99226195,0.0036568656,0.00059513416,0.0005524552,0.0011674169,0.00063941116,0.000017639555,0.000033747277,0.0010753719],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817014,0.000202864,0.00072922447,0.0003249492,0.00018261891,0.00039020774],"domain_scores_gemma":[0.99779063,0.00032690217,0.00079137355,0.00025267768,0.00064095686,0.00019746715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002868131,0.00030550643,0.0010373689,0.0002078518,0.00011393162,0.00001384298,0.00011161864,0.00015991653,0.00036931116],"category_scores_gemma":[0.00006113397,0.00015732579,0.00019231242,0.00019476916,0.00030927427,0.00025203195,0.000072841765,0.00014918768,0.0000030593026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16846265,0.007962408,0.5004124,0.0023663251,0.0032822536,0.03531452,0.01795137,0.000034375753,0.02153475,0.00003891093,0.0028435583,0.23979649],"study_design_scores_gemma":[0.03003193,0.13514909,0.3571156,0.015463148,0.009703789,0.029822383,0.008038866,0.0012305654,0.38715205,0.0003478064,0.024513517,0.0014312696],"about_ca_topic_score_codex":0.0022167666,"about_ca_topic_score_gemma":0.03819801,"teacher_disagreement_score":0.3656173,"about_ca_system_score_codex":0.002191121,"about_ca_system_score_gemma":0.0013048719,"threshold_uncertainty_score":0.97935236},"labels":[],"label_agreement":null},{"id":"W2797366988","doi":"10.1016/s1556-0864(18)30402-7","title":"128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Gefitinib; Internal medicine; Erlotinib; Oncology; Discontinuation; Hazard ratio; Erlotinib Hydrochloride; Lung cancer; T790M; Progression-free survival; Ceritinib; Cancer; Chemotherapy; Epidermal growth factor receptor; Crizotinib; Confidence interval","score_opus":0.011624847890201916,"score_gpt":0.42550727448115244,"score_spread":0.41388242659095054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797366988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924203,0.0010160932,0.000024573177,0.004158194,0.0004390303,0.00064651325,0.00004256547,0.000015564256,0.0012371585],"genre_scores_gemma":[0.9960836,0.00030902907,0.0026875227,0.000547187,0.00013282617,0.000015154241,0.00004654327,0.000032999396,0.00014514096],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982125,0.00011426579,0.00073750346,0.00020355583,0.00045641093,0.00027573376],"domain_scores_gemma":[0.9967836,0.00012562274,0.00089143094,0.00023588489,0.0017949422,0.00016849834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018491404,0.0002263614,0.00090489833,0.00030256677,0.00009190217,0.000009678918,0.00013131017,0.00016315076,0.00019935695],"category_scores_gemma":[0.00014582378,0.00013346733,0.00014187623,0.0003060916,0.00016645745,0.00016708876,0.000027985,0.00027037185,0.000007953513],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064378396,0.0013412039,0.4036213,0.00009073578,0.00055627775,0.00020162472,0.0044269944,0.000026861519,0.00029192946,0.000008214843,0.0002132627,0.5248432],"study_design_scores_gemma":[0.042325202,0.22362375,0.68485373,0.0021604397,0.0011872194,0.00018923687,0.0033982752,0.000014318082,0.01574912,0.00011358849,0.026031848,0.0003532608],"about_ca_topic_score_codex":0.000051743256,"about_ca_topic_score_gemma":0.00024761274,"teacher_disagreement_score":0.52448994,"about_ca_system_score_codex":0.0007765729,"about_ca_system_score_gemma":0.0007842722,"threshold_uncertainty_score":0.54426396},"labels":[],"label_agreement":null},{"id":"W2797398460","doi":"10.1016/s1556-0864(18)30503-3","title":"231P_PR Impact of the continuity of nursing care delivered by a pivot nurse in oncology on improving satisfaction and quality of life of patients with advanced lung cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Cegep regional de Lanaudiere","funders":"","keywords":"Medicine; Cohort; Family medicine; Quality of life (healthcare); Nursing; Health care; Patient satisfaction; Internal medicine","score_opus":0.058875067301535425,"score_gpt":0.5201528663749422,"score_spread":0.46127779907340677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797398460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996969,0.0019642503,0.0000782345,0.00011663589,0.000245397,0.00029313267,0.000102175705,0.0000015003644,0.0002296697],"genre_scores_gemma":[0.99876523,0.0002062899,0.0009308667,0.00003159391,0.0000479493,0.0000021224575,0.0000024167625,0.000009237345,0.0000042875736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980812,0.000425705,0.00093487673,0.00012007506,0.00028933553,0.0001488237],"domain_scores_gemma":[0.99532956,0.00040409324,0.0027018078,0.00015367978,0.0013302636,0.00008056766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047073152,0.00012449938,0.0010756187,0.00015081328,0.000020164447,9.636045e-7,0.0000856641,0.0001594666,0.00002016733],"category_scores_gemma":[0.00072129135,0.00007877345,0.00013374117,0.00018446166,0.00044413842,0.00009299751,0.000019733767,0.00026643038,3.119635e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014016876,0.00043044068,0.7396537,0.0003294442,0.00018085612,0.0000013003825,0.00842877,0.00003680071,0.041124173,0.0000037043885,0.000052620922,0.1957413],"study_design_scores_gemma":[0.0042019654,0.010418041,0.9417736,0.002373395,0.00030110328,0.000003232399,0.005012386,0.00004170235,0.035764042,0.000012426932,0.000033025175,0.000065079694],"about_ca_topic_score_codex":0.0015226328,"about_ca_topic_score_gemma":0.0009534365,"teacher_disagreement_score":0.20211987,"about_ca_system_score_codex":0.00076929666,"about_ca_system_score_gemma":0.0008286177,"threshold_uncertainty_score":0.32122883},"labels":[],"label_agreement":null},{"id":"W2797413838","doi":"10.1016/s1556-0864(18)30413-1","title":"139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Lung cancer; Quality of life (healthcare); Internal medicine; Clinical trial; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.013171972127239433,"score_gpt":0.365184037464687,"score_spread":0.35201206533744756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797413838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395555,0.0010564455,0.000062686435,0.0008955765,0.002242861,0.00096907286,0.00044619,0.000019786808,0.0003518462],"genre_scores_gemma":[0.993962,0.000085152584,0.005210307,0.00019223137,0.0002687104,0.000036249745,0.0001392938,0.00005825314,0.000047825826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99717087,0.00016462358,0.0013182263,0.0003586894,0.0005546992,0.00043291494],"domain_scores_gemma":[0.9952447,0.00023370082,0.0018129998,0.00028174632,0.0021209614,0.00030590483],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012386794,0.00036291248,0.0012696985,0.00034029307,0.00009582874,0.000014766801,0.00015011452,0.00022744942,0.00032434307],"category_scores_gemma":[0.00021917575,0.00025652672,0.00020571862,0.00039197487,0.00016434872,0.0002629687,0.00005651976,0.00043233478,0.0000041202356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067970835,0.0014224066,0.8593962,0.00024453524,0.0013492599,0.00029799182,0.008166465,0.000044470187,0.004670435,8.4484736e-7,0.0011751695,0.055261377],"study_design_scores_gemma":[0.05360169,0.039720904,0.78354865,0.0018077632,0.003404713,0.0000146801585,0.0038675568,0.00002731086,0.11078897,0.000008503259,0.0026439826,0.0005652457],"about_ca_topic_score_codex":0.00033603594,"about_ca_topic_score_gemma":0.0005049807,"teacher_disagreement_score":0.10611854,"about_ca_system_score_codex":0.0019736676,"about_ca_system_score_gemma":0.0016494031,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W2797575568","doi":"10.1016/s1556-0864(18)30345-9","title":"69P The diabetes drug canagliflozin sensitizes non-small cell lung cancer (NSCLC) to radiotherapy and chemotherapy","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"AMPK; Canagliflozin; Medicine; Lipogenesis; Cancer research; PI3K/AKT/mTOR pathway; Internal medicine; Endocrinology; Protein kinase B; Pharmacology; Protein kinase A; Phosphorylation; Lipid metabolism; Apoptosis; Type 2 diabetes; Diabetes mellitus; Chemistry; Biochemistry","score_opus":0.006694201627359346,"score_gpt":0.3250993344435143,"score_spread":0.31840513281615496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797575568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8785807,0.11704313,0.00033209642,0.0023447715,0.0010919747,0.00020657308,0.000011300637,0.0000038012424,0.00038564426],"genre_scores_gemma":[0.913658,0.057175685,0.0032910677,0.018737467,0.0060386914,0.00002779537,0.0000029164216,0.000060846454,0.0010075368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986336,0.00021982071,0.00036867463,0.00025001194,0.00014782448,0.00038006826],"domain_scores_gemma":[0.998828,0.00005603723,0.0003403966,0.00027138673,0.00030502226,0.00019915766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079042313,0.00020692153,0.00042470772,0.000083510604,0.00012885773,0.00003858323,0.00031774424,0.00016432322,0.00008799225],"category_scores_gemma":[0.000033551216,0.00014203876,0.00012816183,0.00012680842,0.00018974666,0.00000768732,0.00006147992,0.00020345155,0.0000023642115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007018288,0.00009976638,0.0064442777,0.00006019176,0.00040442357,0.000010415342,0.0017815834,0.00004323448,0.33733407,0.000004361893,0.102869004,0.55024683],"study_design_scores_gemma":[0.00075271126,0.0007325574,0.0033698182,0.000045779456,0.00012769736,0.00002424226,0.0002479869,0.00011196293,0.3159514,0.000027486281,0.6783997,0.0002086652],"about_ca_topic_score_codex":0.000077296994,"about_ca_topic_score_gemma":0.0005279133,"teacher_disagreement_score":0.5755307,"about_ca_system_score_codex":0.000087009066,"about_ca_system_score_gemma":0.00043848535,"threshold_uncertainty_score":0.57921726},"labels":[],"label_agreement":null},{"id":"W2797717415","doi":"10.1016/s1556-0864(18)30462-3","title":"188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Pemetrexed; Lung cancer; Chemotherapy; Oncology; Internal medicine; Chemotherapy regimen; Surgery; Cancer; Immunotherapy; Cisplatin","score_opus":0.017137625849516266,"score_gpt":0.3920154032273718,"score_spread":0.3748777773778555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797717415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935293,0.0005375385,0.00018089428,0.0016011598,0.0011378286,0.0008148328,0.000014330149,0.000012313717,0.0021717767],"genre_scores_gemma":[0.99619126,0.0005984206,0.0020212438,0.00027236232,0.00041800077,0.000046683854,0.00001778019,0.000047924445,0.0003863033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822986,0.00009715804,0.0006593809,0.00029498362,0.0002963443,0.0004222645],"domain_scores_gemma":[0.99847203,0.00015048504,0.00057928666,0.00023764755,0.00036608387,0.00019445481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018520193,0.00029954486,0.0008357989,0.0003673991,0.00007201212,0.000014672653,0.00013260494,0.00017463099,0.00017508572],"category_scores_gemma":[0.000027262691,0.00020788494,0.00012698521,0.00031341118,0.000056166868,0.00016631317,0.000022443004,0.00033443636,0.000005915648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1394933,0.0070198723,0.6435942,0.00019155837,0.0010217442,0.00060620747,0.007103313,0.001712518,0.00043661642,0.000006424934,0.00025172008,0.1985625],"study_design_scores_gemma":[0.10913671,0.029786544,0.8508243,0.00077051116,0.0010481909,0.0000368748,0.00034838036,0.0007295459,0.0012991491,0.00002162105,0.00566051,0.0003376618],"about_ca_topic_score_codex":0.0005919073,"about_ca_topic_score_gemma":0.004588551,"teacher_disagreement_score":0.20723008,"about_ca_system_score_codex":0.0033866393,"about_ca_system_score_gemma":0.001286482,"threshold_uncertainty_score":0.88559437},"labels":[],"label_agreement":null},{"id":"W2797855100","doi":"10.1016/s1556-0864(18)30408-8","title":"133PD Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for non-small cell lung cancer (NSCLC): A systematic review and meta-analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Mount Sinai Hospital; Western University","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Oncology; Hazard ratio; Subgroup analysis; Lung cancer; Odds ratio; Epidermal growth factor receptor; Randomized controlled trial; Adjuvant; Confidence interval; Cancer","score_opus":0.06433220985350852,"score_gpt":0.46556820384650194,"score_spread":0.4012359939929934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797855100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019966776,0.9902835,0.00042366123,0.0018577623,0.0006521894,0.0059030494,0.00072619657,0.0000142605095,0.00011944164],"genre_scores_gemma":[0.000056277528,0.9901267,0.004181847,0.0009906152,0.0007167288,0.0011934856,0.00011755169,0.00009741944,0.0025193412],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99469554,0.000758116,0.003119746,0.0005576053,0.00039384168,0.00047515004],"domain_scores_gemma":[0.9916451,0.0008152924,0.0052519073,0.0005080328,0.0012763893,0.00050325965],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014278875,0.00077126874,0.014599546,0.0008189163,0.0001431024,0.000044466247,0.00030099874,0.00049439125,0.0005019412],"category_scores_gemma":[0.00044535415,0.0004329212,0.005019945,0.0008010416,0.00011163522,0.00015371363,0.000081254824,0.00060252444,0.000014273332],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083789746,0.00034312188,0.000008377404,0.8057314,0.17113613,0.0001157604,0.00017350868,3.134489e-7,0.0000020354921,0.0000024629883,0.010577807,0.0118252905],"study_design_scores_gemma":[0.0005092565,0.0010872044,0.0000023469222,0.06259121,0.8017324,0.00034337206,0.000031087315,0.000005127668,0.000012635851,0.000002752739,0.13339293,0.00028964653],"about_ca_topic_score_codex":0.00004618888,"about_ca_topic_score_gemma":0.00004138528,"teacher_disagreement_score":0.7431402,"about_ca_system_score_codex":0.0014568797,"about_ca_system_score_gemma":0.0024433997,"threshold_uncertainty_score":0.99981225},"labels":[],"label_agreement":null},{"id":"W2797971622","doi":"10.1016/s1556-0864(18)30504-5","title":"232TiP Lanreotide autogel/depot in lung neuroendocrine tumours: The randomized, double-blind, placebo-controlled, international phase 3 SPINET Study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lanreotide; Clinical endpoint; Internal medicine; Placebo; Neuroendocrine tumors; Response Evaluation Criteria in Solid Tumors; Lung; Oncology; Surrogate endpoint; Phases of clinical research; Progressive disease; Gastroenterology; Surgery; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.043221516697823675,"score_gpt":0.4749174384288896,"score_spread":0.43169592173106597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2797971622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621176,0.00049657654,0.00011249539,0.026721194,0.0021861822,0.003760685,0.000004634729,0.000033295222,0.0045673456],"genre_scores_gemma":[0.9935296,0.0001992322,0.00067506236,0.0008824643,0.0026237892,0.00018677567,0.0000042272745,0.000046708352,0.0018521281],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943812,0.0016844443,0.0017950844,0.000375397,0.001096065,0.0006678421],"domain_scores_gemma":[0.99564815,0.0016242731,0.0011939683,0.00043663097,0.0007711763,0.0003258329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032052763,0.00033907767,0.0019286784,0.0009595608,0.00011882547,0.00007746329,0.0008243671,0.000020420866,0.00051340304],"category_scores_gemma":[0.0032203156,0.00019997904,0.00043924907,0.00049588835,0.0005265257,0.00035326343,0.00025353234,0.001513013,0.000052946314],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9410843,0.003364106,0.004779617,0.00003222231,0.0005543355,0.040381756,0.00023573451,0.00007584799,0.0006606208,0.000044936893,0.0032260243,0.0055604633],"study_design_scores_gemma":[0.93765867,0.00931582,0.00093928626,0.00012879744,0.00074186054,0.035732273,0.00107831,0.002457778,0.0011881214,0.00017890139,0.010397769,0.00018240472],"about_ca_topic_score_codex":0.000073978204,"about_ca_topic_score_gemma":0.0003080112,"teacher_disagreement_score":0.031412024,"about_ca_system_score_codex":0.00039003024,"about_ca_system_score_gemma":0.00065930904,"threshold_uncertainty_score":0.8154909},"labels":[],"label_agreement":null},{"id":"W2798092120","doi":"10.1016/s1556-0864(18)30356-3","title":"81P The influence of comorbidity on health utility score (HUS) and health-related quality of life (HRQoL) in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Folate and B Vitamins Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Quality of life (healthcare); Lung cancer; COPD; Oncology; Performance status; non-small cell lung cancer (NSCLC); Cancer; Disease","score_opus":0.11222667527590588,"score_gpt":0.48229981810786077,"score_spread":0.3700731428319549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798092120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787883,0.0052721607,0.000036618057,0.013866799,0.00035364623,0.0011767385,0.000057416466,0.0000074893533,0.00044084276],"genre_scores_gemma":[0.9944555,0.0022045749,0.00039654956,0.0025650791,0.00019386566,0.000017773022,0.0000034172997,0.00002338465,0.00013982588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99502563,0.0012908087,0.002138474,0.0003606659,0.0005430615,0.00064134947],"domain_scores_gemma":[0.99539965,0.00058222207,0.001900724,0.00048681904,0.0009840117,0.0006465515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061075455,0.00026075172,0.0017229248,0.0003933896,0.000147805,0.00001203176,0.00044344217,0.0002512682,0.00014298249],"category_scores_gemma":[0.00030108905,0.00018160301,0.00016002884,0.00070338446,0.0004449375,0.000086308755,0.00018644208,0.0013066953,0.000003412229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01311686,0.0022887648,0.9207452,0.005408659,0.0002819692,0.00006222537,0.011885962,0.0009377503,0.012915729,0.000008965578,0.011260328,0.0210876],"study_design_scores_gemma":[0.0027846897,0.004200794,0.98443645,0.001598976,0.0000909659,0.000026308397,0.000801691,0.0015989584,0.0035469837,0.000020026895,0.0007413088,0.00015283808],"about_ca_topic_score_codex":0.031569563,"about_ca_topic_score_gemma":0.024988716,"teacher_disagreement_score":0.06369127,"about_ca_system_score_codex":0.0010014399,"about_ca_system_score_gemma":0.005514692,"threshold_uncertainty_score":0.9928027},"labels":[],"label_agreement":null},{"id":"W2798175078","doi":"10.1016/s1556-0864(18)30417-9","title":"143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Beijing Municipal Administration of Hospitals","keywords":"Afatinib; Medicine; Internal medicine; Oncology; Gefitinib; Lung cancer; Brain metastasis; Chemotherapy; Lung; Metastasis; Cancer; Epidermal growth factor receptor","score_opus":0.011749373589137637,"score_gpt":0.4082338298060519,"score_spread":0.39648445621691425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2798175078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994355,0.00027047136,0.003516604,0.00030895468,0.00028734162,0.00084490044,0.000017444168,0.000012413652,0.00038682108],"genre_scores_gemma":[0.9871398,0.000009557257,0.012430902,0.0000476091,0.00024152406,0.000031488584,0.000031469324,0.000016391332,0.000051263665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986163,0.00017155669,0.0005804439,0.0001763824,0.00021300827,0.00024235512],"domain_scores_gemma":[0.9979794,0.00030635003,0.0008131251,0.00008824863,0.0006746091,0.0001382544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038553562,0.0001323444,0.00059813104,0.00036475164,0.00013226757,0.000025216423,0.000053305845,0.000092422764,0.0000127513],"category_scores_gemma":[0.00012970694,0.00008086189,0.000083117746,0.0004230659,0.0000665391,0.00014141842,0.000016172358,0.00014133817,6.016207e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0090249255,0.00063579617,0.8807804,0.0007379806,0.0022397023,0.0004013287,0.0065895338,0.00025306296,0.0001230263,0.00002561965,0.00007526234,0.09911338],"study_design_scores_gemma":[0.006884404,0.009771381,0.9548962,0.005230475,0.0072852746,0.0012377977,0.00850368,0.0056961067,0.00018999387,0.000005876508,0.00011314343,0.00018566813],"about_ca_topic_score_codex":0.00002479765,"about_ca_topic_score_gemma":0.00009746306,"teacher_disagreement_score":0.098927714,"about_ca_system_score_codex":0.0009826404,"about_ca_system_score_gemma":0.0004188634,"threshold_uncertainty_score":0.32974523},"labels":[],"label_agreement":null},{"id":"W2799326353","doi":"10.1016/j.jtho.2018.04.028","title":"The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Positron emission tomography; Overall survival; Progression-free survival; Positron Emission Tomography-Computed Tomography; Radiology; Nuclear medicine; Oncology","score_opus":0.007685405533805449,"score_gpt":0.3764503604881734,"score_spread":0.36876495495436795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799326353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967031,0.00053046003,0.000020142712,0.0014132373,0.00025232384,0.0003214695,0.000011153338,0.0000042999927,0.0007438517],"genre_scores_gemma":[0.9990768,0.00019175826,0.0005426558,0.00004722124,0.00009344037,0.0000052592254,0.000003918663,0.00001530153,0.000023686538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859005,0.00017794412,0.00040985137,0.00015150606,0.00043404967,0.0002365674],"domain_scores_gemma":[0.99845254,0.00030959386,0.0005267085,0.00021743383,0.00032945845,0.0001642561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055662706,0.00015466254,0.0004846729,0.00013049477,0.00007387736,0.000012840188,0.00012694133,0.00008036891,0.000012370888],"category_scores_gemma":[0.00009208168,0.00007305358,0.000105842766,0.00015342058,0.00016609346,0.00009022494,0.000047919708,0.00025096038,3.1734072e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022349203,0.0013724433,0.8353844,0.000027069771,0.0002718046,0.000034087003,0.0001518675,0.000009386044,0.00032838233,0.000008839961,0.0012807712,0.13878168],"study_design_scores_gemma":[0.0071754996,0.033217646,0.95633787,0.0010075927,0.00012719176,0.000012810581,0.0000862004,0.0000195986,0.0013894818,0.00010181528,0.00044034017,0.00008396039],"about_ca_topic_score_codex":0.00004030305,"about_ca_topic_score_gemma":0.00002695098,"teacher_disagreement_score":0.13869773,"about_ca_system_score_codex":0.00046407542,"about_ca_system_score_gemma":0.0002991365,"threshold_uncertainty_score":0.29790387},"labels":[],"label_agreement":null},{"id":"W2800017367","doi":"10.1016/j.jtho.2018.03.007","title":"Anticipating the Next Step in the Management of ALK-Positive NSCLC","year":2018,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.04491257495077399,"score_gpt":0.4625493609170052,"score_spread":0.4176367859662312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800017367","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027366534,0.0015292588,0.00027067878,0.9242097,0.0012298515,0.0009142376,0.000018127694,0.0000042578827,0.044457365],"genre_scores_gemma":[0.26349917,0.00097222126,0.011247178,0.7105251,0.009182809,0.00008595048,0.00006964655,0.000079386446,0.004338511],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819076,0.00038737277,0.00065785786,0.00012771857,0.0004103397,0.00022596409],"domain_scores_gemma":[0.9979982,0.00039749034,0.0010439978,0.0002717762,0.00026115627,0.000027384713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084458885,0.0001612692,0.0005639069,0.00017816607,0.00007141362,0.000018232253,0.0003018343,0.00024940065,0.000078881174],"category_scores_gemma":[0.000023451026,0.00007593536,0.0002052275,0.00020409081,0.00016515875,0.000060824972,0.000049519924,0.0011244467,0.000009042648],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055573304,0.0004247558,0.0004265207,0.0005088536,0.002712084,0.007318657,0.0056308415,0.0000051601373,0.000029985024,0.000036379326,0.75219554,0.23015548],"study_design_scores_gemma":[0.001450909,0.0033985872,0.009878552,0.0022965518,0.006263416,0.0017714388,0.0051414706,0.000031338375,0.00006019401,0.00022415548,0.9693567,0.00012665038],"about_ca_topic_score_codex":0.000037483424,"about_ca_topic_score_gemma":0.000014685933,"teacher_disagreement_score":0.23613265,"about_ca_system_score_codex":0.0003663853,"about_ca_system_score_gemma":0.00031870062,"threshold_uncertainty_score":0.4885224},"labels":[],"label_agreement":null},{"id":"W2800655067","doi":"10.1016/j.jtho.2018.04.020","title":"Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Osimertinib; Afatinib; Medicine; T790M; Oncology; Internal medicine; Epidermal growth factor receptor; Erlotinib; Receptor; Gefitinib","score_opus":0.027782159604277618,"score_gpt":0.4703620014734104,"score_spread":0.4425798418691328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800655067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96410745,0.0008267161,0.00023036789,0.008574284,0.0010470984,0.00030434868,0.000008964986,0.000020956639,0.024879793],"genre_scores_gemma":[0.9916669,0.000063286745,0.0052525997,0.0010599059,0.0006754479,0.0000101216665,0.000008087218,0.000023326776,0.0012402855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983334,0.00015533883,0.00078038906,0.00016915066,0.00026237598,0.00029937818],"domain_scores_gemma":[0.998451,0.00014914795,0.00053869036,0.00018949597,0.0004626909,0.0002089966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052148214,0.00015231535,0.00056673255,0.0003512822,0.000071494265,0.000014042436,0.00012522566,0.00015815646,0.000602556],"category_scores_gemma":[0.00023917288,0.00011133013,0.0001397837,0.00037862823,0.00015772779,0.00012932149,0.000028743394,0.00034147303,0.00007769934],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028302548,0.005905294,0.04373429,0.00027428655,0.0021672654,0.009311046,0.013419757,0.00006307712,0.059260376,0.00037314912,0.037885386,0.79930353],"study_design_scores_gemma":[0.021918101,0.039609123,0.46404475,0.0021621247,0.004202012,0.006712233,0.0061510545,0.0005892826,0.035365175,0.0024921533,0.41592866,0.0008253377],"about_ca_topic_score_codex":0.00007250452,"about_ca_topic_score_gemma":0.00014985207,"teacher_disagreement_score":0.7984782,"about_ca_system_score_codex":0.0006766883,"about_ca_system_score_gemma":0.0010624044,"threshold_uncertainty_score":0.65975654},"labels":[],"label_agreement":null},{"id":"W2802627246","doi":"10.1016/j.jtho.2018.04.023","title":"New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Mesothelioma; Pathology; Cytokeratin; Cancer; Biopsy; Fluorescence in situ hybridization; H&E stain; Oncology; Internal medicine; Immunohistochemistry","score_opus":0.07909986076760045,"score_gpt":0.4089266684896392,"score_spread":0.32982680772203876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802627246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855957,0.0018394365,0.0004084875,0.009442415,0.0009046666,0.0003629135,0.00013529685,0.0000070632577,0.0013040069],"genre_scores_gemma":[0.99619687,0.00014127676,0.0010874511,0.001447716,0.0008373396,0.000010296837,0.000074366115,0.000009668727,0.00019501903],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976679,0.0003652494,0.00060511567,0.000337727,0.0009009687,0.00012300126],"domain_scores_gemma":[0.9974018,0.0009874922,0.0006010863,0.0005343633,0.00035862072,0.00011668248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014186318,0.0001489321,0.0002964789,0.00008870581,0.000120902805,0.000014076558,0.0003676401,0.00008791192,0.0008366133],"category_scores_gemma":[0.0028118575,0.000071285445,0.00015191194,0.0001449327,0.00036566812,0.00012505066,0.00007811318,0.00024880472,0.00006348418],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013829519,0.004801851,0.34142667,0.000039870123,0.0012628201,0.00010650529,0.0027029586,0.00015356483,0.037740607,0.00055387046,0.06920612,0.52817565],"study_design_scores_gemma":[0.0023348508,0.0018291586,0.9403107,0.00027839563,0.00060839264,0.00025695754,0.0002587778,0.00054275524,0.013196723,0.002145814,0.038127765,0.000109673296],"about_ca_topic_score_codex":0.000107003456,"about_ca_topic_score_gemma":0.00005871509,"teacher_disagreement_score":0.59888405,"about_ca_system_score_codex":0.00039462655,"about_ca_system_score_gemma":0.0005879677,"threshold_uncertainty_score":0.9160329},"labels":[],"label_agreement":null},{"id":"W2802736274","doi":"10.1016/j.jtho.2018.02.018","title":"Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All","year":2018,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Germline; Variation (astronomy); Lung cancer; Germline mutation; Oncology; Genetics; Mutation; Biology","score_opus":0.016681530137523916,"score_gpt":0.3983757610831943,"score_spread":0.38169423094567034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802736274","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1361274,0.0075933253,0.00078180176,0.0038814335,0.8503772,0.00042545938,0.0005407488,0.000013105088,0.00025954406],"genre_scores_gemma":[0.033380028,0.0069108712,0.012714935,0.0005467684,0.9409737,0.000044288285,0.00012931923,0.00009350738,0.0052066115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975374,0.00033682917,0.0008491886,0.00048959506,0.0004541041,0.00033290242],"domain_scores_gemma":[0.9962783,0.00040383002,0.0013578434,0.00040431952,0.0014085822,0.00014711625],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015321185,0.000308153,0.00072400284,0.00010464195,0.0000927333,0.00005644274,0.0003828248,0.0015350701,0.00030741328],"category_scores_gemma":[0.0018162221,0.00024981142,0.00017600687,0.000092170114,0.00021213708,0.000016413916,0.00021407969,0.0007270364,0.0000022586134],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014929698,0.00018010336,0.000087281376,0.0002521731,0.0008929494,0.00001647039,0.0002579054,0.000050870385,0.12460613,8.888897e-7,0.86372644,0.008435845],"study_design_scores_gemma":[0.00068238936,0.0013338344,0.00031379465,0.00012361168,0.00087136845,0.000036845904,0.000042743162,0.00004559841,0.017405473,0.00013916635,0.9786928,0.00031236786],"about_ca_topic_score_codex":0.0000908353,"about_ca_topic_score_gemma":0.00082424004,"teacher_disagreement_score":0.1149664,"about_ca_system_score_codex":0.0007568374,"about_ca_system_score_gemma":0.0026904666,"threshold_uncertainty_score":0.9999954},"labels":[],"label_agreement":null},{"id":"W2803642760","doi":"10.1016/j.jtho.2018.05.015","title":"Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":179,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; McMaster University; Juravinski Cancer Centre","funders":"Gilead Sciences; Amgen; Pfizer; Samsung; Genentech; Celgene; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Erlotinib; Nivolumab; Oncology; Mutant; Internal medicine; Epidermal growth factor receptor; Cancer; Immunotherapy; Genetics; Gene","score_opus":0.012998529033252212,"score_gpt":0.36691182312771664,"score_spread":0.3539132940944644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803642760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99404216,0.00029315945,0.00009903921,0.00177053,0.0007904622,0.00028842027,0.0000026742694,0.000008943711,0.002704638],"genre_scores_gemma":[0.99542767,0.00005350369,0.002955351,0.00092135515,0.00033517805,0.0000031971788,0.000002197318,0.000019336572,0.00028218914],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986471,0.00010002567,0.00056707213,0.00013798715,0.00029358166,0.0002542634],"domain_scores_gemma":[0.9987393,0.00006306941,0.0005325525,0.00017034505,0.0003849925,0.00010975471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004892471,0.00012901587,0.00051744265,0.00024089238,0.000042666452,0.00000767462,0.0001308347,0.00012806118,0.00025618938],"category_scores_gemma":[0.00007136021,0.00008737395,0.00009905524,0.00029683977,0.00019540732,0.00013219062,0.000021367901,0.00032821533,0.00001350747],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20953792,0.0009954243,0.059903942,0.000051656207,0.00028573707,0.00034504512,0.0011021987,0.000006278004,0.005787284,0.000006274326,0.0014457147,0.72053254],"study_design_scores_gemma":[0.037283044,0.05255484,0.7740978,0.0010593074,0.00028715853,0.0010070134,0.000882486,0.000044167056,0.005776106,0.00007706073,0.1266061,0.0003249341],"about_ca_topic_score_codex":0.000017528746,"about_ca_topic_score_gemma":0.0001158157,"teacher_disagreement_score":0.7202076,"about_ca_system_score_codex":0.0008108007,"about_ca_system_score_gemma":0.00071114104,"threshold_uncertainty_score":0.35630062},"labels":[],"label_agreement":null},{"id":"W2803880880","doi":"10.1016/j.jtho.2018.02.013","title":"Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Clinical trial; Lung cancer; Inclusion and exclusion criteria; Medical physics; Intensive care medicine; Standard of care; Inclusion (mineral); Outcome (game theory); Clinical Practice; Family medicine; Alternative medicine; Oncology; Surgery; Internal medicine; Pathology","score_opus":0.21930128236929497,"score_gpt":0.709621805487233,"score_spread":0.490320523117938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803880880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7856091,0.002688938,0.030174457,0.1621221,0.013350193,0.002095666,0.00020039458,0.000043286713,0.0037158453],"genre_scores_gemma":[0.95002836,0.000331392,0.040860087,0.0030743708,0.005184877,0.00006659699,0.000016457963,0.000021091035,0.00041675312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975222,0.0005157318,0.0014387562,0.0001810788,0.00014142148,0.00020084211],"domain_scores_gemma":[0.99631196,0.0012926995,0.0012271067,0.00016616801,0.00085080037,0.00015123707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048454464,0.00011479633,0.00090125564,0.00016233369,0.00021475961,0.000021822254,0.00010112003,0.00016478455,0.00061114907],"category_scores_gemma":[0.0026885576,0.000081375314,0.00036164073,0.0001341574,0.00012860761,0.00014907565,0.000047935184,0.00023991418,0.000002422576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061869496,0.00093575346,0.026336705,0.00018312337,0.001742456,0.000059264523,0.0034890645,0.0000035242033,0.0017781224,0.0000953214,0.15188628,0.8073034],"study_design_scores_gemma":[0.01189186,0.009541788,0.040707536,0.0019224967,0.01201712,0.0008584617,0.0042680087,0.0018144706,0.0030996995,0.0032740005,0.9102039,0.0004006804],"about_ca_topic_score_codex":0.000014696256,"about_ca_topic_score_gemma":0.00003204765,"teacher_disagreement_score":0.80690277,"about_ca_system_score_codex":0.00087545783,"about_ca_system_score_gemma":0.0012727171,"threshold_uncertainty_score":0.6691654},"labels":[],"label_agreement":null},{"id":"W2804957255","doi":"10.1016/j.jtho.2018.05.013","title":"PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":807,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Intraclass correlation; Immunohistochemistry; Lung cancer; Internal medicine; Concordance; Pathology","score_opus":0.15394022752030842,"score_gpt":0.5666192394865217,"score_spread":0.41267901196621326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804957255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955139,0.00029316146,0.000046239158,0.0007058776,0.00067786843,0.00059483683,0.000015984606,0.000009681627,0.002142435],"genre_scores_gemma":[0.9975194,0.00022954449,0.001397401,0.00018712408,0.00054805446,0.000006869729,0.000004273589,0.000012151829,0.000095212396],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957832,0.0006870411,0.0026900228,0.00027059854,0.00033588256,0.00023323092],"domain_scores_gemma":[0.996622,0.00056257023,0.0016116655,0.00051496975,0.0005529689,0.00013578036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065952833,0.00016242357,0.0011976702,0.00020112375,0.000040016082,0.000006197468,0.00027529645,0.00022779213,0.000101891135],"category_scores_gemma":[0.0013609927,0.00012441343,0.00032751178,0.00033011055,0.0006531575,0.00006063213,0.000068544556,0.00065764884,0.000003430333],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58992124,0.027130745,0.14136496,0.00025286493,0.0011282369,0.00041910468,0.0054368977,0.0000020372186,0.097932525,0.0000032319704,0.0049837045,0.13142444],"study_design_scores_gemma":[0.048175994,0.060883656,0.844979,0.0005835787,0.0005961601,0.00075330393,0.008385386,0.00006714664,0.014122504,0.00006104256,0.021101546,0.0002906719],"about_ca_topic_score_codex":0.0004950593,"about_ca_topic_score_gemma":0.00013307274,"teacher_disagreement_score":0.70361406,"about_ca_system_score_codex":0.0005601404,"about_ca_system_score_gemma":0.0020566527,"threshold_uncertainty_score":0.50734323},"labels":[],"label_agreement":null},{"id":"W2807519281","doi":"10.1016/j.jtho.2018.05.030","title":"Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC","year":2018,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":662,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Roche","keywords":"Medicine; Liquid biopsy; Anaplastic lymphoma kinase; Lung cancer; Circulating tumor cell; Oncology; Molecular pathology; Biopsy; Molecular diagnostics; Internal medicine; Pathology; Intensive care medicine; Cancer; Medical physics; Bioinformatics","score_opus":0.02515770169668327,"score_gpt":0.4100484760315295,"score_spread":0.3848907743348462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807519281","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003767279,0.9888159,0.0020077736,0.00042807873,0.0030179122,0.0009832724,0.00075182447,0.0000027051838,0.00022526114],"genre_scores_gemma":[0.00013450306,0.9887329,0.004915893,0.0008101968,0.004585919,0.00021310011,0.00017368949,0.00008321457,0.00035059807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763936,0.00019989896,0.0011905077,0.00041474987,0.00014747784,0.0004079792],"domain_scores_gemma":[0.99647593,0.0003961261,0.0020203444,0.00050345756,0.0004397887,0.00016433775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073131896,0.00041793537,0.0012878989,0.00007030188,0.00011672066,0.000041165287,0.000783406,0.0005624554,0.00007615112],"category_scores_gemma":[0.0001631213,0.00027492768,0.00083780894,0.00009594965,0.00010605276,0.0000058055452,0.000251817,0.0003797996,0.0000067536876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016424052,0.00026942385,0.0000107189135,0.0026790805,0.0012389185,0.00004422365,0.00018044836,0.00003998779,0.003480623,0.000004170184,0.09494867,0.8954613],"study_design_scores_gemma":[0.00056686567,0.0021990684,0.0000035144249,0.0019392163,0.0020229893,0.000053165593,0.00007095142,0.0000047446274,0.0009918154,0.000020876147,0.99181044,0.00031635986],"about_ca_topic_score_codex":0.000040113708,"about_ca_topic_score_gemma":0.00019608175,"teacher_disagreement_score":0.89686173,"about_ca_system_score_codex":0.00033997023,"about_ca_system_score_gemma":0.0029611355,"threshold_uncertainty_score":0.9999703},"labels":[],"label_agreement":null},{"id":"W2809721683","doi":"10.1016/j.jtho.2018.06.016","title":"Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre","funders":"National Institute for Occupational Safety and Health; National Institute of General Medical Sciences; National Institute of Environmental Health Sciences; Canadian Cancer Society Research Institute; National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; Princess Margaret Hospital Foundation; National Human Genome Research Institute; World Health Organization","keywords":"Exome; Allele; Genetics; Medicine; Lung cancer; Genome-wide association study; Gene; Exome sequencing; Single-nucleotide polymorphism; Bioinformatics; Genotype; Biology; Oncology; Mutation","score_opus":0.014577304658999247,"score_gpt":0.43538794440216555,"score_spread":0.4208106397431663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809721683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465007,0.0012171338,0.0007251751,0.0023470053,0.00032169232,0.00027026772,0.000047661953,0.0000029945493,0.00041801165],"genre_scores_gemma":[0.9983962,0.0002573479,0.0007826979,0.00019310552,0.00027260167,0.000006001163,0.0000027951464,0.0000053869057,0.00008384042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917597,0.00014038972,0.00036801005,0.000102317994,0.0000830023,0.00013032749],"domain_scores_gemma":[0.9988481,0.00010229288,0.0003296672,0.00009993604,0.00050695176,0.00011306659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054802094,0.00007467492,0.00039734572,0.00013372373,0.000037532114,0.0000037580203,0.000043537544,0.00008782263,0.00014948193],"category_scores_gemma":[0.00025969007,0.00004862226,0.000052713287,0.00016478499,0.0000839353,0.000067867535,0.000022181428,0.00015662723,0.0000013759053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039259903,0.0006701083,0.7846884,0.00009865215,0.0005279921,0.00007177498,0.004567322,0.000024638486,0.00830017,0.000053193435,0.0021538695,0.19491786],"study_design_scores_gemma":[0.002500595,0.003633783,0.97810626,0.00028369416,0.0006906883,0.00017813384,0.0004991464,0.00023133989,0.005063112,0.0003833998,0.008357764,0.00007210398],"about_ca_topic_score_codex":0.00019569685,"about_ca_topic_score_gemma":0.00086609955,"teacher_disagreement_score":0.19484575,"about_ca_system_score_codex":0.00054193067,"about_ca_system_score_gemma":0.0005045698,"threshold_uncertainty_score":0.19827582},"labels":[],"label_agreement":null},{"id":"W2822628871","doi":"10.1016/j.jtho.2018.06.011","title":"Scientific Advances and New Frontiers in Mesothelioma Therapeutics","year":2018,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; University of Hawaiʻi Foundation; U.S. Department of Defense","keywords":"Medicine; Mesothelioma; Tunica vaginalis; Lung cancer; Asbestos; Peritoneal mesothelioma; Pericardium; Oncology; Internal medicine; General surgery; Pathology","score_opus":0.06959764444594024,"score_gpt":0.46646608812964263,"score_spread":0.3968684436837024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2822628871","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006718058,0.99720013,0.000039750914,0.00026500382,0.0012941071,0.00019307801,0.000010920063,0.0000033317021,0.00032185868],"genre_scores_gemma":[0.000035722533,0.99250585,0.005679401,0.00014289573,0.00045459732,0.0000023420107,0.000011899089,0.000019001047,0.0011482685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865156,0.00014102487,0.0006201409,0.00018085897,0.00024779103,0.0001585903],"domain_scores_gemma":[0.99890375,0.00009814683,0.0006311953,0.00012665858,0.00004471102,0.00019551978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004112658,0.00018014533,0.0012338825,0.0004904195,0.000041216445,0.000021852324,0.00013109634,0.00019905882,0.000070078575],"category_scores_gemma":[0.00004827013,0.00011811475,0.00024331342,0.00023925724,0.00030019868,0.0001244672,0.000041827247,0.0002979434,0.000017910816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029086068,0.00015997949,0.0011921047,0.002660188,0.00014798129,0.00013108028,0.000037626396,1.7720409e-7,0.0000010597649,0.0000024668477,0.0043660095,0.9910105],"study_design_scores_gemma":[0.00024941453,0.0007848303,0.00083188445,0.0042201616,0.0015759612,0.0009363502,0.0000474562,0.0000021707692,0.000001665853,0.0005147562,0.99073756,0.000097802826],"about_ca_topic_score_codex":0.0000011765281,"about_ca_topic_score_gemma":0.0000034561263,"teacher_disagreement_score":0.9909127,"about_ca_system_score_codex":0.00032108932,"about_ca_system_score_gemma":0.0008904262,"threshold_uncertainty_score":0.48165798},"labels":[],"label_agreement":null},{"id":"W2884617673","doi":"10.1016/j.jtho.2018.07.008","title":"CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non–Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Natural Science Foundation of China","keywords":"Crizotinib; Anaplastic lymphoma kinase; Cancer research; ALK inhibitor; Fusion gene; Molecular biology; Receptor tyrosine kinase; Biology; Lung cancer; Medicine; Signal transduction; Gene; Cell biology; Genetics; Oncology","score_opus":0.038738264174478565,"score_gpt":0.47200986640491716,"score_spread":0.4332716022304386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884617673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96284163,0.00073038327,0.00095946004,0.014463,0.0013648288,0.00055414625,0.000013361045,0.0000100299285,0.019063149],"genre_scores_gemma":[0.977396,0.00015076561,0.012797775,0.002720422,0.0010027557,0.000051255854,0.0000032087805,0.000029260147,0.0058485703],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986139,0.00007723713,0.0005042339,0.0002062619,0.0002671287,0.00033125555],"domain_scores_gemma":[0.9987044,0.000090439295,0.00036071436,0.00020986325,0.00036519766,0.00026940912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060544617,0.00015954915,0.0005106724,0.00044957318,0.00007027329,0.000016436758,0.00015321355,0.00013429797,0.00044787873],"category_scores_gemma":[0.00006852047,0.00012079698,0.000120596094,0.00032754484,0.000054830412,0.00009303377,0.00005473499,0.00030254034,0.000023574798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023969645,0.0066711293,0.14564718,0.0006525305,0.0014749714,0.0030673887,0.06293182,0.0002943739,0.19452871,0.00007014945,0.12126422,0.43942788],"study_design_scores_gemma":[0.012597043,0.013761924,0.25863215,0.0016299196,0.0028395907,0.0009698927,0.006487792,0.00036713033,0.02348582,0.000078398654,0.6786642,0.0004861422],"about_ca_topic_score_codex":0.0002457948,"about_ca_topic_score_gemma":0.00075134,"teacher_disagreement_score":0.5574,"about_ca_system_score_codex":0.0011958199,"about_ca_system_score_gemma":0.001041185,"threshold_uncertainty_score":0.4925958},"labels":[],"label_agreement":null},{"id":"W2890521724","doi":"10.1016/j.jtho.2018.07.026","title":"PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pemetrexed; Pembrolizumab; Medicine; Placebo; Internal medicine; Carboplatin; Quality of life (healthcare); Oncology; Cisplatin; Chemotherapy; Cancer; Pathology","score_opus":0.04196411465326621,"score_gpt":0.4600915825657306,"score_spread":0.41812746791246436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890521724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864447,0.0005396798,0.0004551616,0.005973244,0.00048308054,0.00056767283,0.000016477808,0.000015129909,0.0055048126],"genre_scores_gemma":[0.9934265,0.000054321874,0.004412727,0.0006740341,0.00027581496,0.000011659945,0.000009934263,0.000028995364,0.0011060218],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9970514,0.0003826503,0.0015461346,0.00021134394,0.00045107276,0.00035738086],"domain_scores_gemma":[0.9966098,0.0004780969,0.0017719186,0.0002604116,0.0005428685,0.000336911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012743375,0.00020172352,0.0012811053,0.00043875197,0.00008283435,0.00000839013,0.00014296696,0.00022515109,0.00048288284],"category_scores_gemma":[0.0006138537,0.00012834184,0.00013476884,0.00057063,0.0002243726,0.00013378529,0.00003155434,0.0005207038,0.000015930134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44925126,0.010189507,0.1635728,0.0018395387,0.0037275644,0.0024304134,0.032332264,0.00048544517,0.003782687,0.00021689906,0.01889388,0.31327772],"study_design_scores_gemma":[0.07903693,0.08347231,0.8081982,0.0020016881,0.0016606367,0.004321737,0.007914078,0.0006372409,0.0018261789,0.00039392873,0.00988427,0.00065280683],"about_ca_topic_score_codex":0.00074093044,"about_ca_topic_score_gemma":0.001884301,"teacher_disagreement_score":0.64462537,"about_ca_system_score_codex":0.0009356904,"about_ca_system_score_gemma":0.0040535647,"threshold_uncertainty_score":0.719085},"labels":[],"label_agreement":null},{"id":"W2892310829","doi":"10.1016/j.jtho.2018.09.006","title":"Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme; National Cancer Institute; National Institutes of Health; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Stage (stratigraphy); Oncology; Mutation; Cancer research; Lung; Gene; Basal cell; Internal medicine; Squamous-cell carcinoma of the lung; Carcinoma; Lung cancer; Gene mutation; Pathology; Genetics; Biology","score_opus":0.01350046462277225,"score_gpt":0.3431897313177978,"score_spread":0.3296892666950255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892310829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627405,0.0012458107,0.0013135726,0.0003897241,0.00018061431,0.00047017587,0.0000053701415,0.0000037413795,0.0001169573],"genre_scores_gemma":[0.993708,0.00002181691,0.0057500033,0.00006411454,0.00029443632,0.000011830102,0.000004071608,0.000012889148,0.0001327963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991212,0.00008483191,0.00040784976,0.00010858255,0.00015547834,0.00012208811],"domain_scores_gemma":[0.9988364,0.0001541958,0.000622594,0.00006511418,0.0002706746,0.000051043175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045267044,0.00008876218,0.0003067602,0.00021552404,0.00003696251,0.0000066205794,0.00005003626,0.00011636371,0.000024795358],"category_scores_gemma":[0.000049439543,0.00006227285,0.000058105645,0.00012573709,0.00010407408,0.0001030563,0.000010843911,0.00016164433,1.8640425e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09187168,0.00037523577,0.16980658,0.00059663574,0.0000812521,0.00031592872,0.0063902833,0.00016374433,0.6900611,0.0000025663235,0.00061566534,0.039719358],"study_design_scores_gemma":[0.008143587,0.023006067,0.42330208,0.00044585761,0.00035600242,0.00068001566,0.0017050931,0.0031736076,0.53758705,0.00003308513,0.0014112252,0.0001563174],"about_ca_topic_score_codex":0.000071165254,"about_ca_topic_score_gemma":0.000032565047,"teacher_disagreement_score":0.25349548,"about_ca_system_score_codex":0.00014730384,"about_ca_system_score_gemma":0.00021837038,"threshold_uncertainty_score":0.2539413},"labels":[],"label_agreement":null},{"id":"W2892837443","doi":"10.1016/j.jtho.2018.08.2036","title":"Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Mesothelioma Applied Research Foundation","keywords":"Medicine; Mesothelioma; Malignancy; Lung cancer; Cancer; Asbestos; Foundation (evidence); Oncology; Intensive care medicine; Pathology; Internal medicine","score_opus":0.06195929712655243,"score_gpt":0.4754812113492143,"score_spread":0.4135219142226618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892837443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870139,0.003745105,0.00007682026,0.0068283426,0.001059981,0.0008804742,0.0001023971,0.0000033440253,0.0002896372],"genre_scores_gemma":[0.9957931,0.0021356156,0.0006577594,0.0000728858,0.0010947525,0.000106661326,0.000015989666,0.000010547124,0.00011268738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815655,0.00012449427,0.00059522246,0.00016823519,0.00082737056,0.00012812947],"domain_scores_gemma":[0.99779975,0.00050194596,0.00087252975,0.00010751161,0.0006669811,0.000051275445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017058647,0.00010383738,0.0002822518,0.00014241204,0.00018055577,0.000018221093,0.00014391982,0.00005969508,0.00004291281],"category_scores_gemma":[0.00008454143,0.00006250599,0.00005649295,0.00017743777,0.00021728393,0.000073283074,0.00010664036,0.00017706021,3.638317e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009497454,0.0019258772,0.57104427,0.00053416676,0.0040125065,0.00006773684,0.0027582361,0.00011405964,0.0039189747,0.0013446105,0.005594088,0.39918804],"study_design_scores_gemma":[0.0017846084,0.0005909386,0.9621659,0.00042686588,0.0010513152,0.00007231113,0.0027413783,0.00056124886,0.0006032143,0.0007504889,0.02916718,0.00008454709],"about_ca_topic_score_codex":0.00012777912,"about_ca_topic_score_gemma":0.00015654048,"teacher_disagreement_score":0.3991035,"about_ca_system_score_codex":0.00047395058,"about_ca_system_score_gemma":0.00021019981,"threshold_uncertainty_score":0.25489202},"labels":[],"label_agreement":null},{"id":"W2895657963","doi":"10.1016/j.jtho.2018.09.019","title":"Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; European Organisation for Research and Treatment of Cancer; Ministère des Affaires Sociales et de la Santé; Cancer Research UK","keywords":"Prophylactic cranial irradiation; Medicine; Conventional PCI; Univariate analysis; Chemoradiotherapy; Radiation therapy; Brain metastasis; Lung cancer; Internal medicine; Stage (stratigraphy); Nuclear medicine; Surgery; Multivariate analysis; Oncology; Radiology; Cancer; Metastasis; Myocardial infarction","score_opus":0.02859961238320336,"score_gpt":0.4390860858578507,"score_spread":0.41048647347464734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895657963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98266983,0.0013047929,0.00062057015,0.0059481016,0.0030525785,0.005552627,0.00012642218,0.000015486154,0.0007095644],"genre_scores_gemma":[0.9918488,0.00020714788,0.0009906018,0.0010311863,0.004479875,0.00042370826,0.000017630024,0.000033526245,0.00096748234],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759144,0.0005474378,0.0008209287,0.0002489235,0.00044263114,0.00034866153],"domain_scores_gemma":[0.9950441,0.0021155952,0.0009543696,0.00017872501,0.0015521323,0.00015503728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018533164,0.00020189844,0.0010996547,0.00015902925,0.0002540295,0.000040735704,0.00021856697,0.00016617092,0.00042454386],"category_scores_gemma":[0.0029150124,0.000117334865,0.00035926778,0.00019131986,0.0004264944,0.00019457166,0.00006387784,0.00066929916,0.0000063301527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96736205,0.0012091062,0.002620468,0.00020127448,0.0010029768,0.000031093416,0.004063384,9.3251134e-7,0.001409392,0.000009170007,0.009444093,0.012646079],"study_design_scores_gemma":[0.9545202,0.019306293,0.0044416366,0.00015189596,0.0026734802,0.000014794433,0.00050199946,0.0008379486,0.0039934083,0.00025839533,0.013118612,0.0001812842],"about_ca_topic_score_codex":0.00012260619,"about_ca_topic_score_gemma":0.00010217114,"teacher_disagreement_score":0.018097186,"about_ca_system_score_codex":0.0013494686,"about_ca_system_score_gemma":0.0019598939,"threshold_uncertainty_score":0.4784777},"labels":[],"label_agreement":null},{"id":"W2896469588","doi":"10.1016/j.jtho.2018.08.1799","title":"P3.11-03 Implementing Lung Cancer Screening in Canada: Evidence on Adherence and Budget Impact from the Pan-Canadian Early Detection Study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Logistic regression; Cancer; Cancer screening; Family medicine; Internal medicine; Demography","score_opus":0.0902100088984265,"score_gpt":0.47006306696506156,"score_spread":0.37985305806663505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896469588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526435,0.0015954699,0.00009538343,0.0021224443,0.0004287276,0.00035293834,0.000012560691,0.0000035542405,0.00012457535],"genre_scores_gemma":[0.9977227,0.000084943014,0.0002904451,0.001105432,0.0007592963,0.000010163441,5.123577e-7,0.000011649595,0.000014881048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979925,0.0003110226,0.00056412467,0.00021769687,0.00044189967,0.00047275037],"domain_scores_gemma":[0.9982698,0.00045385942,0.0004789721,0.0001837325,0.00032488728,0.00028878028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015447187,0.00015919934,0.0004368368,0.0001650765,0.00021965291,0.000042929485,0.00022396797,0.00007741892,0.000188313],"category_scores_gemma":[0.00045621215,0.000107214306,0.000062995874,0.00032962963,0.000063839645,0.0002585743,0.000056816058,0.0005887622,0.0000018510563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011078705,0.00001797782,0.7999697,0.000005213259,0.000099251585,0.00032735133,0.0010357853,0.000017818062,0.0005526294,3.5772425e-7,0.0007802058,0.19608589],"study_design_scores_gemma":[0.0005818315,0.003890232,0.9878663,0.0007671799,0.00022681073,0.0001640054,0.004679239,0.00050338166,0.00044150988,0.000013374531,0.0007628047,0.000103370745],"about_ca_topic_score_codex":0.9947796,"about_ca_topic_score_gemma":0.99937135,"teacher_disagreement_score":0.19598252,"about_ca_system_score_codex":0.0024653014,"about_ca_system_score_gemma":0.0045057405,"threshold_uncertainty_score":0.799299},"labels":[],"label_agreement":null},{"id":"W2897029126","doi":"10.1016/j.jtho.2018.08.1906","title":"P3.15-30 Treatment Patterns and Survival of Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Era of Novel Therapies","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Targeted therapy; Lung cancer; Chemotherapy; Radiation therapy; Immunotherapy; Population; Palliative care; Cancer","score_opus":0.02091967962354643,"score_gpt":0.39365789217145725,"score_spread":0.37273821254791084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897029126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99709696,0.0005394371,0.0003154396,0.00078025024,0.00019457533,0.0003890707,0.00007984049,0.0000015340087,0.000602881],"genre_scores_gemma":[0.9981166,0.00033873838,0.0011049579,0.00014296615,0.00012659848,0.000014356921,0.000005018874,0.000012123306,0.00013864176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991131,0.00007953136,0.0003756308,0.00010189621,0.00019079303,0.0001390798],"domain_scores_gemma":[0.99885637,0.00012392936,0.00053212966,0.00013428362,0.0002992996,0.00005399657],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002050038,0.000121317076,0.00044292695,0.00009344157,0.00003441138,0.00000530123,0.0000787583,0.000060711813,0.00009681243],"category_scores_gemma":[0.0000069905327,0.000061076265,0.000059490318,0.00009717611,0.0001110427,0.000054943837,0.000013791874,0.00013846824,3.187161e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002154581,0.0025083576,0.9472017,0.00014002115,0.00055664434,0.000035222005,0.014064303,0.000018972481,0.0006259763,0.0000056353865,0.000047327805,0.03264123],"study_design_scores_gemma":[0.0071660485,0.010746269,0.97545147,0.00030874313,0.0008711932,0.00001609687,0.002732463,0.000059661106,0.0014114205,0.00000456532,0.0011612757,0.000070809896],"about_ca_topic_score_codex":0.00059236994,"about_ca_topic_score_gemma":0.0011019665,"teacher_disagreement_score":0.032570418,"about_ca_system_score_codex":0.00023401785,"about_ca_system_score_gemma":0.0004819926,"threshold_uncertainty_score":0.2490618},"labels":[],"label_agreement":null},{"id":"W2897415577","doi":"10.1016/j.jtho.2018.08.1971","title":"P3.17-15 Therapeutic Outcome of Surgery for Superior Sulcus Tumor","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Ear and Head Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Pathological; Adenocarcinoma; Stage (stratigraphy); Induction chemotherapy; Sulcus; Chemoradiotherapy; Surgery; Thoracoscopy; Univariate analysis; Multivariate analysis; Chemotherapy; Radiology; Cancer; Internal medicine","score_opus":0.10314582876522727,"score_gpt":0.4698801419937778,"score_spread":0.36673431322855055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897415577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989342,0.0007097463,0.0005204234,0.006199956,0.0013147664,0.00023429035,0.000008451683,0.000011564617,0.0016588309],"genre_scores_gemma":[0.9920285,0.000029919713,0.0032882192,0.0017908489,0.0013771976,0.000004407063,0.0000018260627,0.000026802505,0.0014522851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821615,0.00011662566,0.0009868804,0.00012050328,0.00023794855,0.00032187824],"domain_scores_gemma":[0.9977111,0.00069007906,0.00063195213,0.00019384893,0.00057784305,0.0001951705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016702551,0.00013286014,0.0010570738,0.0003159057,0.000054957396,0.000006293376,0.00013066483,0.0001274745,0.00056397746],"category_scores_gemma":[0.00041511803,0.00009450657,0.00043241488,0.00013873263,0.0002323394,0.000079643614,0.00002303716,0.00029092707,0.000024039913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028057298,0.0021880094,0.6873236,0.0012665632,0.0010232982,0.0014486809,0.0016916336,0.0000030129283,0.05486714,0.0003187128,0.055972874,0.16583921],"study_design_scores_gemma":[0.0041829916,0.021992188,0.5094529,0.0006927652,0.0022387304,0.014261827,0.0016867167,0.00019897979,0.04166243,0.0019868736,0.40114087,0.0005027228],"about_ca_topic_score_codex":0.00000790138,"about_ca_topic_score_gemma":0.00003240433,"teacher_disagreement_score":0.345168,"about_ca_system_score_codex":0.00014242492,"about_ca_system_score_gemma":0.0006711249,"threshold_uncertainty_score":0.6175158},"labels":[],"label_agreement":null},{"id":"W2897510230","doi":"10.1016/j.jtho.2018.08.1780","title":"P3.09-11 Genomic Organization at Large Scales (GOALS) within Nuclei and Cell Sociology for Predicting Lung Cancer Outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Stromal cell; Nucleus; Medicine; Cell; Lung cancer; Stain; Pathology; Feulgen stain; Outcome (game theory); Biology; Genetics; Mathematics; Psychiatry","score_opus":0.012329085337085502,"score_gpt":0.39450659283195355,"score_spread":0.38217750749486806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897510230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97925866,0.0010073124,0.007803545,0.010195064,0.001325369,0.0002174504,0.000007990884,0.000021495242,0.00016310657],"genre_scores_gemma":[0.9823002,0.00017442116,0.013157829,0.002199433,0.0014835537,0.000004070251,0.0000071826207,0.000043546734,0.00062975625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986418,0.00014494496,0.0005806896,0.00018643039,0.0001512015,0.00029496025],"domain_scores_gemma":[0.9982373,0.00034953226,0.00073647517,0.00010383721,0.00037696937,0.00019590203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013027046,0.00014079052,0.0005991568,0.00014610226,0.00025090645,0.000014411021,0.00011983939,0.00021699729,0.00016715744],"category_scores_gemma":[0.0008858758,0.00010569651,0.000087028966,0.00008382844,0.0002720479,0.00007939701,0.00009751799,0.0004109032,0.000004068717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046000638,0.00013249539,0.9528569,0.00020546543,0.00017604943,0.000043615695,0.0027634439,0.000041193027,0.027639639,0.00007601755,0.006098701,0.009506496],"study_design_scores_gemma":[0.011158516,0.0053338953,0.7784906,0.0005673535,0.0029198623,0.003198548,0.0021818602,0.1056739,0.007812577,0.00082321826,0.08119464,0.0006450268],"about_ca_topic_score_codex":0.000013533911,"about_ca_topic_score_gemma":0.000040336396,"teacher_disagreement_score":0.17436628,"about_ca_system_score_codex":0.00039265986,"about_ca_system_score_gemma":0.0002781407,"threshold_uncertainty_score":0.43101788},"labels":[],"label_agreement":null},{"id":"W2898083831","doi":"10.1016/j.jtho.2018.08.1451","title":"P2.15-10 Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Crizotinib; Cohort; Lung cancer; Quality of life (healthcare); Internal medicine; Ceritinib; Cancer; Cohort study; ALK inhibitor","score_opus":0.03149558017327234,"score_gpt":0.34548032114253785,"score_spread":0.3139847409692655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898083831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886789,0.002229705,0.00030423765,0.00033290414,0.00085248885,0.0002735315,0.000085370215,0.0000037076074,0.0072391764],"genre_scores_gemma":[0.9975378,0.00038089536,0.0012207143,0.00029503007,0.00024464887,0.000006135635,0.0000017680142,0.0000236958,0.00028930345],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752486,0.0000713282,0.0016502591,0.0002667987,0.000056834444,0.00042989978],"domain_scores_gemma":[0.9961129,0.00007203016,0.003147323,0.00026036624,0.00025424303,0.00015316639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016658022,0.00018293431,0.0012546455,0.0003761036,0.00007301085,0.000017719065,0.00035430538,0.0001846029,0.0005072039],"category_scores_gemma":[0.000114055205,0.00017225646,0.0001223204,0.0002222435,0.00020079999,0.00031934975,0.000055602944,0.00030409513,0.000028775563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012087538,0.00036255637,0.93938386,0.00012308081,0.000035871948,0.0000064178607,0.00080044364,0.0000160165,0.000003989889,0.00002424757,0.0020137774,0.05602099],"study_design_scores_gemma":[0.0017283716,0.0027648788,0.98294276,0.00019760038,0.000018722232,0.000004578118,0.00006129053,0.00025485668,0.00022568057,0.00048594573,0.011130471,0.00018482281],"about_ca_topic_score_codex":0.0009954143,"about_ca_topic_score_gemma":0.0023684897,"teacher_disagreement_score":0.055836167,"about_ca_system_score_codex":0.0005758984,"about_ca_system_score_gemma":0.0006514175,"threshold_uncertainty_score":0.7024415},"labels":[],"label_agreement":null},{"id":"W2898096006","doi":"10.1016/j.jtho.2018.08.1726","title":"P3.04-19 Do Advanced Lung Cancer Patients Derive Similar Survival Benefits from Immunotherapy? A Systematic Review and Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Meta-analysis; Lung cancer; Subgroup analysis; Oncology; Randomized controlled trial; Immunotherapy; Cancer; Confidence interval","score_opus":0.0676536742065104,"score_gpt":0.45838238290408695,"score_spread":0.39072870869757653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898096006","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013747625,0.99508804,0.000040808398,0.0006726696,0.0006951054,0.002812677,0.00046957083,0.0000145597105,0.00006906904],"genre_scores_gemma":[0.000035496058,0.9961221,0.0008680604,0.0019664455,0.0002527882,0.000258765,0.000071505165,0.0000897443,0.00033506262],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99285847,0.0018348028,0.0035779052,0.00057505775,0.0007393026,0.00041449038],"domain_scores_gemma":[0.990604,0.0009140976,0.0064750626,0.00078052713,0.0009332083,0.00029310808],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023549283,0.0008122621,0.017426638,0.0006799867,0.00011939473,0.000050086517,0.0005405514,0.0006082492,0.0015529137],"category_scores_gemma":[0.00032852116,0.00048085983,0.0057436097,0.0010741241,0.000183126,0.00016931446,0.00009688531,0.0007951825,0.0000070064884],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010930322,0.00024533112,0.00002939397,0.3724053,0.48781082,0.00007416449,0.00016382596,9.385742e-7,0.0000014731532,7.4489225e-7,0.0011380545,0.13703693],"study_design_scores_gemma":[0.00074217573,0.00096670474,0.000051058218,0.06515101,0.76697433,0.00015198906,0.000030681083,0.000001466597,7.539593e-7,0.0000047238386,0.16557635,0.00034871834],"about_ca_topic_score_codex":0.00008728316,"about_ca_topic_score_gemma":0.00013387275,"teacher_disagreement_score":0.30725428,"about_ca_system_score_codex":0.001171165,"about_ca_system_score_gemma":0.0011591087,"threshold_uncertainty_score":0.9997643},"labels":[],"label_agreement":null},{"id":"W2898097887","doi":"10.1016/j.jtho.2018.08.876","title":"P1.13-19 Treatment Cessation for Improved Detection of EGFR-Mutated Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer (aNSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Osimertinib; Lung cancer; Internal medicine; Oncology; T790M; Context (archaeology); Smoking cessation; Cancer; Epidermal growth factor receptor; Pathology; Erlotinib","score_opus":0.011909559749458306,"score_gpt":0.3503669102303037,"score_spread":0.3384573504808454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898097887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887959,0.0008476933,0.008974725,0.00012546992,0.0007114382,0.00038348968,0.000033773013,0.0000022042518,0.0001253389],"genre_scores_gemma":[0.99622595,0.000396627,0.0025574658,0.00012183804,0.00057646877,0.000042000007,0.00001579099,0.000021055002,0.00004280658],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989534,0.000057290374,0.0005393908,0.00018997578,0.00005448541,0.00020547002],"domain_scores_gemma":[0.99858147,0.000076185424,0.0008001683,0.00013283952,0.00033412268,0.000075216136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029434136,0.00013415665,0.0003177682,0.00011635085,0.000051052288,0.000009236093,0.000109430606,0.00014692883,0.0000063476236],"category_scores_gemma":[0.00012313912,0.0001244743,0.00013031192,0.00010448639,0.000047155063,0.000007950273,0.000028283275,0.000081963255,2.365143e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001370196,0.00016140004,0.0022283038,0.00006552365,0.000061312356,0.000005358304,0.00033590588,0.0012484397,0.9262503,6.743384e-7,0.000040183368,0.06823241],"study_design_scores_gemma":[0.0025212292,0.0051335664,0.0055643744,0.000053429092,0.00016305216,0.000040415267,0.00024939686,0.005873912,0.9760979,0.00007023974,0.004080788,0.00015170478],"about_ca_topic_score_codex":0.0001929544,"about_ca_topic_score_gemma":0.0023628687,"teacher_disagreement_score":0.0680807,"about_ca_system_score_codex":0.00043433413,"about_ca_system_score_gemma":0.00064765115,"threshold_uncertainty_score":0.5075914},"labels":[],"label_agreement":null},{"id":"W2898114027","doi":"10.1016/j.jtho.2018.08.482","title":"MA20.01 Lung Cancer Screenee Selection by USPSTF versus PLCOm2012 Criteria – Preliminary ILST Findings","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer screening; National Lung Screening Trial; Lung cancer; Task force; Medicaid; Family medicine; Internal medicine; Cancer; Health care","score_opus":0.028073583107013335,"score_gpt":0.4505996783777151,"score_spread":0.42252609527070173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898114027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765239,0.0036853952,0.0001892903,0.012425731,0.0036864732,0.00029735357,0.00002133946,0.00002593451,0.003144609],"genre_scores_gemma":[0.99216497,0.00093082443,0.0026227853,0.0008279416,0.0024265456,0.000031070093,0.000009246331,0.000032753254,0.0009538764],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985332,0.00012225317,0.0004896173,0.00021452966,0.00029930688,0.00034112207],"domain_scores_gemma":[0.99863625,0.00017788442,0.00039865082,0.00015070174,0.00038795275,0.00024853478],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041390132,0.0001910117,0.00054948375,0.00018525976,0.00013145377,0.000024175339,0.00012641982,0.00022118619,0.0018231068],"category_scores_gemma":[0.00008069334,0.00014900013,0.00016967332,0.00021551142,0.00011844885,0.00020479433,0.00004494548,0.00033810077,0.000025759378],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02985152,0.0014633198,0.06594253,0.0002281748,0.0015024132,0.00031252738,0.0006863067,0.0000066771586,0.00870464,0.000027404874,0.7923661,0.09890837],"study_design_scores_gemma":[0.015228727,0.06759837,0.20333749,0.0018884636,0.0076420805,0.0032777295,0.0005136855,0.0010407852,0.0809906,0.000118048716,0.6176726,0.00069142046],"about_ca_topic_score_codex":0.0001413883,"about_ca_topic_score_gemma":0.00013564248,"teacher_disagreement_score":0.17469351,"about_ca_system_score_codex":0.0019812314,"about_ca_system_score_gemma":0.0005118802,"threshold_uncertainty_score":0.99908936},"labels":[],"label_agreement":null},{"id":"W2898116257","doi":"10.1016/j.jtho.2018.08.073","title":"MTE18.01 Case-Based Management of Patients with Inadequate Tissue for Molecular Tests","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Molecular Biology Techniques and Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Genotyping; Medicine; KRAS; Liquid biopsy; Biopsy; Oncology; Internal medicine; Cancer; Genotype; Biology; Gene; Genetics; Colorectal cancer","score_opus":0.011943014004823654,"score_gpt":0.3840170347795539,"score_spread":0.37207402077473023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898116257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80934805,0.00014390811,0.18895766,0.0003923398,0.00008018962,0.00044357928,0.000030848452,0.0000053235126,0.0005981239],"genre_scores_gemma":[0.89442366,0.000018971268,0.10499948,0.0003022167,0.000088098845,0.000039052215,0.00004330892,0.000020270929,0.00006493823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999032,0.00008313955,0.00038792245,0.00019713871,0.00010447624,0.00019531991],"domain_scores_gemma":[0.99857515,0.00001970959,0.00053175254,0.000292227,0.00050195376,0.00007918678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003157048,0.00013636207,0.00025349672,0.00008204824,0.000060473616,0.0000055343535,0.00022870667,0.00019076437,0.000014999046],"category_scores_gemma":[0.00002493511,0.00010785789,0.00009699301,0.000110208646,0.00019551437,0.000003374751,0.00006214139,0.00008815088,0.0000013403247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060645593,0.0020364234,0.003342077,0.0003551875,0.0010142295,0.0008954217,0.00005757244,0.00012794154,0.5525689,0.0013161285,0.0074316645,0.42478988],"study_design_scores_gemma":[0.0015682868,0.014236802,0.0027451413,0.0000844914,0.0003564392,0.00045579363,0.000048778813,0.0000400798,0.81965524,0.0004994527,0.16005242,0.00025706182],"about_ca_topic_score_codex":0.0000031099573,"about_ca_topic_score_gemma":0.000012336537,"teacher_disagreement_score":0.42453283,"about_ca_system_score_codex":0.000032501957,"about_ca_system_score_gemma":0.00010705887,"threshold_uncertainty_score":0.43983173},"labels":[],"label_agreement":null},{"id":"W2898119247","doi":"10.1016/j.jtho.2018.08.056","title":"MTE05.02 Role of Pneumonectomy in N2 Disease","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Pneumonectomy; Intensive care medicine; Internal medicine; Lung","score_opus":0.02524413284901265,"score_gpt":0.43840267003973366,"score_spread":0.413158537190721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898119247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97905016,0.0026808751,0.00008180372,0.009810106,0.00057813857,0.00008223002,0.0000023680052,0.000007349467,0.0077069416],"genre_scores_gemma":[0.995807,0.00015452276,0.0020729348,0.0009843967,0.000647409,0.0000021732374,7.93425e-7,0.000008669774,0.00032210018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987093,0.00020584142,0.0005529126,0.000109928995,0.0002196572,0.00020235161],"domain_scores_gemma":[0.9987364,0.00022134071,0.00036870202,0.00014913596,0.00029077881,0.00023366537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091172854,0.00009369432,0.0006207502,0.000249287,0.000028761737,0.0000019074928,0.0001109129,0.000096693504,0.00012810575],"category_scores_gemma":[0.0010666013,0.00006697126,0.000119201606,0.00017523956,0.0004902176,0.00004642229,0.000049206043,0.00040758774,0.000023878869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005115879,0.0017268644,0.6674504,0.00024021535,0.00028614607,0.004146731,0.0030553397,0.000003303005,0.031772833,0.000103871775,0.011815244,0.27428317],"study_design_scores_gemma":[0.0028817514,0.0082687475,0.8619562,0.00087693916,0.00086468406,0.0024420233,0.0018436054,0.0002124165,0.0073914756,0.0037858072,0.10926986,0.00020650045],"about_ca_topic_score_codex":0.000008385897,"about_ca_topic_score_gemma":0.00001128315,"teacher_disagreement_score":0.27407667,"about_ca_system_score_codex":0.00007649744,"about_ca_system_score_gemma":0.0003497738,"threshold_uncertainty_score":0.27310085},"labels":[],"label_agreement":null},{"id":"W2898123513","doi":"10.1016/j.jtho.2018.08.1724","title":"P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Atezolizumab; Medicine; Docetaxel; Oncology; Nivolumab; Lung cancer; Internal medicine; Cancer; Immunotherapy","score_opus":0.22418106120499373,"score_gpt":0.5057818398399055,"score_spread":0.28160077863491184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898123513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436147,0.0028588357,0.005691336,0.0021582833,0.0014068729,0.0023966487,0.00028931492,0.0000053602967,0.00083189976],"genre_scores_gemma":[0.99083036,0.00034227018,0.0066220285,0.00118291,0.00028377838,0.00032449112,0.000009591787,0.000042819633,0.00036176795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99384713,0.00080895616,0.0043916265,0.0003418168,0.00009819924,0.00051224034],"domain_scores_gemma":[0.99018985,0.0032185114,0.00566213,0.0002838664,0.0004355196,0.00021009748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012582017,0.00022452207,0.0021685227,0.0004571278,0.000082575745,0.000015806045,0.00038925197,0.00013503194,0.00025637972],"category_scores_gemma":[0.0016312726,0.00022405898,0.00016471474,0.00030982398,0.00007745982,0.00028798432,0.000038301554,0.00024654568,0.000012440863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.054094017,0.004402497,0.61606914,0.03780333,0.003975362,0.0003972079,0.018091211,0.034920663,0.0015292638,0.002512049,0.08775971,0.13844559],"study_design_scores_gemma":[0.068714686,0.03311954,0.4331559,0.012725739,0.0018258789,0.0007750551,0.016553087,0.14263782,0.015437073,0.011219588,0.25887388,0.004961752],"about_ca_topic_score_codex":0.15176737,"about_ca_topic_score_gemma":0.58123755,"teacher_disagreement_score":0.42947018,"about_ca_system_score_codex":0.005914164,"about_ca_system_score_gemma":0.0063403817,"threshold_uncertainty_score":0.99929273},"labels":[],"label_agreement":null},{"id":"W2898124802","doi":"10.1016/j.jtho.2018.08.330","title":"MA02.11 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Oncology; Lung cancer; Genotyping; Liquid biopsy; Internal medicine; Clinical endpoint; Clinical trial; Cancer; Genotype; Gene; Genetics","score_opus":0.017977069198978256,"score_gpt":0.42881479246779763,"score_spread":0.4108377232688194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898124802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874199,0.0011537034,0.0002578114,0.0065451274,0.0016918711,0.00064435165,0.0000025489228,0.000013263875,0.0022714166],"genre_scores_gemma":[0.9896546,0.00012695004,0.008090147,0.0007367832,0.0012463244,0.000021134252,0.0000014467452,0.000039574883,0.00008301504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781734,0.00038611065,0.0006443679,0.0002710872,0.0003894245,0.0004916467],"domain_scores_gemma":[0.99828446,0.00033077295,0.00039007328,0.00020315082,0.00031357128,0.00047794398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016814906,0.00019345271,0.00068610965,0.00068448443,0.00011504034,0.000029315246,0.00023668539,0.00015971319,0.00009545928],"category_scores_gemma":[0.002752999,0.00016393495,0.000088947745,0.00046879356,0.00017271357,0.000097936805,0.000061851126,0.00115837,0.000008512528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023478128,0.002102634,0.85857254,0.00014348797,0.00089369784,0.018738896,0.0054008625,0.0009909784,0.009394414,0.0006202548,0.00058116444,0.10021324],"study_design_scores_gemma":[0.04215441,0.081230775,0.71712106,0.0046305326,0.01027093,0.008361428,0.014112152,0.018114233,0.03279416,0.0015741533,0.06766646,0.0019697149],"about_ca_topic_score_codex":0.020396603,"about_ca_topic_score_gemma":0.0152948545,"teacher_disagreement_score":0.14145151,"about_ca_system_score_codex":0.0010348766,"about_ca_system_score_gemma":0.00167981,"threshold_uncertainty_score":0.98612666},"labels":[],"label_agreement":null},{"id":"W2898134598","doi":"10.1016/j.jtho.2018.08.093","title":"PC01.03 PRO IO in Mesothelioma Should Only Be Given on Clinical Trials","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tremelimumab; Pemetrexed; Medicine; Durvalumab; Mesothelioma; Internal medicine; Oncology; Nivolumab; Clinical endpoint; Cisplatin; Hazard ratio; Bevacizumab; Chemotherapy; Surgery; Ipilimumab; Clinical trial; Cancer; Confidence interval; Immunotherapy; Pathology","score_opus":0.24259275328084673,"score_gpt":0.5688392465639147,"score_spread":0.326246493283068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898134598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973284,0.0002433904,0.000015188456,0.018290447,0.0010616878,0.00028164985,0.000017322971,0.000008250566,0.0067980476],"genre_scores_gemma":[0.98861766,0.00012824788,0.0014815414,0.0061357194,0.0024646248,0.0000046228047,0.0000069025446,0.000017214825,0.0011434663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703145,0.0008966327,0.0013116315,0.00017328633,0.00039170613,0.00019529041],"domain_scores_gemma":[0.9977765,0.000999635,0.000715972,0.00015827114,0.000089432535,0.0002601919],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036124599,0.00013137785,0.00088531803,0.0002424839,0.000037342485,0.000007713823,0.00013523255,0.00022992733,0.0009234742],"category_scores_gemma":[0.0020392383,0.00008767318,0.00033073814,0.0001351635,0.00024142218,0.00008102475,0.000040275307,0.00045222105,0.00017765602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05393922,0.00692974,0.4737199,0.000087387736,0.0005033521,0.0016110507,0.00036254895,0.000014746581,0.0033047847,0.00019399713,0.07649501,0.38283828],"study_design_scores_gemma":[0.0029255603,0.01967207,0.8339047,0.0002554899,0.00043764687,0.00063741935,0.00021548105,0.00004448092,0.0010241175,0.0009309068,0.13982135,0.00013078541],"about_ca_topic_score_codex":0.000005598606,"about_ca_topic_score_gemma":0.000021228938,"teacher_disagreement_score":0.38270748,"about_ca_system_score_codex":0.0002778334,"about_ca_system_score_gemma":0.00047256437,"threshold_uncertainty_score":0.9999898},"labels":[],"label_agreement":null},{"id":"W2898140692","doi":"10.1016/j.jtho.2018.08.337","title":"MA03.09 Transcriptome-Wide Association Study Reveals Candidate Causal Genes for Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Lung cancer; Genome-wide association study; Adenocarcinoma; Expression quantitative trait loci; Medicine; Transcriptome; Cancer; Candidate gene; Genetic association; Oncology; Gene; Genetics; Biology; Internal medicine; Gene expression; Single-nucleotide polymorphism; Genotype","score_opus":0.02206461038929712,"score_gpt":0.41752069869307906,"score_spread":0.3954560883037819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898140692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879728,0.0014989196,0.0051180455,0.0027971235,0.0019106113,0.0003731909,0.000024363391,0.0000051690636,0.0002997867],"genre_scores_gemma":[0.99294883,0.00041453197,0.00080968515,0.00073551113,0.0018304479,0.0000644763,0.000012016739,0.000019956404,0.0031645459],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99864036,0.00023953566,0.00048567634,0.00020879129,0.00019607034,0.00022954722],"domain_scores_gemma":[0.99826396,0.000051222796,0.0007378603,0.00017340336,0.0006709374,0.000102645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009803986,0.00012393844,0.00028523864,0.000099608136,0.000113981674,0.000021836197,0.00021175889,0.0002102349,0.000064175336],"category_scores_gemma":[0.00021286598,0.00010470862,0.00012642672,0.00010658669,0.000035134082,0.000010580036,0.000025990754,0.000119560966,0.0000016348736],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013935673,0.00028350594,0.12478063,0.0000306009,0.00032657958,0.000004789754,0.00042502081,0.000025008756,0.73877835,0.000003470463,0.10384363,0.030104844],"study_design_scores_gemma":[0.0024579363,0.005990245,0.083065964,0.000064745924,0.00067354453,0.000029483683,0.0012220258,0.00012350545,0.22359656,0.00011705521,0.6822959,0.00036302285],"about_ca_topic_score_codex":0.00001681395,"about_ca_topic_score_gemma":0.00023067313,"teacher_disagreement_score":0.5784523,"about_ca_system_score_codex":0.00025381544,"about_ca_system_score_gemma":0.00040561715,"threshold_uncertainty_score":0.42698938},"labels":[],"label_agreement":null},{"id":"W2898169039","doi":"10.1016/j.jtho.2018.08.471","title":"MA18.09 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.2706658328620985,"score_gpt":0.5320604041745772,"score_spread":0.26139457131247873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898169039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642602,0.003101295,0.0020504296,0.024269192,0.002492775,0.0004735008,0.00009412081,0.000015564956,0.0032429094],"genre_scores_gemma":[0.99067444,0.0002587998,0.005537174,0.0028124203,0.00053920806,0.000009978126,0.000006565017,0.000023786548,0.00013766001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9896181,0.0013174436,0.008081076,0.00034892024,0.00014757276,0.0004868608],"domain_scores_gemma":[0.98868513,0.001012804,0.009373458,0.0003916719,0.00029640098,0.00024052338],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033710867,0.0001866955,0.0021096524,0.00082599703,0.000102819715,0.000016943177,0.0004423192,0.00024154499,0.0005469229],"category_scores_gemma":[0.0045262245,0.00020910737,0.00018543904,0.000417239,0.0002798971,0.0004990681,0.00006562017,0.00042210842,0.00024187649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019237585,0.0016974664,0.85740733,0.0012999037,0.00040790145,0.00002857429,0.013671358,0.00041711962,0.000084235304,0.005087623,0.044862922,0.07311178],"study_design_scores_gemma":[0.0025541119,0.004238718,0.88329726,0.000632244,0.000022685728,0.000115655916,0.0030601984,0.0018406076,0.0001303964,0.019310893,0.084407136,0.0003901109],"about_ca_topic_score_codex":0.00045122326,"about_ca_topic_score_gemma":0.0006936716,"teacher_disagreement_score":0.07272167,"about_ca_system_score_codex":0.0014208956,"about_ca_system_score_gemma":0.0012162604,"threshold_uncertainty_score":0.994998},"labels":[],"label_agreement":null},{"id":"W2898173281","doi":"10.1016/j.jtho.2018.08.538","title":"MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Crizotinib; Alectinib; Medicine; Lung cancer; Ceritinib; Cohort; Anaplastic lymphoma kinase; Concomitant; Internal medicine; Oncology; ALK inhibitor; Tyrosine-kinase inhibitor; Cancer research; Cancer","score_opus":0.052950821730096645,"score_gpt":0.47823845112969793,"score_spread":0.4252876293996013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898173281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858499,0.0004973453,0.00017482489,0.004472489,0.0002648152,0.0004684484,0.000027749438,0.0000029212517,0.008241511],"genre_scores_gemma":[0.99582505,0.000058083053,0.0034820633,0.00020194483,0.00011105022,0.000013786413,0.00002295199,0.000009804108,0.00027526572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983591,0.00033807685,0.0007847776,0.00011587112,0.00025385368,0.00014831255],"domain_scores_gemma":[0.9982661,0.00035644256,0.0007969875,0.00015386943,0.00037689274,0.000049710543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056572625,0.000108981876,0.00046888707,0.00029859488,0.000043099877,0.000005667197,0.00011185864,0.0000888825,0.000040725987],"category_scores_gemma":[0.00012711766,0.00007299237,0.000111417765,0.00036490613,0.00020434092,0.00014650177,0.00001505202,0.00018011841,0.00000262232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049860273,0.019784693,0.41402957,0.0007452632,0.006168733,0.0041331793,0.26027715,0.0007211912,0.09919666,0.0062476615,0.010062164,0.12877348],"study_design_scores_gemma":[0.020219209,0.007130138,0.8911164,0.002139522,0.0036536867,0.00036814046,0.017301893,0.000351747,0.039678685,0.009546592,0.008183594,0.0003104302],"about_ca_topic_score_codex":0.00024508196,"about_ca_topic_score_gemma":0.0030795408,"teacher_disagreement_score":0.4770868,"about_ca_system_score_codex":0.00063661434,"about_ca_system_score_gemma":0.00069428893,"threshold_uncertainty_score":0.29765424},"labels":[],"label_agreement":null},{"id":"W2898174900","doi":"10.1016/j.jtho.2018.08.1679","title":"P3.03-02 Single-Cell RNA-Seq in Human Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Transcriptome; Lung cancer; RNA-Seq; Complementary DNA; cDNA library; RNA; Gene; Cancer; Computational biology; Gene expression; Gene expression profiling; Biology; Cancer research; Medicine; Molecular biology; Genetics; Oncology","score_opus":0.019023059709085376,"score_gpt":0.3823661112084824,"score_spread":0.36334305149939705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898174900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98554176,0.0031181455,0.00037174192,0.0008139898,0.001226923,0.00009202749,0.000011397226,0.00000250008,0.008821534],"genre_scores_gemma":[0.9941016,0.0006296779,0.001346653,0.00087358564,0.0023329034,0.0000054015945,0.0000060579646,0.00002348691,0.0006806607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998849,0.00009239166,0.00048054534,0.00018934878,0.00011399298,0.0002747208],"domain_scores_gemma":[0.99895525,0.000039145485,0.0004367309,0.00019666369,0.0002516553,0.00012056898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040332196,0.00013588008,0.0002964371,0.00012392087,0.00006190298,0.000021068157,0.0002768565,0.00023770989,0.00013248964],"category_scores_gemma":[0.000091384376,0.00012780853,0.00011589219,0.00010457916,0.00013412577,0.000005943664,0.00011364122,0.00022199145,0.0000064821043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005973084,0.0005180045,0.0045542023,0.000033157336,0.0000629487,0.00009069265,0.00018918279,0.00019655649,0.94090104,0.00002734774,0.024180645,0.02864894],"study_design_scores_gemma":[0.0014873408,0.0075563733,0.002515899,0.00009587169,0.00014769408,0.0001965246,0.00018186854,0.00014192793,0.6911467,0.00037165053,0.295798,0.0003601672],"about_ca_topic_score_codex":0.00007564527,"about_ca_topic_score_gemma":0.00091522903,"teacher_disagreement_score":0.27161735,"about_ca_system_score_codex":0.00023350402,"about_ca_system_score_gemma":0.0004343602,"threshold_uncertainty_score":0.5211881},"labels":[],"label_agreement":null},{"id":"W2898178720","doi":"10.1016/j.jtho.2018.08.280","title":"OA08.07 In Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue-of-Origin Markers","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"microRNA; In silico; Computational biology; Biology; Gene; Untranslated region; RNA; Genetics","score_opus":0.04859692488308954,"score_gpt":0.4420681023815785,"score_spread":0.393471177498489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898178720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990388,0.0013087711,0.00025348354,0.0054969755,0.00079528405,0.00019145018,0.000010980377,0.0000055436485,0.0015495355],"genre_scores_gemma":[0.99317324,0.00020466285,0.004920352,0.00051013136,0.0002463739,0.0000035781304,0.000002501035,0.000016934679,0.00092220114],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973091,0.00038261566,0.0014201419,0.00019681918,0.00033515538,0.00035620318],"domain_scores_gemma":[0.99783975,0.00055951276,0.000945146,0.00021107537,0.000319817,0.00012468106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024036719,0.00017987037,0.0012863076,0.00067652966,0.000023627046,0.0000038323647,0.00020467231,0.00021576889,0.00007817261],"category_scores_gemma":[0.0013689181,0.0001289087,0.0001313143,0.0005222474,0.0007956869,0.0001246022,0.000073391144,0.0005277986,0.000008851302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076597836,0.0017745042,0.4571267,0.0004654165,0.0003406827,0.0034789778,0.0032328707,0.000010660732,0.48655117,0.00008963087,0.0054411697,0.033828434],"study_design_scores_gemma":[0.007820185,0.013245472,0.89046115,0.004158907,0.0005699646,0.005917807,0.0030564757,0.00018255226,0.061612163,0.0008701693,0.011725991,0.00037913577],"about_ca_topic_score_codex":0.00011486356,"about_ca_topic_score_gemma":0.00012233108,"teacher_disagreement_score":0.43333447,"about_ca_system_score_codex":0.00018533705,"about_ca_system_score_gemma":0.00043192404,"threshold_uncertainty_score":0.5256744},"labels":[],"label_agreement":null},{"id":"W2898188409","doi":"10.1016/j.jtho.2018.08.959","title":"P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Chemotherapy; Radiation therapy; Internal medicine; Cancer; Oncology; Surgery","score_opus":0.029739129605074143,"score_gpt":0.3528996003894662,"score_spread":0.3231604707843921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898188409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495125,0.000113707974,0.00012641084,0.0009565766,0.0019325193,0.00034084532,0.00007425441,0.0000028669185,0.0015015656],"genre_scores_gemma":[0.99577475,0.000097443626,0.00048445672,0.0008935095,0.00040761082,0.0000091362745,0.000027247585,0.000015116198,0.00229073],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868023,0.00008640115,0.0005853243,0.00016578037,0.00018378893,0.00029846668],"domain_scores_gemma":[0.99886894,0.00018819145,0.00039316175,0.00013725976,0.00019560274,0.00021685529],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031272456,0.0001502422,0.0006773657,0.00012512876,0.000056141398,0.000011465692,0.00006971985,0.000098432756,0.00092421385],"category_scores_gemma":[0.000055112017,0.00011653496,0.0000724862,0.000045710764,0.00005791163,0.00008240681,0.000027840551,0.00024608904,8.028963e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022212317,0.0010683927,0.48143178,0.00021931711,0.00058987446,0.0020408826,0.0050994116,0.000008343429,0.00249006,0.00001985545,0.008675131,0.47614464],"study_design_scores_gemma":[0.0065075103,0.016818829,0.4185949,0.00018758165,0.00023958679,0.00036637395,0.0014787299,0.0001320333,0.0030142164,0.00001836844,0.5524214,0.00022048641],"about_ca_topic_score_codex":0.65672743,"about_ca_topic_score_gemma":0.98717844,"teacher_disagreement_score":0.54374623,"about_ca_system_score_codex":0.0033711365,"about_ca_system_score_gemma":0.0047556395,"threshold_uncertainty_score":0.9999891},"labels":[],"label_agreement":null},{"id":"W2898201615","doi":"10.1016/j.jtho.2018.08.1077","title":"P2.01-23 Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Internal medicine; Oncology; Anaplastic lymphoma kinase; Lung cancer; Targeted therapy; Crizotinib; Cancer; Cancer research","score_opus":0.017870239617701726,"score_gpt":0.42931481677263383,"score_spread":0.4114445771549321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898201615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853325,0.0014729785,0.001047831,0.006629297,0.0016075388,0.0007306873,0.000055106466,0.000021220236,0.003102875],"genre_scores_gemma":[0.98250836,0.000504948,0.0114063965,0.0013919694,0.0010227775,0.00006948593,0.00001744556,0.000048197802,0.0030303989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997882,0.00024243048,0.0008164042,0.00030857263,0.00029601608,0.00045458757],"domain_scores_gemma":[0.9979634,0.0003534878,0.0005385334,0.00028063392,0.0004499713,0.00041394559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007873947,0.00024937704,0.00069061434,0.0006363868,0.000093644696,0.000018248063,0.0002090105,0.00019599753,0.0003117857],"category_scores_gemma":[0.0002548502,0.00019494718,0.00017208191,0.00046506902,0.000114436945,0.00015977383,0.00006310497,0.00034435463,0.00003263776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03844213,0.0019664546,0.4993802,0.0004144617,0.0013230115,0.0033292333,0.004198846,0.0002253092,0.04287342,0.000002321211,0.023962267,0.38388234],"study_design_scores_gemma":[0.016613236,0.017233683,0.8596615,0.0031924956,0.003649827,0.0014272063,0.0013769342,0.0013466866,0.033361595,0.000022458938,0.061466876,0.00064751116],"about_ca_topic_score_codex":0.000087843786,"about_ca_topic_score_gemma":0.000894459,"teacher_disagreement_score":0.38323483,"about_ca_system_score_codex":0.0013380485,"about_ca_system_score_gemma":0.0019468517,"threshold_uncertainty_score":0.7949715},"labels":[],"label_agreement":null},{"id":"W2898210229","doi":"10.1016/j.jtho.2018.08.868","title":"P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Gefitinib; Osimertinib; Internal medicine; Observational study; Toxicity; Oncology; Dermatology; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.017464433877562375,"score_gpt":0.45503046161288235,"score_spread":0.43756602773532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898210229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748434,0.00008115896,0.0002569327,0.0024548422,0.00046117025,0.00052744633,0.000009799538,0.000014147481,0.021351133],"genre_scores_gemma":[0.9779778,0.000031154013,0.019627925,0.000443271,0.00027791463,0.000044690467,0.000020158897,0.000020014646,0.0015570681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865645,0.00010565152,0.000534177,0.00015425368,0.00031515263,0.00023433802],"domain_scores_gemma":[0.998563,0.000111908215,0.0005035342,0.00014590031,0.0005422074,0.0001334721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024226043,0.00014113181,0.0004475181,0.00042096776,0.00008203315,0.00001562475,0.000082952145,0.00006856231,0.00014734216],"category_scores_gemma":[0.000050886803,0.00009594252,0.000067787914,0.0003632237,0.00014658443,0.00024679664,0.000020253077,0.00024102612,0.000007021431],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004742823,0.0031579405,0.7201737,0.00010547357,0.0005230711,0.00047588462,0.003978647,0.0001053077,0.00027605312,0.00040473256,0.0014194591,0.26463687],"study_design_scores_gemma":[0.006764118,0.009997664,0.9607386,0.00061703427,0.0006428038,0.00012594284,0.0019555783,0.000051013638,0.000374734,0.00051676447,0.018057294,0.00015846167],"about_ca_topic_score_codex":0.00008049586,"about_ca_topic_score_gemma":0.0021897834,"teacher_disagreement_score":0.2644784,"about_ca_system_score_codex":0.0012440472,"about_ca_system_score_gemma":0.0012161143,"threshold_uncertainty_score":0.39124227},"labels":[],"label_agreement":null},{"id":"W2898221023","doi":"10.1016/j.jtho.2018.08.384","title":"MA08.11 Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nivolumab; Tolerability; Radiosurgery; Brain metastasis; Cohort; Adverse effect; Oncology; Internal medicine; Cyberknife; Surgery; Radiation therapy; Metastasis; Cancer; Immunotherapy","score_opus":0.05165867773860113,"score_gpt":0.41323722544701047,"score_spread":0.36157854770840936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898221023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533826,0.0005147838,0.0004970771,0.002352608,0.00016729016,0.0006892039,0.0004013459,0.000003741606,0.00003569247],"genre_scores_gemma":[0.98710066,0.000040443025,0.012395617,0.0001679454,0.00009672854,0.0000073876668,0.000100524,0.00002424602,0.000066455366],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99786925,0.0003747575,0.00097490265,0.00025079167,0.00026916605,0.00026112184],"domain_scores_gemma":[0.9966898,0.0012190184,0.0011725036,0.000430416,0.00032037697,0.00016789768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013193354,0.00020858963,0.0013274545,0.00036189653,0.00006352351,0.0000073078945,0.00013076128,0.00008740921,0.000049489252],"category_scores_gemma":[0.00039051948,0.00013958958,0.00012907732,0.00020891994,0.00024800666,0.00021523456,0.000067911285,0.00008864308,3.5646056e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09044421,0.023946106,0.19419357,0.00035815107,0.0032781991,0.0005009272,0.0024222697,0.0000033839901,0.00072750973,0.00008463455,0.0023763666,0.68166465],"study_design_scores_gemma":[0.14862329,0.46741548,0.33296457,0.001653863,0.00634693,0.0013893702,0.0014446856,0.00036613393,0.0033705854,0.00022827313,0.035698567,0.00049825106],"about_ca_topic_score_codex":0.00009254998,"about_ca_topic_score_gemma":0.0001248224,"teacher_disagreement_score":0.6811664,"about_ca_system_score_codex":0.00022941559,"about_ca_system_score_gemma":0.00043528187,"threshold_uncertainty_score":0.56922984},"labels":[],"label_agreement":null},{"id":"W2898224495","doi":"10.1016/j.jtho.2018.08.438","title":"MA14.11 Factors Associated with Early Mortality in Non-Small Cell Lung Cancer Patients Following Systemic Anti-Cancer Treatment","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Population; Regimen; Cancer; Logistic regression; Disease; Performance status; Univariate analysis; Multivariate analysis","score_opus":0.02800090055143276,"score_gpt":0.4166349053164878,"score_spread":0.388634004765055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898224495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701697,0.00055223296,0.00003213512,0.00015456222,0.0010236404,0.0006131747,0.000043673805,0.000012146264,0.0005514904],"genre_scores_gemma":[0.9987748,0.000112112735,0.0001080324,0.00009235951,0.00022055519,0.00004809112,0.000016479948,0.000030131867,0.0005973945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984704,0.00012832295,0.0005750096,0.0002112751,0.00028373266,0.0003312508],"domain_scores_gemma":[0.99847835,0.00007917573,0.00074171205,0.00014481749,0.00037752165,0.000178432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020709287,0.00022241929,0.000791793,0.00021623047,0.00008697164,0.000017394776,0.00009370495,0.0001666516,0.000066044784],"category_scores_gemma":[0.000026767877,0.00014080555,0.00018775683,0.0002726282,0.00005225048,0.00014419573,0.000016828448,0.0001890114,0.0000020718485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023278872,0.0012553893,0.9907536,0.00005889372,0.0012379101,0.00017447949,0.003113504,0.00004264534,0.0008967106,3.8286998e-7,0.00009614968,0.002137554],"study_design_scores_gemma":[0.004917631,0.003707448,0.9836381,0.00088465813,0.0028970486,0.000009772208,0.00047056787,0.000052825835,0.0030963286,0.0000020791597,0.00018397941,0.00013956112],"about_ca_topic_score_codex":0.0015753536,"about_ca_topic_score_gemma":0.0025152431,"teacher_disagreement_score":0.0071154917,"about_ca_system_score_codex":0.003645415,"about_ca_system_score_gemma":0.0010756948,"threshold_uncertainty_score":0.95326334},"labels":[],"label_agreement":null},{"id":"W2898234690","doi":"10.1016/j.jtho.2018.12.006","title":"EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Germline; Lung cancer; Germline mutation; Medicine; T790M; Epidermal growth factor receptor; Cancer research; Cancer; Mutation; Oncology; Genetics; Internal medicine; Biology; Gene; Gefitinib","score_opus":0.008632132505897637,"score_gpt":0.42818809126769625,"score_spread":0.41955595876179863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898234690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917206,0.0030562046,0.000014780663,0.0042981207,0.00026701248,0.00048730455,0.000026269361,0.0000029629557,0.0001267192],"genre_scores_gemma":[0.99804795,0.000529117,0.0006596318,0.00046889854,0.00008803378,0.00003226404,0.0000041781022,0.000010568259,0.00015936367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991222,0.00007646146,0.00039452995,0.00015816106,0.0000939402,0.00015470585],"domain_scores_gemma":[0.9993627,0.0000981114,0.00017417224,0.0000812716,0.00015495275,0.00012877809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017782007,0.00011189004,0.0004059789,0.0002448103,0.000022998747,0.000008498679,0.000042201238,0.000073594,0.00009430406],"category_scores_gemma":[0.00005864283,0.000067777546,0.000035221892,0.00021047075,0.000037121717,0.000089032525,0.000029641076,0.00018606726,0.0000010426699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004123623,0.00032591075,0.90272456,0.000072946925,0.00006783442,0.000023255101,0.0033477535,0.00044260456,0.0009470507,0.000001187493,0.00005431875,0.09158024],"study_design_scores_gemma":[0.0020622043,0.00072835776,0.9952618,0.00018801453,0.0001161614,0.00003531703,0.0003711334,0.0004685192,0.000072779694,0.000109864384,0.000518192,0.00006765273],"about_ca_topic_score_codex":0.0005069904,"about_ca_topic_score_gemma":0.0075923395,"teacher_disagreement_score":0.09253727,"about_ca_system_score_codex":0.0006111309,"about_ca_system_score_gemma":0.0003890602,"threshold_uncertainty_score":0.42367035},"labels":[],"label_agreement":null},{"id":"W2898240093","doi":"10.1016/j.jtho.2018.08.580","title":"P1.01-24 Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Lung cancer; Exact test; Proportional hazards model; Univariate analysis; Oncology; Nivolumab; Pneumonitis; Cancer; Immunotherapy; Multivariate analysis; Lung","score_opus":0.024906584256811845,"score_gpt":0.45849635894258267,"score_spread":0.4335897746857708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898240093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954145,0.002021406,0.00034874567,0.0005707732,0.00047191148,0.0006361054,0.0000100723355,0.000005990444,0.00052047527],"genre_scores_gemma":[0.9850019,0.0012781897,0.012451059,0.00047799543,0.00029266457,0.000015326843,0.0000061910123,0.000035686648,0.00044097772],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982166,0.0002145334,0.00095667917,0.00017208078,0.00021323534,0.0002268195],"domain_scores_gemma":[0.9980643,0.00024782293,0.00096548354,0.00018423896,0.00040630353,0.00013189705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042835067,0.00016830747,0.0008882333,0.00025775688,0.000038628456,0.0000070079727,0.00012443183,0.00010911228,0.00020912262],"category_scores_gemma":[0.000033956174,0.00010578369,0.00017508649,0.00028786602,0.00016725108,0.00007728983,0.000009706413,0.00029520658,0.0000020968812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016332293,0.005938195,0.7746663,0.0001127557,0.0018168911,0.00018018532,0.002621625,0.000035657453,0.0021779723,0.0000015878759,0.001043589,0.19507295],"study_design_scores_gemma":[0.033279117,0.028731044,0.9212241,0.00076821545,0.0021596139,0.00011066309,0.00022608753,0.00024288165,0.0044210344,0.00000817219,0.008638804,0.00019024627],"about_ca_topic_score_codex":0.0001361199,"about_ca_topic_score_gemma":0.000109961926,"teacher_disagreement_score":0.1948827,"about_ca_system_score_codex":0.0005615574,"about_ca_system_score_gemma":0.0011968241,"threshold_uncertainty_score":0.43137336},"labels":[],"label_agreement":null},{"id":"W2898254339","doi":"10.1016/j.jtho.2018.08.298","title":"OA11.06 Two BRM Promoter Polymorphisms Do Not Predict Susceptibility or Prognosis of Thymoma","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Thymoma; Internal medicine; Oncology; Cancer; Proportional hazards model; Immunology","score_opus":0.03765248196336767,"score_gpt":0.40818861511712357,"score_spread":0.3705361331537559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898254339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98911095,0.000212094,0.00017233226,0.005368871,0.0008180463,0.0005522742,0.000021643202,0.000024933765,0.0037188502],"genre_scores_gemma":[0.98823404,0.00003510843,0.008006657,0.00057048467,0.0018827079,0.000008531648,0.0000039194647,0.000033292486,0.0012252511],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99683756,0.0003524171,0.0013620735,0.00031595,0.0006851071,0.00044687383],"domain_scores_gemma":[0.9965967,0.00021463633,0.0011988658,0.00048377403,0.0011351898,0.00037081767],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020450174,0.00026286932,0.0011876242,0.00032731306,0.00008360502,0.00001940655,0.00034806918,0.0003143897,0.0021959257],"category_scores_gemma":[0.0005000216,0.00016492727,0.00038237777,0.00035374326,0.0005696001,0.00017115368,0.000121398654,0.00061749114,0.00005969165],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03907942,0.0063402234,0.29771897,0.00064946286,0.0012414033,0.0023475175,0.0034828698,0.0000013218477,0.14477208,0.00039574227,0.01464081,0.48933017],"study_design_scores_gemma":[0.011531718,0.09561371,0.48923612,0.0018952579,0.0029792693,0.024211857,0.0009856331,0.00027310927,0.25581828,0.002651239,0.1140233,0.0007805178],"about_ca_topic_score_codex":0.000033168875,"about_ca_topic_score_gemma":0.00007395291,"teacher_disagreement_score":0.48854965,"about_ca_system_score_codex":0.0002367025,"about_ca_system_score_gemma":0.0009468888,"threshold_uncertainty_score":0.9987162},"labels":[],"label_agreement":null},{"id":"W2898256364","doi":"10.1016/j.jtho.2018.08.1082","title":"P2.01-28 Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010 – 2014 Diagnoses","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Lung cancer; Regimen; Systemic therapy; Oncology; Confidence interval; non-small cell lung cancer (NSCLC); Overall survival; Statistical significance; Cancer; Breast cancer","score_opus":0.044355790065831624,"score_gpt":0.4331714993479645,"score_spread":0.3888157092821329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898256364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919557,0.0017892151,0.00008960467,0.0027238105,0.0009370584,0.0003598066,0.00004988125,0.0000064843944,0.0020884206],"genre_scores_gemma":[0.9959764,0.0018956282,0.00016170218,0.0004701631,0.00059161044,0.000011283345,0.0000047751814,0.000016727387,0.00087174424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99881095,0.00020284945,0.00042833333,0.00013005297,0.00023157321,0.00019624086],"domain_scores_gemma":[0.9984339,0.00043533064,0.0005574941,0.00021681222,0.00020713064,0.00014931803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037972105,0.00015506531,0.0005097358,0.00012045801,0.00007529735,0.000013551563,0.00007868156,0.00009866218,0.00029588293],"category_scores_gemma":[0.00008387138,0.00007929062,0.00012505891,0.000048500475,0.00011223828,0.00007675328,0.000021616821,0.0001482152,0.0000145904805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014786549,0.007351813,0.6860914,0.0011875336,0.010380587,0.002333167,0.01960523,0.00006819862,0.021613281,0.0016575607,0.054747723,0.18017694],"study_design_scores_gemma":[0.008018434,0.0350764,0.91091645,0.0012158699,0.003387991,0.0020605389,0.0051422603,0.000051773022,0.0070914584,0.000240997,0.026528893,0.00026892332],"about_ca_topic_score_codex":0.00014995679,"about_ca_topic_score_gemma":0.000084143954,"teacher_disagreement_score":0.22482505,"about_ca_system_score_codex":0.00048678927,"about_ca_system_score_gemma":0.00043839967,"threshold_uncertainty_score":0.32397103},"labels":[],"label_agreement":null},{"id":"W2898257589","doi":"10.1016/j.jtho.2018.08.831","title":"P1.11-15 Application of Lung-RADS vs. PAN-CAN Nodule Risk Calculation in the Alberta Lung Cancer Screening Study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Malignancy; Concordance; Radiology; Nodule (geology); Lung; Nuclear medicine; Internal medicine","score_opus":0.019523123291827663,"score_gpt":0.4299717808889272,"score_spread":0.41044865759709953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898257589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031985,0.00071274396,0.0008777013,0.006619405,0.0002829694,0.00079608493,0.000005776631,0.0000039657866,0.0003814835],"genre_scores_gemma":[0.99793714,0.00018329469,0.000638154,0.0003841151,0.0006930747,0.000079724196,0.000004162604,0.000015011958,0.0000652935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982954,0.00034827788,0.000645252,0.00017763706,0.00034858697,0.00018480507],"domain_scores_gemma":[0.9981908,0.00027325682,0.00089700153,0.00027787968,0.00029007788,0.000070937494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011000232,0.00013082281,0.00050426327,0.00017793302,0.00007897873,0.000010209511,0.00016518358,0.000105231506,0.00004998255],"category_scores_gemma":[0.00010826896,0.00008190785,0.00011694041,0.00031811153,0.00007889412,0.00008065327,0.000031628857,0.00027353095,0.0000018701581],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000888298,0.0012692208,0.91601676,0.0000517725,0.0003208905,0.000029122117,0.0037729447,0.00011780982,0.00008960012,0.00002089329,0.0017687528,0.07565394],"study_design_scores_gemma":[0.0021467665,0.0029154168,0.9840033,0.0002221274,0.0015523485,0.00008660496,0.0007538194,0.0033344114,0.0004873037,0.00002924335,0.004387205,0.00008144411],"about_ca_topic_score_codex":0.006071581,"about_ca_topic_score_gemma":0.022621728,"teacher_disagreement_score":0.0755725,"about_ca_system_score_codex":0.0007100478,"about_ca_system_score_gemma":0.00025902985,"threshold_uncertainty_score":0.99521285},"labels":[],"label_agreement":null},{"id":"W2898263433","doi":"10.1016/j.jtho.2018.08.1727","title":"P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Immune system; Adverse effect; Oncology; Immune checkpoint; Correlation; Immunology; Internal medicine; Immunotherapy","score_opus":0.007345838563558819,"score_gpt":0.320942653332588,"score_spread":0.3135968147690292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898263433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705356,0.0010146932,0.000048971455,0.00062036456,0.0007662618,0.00031874652,0.000008425646,0.000006387672,0.00016261249],"genre_scores_gemma":[0.99812573,0.00009467375,0.0014962453,0.000066856526,0.00006736882,0.0000024195424,0.000012054076,0.000018756562,0.0001159043],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99783313,0.0003138035,0.0012524723,0.0001497681,0.00027697385,0.00017387014],"domain_scores_gemma":[0.99779695,0.0001827336,0.0014131343,0.0001823698,0.0003457687,0.00007904004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011898488,0.00014899072,0.0005897055,0.0003291842,0.000040105715,0.0000020522755,0.00008789448,0.00020936421,0.00012073177],"category_scores_gemma":[0.000210658,0.00011110031,0.00014179469,0.00031429797,0.00023119945,0.00019324617,0.00003457303,0.00035773346,0.0000037258749],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49869037,0.0009581438,0.19021966,0.000035160236,0.00046872933,0.000068120826,0.0027602601,0.000026323321,0.15307027,7.894705e-7,0.000046650875,0.15365554],"study_design_scores_gemma":[0.013760916,0.013006795,0.9565365,0.0010501938,0.00018165787,0.000070085334,0.0005829122,0.00006195065,0.013550117,0.000048709633,0.0010313615,0.00011880064],"about_ca_topic_score_codex":0.000065512446,"about_ca_topic_score_gemma":0.00003199036,"teacher_disagreement_score":0.76631683,"about_ca_system_score_codex":0.0004235521,"about_ca_system_score_gemma":0.00036467653,"threshold_uncertainty_score":0.4530539},"labels":[],"label_agreement":null},{"id":"W2898265358","doi":"10.1016/j.jtho.2018.08.282","title":"OA09.02 Acceptance of Smoking Cessation Services in Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer screening; Teachable moment; Referral; Family medicine; Lung cancer; Cancer; Physical therapy; Internal medicine","score_opus":0.05950021439093509,"score_gpt":0.44737160061251724,"score_spread":0.3878713862215821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898265358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919662,0.004342754,0.00091271685,0.00082960003,0.0010715651,0.00034750937,0.000039171657,0.000008792502,0.00048172314],"genre_scores_gemma":[0.99160874,0.00038986473,0.0062334803,0.0004854685,0.0010371307,0.000039144365,0.000008447018,0.000021690777,0.00017605367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998069,0.000112618975,0.00080150424,0.00023400078,0.00042680948,0.0003561004],"domain_scores_gemma":[0.99695396,0.00015583201,0.0014736508,0.00017344188,0.0011142774,0.00012883078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073388004,0.00017658132,0.0007888271,0.0002469781,0.00014345882,0.00001435194,0.00024580795,0.0001732725,0.0005580808],"category_scores_gemma":[0.000072711,0.00015243722,0.00014212403,0.00032022153,0.00007568786,0.0003360877,0.00007979178,0.00042732738,7.6971213e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062916703,0.00006432797,0.91235435,0.0004072491,0.0001835259,0.000027453945,0.0077939723,0.0011489302,0.0013138355,0.000006014428,0.0006782518,0.06973042],"study_design_scores_gemma":[0.0026983535,0.0037517108,0.9724368,0.0021875096,0.0009027626,0.00009140872,0.0036198786,0.0008383349,0.0066700936,0.00007752544,0.006538846,0.00018680804],"about_ca_topic_score_codex":0.09730059,"about_ca_topic_score_gemma":0.736549,"teacher_disagreement_score":0.63924843,"about_ca_system_score_codex":0.0030544586,"about_ca_system_score_gemma":0.00097038475,"threshold_uncertainty_score":0.90871054},"labels":[],"label_agreement":null},{"id":"W2898272834","doi":"10.1016/j.jtho.2018.08.780","title":"P1.09-04 Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Histology; Immunohistochemistry; Medicine; Staining; Cytology; Lung cancer; Pathology; PD-L1; Internal medicine; Cancer; Immunotherapy","score_opus":0.05723737596441916,"score_gpt":0.375391455338915,"score_spread":0.3181540793744958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898272834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859885,0.0002226591,0.0016445597,0.0028945606,0.0005785364,0.00021320829,7.0554523e-7,0.0000052211853,0.008452052],"genre_scores_gemma":[0.97418064,0.00007257388,0.023096094,0.0010633154,0.00079307024,0.0000025936165,0.0000022135812,0.0000134911115,0.00077601086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99872804,0.0001830906,0.0006123694,0.000100714286,0.00021457512,0.00016123685],"domain_scores_gemma":[0.9987667,0.00014137926,0.0005818838,0.00017711225,0.0002931092,0.000039818715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011043528,0.000098645134,0.00035896437,0.00019305482,0.00004597459,0.000009776402,0.00015544386,0.00013013891,0.00021381715],"category_scores_gemma":[0.00009833093,0.000060854352,0.00010494677,0.00028248402,0.00016345263,0.00009713085,0.000015330603,0.00029763192,0.0000030540127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074292995,0.0017150068,0.18298754,0.00022990743,0.00085143524,0.0020165173,0.047257658,0.0026371928,0.031962547,0.00001512889,0.021475898,0.6345582],"study_design_scores_gemma":[0.009320815,0.025697593,0.81632483,0.0018142095,0.00087305304,0.01576575,0.0028939617,0.004477968,0.012277871,0.00031478383,0.10982771,0.00041147304],"about_ca_topic_score_codex":0.0007126053,"about_ca_topic_score_gemma":0.0019406069,"teacher_disagreement_score":0.6341467,"about_ca_system_score_codex":0.0005349812,"about_ca_system_score_gemma":0.00046392303,"threshold_uncertainty_score":0.24815685},"labels":[],"label_agreement":null},{"id":"W2898275110","doi":"10.1016/j.jtho.2018.08.466","title":"MA18.02 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Crizotinib; Ceritinib; Oncology; Progression-free survival; Internal medicine; Overall survival; Lung cancer","score_opus":0.03575520757573197,"score_gpt":0.46958224673083526,"score_spread":0.4338270391551033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898275110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955616,0.00037292336,0.001437799,0.0009215161,0.000093242685,0.00019431608,0.000002542099,0.000002677376,0.0014133627],"genre_scores_gemma":[0.9949781,0.00006365848,0.004565423,0.000030282381,0.0001041964,0.0000069250377,0.000003391134,0.0000059266963,0.0002421483],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993271,0.00006111304,0.00034361842,0.000068937945,0.00009640519,0.00010282957],"domain_scores_gemma":[0.99932593,0.000048317375,0.00029233485,0.00008016779,0.00019530879,0.000057928948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002717945,0.00007674789,0.00024716984,0.00015365156,0.00004530196,0.00000467261,0.000034335742,0.000058594585,0.000024388077],"category_scores_gemma":[0.000030335203,0.000039633287,0.000065982174,0.00011379553,0.00006906685,0.00008226975,0.000010569767,0.000070467395,0.0000023679388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004994476,0.0022970599,0.13924457,0.00006020497,0.0016173745,0.00009908756,0.021194736,0.004114019,0.010156502,0.0002733834,0.0008179386,0.81513065],"study_design_scores_gemma":[0.007111618,0.024924412,0.9329866,0.00043539813,0.0016104167,0.0016298234,0.0019553474,0.010478856,0.012836858,0.0024581149,0.00336783,0.00020471647],"about_ca_topic_score_codex":0.00008796985,"about_ca_topic_score_gemma":0.00005238763,"teacher_disagreement_score":0.8149259,"about_ca_system_score_codex":0.0019055392,"about_ca_system_score_gemma":0.0013222275,"threshold_uncertainty_score":0.49829188},"labels":[],"label_agreement":null},{"id":"W2898275404","doi":"10.1016/j.jtho.2018.08.1067","title":"P2.01-13 Number, Rather Than Location of Metastases, Dictates Outcome in Stage IV, M1b, Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Proportional hazards model; Lung cancer; Stage (stratigraphy); Confounding; Oncology; Survival analysis; Cancer; Retrospective cohort study; Distant metastasis; Metastasis; Gastroenterology","score_opus":0.026977024665532232,"score_gpt":0.4200887657852299,"score_spread":0.39311174111969766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898275404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915226,0.0029060042,0.0002519283,0.0022456562,0.00080330885,0.00036838232,0.000025050662,0.000006561989,0.001870522],"genre_scores_gemma":[0.99466836,0.0008653016,0.0023402795,0.0004060825,0.0004631262,0.000029052526,0.000005813497,0.00002693386,0.0011950497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830014,0.00016459046,0.0008402659,0.00018110742,0.00025268886,0.00026123744],"domain_scores_gemma":[0.99806535,0.00017916347,0.0008814629,0.00022145707,0.0005008717,0.00015166966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071580755,0.00017882604,0.0007930667,0.00019822501,0.000033007265,0.000009055316,0.0001400862,0.00013515312,0.00076933263],"category_scores_gemma":[0.000058165686,0.00012700642,0.00014725981,0.0002903118,0.00010812973,0.00010676162,0.00003971317,0.00027895608,0.000024985617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013224992,0.0015821818,0.9796092,0.00052718946,0.00037785078,0.00028430417,0.0013095636,0.000078123274,0.0011973577,0.00001321445,0.0034998106,0.010198692],"study_design_scores_gemma":[0.009158657,0.0066986154,0.89384365,0.0015811785,0.0030254587,0.00028417373,0.0016056441,0.00068766397,0.053113144,0.00009668248,0.029535372,0.0003697529],"about_ca_topic_score_codex":0.0008344124,"about_ca_topic_score_gemma":0.0022159675,"teacher_disagreement_score":0.085765556,"about_ca_system_score_codex":0.0010149676,"about_ca_system_score_gemma":0.000784485,"threshold_uncertainty_score":0.84236526},"labels":[],"label_agreement":null},{"id":"W2898275725","doi":"10.1016/j.jtho.2018.08.1450","title":"P2.15-09 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Oncology; Overall survival; Internal medicine","score_opus":0.027736596457365623,"score_gpt":0.4031379666839387,"score_spread":0.37540137022657305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898275725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626064,0.0003378484,0.00018427959,0.00015841011,0.00009309495,0.00036939053,0.000017412838,0.0000018238381,0.0025771228],"genre_scores_gemma":[0.99863756,0.00014250504,0.0010687481,0.000022118447,0.000065605826,0.000004861969,0.000005162092,0.00001042153,0.000043015232],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987818,0.00016979827,0.00057651056,0.00011886947,0.00016644831,0.00018659105],"domain_scores_gemma":[0.9986321,0.00018390665,0.00070043677,0.00015413722,0.0002498126,0.00007961722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045957332,0.00013162124,0.000654125,0.00023649834,0.0000298237,0.0000029132086,0.000077775134,0.00009009129,0.00003014482],"category_scores_gemma":[0.00009105361,0.00007189308,0.00009297936,0.0001691902,0.00018919671,0.00015542902,0.000019347137,0.00019542438,3.678739e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025677504,0.0009238837,0.6717691,0.000049748254,0.00021627938,0.00003665865,0.0026898757,0.005409033,0.004092925,0.000009193813,0.000060553237,0.28906527],"study_design_scores_gemma":[0.009291444,0.020274192,0.9595434,0.0003423106,0.0001360659,0.00007266245,0.00077465666,0.008951749,0.00039726283,0.00006009771,0.00006868074,0.00008749296],"about_ca_topic_score_codex":0.0003554197,"about_ca_topic_score_gemma":0.00075267087,"teacher_disagreement_score":0.28897777,"about_ca_system_score_codex":0.0013476732,"about_ca_system_score_gemma":0.0009630893,"threshold_uncertainty_score":0.35241187},"labels":[],"label_agreement":null},{"id":"W2898276146","doi":"10.1016/j.jtho.2018.08.281","title":"OA09.01 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Smoking cessation; Psychological intervention; Action plan; Intervention (counseling); Family medicine; Lung cancer; Cancer; Health care; Nursing; Oncology; Internal medicine; Economic growth","score_opus":0.10007730632883513,"score_gpt":0.4275619237677787,"score_spread":0.3274846174389435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898276146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98896277,0.0004231914,0.0018079097,0.00496841,0.0007003934,0.0004633693,0.0000011772335,0.000003829097,0.0026689407],"genre_scores_gemma":[0.9956993,0.000006080948,0.0026325947,0.0010219612,0.00037610228,0.000015304975,4.4954632e-7,0.0000067910237,0.00024140121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982487,0.00022290084,0.0006831,0.00012829385,0.00051507074,0.00020192104],"domain_scores_gemma":[0.9985799,0.000074515854,0.00060074334,0.00017051578,0.00045482363,0.0001194764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011725914,0.00009506085,0.0004879213,0.0002380117,0.00005259048,0.000008690746,0.00021634332,0.00010971961,0.000051003655],"category_scores_gemma":[0.0003112561,0.000061566476,0.00010537666,0.0003891268,0.000057474066,0.0001135944,0.000054826975,0.0002965823,0.0000029170449],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061663752,0.0006099397,0.9300891,0.003002122,0.00037452392,0.00006492579,0.021991344,0.004823332,0.005873691,0.0009682345,0.017429758,0.008606659],"study_design_scores_gemma":[0.0009006584,0.0019221285,0.96943074,0.013152603,0.00050839793,0.0007882064,0.006824723,0.00035243126,0.001074526,0.00047046717,0.0044264756,0.00014863195],"about_ca_topic_score_codex":0.014714822,"about_ca_topic_score_gemma":0.06998695,"teacher_disagreement_score":0.05527212,"about_ca_system_score_codex":0.0032528334,"about_ca_system_score_gemma":0.0012330887,"threshold_uncertainty_score":0.99184626},"labels":[],"label_agreement":null},{"id":"W2898278081","doi":"10.1016/j.jtho.2018.09.026","title":"Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Narodowe Centrum Badań i Rozwoju; Ministry of Health, British Columbia","keywords":"Ground-glass opacity; Medicine; Adenocarcinoma; Stage (stratigraphy); Lung; Proportional hazards model; Radiology; Nuclear medicine; Internal medicine; Cancer; Biology","score_opus":0.06819685458404864,"score_gpt":0.45358437397185924,"score_spread":0.3853875193878106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898278081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190325,0.00030891589,0.00006244062,0.0063588335,0.0006091377,0.00047200624,0.000023511726,0.0000051564552,0.00025675417],"genre_scores_gemma":[0.9977249,0.00023614053,0.0009180003,0.0006353869,0.00042347104,0.000018402196,0.0000034069603,0.000011382491,0.000028920402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972915,0.00081031595,0.0011628075,0.00022939949,0.00029362322,0.0002123232],"domain_scores_gemma":[0.9954611,0.0026742646,0.001118842,0.00026791386,0.00032648773,0.0001513913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029128692,0.00015648128,0.000844495,0.00011496193,0.000060891907,0.000014613636,0.00016673622,0.00016302956,0.00007547494],"category_scores_gemma":[0.0013477008,0.00008906048,0.00015495285,0.0001621719,0.0005764726,0.000051053743,0.00007198898,0.000536342,0.0000031189402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003519524,0.002262522,0.9764022,0.00016184199,0.00007877123,0.0005747319,0.00017055163,8.535315e-7,0.00006147214,0.000044958826,0.0003828778,0.016339673],"study_design_scores_gemma":[0.0014736161,0.011077384,0.9835966,0.0006137377,0.0003487446,0.00014810404,0.00010448366,0.0014869833,0.00024577332,0.000028699715,0.00080337893,0.0000724511],"about_ca_topic_score_codex":0.000025317406,"about_ca_topic_score_gemma":0.0000499962,"teacher_disagreement_score":0.016267221,"about_ca_system_score_codex":0.0003392048,"about_ca_system_score_gemma":0.00037562905,"threshold_uncertainty_score":0.36317807},"labels":[],"label_agreement":null},{"id":"W2898290327","doi":"10.1016/j.jtho.2018.08.424","title":"MA13.05 The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Laurentian University","funders":"","keywords":"Medicine; Malignancy; Radiology; Lymph node; Receiver operating characteristic; Biopsy; Lung cancer; Internal medicine","score_opus":0.027037318132066522,"score_gpt":0.36076522510431375,"score_spread":0.33372790697224725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898290327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97327536,0.00031941402,0.0033983404,0.02031839,0.0016322437,0.00020585275,0.000011864945,0.000012768121,0.00082575344],"genre_scores_gemma":[0.9799181,0.00006158662,0.010367887,0.007745696,0.001782811,0.0000104763885,0.000009248761,0.00003335669,0.00007080407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968507,0.00030311756,0.0010730062,0.00024913705,0.0010935366,0.0004304899],"domain_scores_gemma":[0.99660265,0.00048341698,0.0010553999,0.00026188063,0.0011855222,0.00041113107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023078835,0.00023274551,0.0006913821,0.0006184381,0.00019341244,0.000026745602,0.00045606116,0.00015154116,0.00015421536],"category_scores_gemma":[0.0017622627,0.0001610474,0.00023094637,0.00078793435,0.0004404469,0.00012220544,0.000094896,0.00053188787,0.0000052503524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035410628,0.0007721839,0.7174603,0.00050645694,0.0008140919,0.0011336972,0.0014016643,0.0009637879,0.018952057,0.00030722623,0.024728328,0.22941914],"study_design_scores_gemma":[0.0069795577,0.0039025869,0.8752174,0.00384649,0.0018135225,0.0218793,0.00097615685,0.016244547,0.009075121,0.0020836906,0.05711818,0.0008634631],"about_ca_topic_score_codex":0.004262256,"about_ca_topic_score_gemma":0.002324663,"teacher_disagreement_score":0.22855568,"about_ca_system_score_codex":0.00044186143,"about_ca_system_score_gemma":0.0033611143,"threshold_uncertainty_score":0.6567322},"labels":[],"label_agreement":null},{"id":"W2898304589","doi":"10.1016/j.jtho.2018.08.1001","title":"P1.16-32 Lung Cancer Completeness of Resection in Uniportal Versus Multiportal Video-Assisted Thoracoscopic Surgery Lobectomy","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Lymphadenectomy; Surgery; Lung cancer; VATS lobectomy; Pneumonectomy; Cardiothoracic surgery; Lymph node; Stage (stratigraphy); Video-assisted thoracoscopic surgery; Radiology; Oncology; Internal medicine","score_opus":0.05932588995186174,"score_gpt":0.4645697967080018,"score_spread":0.4052439067561401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898304589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99185044,0.0017497635,0.0000663062,0.0014505772,0.0035623137,0.00033455665,0.000012201487,0.0000116715455,0.0009621872],"genre_scores_gemma":[0.997618,0.00051977317,0.0006667312,0.00011257322,0.00092616654,0.00003456628,0.000011787145,0.000025561176,0.00008481946],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977009,0.00024498324,0.0010959541,0.00023409649,0.00040592084,0.0003181182],"domain_scores_gemma":[0.99724346,0.0005761266,0.001143994,0.00023593231,0.0006177415,0.00018274681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085572805,0.00019503507,0.0010740369,0.0005129408,0.00005852327,0.000009770652,0.00011307621,0.00020981416,0.00039737174],"category_scores_gemma":[0.00020890495,0.00015227962,0.00026628852,0.00049434917,0.00019967373,0.00016183924,0.000039349372,0.00036097557,0.0000034892853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018326206,0.0017597247,0.863391,0.00047889986,0.0009908732,0.0012428248,0.00034353088,0.000031461335,0.0020710987,0.000014130144,0.0075252303,0.103825055],"study_design_scores_gemma":[0.0059900456,0.005051428,0.95635206,0.001979931,0.0013195553,0.0006657177,0.00042853242,0.00021661264,0.019259462,0.000028678622,0.008494702,0.00021330715],"about_ca_topic_score_codex":0.0010889891,"about_ca_topic_score_gemma":0.007683082,"teacher_disagreement_score":0.103611745,"about_ca_system_score_codex":0.0022784178,"about_ca_system_score_gemma":0.0013839924,"threshold_uncertainty_score":0.6209783},"labels":[],"label_agreement":null},{"id":"W2898310631","doi":"10.1016/j.jtho.2018.08.784","title":"P1.09-08 Integrating NGS Information for Staging Multiple Lung Adenocarcinoma: A McGill University Health Centre Retrospective Study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Adenocarcinoma; KRAS; Stage (stratigraphy); Neuroblastoma RAS viral oncogene homolog; Lung cancer; Internal medicine; Oncology; Lung; PDGFRA; Pathology; Cancer; Pathological; Stromal cell; Colorectal cancer; GiST","score_opus":0.019190825211845883,"score_gpt":0.4146866018561452,"score_spread":0.3954957766442993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898310631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837687,0.00014142686,0.005600997,0.007031185,0.00076000654,0.0013141816,0.0001419222,0.000028344675,0.0012132507],"genre_scores_gemma":[0.9890168,0.0000149255875,0.009988652,0.00037536025,0.0002476629,0.0000022024,0.000013735787,0.000008706686,0.00033196755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989832,0.00011199933,0.00041228675,0.00010953747,0.00017278262,0.00021021454],"domain_scores_gemma":[0.99815744,0.00009090619,0.00073044706,0.00010494964,0.0007672841,0.00014894555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005012988,0.00010612026,0.0003993249,0.0002403471,0.00031157536,0.000009227347,0.00007775712,0.000060533912,0.000026511498],"category_scores_gemma":[0.000209115,0.00008496021,0.00010264849,0.00019663242,0.000040367624,0.00041010522,0.000031111762,0.00022693141,0.000004635459],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061689247,0.001953272,0.6696877,0.0002881424,0.0015801155,0.00019010725,0.05839017,0.000023142986,0.00014608732,0.00030633694,0.01392145,0.24734458],"study_design_scores_gemma":[0.019806357,0.03207184,0.60681975,0.00065252493,0.0028042493,0.00064072653,0.21125136,0.0038116712,0.00039189545,0.00023707717,0.12113889,0.00037362784],"about_ca_topic_score_codex":0.00024595557,"about_ca_topic_score_gemma":0.00038505063,"teacher_disagreement_score":0.24697095,"about_ca_system_score_codex":0.0034209504,"about_ca_system_score_gemma":0.00068679877,"threshold_uncertainty_score":0.89456666},"labels":[],"label_agreement":null},{"id":"W2898312337","doi":"10.1016/j.jtho.2018.08.1288","title":"P2.06-33 Heterogeneity in Care Pathways for Patients with Malignant Pleural Mesothelioma Presenting at a Quaternary Thoracic Oncology Center in Quebec","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lymph node; Retrospective cohort study; Mesothelioma; Palliative care; Radiology; Internal medicine; Pathology","score_opus":0.025387011630224277,"score_gpt":0.3763812355107672,"score_spread":0.3509942238805429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898312337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99769974,0.00023374884,0.000021209265,0.00067532423,0.00033324998,0.00059472426,0.00011656282,0.000008982759,0.00031647837],"genre_scores_gemma":[0.997122,0.000018769228,0.0016703359,0.00045671212,0.00031722116,0.00003494385,0.00010742191,0.000031756295,0.0002408317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788344,0.000281072,0.00076295715,0.00028996868,0.00035573688,0.00042681565],"domain_scores_gemma":[0.998675,0.00016736047,0.0005775505,0.00017587743,0.00019214107,0.00021210586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032583944,0.00022202874,0.00064618624,0.0003366789,0.000079246405,0.00001166525,0.0001726715,0.00018867812,0.00007585087],"category_scores_gemma":[0.00007791623,0.0001577016,0.00017423356,0.00015091158,0.00019974961,0.00020238494,0.00013468851,0.00023755117,0.00002103023],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016603919,0.0018312652,0.957488,0.00019950602,0.00008897581,0.0006169885,0.0013451163,0.000025375728,0.0013850383,0.0000032628338,0.00029316536,0.020119373],"study_design_scores_gemma":[0.0037303276,0.006830372,0.97774744,0.00037363073,0.00016308928,0.000314321,0.0007393428,0.0001416481,0.0025295238,0.000060939386,0.007188465,0.00018088364],"about_ca_topic_score_codex":0.0003236935,"about_ca_topic_score_gemma":0.008414774,"teacher_disagreement_score":0.020259442,"about_ca_system_score_codex":0.0018212524,"about_ca_system_score_gemma":0.00032570833,"threshold_uncertainty_score":0.6430884},"labels":[],"label_agreement":null},{"id":"W2898315580","doi":"10.1016/j.jtho.2018.08.647","title":"P1.01-91 A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Ifosfamide; Vinorelbine; Medicine; Chemotherapy; Lung cancer; Internal medicine; Oncology; Cohort; Surgery; Urology; Etoposide; Cisplatin","score_opus":0.02175414671195695,"score_gpt":0.45420331419668747,"score_spread":0.4324491674847305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898315580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963941,0.0014481265,0.00014514719,0.00054828834,0.00029661265,0.0006012873,0.000013250194,0.0000045425627,0.0005486757],"genre_scores_gemma":[0.9953477,0.0003387663,0.0038120106,0.00008108448,0.00022400443,0.000020843958,0.0000026716114,0.000017917222,0.00015503004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984683,0.00008894929,0.000891507,0.00016792312,0.00018940672,0.00019395347],"domain_scores_gemma":[0.9981809,0.00022487881,0.0009459675,0.00015999548,0.0003625863,0.00012566484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003595462,0.00015128437,0.00078808615,0.00029771018,0.000049900304,0.000004319753,0.00008832413,0.000093831884,0.00007895543],"category_scores_gemma":[0.00011661586,0.00011221399,0.00007653326,0.00028525572,0.00010082457,0.000100195124,0.00004878498,0.00023450721,4.4106383e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015936151,0.018638741,0.5516802,0.0012269275,0.0011362121,0.0007857413,0.029463965,0.0011570166,0.07707309,0.000004628677,0.00041027347,0.30248708],"study_design_scores_gemma":[0.11094521,0.10387266,0.6737652,0.004057068,0.007893682,0.00058635074,0.020325238,0.007117749,0.06829626,0.00014181201,0.00239046,0.00060830335],"about_ca_topic_score_codex":0.0003471344,"about_ca_topic_score_gemma":0.0014379743,"teacher_disagreement_score":0.30187875,"about_ca_system_score_codex":0.0002898805,"about_ca_system_score_gemma":0.00047795134,"threshold_uncertainty_score":0.45759538},"labels":[],"label_agreement":null},{"id":"W2898323173","doi":"10.1016/j.jtho.2018.08.467","title":"MA18.03 How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Statistics Canada","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Clinical trial; Cohort; Surgery; Cancer; Chemotherapy; Internal medicine; Oncology; General surgery","score_opus":0.02523285328223142,"score_gpt":0.37759438176632903,"score_spread":0.35236152848409763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898323173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976612,0.00026124605,0.0000015542249,0.012618667,0.001174189,0.00024046257,0.00000773204,0.000002713228,0.009081445],"genre_scores_gemma":[0.9898019,0.00010770409,0.00006927186,0.0064992844,0.0006361295,0.000019333638,0.0000028627128,0.000009977317,0.0028535335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985829,0.00022748283,0.00038042845,0.00013924159,0.00038733293,0.0002826267],"domain_scores_gemma":[0.99872804,0.00018677097,0.00049335713,0.00022421725,0.00025891195,0.00010867706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039523822,0.00013389892,0.00039501808,0.000103960134,0.00012546501,0.00001981518,0.00032750441,0.00007055199,0.00081931305],"category_scores_gemma":[0.000063894215,0.000068591595,0.00008018333,0.00025160404,0.00016549895,0.00012364173,0.000032895605,0.0006101332,0.0000010188587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013405718,0.00012157203,0.89316326,0.000019714498,0.000078938065,0.00039676728,0.008401407,0.000004866673,0.000077617085,0.0000027455633,0.069131345,0.027261175],"study_design_scores_gemma":[0.000813529,0.00061917637,0.7838058,0.000097591175,0.000112471025,0.000086196975,0.0026939493,0.000036910747,0.00026895414,0.000004476711,0.21138428,0.0000767092],"about_ca_topic_score_codex":0.652014,"about_ca_topic_score_gemma":0.9931063,"teacher_disagreement_score":0.34109232,"about_ca_system_score_codex":0.0031746184,"about_ca_system_score_gemma":0.0030470698,"threshold_uncertainty_score":0.8970903},"labels":[],"label_agreement":null},{"id":"W2898328081","doi":"10.1016/j.jtho.2018.08.1554","title":"P2.17-28 Real-World Data: Survival Outcomes of Chemotherapy Regimens Given Concurrently with Radiotherapy for Locally Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Carboplatin; Internal medicine; Oncology; Regimen; Vinorelbine; Chemotherapy; Cisplatin; Lung cancer; Hazard ratio; Etoposide; Chemotherapy regimen; Radiation therapy; Confidence interval","score_opus":0.04571392943954651,"score_gpt":0.45468041308637375,"score_spread":0.40896648364682725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898328081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9088449,0.0029135484,0.0080760205,0.06801609,0.0032734552,0.002499545,0.00021183702,0.00005461592,0.0061099795],"genre_scores_gemma":[0.92293316,0.004008927,0.0658708,0.0023729482,0.0019868985,0.00004684139,0.000051641444,0.00010233102,0.0026264763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982215,0.000114095164,0.0007064088,0.00029604018,0.00035524537,0.00030667218],"domain_scores_gemma":[0.9968343,0.00050649635,0.0012300373,0.0005726916,0.00066677236,0.00018971872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074417563,0.00023371406,0.0013765548,0.0001972431,0.000056786554,0.0000110134915,0.000319618,0.00008917883,0.00010372801],"category_scores_gemma":[0.00005660121,0.0001476132,0.00018739619,0.00022031774,0.00036304153,0.00016585652,0.000032821594,0.00020183448,0.000001999241],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049497306,0.0034979251,0.23853639,0.00029277385,0.0062101926,0.00023172496,0.0010561051,0.000027040342,0.0018721822,0.0002889589,0.058983672,0.63950574],"study_design_scores_gemma":[0.031306103,0.05704649,0.2266089,0.0012252791,0.0022170648,0.0003846858,0.0005316651,0.00018838812,0.009205839,0.00017903464,0.67065537,0.00045117314],"about_ca_topic_score_codex":0.000054428776,"about_ca_topic_score_gemma":0.0008037523,"teacher_disagreement_score":0.63905454,"about_ca_system_score_codex":0.0006767058,"about_ca_system_score_gemma":0.0008512159,"threshold_uncertainty_score":0.60194916},"labels":[],"label_agreement":null},{"id":"W2898333243","doi":"10.1016/j.jtho.2018.08.1441","title":"P2.13-46 Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Lung cancer; Medicine; Mutation; Cancer research; Adenocarcinoma; Afatinib; Epidermal growth factor receptor; Protein kinase domain; Cancer; Pleural effusion; Oncology; Lung; Internal medicine; Tyrosine kinase; Pathology; Gene; Receptor; Gefitinib; Biology; Genetics","score_opus":0.01718842428348755,"score_gpt":0.4322136961175025,"score_spread":0.41502527183401494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898333243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306333,0.0006135534,0.00020549988,0.0033890144,0.00079134473,0.00046625396,0.000038240378,0.0000084281555,0.0014243359],"genre_scores_gemma":[0.9951482,0.000121127305,0.003561596,0.0005647357,0.00034862943,0.000024740932,0.0000376777,0.000019847508,0.00017344387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836415,0.00018186083,0.00080373936,0.00015426672,0.0002940889,0.00020192009],"domain_scores_gemma":[0.9980522,0.00016377734,0.00068243337,0.00013142596,0.00080384256,0.00016631848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020729376,0.00015900876,0.00059579057,0.00039540307,0.0000718921,0.0000072544017,0.00009894953,0.00014124245,0.00018025584],"category_scores_gemma":[0.00007158758,0.0001187876,0.00013415156,0.00039893587,0.00024599285,0.00020002575,0.000015081213,0.0002664428,0.000004205266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032957525,0.0017127212,0.8861451,0.0005699513,0.001130619,0.00021273672,0.026623437,0.00051838433,0.022908222,0.00006444561,0.001819949,0.054998696],"study_design_scores_gemma":[0.006148946,0.0032552045,0.9813575,0.00056617544,0.0009556222,0.00014232064,0.00082246517,0.00031790257,0.0023676453,0.0010554931,0.0028594644,0.00015127168],"about_ca_topic_score_codex":0.00021499873,"about_ca_topic_score_gemma":0.0007621482,"teacher_disagreement_score":0.0952124,"about_ca_system_score_codex":0.0005971339,"about_ca_system_score_gemma":0.00089699274,"threshold_uncertainty_score":0.48440176},"labels":[],"label_agreement":null},{"id":"W2898338151","doi":"10.1016/j.jtho.2018.08.1564","title":"P3.01-04 Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Immune system; Oncology; Institution; Internal medicine; Immunology","score_opus":0.021264394917971916,"score_gpt":0.35837666064516016,"score_spread":0.3371122657271882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898338151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099374,0.0012695282,0.000023887507,0.0038422362,0.001626425,0.00031979586,0.000006942779,0.000011608763,0.0019058287],"genre_scores_gemma":[0.99818057,0.00017990876,0.000559913,0.000523101,0.00016315636,0.00001072261,0.000006672765,0.000017688037,0.00035828742],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99768645,0.00014888927,0.0013521947,0.00019788282,0.00024430655,0.0003702883],"domain_scores_gemma":[0.9985552,0.000054560573,0.0007318629,0.00021605536,0.00018714242,0.00025522007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001121378,0.00019202898,0.0006332751,0.0006105658,0.00012032173,0.000008109104,0.0001500673,0.0002973904,0.0005702269],"category_scores_gemma":[0.00031109978,0.00015591951,0.00023380572,0.00045560428,0.00040042974,0.00027908626,0.000044220542,0.00047704863,0.000015395217],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02727281,0.0016600175,0.10366623,0.00014418339,0.00083791395,0.0025896686,0.017660644,0.000013875118,0.17748894,0.000034589637,0.0012740885,0.667357],"study_design_scores_gemma":[0.010078273,0.007226759,0.85791975,0.0015974962,0.00025853858,0.0052293614,0.006654724,0.000109305525,0.017025806,0.00013648745,0.09325606,0.00050741265],"about_ca_topic_score_codex":0.009480068,"about_ca_topic_score_gemma":0.01820466,"teacher_disagreement_score":0.75425357,"about_ca_system_score_codex":0.0016878495,"about_ca_system_score_gemma":0.00095788174,"threshold_uncertainty_score":0.99971056},"labels":[],"label_agreement":null},{"id":"W2898341387","doi":"10.1016/j.jtho.2018.08.028","title":"ES03.03 When to Repeat Pleural Biopsies","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Mesothelioma; Pleural effusion; Radiology; Malignancy; Biopsy; Context (archaeology); Thoracoscopy; Pleural disease; Pleural fluid; Pleural thickening; Respiratory disease; Pathology; Lung; Internal medicine","score_opus":0.028192911822828702,"score_gpt":0.414956312860873,"score_spread":0.3867634010380443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898341387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98274523,0.00020799963,0.00007814306,0.0095195295,0.00061795715,0.00009218002,0.0000070349006,0.00001040148,0.0067215],"genre_scores_gemma":[0.9835544,0.000021984382,0.008767869,0.0034953377,0.0011781255,0.0000020775876,0.0000042785823,0.000011121964,0.0029647753],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99910766,0.000056459707,0.00033248836,0.00010512537,0.00024033393,0.0001579384],"domain_scores_gemma":[0.9992554,0.00006207016,0.0001741831,0.0001231169,0.000115879724,0.00026931317],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002217557,0.00008920953,0.00028527828,0.00013651027,0.00005480153,0.000007816474,0.00009734371,0.00006975969,0.0010454487],"category_scores_gemma":[0.00016025781,0.00006349284,0.00011676236,0.00008059264,0.0001350162,0.00009189232,0.00005378406,0.00013311616,0.00041714121],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021617979,0.0018185502,0.3429592,0.0001354039,0.00044049518,0.0014732116,0.0019707563,0.00002792266,0.055781197,0.00015856225,0.21224359,0.36137313],"study_design_scores_gemma":[0.00066773576,0.008999485,0.6394383,0.0001372761,0.00035535367,0.0022014473,0.000422622,0.000025554016,0.0076538115,0.0010519499,0.33891007,0.00013639496],"about_ca_topic_score_codex":0.0000075336175,"about_ca_topic_score_gemma":0.00000776833,"teacher_disagreement_score":0.36123675,"about_ca_system_score_codex":0.00021696936,"about_ca_system_score_gemma":0.00012713933,"threshold_uncertainty_score":0.99986774},"labels":[],"label_agreement":null},{"id":"W2898346666","doi":"10.1016/j.jtho.2018.08.1124","title":"P2.01-70 Tumor Treating Fields and Radiosurgery for Supra- and/or Infratentorial Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Study","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiosurgery; Clinical endpoint; Lung cancer; Adverse effect; non-small cell lung cancer (NSCLC); Oncology; Neurocognitive; Internal medicine; Radiology; Clinical trial; Radiation therapy","score_opus":0.05462977729715227,"score_gpt":0.4499984305516568,"score_spread":0.3953686532545045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898346666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991058,0.0009843892,0.00030222727,0.0060986793,0.0006530668,0.000737589,0.00006376041,0.0000063228617,0.0000959581],"genre_scores_gemma":[0.9897201,0.00006006932,0.006704625,0.0014211388,0.0018982458,0.00003965198,0.000014178821,0.000017273736,0.00012471492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977886,0.0008131904,0.00069707993,0.00021790538,0.00023286298,0.00025033377],"domain_scores_gemma":[0.9956224,0.003407716,0.0004650078,0.00018646626,0.00014543693,0.00017297105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029222115,0.00019041108,0.0008438317,0.00020672794,0.000121532255,0.00004459137,0.00010081497,0.000088552384,0.0002982738],"category_scores_gemma":[0.0018171681,0.00010324176,0.00013314969,0.00017412008,0.00013277668,0.00012817352,0.00003952126,0.00025387318,0.0000015039599],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06859239,0.011041622,0.025232352,0.0001380372,0.0029396224,0.008349489,0.012295642,0.0000033044762,0.001778025,0.00007913186,0.057459887,0.8120905],"study_design_scores_gemma":[0.12986675,0.324077,0.0776728,0.001008636,0.016480567,0.015403605,0.059536815,0.0010615425,0.0061247367,0.003398542,0.36418217,0.0011868149],"about_ca_topic_score_codex":0.00016590134,"about_ca_topic_score_gemma":0.00035589916,"teacher_disagreement_score":0.81090367,"about_ca_system_score_codex":0.000089691275,"about_ca_system_score_gemma":0.0002933793,"threshold_uncertainty_score":0.42100766},"labels":[],"label_agreement":null},{"id":"W2898354241","doi":"10.1016/j.jtho.2018.08.1767","title":"P3.08-16 Prognostic Value of PDL-1 Expression and Correlation Between Primary Tissue and Brain Metastases in Oligometastatic NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Oncology; Primary tumor; Biopsy; Lung cancer; Incidence (geometry); Cohort; Immunohistochemistry; Cancer; Pathology; Metastasis","score_opus":0.0320720943749037,"score_gpt":0.44708829714619647,"score_spread":0.41501620277129275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898354241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899955,0.003893663,0.0015199808,0.0033747356,0.0001554402,0.0004314769,0.000014396871,0.0000054354746,0.00060940784],"genre_scores_gemma":[0.9895914,0.0003447752,0.009427574,0.00015291134,0.00031260072,0.0000071852296,0.000006667941,0.000013898749,0.00014296],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812734,0.0004953243,0.000626174,0.00016050816,0.0003684166,0.00022223123],"domain_scores_gemma":[0.997463,0.0014748703,0.0005014146,0.000114912385,0.00029035818,0.00015543275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017758445,0.00012597084,0.0007734885,0.00044681,0.000051960367,0.000009129508,0.00006641851,0.0000941656,0.00004176554],"category_scores_gemma":[0.0017435205,0.00009107017,0.000040028306,0.00024950967,0.0004127815,0.00018092645,0.00012555068,0.00034228904,0.000002552825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052318457,0.00058046635,0.35249397,0.0018581403,0.0005767587,0.0005393606,0.0038887137,0.000009452528,0.07580515,0.00005777396,0.0073944177,0.5515639],"study_design_scores_gemma":[0.005060487,0.020612594,0.9275934,0.0028679548,0.0011446846,0.0014765266,0.0012080742,0.00011953972,0.025869833,0.0019892477,0.011823354,0.00023430273],"about_ca_topic_score_codex":0.00003115623,"about_ca_topic_score_gemma":0.000025257714,"teacher_disagreement_score":0.5750994,"about_ca_system_score_codex":0.0002642455,"about_ca_system_score_gemma":0.0003547349,"threshold_uncertainty_score":0.3713734},"labels":[],"label_agreement":null},{"id":"W2898363961","doi":"10.1016/j.jtho.2018.08.598","title":"P1.01-42 Real-World Evaluation of Tolerability in Older Adult Patients (≥75 years old) with EGFR-mutated NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Afatinib; Gefitinib; Internal medicine; Tolerability; Observational study; Quality of life (healthcare); Oncology; Adverse effect; Epidermal growth factor receptor; Cancer","score_opus":0.02458887489881074,"score_gpt":0.45411237828709883,"score_spread":0.4295235033882881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898363961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157655,0.000050163646,0.000032409727,0.00079782575,0.00036778738,0.0005210086,0.0000080885775,0.0000067377478,0.006639456],"genre_scores_gemma":[0.99735296,0.000021847081,0.0019522,0.00023668412,0.00016244022,0.000013951656,0.000017128037,0.0000147421915,0.00022802466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982052,0.00027151685,0.0006521433,0.00015775955,0.00053719856,0.00017617989],"domain_scores_gemma":[0.9971815,0.000084614905,0.0006529394,0.00018937029,0.0017807138,0.00011088015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085259345,0.0001123146,0.00047641792,0.00030789126,0.000029745539,0.0000056547437,0.00007637513,0.000093488066,0.00029995586],"category_scores_gemma":[0.00018062623,0.00008029284,0.00007368962,0.00040859435,0.00013851558,0.0001346347,0.000016403092,0.00020691202,0.000007808123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004724321,0.002820264,0.7064773,0.000078433004,0.00039280558,0.00007665141,0.004196662,0.00008831845,0.00034242452,0.00002636287,0.0011989881,0.27957746],"study_design_scores_gemma":[0.0063080657,0.0042642658,0.986013,0.00034991268,0.0009903173,0.00004460605,0.00038174004,0.00022243355,0.00066161284,0.00020158065,0.00048744545,0.00007501182],"about_ca_topic_score_codex":0.0003227859,"about_ca_topic_score_gemma":0.0013416405,"teacher_disagreement_score":0.2795357,"about_ca_system_score_codex":0.0011004555,"about_ca_system_score_gemma":0.00095715316,"threshold_uncertainty_score":0.32843062},"labels":[],"label_agreement":null},{"id":"W2898370134","doi":"10.1016/j.jtho.2018.08.1494","title":"P2.16-19 Feasibility and Outcomes of Radiofrequency Ablation as Salvage Modality After Hypofractionated Radiation/SBRT for Early NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Salvage therapy; Radiology; Radiation therapy; Pneumothorax; Surgery; Nuclear medicine; Chemotherapy","score_opus":0.031929422568622155,"score_gpt":0.4344685748757308,"score_spread":0.4025391523071087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898370134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883161,0.0010613479,0.00048367472,0.008418542,0.0005712137,0.0005484081,0.00003017468,0.000009513969,0.0005609809],"genre_scores_gemma":[0.99579155,0.000276792,0.0027194358,0.0006194137,0.00034937423,0.000028872144,0.000008691318,0.000012609143,0.0001932815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865824,0.00014366314,0.0006325127,0.00017944319,0.00023212927,0.00015401273],"domain_scores_gemma":[0.99796057,0.00041647005,0.0006757806,0.00018714246,0.00059302576,0.00016704269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008099404,0.00012756532,0.00058252516,0.00015513683,0.000060337683,0.0000108719305,0.000055445107,0.00016145008,0.00019313638],"category_scores_gemma":[0.00047824197,0.000093970746,0.00018206378,0.00011601918,0.00014345678,0.0002695016,0.000014547242,0.00015129622,0.000006479851],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048341653,0.000903633,0.8822366,0.00013028765,0.0005829062,0.00003341186,0.0005406071,0.0000024737003,0.0005384399,0.00008262047,0.0009668365,0.10914802],"study_design_scores_gemma":[0.0027673522,0.00440007,0.9821718,0.00006424984,0.00070807425,0.00018403203,0.00008048567,0.00002557597,0.002612297,0.0028430498,0.004063648,0.00007938966],"about_ca_topic_score_codex":0.00017071745,"about_ca_topic_score_gemma":0.000045618806,"teacher_disagreement_score":0.109068625,"about_ca_system_score_codex":0.0015040901,"about_ca_system_score_gemma":0.00049504766,"threshold_uncertainty_score":0.39331436},"labels":[],"label_agreement":null},{"id":"W2898379648","doi":"10.1016/j.jtho.2018.08.981","title":"P1.16-12 Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit from Adjuvant Chemotherapy","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Medicine; Oncology; Internal medicine; Immunohistochemistry; Biomarker; Adjuvant; Tissue microarray; Adjuvant chemotherapy; Chemotherapy; Stage (stratigraphy); Multivariate analysis; Pathology; Cancer","score_opus":0.032323561277669374,"score_gpt":0.3877315770991356,"score_spread":0.3554080158214662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898379648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902744,0.00061900564,0.0008001076,0.007212375,0.0005611916,0.00017257807,0.0000063101406,0.000008189197,0.00034584152],"genre_scores_gemma":[0.9962232,0.00027807476,0.0023399007,0.0008527627,0.00015834717,0.0000026272369,0.000007787445,0.000017241202,0.000120070654],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99841195,0.00012292126,0.0007891726,0.00016625137,0.00032959323,0.00018010313],"domain_scores_gemma":[0.9983598,0.00027659617,0.0008382334,0.00018243022,0.00019405143,0.00014889694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090654875,0.00011960459,0.000611293,0.00031396278,0.000033623524,0.000012450773,0.00012071537,0.00014688651,0.00009846452],"category_scores_gemma":[0.00053610525,0.00008612011,0.00008783502,0.00014024132,0.0002253305,0.00009470811,0.00004108315,0.0003873271,0.0000018047597],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019102348,0.00035163978,0.17543508,0.000036308487,0.00017157891,0.00008844273,0.0016775117,0.0000024961378,0.033996202,0.000008278369,0.00079916907,0.78552306],"study_design_scores_gemma":[0.0022791794,0.0012899624,0.9824378,0.00033148009,0.00014067187,0.00024699344,0.00040713817,0.0021345655,0.0060509485,0.00092863216,0.003673103,0.00007950645],"about_ca_topic_score_codex":0.0001415073,"about_ca_topic_score_gemma":0.00004824393,"teacher_disagreement_score":0.8070027,"about_ca_system_score_codex":0.00016381491,"about_ca_system_score_gemma":0.00011834038,"threshold_uncertainty_score":0.35118762},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2898381418","doi":"10.1016/j.jtho.2018.08.872","title":"P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; T790M; Lung cancer; Oncology; Gastroenterology; Cancer; Adenocarcinoma","score_opus":0.023622924812197785,"score_gpt":0.4398612666076692,"score_spread":0.4162383417954714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898381418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944614,0.0006014052,0.0015190303,0.0005810634,0.00019335707,0.00011126992,0.0000022808892,0.0000022130769,0.0025279736],"genre_scores_gemma":[0.98141515,0.00003889692,0.018167727,0.00004163104,0.00006941425,0.0000035940893,0.0000012969895,0.0000049438027,0.0002573695],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992237,0.000045805507,0.00047591556,0.00006303313,0.000114940514,0.000076609605],"domain_scores_gemma":[0.99911785,0.00006811767,0.00042306172,0.000060057664,0.00028078957,0.00005012506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027070055,0.000051823154,0.0002657141,0.00021529762,0.000033579807,0.0000017466613,0.000030790947,0.000058975354,0.000028654145],"category_scores_gemma":[0.000080757425,0.000040893257,0.000028718157,0.00015179106,0.000105621264,0.00006008889,0.000010060178,0.00008996567,0.0000012684241],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037225015,0.0012614554,0.025526436,0.00042825117,0.00060409156,0.00013189107,0.020780498,0.000019752635,0.10918705,0.00008911561,0.00033964386,0.83790934],"study_design_scores_gemma":[0.004696132,0.00472737,0.7133103,0.0008867717,0.00081746967,0.00056321616,0.0059356866,0.000055123215,0.22148542,0.0010078526,0.046358503,0.00015613307],"about_ca_topic_score_codex":0.000014037165,"about_ca_topic_score_gemma":0.0009005655,"teacher_disagreement_score":0.8377532,"about_ca_system_score_codex":0.00025840293,"about_ca_system_score_gemma":0.0005989659,"threshold_uncertainty_score":0.16675787},"labels":[],"label_agreement":null},{"id":"W2898391067","doi":"10.1016/j.jtho.2018.08.967","title":"P1.15-34 Treatment Patterns and Outcomes of Stage III Non-Small Cell Lung Cancer (NSCLC): Real World Evidence of How our Patients Fare","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Lung cancer; Cancer registry; Perioperative; Cancer; Population; Medical record; Chemotherapy; Oncology; Cohort; Surgery","score_opus":0.03304343641617705,"score_gpt":0.4459690156488541,"score_spread":0.41292557923267703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898391067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947311,0.0008973669,0.00011575969,0.0022890824,0.000611521,0.00045701928,0.000079991296,0.000004836584,0.0008132649],"genre_scores_gemma":[0.9929926,0.001209806,0.0011141903,0.00014439797,0.00022247569,0.000017865805,0.0000052601954,0.000018815803,0.0042746365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870354,0.00008853605,0.0005648612,0.00017485513,0.00025226903,0.00021590976],"domain_scores_gemma":[0.9978563,0.00012407423,0.0010775069,0.00020328216,0.00056428014,0.00017453618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017978545,0.0001866824,0.00081511773,0.00025373552,0.00005478969,0.00000914878,0.00010411424,0.000091982445,0.00007923487],"category_scores_gemma":[0.000032259635,0.00012261429,0.00016549176,0.000135599,0.00007024718,0.00013660631,0.000043193373,0.00013667725,7.9085635e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011730096,0.0008886684,0.94910717,0.00033527473,0.00068234955,0.000073423886,0.0024235127,0.0000052417563,0.0009302632,0.0000027029798,0.00059099594,0.043787416],"study_design_scores_gemma":[0.004874776,0.009418873,0.9687481,0.0011410399,0.0026184565,0.00001956598,0.002033078,0.000045736822,0.009677018,0.0000055999344,0.0012857558,0.0001320216],"about_ca_topic_score_codex":0.001377052,"about_ca_topic_score_gemma":0.0025308642,"teacher_disagreement_score":0.043655396,"about_ca_system_score_codex":0.00080578506,"about_ca_system_score_gemma":0.00073315325,"threshold_uncertainty_score":0.50000656},"labels":[],"label_agreement":null},{"id":"W2898393867","doi":"10.1016/j.jtho.2018.08.1344","title":"P2.10-15 RADON: #1 Cause of Lung Cancer in Non-Smokers","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radioactivity and Radon Measurements","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of Canada; Health Canada","funders":"","keywords":"Radon; Lung cancer; Medicine; Environmental health; Population; International agency; Cancer; Nuclear medicine; Oncology; Internal medicine","score_opus":0.09054142863927601,"score_gpt":0.5502037683782022,"score_spread":0.4596623397389262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898393867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834495,0.00068483263,0.00022058579,0.003921143,0.004338414,0.00032768224,0.000009260132,0.000006753189,0.0070418376],"genre_scores_gemma":[0.99516433,0.00039265,0.0006910275,0.00061631884,0.0013265961,0.000012724027,4.6968552e-7,0.00001950732,0.0017763661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99687105,0.0011240686,0.0010575234,0.00014658828,0.0003703204,0.000430456],"domain_scores_gemma":[0.9972181,0.00042349077,0.0013916643,0.00020759692,0.0005896106,0.00016958384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029247338,0.00013757932,0.00069088524,0.00037113228,0.00018314921,0.0000029030305,0.0002953751,0.0003695563,0.0019564333],"category_scores_gemma":[0.0003149769,0.00010876042,0.000119456876,0.0003339424,0.0001848455,0.00023055046,0.000060318507,0.001046038,0.00004103444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008032358,0.0013213777,0.6370959,0.0010829242,0.0008361131,0.00051309663,0.016683811,0.00014018491,0.026513353,0.00003748595,0.21171734,0.096025996],"study_design_scores_gemma":[0.00740555,0.0047375625,0.8035875,0.0045475173,0.000803974,0.00023648463,0.006848497,0.0011979083,0.009175082,0.00030072912,0.1605439,0.0006153107],"about_ca_topic_score_codex":0.00023761447,"about_ca_topic_score_gemma":0.0014046317,"teacher_disagreement_score":0.16649152,"about_ca_system_score_codex":0.000977291,"about_ca_system_score_gemma":0.001515919,"threshold_uncertainty_score":0.9989559},"labels":[],"label_agreement":null},{"id":"W2898431847","doi":"10.1016/j.jtho.2018.08.945","title":"P1.15-13 Wait Times for Diagnosis and Treatment of Lung Cancer Across the Province of Quebec, Canada","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Lung cancer; Medical record; Cancer; Clinical Practice; General surgery; Emergency medicine; Family medicine; Surgery; Internal medicine","score_opus":0.046902450852395625,"score_gpt":0.4470190389078876,"score_spread":0.40011658805549194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898431847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985916,0.005604835,0.00005167407,0.0074930103,0.0003503826,0.0003366525,0.00003932093,0.0000017158164,0.00020640629],"genre_scores_gemma":[0.9969569,0.0007821052,0.00048436938,0.0004550275,0.00051279983,0.000026463584,8.5605427e-7,0.000007643676,0.0007738465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989976,0.00005600807,0.00043755976,0.0000970145,0.00021393635,0.00019784519],"domain_scores_gemma":[0.9984244,0.0003070022,0.0006053337,0.0001223897,0.00044665067,0.00009418866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003231639,0.00009755828,0.0005059883,0.00003156714,0.00007167573,0.0000055504584,0.00010853741,0.00007181301,0.00007864021],"category_scores_gemma":[0.00011601559,0.00005612215,0.00009316201,0.000079851496,0.00021501914,0.000066831875,0.000024387447,0.00008103772,1.1673755e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062733195,0.00033163204,0.25592756,0.00033137994,0.00086328055,0.00020301835,0.0026854603,0.000046076177,0.0011763409,0.000058776404,0.08775493,0.6443482],"study_design_scores_gemma":[0.0058471123,0.026007636,0.37247205,0.001957529,0.0033713982,0.00094447343,0.006733611,0.0011530552,0.11715089,0.00024094663,0.4637247,0.000396597],"about_ca_topic_score_codex":0.26155433,"about_ca_topic_score_gemma":0.90247506,"teacher_disagreement_score":0.6439516,"about_ca_system_score_codex":0.00069494353,"about_ca_system_score_gemma":0.0025841699,"threshold_uncertainty_score":0.743363},"labels":[],"label_agreement":null},{"id":"W2898445532","doi":"10.1016/j.jtho.2018.08.1410","title":"P2.13-15 Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Medicine; HRAS; PTEN; Internal medicine; Oncology; Lung cancer; Adenocarcinoma; Exon; Cancer research; Cancer; Afatinib; KRAS; Gefitinib; Gene; Epidermal growth factor receptor; PI3K/AKT/mTOR pathway; Genetics; Signal transduction; Colorectal cancer; Biology","score_opus":0.017331345528136075,"score_gpt":0.41609928299778154,"score_spread":0.39876793746964545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898445532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742634,0.0008160641,0.0048990683,0.0036896206,0.00043032717,0.00037508702,0.00006440304,0.0000075225166,0.002291576],"genre_scores_gemma":[0.97286767,0.00016105417,0.024830973,0.00029566328,0.00014079182,0.000010013288,0.0000054926177,0.000015635715,0.0016727338],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99861693,0.000118539916,0.0006264002,0.00016899199,0.00030017734,0.00016896804],"domain_scores_gemma":[0.9983392,0.00021515928,0.00048354513,0.00021637329,0.0005674559,0.00017826288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004410619,0.00012154423,0.0005054394,0.0002744951,0.00006828672,0.0000060194816,0.00012312655,0.00010508899,0.000100553385],"category_scores_gemma":[0.00016257454,0.000094893716,0.00009077393,0.00023504626,0.00022558804,0.00013110744,0.0000412818,0.00014724575,0.0000028544448],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033467583,0.00388049,0.035482567,0.004957854,0.0032791873,0.0012219897,0.023568038,0.00007396234,0.65439016,0.0067990157,0.012078622,0.2208005],"study_design_scores_gemma":[0.0042460696,0.019814702,0.8804129,0.003054998,0.0060890084,0.0011610693,0.002096189,0.000026128311,0.06739631,0.007358669,0.00794462,0.0003993868],"about_ca_topic_score_codex":0.000013937553,"about_ca_topic_score_gemma":0.00008527596,"teacher_disagreement_score":0.8449303,"about_ca_system_score_codex":0.00031328012,"about_ca_system_score_gemma":0.0006468007,"threshold_uncertainty_score":0.38696533},"labels":[],"label_agreement":null},{"id":"W2898446034","doi":"10.1016/j.jtho.2018.08.1819","title":"P3.11-23 Adherence to Annual Low-Dose CT Lung Cancer Screening at a Large Academic Institution","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Descriptive statistics; Demographics; Academic institution; Confidence interval; Cohort; Population; Retrospective cohort study; Family medicine; Quarter (Canadian coin); Emergency medicine; Physical therapy; Internal medicine; Demography; Environmental health","score_opus":0.049472890032047336,"score_gpt":0.47955288863094553,"score_spread":0.43007999859889817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898446034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98419654,0.0034133804,0.0013295293,0.007259088,0.0019016144,0.00026653407,0.000030247345,0.000022558726,0.001580483],"genre_scores_gemma":[0.98868704,0.00076834694,0.0026166174,0.0034678753,0.002674028,0.00001841431,0.0000018285687,0.000017979726,0.0017478545],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982151,0.00012492514,0.0006309095,0.00021495251,0.0003555867,0.00045854464],"domain_scores_gemma":[0.9984125,0.00009443661,0.0004301693,0.00014487848,0.0005662801,0.00035174924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092682085,0.00017206046,0.000728386,0.00023970226,0.00022829162,0.0000062354056,0.00017759562,0.0001558812,0.00030064015],"category_scores_gemma":[0.00035610932,0.0001332967,0.00013206834,0.00034041473,0.00015845793,0.00021115801,0.0001725294,0.00063709705,0.00006335426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015819509,0.0005181362,0.15555091,0.00042255907,0.0006182055,0.0018457823,0.009717079,0.000054418986,0.020323884,0.00008896771,0.19694221,0.59809834],"study_design_scores_gemma":[0.004736569,0.014227048,0.120604716,0.0038308443,0.00083997287,0.0034319337,0.0018447575,0.0007429163,0.00926424,0.00003789759,0.8399918,0.0004472841],"about_ca_topic_score_codex":0.00007016863,"about_ca_topic_score_gemma":0.00085354137,"teacher_disagreement_score":0.6430496,"about_ca_system_score_codex":0.00091229967,"about_ca_system_score_gemma":0.0008264006,"threshold_uncertainty_score":0.54356813},"labels":[],"label_agreement":null},{"id":"W2898447721","doi":"10.1016/j.jtho.2018.08.846","title":"P1.12-11 2010 – 2015 Extensive Stage SCLC Diagnoses in a Canadian Institution: Baseline Characteristics That Impact on the Overall Survival","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Radiation therapy; Lung cancer; Statistical significance; Confidence interval; Internal medicine; Cancer; Survival analysis; Stage (stratigraphy); Oncology; Conventional PCI","score_opus":0.06932617902037251,"score_gpt":0.46729817399630774,"score_spread":0.3979719949759352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898447721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9336731,0.00045883143,0.000031608386,0.060662933,0.0024108335,0.00042579824,0.00010626475,0.000008432697,0.0022222064],"genre_scores_gemma":[0.99249274,0.0009097238,0.00015806343,0.0028873659,0.002103585,0.0000114069335,0.000007855673,0.00002031705,0.0014089494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975747,0.00052310573,0.000512814,0.00019371994,0.0005632308,0.0006324182],"domain_scores_gemma":[0.9967982,0.0009940257,0.00042753058,0.0003270239,0.0009008472,0.0005523802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028158294,0.00022053912,0.0007514727,0.00039558872,0.00017596655,0.000036267524,0.00026731275,0.00016522262,0.00072828494],"category_scores_gemma":[0.003779931,0.00012516795,0.00016245586,0.0002228837,0.0005034281,0.00017851716,0.00008078448,0.0008860552,0.000052984222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011562597,0.0009747173,0.5733985,0.00016699368,0.00085387815,0.012563912,0.0025453186,0.000037958915,0.0009385836,0.0004678665,0.3603196,0.036170088],"study_design_scores_gemma":[0.0011777931,0.0039071054,0.7569411,0.0004191083,0.00012647909,0.0005172252,0.0005248855,0.00014875724,0.00034256533,0.000072403454,0.23566969,0.00015289636],"about_ca_topic_score_codex":0.036100328,"about_ca_topic_score_gemma":0.26449886,"teacher_disagreement_score":0.22839853,"about_ca_system_score_codex":0.0028390628,"about_ca_system_score_gemma":0.0045945127,"threshold_uncertainty_score":0.9703184},"labels":[],"label_agreement":null},{"id":"W2898452066","doi":"10.1016/j.jtho.2018.08.845","title":"P1.12-10 Patterns of Curative Chemo-Radiotherapy Regimen and Impacts on the Outcome of Limited Stage SCLC in a Canadian Institution: 2010 – 2015 Diagnoses","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Conventional PCI; Radiation therapy; Statistical significance; Internal medicine; Exact test; Regimen; Stage (stratigraphy); Lung cancer; Confidence interval; Surgery","score_opus":0.07010327992927107,"score_gpt":0.4832179830159742,"score_spread":0.4131147030867031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898452066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9542594,0.00093223836,0.000010079166,0.042209808,0.00029340983,0.00035087392,0.00003488398,0.000002568056,0.0019067486],"genre_scores_gemma":[0.99641937,0.0013458065,0.00018510256,0.00081288756,0.00026513005,0.000007281357,0.000001130687,0.000010461911,0.0009528416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984964,0.00023611638,0.00053498836,0.00011782434,0.00031566442,0.0002989708],"domain_scores_gemma":[0.9980702,0.00051143824,0.0005233977,0.00020899877,0.00043136624,0.0002546053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012121948,0.00012853449,0.00064412056,0.00035690988,0.00005829668,0.000007382436,0.00016230003,0.000113716786,0.0002636118],"category_scores_gemma":[0.0012366403,0.00007607164,0.00007181978,0.00021244543,0.000500224,0.00011753686,0.000037873506,0.0004265629,0.0000020070777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006882198,0.00059538876,0.91793185,0.00031952455,0.00089314784,0.0007350016,0.009269911,0.000009296704,0.004471833,0.00036792448,0.042772777,0.015751155],"study_design_scores_gemma":[0.002990741,0.012389086,0.8932701,0.0010578786,0.00013227476,0.00026725692,0.00270355,0.00005947341,0.009308081,0.00006934513,0.07760072,0.00015149181],"about_ca_topic_score_codex":0.01982815,"about_ca_topic_score_gemma":0.14020003,"teacher_disagreement_score":0.120371886,"about_ca_system_score_codex":0.0010487507,"about_ca_system_score_gemma":0.0014537353,"threshold_uncertainty_score":0.9866989},"labels":[],"label_agreement":null},{"id":"W2898479805","doi":"10.1016/j.jtho.2018.08.267","title":"OA06.06 MISSILE-NSCLC: A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early-Stage Non-Small Cell Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; SABR volatility model; Clinical endpoint; Radiation therapy; Regimen; Surgery; Stage (stratigraphy); Lung cancer; Internal medicine; Randomized controlled trial","score_opus":0.05724673192018446,"score_gpt":0.42676273465058223,"score_spread":0.36951600273039775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898479805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99143875,0.002883331,0.0003282414,0.0028110829,0.0014164334,0.0007148287,0.000006111595,0.0000054749376,0.000395778],"genre_scores_gemma":[0.9960249,0.0012015868,0.00053480203,0.0002970967,0.0014242872,0.000051311057,0.0000017141133,0.000024189916,0.00044011167],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99806106,0.0003099729,0.00089257956,0.00017407756,0.0003057175,0.00025661878],"domain_scores_gemma":[0.9977298,0.00052343844,0.0010640897,0.00023786696,0.00031472655,0.00013009332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013853976,0.00017966752,0.0008693245,0.00030373153,0.00008231937,0.000017373548,0.0001419064,0.00014848451,0.00018561969],"category_scores_gemma":[0.00011305765,0.00010909204,0.00028533215,0.00025068969,0.000102250255,0.00012465958,0.000024326371,0.0004009132,0.000001494266],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34912574,0.015437741,0.12728891,0.0010068656,0.0027877335,0.0016454343,0.036149193,0.00016087262,0.037144657,0.00001500233,0.013615675,0.41562217],"study_design_scores_gemma":[0.39779067,0.104674496,0.13383651,0.011324156,0.007486488,0.0011728909,0.0041014063,0.0072585535,0.2761299,0.0000776309,0.054861404,0.0012859103],"about_ca_topic_score_codex":0.0005238905,"about_ca_topic_score_gemma":0.00054559606,"teacher_disagreement_score":0.41433626,"about_ca_system_score_codex":0.0018276761,"about_ca_system_score_gemma":0.0016214704,"threshold_uncertainty_score":0.47793096},"labels":[],"label_agreement":null},{"id":"W2898480972","doi":"10.1016/j.jtho.2018.08.1278","title":"P2.06-23 Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Hazard ratio; Proportional hazards model; Logistic regression; Mesothelioma; Epigenetics; Lung cancer; Pathology; Genetics; Biology; Confidence interval; Gene","score_opus":0.012911405794427991,"score_gpt":0.3337777978712998,"score_spread":0.3208663920768718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898480972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997659,0.0004564217,0.000050114162,0.0011978379,0.00016566759,0.0001235268,0.00003488169,0.0000048202073,0.00030770543],"genre_scores_gemma":[0.9967125,0.000117310294,0.0020551994,0.00016550599,0.0003493605,0.0000016567951,0.000008285701,0.000011003229,0.00057915866],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888176,0.00015452378,0.00034776452,0.00012256867,0.00034527358,0.00014811603],"domain_scores_gemma":[0.99887264,0.00012152406,0.00064036436,0.00008192205,0.00013700082,0.00014655605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005180811,0.0001116085,0.00038511987,0.000107151835,0.00005671318,0.00000902703,0.000047281163,0.000095585536,0.000072435454],"category_scores_gemma":[0.00008059157,0.00007284048,0.000056949426,0.00007734419,0.00017132604,0.000120342396,0.00003677296,0.00015748205,0.000007701977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002824252,0.0002863881,0.97190446,0.000030069079,0.0002073145,0.00009784869,0.000249757,0.0000019315066,0.008044619,0.000018555462,0.00030371503,0.016031122],"study_design_scores_gemma":[0.0017909096,0.0058350125,0.98628724,0.00011240665,0.00058157527,0.00075602805,0.00018006716,0.000025514875,0.002909169,0.00022275397,0.0012147931,0.00008454809],"about_ca_topic_score_codex":0.000024703455,"about_ca_topic_score_gemma":0.000065666296,"teacher_disagreement_score":0.015946575,"about_ca_system_score_codex":0.00014577196,"about_ca_system_score_gemma":0.000102630795,"threshold_uncertainty_score":0.29703483},"labels":[],"label_agreement":null},{"id":"W2898482351","doi":"10.1016/j.jtho.2018.08.1370","title":"P2.11-23 Risk Perception Among a Lung Cancer Screening Population","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Family history; Risk perception; Population; Cancer; Multivariate analysis; Medical history; Internal medicine; Physical therapy; Demography; Perception; Environmental health; Psychology","score_opus":0.0590702627145987,"score_gpt":0.47705031145186466,"score_spread":0.41798004873726596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898482351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887555,0.00054932723,0.0071003693,0.0014785405,0.0008960547,0.0001559178,0.0000040825803,0.000021093967,0.0010390736],"genre_scores_gemma":[0.98299193,0.00020645339,0.012867554,0.00062303816,0.0029427253,0.000004561032,0.0000055452915,0.000017083714,0.0003411285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983222,0.00020283992,0.0005969802,0.00016826754,0.00042928878,0.0002804362],"domain_scores_gemma":[0.9980839,0.000066144254,0.0008861978,0.00014962,0.0006056621,0.00020847926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011521906,0.0001347574,0.00046831046,0.00023778017,0.00017056568,0.000022172266,0.00012727943,0.00021226532,0.0005337457],"category_scores_gemma":[0.00028089763,0.000109061424,0.00018457744,0.00026547172,0.00012119802,0.00037194218,0.000039091046,0.0004819621,0.000013384838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012656896,0.000041455798,0.8004822,0.000026214711,0.000093496164,0.0001012734,0.0005614771,0.000117930605,0.0010158606,0.000005407947,0.005469991,0.190819],"study_design_scores_gemma":[0.000627467,0.0014607564,0.9851583,0.0005338854,0.0006703541,0.0006302441,0.0008275819,0.0041875807,0.00018423921,0.00007823509,0.0055278973,0.00011343464],"about_ca_topic_score_codex":0.0015429014,"about_ca_topic_score_gemma":0.0013827834,"teacher_disagreement_score":0.19070555,"about_ca_system_score_codex":0.0006676053,"about_ca_system_score_gemma":0.00021875452,"threshold_uncertainty_score":0.5844141},"labels":[],"label_agreement":null},{"id":"W2898483684","doi":"10.1016/j.jtho.2018.08.961","title":"P1.15-28 Real World Treatment Patterns and Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Erlotinib; Afatinib; Oncology; Stage (stratigraphy); Lung cancer; Cancer registry; Cohort; Population; Radiation therapy; Cancer; Epidermal growth factor receptor","score_opus":0.021860780063442664,"score_gpt":0.39339348510295974,"score_spread":0.3715327050395171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898483684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882614,0.0003209745,0.00003300369,0.00097105314,0.00086295087,0.00027763957,0.000042566575,0.0000025402003,0.009227856],"genre_scores_gemma":[0.9899659,0.00031591524,0.00056384533,0.00017819216,0.0002727116,0.000013213895,0.0000072919324,0.000015595666,0.008667327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883556,0.00007560959,0.0005103821,0.00015325464,0.00018710547,0.00023805536],"domain_scores_gemma":[0.99893904,0.00009882405,0.00044999388,0.00013862153,0.0001867046,0.00018680863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001857258,0.0001525215,0.0006002046,0.00019379077,0.00004250102,0.0000064907895,0.00006922045,0.00007155654,0.00052903197],"category_scores_gemma":[0.0000067238807,0.000111402995,0.000068801484,0.000117301686,0.000057013902,0.000055272278,0.000023658049,0.00020893765,4.7093346e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001067718,0.00048609547,0.9741907,0.000096089294,0.00036977232,0.0007062608,0.0028009543,0.000022409278,0.00041691607,0.0000060345915,0.0009870048,0.01885004],"study_design_scores_gemma":[0.003628382,0.0028923084,0.97280097,0.00029320538,0.0009127808,0.000060674345,0.0009016158,0.00005599612,0.0021768343,0.000007703954,0.016157057,0.000112464055],"about_ca_topic_score_codex":0.95347005,"about_ca_topic_score_gemma":0.99902934,"teacher_disagreement_score":0.045559276,"about_ca_system_score_codex":0.004083456,"about_ca_system_score_gemma":0.00684224,"threshold_uncertainty_score":0.9997397},"labels":[],"label_agreement":null},{"id":"W2898508276","doi":"10.1016/j.jtho.2018.08.120","title":"PC09.05 Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - SCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Etoposide; Small Cell Lung Carcinoma; Malignancy; Oncology; Small-cell carcinoma; Internal medicine; Lung cancer; Chemotherapy; Stage (stratigraphy); Large cell; Disease; Carcinoma; Cancer; Pathology; Adenocarcinoma","score_opus":0.06258033864574848,"score_gpt":0.43777284159043095,"score_spread":0.3751925029446825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898508276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9700143,0.00073026377,0.00006797731,0.018338159,0.0016318528,0.0006227726,0.000033169366,0.00008612765,0.008475431],"genre_scores_gemma":[0.9742608,0.00043340487,0.0022706287,0.0053845886,0.0019814323,0.000015616115,0.000009946805,0.000109926994,0.015533647],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952812,0.0006610602,0.0012162012,0.0005171439,0.0009875749,0.001336824],"domain_scores_gemma":[0.9959381,0.00055157533,0.00083508313,0.0006491329,0.0010562137,0.00096987834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059804524,0.00045569558,0.0013232031,0.00084680325,0.00023258329,0.000051687122,0.0006259964,0.00005156742,0.0017792549],"category_scores_gemma":[0.0009778802,0.0003173399,0.00036809623,0.0008343929,0.00045718838,0.00042485187,0.00031086055,0.0015171525,0.00019924564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05502362,0.0062295785,0.025236117,0.00070869824,0.0004441643,0.4719331,0.0004263542,0.000009148242,0.10425307,0.000044044144,0.28925097,0.04644115],"study_design_scores_gemma":[0.008144347,0.033857685,0.0067102774,0.0001888195,0.0005996568,0.11298896,0.00046694698,0.00020805107,0.14928053,0.00008349212,0.6870924,0.0003788271],"about_ca_topic_score_codex":0.000048603863,"about_ca_topic_score_gemma":0.00018888111,"teacher_disagreement_score":0.39784142,"about_ca_system_score_codex":0.0004307489,"about_ca_system_score_gemma":0.0011413997,"threshold_uncertainty_score":0.9999279},"labels":[],"label_agreement":null},{"id":"W2898521424","doi":"10.1016/j.jtho.2018.08.1191","title":"P2.03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; KRAS; Lung cancer; Turnaround time; Genotyping; Oncology; Clinical trial; Health care; Internal medicine; Clinical endpoint; Cancer; Family medicine; Genotype","score_opus":0.09558657217526481,"score_gpt":0.41345641907234,"score_spread":0.3178698468970752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898521424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99118143,0.0023230196,0.00073558994,0.0038744863,0.0013146346,0.00016262614,0.000009461771,0.0000012551516,0.00039749965],"genre_scores_gemma":[0.9926663,0.00038307716,0.0010976159,0.003470845,0.0023043524,0.000010585863,0.0000055445157,0.000014160884,0.000047540783],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875855,0.00024480926,0.00039200945,0.00017149886,0.0001383239,0.00029480725],"domain_scores_gemma":[0.9986877,0.0000872138,0.00036766354,0.00024641294,0.00048569497,0.00012535992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064779137,0.00012407392,0.00020485125,0.000093237104,0.00029870504,0.00010079472,0.00035725886,0.00016964976,0.000040093473],"category_scores_gemma":[0.00021885792,0.00008231032,0.00007470553,0.000175265,0.00023453284,0.00001672002,0.00008474397,0.0002628553,0.0000010259954],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003118742,0.00004556791,0.011536272,0.000015626543,0.00015445292,0.00009227345,0.003201326,0.0071401484,0.9345903,0.00015002015,0.01016325,0.032598905],"study_design_scores_gemma":[0.002005263,0.0025287883,0.014809523,0.00018315815,0.00039060312,0.0021280118,0.014487272,0.11820487,0.28707445,0.00036892272,0.5568375,0.0009816834],"about_ca_topic_score_codex":0.048419002,"about_ca_topic_score_gemma":0.6261937,"teacher_disagreement_score":0.64751583,"about_ca_system_score_codex":0.0012589929,"about_ca_system_score_gemma":0.002780514,"threshold_uncertainty_score":0.95791763},"labels":[],"label_agreement":null},{"id":"W2898524673","doi":"10.1016/j.jtho.2018.08.392","title":"MA09.10 Molecular Profiling and PD-L1 Status in 900 Cases of Surgically Resected Non-Small Cell Lung Cancer with Clinical and Pathological Correlation","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; KRAS; Lung cancer; Adenocarcinoma; Oncology; Internal medicine; Stage (stratigraphy); Cancer; Pathological; Gene mutation; Pathology; Mutation; Gene; Colorectal cancer; Biology","score_opus":0.029476280995328286,"score_gpt":0.43072214414915144,"score_spread":0.40124586315382316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898524673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957545,0.00240195,0.00014082156,0.00066399755,0.00015031395,0.0003305021,0.0000067666942,0.0000039626093,0.0005472014],"genre_scores_gemma":[0.991452,0.0017320018,0.006446422,0.00013534707,0.00015071596,0.000012327413,0.000003217983,0.000011451587,0.000056566176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99852186,0.0002583962,0.0006416648,0.000203236,0.00016951226,0.00020533275],"domain_scores_gemma":[0.998388,0.0004584631,0.00049302075,0.00010399473,0.0003753078,0.0001812298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007073141,0.000121769466,0.0006363489,0.00013117149,0.000028397651,0.000007894104,0.000039926235,0.00019814828,0.00006662677],"category_scores_gemma":[0.0001782596,0.00007664159,0.000058838115,0.00014281909,0.00026814357,0.000048979135,0.0000389625,0.00033682006,5.4777865e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008090297,0.00069267844,0.9721404,0.00016259974,0.000114865215,0.0037194355,0.00023886509,0.000033912525,0.001158361,0.000007451353,0.00013322096,0.0135079175],"study_design_scores_gemma":[0.005208511,0.015749099,0.96982914,0.0006913222,0.0007504217,0.0014686885,0.0002076952,0.0008423271,0.004572045,0.000033149518,0.00053308986,0.000114524024],"about_ca_topic_score_codex":0.000073483396,"about_ca_topic_score_gemma":0.0002127015,"teacher_disagreement_score":0.015056421,"about_ca_system_score_codex":0.00019872519,"about_ca_system_score_gemma":0.00053741375,"threshold_uncertainty_score":0.31253535},"labels":[],"label_agreement":null},{"id":"W2898528000","doi":"10.1016/j.jtho.2018.08.635","title":"P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Regimen; Internal medicine; Oncology; Adverse effect; Cohort; Expanded access; Lung cancer; Clinical endpoint; Cancer; Clinical trial; Immunotherapy","score_opus":0.028992896876272097,"score_gpt":0.39115500225825217,"score_spread":0.36216210538198007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898528000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680336,0.008111694,0.003587654,0.015108696,0.0024334153,0.0014968337,0.00009042072,0.000021737342,0.0011159185],"genre_scores_gemma":[0.99118125,0.0018829847,0.0049571665,0.0005302792,0.000833851,0.000026337526,0.000009624728,0.000035453355,0.0005430356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978627,0.00010539885,0.0012273788,0.00018751105,0.00030660833,0.000310407],"domain_scores_gemma":[0.99682283,0.0006189356,0.001469326,0.000417094,0.00056572934,0.00010605437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083181943,0.00023284924,0.0010651614,0.0001915338,0.0001344433,0.0000052068167,0.00024345421,0.0002047847,0.00029544535],"category_scores_gemma":[0.00010797122,0.0001389203,0.00060586195,0.00026169635,0.00045465652,0.0000786888,0.000022684146,0.00016208396,0.000003352025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27234322,0.0011730316,0.0003662223,0.00025612258,0.0013417458,0.000045807195,0.00093329337,0.00012562507,0.04489001,0.000015046702,0.0014539568,0.6770559],"study_design_scores_gemma":[0.05512088,0.06973945,0.013708851,0.0009044407,0.002278932,0.00057235657,0.0007750449,0.0025229088,0.25794816,0.00017203897,0.59594655,0.00031039494],"about_ca_topic_score_codex":0.000061307954,"about_ca_topic_score_gemma":0.00025363825,"teacher_disagreement_score":0.67674553,"about_ca_system_score_codex":0.00096672465,"about_ca_system_score_gemma":0.0011251073,"threshold_uncertainty_score":0.56650054},"labels":[],"label_agreement":null},{"id":"W2898540510","doi":"10.1016/j.jtho.2018.08.606","title":"P1.01-50 Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Lung cancer; Gastroenterology; Pneumonitis; Adverse effect; Cancer; Lung; Immunotherapy","score_opus":0.019155735096526506,"score_gpt":0.39141899903739846,"score_spread":0.37226326394087195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898540510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563617,0.00075190485,0.000078196405,0.0004137537,0.00053311215,0.00025654462,0.000006722259,0.0000046867685,0.0023188896],"genre_scores_gemma":[0.9945605,0.00023650887,0.004082203,0.00032064217,0.00017345321,0.000009416103,0.0000016336772,0.00001853082,0.0005971537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983909,0.00014324374,0.00071911665,0.00015073919,0.00034091313,0.0002550727],"domain_scores_gemma":[0.9984565,0.00009177838,0.00084149314,0.00018493719,0.00031834497,0.00010697211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004643602,0.00014163002,0.0006281276,0.00036676574,0.00003527799,0.0000063383864,0.0001695251,0.00006751503,0.0005541911],"category_scores_gemma":[0.000023823924,0.00009876192,0.00010806549,0.00044230284,0.00029246704,0.00013467381,0.000027153344,0.0002754901,0.000001752827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08435602,0.0021451323,0.79140055,0.00033415185,0.00051146036,0.0002058423,0.0071242563,0.000011619969,0.016416337,0.000004841076,0.0029518595,0.094537936],"study_design_scores_gemma":[0.012107074,0.010925457,0.940787,0.0011012221,0.0006153795,0.00009946725,0.0013394442,0.00008445668,0.0175337,0.000016169522,0.015127061,0.0002635244],"about_ca_topic_score_codex":0.00061959465,"about_ca_topic_score_gemma":0.002025361,"teacher_disagreement_score":0.1493865,"about_ca_system_score_codex":0.00056301145,"about_ca_system_score_gemma":0.0007517738,"threshold_uncertainty_score":0.60680044},"labels":[],"label_agreement":null},{"id":"W2898540761","doi":"10.1016/j.jtho.2018.08.1698","title":"P3.03-21 CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage Non-Small Cell Lung Cancer Patients","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; CXCR4; Stage (stratigraphy); Oncology; Internal medicine; Tissue microarray; Immunohistochemistry; Proportional hazards model; Cancer; Survival analysis; Pathology; Receptor; Biology","score_opus":0.020166396533744767,"score_gpt":0.41012878725678936,"score_spread":0.3899623907230446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898540761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955427,0.0002044568,0.000064742424,0.00068522687,0.0008421886,0.0003666734,0.00007436864,0.0000071852414,0.0022124348],"genre_scores_gemma":[0.99541664,0.000042481344,0.00085586554,0.0006559177,0.00023750047,0.000026599297,0.000009129589,0.000024778603,0.0027311116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998418,0.0001408812,0.0005744738,0.00020662784,0.00034881287,0.00031124355],"domain_scores_gemma":[0.99825287,0.00010200255,0.00071071554,0.00014386383,0.0006077835,0.00018275552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031796022,0.00018020147,0.0005547168,0.00020119292,0.00005932182,0.000018287585,0.00011700938,0.00017395396,0.00036922554],"category_scores_gemma":[0.00007376728,0.00012035249,0.00009503152,0.00024328046,0.00007494503,0.00017908507,0.000042108284,0.00040543778,0.0000126451905],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028980728,0.0010384802,0.98690134,0.00007603272,0.00017592982,0.0002525088,0.0028034095,0.0000049962223,0.00032835614,4.78819e-7,0.00096010364,0.004560309],"study_design_scores_gemma":[0.0048081344,0.0052919583,0.98359126,0.0010187489,0.000615429,0.000013336848,0.00021675011,0.00009506757,0.0015818716,0.000008386995,0.0025918642,0.00016719468],"about_ca_topic_score_codex":0.00028534964,"about_ca_topic_score_gemma":0.00048787412,"teacher_disagreement_score":0.0043931147,"about_ca_system_score_codex":0.0010942611,"about_ca_system_score_gemma":0.00071746565,"threshold_uncertainty_score":0.4907832},"labels":[],"label_agreement":null},{"id":"W2898544736","doi":"10.1016/j.jtho.2018.08.1298","title":"P2.09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pathology; Medicine; Stromal cell; Infiltration (HVAC); Immune system; Cell; Lung; Carcinoma; Biology; Immunology; Internal medicine","score_opus":0.017575113156483683,"score_gpt":0.3574076070987257,"score_spread":0.339832493942242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898544736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950468,0.0007494093,0.0000976936,0.001052754,0.0009940796,0.00024173423,0.000010765338,0.000013630474,0.0017931531],"genre_scores_gemma":[0.99782085,0.00007649038,0.00019161837,0.0005871997,0.00048277396,0.00000425011,0.0000074700883,0.00002392637,0.00080543454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99801344,0.00028575165,0.0009278026,0.00015358502,0.00029479334,0.00032465442],"domain_scores_gemma":[0.99835527,0.0001392634,0.0009198792,0.00019254071,0.00028294636,0.00011010117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012143429,0.00016239611,0.00057360064,0.00035182477,0.00006445909,0.000022379149,0.00016541484,0.00020602002,0.0004383077],"category_scores_gemma":[0.00011443837,0.0001364525,0.00020004444,0.00031457967,0.00011134088,0.00017730486,0.000028936622,0.00053202687,0.000013001259],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01802822,0.0012355722,0.78167343,0.0001620643,0.00018387796,0.0016832572,0.0038937202,0.000004725227,0.16816252,0.0000038399644,0.0014107383,0.023558035],"study_design_scores_gemma":[0.0045582782,0.0073245103,0.9472375,0.00017555458,0.0001531535,0.00046199557,0.0007245551,0.00013698553,0.034715824,0.000016140175,0.004339644,0.00015586302],"about_ca_topic_score_codex":0.00067043095,"about_ca_topic_score_gemma":0.00054734683,"teacher_disagreement_score":0.16556408,"about_ca_system_score_codex":0.00096861576,"about_ca_system_score_gemma":0.00059136085,"threshold_uncertainty_score":0.5564371},"labels":[],"label_agreement":null},{"id":"W2898547276","doi":"10.1016/j.jtho.2018.08.564","title":"P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Pemetrexed; Lung cancer; Adenocarcinoma; Internal medicine; Chemotherapy; Progressive disease; Oncology; Docetaxel; Surgery; Bone metastasis; Cancer; Gastroenterology; Metastasis; Immunotherapy; Cisplatin","score_opus":0.01899642676788839,"score_gpt":0.3821546776044433,"score_spread":0.36315825083655495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898547276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99288684,0.0014667335,0.00005720382,0.0045126425,0.00057431794,0.0002786751,0.00004484706,0.000008829042,0.00016989504],"genre_scores_gemma":[0.9970655,0.0002526273,0.00016247499,0.0013727319,0.0002668624,0.0000028952197,0.000011951603,0.000025531013,0.00083945267],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975844,0.0006685643,0.00090320024,0.00019306746,0.00035700112,0.00029377665],"domain_scores_gemma":[0.99793005,0.00035551842,0.0007975397,0.00025937657,0.000367392,0.0002901439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095057837,0.00018834742,0.00072530576,0.00046240367,0.0000394837,0.0000093144545,0.00019614691,0.00019236653,0.00046192718],"category_scores_gemma":[0.00049995363,0.00014528629,0.00023450561,0.0004053393,0.00024718366,0.00012561768,0.00003998175,0.00030405688,0.000015705886],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46947503,0.0015074548,0.16780117,0.000057265697,0.00035546932,0.00056096434,0.0012532925,7.765968e-7,0.067669466,2.5949308e-7,0.03854319,0.25277564],"study_design_scores_gemma":[0.008409282,0.012326613,0.9110258,0.00058798847,0.00029164547,0.00020458139,0.00022797042,0.000018857389,0.008971236,0.000017377974,0.05775264,0.00016599912],"about_ca_topic_score_codex":0.00014366013,"about_ca_topic_score_gemma":0.000044717675,"teacher_disagreement_score":0.7432246,"about_ca_system_score_codex":0.00046189534,"about_ca_system_score_gemma":0.0011439521,"threshold_uncertainty_score":0.5924603},"labels":[],"label_agreement":null},{"id":"W2898549705","doi":"10.1016/j.jtho.2018.08.999","title":"P1.16-30 Quality of Lymphadenectomy During Lobectomy for Non-Small Cell Lung Cancer: VATS Versus Thoracotomy","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Thoracotomy; Lymphadenectomy; Dissection (medical); Lung cancer; Lymph node; VATS lobectomy; Surgery; Cardiothoracic surgery; Pneumonectomy; Oncology; Internal medicine","score_opus":0.039913626608585995,"score_gpt":0.45307295936771047,"score_spread":0.4131593327591245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898549705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893734,0.0026189059,0.0003561305,0.0016430597,0.0021999858,0.00079162023,0.000030130954,0.000016758342,0.0029700203],"genre_scores_gemma":[0.99198663,0.00071058766,0.0044922745,0.00019933516,0.0020535383,0.0000956744,0.0000043994946,0.000041734183,0.00041581364],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976275,0.00016666148,0.001093156,0.00030202488,0.00036454457,0.00044608803],"domain_scores_gemma":[0.9963518,0.0005995889,0.0014717298,0.0003373445,0.00095113885,0.00028840615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089909486,0.00026299935,0.0011978218,0.00024255847,0.000119436816,0.000015595546,0.00024256867,0.0002442422,0.00036270378],"category_scores_gemma":[0.00014051305,0.00020531005,0.00046333924,0.00023227527,0.00015594035,0.00012068765,0.00007279141,0.00023571619,0.000008636655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092018515,0.008439969,0.63797325,0.010423021,0.007418591,0.0008154168,0.0043001766,0.000094112336,0.057228304,0.000121093224,0.026548453,0.15461911],"study_design_scores_gemma":[0.04080294,0.017094621,0.31190327,0.0021065664,0.006715027,0.00037319856,0.0009976954,0.00017701996,0.5855847,0.0001583531,0.033426013,0.00066055794],"about_ca_topic_score_codex":0.00024206648,"about_ca_topic_score_gemma":0.0002577993,"teacher_disagreement_score":0.52835643,"about_ca_system_score_codex":0.0024643117,"about_ca_system_score_gemma":0.0014656208,"threshold_uncertainty_score":0.83723},"labels":[],"label_agreement":null},{"id":"W2898568148","doi":"10.1016/j.jtho.2018.08.844","title":"P1.12-09 The Effect of Site of First Chemotherapy on Small Cell Lung Cancer Patient Outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Cohort; Internal medicine; Neutropenia; Lung cancer; Febrile neutropenia; Chemotherapy; Retrospective cohort study; Cancer; Surgery","score_opus":0.02011478323117746,"score_gpt":0.43761888045381286,"score_spread":0.41750409722263543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898568148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831155,0.0017534283,0.00001885809,0.011010276,0.000638012,0.00050364825,0.0000115333105,0.0000049727314,0.0029437502],"genre_scores_gemma":[0.9974853,0.0007548263,0.00025364713,0.0006211579,0.0003870487,0.000016042048,3.793854e-7,0.000020028487,0.00046161472],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998272,0.0002809415,0.00057970703,0.00012785566,0.00047867405,0.00026079535],"domain_scores_gemma":[0.9974065,0.0010030402,0.00084001425,0.0002739568,0.00037618243,0.000100298865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009896059,0.00016064777,0.00089089986,0.00016901898,0.00007399275,0.0000041710096,0.0002000881,0.00010110088,0.00021216656],"category_scores_gemma":[0.00029936054,0.00007994799,0.00026681746,0.0001552576,0.0003400584,0.000030073892,0.0000752742,0.00040820325,0.0000043119794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016460648,0.00060389086,0.7910395,0.0012439402,0.0014524888,0.000106551015,0.0067940964,0.000051297604,0.009627599,0.0000045983593,0.024059549,0.14855583],"study_design_scores_gemma":[0.00792851,0.0818759,0.39307502,0.0016743735,0.0014643288,0.00014381738,0.0006447629,0.00022767334,0.41556376,0.000034206987,0.097112015,0.00025563315],"about_ca_topic_score_codex":0.000116477895,"about_ca_topic_score_gemma":0.0002720787,"teacher_disagreement_score":0.40593618,"about_ca_system_score_codex":0.0004699092,"about_ca_system_score_gemma":0.00027117188,"threshold_uncertainty_score":0.32601842},"labels":[],"label_agreement":null},{"id":"W2898572303","doi":"10.1016/j.jtho.2018.08.035","title":"ES05.04 Challenges and Solutions in Engaging with the Health Technology Assessment Process in Canada","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Context (archaeology); Health technology; Taxpayer; Quality of life (healthcare); Lung cancer; Clinical trial; Health care; Family medicine; Nursing; Economic growth; Oncology; Internal medicine; Political science","score_opus":0.3298842175219035,"score_gpt":0.5270325125436094,"score_spread":0.1971482950217059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898572303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6026533,0.0076406654,0.00027046519,0.38803783,0.00024967687,0.00021861076,0.0000065412005,0.000003523048,0.00091939885],"genre_scores_gemma":[0.9927393,0.0010871794,0.0016088105,0.0043401034,0.00017408757,0.000025827181,4.810493e-7,0.000010667613,0.000013537419],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99662066,0.00054826186,0.0021602793,0.00021360164,0.00007813901,0.0003790744],"domain_scores_gemma":[0.9964166,0.00078524306,0.002423707,0.00017769552,0.000099593366,0.00009710735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015813475,0.00010465674,0.0008370661,0.00054384896,0.00015223447,0.000013006902,0.00024210477,0.000091456764,0.000024409035],"category_scores_gemma":[0.0006797747,0.00009059315,0.000019514886,0.0002502672,0.00014334614,0.00020120494,0.00004195493,0.00053804286,0.0000058383453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048443992,0.0009146415,0.5822903,0.0018470044,0.00035371562,0.00013740662,0.05076033,0.0017521683,0.0000050190624,0.15442088,0.015208359,0.19182576],"study_design_scores_gemma":[0.0022854295,0.0032367806,0.68612564,0.000837332,0.000017593606,0.0007816431,0.17124116,0.0051324926,0.000006404814,0.037290234,0.09253375,0.00051151216],"about_ca_topic_score_codex":0.046686545,"about_ca_topic_score_gemma":0.88955235,"teacher_disagreement_score":0.8428658,"about_ca_system_score_codex":0.0035661466,"about_ca_system_score_gemma":0.0058599687,"threshold_uncertainty_score":0.9997759},"labels":[],"label_agreement":null},{"id":"W2898574100","doi":"10.1016/j.jtho.2018.08.1408","title":"P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McGill University Health Centre","funders":"","keywords":"Medicine; Osimertinib; Afatinib; Internal medicine; T790M; Oncology; Gefitinib; Lung cancer; Erlotinib; Radiation therapy; Cancer; Epidermal growth factor receptor","score_opus":0.01795045282709801,"score_gpt":0.43276516897080336,"score_spread":0.41481471614370535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898574100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837912,0.00036843747,0.00005639292,0.0011979933,0.0005330884,0.00078398216,0.000036393143,0.000007740079,0.013224772],"genre_scores_gemma":[0.9961206,0.00016927092,0.0006001978,0.00029702112,0.00033249633,0.000039312294,0.000018340326,0.000027283237,0.0023955123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976562,0.00022654365,0.001101138,0.00027395593,0.0003179431,0.0004241906],"domain_scores_gemma":[0.99741435,0.00012540261,0.0009208148,0.0003056939,0.0007791647,0.00045457142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068270235,0.00021586152,0.0011454944,0.0017889747,0.00009610444,0.0000140728025,0.00019906492,0.00014972338,0.00065695745],"category_scores_gemma":[0.000050013725,0.0001732803,0.00022220095,0.0018806104,0.00009440223,0.00009705677,0.000030967574,0.00040987038,0.000007432411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008365842,0.0013826961,0.9737945,0.000047960362,0.003913402,0.0006993246,0.004785279,0.0006485859,0.00030281063,8.922081e-7,0.0024556413,0.011132288],"study_design_scores_gemma":[0.003460314,0.003645259,0.97184324,0.00016592306,0.014297137,0.00004040187,0.002412797,0.00092050177,0.001050751,0.000008055858,0.001993766,0.00016186753],"about_ca_topic_score_codex":0.31617677,"about_ca_topic_score_gemma":0.80645525,"teacher_disagreement_score":0.49027848,"about_ca_system_score_codex":0.0022847196,"about_ca_system_score_gemma":0.0037270144,"threshold_uncertainty_score":0.7193224},"labels":[],"label_agreement":null},{"id":"W2898574631","doi":"10.1016/j.jtho.2018.08.1058","title":"P2.01-04 Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Context (archaeology); Oncology; Internal medicine; Lung cancer; Stage (stratigraphy); Epidermal growth factor receptor; Cancer; Erlotinib; Targeted therapy","score_opus":0.0922577030696552,"score_gpt":0.39549546918599315,"score_spread":0.30323776611633796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898574631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962873,0.0004243787,0.00029635523,0.0063426145,0.000113531874,0.0006428632,0.000008120256,0.0000054532006,0.0025379402],"genre_scores_gemma":[0.9820018,0.000016641643,0.016429337,0.0012095494,0.0001899477,0.000057906607,0.0000040904597,0.00001560008,0.0000751492],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863106,0.0002107501,0.0005748889,0.00014973969,0.00019291481,0.00024065224],"domain_scores_gemma":[0.9981261,0.00071730954,0.0004049661,0.00018695786,0.00045884398,0.00010582362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010009089,0.00012493257,0.0005184549,0.00020122378,0.000043426233,0.0000085974225,0.00018097868,0.000105299136,0.00009184328],"category_scores_gemma":[0.0010617891,0.00008228986,0.00014058503,0.0002846637,0.0000702354,0.000066903485,0.000033738943,0.00020594514,0.000023526565],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044051763,0.0010856292,0.12161691,0.00013723722,0.00018938389,0.00063274894,0.0031034446,0.0000038348776,0.07317773,0.00002845387,0.0032015198,0.79241794],"study_design_scores_gemma":[0.016299998,0.09493779,0.057661194,0.0070898603,0.0027449941,0.0039659864,0.005310434,0.002454145,0.5507293,0.0007688203,0.25713953,0.000897984],"about_ca_topic_score_codex":0.000018777002,"about_ca_topic_score_gemma":0.000012670068,"teacher_disagreement_score":0.79151994,"about_ca_system_score_codex":0.00015676474,"about_ca_system_score_gemma":0.00021226336,"threshold_uncertainty_score":0.3355683},"labels":[],"label_agreement":null},{"id":"W2898579231","doi":"10.1016/j.jtho.2018.08.1473","title":"P2.15-31 The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Population; Cancer registry; Cohort; Retrospective cohort study; Cancer; Adenocarcinoma; Chemotherapy; Disease; Internal medicine; Emergency medicine","score_opus":0.019911780845701187,"score_gpt":0.3097531969337202,"score_spread":0.28984141608801905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898579231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98548824,0.0035585559,0.00020877032,0.0016189484,0.000842585,0.00036386042,0.00006465283,7.7230715e-7,0.007853591],"genre_scores_gemma":[0.9983285,0.00043032432,0.00033648498,0.00026120734,0.0002906726,0.000019190815,0.0000012081126,0.000010303101,0.00032210228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983272,0.000051852025,0.0011231028,0.00016345042,0.000050059727,0.00028433843],"domain_scores_gemma":[0.99807626,0.00021221723,0.0012982015,0.00023566771,0.00010598803,0.00007165819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008872626,0.0001388493,0.0007515142,0.0002468197,0.00004280846,0.00000891701,0.0004021585,0.00011485107,0.00011407604],"category_scores_gemma":[0.000045485507,0.000101938465,0.00010956138,0.00021075385,0.000078325866,0.00012591547,0.00002585046,0.00022667603,0.0000057753264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056311145,0.00027485608,0.95941496,0.000023945066,0.00007396347,0.000011952308,0.0055605,0.0010362878,0.00007652787,0.0003540509,0.005663347,0.026946504],"study_design_scores_gemma":[0.00096978527,0.0018431151,0.90478957,0.00007601086,0.00003797756,0.0000049426108,0.0007256485,0.00007077372,0.00044209333,0.00060380495,0.09030614,0.00013014718],"about_ca_topic_score_codex":0.87932104,"about_ca_topic_score_gemma":0.9850056,"teacher_disagreement_score":0.10568454,"about_ca_system_score_codex":0.007600757,"about_ca_system_score_gemma":0.0021217985,"threshold_uncertainty_score":0.9962089},"labels":[],"label_agreement":null},{"id":"W2898590422","doi":"10.1016/j.jtho.2018.08.499","title":"MA21.10 Large-Scale Discovery of Novel Human Oncofetal Transcripts in Lung","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"","keywords":"microRNA; Transcriptome; Biology; Computational biology; Gene; Gene expression profiling; Gene expression; Cancer research; Genetics","score_opus":0.020498348711008536,"score_gpt":0.4042001945036297,"score_spread":0.3837018457926212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898590422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94861144,0.00077404856,0.04620928,0.00037879206,0.0005752642,0.00018438706,0.00003486479,0.0000030016786,0.0032289433],"genre_scores_gemma":[0.99527436,0.000093889335,0.0024524694,0.00014290008,0.0005956681,0.00000486923,0.000016384254,0.000030163239,0.0013892865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981931,0.00020017847,0.0006653233,0.00024596127,0.00031051785,0.0003849068],"domain_scores_gemma":[0.99883336,0.000020375306,0.00040030657,0.00028363522,0.00035158114,0.000110748195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010161122,0.00015801785,0.0004276417,0.000257047,0.0000605681,0.00001588412,0.00040643616,0.00037756446,0.00012302415],"category_scores_gemma":[0.00010008963,0.0001467905,0.00023828093,0.00022018176,0.00021619925,0.000019236813,0.00012838149,0.00040141915,0.0000035531766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014225965,0.00066461245,0.00011188685,0.000049075566,0.0001090831,0.000052925516,0.00023206795,0.000057439593,0.99276334,0.000060873306,0.001578248,0.0028978474],"study_design_scores_gemma":[0.0026461538,0.005467652,0.0012521786,0.00012614348,0.00009618578,0.00039300259,0.00042034424,0.00032172594,0.9467997,0.000111668945,0.042140584,0.00022466143],"about_ca_topic_score_codex":0.000020231662,"about_ca_topic_score_gemma":0.00057007023,"teacher_disagreement_score":0.046662953,"about_ca_system_score_codex":0.00015565459,"about_ca_system_score_gemma":0.000514553,"threshold_uncertainty_score":0.59859425},"labels":[],"label_agreement":null},{"id":"W2898598795","doi":"10.1016/j.jtho.2018.10.006","title":"Predicting Malignancy Risk of Screen-Detected Lung Nodules–Mean Diameter or Volume","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University of Calgary; University of Ottawa; Juravinski Hospital; Dalhousie University; Ottawa Hospital; University Health Network; Memorial University of Newfoundland; Foothills Medical Centre; Brock University; Institut universitaire de cardiologie et de pneumologie de Québec; Vancouver Coastal Health","funders":"Terry Fox Research Institute; AstraZeneca; Pfizer","keywords":"Medicine; Lung cancer screening; Lung cancer; Malignancy; Receiver operating characteristic; Radiology; Nodule (geology); National Lung Screening Trial; Nuclear medicine; Logistic regression; Lung; Internal medicine","score_opus":0.020021885164327714,"score_gpt":0.38604105697616486,"score_spread":0.36601917181183713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898598795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445873,0.00089508726,0.0007601813,0.0012497422,0.0009120107,0.00028519274,0.000030917687,0.000019822472,0.0013882994],"genre_scores_gemma":[0.9837731,0.00046758793,0.013529346,0.0002074975,0.0014015599,0.00000788438,0.0000024153342,0.000029972934,0.0005806362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807405,0.00024588025,0.000852013,0.00019758477,0.00034017887,0.00029026577],"domain_scores_gemma":[0.99724734,0.00028673452,0.0012793741,0.00029060798,0.00067935215,0.00021660123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000767913,0.00017397864,0.0007797194,0.00024519514,0.00007872759,0.00001002884,0.00015252129,0.0001851389,0.0007202113],"category_scores_gemma":[0.00045596863,0.0001113937,0.0002612853,0.00025404317,0.00017945949,0.000114083865,0.000058336387,0.0003563359,0.000021569647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005349864,0.0010316899,0.85878426,0.0002075703,0.0014485591,0.0006544028,0.000875917,0.000005911367,0.001411432,0.0000051221737,0.007206839,0.12301845],"study_design_scores_gemma":[0.00496053,0.028887965,0.9186019,0.0020976309,0.0050252904,0.0023082374,0.0005157726,0.00103412,0.025266953,0.00011646293,0.010935656,0.00024951313],"about_ca_topic_score_codex":0.00010068868,"about_ca_topic_score_gemma":0.00025983262,"teacher_disagreement_score":0.12276894,"about_ca_system_score_codex":0.00058059633,"about_ca_system_score_gemma":0.0004839119,"threshold_uncertainty_score":0.78858083},"labels":[],"label_agreement":null},{"id":"W2898605921","doi":"10.1016/j.jtho.2018.08.608","title":"P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Hôpital de l'Enfant-Jésus","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Pemetrexed; Internal medicine; Clinical endpoint; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Lung cancer; Cancer; Immunotherapy; Pembrolizumab; Progressive disease; Randomized controlled trial; Cisplatin; Ipilimumab","score_opus":0.018443874309196764,"score_gpt":0.3618502880888733,"score_spread":0.34340641377967657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898605921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956667,0.0003615521,0.00022763206,0.001013262,0.0006084116,0.0015066775,0.000008911527,0.000008155226,0.00059870305],"genre_scores_gemma":[0.99533135,0.00016289079,0.0032692805,0.0005954715,0.00033943512,0.000017582059,0.0000050413737,0.000037578633,0.00024135987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969845,0.0005125526,0.0014684054,0.0002213531,0.00050395523,0.0003092353],"domain_scores_gemma":[0.99685025,0.00090545614,0.0014991609,0.00023740661,0.00037220767,0.00013551363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022979414,0.00026041028,0.0019606678,0.0004396632,0.000057322406,0.000014815576,0.00015489395,0.00017751999,0.00036183093],"category_scores_gemma":[0.00046493116,0.00015375913,0.0002631853,0.00036831608,0.00062941486,0.00013892868,0.000023134335,0.00035140282,0.0000019961196],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89054614,0.0016143165,0.0010085745,0.00009249192,0.0005251532,0.000080522994,0.001298361,0.0000011954565,0.0013721149,0.0000016921886,0.00034157457,0.10311784],"study_design_scores_gemma":[0.9419646,0.04187044,0.01129323,0.00028332867,0.00072831096,0.00031497635,0.00041278766,0.00009768573,0.0015188314,0.000058901915,0.0012724428,0.0001844646],"about_ca_topic_score_codex":0.00008915628,"about_ca_topic_score_gemma":0.00015136444,"teacher_disagreement_score":0.10293338,"about_ca_system_score_codex":0.00033051523,"about_ca_system_score_gemma":0.0007925323,"threshold_uncertainty_score":0.62701154},"labels":[],"label_agreement":null},{"id":"W2898606672","doi":"10.1016/j.jtho.2018.08.1449","title":"P2.15-08 Impact and Feasibility of a Support Group for Women with Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Psychosocial; Hospital Anxiety and Depression Scale; Lung cancer; Quality of life (healthcare); Social support; Intervention (counseling); Physical therapy; Anxiety; Checklist; Depression (economics); Palliative care; Cancer; Performance status; Internal medicine; Nursing; Psychiatry; Psychotherapist","score_opus":0.03282263829382675,"score_gpt":0.4577156451253015,"score_spread":0.42489300683147474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898606672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99618304,0.0007235263,0.00049956416,0.0009946349,0.00045653497,0.0002978157,0.00003290984,0.000005062242,0.0008068891],"genre_scores_gemma":[0.99790114,0.00008967105,0.000684924,0.00032561985,0.00065788656,0.000017230785,0.0000015273642,0.000014751134,0.00030721928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989731,0.0000727969,0.00038195756,0.00013466914,0.00018978213,0.00024773928],"domain_scores_gemma":[0.99847126,0.00011480753,0.00046813372,0.00014465391,0.0005670666,0.00023405893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009393507,0.00011288844,0.00062752684,0.0001176546,0.00003598746,0.000006286779,0.00007814353,0.00011310105,0.0004888412],"category_scores_gemma":[0.00007083182,0.00007202408,0.000101901445,0.00013603567,0.00021282461,0.00009364672,0.000023866349,0.00019098994,4.4830207e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07106661,0.00064539775,0.7087633,0.0012249841,0.001009938,0.00015034365,0.010925067,0.000002456403,0.008656178,0.000022593671,0.008455092,0.18907802],"study_design_scores_gemma":[0.0077639236,0.08751717,0.84217364,0.0005961072,0.0014774562,0.003332069,0.005704238,0.00012706516,0.0034826237,0.0006499121,0.0468244,0.00035141944],"about_ca_topic_score_codex":0.00012919058,"about_ca_topic_score_gemma":0.0015171936,"teacher_disagreement_score":0.1887266,"about_ca_system_score_codex":0.0006619982,"about_ca_system_score_gemma":0.0009264421,"threshold_uncertainty_score":0.53524685},"labels":[],"label_agreement":null},{"id":"W2898609319","doi":"10.1016/j.jtho.2018.08.1331","title":"P2.10-02 Variations in Smoking Cessation Activities at Ontario’s Regional Cancer Centres","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Referral; Cancer; Internal medicine; Smoking cessation; Lung cancer screening; Lung; Oncology; Pathology; Family medicine","score_opus":0.05026874355298147,"score_gpt":0.4282711153251057,"score_spread":0.37800237177212426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898609319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887323,0.00027663948,0.00011285801,0.006678457,0.0010765828,0.00008621647,0.0000051237116,0.000006371642,0.0030254594],"genre_scores_gemma":[0.9941574,0.0001661416,0.0004466488,0.00050482806,0.0011385522,0.000005034658,0.0000045335023,0.000010258692,0.003566602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989826,0.00008211747,0.00039256216,0.00011054304,0.00024678063,0.00018539169],"domain_scores_gemma":[0.99901617,0.00012234626,0.0004783459,0.00009351749,0.00019532505,0.0000942971],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031697095,0.00009327247,0.0003379036,0.00025669098,0.00008313691,0.0000113567485,0.00007156012,0.00013631978,0.003557189],"category_scores_gemma":[0.000052069812,0.00007603447,0.00009286085,0.00013878885,0.000098313474,0.0001737159,0.000030318013,0.00031622115,0.0000057594734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053206338,0.0004945025,0.8324307,0.0000497495,0.0003104532,0.00017626828,0.013129345,0.000093481525,0.00315067,0.00017597713,0.039628305,0.10503988],"study_design_scores_gemma":[0.0009589271,0.00087215967,0.6869908,0.00018177184,0.00015698507,0.00028215145,0.0005419625,0.00006521027,0.001098563,0.0002442456,0.3085197,0.00008755483],"about_ca_topic_score_codex":0.009536679,"about_ca_topic_score_gemma":0.18413371,"teacher_disagreement_score":0.2688914,"about_ca_system_score_codex":0.0031974562,"about_ca_system_score_gemma":0.0011458033,"threshold_uncertainty_score":0.9973537},"labels":[],"label_agreement":null},{"id":"W2903702568","doi":"10.1016/j.jtho.2018.12.004","title":"Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; BC Cancer Foundation; Terry Fox Research Institute","keywords":"Medicine; Carcinogenesis; Lung; Computational biology; Cancer research; Bioinformatics; Oncology; Internal medicine; Cancer; Biology","score_opus":0.03143621481148893,"score_gpt":0.4931988677928231,"score_spread":0.4617626529813342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903702568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99020934,0.0012745125,0.00060427067,0.0013089561,0.00068260386,0.00022982707,0.000021570955,0.000009007288,0.0056599085],"genre_scores_gemma":[0.99460465,0.0002752446,0.0019077117,0.00032876618,0.00043547354,0.000007648847,0.000013276493,0.00001535992,0.0024118603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986536,0.00018536227,0.00062470563,0.00014585206,0.00022213453,0.00016835106],"domain_scores_gemma":[0.99729824,0.00022168389,0.0007269393,0.00014340514,0.00146834,0.0001414182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002646956,0.0001528091,0.0007068518,0.0003540843,0.00009009549,0.000013025728,0.00011872128,0.00010234483,0.0006806427],"category_scores_gemma":[0.00031451642,0.00009768775,0.0001961353,0.00033763406,0.0003546318,0.00015877468,0.000033697976,0.00019732067,0.00005016863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010995747,0.0032310772,0.05010859,0.00028026296,0.015055901,0.0023838591,0.048296742,0.00012289066,0.7868026,0.00037150166,0.036321655,0.0460292],"study_design_scores_gemma":[0.008791301,0.031672914,0.303245,0.0014210417,0.017417036,0.0038513814,0.036018707,0.00072796695,0.5597265,0.0010245367,0.03541936,0.0006842723],"about_ca_topic_score_codex":0.000121775105,"about_ca_topic_score_gemma":0.00012535826,"teacher_disagreement_score":0.25313643,"about_ca_system_score_codex":0.0006349985,"about_ca_system_score_gemma":0.0014454793,"threshold_uncertainty_score":0.74525607},"labels":[],"label_agreement":null},{"id":"W2903909248","doi":"10.1016/j.jtho.2018.12.005","title":"Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; Foghorn Therapeutics; Helsinn; Amgen; Pfizer; Japan Society for the Promotion of Science; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Immunohistochemistry; Lung cancer; Cancer; Oncology; Lung; Pathology; Intensive care medicine; Internal medicine","score_opus":0.08770703621495037,"score_gpt":0.5478132159775934,"score_spread":0.460106179762643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903909248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7892162,0.014179309,0.0012052424,0.18548067,0.0031174384,0.0003426931,0.000013234984,0.000011998765,0.0064331805],"genre_scores_gemma":[0.9614168,0.0028170638,0.025678296,0.003738372,0.0028135139,0.00008854413,0.000008138231,0.000020049145,0.003419265],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99907804,0.00009727125,0.0004455799,0.000105411695,0.00009752658,0.00017615485],"domain_scores_gemma":[0.9968759,0.0017167531,0.0008048494,0.00009882868,0.00041385935,0.000089806264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009317659,0.00007931736,0.00038066023,0.00011322553,0.00007871613,0.0000048978363,0.00008986154,0.00011774947,0.00018566893],"category_scores_gemma":[0.008038963,0.000061766936,0.00007151018,0.00010968722,0.00023628445,0.00007218781,0.00002602419,0.00040336483,0.0000054850093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002813963,0.0019293332,0.15897469,0.0007889517,0.00066933327,0.00079735497,0.004052086,0.0000027290641,0.03075404,0.000026322952,0.3565401,0.4426511],"study_design_scores_gemma":[0.005383268,0.009012932,0.029068341,0.003729585,0.0032840362,0.005617168,0.004842767,0.00044751188,0.009360027,0.0006413097,0.92821413,0.00039892085],"about_ca_topic_score_codex":0.00004057426,"about_ca_topic_score_gemma":0.000031668787,"teacher_disagreement_score":0.57167405,"about_ca_system_score_codex":0.00023785376,"about_ca_system_score_gemma":0.00046429204,"threshold_uncertainty_score":0.96239704},"labels":[{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"methods","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"grok","categories":[],"domain":null,"study_design":"not_applicable","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"opus","categories":[],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2912107322","doi":"10.1016/j.jtho.2019.02.001","title":"Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Company; Astellas Pharma Canada; Meso Scale Diagnostics; AbbVie; Takeda Pharmaceuticals North America; EMD Serono; Novartis; Bayer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer","keywords":"Osimertinib; Medicine; Durvalumab; T790M; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer; Gefitinib; Erlotinib; Nivolumab","score_opus":0.027435261544773444,"score_gpt":0.4405778436775608,"score_spread":0.4131425821327874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912107322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774047,0.0047394964,0.00010163118,0.0050151753,0.002750525,0.0010412165,0.0000065250456,0.00003055469,0.008910152],"genre_scores_gemma":[0.99444216,0.0004985453,0.0015469294,0.001117875,0.00045837773,0.000034711135,0.000026887175,0.000060672686,0.0018138533],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971683,0.0002976987,0.0012071885,0.00036886896,0.0004891412,0.00046881635],"domain_scores_gemma":[0.9976627,0.00038028555,0.0010470306,0.00038545058,0.00029080498,0.00023369632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084729097,0.00030738587,0.0011399084,0.00033319223,0.000089864596,0.000031036132,0.00019598025,0.0002680008,0.00026874684],"category_scores_gemma":[0.00016596458,0.00023849668,0.0005130347,0.0003550413,0.00007096183,0.00030822709,0.000035124594,0.0006147041,0.000039253653],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088563345,0.004952964,0.1575893,0.0001688629,0.009899967,0.030049326,0.022544036,0.00083990337,0.016518444,0.00011546683,0.0033256456,0.66543275],"study_design_scores_gemma":[0.18975453,0.056635782,0.45671234,0.003496486,0.0069236485,0.020326454,0.007931989,0.0010424474,0.019903064,0.000706819,0.23443536,0.0021310668],"about_ca_topic_score_codex":0.0002858063,"about_ca_topic_score_gemma":0.00005694566,"teacher_disagreement_score":0.66330165,"about_ca_system_score_codex":0.0019475485,"about_ca_system_score_gemma":0.0019174638,"threshold_uncertainty_score":0.97256124},"labels":[],"label_agreement":null},{"id":"W2912489644","doi":"10.1016/j.jtho.2019.01.031","title":"Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"Bristol-Myers Squibb Canada; University of Toronto; Princess Margaret Cancer Foundation; Pfizer Canada; AbbVie; Takeda Pharmaceutical Company; Novartis; Roche; Bayer","keywords":"Medicine; Term (time); Computed tomography; Cancer; Lung cancer; Interval (graph theory); Radiology; Oncology; Internal medicine","score_opus":0.014551019041672927,"score_gpt":0.3975678498367701,"score_spread":0.3830168307950972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912489644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541306,0.0012708617,0.0005520439,0.0013200584,0.00059520133,0.00075979397,0.000023530529,0.0000063428233,0.000059119393],"genre_scores_gemma":[0.99773884,0.00026518945,0.0015914866,0.00014021686,0.00014484198,0.00003606979,0.000005633107,0.000020837015,0.000056869783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860036,0.000109029075,0.0006431485,0.00017780722,0.00024248158,0.00022718303],"domain_scores_gemma":[0.9982462,0.00035053017,0.0008588053,0.0001817337,0.00024073292,0.00012202711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003275102,0.00017887069,0.0011698665,0.00033629857,0.00002067378,0.000007655245,0.00011110989,0.00010520339,0.00007635493],"category_scores_gemma":[0.000024677025,0.000104515006,0.00028844646,0.00015363954,0.000054076037,0.0000712427,0.00003659198,0.0002921197,3.5696232e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006027763,0.001053467,0.95048046,0.00048031277,0.001417177,0.00022293998,0.00029357275,0.00024183947,0.00010206675,0.000003964395,0.0002114835,0.03946497],"study_design_scores_gemma":[0.005452131,0.004927758,0.9840689,0.002197796,0.0011524736,0.00011250386,0.00006678543,0.000469648,0.0014048296,0.000008764057,0.000041870415,0.00009658048],"about_ca_topic_score_codex":0.0000831923,"about_ca_topic_score_gemma":0.00056843745,"teacher_disagreement_score":0.03936839,"about_ca_system_score_codex":0.0005864684,"about_ca_system_score_gemma":0.0002141154,"threshold_uncertainty_score":0.42619982},"labels":[],"label_agreement":null},{"id":"W2912617737","doi":"10.1016/j.jtho.2019.01.015","title":"Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Natural Science Foundation of China","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Acquired resistance; Adenocarcinoma; Pharmacology; Cancer research; Cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Gefitinib","score_opus":0.020512832974411158,"score_gpt":0.4515014186261033,"score_spread":0.4309885856516922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912617737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98328584,0.0016577072,0.0003546058,0.010189513,0.0009454022,0.0005345458,0.00001281251,0.000020821073,0.0029987348],"genre_scores_gemma":[0.9927667,0.00027434665,0.0033576386,0.000809265,0.0002380269,0.000013378698,0.000029427898,0.000028010067,0.0024832494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985366,0.00015338449,0.0005602215,0.00021423229,0.00029438417,0.00024119121],"domain_scores_gemma":[0.99852675,0.00019773903,0.00042955016,0.0001970254,0.0004155813,0.00023335837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000516338,0.00016269136,0.0005490692,0.0004615401,0.00012103682,0.000040400577,0.000106172214,0.00013093051,0.0001686502],"category_scores_gemma":[0.00010894082,0.00013074762,0.00011686824,0.0003734398,0.000051027637,0.0002644777,0.000030403078,0.00029891054,0.00002601017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049770786,0.002001982,0.61681783,0.00025582116,0.0014483513,0.0008152307,0.009311835,0.00021063848,0.11880101,0.0013230147,0.0035277167,0.2405095],"study_design_scores_gemma":[0.007309364,0.005848635,0.9438875,0.0003297636,0.0007187916,0.0012681278,0.0012538695,0.0004746193,0.0050245374,0.00030096204,0.03335538,0.0002284752],"about_ca_topic_score_codex":0.000033153567,"about_ca_topic_score_gemma":0.0000052093214,"teacher_disagreement_score":0.32706967,"about_ca_system_score_codex":0.00046880072,"about_ca_system_score_gemma":0.00059816195,"threshold_uncertainty_score":0.5331733},"labels":[],"label_agreement":null},{"id":"W2913193115","doi":"10.1016/j.jtho.2016.08.147","title":"The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"National Cancer Institute; Mesothelioma Applied Research Foundation","keywords":"Medicine; Mesothelioma; Hazard ratio; AJCC staging system; Pathological; Radiology; Oncology; Internal medicine; Cancer; Pathology; Staging system; Confidence interval","score_opus":0.05406224664946664,"score_gpt":0.4219777781815204,"score_spread":0.36791553153205375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913193115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644149,0.0004486437,0.0010738882,0.0312667,0.0006103881,0.0019018556,0.00010850723,0.0000036449471,0.00017144717],"genre_scores_gemma":[0.9981946,0.000102021666,0.0008538574,0.0002760672,0.00027503146,0.000086637345,0.0000030312963,0.000013721226,0.00019505448],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983245,0.00032190123,0.0006974182,0.000107278705,0.000375718,0.00017316299],"domain_scores_gemma":[0.9973093,0.0012194865,0.0009973183,0.000262557,0.00017935521,0.000031961255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001511083,0.00010592255,0.00027489485,0.0001008744,0.00022035874,0.000009394132,0.00036022445,0.000071705945,0.000010776508],"category_scores_gemma":[0.00083048444,0.000034416036,0.00031884364,0.0002128733,0.00028441777,0.00012248669,0.000045211826,0.00012768888,4.1149428e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015032507,0.0023232282,0.2276125,0.0010824449,0.000581337,0.000008648546,0.003985262,0.000038825543,0.32412517,0.009335493,0.02874316,0.38713142],"study_design_scores_gemma":[0.0030865285,0.0028261046,0.88489383,0.0019900661,0.0010683187,0.00026117035,0.0057237265,0.0005689809,0.048185535,0.010726491,0.040492795,0.00017644359],"about_ca_topic_score_codex":0.0000064825954,"about_ca_topic_score_gemma":0.000019565185,"teacher_disagreement_score":0.65728134,"about_ca_system_score_codex":0.00020847701,"about_ca_system_score_gemma":0.00034171555,"threshold_uncertainty_score":0.16948436},"labels":[],"label_agreement":null},{"id":"W2917136425","doi":"10.1016/j.jtho.2018.12.019","title":"Lung Cancer Screening in Never-Smokers","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; National Lung Screening Trial; Cancer; Stage (stratigraphy); Mortality rate; Internal medicine; Lung; Randomized controlled trial; Oncology","score_opus":0.030152381696123675,"score_gpt":0.4410433809661517,"score_spread":0.41089099927002803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917136425","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022227244,0.009711077,0.000040295916,0.9617609,0.0033507464,0.0005022092,0.000020661259,0.000009750753,0.0023771203],"genre_scores_gemma":[0.019389782,0.004190368,0.0028368116,0.9551164,0.011994967,0.0000601111,0.000046624842,0.000111782894,0.0062531554],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997731,0.00021211048,0.00083641865,0.00028061433,0.0005028063,0.00043709326],"domain_scores_gemma":[0.9978942,0.00039093423,0.0010900589,0.0002829841,0.0002453103,0.00009646046],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00048967823,0.00030148306,0.0014797986,0.0005659197,0.000025584055,0.000017376798,0.0002111233,0.0009576226,0.00056907424],"category_scores_gemma":[0.00006238746,0.00022506109,0.00041669607,0.0002061487,0.000054898206,0.00014455842,0.000054877924,0.0029423248,0.000017607836],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006530291,0.00015545682,0.054580543,0.00059548183,0.00094601995,0.010145197,0.000121766345,0.000069120164,0.000010875797,7.4812147e-7,0.8889958,0.04372594],"study_design_scores_gemma":[0.0019251774,0.0012088638,0.015622561,0.0031704723,0.0017892296,0.0010515878,0.00004288077,0.000058138932,0.00009940867,0.000012564306,0.9748233,0.00019580337],"about_ca_topic_score_codex":0.0002598629,"about_ca_topic_score_gemma":0.000058111982,"teacher_disagreement_score":0.08582749,"about_ca_system_score_codex":0.002965705,"about_ca_system_score_gemma":0.0016510615,"threshold_uncertainty_score":0.99935794},"labels":[],"label_agreement":null},{"id":"W2920658753","doi":"10.1016/j.jtho.2019.03.002","title":"Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Merck Sharp and Dohme; Boehringer Ingelheim; Novartis Pharmaceuticals Corporation; Celgene; Roche; AbbVie; Merck; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ceritinib; Internal medicine; Gastroenterology; Tolerability; Confidence interval; Adverse effect; Anaplastic lymphoma kinase; Pleural effusion","score_opus":0.016746586295062347,"score_gpt":0.3646053398538381,"score_spread":0.3478587535587757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920658753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937608,0.00028436107,0.000012655345,0.0017096747,0.00043194293,0.002079474,0.00029801423,0.000011723383,0.0014113393],"genre_scores_gemma":[0.99729764,0.0000669312,0.0018845161,0.00019348618,0.00017146188,0.000013809431,0.00015559723,0.00003848928,0.00017804565],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975434,0.00040146586,0.00087652623,0.00035737627,0.00052708626,0.00029413338],"domain_scores_gemma":[0.9964439,0.0014865896,0.000987818,0.00036942158,0.00052731525,0.00018491059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044466608,0.00028291973,0.00095374294,0.00017704304,0.00009228419,0.000020249525,0.00017390687,0.00013603664,0.00007651107],"category_scores_gemma":[0.00026835728,0.00014882073,0.00007588794,0.00040838504,0.00016741994,0.00018199305,0.00006968768,0.0005119755,0.0000056506233],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74626786,0.012367333,0.12226704,0.00007781536,0.003356487,0.0003566248,0.010942483,0.000101910315,0.00077614613,0.000007656111,0.000553922,0.102924764],"study_design_scores_gemma":[0.100645915,0.06203966,0.8297837,0.00093634357,0.0015163758,0.00004488331,0.0028582576,0.000005643272,0.00021721797,0.0000014572885,0.0017869951,0.00016357155],"about_ca_topic_score_codex":0.00012019401,"about_ca_topic_score_gemma":0.00023737189,"teacher_disagreement_score":0.7075167,"about_ca_system_score_codex":0.0006485767,"about_ca_system_score_gemma":0.0009343367,"threshold_uncertainty_score":0.60687333},"labels":[],"label_agreement":null},{"id":"W2925139051","doi":"10.1016/j.jtho.2019.03.007","title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":491,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme; Genentech; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Roche; Novartis; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer; AbbVie; Merck","keywords":"Alectinib; Medicine; Lung cancer; Crizotinib; Oncology; Internal medicine; Cancer research","score_opus":0.017898352291574746,"score_gpt":0.4489390676521736,"score_spread":0.43104071536059885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925139051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941905,0.00061233697,0.00001043805,0.0018672638,0.00015193608,0.00198448,0.00016464149,0.000002114677,0.0010163045],"genre_scores_gemma":[0.9994185,0.00025705513,0.00006387488,0.00014357205,0.000039872128,0.0000072125317,0.00001840373,0.000009440504,0.000042089294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982459,0.00053530664,0.00059957866,0.00021549029,0.00021913675,0.00018457827],"domain_scores_gemma":[0.99801016,0.00067913317,0.00068009086,0.00042165894,0.00014668926,0.00006224732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085017533,0.00016745894,0.00057980313,0.00010102243,0.00006758477,0.000009902717,0.00028214694,0.00008271818,0.00005833247],"category_scores_gemma":[0.00011180607,0.00007306245,0.00006835082,0.00047482346,0.000089264264,0.00008248332,0.00012016394,0.00035980841,3.340352e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07940067,0.023536874,0.6442787,0.00016321633,0.003032545,0.00072330754,0.03783946,0.004763978,0.014546775,0.000038044738,0.00069111004,0.1909853],"study_design_scores_gemma":[0.030204805,0.007596022,0.9545509,0.0004934862,0.0013734747,0.00021669992,0.003645932,0.0013176049,0.00035268432,0.000010544515,0.00015154561,0.000086267144],"about_ca_topic_score_codex":0.00081482594,"about_ca_topic_score_gemma":0.0006822101,"teacher_disagreement_score":0.31027222,"about_ca_system_score_codex":0.00046709453,"about_ca_system_score_gemma":0.00072905986,"threshold_uncertainty_score":0.29794002},"labels":[],"label_agreement":null},{"id":"W2937947516","doi":"10.1016/j.jtho.2019.04.008","title":"Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 5p15.33 TERT-CLPTM1Ll Region","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genetic Associations and Epidemiology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"National Institute of Environmental Health Sciences; Helmholtz Zentrum München; Health Technology Assessment Programme; National Institutes of Health; Instituto de Salud Carlos III; Xunta de Galicia; Bundesamt für Strahlenschutz; Deutsche Krebshilfe; Associazione Italiana per la Ricerca sul Cancro; Sheffield Hospitals Charity; Ministero della Salute; U.S. Department of Health and Human Services; Deutscher Akademischer Austauschdienst; National Institute for Health and Care Research; Society of Memorial Sloan Kettering; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Bayer; Cancer Prevention and Research Institute of Texas; AbbVie; Roy Castle Lung Cancer Foundation; World Health Organization; Canada Research Chairs; Medtronic; Takeda Pharmaceutical Company; Canadian Cancer Society Research Institute; Roche; Deutsche Forschungsgemeinschaft; Merck; Princess Margaret Hospital Foundation; Bristol-Myers Squibb; AstraZeneca; Philips","keywords":"Medicine; Variation (astronomy); Descent (aeronautics); Lung cancer; Lung; Oncology; Cancer; Internal medicine","score_opus":0.013703968784547023,"score_gpt":0.3335071091634444,"score_spread":0.31980314037889734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937947516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630666,0.00067446096,0.0006950347,0.0014701072,0.00021245853,0.00020899976,0.000008660146,0.0000012897267,0.0004223211],"genre_scores_gemma":[0.99725026,0.00097097707,0.0008287329,0.0007088525,0.00011477971,0.000005235189,0.000006596363,0.000014707151,0.00009986557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997202,0.001589609,0.0006409483,0.00018420462,0.00014680214,0.00023643357],"domain_scores_gemma":[0.9982198,0.00013054868,0.0012174919,0.00020997952,0.00018345541,0.000038757407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018997132,0.00012468424,0.00036354866,0.00012588105,0.000028895065,0.0000064575843,0.00027194782,0.00020171002,0.00001747218],"category_scores_gemma":[0.0002974124,0.00008660825,0.00009364183,0.00020928276,0.00004925954,0.000008437869,0.00004420574,0.00030335697,0.0000016111894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039778446,0.00022806173,0.97736603,0.000016507254,0.00016184316,0.000033521857,0.001118104,0.0047015143,0.007950219,0.0000034222628,0.0013789873,0.0066439766],"study_design_scores_gemma":[0.0008788376,0.0010070613,0.99423134,0.00007443901,0.000109303415,0.000058642836,0.00026484148,0.0006736826,0.00026225374,0.00005448331,0.0022843336,0.00010079006],"about_ca_topic_score_codex":0.00018194309,"about_ca_topic_score_gemma":0.00041784538,"teacher_disagreement_score":0.016865272,"about_ca_system_score_codex":0.00018628742,"about_ca_system_score_gemma":0.00025120715,"threshold_uncertainty_score":0.35317817},"labels":[],"label_agreement":null},{"id":"W2938119283","doi":"10.1016/j.jtho.2019.04.005","title":"Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Foundation; Eisai; Genzyme; AstraZeneca","keywords":"Medicine; Chemoradiotherapy; Radiation therapy; Stage (stratigraphy); Internal medicine; Multivariate analysis; Oncology; Immunotherapy; Adjuvant; Surgery; Cohort; Cancer","score_opus":0.02221124423609675,"score_gpt":0.411231990173026,"score_spread":0.3890207459369292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2938119283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98577577,0.004033663,0.0000025160168,0.003908543,0.00019457229,0.0009105347,0.000024173642,0.0000023472348,0.005147888],"genre_scores_gemma":[0.99140936,0.007614152,0.00025117956,0.000089791865,0.00010061896,0.000036014615,0.0000037504842,0.000013228393,0.00048192873],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979172,0.00044015024,0.0009896973,0.00013644958,0.00033066186,0.00018587924],"domain_scores_gemma":[0.99732566,0.00068297854,0.0012604349,0.00051070447,0.00017121936,0.000048998376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075822184,0.0001819534,0.0011456469,0.00014601498,0.000024715542,0.0000039099573,0.00018694786,0.00008886286,0.00020952438],"category_scores_gemma":[0.000012303979,0.000080102756,0.00044241935,0.00025394763,0.00012374591,0.000048103437,0.000013336323,0.00016083698,0.0000021460933],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014773135,0.014580712,0.39964604,0.00010576801,0.0023517741,0.0001231239,0.012605487,0.00012138299,0.00992583,0.00088523823,0.00011250937,0.544769],"study_design_scores_gemma":[0.019104151,0.054694153,0.74710095,0.0006447366,0.0016709347,0.00016331603,0.0064143413,0.000062072235,0.12984571,0.00066293124,0.039473116,0.00016357204],"about_ca_topic_score_codex":0.003857637,"about_ca_topic_score_gemma":0.00096327387,"teacher_disagreement_score":0.54460543,"about_ca_system_score_codex":0.0013445171,"about_ca_system_score_gemma":0.00080123794,"threshold_uncertainty_score":0.5831619},"labels":[],"label_agreement":null},{"id":"W2939133296","doi":"10.1016/j.jtho.2019.03.023","title":"18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Cancer Society Research Institute; NIHR Maudsley Biomedical Research Centre; Manchester Biomedical Research Centre; European Organisation for Research and Treatment of Cancer; National Institute for Health and Care Research; Ministère des Affaires Sociales et de la Santé; Cancer Research UK; Cancer Research UK Manchester Centre; Elekta; University of Manchester; Engineering and Physical Sciences Research Council; National Cancer Research Institute; AstraZeneca; Cancer Research Institute","keywords":"Medicine; Nuclear medicine; Confidence interval; Hazard ratio; Positron emission tomography; Bone scintigraphy; Scintigraphy; Radiology; Internal medicine","score_opus":0.020019066259394966,"score_gpt":0.4464594834922874,"score_spread":0.42644041723289244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939133296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835664,0.0015589457,0.000011732441,0.0065365247,0.0011858657,0.0028010148,0.0000029811506,0.0000041434528,0.004332409],"genre_scores_gemma":[0.996747,0.0005735462,0.00016334592,0.00037465582,0.00019709089,0.000051130435,9.2102675e-7,0.000011072302,0.0018812311],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953395,0.0018832954,0.0015747377,0.00015763266,0.0007645274,0.00028028834],"domain_scores_gemma":[0.9942909,0.0032172112,0.0014797626,0.0003406184,0.00056167087,0.00010983048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007116244,0.0001581217,0.004812764,0.00087997323,0.000031985248,0.000008914631,0.00031078924,0.000029993353,0.00055366853],"category_scores_gemma":[0.004361599,0.000078147015,0.001742109,0.00095391826,0.0003197923,0.00007640583,0.00011248656,0.0006799981,0.000010715385],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.980459,0.0005122647,0.006822284,0.000067736095,0.008590573,0.0005373402,0.00022352592,0.00011513905,0.0008562742,0.000037263653,0.0006207864,0.0011578199],"study_design_scores_gemma":[0.9807165,0.00184831,0.004792031,0.00016621401,0.00837792,0.0003934262,0.00036570185,0.0012452923,0.0004742364,0.00010642716,0.00143626,0.00007765659],"about_ca_topic_score_codex":0.00006840318,"about_ca_topic_score_gemma":0.00010519426,"teacher_disagreement_score":0.013180624,"about_ca_system_score_codex":0.000554034,"about_ca_system_score_gemma":0.0012325568,"threshold_uncertainty_score":0.60622823},"labels":[],"label_agreement":null},{"id":"W2944196441","doi":"10.1016/j.jtho.2019.04.018","title":"Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre","funders":"","keywords":"Medicine; SABR volatility model; Radiosurgery; Radiation therapy; Ablative case; Lung; Dose fractionation; Lung cancer; Retrospective cohort study; Surgery; Internal medicine","score_opus":0.04364703103818911,"score_gpt":0.47370225624701656,"score_spread":0.43005522520882744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944196441","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017398188,0.9907269,0.00030629005,0.00020355573,0.00055720727,0.00806437,0.000050821793,0.000005431005,0.000068040776],"genre_scores_gemma":[0.00016669904,0.99874806,0.0005323208,0.000092274575,0.00011123396,0.00021925784,0.00001702819,0.000047393456,0.00006569936],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9957624,0.0016586006,0.0018213771,0.00025387527,0.00025468713,0.00024903615],"domain_scores_gemma":[0.99053216,0.0052541993,0.0034082038,0.00031760204,0.00034688957,0.0001409253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023275008,0.00037294312,0.008388218,0.0002244945,0.000035011224,0.000008889717,0.000146723,0.0002894856,0.0000199323],"category_scores_gemma":[0.00051832065,0.00021339137,0.0011461426,0.00018296362,0.00006557893,0.000080131766,0.000014736351,0.0003875613,0.0000013989852],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087554887,0.0003457239,0.00003855035,0.8391128,0.0058262357,0.000070594215,0.00006527476,2.987676e-7,8.0003855e-7,0.000021340578,0.00014257448,0.15350021],"study_design_scores_gemma":[0.0014956825,0.0033872053,0.000062632396,0.85586804,0.052509673,0.002817206,0.000021960837,0.0000033049012,0.000004748878,0.00000792571,0.08367529,0.00014634912],"about_ca_topic_score_codex":0.0000024525416,"about_ca_topic_score_gemma":8.5315605e-7,"teacher_disagreement_score":0.15335387,"about_ca_system_score_codex":0.0024455665,"about_ca_system_score_gemma":0.001409278,"threshold_uncertainty_score":0.8701847},"labels":[],"label_agreement":null},{"id":"W2944358149","doi":"10.1016/j.jtho.2019.04.024","title":"A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Alberta; Brock University; Alberta Health; University of Calgary","funders":"BC Cancer Agency; Brock University; Alberta Cancer Foundation; University of Calgary; Pancreatic Cancer Action Network","keywords":"Medicine; Smoking cessation; Lung cancer; Lung cancer screening; Randomized controlled trial; Oncology; Internal medicine; Pathology","score_opus":0.03224764644291921,"score_gpt":0.4494150117707793,"score_spread":0.4171673653278601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944358149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99573183,0.00025016256,0.00026074474,0.00030386442,0.00054786867,0.0025811323,6.860613e-7,0.000012937359,0.00031078316],"genre_scores_gemma":[0.99917066,0.000038768096,0.0004246994,0.000046599343,0.00008953753,0.00012624639,0.000003313032,0.000012965682,0.00008722392],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973196,0.0007923037,0.0012061414,0.0001197145,0.00041179388,0.00015047098],"domain_scores_gemma":[0.9974217,0.0004119482,0.001477722,0.000110246336,0.0005250373,0.000053372623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036802161,0.000120898105,0.0018763795,0.0005630375,0.000018925419,0.000012427492,0.00008774562,0.00015435193,0.00018989535],"category_scores_gemma":[0.0004402141,0.00007974086,0.00023177505,0.00037388538,0.00003860345,0.00012436364,0.00001650893,0.0005049247,1.4953638e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29846126,0.0015096696,0.61430097,0.00006534521,0.00049375225,0.00006413224,0.0022172367,0.00029946023,0.00074061716,0.0000035432606,0.000017139902,0.08182686],"study_design_scores_gemma":[0.70926815,0.0036482385,0.2692587,0.0010464469,0.003150273,0.00011881499,0.007003171,0.005831585,0.00044505074,0.000021211965,0.00009086388,0.00011748653],"about_ca_topic_score_codex":0.00026027864,"about_ca_topic_score_gemma":0.00006633655,"teacher_disagreement_score":0.4108069,"about_ca_system_score_codex":0.00034913965,"about_ca_system_score_gemma":0.00037704958,"threshold_uncertainty_score":0.32517377},"labels":[],"label_agreement":null},{"id":"W2944876049","doi":"10.1016/j.jtho.2019.04.029","title":"A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Institutes of Health; Ariad Pharmaceuticals; Roche; Bristol-Myers Squibb; Genentech; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Mesothelioma; Lung cancer; Oncology; Internal medicine; Cancer; General surgery; Pathology","score_opus":0.2070314905114486,"score_gpt":0.5384342974268073,"score_spread":0.33140280691535867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944876049","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025162455,0.9293469,0.0011102465,0.0050973445,0.00590897,0.025031647,0.00782508,0.00003454882,0.00048277818],"genre_scores_gemma":[0.37465832,0.60531235,0.0013255817,0.0002512602,0.0068755285,0.0072612073,0.0020371357,0.00021593251,0.0020626672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956372,0.0005773439,0.0013477416,0.0003340769,0.0018125813,0.00029106942],"domain_scores_gemma":[0.9930256,0.003017716,0.0025202213,0.0002048439,0.0011413358,0.00009030625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030892142,0.00030032665,0.0014659805,0.0003260889,0.00031977284,0.00005761649,0.0004072694,0.00024065583,0.000072369425],"category_scores_gemma":[0.00035293485,0.00015479993,0.00068311824,0.0002833947,0.00011415306,0.00011587539,0.000070770526,0.000421524,0.0000035203916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026919268,0.004106296,0.006934164,0.016007751,0.02491284,0.00007468288,0.0010976184,0.002727131,0.00017768839,0.00088035385,0.0063224174,0.9098398],"study_design_scores_gemma":[0.010543845,0.003180666,0.0062056044,0.012611612,0.020195775,0.00008306023,0.0018143184,0.0028615943,0.000091306014,0.000118674245,0.9419005,0.0003930425],"about_ca_topic_score_codex":0.00025638295,"about_ca_topic_score_gemma":0.000073894626,"teacher_disagreement_score":0.9355781,"about_ca_system_score_codex":0.008374838,"about_ca_system_score_gemma":0.0034984539,"threshold_uncertainty_score":0.99543184},"labels":[],"label_agreement":null},{"id":"W2945581577","doi":"10.1016/j.jtho.2019.02.010","title":"ALK-Positive Lung Adenocarcinoma Arising in an Adolescent Treated for Relapsed Neuroblastoma","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Congenital Diaphragmatic Hernia Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Adenocarcinoma; Neuroblastoma; Adenocarcinoma of the lung; Lung cancer; Lung; Radiation therapy; Oncology; Internal medicine; Cancer","score_opus":0.03255271896947862,"score_gpt":0.393931702345621,"score_spread":0.3613789833761424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945581577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5536916,0.0022477019,0.00025501705,0.43802294,0.0020979932,0.0023189862,0.000076143195,0.000035519162,0.00125408],"genre_scores_gemma":[0.52001834,0.00019213908,0.0043915696,0.4617014,0.009318361,0.0000796899,0.00020147789,0.00035223638,0.003744832],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961588,0.00070078706,0.0015235394,0.00045767345,0.0005081249,0.0006511189],"domain_scores_gemma":[0.9959559,0.0012137039,0.0014762674,0.0004127611,0.0007857436,0.00015565219],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0007856913,0.000502786,0.0022694764,0.0010120664,0.00006423436,0.000035823246,0.000316968,0.0011955092,0.000046352823],"category_scores_gemma":[0.00061036187,0.00042064505,0.00053714396,0.00027295633,0.00012766432,0.00017751039,0.00009690767,0.0034013921,0.000023660352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010746237,0.001081736,0.038936343,0.002917292,0.0014160806,0.026159294,0.0021250274,0.000018316778,0.002117351,0.0000017690919,0.8485722,0.065908365],"study_design_scores_gemma":[0.0147574125,0.036914892,0.43453696,0.010030384,0.010021841,0.01580994,0.0012626246,0.0021243123,0.0009993148,0.00019535064,0.4716315,0.0017154686],"about_ca_topic_score_codex":0.000015456073,"about_ca_topic_score_gemma":0.000053730888,"teacher_disagreement_score":0.39560062,"about_ca_system_score_codex":0.0015469126,"about_ca_system_score_gemma":0.0008638537,"threshold_uncertainty_score":0.9998245},"labels":[],"label_agreement":null},{"id":"W2945728263","doi":"10.1016/j.jtho.2019.03.001","title":"Improving Surveillance following Treatment for Lung Cancer","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Randomized controlled trial; Cancer; Surgery; Oncology; Internal medicine","score_opus":0.02793530420935066,"score_gpt":0.4339105668668324,"score_spread":0.40597526265748174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945728263","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022016468,0.021622093,0.0006187626,0.94080514,0.011861888,0.0021059671,0.0001582293,0.000027476797,0.00078400713],"genre_scores_gemma":[0.05237441,0.008293934,0.017059727,0.83016795,0.06156004,0.0011560076,0.000409277,0.000507406,0.028471237],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978028,0.00014165079,0.00081125216,0.0003679885,0.00037380852,0.0005024891],"domain_scores_gemma":[0.9969226,0.00086409575,0.0014130969,0.0003528564,0.00034202693,0.00010533635],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045363719,0.0004035617,0.0019064335,0.00026663195,0.000068584035,0.000029714018,0.00017267815,0.00079323386,0.000097356155],"category_scores_gemma":[0.0000958031,0.0002740106,0.0012497553,0.000098148164,0.000030217006,0.00007983882,0.000030489266,0.0008421738,0.0000056202507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009323024,0.00028019538,0.014983588,0.0012029693,0.0035737054,0.0027758644,0.00011805889,0.000025602494,0.000084938234,5.2019413e-7,0.83745056,0.13857166],"study_design_scores_gemma":[0.0035218468,0.005641752,0.0006249089,0.0010373169,0.0045186877,0.00051840296,0.000022235463,0.00014000884,0.0003415021,0.000008085009,0.9833744,0.00025084516],"about_ca_topic_score_codex":0.00015633459,"about_ca_topic_score_gemma":0.00007470663,"teacher_disagreement_score":0.14592382,"about_ca_system_score_codex":0.007322181,"about_ca_system_score_gemma":0.0024712796,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W2946323101","doi":"10.1016/j.jtho.2019.03.030","title":"The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health","keywords":"Medicine; Lung cancer; Mesothelioma; Malignancy; Cancer; Radiation therapy; Oncology; Internal medicine; Pathology","score_opus":0.2482894746662792,"score_gpt":0.5362825823555962,"score_spread":0.287993107689317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946323101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029635623,0.9588169,0.00015480015,0.0030164875,0.0019331423,0.0056925425,0.00073304406,0.000003765336,0.000013692113],"genre_scores_gemma":[0.028911678,0.9683669,0.00015015983,0.00006345864,0.001024199,0.001165191,0.00012190526,0.000031668988,0.00016484372],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970488,0.00043400886,0.0011249392,0.00021500202,0.0009893533,0.00018787848],"domain_scores_gemma":[0.98866564,0.008033155,0.0023939111,0.00023120917,0.0006360014,0.00004009701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017302079,0.00023567432,0.00089993817,0.00018595169,0.00032404298,0.00004492075,0.00038162252,0.00016065438,0.000019661251],"category_scores_gemma":[0.00026136386,0.00010047445,0.0003755015,0.00023143504,0.0001897389,0.00015923951,0.000055381963,0.00020769534,3.5359815e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035083282,0.00091141055,0.004279168,0.0004931465,0.0036155614,5.506276e-7,0.0010904049,0.0003461703,0.00008772031,0.00012851857,0.001148403,0.9843906],"study_design_scores_gemma":[0.0025194874,0.0021543799,0.031010805,0.0017071969,0.00203681,0.000010573499,0.00074142934,0.0011722462,0.00013703005,0.000103770086,0.9582723,0.0001339888],"about_ca_topic_score_codex":0.00044333213,"about_ca_topic_score_gemma":0.00016168845,"teacher_disagreement_score":0.9842566,"about_ca_system_score_codex":0.0014479258,"about_ca_system_score_gemma":0.00079040305,"threshold_uncertainty_score":0.40972292},"labels":[],"label_agreement":null},{"id":"W2946456966","doi":"10.1016/j.jtho.2019.05.010","title":"Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Astellas Pharma Global Development; Ipsen; Astellas Pharma; MedImmune; Daiichi-Sankyo; Celldex Therapeutics; Helsinn; University of Texas Southwestern Medical Center; Merck; Spectrum Pharmaceuticals; North Carolina GlaxoSmithKline Foundation; Novartis; Celgene; Pfizer; Biogen; GlaxoSmithKline; Roche; Takeda Pharmaceutical Company; AbbVie; Genentech; Aeglea BioTherapeutics; Biogen Idec; Merck Sharp and Dohme; Genzyme; Bayer Corporation; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Intuitive Surgical","keywords":"Medicine; Nivolumab; Clinical endpoint; Lung cancer; Quality of life (healthcare); Adverse effect; Internal medicine; Population; Incidence (geometry); Randomized controlled trial; Performance status; Cancer; Surgery; Immunotherapy; Nursing","score_opus":0.016731925908331845,"score_gpt":0.34291538502650565,"score_spread":0.3261834591181738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946456966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969937,0.0010347229,0.000008770741,0.00023789679,0.00018122251,0.0014700495,0.00002120641,0.000010532291,0.00004184887],"genre_scores_gemma":[0.99738103,0.000969771,0.0012063716,0.00025876108,0.00001806108,0.000011431107,0.000015685515,0.000042416472,0.000096485914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99712527,0.00023498657,0.0013997174,0.00031593477,0.00049050973,0.00043357484],"domain_scores_gemma":[0.99635506,0.00017743604,0.002586812,0.00021477646,0.00039963945,0.00026625805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060902553,0.0002702206,0.0012057045,0.00028376,0.00007542903,0.000013098996,0.00009665858,0.00015537256,0.00006576015],"category_scores_gemma":[0.00005504561,0.00016073867,0.00004256045,0.00044484404,0.00016039873,0.00022439004,0.00006095552,0.00047333929,3.056268e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19796896,0.0006052357,0.712371,0.0006905146,0.00041666764,0.000035637917,0.0034003095,0.00014933001,0.00034759514,4.077715e-8,0.000030141648,0.08398455],"study_design_scores_gemma":[0.04344217,0.025012914,0.9276953,0.0021621978,0.00017545608,0.000053436335,0.0008296131,0.00008779568,0.00016856128,2.2619327e-7,0.00015190482,0.00022044516],"about_ca_topic_score_codex":0.00062993844,"about_ca_topic_score_gemma":0.0005908724,"teacher_disagreement_score":0.21532425,"about_ca_system_score_codex":0.0006377441,"about_ca_system_score_gemma":0.0016964388,"threshold_uncertainty_score":0.65547323},"labels":[],"label_agreement":null},{"id":"W2947120713","doi":"10.1016/j.jtho.2019.05.031","title":"Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; Center for Cancer Research","keywords":"Medicine; Body mass index; Oncology; Lung cancer; Internal medicine; Lung","score_opus":0.016501875102166465,"score_gpt":0.3633890831132918,"score_spread":0.3468872080111254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947120713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970533,0.00032799988,0.000015472255,0.0015568578,0.00052809675,0.00022998305,0.00002442364,0.0000015091089,0.00026235715],"genre_scores_gemma":[0.9992155,0.00020305604,0.000049550097,0.00031013397,0.000095585616,0.0000036750098,0.0000030437807,0.000007883025,0.00011156408],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899054,0.00007763384,0.0003635241,0.00012304867,0.00032094622,0.00012430626],"domain_scores_gemma":[0.998957,0.000083405976,0.000549555,0.000106546795,0.00022843265,0.00007507559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031544777,0.000095628915,0.0005661025,0.00034350652,0.00001519406,0.0000097645325,0.000093384086,0.00008845679,0.00016357597],"category_scores_gemma":[0.000035743666,0.000056778124,0.00008241459,0.00024833615,0.00007701267,0.00010179376,0.000051182134,0.00027403276,1.4548537e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030442767,0.00012714734,0.98899484,0.00003290785,0.0012507034,0.000010754326,0.0002200384,0.00004445228,0.00032281806,0.000008653594,0.000062792744,0.005880618],"study_design_scores_gemma":[0.0025339187,0.0005131285,0.99347,0.00015037018,0.0013558151,0.0000102012555,0.000119760065,0.0011368853,0.00004285572,0.000009212998,0.0005977843,0.000060057744],"about_ca_topic_score_codex":0.00048768087,"about_ca_topic_score_gemma":0.0009600751,"teacher_disagreement_score":0.0058205603,"about_ca_system_score_codex":0.00023665257,"about_ca_system_score_gemma":0.00021245558,"threshold_uncertainty_score":0.23153447},"labels":[],"label_agreement":null},{"id":"W2949974400","doi":"10.1016/j.jtho.2019.06.011","title":"Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Center for Visual Science; University of Rochester; Roche; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Oncology; Internal medicine; Intensive care medicine; Radiation therapy; Disease","score_opus":0.060441839207503116,"score_gpt":0.5129046576498438,"score_spread":0.4524628184423407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949974400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013947259,0.992972,0.00031349942,0.00048720685,0.0022650296,0.0019398185,0.000011670436,0.000009161965,0.0006068763],"genre_scores_gemma":[0.0010223538,0.99504644,0.0021044717,0.000062849766,0.0008605985,0.00022717335,0.000012232503,0.000047403075,0.0006165009],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729526,0.0004845998,0.001329609,0.00035947695,0.00021366942,0.0003173847],"domain_scores_gemma":[0.9965351,0.0007723419,0.002096791,0.00021959696,0.00021695248,0.00015917665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012757112,0.00034109174,0.0031773103,0.0006508193,0.000047507194,0.00001821136,0.00012845421,0.0007386366,0.000028416953],"category_scores_gemma":[0.00015679502,0.00024039157,0.0006713263,0.00024259753,0.00007609345,0.00024514535,0.000045234683,0.00070367235,0.0000151058775],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012080297,0.00059490633,0.00021811096,0.013684568,0.0003797415,0.00013789885,0.00006899012,8.876449e-7,0.0000021478543,0.000007802851,0.00033680396,0.9833601],"study_design_scores_gemma":[0.0012562908,0.015126145,0.00040010814,0.015914498,0.0056996825,0.0020877102,0.0000458368,0.0000027557032,0.000016753862,0.00023457989,0.9590403,0.00017538019],"about_ca_topic_score_codex":0.0000100075,"about_ca_topic_score_gemma":0.00016063321,"teacher_disagreement_score":0.98318475,"about_ca_system_score_codex":0.0029489414,"about_ca_system_score_gemma":0.0015666666,"threshold_uncertainty_score":0.9802884},"labels":[],"label_agreement":null},{"id":"W2952070327","doi":"10.1016/j.jtho.2019.02.012","title":"Lung Cancer in Canada","year":2019,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; London Health Sciences Centre; Western University; Vancouver General Hospital; University of Calgary; Centre Hospitalier de l’Université de Montréal; University of British Columbia; BC Cancer Agency","funders":"Olympus; Celgene; Novartis; Eisai; Merck; Roche; Genzyme; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Health care; Cancer; Clinical trial; Medical care; Family medicine; Intensive care medicine; Nursing; Oncology; Economic growth; Pathology","score_opus":0.010302884206067347,"score_gpt":0.4169906022052275,"score_spread":0.40668771799916015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952070327","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017369814,0.012935701,0.0000011916582,0.00500831,0.96265054,0.00030638158,0.00010658862,0.0000026485952,0.0016188072],"genre_scores_gemma":[0.04081062,0.010524451,0.00014966461,0.0004818026,0.9457061,0.000036056128,0.000032278313,0.00005803592,0.0022009758],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978343,0.000120530254,0.0007711107,0.00020798903,0.00076359796,0.0003024213],"domain_scores_gemma":[0.9973238,0.00081527536,0.0009889096,0.00021979515,0.00046791733,0.00018427809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003958061,0.0002299001,0.0014182191,0.0002263989,0.00001551499,0.000008391783,0.00018544085,0.0005287281,0.0004670372],"category_scores_gemma":[0.00024038032,0.00016866454,0.00018461779,0.00013816492,0.000020626596,0.000048665162,0.000040831383,0.0014478982,0.0000050337453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001048298,0.0001838927,0.019250153,0.0005772422,0.0005567163,0.0027316262,0.000056701323,0.00006868454,0.0000035870544,6.541009e-7,0.945687,0.02983545],"study_design_scores_gemma":[0.0016562715,0.00087174185,0.004693526,0.0020333445,0.001222696,0.00009678819,0.000058416186,0.000022287155,0.000042612002,0.000005997843,0.98915875,0.00013754684],"about_ca_topic_score_codex":0.54942673,"about_ca_topic_score_gemma":0.9196247,"teacher_disagreement_score":0.37019795,"about_ca_system_score_codex":0.030405872,"about_ca_system_score_gemma":0.0579285,"threshold_uncertainty_score":0.97331625},"labels":[],"label_agreement":null},{"id":"W2952953974","doi":"10.1016/j.jtho.2019.06.010","title":"Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"Foundation Medicine; EMD Serono; Eisai; Daiichi-Sankyo; Pfizer; Incyte; Genentech; IFM Therapeutics; Horizon Pharma; Exelixis; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Roche; Celgene; Novartis; AbbVie; MedImmune; Merck; Boehringer Ingelheim; Amgen; PharmaMar; Daiichi Sankyo Europe; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Common Terminology Criteria for Adverse Events; Tolerability; Adverse effect; Internal medicine; Oncology; Cohort; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.023076036204060287,"score_gpt":0.4132323152498739,"score_spread":0.3901562790458136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952953974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764305,0.00027449525,0.00001908454,0.00060232065,0.0007166574,0.00036082766,0.0000024468857,0.0000031052664,0.00037802898],"genre_scores_gemma":[0.99894524,0.00015472018,0.00050919334,0.00016540881,0.000059467813,0.0000014699988,0.0000013181939,0.000011473134,0.00015170132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845994,0.00022974242,0.00073378853,0.00015943457,0.0002590976,0.00015797268],"domain_scores_gemma":[0.9985116,0.00024603042,0.0007348829,0.00019482101,0.00022229849,0.000090329166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010887347,0.000111147565,0.0008466617,0.00014699053,0.000012889817,0.000004502345,0.000095159565,0.00016143547,0.000101930316],"category_scores_gemma":[0.00009648885,0.000076660945,0.00015028399,0.00014562052,0.00015904849,0.00014755623,0.00004227351,0.00038591377,0.0000016524269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057948824,0.00072521437,0.5836111,0.00008254353,0.0001111456,0.000021159174,0.000078749865,7.890966e-7,0.0009154579,4.458217e-7,0.000017085327,0.3564875],"study_design_scores_gemma":[0.014810499,0.014788374,0.96889144,0.00040344594,0.00011059729,0.00008969372,0.000040031402,0.0000041661106,0.0004270647,0.00001318495,0.0003459521,0.00007552023],"about_ca_topic_score_codex":0.000010160491,"about_ca_topic_score_gemma":0.000074857875,"teacher_disagreement_score":0.3852804,"about_ca_system_score_codex":0.00018837508,"about_ca_system_score_gemma":0.00035919953,"threshold_uncertainty_score":0.31261426},"labels":[],"label_agreement":null},{"id":"W2953576895","doi":"10.1016/j.jtho.2019.06.015","title":"A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Science Foundation of Sri Lanka; Roche; AstraZeneca Canada; Novartis; Pfizer Canada; Merck; U.S. Department of Energy; American Lung Association; AstraZeneca; Eli Lilly and Company; National Institutes of Health; National Science Foundation","keywords":"Osimertinib; Medicine; Neratinib; Exon; Cancer research; Adenocarcinoma; Mutation; Lung cancer; Oncology; Internal medicine; Genetics; Gene; Cancer; Biology; Trastuzumab","score_opus":0.017619743583859447,"score_gpt":0.3968537430336336,"score_spread":0.37923399944977415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953576895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793308,0.0011303949,0.00033466695,0.016185652,0.0005059258,0.00061968,0.00003324047,0.000010279691,0.0018493937],"genre_scores_gemma":[0.98563784,0.00007080052,0.009441217,0.002431593,0.00027585737,0.000013464653,0.00001542002,0.000022981398,0.0020908103],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99848145,0.000112092865,0.00063422613,0.0002513547,0.00026452666,0.00025636045],"domain_scores_gemma":[0.99853355,0.0002907658,0.00046132368,0.00014957809,0.0003458236,0.00021897144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042362412,0.00017088295,0.0006000661,0.0003269204,0.000051353218,0.000022290576,0.0000674665,0.00015290378,0.000085569845],"category_scores_gemma":[0.00018987655,0.0001387998,0.000083018545,0.0002705873,0.00005119591,0.00019487087,0.000032690365,0.00021191326,0.000020070836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030111693,0.0032194771,0.31722268,0.0013692739,0.0023374616,0.005890148,0.082681924,0.0005481659,0.44238925,0.00038993184,0.021727161,0.092112824],"study_design_scores_gemma":[0.016690288,0.008592741,0.8930704,0.002156907,0.0021415784,0.0044629094,0.014166837,0.0017222218,0.04378631,0.00019880585,0.012338071,0.00067294564],"about_ca_topic_score_codex":0.000039786493,"about_ca_topic_score_gemma":0.00016080058,"teacher_disagreement_score":0.5758477,"about_ca_system_score_codex":0.000537653,"about_ca_system_score_gemma":0.00056572206,"threshold_uncertainty_score":0.56600916},"labels":[],"label_agreement":null},{"id":"W2954778487","doi":"10.1016/j.jtho.2019.06.020","title":"Pathologic Considerations and Standardization in Mesothelioma Clinical Trials","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Bayer Fund; Elekta; AbbVie; Merck; Bristol-Myers Squibb; Genentech; AstraZeneca; Boehringer Ingelheim; Foundation for the National Institutes of Health","keywords":"Medicine; Standardization; Mesothelioma; Clinical trial; Intensive care medicine; Oncology; Pathology; Medical physics; Internal medicine","score_opus":0.1051747790280859,"score_gpt":0.5374452091536488,"score_spread":0.4322704301255629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954778487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484175,0.0006897708,0.0001924622,0.002664052,0.00029715363,0.00019374199,0.000010873433,0.0000033842473,0.0011068196],"genre_scores_gemma":[0.9954838,0.00043334163,0.0029556702,0.0008794648,0.00012500503,0.0000015585146,0.000004311362,0.000004517937,0.00011233928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982191,0.0006687962,0.0008124668,0.0000863747,0.00014274461,0.000070535076],"domain_scores_gemma":[0.9984193,0.00096029177,0.00040975524,0.00006243975,0.000056506065,0.00009172496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031327705,0.000056214612,0.00053950434,0.00012719414,0.000017070226,0.0000070297006,0.000020037292,0.000103567414,0.00049740437],"category_scores_gemma":[0.0012784818,0.000038454913,0.0001040832,0.0000549595,0.00006812565,0.00007789148,0.0000126804325,0.00016785429,0.000017901642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003555001,0.0006899048,0.9293194,0.000047796817,0.00008499325,0.00062637526,0.00014833867,0.00012478585,0.0035064248,0.00031868345,0.001428405,0.0601499],"study_design_scores_gemma":[0.002039544,0.0026840272,0.9827604,0.00008475737,0.00021786842,0.0013261092,0.00024206871,0.00008925398,0.0002771317,0.0053453725,0.0048746304,0.000058810307],"about_ca_topic_score_codex":8.889137e-7,"about_ca_topic_score_gemma":0.0000023543491,"teacher_disagreement_score":0.06009109,"about_ca_system_score_codex":0.000079111145,"about_ca_system_score_gemma":0.00017575957,"threshold_uncertainty_score":0.5446229},"labels":[],"label_agreement":null},{"id":"W2966201555","doi":"10.1016/j.jtho.2019.07.023","title":"Gram-Negative Pneumonia Augments Non–Small Cell Lung Cancer Metastasis through Host Toll-like Receptor 4 Activation","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"TLR4; Metastasis; Lipopolysaccharide; Medicine; In vivo; Innate immune system; Toll-like receptor; Cancer research; Immunology; Immune system; Biology; Cancer; Internal medicine","score_opus":0.015332431938158336,"score_gpt":0.3449681084688333,"score_spread":0.32963567653067494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966201555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98972404,0.0013609647,0.0006072641,0.0017604745,0.0040898975,0.000476275,0.0000149357975,0.00001751364,0.0019486247],"genre_scores_gemma":[0.98990774,0.0008328232,0.0013423415,0.0005058862,0.00014939198,0.000026963025,0.000028863613,0.000030189298,0.0071758013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976261,0.0008184451,0.0008224817,0.00023680493,0.00009563978,0.00040048274],"domain_scores_gemma":[0.99747103,0.00042660005,0.0014314429,0.00024276174,0.000393685,0.00003446377],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080858,0.00025001355,0.0006997207,0.00024780942,0.00015623814,0.000023385051,0.00034433586,0.00045619943,0.0016300492],"category_scores_gemma":[0.00009972183,0.00020455343,0.00024295803,0.00023320041,0.000091380614,0.0005651511,0.00009051175,0.0007411747,0.0004653547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003217459,0.00026415507,0.0014529645,0.00008024673,0.00065528264,0.000009595568,0.002331762,0.000060584563,0.9638381,0.000019694042,0.0067446036,0.021325545],"study_design_scores_gemma":[0.0017300522,0.0013601521,0.0058238734,0.00018235046,0.00035209698,0.000106101426,0.0012882885,0.00001574983,0.86578643,0.000060355254,0.123052806,0.00024176162],"about_ca_topic_score_codex":0.000109336695,"about_ca_topic_score_gemma":0.000017003984,"teacher_disagreement_score":0.1163082,"about_ca_system_score_codex":0.0005569022,"about_ca_system_score_gemma":0.000560479,"threshold_uncertainty_score":0.9992826},"labels":[],"label_agreement":null},{"id":"W2969253025","doi":"10.1016/j.jtho.2019.04.023","title":"Nivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Fudan University; National Natural Science Foundation of China","keywords":"Medicine; Gastroenterology; Nivolumab; Primary sclerosing cholangitis; Internal medicine; Prednisone; Autoimmune hepatitis; Ursodeoxycholic acid; Hepatitis; Cancer; Immunotherapy","score_opus":0.030185527861836852,"score_gpt":0.3657268204259612,"score_spread":0.33554129256412435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969253025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88387215,0.001430784,0.00009127485,0.11068066,0.00197098,0.00044694982,0.000029539038,0.000023310498,0.001454347],"genre_scores_gemma":[0.60448736,0.00052552845,0.0044597466,0.37706664,0.00976671,0.000012538844,0.00039768152,0.00021370409,0.0030701028],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764735,0.00047299018,0.00075733906,0.0002384387,0.0005182726,0.000365604],"domain_scores_gemma":[0.9970327,0.00018861287,0.0015647842,0.0004813453,0.0006173294,0.000115234536],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004408188,0.0003262146,0.0011232329,0.0004148661,0.00012778,0.000080635225,0.00028479632,0.0009604511,0.00045463297],"category_scores_gemma":[0.00008115404,0.00023420856,0.0003487842,0.00015719865,0.000086584514,0.00046165328,0.000095820076,0.0039047857,0.00005305385],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005793481,0.00035470774,0.0027961535,0.0013148459,0.0009825261,0.0065882034,0.00051330036,0.0000025186796,0.07619002,2.752876e-7,0.6944437,0.21102025],"study_design_scores_gemma":[0.0047486415,0.019882014,0.112715945,0.0067483364,0.0034651363,0.014408167,0.00034721172,0.000031381598,0.005078144,0.000038357924,0.83184475,0.00069193897],"about_ca_topic_score_codex":0.00003862975,"about_ca_topic_score_gemma":0.0000024414835,"teacher_disagreement_score":0.27938482,"about_ca_system_score_codex":0.0006791185,"about_ca_system_score_gemma":0.0017652108,"threshold_uncertainty_score":0.99839324},"labels":[],"label_agreement":null},{"id":"W2970658276","doi":"10.1016/j.jtho.2019.08.012","title":"Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Genentech; National Institutes of Health; Bayer Fund; Douglas Pharmaceuticals; University of Chicago; Roche; Meso Scale Diagnostics; MedImmune; GlaxoSmithKline; Merck; Clovis Oncology; Varian Medical Systems; Inventiva Pharma; Intuitive Surgical; Pfizer; Pharmaceuticals Bayer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Aldeyra Therapeutics; Boehringer Ingelheim","keywords":"Medicine; Mesothelioma; Clinical trial; Pleural disease; Multidisciplinary approach; Malignancy; Lung cancer; Modalities; Medical physics; Radiology; Pathology; Internal medicine; Respiratory disease; Lung","score_opus":0.29459562485404983,"score_gpt":0.6039277397104187,"score_spread":0.30933211485636886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970658276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878879,0.001624773,0.001515513,0.0050072633,0.0013225392,0.0023558426,0.00019819298,0.0000074264344,0.000080522106],"genre_scores_gemma":[0.9964767,0.00036868348,0.0022005301,0.00018603886,0.0006104676,0.0000671785,0.000035319532,0.000018661332,0.000036427027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9874709,0.007096225,0.004057936,0.0002694756,0.00090506446,0.00020035896],"domain_scores_gemma":[0.9520384,0.041879408,0.0050156517,0.00021027504,0.0007683162,0.00008795203],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06433903,0.00015907202,0.001321266,0.00018798254,0.00023925964,0.000053413798,0.00017630728,0.00013604567,0.000102710015],"category_scores_gemma":[0.014930998,0.000090297945,0.00028611367,0.0001523514,0.0002082588,0.0001043058,0.00010266734,0.00045164075,8.373953e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0132765705,0.00077037537,0.9447371,0.00009200581,0.0024215158,0.000017171578,0.0019626839,0.006159501,0.005838722,0.00018114907,0.0014871126,0.023056135],"study_design_scores_gemma":[0.012607158,0.0038532976,0.91594946,0.0012411118,0.0047175307,0.0000615893,0.029354848,0.025579473,0.0023223225,0.0025321292,0.0015172594,0.0002637998],"about_ca_topic_score_codex":0.000074596945,"about_ca_topic_score_gemma":0.000040555413,"teacher_disagreement_score":0.04940803,"about_ca_system_score_codex":0.00043535713,"about_ca_system_score_gemma":0.00054723636,"threshold_uncertainty_score":0.99336666},"labels":[],"label_agreement":null},{"id":"W2971309637","doi":"10.1016/j.jtho.2019.08.009","title":"Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Genentech; National Institutes of Health; Sierra Oncology; Bayer Fund; Lung Cancer Research Foundation; Spectrum Pharmaceuticals; Exelixis; GlaxoSmithKline; Bayer; AstraZeneca; Rexanna's Foundation; Boehringer Ingelheim","keywords":"Medicine; Gemcitabine; Immune checkpoint; Immunotherapy; Immune system; Pharmacology; Immunogenic cell death; Blockade; Combination therapy; Chemotherapy; Oncology; Cancer research; Immunology; Internal medicine; Receptor","score_opus":0.006612623437811281,"score_gpt":0.2982258224659358,"score_spread":0.29161319902812455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971309637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765009,0.020035326,0.0000035486469,0.0014591368,0.0010890454,0.0008434535,0.000005103736,0.00000271953,0.000060708124],"genre_scores_gemma":[0.9987899,0.0006999334,0.000042330987,0.00002552577,0.000028904102,0.000025678846,0.000004267109,0.000013455525,0.00037001324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976402,0.0010870841,0.0007679317,0.00015348151,0.00008970581,0.0002616066],"domain_scores_gemma":[0.9977646,0.00071811624,0.0011521598,0.0002999775,0.000052797783,0.000012367862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011372683,0.00019453245,0.00065207307,0.00007239969,0.000107824766,0.000008525039,0.0003381396,0.00020312377,0.000038268725],"category_scores_gemma":[0.00007044194,0.0000885125,0.00016533413,0.00013614698,0.00048402598,0.000067239635,0.00012365321,0.00039379406,0.0000041825083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013198,0.0004585154,0.020755477,0.000060082624,0.0002501441,0.0000028516295,0.0011711969,0.00006864733,0.9016599,0.000006170284,0.000050514267,0.07419672],"study_design_scores_gemma":[0.0033733388,0.0055496525,0.044027317,0.00017374703,0.00019256408,0.00017373475,0.00034480583,0.0000284776,0.943373,0.00003923309,0.0026423412,0.000081764636],"about_ca_topic_score_codex":0.00008158611,"about_ca_topic_score_gemma":0.000020037905,"teacher_disagreement_score":0.074114956,"about_ca_system_score_codex":0.0002704675,"about_ca_system_score_gemma":0.00008306692,"threshold_uncertainty_score":0.3609435},"labels":[],"label_agreement":null},{"id":"W2972289446","doi":"10.1016/j.jtho.2019.08.2503","title":"Impact of Specimen Characteristics on PD-L1 Testing in Non–Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Université Laval; Montreal Heart Institute","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; PD-L1; Cancer; Biopsy; Immunohistochemistry; clone (Java method); Pathology; Immunotherapy","score_opus":0.04424345787969483,"score_gpt":0.4129967866273894,"score_spread":0.3687533287476946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972289446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950653,0.00015190018,0.000027883618,0.0013029712,0.00078890723,0.00040323543,0.000027333374,0.0000044267886,0.0022280624],"genre_scores_gemma":[0.99680173,0.00011949316,0.0023906117,0.00015474232,0.00029509712,0.00000428816,0.0000056261642,0.00001957623,0.00020883593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818605,0.00021105762,0.001036771,0.00013352095,0.00021858787,0.00021403868],"domain_scores_gemma":[0.9963882,0.0008162086,0.0020610038,0.00023408588,0.00043878326,0.000061742365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011681509,0.00014864022,0.0006065174,0.0002642293,0.000043473065,0.000009326267,0.00020201794,0.00013755153,0.0002435612],"category_scores_gemma":[0.00047562475,0.000101410515,0.00021388663,0.0005394545,0.000057325342,0.00008768825,0.000043081225,0.0004909787,0.0000022525421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036017997,0.0005212677,0.5964222,0.00023064244,0.00017944166,0.000014462262,0.0007411869,0.00031499425,0.29676807,7.6353666e-7,0.00056907476,0.10063614],"study_design_scores_gemma":[0.0018390126,0.0032721255,0.9635128,0.0016897816,0.0002584384,0.00014725969,0.00024460623,0.0009906703,0.027492944,0.000014862474,0.00042728227,0.00011022576],"about_ca_topic_score_codex":0.000312712,"about_ca_topic_score_gemma":0.000024696703,"teacher_disagreement_score":0.3670906,"about_ca_system_score_codex":0.00091785897,"about_ca_system_score_gemma":0.0010045042,"threshold_uncertainty_score":0.41354007},"labels":[],"label_agreement":null},{"id":"W2974545606","doi":"10.1016/j.jtho.2019.08.2506","title":"EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Vancouver General Hospital","funders":"Pharmaceuticals Bayer; Sandoz; Merck Sharp and Dohme; Genentech; Direction Générale de l’offre de Soins; National Institutes of Health; Siemens; AstraZeneca; Institut National Du Cancer; Institut National de la Santé et de la Recherche Médicale; LabEx DEvweCAN; Singapore Police Force; Douglas Pharmaceuticals; Merck; Centre International de Recherche sur le Cancer; Boehringer Ingelheim; University of Chicago; World Health Organization; Agence Nationale de la Recherche; CNIB; Roche; Novartis; European Network for Rare Adult Solid Cancers; AbbVie; Bristol-Myers Squibb; Eli Lilly and Company; National Cancer Institute; Bayer; Pfizer","keywords":"Medicine; Mesothelioma; Multidisciplinary approach; Medical physics; Radiology; Oncology; Pathology","score_opus":0.045656292995337834,"score_gpt":0.4155681789107167,"score_spread":0.3699118859153788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974545606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905937,0.00051008054,0.00042518665,0.0059313755,0.00024030438,0.0006203923,0.000025219399,0.0000075253806,0.0016462523],"genre_scores_gemma":[0.98470265,0.000022545539,0.014356297,0.00019335489,0.00016350618,0.000022523222,0.000032688113,0.000013755818,0.000492677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987481,0.00012514932,0.000558294,0.00013719487,0.00028412766,0.00014708721],"domain_scores_gemma":[0.99864405,0.00019784484,0.00076951715,0.0001669894,0.00014374075,0.00007785919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006070787,0.000111484456,0.00041123584,0.000104851846,0.000064555745,0.000004690028,0.00017095396,0.00010197579,0.00006786713],"category_scores_gemma":[0.00016647429,0.00006244828,0.0002209372,0.000107560285,0.00016501814,0.00010054372,0.000054037522,0.0001925687,0.000007465497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027107524,0.0062762653,0.5057742,0.0024062947,0.0009074927,0.000094805575,0.0036838085,0.001362466,0.19818816,0.0014159842,0.0070069055,0.24577612],"study_design_scores_gemma":[0.001481233,0.0035605265,0.97403204,0.00011601165,0.00061184267,0.000905467,0.0051763444,0.008167152,0.0022861564,0.00062308257,0.0029072713,0.00013284195],"about_ca_topic_score_codex":0.0000043709365,"about_ca_topic_score_gemma":6.5507624e-7,"teacher_disagreement_score":0.4682579,"about_ca_system_score_codex":0.00024435873,"about_ca_system_score_gemma":0.00026418583,"threshold_uncertainty_score":0.25465667},"labels":[],"label_agreement":null},{"id":"W2979633452","doi":"10.1016/j.jtho.2019.09.010","title":"Intraluminal Superior Vena Cava Invasion","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Central Venous Catheters and Hemodialysis","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Superior vena cava syndrome; Superior vena cava; Surgery; Malignancy; Radiology; Pneumothorax; Internal medicine","score_opus":0.0444015886786128,"score_gpt":0.4536723612766656,"score_spread":0.4092707725980528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979633452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868465,0.00028660873,0.00007604133,0.0038109766,0.0029720305,0.00025828058,0.0000045214074,0.000011726195,0.0057332977],"genre_scores_gemma":[0.9942402,0.00020477454,0.0013606278,0.0012316895,0.0009850569,0.000003943052,0.0000032063444,0.000019276507,0.0019511908],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771845,0.000603622,0.0008282402,0.00014121554,0.0002502147,0.0004582618],"domain_scores_gemma":[0.99820966,0.00038622433,0.0007160709,0.00020515142,0.00026813417,0.000214781],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001401984,0.0001232444,0.0006386136,0.00020065068,0.00020125182,0.000006983548,0.00026279298,0.00029780922,0.003054027],"category_scores_gemma":[0.0001287837,0.00009224923,0.00023798742,0.00015927506,0.00004890429,0.00015953352,0.00008370369,0.0010188189,0.0008207005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064203595,0.0015468579,0.2986194,0.0008593824,0.0004928327,0.0008245824,0.028085167,0.00008090437,0.10078048,0.0007206811,0.05984984,0.50171953],"study_design_scores_gemma":[0.0027652632,0.006371065,0.0928614,0.00075368746,0.0006155617,0.0007183291,0.011480231,0.00020198508,0.002110634,0.0016774349,0.8799656,0.0004787839],"about_ca_topic_score_codex":0.0000437003,"about_ca_topic_score_gemma":0.00006337515,"teacher_disagreement_score":0.8201158,"about_ca_system_score_codex":0.00056866,"about_ca_system_score_gemma":0.000881349,"threshold_uncertainty_score":0.99995726},"labels":[],"label_agreement":null},{"id":"W2980670340","doi":"10.1016/j.jtho.2019.10.006","title":"Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Ignyta; EMD Serono; Eisai; Natera; Ariad Pharmaceuticals; Genentech; Bristol-Myers Squibb; AstraZeneca; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Daiichi-Sankyo","keywords":"Ceritinib; Medicine; Nivolumab; Cohort; Internal medicine; Lung cancer; Gastroenterology; Cancer; Anaplastic lymphoma kinase; Oncology; Immunotherapy; Malignant pleural effusion","score_opus":0.021819599369042156,"score_gpt":0.45051293979249973,"score_spread":0.4286933404234576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980670340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941588,0.00029336556,0.000014544764,0.0002710179,0.00048915594,0.0025596605,0.00008230403,0.000006318377,0.0021248376],"genre_scores_gemma":[0.9941646,0.00005586172,0.004946329,0.00013312289,0.000069029935,0.00004487151,0.000036362067,0.000031836513,0.00051799836],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810517,0.00019759385,0.000844107,0.00027605667,0.00030914714,0.0002679146],"domain_scores_gemma":[0.99781805,0.00008527048,0.0010241186,0.00031661958,0.00056215003,0.00019380533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040609558,0.00018859451,0.00088103855,0.00023626641,0.000044231107,0.000017169994,0.0002749824,0.00009387586,0.000051591018],"category_scores_gemma":[0.00004150105,0.00013859732,0.000041104136,0.00024385499,0.000040543797,0.00033294727,0.000066431545,0.00033534144,0.000002810621],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26687175,0.115042366,0.26696122,0.00048861216,0.0012267529,0.00091061497,0.013330856,0.0006071832,0.0050672274,9.2334096e-7,0.000464154,0.32902834],"study_design_scores_gemma":[0.58298165,0.1716865,0.22789939,0.001408561,0.002563105,0.000051178824,0.007218678,0.0009351566,0.0018572471,0.000004132759,0.0030208852,0.0003735367],"about_ca_topic_score_codex":0.0004825233,"about_ca_topic_score_gemma":0.0008199815,"teacher_disagreement_score":0.32865483,"about_ca_system_score_codex":0.0008715061,"about_ca_system_score_gemma":0.0010967185,"threshold_uncertainty_score":0.56518346},"labels":[],"label_agreement":null},{"id":"W2981177537","doi":"10.1016/j.jtho.2019.10.005","title":"A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Merck Sharp and Dohme; Imclone; Astellas Pharma; Pharmacyclics; Roche España; Cilag; AstraZeneca España; Puma Biotechnology; Daiichi-Sankyo; Celldex Therapeutics; Taiho Pharmaceutical; Halozyme; Luitpold Pharmaceuticals; BioMarin Pharmaceutical; GlaxoSmithKline España; AbbVie; Novartis; Celgene; Alexion Pharmaceuticals; Gilead Sciences; Roche; Exelixis; Kyowa Hakko Kirin; Sanofi; Merck; GlaxoSmithKline; Genentech; Hospira; Boehringer Ingelheim; Amgen; Incyte; Pfizer; Asana Biosciences; AstraZeneca; Boehringer Ingelheim España; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Darbepoetin alfa; Placebo; Anemia; Chemotherapy; Epoetin alfa; Oncology; Internal medicine","score_opus":0.017970755654224173,"score_gpt":0.3831675726813219,"score_spread":0.3651968170270977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981177537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908902,0.0001573051,0.000034881705,0.00067274703,0.00023391118,0.007715505,0.0000041286157,0.000003954932,0.0002873793],"genre_scores_gemma":[0.9990596,0.00007167268,0.00059074874,0.00006572995,0.00005923999,0.000044428958,0.0000040660907,0.000019982628,0.000084539875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975726,0.00035562456,0.001273269,0.0002171076,0.0003581831,0.0002231943],"domain_scores_gemma":[0.9965816,0.0008601975,0.0017729447,0.00029727686,0.00038388756,0.00010408809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014721764,0.00023458873,0.0023502058,0.00017563872,0.000044861587,0.00000608449,0.00015193474,0.00015531626,0.00003943373],"category_scores_gemma":[0.00015069524,0.00012426301,0.0002703415,0.00017189357,0.00014535231,0.00007388199,0.00004142933,0.00036795548,3.80331e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89060384,0.008380844,0.0550271,0.00014645989,0.00061084604,0.000017952729,0.0015171161,0.000023040071,0.0010304599,0.000003333382,0.000005489168,0.04263353],"study_design_scores_gemma":[0.94432074,0.019294485,0.03204116,0.00047390314,0.0010736332,0.000060499482,0.0005871702,0.000020989413,0.0019914585,0.0000038404028,0.00002638089,0.000105729385],"about_ca_topic_score_codex":0.000019448307,"about_ca_topic_score_gemma":0.000046691854,"teacher_disagreement_score":0.053716924,"about_ca_system_score_codex":0.00020057727,"about_ca_system_score_gemma":0.00037713573,"threshold_uncertainty_score":0.50672984},"labels":[],"label_agreement":null},{"id":"W2981364823","doi":"10.1016/j.jtho.2019.08.1461","title":"P2.03-14 Developing an Immunogenic Model of Non Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"KRAS; Lung cancer; Carcinogenesis; Adenocarcinoma; Cancer research; Medicine; Immunohistochemistry; Oncogene; Lung; Cancer; Biology; Pathology; Cell cycle; Internal medicine; Colorectal cancer","score_opus":0.02428298648711889,"score_gpt":0.3670972754689424,"score_spread":0.3428142889818235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981364823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558676,0.007953442,0.0017736655,0.0003186652,0.0022893199,0.00018976635,0.000011494173,0.000010365812,0.0018664906],"genre_scores_gemma":[0.9897822,0.00069579756,0.0023290233,0.00029325593,0.000052418076,0.00000516824,0.000006258162,0.000026556461,0.006809324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979945,0.00048635947,0.00088846026,0.00018655621,0.000055640783,0.00038847214],"domain_scores_gemma":[0.9980965,0.00017876206,0.0009794696,0.0002840441,0.00042647167,0.000034731383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086262217,0.0002067415,0.0007741154,0.0003138616,0.00007127817,0.000009113659,0.00055694906,0.00045271395,0.0006418042],"category_scores_gemma":[0.000046660887,0.00016939105,0.00024401395,0.00012075026,0.00011520845,0.00018519578,0.00012278781,0.00067673484,0.0001125243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003970905,0.00023557803,0.001352607,0.00011476824,0.00031430644,0.000010863388,0.0012778365,0.0006396999,0.97515583,0.00004940079,0.0007862892,0.0160919],"study_design_scores_gemma":[0.0019006633,0.002766781,0.003183903,0.00029643008,0.00030145104,0.00051981624,0.0009379633,0.0010427188,0.9774354,0.000074341595,0.011216426,0.0003240756],"about_ca_topic_score_codex":0.000049720184,"about_ca_topic_score_gemma":0.000030584186,"teacher_disagreement_score":0.015767826,"about_ca_system_score_codex":0.00031255398,"about_ca_system_score_gemma":0.0013491475,"threshold_uncertainty_score":0.7027306},"labels":[],"label_agreement":null},{"id":"W2981369308","doi":"10.1016/j.jtho.2019.08.1192","title":"P1.14-41 The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Olaparib; Cancer research; PARP inhibitor; Clonogenic assay; Medicine; Cell culture; Molecular biology; Biology; Poly ADP ribose polymerase; Polymerase; Genetics; DNA","score_opus":0.011966453007747574,"score_gpt":0.3631862019969051,"score_spread":0.35121974898915753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981369308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624099,0.0064803963,0.00011432027,0.024666881,0.0039265356,0.0011300917,0.000018119224,0.000010527569,0.0012432401],"genre_scores_gemma":[0.99544775,0.00075534004,0.00017365259,0.0019348187,0.00079528976,0.00003772345,0.0000012634381,0.000028458518,0.00082567945],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970945,0.00083737687,0.00085972634,0.00022175064,0.0006802876,0.00030633505],"domain_scores_gemma":[0.99652296,0.00077878573,0.0015013482,0.00034700774,0.00074823736,0.000101651945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021990696,0.00021773319,0.00072486093,0.00012328023,0.00021120974,0.000026921736,0.00031241908,0.00021294477,0.00017354137],"category_scores_gemma":[0.00016078012,0.00010360367,0.00028511597,0.00041646574,0.0005473349,0.00013963529,0.00010878962,0.0009373591,0.000007646227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03577878,0.0030754937,0.06700038,0.0011190603,0.0026612694,0.00008536821,0.028568316,0.0022154138,0.6181594,0.003080099,0.17755435,0.06070203],"study_design_scores_gemma":[0.034193218,0.006388429,0.090568334,0.0024334136,0.002637158,0.0017976881,0.0043943315,0.0040986575,0.68408793,0.003001527,0.1656703,0.0007289891],"about_ca_topic_score_codex":0.00004195429,"about_ca_topic_score_gemma":0.000028759741,"teacher_disagreement_score":0.06592851,"about_ca_system_score_codex":0.0007366298,"about_ca_system_score_gemma":0.00085082976,"threshold_uncertainty_score":0.4224835},"labels":[],"label_agreement":null},{"id":"W2981420871","doi":"10.1016/j.jtho.2019.08.555","title":"MA07.11 Survival Outcomes Based on Gender of Advanced Nonsmall Cell Lung Cancer Patients Treated with Pembrolizumab or Nivolumab in Everyday Clinical Practice","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Nivolumab; Pembrolizumab; Internal medicine; Lung cancer; Cohort; Discontinuation; Oncology; Performance status; Cancer; Proportional hazards model; Immunotherapy","score_opus":0.031015507604992963,"score_gpt":0.43560339426023886,"score_spread":0.4045878866552459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981420871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941799,0.00027739131,0.000034799526,0.001136754,0.0010230284,0.0005773126,0.000014846981,0.000008025993,0.002747962],"genre_scores_gemma":[0.9950946,0.00024617178,0.0020946178,0.0013759529,0.00009063756,0.000009492524,0.000005881213,0.000034820994,0.0010478409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99707085,0.000585978,0.001240135,0.0002554964,0.0005480919,0.0002994632],"domain_scores_gemma":[0.99618435,0.0012398653,0.0015723575,0.00028549708,0.00058318296,0.0001347459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012107868,0.00022674132,0.0011812178,0.00031002238,0.00002408574,0.0000069961216,0.00017871376,0.00025667867,0.00048760851],"category_scores_gemma":[0.0002967846,0.00013898124,0.0002635067,0.000335536,0.00009384263,0.00018559977,0.000022174672,0.0005720076,0.0000045817237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19734856,0.0029854986,0.7815945,0.00018571754,0.0003228469,0.00025102083,0.00015732026,0.0002426326,0.0006510261,6.6446813e-7,0.00042081592,0.015839392],"study_design_scores_gemma":[0.03412576,0.017994616,0.933931,0.000494214,0.0006695919,0.00008163515,0.00043472744,0.00038733112,0.0009261981,9.3013773e-7,0.010739723,0.00021429246],"about_ca_topic_score_codex":0.00015939228,"about_ca_topic_score_gemma":0.0002817297,"teacher_disagreement_score":0.1632228,"about_ca_system_score_codex":0.00075247505,"about_ca_system_score_gemma":0.0016831814,"threshold_uncertainty_score":0.56674904},"labels":[],"label_agreement":null},{"id":"W2981423664","doi":"10.1016/j.jtho.2019.08.1673","title":"P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lung cancer; Durvalumab; Quality assurance; Oncology; Medical physics; Cancer; Internal medicine; Pathology; Immunotherapy; External quality assessment","score_opus":0.05809206462201901,"score_gpt":0.4309762567463521,"score_spread":0.3728841921243331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981423664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887676,0.0014616003,0.0012978701,0.0018782177,0.0036639147,0.0011490933,0.00015307077,0.00001524219,0.001613393],"genre_scores_gemma":[0.9818331,0.0001535971,0.012837381,0.0024534038,0.0010052737,0.00005929963,0.00001839792,0.00003890349,0.0016006513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982681,0.00015525994,0.00070592895,0.0002541411,0.00019645512,0.00042006143],"domain_scores_gemma":[0.99699277,0.0011290011,0.0008991805,0.00021486224,0.00062651705,0.00013769898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022603814,0.00020950729,0.0007503161,0.0001137834,0.000076095705,0.000020134026,0.0002207176,0.00028997083,0.00007716555],"category_scores_gemma":[0.00044752267,0.00015828222,0.00034209015,0.00022783244,0.000066027,0.000063770436,0.000029929073,0.00030677306,0.0000064767473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09193702,0.0010590926,0.46143928,0.0013039683,0.00061213993,0.0001850686,0.00041981906,0.00017190524,0.051277183,0.000007648641,0.04104705,0.35053983],"study_design_scores_gemma":[0.015703667,0.032478347,0.87311935,0.001333707,0.0009992761,0.0010927736,0.00043186077,0.0017203185,0.010977394,0.00017070034,0.06138662,0.00058599043],"about_ca_topic_score_codex":0.00013685225,"about_ca_topic_score_gemma":0.00022806496,"teacher_disagreement_score":0.41168007,"about_ca_system_score_codex":0.0009781242,"about_ca_system_score_gemma":0.0011459215,"threshold_uncertainty_score":0.64545614},"labels":[],"label_agreement":null},{"id":"W2981427216","doi":"10.1016/j.jtho.2019.08.734","title":"P1.01-19 Predictive and Prognostic Values of ctDNA Clearance in Osimertinib Treated Advanced Non-Small Cell Lung Cancer Cohort","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital","funders":"","keywords":"Osimertinib; Medicine; Lung cancer; T790M; Internal medicine; Oncology; Radiological weapon; Prospective cohort study; Mutation; Cancer; Adenocarcinoma; Surgery; Gene; Genetics","score_opus":0.006403033093456107,"score_gpt":0.3228738835610007,"score_spread":0.3164708504675446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981427216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908776,0.0071181213,0.00018800245,0.00013204814,0.00038794015,0.0004684472,0.00003556738,0.0000023001683,0.0007899481],"genre_scores_gemma":[0.9939002,0.0045688413,0.0009607247,0.00016015476,0.000160049,0.000019318457,0.000009086323,0.000022275857,0.00019934193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878174,0.00009948943,0.00053084467,0.00024617088,0.00011075588,0.00023098798],"domain_scores_gemma":[0.9987974,0.00012530695,0.0005985822,0.00017253462,0.00019346362,0.00011272521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036729814,0.000157432,0.0004744567,0.000105513776,0.00002274316,0.000008471135,0.00017420195,0.00020866863,0.000017052122],"category_scores_gemma":[0.00014089928,0.00014350694,0.000089508816,0.000115070776,0.00008728702,0.000008860989,0.00008332971,0.00021102384,9.600169e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036352638,0.00030319282,0.7643853,0.00020379169,0.00016766941,0.000035394616,0.00032138557,0.0043026283,0.21328774,0.0000034141062,0.0006239025,0.012730327],"study_design_scores_gemma":[0.0036515512,0.0066104853,0.7535574,0.00040890975,0.00046382396,0.00010712059,0.00046260093,0.0021933601,0.22618413,0.0000906046,0.005876491,0.0003935365],"about_ca_topic_score_codex":0.00006775479,"about_ca_topic_score_gemma":0.00009281869,"teacher_disagreement_score":0.012896386,"about_ca_system_score_codex":0.000108335225,"about_ca_system_score_gemma":0.00050127297,"threshold_uncertainty_score":0.5852043},"labels":[],"label_agreement":null},{"id":"W2981445692","doi":"10.1016/j.jtho.2019.08.1333","title":"P1.18-17 Survival After Adjuvant Chemotherapy in Completely Resected N1 Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Regimen; Lung cancer; Surgery; Chemotherapy; Internal medicine; Pneumonectomy; Stage (stratigraphy); Cancer; Clinical trial; Oncology; Randomized controlled trial; Adjuvant therapy","score_opus":0.02498238111616657,"score_gpt":0.4013635740913099,"score_spread":0.37638119297514333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981445692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98361963,0.0038341132,0.000023395814,0.005632921,0.0013605863,0.0005588796,0.000012784878,0.000009074359,0.0049486384],"genre_scores_gemma":[0.9934749,0.001620818,0.0010565161,0.0015657131,0.00055877154,0.000046159243,0.0000047928224,0.000037403435,0.0016349396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823385,0.00016413683,0.0006592353,0.00024831464,0.000314263,0.0003801974],"domain_scores_gemma":[0.99858654,0.00021511262,0.00048368235,0.0002661305,0.00024864302,0.00019988597],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005296024,0.00021457419,0.0010042811,0.0002604973,0.000023048855,0.000015018424,0.00016331731,0.00019990135,0.0020372798],"category_scores_gemma":[0.000016784012,0.00015688792,0.00021978267,0.00023529574,0.000044208547,0.00008141873,0.000041840216,0.0005480437,0.000028874596],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009363721,0.0018337766,0.9378094,0.0004396673,0.00047551902,0.0016689643,0.0011834665,0.00010718102,0.004585928,0.0000028175962,0.01274979,0.029779734],"study_design_scores_gemma":[0.008620427,0.0038831036,0.94321465,0.00097454194,0.00047429517,0.00022287693,0.00024582617,0.00028132164,0.0049162563,0.000026613747,0.036917157,0.00022291279],"about_ca_topic_score_codex":0.00024993042,"about_ca_topic_score_gemma":0.000766346,"teacher_disagreement_score":0.029556822,"about_ca_system_score_codex":0.001660088,"about_ca_system_score_gemma":0.0008287486,"threshold_uncertainty_score":0.998875},"labels":[],"label_agreement":null},{"id":"W2981451418","doi":"10.1016/j.jtho.2019.08.1582","title":"P2.04-77 Hyperprogression with Immunotherapy in Metastatic Non-Small Cell Lung Cancer: Hôpital Charles-LeMoyne Experience","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Lung cancer; Immunotherapy; Internal medicine; Cancer; Retrospective cohort study; Oncology; Disease; Cancer immunotherapy; Pathological; Medical record","score_opus":0.014374700161792254,"score_gpt":0.37626157438802665,"score_spread":0.3618868742262344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981451418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816902,0.014229796,0.00017767257,0.0016313175,0.00085239456,0.0006324743,0.0000040818068,0.000010901187,0.0007711065],"genre_scores_gemma":[0.98882616,0.0042703613,0.005138989,0.00078071497,0.00018320914,0.000037436166,0.0000027055708,0.00004023334,0.0007202063],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99807316,0.00015978309,0.00076783425,0.0002502139,0.00036091384,0.00038809708],"domain_scores_gemma":[0.99846137,0.00012093751,0.000819658,0.00027871857,0.00018589533,0.00013340467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007271877,0.00024344704,0.0008783054,0.00032661343,0.00004680581,0.00002195184,0.00025943218,0.0001382055,0.00060705794],"category_scores_gemma":[0.000011189535,0.0001602183,0.00020322445,0.0003882169,0.00012521005,0.00020659096,0.000030237663,0.00055210316,0.000008583115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04978101,0.0016833643,0.26696756,0.0005301637,0.0005787947,0.0014227134,0.009110206,0.000098459146,0.29380342,0.0000025353925,0.00062280544,0.37539896],"study_design_scores_gemma":[0.061042704,0.048464645,0.522254,0.010367537,0.0014922336,0.0115401205,0.030935878,0.00277419,0.19988388,0.000056398734,0.10914575,0.0020426472],"about_ca_topic_score_codex":0.00012015627,"about_ca_topic_score_gemma":0.00007194416,"teacher_disagreement_score":0.3733563,"about_ca_system_score_codex":0.0006324494,"about_ca_system_score_gemma":0.00096546276,"threshold_uncertainty_score":0.6646859},"labels":[],"label_agreement":null},{"id":"W2981461253","doi":"10.1016/j.jtho.2019.02.016","title":"Lung Cancer in the Middle East and North Africa Region","year":2019,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Les Laboratories Pierre Fabre; Sanofi; Roche; Novartis; Pfizer; Eli Lilly and Company","keywords":"Middle East; Medicine; Incidence (geometry); Population; Lung cancer; Tobacco control; Socioeconomics; Environmental health; Geography; Public health; Pathology","score_opus":0.04774636572610958,"score_gpt":0.4225679717225573,"score_spread":0.3748216059964477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981461253","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.042161856,0.030573543,0.000028266915,0.0099090235,0.90852,0.00087872735,0.00009527903,0.000008381204,0.00782497],"genre_scores_gemma":[0.08527349,0.008643122,0.00035491915,0.00038762297,0.89830184,0.000060881022,0.000059180238,0.00005692689,0.006862003],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998672,0.0001619713,0.00042987234,0.00015325382,0.00039358588,0.00018928373],"domain_scores_gemma":[0.99834454,0.00043460377,0.00065775187,0.00017314228,0.00030980594,0.00008017245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033035874,0.00016035819,0.0006287843,0.00017293969,0.000045125606,0.000019386745,0.0001483113,0.00038707,0.000027988242],"category_scores_gemma":[0.00018760152,0.00009162638,0.00011620925,0.0001630473,0.00005828104,0.00007302282,0.0000265884,0.0010005,0.0000027471415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086152076,0.00022222001,0.0021877943,0.00029236596,0.00035247373,0.0008104303,0.007672595,0.000014014162,0.0000025033946,0.0000027233857,0.96343285,0.024148505],"study_design_scores_gemma":[0.0012341432,0.0011637177,0.0023325325,0.00064744265,0.0018414775,0.00034407966,0.00116961,0.00001647065,4.1851246e-7,0.00001943929,0.9911455,0.00008516933],"about_ca_topic_score_codex":0.00006883569,"about_ca_topic_score_gemma":0.00035637134,"teacher_disagreement_score":0.043111637,"about_ca_system_score_codex":0.0008462286,"about_ca_system_score_gemma":0.0022674093,"threshold_uncertainty_score":0.43467307},"labels":[],"label_agreement":null},{"id":"W2981466292","doi":"10.1016/j.jtho.2019.08.995","title":"P1.06-08 WDPM-Like but Not Cribriform as Secondary Growth Patterns Modify Survival in Epithelioid Malignant Pleural Mesothelioma","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Mesothelioma; Cribriform; Pathology; Adenocarcinoma; Epithelioid cell; Epithelioid hemangioendothelioma; Immunohistochemistry; Internal medicine; Cancer","score_opus":0.018154944199982575,"score_gpt":0.34147951050327924,"score_spread":0.32332456630329665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981466292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920062,0.00033430086,0.000027162521,0.0028657052,0.0009625563,0.000273693,0.00010899157,0.0000141170085,0.0034072879],"genre_scores_gemma":[0.99415857,0.00023316052,0.0004059003,0.0024381408,0.00036535965,0.0000063647904,0.000048188336,0.000035990484,0.0023083354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777025,0.00018177983,0.00081054354,0.0002563254,0.0005855624,0.00039554448],"domain_scores_gemma":[0.9987027,0.00019873632,0.0004740895,0.00021372006,0.00009378117,0.00031698396],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058727385,0.00025134624,0.0007841549,0.00037545155,0.000044885815,0.000017415965,0.00023074444,0.00020407893,0.0017916188],"category_scores_gemma":[0.00007101557,0.00018555051,0.0003043322,0.00014904472,0.00008974539,0.0002844494,0.00010853547,0.000569115,0.0004967089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012904472,0.0019569658,0.90450627,0.00058202207,0.00039123147,0.003844539,0.0005024992,0.00011507714,0.0455433,0.0002461236,0.0015463105,0.027861193],"study_design_scores_gemma":[0.0025992382,0.003133372,0.9762757,0.0002685569,0.0002253233,0.0026077782,0.0008114501,0.00015535895,0.006842835,0.0006526142,0.0061766906,0.00025112522],"about_ca_topic_score_codex":0.00010925433,"about_ca_topic_score_gemma":0.000032276483,"teacher_disagreement_score":0.071769394,"about_ca_system_score_codex":0.0004977351,"about_ca_system_score_gemma":0.0004370556,"threshold_uncertainty_score":0.9991209},"labels":[],"label_agreement":null},{"id":"W2981470277","doi":"10.1016/j.jtho.2019.08.141","title":"ES16.02 MRI-Based Radiotherapy","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Radiation therapy; Magnetic resonance imaging; Lung cancer; Radiation treatment planning; Radiology; Medical physics; Pathology","score_opus":0.016731954688568938,"score_gpt":0.41901940084838046,"score_spread":0.40228744615981155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981470277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584597,0.0034625297,0.00045212655,0.029024782,0.0016506545,0.00031513648,0.000002508296,0.000014622314,0.0066179703],"genre_scores_gemma":[0.98363656,0.0005959125,0.01015623,0.0037199573,0.00061801315,0.0000061555806,0.00000216608,0.000021257805,0.001243721],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990211,0.00008951335,0.0003627652,0.00011883228,0.00023167516,0.00017611396],"domain_scores_gemma":[0.99895155,0.00017425214,0.00035683985,0.00020000068,0.00016241825,0.00015490834],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037388908,0.00010986977,0.00055199605,0.00015213342,0.000020844642,0.0000088135885,0.00009133599,0.00011732868,0.0013061187],"category_scores_gemma":[0.00002119078,0.000073891584,0.00022972988,0.00010852674,0.00003466585,0.000056104105,0.000008192541,0.00023990516,0.00008236187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011493308,0.004986244,0.33950198,0.00052179385,0.0020310006,0.0028213814,0.0006549228,0.0007817747,0.009338352,0.00020932293,0.107836716,0.5198232],"study_design_scores_gemma":[0.009071393,0.020812698,0.07045137,0.0005715758,0.00087067444,0.0019952802,0.0001319636,0.00045716035,0.018862216,0.00017051739,0.8763877,0.00021742447],"about_ca_topic_score_codex":0.0000066861144,"about_ca_topic_score_gemma":0.000005313407,"teacher_disagreement_score":0.768551,"about_ca_system_score_codex":0.0009933917,"about_ca_system_score_gemma":0.00067420834,"threshold_uncertainty_score":0.99960685},"labels":[],"label_agreement":null},{"id":"W2981472215","doi":"10.1016/j.jtho.2019.08.1233","title":"P1.16-07 Real World Evidence of the Impact of Immunotherapy in Patients with Advanced Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Lung cancer; Immunotherapy; Oncology; Internal medicine; Population; Cancer; Performance status; Targeted therapy; Biomarker; Stage (stratigraphy); Chemotherapy","score_opus":0.01055610398592287,"score_gpt":0.4332620181733169,"score_spread":0.422705914187394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981472215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963185,0.0012582822,0.00004669357,0.001160849,0.00033588381,0.000251881,0.0000012168874,0.0000020012083,0.0006246862],"genre_scores_gemma":[0.99803305,0.0005631416,0.0009583681,0.00015785752,0.000065592445,0.0000017529841,3.8701387e-7,0.00001458205,0.0002052486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986829,0.00017796387,0.00055355555,0.00009287682,0.00032460986,0.00016810215],"domain_scores_gemma":[0.9982194,0.00025336078,0.0010169714,0.000203331,0.00024016053,0.000066795255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072818855,0.00009996217,0.00061114173,0.00019063104,0.000014316006,0.0000029196005,0.00020633415,0.00005509938,0.00022653746],"category_scores_gemma":[0.00017764966,0.000051563427,0.00016264751,0.0002967672,0.00010929223,0.0001131914,0.000029210169,0.000626417,5.7690477e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005592878,0.00022889787,0.8821926,0.00009390747,0.00014757055,0.000008531904,0.00030701957,0.0017240571,0.004731163,0.0000038096764,0.00018990823,0.10477967],"study_design_scores_gemma":[0.0024275214,0.0026832395,0.99063796,0.0027283242,0.00008343551,0.000025113546,0.00004204009,0.0006601336,0.00042865227,0.000026010935,0.00020246819,0.000055093173],"about_ca_topic_score_codex":0.00041679104,"about_ca_topic_score_gemma":0.00004214393,"teacher_disagreement_score":0.108445376,"about_ca_system_score_codex":0.0005769109,"about_ca_system_score_gemma":0.00071044953,"threshold_uncertainty_score":0.2721505},"labels":[],"label_agreement":null},{"id":"W2981476024","doi":"10.1016/j.jtho.2019.08.1556","title":"P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Nivolumab; Medicine; Internal medicine; Oncology; Immunotherapy; Gene; Log-rank test; Cancer research; Cancer; Overall survival; Biology; Genetics","score_opus":0.013452686025996505,"score_gpt":0.35171045269305967,"score_spread":0.33825776666706314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981476024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98766506,0.0048656776,0.000025558953,0.0025684624,0.0013027565,0.0014438616,0.0000388406,0.000016617636,0.002073148],"genre_scores_gemma":[0.99138886,0.0004912245,0.003412783,0.00034625537,0.00032635155,0.000014788361,0.0000152327075,0.000036770256,0.003967713],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99670327,0.00033015513,0.0017789918,0.00033454594,0.00045648153,0.00039655817],"domain_scores_gemma":[0.99716336,0.00027498344,0.0014740749,0.0005047093,0.00040639818,0.00017649737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017576077,0.0002473371,0.001244258,0.0005478152,0.000032270542,0.000009760257,0.0003587035,0.00041580125,0.000119108765],"category_scores_gemma":[0.00046713202,0.00020165052,0.00033023494,0.0006805014,0.00008919762,0.00014791536,0.00006352999,0.00070914824,0.000011500755],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5779872,0.0005084336,0.0004441384,0.00010542154,0.00023497448,0.00020295999,0.0007113552,0.00009386465,0.39447066,0.0000021460048,0.0008990571,0.02433981],"study_design_scores_gemma":[0.3387006,0.055489346,0.19875152,0.00439721,0.00065646035,0.0008839753,0.0009770235,0.00008427547,0.24837802,0.0001105367,0.15081094,0.00076009193],"about_ca_topic_score_codex":0.000036464604,"about_ca_topic_score_gemma":0.00016992216,"teacher_disagreement_score":0.23928659,"about_ca_system_score_codex":0.001036797,"about_ca_system_score_gemma":0.0012120875,"threshold_uncertainty_score":0.82230693},"labels":[],"label_agreement":null},{"id":"W2981476678","doi":"10.1016/j.jtho.2019.08.286","title":"PC01.02 Real World Research Groups — ROS1ders","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Disease; Cancer; Family medicine; Oncology; Internal medicine; Adenocarcinoma","score_opus":0.06200485756519249,"score_gpt":0.5431354208941708,"score_spread":0.4811305633289783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981476678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8623365,0.00046133573,0.000031783427,0.011368887,0.001142815,0.0002986599,0.0000027003273,0.0000118654025,0.12434541],"genre_scores_gemma":[0.9738535,0.00023753433,0.0025889694,0.00044004145,0.00062316214,0.00000608501,0.000004776353,0.000018741319,0.022227183],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99856335,0.00019553084,0.00039125618,0.00013481769,0.0004271433,0.00028791587],"domain_scores_gemma":[0.99860793,0.00026185956,0.0002370949,0.00020099433,0.000488603,0.00020349996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010454138,0.000088272034,0.0004057884,0.00048464132,0.0000702889,0.000015826456,0.00012100762,0.000099321,0.0007369215],"category_scores_gemma":[0.00006551423,0.0000627058,0.00013515215,0.0003965676,0.00008745905,0.0001258144,0.00003678205,0.00060520304,0.0002250802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0096529955,0.00328252,0.27233052,0.00044536788,0.0022576358,0.0039990502,0.0059612365,0.000120128134,0.012808281,0.005410195,0.14751965,0.53621244],"study_design_scores_gemma":[0.006000452,0.01394184,0.2904588,0.00056077284,0.0012391313,0.0023005991,0.00528689,0.00007730486,0.0020758891,0.0051530064,0.67264086,0.00026445842],"about_ca_topic_score_codex":0.000068961584,"about_ca_topic_score_gemma":0.00009475075,"teacher_disagreement_score":0.535948,"about_ca_system_score_codex":0.0009366895,"about_ca_system_score_gemma":0.0010260729,"threshold_uncertainty_score":0.8068774},"labels":[],"label_agreement":null},{"id":"W2981525398","doi":"10.1016/j.jtho.2019.08.586","title":"MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Rash; Carboplatin; Tremelimumab; Gemcitabine; Oncology; Tolerability; Adverse effect; Pemetrexed; Nausea; Gastroenterology; Chemotherapy; Cisplatin; Nivolumab; Cancer; Ipilimumab; Immunotherapy","score_opus":0.01567304170146937,"score_gpt":0.38731438004835966,"score_spread":0.3716413383468903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981525398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956896,0.00030665848,0.000019273275,0.0007565284,0.0007938785,0.0011813848,0.000007869653,0.000014006272,0.0012308247],"genre_scores_gemma":[0.9981603,0.000036635956,0.0007954022,0.00046121,0.00014351704,0.000013533262,0.000009581975,0.000035663797,0.0003441281],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975493,0.0002540293,0.0009808852,0.00026634792,0.0005832619,0.00036617665],"domain_scores_gemma":[0.99816924,0.00012903036,0.0009116884,0.00033141286,0.00031041112,0.00014821398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083316164,0.0002463181,0.0009617732,0.00045493385,0.00004396091,0.0000179681,0.00021309542,0.00017390064,0.0005258398],"category_scores_gemma":[0.000056574398,0.00017227838,0.0001590164,0.0004525995,0.00007566954,0.00026292074,0.000040205665,0.00065039453,0.000024242383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30678344,0.011628989,0.28549805,0.00008503727,0.0006784834,0.0005766728,0.0021815402,0.000037050413,0.004592576,0.0000021170972,0.00049571897,0.38744032],"study_design_scores_gemma":[0.19302745,0.13933375,0.6430934,0.00079547265,0.00055454095,0.0004820284,0.0053511597,0.00004016886,0.0012605281,0.000034189852,0.01556221,0.00046508643],"about_ca_topic_score_codex":0.00003500545,"about_ca_topic_score_gemma":0.00011147834,"teacher_disagreement_score":0.38697526,"about_ca_system_score_codex":0.00075894414,"about_ca_system_score_gemma":0.00065403566,"threshold_uncertainty_score":0.70253086},"labels":[],"label_agreement":null},{"id":"W2981560305","doi":"10.1016/j.jtho.2019.08.2247","title":"EP1.12-02 SCLC Treatment Uptake and Survival Outcomes: A 2-Year Comparison Between 2 Tertiary Referral Centers in Alberta, Canada","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Hazard ratio; Internal medicine; Radiation therapy; Referral; Guideline; Proportional hazards model; Lung cancer; Retrospective cohort study; Cancer; Oncology; Conventional PCI; Family medicine; Confidence interval; Pathology","score_opus":0.05230667235199401,"score_gpt":0.4400525911824128,"score_spread":0.3877459188304188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981560305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785807,0.00039008228,0.00000239835,0.017354056,0.0006662594,0.0003613787,0.000010872971,0.000004204116,0.0026300354],"genre_scores_gemma":[0.9970906,0.00018497894,0.00028627727,0.00034117515,0.00020723756,0.0000060060192,0.00000610705,0.000018488274,0.0018591501],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795896,0.0002513149,0.0007047795,0.00020377315,0.00045993074,0.0004212379],"domain_scores_gemma":[0.9985306,0.00055774744,0.00032401353,0.00019580165,0.00011017124,0.00028161742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053626206,0.0001965004,0.0012558928,0.0002191893,0.000040308812,0.000011767725,0.000136214,0.00010710713,0.000086622895],"category_scores_gemma":[0.0001680112,0.00013341675,0.00011066526,0.00010554214,0.00008114447,0.000091147645,0.00008390911,0.00048798058,0.0000095523255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012075513,0.0001947172,0.97320807,0.00008593195,0.0005327921,0.00030704134,0.00069640763,0.000006907074,0.00007759279,0.000004013114,0.0026071698,0.02107181],"study_design_scores_gemma":[0.003252256,0.0028033818,0.95773315,0.00016535258,0.00021260817,0.00009864569,0.0015993724,0.000022120284,0.00009187025,0.000014294025,0.03390075,0.000106197054],"about_ca_topic_score_codex":0.18415625,"about_ca_topic_score_gemma":0.5897492,"teacher_disagreement_score":0.40559295,"about_ca_system_score_codex":0.0027156114,"about_ca_system_score_gemma":0.0015029226,"threshold_uncertainty_score":0.82127655},"labels":[],"label_agreement":null},{"id":"W2981585990","doi":"10.1016/j.jtho.2019.08.529","title":"MA05.01 Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Pemetrexed; Nivolumab; Decortication; Radiation therapy; Pembrolizumab; Mesothelioma; Surgery; Radiology; Chemotherapy; Internal medicine; Immunotherapy; Cancer; Pathology","score_opus":0.04048503298205606,"score_gpt":0.40143495145332253,"score_spread":0.36094991847126645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981585990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99503756,0.0016082168,0.0000097142165,0.0018011729,0.00058645266,0.00042221756,0.000030411959,0.000014478653,0.00048975745],"genre_scores_gemma":[0.9950282,0.00051420275,0.0011038511,0.0018150918,0.0003905302,0.000013412246,0.0000120973245,0.000031228577,0.0010913833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979909,0.0002606261,0.0007583441,0.00025274957,0.00040778532,0.00032959308],"domain_scores_gemma":[0.99885356,0.000231595,0.00043216939,0.00021143988,0.000069019894,0.00020219196],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006359935,0.00024444796,0.0007674042,0.00028524833,0.000041428964,0.000017556293,0.00015557425,0.00019361993,0.0042525767],"category_scores_gemma":[0.00004491587,0.00015249677,0.0002615539,0.0002021867,0.000094576404,0.00024685878,0.00006933498,0.00044368327,0.0000736446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05185208,0.0024879335,0.82830936,0.00011626397,0.00033783735,0.0038161692,0.00072708406,0.00013834261,0.07133965,0.0000067720066,0.00042626838,0.040442232],"study_design_scores_gemma":[0.004722553,0.0038237106,0.9725169,0.00017691628,0.000051138795,0.0023681023,0.00023863277,0.00023158605,0.010145407,0.00011550663,0.005413128,0.0001964251],"about_ca_topic_score_codex":0.000024725452,"about_ca_topic_score_gemma":0.00003310927,"teacher_disagreement_score":0.14420754,"about_ca_system_score_codex":0.00035417307,"about_ca_system_score_gemma":0.00028360283,"threshold_uncertainty_score":0.99665767},"labels":[],"label_agreement":null},{"id":"W2981593005","doi":"10.1016/j.jtho.2019.08.2115","title":"EP1.03-34 Single Center Epidemiological Prevalence Study of Molecular Mutation in Bangladeshi Patients with Advanced Stage Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Science North","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Internal medicine; T790M; Cancer; Biopsy; Outpatient clinic; Single Center; Oncology; Gastroenterology; Pathology; Adenocarcinoma; ROS1","score_opus":0.015590104630153387,"score_gpt":0.3989717494112591,"score_spread":0.38338164478110576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981593005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967363,0.00044335658,0.00018548245,0.0002911437,0.00025653534,0.0011945319,0.0000170447,0.00000474024,0.00087088614],"genre_scores_gemma":[0.9967462,0.000050968363,0.0026321413,0.00021767602,0.000030832874,0.00003121673,0.000009917758,0.000015838717,0.00026523462],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984667,0.00023933916,0.0006319655,0.00020633792,0.00024451094,0.00021119091],"domain_scores_gemma":[0.99839646,0.00015670226,0.00082232244,0.00016442788,0.00034283212,0.000117273055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032467907,0.00014759901,0.0006140249,0.00017964929,0.000020250991,0.0000045447887,0.000105661136,0.000098625074,0.00014680198],"category_scores_gemma":[0.000082653394,0.00009645931,0.00007652359,0.00018674537,0.000035075707,0.00012987567,0.000028093662,0.0002726127,0.0000027113363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024420829,0.0056370157,0.97265273,0.0003994005,0.00019677136,0.00031252968,0.001925924,0.0038194268,0.0039586374,0.0000019504314,0.000026537024,0.008626971],"study_design_scores_gemma":[0.014396902,0.025495969,0.95224655,0.00072587916,0.00094651524,0.00005355139,0.0026236703,0.00021772069,0.0028040244,0.000016721027,0.00029657385,0.00017590124],"about_ca_topic_score_codex":0.000046525463,"about_ca_topic_score_gemma":0.000060379036,"teacher_disagreement_score":0.020406181,"about_ca_system_score_codex":0.00077040895,"about_ca_system_score_gemma":0.00034803062,"threshold_uncertainty_score":0.39334965},"labels":[],"label_agreement":null},{"id":"W2981599940","doi":"10.1016/j.jtho.2019.08.1813","title":"P2.14-28 Real-World Management and Outcomes of Uncommon EGFR Mutation-Positive NSCLC Patients at Two Tertiary Canadian Cancer Centres","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gefitinib; Lung cancer; Internal medicine; Cohort; Oncology; Cancer; Population; Mutation; Epidermal growth factor receptor","score_opus":0.00936022518894539,"score_gpt":0.3967298458148208,"score_spread":0.3873696206258754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981599940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775387,0.00046583876,0.000005264011,0.0042775366,0.00073290244,0.00046381203,0.00006409428,0.0000045249362,0.016447319],"genre_scores_gemma":[0.992672,0.0002260447,0.0009146924,0.0008912505,0.000060375904,0.000010146447,0.000033190558,0.000015347416,0.005176904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890935,0.0000792889,0.0004402001,0.00013774422,0.00022299887,0.00021042905],"domain_scores_gemma":[0.99880105,0.00010391016,0.00045899968,0.00012777084,0.0002675867,0.00024067362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012467854,0.00012984195,0.00045413352,0.00037109357,0.00006333893,0.00000780665,0.00006948164,0.00005408077,0.00024088452],"category_scores_gemma":[0.000012994556,0.000095394564,0.000092383794,0.00013400221,0.000050121518,0.00010790248,0.000034939036,0.00013009849,0.000009601597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004218883,0.00022906612,0.91432714,0.00007713309,0.000912929,0.0002154225,0.0008735957,0.00005425922,0.00003244533,0.000078320816,0.0021372463,0.08064055],"study_design_scores_gemma":[0.00283087,0.00065906515,0.98761594,0.00023131518,0.0010904754,0.000040064977,0.00039517114,0.000021065991,0.00028901032,0.000094924726,0.006648459,0.000083640974],"about_ca_topic_score_codex":0.022336323,"about_ca_topic_score_gemma":0.09506993,"teacher_disagreement_score":0.08055691,"about_ca_system_score_codex":0.0017692515,"about_ca_system_score_gemma":0.00042500306,"threshold_uncertainty_score":0.984174},"labels":[],"label_agreement":null},{"id":"W2981621614","doi":"10.1016/j.jtho.2019.08.060","title":"PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Lung; Internal medicine","score_opus":0.023956229797011504,"score_gpt":0.4722920417351263,"score_spread":0.4483358119381148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981621614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833166,0.0013038921,0.00008021347,0.003840728,0.004398956,0.0018738458,0.0002437034,0.000015486248,0.00492655],"genre_scores_gemma":[0.98934066,0.00035139633,0.003518862,0.00039239542,0.0029475319,0.000075423435,0.00014510147,0.000041137337,0.0031874813],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972474,0.00019066129,0.0013029769,0.0003826222,0.0005213413,0.00035499636],"domain_scores_gemma":[0.9974023,0.0004634504,0.0011595965,0.00025886222,0.0004402742,0.0002755039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008363887,0.0002535979,0.00091350323,0.0003925142,0.00012368475,0.000026652502,0.00022252806,0.0002989407,0.0004293952],"category_scores_gemma":[0.00019421666,0.00020583578,0.00025845427,0.00028128983,0.000041208797,0.00029701018,0.000051333947,0.000600112,0.000017393717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9495823,0.0072097313,0.0011952881,0.000110374654,0.0005364775,0.0004400887,0.0035457017,0.0022293588,0.002868915,0.000012523256,0.006127322,0.026141962],"study_design_scores_gemma":[0.9241597,0.026955727,0.0017956429,0.00064167456,0.0015708607,0.00008963101,0.00061673264,0.0038383848,0.0011508362,0.000112529284,0.038729787,0.00033849987],"about_ca_topic_score_codex":0.00033988917,"about_ca_topic_score_gemma":0.0004636056,"teacher_disagreement_score":0.032602463,"about_ca_system_score_codex":0.0018560926,"about_ca_system_score_gemma":0.0034631717,"threshold_uncertainty_score":0.83937395},"labels":[],"label_agreement":null},{"id":"W2981636516","doi":"10.1016/j.jtho.2019.08.1185","title":"P1.14-34 The Landscape of MET Alterations in Chinese Non-Small Cell Lung Cancer Patients","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Adenosquamous carcinoma; Adenocarcinoma; Lung cancer; Indel; Cancer research; Oncology; Internal medicine; Cancer; Exon; Carcinoma; Fusion gene; Druggability; Stage (stratigraphy); Gene; Genetics; Single-nucleotide polymorphism; Biology; Genotype","score_opus":0.012926763377884325,"score_gpt":0.35951836013395067,"score_spread":0.3465915967560663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981636516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881939,0.0028409616,0.000014085676,0.0018905771,0.00094963005,0.00029833696,0.00000828389,0.0000024028523,0.005801798],"genre_scores_gemma":[0.99800473,0.00031138252,0.00028450118,0.00046778415,0.00030470378,0.000010775048,0.000003190569,0.000011134748,0.00060181826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998941,0.000092685965,0.0004991247,0.00010593826,0.00019534213,0.0001659217],"domain_scores_gemma":[0.99887747,0.00017451677,0.00044143092,0.00015736217,0.00028905974,0.000060191935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035502398,0.000113508184,0.00053734676,0.00017845219,0.00003275266,0.0000066552666,0.00014286293,0.00007958455,0.00015583176],"category_scores_gemma":[0.00005491394,0.00006448552,0.00015023105,0.00023049414,0.000035052715,0.000069840244,0.000055483044,0.0003557809,0.000004796794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070736615,0.00035878457,0.98541915,0.00014316992,0.00013927501,0.000028607601,0.003089417,0.000083583545,0.0012571316,0.0000025208547,0.00415215,0.004618813],"study_design_scores_gemma":[0.0022929835,0.0017271861,0.9917553,0.00016972986,0.00029423655,0.00004297871,0.00071059767,0.00021025601,0.0006925887,0.000022137354,0.0020045827,0.000077437675],"about_ca_topic_score_codex":0.00008190016,"about_ca_topic_score_gemma":0.00036618643,"teacher_disagreement_score":0.009810786,"about_ca_system_score_codex":0.00016631596,"about_ca_system_score_gemma":0.00032243284,"threshold_uncertainty_score":0.2629643},"labels":[],"label_agreement":null},{"id":"W2981636558","doi":"10.1016/j.jtho.2019.10.013","title":"Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Université de Sherbrooke; University of Alberta","funders":"Takeda Oncology; EMD Serono; National Institutes of Health; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; Clovis Oncology; University of Texas Southwestern Medical Center; Merck Sharp and Dohme; Genzyme; Takeda Pharmaceuticals U.S.A.; Foundation Medicine; United Therapeutics Corporation; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Purdue University; MedImmune; Sanofi; GlaxoSmithKline; Roche; AbbVie; Genentech; Aeglea BioTherapeutics; Amgen; Daiichi Sankyo Europe; National Cancer Institute; Intuitive Surgical; Moderna; Pfizer; AstraZeneca; Purdue Pharma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Paclitaxel; Hazard ratio; Internal medicine; Oncology; Placebo; Clinical endpoint; Population; Gastroenterology; Confidence interval; Randomized controlled trial; Chemotherapy; Pathology","score_opus":0.12534256394026563,"score_gpt":0.5412142173577857,"score_spread":0.4158716534175201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981636558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98016304,0.009803067,0.00019778097,0.002209798,0.001006075,0.0041337903,0.000044821056,0.000014369809,0.002427277],"genre_scores_gemma":[0.9945428,0.0013000838,0.000888397,0.00032307184,0.00025650702,0.00011662317,0.000013921911,0.000039852282,0.0025187875],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99609345,0.001083913,0.0013478388,0.000358822,0.0006875956,0.0004283924],"domain_scores_gemma":[0.9918698,0.0049761045,0.0014444939,0.0003452272,0.0010847688,0.00027957893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003841329,0.0003317407,0.0029701635,0.0005660837,0.00017008395,0.000017869892,0.00022278269,0.0002006233,0.000323972],"category_scores_gemma":[0.0019610017,0.00021589463,0.0004751708,0.00032892026,0.0005048514,0.00024892544,0.00018125448,0.0005559537,0.000004472546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94544506,0.0025612612,0.00035358893,0.00030666706,0.0074998685,0.00015875888,0.006320353,0.000031406442,0.007330481,0.000015215113,0.002481973,0.02749536],"study_design_scores_gemma":[0.87784195,0.09849394,0.0016755813,0.0002832824,0.0025177072,0.00021178038,0.012393415,0.0011014157,0.0015380144,0.00021644562,0.0034657225,0.0002607692],"about_ca_topic_score_codex":0.000074801326,"about_ca_topic_score_gemma":0.000053040825,"teacher_disagreement_score":0.09593268,"about_ca_system_score_codex":0.0008884407,"about_ca_system_score_gemma":0.0015097333,"threshold_uncertainty_score":0.88039273},"labels":[],"label_agreement":null},{"id":"W2981641893","doi":"10.1016/j.jtho.2019.08.1440","title":"P2.01-97 Angiotensin-Converting Enzyme Inhibitor Is Associated with Decreased Survival in NSCLC Patients Treated with PD-1 Checkpoint Blockers","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; ACE inhibitor; Lung cancer; Oncology; Retrospective cohort study; Angiotensin-converting enzyme; Proportional hazards model; Cancer; Heart failure; Pharmacology; Blood pressure","score_opus":0.00914049805726489,"score_gpt":0.2833945611427974,"score_spread":0.27425406308553246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981641893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964061,0.0004507157,0.000029724803,0.00038932497,0.001971342,0.00026566838,0.000017060469,0.000007822668,0.00046224054],"genre_scores_gemma":[0.99635905,0.00007525039,0.00048199258,0.00056410924,0.0018709941,0.0000046509867,0.000048649086,0.00004376619,0.00055153936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802715,0.00027971627,0.00061948056,0.00032711626,0.00031621172,0.00043031428],"domain_scores_gemma":[0.9981362,0.000054963664,0.0008487828,0.00023997723,0.0005185175,0.00020153947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006241209,0.00026678646,0.000695493,0.00017992023,0.000046017165,0.000019722527,0.00019359736,0.0003437643,0.000047151985],"category_scores_gemma":[0.00018023874,0.00019858521,0.00016938538,0.00026267095,0.00009893006,0.000018421857,0.000055066183,0.0003428044,0.000008267647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024696361,0.0018950205,0.6508262,0.000060553775,0.0015963512,0.000056546967,0.00088144507,0.00015060055,0.27709714,0.0000037378868,0.015597622,0.027138403],"study_design_scores_gemma":[0.026035808,0.017790753,0.41580084,0.0009050527,0.0010795557,0.00042902387,0.0012865791,0.00021765883,0.32839033,0.00002160067,0.20656076,0.001482024],"about_ca_topic_score_codex":0.00010619957,"about_ca_topic_score_gemma":0.00042980973,"teacher_disagreement_score":0.23502538,"about_ca_system_score_codex":0.00021305875,"about_ca_system_score_gemma":0.0006430221,"threshold_uncertainty_score":0.809807},"labels":[],"label_agreement":null},{"id":"W2981643100","doi":"10.1016/j.jtho.2019.08.701","title":"MA24.02 Developing Regional Activity for a National Charity: The Lung Cancer Canada Experience","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; General partnership; Psychosocial; Stakeholder; Lung cancer; Mandate; Summit; Public relations; Psychosocial support; Social media; Cancer; Support group; Family medicine; Nursing; Political science; Business; Oncology; Finance; Internal medicine","score_opus":0.12715812876517718,"score_gpt":0.502158651832841,"score_spread":0.37500052306766385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981643100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96142244,0.0008821843,0.00098221,0.034478668,0.0010309048,0.00027212148,0.0000086144555,0.0000041032085,0.00091873395],"genre_scores_gemma":[0.98906356,0.00006295764,0.0024025661,0.007124078,0.0006519164,0.000027375738,0.000001141243,0.000007646212,0.0006587826],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987056,0.00006151528,0.00029194608,0.00012719248,0.00059009675,0.00022360747],"domain_scores_gemma":[0.9983697,0.00030190498,0.0004129212,0.000089874855,0.00073248753,0.000093092334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006624417,0.00009375972,0.0003175121,0.000056275007,0.000106060994,0.000012320147,0.0001952455,0.00008035945,0.00017209788],"category_scores_gemma":[0.00020416615,0.00006249123,0.0000948746,0.00014608678,0.000050513358,0.00016107498,0.000034550474,0.00031322293,8.942154e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015775453,0.00026392387,0.2352542,0.0007870809,0.0011332873,0.0005096911,0.0045596943,0.0006569848,0.019098034,0.0031353373,0.47055155,0.24827476],"study_design_scores_gemma":[0.0016811526,0.0010333908,0.2423772,0.00083576323,0.00024047085,0.0032477402,0.003173636,0.003073908,0.005124168,0.00058739126,0.7383019,0.00032327886],"about_ca_topic_score_codex":0.011701179,"about_ca_topic_score_gemma":0.050650917,"teacher_disagreement_score":0.26775035,"about_ca_system_score_codex":0.0019573092,"about_ca_system_score_gemma":0.008329279,"threshold_uncertainty_score":0.9972926},"labels":[],"label_agreement":null},{"id":"W2981662390","doi":"10.1016/j.jtho.2019.08.259","title":"IBS30.03 Risk Assessment to Establish Screening Programs: The Canadian Point of View","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Population; Risk assessment; Task force; Prospective cohort study; Smoking cessation; Physical therapy; Family medicine; Demography; Environmental health; Internal medicine; Pathology","score_opus":0.02589377728079782,"score_gpt":0.42403122121422343,"score_spread":0.3981374439334256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981662390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9328124,0.0015086966,0.00016508067,0.04662384,0.0010458804,0.0012673609,0.000013999891,0.000008825017,0.016553938],"genre_scores_gemma":[0.98547417,0.00029692636,0.012019114,0.0017271683,0.00024078003,0.00002320634,0.0000035051391,0.000016577962,0.00019854814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984143,0.00023463748,0.0005551468,0.00014441417,0.00036173625,0.00028980084],"domain_scores_gemma":[0.99804944,0.0001981621,0.00060162257,0.0002944201,0.00046400636,0.0003923517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015673597,0.00012861873,0.0006138873,0.00020643201,0.000078500365,0.00003103154,0.00018658675,0.00011298826,0.00029764927],"category_scores_gemma":[0.00011421429,0.00007423402,0.00020793304,0.00026082096,0.000048691047,0.00009358175,0.00004174189,0.00047459023,0.000027631335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041373703,0.00057506986,0.40368325,0.00013448956,0.0006897563,0.00026325957,0.00071658083,0.00011494209,0.000056114754,0.00016909075,0.008333705,0.58485],"study_design_scores_gemma":[0.002061934,0.013643782,0.5185635,0.0015390117,0.0017279624,0.0009512074,0.0017383851,0.00009966957,0.0005530976,0.00029356178,0.45864427,0.00018363413],"about_ca_topic_score_codex":0.016049508,"about_ca_topic_score_gemma":0.049655516,"teacher_disagreement_score":0.5846664,"about_ca_system_score_codex":0.0015760821,"about_ca_system_score_gemma":0.0018845182,"threshold_uncertainty_score":0.9905027},"labels":[],"label_agreement":null},{"id":"W2981678140","doi":"10.1016/j.jtho.2019.08.1406","title":"P2.01-63 Radiosurgery Followed by Tumor Treating Fields (TTFields) for Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiosurgery; Clinical endpoint; Lung cancer; Adverse effect; Oncology; Internal medicine; Radiology; Randomized controlled trial; Radiation therapy","score_opus":0.047219465631438466,"score_gpt":0.46924587812131857,"score_spread":0.4220264124898801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981678140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717201,0.000748332,0.0012801924,0.02321521,0.00037097838,0.00076224975,0.00007860408,0.000009526384,0.0018148157],"genre_scores_gemma":[0.9921054,0.000031229738,0.0024139897,0.003425077,0.00097226823,0.00007265531,0.000051983996,0.000015116485,0.0009122362],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998277,0.00029327816,0.00076807063,0.00018914258,0.00022476405,0.00024773212],"domain_scores_gemma":[0.9946266,0.0044427123,0.00047411976,0.00023491622,0.00007811074,0.00014357331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016231943,0.00015181588,0.00072302576,0.00007880263,0.00005992196,0.000022145014,0.00022712452,0.00017148661,0.00087852],"category_scores_gemma":[0.0010929022,0.000100990546,0.00035078835,0.00019531291,0.000053753596,0.00009085858,0.000016445425,0.0005491477,0.000009802602],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14393298,0.0049159355,0.00052172446,0.00018215072,0.00073870237,0.00064068707,0.000762865,0.000025843414,0.3024268,0.00008005059,0.39063534,0.15513694],"study_design_scores_gemma":[0.09876759,0.008420915,0.000139621,0.00022847946,0.0018705988,0.0010563484,0.0016408755,0.0011108103,0.13163342,0.0007323955,0.75402886,0.00037005954],"about_ca_topic_score_codex":0.000014590689,"about_ca_topic_score_gemma":0.0000035104442,"teacher_disagreement_score":0.36339355,"about_ca_system_score_codex":0.00010934876,"about_ca_system_score_gemma":0.00026905414,"threshold_uncertainty_score":0.9619178},"labels":[],"label_agreement":null},{"id":"W2981681194","doi":"10.1016/j.jtho.2019.08.1242","title":"P1.16-16 Lung Cancer Control in Sub-Saharan Africa: Experience at Ampath Oncology in Western Kenya","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Western University; Bristol-Myers Squibb Foundation","keywords":"Medicine; Lung cancer; Sputum; Biopsy; Internal medicine; Lung; Cancer; Radiology; Tuberculosis; Pathology","score_opus":0.02113165023939008,"score_gpt":0.40796965883569836,"score_spread":0.3868380085963083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981681194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9753732,0.012721779,0.000023522407,0.006334539,0.0016666641,0.00069777627,0.000010097193,0.000009107727,0.003163297],"genre_scores_gemma":[0.9927418,0.004344253,0.00007917258,0.0012303487,0.00035093233,0.00013704239,0.0000028492573,0.000026031903,0.0010875551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975364,0.00032858434,0.0009766682,0.0003196095,0.0003296365,0.00050910836],"domain_scores_gemma":[0.9982089,0.0004170105,0.0007195119,0.00025961234,0.00015554488,0.00023944305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071475556,0.00023464656,0.001298364,0.00037877014,0.00003149892,0.000010069191,0.00020458191,0.00028947945,0.0008034208],"category_scores_gemma":[0.000064135435,0.00017655699,0.00019205647,0.00028293912,0.000093528426,0.00017874618,0.00006704321,0.0005740883,0.00004389007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043557812,0.0014104024,0.94979095,0.00012256956,0.00018923273,0.0014206952,0.0027382697,0.000109177796,0.0021771723,0.0000035428093,0.008060796,0.029621387],"study_design_scores_gemma":[0.018967189,0.008142287,0.64913696,0.0017464526,0.00064025016,0.0013717958,0.00093661813,0.00023044483,0.0029757891,0.0000531824,0.3154006,0.0003984433],"about_ca_topic_score_codex":0.00023522807,"about_ca_topic_score_gemma":0.0047860295,"teacher_disagreement_score":0.3073398,"about_ca_system_score_codex":0.011921846,"about_ca_system_score_gemma":0.0009775208,"threshold_uncertainty_score":0.99187124},"labels":[],"label_agreement":null},{"id":"W2981703267","doi":"10.1016/j.jtho.2019.08.453","title":"OA09.01 Opt-Out Smoking Cessation Program in Lung Cancer Screening Provides Excellent Quit Rates","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Health","funders":"","keywords":"Medicine; Smoking cessation; Nicotine replacement therapy; Family medicine; Quit smoking; Quitline; Lung cancer screening; Referral; Lung cancer; Physical therapy; Internal medicine","score_opus":0.04838962194209239,"score_gpt":0.46115735606448255,"score_spread":0.41276773412239015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981703267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946249,0.0005732503,0.00032012287,0.0018039657,0.0011677702,0.00058809354,0.0000012024931,0.000027359023,0.0008933002],"genre_scores_gemma":[0.9972352,0.00014727979,0.0014833569,0.00018496865,0.00044761132,0.000041394804,0.000008078882,0.00002373341,0.00042836758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998262,0.00018040392,0.0006691459,0.00018371301,0.0004282584,0.0002764632],"domain_scores_gemma":[0.9986593,0.00011950316,0.0007184482,0.0001414013,0.000259155,0.000102200116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011851635,0.00014622296,0.00050159614,0.00037782072,0.000047314603,0.000038700622,0.00012781372,0.00022452293,0.00037881976],"category_scores_gemma":[0.00008257583,0.00011902457,0.00012309971,0.00022985142,0.000040352967,0.00028453185,0.00003669856,0.0006041469,0.0000019986978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005810267,0.00027761294,0.6982824,0.00015992158,0.000059812293,0.00008490961,0.00086311105,0.00019444163,0.0026526214,0.000005663105,0.00019352067,0.29664493],"study_design_scores_gemma":[0.0025888216,0.002028521,0.9742987,0.0015568425,0.00065084366,0.00024032607,0.0018275044,0.0014168734,0.0072309,0.000066693196,0.007878821,0.00021514673],"about_ca_topic_score_codex":0.000095588155,"about_ca_topic_score_gemma":0.0000752169,"teacher_disagreement_score":0.29642978,"about_ca_system_score_codex":0.00061862357,"about_ca_system_score_gemma":0.000419072,"threshold_uncertainty_score":0.4853681},"labels":[],"label_agreement":null},{"id":"W2981714476","doi":"10.1016/j.jtho.2019.08.593","title":"MA12.02 Growth Patterns in Epithelioid Malignant Pleural Mesothelioma: A Clinicopathological Review of 614 Cases Over 15 Years","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Mesothelioma; Grading (engineering); Cohort; Retrospective cohort study; Overall survival; Pathology; Radiology; Internal medicine","score_opus":0.08138192123079707,"score_gpt":0.4747418796162103,"score_spread":0.3933599583854132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981714476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021756316,0.97631633,0.0000034848686,0.00024539846,0.0005083335,0.00071114616,0.00027941793,0.0000062352387,0.00017332658],"genre_scores_gemma":[0.0040757675,0.9939215,0.00031884797,0.00097210926,0.0003355114,0.000020723593,0.000083888626,0.0000456586,0.00022595479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956158,0.00085239427,0.0023242442,0.00032885428,0.0005674977,0.0003112307],"domain_scores_gemma":[0.99621654,0.00080100185,0.0023368055,0.00031881116,0.00010255598,0.00022428001],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012702851,0.00039771645,0.00414656,0.0004920224,0.0000132327295,0.000005869772,0.00032741862,0.00043106408,0.0012177039],"category_scores_gemma":[0.0006103058,0.0002498575,0.0013934062,0.0002958351,0.0001488126,0.00009101843,0.00015830962,0.0008015004,0.00012326731],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010891376,0.002056018,0.020946717,0.17143758,0.00032021737,0.013958076,0.00003467737,7.1955935e-7,0.000008048875,0.00001792218,0.0026278957,0.787503],"study_design_scores_gemma":[0.001115938,0.005903906,0.082684524,0.27142328,0.007396471,0.020076571,0.000041619267,0.0000018045862,0.0000046678942,0.00006923427,0.61082774,0.0004542527],"about_ca_topic_score_codex":0.000014081335,"about_ca_topic_score_gemma":0.0000037582436,"teacher_disagreement_score":0.78704876,"about_ca_system_score_codex":0.00047068074,"about_ca_system_score_gemma":0.0007298754,"threshold_uncertainty_score":0.99999535},"labels":[],"label_agreement":null},{"id":"W2981759705","doi":"10.1016/j.jtho.2019.08.1710","title":"P2.11-10 Discovery of Potential Biomarkers That Discriminate Early Stage NSCLC from Controls by Non-Targeted Metabolomics Profiling","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Metabolomics; Metabolome; Lung cancer; Oncology; Stage (stratigraphy); Adenocarcinoma; Carcinoma; Internal medicine; Concordance; Metabolite; Cancer; Bioinformatics; Biology","score_opus":0.010663085844505609,"score_gpt":0.3424001193653149,"score_spread":0.3317370335208093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981759705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829232,0.0011438768,0.010011411,0.0030482884,0.0017788031,0.00037109616,0.00007604651,0.0000126444465,0.0006346076],"genre_scores_gemma":[0.9857457,0.00018679137,0.011600033,0.0004163261,0.00036104044,0.0000028442153,0.000053307354,0.00004477847,0.0015891661],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752593,0.0003122965,0.00094512606,0.00027561162,0.000545526,0.0003955132],"domain_scores_gemma":[0.9974474,0.00037243098,0.001418162,0.00028849914,0.00022162909,0.0002519248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014161221,0.00024552856,0.001318877,0.00026869038,0.000050545583,0.00004701578,0.0003213376,0.00025058383,0.000224851],"category_scores_gemma":[0.00042050082,0.00018067153,0.0004098152,0.00015146566,0.00021622043,0.00038970704,0.00009310614,0.0008830985,0.00001235818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072518913,0.00053601875,0.057155505,0.00018248902,0.0013237415,0.00048009574,0.00039354563,0.0001418597,0.8983665,0.000035097415,0.0024993496,0.03163389],"study_design_scores_gemma":[0.042205907,0.015161446,0.30383748,0.0027474384,0.011113834,0.0017159834,0.008307197,0.06850041,0.47922584,0.0012941441,0.06386687,0.0020234606],"about_ca_topic_score_codex":0.00021123854,"about_ca_topic_score_gemma":0.0000033108934,"teacher_disagreement_score":0.41914067,"about_ca_system_score_codex":0.0001607838,"about_ca_system_score_gemma":0.00042255557,"threshold_uncertainty_score":0.7367571},"labels":[],"label_agreement":null},{"id":"W2981809197","doi":"10.1016/j.jtho.2019.08.2235","title":"EP1.11-14 Knowledge and Perspectives of Indian Medical Practitioners to Lung Cancer: A Regional Sample Survey","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Healthcare Systems and Reforms","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Referral; Family medicine; Specialty; Outreach; Quarter (Canadian coin); Health care; Cancer; Lung cancer screening; Internal medicine","score_opus":0.0610149044015846,"score_gpt":0.41307004067094955,"score_spread":0.35205513626936497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981809197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805148,0.0065375334,0.00027596197,0.009896843,0.0012201909,0.00018311203,0.00008916037,0.000003254557,0.0012791492],"genre_scores_gemma":[0.9971578,0.0013736486,0.0005253028,0.00023205052,0.00032908592,0.000005126438,0.0000032601506,0.000012214152,0.0003614877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985187,0.00014789405,0.00085894816,0.00018331129,0.0000866477,0.00020448447],"domain_scores_gemma":[0.99807364,0.00027284454,0.0009875761,0.00011871286,0.00026035984,0.00028688562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003223832,0.00009446895,0.0006740908,0.00039749598,0.000046457135,0.000011279392,0.00016873739,0.00023614775,0.00039945645],"category_scores_gemma":[0.0007324873,0.000076393524,0.00009063941,0.0002411214,0.00006841779,0.0001639064,0.000039103605,0.00031565374,0.000022613323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039066226,0.00033982057,0.934423,0.00042676306,0.00024841,0.000029441644,0.013851453,0.00003396547,0.000018474242,0.0047580814,0.005700025,0.039779864],"study_design_scores_gemma":[0.00075314613,0.0011409863,0.8624573,0.00030497395,0.000008997352,0.0003853899,0.003137695,0.00017180706,0.000015438285,0.0010924515,0.1303151,0.00021677172],"about_ca_topic_score_codex":0.0061491095,"about_ca_topic_score_gemma":0.00342088,"teacher_disagreement_score":0.124615066,"about_ca_system_score_codex":0.00044554018,"about_ca_system_score_gemma":0.00067801046,"threshold_uncertainty_score":0.9295655},"labels":[],"label_agreement":null},{"id":"W2981822363","doi":"10.1016/j.jtho.2019.08.1527","title":"P2.04-22 Programmed Death 1-mRNA Expression Predicts Benefit to Anti-PD1 Monotherapy in a Prospective Cohort of Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Oncology; Cohort; Internal medicine; Prospective cohort study","score_opus":0.013894854399624543,"score_gpt":0.3731552329488857,"score_spread":0.35926037854926113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981822363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929876,0.0013814692,0.00011146441,0.0011989825,0.0006564582,0.0017369458,0.000006273619,0.000017066162,0.0019037662],"genre_scores_gemma":[0.9914831,0.0005426357,0.0066738203,0.00046881108,0.00017752772,0.00004783262,0.0000033967433,0.00003384734,0.00056900823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785084,0.00011686608,0.0009623199,0.00027451184,0.00044626664,0.000349177],"domain_scores_gemma":[0.9982192,0.000118818774,0.0008204357,0.00029770963,0.00036283347,0.00018101452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009784988,0.00021118499,0.0010311368,0.00043651168,0.000027513288,0.0000099673,0.00022202371,0.00023712723,0.00020261348],"category_scores_gemma":[0.00008524953,0.00015817866,0.00024094735,0.0004532599,0.0000666494,0.00017207462,0.000041287094,0.0004251088,0.000006427167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049210645,0.0010126235,0.39509583,0.00010671556,0.00028889053,0.0001231392,0.0011311984,0.00009227252,0.32017228,0.000009585643,0.00024941258,0.2325074],"study_design_scores_gemma":[0.009125046,0.012343377,0.8575308,0.0014665724,0.00012912147,0.00043666645,0.00055050175,0.00004048062,0.10375866,0.00016742868,0.014249733,0.000201612],"about_ca_topic_score_codex":0.00004114237,"about_ca_topic_score_gemma":0.000028585717,"teacher_disagreement_score":0.46243498,"about_ca_system_score_codex":0.0006426956,"about_ca_system_score_gemma":0.0004879298,"threshold_uncertainty_score":0.64503384},"labels":[],"label_agreement":null},{"id":"W2981824263","doi":"10.1016/j.jtho.2019.08.1184","title":"P1.14-33 Canagliflozin Inhibits Lung Cancer Survival and Enhances Its Response to Radiotherapy; Effective Blockade of mTOR Pathway, HIF1a, and Mitosis","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Health Research","keywords":"Medicine; AMPK; Cancer research; PI3K/AKT/mTOR pathway; Clonogenic assay; Protein kinase B; Lung cancer; Radiation therapy; Internal medicine; Apoptosis; Kinase; Protein kinase A; Biology","score_opus":0.00848364674362762,"score_gpt":0.35069227533333325,"score_spread":0.34220862858970563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981824263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8041109,0.19421937,0.00003950494,0.0003645141,0.0008831627,0.0002728676,0.000048277187,0.0000020047403,0.00005939889],"genre_scores_gemma":[0.9653567,0.032771233,0.0004895173,0.0003867465,0.0006645299,0.000022265682,0.0000016316445,0.000024225987,0.0002831593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828523,0.00057737884,0.00040797694,0.0002766352,0.00019015538,0.00026264798],"domain_scores_gemma":[0.9987856,0.00016829754,0.0004283536,0.00016183742,0.0002580166,0.00019789652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010528727,0.00018773216,0.0006142454,0.000113876355,0.000040240233,0.00001538937,0.00016139407,0.00023151879,0.000052896023],"category_scores_gemma":[0.00018097223,0.00015652787,0.000096861804,0.0001238642,0.00008372636,0.000013782487,0.00007806305,0.00021122767,8.169074e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004989374,0.00006163141,0.0034451468,0.00010251544,0.00027835896,0.000007095301,0.00038469527,0.000038702336,0.8004618,0.0000033001002,0.00075027876,0.18947709],"study_design_scores_gemma":[0.001180651,0.0022629136,0.009317274,0.00014492939,0.0001270218,0.00003271456,0.00020223444,0.000025341667,0.80916166,0.00000937767,0.17733428,0.00020162034],"about_ca_topic_score_codex":0.00006291159,"about_ca_topic_score_gemma":0.00035456187,"teacher_disagreement_score":0.18927547,"about_ca_system_score_codex":0.00009249192,"about_ca_system_score_gemma":0.00041916384,"threshold_uncertainty_score":0.63830215},"labels":[],"label_agreement":null},{"id":"W2981882650","doi":"10.1016/j.jtho.2019.08.687","title":"MA22.07 A Culturally Safe Advocacy Model of Care for Inuit Cancer Patients and Their Families","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Indigenous Studies and Ecology","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Equity (law); Context (archaeology); Indigenous; Government (linguistics); Health care; Cornerstone; Nursing; Economic growth; Public relations; Political science; Geography","score_opus":0.03332406453429803,"score_gpt":0.4442560564588825,"score_spread":0.41093199192458446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981882650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929176,0.0011497358,0.00006298751,0.0011472779,0.0013826335,0.0009404926,0.00011183603,0.000004728418,0.0022827343],"genre_scores_gemma":[0.99551404,0.0011558736,0.0012374271,0.00088442117,0.00020881648,0.000048997903,0.0000043594046,0.000016309206,0.0009297885],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99835724,0.0001904562,0.0007298511,0.00012904986,0.00009648535,0.00049693446],"domain_scores_gemma":[0.9969962,0.00042167102,0.0009935641,0.00009646453,0.0014151661,0.00007690139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047965764,0.00013816425,0.0007630713,0.00010423866,0.0005678417,0.0000021637638,0.00016457583,0.0002653517,0.00012497869],"category_scores_gemma":[0.00011367299,0.00008817894,0.00012159667,0.00005547509,0.000062635336,0.000088474764,0.00015498434,0.0004045182,0.00001131435],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041515413,0.00032302336,0.14156663,0.002281561,0.00041574187,0.0000034431325,0.76857114,0.0009871492,0.0011790772,0.00016441967,0.0063325553,0.074023716],"study_design_scores_gemma":[0.00652928,0.014617472,0.05685298,0.00076975516,0.0004628562,0.000021303149,0.81311846,0.0016929752,0.0003236483,0.0020810056,0.10298249,0.00054777774],"about_ca_topic_score_codex":0.00028583826,"about_ca_topic_score_gemma":0.009922911,"teacher_disagreement_score":0.09664993,"about_ca_system_score_codex":0.00066096184,"about_ca_system_score_gemma":0.0014962081,"threshold_uncertainty_score":0.5537218},"labels":[],"label_agreement":null},{"id":"W2981887067","doi":"10.1016/j.jtho.2019.08.2187","title":"EP1.07-02 Role of Nurse in Patient Care During Immunotherapy Treatment Through Example of Canada and Poland","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Polish Law and Legal System","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Competence (human resources); Nursing; Cancer treatment; Clinical trial; Scope (computer science); Family medicine; Cancer; Management; Internal medicine","score_opus":0.010944635063954182,"score_gpt":0.34042797722692897,"score_spread":0.3294833421629748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981887067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855479,0.002407501,4.4055156e-7,0.0002022316,0.0004017288,0.00015437092,0.000010897334,0.00000140873,0.011273493],"genre_scores_gemma":[0.9994785,0.00015988325,0.00008227456,0.0000226695,0.00007968843,0.0000016689505,3.7137238e-7,0.000005199471,0.00016971694],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987886,0.0002737408,0.0004335888,0.0000806735,0.0002271465,0.00019627147],"domain_scores_gemma":[0.9990889,0.00011461822,0.0005295438,0.00009055439,0.00011258543,0.00006378912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002577263,0.00007380205,0.0004186036,0.00005167875,0.00005506069,0.0000065487725,0.00011214129,0.00008521015,0.0000654297],"category_scores_gemma":[0.000019978279,0.000057350237,0.000056240504,0.00008195471,0.00006848682,0.00012438324,0.000010445752,0.00009161058,5.1799157e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002148664,0.00065174856,0.43524843,0.00022124234,0.00031360498,0.00018567321,0.40473473,0.00018462304,0.02769458,0.0023796514,0.00017934378,0.1260577],"study_design_scores_gemma":[0.004337226,0.007995032,0.26480225,0.00057927635,0.00011392648,0.00014719796,0.26685306,0.0000066460884,0.032250978,0.0010153436,0.42146873,0.00043031102],"about_ca_topic_score_codex":0.7611453,"about_ca_topic_score_gemma":0.6859643,"teacher_disagreement_score":0.42128938,"about_ca_system_score_codex":0.0008481525,"about_ca_system_score_gemma":0.0012320955,"threshold_uncertainty_score":0.319766},"labels":[],"label_agreement":null},{"id":"W2981888282","doi":"10.1016/j.jtho.2019.08.1709","title":"P2.11-09 Australia-Wide Cross-Sectional Survey of General Practitioners’ Knowledge and Practice of Lung Cancer Screening","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bentley (Canada)","funders":"","keywords":"Medicine; Lung cancer screening; Family medicine; Respondent; Logistic regression; Demographics; Cross-sectional study; Lung cancer; Demography; Internal medicine; Pathology","score_opus":0.07395906576353763,"score_gpt":0.5068126662436997,"score_spread":0.4328536004801621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981888282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367607,0.002352218,0.00010222257,0.001403876,0.00091641786,0.00023921738,0.000040158186,0.0000035993316,0.001266224],"genre_scores_gemma":[0.9934297,0.00073727476,0.0042282897,0.00014030146,0.0002959081,0.000008058531,0.000012534517,0.000014895908,0.0011330049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820906,0.00040117418,0.000735965,0.00017472293,0.00030339148,0.00017570068],"domain_scores_gemma":[0.99535096,0.0015988422,0.0014114212,0.0001433127,0.0013562312,0.0001392063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018070051,0.00013105242,0.0006292267,0.00018260772,0.000038479644,0.000012946171,0.000077224344,0.00016798083,0.00038916303],"category_scores_gemma":[0.00071433105,0.000103286045,0.0001319145,0.00018505701,0.00011543721,0.00031647444,0.00004222335,0.00029717077,0.0000036178278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033497298,0.00077328604,0.9872687,0.00027225105,0.000815824,0.000056333207,0.00022205382,0.00024237917,0.0013941922,0.000039657087,0.0030380343,0.002527552],"study_design_scores_gemma":[0.0019014331,0.00165425,0.9825687,0.0002679395,0.000532912,0.00085229095,0.00006266817,0.00008974385,0.002362604,0.000010457476,0.009616302,0.00008069987],"about_ca_topic_score_codex":0.0013738334,"about_ca_topic_score_gemma":0.0003813513,"teacher_disagreement_score":0.0065782676,"about_ca_system_score_codex":0.00053095026,"about_ca_system_score_gemma":0.00071770354,"threshold_uncertainty_score":0.42610624},"labels":[],"label_agreement":null},{"id":"W2981939799","doi":"10.1016/j.jtho.2019.08.473","title":"OA12.03 Initial Reporting of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg; University of Texas MD Anderson Cancer Center; Universität des Saarlandes; Johannes Gutenberg-Universität Mainz; NRG Oncology; Thomas Jefferson University; Erasmus+; Albert-Ludwigs-Universität Freiburg; Hamilton Health Sciences","keywords":"Medicine; Internal medicine; Carboplatin; Clinical endpoint; Metformin; Chemoradiotherapy; Oncology; Regimen; Randomized controlled trial; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Lung cancer; Cumulative incidence; Hazard ratio; Phases of clinical research; Chemotherapy; Confidence interval; Cohort; Cisplatin","score_opus":0.03828137303503014,"score_gpt":0.4626978119202523,"score_spread":0.4244164388852221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981939799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98974043,0.00094702694,0.0010018722,0.0012021443,0.0022172483,0.0014264698,0.0000025440293,0.0000076018146,0.0034546836],"genre_scores_gemma":[0.9950075,0.00041400205,0.00343951,0.0002316027,0.00042984352,0.000013858304,0.0000049838336,0.000020234525,0.00043842578],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946447,0.00029068292,0.00409478,0.00018274457,0.0005143851,0.00027270784],"domain_scores_gemma":[0.99114597,0.0005526778,0.0075784978,0.00023295011,0.0003755126,0.000114383765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054178205,0.00019687605,0.0032865517,0.00055366015,0.000019613106,0.0000049205814,0.00018924296,0.00015742709,0.000397363],"category_scores_gemma":[0.0019629947,0.00014570924,0.0006344492,0.0003500961,0.00015776147,0.00016606857,0.000050504852,0.0004509977,0.0000018806461],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60337794,0.0014009195,0.0004480066,0.00021768246,0.0003490687,0.0002613206,0.0005273126,0.000043150005,0.005036232,0.000041782278,0.00022534127,0.38807124],"study_design_scores_gemma":[0.96140563,0.016507786,0.00022185434,0.0005770291,0.0007210333,0.0003585043,0.00062682113,0.00035654852,0.011197088,0.0001222295,0.007752422,0.00015304325],"about_ca_topic_score_codex":0.000020916694,"about_ca_topic_score_gemma":0.000009463543,"teacher_disagreement_score":0.38791817,"about_ca_system_score_codex":0.00028732908,"about_ca_system_score_gemma":0.0007760189,"threshold_uncertainty_score":0.59418505},"labels":[],"label_agreement":null},{"id":"W2981943177","doi":"10.1016/j.jtho.2019.08.228","title":"IBS14.02 Best Management of Early Stage NSCLC in ILD Patients","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Interstitial lung disease; SABR volatility model; Tolerability; Pulmonary toxicity; Stage (stratigraphy); Internal medicine; Idiopathic pulmonary fibrosis; Radiation therapy; Lung cancer; Oncology; Lung; Adverse effect","score_opus":0.0140861869817639,"score_gpt":0.36481958969353306,"score_spread":0.35073340271176917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981943177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812481,0.00031931998,0.000024671113,0.00040481277,0.0007742218,0.00028312908,0.000015418958,0.0000033893396,0.016926937],"genre_scores_gemma":[0.9964096,0.00017105213,0.0008343935,0.00017842285,0.000116410054,0.0000023219118,0.000004380278,0.000014356296,0.0022690517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859786,0.00009363926,0.00065302383,0.00012592277,0.0003250875,0.00020444042],"domain_scores_gemma":[0.9989472,0.000039649807,0.00049136824,0.00017541462,0.00021795856,0.00012838277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003649932,0.000111914414,0.00052399095,0.00024764152,0.000013822861,0.0000052359196,0.00015253082,0.00011695943,0.00030676584],"category_scores_gemma":[0.000017986364,0.00009089549,0.00019866375,0.00015317586,0.000047950474,0.00012758808,0.00006736011,0.00029745713,0.000058539666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0919843,0.009941757,0.6532803,0.0036066123,0.00091650174,0.0043559885,0.0012549795,0.00010732534,0.0040810523,0.0014506625,0.0024002506,0.22662026],"study_design_scores_gemma":[0.0066458383,0.08222167,0.8617904,0.0051744133,0.0010054332,0.0002004677,0.0023381736,0.00012157531,0.0008968248,0.000303892,0.03894886,0.00035244055],"about_ca_topic_score_codex":0.00003771714,"about_ca_topic_score_gemma":0.0000028779764,"teacher_disagreement_score":0.22626781,"about_ca_system_score_codex":0.00026039293,"about_ca_system_score_gemma":0.0001377408,"threshold_uncertainty_score":0.37066105},"labels":[],"label_agreement":null},{"id":"W2981956709","doi":"10.1016/j.jtho.2019.08.374","title":"MS16.04 Bronchoscopic Lung Cancer Ablation","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Bronchopleural fistula; Pneumothorax; Radiofrequency ablation; Radiology; Percutaneous; Surgery; Radiation therapy; Treatment of lung cancer; Microwave ablation; Stage (stratigraphy); Cryotherapy; Population; Ablation; Pneumonectomy; Oncology; Internal medicine","score_opus":0.016114963415045532,"score_gpt":0.43262332589885905,"score_spread":0.4165083624838135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981956709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786632,0.0043569137,0.00005961023,0.009453162,0.0018788934,0.0002671444,0.0000024431845,0.000008752349,0.0053098453],"genre_scores_gemma":[0.9943037,0.001020154,0.0011550541,0.0009340438,0.00067463255,0.000011000808,0.0000023572231,0.000013976234,0.0018850549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990829,0.00006001017,0.00035886315,0.000115382,0.00022021263,0.00016259462],"domain_scores_gemma":[0.9990519,0.00009585138,0.00038915893,0.00014272165,0.00019844055,0.00012190293],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024719595,0.00009618249,0.00043569223,0.00011896585,0.000024529192,0.000009037964,0.000066902,0.00011119557,0.0016281172],"category_scores_gemma":[0.000025441146,0.00006812411,0.00013004587,0.00010686369,0.000021267404,0.00010815898,0.000017488865,0.00023074975,0.00004457976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012044971,0.00065193255,0.7992683,0.00035177075,0.00071009627,0.00025932447,0.00062824046,0.00016553793,0.002022662,0.000082943516,0.02562545,0.16902925],"study_design_scores_gemma":[0.0050194417,0.005931534,0.72387284,0.0015344048,0.002083219,0.00086921715,0.00021834818,0.00056151306,0.0073866462,0.00025818896,0.25204694,0.00021770237],"about_ca_topic_score_codex":0.0000530084,"about_ca_topic_score_gemma":0.000039143833,"teacher_disagreement_score":0.2264215,"about_ca_system_score_codex":0.0014697127,"about_ca_system_score_gemma":0.0005707965,"threshold_uncertainty_score":0.9992845},"labels":[],"label_agreement":null},{"id":"W2981978294","doi":"10.1016/j.jtho.2019.08.839","title":"P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L)","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Crizotinib; Quality of life (healthcare); Oncology; Internal medicine; Nursing; Lung cancer","score_opus":0.10817143177756502,"score_gpt":0.48927874484780903,"score_spread":0.38110731307024404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981978294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99201584,0.0014497654,0.000013292465,0.0040076245,0.0005595006,0.0014994226,0.000081464634,0.000011597052,0.0003614989],"genre_scores_gemma":[0.998017,0.00021512737,0.0010561405,0.000315245,0.00012948885,0.000008426734,0.00006552226,0.000037415906,0.00015562466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99224764,0.0014670426,0.0045514135,0.00046521652,0.000781927,0.00048678447],"domain_scores_gemma":[0.99298996,0.0012219716,0.003963465,0.0011751319,0.00029285878,0.00035664506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0062674624,0.000299118,0.003045039,0.00067104684,0.000029465727,0.0000055966607,0.0006411456,0.00030810985,0.00047038644],"category_scores_gemma":[0.0024082088,0.0002495582,0.00014715607,0.00079993653,0.00012725683,0.0002542611,0.0002909721,0.0011592448,0.000017817461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.066526346,0.05703552,0.7553988,0.0025995327,0.0015952638,0.0013313422,0.010843954,0.0005021362,0.0027850517,0.00002595339,0.0018897328,0.099466376],"study_design_scores_gemma":[0.18940127,0.09059685,0.6939731,0.0039917426,0.0009323822,0.0011026543,0.011070776,0.003521241,0.0007849863,0.00025078407,0.0037498097,0.0006243658],"about_ca_topic_score_codex":0.003664803,"about_ca_topic_score_gemma":0.004825827,"teacher_disagreement_score":0.122874916,"about_ca_system_score_codex":0.0017535861,"about_ca_system_score_gemma":0.0038914003,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W2982001755","doi":"10.1016/j.jtho.2019.08.1907","title":"P2.16-40 Acknowledging Social and Economic Inequities Experienced by Canada’s Inuit: Implications for Diagnosis and Treatment of Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Population; Mainstream; Health care; Indigenous; Government (linguistics); Palliative care; Socioeconomics; Economic growth; Nursing; Family medicine; Environmental health; Political science; Sociology; Pathology","score_opus":0.07801476904714581,"score_gpt":0.5384940080069934,"score_spread":0.4604792389598476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982001755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97975767,0.0030173569,0.000013604974,0.015430455,0.00068003277,0.0004124869,0.00015508155,0.000004000104,0.00052929815],"genre_scores_gemma":[0.99679124,0.0016837618,0.000183326,0.0003058308,0.00021313476,0.00031632115,0.0000034685302,0.00000964584,0.00049327186],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.998808,0.00028778423,0.0005843881,0.0000939492,0.00004050075,0.00018536406],"domain_scores_gemma":[0.9976669,0.0011494565,0.0007454003,0.00011313524,0.00025065214,0.000074466356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031743932,0.00007988087,0.00038253158,0.00006254031,0.00034991387,0.000004559794,0.00011953695,0.00011892452,0.00014254391],"category_scores_gemma":[0.00006728385,0.00006772291,0.000038463164,0.000027070952,0.000059566966,0.000060508584,0.000049304075,0.00016250987,4.4934552e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000617006,0.00009876691,0.74272436,0.00055155944,0.00015701949,3.7278292e-7,0.086680956,0.0000074897266,0.00035028943,0.0010769698,0.035103485,0.1326317],"study_design_scores_gemma":[0.0041139987,0.0043095974,0.2914369,0.0016979148,0.0005331215,0.000047153953,0.17413557,0.0009815086,0.0015032382,0.0016204739,0.51896554,0.00065496465],"about_ca_topic_score_codex":0.051579323,"about_ca_topic_score_gemma":0.3288569,"teacher_disagreement_score":0.48386207,"about_ca_system_score_codex":0.002179867,"about_ca_system_score_gemma":0.0030391372,"threshold_uncertainty_score":0.9547363},"labels":[],"label_agreement":null},{"id":"W2982040065","doi":"10.1016/j.jtho.2019.08.424","title":"OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Ipilimumab; Cohort; Internal medicine; Nivolumab; Discontinuation; Oncology; Adverse effect; Cancer; Immunotherapy","score_opus":0.015037087101347242,"score_gpt":0.3432745938222109,"score_spread":0.32823750672086366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982040065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951262,0.00027218356,0.000036835754,0.001375858,0.00051732565,0.00042617565,0.00000867956,0.000008025374,0.0022287015],"genre_scores_gemma":[0.99602807,0.0000716816,0.002500516,0.0005275242,0.0003858838,0.000004114956,0.0000053679373,0.000029229494,0.00044763385],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987733,0.0000665485,0.0004990761,0.00017360436,0.00025803127,0.00022945572],"domain_scores_gemma":[0.998992,0.000055258417,0.00051506236,0.00017119589,0.00016925347,0.00009722849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002889414,0.00016134074,0.0005428407,0.00023797007,0.000047350506,0.000012658935,0.00008427538,0.00012359329,0.00043304238],"category_scores_gemma":[0.000023496514,0.00010651187,0.00006659902,0.00023372477,0.00009519519,0.00017239027,0.00001887006,0.00031482603,0.000009357315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11848512,0.001101706,0.6706893,0.00011605856,0.00029243284,0.00009896071,0.0008141178,0.00016225928,0.00041772547,0.000015929216,0.0006418794,0.20716453],"study_design_scores_gemma":[0.024717752,0.015700106,0.9193359,0.00072853465,0.0002006251,0.00037576552,0.00030579857,0.00005594561,0.0002246023,0.000073286144,0.0380533,0.00022836459],"about_ca_topic_score_codex":0.00003351874,"about_ca_topic_score_gemma":0.0006957463,"teacher_disagreement_score":0.24864665,"about_ca_system_score_codex":0.00034841473,"about_ca_system_score_gemma":0.00023765383,"threshold_uncertainty_score":0.47415102},"labels":[],"label_agreement":null},{"id":"W2982042823","doi":"10.1016/j.jtho.2019.08.2257","title":"EP1.12-12 Factors Associated with Survival Outcomes Among Relapsed SCLC Diagnosed at a Canadian Cancer Centre","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Proportional hazards model; Hazard ratio; Lung cancer; Stage (stratigraphy); Multivariate analysis; Oncology; Survival analysis; Chemotherapy; Retrospective cohort study; Cancer; Confidence interval","score_opus":0.0420348322713473,"score_gpt":0.41250479156459924,"score_spread":0.37046995929325194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982042823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98436654,0.00037504462,0.0000014107117,0.008743283,0.0013487703,0.00054647005,0.000049473078,0.000021325779,0.0045476947],"genre_scores_gemma":[0.9878702,0.0002057966,0.00005394204,0.00046984246,0.00019566121,0.000010023643,0.000013724687,0.000046436784,0.011134362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971799,0.00038897587,0.0005566314,0.00026002043,0.0008195784,0.0007948873],"domain_scores_gemma":[0.996713,0.0009519753,0.0006996091,0.00026193872,0.00057808403,0.00079538266],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008715805,0.00027520105,0.0013024596,0.0004211289,0.00015506742,0.000021574606,0.00025090118,0.00026197807,0.00107844],"category_scores_gemma":[0.0012379792,0.00017560029,0.0002363139,0.00027032418,0.00021316676,0.00017287627,0.00008687573,0.00087655935,0.000027226375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010452758,0.00016389647,0.984342,0.00006093493,0.0015319211,0.001401198,0.001343103,0.000038623686,0.00016687735,0.0000027141512,0.007907388,0.0019960655],"study_design_scores_gemma":[0.003365275,0.0014712064,0.9801669,0.0004411179,0.00048206843,0.00003825457,0.0011965748,0.000016778627,0.00020795806,0.000008377969,0.01241864,0.00018684698],"about_ca_topic_score_codex":0.033180024,"about_ca_topic_score_gemma":0.6732214,"teacher_disagreement_score":0.6400414,"about_ca_system_score_codex":0.006982632,"about_ca_system_score_gemma":0.0030779713,"threshold_uncertainty_score":0.9998347},"labels":[],"label_agreement":null},{"id":"W2982047090","doi":"10.1016/j.jtho.2019.08.1872","title":"P2.16-05 Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Population; Lung cancer; Cancer; ROS1; Fluorescence in situ hybridization; Oncology; Gold standard (test); Internal medicine; Pathology; Adenocarcinoma; Environmental health; Gene; Biology","score_opus":0.026911764099217327,"score_gpt":0.3693624897045964,"score_spread":0.3424507256053791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982047090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957606,0.00091440766,0.0002144955,0.0004205578,0.0006513536,0.00020904721,0.000015910304,0.0000046478817,0.0018089585],"genre_scores_gemma":[0.9973045,0.000051151084,0.0018195694,0.00036130912,0.0003360322,0.000012343109,0.00002589185,0.000020177535,0.00006900455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848247,0.00018386687,0.00070608116,0.00021252116,0.00013786007,0.00027720953],"domain_scores_gemma":[0.99850315,0.00023497966,0.00070048013,0.00019655935,0.0002269696,0.00013784006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010152506,0.00013862636,0.00040405215,0.00022822831,0.000039019884,0.000033846256,0.00021333095,0.00022229162,0.00002872858],"category_scores_gemma":[0.00080639083,0.00013697997,0.0000866624,0.000246665,0.000018626735,0.000011937892,0.000070253125,0.00028726898,0.0000011141548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039886712,0.00013308617,0.9555328,0.00017815924,0.000029929093,0.00007439311,0.00004240351,0.014114056,0.011450232,0.000053658154,0.00029362002,0.01769883],"study_design_scores_gemma":[0.006720365,0.0041812193,0.9007603,0.0020056723,0.00024494893,0.0006720528,0.0023004296,0.0524278,0.013627439,0.00021907227,0.01568544,0.0011552864],"about_ca_topic_score_codex":0.0029390887,"about_ca_topic_score_gemma":0.006867117,"teacher_disagreement_score":0.05477249,"about_ca_system_score_codex":0.0008771136,"about_ca_system_score_gemma":0.0010580021,"threshold_uncertainty_score":0.5585881},"labels":[],"label_agreement":null},{"id":"W2982051750","doi":"10.1016/j.jtho.2019.08.688","title":"MA22.09 Challenging Negative Stereotypes Around Lung Cancer in Ireland","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Quarter (Canadian coin); Family medicine; Disease; Irish; Pathology","score_opus":0.04946321856358949,"score_gpt":0.45167597212596305,"score_spread":0.40221275356237357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982051750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813684,0.004686346,0.00009275594,0.0049221553,0.0008685687,0.00018459142,0.000002123852,0.0000064737646,0.007868567],"genre_scores_gemma":[0.9967914,0.0006065631,0.0008957771,0.000601308,0.0004735302,0.000003477762,4.7391669e-7,0.00001180827,0.00061565166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987581,0.00010563926,0.00046304433,0.00013750406,0.00027387778,0.00026184897],"domain_scores_gemma":[0.9990411,0.00016471872,0.00039223567,0.00011524154,0.00016699571,0.00011971403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006470152,0.00011627301,0.00056035776,0.00022685608,0.000027203285,0.000012388076,0.00012417111,0.00013883066,0.0004176591],"category_scores_gemma":[0.00008152804,0.00009034116,0.00010486129,0.00017044567,0.000037955986,0.00021907523,0.000036973703,0.0005778024,0.0000228892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006006362,0.00020363896,0.78990674,0.0003117452,0.0003711721,0.0019948666,0.003187458,0.0023011446,0.002700931,0.0001266619,0.0017253103,0.19116396],"study_design_scores_gemma":[0.009068634,0.008639113,0.89654756,0.006738395,0.0010830205,0.0060253013,0.017942552,0.010350355,0.002878493,0.0016074195,0.038363792,0.0007553545],"about_ca_topic_score_codex":0.00014085103,"about_ca_topic_score_gemma":0.00023288348,"teacher_disagreement_score":0.1904086,"about_ca_system_score_codex":0.00071059086,"about_ca_system_score_gemma":0.00044740614,"threshold_uncertainty_score":0.45730743},"labels":[],"label_agreement":null},{"id":"W2982060206","doi":"10.1016/j.jtho.2019.08.634","title":"MA16.09 Clinical Practice and Outcomes in Patients with Stage III Unresectable Non-Small-Cell Lung Canceran Academic Centre, Canada","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Radiation therapy; Proportional hazards model; Lung cancer; Multivariate analysis; Retrospective cohort study; Cohort; Oncology; Surgery","score_opus":0.013554247824153636,"score_gpt":0.42283534156579977,"score_spread":0.4092810937416461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982060206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905924,0.0004922063,0.000018678884,0.0036323667,0.00070857647,0.00055027433,0.000016525195,0.0000031350132,0.0039858185],"genre_scores_gemma":[0.99262506,0.0002507144,0.0016648537,0.0014492659,0.00010058301,0.000003872388,0.0000075228018,0.000017727538,0.0038804205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984468,0.00014398742,0.000655282,0.00017979355,0.00030730182,0.0002668349],"domain_scores_gemma":[0.9981532,0.00047987513,0.00068844954,0.00014166323,0.0003057751,0.00023104915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047812192,0.00013852917,0.0006447796,0.00011173881,0.000037096448,0.000009012697,0.00009005574,0.00014429071,0.000083976985],"category_scores_gemma":[0.00013308108,0.00009230122,0.000047362035,0.00013276824,0.000033037424,0.00023036337,0.00003306225,0.0007498116,0.0000029764776],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029764394,0.0005053582,0.98475474,0.00008749717,0.0003044994,0.00028786054,0.00038271432,0.00006322842,0.000010010731,0.0000044479275,0.0013868677,0.009236351],"study_design_scores_gemma":[0.011880804,0.002297885,0.9459927,0.00019897452,0.0008246332,0.000060222974,0.0014881623,0.00005772374,0.00003721589,0.0000047072826,0.037031777,0.00012518991],"about_ca_topic_score_codex":0.028974485,"about_ca_topic_score_gemma":0.07173048,"teacher_disagreement_score":0.042755995,"about_ca_system_score_codex":0.0011308299,"about_ca_system_score_gemma":0.0037020787,"threshold_uncertainty_score":0.9774917},"labels":[],"label_agreement":null},{"id":"W2982063399","doi":"10.1016/j.jtho.2019.08.527","title":"MA04.10 Development and Validation of a Gene Expression-Based Prognostic Signature in Early-Stage Squamous Cell Carcinoma of the Lung","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Stage (stratigraphy); Gene signature; Oncology; Basal cell; Lung; Signature (topology); Squamous-cell carcinoma of the lung; Gene expression; Internal medicine; Gene; Cancer research; Pathology; Genetics; Biology","score_opus":0.012718554698975771,"score_gpt":0.3540706444717813,"score_spread":0.34135208977280557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982063399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99779665,0.00076410954,0.00009095897,0.0003098372,0.00015385637,0.00040983007,0.0000054020506,0.000001556638,0.0004678188],"genre_scores_gemma":[0.99489146,0.0000028930338,0.0044798427,0.000048393296,0.000024997435,0.000006765534,0.0000042174925,0.000008131974,0.0005333168],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991226,0.0000998273,0.00040442287,0.00008532649,0.00019213246,0.00009569452],"domain_scores_gemma":[0.99895704,0.0001666688,0.0005354318,0.00010883869,0.00018287021,0.00004914867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002324137,0.00007731511,0.00029348937,0.00013804004,0.000020121548,0.0000029967348,0.00006761569,0.000099584104,0.000070734925],"category_scores_gemma":[0.00006168209,0.000046707297,0.00005518499,0.00012451963,0.000032042535,0.000044272765,0.000018495064,0.00017162239,8.5634304e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011434434,0.00078101695,0.8849915,0.00062241155,0.000048285936,0.000086943925,0.0038627696,0.0006961261,0.10394158,0.0000037394432,0.00017002868,0.0036521405],"study_design_scores_gemma":[0.0023965538,0.0011758484,0.45917842,0.00026183735,0.0002604568,0.000037318365,0.00043409455,0.00011335829,0.5354779,0.000009484617,0.0005989271,0.00005583906],"about_ca_topic_score_codex":0.000013172243,"about_ca_topic_score_gemma":0.0000041275657,"teacher_disagreement_score":0.43153626,"about_ca_system_score_codex":0.00020260784,"about_ca_system_score_gemma":0.0008791185,"threshold_uncertainty_score":0.19046684},"labels":[],"label_agreement":null},{"id":"W2982136902","doi":"10.1016/j.jtho.2019.08.2222","title":"EP1.11-01 Lung Cancer Screening and Canada’s Inuit: A Missed Opportunity","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Life expectancy; Population; Demography; Lung cancer; Incidence (geometry); Lung cancer screening; Cancer; Gerontology; Environmental health; Internal medicine","score_opus":0.09395342587525865,"score_gpt":0.5252068799500609,"score_spread":0.4312534540748022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982136902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9484973,0.0012124068,0.000062060535,0.042889934,0.0018749496,0.00028723845,0.00002171329,0.000013168712,0.0051412564],"genre_scores_gemma":[0.9872197,0.00027810424,0.0013768505,0.007659985,0.0003187232,0.000014938569,0.0000020729174,0.000017014821,0.0031126437],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682647,0.0016177387,0.0008576462,0.000119472854,0.00022918529,0.00034948325],"domain_scores_gemma":[0.9963041,0.0013302286,0.0011561491,0.00028654377,0.00058368046,0.00033928908],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018837294,0.00011368882,0.00045240636,0.00011457812,0.00039490865,0.000006309763,0.00032815206,0.00024242923,0.0013222846],"category_scores_gemma":[0.0004999025,0.00009555485,0.000052575542,0.000082029386,0.000039818435,0.000088582805,0.00014848557,0.0014410805,0.000004408049],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013685336,0.00008692159,0.7304173,0.0013250489,0.00019616405,0.00011654263,0.020210214,0.00006689069,0.0004650722,0.00043227774,0.13644738,0.10886765],"study_design_scores_gemma":[0.0017851802,0.0009362036,0.1640217,0.005188288,0.00027375264,0.00037385282,0.053413875,0.0036563152,0.000086349144,0.0003630584,0.7693776,0.00052386755],"about_ca_topic_score_codex":0.33018586,"about_ca_topic_score_gemma":0.6369988,"teacher_disagreement_score":0.63293016,"about_ca_system_score_codex":0.0010683791,"about_ca_system_score_gemma":0.010994905,"threshold_uncertainty_score":0.99959064},"labels":[],"label_agreement":null},{"id":"W2982138023","doi":"10.1016/j.jtho.2019.08.317","title":"MS04.04 Optimal Clinical Trial Design for Adjuvant Systemic Therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Oncology; Clinical trial; Generalizability theory; Systemic therapy; Adjuvant therapy; Stage (stratigraphy); Intensive care medicine; Internal medicine; Adjuvant; Cancer; Breast cancer","score_opus":0.7109457035851906,"score_gpt":0.6913900502921834,"score_spread":0.019555653293007236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982138023","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32367072,0.00034075775,0.6583616,0.0009690877,0.013419775,0.0027797746,0.000022519955,0.00003452216,0.00040125198],"genre_scores_gemma":[0.06755219,0.00026136043,0.92747045,0.00038764626,0.003800024,0.00004664115,4.0376455e-7,0.00006010054,0.0004212217],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9883025,0.006218388,0.0041750274,0.0003563031,0.0004975712,0.00045016338],"domain_scores_gemma":[0.8423397,0.15322219,0.003073044,0.0004533015,0.0006389811,0.00027276116],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.036374565,0.00026458295,0.0026631744,0.0001504742,0.00005690283,0.00003769159,0.00071543024,0.00072680926,0.00041034128],"category_scores_gemma":[0.088077165,0.00018318385,0.0009431501,0.00014791847,0.00017714607,0.000110635905,0.0000766373,0.00094734214,0.00007290903],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4516419,0.002407171,0.00015171841,0.00026981375,0.00089662283,0.00013841975,0.0001674627,0.00011401498,0.00091300986,0.0073223305,0.020118017,0.51585954],"study_design_scores_gemma":[0.11633316,0.089776345,0.00013999222,0.000602471,0.001119569,0.0009854775,0.00037318424,0.0016579559,0.0015601233,0.7608708,0.025952963,0.0006279251],"about_ca_topic_score_codex":5.088803e-7,"about_ca_topic_score_gemma":2.2131583e-7,"teacher_disagreement_score":0.7535485,"about_ca_system_score_codex":0.00021150615,"about_ca_system_score_gemma":0.0008448011,"threshold_uncertainty_score":0.99225515},"labels":[],"label_agreement":null},{"id":"W2982142323","doi":"10.1016/j.jtho.2019.08.695","title":"MA23.06 Development of a Novel Genetically Engineered Mouse Model of Malignant Pleural Mesothelioma","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Mesothelioma; CDKN2A; Asbestos; Medicine; Pleural disease; Pathology; Cancer research; Pleural effusion; Respiratory disease; Cancer; Lung; Internal medicine","score_opus":0.02946915334534712,"score_gpt":0.37280849606194116,"score_spread":0.34333934271659405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982142323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99117404,0.0004346033,0.007788008,0.000105269675,0.00007085891,0.00014733964,0.000039650375,0.0000014791163,0.00023877043],"genre_scores_gemma":[0.95659155,0.00011106443,0.04247669,0.000033445605,0.000048680897,0.0000045174856,0.000011374261,0.000016176033,0.0007064968],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987605,0.00004963552,0.0005655598,0.00014212752,0.0002561389,0.00022604101],"domain_scores_gemma":[0.9989856,0.000021211064,0.0003752272,0.00019934092,0.00029650578,0.00012215314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033941714,0.00012178507,0.0003734551,0.0001329903,0.000015463389,0.000004190703,0.00025201184,0.00013788718,0.000027938415],"category_scores_gemma":[0.000048692524,0.000095903386,0.0001456157,0.000070155496,0.000057959824,0.000005052069,0.00010640152,0.00010633746,0.000003972898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011851361,0.0005160706,0.0006602366,0.00006606817,0.00031566716,0.000007595642,0.000118142336,0.0024690484,0.98518914,0.000018258315,0.00015071819,0.009303921],"study_design_scores_gemma":[0.0014913037,0.001776409,0.0008225999,0.000037115977,0.000047541387,0.0000940517,0.00006308489,0.0015400116,0.9918038,0.000024653129,0.002195237,0.00010416524],"about_ca_topic_score_codex":0.000006506609,"about_ca_topic_score_gemma":0.00002263076,"teacher_disagreement_score":0.034688685,"about_ca_system_score_codex":0.00007437757,"about_ca_system_score_gemma":0.00089565146,"threshold_uncertainty_score":0.39108267},"labels":[],"label_agreement":null},{"id":"W2982143449","doi":"10.1016/j.jtho.2019.08.698","title":"MA23.10 Low Number of Mutations and Frequent Co-Deletions of CDKN2A and IFN Type I Characterize Malignant Pleural Mesothelioma","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Imperial College London","keywords":"CDKN2A; Copy number analysis; Molecular Inversion Probe; Medicine; Exome sequencing; Genotyping; Mesothelioma; Copy-number variation; Lung cancer; SNP genotyping; SNP array; Oncology; Genotype; Cancer research; Genetics; Single-nucleotide polymorphism; Cancer; Mutation; Biology; Internal medicine; Pathology; Gene; Genome","score_opus":0.017471658652886777,"score_gpt":0.38276151173805034,"score_spread":0.36528985308516354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982143449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977354,0.00025662375,0.000008009715,0.00087610306,0.0001138145,0.00011913514,0.00007445896,0.000002471248,0.0008140208],"genre_scores_gemma":[0.9977645,0.00017012688,0.001080854,0.00013954136,0.00005515391,0.0000014579888,0.000028002027,0.00000843269,0.00075190014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992024,0.000058424554,0.00039292843,0.000082686165,0.00017359424,0.000089969995],"domain_scores_gemma":[0.9992161,0.00010783807,0.00038166367,0.00007969631,0.00010438407,0.00011031535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014717811,0.00007815679,0.00034886092,0.000093985094,0.000021431719,0.0000032983546,0.000040549538,0.00006575152,0.0013476856],"category_scores_gemma":[0.00004338318,0.00005891528,0.00006695717,0.00006748381,0.00015134156,0.00008234513,0.000022789054,0.00009453915,0.000026554271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005148848,0.0013498403,0.6876129,0.0006133328,0.0003946732,0.00014812045,0.00046241292,0.00001926046,0.2862,0.00027314015,0.00097290997,0.01680459],"study_design_scores_gemma":[0.0008770958,0.0016182025,0.9876941,0.00018505182,0.00029538228,0.001214817,0.00024460285,0.00005029602,0.0048863934,0.00028146713,0.0025850642,0.00006756521],"about_ca_topic_score_codex":0.00001073584,"about_ca_topic_score_gemma":0.0000018013592,"teacher_disagreement_score":0.3000812,"about_ca_system_score_codex":0.00005332632,"about_ca_system_score_gemma":0.000112705355,"threshold_uncertainty_score":0.99956524},"labels":[],"label_agreement":null},{"id":"W2982178304","doi":"10.1016/j.jtho.2019.08.966","title":"P1.04-63 Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metastasis and carcinoma case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"CDKN2A; Medicine; Immunohistochemistry; Immune system; Lung cancer; Immune checkpoint; Pathology; Lung; Cancer research; Cancer; Internal medicine; Immunology; Immunotherapy","score_opus":0.019337943691750313,"score_gpt":0.3587160748606936,"score_spread":0.33937813116894333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982178304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957192,0.0016852329,0.00021539672,0.00072681636,0.00016608083,0.0002647756,0.0000044664725,0.0000023515445,0.0012156923],"genre_scores_gemma":[0.99768215,0.000091508,0.0019277247,0.000066580535,0.000056581768,0.000004567431,0.0000052348373,0.0000106353145,0.0001550363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986441,0.00020336073,0.00062661147,0.0001359707,0.00023762688,0.00015229781],"domain_scores_gemma":[0.9988188,0.00023007455,0.0005609549,0.00012414543,0.00019028237,0.00007574061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007279847,0.00011110742,0.0006524282,0.0004351579,0.000024792998,0.000005222222,0.00005006557,0.00009807603,0.00009075178],"category_scores_gemma":[0.0001156143,0.000078857505,0.000055422617,0.00025346724,0.000086002656,0.00012229655,0.00003505496,0.0003586477,0.0000018860559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028411418,0.0003274129,0.9670623,0.00026691717,0.000049802922,0.0006937332,0.0019998904,0.00018430095,0.015097111,0.000057605594,0.00028375763,0.011136033],"study_design_scores_gemma":[0.0027824244,0.0025207675,0.9856524,0.00060512795,0.00021320992,0.0014391346,0.0030836463,0.0010874073,0.0018257751,0.00006999991,0.00062823587,0.00009185664],"about_ca_topic_score_codex":0.00003168989,"about_ca_topic_score_gemma":0.00011861311,"teacher_disagreement_score":0.01859012,"about_ca_system_score_codex":0.0001606316,"about_ca_system_score_gemma":0.00027056137,"threshold_uncertainty_score":0.32157156},"labels":[],"label_agreement":null},{"id":"W2982182632","doi":"10.1016/j.jtho.2019.08.458","title":"OA09.07 Implementing an Opt-Out Approach to Smoking Cessation Referrals for Cancer Patients in Ontario, Canada","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Referral; Smoking cessation; Family medicine; Cancer; Health care; Internal medicine","score_opus":0.07399231064301977,"score_gpt":0.4306681768950898,"score_spread":0.35667586625207004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982182632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961057,0.000009636186,0.00017225117,0.00039330806,0.001231507,0.0005165761,0.000007188064,0.000004283884,0.0015596078],"genre_scores_gemma":[0.9976275,0.0000024244544,0.0011568974,0.00053959293,0.00018191729,0.000030120917,0.000053304386,0.000016760825,0.0003915062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984938,0.00008114651,0.0006042571,0.00017012909,0.00036579365,0.0002848946],"domain_scores_gemma":[0.9988125,0.000054236167,0.00051544403,0.000121238554,0.00036630186,0.00013028213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094885856,0.00010864857,0.00040486685,0.00021119401,0.00005009556,0.000016888021,0.00011484836,0.00011847209,0.00022398218],"category_scores_gemma":[0.000058277616,0.00009511792,0.0000567723,0.00010280918,0.0000069392954,0.00019354188,0.000025367244,0.00033174135,3.913131e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005403394,0.00026678087,0.96363974,0.000047978447,0.00003500209,0.000005714809,0.0017178985,0.00016189147,0.0005907029,0.000011427298,0.0008961826,0.032086357],"study_design_scores_gemma":[0.0015638703,0.0011031395,0.9766037,0.0001226657,0.00017819954,0.000019057876,0.0010509165,0.00004987075,0.00093614135,0.000030382307,0.018232701,0.000109375214],"about_ca_topic_score_codex":0.46401095,"about_ca_topic_score_gemma":0.90248764,"teacher_disagreement_score":0.43847668,"about_ca_system_score_codex":0.0032317603,"about_ca_system_score_gemma":0.0018232069,"threshold_uncertainty_score":0.8450941},"labels":[],"label_agreement":null},{"id":"W2982231393","doi":"10.1016/j.jtho.2019.08.158","title":"ES20.03 Tobacco Control Integration in Cancer Care: The Canadian Experience","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Smoking cessation; Referral; Tobacco control; Family medicine; Cancer; Health care; Nursing; Public health; Internal medicine","score_opus":0.02854869098889481,"score_gpt":0.34645252058400355,"score_spread":0.31790382959510877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982231393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9467208,0.007361364,0.00012449498,0.007947457,0.002882476,0.00023598173,0.000038727736,0.00000406247,0.034684658],"genre_scores_gemma":[0.99706405,0.0004152531,0.000117782336,0.0017373726,0.00026830367,0.000016160515,9.024401e-7,0.000011860801,0.00036831872],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871325,0.0000375826,0.00075420324,0.00016039057,0.000034292436,0.00030026436],"domain_scores_gemma":[0.99872965,0.00008164532,0.0007788126,0.0001855089,0.00011779552,0.00010659086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071887445,0.00011263127,0.0005053474,0.00028761997,0.00007242707,0.000057708712,0.0003696464,0.00017647397,0.0004799926],"category_scores_gemma":[0.0001498625,0.00009281191,0.00011368404,0.00016686207,0.000072722476,0.00040356943,0.000016362254,0.00040801277,0.0001732169],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037556177,0.00006419339,0.6909213,0.000015719199,0.00005597706,0.000038268372,0.010109822,0.0011542918,0.000059552305,0.021723341,0.002354237,0.27312773],"study_design_scores_gemma":[0.001645054,0.00075898704,0.38261902,0.000112558475,0.000023609045,0.00007033535,0.007110947,0.00057055155,0.00022397596,0.008103468,0.59835523,0.00040626153],"about_ca_topic_score_codex":0.04690188,"about_ca_topic_score_gemma":0.27555484,"teacher_disagreement_score":0.59600097,"about_ca_system_score_codex":0.0019132416,"about_ca_system_score_gemma":0.0006498996,"threshold_uncertainty_score":0.9594449},"labels":[],"label_agreement":null},{"id":"W2982231681","doi":"10.1016/j.jtho.2019.08.1269","title":"P1.16-43 Prevalence of Clinical and Sub-Clinical Malnutrition in Advanced Non-Small-Cell Lung Cancer Patients and Association with Outcome","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Underweight; Internal medicine; Malnutrition; Lung cancer; Wasting; Overweight; Logistic regression; Proportional hazards model; Cancer; Weight loss; Body mass index; Obesity","score_opus":0.048853626510987666,"score_gpt":0.49720879954305214,"score_spread":0.44835517303206446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982231681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953756,0.00081854366,0.000034606022,0.0024698758,0.000611849,0.00046557107,0.000006720263,0.000003345693,0.00021389502],"genre_scores_gemma":[0.99075145,0.0044613816,0.0035362332,0.00085148873,0.00017183773,0.000005586389,0.000001860504,0.000009822519,0.00021031912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976506,0.00031219563,0.0014554701,0.00017054258,0.00023826012,0.00017291529],"domain_scores_gemma":[0.9972858,0.0006227067,0.0014633121,0.00007822958,0.00038001407,0.0001699714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002498812,0.00009139156,0.000809098,0.00015510508,0.000020380809,0.0000046634354,0.00005113157,0.00024854465,0.00003388669],"category_scores_gemma":[0.0003093925,0.000072088376,0.000071354945,0.000104796956,0.00005825921,0.00011960724,0.000026932612,0.0007036069,0.0000013019452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032290828,0.00080729363,0.9763214,0.0018920926,0.000030900082,0.000017200447,0.00007430038,0.0000016514202,0.00015294195,0.0000021195272,0.0002212766,0.017249737],"study_design_scores_gemma":[0.008521715,0.0035859754,0.9855837,0.0010712036,0.00019398953,0.000031341704,0.000076809876,0.00013403999,0.00017945566,0.000033056247,0.0005218005,0.00006688134],"about_ca_topic_score_codex":0.000009871473,"about_ca_topic_score_gemma":0.000037154838,"teacher_disagreement_score":0.017182857,"about_ca_system_score_codex":0.00025127112,"about_ca_system_score_gemma":0.00028675207,"threshold_uncertainty_score":0.3056861},"labels":[],"label_agreement":null},{"id":"W2982238418","doi":"10.1016/j.jtho.2019.08.543","title":"MA06.07 E1505: Adjuvant Chemotherapy +/- Bevacizumab for Early Stage NSCLC: Updated Chemotherapy Subset Analysis","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Docetaxel; Bevacizumab; Gemcitabine; Regimen; Vinorelbine; Internal medicine; Chemotherapy; Pemetrexed; Histology; Oncology; Stage (stratigraphy); Adjuvant; Chemotherapy regimen; Cisplatin; Biology","score_opus":0.022987012161067022,"score_gpt":0.4307940233050613,"score_spread":0.40780701114399426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982238418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98566186,0.00084221724,0.00069137325,0.00934234,0.00084987417,0.0008723056,0.00007174345,0.00003136278,0.0016369172],"genre_scores_gemma":[0.9787967,0.000673069,0.0036539636,0.0038570978,0.0007068678,0.000023343577,0.00009393618,0.000059332735,0.012135698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978182,0.00017141964,0.0008629462,0.00032926514,0.0003329784,0.00048519028],"domain_scores_gemma":[0.9976801,0.0002485304,0.00095955015,0.00034401694,0.00048309867,0.0002846596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008100139,0.00030459592,0.0015924091,0.0006496053,0.00006420004,0.000023393406,0.0002610614,0.0003357224,0.0068228166],"category_scores_gemma":[0.000022685876,0.00023724265,0.0008378099,0.0006317818,0.00008894991,0.00016260578,0.000023503413,0.00046173288,0.0000922135],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14165902,0.007038015,0.23641996,0.00039453665,0.03278345,0.0009812989,0.004245826,0.0002800555,0.0723266,0.00010688948,0.067948006,0.43581635],"study_design_scores_gemma":[0.031873755,0.026496118,0.1906047,0.000087540495,0.01025491,0.00066694955,0.0005348526,0.0010624527,0.02676234,0.00024742333,0.7108131,0.0005958794],"about_ca_topic_score_codex":0.000045905006,"about_ca_topic_score_gemma":0.000047050653,"teacher_disagreement_score":0.64286506,"about_ca_system_score_codex":0.0006768265,"about_ca_system_score_gemma":0.00061083084,"threshold_uncertainty_score":0.9940851},"labels":[],"label_agreement":null},{"id":"W2982239275","doi":"10.1016/j.jtho.2019.08.2370","title":"EP1.16-05 Real World Outcomes of Advanced NSCLC Patients with Liver Metastases","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Metastasis; Clinical endpoint; Systemic therapy; Cohort; Population; Performance status; Stage (stratigraphy); Cancer; Clinical trial","score_opus":0.011515542800591949,"score_gpt":0.3777532496586298,"score_spread":0.3662377068580378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982239275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911448,0.00019783717,0.0002786813,0.0021092657,0.000638319,0.00020352352,0.000004043067,0.000009108664,0.005414467],"genre_scores_gemma":[0.97985786,0.00009322498,0.017407106,0.00083884055,0.00011503952,0.0000012867648,0.0000072128564,0.000022741326,0.0016566636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846166,0.00015976375,0.00058771967,0.00013614036,0.0004375917,0.00021710584],"domain_scores_gemma":[0.99803495,0.00037304248,0.0008637229,0.0001938052,0.00034599728,0.00018847879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006583671,0.00014166911,0.0009057497,0.0003152565,0.000025720306,0.0000062823847,0.00015449127,0.00006204612,0.00033100208],"category_scores_gemma":[0.0003332044,0.00008677635,0.00016822947,0.00019500009,0.00011672758,0.00013533047,0.000043295964,0.00059489626,0.000012819057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032072342,0.00069183647,0.65964055,0.00012705699,0.0004446127,0.0002411322,0.00019994909,0.00013833269,0.0006194184,0.00008200872,0.0020588401,0.33254904],"study_design_scores_gemma":[0.0059509454,0.00621442,0.93447477,0.00049398065,0.0008970438,0.00029642845,0.0002692983,0.00019699673,0.0005402375,0.00009781396,0.050387315,0.00018078045],"about_ca_topic_score_codex":0.000035768953,"about_ca_topic_score_gemma":0.000015380127,"teacher_disagreement_score":0.33236825,"about_ca_system_score_codex":0.00018433346,"about_ca_system_score_gemma":0.00025330635,"threshold_uncertainty_score":0.36242408},"labels":[],"label_agreement":null},{"id":"W2982248538","doi":"10.1016/j.jtho.2019.08.904","title":"P1.04-01 Body Mass Index and Age Do Not Influence Survival in Patients with Lung Cancers Treated with PD1/PDL1 Immune Checkpoint Inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Body mass index; Internal medicine; Proportional hazards model; Hazard ratio; Oncology; Lung cancer; Overweight; Univariate analysis; Confidence interval; Retrospective cohort study; Multivariate analysis","score_opus":0.007379600913020159,"score_gpt":0.3108634258425638,"score_spread":0.3034838249295437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982248538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761444,0.00044159612,0.000010032533,0.000518426,0.00033193294,0.00049164105,0.000005781624,0.000010535627,0.00057562476],"genre_scores_gemma":[0.998952,0.00015967949,0.00027293526,0.00023754353,0.00009055078,0.0000069169255,0.0000056365607,0.00003143637,0.0002433255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803907,0.00016181142,0.000762284,0.00024359171,0.00045068876,0.0003425293],"domain_scores_gemma":[0.9985041,0.000098460405,0.00079281157,0.0002255222,0.00022631527,0.00015278948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000723378,0.00024432447,0.0008514712,0.00034071956,0.00004196989,0.000027325104,0.0001340901,0.00020505131,0.00009415226],"category_scores_gemma":[0.000033026114,0.00015871745,0.00009334622,0.00041928838,0.00021278918,0.00024254904,0.00003072106,0.00060786086,0.0000021265564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072244056,0.00023644786,0.8952114,0.00011632119,0.000405936,0.00041779922,0.00037549378,0.00011076368,0.017969506,0.0000010704225,0.000034189,0.012877033],"study_design_scores_gemma":[0.011675466,0.007184,0.97434795,0.00082133565,0.00017922546,0.00017549432,0.0004069876,0.000037424234,0.0037896924,0.000004141393,0.0011706206,0.00020768635],"about_ca_topic_score_codex":0.00059898826,"about_ca_topic_score_gemma":0.00023051069,"teacher_disagreement_score":0.079136536,"about_ca_system_score_codex":0.0011836782,"about_ca_system_score_gemma":0.00067986874,"threshold_uncertainty_score":0.647231},"labels":[],"label_agreement":null},{"id":"W2982251565","doi":"10.1016/j.jtho.2019.08.1453","title":"P2.03-06 Detection of ctDNA and Correlation with Tumor Mutation Testing in Early Stage NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Stage (stratigraphy); Adenocarcinoma; Oncology; Cancer; Lung cancer; Circulating tumor DNA; Internal medicine; Digital polymerase chain reaction; DNA sequencing; Cancer research; DNA; Gene; Polymerase chain reaction; Biology; Genetics","score_opus":0.009721126855180668,"score_gpt":0.30722028993161316,"score_spread":0.2974991630764325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982251565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971151,0.00025715886,0.001980815,0.000044449218,0.00015467391,0.00010601825,0.0000037997504,0.0000010731612,0.0003369391],"genre_scores_gemma":[0.9976574,0.000037120404,0.0020953119,0.000043657274,0.000090919006,0.000001511523,0.0000035805642,0.000008646938,0.00006184327],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994101,0.000053608877,0.00027782837,0.00009778397,0.000073286596,0.000087415865],"domain_scores_gemma":[0.9991737,0.0000855583,0.0004694063,0.0000712348,0.00016515348,0.000034975626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030594287,0.00006404283,0.0001636787,0.00009164877,0.000015361456,0.000008144514,0.00004704996,0.00008206737,0.0000029453593],"category_scores_gemma":[0.00017601832,0.0000565852,0.000023902376,0.00008799742,0.000032992037,0.000009044151,0.000021899557,0.00011876496,0.0000012750828],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015539002,0.00010355903,0.19224246,0.000061334686,0.00003941606,0.000047600635,0.00028045537,0.0053791828,0.7407251,0.000016355289,0.000017546214,0.05953309],"study_design_scores_gemma":[0.0029361744,0.014945025,0.7351756,0.00021549623,0.0001285706,0.0009762299,0.0009202151,0.0035122016,0.23615687,0.0002416426,0.0044907043,0.00030124912],"about_ca_topic_score_codex":0.000057051966,"about_ca_topic_score_gemma":0.0001648258,"teacher_disagreement_score":0.54293317,"about_ca_system_score_codex":0.000054187243,"about_ca_system_score_gemma":0.00017617433,"threshold_uncertainty_score":0.23074774},"labels":[],"label_agreement":null},{"id":"W2982254254","doi":"10.1016/j.jtho.2019.08.2480","title":"WS04.05 Developing the IASLC Lung Cancer Staging Database and Recommendations for the 9th Edition","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Lung cancer; Lung cancer staging; Context (archaeology); Cancer; Database; Biostatistics; Oncology; Medical physics; Internal medicine; Epidemiology","score_opus":0.04275498396492477,"score_gpt":0.4658831220818437,"score_spread":0.4231281381169189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982254254","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21847948,0.00984183,0.014027493,0.74531054,0.009917213,0.0017173925,0.00010118611,0.000015834536,0.0005890012],"genre_scores_gemma":[0.9652275,0.01019714,0.012516642,0.008714806,0.0021572285,0.0001855448,0.000033563127,0.000028580762,0.00093898084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992977,0.000071721086,0.0002719431,0.00009909945,0.000120885896,0.00013865707],"domain_scores_gemma":[0.99847066,0.0008320511,0.00032033623,0.00013849717,0.00018741867,0.000051038136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071121653,0.000079346755,0.00022528262,0.000056921315,0.0001844543,0.000021932985,0.00008022956,0.00004072405,0.00013082588],"category_scores_gemma":[0.00006977543,0.000038803242,0.00006672913,0.00008185405,0.000041159863,0.00012654612,0.000035204794,0.00020239364,0.000001826795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012575088,0.00030672344,0.050037067,0.0005079567,0.001484598,0.000052718173,0.0022845322,0.000103072205,0.0003989441,0.0012318577,0.34056193,0.6017731],"study_design_scores_gemma":[0.0026805063,0.0011154334,0.022711864,0.001314709,0.0021389578,0.0007046123,0.0026690597,0.001593744,0.0014143188,0.00034096034,0.96317387,0.00014199129],"about_ca_topic_score_codex":0.000039657414,"about_ca_topic_score_gemma":0.00007549179,"teacher_disagreement_score":0.74674803,"about_ca_system_score_codex":0.0006055389,"about_ca_system_score_gemma":0.00049623486,"threshold_uncertainty_score":0.15834631},"labels":[],"label_agreement":null},{"id":"W2983766759","doi":"10.1016/j.jtho.2019.10.023","title":"SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":308,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Marie-Josée and Henry R. Kravis Center for Molecular Oncology; National Institutes of Health","keywords":"Medicine; SMARCA4; Pathology; Thoracic Neoplasm; Sarcoma; Oncology","score_opus":0.013975676985046767,"score_gpt":0.3325555856768614,"score_spread":0.31857990869181463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983766759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840608,0.0064808987,0.000745856,0.0005876221,0.0015538569,0.00047450146,0.00001768698,0.00004167434,0.006037082],"genre_scores_gemma":[0.99450576,0.0003573282,0.0013802431,0.00040117107,0.00039817346,0.000012437613,0.00010238613,0.00010416928,0.0027383496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99550825,0.00086601917,0.0014778891,0.00070747687,0.0006980561,0.00074232306],"domain_scores_gemma":[0.99661547,0.00010647488,0.0015167748,0.000948479,0.00050485524,0.0003079745],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016716458,0.00051012496,0.0010524841,0.00033798706,0.00016351232,0.00007577229,0.0008211505,0.00063187233,0.00023796648],"category_scores_gemma":[0.0001294906,0.00042699953,0.00062901695,0.00038485182,0.00020552303,0.000029346309,0.0004155728,0.0008785744,0.000059973805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045357393,0.0014351893,0.08837945,0.00051595946,0.0010825911,0.00035083242,0.00078094867,0.0025574572,0.818715,0.000060318085,0.0036816949,0.07790482],"study_design_scores_gemma":[0.007889602,0.01413992,0.35038456,0.0021303764,0.0021425441,0.012774461,0.002738083,0.004985557,0.48472396,0.0030089999,0.11088462,0.0041972916],"about_ca_topic_score_codex":0.000040933963,"about_ca_topic_score_gemma":0.000020576446,"teacher_disagreement_score":0.33399102,"about_ca_system_score_codex":0.0004949948,"about_ca_system_score_gemma":0.0010787398,"threshold_uncertainty_score":0.9998182},"labels":[],"label_agreement":null},{"id":"W2989335748","doi":"10.1016/j.jtho.2019.10.019","title":"The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Lymph node; Dissection (medical); Resection margin; Carcinoma; Surgery; Radiology; Lung; Resection; Oncology; Internal medicine","score_opus":0.023124577961426706,"score_gpt":0.41932208415401584,"score_spread":0.39619750619258914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989335748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852324,0.0084044635,0.00028947042,0.0024874995,0.0009371155,0.002392796,0.00011264924,0.0000058339338,0.00013777756],"genre_scores_gemma":[0.9912618,0.0033587727,0.0029584216,0.00018445829,0.0004273567,0.0005233949,0.000010269245,0.000034348417,0.0012412126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983286,0.00011880309,0.0006655585,0.00024759278,0.0002474205,0.0003919811],"domain_scores_gemma":[0.99744403,0.0005970699,0.0009627795,0.00018651121,0.00068896916,0.000120665245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010623349,0.00017232841,0.0008297988,0.00039349802,0.00013131106,0.000030844298,0.00010167221,0.00009725586,0.000037127225],"category_scores_gemma":[0.00009453886,0.00010603674,0.00027468224,0.00035151528,0.00006340555,0.000087426386,0.00003435218,0.00021110813,1.1556011e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012185628,0.0005145663,0.928203,0.002621427,0.0065943804,0.00002497681,0.002589872,0.0005541818,0.004246375,0.000028079809,0.0131136095,0.02932391],"study_design_scores_gemma":[0.02669024,0.028137991,0.5452488,0.0047275997,0.1093824,0.00014392944,0.013375479,0.05595035,0.12116803,0.00019970567,0.093836196,0.0011392479],"about_ca_topic_score_codex":0.0009563037,"about_ca_topic_score_gemma":0.002480564,"teacher_disagreement_score":0.38295418,"about_ca_system_score_codex":0.0015915746,"about_ca_system_score_gemma":0.0017615315,"threshold_uncertainty_score":0.4324053},"labels":[],"label_agreement":null},{"id":"W2989867317","doi":"10.1016/j.jtho.2019.09.007","title":"Old Soldiers Never Die: Is There Still a Role for Immunohistochemistry in the Era of Next-Generation Sequencing Panel Testing?","year":2019,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Guideline; Lung cancer; Targeted therapy; Internal medicine; Oncology; ROS1; Cancer; Crizotinib; Biomarker; Tyrosine kinase; Family medicine; Pathology; Adenocarcinoma; Receptor","score_opus":0.07770742997883114,"score_gpt":0.41005362564790665,"score_spread":0.33234619566907553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989867317","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47387424,0.009847497,0.00023414147,0.5096189,0.0015829535,0.001663358,0.0001516857,0.000012349373,0.003014905],"genre_scores_gemma":[0.41565973,0.00049726386,0.014596874,0.5508825,0.009388369,0.00017579213,0.00032391283,0.00013912842,0.0083364565],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843603,0.00011816022,0.0007177943,0.00018783979,0.00029522134,0.00024496764],"domain_scores_gemma":[0.99747026,0.00052718486,0.0012059902,0.0002896359,0.00047516535,0.000031779833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048863684,0.00021432793,0.0007190463,0.00012098348,0.000050634982,0.00001997787,0.0002208869,0.0005424093,0.00004763313],"category_scores_gemma":[0.0002455544,0.00013688844,0.0002578531,0.000117362775,0.00006948206,0.00013058337,0.000019592804,0.0014467499,0.0000024119654],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010260742,0.00045825,0.0016024272,0.0018496902,0.0017222496,0.0014706928,0.01194647,0.0002533892,0.1552218,0.000004523805,0.72549385,0.09895058],"study_design_scores_gemma":[0.0054142233,0.006938172,0.0021674794,0.0032051732,0.0070981453,0.0036746948,0.0051499396,0.0017427092,0.009685087,0.00059431075,0.95370334,0.0006267306],"about_ca_topic_score_codex":0.00016424425,"about_ca_topic_score_gemma":0.000006005277,"teacher_disagreement_score":0.22820948,"about_ca_system_score_codex":0.0012843618,"about_ca_system_score_gemma":0.0018959357,"threshold_uncertainty_score":0.62854886},"labels":[],"label_agreement":null},{"id":"W2991627091","doi":"10.1016/j.jtho.2019.11.004","title":"Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Servier; Berlin Mathematical School; Exelixis; Meso Scale Diagnostics; Takeda Pharmaceutical Company; AbbVie; Gilead Sciences; Takeda Oncology; University of Colorado; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Novartis; GlaxoSmithKline; Sanofi-Aventis Deutschland; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Refractory (planetary science); Oncology; Internal medicine; Lung cancer","score_opus":0.025982608381588577,"score_gpt":0.4525316280524112,"score_spread":0.42654901967082265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991627091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901568,0.00025013523,0.000006885005,0.0038874643,0.0017905161,0.0008873419,0.000009154449,0.000005081704,0.0030065984],"genre_scores_gemma":[0.99803776,0.00007240269,0.00022127508,0.00085257646,0.00038963766,0.000017409786,0.0000047557696,0.000014063957,0.00039010833],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998344,0.00033822737,0.0006856916,0.00015372108,0.0002784058,0.00019993965],"domain_scores_gemma":[0.99863887,0.00059217017,0.00042865716,0.00017577916,0.00007878835,0.00008575377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009856882,0.00013897613,0.0006792931,0.00025770735,0.000030940926,0.000018234805,0.00012347108,0.00014566725,0.00008373351],"category_scores_gemma":[0.00026529178,0.00008109232,0.00012283065,0.00014680176,0.000045335764,0.00011388366,0.000015698384,0.0005427277,0.000021996211],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32843962,0.011643711,0.13962333,0.00041750507,0.0011606616,0.004392328,0.019041086,0.0000415223,0.0050634295,0.00065906666,0.0027382616,0.48677948],"study_design_scores_gemma":[0.7019049,0.07812248,0.15848754,0.0022150862,0.002196669,0.005336233,0.01739861,0.00015481598,0.00028286062,0.0007919473,0.032548044,0.00056082534],"about_ca_topic_score_codex":0.000050818748,"about_ca_topic_score_gemma":0.00007528784,"teacher_disagreement_score":0.48621866,"about_ca_system_score_codex":0.00034623663,"about_ca_system_score_gemma":0.0005349457,"threshold_uncertainty_score":0.3306849},"labels":[],"label_agreement":null},{"id":"W2993751725","doi":"10.1016/j.jtho.2019.11.023","title":"Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; EMD Serono; Daiichi-Sankyo; Clovis Oncology; Sanofi; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; Seattle Genetics; Merck KGaA; Regeneron Pharmaceuticals; Institute of Cancer Research; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Roche; Celgene; Novartis; Amgen; Boehringer Ingelheim; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Bayer; Illumina; Merck; Eli Lilly and Company; Samsung; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Clinical trial; DNA; Oncology; Genetics; Internal medicine","score_opus":0.03973765988084979,"score_gpt":0.5141260334831764,"score_spread":0.47438837360232666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993751725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996129,0.0002773673,0.000042541076,0.001483887,0.00030091015,0.0003829303,0.0000040428195,0.000001405975,0.0013779517],"genre_scores_gemma":[0.99896723,0.000030737378,0.00070964696,0.00006536967,0.0001890099,0.0000034580173,0.0000027871854,0.0000044568956,0.000027275211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998774,0.00026427442,0.0006544912,0.00007303182,0.00013629337,0.000097916185],"domain_scores_gemma":[0.99878156,0.0005314825,0.0004300329,0.00011986241,0.00009433652,0.000042743315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011399823,0.00005644202,0.00036149262,0.00018750028,0.00001739462,0.0000045100264,0.000067372086,0.00009563039,0.00003355568],"category_scores_gemma":[0.00046993405,0.0000334839,0.0001375454,0.000185687,0.00005164877,0.00008551213,0.000014159912,0.0002825542,0.0000016027192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012744619,0.0018722167,0.92684984,0.000046447956,0.00031121922,0.00018628106,0.0030799408,0.0004920498,0.00074581243,0.0001837914,0.00025187136,0.053235915],"study_design_scores_gemma":[0.022252927,0.0063804793,0.9676522,0.00011855057,0.00031803412,0.0003705752,0.0011798043,0.0003419183,0.000006212829,0.0012384166,0.000107241984,0.000033627814],"about_ca_topic_score_codex":0.00015882475,"about_ca_topic_score_gemma":0.00015119673,"teacher_disagreement_score":0.053202286,"about_ca_system_score_codex":0.00044557347,"about_ca_system_score_gemma":0.00073987857,"threshold_uncertainty_score":0.13654338},"labels":[],"label_agreement":null},{"id":"W2995123342","doi":"10.1016/j.jtho.2019.12.107","title":"PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Genentech; Takeda Pharmaceuticals U.S.A.; Meso Scale Diagnostics; AbbVie; Chugai Pharmaceutical; Roche; EMD Serono; Novartis; MedImmune; Agilent Technologies; GlaxoSmithKline; Merck; Bayer; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Companion diagnostic; Lung cancer; Immunohistochemistry; Oncology; Cancer; Clinical trial; Pathology; Internal medicine","score_opus":0.08695334608872189,"score_gpt":0.500247038117566,"score_spread":0.4132936920288441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995123342","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005454417,0.99013954,0.000059185943,0.0041949144,0.0028108973,0.0014400199,0.00019528918,0.000008267546,0.00060642866],"genre_scores_gemma":[0.00009119249,0.99420345,0.0017385086,0.0011025649,0.002110725,0.00008789107,0.000018358898,0.00006405061,0.00058328884],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969927,0.0007243744,0.0013529207,0.0003224963,0.0002229553,0.0003845363],"domain_scores_gemma":[0.9929663,0.0038678914,0.002205569,0.0003762069,0.0005014521,0.000082613806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018985507,0.00036426002,0.0029834083,0.00029805533,0.00007564048,0.000019358968,0.00047774788,0.0006780794,0.000205676],"category_scores_gemma":[0.0007444787,0.00021144951,0.0009490091,0.0003998429,0.0001785769,0.00006919771,0.00007626995,0.0015329377,0.000006296207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002654363,0.00015595036,0.00040506036,0.0020487022,0.001100324,0.00027233196,0.0006147987,0.0000022879904,0.000035763987,0.000006866596,0.015556855,0.9771467],"study_design_scores_gemma":[0.0017302705,0.0018072174,0.001452168,0.016774304,0.004811712,0.002028957,0.00069800304,0.000023428365,0.000003340532,0.000101538724,0.9703251,0.00024392828],"about_ca_topic_score_codex":0.00045137305,"about_ca_topic_score_gemma":0.00027940574,"teacher_disagreement_score":0.9769028,"about_ca_system_score_codex":0.0025700396,"about_ca_system_score_gemma":0.0035398046,"threshold_uncertainty_score":0.86226606},"labels":[],"label_agreement":null},{"id":"W2995704628","doi":"10.1016/j.jtho.2019.12.108","title":"Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; Queen's University","funders":"","keywords":"Medicine; Mediastinum; Radiology; Thymoma; Lesion; Solitary fibrous tumor; Pathology","score_opus":0.06002550078268444,"score_gpt":0.455438552217136,"score_spread":0.39541305143445155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995704628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854998,0.0004444479,0.008873673,0.0025852167,0.0019604291,0.00014155982,0.00018316176,0.000007495415,0.00030419117],"genre_scores_gemma":[0.9901633,0.00024834267,0.00849782,0.00018037255,0.00045014825,0.0000021413641,0.00017490322,0.000008373255,0.00027454275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853635,0.00012282422,0.0007044381,0.00014163669,0.00029629385,0.00019846525],"domain_scores_gemma":[0.9981778,0.00025417606,0.0006910619,0.00018563414,0.000548915,0.00014236673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008133994,0.000121045996,0.00059363886,0.00011814552,0.000051953153,0.000005012519,0.00020244815,0.00011934498,0.0004605003],"category_scores_gemma":[0.0006566055,0.00008465553,0.00020158055,0.00012813408,0.0002213805,0.0001493261,0.000087419,0.00036287305,0.000053485626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015998784,0.0065081078,0.485948,0.00057246274,0.001758238,0.0028849621,0.0018984145,0.0005865522,0.17100912,0.009529773,0.01629272,0.28701288],"study_design_scores_gemma":[0.0043890793,0.0032887117,0.50673944,0.0005401986,0.00034087463,0.02085175,0.0009806977,0.00084765657,0.004485071,0.0001437574,0.45719683,0.00019594675],"about_ca_topic_score_codex":0.000015208738,"about_ca_topic_score_gemma":0.0000106859825,"teacher_disagreement_score":0.4409041,"about_ca_system_score_codex":0.00021297907,"about_ca_system_score_gemma":0.0004928994,"threshold_uncertainty_score":0.50421554},"labels":[],"label_agreement":null},{"id":"W2995889981","doi":"10.1016/j.jtho.2019.12.109","title":"Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":438,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Merck Sharp and Dohme; EMD Serono; Genentech; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; National Cancer Institute; Servier; Daiichi-Sankyo; Puma Biotechnology; AbbVie; Aminex Therapeutics; Roche; Celgene; Novartis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.059163210304026236,"score_gpt":0.4761060156971092,"score_spread":0.416942805393083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995889981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97932595,0.013174916,0.0000038134315,0.005980822,0.00034175275,0.0010635002,0.000057623205,0.0000054341485,0.000046178102],"genre_scores_gemma":[0.9892213,0.008209273,0.0015754156,0.00043277798,0.00021518851,0.000026534315,0.000004715879,0.000024299547,0.0002905317],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9973777,0.00047716743,0.0009159373,0.00026105915,0.000661843,0.0003062979],"domain_scores_gemma":[0.99612486,0.0017559122,0.0008028324,0.00033126475,0.0008797534,0.000105354346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009996665,0.00023585594,0.0012188507,0.00019997443,0.000041008352,0.00001304516,0.00020586938,0.00006152418,0.000064563406],"category_scores_gemma":[0.0013510259,0.000096139804,0.000093518254,0.0003036593,0.00035347018,0.00014376295,0.00014912774,0.0005562214,0.0000035633914],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.51616615,0.0013252513,0.26882708,0.00043115608,0.0028220534,0.0005481734,0.015525577,0.00004368871,0.000089324414,0.0000012159401,0.0025922495,0.19162807],"study_design_scores_gemma":[0.03753588,0.04060886,0.9068954,0.0031642818,0.00083806395,0.000166499,0.004564982,0.00005816817,0.0002884336,0.00012787804,0.0055072526,0.0002443253],"about_ca_topic_score_codex":0.00008047243,"about_ca_topic_score_gemma":0.0005026085,"teacher_disagreement_score":0.6380683,"about_ca_system_score_codex":0.0002783923,"about_ca_system_score_gemma":0.00062674616,"threshold_uncertainty_score":0.39204672},"labels":[],"label_agreement":null},{"id":"W3002081870","doi":"10.1016/j.jtho.2019.12.016","title":"IA16 A New Generation of Anti-Myc Mini-Proteins as Potential Therapy for NSCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Medicine; Cancer research; Lung cancer; In vivo; Cancer; Transgene; Clinical trial; non-small cell lung cancer (NSCLC); In vitro; Targeted therapy; Bioinformatics; Oncology; Internal medicine; Gene; Biology; A549 cell; Genetics","score_opus":0.04989013688857875,"score_gpt":0.424416589568232,"score_spread":0.3745264526796533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002081870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807562,0.0023136316,0.01033781,0.005887936,0.00022405591,0.00030551947,0.000021969377,0.0000020023356,0.00015085394],"genre_scores_gemma":[0.99146336,0.0007447231,0.0054198294,0.00054032577,0.0015989159,0.000007846879,0.000029047016,0.000013550389,0.00018242028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917275,0.00008523203,0.00029705046,0.00013965627,0.00014602549,0.00015927204],"domain_scores_gemma":[0.9992126,0.000009837866,0.00030427493,0.00009864346,0.00020117057,0.00017343313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016479114,0.000091281814,0.00024618107,0.00004474787,0.000036520985,0.000011771782,0.00015882774,0.00012763767,0.000054086708],"category_scores_gemma":[0.000111498564,0.000073316914,0.0001945602,0.000061389546,0.000040227053,0.0000070628207,0.00003426649,0.00008753579,0.0000031768548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033734117,0.00016110107,0.00013151954,0.000013290584,0.00023259154,0.000030493697,0.00008002251,0.000056118875,0.8486028,0.000007247628,0.01002346,0.137288],"study_design_scores_gemma":[0.002641172,0.013702592,0.0003936127,0.000011264685,0.00006420994,0.00014566311,0.0000711448,0.000098445445,0.8873905,0.00013442105,0.095253795,0.00009317711],"about_ca_topic_score_codex":0.000032850803,"about_ca_topic_score_gemma":0.000025771173,"teacher_disagreement_score":0.13719483,"about_ca_system_score_codex":0.00003038378,"about_ca_system_score_gemma":0.0008011788,"threshold_uncertainty_score":0.2989777},"labels":[],"label_agreement":null},{"id":"W3003197494","doi":"10.1016/j.jtho.2020.01.005","title":"IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":450,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; Ethicon; Chugai Pharmaceutical; EMD Serono; Genentech; National Institutes of Health; Derfner Foundation; Regeneron Pharmaceuticals; Takeda Pharmaceuticals U.S.A.; Roche; Free To Breathe; Astellas Pharma US; Genomic Health; AbbVie; Merck; Spectrum Pharmaceuticals; University of Texas MD Anderson Cancer Center; Medtronic; International Business Machines Corporation; Novartis; Ono Pharmaceutical; U.S. Department of Defense; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Commonwealth Foundation for Cancer Research Foundation; Bayer HealthCare; Lung Cancer Research Foundation; Meso Scale Diagnostics; MedImmune; Sanofi; Amgen; Boehringer Ingelheim; Pfizer","keywords":"Medicine; Lung cancer; Multidisciplinary approach; Neoadjuvant therapy; Resection; Radiology; Cancer; Oncology; Surgical resection; Lung; Internal medicine; Surgery; Breast cancer","score_opus":0.10434583109280635,"score_gpt":0.5614729024873731,"score_spread":0.45712707139456676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003197494","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004426786,0.9859138,0.00022338753,0.0090252785,0.002027879,0.0019043634,0.00023098988,0.000010355911,0.0002212353],"genre_scores_gemma":[0.0007190892,0.98564553,0.011039728,0.00017634229,0.0013299346,0.00079941895,0.00007481137,0.000052886826,0.00016226208],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99728084,0.0004157181,0.0014568714,0.0003266222,0.00026891977,0.0002510293],"domain_scores_gemma":[0.99627495,0.00056015723,0.0022880214,0.00026345224,0.00043098672,0.0001824117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007105114,0.000349212,0.0028426577,0.00032917233,0.00007011727,0.000012149636,0.00016127473,0.00037954832,0.00038860575],"category_scores_gemma":[0.000055833105,0.00022011231,0.0011447975,0.0002570379,0.00006350915,0.00007770482,0.00007217787,0.0006823241,0.0000020632815],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010926318,0.0011819463,0.00062559184,0.0071176887,0.0018083232,0.00058114383,0.00021992633,0.0000033726517,0.0000061008436,0.000008714332,0.008940786,0.97841376],"study_design_scores_gemma":[0.0014287222,0.0074402504,0.0014079593,0.014817153,0.005863135,0.00078111154,0.00007534044,0.000035403136,0.000017487315,0.000038111335,0.96791875,0.00017659794],"about_ca_topic_score_codex":0.000009132947,"about_ca_topic_score_gemma":0.000024934236,"teacher_disagreement_score":0.97823715,"about_ca_system_score_codex":0.0030649106,"about_ca_system_score_gemma":0.0022983311,"threshold_uncertainty_score":0.89759195},"labels":[],"label_agreement":null},{"id":"W3003747453","doi":"10.1016/j.jtho.2020.01.016","title":"New Approaches to SCLC Therapy: From the Laboratory to the Clinic","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Pharmaceuticals; National Cancer Institute; National Health and Medical Research Council; Daiichi Sankyo Europe; Agios Pharmaceuticals; Karolinska Institutet; Takeda Oncology; EMD Serono; Ipsen; PharmaMar; Astellas Pharma; Merck; Kyowa Hakko Kirin; Daiichi-Sankyo; Syndax Pharmaceuticals; Cancer Research UK; AstraZeneca; International Association for the Study of Lung Cancer; Genentech; ANGLE; Bayer Fund; Meso Scale Diagnostics; Astex Pharmaceuticals; TG Therapeutics; Aeglea BioTherapeutics; Pfizer Pharmaceuticals; Marshfield Clinic Research Foundation; Memorial Sloan-Kettering Cancer Center; Merck KGaA; National Institutes of Health; Regeneron Pharmaceuticals; Victorian Cancer Agency; Incyte; Medical Research Council; University of Texas Southwestern Medical Center; AbbVie; Celgene; Novartis; Foundation Medicine; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; G1 Therapeutics; Lung Cancer Research Foundation; Cold Spring Harbor Laboratory; Roche; Astellas Pharma US; Amgen; Ariad Pharmaceuticals; Boehringer Ingelheim; Pfizer","keywords":"Medicine; Intensive care medicine; Lung cancer; Clinical trial; Immunotherapy; Disease; Oncology; Cancer; Internal medicine","score_opus":0.36389056416098625,"score_gpt":0.5524615542292449,"score_spread":0.18857099006825867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003747453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018196803,0.8442825,0.0001175665,0.15194842,0.0011582715,0.0015516689,0.000051101426,0.000013490629,0.0008587934],"genre_scores_gemma":[0.000011532372,0.97876924,0.0028187952,0.008061919,0.009065961,0.00007930039,0.0000052460023,0.00006748082,0.0011205341],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956785,0.0015758207,0.001195244,0.0003633481,0.0007776457,0.0004094752],"domain_scores_gemma":[0.99493426,0.002553273,0.00095261395,0.000696155,0.00023640058,0.0006272874],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0026551618,0.0003958338,0.0030205832,0.0001777617,0.00014925157,0.00005547711,0.0012942306,0.00031069454,0.0003385707],"category_scores_gemma":[0.0017496084,0.00016309139,0.00076866295,0.0009952128,0.00011856311,0.00005181916,0.00044027047,0.0023912378,0.000613154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056386297,0.000049286708,0.000011630572,0.00042216622,0.001297344,0.00017641485,0.00085870514,4.1181866e-7,6.024265e-7,0.00000514197,0.28768876,0.70892566],"study_design_scores_gemma":[0.00030554796,0.0025318237,0.000104126986,0.0039305254,0.0016791504,0.00015860827,0.00037480003,2.800623e-7,0.0000025899296,0.000049312195,0.99071866,0.00014457187],"about_ca_topic_score_codex":0.00003964009,"about_ca_topic_score_gemma":0.000065983186,"teacher_disagreement_score":0.7087811,"about_ca_system_score_codex":0.0009235625,"about_ca_system_score_gemma":0.00798034,"threshold_uncertainty_score":0.9999103},"labels":[],"label_agreement":null},{"id":"W3008790677","doi":"10.1016/j.jtho.2020.02.005","title":"A Primer on Interstitial Lung Disease and Thoracic Radiation","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; London Health Sciences Centre","funders":"Varian Medical Systems; Merck; AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Interstitial lung disease; Radiation oncologist; Lung cancer; Radiation therapy; Lung; Intensive care medicine; Disease; Oncology; Internal medicine; Radiology","score_opus":0.032440241615063814,"score_gpt":0.4422170015879352,"score_spread":0.4097767599728714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008790677","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009390001,0.99488646,0.00017140002,0.0017035115,0.0014426035,0.0006630351,0.00008765843,0.000020797637,0.00093063404],"genre_scores_gemma":[0.0019881607,0.993308,0.00027280106,0.00066026323,0.0033949378,0.000018873101,0.000063237196,0.00006694402,0.00022676862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732983,0.0005161051,0.0011248131,0.0003559306,0.00039658748,0.0002767509],"domain_scores_gemma":[0.997193,0.00025672864,0.0013001638,0.00023492919,0.00017298908,0.00084219157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004262591,0.00042981794,0.002474279,0.0004596396,0.00007364742,0.000038042086,0.00020783242,0.00039156424,0.00013429644],"category_scores_gemma":[0.0003859333,0.00031309156,0.0010434407,0.0002187966,0.00013543396,0.00013861603,0.00010004602,0.0011928108,0.00004553695],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011295567,0.0002928508,0.000007981139,0.014633927,0.00060992764,0.004197286,0.000062488085,4.397241e-7,0.000002269719,0.000062624335,0.0046807383,0.9641539],"study_design_scores_gemma":[0.00027537716,0.007061288,0.000032397103,0.024087943,0.011429683,0.002270263,0.000027209137,0.00009013162,0.0000011268243,0.00003877845,0.9544421,0.00024374036],"about_ca_topic_score_codex":0.0000022555203,"about_ca_topic_score_gemma":2.4619362e-7,"teacher_disagreement_score":0.96391016,"about_ca_system_score_codex":0.00081293803,"about_ca_system_score_gemma":0.0020169332,"threshold_uncertainty_score":0.9999321},"labels":[],"label_agreement":null},{"id":"W3012115385","doi":"10.1016/j.jtho.2020.01.025","title":"Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia; University Health Network","funders":"Genentech; Singapore Police Force; National Cancer Institute; National Institutes of Health; Institut National Du Cancer; Intuitive Surgical; Meso Scale Diagnostics; World Health Organization; International Association for the Study of Lung Cancer; Roche","keywords":"Mesothelioma; Medicine; BAP1; CDKN2A; Pathology; Radiology; Oncology; Internal medicine; Cancer","score_opus":0.10646310642407146,"score_gpt":0.3797295815886291,"score_spread":0.2732664751645576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012115385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518365,0.0011276358,0.00082389684,0.0021104764,0.000087940076,0.00034523313,0.0001271869,0.000003895364,0.00019007707],"genre_scores_gemma":[0.9977059,0.00003427595,0.0014108049,0.00069621304,0.0000566331,0.000010340024,0.00007282191,0.0000073892897,0.0000056373933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976927,0.000674597,0.00049605005,0.00016539982,0.00088928343,0.00008198562],"domain_scores_gemma":[0.9987697,0.00017318007,0.0005588569,0.00009272767,0.0003284637,0.00007704785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042256826,0.00012481755,0.0003349021,0.00005138304,0.000078827026,0.0000072311836,0.00020125089,0.000073024064,0.00010074073],"category_scores_gemma":[0.00020376753,0.00006819823,0.00012707942,0.00011907828,0.00023153561,0.00007004387,0.00007592111,0.0002822819,0.0000012836393],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010737394,0.011720052,0.4715665,0.00016190777,0.0022055137,0.00025026704,0.009193815,0.014080897,0.39605007,0.00011580514,0.00039522446,0.083522536],"study_design_scores_gemma":[0.0041853157,0.0013848067,0.9758513,0.00008140376,0.0010112579,0.0004240908,0.003470804,0.0113401115,0.0015378247,0.00010037406,0.00052713987,0.00008559875],"about_ca_topic_score_codex":0.0000141910305,"about_ca_topic_score_gemma":0.0000031090615,"teacher_disagreement_score":0.50428474,"about_ca_system_score_codex":0.0001093101,"about_ca_system_score_gemma":0.00014576822,"threshold_uncertainty_score":0.2781043},"labels":[],"label_agreement":null},{"id":"W3012587651","doi":"10.1016/j.jtho.2020.02.004","title":"Reply and Commentary to “Smoking Cessation Interventions in the Setting of Low-Dose Computed Tomography: Are They Effective?”","year":2020,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer screening; Psychological intervention; Lung cancer; Context (archaeology); Randomized controlled trial; Intervention (counseling); Clinical trial; Family medicine; Physical therapy; Oncology; Internal medicine; Psychiatry; Pathology","score_opus":0.02561287765958262,"score_gpt":0.3951694402647948,"score_spread":0.36955656260521214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012587651","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1621605,0.000959358,0.000062359584,0.83555436,0.00044425737,0.00072389684,0.000025633413,0.000005776318,0.00006384391],"genre_scores_gemma":[0.57984483,0.00008677686,0.00064904,0.41830426,0.0010213499,0.000036968006,0.000037453305,0.00001627278,0.0000030139195],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99785405,0.0007447377,0.00075055996,0.00019505004,0.0002936373,0.00016198825],"domain_scores_gemma":[0.99749446,0.0009118193,0.0011798673,0.00018262875,0.00016881526,0.00006242964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007896276,0.00018149633,0.0008514477,0.00041843945,0.000051433875,0.000019191937,0.00016624616,0.00017737887,0.000012033976],"category_scores_gemma":[0.00010692668,0.000118732976,0.00034818484,0.00025358138,0.000044537923,0.000058098034,0.00007630762,0.0012814283,5.417229e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077766035,0.0007038731,0.16437815,0.0030153752,0.0012674782,0.0032697378,0.003925613,0.000034692763,0.000027740822,0.0000017576748,0.76466036,0.05793758],"study_design_scores_gemma":[0.0037792018,0.0098285405,0.79606855,0.022136195,0.0036395574,0.0014241999,0.0017783821,0.000058997248,0.00027319381,0.0004436116,0.16028167,0.00028788342],"about_ca_topic_score_codex":0.00012130714,"about_ca_topic_score_gemma":0.00014263472,"teacher_disagreement_score":0.63169044,"about_ca_system_score_codex":0.00051456253,"about_ca_system_score_gemma":0.00007735699,"threshold_uncertainty_score":0.55672395},"labels":[],"label_agreement":null},{"id":"W3016631762","doi":"10.1016/j.jtho.2020.03.029","title":"Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Nova Scotia Health Authority; Jewish General Hospital; Dalhousie University; University of Ottawa; Ottawa Hospital; University of Manitoba; McGill University; London Health Sciences Centre; Saint John Regional Hospital; University of British Columbia; Sunnybrook Health Science Centre; McMaster University; Manitoba Health; Credit Valley Hospital; Southlake Regional Health Center; Trillium Health Centre; St. Joseph’s Healthcare Hamilton; Institut universitaire de cardiologie et de pneumologie de Québec; McGill University Health Centre; Royal University Hospital; University of Toronto; University of Calgary; Health Sciences Centre; University of Alberta; University Health Network; Health Sciences North; Queen's University; Kingston General Hospital; Centre Hospitalier de l’Université de Montréal; Saskatchewan Health Authority; Université Laval; University of Saskatchewan","funders":"EMD Serono; Pfizer Canada; Merck; Merck Canada; AstraZeneca Canada; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Standardization; Immunohistochemistry; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.04385648591046105,"score_gpt":0.42259447846627346,"score_spread":0.3787379925558124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016631762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893776,0.001406823,0.0002569151,0.007299092,0.00023776924,0.001004731,0.000054874065,0.000008725467,0.00035346125],"genre_scores_gemma":[0.9953326,0.00036990177,0.0024267617,0.0015786466,0.00017337984,0.00003048759,0.000016513999,0.000024570241,0.000047145564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998632,0.00009526094,0.0006695266,0.00015003837,0.00021087275,0.00024228917],"domain_scores_gemma":[0.9985435,0.000099442914,0.00051442743,0.0001190071,0.0005720043,0.00015163877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057410443,0.00014554273,0.0005240542,0.00021858029,0.000038860926,0.000011792809,0.00013140118,0.00018783486,0.00002703908],"category_scores_gemma":[0.00028963175,0.000115544986,0.0001400013,0.00031640218,0.00005683628,0.00006480103,0.000007692425,0.00026605235,5.509552e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17239007,0.0007765676,0.0113199,0.00045951674,0.0006151844,0.00027038003,0.0038973792,0.000021293159,0.49195576,0.000007662054,0.004532524,0.31375378],"study_design_scores_gemma":[0.04336703,0.028950239,0.04384318,0.0014264748,0.00033222028,0.00030568568,0.0014395956,0.00025537302,0.45414522,0.000032636715,0.42533493,0.0005674079],"about_ca_topic_score_codex":0.0006431263,"about_ca_topic_score_gemma":0.00094167504,"teacher_disagreement_score":0.4208024,"about_ca_system_score_codex":0.0011288375,"about_ca_system_score_gemma":0.004544438,"threshold_uncertainty_score":0.8061637},"labels":[],"label_agreement":null},{"id":"W3016754864","doi":"10.1016/j.jtho.2020.03.014","title":"Malignant Mesothelioma In Situ: Clinical and Pathologic Implications","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Vancouver General Hospital; University Health Network; University of British Columbia; University of British Columbia Hospital","funders":"University of British Columbia","keywords":"Medicine; Mesothelioma; Peritoneal mesothelioma; Radiation therapy; Chemotherapy; Guideline; Oncology; Surgery; Pathology","score_opus":0.0660731549737947,"score_gpt":0.45474654230901496,"score_spread":0.3886733873352203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016754864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654229,0.00065857323,0.0000640454,0.032639906,0.00006501684,0.00008326912,0.000005778952,0.000004691713,0.0010557865],"genre_scores_gemma":[0.9925518,0.00038125357,0.0026405528,0.004207669,0.00017780426,0.000002109346,0.0000028512286,0.0000050959516,0.000030845134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915296,0.000112947964,0.00045358945,0.000103350154,0.000089894966,0.000087256085],"domain_scores_gemma":[0.99939257,0.00012461841,0.00018731084,0.000057164103,0.000027548158,0.0002108048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002953118,0.00005893102,0.00029954023,0.000058821635,0.00001787495,0.0000034291627,0.00005397769,0.000080181344,0.0000682125],"category_scores_gemma":[0.00019554798,0.000041565538,0.00008262585,0.00008830208,0.0001166324,0.000048527923,0.000038134156,0.00019226903,0.000019392148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016287824,0.0005535815,0.888536,0.000036207635,0.000035002362,0.00091423595,0.00011764288,0.000005251913,0.012631034,0.00013354463,0.0012411664,0.09416758],"study_design_scores_gemma":[0.00057930214,0.0018517314,0.98911864,0.00002746348,0.000108506305,0.0010009563,0.00012320995,0.000018550709,0.00020822263,0.0008347643,0.006087456,0.000041178708],"about_ca_topic_score_codex":8.2200654e-7,"about_ca_topic_score_gemma":0.0000018931479,"teacher_disagreement_score":0.10058269,"about_ca_system_score_codex":0.00004163877,"about_ca_system_score_gemma":0.000097719625,"threshold_uncertainty_score":0.16949934},"labels":[],"label_agreement":null},{"id":"W3016785729","doi":"10.1016/j.jtho.2019.11.013","title":"The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Merck; Boehringer Ingelheim; AstraZeneca; Varian Medical Systems; Pfizer","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Cancer; Internal medicine; TNM staging system; Perioperative; Lymph node; Cancer staging; Oncology; Family medicine; Neoplasm staging; Surgery","score_opus":0.02488555473876381,"score_gpt":0.4208357232372718,"score_spread":0.395950168498508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016785729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98071796,0.00027757735,0.00013014894,0.014581194,0.0015620297,0.0022734392,0.00037002203,0.0000024248036,0.00008521353],"genre_scores_gemma":[0.9986069,0.00030370007,0.000017733128,0.00015060141,0.00045285193,0.00016742352,0.0000043335303,0.000018762692,0.0002776562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976308,0.00044652846,0.0009244337,0.0001475072,0.00067247136,0.0001782566],"domain_scores_gemma":[0.9924825,0.001357327,0.00448966,0.00028497403,0.0013577807,0.000027788372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024411243,0.00015414193,0.00054511055,0.00012750455,0.00016021493,0.00001829692,0.0005252466,0.00006136237,0.000027420285],"category_scores_gemma":[0.00045319553,0.000060709906,0.00031797474,0.00021999978,0.0002195702,0.000088755136,0.0000662912,0.0003838139,5.4809433e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063802386,0.0008668657,0.9122149,0.00015993514,0.0028105008,5.908122e-7,0.005460571,0.0030071298,0.034885395,0.0007110851,0.00413666,0.029366158],"study_design_scores_gemma":[0.0030696208,0.0020481038,0.9673926,0.0004980741,0.00062315236,0.000009275231,0.0069340053,0.015378546,0.0026209527,0.00015270407,0.00119875,0.00007421279],"about_ca_topic_score_codex":0.0021461598,"about_ca_topic_score_gemma":0.0010779032,"teacher_disagreement_score":0.055177733,"about_ca_system_score_codex":0.0010496543,"about_ca_system_score_gemma":0.0009426309,"threshold_uncertainty_score":0.3244366},"labels":[],"label_agreement":null},{"id":"W3017322331","doi":"10.1016/j.jtho.2020.03.028","title":"Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":607,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"Eli Lilly Japan; Incyte; Yuhan; F. Hoffmann-La Roche; Roche; Chugai Pharmaceutical; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Medicine; Carboplatin; Hazard ratio; Internal medicine; Oncology; Population; Paclitaxel; Randomized controlled trial; Chemotherapy; Confidence interval; Cancer; Cisplatin; Pembrolizumab; Immunotherapy","score_opus":0.02215734906571848,"score_gpt":0.3832901829427656,"score_spread":0.36113283387704714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017322331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98541594,0.0017477251,0.00013373431,0.010729228,0.00031180785,0.0010860581,0.000015014387,0.000009334781,0.00055115693],"genre_scores_gemma":[0.99742514,0.00033272768,0.0012819837,0.0006891879,0.00018774444,0.000017553546,0.000016617001,0.000015424966,0.00003363478],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99750525,0.000536033,0.001286856,0.00021687163,0.00026050935,0.00019446797],"domain_scores_gemma":[0.9977614,0.0009589323,0.0009177062,0.000110719906,0.00011084785,0.000140358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001461796,0.00016363236,0.0013416413,0.00025557974,0.000024346,0.000014179473,0.000085826105,0.00017645446,0.000030735173],"category_scores_gemma":[0.0010003028,0.00011737384,0.00013418125,0.00033868777,0.00014679333,0.00014846286,0.00001986103,0.0005053696,6.968144e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88341546,0.0007001358,0.000074713775,0.000020415468,0.00012421816,0.0007320888,0.0036357255,0.000013303791,0.0055870917,0.000003947165,0.000107934815,0.10558497],"study_design_scores_gemma":[0.9791423,0.014890978,0.0009992055,0.00027909738,0.00019222761,0.00018001966,0.0010670583,0.0007721705,0.0009527798,0.0001237083,0.0012756214,0.00012485433],"about_ca_topic_score_codex":0.000285171,"about_ca_topic_score_gemma":0.00027432895,"teacher_disagreement_score":0.105460115,"about_ca_system_score_codex":0.00033055732,"about_ca_system_score_gemma":0.0004996843,"threshold_uncertainty_score":0.47863665},"labels":[],"label_agreement":null},{"id":"W3020016069","doi":"10.1016/j.jtho.2020.02.017","title":"Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma","year":2020,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Mesothelioma; General surgery; Pathology","score_opus":0.04707486406784745,"score_gpt":0.432575618343977,"score_spread":0.38550075427612956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020016069","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055430075,0.0006871425,0.00014605375,0.99100703,0.0006205372,0.0005219867,0.00027856758,0.000015341833,0.0011803464],"genre_scores_gemma":[0.0012549325,0.00034862882,0.0069948384,0.98463744,0.003094059,0.000038740658,0.00018805313,0.00005919727,0.0033841252],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981119,0.00017132977,0.00065333035,0.0002812683,0.00051599555,0.00026615828],"domain_scores_gemma":[0.9984813,0.00045158013,0.00046971077,0.00017498485,0.00012173288,0.0003007399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002781216,0.00026649408,0.0010205742,0.00020525542,0.000054346005,0.000017301261,0.00012642647,0.00023245536,0.0003411478],"category_scores_gemma":[0.00012640766,0.00018380837,0.0006271154,0.00008579652,0.000053763215,0.000052969757,0.000046557485,0.0006156167,0.000050927214],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008007589,0.0002573872,0.00025661322,0.00010333033,0.0005774056,0.009547162,0.00008161583,0.000011814061,0.00011860637,0.0000037103794,0.9572455,0.023789264],"study_design_scores_gemma":[0.0013729879,0.010109314,0.00057288876,0.00020623907,0.000864806,0.0019720453,0.000033403034,0.0000065973163,0.00017223346,0.00011581882,0.98441505,0.00015859985],"about_ca_topic_score_codex":0.00000738283,"about_ca_topic_score_gemma":0.0000010211996,"teacher_disagreement_score":0.027169565,"about_ca_system_score_codex":0.0011423342,"about_ca_system_score_gemma":0.00060698506,"threshold_uncertainty_score":0.7495488},"labels":[],"label_agreement":null},{"id":"W3033203711","doi":"10.1016/j.jtho.2020.05.019","title":"The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":292,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Merck Sharp and Dohme; EMD Serono; Johnson and Johnson; Illumina; Roche; AstraZeneca; Novartis; Amgen; Pfizer; Merck","keywords":"Medicine; Biomarker; Immunotherapy; Lung cancer; Oncology; Clinical trial; Companion diagnostic; Surrogate endpoint; Cancer; Immune checkpoint; Disease; Internal medicine; Bioinformatics; Biology","score_opus":0.06436462107388363,"score_gpt":0.463307146434376,"score_spread":0.39894252536049235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033203711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012296694,0.960208,0.000008363053,0.024440506,0.00088929554,0.0020053408,0.00008638112,0.0000042437437,0.00006116739],"genre_scores_gemma":[0.010601015,0.9881298,0.000070316324,0.00016496576,0.0007650147,0.00018898363,0.000006974844,0.000028547858,0.000044368633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720967,0.0010278272,0.0010367994,0.00020302962,0.00038499755,0.00013769048],"domain_scores_gemma":[0.99129605,0.004053588,0.0036027513,0.00023882533,0.00077373843,0.000035067813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00239982,0.00021533921,0.0012912864,0.00009951788,0.00015238713,0.000026912934,0.0005137428,0.00019088357,0.000027920334],"category_scores_gemma":[0.0006024929,0.0000981176,0.00040382965,0.00014470183,0.0001848101,0.000069651804,0.00005445922,0.00045260214,1.6658362e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077470145,0.00032099758,0.00012771392,0.0004326166,0.0073575657,0.000031617,0.011079584,5.054663e-7,0.00010923511,0.000032842705,0.00041387262,0.9723464],"study_design_scores_gemma":[0.0039481656,0.0075116926,0.0053230464,0.002355454,0.0064708516,0.000581028,0.043580085,0.00007173889,0.000026172384,0.00033936105,0.92962587,0.00016652135],"about_ca_topic_score_codex":0.00053512835,"about_ca_topic_score_gemma":0.00049846456,"teacher_disagreement_score":0.9721799,"about_ca_system_score_codex":0.0008881908,"about_ca_system_score_gemma":0.0010955104,"threshold_uncertainty_score":0.40011194},"labels":[],"label_agreement":null},{"id":"W3035834839","doi":"10.1016/j.jtho.2020.06.001","title":"A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":541,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University Health Network; Health Sciences Centre","funders":"Merck Sharp and Dohme; National Institutes of Health; New York University; Chugai Pharmaceutical; Roche; International Association for the Study of Lung Cancer; Novartis; National Cancer Institute; AbbVie; Merck; GlaxoSmithKline; Intuitive Surgical; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Grading (engineering); Lung cancer; Adenocarcinoma; Pathology; Lung; Oncology; Cancer; Internal medicine","score_opus":0.03829380248796443,"score_gpt":0.3959802518773295,"score_spread":0.35768644938936506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035834839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8905515,0.002929037,0.00032742496,0.10241003,0.0015367976,0.0020644618,0.000114370756,0.0000071593,0.000059197544],"genre_scores_gemma":[0.9966749,0.00010843811,0.00050168595,0.0009300294,0.0013512193,0.00038368333,0.000008456717,0.00001440986,0.00002716834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987493,0.00019463118,0.00051629567,0.00014133345,0.0002641143,0.00013428836],"domain_scores_gemma":[0.99563366,0.0026151272,0.0010683403,0.00010981746,0.0005164311,0.000056647263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073398167,0.00010133053,0.00048247437,0.000038753773,0.000103432176,0.000013415055,0.0002462479,0.00008771006,0.000011518369],"category_scores_gemma":[0.00044051197,0.000052704858,0.00019517857,0.000081888975,0.000027699092,0.00005180311,0.00005242722,0.00021527433,4.014986e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00500734,0.0010505827,0.954175,0.000248681,0.0035661403,0.00021230223,0.007851621,0.000081473794,0.0009494348,0.000083630526,0.017658932,0.0091148615],"study_design_scores_gemma":[0.015428763,0.019394714,0.8796482,0.0010627895,0.016947223,0.00063348643,0.046398073,0.0064385897,0.0045904624,0.00035784472,0.008840223,0.00025962474],"about_ca_topic_score_codex":0.00012208962,"about_ca_topic_score_gemma":0.00027193085,"teacher_disagreement_score":0.10612339,"about_ca_system_score_codex":0.0014807526,"about_ca_system_score_gemma":0.0005930939,"threshold_uncertainty_score":0.38721165},"labels":[],"label_agreement":null},{"id":"W3037506839","doi":"10.1016/j.jtho.2020.06.015","title":"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Bayer; Servier; Astellas Pharma; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; F. Hoffmann-La Roche; AbbVie; Merck; Spectrum Pharmaceuticals; Celgene; Novartis; Sanofi; PharmaMar; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Roche; Astellas Pharma US","keywords":"Medicine; Pembrolizumab; Oncology; Placebo; Protocol (science); Internal medicine; Chemotherapy; Randomized controlled trial; Immunotherapy; Cancer; Pathology; Alternative medicine","score_opus":0.033090687614001496,"score_gpt":0.3841235725741152,"score_spread":0.35103288496011376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037506839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95689076,0.00010242845,0.0006983184,0.0019424022,0.00011873586,0.039776266,0.000009408229,0.000006474519,0.0004551775],"genre_scores_gemma":[0.9950327,0.000025701891,0.0016336637,0.0005095219,0.00012712211,0.0025802294,0.000005917028,0.000024344972,0.000060797316],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956783,0.00091074413,0.0022747223,0.00021162449,0.00068149186,0.00024309166],"domain_scores_gemma":[0.9952867,0.00090314494,0.0029748674,0.00021331864,0.0004798811,0.00014210181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002059512,0.0002490053,0.0042321356,0.0007899617,0.000023985092,0.000008355512,0.00021496955,0.00014645797,0.00041984237],"category_scores_gemma":[0.00054166507,0.00015449214,0.0011155028,0.0011052486,0.0002745107,0.000090907924,0.000019211748,0.0003953413,6.807962e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97224337,0.0020194242,0.0005346679,0.00017556448,0.0069219037,0.000074067655,0.0011958593,0.00030165532,0.00037073862,0.0000048348716,0.00012094441,0.016036987],"study_design_scores_gemma":[0.968631,0.02010079,0.003651335,0.00012682234,0.0050888667,0.000020844456,0.0001773716,0.0010221826,0.00052109483,0.000014275251,0.00051653857,0.00012883701],"about_ca_topic_score_codex":0.00003148515,"about_ca_topic_score_gemma":0.000027386348,"teacher_disagreement_score":0.03814191,"about_ca_system_score_codex":0.00033578402,"about_ca_system_score_gemma":0.0011292817,"threshold_uncertainty_score":0.63000065},"labels":[],"label_agreement":null},{"id":"W3040714822","doi":"10.1016/j.jtho.2020.06.021","title":"Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Ipsen; BTG; AstraZeneca; Thermo Fisher Scientific; AbbVie Canada; Boehringer Ingelheim; Medtronic; AbbVie; Merck; Bayer; Novartis; EpicentRx; Pfizer","keywords":"Medicine; Neuroendocrine tumors; Commonwealth; Evidence-based practice; MEDLINE; Guideline; Pathology; Alternative medicine; Political science; Law","score_opus":0.09623477790388303,"score_gpt":0.5020096847840411,"score_spread":0.40577490688015805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040714822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1259973,0.6801796,0.00003631864,0.17489532,0.001187728,0.015900657,0.0016849481,0.000064593,0.000053514865],"genre_scores_gemma":[0.017256984,0.9731453,0.004672109,0.0032678107,0.0007386604,0.00054253096,0.000082436105,0.00020962248,0.00008451485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9883216,0.0038972017,0.0036690722,0.0010836099,0.0020379764,0.0009905087],"domain_scores_gemma":[0.98398143,0.0032505533,0.004951653,0.0009963899,0.006259042,0.0005609316],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0015332206,0.00099008,0.0035194738,0.0003593339,0.0006025909,0.0001735595,0.0014742524,0.000008444121,0.000009351309],"category_scores_gemma":[0.0030952054,0.000508724,0.0006433462,0.0019858223,0.0033319613,0.00033556155,0.0018190885,0.0018089154,5.985247e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027771179,0.0028835712,0.015097827,0.025158525,0.0065658987,0.02097112,0.0006920774,0.0002686533,0.0000299798,0.00027933743,0.23892331,0.66135854],"study_design_scores_gemma":[0.007694242,0.0071256426,0.0037193554,0.0028911124,0.0027413724,0.013220714,0.0026881213,0.0011452673,0.00011730635,0.000016886152,0.95821005,0.00042995653],"about_ca_topic_score_codex":0.00009662254,"about_ca_topic_score_gemma":0.0001537172,"teacher_disagreement_score":0.71928674,"about_ca_system_score_codex":0.0002920028,"about_ca_system_score_gemma":0.0014263768,"threshold_uncertainty_score":0.9997364},"labels":[],"label_agreement":null},{"id":"W3044930133","doi":"10.1016/j.jtho.2020.07.005","title":"Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance)","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Genentech; National Institutes of Health; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Oncology; Stage (stratigraphy); Internal medicine; Prospective cohort study; Cohort study; Lung cancer","score_opus":0.029541895144846158,"score_gpt":0.4068102043047985,"score_spread":0.3772683091599523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044930133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902808,0.0034395498,0.00029330092,0.00474265,0.0003522922,0.00063430757,0.000025522648,0.000008558944,0.00022299164],"genre_scores_gemma":[0.9955199,0.00039821747,0.0033096767,0.00032186278,0.00031959053,0.0000433882,0.0000035507924,0.000011844809,0.0000720118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873906,0.000094956325,0.00053031626,0.00016953486,0.00030270984,0.0001634345],"domain_scores_gemma":[0.99872744,0.00015708184,0.00054662366,0.0000730373,0.0003539908,0.00014184225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022492716,0.0001330354,0.00054365944,0.000100860685,0.000030404159,0.000008038796,0.00009001361,0.00012607271,0.00013525196],"category_scores_gemma":[0.00030416754,0.000094997646,0.00013112766,0.00023801063,0.000080418155,0.00014483756,0.000023482915,0.0003820058,0.0000021185087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028621496,0.0014672864,0.9759458,0.0005048131,0.00035471068,0.0009407048,0.0025094529,0.0059702424,0.0032586264,0.00008076396,0.00060704385,0.005498425],"study_design_scores_gemma":[0.004743776,0.004090401,0.9585259,0.000751111,0.0006982439,0.00005528981,0.00019983802,0.0016228281,0.027707715,0.00002995612,0.0014408145,0.00013410999],"about_ca_topic_score_codex":0.00008819841,"about_ca_topic_score_gemma":0.00010796914,"teacher_disagreement_score":0.024449088,"about_ca_system_score_codex":0.00117609,"about_ca_system_score_gemma":0.0010172641,"threshold_uncertainty_score":0.38738918},"labels":[],"label_agreement":null},{"id":"W3058366262","doi":"10.1016/j.jtho.2020.08.006","title":"Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Demography; Task force; Cohort; Ethnic group; Population; Cancer; African american; Gerontology; Health equity; Internal medicine; Environmental health; Public health; Pathology","score_opus":0.027286916773536823,"score_gpt":0.4309222564432781,"score_spread":0.40363533966974124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3058366262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769241,0.0036399337,0.0054536867,0.012585119,0.00066600926,0.00037737234,0.00021519864,0.00003538626,0.00010315573],"genre_scores_gemma":[0.98780876,0.005432805,0.0050851824,0.00080939155,0.0006442774,0.00003625617,0.000064269996,0.000024847519,0.000094176765],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99823236,0.00025550483,0.00065849745,0.00027556863,0.00031314592,0.00026489975],"domain_scores_gemma":[0.9980086,0.0002898129,0.0008054437,0.00015859307,0.0004607278,0.0002768411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005071949,0.00019461577,0.0006394149,0.00013114029,0.00014109848,0.000034346744,0.00012397156,0.000140056,0.00005646407],"category_scores_gemma":[0.00013261921,0.00015376462,0.00018968529,0.00024885466,0.00006755108,0.0003164956,0.00007234154,0.0004837694,8.906649e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08501774,0.0020924902,0.36492354,0.0042697117,0.008615919,0.0005517003,0.033207875,0.38731375,0.002605125,0.000030962146,0.029924763,0.08144645],"study_design_scores_gemma":[0.007079116,0.0065330556,0.055031404,0.0020891104,0.007628789,0.00010473551,0.0033339984,0.90990824,0.004191264,0.0002820779,0.0035193108,0.0002989125],"about_ca_topic_score_codex":0.00074319204,"about_ca_topic_score_gemma":0.00012995292,"teacher_disagreement_score":0.5225945,"about_ca_system_score_codex":0.0009676692,"about_ca_system_score_gemma":0.00034517446,"threshold_uncertainty_score":0.62703395},"labels":[],"label_agreement":null},{"id":"W3084355783","doi":"10.1016/j.jtho.2020.08.022","title":"Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; National Institutes of Health; Innovent Biologics; Jounce Therapeutics; Jazz Pharmaceuticals; Varian Medical Systems; Sierra Oncology; F. Hoffmann-La Roche; Novartis; National Cancer Institute; Johnson and Johnson; AbbVie; MedImmune; Merck; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Common Terminology Criteria for Adverse Events; Internal medicine; Neutropenia; Oncology; Pneumonitis; Chemoradiotherapy; Radiation therapy; Progression-free survival; Surgery; Chemotherapy; Cancer; Immunotherapy","score_opus":0.11394025076929282,"score_gpt":0.5265962188109286,"score_spread":0.41265596804163573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084355783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682306,0.004062353,0.0007523131,0.02516142,0.000458896,0.0009525289,0.000027531316,0.000007842872,0.00034651143],"genre_scores_gemma":[0.99431896,0.0027089892,0.00093078124,0.00072917587,0.0011851233,0.000019406334,0.0000045584948,0.000012977252,0.00009003929],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99884385,0.000108521504,0.0005011724,0.000114648814,0.00027228004,0.0001595303],"domain_scores_gemma":[0.9984228,0.00033476038,0.0005563417,0.00007399906,0.00042152277,0.00019060436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058383937,0.000095203606,0.00065362256,0.00009027251,0.00003625074,0.000007402107,0.000081314276,0.00007909102,0.000037149824],"category_scores_gemma":[0.00092284963,0.00006887132,0.00014198151,0.00012624601,0.00012371005,0.000079295474,0.00002903603,0.00024990542,7.330869e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35286382,0.0012587575,0.00017795902,0.0004156317,0.00044335925,0.000060485338,0.0013388045,0.0000039986285,0.016014833,0.000048727205,0.010241654,0.61713195],"study_design_scores_gemma":[0.4222257,0.15192217,0.00094663544,0.00016362926,0.0005374862,0.00016869213,0.00086092367,0.0017404818,0.029869977,0.00010189957,0.39129663,0.00016577197],"about_ca_topic_score_codex":0.0000018707134,"about_ca_topic_score_gemma":9.592416e-7,"teacher_disagreement_score":0.6169662,"about_ca_system_score_codex":0.00016468279,"about_ca_system_score_gemma":0.0006056464,"threshold_uncertainty_score":0.2808491},"labels":[],"label_agreement":null},{"id":"W3088068442","doi":"10.1016/j.jtho.2020.07.011","title":"How Is Receptor Activator of Nuclear Factor-κβ/Receptor Activator of Nuclear Factor-κβ Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet?","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Amgen Canada; Amgen","keywords":"Medicine; Activator (genetics); Oncology; Receptor; Cancer research; Internal medicine; Nuclear receptor; Transcription factor; Gene; Biology; Genetics","score_opus":0.03680684340770763,"score_gpt":0.3746287906146266,"score_spread":0.337821947206919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088068442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97242457,0.0005963278,0.000035616235,0.023415748,0.0013622219,0.0013153923,0.000346239,0.00006453406,0.00043935492],"genre_scores_gemma":[0.97969276,0.00030547925,0.015989512,0.0027989352,0.00074352947,0.00001750802,0.00004640061,0.00020033034,0.00020556997],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99516445,0.00068503706,0.0018453967,0.0006303275,0.0007641898,0.00091058936],"domain_scores_gemma":[0.99307054,0.0007701961,0.0033229936,0.00045949288,0.0010395476,0.0013372452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006937035,0.000610043,0.002768798,0.00037248377,0.00026312674,0.000042337128,0.0005361509,0.0010488442,0.0019636392],"category_scores_gemma":[0.0019509933,0.0005040474,0.00078481616,0.00044797093,0.00032454482,0.0006865044,0.00015404212,0.0012372773,0.00008196657],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056136005,0.0030114038,0.0014128238,0.0009516789,0.002075932,0.00017978983,0.013484942,0.0000020891703,0.8417127,0.000106053885,0.01374373,0.06718286],"study_design_scores_gemma":[0.010350512,0.054643273,0.0013828613,0.0004245884,0.00056618406,0.0003342914,0.00828573,0.00006725979,0.2618322,0.0001762352,0.66141695,0.0005199008],"about_ca_topic_score_codex":0.00010014321,"about_ca_topic_score_gemma":0.00000401581,"teacher_disagreement_score":0.64767325,"about_ca_system_score_codex":0.00093628076,"about_ca_system_score_gemma":0.002437265,"threshold_uncertainty_score":0.99974114},"labels":[],"label_agreement":null},{"id":"W3089522740","doi":"10.1016/j.jtho.2020.09.013","title":"American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Takeda Pharmaceutical Company; Varian Medical Systems; Genentech; RefleXion Medical; AstraZeneca","keywords":"Medicine; Radiation therapy; Prophylactic cranial irradiation; Chemoimmunotherapy; Medical physics; Clinical trial; Randomized controlled trial; Oncology; Radiology; Surgery; Internal medicine; Immunotherapy; Cancer","score_opus":0.09826513809280533,"score_gpt":0.49856045829038376,"score_spread":0.4002953201975784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089522740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88974327,0.0010350713,0.0027256191,0.10471383,0.00063376134,0.0008998669,0.00003297282,0.000030899188,0.00018468882],"genre_scores_gemma":[0.94551194,0.004006669,0.021774774,0.025019543,0.003041765,0.000041763702,0.000010429954,0.00005552747,0.00053756114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984918,0.00019804889,0.0004393246,0.0002063971,0.0003604302,0.0003040052],"domain_scores_gemma":[0.9980082,0.00044972412,0.00050106266,0.00014709696,0.0006258202,0.00026808752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006429296,0.00015362776,0.0007220032,0.000069803355,0.00009697491,0.000030239999,0.00013802468,0.00008147787,0.000049849346],"category_scores_gemma":[0.0009917581,0.000109920875,0.00034261274,0.00022383248,0.00020816016,0.0001536161,0.000036448153,0.0004583332,0.0000070870938],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03361372,0.0005554677,0.002166332,0.00029926418,0.0013254676,0.0002601882,0.00600316,0.00008709986,0.050398696,0.000037953254,0.1389148,0.7663379],"study_design_scores_gemma":[0.0074779154,0.04140462,0.04402847,0.0001436109,0.0003748477,0.00016883688,0.002700228,0.0035485516,0.018124925,0.00011569666,0.8816057,0.00030663778],"about_ca_topic_score_codex":0.000015575684,"about_ca_topic_score_gemma":0.0000019308534,"teacher_disagreement_score":0.7660312,"about_ca_system_score_codex":0.00048707562,"about_ca_system_score_gemma":0.00052854256,"threshold_uncertainty_score":0.4482443},"labels":[],"label_agreement":null},{"id":"W3089717675","doi":"10.1016/j.jtho.2020.09.004","title":"Identification and Resolution of Asymptomatic COVID-19 Pneumonitis and Colitis: Serial Assessment of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Evaluation of Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Medicine; Fluorodeoxyglucose; Chest radiograph; Radiology; Positron emission tomography; Asymptomatic; Lung cancer; Solitary pulmonary nodule; Nodule (geology); Standardized uptake value; Lung; Nuclear medicine; Atelectasis; Ground-glass opacity; Mediastinal lymphadenopathy; Radiography; Cancer; Pathology; Biopsy; Computed tomography; Internal medicine; Adenocarcinoma","score_opus":0.06018396778772396,"score_gpt":0.52479049326001,"score_spread":0.4646065254722861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089717675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97771007,0.0021481616,0.008421994,0.010260419,0.00018670369,0.0011791126,0.00007376801,0.000007714161,0.00001204188],"genre_scores_gemma":[0.9952629,0.0009595371,0.003345388,0.00021178144,0.00015280514,0.00004274839,0.000010289889,0.0000103225675,0.000004178235],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968603,0.0006886996,0.0012784095,0.00021663513,0.0007875937,0.00016831374],"domain_scores_gemma":[0.9939086,0.0023084932,0.0015792414,0.0001336585,0.001761763,0.00030826393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038442882,0.00012259027,0.00082645443,0.00039139338,0.00007044085,0.000008747436,0.00010513433,0.00014894872,0.00001731551],"category_scores_gemma":[0.008260808,0.00010470095,0.0001900892,0.00040534057,0.00026932772,0.0001268545,0.000086205124,0.00021596953,2.2907024e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018729407,0.0015023642,0.16285984,0.01958374,0.0021251736,0.000021929602,0.0032045771,0.0018349617,0.63088316,0.00013150032,0.001530158,0.15759319],"study_design_scores_gemma":[0.0070906626,0.008106817,0.83178085,0.001192368,0.003213336,0.000027474327,0.00042183787,0.12705883,0.019712906,0.0009814542,0.0002733472,0.00014010593],"about_ca_topic_score_codex":0.000056638382,"about_ca_topic_score_gemma":0.000015741352,"teacher_disagreement_score":0.668921,"about_ca_system_score_codex":0.00034020998,"about_ca_system_score_gemma":0.0015674216,"threshold_uncertainty_score":0.98895556},"labels":[],"label_agreement":null},{"id":"W3094192068","doi":"10.1016/j.jtho.2020.09.027","title":"Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Janssen Biotech; Fonds de Recherche du Québec - Santé; University of Texas MD Anderson Cancer Center; Bill and Katie Weaver Charitable Trust; EMD Serono; Cancer Prevention and Research Institute of Texas; Genentech; Innovent Biologics; Astellas Pharma; Bayer Fund; Takeda Pharmaceutical Company; Ribon Therapeutics; Merck; Spectrum Pharmaceuticals; North Carolina GlaxoSmithKline Foundation; National Cancer Institute; Bayer; Exelixis; Sanofi; GlaxoSmithKline; Society for Immunotherapy of Cancer; Astellas Pharma US; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Infiltration (HVAC); Cytotoxic T cell; Chemotherapy; Oncology; Cell; Internal medicine; Cancer research; In vitro","score_opus":0.02015960351542771,"score_gpt":0.3554963304333422,"score_spread":0.3353367269179145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094192068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781362,0.008505164,0.000099462486,0.009124821,0.00019965555,0.00035950428,0.0000037707175,0.000013297251,0.003558164],"genre_scores_gemma":[0.989832,0.0039120726,0.0015827365,0.0034887455,0.0005114095,0.0000059978133,0.000003828306,0.00002687914,0.00063636503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821895,0.0002641126,0.0007601954,0.00020956047,0.00029121526,0.00025593644],"domain_scores_gemma":[0.9987462,0.00018589935,0.0005624755,0.00015107109,0.00012140596,0.00023295144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007974918,0.00017725586,0.00061386125,0.0002298688,0.000054975604,0.000027395809,0.00013792021,0.0002123246,0.00041815077],"category_scores_gemma":[0.00007231275,0.00014684045,0.00010458738,0.00030407053,0.00009657398,0.00019292234,0.00003297808,0.00049685856,0.000008836207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019838033,0.00046472056,0.0020136822,0.00027629422,0.000041330382,0.00065239065,0.0019919502,0.000022360318,0.9236465,7.137034e-7,0.0101483,0.040903717],"study_design_scores_gemma":[0.008209654,0.00935331,0.0128143225,0.0002412121,0.00014993842,0.00072192884,0.0023100579,0.00011656503,0.91812897,0.000045673558,0.04767481,0.0002335558],"about_ca_topic_score_codex":0.000248881,"about_ca_topic_score_gemma":0.000074548836,"teacher_disagreement_score":0.040670164,"about_ca_system_score_codex":0.00029474447,"about_ca_system_score_gemma":0.0006569137,"threshold_uncertainty_score":0.598798},"labels":[],"label_agreement":null},{"id":"W3094552190","doi":"10.1016/j.jtho.2020.10.007","title":"Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Merck Sharp and Dohme; Boehringer Ingelheim; Daiichi Sankyo Company; Clovis Oncology; F. Hoffmann-La Roche; Roche; Novartis; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Fluorescence in situ hybridization; Immunohistochemistry; In situ hybridization; In situ; Pathology; Internal medicine; Oncology; Gene; Genetics; Biology; Gene expression","score_opus":0.014438887838654395,"score_gpt":0.41802516681540647,"score_spread":0.4035862789767521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094552190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962497,0.00005983432,0.000089595706,0.002253662,0.00008446862,0.0010557871,0.000015806994,0.000004130517,0.00018703364],"genre_scores_gemma":[0.99833685,0.000010337995,0.00067953154,0.00083505944,0.000038315797,0.000032933964,0.000026838527,0.000012302715,0.00002780984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853826,0.00018795193,0.00055818626,0.00017353051,0.00027261474,0.00026947857],"domain_scores_gemma":[0.999161,0.0001637313,0.00030552276,0.000106303305,0.00012385681,0.00013960466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021190442,0.00014561317,0.0005051739,0.00014181292,0.00003579028,0.00001635152,0.00013029123,0.000049376566,0.0000144000705],"category_scores_gemma":[0.0002819435,0.00008550542,0.00004408253,0.0004105142,0.000026048312,0.00014109172,0.000026047215,0.00029682054,0.0000010215491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021331612,0.004598006,0.91002035,0.000025382533,0.00015564339,0.0012024761,0.015758092,0.0000825186,0.0072268643,2.0526986e-7,0.00018617374,0.039412696],"study_design_scores_gemma":[0.029889343,0.01178579,0.94341433,0.00022249552,0.00034307688,0.000045411314,0.012312234,0.00006553278,0.0016018207,0.0000017898099,0.00016915117,0.00014904642],"about_ca_topic_score_codex":0.00007242043,"about_ca_topic_score_gemma":0.000099179786,"teacher_disagreement_score":0.03926365,"about_ca_system_score_codex":0.00093160133,"about_ca_system_score_gemma":0.0005235555,"threshold_uncertainty_score":0.34868097},"labels":[],"label_agreement":null},{"id":"W3096676736","doi":"10.1016/j.jtho.2020.10.020","title":"American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"Takeda Pharmaceuticals U.S.A.; RefleXion Medical; American Radium Society; Varian Medical Systems; GlaxoSmithKline; Genentech; Philips; Aptitude Health; Australian Carbon Innovation; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Radium; Stage (stratigraphy); Radiation therapy; Radiation oncology; Medical physics; Oncology; Internal medicine; Radiochemistry","score_opus":0.0771952621113736,"score_gpt":0.47788536030754053,"score_spread":0.4006900981961669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096676736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82420766,0.002998555,0.0054984917,0.16503352,0.0007991422,0.001139689,0.000054842636,0.000049593546,0.00021850066],"genre_scores_gemma":[0.91281456,0.012799123,0.04725532,0.020240828,0.005786743,0.00007032905,0.00002436156,0.000085036154,0.0009236958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99827844,0.00022127372,0.0005476458,0.00022198557,0.0003799563,0.000350677],"domain_scores_gemma":[0.99794835,0.00043209613,0.0005807635,0.00015358032,0.00055020035,0.0003349982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077513274,0.00016886645,0.0008075903,0.00006133253,0.00010514529,0.000041448937,0.00017967942,0.00010538028,0.000071168106],"category_scores_gemma":[0.0009492996,0.00012521454,0.00040046702,0.0003535373,0.00023333546,0.0002344723,0.000058698493,0.0005358941,0.000006479999],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020888025,0.0005281841,0.0060232375,0.0004333793,0.0018353405,0.00028183346,0.0064097876,0.000057015364,0.040064353,0.000017687795,0.24628268,0.67717844],"study_design_scores_gemma":[0.0051768334,0.01893508,0.023612263,0.000077550205,0.0004037256,0.00019489849,0.0019204972,0.0036385993,0.007219105,0.000060233826,0.93852377,0.00023746972],"about_ca_topic_score_codex":0.00001990912,"about_ca_topic_score_gemma":0.0000038245325,"teacher_disagreement_score":0.6922411,"about_ca_system_score_codex":0.00049799937,"about_ca_system_score_gemma":0.00070484396,"threshold_uncertainty_score":0.5106101},"labels":[],"label_agreement":null},{"id":"W3106369794","doi":"10.1016/j.jtho.2020.10.127","title":"Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"Bayer Fund; Merck Sharp and Dohme; Jazz Pharmaceuticals; Takeda Pharmaceuticals U.S.A.; Patient-Centered Outcomes Research Institute; International Association for the Study of Lung Cancer; Roche; National Academy of Medicine; Merck; Takeda Pharmaceuticals International; Bayer; American College of Radiology; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; American Thoracic Society; Pfizer; Boehringer Ingelheim; Amgen; American Cancer Society; American Lung Association","keywords":"Overdiagnosis; Medicine; Lung cancer; Lung cancer screening; Intensive care medicine; Population; Cancer; Family medicine; Environmental health; Oncology; Pathology; Internal medicine","score_opus":0.23405061909373415,"score_gpt":0.5482019326469956,"score_spread":0.3141513135532614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106369794","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007678432,0.98068374,0.000023087534,0.017577926,0.0001801062,0.0012966769,0.00019926378,0.00000196286,0.000029544313],"genre_scores_gemma":[0.000013039724,0.99637926,0.002652036,0.00043987305,0.00039572627,0.000036492227,0.000057902525,0.000020689715,0.0000050041926],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984149,0.00018251625,0.00091056083,0.00020954013,0.00017394382,0.00010857383],"domain_scores_gemma":[0.9973858,0.00040040707,0.0016648361,0.0002866359,0.00016209022,0.00010024034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095748383,0.00017529662,0.0019964222,0.00006779282,0.000034739438,0.0000057657344,0.00019057709,0.0001096999,0.000013055416],"category_scores_gemma":[0.00020728935,0.00009399291,0.00023308673,0.000087930595,0.000037781618,0.0000590069,0.00020160463,0.00022979871,1.5097034e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048105394,0.000045761095,0.00004597276,0.14652658,0.00068646687,0.000014735632,0.000048192793,1.402711e-8,3.0826598e-8,0.00001661047,0.0021063592,0.8504612],"study_design_scores_gemma":[0.000523717,0.0009456182,0.000110758345,0.14491613,0.012414947,0.0007788102,0.00006314841,0.0000043349373,6.40827e-7,0.0000047269727,0.8401815,0.00005561264],"about_ca_topic_score_codex":0.0000033930662,"about_ca_topic_score_gemma":0.000022494663,"teacher_disagreement_score":0.8504056,"about_ca_system_score_codex":0.00018151414,"about_ca_system_score_gemma":0.00055135245,"threshold_uncertainty_score":0.38329196},"labels":[],"label_agreement":null},{"id":"W3107628190","doi":"10.1016/j.jtho.2020.11.002","title":"Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Institute for Health and Care Research; Cancer Research UK; Les Laboratories Pierre Fabre; AstraZeneca; Manchester Biomedical Research Centre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Radiation therapy; Cardiac toxicity; Toxicity; Lung cancer; Intensive care medicine; Disease; Cardiology; Internal medicine; Oncology","score_opus":0.08470044358719478,"score_gpt":0.47051526339955757,"score_spread":0.38581481981236276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107628190","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002007375,0.99336636,0.00018148737,0.0017260099,0.0013679803,0.0006546645,0.000023723962,0.00002487089,0.00064752065],"genre_scores_gemma":[0.00044168378,0.9886723,0.0050476408,0.000192802,0.0054426403,0.000013310712,0.0000070773294,0.000059380334,0.00012317784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966598,0.0009619855,0.0013651386,0.00033077114,0.00043300574,0.00024926],"domain_scores_gemma":[0.9959524,0.0008612437,0.0022022016,0.0002958228,0.00038309518,0.00030523035],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015623467,0.00039540496,0.004172082,0.0003922255,0.00009744771,0.000022909133,0.00020309519,0.0007930005,0.000048112608],"category_scores_gemma":[0.0004935339,0.0003085343,0.0012704514,0.0006300507,0.00017786445,0.00018151462,0.000050028066,0.001512715,0.000002390968],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029370227,0.00010417379,0.000014690436,0.011090277,0.0010789613,0.00014791555,0.0005104203,2.46778e-7,0.0022253322,0.000012640807,0.00038376183,0.9841379],"study_design_scores_gemma":[0.0001516138,0.0012832781,0.000041020296,0.015585807,0.003944486,0.0037007956,0.00019642526,0.0000033951621,0.0015073405,0.000027153386,0.9733462,0.00021253062],"about_ca_topic_score_codex":0.000004931099,"about_ca_topic_score_gemma":0.0000020837927,"teacher_disagreement_score":0.98392534,"about_ca_system_score_codex":0.0007533859,"about_ca_system_score_gemma":0.0015507864,"threshold_uncertainty_score":0.9999367},"labels":[],"label_agreement":null},{"id":"W3111583901","doi":"10.1016/j.jtho.2020.11.013","title":"Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Boehringer Ingelheim; Takeda Oncology; National Cancer Institute; AbbVie Canada; National Institutes of Health; Cancer Center, University of Colorado; AbbVie","keywords":"Medicine; Observational study; Pulmonary function testing; Internal medicine","score_opus":0.09547113000828117,"score_gpt":0.4437106657822433,"score_spread":0.3482395357739621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111583901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98672193,0.00011594646,0.0003457393,0.010503657,0.00018880701,0.00053639687,0.000008362969,0.000021589962,0.0015575481],"genre_scores_gemma":[0.99721557,0.000007696372,0.0007510969,0.0012735364,0.00052008807,0.000025458057,0.000029619403,0.000014728336,0.00016220941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99901444,0.00013020688,0.00031130423,0.00012946386,0.00030431408,0.00011029983],"domain_scores_gemma":[0.99847156,0.00011345592,0.00058848027,0.0000535623,0.000659201,0.000113770686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002822741,0.00009562024,0.00032385124,0.00008184238,0.00008578979,0.000013770904,0.000038055157,0.000069782065,0.000050103834],"category_scores_gemma":[0.00023299294,0.00006915326,0.00004753031,0.00030281578,0.000026642192,0.00017969777,0.000011561768,0.0002609768,0.0000040430273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005503433,0.0018511066,0.9512306,0.00004221581,0.0015856369,0.0007227728,0.007829888,0.0001111582,0.0016477534,0.000044938475,0.00044921628,0.028981306],"study_design_scores_gemma":[0.0016829686,0.015051586,0.9786406,0.000116827745,0.0013772635,0.00012895699,0.0020101187,0.000104336876,0.00012861342,0.00013090105,0.000560275,0.000067544526],"about_ca_topic_score_codex":0.000010744892,"about_ca_topic_score_gemma":0.000028908082,"teacher_disagreement_score":0.02891376,"about_ca_system_score_codex":0.000437946,"about_ca_system_score_gemma":0.00049349444,"threshold_uncertainty_score":0.2819988},"labels":[],"label_agreement":null},{"id":"W3119106339","doi":"10.1016/j.jtho.2020.10.084","title":"PR01.07 Predicting Changes in Lung Cancer Risk in the At-Risk Screen Ineligible Population","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Population; Risk assessment; Internal medicine; Environmental health","score_opus":0.025212825120647323,"score_gpt":0.4241849730893665,"score_spread":0.39897214796871916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119106339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768611,0.007886528,0.00001036819,0.013934917,0.0003990832,0.0002549946,0.000017279868,0.0000051057127,0.00063058175],"genre_scores_gemma":[0.98884207,0.009127691,0.0006052545,0.00059304305,0.0006519057,0.00003813728,0.000011249245,0.00001228933,0.00011836148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984171,0.00047336562,0.00046724683,0.00015551661,0.000272198,0.00021457304],"domain_scores_gemma":[0.9986943,0.0003407968,0.00060276064,0.00015972531,0.0001347514,0.00006764846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012040974,0.000109527726,0.0004410383,0.0001886059,0.00006567231,0.000012608708,0.00008552307,0.00012453299,0.00014760939],"category_scores_gemma":[0.00028424629,0.00006988709,0.00008936029,0.00033664049,0.000020568299,0.000075404656,0.000045413162,0.0005032468,0.000002680503],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051289407,0.0003537383,0.94447744,0.000067000496,0.00012667854,0.00068283867,0.0013212698,0.00046935445,0.000050010643,0.0000049040727,0.0015887432,0.05034514],"study_design_scores_gemma":[0.0016377269,0.00058078504,0.9903129,0.0005824163,0.00060110877,0.00038155724,0.0006021015,0.00059204444,0.00059664046,0.00009255209,0.0039563184,0.00006385178],"about_ca_topic_score_codex":0.0024255796,"about_ca_topic_score_gemma":0.03344059,"teacher_disagreement_score":0.05028129,"about_ca_system_score_codex":0.0017969394,"about_ca_system_score_gemma":0.0003079339,"threshold_uncertainty_score":0.9841966},"labels":[],"label_agreement":null},{"id":"W3119323676","doi":"10.1016/j.jtho.2020.10.079","title":"PR01.02 Smoking Cessation After Lung Cancer Diagnosis and Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Lung cancer; Smoking cessation; Cohort; Internal medicine; Logistic regression; Prospective cohort study; Cohort study; Population; Incidence (geometry); Oncology; Environmental health; Pathology","score_opus":0.021807930871274504,"score_gpt":0.4131129298747917,"score_spread":0.3913049990035172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119323676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9254912,0.06979471,0.00001551322,0.0028403925,0.00094330753,0.0004894254,0.000029516328,0.0000055571923,0.000390351],"genre_scores_gemma":[0.9604213,0.037722,0.00018506257,0.00056858663,0.0005261357,0.0002843592,0.0000013201558,0.000017896866,0.00027330982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980444,0.00049307744,0.00067277515,0.00020856925,0.0003641726,0.00021705369],"domain_scores_gemma":[0.99784285,0.00054997316,0.0007612549,0.00018779578,0.0005574218,0.00010068069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013169841,0.00015585247,0.0009068642,0.0001060775,0.00012298179,0.000012427415,0.000090326685,0.00011817456,0.0004945041],"category_scores_gemma":[0.0002141599,0.000101651516,0.00013225141,0.00023262037,0.00011558916,0.00012441706,0.00010684639,0.0006021278,1.7600809e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070199475,0.00037464232,0.9191119,0.0004109426,0.0018057702,0.00020668046,0.004615726,0.000021098145,0.00023341042,2.8346884e-7,0.003682446,0.06883507],"study_design_scores_gemma":[0.0013704797,0.0007191584,0.98666555,0.00056182005,0.0035043412,0.00010785715,0.0014146181,0.00009639648,0.0009821207,0.0000064423443,0.004475101,0.000096099204],"about_ca_topic_score_codex":0.0002930705,"about_ca_topic_score_gemma":0.0040862653,"teacher_disagreement_score":0.068738975,"about_ca_system_score_codex":0.00063060794,"about_ca_system_score_gemma":0.00082995417,"threshold_uncertainty_score":0.54144734},"labels":[],"label_agreement":null},{"id":"W3119533143","doi":"10.1016/j.jtho.2020.10.137","title":"MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"KRAS; Docetaxel; Medicine; Clinical endpoint; Oncology; Internal medicine; Cancer; Chemotherapy; Phases of clinical research; Progression-free survival; Clinical trial","score_opus":0.01519236063026138,"score_gpt":0.41002208929297873,"score_spread":0.39482972866271737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119533143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578214,0.0011953838,0.000100662146,0.00020898222,0.00073847076,0.0016366052,0.000034172837,0.000013276276,0.0002903004],"genre_scores_gemma":[0.997175,0.0001347272,0.0020273796,0.000088144545,0.00014524069,0.000120796525,0.000035862693,0.000045408215,0.00022748596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767756,0.0002232391,0.0009709364,0.00033905514,0.00042579926,0.00036339925],"domain_scores_gemma":[0.9972031,0.00015691588,0.0010630018,0.00025179808,0.0011029792,0.00022221853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002229672,0.00029814854,0.0009517042,0.00034116302,0.0000712767,0.000020062638,0.00011079331,0.00013698512,0.000080231395],"category_scores_gemma":[0.000090116126,0.00022636897,0.0001380222,0.00047635756,0.000046899266,0.00027748212,0.00004005661,0.00040389044,0.0000020991354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050426126,0.03381595,0.8432593,0.0006462893,0.002266467,0.0031988272,0.017141169,0.001968873,0.004410539,7.111313e-7,0.00022322887,0.04264252],"study_design_scores_gemma":[0.2704492,0.045563065,0.6311642,0.0033614754,0.011356482,0.00012343959,0.0134457685,0.0015637384,0.021270536,0.0000032741125,0.0010040698,0.0006947867],"about_ca_topic_score_codex":0.0003743235,"about_ca_topic_score_gemma":0.000907326,"teacher_disagreement_score":0.22002307,"about_ca_system_score_codex":0.0013979168,"about_ca_system_score_gemma":0.0013536165,"threshold_uncertainty_score":0.9231059},"labels":[],"label_agreement":null},{"id":"W3120496075","doi":"10.1016/j.jtho.2020.10.090","title":"TT01.01 Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Bevacizumab; Pemetrexed; Oncology; Internal medicine; Carboplatin; Anaplastic lymphoma kinase; Chemotherapy; Progression-free survival; Paclitaxel; Lung cancer; Cisplatin","score_opus":0.01768990500250467,"score_gpt":0.41899168802046,"score_spread":0.4013017830179553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120496075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306464,0.00022143924,0.000038558654,0.0031893242,0.00013892377,0.00035684084,0.000011030907,0.000009073619,0.0029701455],"genre_scores_gemma":[0.9916768,0.00023703072,0.005156244,0.0006452224,0.00007842891,0.00001118981,0.000025033096,0.000032482465,0.0021375732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986989,0.00012254925,0.00051760295,0.00016577858,0.0002979531,0.00019724439],"domain_scores_gemma":[0.9985262,0.00019794547,0.0005232122,0.00016645277,0.00048231738,0.00010383407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015237258,0.00018378807,0.0008883609,0.0002705784,0.000040316718,0.000009734997,0.00007005418,0.00008507603,0.00010441282],"category_scores_gemma":[0.000034428103,0.00009580365,0.00014566486,0.0005160879,0.000057824047,0.00013177193,0.0000095890555,0.00020853781,8.8131117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015250435,0.002520517,0.90693706,0.00002543339,0.002038083,0.0011500504,0.0011918403,0.000022580583,0.00034431423,0.000007702022,0.00011050084,0.07040147],"study_design_scores_gemma":[0.01643826,0.009410031,0.9648921,0.00057420606,0.0007473025,0.00010112318,0.0005915833,0.000004777754,0.00553134,0.000021478865,0.001560177,0.00012763802],"about_ca_topic_score_codex":0.00013990719,"about_ca_topic_score_gemma":0.0006748299,"teacher_disagreement_score":0.07027383,"about_ca_system_score_codex":0.00045845244,"about_ca_system_score_gemma":0.0010222493,"threshold_uncertainty_score":0.39067593},"labels":[],"label_agreement":null},{"id":"W3123363775","doi":"10.1016/j.jtho.2020.11.018","title":"Meeting Immunotherapy Resistance in Lung Cancer","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Takeda Canada; Pfizer Canada; Amgen Canada; Princess Margaret Cancer Foundation; Merck Sharp and Dohme; Open Society Institute; Roche; Boehringer Ingelheim; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Immunotherapy; Oncology; Cancer; Internal medicine","score_opus":0.024147572562883156,"score_gpt":0.40616278526307026,"score_spread":0.3820152127001871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123363775","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019576455,0.16522571,0.00002670068,0.80601054,0.0032654342,0.00028880328,0.0000146202065,0.000011735771,0.00557997],"genre_scores_gemma":[0.003223231,0.036083587,0.0054117134,0.92346424,0.01247583,0.00004368731,0.00003889567,0.00015349855,0.0191053],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968533,0.00050607393,0.0013730024,0.0002864549,0.00052952697,0.00045162896],"domain_scores_gemma":[0.9972302,0.00033390432,0.0016122401,0.00033956915,0.000422623,0.000061464845],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012890719,0.00031164844,0.0014840384,0.00052394206,0.000050407194,0.000029717976,0.0002987427,0.0011222987,0.0008804878],"category_scores_gemma":[0.00010389823,0.00025822065,0.00057390076,0.00045330834,0.00012611058,0.00008915274,0.000033781198,0.0034140188,0.0000018978865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007659668,0.000156892,0.0011077517,0.000857339,0.0010173421,0.01328237,0.00055243407,0.000002593872,0.0052465717,7.103312e-7,0.92882556,0.041290756],"study_design_scores_gemma":[0.0019293447,0.00038287646,0.0020097452,0.004430696,0.0003203094,0.0010729731,0.00010893678,0.000004462882,0.0007931795,0.00003601878,0.9886775,0.00023396726],"about_ca_topic_score_codex":0.00011228373,"about_ca_topic_score_gemma":0.00038381811,"teacher_disagreement_score":0.12914214,"about_ca_system_score_codex":0.002213787,"about_ca_system_score_gemma":0.002609537,"threshold_uncertainty_score":0.999987},"labels":[],"label_agreement":null},{"id":"W3124917933","doi":"10.1016/j.jtho.2020.11.029","title":"Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Merck Sharp and Dohme; Roche Italia; Daiichi Sankyo Company; Clovis Oncology; Merck KGaA; United Therapeutics Corporation; Celgene; Bayer; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Nivolumab; Adverse effect; Lung cancer; Internal medicine; Oncology; Scopus; Clinical trial; Docetaxel; Cancer; MEDLINE; Immunotherapy","score_opus":0.04296113153062505,"score_gpt":0.37961464062165257,"score_spread":0.33665350909102754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124917933","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10098176,0.0081614945,0.0020843807,0.88043475,0.004760777,0.002180002,0.0001910765,0.00005019298,0.0011555416],"genre_scores_gemma":[0.028162032,0.00084299385,0.14703946,0.7979899,0.013350224,0.00018919972,0.0012580935,0.00032909858,0.010838999],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960001,0.00044309697,0.0019029861,0.00046632712,0.00059987814,0.0005876262],"domain_scores_gemma":[0.99586624,0.0009181396,0.0020029305,0.0004615239,0.000556924,0.00019425213],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013008445,0.00043236496,0.0019823976,0.0002914613,0.000085429565,0.00001650172,0.00044082047,0.0016335744,0.0005380411],"category_scores_gemma":[0.00078587455,0.00037297877,0.0012824321,0.00037154494,0.00007539789,0.000097964796,0.00011065255,0.0024824007,0.000012550497],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045308046,0.001299645,0.00022163599,0.001171796,0.014376518,0.0043957066,0.002550868,0.000042245116,0.05004281,0.000001094281,0.80150205,0.07908758],"study_design_scores_gemma":[0.0076071178,0.0044504805,0.0025716177,0.0022209724,0.0037770802,0.0017531426,0.00064540695,0.000081235004,0.0014827306,0.00012790719,0.9747069,0.00057542877],"about_ca_topic_score_codex":0.00006340592,"about_ca_topic_score_gemma":0.0000066791636,"teacher_disagreement_score":0.17320482,"about_ca_system_score_codex":0.0010760264,"about_ca_system_score_gemma":0.0012598607,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W3126976291","doi":"10.1016/j.jtho.2020.12.017","title":"Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"National Cancer Institute; National Institutes of Health; Gilead Sciences; Roche; U.S. Public Health Service; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Merck; Amgen","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Incidence (geometry); Bevacizumab; Smoking cessation; Prospective cohort study; Stage (stratigraphy); Clinical endpoint; Randomization; Cancer; Chemotherapy; Randomized controlled trial; Surgery; Confidence interval; Pathology","score_opus":0.026773026822406266,"score_gpt":0.4032946056313137,"score_spread":0.3765215788089074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126976291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996348,0.00026597775,0.000013621619,0.0011270328,0.0011016561,0.00037297,0.000014026963,0.0000067713563,0.0007498968],"genre_scores_gemma":[0.99691063,0.000052734955,0.001955124,0.0002295943,0.00045180976,0.000033082302,0.000028709626,0.000021185619,0.00031710212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827874,0.0001471454,0.0007350927,0.00022715697,0.00039499663,0.00021689724],"domain_scores_gemma":[0.99846244,0.00013490929,0.0006736179,0.00025411387,0.000312662,0.00016224799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033354838,0.00014222173,0.00070051284,0.00014060212,0.000030409541,0.000019951725,0.00007081169,0.00014324034,0.00039917487],"category_scores_gemma":[0.00013902897,0.00010171741,0.00016085403,0.00016943889,0.000035249377,0.000111944886,0.000040351893,0.00040618217,0.000004481952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033327635,0.0034011588,0.8928445,0.000016404383,0.00028967185,0.030205103,0.00024925813,0.0000038100961,0.000032004486,0.0000017097441,0.0003824873,0.039246235],"study_design_scores_gemma":[0.038847797,0.006273236,0.9444482,0.00030642565,0.00095808745,0.00047388897,0.00014400399,9.076663e-7,0.00083322177,0.000014507425,0.0075984253,0.00010132452],"about_ca_topic_score_codex":0.0001888981,"about_ca_topic_score_gemma":0.00034599582,"teacher_disagreement_score":0.051603656,"about_ca_system_score_codex":0.0011204558,"about_ca_system_score_gemma":0.0009074172,"threshold_uncertainty_score":0.4370685},"labels":[],"label_agreement":null},{"id":"W3127694095","doi":"10.1016/j.jtho.2021.02.003","title":"Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Brock University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Lung cancer screening; Lung cancer; Computed tomography; National Lung Screening Trial; Cancer; Lung; Radiology; Computed tomographic; Oncology; Internal medicine","score_opus":0.020062984469309913,"score_gpt":0.3814399442823898,"score_spread":0.3613769598130799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127694095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903197,0.0069472734,0.0001454733,0.0016765605,0.00023549279,0.00051538355,0.000010641632,0.000002986056,0.00014647967],"genre_scores_gemma":[0.993764,0.00016440074,0.005110347,0.0006636138,0.00020223674,0.00005034764,0.000004911311,0.000014644439,0.000025493966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841297,0.00021785588,0.00047638148,0.00018004328,0.00053627003,0.00017647751],"domain_scores_gemma":[0.99856085,0.00017929239,0.0005788825,0.0000872727,0.000518077,0.000075619435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005065563,0.00013987052,0.00058316736,0.00029661405,0.00002970503,0.000008914596,0.000079082536,0.000081341524,0.000046427296],"category_scores_gemma":[0.000034379067,0.00008222652,0.0000701908,0.0003494908,0.00010519517,0.0001172554,0.000024079774,0.00036416354,2.8105996e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04024363,0.0009478249,0.92387635,0.00014258166,0.0005317269,0.00013527017,0.0011277831,0.00068333524,0.000013169934,0.0000051022907,0.0005231299,0.03177012],"study_design_scores_gemma":[0.043240216,0.002030449,0.9500323,0.0021802783,0.0005642402,0.00005752131,0.00016347335,0.0007008207,0.000048938706,0.0000030074946,0.0008835856,0.00009515556],"about_ca_topic_score_codex":0.0002529383,"about_ca_topic_score_gemma":0.0018137456,"teacher_disagreement_score":0.031674966,"about_ca_system_score_codex":0.0013240933,"about_ca_system_score_gemma":0.001557381,"threshold_uncertainty_score":0.3462458},"labels":[],"label_agreement":null},{"id":"W3128342266","doi":"10.1016/j.jtho.2021.01.1605","title":"A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Janssen Biotech; Foundation Medicine; Chugai Pharmaceutical; Genentech; Clinical Excellence Commission; Lunit; Relay Therapeutics; Northwell Health; Apollomics; Pfizer; Incyte; Siemens Medical Solutions USA; AstraZeneca; Novocure; Commission for Environmental Cooperation; MedStar Health Research Institute; Regeneron Pharmaceuticals; Array BioPharma; Agios Pharmaceuticals; Roche; Novartis; Heron Therapeutics; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Medtronic; Ariad Pharmaceuticals; Siemens Healthineers; Amgen; Boehringer Ingelheim; Exelixis; American Lung Association","keywords":"Medicine; Lung cancer; Cancer; Internal medicine; Oncology","score_opus":0.01810293350768457,"score_gpt":0.4496206825810844,"score_spread":0.43151774907339985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128342266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978598,0.00063154206,0.000023416998,0.00025196612,0.00013343032,0.000817827,0.000021393927,0.0000056949348,0.00025498224],"genre_scores_gemma":[0.99740154,0.00002923868,0.0020852722,0.00009401552,0.000096386095,0.00005470759,0.000016181331,0.000020849067,0.00020180045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984861,0.00022083774,0.0006091003,0.00017018076,0.00032832986,0.00018547397],"domain_scores_gemma":[0.9981677,0.00007167096,0.00070759776,0.00017218142,0.0007449794,0.00013589417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018653547,0.00015140524,0.00079555466,0.00022866821,0.000032152475,0.000008417671,0.000059427843,0.00006267406,0.0001095855],"category_scores_gemma":[0.00005187144,0.00009033859,0.00006021854,0.00044744727,0.0000390159,0.00012126031,0.000017840348,0.00023060295,4.3080556e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018102752,0.029671615,0.85672945,0.0002468567,0.0032210562,0.001694649,0.010870989,0.00014352245,0.000586988,0.0000020981881,0.00037576907,0.078354284],"study_design_scores_gemma":[0.18170471,0.21587922,0.5552194,0.0035833586,0.017873261,0.000813554,0.015313478,0.00012994939,0.0072241346,0.000012220476,0.0017696267,0.00047704397],"about_ca_topic_score_codex":0.00017962219,"about_ca_topic_score_gemma":0.00064164127,"teacher_disagreement_score":0.30150998,"about_ca_system_score_codex":0.0005960825,"about_ca_system_score_gemma":0.0013286226,"threshold_uncertainty_score":0.36839008},"labels":[],"label_agreement":null},{"id":"W3132559292","doi":"10.1016/j.jtho.2021.02.009","title":"Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Merck Sharp and Dohme; Ono Pharmaceutical; PharmaMar; Shionogi; Astellas Pharma; Daiichi-Sankyo; Cancer Research UK; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Amgen; Boehringer Ingelheim; Taiho Pharmaceutical; F. Hoffmann-La Roche; Chugai Pharmaceutical; Roche; Novartis; AbbVie; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Topotecan; Second line; Oncology; Internal medicine; Phase (matter); First line; Chemotherapy","score_opus":0.0525605755118861,"score_gpt":0.4658585770188332,"score_spread":0.4132980015069471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132559292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826578,0.0026087055,0.000016057156,0.013231127,0.00015764823,0.00070511183,0.000057262074,0.0000069987923,0.00055932073],"genre_scores_gemma":[0.9968764,0.001094153,0.0009373005,0.00041213314,0.00035673566,0.000008017928,0.000013957701,0.000018494646,0.00028280923],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9972834,0.0006778593,0.00096113683,0.00026941215,0.00054228544,0.00026589233],"domain_scores_gemma":[0.9965735,0.0015746191,0.00062165956,0.0003979636,0.0006810997,0.00015115648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015614392,0.00018365683,0.0011015479,0.0001513829,0.00008508181,0.000016370403,0.0002134657,0.00007917306,0.0001922984],"category_scores_gemma":[0.000979495,0.00010421059,0.000073479336,0.00043183693,0.00028233996,0.00008308174,0.00013489972,0.00078751193,0.0000016694617],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52331597,0.016417196,0.031990185,0.00015890981,0.005002263,0.012499391,0.02163609,0.00026781904,0.02436025,0.000026923406,0.003938362,0.3603866],"study_design_scores_gemma":[0.16721794,0.07160321,0.6943872,0.0010640085,0.0007847008,0.0019271377,0.016109822,0.00013593832,0.02164434,0.00032630062,0.024468487,0.00033093744],"about_ca_topic_score_codex":0.0004088638,"about_ca_topic_score_gemma":0.0015792612,"teacher_disagreement_score":0.662397,"about_ca_system_score_codex":0.00043337737,"about_ca_system_score_gemma":0.0015215356,"threshold_uncertainty_score":0.42495844},"labels":[],"label_agreement":null},{"id":"W3133838590","doi":"10.1016/j.jtho.2021.02.010","title":"Crizotinib in Patients With MET-Amplified NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Genentech; Exelixis; Revolution Medicines; Foundation Medicine; Sierra Oncology; Pfizer; Incyte; Astex Pharmaceuticals; Bayer Fund; AstraZeneca; Novocure; Merck KGaA; Jounce Therapeutics; Ariad Pharmaceuticals; Takeda Pharmaceutical Company; Amgen; Roche; Spectrum Pharmaceuticals; Merck; GlaxoSmithKline; Array BioPharma; G1 Therapeutics; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Fluorescence in situ hybridization; Internal medicine; ROS1; Retrospective cohort study; Gene duplication; Gastroenterology; Progression-free survival; Hazard ratio; Oncology; Confidence interval; Overall survival; Adenocarcinoma; Lung cancer; Gene; Cancer; Genetics","score_opus":0.019470229925141896,"score_gpt":0.4345962996276041,"score_spread":0.4151260697024622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133838590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873625,0.000312685,0.00017688112,0.0026231464,0.00035725473,0.00012716647,0.000004124761,0.000004667282,0.009031571],"genre_scores_gemma":[0.9891079,0.000020575399,0.009344929,0.00068251335,0.00011321037,0.0000034893956,0.000012149737,0.000010865772,0.0007043517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991839,0.00007846681,0.0003200283,0.00009531993,0.00018703828,0.0001352465],"domain_scores_gemma":[0.9990696,0.00006996074,0.00022886616,0.00010956604,0.00041797484,0.0001040815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014814673,0.00007507085,0.00035388992,0.00012884436,0.000024286888,0.000007454973,0.000041789168,0.00006645669,0.0001855218],"category_scores_gemma":[0.00009685757,0.000049732385,0.00006386461,0.00020626563,0.000028036122,0.000078230354,0.000014154876,0.00021264018,0.000008297559],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00527274,0.0038533215,0.588481,0.00008129797,0.00081239984,0.0028413665,0.0013496089,0.000045378747,0.00044606742,0.0001931479,0.0022630412,0.3943606],"study_design_scores_gemma":[0.007749116,0.0055735717,0.94177186,0.0002807512,0.00090762007,0.00056915317,0.0007881198,0.0000034311224,0.0009840607,0.0002193579,0.041050237,0.000102714155],"about_ca_topic_score_codex":0.0000062392755,"about_ca_topic_score_gemma":0.0000257952,"teacher_disagreement_score":0.3942579,"about_ca_system_score_codex":0.00032844,"about_ca_system_score_gemma":0.0009325574,"threshold_uncertainty_score":0.20313336},"labels":[],"label_agreement":null},{"id":"W3134569327","doi":"10.1016/j.jtho.2020.12.026","title":"The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"National Cancer Institute; EMD Serono; Regeneron Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Foghorn Therapeutics; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Pfizer; Genentech","keywords":"Medicine; Lung cancer; Pembrolizumab; Turnaround time; Internal medicine; Oncology; Medical physics; Cancer; Family medicine","score_opus":0.07540617302975257,"score_gpt":0.47785478885301935,"score_spread":0.4024486158232668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134569327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827158,0.0017294355,0.00025447115,0.011497643,0.0024300234,0.0011045642,0.000056113375,0.000004314912,0.00020764706],"genre_scores_gemma":[0.99765056,0.00013894305,0.00053465023,0.00046444562,0.0005744748,0.000109167166,0.000005827354,0.0000084335115,0.0005134829],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99883944,0.00016518186,0.00047010946,0.00008858598,0.0002896094,0.00014709024],"domain_scores_gemma":[0.9941934,0.0034434444,0.0008416237,0.00009501752,0.0013968849,0.00002967341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030441277,0.000071270886,0.00025837874,0.000025197436,0.00013849018,0.000029202387,0.00015534964,0.000072360766,0.0000054872016],"category_scores_gemma":[0.0027335086,0.000038572653,0.00014261046,0.00016854265,0.000023338845,0.000029882296,0.000020035506,0.00013884163,7.471737e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020514734,0.0008542236,0.45684683,0.00002918554,0.002201372,0.000010820563,0.0002771329,0.000032504446,0.0019116339,0.000011546479,0.009618084,0.5076919],"study_design_scores_gemma":[0.005896127,0.0059208716,0.9417707,0.00016814908,0.00079892087,0.00008377945,0.0012759143,0.0006664802,0.0019053736,0.00008890777,0.041351944,0.00007286525],"about_ca_topic_score_codex":0.00018014571,"about_ca_topic_score_gemma":0.0018369149,"teacher_disagreement_score":0.5076191,"about_ca_system_score_codex":0.00095395587,"about_ca_system_score_gemma":0.0009395649,"threshold_uncertainty_score":0.32724628},"labels":[],"label_agreement":null},{"id":"W3135583340","doi":"10.1016/j.jtho.2020.11.027","title":"Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Takeda Canada; Merck Sharp and Dohme; Novartis Farmacéutica; Boehringer Ingelheim; Merck; GlaxoSmithKline; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Lung cancer; Placebo; Clinical endpoint; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Clinical trial; Adjuvant therapy; Chemotherapy; Cancer; Erlotinib; Epidermal growth factor receptor; Pathology","score_opus":0.03755095383676668,"score_gpt":0.48562114779050386,"score_spread":0.44807019395373715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135583340","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01346547,0.080666006,0.001695446,0.051843587,0.84110296,0.004438815,0.0051782583,0.00001845114,0.0015910174],"genre_scores_gemma":[0.14243102,0.023411186,0.0065093446,0.002942252,0.81860024,0.00038627425,0.00049237505,0.00029687033,0.0049304455],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99708354,0.00023634419,0.0011596436,0.00022854088,0.0010077034,0.00028422885],"domain_scores_gemma":[0.992363,0.0023866317,0.0016971817,0.00051130826,0.002897836,0.00014407616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010297615,0.00028776904,0.0016135676,0.00016794569,0.00015017364,0.000018113364,0.00042744985,0.0004988032,0.0001866671],"category_scores_gemma":[0.000975512,0.0001377425,0.0006643021,0.00023840414,0.00017030168,0.000046435074,0.0000738986,0.0008618307,5.461453e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019683791,0.00041766837,0.000054812164,0.0005131462,0.0035448405,0.00015542332,0.00893756,0.00011620953,0.001662858,0.000038062914,0.7465446,0.21833101],"study_design_scores_gemma":[0.0029537878,0.012201115,0.00010039282,0.0006639163,0.0026265702,0.00003619084,0.0070871157,0.0000035571913,0.005115151,0.000027969747,0.9690699,0.00011436529],"about_ca_topic_score_codex":0.00008661508,"about_ca_topic_score_gemma":0.00022383123,"teacher_disagreement_score":0.22252524,"about_ca_system_score_codex":0.00080377085,"about_ca_system_score_gemma":0.0062109814,"threshold_uncertainty_score":0.9994229},"labels":[],"label_agreement":null},{"id":"W3135934225","doi":"10.1016/j.jtho.2021.01.549","title":"P16.03 Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Randomized controlled trial; Overall survival; Immune system; Immunology","score_opus":0.028695556838341678,"score_gpt":0.3669351624204483,"score_spread":0.33823960558210664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135934225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993538,0.00022033135,0.0000025520326,0.0016925305,0.00046019818,0.00016717866,0.00002111545,0.0000075264697,0.0038905316],"genre_scores_gemma":[0.9987297,0.00014362493,0.00010494601,0.00038503582,0.000079293604,0.0000027858798,0.00004798558,0.000017894534,0.0004887322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981977,0.00026302921,0.0007746969,0.00015179171,0.00030512552,0.0003076552],"domain_scores_gemma":[0.99843603,0.000069255104,0.00062722055,0.00016055083,0.00048322335,0.00022371672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075811817,0.00014524058,0.00056780817,0.00039273684,0.000056869656,0.000018237755,0.00005603836,0.00018101514,0.00029965807],"category_scores_gemma":[0.00015529491,0.00011199253,0.00017829257,0.00061177276,0.00007693207,0.0001407841,0.000015053979,0.0005214683,0.0000035884066],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033116066,0.00071532256,0.9778187,0.00004553732,0.0005095847,0.0017853645,0.00088017713,0.0000036194604,0.0066251555,0.000003986048,0.00029424208,0.008006659],"study_design_scores_gemma":[0.0027083594,0.0015719618,0.98395187,0.00043874912,0.00020750103,0.000093666844,0.00030919243,0.0000026053337,0.009096323,0.00002980593,0.0014754379,0.0001145534],"about_ca_topic_score_codex":0.058724023,"about_ca_topic_score_gemma":0.40654317,"teacher_disagreement_score":0.34781912,"about_ca_system_score_codex":0.0023326215,"about_ca_system_score_gemma":0.0022123943,"threshold_uncertainty_score":0.94754404},"labels":[],"label_agreement":null},{"id":"W3136330176","doi":"10.1016/j.jtho.2021.02.024","title":"Tobacco Smoking and Risk of Second Primary Lung Cancer","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; Pharmacyclics; Centers for Disease Control and Prevention; Clovis Oncology; National Institutes of Health; Helsinn; ACEA Biosciences; Pfizer; Daiichi Sankyo Europe; World Health Organization; Exelixis; Centre International de Recherche sur le Cancer; Celgene; Myriad Genetics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Primary (astronomy); Environmental health; Oncology; Primary cancer; Internal medicine; Cancer","score_opus":0.043188087231221556,"score_gpt":0.4503426521901326,"score_spread":0.407154564958911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136330176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007546848,0.98739165,0.0000144176,0.000109971515,0.0013638869,0.000338194,0.00010510208,0.0000050151516,0.0031248992],"genre_scores_gemma":[0.00005533047,0.99636066,0.0014503485,0.00032705546,0.0009356198,0.000011345588,0.00002753646,0.00004604192,0.00078606233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99705696,0.0005639415,0.0015661289,0.00027369676,0.00027543225,0.00026383527],"domain_scores_gemma":[0.9953997,0.00063573173,0.0030891255,0.00028820132,0.0003547152,0.00023248348],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011908553,0.00032952332,0.00448307,0.00040972527,0.000050728562,0.000013961546,0.0001945232,0.00059264427,0.0016705068],"category_scores_gemma":[0.00018389591,0.00024507468,0.0008269787,0.0002491622,0.00013304023,0.00012817945,0.00012931215,0.0016879836,7.611102e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019613175,0.000085068204,0.0017535955,0.022325652,0.0028608837,0.0006269406,0.00012925333,0.0000010098246,0.0000084550065,0.0000028036643,0.005414223,0.966596],"study_design_scores_gemma":[0.00061184296,0.000510986,0.00086080696,0.016659595,0.011890551,0.0032746946,0.00006421992,0.0000023395726,0.000010236508,0.000004606853,0.96592563,0.0001844592],"about_ca_topic_score_codex":0.000025934685,"about_ca_topic_score_gemma":0.00005934047,"teacher_disagreement_score":0.96641153,"about_ca_system_score_codex":0.0012134223,"about_ca_system_score_gemma":0.0060473494,"threshold_uncertainty_score":0.9995874},"labels":[],"label_agreement":null},{"id":"W3136350579","doi":"10.1016/j.jtho.2021.01.567","title":"P19.06 Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Radiosurgery; Lung cancer; Oncology; Glioblastoma; Metis; Internal medicine; Radiation therapy; Database; Cancer research","score_opus":0.04287772906356191,"score_gpt":0.4333035361423986,"score_spread":0.3904258070788367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136350579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665728,0.0041703116,0.00031987485,0.027372241,0.00061377324,0.0005053141,0.00012309608,0.000006264761,0.00031632607],"genre_scores_gemma":[0.9915407,0.00008031501,0.0041318047,0.0029184977,0.0008504636,0.000099115765,0.00012814312,0.00002024788,0.00023074726],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976478,0.00075732643,0.00084391504,0.00020276557,0.00028241365,0.000265785],"domain_scores_gemma":[0.9936839,0.0052191433,0.0005798575,0.00022226645,0.00016705862,0.00012779227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001616735,0.00017559054,0.0009881112,0.00016658813,0.000074993884,0.000035982917,0.00012653813,0.00012650684,0.0003942734],"category_scores_gemma":[0.002333082,0.000109818335,0.00054447475,0.00025471795,0.000038954986,0.0000885169,0.000021815893,0.00027923263,0.0000043828923],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060300224,0.012876723,0.0026371274,0.00005796304,0.0017522137,0.015683502,0.0010845779,0.000011733209,0.023505405,0.000039454182,0.6188578,0.26319325],"study_design_scores_gemma":[0.25987485,0.022356315,0.001674118,0.0005995587,0.0061775115,0.0035958877,0.004245153,0.00023364364,0.093459934,0.0008181101,0.60650206,0.00046285064],"about_ca_topic_score_codex":0.00005351953,"about_ca_topic_score_gemma":0.00009608778,"teacher_disagreement_score":0.2627304,"about_ca_system_score_codex":0.00021026123,"about_ca_system_score_gemma":0.0005221888,"threshold_uncertainty_score":0.44782618},"labels":[],"label_agreement":null},{"id":"W3137057543","doi":"10.1016/j.jtho.2021.10.014","title":"Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Eli Lilly Japan; Merck Sharp and Dohme; Ono Pharmaceutical; Teijin Pharma; Daiichi-Sankyo; Taiho Pharmaceutical; Chugai Pharmaceutical; Roche; Novartis; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Boehringer Ingelheim; Amgen; Pfizer; Bayer; Shire; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Chemotherapy; Adjuvant; Adjuvant chemotherapy; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.04007172802736948,"score_gpt":0.45780914123256194,"score_spread":0.4177374132051925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137057543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666819,0.0037753154,0.00024379794,0.02814228,0.00041123346,0.00042779418,0.000050378814,0.0000143809575,0.00025293784],"genre_scores_gemma":[0.98046863,0.0013342984,0.009539153,0.0069982177,0.00018886544,0.000022724884,0.00005934626,0.00003174883,0.0013570223],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988251,0.00015613985,0.00046274194,0.00019552,0.00017348643,0.00018705371],"domain_scores_gemma":[0.9979735,0.0004960818,0.00033467243,0.00015326714,0.00087536185,0.00016714085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016450984,0.00016194898,0.00067370164,0.00010201412,0.00009676269,0.00003898476,0.00005758613,0.0001402084,0.00026887367],"category_scores_gemma":[0.0003628066,0.000106923,0.00016507092,0.00013944396,0.000067665525,0.00018537696,0.000015195688,0.00022202525,0.000003576818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027468434,0.0026580575,0.07702761,0.000041680123,0.0073269354,0.0023774258,0.010648885,0.000015017608,0.17175858,0.000076022916,0.008222668,0.6923787],"study_design_scores_gemma":[0.029053848,0.0135667445,0.73325574,0.0003996426,0.0018827094,0.0019992886,0.004020365,0.0001295599,0.10217078,0.0011222984,0.112022914,0.00037611063],"about_ca_topic_score_codex":0.00009072867,"about_ca_topic_score_gemma":0.000047903257,"teacher_disagreement_score":0.6920026,"about_ca_system_score_codex":0.00024944023,"about_ca_system_score_gemma":0.0010757108,"threshold_uncertainty_score":0.43601936},"labels":[],"label_agreement":null},{"id":"W3137082731","doi":"10.1016/j.jtho.2021.01.118","title":"FP09.01 Economic Impact of Screening Selection with the PLCOm2012 Risk Model Versus USPSTF-Guidelines in the International Lung Screening Trial (ILST)","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; Simon Fraser University","funders":"","keywords":"Medicine; Selection (genetic algorithm); Lung cancer screening; Lung cancer; Intensive care medicine; Oncology; Machine learning","score_opus":0.06724809098905883,"score_gpt":0.47072384085478963,"score_spread":0.4034757498657308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137082731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829641,0.0008067476,0.0040128096,0.010703344,0.0005852286,0.00026064794,0.0000123870905,0.0000043915315,0.0006503335],"genre_scores_gemma":[0.9895954,0.00044733932,0.008507555,0.00021869561,0.0011287464,0.000014699423,0.000006556765,0.000014035834,0.00006695125],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99853134,0.00025709142,0.0006070318,0.00014047703,0.00029157655,0.0001725006],"domain_scores_gemma":[0.9980224,0.00059780653,0.0008321268,0.00015625241,0.00033093436,0.000060472896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014106969,0.0001339098,0.0004443225,0.0001441798,0.00007276698,0.000028754559,0.00018596095,0.000089524954,0.00010043003],"category_scores_gemma":[0.00020241467,0.00006640964,0.00028679523,0.0001453103,0.000050057693,0.00015211158,0.00003737976,0.00045963057,9.778638e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23682581,0.00095810724,0.14037898,0.00003780934,0.0050771777,0.00036492836,0.0015767353,0.43634427,0.0003089082,0.00011717808,0.022656018,0.15535407],"study_design_scores_gemma":[0.17979424,0.027748594,0.17360692,0.0013602182,0.008095389,0.005015176,0.005125856,0.58295965,0.002829725,0.00026140007,0.012636151,0.0005666969],"about_ca_topic_score_codex":0.00043787397,"about_ca_topic_score_gemma":0.001218908,"teacher_disagreement_score":0.15478738,"about_ca_system_score_codex":0.001217611,"about_ca_system_score_gemma":0.0013263444,"threshold_uncertainty_score":0.31840107},"labels":[],"label_agreement":null},{"id":"W3137210471","doi":"10.1016/j.jtho.2021.01.263","title":"MA13.01 A Validation Study on DNA Repair Gene Variant for Lung Cancer Survival Prediction after Chemoradiation: A Secondary Analysis for RTOG-0617 Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Oncology; ERCC2; DNA repair; Radiation therapy; Internal medicine; Chemoradiotherapy; Biomarker; Cohort; Gene; Genetics; Nucleotide excision repair; Biology","score_opus":0.02325730726251165,"score_gpt":0.38386200487127714,"score_spread":0.3606046976087655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137210471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814972,0.0007914354,0.014487491,0.0005055344,0.0014607458,0.0008392834,0.0003607343,0.000006341474,0.000051188174],"genre_scores_gemma":[0.99460924,0.0001543102,0.0024938271,0.0002861809,0.0017577913,0.00032104083,0.00015698465,0.000026406975,0.00019419836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839306,0.00021717309,0.0006340214,0.00036842944,0.00018364377,0.00020370021],"domain_scores_gemma":[0.9982827,0.0001497248,0.00049572095,0.0003044101,0.00066722004,0.000100225494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010599726,0.00016540907,0.0004852559,0.0001612924,0.00010076811,0.000040084487,0.00012645578,0.00016373837,0.000051710405],"category_scores_gemma":[0.00028907956,0.00015965075,0.00040607806,0.00023469154,0.000018446668,0.000011225899,0.0000612453,0.00013485418,3.1076405e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045134343,0.019697642,0.64011633,0.0004393956,0.036202442,0.0009705344,0.0048322002,0.04193698,0.13563333,0.000036656864,0.023193896,0.051806226],"study_design_scores_gemma":[0.019523297,0.042051844,0.722385,0.00007242912,0.025126943,0.00028273393,0.007435745,0.008759108,0.11968208,0.00021279769,0.05329527,0.001172738],"about_ca_topic_score_codex":0.000016646643,"about_ca_topic_score_gemma":0.00050065585,"teacher_disagreement_score":0.08226866,"about_ca_system_score_codex":0.00025347833,"about_ca_system_score_gemma":0.0008698745,"threshold_uncertainty_score":0.65103686},"labels":[],"label_agreement":null},{"id":"W3137239260","doi":"10.1016/j.jtho.2021.01.530","title":"P14.24 Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; T-cell receptor; Immune system; Stage (stratigraphy); Medicine; Repertoire; Immunology; Oncology; Immunotherapy; T cell; Biology","score_opus":0.019441310107998565,"score_gpt":0.3695756449481801,"score_spread":0.3501343348401816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137239260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948741,0.0026857418,0.000041592357,0.00105434,0.0006335459,0.00009618749,0.000010625757,0.0000030499268,0.00060077186],"genre_scores_gemma":[0.9985258,0.0005983098,0.00036545887,0.000032230215,0.000165481,0.0000010537204,0.000003453264,0.000007595194,0.00030059277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99847496,0.0002595937,0.0007463255,0.00010864935,0.00028789713,0.00012254949],"domain_scores_gemma":[0.9986911,0.00011931849,0.0007144043,0.00011808322,0.0002936895,0.00006340345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011785926,0.00008218079,0.0005374478,0.00018687328,0.000019451714,0.000003278095,0.00005385961,0.00014484575,0.00011380995],"category_scores_gemma":[0.00030642925,0.00007329075,0.0001223724,0.0002697412,0.00011485061,0.00009977654,0.000026630545,0.00023610977,3.3628007e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023888096,0.0008018627,0.45448902,0.00079999253,0.00042986238,0.00031179033,0.0011839713,0.000039776416,0.49417922,0.00006222456,0.000091046146,0.023723155],"study_design_scores_gemma":[0.0035270422,0.0011323751,0.9223218,0.0002681308,0.00013727117,0.00052281533,0.0011409409,0.000038789905,0.06973187,0.00009898322,0.0010189811,0.00006103242],"about_ca_topic_score_codex":0.0001370846,"about_ca_topic_score_gemma":0.00012885462,"teacher_disagreement_score":0.46783277,"about_ca_system_score_codex":0.0005613853,"about_ca_system_score_gemma":0.00091792125,"threshold_uncertainty_score":0.298871},"labels":[],"label_agreement":null},{"id":"W3137736070","doi":"10.1016/j.jtho.2021.01.1184","title":"P79.05 Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Lung cancer; Pembrolizumab; Stage (stratigraphy); Internal medicine; Chemotherapy; Immunotherapy; Randomized controlled trial; Neoadjuvant therapy; Cancer","score_opus":0.023053894360969898,"score_gpt":0.4153785200569625,"score_spread":0.39232462569599263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137736070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752725,0.009639202,0.0025560893,0.006433508,0.0028162827,0.001836813,0.00005255052,0.000010247867,0.0013828389],"genre_scores_gemma":[0.94317746,0.013972372,0.013901711,0.004230107,0.0027389294,0.0002308901,0.00003227561,0.00011230122,0.021603927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99722433,0.00034141995,0.0014920292,0.00024785707,0.0003171359,0.00037724563],"domain_scores_gemma":[0.99686867,0.0004903236,0.0014049766,0.00029574064,0.0007639719,0.00017631621],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022037257,0.00025280568,0.0021160124,0.000211101,0.00011686761,0.000018928571,0.00021638525,0.00028320463,0.0012355751],"category_scores_gemma":[0.00018533593,0.0001864843,0.001065709,0.0002461505,0.00015928347,0.000105779916,0.000040924973,0.00040195888,6.7740126e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7536717,0.002202931,0.00001413446,0.00033661988,0.001018989,0.00017662905,0.000936609,0.000026572023,0.16011642,0.0000046188125,0.0058639017,0.07563087],"study_design_scores_gemma":[0.7752221,0.010178743,0.00001671111,0.00029587143,0.0010752958,0.00026538724,0.00033278068,0.00072975014,0.12839697,0.00002541125,0.083302304,0.00015866877],"about_ca_topic_score_codex":0.000094283416,"about_ca_topic_score_gemma":0.00004403906,"teacher_disagreement_score":0.07743841,"about_ca_system_score_codex":0.0004820192,"about_ca_system_score_gemma":0.0032199838,"threshold_uncertainty_score":0.9996774},"labels":[],"label_agreement":null},{"id":"W3138055652","doi":"10.1016/j.jtho.2021.01.191","title":"MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Durvalumab; Lactate dehydrogenase; Lung cancer; Internal medicine; Oncology; Immune system; Chemoradiotherapy; Cancer; Immunology; Immunotherapy; Nivolumab","score_opus":0.009300855788339783,"score_gpt":0.35029929619683065,"score_spread":0.34099844040849087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138055652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968304,0.0008273206,0.000033669337,0.0013258063,0.0002303021,0.00028087714,0.000004458516,0.000005014753,0.00046214886],"genre_scores_gemma":[0.99479455,0.00019126514,0.00415472,0.00073320145,0.000045247492,0.000011884225,0.0000049022924,0.000014459294,0.000049766433],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985243,0.00022526947,0.0006030964,0.00014899473,0.00033263015,0.00016571407],"domain_scores_gemma":[0.99846935,0.00013902379,0.00050784106,0.00016755967,0.000592767,0.00012345264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040498035,0.00013462015,0.0005992054,0.00020147163,0.000019608799,0.000008397611,0.00006667875,0.00013512094,0.00017863578],"category_scores_gemma":[0.00024290978,0.000096960415,0.00008806076,0.00017201756,0.00014977784,0.00014659326,0.000037700367,0.00022350752,0.0000026896282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019094568,0.0007564069,0.8395223,0.00008340012,0.00026532737,0.0005123233,0.00022880314,0.0000027887174,0.00052259973,0.0000054484385,0.000046089222,0.13895997],"study_design_scores_gemma":[0.0064659617,0.002117611,0.9846065,0.0003226817,0.00016075425,0.00016569928,0.00023188733,0.0000066827665,0.004525718,0.0000963041,0.0012046323,0.000095565076],"about_ca_topic_score_codex":0.0000018963177,"about_ca_topic_score_gemma":0.000010727373,"teacher_disagreement_score":0.14508423,"about_ca_system_score_codex":0.00017314084,"about_ca_system_score_gemma":0.00060294784,"threshold_uncertainty_score":0.3953931},"labels":[],"label_agreement":null},{"id":"W3138057381","doi":"10.1016/j.jtho.2021.01.978","title":"P62.04 Metabolic Profile of Urine of Early Stage Non Small Cell Lung Cancer Patients Before and After Surgical Resection Using Mass Spectrometry","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Metabolomics and Mass Spectrometry Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Lung cancer; Urinary system; Stage (stratigraphy); Biopsy; Urine; Prospective cohort study; Biomarker; Lung; Radiology; Urology; Internal medicine; Oncology","score_opus":0.010619558874058228,"score_gpt":0.32962366726804454,"score_spread":0.3190041083939863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138057381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135387,0.007339382,0.0003198317,0.000058686957,0.00039763522,0.00012557498,0.000059036294,0.0000010375056,0.00034492856],"genre_scores_gemma":[0.98853505,0.002546492,0.008036208,0.00001691,0.00028865098,0.0000048924835,0.000007795179,0.000016983991,0.0005470314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867946,0.00015932196,0.0005641267,0.00020686856,0.00017273419,0.00021746832],"domain_scores_gemma":[0.99850553,0.000022510923,0.0007180744,0.00015302055,0.0005177925,0.00008303942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038264995,0.00014615024,0.0005897247,0.00018739418,0.000035661877,0.000008430457,0.0001035348,0.00017603484,0.00007419679],"category_scores_gemma":[0.00006403034,0.00012251758,0.0001647606,0.00023773355,0.0000831812,0.000010350107,0.00015172249,0.00020815073,1.405019e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015958876,0.00036961253,0.30124646,0.00026240383,0.00038509138,0.00006772422,0.00011688204,0.000022473214,0.6942331,0.000015559322,0.00004478432,0.0016400155],"study_design_scores_gemma":[0.0011915127,0.002343182,0.216062,0.000050375216,0.000367758,0.00006275686,0.00013346694,0.000045891553,0.7765072,0.000037541064,0.0030612072,0.00013711675],"about_ca_topic_score_codex":0.00003663075,"about_ca_topic_score_gemma":0.00008988417,"teacher_disagreement_score":0.085184455,"about_ca_system_score_codex":0.00004684168,"about_ca_system_score_gemma":0.00027555964,"threshold_uncertainty_score":0.4996122},"labels":[],"label_agreement":null},{"id":"W3138206800","doi":"10.1016/j.jtho.2021.01.515","title":"P14.09 Early Expansion of M-MDSCs and High Plasma TSLP levels as Predictors of Primary Resistance to PD1 Inhibitors in Metastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Thymic stromal lymphopoietin; Medicine; Myeloid; Cytokine; Immunology; Cancer research; Lung cancer; Oncology","score_opus":0.017727097857562497,"score_gpt":0.3229670785513359,"score_spread":0.3052399806937734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138206800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866554,0.008863157,0.000078195306,0.0007893935,0.0024315864,0.00019280547,0.00003132686,0.000005981402,0.0009521497],"genre_scores_gemma":[0.9938038,0.000403348,0.0036897457,0.00016202129,0.000059600803,0.000006140597,0.0000063691487,0.000022867149,0.0018461187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99712753,0.00084481336,0.0013243125,0.0002498066,0.00013393663,0.00031960438],"domain_scores_gemma":[0.9974448,0.0007380168,0.0010553158,0.00027846277,0.00043121845,0.00005214932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011144533,0.00019882029,0.0010992541,0.00039412937,0.00004584866,0.0000061460037,0.00027627134,0.00033289913,0.00019275938],"category_scores_gemma":[0.0005286152,0.00017891973,0.0001332499,0.00039768533,0.0003239472,0.0001663946,0.0001937665,0.00063518423,0.000014548994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043869256,0.00039631588,0.004753882,0.00028414602,0.00041033974,0.00032340016,0.002893451,0.00006512923,0.9373097,0.000105743995,0.002758951,0.04631205],"study_design_scores_gemma":[0.0023242778,0.0022479028,0.07454975,0.0008318161,0.0002595769,0.00064976927,0.00093043805,5.233609e-7,0.89798146,0.0005406047,0.019475603,0.00020828756],"about_ca_topic_score_codex":0.000053296917,"about_ca_topic_score_gemma":0.000099722994,"teacher_disagreement_score":0.06979586,"about_ca_system_score_codex":0.00029940676,"about_ca_system_score_gemma":0.0010966734,"threshold_uncertainty_score":0.7296135},"labels":[],"label_agreement":null},{"id":"W3138270384","doi":"10.1016/j.jtho.2021.01.031","title":"ES12.02 Defining High Risk","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Risk analysis (engineering)","score_opus":0.06236138591952019,"score_gpt":0.4538612868197403,"score_spread":0.39149990090022013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138270384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767365,0.0039304364,0.0010715774,0.0058375713,0.0011181189,0.000041102652,0.0000043176383,0.000012297969,0.011248119],"genre_scores_gemma":[0.96406424,0.0005400394,0.032150574,0.0020058888,0.0006615529,9.855717e-7,0.0000028840168,0.000011319223,0.0005625403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985836,0.00020038107,0.00051303103,0.00012934691,0.0003385671,0.00023505636],"domain_scores_gemma":[0.99831295,0.00020819114,0.0005475228,0.00016679236,0.00055839785,0.00020613727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089222455,0.00009852039,0.00052574393,0.00010571199,0.00007317364,0.000016199892,0.000108335866,0.00015323101,0.0005407879],"category_scores_gemma":[0.0009247045,0.0000799117,0.00019439211,0.00024145379,0.000051398016,0.000120673016,0.000052150335,0.00066827843,0.00006303661],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025934654,0.0003137592,0.10622901,0.000075606506,0.00044957263,0.016098753,0.0006092284,0.00023442683,0.0042282934,0.00077021745,0.026752075,0.8416456],"study_design_scores_gemma":[0.004799611,0.010802976,0.31495252,0.0014355772,0.0033049623,0.06910693,0.0064875493,0.00025481964,0.03348,0.008193858,0.54663867,0.0005425422],"about_ca_topic_score_codex":0.000052914562,"about_ca_topic_score_gemma":0.000047833615,"teacher_disagreement_score":0.8411031,"about_ca_system_score_codex":0.00029507087,"about_ca_system_score_gemma":0.001013036,"threshold_uncertainty_score":0.5921248},"labels":[],"label_agreement":null},{"id":"W3138307077","doi":"10.1016/j.jtho.2021.01.149","title":"FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Resistance (ecology); Multicenter study; Cancer; Epidermal growth factor receptor; Randomized controlled trial","score_opus":0.02324870945167406,"score_gpt":0.4558550673411255,"score_spread":0.43260635788945145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138307077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649686,0.00028617034,0.0009051058,0.0013842721,0.00016269452,0.00027494697,0.000023485252,0.000004516231,0.00046195704],"genre_scores_gemma":[0.99088126,0.000020960639,0.008188037,0.00024599023,0.000033530392,0.000007938984,0.000017974884,0.00001311049,0.0005911717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980786,0.0002985353,0.00097517733,0.00019714184,0.00028518637,0.0001653561],"domain_scores_gemma":[0.9979607,0.00012156501,0.00078918005,0.0003234088,0.000650172,0.0001549708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053232507,0.000116682764,0.0009502385,0.00057180866,0.00002295537,0.0000058504975,0.00012692135,0.000091947055,0.00012491446],"category_scores_gemma":[0.00022306161,0.00009552923,0.00020049704,0.0010715545,0.00003723062,0.00008684482,0.00003410567,0.00019740046,0.0000017796312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025505794,0.036601014,0.5179086,0.00055416994,0.027314782,0.010724301,0.036877368,0.0032787514,0.29530895,0.0002512984,0.0013061797,0.04436883],"study_design_scores_gemma":[0.010722678,0.0077787996,0.8527204,0.0007233181,0.025182916,0.0002075318,0.035934187,0.00071366644,0.06380137,0.0005033003,0.001416481,0.00029537268],"about_ca_topic_score_codex":0.00009137919,"about_ca_topic_score_gemma":0.0017635903,"teacher_disagreement_score":0.3348118,"about_ca_system_score_codex":0.00042730558,"about_ca_system_score_gemma":0.0006967596,"threshold_uncertainty_score":0.38955688},"labels":[],"label_agreement":null},{"id":"W3138360976","doi":"10.1016/j.jtho.2021.01.808","title":"P39.08 The Effect of COVID-19 on Anxiety in Canadian Lung Cancer Patients","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anxiety; Coronavirus disease 2019 (COVID-19); Lung cancer; Pandemic; 2019-20 coronavirus outbreak; Cancer; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Disease; Intensive care medicine; Internal medicine; Psychiatry; Pathology; Infectious disease (medical specialty)","score_opus":0.03257573312541402,"score_gpt":0.49511812076385614,"score_spread":0.46254238763844213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138360976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92844045,0.0012444903,0.0000055379355,0.06849621,0.0008253106,0.00028618347,0.000018852876,0.0000028982984,0.00068004057],"genre_scores_gemma":[0.9872561,0.00048267381,0.000033608278,0.01182233,0.00027942125,0.000006088619,0.0000041959483,0.000011854053,0.00010369947],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980474,0.0006385305,0.0005240206,0.00012617733,0.00030339992,0.0003604603],"domain_scores_gemma":[0.997491,0.0008677654,0.0003880476,0.00018999325,0.00027973694,0.0007834705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014733337,0.00011715091,0.00059408345,0.000294328,0.00006876343,0.000006205377,0.00012564452,0.00018858109,0.00028862848],"category_scores_gemma":[0.0031413701,0.00007300005,0.00014540613,0.00036511195,0.00005927467,0.00004536647,0.000024564612,0.0006711949,0.0000032902255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002399051,0.00016596066,0.9090431,0.0006896161,0.00009842731,0.00085328706,0.0013722329,0.00016419106,0.00027825817,0.000013413721,0.0114258565,0.0734966],"study_design_scores_gemma":[0.0036643236,0.0058644814,0.7595928,0.0006364244,0.00035618697,0.00041795554,0.00024824802,0.0001267277,0.0028788701,0.000043378277,0.22604428,0.00012635285],"about_ca_topic_score_codex":0.06971858,"about_ca_topic_score_gemma":0.3272233,"teacher_disagreement_score":0.25750473,"about_ca_system_score_codex":0.0037673744,"about_ca_system_score_gemma":0.012670203,"threshold_uncertainty_score":0.992927},"labels":[],"label_agreement":null},{"id":"W3138499455","doi":"10.1016/j.jtho.2021.01.011","title":"PL03.06 Improving Outcomes with Immunotherapy: Lessons from Other Diseases","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Metis; Medicine; Mainstream; Agency (philosophy); Indigenous; Service delivery framework; Service (business); Nursing; Family medicine; Economic growth; Political science; Ecology","score_opus":0.033170792384160985,"score_gpt":0.415844352254382,"score_spread":0.382673559870221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138499455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97062534,0.0065364717,0.00080785435,0.01982845,0.0004876337,0.0001235091,0.00004971902,0.000025996393,0.0015150025],"genre_scores_gemma":[0.9831261,0.00045703148,0.010637742,0.0035472105,0.00052234315,0.000006887253,0.0000051434627,0.000044199143,0.0016533328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985448,0.00020459264,0.0004998054,0.0001766479,0.0003223725,0.00025177482],"domain_scores_gemma":[0.9982653,0.0004052047,0.0004923847,0.00026222735,0.0004196434,0.00015520958],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021978996,0.00017365684,0.00090643216,0.00011341168,0.00009270141,0.000021956868,0.00011815985,0.00010984387,0.0004871119],"category_scores_gemma":[0.0003701192,0.00011381315,0.00020871323,0.00014723468,0.00012159806,0.00011912357,0.00005967854,0.00038437961,0.000028991199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012002419,0.00088764087,0.83114433,0.000050682396,0.0015501606,0.0032862364,0.00094124925,0.0000050542767,0.011007361,0.00004425803,0.0025662654,0.1473165],"study_design_scores_gemma":[0.0022651237,0.0015125857,0.89460605,0.00028632162,0.0010389527,0.00082815473,0.0009072549,0.000016843967,0.0035231952,0.0003898734,0.09441993,0.00020573942],"about_ca_topic_score_codex":0.00030642768,"about_ca_topic_score_gemma":0.0010086618,"teacher_disagreement_score":0.14711076,"about_ca_system_score_codex":0.00027962265,"about_ca_system_score_gemma":0.00092593615,"threshold_uncertainty_score":0.5333534},"labels":[],"label_agreement":null},{"id":"W3139036521","doi":"10.1016/j.jtho.2021.01.085","title":"FP03.03 Clinical Activity of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Regimen; Oncology; Lung cancer; Chemotherapy; Internal medicine; Monoclonal antibody; Stage (stratigraphy); Cisplatin; Cancer; Antibody; Immunotherapy; Immunology","score_opus":0.04313495739633973,"score_gpt":0.477689935984453,"score_spread":0.43455497858811326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139036521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945505,0.0020433555,0.0009654195,0.0007047767,0.0005448034,0.00018384797,0.000022904544,0.0000031658465,0.0009811841],"genre_scores_gemma":[0.9939136,0.0016908306,0.0029733134,0.00015454661,0.00052101037,0.000006046702,0.000025575291,0.000022888675,0.00069219054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971266,0.0010122742,0.0008685272,0.00035604718,0.00026903255,0.00036751613],"domain_scores_gemma":[0.9979516,0.00009448125,0.0006745184,0.00035137538,0.00068779074,0.00024023265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015754763,0.00017669552,0.0006645411,0.00017459852,0.0000540826,0.000021514215,0.00037171436,0.00049184286,0.00021704825],"category_scores_gemma":[0.00032962803,0.00016593248,0.0002800617,0.0002651466,0.0001516736,0.000022428983,0.0002133764,0.0006942574,0.000003931086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026432727,0.001408598,0.10313201,0.00013829753,0.00013316565,0.00046987087,0.000101533566,0.00073326676,0.8429801,0.000008541204,0.0007745357,0.0474768],"study_design_scores_gemma":[0.003973884,0.003255808,0.17363378,0.00013074119,0.00012237071,0.00038621246,0.00031851753,0.003224031,0.7896376,0.00007670862,0.024856921,0.00038337932],"about_ca_topic_score_codex":0.00013645843,"about_ca_topic_score_gemma":0.00095016044,"teacher_disagreement_score":0.070501775,"about_ca_system_score_codex":0.00014948266,"about_ca_system_score_gemma":0.0026899264,"threshold_uncertainty_score":0.676653},"labels":[],"label_agreement":null},{"id":"W3139044601","doi":"10.1016/j.jtho.2021.03.003","title":"The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institutes of Health; Association of Community Cancer Centers; Pfizer; Intuitive Surgical; Amgen; University of Colorado; National Cancer Institute; AbbVie; Gilead Sciences; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; International Association for the Study of Lung Cancer; American Cancer Society","keywords":"Medicine; Lung cancer; Association (psychology); Cancer; Database; Family medicine; Oncology; Internal medicine","score_opus":0.05223508326197522,"score_gpt":0.4841095428410118,"score_spread":0.4318744595790366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139044601","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006279726,0.20318736,0.00008185162,0.025252871,0.75981754,0.0025650016,0.00071975857,0.000008658747,0.0020872543],"genre_scores_gemma":[0.020092003,0.3407692,0.00055990054,0.00025148198,0.6275614,0.00087559805,0.00036788234,0.000092439834,0.0094300965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983884,0.00020868497,0.00048770328,0.00014718744,0.0006394101,0.00012858122],"domain_scores_gemma":[0.9943515,0.0023091459,0.0013429453,0.00016871377,0.0017852375,0.000042448595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012359313,0.0001348861,0.00047882771,0.00011120396,0.00012485993,0.000030147385,0.00018067904,0.00020817434,0.000007787984],"category_scores_gemma":[0.0011832317,0.00007380694,0.000120477656,0.000045660167,0.00004647206,0.00007452179,0.000074327705,0.00049616076,3.75373e-8],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016076767,0.0009419756,0.00015004343,0.00029752782,0.010101279,0.00020416762,0.005460296,0.0000071073127,0.00004988968,0.00008997791,0.8268163,0.15427376],"study_design_scores_gemma":[0.0018238348,0.0016207844,0.00029718713,0.0003076022,0.0054690847,0.0000318695,0.013332282,0.00003610571,0.000027314018,0.0000326747,0.9769544,0.00006688924],"about_ca_topic_score_codex":0.00013282266,"about_ca_topic_score_gemma":0.00053692615,"teacher_disagreement_score":0.15420687,"about_ca_system_score_codex":0.0011413862,"about_ca_system_score_gemma":0.0039448654,"threshold_uncertainty_score":0.6998022},"labels":[],"label_agreement":null},{"id":"W3145651314","doi":"10.1016/s1556-0864(21)01985-7","title":"143P Physician perceptions of barriers to epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Stage (stratigraphy); Mutation; Cancer research; Cancer; Genetics; Gene","score_opus":0.01918052090929674,"score_gpt":0.4075956766757863,"score_spread":0.38841515576648955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145651314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912161,0.00055061415,0.0014066707,0.0031168472,0.00067894475,0.0004386338,0.00009338439,0.000011654961,0.0024871514],"genre_scores_gemma":[0.9729635,0.000100927784,0.02477569,0.00093204825,0.00032439307,0.00004318195,0.000023785457,0.000032766267,0.0008036817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982756,0.00016569151,0.0007632801,0.00024016017,0.0002405174,0.0003147496],"domain_scores_gemma":[0.9977402,0.00022359366,0.0006257675,0.00015976945,0.0008833789,0.0003672618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022346037,0.00018729192,0.00066550565,0.000310908,0.000106616746,0.000012855431,0.00010495432,0.00012949633,0.00040857153],"category_scores_gemma":[0.0005252524,0.00016704931,0.00017605095,0.00060372066,0.000048635764,0.00021019884,0.00003759943,0.000386463,0.0000061463584],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016757594,0.0015602454,0.19702978,0.0010064751,0.00063173566,0.0012983797,0.025400005,0.007157452,0.5360091,0.000027417136,0.0016901676,0.2265135],"study_design_scores_gemma":[0.015072221,0.007911214,0.7178385,0.004736471,0.0035902655,0.0006019405,0.06849562,0.0026930268,0.16988775,0.00017844402,0.007891575,0.0011029548],"about_ca_topic_score_codex":0.00015370587,"about_ca_topic_score_gemma":0.0002471947,"teacher_disagreement_score":0.52080876,"about_ca_system_score_codex":0.0011467692,"about_ca_system_score_gemma":0.0028391005,"threshold_uncertainty_score":0.6812073},"labels":[],"label_agreement":null},{"id":"W3146336845","doi":"10.1016/s1556-0864(21)02033-5","title":"191TiP Accelerating lung cancer diagnosis through liquid biopsy","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Liquid biopsy; Biopsy; Radiology; Lung; Pathology; Cancer; Internal medicine","score_opus":0.02748494641017393,"score_gpt":0.40262773129848106,"score_spread":0.37514278488830716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3146336845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698424,0.01968473,0.0019128071,0.003966501,0.0019078467,0.00007618321,0.00004680071,0.000004013602,0.0025587245],"genre_scores_gemma":[0.96132684,0.016875954,0.015188969,0.0029078755,0.003212909,0.000046707388,0.000028279657,0.000038739876,0.00037374784],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987662,0.0001227791,0.0004920348,0.00022181883,0.00013681855,0.00026038778],"domain_scores_gemma":[0.9986418,0.00010459132,0.0004549532,0.00022048262,0.00046612223,0.000112067835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002745256,0.00014769073,0.0003373912,0.000040771152,0.00009037013,0.000038879567,0.0002179005,0.00023004676,0.00026269795],"category_scores_gemma":[0.00039423295,0.00013909252,0.00020114456,0.00013409115,0.000059302194,0.000010401479,0.00017145496,0.00023550336,0.0000029520718],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016404056,0.0007893358,0.026731333,0.00016962952,0.0008841623,0.001298553,0.00063705037,0.0013276741,0.7454555,0.00030217224,0.11332454,0.10743965],"study_design_scores_gemma":[0.00055695727,0.0011633739,0.00091727293,0.00009216949,0.00022449702,0.0009618331,0.00032378727,0.000039253697,0.49294835,0.00011154695,0.5024126,0.00024834607],"about_ca_topic_score_codex":0.000028295437,"about_ca_topic_score_gemma":0.00014036485,"teacher_disagreement_score":0.38908806,"about_ca_system_score_codex":0.00013583533,"about_ca_system_score_gemma":0.001031007,"threshold_uncertainty_score":0.5672028},"labels":[],"label_agreement":null},{"id":"W3147029691","doi":"10.1016/s1556-0864(21)01919-5","title":"77TiP From liquid biopsy to cure: Using CtDNA detection of minimal residual disease to identify patients for curative therapy after non-small cell lung cancer (NSCLC) resection","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Stage (stratigraphy); Lung cancer; Randomized controlled trial; Clinical trial; Adjuvant; Surgery","score_opus":0.019607611849522727,"score_gpt":0.3862533625114777,"score_spread":0.36664575066195493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147029691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826128,0.0022222812,0.012745057,0.00040316512,0.0013729329,0.00034674947,0.00027937884,0.0000013833605,0.00001628406],"genre_scores_gemma":[0.9929331,0.00046404923,0.0049583646,0.0004491648,0.0010514682,0.000045980818,0.000029646748,0.000025885072,0.00004236135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988137,0.00011662596,0.00046387003,0.00026955476,0.00013572382,0.00020054875],"domain_scores_gemma":[0.9982758,0.00007253239,0.00040386696,0.00017845856,0.000866265,0.00020303302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001920624,0.00014336202,0.0002765495,0.000109970315,0.000059460388,0.000023761813,0.000130161,0.00016237491,0.000017411403],"category_scores_gemma":[0.0002009561,0.00013968906,0.00016518807,0.00013782046,0.000026114863,0.000010820432,0.00009824885,0.000115484705,7.2063284e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023087945,0.00032541328,0.004311135,0.000038311995,0.00012296424,0.000019589574,0.0003785011,0.0007724553,0.9635746,2.553868e-7,0.0011029615,0.0062658666],"study_design_scores_gemma":[0.0011242238,0.004126737,0.025625877,0.000108491084,0.00018879514,0.0000075454996,0.00018259019,0.00009132934,0.9598519,0.000024784375,0.008481665,0.00018602858],"about_ca_topic_score_codex":0.00007566305,"about_ca_topic_score_gemma":0.0003388813,"teacher_disagreement_score":0.021963721,"about_ca_system_score_codex":0.0001918997,"about_ca_system_score_gemma":0.0007186286,"threshold_uncertainty_score":0.56963545},"labels":[],"label_agreement":null},{"id":"W3147445522","doi":"10.1016/s1556-0864(21)01939-0","title":"97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Ono Pharmaceutical; Astellas Pharma; F. Hoffmann-La Roche; Sanofi; Servier; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Chemotherapy; Immunotherapy; Cancer","score_opus":0.015216673979625726,"score_gpt":0.3473521490314572,"score_spread":0.3321354750518315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147445522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866292,0.0018575883,0.0021842602,0.0067123,0.0016053464,0.000508105,0.00005798429,0.00002160338,0.00042362194],"genre_scores_gemma":[0.9818277,0.00068599894,0.012696054,0.0027847902,0.00074742595,0.000020632518,0.00007544426,0.000065420965,0.0010965734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99814296,0.000092288465,0.0007309932,0.00028208178,0.00039989766,0.00035176653],"domain_scores_gemma":[0.9975057,0.00039453595,0.00073150074,0.0003168176,0.0008634971,0.00018791408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002890339,0.0002463561,0.00090895745,0.00013856236,0.00010714965,0.000022101582,0.00017857988,0.00024973502,0.00045387776],"category_scores_gemma":[0.00022643979,0.00018241552,0.0003991559,0.00025150648,0.0000981797,0.00014576047,0.000026914426,0.00036358106,0.000006060049],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44361135,0.0017394988,0.0075524636,0.00016846984,0.0013564371,0.00039364296,0.0012389327,0.00006667939,0.0057102544,0.0000075445364,0.0072794734,0.53087527],"study_design_scores_gemma":[0.24924646,0.051374152,0.0897646,0.0014119248,0.0020377464,0.0010294565,0.0020876816,0.00026163398,0.03166948,0.00066526525,0.5694451,0.0010065106],"about_ca_topic_score_codex":0.000032153082,"about_ca_topic_score_gemma":0.00016120492,"teacher_disagreement_score":0.5621656,"about_ca_system_score_codex":0.0007117093,"about_ca_system_score_gemma":0.0010940522,"threshold_uncertainty_score":0.7438689},"labels":[],"label_agreement":null},{"id":"W3147842235","doi":"10.1016/s1556-0864(21)02027-x","title":"185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Carboplatin; Nivolumab; Trastuzumab; Phases of clinical research; Lapatinib; Immunotherapy; Chemotherapy; Cancer; Cisplatin; Breast cancer","score_opus":0.023105249282846383,"score_gpt":0.44140608400617776,"score_spread":0.41830083472333135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147842235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960877,0.0006546971,0.00026189716,0.0006287168,0.000063007246,0.0022100387,0.000010453917,0.000007481011,0.00007603499],"genre_scores_gemma":[0.9904099,0.00024164746,0.008823983,0.0000846552,0.000030612187,0.0001722864,0.00002639427,0.000034186407,0.00017629993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982607,0.0002612862,0.0005953033,0.00031847454,0.00033679328,0.00022747557],"domain_scores_gemma":[0.9985334,0.00021454607,0.00059083535,0.00014079969,0.00037630124,0.00014410146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032085777,0.00025029664,0.00069704093,0.00025821268,0.00010164692,0.0000276702,0.00004002275,0.00006855056,0.000044884462],"category_scores_gemma":[0.00006604617,0.00015825828,0.00003497866,0.00036060982,0.000045068555,0.00023670023,0.00001649554,0.00021900334,2.2355513e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039240554,0.022100378,0.3653404,0.00030160722,0.0005195119,0.0009925348,0.01245375,0.0024906301,0.0011478578,8.267267e-7,0.000005376042,0.5554066],"study_design_scores_gemma":[0.16522571,0.11616129,0.70147955,0.002143366,0.002438465,0.00045700304,0.0049285768,0.004942904,0.0018190318,0.000040109273,0.000053132633,0.00031087105],"about_ca_topic_score_codex":0.0003449473,"about_ca_topic_score_gemma":0.0034194984,"teacher_disagreement_score":0.55509573,"about_ca_system_score_codex":0.0013650211,"about_ca_system_score_gemma":0.0014501059,"threshold_uncertainty_score":0.64535856},"labels":[],"label_agreement":null},{"id":"W3150184237","doi":"10.1016/j.jtho.2021.02.015","title":"Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Thymoma; Stage (stratigraphy); Radiation oncology; General surgery; Surgery; Radiation therapy","score_opus":0.04042359886020345,"score_gpt":0.40217028485248996,"score_spread":0.3617466859922865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3150184237","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05072653,0.046253912,0.00023739562,0.8977176,0.0032999474,0.0011286173,0.00007506984,0.0000114385175,0.000549517],"genre_scores_gemma":[0.026376411,0.10341367,0.021627,0.7328359,0.04235261,0.0002845339,0.0024903107,0.0005585328,0.07006102],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600995,0.00084457267,0.0015103546,0.00045340727,0.000604479,0.000577215],"domain_scores_gemma":[0.9961001,0.00089001755,0.0014776073,0.00041225768,0.00094387884,0.00017611054],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012821772,0.00043617596,0.002124513,0.00091029826,0.00014565728,0.0001206642,0.00032881627,0.0013888896,0.0011706476],"category_scores_gemma":[0.0004765841,0.0003502028,0.0005570737,0.00045235548,0.000119719516,0.0003610468,0.00011648415,0.0035365424,0.000011651368],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031506545,0.00038966877,0.000068411966,0.0002765421,0.00045194934,0.010691466,0.0016369073,0.000005856811,0.0016633968,0.00003417387,0.62320924,0.3584217],"study_design_scores_gemma":[0.00342358,0.006524742,0.00033223338,0.002617448,0.00041956158,0.0026080443,0.0012398417,0.00009357893,0.0005688444,0.00028212427,0.9815968,0.00029315436],"about_ca_topic_score_codex":0.000024261706,"about_ca_topic_score_gemma":0.000071775445,"teacher_disagreement_score":0.3583876,"about_ca_system_score_codex":0.0010240241,"about_ca_system_score_gemma":0.0018179462,"threshold_uncertainty_score":0.9999075},"labels":[],"label_agreement":null},{"id":"W3151729207","doi":"10.1016/s1556-0864(21)01986-9","title":"144P Delays in epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/ IIIc/ IV) non-small cell lung cancer (NSCLC) patients and their impact on the use of first line tyrosine kinase inhibitor (TKIs) in a real-world setting","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Epidermal growth factor receptor; Internal medicine; Lung cancer; Stage (stratigraphy); Lung; Cancer; Pathology","score_opus":0.03451590880602718,"score_gpt":0.3889431964996445,"score_spread":0.3544272876936173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151729207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639803,0.00047169923,0.00005273556,0.0019530009,0.00023838125,0.0006155766,0.000110844536,0.000005601424,0.00015412224],"genre_scores_gemma":[0.996214,0.0003340844,0.0028471784,0.0002958226,0.00012778955,0.000035971287,0.00003173777,0.00003009299,0.000083351886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998011,0.0002808513,0.0009764386,0.00024046187,0.00017923696,0.00031201262],"domain_scores_gemma":[0.9969324,0.0014628138,0.00088085205,0.00014031676,0.00045826688,0.00012538712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042230528,0.00023821693,0.00067376613,0.00046822787,0.00006479885,0.00002006672,0.000072371644,0.00011792286,0.000045250483],"category_scores_gemma":[0.0008903224,0.00015012073,0.0001038259,0.0007295125,0.00004801352,0.0002619249,0.0000503269,0.0005531244,4.19158e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020988865,0.0014691405,0.9315153,0.00032287557,0.000100939986,0.0004969184,0.0052017635,0.0055134683,0.010576338,0.000002962596,0.00012072626,0.042580724],"study_design_scores_gemma":[0.0076215556,0.0024777257,0.95431024,0.0033801752,0.00019310559,0.000046722642,0.0012252136,0.0064319973,0.023847371,0.000024033965,0.0002190891,0.00022275266],"about_ca_topic_score_codex":0.0012592995,"about_ca_topic_score_gemma":0.0050808648,"teacher_disagreement_score":0.042357974,"about_ca_system_score_codex":0.0014195505,"about_ca_system_score_gemma":0.0008403729,"threshold_uncertainty_score":0.6121746},"labels":[],"label_agreement":null},{"id":"W3153258297","doi":"10.1016/j.jtho.2021.03.023","title":"Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"KRAS; Lung cancer; Adenocarcinoma; Medicine; Somatic evolution in cancer; Lung; Pathology; Cancer research; Biology; Cancer; Internal medicine; Colorectal cancer","score_opus":0.040609732730399084,"score_gpt":0.42007650932922397,"score_spread":0.3794667765988249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153258297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872816,0.0073096585,0.001344116,0.0024880476,0.000093207265,0.00023497114,0.000026778027,0.0000044726025,0.0012171309],"genre_scores_gemma":[0.98751116,0.00028891393,0.01158222,0.0003305281,0.00004890911,0.000014262345,0.00007588064,0.00001215415,0.00013594376],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981858,0.0003712027,0.0006793549,0.00021260287,0.00037306084,0.00017793744],"domain_scores_gemma":[0.9971035,0.0007005214,0.0008908814,0.00020666629,0.0009302412,0.00016815895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003381766,0.00015825548,0.0010725039,0.00032104919,0.00006189522,0.000011407803,0.00008109743,0.00012216555,0.00011175838],"category_scores_gemma":[0.00016684,0.00011441552,0.00029188526,0.00080218114,0.00009316257,0.000085672604,0.000030420299,0.00032976063,0.0000026767011],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027734872,0.0018681621,0.95603895,0.00021901075,0.012625662,0.0037584163,0.001540006,0.0064814608,0.01098121,0.0003362025,0.001655967,0.0017214566],"study_design_scores_gemma":[0.0043945806,0.0076936055,0.6558697,0.00083736156,0.048305824,0.0014941947,0.001856787,0.0014712268,0.27666748,0.00016649124,0.00090959354,0.00033315714],"about_ca_topic_score_codex":0.000029655397,"about_ca_topic_score_gemma":0.00021105343,"teacher_disagreement_score":0.30016926,"about_ca_system_score_codex":0.0006334122,"about_ca_system_score_gemma":0.0017997372,"threshold_uncertainty_score":0.46657294},"labels":[],"label_agreement":null},{"id":"W3154550237","doi":"10.1016/j.jtho.2021.03.025","title":"Cannabis Use, Pulmonary Function, and Lung Cancer Susceptibility: A Mendelian Randomization Study","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto","funders":"National Cancer Institute; College of Medicine, Seoul National University; Audrey and Theodor Geisel School of Medicine at Dartmouth; Norris Cotton Cancer Center; University of Texas MD Anderson Cancer Center; BC Cancer Agency; Vanderbilt University; Nanjing Medical University; Radboud Universitair Medisch Centrum; Universität Salzburg; Umeå Universitet; Seoul National University; University of Toronto; Lunds Universitet; Gentofte Hospital; Cancer Institute, University of Pittsburgh; Radboud Universiteit; American Cancer Society; Vanderbilt University Medical Center; Canada Research Chairs; Washington State University; University of Pittsburgh; Dartmouth College; Harvard School of Public Health; Centre International de Recherche sur le Cancer; World Health Organization; Universidad de Oviedo; Moffitt Cancer Center","keywords":"Medicine; Mendelian randomization; Lung cancer; Cancer; Mendelian inheritance; Pulmonary function testing; Lung function; Oncology; Internal medicine; Lung; Genetics; Gene","score_opus":0.055720011095714596,"score_gpt":0.4753134853775102,"score_spread":0.4195934742817956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154550237","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017348483,0.9915724,0.000064748965,0.00330318,0.0011926698,0.0019502563,0.00002818613,0.00001236756,0.00014139205],"genre_scores_gemma":[0.00042141374,0.98620325,0.00008625061,0.00017065632,0.0011740422,0.00017837208,0.000035119392,0.00007123752,0.011659661],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951555,0.0016255287,0.0016407617,0.0004885393,0.0006910679,0.00039861538],"domain_scores_gemma":[0.9962058,0.00011225181,0.0012382839,0.00040902055,0.0015794934,0.00045513766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025923734,0.00041139493,0.0038736945,0.0007827454,0.00013697219,0.00009229687,0.00017413718,0.0005281007,0.0005828881],"category_scores_gemma":[0.00073592464,0.00028798654,0.00071891275,0.00081010757,0.00013789714,0.00020117879,0.00016589275,0.0014926674,0.0000019678873],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018099099,0.001021106,0.0011780093,0.008212589,0.0016114386,0.0013376242,0.00014405741,0.00000305882,0.000007983436,0.0000034001016,0.059153482,0.9255173],"study_design_scores_gemma":[0.0019136897,0.0019244105,0.0007454328,0.005095367,0.009840313,0.003637161,0.00054530724,0.00002384197,7.788336e-7,0.00000774637,0.9760406,0.00022535429],"about_ca_topic_score_codex":0.00020019495,"about_ca_topic_score_gemma":0.00035053233,"teacher_disagreement_score":0.925292,"about_ca_system_score_codex":0.0014327813,"about_ca_system_score_gemma":0.0062421327,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W3157993774","doi":"10.1016/j.jtho.2021.03.010","title":"Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Smoking cessation; Lung cancer; Cancer; Public health; Disease; Surgeon general; Family medicine; Clinical trial; Cancer prevention; Health promotion; Gerontology; Physical therapy; Internal medicine; Pathology","score_opus":0.1069302646088639,"score_gpt":0.5009390549216342,"score_spread":0.39400879031277025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157993774","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3969739,0.0243896,5.0693126e-7,0.5747215,0.0027778866,0.00045481932,0.0004478053,0.0000052686405,0.00022867935],"genre_scores_gemma":[0.8013556,0.00852857,0.00020656009,0.18306988,0.004196016,0.0004379764,0.000060761846,0.000114343886,0.00203031],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967011,0.00042471138,0.001259452,0.00040784437,0.000672837,0.0005340278],"domain_scores_gemma":[0.996193,0.0013863781,0.0010886773,0.00048380642,0.0007057054,0.00014241342],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025826076,0.00047118933,0.0023473944,0.0002809465,0.0000905953,0.000022072594,0.0002586942,0.0008426346,0.0013215519],"category_scores_gemma":[0.00017828098,0.00026505484,0.0006688672,0.00020352873,0.0002462766,0.00006836153,0.00011168221,0.0012958625,0.0000020032387],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061980664,0.0010320258,0.6404981,0.001990908,0.0022063334,0.02851901,0.0025232306,0.00003780439,0.000070799964,9.109745e-7,0.22471212,0.09778893],"study_design_scores_gemma":[0.003463418,0.002943893,0.31882042,0.005457681,0.007012761,0.00081356964,0.0008009401,0.000003926441,0.004331514,0.000008780918,0.656015,0.00032808929],"about_ca_topic_score_codex":0.002498134,"about_ca_topic_score_gemma":0.0154688405,"teacher_disagreement_score":0.43130288,"about_ca_system_score_codex":0.0112315575,"about_ca_system_score_gemma":0.0029259166,"threshold_uncertainty_score":0.99998015},"labels":[],"label_agreement":null},{"id":"W3158093472","doi":"10.1016/j.jtho.2021.04.002","title":"Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Western University","funders":"","keywords":"Medicine; Lung cancer; Radiosurgery; Stage (stratigraphy); Ablative case; Radiology; Radiation therapy; Medical physics; Oncology","score_opus":0.0980646916831539,"score_gpt":0.5310427103115425,"score_spread":0.4329780186283886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158093472","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000121993535,0.98845273,0.0015469745,0.0062714824,0.0014350455,0.0018164528,0.000020714228,0.0000096643535,0.00043471548],"genre_scores_gemma":[0.000049670187,0.98440933,0.01135216,0.0006779637,0.0025562937,0.0005822759,0.000036801168,0.000064342996,0.00027117648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976182,0.00032059918,0.001048321,0.00034796103,0.00032268936,0.00034225694],"domain_scores_gemma":[0.9967491,0.0008340349,0.0013880233,0.00026499777,0.00040390796,0.00035995405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007755617,0.00032766163,0.0030713389,0.00038342527,0.00007227285,0.00003721437,0.00012073771,0.00041790042,0.0000695832],"category_scores_gemma":[0.00043863707,0.00023193187,0.00091663527,0.00027920306,0.000019228073,0.00010421631,0.000050078128,0.0007139763,0.0000035499029],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023753691,0.0010833165,0.000017466065,0.01936899,0.0027462537,0.0003747212,0.00019546885,0.000019780702,1.17978665e-7,0.00003843888,0.038183097,0.93773484],"study_design_scores_gemma":[0.0007166709,0.0013679991,0.0000079515185,0.018051917,0.016262043,0.0046864767,0.00007196125,0.0001339628,0.0000016965865,0.0000017912954,0.9585232,0.00017429181],"about_ca_topic_score_codex":0.000008397496,"about_ca_topic_score_gemma":0.0000047176827,"teacher_disagreement_score":0.9375605,"about_ca_system_score_codex":0.0049702204,"about_ca_system_score_gemma":0.0044272253,"threshold_uncertainty_score":0.9988495},"labels":[],"label_agreement":null},{"id":"W3158697155","doi":"10.1016/j.jtho.2021.03.028","title":"Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority; Queen's University; Princess Margaret Cancer Centre; Saskatchewan Health; University Health Network; University of Toronto; Saskatchewan Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Boehringer Ingelheim; Roche; Merck; AstraZeneca; Pfizer; Takeda Pharmaceutical Company; Bristol-Myers Squibb","keywords":"Medicine; Concordance; Biopsy; Lung cancer; Adenocarcinoma; Population; Internal medicine; Biomarker; Oncology; Cancer; Immunohistochemistry; Pathology; Gastroenterology","score_opus":0.057276530612910034,"score_gpt":0.4899315111543924,"score_spread":0.4326549805414823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158697155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876788,0.010592246,0.000054695305,0.0013438911,0.00016915848,0.00010960413,0.000007296785,0.0000021715505,0.000042096795],"genre_scores_gemma":[0.9953148,0.0010992077,0.0031232126,0.00034051263,0.00007998452,0.000003038163,0.0000024263034,0.000006678946,0.000030139936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982583,0.0005035584,0.0008239925,0.00015227553,0.00014211844,0.00011974716],"domain_scores_gemma":[0.9984401,0.0006808371,0.0005747013,0.00008830509,0.00014649515,0.00006959693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018071873,0.00008135087,0.0004667083,0.00010098982,0.000019546149,0.000005030274,0.000043339707,0.0001525232,0.000032774893],"category_scores_gemma":[0.0006955738,0.000065242166,0.0000552785,0.00018064301,0.00007375417,0.00006747025,0.000028370463,0.0003184432,3.258755e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004133098,0.00021333895,0.8946308,0.0002608231,0.000028753933,0.000095780655,0.00007426163,0.000021854717,0.048521467,2.1976165e-7,0.000084009735,0.051935628],"study_design_scores_gemma":[0.0023503304,0.0006898791,0.9806909,0.0015923054,0.00007733841,0.0001425643,0.000052496827,0.00089560857,0.013302335,0.000013785577,0.00013197403,0.000060481954],"about_ca_topic_score_codex":0.0001545025,"about_ca_topic_score_gemma":0.00023697398,"teacher_disagreement_score":0.08606014,"about_ca_system_score_codex":0.00021107691,"about_ca_system_score_gemma":0.00039034974,"threshold_uncertainty_score":0.26604983},"labels":[],"label_agreement":null},{"id":"W3158903821","doi":"10.1016/j.jtho.2021.03.005","title":"Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia; Princess Margaret Cancer Centre; Canada Research Chairs; BC Cancer Agency","funders":"","keywords":"Scopus; Transparency (behavior); Publication; Citation; Medicine; Publishing; Library science; Impact factor; Honesty; Scientific misconduct; Political science; MEDLINE; Law; Alternative medicine; Computer science; Pathology","score_opus":0.3784963260579733,"score_gpt":0.634109747195302,"score_spread":0.2556134211373287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158903821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8838247,0.0013995805,0.0003406958,0.10751952,0.0016388523,0.00028510395,0.00016904534,0.000023477356,0.004799022],"genre_scores_gemma":[0.9842502,0.00048667088,0.00088345184,0.0128090475,0.0010473529,0.000018296792,0.000012227331,0.00001964182,0.00047311324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99389684,0.0038135084,0.0010651066,0.00032508612,0.0002037457,0.0006956867],"domain_scores_gemma":[0.99644244,0.0014345171,0.00035532244,0.00016254133,0.00044064558,0.0011645621],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003501242,0.00025253426,0.0007330481,0.0005221424,0.00026548342,0.00002996564,0.00026987062,0.00100226,0.00047830626],"category_scores_gemma":[0.0024431937,0.0002438672,0.00012773325,0.0007780845,0.00017900247,0.00020459035,0.0000847183,0.0038221402,0.000042797124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019248556,0.0036092852,0.022064185,0.0004313731,0.00045079313,0.0063277823,0.0055384887,0.0007151812,0.26610124,0.012565992,0.009159929,0.6537872],"study_design_scores_gemma":[0.005468919,0.004920462,0.05635553,0.0007758277,0.0005116047,0.0044965423,0.0027279002,0.0003635517,0.2433147,0.012109012,0.6680624,0.00089358265],"about_ca_topic_score_codex":0.00004553573,"about_ca_topic_score_gemma":0.00014685717,"teacher_disagreement_score":0.65890247,"about_ca_system_score_codex":0.0007662564,"about_ca_system_score_gemma":0.0020048849,"threshold_uncertainty_score":0.9984761},"labels":[],"label_agreement":null},{"id":"W3164830456","doi":"10.1016/j.jtho.2020.11.020","title":"Lung Cancer in Singapore","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Medtronic; GlaxoSmithKline; Stryker; Pfizer; Celgene; AstraZeneca; Takeda Pharmaceutical Company; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Demography; Southeast asia; Population; Cancer; Gerontology; Traditional medicine; Socioeconomics; Environmental health; Ancient history; Oncology; Internal medicine","score_opus":0.023966378931626814,"score_gpt":0.4635257148319949,"score_spread":0.4395593359003681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164830456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94673365,0.013928436,0.000021729044,0.03361372,0.0009869889,0.000082838196,0.0000032108983,0.000004094508,0.0046253223],"genre_scores_gemma":[0.99402714,0.002211233,0.0014810016,0.0011750278,0.0004420888,0.0000073304373,0.0000014989289,0.000009456461,0.0006452192],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991932,0.00007887537,0.00034072128,0.00009557469,0.00014999555,0.00014164658],"domain_scores_gemma":[0.99928427,0.00008794531,0.00020996186,0.00009826034,0.00021807643,0.00010149142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023570441,0.00006996589,0.00040780887,0.00010155449,0.000016618453,0.000006351254,0.00004039715,0.00008591525,0.0006074878],"category_scores_gemma":[0.00007030911,0.000051907664,0.000113028735,0.00017575601,0.000022874985,0.000050564067,0.000019991345,0.0002542364,0.0000031691463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009724024,0.0016597774,0.55365235,0.00025174642,0.00048797732,0.0177778,0.0007475491,0.00013794047,0.0019840023,0.00007311404,0.019035466,0.40321988],"study_design_scores_gemma":[0.0059514632,0.002577947,0.7246608,0.0027843702,0.0019338956,0.008147376,0.0009363055,0.00028317948,0.02930891,0.00045163414,0.22271757,0.00024654216],"about_ca_topic_score_codex":0.000025580683,"about_ca_topic_score_gemma":0.00027145798,"teacher_disagreement_score":0.40297332,"about_ca_system_score_codex":0.00136635,"about_ca_system_score_gemma":0.0012502787,"threshold_uncertainty_score":0.66515654},"labels":[],"label_agreement":null},{"id":"W3165420531","doi":"10.1016/j.jtho.2021.05.003","title":"Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Chinook Therapeutics; Janssen Pharmaceuticals; Yuhan; Loxo Oncology; TG Therapeutics; Takeda Pharmaceutical Company; AbbVie; Roche; Novartis; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Celgene; Bayer; Aimmune Therapeutics; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Confidence interval; Stage (stratigraphy); Univariate analysis; Multivariate analysis; Proportional hazards model; Chemoradiotherapy; Performance status; Oncology; Cancer","score_opus":0.07614391861067087,"score_gpt":0.5020628422266695,"score_spread":0.42591892361599865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165420531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765104,0.000026915888,0.00000998874,0.0011570294,0.00021372765,0.0004328534,0.00008602404,0.0000031750471,0.0004192338],"genre_scores_gemma":[0.99621683,0.00008990864,0.0021880516,0.00014970124,0.00006604437,0.000008521266,0.000040339564,0.000010574577,0.0012300378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825084,0.00019543384,0.0009684223,0.00017415213,0.0002830537,0.00012809268],"domain_scores_gemma":[0.9981986,0.0004243217,0.00065992266,0.00016645115,0.00043835322,0.00011233055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033742058,0.00012248755,0.00073487195,0.00015980663,0.000028646426,0.000007373728,0.000041823576,0.00006509338,0.00002926841],"category_scores_gemma":[0.00013101063,0.000075948315,0.0000909234,0.00015527774,0.000048586237,0.00008846566,0.000024857201,0.00017489084,5.84919e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005596516,0.01003795,0.96327233,0.000020366519,0.0009930151,0.0005692572,0.0010004013,0.000016322105,0.0000027887822,0.000005364424,0.00003422274,0.018451465],"study_design_scores_gemma":[0.022748837,0.009206329,0.965091,0.00012137079,0.0008995381,0.00001612659,0.0011515906,0.000010996526,0.000018215134,0.0000053213666,0.0006730523,0.000057633104],"about_ca_topic_score_codex":0.0007242107,"about_ca_topic_score_gemma":0.006337776,"teacher_disagreement_score":0.018393833,"about_ca_system_score_codex":0.00047237572,"about_ca_system_score_gemma":0.00090718194,"threshold_uncertainty_score":0.35366276},"labels":[],"label_agreement":null},{"id":"W3178692152","doi":"10.1016/j.jtho.2021.06.017","title":"Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":645,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Pharmaceuticals; Stand Up To Cancer; EMD Serono; Genentech; European Society for Medical Oncology; Eisai; Daiichi-Sankyo; European School of Oncology; National Institutes of Health; Rosetrees Trust; Cancer Research UK; ANGLE; Mirati Therapeutics; Bayer Fund; Clovis Oncology; Astex Pharmaceuticals; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Intel Corporation; Exelixis; ACEA Biosciences; Novartis; Celgene; National Cancer Institute; Gilead Sciences; Francis Crick Institute; Stanford University; International Association for the Study of Lung Cancer; Merck; GlaxoSmithKline; Royal Society; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Boehringer Ingelheim; Amgen; Roche","keywords":"Liquid biopsy; Medicine; Lung cancer; Cancer; Oncology; Adenocarcinoma; Personalized medicine; Biopsy; Precision medicine; Erlotinib; Internal medicine; Bioinformatics; Pathology","score_opus":0.040545074818921945,"score_gpt":0.46721143980907626,"score_spread":0.4266663649901543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178692152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066148653,0.9853637,0.00065834756,0.001489162,0.0033313527,0.0013624775,0.0011569229,9.1147587e-7,0.000022262933],"genre_scores_gemma":[0.0013063027,0.9953771,0.00079704134,0.00018913034,0.0016650894,0.00032472404,0.0001427568,0.000027529442,0.00017029502],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983544,0.0001909654,0.0009217056,0.00019624773,0.00018208286,0.00015463449],"domain_scores_gemma":[0.994445,0.0019469371,0.0025108675,0.00022480928,0.0008365892,0.00003578465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010598352,0.0001720866,0.0008005526,0.000037725444,0.0000765329,0.000025742285,0.0004683669,0.0002151081,0.000013777385],"category_scores_gemma":[0.0010593473,0.00010293499,0.00048092683,0.00006082267,0.000029626186,0.0000019675174,0.00013455158,0.00018879048,1.3132123e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018450508,0.0005474673,0.000076547374,0.0005152818,0.0062953536,0.000009140035,0.00026575077,0.00030156958,0.00077329995,0.000018941484,0.040288452,0.9490631],"study_design_scores_gemma":[0.0008290156,0.0015138962,0.000011952176,0.00061138254,0.0026235804,0.000014837143,0.00053265836,0.000020927191,0.00016646953,0.000011685774,0.993557,0.00010661506],"about_ca_topic_score_codex":0.000045306337,"about_ca_topic_score_gemma":0.00036564795,"teacher_disagreement_score":0.9532685,"about_ca_system_score_codex":0.00046339718,"about_ca_system_score_gemma":0.0016274954,"threshold_uncertainty_score":0.41975668},"labels":[],"label_agreement":null},{"id":"W3183073911","doi":"10.1016/j.jtho.2021.06.015","title":"High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; Vancouver General Hospital; University of British Columbia","funders":"BC Cancer Agency; Terry Fox Research Institute","keywords":"Medicine; Lung cancer; Environmental health; Air pollution; Oncology","score_opus":0.02945179588546716,"score_gpt":0.38956961911139515,"score_spread":0.360117823225928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183073911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96481663,0.00038139793,0.00058842846,0.031350512,0.0017658357,0.00012710414,0.000008047906,0.000013173468,0.000948891],"genre_scores_gemma":[0.98808044,0.00018907392,0.0038706535,0.006883196,0.00028422094,0.0000059125373,0.0000025286793,0.000017245784,0.00066674675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783254,0.00040388387,0.00051859696,0.00022846198,0.0005566419,0.00045987216],"domain_scores_gemma":[0.99856687,0.000116745294,0.0006449735,0.00019801111,0.00007626644,0.00039715867],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008368828,0.00016840201,0.00040183647,0.000067235545,0.00018964434,0.000017093173,0.00019961719,0.00022079278,0.0023016033],"category_scores_gemma":[0.00010630753,0.00013256357,0.0001041031,0.00034621125,0.0002683461,0.0006820599,0.00009712304,0.0005500122,0.000027134753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0149363885,0.0013419988,0.43106645,0.00025928384,0.0008329708,0.0027037202,0.006277782,0.14233552,0.002863876,0.00023455449,0.25267643,0.14447102],"study_design_scores_gemma":[0.0022564621,0.0021321897,0.90976316,0.00015293264,0.0003237891,0.00022732378,0.0014613802,0.0002534754,0.002670539,0.000100436126,0.08036628,0.0002920254],"about_ca_topic_score_codex":0.000908822,"about_ca_topic_score_gemma":0.0019589968,"teacher_disagreement_score":0.4786967,"about_ca_system_score_codex":0.0021597203,"about_ca_system_score_gemma":0.0005532915,"threshold_uncertainty_score":0.99861044},"labels":[],"label_agreement":null},{"id":"W3186488369","doi":"10.1016/j.jtho.2021.07.008","title":"Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Janssen Pharmaceuticals; Foundation Medicine; EMD Serono; Genentech; G1 Therapeutics; Puma Biotechnology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Pfizer; Incyte; F. Hoffmann-La Roche; AbbVie; Daiichi-Sankyo; Teva Pharmaceutical Industries; Roche; Novartis; Sanofi; Merck; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen","keywords":"Medicine; Alectinib; Internal medicine; Clinical endpoint; Oncology; Cohort; Asymptomatic; Confidence interval; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Clinical trial; Phases of clinical research; Crizotinib; Lung cancer","score_opus":0.043952505470356826,"score_gpt":0.4840153234446429,"score_spread":0.44006281797428604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186488369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583907,0.0007032095,0.00039516107,0.005448241,0.0009216933,0.0011489087,0.00020351936,0.0000070205706,0.005333182],"genre_scores_gemma":[0.9910618,0.00022009746,0.0068643335,0.0002382324,0.00032264777,0.00004141883,0.00004400214,0.000019127652,0.0011883227],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977604,0.00052505126,0.0009752289,0.00020206925,0.0003126698,0.00022458554],"domain_scores_gemma":[0.9973814,0.0008792846,0.0009436428,0.00022116773,0.00044716412,0.00012737837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056965504,0.00017655504,0.0008612625,0.00017171721,0.000091568894,0.0000112910675,0.00009969186,0.000094849776,0.000097332675],"category_scores_gemma":[0.00086982787,0.00010114487,0.0002897004,0.00040857785,0.00010822705,0.00013919531,0.000034546752,0.0002838162,0.0000018279611],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43161213,0.016170405,0.0026001765,0.00009632018,0.00722267,0.014061864,0.007522974,0.0005025195,0.0036866583,0.00004296231,0.0005162249,0.5159651],"study_design_scores_gemma":[0.74634683,0.07396015,0.017303526,0.0024432824,0.026237093,0.008856805,0.009116647,0.0002535576,0.088865444,0.00020811977,0.025965292,0.00044324392],"about_ca_topic_score_codex":0.00006528822,"about_ca_topic_score_gemma":0.00039872187,"teacher_disagreement_score":0.5155219,"about_ca_system_score_codex":0.00052749336,"about_ca_system_score_gemma":0.002184871,"threshold_uncertainty_score":0.4124568},"labels":[],"label_agreement":null},{"id":"W3189724491","doi":"10.1016/j.jtho.2021.07.017","title":"Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Bristol-Myers Squibb Canada; Saitama Medical University; Terry Fox Foundation; Boehringer Ingelheim; F. Hoffmann-La Roche; Roche; AbbVie; Merck; Terry Fox Research Institute; Bayer; AstraZeneca; Novartis; Princess Margaret Cancer Foundation; Pfizer","keywords":"Multidrug tolerance; Cancer cell; Medicine; Mechanism (biology); Drug; Cancer therapy; Cancer; Drug resistance; Cancer stem cell; Population; Cancer research; Bioinformatics; Pharmacology; Biology; Genetics; Internal medicine; Bacteria; Biofilm","score_opus":0.11883701485988694,"score_gpt":0.5200509586028296,"score_spread":0.4012139437429426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3189724491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006309525,0.99500555,0.0002033754,0.0020312304,0.0012890709,0.00067837554,0.00004970477,0.0000021169296,0.00010960085],"genre_scores_gemma":[0.00017642177,0.9962543,0.0015897892,0.00034782678,0.0011670256,0.000042033902,0.00000940325,0.00002829484,0.0003848562],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99789613,0.00036981757,0.0012040421,0.00019975018,0.0001753266,0.00015492794],"domain_scores_gemma":[0.99674475,0.00074689905,0.0017390376,0.00024964905,0.00040522288,0.00011446383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017656438,0.00018975521,0.0024299312,0.00010775148,0.000042454496,0.0000118417165,0.0001615614,0.00026442253,0.00014613576],"category_scores_gemma":[0.000052905045,0.000098975965,0.0011608693,0.000117507276,0.00007781662,0.000026940419,0.000040361123,0.0005175672,7.029276e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003307804,0.00017687914,0.000004463358,0.0029061541,0.00089688454,0.000015987454,0.00014374226,2.747777e-7,0.00003242707,0.000025828704,0.0053592296,0.99010736],"study_design_scores_gemma":[0.00070483965,0.0011124393,0.0000069987395,0.0031290592,0.0053792996,0.0005964031,0.0002227813,0.000006924975,0.0001306619,0.000028448872,0.98859555,0.00008660567],"about_ca_topic_score_codex":0.000010063623,"about_ca_topic_score_gemma":0.000013660772,"teacher_disagreement_score":0.99002075,"about_ca_system_score_codex":0.00012105133,"about_ca_system_score_gemma":0.0014774498,"threshold_uncertainty_score":0.40361226},"labels":[],"label_agreement":null},{"id":"W3194568473","doi":"10.1016/j.jtho.2021.07.031","title":"Screening for Lung Cancer in Individuals Who Never Smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Cancer Care Ontario; Brock University","funders":"International Association for the Study of Lung Cancer","keywords":"Medicine; Lung cancer; Lung cancer screening; National Lung Screening Trial; Smoking cessation; Population; Cancer; Lung; Environmental health; Intensive care medicine; Internal medicine; Pathology","score_opus":0.0410494091547929,"score_gpt":0.45923459991267734,"score_spread":0.41818519075788446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194568473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98827237,0.0017552179,0.0027430125,0.0055155517,0.0007858073,0.00085586647,0.00003746805,0.0000040309196,0.00003069199],"genre_scores_gemma":[0.99634254,0.0004501431,0.0018882109,0.00024549896,0.00058759464,0.00026155732,0.0000060320995,0.000016566588,0.0002018361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855524,0.00014418633,0.00063432707,0.0001778899,0.00032723785,0.00016111396],"domain_scores_gemma":[0.99737906,0.0006603743,0.0010771415,0.00011879349,0.0007031826,0.00006145191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014815881,0.000104335435,0.00046779175,0.00015292298,0.000097472985,0.000030263298,0.00008343783,0.000115288145,0.000026559675],"category_scores_gemma":[0.00031072547,0.00007720158,0.00010662302,0.00014441878,0.000017372378,0.0002878263,0.00003825784,0.00023731161,1.0551497e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000714397,0.00045025154,0.88754797,0.00006096168,0.0015810408,0.00005892074,0.0015293566,0.0006598425,0.00015069147,0.000003827322,0.00037338858,0.10686937],"study_design_scores_gemma":[0.004022178,0.0014038874,0.9826246,0.00040459022,0.001822297,0.0001186236,0.0013737504,0.0047678477,0.00094323675,0.00001598172,0.0024301102,0.0000729181],"about_ca_topic_score_codex":0.0008158507,"about_ca_topic_score_gemma":0.003572661,"teacher_disagreement_score":0.10679645,"about_ca_system_score_codex":0.0010783727,"about_ca_system_score_gemma":0.00030828465,"threshold_uncertainty_score":0.3148189},"labels":[],"label_agreement":null},{"id":"W3199678110","doi":"10.1016/j.jtho.2021.06.026","title":"Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tyrosine-kinase inhibitor; Breather; Internal medicine; Oncology; Cancer","score_opus":0.026132655338786708,"score_gpt":0.4138631502951667,"score_spread":0.38773049495637996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199678110","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08153141,0.0074032485,0.00026471214,0.90130997,0.0022649618,0.0018117442,0.00013096801,0.000053384047,0.005229588],"genre_scores_gemma":[0.041818447,0.002253099,0.025340434,0.77395034,0.0199708,0.0003163247,0.00040095672,0.0005030004,0.13544658],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690527,0.00033863838,0.0010758712,0.00047548537,0.00057162903,0.0006331159],"domain_scores_gemma":[0.99757653,0.00025441006,0.0007375398,0.00043176525,0.00071316416,0.00028660242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049279135,0.00047939701,0.0017953119,0.0007964709,0.00008356256,0.00006214518,0.0002724571,0.0008355048,0.0009314138],"category_scores_gemma":[0.00025083133,0.00033729165,0.00038419335,0.00072623964,0.000040206538,0.0001865963,0.00007429927,0.0019382028,0.00009993598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008291343,0.0010265474,0.00017117092,0.00022077924,0.0009225387,0.049401935,0.0007707536,0.00013954187,0.008274257,6.137309e-7,0.5148249,0.4159556],"study_design_scores_gemma":[0.0062796604,0.009325358,0.00047744284,0.0031156612,0.00079126185,0.0063382853,0.00043170806,0.000020456433,0.0018305028,0.000030380726,0.9709616,0.00039773743],"about_ca_topic_score_codex":0.000058144553,"about_ca_topic_score_gemma":0.000056443238,"teacher_disagreement_score":0.45613664,"about_ca_system_score_codex":0.0021569955,"about_ca_system_score_gemma":0.0034610962,"threshold_uncertainty_score":0.9999819},"labels":[],"label_agreement":null},{"id":"W3204380660","doi":"10.1016/j.jtho.2021.09.014","title":"IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Merck Sharp and Dohme; Genentech; Eisai; Daiichi-Sankyo; Mirati Therapeutics; Clovis Oncology; Johnson and Johnson; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Boehringer Ingelheim Japan; Taiho Pharmaceutical; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Bayer; Gilead Sciences; Roche; Celgene; Novartis; Exelixis; Sanofi; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Incyte; Pfizer; Canadian Asian Studies Association; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Bevacizumab; Carboplatin; Hazard ratio; Internal medicine; Oncology; Paclitaxel; Chemotherapy; Confidence interval; Gastroenterology; Cancer; Nivolumab; Cisplatin; Immunotherapy","score_opus":0.09509215825979998,"score_gpt":0.44258168266416087,"score_spread":0.34748952440436087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204380660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98185396,0.0031038108,0.0009708856,0.013278088,0.00009049776,0.00059223606,0.00004691966,0.000005251424,0.00005837153],"genre_scores_gemma":[0.97730905,0.0006378474,0.018852,0.0028572648,0.00010046348,0.00007858177,0.000033748078,0.00002402071,0.000107023945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794847,0.00061213644,0.0006492907,0.00022715068,0.00028629616,0.00027663846],"domain_scores_gemma":[0.99761796,0.0013876626,0.00041531274,0.00020223389,0.00025930753,0.000117531024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008329223,0.00020446726,0.00076274684,0.00029863397,0.00007729949,0.000032375487,0.000097016324,0.00009332303,0.00018070848],"category_scores_gemma":[0.00038882974,0.00010244152,0.00014465701,0.00049870054,0.000120346434,0.00016338585,0.000026011821,0.00030948123,0.0000012422892],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12673822,0.007811562,0.0044016945,0.00055036164,0.0024403285,0.05856907,0.03010977,0.00065659994,0.0011327205,0.00028000074,0.0071693202,0.76014036],"study_design_scores_gemma":[0.13504916,0.15950777,0.1397566,0.0030557325,0.009295251,0.10752152,0.20440568,0.0028749758,0.015429729,0.002033023,0.21928704,0.0017835143],"about_ca_topic_score_codex":0.000042452637,"about_ca_topic_score_gemma":0.0024815218,"teacher_disagreement_score":0.75835687,"about_ca_system_score_codex":0.0004176819,"about_ca_system_score_gemma":0.0014940992,"threshold_uncertainty_score":0.41774437},"labels":[],"label_agreement":null},{"id":"W3205799257","doi":"10.1016/j.jtho.2021.08.087","title":"OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre; Vancouver Biotech (Canada); University of Calgary","funders":"","keywords":"Medicine; Liquid biopsy; Lung cancer; Biopsy; Oncology; Profiling (computer programming); Lung; Internal medicine; Pathology; Cancer","score_opus":0.010708444484101461,"score_gpt":0.34580770345637224,"score_spread":0.3350992589722708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205799257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886891,0.0075984444,0.0014089183,0.00065497245,0.0010410438,0.00025404282,0.00006200461,9.099632e-7,0.00029051746],"genre_scores_gemma":[0.983738,0.0031206058,0.011927942,0.00032207766,0.0006821014,0.000034490797,0.000015054807,0.000026074613,0.00013367277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886775,0.00007758651,0.000581111,0.00019743896,0.000047897945,0.00022824126],"domain_scores_gemma":[0.998793,0.0001385795,0.0005926102,0.00021982202,0.0001935866,0.00006239495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004928027,0.00012609723,0.00035761722,0.00006296238,0.00003989846,0.000010959912,0.00026779005,0.0001688188,0.000014689802],"category_scores_gemma":[0.00009469992,0.00010632237,0.00019548996,0.000056654397,0.000052655512,0.0000045522775,0.0001146275,0.0001672163,7.2961814e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014566998,0.00010360986,0.0031433788,0.000117969335,0.00009484331,0.000024287203,0.00014631277,0.028608054,0.9601972,0.000060682356,0.0004391002,0.0056078457],"study_design_scores_gemma":[0.001280353,0.001323194,0.0018786256,0.00006319321,0.00015453539,0.0001276143,0.0004585537,0.001402191,0.9742895,0.00011739488,0.018729135,0.00017575694],"about_ca_topic_score_codex":0.00003071292,"about_ca_topic_score_gemma":0.00023534593,"teacher_disagreement_score":0.027205862,"about_ca_system_score_codex":0.00028016302,"about_ca_system_score_gemma":0.0021629832,"threshold_uncertainty_score":0.43357003},"labels":[],"label_agreement":null},{"id":"W3205839529","doi":"10.1016/j.jtho.2021.08.633","title":"P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; C-Met; Oncology; Internal medicine; Cancer research; Receptor; Hepatocyte growth factor","score_opus":0.0346632945479579,"score_gpt":0.4235644386129399,"score_spread":0.388901144064982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205839529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776465,0.0013385756,0.000017321829,0.0001252809,0.00012298103,0.0003274367,0.000034612694,0.0000029713965,0.00026616527],"genre_scores_gemma":[0.99251944,0.00058471103,0.0064686956,0.00003100703,0.00011840525,0.000007161574,0.0000051395127,0.000011850456,0.00025361354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977048,0.0007947305,0.00090535125,0.00021491986,0.00018696793,0.00019320498],"domain_scores_gemma":[0.9975503,0.0004725308,0.0012657394,0.00028313903,0.0003170166,0.00011128033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005956568,0.00018491092,0.0011625628,0.00031334363,0.00002249213,0.0000014945526,0.00011368029,0.00032982556,0.00018583528],"category_scores_gemma":[0.00046122883,0.00011776162,0.00025109717,0.00016589223,0.00020863433,0.00010043977,0.00008186489,0.00034166736,0.0000010267252],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01085198,0.0016843743,0.055340853,0.00063430436,0.0001352089,0.00024705043,0.00087322184,0.000066482324,0.90460837,0.000013506089,0.000059094087,0.025485583],"study_design_scores_gemma":[0.00273526,0.037195314,0.26340058,0.0029104496,0.00023682108,0.00058544916,0.00023160852,0.000015452466,0.6922039,0.00031746036,0.00008430065,0.00008343355],"about_ca_topic_score_codex":0.000019004614,"about_ca_topic_score_gemma":0.0000041685216,"teacher_disagreement_score":0.21240447,"about_ca_system_score_codex":0.00017831214,"about_ca_system_score_gemma":0.0007723908,"threshold_uncertainty_score":0.48021796},"labels":[],"label_agreement":null},{"id":"W3206007763","doi":"10.1016/j.jtho.2021.08.147","title":"MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Takeda (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Cohort; Oncology; Internal medicine","score_opus":0.020441402663337018,"score_gpt":0.4472418970218791,"score_spread":0.4268004943585421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206007763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97128433,0.00013984181,0.000029999128,0.0018298327,0.00042495748,0.0002322949,0.000035426176,0.0000043159935,0.026018996],"genre_scores_gemma":[0.9911176,0.00017704398,0.0021393988,0.0003777103,0.00006654496,0.000006921745,0.000019664965,0.000013902778,0.006081211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863684,0.00015081256,0.0006383494,0.0001275821,0.0002747213,0.00017171405],"domain_scores_gemma":[0.9984723,0.00017129231,0.00052765344,0.00014669623,0.0005628636,0.00011921694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025050354,0.0001094927,0.0006793263,0.00027303075,0.000025304944,0.000006615779,0.00006502215,0.00008362806,0.00015025814],"category_scores_gemma":[0.00012302061,0.00008276772,0.0001593065,0.0002895704,0.000053971915,0.00010821528,0.000031521016,0.00025454516,0.000005891146],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007323964,0.0012781044,0.96891683,0.00003638207,0.0006441234,0.0011294081,0.0009964474,0.000009587823,0.00021132304,0.00010841336,0.0003631082,0.025573865],"study_design_scores_gemma":[0.0021726338,0.0016391706,0.99055886,0.00016955457,0.0006493591,0.00005683693,0.00032268887,0.0000033941262,0.0012993976,0.00008000159,0.002986468,0.000061628],"about_ca_topic_score_codex":0.00044321542,"about_ca_topic_score_gemma":0.0007874867,"teacher_disagreement_score":0.025512237,"about_ca_system_score_codex":0.0006523275,"about_ca_system_score_gemma":0.0009002079,"threshold_uncertainty_score":0.337517},"labels":[],"label_agreement":null},{"id":"W3206685609","doi":"10.1016/j.jtho.2021.08.172","title":"MA12.05 The Impact of the COVID-19 Pandemic on Post-Operative Outcomes of Thoracic Cancer Surgery in Canada","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Elective surgery; Cancer; Transmission (telecommunications); General surgery; Cardiothoracic surgery; Disease; Surgery; Health care; Cancer surgery; Intensive care medicine; Medical emergency; Internal medicine; Infectious disease (medical specialty); Virology","score_opus":0.12237694266773734,"score_gpt":0.5423705966526856,"score_spread":0.41999365398494826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206685609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90781474,0.0012427076,0.0000067112824,0.08970541,0.00077604724,0.0002560692,0.00008128384,0.0000028869038,0.00011414239],"genre_scores_gemma":[0.9807807,0.0007369437,0.000024409057,0.01809445,0.00016124833,0.0000054717902,0.0000026496618,0.000016831607,0.00017726507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659806,0.0011870586,0.0011196119,0.00016312694,0.00056292367,0.00036921544],"domain_scores_gemma":[0.99303675,0.0043051396,0.0011743229,0.00038691532,0.000743439,0.0003534371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018570804,0.00020123665,0.0012869715,0.00023500063,0.0000820942,0.0000065389404,0.00024396575,0.00016525542,0.0003546126],"category_scores_gemma":[0.005106416,0.00009677237,0.00045458283,0.0005636238,0.00014566806,0.00007195805,0.00007130074,0.00096658175,8.316802e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025829547,0.00023047504,0.95191646,0.00025589857,0.00032100015,0.0006658661,0.0015656295,0.0010487883,0.0019013997,0.000007646489,0.006252619,0.03325124],"study_design_scores_gemma":[0.0005113173,0.00076307723,0.99046195,0.00037204757,0.00019321681,0.0012617025,0.0019545727,0.0000304082,0.0014913373,0.00008726474,0.0027766896,0.00009639643],"about_ca_topic_score_codex":0.54968673,"about_ca_topic_score_gemma":0.84075224,"teacher_disagreement_score":0.2910655,"about_ca_system_score_codex":0.0060100956,"about_ca_system_score_gemma":0.07947121,"threshold_uncertainty_score":0.99780566},"labels":[],"label_agreement":null},{"id":"W3206799412","doi":"10.1016/j.jtho.2021.08.171","title":"MA12.03 A Thoracic Cancers International COVID 19 Collaboration Survey on Patients’ Perceptions of COVID-19 (Teravolt-Paper)","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); Medicine; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Perception; Betacoronavirus; Pandemic; Virology; Family medicine; Internal medicine; Outbreak","score_opus":0.08161373879181388,"score_gpt":0.5165224706509008,"score_spread":0.43490873185908696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206799412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91263735,0.00034457294,0.0011940048,0.08113763,0.0026407307,0.0004290418,0.0004523437,0.000025317315,0.0011390131],"genre_scores_gemma":[0.96552134,0.0008280384,0.0012572974,0.0307418,0.0006194358,0.00000939664,0.0002976431,0.00002843893,0.00069658505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99615747,0.001184334,0.0011924959,0.00030893445,0.00082313427,0.00033363389],"domain_scores_gemma":[0.9935601,0.0012988165,0.0011541484,0.00033520377,0.0025236532,0.0011280868],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019830381,0.0002239828,0.000835584,0.00060764526,0.00017408251,0.000036394533,0.00023465797,0.0003193119,0.0021457328],"category_scores_gemma":[0.011073193,0.00019873865,0.00022780028,0.0007341465,0.00015844194,0.00024730948,0.00006967579,0.0006866604,0.000032390475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028239839,0.0035478484,0.71591115,0.0014905031,0.00088114105,0.0017493264,0.011579196,0.002955408,0.008941608,0.0002170292,0.14881359,0.075673364],"study_design_scores_gemma":[0.0033261555,0.0054326556,0.7456538,0.00028794215,0.00032481964,0.0006592413,0.0031520987,0.00011907898,0.000479839,0.00029997056,0.24000797,0.00025641796],"about_ca_topic_score_codex":0.0011229513,"about_ca_topic_score_gemma":0.007555371,"teacher_disagreement_score":0.09119437,"about_ca_system_score_codex":0.006469495,"about_ca_system_score_gemma":0.023019837,"threshold_uncertainty_score":0.9987664},"labels":[],"label_agreement":null},{"id":"W3206825674","doi":"10.1016/j.jtho.2021.08.415","title":"P32.02 2020 in Hindsight: Newly Diagnosed Lung Cancer Patients in the Time of COVID-19 at a Tertiary Canadian Cancer Centre","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Context (archaeology); Coronavirus disease 2019 (COVID-19); Pandemic; Tertiary care; Cancer; Lung cancer; Hindsight bias; Family medicine; Medical diagnosis; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Health care; 2019-20 coronavirus outbreak; Internal medicine; Pathology; Outbreak; Disease","score_opus":0.028265880731474822,"score_gpt":0.4443664171626838,"score_spread":0.416100536431209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206825674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81684977,0.0035873675,0.0000017250984,0.17849581,0.00046566754,0.0003358968,0.00006204891,0.0000028029426,0.0001989304],"genre_scores_gemma":[0.9564755,0.0016239075,0.00006574809,0.04104818,0.00033534176,0.00001283607,0.000016761816,0.000017827344,0.00040388727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974559,0.0006421087,0.00082997757,0.00019560497,0.00039106002,0.00048535693],"domain_scores_gemma":[0.9974653,0.00071567413,0.00053129304,0.00020419536,0.00032521854,0.0007583293],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008010095,0.00016108503,0.0007026914,0.00039526485,0.000065638866,0.000009363788,0.00020916072,0.00024577757,0.0015639104],"category_scores_gemma":[0.001414189,0.000115382565,0.00013482635,0.0005772397,0.00006312376,0.00009723664,0.000050950588,0.0006774689,0.0000062984086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009347215,0.00041727308,0.9119222,0.000399779,0.000075788455,0.0060958844,0.01047161,0.00015941368,0.00029931724,0.000001917093,0.046450052,0.022772051],"study_design_scores_gemma":[0.0030838584,0.00045078297,0.92237204,0.0006287606,0.0001885247,0.00023104798,0.0007092846,0.00020486409,0.0002345079,0.000034026813,0.071738705,0.00012356992],"about_ca_topic_score_codex":0.20130078,"about_ca_topic_score_gemma":0.8478815,"teacher_disagreement_score":0.6465807,"about_ca_system_score_codex":0.0066846735,"about_ca_system_score_gemma":0.018179234,"threshold_uncertainty_score":0.9993488},"labels":[],"label_agreement":null},{"id":"W3206935252","doi":"10.1016/j.jtho.2021.08.070","title":"OA11.03 Oncologic Outcomes of Patients with Resected T3N0M0 Non-small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Proportional hazards model; Hazard ratio; Adenocarcinoma; Oncology; Chemotherapy; Disease; Cancer; Confidence interval","score_opus":0.01890075592644292,"score_gpt":0.3901531567425751,"score_spread":0.3712524008161322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206935252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038786,0.0018849954,0.000029502786,0.0035216985,0.00072701875,0.0003247052,0.000022024933,0.000007535055,0.0030946773],"genre_scores_gemma":[0.9932939,0.00071341376,0.0041100094,0.0007533952,0.0001791247,0.000025222229,0.000012318872,0.000023995191,0.00088862516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834174,0.00016106303,0.00065177074,0.0002051447,0.0003721907,0.00026806927],"domain_scores_gemma":[0.9972009,0.00029621788,0.0008922819,0.00024814226,0.0011658852,0.0001965861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002570267,0.00018580402,0.001031028,0.00015475292,0.000043919747,0.000008581006,0.00012530774,0.00017725873,0.00045388806],"category_scores_gemma":[0.00009930478,0.00011359077,0.00021669918,0.00027788215,0.00006889394,0.00006736124,0.000058533944,0.00036568538,0.0000052131068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018158435,0.0032108151,0.97584003,0.00031348364,0.0008978111,0.001027817,0.00032749306,0.000055772733,0.0004176709,0.0000038269827,0.0049033547,0.011186062],"study_design_scores_gemma":[0.0051624672,0.005226826,0.97215366,0.00040408605,0.0019070044,0.00007802328,0.0002069682,0.000015380552,0.009515223,0.000017849634,0.005193538,0.00011894346],"about_ca_topic_score_codex":0.00005663524,"about_ca_topic_score_gemma":0.00031001275,"teacher_disagreement_score":0.011067119,"about_ca_system_score_codex":0.00126979,"about_ca_system_score_gemma":0.0019146316,"threshold_uncertainty_score":0.4969756},"labels":[],"label_agreement":null},{"id":"W3207260072","doi":"10.1016/j.jtho.2021.08.039","title":"OA02.03 Medical Assistance in Dying (MAiD) in Patients With Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Cancer; Legislation; Palliative care; Radiation therapy; Oncology; Intensive care medicine; Internal medicine; Family medicine; Nursing; Law","score_opus":0.06884583361362252,"score_gpt":0.5067701053469411,"score_spread":0.4379242717333186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207260072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889716,0.005861345,0.0001092956,0.003083771,0.000386824,0.00007412671,0.0000024522344,0.0000027569379,0.0015078445],"genre_scores_gemma":[0.9944967,0.0010094553,0.0034391761,0.00073020894,0.00017847381,0.000003977486,0.0000032676353,0.000011764128,0.00012696684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839103,0.00019980657,0.00059072906,0.00012589178,0.00048994186,0.00020262093],"domain_scores_gemma":[0.99870753,0.00026310672,0.0003792829,0.00010181461,0.00040887343,0.00013938683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056489074,0.00009729073,0.00065970776,0.00019426433,0.00001277579,0.000004032647,0.000096777665,0.00016102295,0.00028798735],"category_scores_gemma":[0.00070755143,0.00007150034,0.00006104141,0.00037210566,0.0000706546,0.00009216242,0.000031671276,0.00057019724,0.0000013835466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016528062,0.0004572581,0.961797,0.00014489853,0.000089963076,0.002053946,0.00092669117,0.000030875442,0.00014610315,0.000009873335,0.00056679494,0.03212382],"study_design_scores_gemma":[0.0045895125,0.0009798084,0.96930104,0.0064850408,0.00016004709,0.000109795015,0.0009189752,0.00015209932,0.0014379196,0.000040602736,0.015699118,0.00012603309],"about_ca_topic_score_codex":0.000043938628,"about_ca_topic_score_gemma":0.0008870073,"teacher_disagreement_score":0.031997785,"about_ca_system_score_codex":0.0005587914,"about_ca_system_score_gemma":0.0013407193,"threshold_uncertainty_score":0.31532595},"labels":[],"label_agreement":null},{"id":"W3207592456","doi":"10.1016/j.jtho.2021.09.008","title":"Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; Compute Canada; Princess Margaret Cancer Foundation; Canadian Cancer Society; AstraZeneca","keywords":"Cancer research; Osimertinib; Gefitinib; Trametinib; Medicine; Gene knockdown; Crizotinib; Dabrafenib; Tyrosine kinase; Vemurafenib; Small interfering RNA; Kinase; Erlotinib; Lung cancer; Epidermal growth factor receptor; Mutation; Targeted therapy; Cancer; Biology; Cell culture; Oncology; MAPK/ERK pathway; Internal medicine; Gene; Melanoma; Transfection; Receptor","score_opus":0.010646522987556873,"score_gpt":0.4262906330278933,"score_spread":0.4156441100403364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207592456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9022856,0.041836716,0.0010357936,0.04655181,0.0023645484,0.0003475876,0.00017127671,0.000026090042,0.005380632],"genre_scores_gemma":[0.96987855,0.0016111173,0.004195781,0.004824934,0.00077739457,0.000029466064,0.00013106572,0.000040712148,0.018510988],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878925,0.00009742896,0.00046081343,0.00016813599,0.00026576448,0.0002186265],"domain_scores_gemma":[0.9986843,0.00006834815,0.0004339441,0.00012177791,0.0004829014,0.00020872822],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015321672,0.000129611,0.0004269661,0.00009440614,0.00009115976,0.000021704342,0.00006204275,0.0001416419,0.0010346401],"category_scores_gemma":[0.00006745689,0.000105693725,0.00014956162,0.00023530418,0.000045411944,0.00020000599,0.000022058872,0.00028212214,0.000010962243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004202682,0.0010819472,0.016350776,0.00014541009,0.001180794,0.0015074502,0.0015947148,0.00010588449,0.0652212,0.000012541316,0.804671,0.10770805],"study_design_scores_gemma":[0.003371245,0.0013163515,0.0025623601,0.0003338922,0.0029345858,0.0013230966,0.0010395856,0.00043642512,0.16262175,0.000116741176,0.8237191,0.00022489295],"about_ca_topic_score_codex":0.00009740039,"about_ca_topic_score_gemma":0.000030406154,"teacher_disagreement_score":0.107483156,"about_ca_system_score_codex":0.0009914334,"about_ca_system_score_gemma":0.0013476757,"threshold_uncertainty_score":0.9998785},"labels":[],"label_agreement":null},{"id":"W3207736600","doi":"10.1016/j.jtho.2021.08.708","title":"P69.03 Chemotherapy Upregulates PD-L1 Expression and Activates cGAS-STING Pathway in Non-Small Cell Lung Cancer Models","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Chemotherapy; Cancer research; Lung cancer; Cisplatin; Sting; Immunotherapy; Pembrolizumab; Cell; Cell culture; Cancer; Oncology; Internal medicine; Biology","score_opus":0.016573425018827772,"score_gpt":0.3344446957343933,"score_spread":0.31787127071556553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207736600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97452134,0.021955097,0.00032290016,0.0010918257,0.00089037704,0.00012195614,0.0000064699025,0.000011010257,0.0010789979],"genre_scores_gemma":[0.99371207,0.001876097,0.0010577872,0.0003411856,0.00008538445,0.000009386004,0.0000047082935,0.00002596549,0.0028874383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980659,0.0006328398,0.0006305167,0.00024030478,0.000044307937,0.00038615998],"domain_scores_gemma":[0.99859387,0.00045444316,0.0005246502,0.00017060053,0.00021426499,0.000042185635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058242516,0.00021643355,0.0006505428,0.00021494225,0.00011066059,0.000023752686,0.00021437577,0.00044092335,0.0004203096],"category_scores_gemma":[0.00008541426,0.00017407894,0.00013269378,0.00013314921,0.00011497771,0.00022075321,0.00012993425,0.0007407353,0.000007788885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025994144,0.00027754245,0.0013683087,0.00007555498,0.00010532518,0.0001233822,0.002208895,0.00019090417,0.96000826,0.0000116212705,0.0007331719,0.032297637],"study_design_scores_gemma":[0.0015869943,0.00046066966,0.0030338138,0.0005128,0.000040404582,0.0006979366,0.0014299697,0.00021581259,0.98420733,0.00018266044,0.007446436,0.00018518518],"about_ca_topic_score_codex":0.00004373992,"about_ca_topic_score_gemma":0.00003542364,"teacher_disagreement_score":0.032112453,"about_ca_system_score_codex":0.00018927282,"about_ca_system_score_gemma":0.00044923622,"threshold_uncertainty_score":0.7098733},"labels":[],"label_agreement":null},{"id":"W3207786785","doi":"10.1016/j.jtho.2021.09.010","title":"First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Cilag; Janssen Pharmaceuticals; Sandoz; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Ipsen; Teijin Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; Clovis Oncology; AstraZeneca; Novocure; Merck KGaA; Taiho Pharmaceutical; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Johnson and Johnson; Teva Pharmaceutical Industries; Servier; Bayer; Gilead Sciences; Sanofi; University of Pennsylvania; Celgene; Novartis; GlaxoSmithKline; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Oncology; Chemotherapy; Hazard ratio; Adverse effect; Confidence interval; Cancer; Immunotherapy","score_opus":0.06623119738577873,"score_gpt":0.44944619521606427,"score_spread":0.38321499783028556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207786785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517897,0.0064511728,0.00018609654,0.034395017,0.0040231682,0.0014285804,0.000039013008,0.000014548357,0.001672737],"genre_scores_gemma":[0.97419584,0.007934226,0.0051948153,0.006582939,0.001990994,0.00012537764,0.00005297332,0.00006904254,0.0038537742],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964158,0.00094121514,0.0016164137,0.00028119105,0.00039785245,0.00034751775],"domain_scores_gemma":[0.9962736,0.0017762787,0.0010663721,0.000446923,0.00029478056,0.0001420695],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031131872,0.0002498945,0.0020532433,0.00011993783,0.00011827186,0.000065350505,0.0004743521,0.0002360919,0.0013115532],"category_scores_gemma":[0.0013901572,0.00015249902,0.00041776986,0.00035587084,0.00022492063,0.00023315812,0.000153503,0.00072366156,0.000018857476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8788446,0.0019307729,0.000111881716,0.00002141471,0.0008093906,0.0008252375,0.0004894265,0.000016436881,0.0014778132,0.000011326828,0.003279408,0.112182274],"study_design_scores_gemma":[0.8965654,0.0034021342,0.00031859716,0.00040611494,0.0005983154,0.0002815522,0.00072346296,0.00014584014,0.0013104628,0.00032122975,0.0957609,0.00016602509],"about_ca_topic_score_codex":0.00012867774,"about_ca_topic_score_gemma":0.00056295464,"teacher_disagreement_score":0.112016246,"about_ca_system_score_codex":0.0006582469,"about_ca_system_score_gemma":0.001614178,"threshold_uncertainty_score":0.99960136},"labels":[],"label_agreement":null},{"id":"W3207929762","doi":"10.1016/j.jtho.2021.08.067","title":"OA10.04 COVID-19 Vaccine Acceptance and Communications Effectiveness Amongst Canadian Lung Cancer Patients.","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Lung cancer; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Virology; Oncology; Internal medicine","score_opus":0.029538535752620398,"score_gpt":0.4408069453238591,"score_spread":0.4112684095712387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207929762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9382386,0.009294114,0.00016996886,0.04489763,0.00090935477,0.0002322746,0.00002489231,0.0000116242745,0.006221543],"genre_scores_gemma":[0.99318784,0.0038241085,0.00042284126,0.002012467,0.00027909921,0.000011587116,0.000004885337,0.000009562012,0.00024761146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795896,0.001082177,0.00034211337,0.00013967315,0.00018706506,0.00029003492],"domain_scores_gemma":[0.99747276,0.0006841566,0.00035392836,0.00022547325,0.0006646048,0.00059908733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011146812,0.00009688687,0.00035412397,0.00014853844,0.0006982116,0.000060053426,0.00041996964,0.00015531098,0.00064416655],"category_scores_gemma":[0.001228182,0.00009311815,0.00007951169,0.000375545,0.000046597295,0.00033105764,0.00007087045,0.0003501441,0.0000032879784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012869593,0.00017204329,0.94629323,0.00007057081,0.000106848456,0.00017453163,0.004999133,0.000020952688,0.00007087262,0.0012767345,0.01023376,0.03645261],"study_design_scores_gemma":[0.00078822987,0.00015471484,0.6784379,0.00009521207,0.0001818699,0.000037973943,0.0021752198,0.000021357284,0.000080290505,0.0009291607,0.31692857,0.0001695289],"about_ca_topic_score_codex":0.027050948,"about_ca_topic_score_gemma":0.6468273,"teacher_disagreement_score":0.61977637,"about_ca_system_score_codex":0.0016895726,"about_ca_system_score_gemma":0.005227417,"threshold_uncertainty_score":0.979428},"labels":[],"label_agreement":null},{"id":"W3208834979","doi":"10.1016/j.jtho.2021.08.015","title":"EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gefitinib; Erlotinib; Medicine; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Oncology; Protein kinase domain; Mutant; EGFR inhibitors; Internal medicine; Exon; Adenocarcinoma; Mutation; Epidermal growth factor receptor; Gene; Cancer; Receptor; Genetics; Biology","score_opus":0.023003212742827166,"score_gpt":0.44351515276307085,"score_spread":0.42051194002024367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208834979","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038061842,0.033043973,0.0004941595,0.06422516,0.85886014,0.0026965654,0.0008178818,0.000053617743,0.0017466675],"genre_scores_gemma":[0.023226772,0.03748612,0.006458298,0.0011596498,0.9213169,0.00031311993,0.0006012865,0.00027278377,0.009165074],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962389,0.00038776742,0.001445997,0.00046029923,0.0009736218,0.0004934259],"domain_scores_gemma":[0.99567264,0.0012010838,0.0013272666,0.0005674687,0.0009585983,0.0002729628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008740107,0.000556324,0.0019611982,0.00040469613,0.00017005188,0.000055501587,0.00025746677,0.0009094626,0.0002265682],"category_scores_gemma":[0.0007002576,0.00029931896,0.0005597077,0.00045722837,0.00014697241,0.00013548326,0.000053703356,0.0014535674,0.0000070569763],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022368213,0.0030675705,0.00021999473,0.00026481884,0.0020522014,0.009735954,0.0022240113,0.0004424532,0.001153869,0.00001548951,0.55433995,0.40411547],"study_design_scores_gemma":[0.009863692,0.01224958,0.00009631913,0.0014740863,0.0018767962,0.00029435378,0.00060639204,0.000015514295,0.0018160638,0.00013148293,0.97132015,0.0002555619],"about_ca_topic_score_codex":0.00012577741,"about_ca_topic_score_gemma":0.0015021438,"teacher_disagreement_score":0.41698018,"about_ca_system_score_codex":0.008046073,"about_ca_system_score_gemma":0.006578162,"threshold_uncertainty_score":0.9999459},"labels":[],"label_agreement":null},{"id":"W3211033342","doi":"10.1016/j.jtho.2021.06.004","title":"EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"University of Ottawa","keywords":"Medicine; Oncology; Mutant; Internal medicine; Targeted therapy; EGFR inhibitors; Epidermal growth factor receptor; Cancer; Gene; Genetics","score_opus":0.02953205224597856,"score_gpt":0.4639302841023304,"score_spread":0.43439823185635185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211033342","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021153966,0.02253694,0.0005277183,0.09286638,0.8580896,0.002274277,0.00025245326,0.00003993488,0.0022587138],"genre_scores_gemma":[0.038549155,0.07403334,0.0038797583,0.0013196899,0.8603357,0.000222118,0.0009885615,0.00023943266,0.020432249],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970392,0.00028846468,0.0011039062,0.00032772624,0.00088604464,0.00035463713],"domain_scores_gemma":[0.99620605,0.0011409343,0.0011875211,0.00039683346,0.0008402619,0.00022842138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063928566,0.00041077088,0.0015015107,0.00034875795,0.00013608737,0.000049413225,0.0002384471,0.0007166327,0.00028769916],"category_scores_gemma":[0.00044873683,0.0002182764,0.00043532037,0.00036729508,0.00007969271,0.00014192612,0.000038643757,0.0011586868,0.000006695046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076352833,0.0019003729,0.00020685134,0.00007787184,0.0014885089,0.0017721221,0.001862394,0.00020784381,0.00010862492,0.000024624585,0.42075467,0.5639608],"study_design_scores_gemma":[0.011509823,0.01314879,0.00035383398,0.00062148535,0.0012343839,0.00019095554,0.0004076722,0.00001179672,0.0003955597,0.00044974865,0.9714935,0.00018249438],"about_ca_topic_score_codex":0.00019014541,"about_ca_topic_score_gemma":0.0012506291,"teacher_disagreement_score":0.56377834,"about_ca_system_score_codex":0.00646783,"about_ca_system_score_gemma":0.008227518,"threshold_uncertainty_score":0.9973949},"labels":[],"label_agreement":null},{"id":"W3211577173","doi":"10.1016/j.jtho.2021.10.023","title":"CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; Centre Hospitalier de l’Université de Montréal; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; Health Sciences Centre; Windsor Regional Hospital; Institut Universitaire de Cardiologie et de Pneumologie de Québec; Alberta Cancer Foundation; Sunnybrook Health Science Centre; Kingston General Hospital; Princess Margaret Cancer Centre","funders":"National Health and Medical Research Council; Canadian Cancer Society Research Institute; Takeda Canada; Merck Sharp and Dohme; Cancer Australia; Astellas Pharma Canada; AbbVie; Roche; Novartis; Sanofi; Merck; Boehringer Ingelheim; Amgen; Pfizer; Celgene; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Chemotherapy; Internal medicine; Randomized controlled trial; Platinum; Immunotherapy; Cancer; Nivolumab","score_opus":0.020163327168845627,"score_gpt":0.4295004179541777,"score_spread":0.4093370907853321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211577173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596083,0.0002469926,0.00095325924,0.0012597322,0.00010712869,0.001124191,0.000016608961,0.0000049446403,0.0003263044],"genre_scores_gemma":[0.9817136,0.000050277322,0.01766392,0.00027557192,0.000056799207,0.00003204162,0.000016915874,0.000023300598,0.00016760168],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981831,0.00036291505,0.0007144411,0.00015899984,0.00042103123,0.0001595148],"domain_scores_gemma":[0.9978828,0.00042049543,0.0008303018,0.0001455897,0.00060071814,0.00012012929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006499101,0.0001649838,0.0014791056,0.00022323952,0.000030274956,0.000010783177,0.00004529479,0.00006203692,0.00015295569],"category_scores_gemma":[0.0002547618,0.000086723274,0.00011087457,0.00027307754,0.00015699849,0.000094552655,0.0000069514144,0.00019497942,3.0341266e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9346077,0.0049844338,0.0031601188,0.000101484206,0.0011520612,0.00041240864,0.0009260682,0.000028322364,0.000098347,0.0000041434705,0.000037388603,0.054487515],"study_design_scores_gemma":[0.9690902,0.023665916,0.0018889894,0.00047968165,0.0026446502,0.00024235164,0.0004005231,0.00023632437,0.0008467377,0.000028828497,0.00037759962,0.00009817378],"about_ca_topic_score_codex":0.000020329337,"about_ca_topic_score_gemma":0.000088590605,"teacher_disagreement_score":0.054389343,"about_ca_system_score_codex":0.00026713684,"about_ca_system_score_gemma":0.0027011966,"threshold_uncertainty_score":0.47918066},"labels":[],"label_agreement":null},{"id":"W3213588480","doi":"10.1016/j.jtho.2021.10.021","title":"The 2021 WHO Classification of Tumors of the Heart","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Section (typography); Cardiac Tumors; Table (database); Pathology; Radiology; Data mining; Computer science","score_opus":0.060047007957380286,"score_gpt":0.46822880941111406,"score_spread":0.4081818014537338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213588480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00086112495,0.9920045,0.000007355709,0.0023956778,0.0017381972,0.00034632487,0.0000129296195,0.0000013228203,0.002632563],"genre_scores_gemma":[0.0016754589,0.9961688,0.0001493464,0.000057887413,0.0007604005,0.000006570015,0.0000044887493,0.000025374087,0.0011516666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966428,0.0009965718,0.0015975327,0.00013858006,0.00045140018,0.00017307258],"domain_scores_gemma":[0.99493665,0.00073563174,0.0030239068,0.0005750327,0.00063964777,0.00008915865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001952847,0.00018749048,0.0031052576,0.00013074455,0.00006843005,0.000009685351,0.00031381144,0.00027438303,0.00008737353],"category_scores_gemma":[0.0007377344,0.00008840398,0.0019405449,0.00046727736,0.00029032925,0.00003006945,0.00011076988,0.00096769194,0.000004534141],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006701435,0.0001686125,0.00008910114,0.0031284355,0.0004763614,0.00006698481,0.000061083,3.560914e-7,0.00005534687,0.0003046447,0.013358003,0.98222405],"study_design_scores_gemma":[0.0001369876,0.0004371058,0.0019361533,0.01391361,0.0027130214,0.004106228,0.00022694228,0.0000011534269,0.00005649635,0.000052167892,0.97635525,0.00006488816],"about_ca_topic_score_codex":0.000005807917,"about_ca_topic_score_gemma":0.0000063613156,"teacher_disagreement_score":0.9821592,"about_ca_system_score_codex":0.0002687703,"about_ca_system_score_gemma":0.0029909122,"threshold_uncertainty_score":0.530575},"labels":[],"label_agreement":null},{"id":"W3214782673","doi":"10.1016/j.jtho.2021.11.008","title":"Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Cancer Care Ontario; Brock University","funders":"American College of Radiology; International Association for the Study of Lung Cancer","keywords":"Medicine; Outbreak; Pandemic; Lung cancer; Cancer; Lung; Lung cancer screening; Intensive care medicine; Coronavirus disease 2019 (COVID-19); Respiratory system; Internal medicine; Pathology; Disease; Infectious disease (medical specialty)","score_opus":0.06039763529298804,"score_gpt":0.46348588853632205,"score_spread":0.403088253243334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214782673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130654,0.0014520047,0.0028093862,0.0027116167,0.0010830228,0.00057888165,0.000017600514,0.000011974048,0.000028957258],"genre_scores_gemma":[0.9962882,0.0010221358,0.0012015201,0.0002827224,0.00091886916,0.0001483323,0.0000036314452,0.000018636765,0.000115970106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982308,0.00027763372,0.00082499086,0.00020067015,0.00031229676,0.00015358243],"domain_scores_gemma":[0.9961244,0.00093268155,0.0014572955,0.00015687254,0.0012434552,0.00008533347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014483754,0.00012256196,0.00045708416,0.00015171363,0.0002695824,0.000039189254,0.000046987978,0.00014547218,0.000028334967],"category_scores_gemma":[0.0010360384,0.00008829948,0.000109638335,0.00014129364,0.000028625234,0.00030973266,0.000041377596,0.0003668815,2.8114012e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010753814,0.00037035282,0.96107316,0.000078943645,0.0018919702,0.00016606835,0.0011327645,0.0014384219,0.0012459261,0.0000040322207,0.00022229481,0.03130071],"study_design_scores_gemma":[0.003081596,0.0011621063,0.98341745,0.0003924585,0.0026710953,0.0007029485,0.00092612643,0.0031333307,0.0027898834,0.000015793195,0.0016103568,0.00009685848],"about_ca_topic_score_codex":0.0010281475,"about_ca_topic_score_gemma":0.0097682085,"teacher_disagreement_score":0.03120385,"about_ca_system_score_codex":0.0014254664,"about_ca_system_score_gemma":0.00053669733,"threshold_uncertainty_score":0.54508895},"labels":[],"label_agreement":null},{"id":"W3215921195","doi":"10.1016/j.jtho.2021.11.003","title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1481,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; BeiGene; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Grading (engineering); SMARCA4; Pathology; Immunohistochemistry; Lung; Adenoma; Internal medicine; Biology","score_opus":0.04722255255441719,"score_gpt":0.5551534797927689,"score_spread":0.5079309272383516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215921195","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015748233,0.99658304,0.00007067555,0.00062732416,0.00052050204,0.00036467647,0.000043613763,0.0000017805648,0.0016309189],"genre_scores_gemma":[0.00080230605,0.9972743,0.0006130818,0.000009247232,0.0004068365,0.000014671846,0.000034098477,0.00002140248,0.00082406274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763167,0.00039612936,0.0013572571,0.00014341573,0.0003038589,0.00016766106],"domain_scores_gemma":[0.99452806,0.00060164864,0.0035641296,0.00031926954,0.0008745484,0.0001123237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006505621,0.00020526545,0.0022403381,0.00019471554,0.000055979082,0.00001051565,0.00020312775,0.0002014581,0.00008707104],"category_scores_gemma":[0.0003541228,0.00010539761,0.00097122655,0.00037316792,0.00015472568,0.00011156047,0.000033196106,0.00043645734,0.000002524531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012240419,0.00027044673,0.0001271839,0.0031695778,0.0015026117,0.0000952583,0.00010850383,0.000004301909,0.000010183959,0.00006990983,0.00396398,0.99055564],"study_design_scores_gemma":[0.0003062798,0.0014875182,0.0006056532,0.017186197,0.006332136,0.0011461776,0.00022472581,0.000008572837,0.000009682637,0.00003437225,0.97257644,0.000082273946],"about_ca_topic_score_codex":0.000012288312,"about_ca_topic_score_gemma":0.00000941654,"teacher_disagreement_score":0.9904734,"about_ca_system_score_codex":0.0010799457,"about_ca_system_score_gemma":0.00599609,"threshold_uncertainty_score":0.999639},"labels":[],"label_agreement":null},{"id":"W4200228455","doi":"10.1016/j.jtho.2021.09.017","title":"Introduction to 2021 WHO Classification of Thoracic Tumors","year":2021,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Centre International de Recherche sur le Cancer; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; International agency; Etiology; Cancer; Lung cancer; Intensive care medicine; Pathology; Oncology; Internal medicine","score_opus":0.019049406021357518,"score_gpt":0.4234764425101411,"score_spread":0.4044270364887836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200228455","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022483792,0.0037021406,0.0001994263,0.035839144,0.9357061,0.0005580187,0.00007013547,0.000011030131,0.0014302637],"genre_scores_gemma":[0.009671584,0.0029016847,0.0030480286,0.0001157001,0.9803294,0.000039322294,0.00019976337,0.000060141356,0.0036343767],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964994,0.000393428,0.0013695436,0.0004392284,0.001020354,0.00027802252],"domain_scores_gemma":[0.9941882,0.0004934873,0.0020289614,0.0005410078,0.002450919,0.00029741542],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001248334,0.000308726,0.0018213423,0.0005559489,0.000050625214,0.00002603175,0.00021786964,0.000825835,0.0006090114],"category_scores_gemma":[0.0017655728,0.00024851717,0.00046193987,0.0004976393,0.00008177511,0.000108690234,0.000073790085,0.0012049737,0.00003748162],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021394384,0.00087918015,0.00024635068,0.0006106311,0.0006248845,0.0004115517,0.00021525708,0.000014910923,0.0008468053,0.000009733645,0.8647537,0.12924752],"study_design_scores_gemma":[0.00050855515,0.0045886924,0.002038079,0.0019545013,0.0021679627,0.00027872427,0.00031838808,0.000005105034,0.0043972004,0.000037415517,0.9835346,0.00017082662],"about_ca_topic_score_codex":0.000025553923,"about_ca_topic_score_gemma":0.000051039595,"teacher_disagreement_score":0.12907669,"about_ca_system_score_codex":0.0029371039,"about_ca_system_score_gemma":0.0036044316,"threshold_uncertainty_score":0.9999967},"labels":[],"label_agreement":null},{"id":"W4200319664","doi":"10.1016/j.jtho.2021.10.012","title":"Prognostic Impact of Ground-Glass Opacity/Lepidic Component in Pulmonary Adenocarcinoma: A Hazy Staging Dilemma","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Adenocarcinoma; Lung cancer; Ground-glass opacity; Stage (stratigraphy); Lung; Radiology; Internal medicine; Oncology; Cancer","score_opus":0.03912055467081827,"score_gpt":0.39695770056094926,"score_spread":0.357837145890131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200319664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.768075,0.009893063,0.000020030966,0.21950778,0.0011844096,0.00071917986,0.000062388826,0.000011905965,0.00052627304],"genre_scores_gemma":[0.9736342,0.0010090735,0.00073640293,0.020968696,0.0030935416,0.00005317733,0.00018183213,0.00008842624,0.00023468262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955354,0.0007983772,0.0017200587,0.00046968056,0.0008147629,0.0006617254],"domain_scores_gemma":[0.9955207,0.00099366,0.002034811,0.00049464946,0.00070966774,0.0002464752],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00089692825,0.00053154724,0.0027585833,0.0009226724,0.000048188493,0.000034265497,0.00031377975,0.00084069936,0.00026068083],"category_scores_gemma":[0.00028435056,0.00039487804,0.0009940643,0.0005250962,0.00018499469,0.00015594365,0.00014595898,0.0031836836,0.000008659841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017648896,0.0033336657,0.65427524,0.0024971883,0.002809074,0.13885951,0.00046386744,0.00008156372,0.00033378924,0.0000034505638,0.1781077,0.017470056],"study_design_scores_gemma":[0.0029700994,0.009061301,0.90156364,0.0071768127,0.0040576514,0.019701777,0.0001957595,0.00012615927,0.000160918,0.00012890298,0.05437636,0.00048061542],"about_ca_topic_score_codex":0.00064989575,"about_ca_topic_score_gemma":0.00004277809,"teacher_disagreement_score":0.24728839,"about_ca_system_score_codex":0.0060311845,"about_ca_system_score_gemma":0.0033887527,"threshold_uncertainty_score":0.99985033},"labels":[],"label_agreement":null},{"id":"W4205108145","doi":"10.1016/j.jtho.2021.12.011","title":"Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Foundation Medicine; Eli Lilly and Company; Ignyta; Takeda Pharmaceuticals U.S.A.; Merck Sharp and Dohme; Institut Gustave-Roussy; Genentech; BeiGene; Regeneron Pharmaceuticals; CMC Microsystems; Aptitude Health; AbbVie; Boehringer Ingelheim; Amgen; Ariad Pharmaceuticals; Chugai Pharmaceutical; Roche; EMD Serono; Novartis; Sanofi; Merck; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Continuation; Disease; Progressive disease; Atherosclerotic cardiovascular disease; MEDLINE","score_opus":0.014409973734452616,"score_gpt":0.4454697753667234,"score_spread":0.43105980163227076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205108145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816998,0.0019780414,0.00011961539,0.0076481206,0.00043397435,0.00048125177,0.00004735772,0.000004297303,0.0075874967],"genre_scores_gemma":[0.9978023,0.000017541925,0.0012486553,0.0003461491,0.00010640398,0.00003229006,0.000025316387,0.000008191177,0.00041312812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99896604,0.00017771703,0.00042334222,0.00008387656,0.00024319971,0.0001058222],"domain_scores_gemma":[0.9988396,0.000116804826,0.0006321869,0.0000776009,0.00023415122,0.00009965191],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031221597,0.000065992266,0.00031976038,0.00021899832,0.000047537094,0.000003070363,0.000056905996,0.000029039551,0.00025819163],"category_scores_gemma":[0.00010774185,0.00005352407,0.00009528,0.00019699664,0.000053028143,0.00007880397,0.00003190997,0.00022642853,0.0000012643133],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020788616,0.00645203,0.14419852,0.00018050511,0.0011018795,0.0067920256,0.014038173,0.0010731338,0.0038481178,0.0008982557,0.0045058485,0.7961229],"study_design_scores_gemma":[0.013803564,0.01824866,0.9068517,0.00065524643,0.0039433814,0.0019439557,0.010196107,0.00059903844,0.0034892468,0.004454042,0.035509966,0.00030507878],"about_ca_topic_score_codex":0.000010246801,"about_ca_topic_score_gemma":0.0000061275846,"teacher_disagreement_score":0.7958178,"about_ca_system_score_codex":0.0005205835,"about_ca_system_score_gemma":0.0009195824,"threshold_uncertainty_score":0.28270173},"labels":[],"label_agreement":null},{"id":"W4206195485","doi":"10.1016/j.jtho.2021.12.014","title":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","year":2022,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; University Health Network; University of British Columbia","funders":"AbbVie; Roche; Bayer; AstraZeneca","keywords":"Mesothelioma; BAP1; Medicine; Pathology; CDKN2A; Fluorescence in situ hybridization; Epithelioid cell; Immunohistochemistry; Cancer; Internal medicine; Biology","score_opus":0.06906958151802331,"score_gpt":0.4520436088713148,"score_spread":0.38297402735329145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206195485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008001207,0.99150825,0.000008118978,0.0051113376,0.0007573685,0.00052712474,0.000059672464,0.0000020285097,0.0012259689],"genre_scores_gemma":[0.0061163534,0.9926019,0.000064743945,0.00007234312,0.00024353444,0.000038921105,0.000029290486,0.000018976165,0.0008139616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968831,0.0009067672,0.0012469988,0.00015215123,0.0006720798,0.00013890342],"domain_scores_gemma":[0.9943294,0.0012327298,0.0037870838,0.0004564619,0.00012899062,0.00006534905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011276259,0.0001839415,0.0009828217,0.00008580305,0.0002142057,0.000007944856,0.00060919765,0.00012232075,0.00017349984],"category_scores_gemma":[0.00047611498,0.00007701156,0.0006327771,0.00034035696,0.0005280104,0.000085185144,0.00012138496,0.00065897166,0.000006360065],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003539153,0.00029008277,0.00057438767,0.0015376733,0.0001906409,0.000006229773,0.00005092882,0.000008392964,0.000033254593,0.0004632562,0.0033815266,0.9931097],"study_design_scores_gemma":[0.00011058497,0.00046363036,0.025544811,0.0016777966,0.0015923297,0.00025708816,0.00054902973,0.000018661598,0.000008497404,0.00020722327,0.9695045,0.00006589634],"about_ca_topic_score_codex":0.0000033928866,"about_ca_topic_score_gemma":0.000006535462,"teacher_disagreement_score":0.99304384,"about_ca_system_score_codex":0.00049602514,"about_ca_system_score_gemma":0.001046211,"threshold_uncertainty_score":0.314044},"labels":[],"label_agreement":null},{"id":"W4207078379","doi":"10.1016/j.jtho.2021.12.009","title":"Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated—A Response to Letter to the Editor","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Internal medicine","score_opus":0.05791389601700381,"score_gpt":0.4424355710287809,"score_spread":0.3845216750117771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207078379","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054058928,0.0010078793,0.00006949522,0.93270934,0.010352046,0.0015263797,0.00013341242,0.000013334933,0.00012919854],"genre_scores_gemma":[0.0038173574,0.00006707035,0.0013362721,0.9362764,0.051259425,0.00071484846,0.000019222758,0.000102440266,0.0064069927],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949073,0.0015616056,0.0009252011,0.0005426907,0.0013278347,0.00073532795],"domain_scores_gemma":[0.9969157,0.0011723491,0.00054706255,0.0005911008,0.0003802667,0.0003934948],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029273608,0.00044541628,0.0013928412,0.0010728276,0.0002233642,0.00007462624,0.00058910664,0.0005626561,0.002221238],"category_scores_gemma":[0.00058868283,0.0003003764,0.00042504637,0.00075512694,0.000057194153,0.00010868733,0.00030436396,0.003465935,0.000027882663],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012462087,0.00016806406,0.0016615755,0.00008152928,0.00076313573,0.0057276785,0.0039214497,0.0010474387,0.000076429824,1.4157247e-7,0.96577084,0.008319656],"study_design_scores_gemma":[0.0013093065,0.004402135,0.008303776,0.0010219268,0.0014573107,0.00035232404,0.00031687788,0.00003726651,0.000060096343,0.0000012887639,0.98245066,0.00028704156],"about_ca_topic_score_codex":0.0005637642,"about_ca_topic_score_gemma":0.0005801705,"teacher_disagreement_score":0.05024157,"about_ca_system_score_codex":0.0064880177,"about_ca_system_score_gemma":0.0023445524,"threshold_uncertainty_score":0.9999448},"labels":[],"label_agreement":null},{"id":"W4210600867","doi":"10.1016/j.jtho.2021.12.015","title":"A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"Genentech; Puma Biotechnology; Italfarmaco; PharmaMar; G1 Therapeutics; Sanofi Genzyme; Merck Sharp and Dohme; Eisai; Sanofi; Apollomics; International Association for the Study of Lung Cancer; BeiGene; AstraZeneca; Novocure; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; EMD Serono; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; Amgen; Pfizer; Bristol-Myers Squibb Foundation","keywords":"Medicine; Procalcitonin; Case fatality rate; Internal medicine; Logistic regression; Pneumonia; Stage (stratigraphy); Cancer; Disease; Epidemiology; Sepsis","score_opus":0.05298130859414155,"score_gpt":0.42778752521292246,"score_spread":0.3748062166187809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210600867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98656493,0.0008387959,0.0010354073,0.008939297,0.00038320664,0.0015198356,0.00065863185,0.000028841087,0.000031063926],"genre_scores_gemma":[0.99436235,0.000044616612,0.0020664984,0.0026545718,0.00036107644,0.00018940939,0.00024502675,0.000037193957,0.00003924172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781966,0.0005183422,0.0005180079,0.00025386654,0.0005690443,0.00032104796],"domain_scores_gemma":[0.9960396,0.0012823805,0.0010872126,0.00037216855,0.0007920912,0.00042653477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074419455,0.00019321378,0.00051800406,0.00011270591,0.00037561858,0.000034483422,0.0002470854,0.00007110191,0.000034621706],"category_scores_gemma":[0.00060748926,0.00011129521,0.0000937268,0.00020518174,0.00013226655,0.0001942508,0.000055776785,0.0004882568,0.0000034962745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.118879475,0.0030202968,0.70222473,0.0007492489,0.00051534484,0.0020302297,0.0035587156,0.00012132979,0.00013270577,0.00026674455,0.0032051238,0.16529606],"study_design_scores_gemma":[0.0034629523,0.01814964,0.9364409,0.0009252487,0.0015282262,0.0003778308,0.004104704,0.00008740726,0.000077437486,0.00016532041,0.034460466,0.00021989497],"about_ca_topic_score_codex":0.0001520961,"about_ca_topic_score_gemma":0.00012872256,"teacher_disagreement_score":0.23421615,"about_ca_system_score_codex":0.00093443773,"about_ca_system_score_gemma":0.002886493,"threshold_uncertainty_score":0.51205146},"labels":[],"label_agreement":null},{"id":"W4214576157","doi":"10.1016/j.jtho.2022.01.008","title":"Reprint of “Introduction to 2021 WHO Classification of Thoracic Tumors”","year":2022,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; International agency; Reprint; Etiology; Cancer; Agency (philosophy); Oncology; Intensive care medicine; Pathology; Internal medicine","score_opus":0.02175467645037184,"score_gpt":0.4270205865129274,"score_spread":0.4052659100625556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214576157","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08453825,0.0022753777,0.00019809228,0.024612201,0.8851673,0.0010834481,0.00016156667,0.000013565484,0.0019502244],"genre_scores_gemma":[0.06780089,0.0029156276,0.0036510476,0.000079052814,0.92249423,0.000101492195,0.00021455581,0.00008235267,0.0026607688],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959207,0.00046922086,0.0017420903,0.0004390309,0.0011930218,0.00023592614],"domain_scores_gemma":[0.99355286,0.0004993502,0.0034374066,0.00069344917,0.0016091871,0.0002077148],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002168505,0.0002675999,0.001822485,0.00065072346,0.000052904856,0.000009329977,0.0002950358,0.0004863769,0.0012425117],"category_scores_gemma":[0.0016388472,0.00022207982,0.0004908691,0.00044514224,0.0000948125,0.000078121826,0.00014126362,0.0012180032,0.000011623069],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004959158,0.0013603669,0.0007045343,0.0007937503,0.00066536816,0.0001817793,0.00037577958,0.00007873602,0.0017836157,0.000025496383,0.8989301,0.09014134],"study_design_scores_gemma":[0.00059023674,0.007919622,0.0048004007,0.00082063326,0.0018855558,0.00022262415,0.00045757947,0.0000071398517,0.0062049013,0.00008988426,0.9768526,0.000148804],"about_ca_topic_score_codex":0.000056832057,"about_ca_topic_score_gemma":0.000025931327,"teacher_disagreement_score":0.08999254,"about_ca_system_score_codex":0.0031719347,"about_ca_system_score_gemma":0.0025228898,"threshold_uncertainty_score":0.9996705},"labels":[],"label_agreement":null},{"id":"W4220659516","doi":"10.1016/j.jtho.2022.02.013","title":"NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"AI in cancer detection","field":"Computer Science","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Université Laval; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Daiichi-Sankyo; Takeda Pharmaceutical Company; AbbVie; Chugai Pharmaceutical; Roche; Novartis; GlaxoSmithKline; Amgen; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company; University of Missouri; U.S. Department of Defense","keywords":"Subtyping; Adenocarcinoma; Cytology; Medicine; Lung cancer; Gold standard (test); Oncology; Carcinoma; Algorithm; Internal medicine; Cancer; Pathology; Computer science","score_opus":0.06734476077710362,"score_gpt":0.3816303051502155,"score_spread":0.3142855443731119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220659516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97672474,0.000641036,0.014546254,0.0027589789,0.0043014693,0.0009293573,0.000073121926,0.0000045493075,0.000020490497],"genre_scores_gemma":[0.9972971,0.000012922124,0.0021299245,0.0001562915,0.00019214512,0.00016093813,0.0000030782185,0.000009942825,0.00003765569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99708223,0.001067993,0.00096387975,0.00029399924,0.00035658112,0.00023533666],"domain_scores_gemma":[0.99405944,0.0033670075,0.0018750064,0.00023284426,0.0004310396,0.000034662044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052036135,0.00012167008,0.00043953006,0.00030018846,0.00020435001,0.000025010275,0.0010911121,0.000098160046,0.000011400154],"category_scores_gemma":[0.00048147436,0.000093349205,0.000115423674,0.00042468778,0.000059103553,0.000115308365,0.0004846003,0.00035181214,6.471878e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009869779,0.00084592134,0.94894034,0.000059991013,0.00013727063,0.000035335685,0.0043189283,0.003094066,0.009147441,0.0001328157,0.0032908882,0.020127216],"study_design_scores_gemma":[0.0037550132,0.0038295616,0.9739899,0.00002184375,0.000084192754,0.00020608796,0.000847794,0.013853655,0.0015282776,0.00028032408,0.0014826411,0.00012072969],"about_ca_topic_score_codex":0.0002183605,"about_ca_topic_score_gemma":0.0016546812,"teacher_disagreement_score":0.025049532,"about_ca_system_score_codex":0.001210099,"about_ca_system_score_gemma":0.00026401237,"threshold_uncertainty_score":0.380667},"labels":[],"label_agreement":null},{"id":"W4220879423","doi":"10.1016/j.jtho.2022.02.011","title":"Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Sanofi Genzyme; Takeda Oncology; EMD Serono; Genentech; National Institutes of Health; Astellas Pharma; Daiichi-Sankyo; Damon Runyon Cancer Research Foundation; Revolution Medicines; American Cancer Society; Society for Immunotherapy of Cancer; Boehringer Ingelheim; AbbVie; Massachusetts Institute of Technology; Takeda Pharmaceutical Company; Broad Institute; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Merck; AstraZeneca; Canadian Asian Studies Association; Daiichi Sankyo Europe; National Cancer Institute; Foghorn Therapeutics; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; American Society of Clinical Oncology; Dana-Farber Cancer Institute; Pfizer; Conquer Cancer Foundation","keywords":"Medicine; Mutant; Adenocarcinoma; Mutation; Cancer research; Resistance (ecology); Lung; Oncology; Internal medicine; Genetics; Cancer; Gene; Biology; Ecology","score_opus":0.027668838212574216,"score_gpt":0.4252409717940304,"score_spread":0.3975721335814562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220879423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97227335,0.010351889,0.0011946112,0.010410568,0.0014645146,0.0004916187,0.000085902044,0.000016852633,0.0037106972],"genre_scores_gemma":[0.99701166,0.00005526298,0.0008106755,0.00021016448,0.00011308155,0.00005359422,0.00002323293,0.000011976061,0.0017103365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838495,0.0002737893,0.00062425254,0.00015739421,0.00033974065,0.0002198669],"domain_scores_gemma":[0.99893594,0.00017007676,0.00043372676,0.00013256034,0.00020314226,0.00012457138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005175885,0.00011000896,0.00039262426,0.00036975337,0.00016500508,0.000007843737,0.00010597662,0.000049927014,0.00029938619],"category_scores_gemma":[0.00013013322,0.000096671996,0.00013314639,0.00039366182,0.0000680942,0.000118133525,0.00004320744,0.0004857385,0.0000070450496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011721642,0.010861924,0.5520606,0.0012272497,0.0030839304,0.020250594,0.05331977,0.011264168,0.019340226,0.008381523,0.04299052,0.26549786],"study_design_scores_gemma":[0.009764201,0.0066870046,0.73459214,0.00039342057,0.0026430641,0.0053696134,0.019441554,0.0011330534,0.0005177859,0.0029298083,0.21608154,0.0004468276],"about_ca_topic_score_codex":0.000035835426,"about_ca_topic_score_gemma":0.000103872815,"teacher_disagreement_score":0.26505104,"about_ca_system_score_codex":0.0040229294,"about_ca_system_score_gemma":0.0013608013,"threshold_uncertainty_score":0.99980044},"labels":[],"label_agreement":null},{"id":"W4220945534","doi":"10.1016/j.jtho.2022.03.005","title":"The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Merck Sharp and Dohme; Boehringer Ingelheim; Varian Medical Systems; Merck; Astellas Pharma; Astellas Pharma US; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ninth; Medicine; Lung cancer; Stage (stratigraphy); Cancer; Lung cancer staging; Oncology; Internal medicine; Medical physics; Mediastinoscopy","score_opus":0.06824404474891252,"score_gpt":0.43737372902803623,"score_spread":0.36912968427912374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220945534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943024,0.00048161746,0.0004507853,0.050927654,0.0020527262,0.0028007396,0.00021493269,0.000003951369,0.0000435862],"genre_scores_gemma":[0.99784344,0.00008296617,0.00015380674,0.00033382693,0.00069871295,0.00044235488,0.0000061551887,0.000017894701,0.00042081115],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99766177,0.0003908239,0.0008882226,0.00013067455,0.00075117784,0.00017732245],"domain_scores_gemma":[0.9944366,0.0019066558,0.002420645,0.0002528175,0.0009553099,0.000027937345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038166372,0.00011016651,0.0003994816,0.00012250744,0.0003756283,0.000019749405,0.0005946693,0.000039509214,0.000041796673],"category_scores_gemma":[0.000945435,0.000049912604,0.00023297424,0.0002529799,0.00007359492,0.00006564406,0.00011848909,0.0003041859,7.4696786e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057039212,0.0068533267,0.11695652,0.00076155335,0.0074576563,0.000021439879,0.07726453,0.006228027,0.4664382,0.0050961114,0.11789168,0.13799174],"study_design_scores_gemma":[0.0091429725,0.015035773,0.53094476,0.000729505,0.0048034433,0.00014860503,0.18273458,0.038857613,0.045344748,0.0011154389,0.17080249,0.0003400559],"about_ca_topic_score_codex":0.00022848276,"about_ca_topic_score_gemma":0.00027817648,"teacher_disagreement_score":0.42109346,"about_ca_system_score_codex":0.0005444662,"about_ca_system_score_gemma":0.0006739227,"threshold_uncertainty_score":0.28890672},"labels":[],"label_agreement":null},{"id":"W4221006613","doi":"10.1016/j.jtho.2022.02.008","title":"The International Association for the Study of Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the Ninth Edition TNM Classification","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Johnson and Johnson; Genentech; National Institutes of Health; Astellas Pharma; Association of Community Cancer Centers; Taiho Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Chugai Pharmaceutical; Hope Foundation; Astellas Pharma US; LUNGevity Foundation; Intuitive Surgical; Pfizer; Covidien; International Association for the Study of Lung Cancer; American Cancer Society","keywords":"Medicine; Lung cancer staging; Ninth; Relevance (law); Lung cancer; Stage (stratigraphy); Medical physics; Pathology","score_opus":0.1258773179369881,"score_gpt":0.5247008015030601,"score_spread":0.398823483566072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221006613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.908873,0.0027157036,0.008942655,0.07012314,0.004587561,0.004509054,0.000042468077,0.000005693637,0.00020071538],"genre_scores_gemma":[0.99316084,0.00030956298,0.004848781,0.000117111296,0.0003389519,0.0009821207,0.0000023875657,0.0000086512855,0.00023161554],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986498,0.00026795786,0.00054323906,0.000087023414,0.00035816323,0.00009381803],"domain_scores_gemma":[0.99517417,0.0027918993,0.0014565655,0.00011458902,0.00044971117,0.000013094503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00494115,0.00006300289,0.00019218141,0.000050480998,0.00053816306,0.000015633836,0.00020561446,0.000026342124,0.000007192389],"category_scores_gemma":[0.00053802854,0.000026504806,0.000086462205,0.00010444669,0.00003140034,0.000039748666,0.00009340639,0.00013199705,9.475629e-9],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029153484,0.001599312,0.25511026,0.00020214403,0.005354369,9.695332e-7,0.030372605,0.0012867947,0.0033943322,0.0009341828,0.0120486375,0.68678105],"study_design_scores_gemma":[0.003778183,0.002285517,0.6151641,0.00023267542,0.0036744056,0.000030736534,0.056484208,0.018580545,0.010347093,0.00026382133,0.28904888,0.000109842666],"about_ca_topic_score_codex":0.00002695081,"about_ca_topic_score_gemma":0.0001855804,"teacher_disagreement_score":0.6866712,"about_ca_system_score_codex":0.0018188495,"about_ca_system_score_gemma":0.0007465968,"threshold_uncertainty_score":0.47562283},"labels":[],"label_agreement":null},{"id":"W4224210070","doi":"10.1016/j.jtho.2022.03.008","title":"Ignoring the Obvious: Smoking Cessation Improves Survival","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Smoking cessation; Oncology; Pathology","score_opus":0.035763008634379485,"score_gpt":0.40251760084422644,"score_spread":0.36675459220984696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224210070","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037090905,0.003075761,0.00002742022,0.94682753,0.008018289,0.00039634414,0.000015743975,0.000019652922,0.0045283707],"genre_scores_gemma":[0.25167307,0.003347696,0.0007420877,0.700215,0.03932192,0.00016994942,0.00015160028,0.00017652499,0.004202162],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755555,0.00045633534,0.0007093383,0.00022215032,0.0007466348,0.00030998336],"domain_scores_gemma":[0.9972346,0.0007518901,0.0013903399,0.00032600752,0.00023000105,0.00006716235],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011427732,0.00024192184,0.00085691747,0.00023709658,0.00018641831,0.000038690425,0.00029919273,0.00041055857,0.0005864595],"category_scores_gemma":[0.00011991849,0.0001455641,0.00041984682,0.00017076657,0.000073608506,0.0000825341,0.00010997193,0.0030231015,0.000004908632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004901344,0.00022368634,0.003331002,0.00031208913,0.0014507434,0.0052382722,0.0005204826,0.00002045157,0.00005032697,0.000008984318,0.88647,0.10188379],"study_design_scores_gemma":[0.00070380536,0.0025863817,0.0038186728,0.00025000423,0.002314433,0.0016489932,0.00036987945,0.000006281629,0.00015565254,0.00017089247,0.9878444,0.00013058819],"about_ca_topic_score_codex":0.00007092607,"about_ca_topic_score_gemma":0.000021123818,"teacher_disagreement_score":0.24661252,"about_ca_system_score_codex":0.0028322418,"about_ca_system_score_gemma":0.0009019331,"threshold_uncertainty_score":0.99927694},"labels":[],"label_agreement":null},{"id":"W4224251450","doi":"10.1016/j.jtho.2022.03.014","title":"Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations","year":2022,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"ARC Training Centre in Lightweight Automotive Structures; Janssen Pharmaceuticals; National Institute of Environmental Health Sciences; Medical Research Council; Genentech; Andrew and Jaime Sullivan Family Foundation; National Institutes of Health; Honeywell; Aldeyra Therapeutics; BeiGene; Clovis Oncology; Astex Pharmaceuticals; Bayer Fund; National Health and Medical Research Council; AstraZeneca; Novocure; Merck Sharp and Dohme; University of Hawaiʻi Foundation; Takeda Pharmaceuticals U.S.A.; AbbVie; Medtronic; Roche; Novartis; EMD Serono; Mesothelioma Applied Research Foundation; Merck; GlaxoSmithKline; National Cancer Institute; Bayer; Maurice and Joanna Sullivan Family Foundation; Bristol-Myers Squibb; U.S. Department of Defense; Eli Lilly and Company; Inventiva Pharma; Pfizer; Ariad Pharmaceuticals; Boehringer Ingelheim","keywords":"Medicine; BAP1; Germline; Mesothelioma; Germline mutation; Oncology; Internal medicine; Intensive care medicine; General surgery; Mutation; Genetics; Pathology; Gene","score_opus":0.025910165940848322,"score_gpt":0.40739288905630966,"score_spread":0.38148272311546133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224251450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07662764,0.92232984,0.0000030662288,0.00012861827,0.000088178596,0.00024911555,0.0001608978,0.000003351164,0.00040926872],"genre_scores_gemma":[0.028352894,0.9708572,0.00035522046,0.000029570585,0.00011981581,0.0000113311935,0.00020088728,0.000025580597,0.000047523863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983754,0.0003019061,0.00064068544,0.00015272331,0.0004210292,0.000108262866],"domain_scores_gemma":[0.99811214,0.0007526898,0.0007430056,0.000085603606,0.00007173736,0.0002348153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024794228,0.0001892678,0.0013082599,0.000226498,0.000070307025,0.0000038798626,0.00007693975,0.00017326753,0.0004807747],"category_scores_gemma":[0.0001402309,0.000106655105,0.00019231648,0.00013191042,0.00027580798,0.000056628072,0.00009167889,0.00048816696,6.01127e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006421141,0.00034395,0.009814113,0.004332618,0.00043609337,0.00044556518,0.00039203442,7.204597e-7,1.6056721e-7,0.000025112724,0.000024246592,0.9835433],"study_design_scores_gemma":[0.0013000808,0.0034106954,0.026945239,0.0048520095,0.002862726,0.003070993,0.0010643067,0.0000026889018,6.830468e-7,0.00004526849,0.9562766,0.000168726],"about_ca_topic_score_codex":0.0000020546354,"about_ca_topic_score_gemma":0.0000017816376,"teacher_disagreement_score":0.98337454,"about_ca_system_score_codex":0.00018352189,"about_ca_system_score_gemma":0.00052592845,"threshold_uncertainty_score":0.5264146},"labels":[],"label_agreement":null},{"id":"W4225130908","doi":"10.1016/j.jtho.2022.04.011","title":"A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genetic Associations and Epidemiology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; BC Cancer Agency; Princess Margaret Cancer Centre; University of British Columbia; University of Toronto","funders":"National Cancer Institute; National Key Research and Development Program of China; Jiangsu Planned Projects for Postdoctoral Research Funds; National Institute of Environmental Health Sciences; Government of Jiangsu Province; Qinglan Project of Jiangsu Province of China; National Institutes of Health; Nanjing Medical University; National Natural Science Foundation of China; Priority Academic Program Development of Jiangsu Higher Education Institutions; Natural Science Foundation of Jiangsu Province; World Health Organization; National Institute on Aging; Centre International de Recherche sur le Cancer; Medical Research Council; China Postdoctoral Science Foundation","keywords":"Medicine; Gene; Ethnic group; Lung cancer; Genetics; Genome; Scale (ratio); Oncology; Biology; Anthropology","score_opus":0.023180640788256417,"score_gpt":0.38673854108563577,"score_spread":0.36355790029737933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225130908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635524,0.00048887916,0.0019514185,0.0005300077,0.00021518569,0.00032850288,0.000025175657,0.0000018790863,0.000103731094],"genre_scores_gemma":[0.99862903,0.00019830214,0.00081928057,0.00011850655,0.00008593165,0.00004199939,0.000028659337,0.000016089274,0.00006218666],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969571,0.0015998826,0.0008001653,0.00024870585,0.00015538308,0.00023875912],"domain_scores_gemma":[0.99883604,0.00006822991,0.00070493325,0.00019157991,0.00014917416,0.000050036262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002281418,0.00011977552,0.00042948473,0.00021687022,0.000056719262,0.0000033591245,0.00021034526,0.00009722739,0.00007502899],"category_scores_gemma":[0.00010198602,0.00010994547,0.00008616195,0.00031365064,0.000031704283,0.000008973996,0.00008303546,0.0003840204,2.4571523e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001714803,0.0021068738,0.80510724,0.00002225434,0.00014768355,0.000050273913,0.0057076924,0.06924755,0.113377936,2.977803e-7,0.00009315866,0.0024242268],"study_design_scores_gemma":[0.002124371,0.0056764353,0.9736408,0.00001388282,0.00013690628,0.00011958784,0.012302942,0.00050628214,0.0034886834,0.000019259513,0.0018072717,0.00016360766],"about_ca_topic_score_codex":0.00012818858,"about_ca_topic_score_gemma":0.007849455,"teacher_disagreement_score":0.16853352,"about_ca_system_score_codex":0.00035931592,"about_ca_system_score_gemma":0.00030831754,"threshold_uncertainty_score":0.44834462},"labels":[],"label_agreement":null},{"id":"W4244361163","doi":"10.1016/j.jtho.2016.11.350","title":"OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Internal medicine; Lung cancer; Incidence (geometry); Retrospective cohort study; Cancer; Venous thromboembolism; Medical record; Chemotherapy; Oncology; Thrombosis","score_opus":0.020370648294505973,"score_gpt":0.4110875120792173,"score_spread":0.3907168637847113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244361163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847159,0.001031233,0.000075595715,0.0051247776,0.00071412965,0.00033501818,0.00004443455,0.00000796955,0.007950948],"genre_scores_gemma":[0.9955363,0.00039829029,0.0011592135,0.00061014673,0.00031605733,0.000015536712,0.0000066861094,0.000029599507,0.0019281331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988537,0.000095594245,0.0004410079,0.00015359728,0.00019963381,0.00025645515],"domain_scores_gemma":[0.9972406,0.00010342393,0.0015521157,0.00030855482,0.0006288225,0.00016650834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038937482,0.00016415691,0.0009496868,0.00012930566,0.00019342736,0.00002366387,0.00020597238,0.00017429198,0.00020258028],"category_scores_gemma":[0.00008727126,0.000111705784,0.00014842881,0.00008556933,0.00013107406,0.0001314181,0.000033719873,0.00033665664,0.0000042526076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017732494,0.020951793,0.35192856,0.002341266,0.033347905,0.012669226,0.055139817,0.00067934144,0.13618648,0.00012411429,0.074705936,0.29419306],"study_design_scores_gemma":[0.013696928,0.009998094,0.91441524,0.0020764903,0.013567221,0.0005064815,0.0008356444,0.00018557126,0.034076992,0.00028151725,0.009976845,0.00038296214],"about_ca_topic_score_codex":0.00070977636,"about_ca_topic_score_gemma":0.000299997,"teacher_disagreement_score":0.5624867,"about_ca_system_score_codex":0.0005466288,"about_ca_system_score_gemma":0.0015219408,"threshold_uncertainty_score":0.45552295},"labels":[],"label_agreement":null},{"id":"W4246327823","doi":"10.1016/j.jtho.2021.01.514","title":"P14.08 WITHDRAWN","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine","score_opus":0.021541697529334457,"score_gpt":0.4697760802409843,"score_spread":0.44823438271164984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246327823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8738322,0.004668528,0.00098587,0.034532215,0.001784765,0.00013076002,0.0000053241242,0.00001683507,0.0840435],"genre_scores_gemma":[0.9742138,0.00020960167,0.0144711,0.0018824498,0.0006080714,0.000002602292,0.000005662057,0.000012163909,0.008594554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993265,0.000058712718,0.00027721806,0.000074990356,0.0001481738,0.00011437826],"domain_scores_gemma":[0.9990983,0.00005760742,0.00021112752,0.0001106479,0.00039170615,0.00013061464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014413356,0.00006212688,0.00030267754,0.00007547389,0.000041449435,0.0000092290675,0.000040179755,0.000071769675,0.0005238129],"category_scores_gemma":[0.00010091264,0.000044440087,0.00011866773,0.00013741654,0.000037082526,0.000065293956,0.00001577751,0.00019294815,0.00003589811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016682101,0.0023624694,0.023070548,0.00015913641,0.001955849,0.019983057,0.0024177877,0.00005063174,0.017070249,0.0006774026,0.05410758,0.87647706],"study_design_scores_gemma":[0.0023556547,0.002740087,0.034300596,0.0001944975,0.0019476163,0.019818984,0.0013746779,0.000017991684,0.011356271,0.0009870458,0.9248024,0.0001041791],"about_ca_topic_score_codex":0.000003226496,"about_ca_topic_score_gemma":0.000009186067,"teacher_disagreement_score":0.8763729,"about_ca_system_score_codex":0.00028942886,"about_ca_system_score_gemma":0.0014934642,"threshold_uncertainty_score":0.5735384},"labels":[],"label_agreement":null},{"id":"W4251148738","doi":"10.1016/j.jtho.2018.08.607","title":"P1.01-51 Real world Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Lung cancer; Adverse effect; Gastroenterology; Cohort; Pneumonitis; Cancer; Oncology; Lung; Immunotherapy","score_opus":0.01938270157736518,"score_gpt":0.3958075948341308,"score_spread":0.37642489325676565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251148738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501956,0.00067595526,0.000059682778,0.0004722692,0.00051430066,0.0002651862,0.0000069911553,0.0000048667275,0.0029811864],"genre_scores_gemma":[0.9960138,0.00023856311,0.0026401414,0.00037927108,0.0001792124,0.000010560929,0.0000017753399,0.000019402203,0.0005172411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983269,0.00015057958,0.000743503,0.0001556967,0.0003553119,0.00026799203],"domain_scores_gemma":[0.9983931,0.000099238096,0.0008593468,0.00019050184,0.00034328917,0.0001145031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042938045,0.00015105728,0.00064094143,0.0003904177,0.000035419125,0.0000066277,0.00017591362,0.00006963173,0.0005591527],"category_scores_gemma":[0.000025800558,0.00010341489,0.00011452686,0.00047289848,0.00029250432,0.00013651358,0.000028238737,0.0002844816,0.0000017286626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14592882,0.0025377497,0.71715736,0.0004439609,0.00063695246,0.00032902273,0.008445811,0.000017510421,0.015206841,0.000009564796,0.003100281,0.10618615],"study_design_scores_gemma":[0.015048476,0.010087178,0.9435649,0.0010339023,0.00063744717,0.00013736448,0.0010878543,0.00010482985,0.016280191,0.000016968736,0.011738669,0.00026221375],"about_ca_topic_score_codex":0.00037299583,"about_ca_topic_score_gemma":0.0012878717,"teacher_disagreement_score":0.22640757,"about_ca_system_score_codex":0.00056649884,"about_ca_system_score_gemma":0.00082011527,"threshold_uncertainty_score":0.612233},"labels":[],"label_agreement":null},{"id":"W4252421162","doi":"10.1016/j.jtho.2016.11.254","title":"OA05.06 Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Radiation therapy; Neutropenia; Etoposide; Randomized controlled trial; Chemotherapy; Surgery; Internal medicine","score_opus":0.15799874968648267,"score_gpt":0.52929168415816,"score_spread":0.3712929344716773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252421162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98802626,0.0020617528,0.0000163149,0.0068153464,0.0012714325,0.0007463909,0.000012348956,0.000005005314,0.0010451737],"genre_scores_gemma":[0.99785954,0.0010814404,0.00020367063,0.0002348097,0.00042248997,0.000016051265,0.0000023035514,0.000014785431,0.00016491137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976513,0.00042592222,0.0008457926,0.00018785379,0.0005738285,0.0003153379],"domain_scores_gemma":[0.99714094,0.00071221386,0.0011994668,0.00038808983,0.0004259223,0.00013334783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012967924,0.00018372493,0.0010311683,0.00017479414,0.00015520248,0.000036717574,0.0004824659,0.00013344252,0.00003688815],"category_scores_gemma":[0.0010146429,0.00011178724,0.00017068256,0.00010209638,0.0005646216,0.00018115644,0.00007745852,0.00064668374,0.0000037651828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17138484,0.0014155104,0.5660008,0.00028498875,0.0007402397,0.0003498595,0.0024800973,0.0000018011611,0.0003941152,0.00003210736,0.005953099,0.25096253],"study_design_scores_gemma":[0.14393046,0.039916344,0.7787064,0.00045952364,0.00043604124,0.00010668625,0.0006912853,0.00007865602,0.00021556269,0.00004742927,0.03521686,0.00019477405],"about_ca_topic_score_codex":0.00018915224,"about_ca_topic_score_gemma":0.0002035808,"teacher_disagreement_score":0.25076774,"about_ca_system_score_codex":0.00053228205,"about_ca_system_score_gemma":0.00028190773,"threshold_uncertainty_score":0.45585513},"labels":[],"label_agreement":null},{"id":"W4253096809","doi":"10.1016/j.jtho.2021.01.723","title":"P35.22 WITHDRAWN","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine","score_opus":0.023723224505432867,"score_gpt":0.41673963735636693,"score_spread":0.3930164128509341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253096809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94499874,0.0070842495,0.00036071282,0.022113364,0.0018399407,0.00007730391,0.0000021182757,0.000012052014,0.023511514],"genre_scores_gemma":[0.97820115,0.0009372956,0.00769298,0.0049381317,0.0009937217,0.0000015332638,0.0000028942177,0.000017582917,0.007214681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99902606,0.000112561254,0.000425585,0.000087517285,0.00020019274,0.00014807718],"domain_scores_gemma":[0.9990206,0.00008123179,0.00031568616,0.00014593916,0.00032795416,0.000108590306],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050994125,0.000077489734,0.00038974689,0.00009802871,0.00003789916,0.000011233913,0.00007417138,0.00012013492,0.0014579005],"category_scores_gemma":[0.000114072325,0.00005805308,0.00022066048,0.00020503448,0.00007947798,0.00006468267,0.000021160618,0.0003087544,0.00001782989],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013377521,0.00070691964,0.0045276633,0.00009688919,0.0007180372,0.0064860415,0.00046650015,0.0000032965436,0.1748886,0.000049834183,0.052172974,0.74650574],"study_design_scores_gemma":[0.002061058,0.0025489673,0.022167502,0.0001810734,0.00031112236,0.022011438,0.0006613742,0.000008603464,0.04401113,0.00022837987,0.9057143,0.00009509773],"about_ca_topic_score_codex":0.000004493661,"about_ca_topic_score_gemma":0.0000112309945,"teacher_disagreement_score":0.85354125,"about_ca_system_score_codex":0.00024182713,"about_ca_system_score_gemma":0.001147892,"threshold_uncertainty_score":0.9994549},"labels":[],"label_agreement":null},{"id":"W4254793532","doi":"10.1097/jto.0000000000000291","title":"The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the N and M Components for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors","year":2014,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Oncology; Pathology; Radiology","score_opus":0.04272395703590851,"score_gpt":0.383316902291384,"score_spread":0.34059294525547545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254793532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661323,0.00046074585,0.008987091,0.020954479,0.0010244205,0.0023184742,0.000040386803,0.000005778098,0.000076334],"genre_scores_gemma":[0.9977326,0.00011348535,0.0009795964,0.00019032099,0.00076051895,0.00007832295,0.0000034598468,0.000023410978,0.00011829064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979819,0.00033230562,0.0009303277,0.00014289656,0.00035635303,0.0002562171],"domain_scores_gemma":[0.99494517,0.0024045869,0.0017808222,0.00033866434,0.00048193228,0.000048818587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004144182,0.00015112155,0.00050632627,0.00008859318,0.00046221665,0.000024828621,0.00038708595,0.000088178356,0.0000033464387],"category_scores_gemma":[0.0007470951,0.000057239737,0.00028063534,0.00013485833,0.00039930863,0.00007481164,0.00006846501,0.0003040164,2.733516e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014363725,0.0008385093,0.019786296,0.0013064642,0.0010372836,0.00000959327,0.0064644357,0.000102628175,0.2837801,0.014717378,0.004774481,0.6528191],"study_design_scores_gemma":[0.009788553,0.0126514435,0.62168676,0.0034746043,0.0044419854,0.0027390986,0.022425327,0.06660573,0.10920206,0.022250762,0.12417033,0.0005633291],"about_ca_topic_score_codex":0.000034500314,"about_ca_topic_score_gemma":0.000035872232,"teacher_disagreement_score":0.6522558,"about_ca_system_score_codex":0.00008451745,"about_ca_system_score_gemma":0.00034561683,"threshold_uncertainty_score":0.35550433},"labels":[],"label_agreement":null},{"id":"W4255129493","doi":"10.1016/j.jtho.2018.08.1199","title":"P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Développement du Porc du Québec","funders":"","keywords":"Germline; Germline mutation; Lung cancer; Medicine; Mutation; Cancer; Genetics; T790M; Cancer research; Epidermal growth factor receptor; Oncology; Internal medicine; Biology; Gene; Gefitinib","score_opus":0.012173944046094998,"score_gpt":0.44192128446168666,"score_spread":0.42974734041559165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255129493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199265,0.0027010255,0.000045435943,0.004306941,0.0003110962,0.00039897521,0.00003271374,0.0000041205253,0.00020701053],"genre_scores_gemma":[0.99741346,0.00048345985,0.0010519245,0.0006176954,0.00027228086,0.000040630108,0.000004253727,0.00001260442,0.00010371304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989748,0.00009371114,0.00045590088,0.00018010433,0.00010586996,0.00018963424],"domain_scores_gemma":[0.99921024,0.00009318609,0.00020073265,0.000082433886,0.00024486746,0.0001685415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021674388,0.00013115029,0.0004123501,0.00027424982,0.00005046454,0.000011027961,0.00004874071,0.000085652006,0.00009239887],"category_scores_gemma":[0.0001045583,0.00008734485,0.00003695832,0.00023042731,0.000108643086,0.00009930901,0.00003597772,0.0001846807,0.0000010305585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055894465,0.00041498998,0.86685216,0.000050460396,0.00008403752,0.000031801752,0.0051775402,0.00006707656,0.0008821762,0.0000012294572,0.00015689836,0.12572269],"study_design_scores_gemma":[0.0019605553,0.0011916511,0.9944633,0.00018709544,0.000164962,0.00004963907,0.0003599555,0.00044953372,0.00015554104,0.00016261406,0.0007760405,0.00007906649],"about_ca_topic_score_codex":0.0006869194,"about_ca_topic_score_gemma":0.027349796,"teacher_disagreement_score":0.12761119,"about_ca_system_score_codex":0.00066725235,"about_ca_system_score_gemma":0.00044792544,"threshold_uncertainty_score":0.9903985},"labels":[],"label_agreement":null},{"id":"W4256062365","doi":"10.1016/j.jtho.2019.08.1295","title":"P1.17-21 Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; SABR volatility model; Ablative case; Lung; Radiation therapy; Radiosurgery; Radiology; Surgery; Nuclear medicine; Internal medicine","score_opus":0.044429220757836695,"score_gpt":0.471741078631508,"score_spread":0.4273118578736713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256062365","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002188688,0.99007493,0.00032572867,0.0002476939,0.0005954918,0.0085605625,0.00006242104,0.0000066971916,0.000104615065],"genre_scores_gemma":[0.00015112464,0.9985269,0.00058121263,0.00012691384,0.00014010475,0.00026095152,0.00002265699,0.000055326123,0.00013484579],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9952785,0.0017968251,0.0020270206,0.00030129778,0.0002990753,0.000297285],"domain_scores_gemma":[0.9898164,0.005571779,0.0037159023,0.0003707577,0.00035571138,0.00016942594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025290807,0.0004379679,0.0089319255,0.0002541703,0.000043804408,0.000011503893,0.00017439698,0.0003380511,0.00003052427],"category_scores_gemma":[0.00050027523,0.00025470002,0.0012831142,0.0002131249,0.000077523204,0.0000953141,0.00001833888,0.00045793605,0.0000015658726],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010098465,0.00041875945,0.000048738653,0.8460908,0.0062636584,0.00009227725,0.0000803374,5.1623334e-7,0.0000010254124,0.000019845622,0.0003341367,0.14564006],"study_design_scores_gemma":[0.0016662206,0.0036205524,0.00008196454,0.8294719,0.050231867,0.0030321607,0.000026589649,0.000004181145,0.000005179394,0.000008848448,0.11167538,0.00017518034],"about_ca_topic_score_codex":0.000003046343,"about_ca_topic_score_gemma":0.000001356867,"teacher_disagreement_score":0.14546488,"about_ca_system_score_codex":0.002744398,"about_ca_system_score_gemma":0.0015317101,"threshold_uncertainty_score":0.9999905},"labels":[],"label_agreement":null},{"id":"W4281491769","doi":"10.1016/j.jtho.2022.03.003","title":"Hyper–Sensitive? Targeted Therapy With a Primed Immune System","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Roche; Takeda Pharmaceutical Company; Pfizer","keywords":"Medicine; Immunotherapy; Oncology; Lung cancer; Cohort; Internal medicine; Targeted therapy; Cancer; Immune system; Immunology","score_opus":0.020798191963922696,"score_gpt":0.3448333240027889,"score_spread":0.3240351320388662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281491769","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09481063,0.029381858,0.00011572845,0.8622917,0.0055200118,0.0015468193,0.00007047612,0.00010719324,0.0061555654],"genre_scores_gemma":[0.13133419,0.0041774376,0.005573258,0.8276964,0.017132381,0.00011894351,0.00035679576,0.0004678004,0.013142809],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996293,0.00085962785,0.0011785486,0.00031904376,0.00087702123,0.00047276533],"domain_scores_gemma":[0.99637365,0.0003185705,0.0022130786,0.00046599045,0.0005210851,0.00010762483],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001288397,0.00043564077,0.0019078036,0.00060618465,0.00014676816,0.00002556175,0.00034222644,0.00080738106,0.00084600446],"category_scores_gemma":[0.000035067238,0.0002890595,0.00068155,0.00041365175,0.00022290529,0.0000806604,0.000052102936,0.0038639938,0.000010761336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11893466,0.0004938984,0.0001251944,0.00075438217,0.0058963816,0.0395354,0.0007961006,0.000004028613,0.024054507,0.0000020670757,0.7017654,0.10763798],"study_design_scores_gemma":[0.0038201683,0.013752605,0.000898335,0.0006322257,0.00074817584,0.038565867,0.0007235652,0.0000048683796,0.004894242,0.0000022603278,0.9356645,0.0002931941],"about_ca_topic_score_codex":0.000057545814,"about_ca_topic_score_gemma":0.0000029285054,"teacher_disagreement_score":0.2338991,"about_ca_system_score_codex":0.0020722602,"about_ca_system_score_gemma":0.002257122,"threshold_uncertainty_score":0.99995613},"labels":[],"label_agreement":null},{"id":"W4281762462","doi":"10.1016/j.jtho.2022.05.003","title":"Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective","year":2022,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Western University; London Health Sciences Centre","funders":"National Medical Research Council; Merck Sharp and Dohme; University of Hong Kong; Royal Australian and New Zealand College of Radiologists; Bayer; AstraZeneca","keywords":"Medicine; Toxicity; Radiation therapy; Lung cancer; Pulmonary toxicity; Lung; Oncology; Medical physics; Radiology; Internal medicine","score_opus":0.06856821218360629,"score_gpt":0.4893819497454989,"score_spread":0.42081373756189266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281762462","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00122333,0.9949301,0.000026072803,0.00078367017,0.00064275385,0.0007550071,0.000013674722,0.000015616555,0.0016098131],"genre_scores_gemma":[0.0014929562,0.99637616,0.00046914956,0.00025305766,0.0011171838,0.00008371004,0.000025758005,0.00005751941,0.00012453055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719274,0.0011915311,0.0006647613,0.0002955703,0.00042114986,0.00023422798],"domain_scores_gemma":[0.9971712,0.0005497604,0.0015965606,0.0002533589,0.00021168713,0.00021742209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012939834,0.00031955354,0.002205982,0.00039425373,0.0001939879,0.000024085944,0.00018432522,0.00023393217,0.00067403394],"category_scores_gemma":[0.00011879521,0.00019397507,0.00054471876,0.00032518484,0.00005012017,0.00014916761,0.000035153516,0.0014862807,0.000004202645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007048658,0.0010715668,0.00009523104,0.0013555445,0.0018381412,0.0012942705,0.0009838212,0.0000040542964,4.4266184e-7,0.00005241692,0.0009188164,0.9916808],"study_design_scores_gemma":[0.00090421224,0.00905197,0.00010398766,0.0033256335,0.0050266655,0.006305291,0.0009792926,0.0000041959147,0.000009144842,0.00003022435,0.97407746,0.00018191105],"about_ca_topic_score_codex":0.000025262358,"about_ca_topic_score_gemma":0.000015052564,"teacher_disagreement_score":0.99149895,"about_ca_system_score_codex":0.009025349,"about_ca_system_score_gemma":0.002678314,"threshold_uncertainty_score":0.9947788},"labels":[],"label_agreement":null},{"id":"W4283453063","doi":"10.1016/j.jtho.2022.05.016","title":"Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Eisai; G1 Therapeutics; Puma Biotechnology; Yuhan; BeiGene; Mirati Therapeutics; Clovis Oncology; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Teva Pharmaceutical Industries; Boehringer Ingelheim Japan; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Bayer; Gilead Sciences; Roche; Novartis; Mesothelioma Applied Research Foundation; GlaxoSmithKline; Canadian Asian Studies Association; AstraZeneca; Ono Pharmaceutical; U.S. Department of Defense; Eli Lilly and Company; Bristol-Myers Squibb; Kyowa Hakko Kirin; Sanofi; Amgen; Boehringer Ingelheim; Pfizer","keywords":"Atezolizumab; Medicine; Placebo; Maintenance therapy; Hazard ratio; Internal medicine; Oncology; Carboplatin; Population; Chemotherapy; Cancer; Confidence interval; Immunotherapy; Pembrolizumab; Pathology; Cisplatin","score_opus":0.025664155582500087,"score_gpt":0.377302734165158,"score_spread":0.35163857858265796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283453063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963266,0.0013049826,0.00005381338,0.0015757092,0.00005256557,0.0004210827,0.000027549266,0.000007257467,0.0002303981],"genre_scores_gemma":[0.9982288,0.00059993594,0.0005410364,0.00021104648,0.000036237932,0.00003105658,0.00001623053,0.000022747005,0.00031294598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781245,0.000266988,0.0007091488,0.00025381602,0.00067830656,0.00027930245],"domain_scores_gemma":[0.99742496,0.00019872678,0.0010640041,0.0002773844,0.00090009585,0.00013483105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077457615,0.00017422922,0.0011962687,0.000654767,0.00010172248,0.0000069062144,0.000114202856,0.00005372422,0.00006629497],"category_scores_gemma":[0.00020516287,0.00011124056,0.00009816038,0.0012423511,0.00025477065,0.0000909308,0.00009986519,0.0005522243,1.218234e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059857897,0.0009049418,0.8910445,0.00012043732,0.0041482574,0.00982878,0.0033597627,0.006079557,0.00024158775,0.000004352982,0.000389253,0.024020696],"study_design_scores_gemma":[0.010299074,0.025510548,0.95627064,0.00024901025,0.0012368241,0.00053362065,0.0020024853,0.00044971617,0.00036040862,0.000010349531,0.002910782,0.00016651888],"about_ca_topic_score_codex":0.00023625213,"about_ca_topic_score_gemma":0.00080034183,"teacher_disagreement_score":0.06522618,"about_ca_system_score_codex":0.0010819125,"about_ca_system_score_gemma":0.00074857194,"threshold_uncertainty_score":0.45362583},"labels":[],"label_agreement":null},{"id":"W4293096174","doi":"10.1016/j.jtho.2022.07.006","title":"2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Disease; Molecular diagnostics; Biomarker; Molecular pathology; Classification scheme; Subject (documents); Bioinformatics; Pathology; Computational biology; Oncology; Data science; Computer science; Biology; Gene; Library science; Genetics","score_opus":0.025494064918205148,"score_gpt":0.4305638088209062,"score_spread":0.40506974390270106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293096174","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023235554,0.015614228,0.0014490006,0.9488561,0.0013018692,0.0011951479,0.00024088575,0.0000147881665,0.0080924],"genre_scores_gemma":[0.36483258,0.03975127,0.026401658,0.5280908,0.011007684,0.0018760413,0.0029002281,0.00061467587,0.024525115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768305,0.00025957476,0.0009095257,0.00031579452,0.00058557617,0.00024650892],"domain_scores_gemma":[0.99700624,0.0001326208,0.0018895736,0.00033065377,0.0005265028,0.00011440984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004656679,0.00023890893,0.0009397445,0.00037803504,0.00008895829,0.000021330508,0.00020679229,0.00050155324,0.0004796519],"category_scores_gemma":[0.00006553981,0.00019969733,0.00023408438,0.00034071968,0.00013289266,0.00008413451,0.00006361048,0.0010361534,0.0000018529317],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009563731,0.00034390864,0.0018090045,0.00086743984,0.0019249683,0.000957668,0.0002387249,0.00001017845,0.012241037,0.000099477395,0.82110703,0.1594442],"study_design_scores_gemma":[0.0010015804,0.0011336092,0.008464734,0.00038434012,0.004338341,0.0008128774,0.00020215433,0.0005977781,0.00019875856,0.00015435825,0.9825464,0.00016508333],"about_ca_topic_score_codex":0.00008524131,"about_ca_topic_score_gemma":0.000009397012,"teacher_disagreement_score":0.42076537,"about_ca_system_score_codex":0.0017000604,"about_ca_system_score_gemma":0.0019475082,"threshold_uncertainty_score":0.8143421},"labels":[],"label_agreement":null},{"id":"W4293096192","doi":"10.1016/j.jtho.2022.05.004","title":"Lung Cancer in Rwanda","year":2022,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Population; Medicine; Economic growth; Developing country; Socioeconomics; Environmental health","score_opus":0.03843419900589197,"score_gpt":0.5296385858690946,"score_spread":0.49120438686320267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293096192","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052657537,0.011716875,0.000011688844,0.02193055,0.9593899,0.00031874122,0.00010739367,0.000011714079,0.0012473584],"genre_scores_gemma":[0.0059489436,0.0077914097,0.00019713942,0.0016918132,0.98148865,0.00002282502,0.000032879074,0.00006175256,0.0027645733],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966989,0.00043293074,0.0011179533,0.00023389289,0.0010763444,0.00043998274],"domain_scores_gemma":[0.9957814,0.0016858121,0.0013204317,0.00024292324,0.00058779406,0.000381626],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002300223,0.0002398339,0.0015570018,0.000871496,0.00006996943,0.0000138583555,0.00028402708,0.0010271501,0.0029368266],"category_scores_gemma":[0.0030188062,0.00020069155,0.00028929694,0.0003601609,0.000055952838,0.00008454143,0.000118233496,0.005001522,0.000004401261],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0041679875,0.00022161208,0.0011369919,0.0010212045,0.00015021965,0.003789849,0.0005403527,0.000029347319,0.000032536685,0.0000013583235,0.8934774,0.09543118],"study_design_scores_gemma":[0.0013914333,0.0026575557,0.0019379259,0.0008466635,0.0005198325,0.00027732184,0.00014842732,0.000018336586,0.000010523135,0.000043577824,0.9920096,0.0001388012],"about_ca_topic_score_codex":0.00065691274,"about_ca_topic_score_gemma":0.0012015617,"teacher_disagreement_score":0.098532245,"about_ca_system_score_codex":0.0070286677,"about_ca_system_score_gemma":0.024659337,"threshold_uncertainty_score":0.99797463},"labels":[],"label_agreement":null},{"id":"W4293511056","doi":"10.1016/j.jtho.2022.08.007","title":"Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline","year":2022,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Ottawa; Queen's University; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Ottawa Hospital; Kingston General Hospital","funders":"Pfizer; Ontario Ministry of Health and Long-Term Care; Eli Lilly and Company","keywords":"Medicine; Guideline; Clinical Practice; Systemic therapy; Intensive care medicine; General surgery; Pathology; Internal medicine; Cancer; Family medicine","score_opus":0.05047015169588832,"score_gpt":0.4834341787245772,"score_spread":0.4329640270286889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293511056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010950517,0.9864579,0.00001679981,0.0002873722,0.0006691828,0.0010266522,0.000114187744,0.000007815193,0.00046959365],"genre_scores_gemma":[0.00046274305,0.9950253,0.0032164676,0.00013721957,0.0007969611,0.000020749436,0.00012296258,0.00005667919,0.00016092537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99335456,0.0017930502,0.00363966,0.00031103363,0.0006666211,0.00023510239],"domain_scores_gemma":[0.99018157,0.0018275025,0.006723248,0.00033752868,0.00064248266,0.0002877005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030465974,0.00035925853,0.004218371,0.00039089998,0.00006691321,0.000012393144,0.00021730954,0.00035586517,0.00026926154],"category_scores_gemma":[0.0011584072,0.00021124682,0.00061591004,0.00030773602,0.00013954812,0.00011845135,0.000094359515,0.0010243537,0.0000068538197],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033138946,0.0016119438,0.00093364954,0.0030523108,0.0016514985,0.0018162252,0.00006605594,4.8569336e-7,8.9233346e-8,0.000013163954,0.0011996209,0.98634106],"study_design_scores_gemma":[0.0030639037,0.011086863,0.00027762304,0.0050374726,0.009619192,0.018679475,0.00009084526,0.0000020026582,1.5442932e-7,0.000008854925,0.951981,0.00015257727],"about_ca_topic_score_codex":0.000010029476,"about_ca_topic_score_gemma":6.950584e-7,"teacher_disagreement_score":0.9861885,"about_ca_system_score_codex":0.00046834015,"about_ca_system_score_gemma":0.0022456634,"threshold_uncertainty_score":0.8614395},"labels":[],"label_agreement":null},{"id":"W4294934458","doi":"10.1016/j.jtho.2022.07.995","title":"EP14.05-020 Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Cancer Care South East; Northeast Cancer Centre; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Internal medicine; Population; Cascade; Lung cancer; Cancer; Database; Environmental health","score_opus":0.04046655758585513,"score_gpt":0.4247877452949683,"score_spread":0.38432118770911317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294934458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615572,0.001429052,0.00013645632,0.03313701,0.0009031562,0.0013176735,0.0013832127,0.000010648065,0.00012559192],"genre_scores_gemma":[0.98884785,0.000035830413,0.0028707623,0.00670702,0.0003678284,0.00017849088,0.00021440128,0.000042560132,0.0007352599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997833,0.00029606634,0.00050564663,0.00023550814,0.0006843093,0.0004454823],"domain_scores_gemma":[0.99695164,0.0010153316,0.0006065764,0.00032021967,0.0007658014,0.00034044776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073618424,0.00018530326,0.0006299586,0.0002336941,0.0006527139,0.000025084992,0.0003338613,0.00006587401,0.0006020811],"category_scores_gemma":[0.0005894254,0.00011220518,0.00015689468,0.0002408175,0.00008703393,0.000084305284,0.000108139946,0.0007738462,0.000001576059],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029561133,0.000299185,0.9637478,0.00011025607,0.0004947326,0.0002510854,0.0005423486,0.0009663156,0.000043387678,0.0000065791505,0.024250802,0.0063314014],"study_design_scores_gemma":[0.0056317993,0.0028814902,0.8885324,0.0001562404,0.0012002158,0.000018805882,0.0011864965,0.0013023652,0.00011465859,0.000024736797,0.09872183,0.00022896641],"about_ca_topic_score_codex":0.09255526,"about_ca_topic_score_gemma":0.2620847,"teacher_disagreement_score":0.16952944,"about_ca_system_score_codex":0.0032698738,"about_ca_system_score_gemma":0.0040182127,"threshold_uncertainty_score":0.9134875},"labels":[],"label_agreement":null},{"id":"W4294934986","doi":"10.1016/j.jtho.2022.07.803","title":"EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; ROS1; Presentation (obstetrics); Internal medicine; Oncology; Cancer research; Radiology; Cancer; Adenocarcinoma","score_opus":0.020157280061994434,"score_gpt":0.4348659768479482,"score_spread":0.4147086967859538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294934986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211293,0.0005598414,0.00009167248,0.005116578,0.00039019441,0.00036223745,0.000047218535,0.000010017855,0.0013092946],"genre_scores_gemma":[0.99561775,0.00015048275,0.0030543786,0.00031611498,0.0000874108,0.000058377278,0.00006907252,0.00001562423,0.0006307744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99887955,0.00018209573,0.0004301764,0.00014504959,0.00022117281,0.0001419588],"domain_scores_gemma":[0.999155,0.00017286613,0.00030423113,0.00009023863,0.0001466541,0.00013105356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002616311,0.00009208122,0.00026875985,0.000318214,0.00032385899,0.000017905077,0.000043850327,0.000044887784,0.0001338349],"category_scores_gemma":[0.000116505915,0.00008128351,0.00004717253,0.00022061638,0.000052967436,0.00018863953,0.00008925675,0.00025865683,0.0000016142518],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027573796,0.003733345,0.68172693,0.00016933306,0.0008604453,0.0009897383,0.028638193,0.002391506,0.008611383,0.0007998071,0.008276637,0.26104534],"study_design_scores_gemma":[0.00934699,0.0065524206,0.9072351,0.00016180934,0.0017596903,0.0017790244,0.0058801305,0.0012466294,0.0007214313,0.0012075943,0.06383582,0.0002733769],"about_ca_topic_score_codex":0.00004718302,"about_ca_topic_score_gemma":0.00013663965,"teacher_disagreement_score":0.26077196,"about_ca_system_score_codex":0.00067988737,"about_ca_system_score_gemma":0.00026612185,"threshold_uncertainty_score":0.33146453},"labels":[],"label_agreement":null},{"id":"W4294935044","doi":"10.1016/j.jtho.2022.07.1058","title":"EP16.02-027 Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec","funders":"","keywords":"Medicine; DNA methylation; Stage (stratigraphy); Oncology; Cell-free fetal DNA; Methylation; Internal medicine; DNA; Cancer research; Genetics; Gene; Gene expression; Biology","score_opus":0.019839399416945677,"score_gpt":0.38711324444460177,"score_spread":0.3672738450276561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294935044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719554,0.00023228844,0.0010012776,0.00027418503,0.0006474249,0.0001651114,0.00019060445,0.000001729936,0.00029184815],"genre_scores_gemma":[0.9969861,0.00005864674,0.0022798541,0.0003856914,0.000114407034,0.000007941149,0.000081344995,0.000014108056,0.00007188738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976912,0.00044215674,0.0011891496,0.00021675492,0.00027114974,0.00018956365],"domain_scores_gemma":[0.99803597,0.0002532491,0.0010468669,0.00031577516,0.00023135084,0.00011681848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015892232,0.00011712909,0.00061889,0.00041510657,0.000053323198,0.000007786146,0.00037123705,0.00013368271,0.000077232784],"category_scores_gemma":[0.0010783998,0.00011525217,0.00036604033,0.00045798253,0.000034637247,0.000005581492,0.00036898445,0.00027211342,5.409492e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012311676,0.0012278443,0.8705166,0.000021623217,0.00092168426,0.000038885744,0.00031013822,0.054279517,0.039267886,0.000010990906,0.0012508461,0.03092283],"study_design_scores_gemma":[0.0023868617,0.006171251,0.96055394,0.000010517471,0.0010804096,0.000006170354,0.00058252807,0.0013550101,0.011873289,0.00009091038,0.015619769,0.00026936745],"about_ca_topic_score_codex":0.00003878988,"about_ca_topic_score_gemma":0.00015172198,"teacher_disagreement_score":0.09003733,"about_ca_system_score_codex":0.00017793765,"about_ca_system_score_gemma":0.00032415372,"threshold_uncertainty_score":0.4699847},"labels":[],"label_agreement":null},{"id":"W4294935455","doi":"10.1016/j.jtho.2022.07.1056","title":"EP16.02-025 SerumTumor Markers as a Surrogate forRadiographicAssessment of Non-Small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Lung cancer; Surrogate endpoint; Oncology; Pathology; Internal medicine","score_opus":0.014883574469335447,"score_gpt":0.39942267917234475,"score_spread":0.3845391047030093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294935455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98107743,0.0041273227,0.000046519282,0.00824979,0.0013762728,0.00055738894,0.000039098457,0.000009046282,0.00451713],"genre_scores_gemma":[0.9935535,0.001888675,0.002484851,0.00091266824,0.00022600913,0.00014148418,0.000006137913,0.000031151998,0.00075549894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791586,0.0002537186,0.0007712312,0.00022518144,0.0004970447,0.00033696776],"domain_scores_gemma":[0.9979022,0.00023315003,0.0010831485,0.0002562042,0.00026921055,0.00025606423],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009463382,0.00019863219,0.0008848139,0.0004333166,0.000117158816,0.000009047989,0.00022285567,0.00008470724,0.0014306724],"category_scores_gemma":[0.000018763589,0.00015971466,0.0004816163,0.00038327524,0.0000691358,0.00006308999,0.000120791046,0.0005631374,0.0000026869525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01188701,0.007130563,0.79167366,0.0017819557,0.0039990395,0.006826257,0.002078506,0.001378529,0.0041554933,0.0000676875,0.053741965,0.11527932],"study_design_scores_gemma":[0.023990268,0.062479477,0.6364917,0.0019388618,0.016475081,0.00880657,0.007886616,0.0022383996,0.02600675,0.00047475146,0.21213904,0.0010724695],"about_ca_topic_score_codex":0.00028539042,"about_ca_topic_score_gemma":0.00009515018,"teacher_disagreement_score":0.15839708,"about_ca_system_score_codex":0.0019265624,"about_ca_system_score_gemma":0.0018236436,"threshold_uncertainty_score":0.99948215},"labels":[],"label_agreement":null},{"id":"W4294935554","doi":"10.1016/j.jtho.2022.07.772","title":"EP08.02-089 Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Toxicity; Tyrosine kinase; Lung cancer; Cancer research; Tyrosine-kinase inhibitor; Immune system; Cancer; Kinase; Pharmacology; Oncology; Immunology; Internal medicine; Receptor; Cell biology; Biology","score_opus":0.011006900022209123,"score_gpt":0.3769497878806218,"score_spread":0.36594288785841267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294935554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874358,0.0069046556,0.000072866715,0.0021929245,0.0020180899,0.0005494149,0.000051775474,0.000008559574,0.00076586625],"genre_scores_gemma":[0.9964045,0.00025437187,0.0018529184,0.0002688365,0.00041096297,0.00013067936,0.00001314085,0.000033161123,0.0006314191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769855,0.00018933328,0.0011863866,0.00022743909,0.00037285252,0.00032544928],"domain_scores_gemma":[0.99827355,0.000066535686,0.0010238924,0.00021175227,0.0002559568,0.00016828845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061428075,0.0002094465,0.0007875882,0.00045037712,0.00008488988,0.000007749138,0.00014427766,0.00011987061,0.0006237167],"category_scores_gemma":[0.000044254677,0.00017914893,0.0003241612,0.0004564022,0.00008335612,0.00014114733,0.00014844531,0.00069154426,0.0000017335499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014505118,0.0065450547,0.12326265,0.0010402821,0.0008067895,0.0050399066,0.009651447,0.007508701,0.7339356,0.0000092036225,0.001922319,0.09577295],"study_design_scores_gemma":[0.015392164,0.010047843,0.094969705,0.0012658212,0.0027607197,0.0010875249,0.004843175,0.00048524453,0.84700805,0.000110108354,0.021432778,0.0005968861],"about_ca_topic_score_codex":0.0002705764,"about_ca_topic_score_gemma":0.00016843506,"teacher_disagreement_score":0.113072455,"about_ca_system_score_codex":0.0022441673,"about_ca_system_score_gemma":0.0015587617,"threshold_uncertainty_score":0.73054814},"labels":[],"label_agreement":null},{"id":"W4294938031","doi":"10.1016/j.jtho.2022.07.881","title":"EP10.01-004 Perspectives of Patients with Metastatic Lung Cancer on Symptom Screening and Patient-Reported Symptom Trajectory Data","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lung cancer; Trajectory; Oncology; Cancer; Internal medicine","score_opus":0.027068449417249642,"score_gpt":0.4198754109361209,"score_spread":0.3928069615188713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294938031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99366325,0.0037891164,0.00023073149,0.0010519064,0.00026175828,0.0004382918,0.0001739796,0.000008926671,0.0003820189],"genre_scores_gemma":[0.99586076,0.00010701575,0.003542586,0.00024317125,0.000056555775,0.000025829942,0.000059229333,0.000023740597,0.000081116224],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99839044,0.0001901182,0.0005082218,0.00023753419,0.00049826765,0.00017540198],"domain_scores_gemma":[0.99812806,0.00017720315,0.0009836353,0.00027934014,0.00029748402,0.00013430309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002516113,0.00014581208,0.0005336466,0.0002691364,0.00014178453,0.000008004516,0.00013261405,0.00003124013,0.00026064768],"category_scores_gemma":[0.00008235509,0.00010306991,0.000066478104,0.00021417259,0.00009794553,0.00014324467,0.00009609021,0.00033429422,1.6080493e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017036129,0.006665532,0.45365834,0.00036161282,0.012462762,0.0013056637,0.03135661,0.0031944648,0.00036663073,0.00006432862,0.0033264416,0.4702015],"study_design_scores_gemma":[0.018137226,0.03284625,0.86001205,0.00087077275,0.017048731,0.0013213347,0.049436014,0.0015075267,0.0003180986,0.000056792298,0.017911555,0.00053366757],"about_ca_topic_score_codex":0.00008189509,"about_ca_topic_score_gemma":0.000029584875,"teacher_disagreement_score":0.46966782,"about_ca_system_score_codex":0.00058046903,"about_ca_system_score_gemma":0.00074836134,"threshold_uncertainty_score":0.4203069},"labels":[],"label_agreement":null},{"id":"W4294938037","doi":"10.1016/j.jtho.2022.07.1050","title":"EP16.02-019 Metabolic Changes in Sputum and Exhaled Breath Condensate of Non-small Cell Lung Cancer Patients after Surgical Resection","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Manitoba Health; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Medicine; Exhaled breath condensate; Lung cancer; Sputum; Resection; Surgical resection; Internal medicine; Oncology; Gastroenterology; Surgery; Pathology; Tuberculosis; Asthma","score_opus":0.014050589949240608,"score_gpt":0.36527340234309225,"score_spread":0.3512228123938516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294938037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888515,0.008190796,0.0000012771278,0.0015881285,0.00058381987,0.00035301514,0.000026002823,0.000002890089,0.00040261055],"genre_scores_gemma":[0.9964058,0.0026048939,0.000120222314,0.00020552627,0.00021392648,0.00010816982,0.0000046760715,0.000015998548,0.0003208101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986709,0.00023347235,0.00044446305,0.00017249488,0.00027313275,0.00020555967],"domain_scores_gemma":[0.99900824,0.00011869247,0.0004751639,0.00010700372,0.00017124959,0.000119631986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049302727,0.00012869977,0.0006763244,0.0003064663,0.000040894214,0.000005347291,0.000065024244,0.000083747414,0.00036973934],"category_scores_gemma":[0.000013112358,0.00009900412,0.00010460525,0.0001926458,0.00004292181,0.000046474404,0.00008596983,0.00035966196,6.424768e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004982679,0.0017243809,0.9688359,0.00028343184,0.00029048306,0.0013050574,0.0010960907,0.0000461196,0.00039580304,0.0000030335293,0.00053859194,0.020498445],"study_design_scores_gemma":[0.0070687192,0.006033662,0.9674273,0.00025278158,0.0011573012,0.0004462909,0.0003042247,0.00011997402,0.0063962876,0.000016025167,0.010649854,0.00012757385],"about_ca_topic_score_codex":0.00021844327,"about_ca_topic_score_gemma":0.00042985278,"teacher_disagreement_score":0.02037087,"about_ca_system_score_codex":0.000596582,"about_ca_system_score_gemma":0.00028253085,"threshold_uncertainty_score":0.40483865},"labels":[],"label_agreement":null},{"id":"W4294938234","doi":"10.1016/j.jtho.2022.07.872","title":"EP08.05-001 Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Radiation Pneumonitis; Lung cancer; Pneumonitis; Oncology; Internal medicine; Lung; Radiology; Cancer; Epidermal growth factor receptor","score_opus":0.022279197782759365,"score_gpt":0.42857966617410453,"score_spread":0.40630046839134515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294938234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935282,0.002798526,0.000024586912,0.000995887,0.00073264446,0.00067808863,0.000029671846,0.000005362899,0.0012070223],"genre_scores_gemma":[0.9985442,0.0004273548,0.00045041635,0.00017139383,0.000091496884,0.00009052128,0.000052459392,0.000020581325,0.00015155475],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99792784,0.0004948894,0.0007177383,0.00016981071,0.00049661833,0.0001931227],"domain_scores_gemma":[0.9980827,0.00014759645,0.00099006,0.000104114304,0.00057243864,0.000103096994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012693166,0.00012677773,0.00045226794,0.00043025814,0.000104858336,0.000010198598,0.000078410565,0.00008015817,0.00026766595],"category_scores_gemma":[0.00012154399,0.00011442827,0.00007114883,0.00038118003,0.000033413566,0.00014318118,0.00004672818,0.00035424638,8.073165e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011474489,0.0016729994,0.33449808,0.00020743124,0.00027241439,0.000100837555,0.004777884,0.0035338528,0.0044921893,0.0000013860644,0.0007273154,0.64856815],"study_design_scores_gemma":[0.011330389,0.0051987865,0.95323706,0.00045009228,0.0044580516,0.0003074794,0.0020953128,0.014768412,0.0048503415,0.00012296395,0.002924593,0.0002565194],"about_ca_topic_score_codex":0.00020199067,"about_ca_topic_score_gemma":0.000074308155,"teacher_disagreement_score":0.6483117,"about_ca_system_score_codex":0.0017810877,"about_ca_system_score_gemma":0.0011695557,"threshold_uncertainty_score":0.46662495},"labels":[],"label_agreement":null},{"id":"W4294939449","doi":"10.1016/j.jtho.2022.07.932","title":"EP13.01-012 Exploring Factors Affecting Variability in Lung Cancer Outcomes Across Southeastern Ontario, Canada","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Demography; Gerontology; Environmental health; Oncology","score_opus":0.1083120651364991,"score_gpt":0.4466836074777128,"score_spread":0.3383715423412137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294939449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478084,0.0003029365,0.00007182152,0.0016205289,0.0026292526,0.00018505323,0.000018738474,0.000009232386,0.00038157438],"genre_scores_gemma":[0.998677,0.00000919793,0.00024120034,0.00061107223,0.00020293817,0.00002030636,0.0000022401452,0.000016709719,0.00021933003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973901,0.00044781683,0.00075983244,0.00022294432,0.0006682473,0.00051107747],"domain_scores_gemma":[0.99836755,0.0004939781,0.00059005205,0.00019208564,0.00013294535,0.00022341285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026931239,0.00018333836,0.00081412913,0.000114128576,0.00021581548,0.000015907262,0.00024886336,0.000072720686,0.0008235438],"category_scores_gemma":[0.00037825585,0.00015307183,0.0001738021,0.00029307822,0.000035894514,0.00022312788,0.00020118774,0.001362197,3.7733193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007809147,0.00009584157,0.97465575,0.000055419532,0.00011672865,0.0008032459,0.009990623,0.0017351374,0.00012750765,0.0000020688533,0.00027300997,0.011363757],"study_design_scores_gemma":[0.0008019353,0.0005151263,0.9674881,0.00013834753,0.00015776175,0.00045806175,0.024116851,0.00011262718,0.00022021135,0.000026332387,0.005800721,0.0001639392],"about_ca_topic_score_codex":0.820567,"about_ca_topic_score_gemma":0.96415406,"teacher_disagreement_score":0.14358707,"about_ca_system_score_codex":0.007367807,"about_ca_system_score_gemma":0.004138329,"threshold_uncertainty_score":0.99644274},"labels":[],"label_agreement":null},{"id":"W4294939891","doi":"10.1016/j.jtho.2022.07.818","title":"EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; KRAS; non-small cell lung cancer (NSCLC); Lung cancer; Antibody; Cancer research; Oncology; Internal medicine; Cancer; Immunology; Colorectal cancer","score_opus":0.033409874385729114,"score_gpt":0.44283939244569553,"score_spread":0.4094295180599664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294939891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930054,0.0028694696,0.00016296859,0.0019021316,0.00057168497,0.000504629,0.0000655746,0.0000030680096,0.0009150971],"genre_scores_gemma":[0.99769205,0.0008462098,0.0009901138,0.00011771738,0.00013657458,0.00002950702,0.0000019016303,0.00001542442,0.00017048839],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983444,0.00030070342,0.0007175811,0.00017696549,0.00026962644,0.00019070564],"domain_scores_gemma":[0.9980239,0.00046769954,0.0010355876,0.00017298135,0.00021272908,0.00008708492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097597623,0.00013524093,0.0007821996,0.00020548244,0.00008078263,0.000005391965,0.00013796175,0.00009482108,0.000045523404],"category_scores_gemma":[0.00006594645,0.00008898989,0.00016981042,0.00022175179,0.00016855456,0.00011425515,0.00011659194,0.00055881334,1.2236026e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009011342,0.0075837057,0.29291698,0.0015715404,0.0025378645,0.0006460105,0.021698548,0.0116140535,0.39480865,0.00008069244,0.0023714064,0.2551592],"study_design_scores_gemma":[0.025027463,0.036632646,0.46333742,0.0018083777,0.014727149,0.0011626076,0.025136355,0.023769457,0.40053675,0.0018384608,0.004999609,0.0010236974],"about_ca_topic_score_codex":0.00038521242,"about_ca_topic_score_gemma":0.00009935698,"teacher_disagreement_score":0.2541355,"about_ca_system_score_codex":0.000318307,"about_ca_system_score_gemma":0.0013106264,"threshold_uncertainty_score":0.36289024},"labels":[],"label_agreement":null},{"id":"W4294940201","doi":"10.1016/j.jtho.2022.07.954","title":"EP14.01-019 Identifying Circulating DNA Methylation Patterns in Small Cell Lung Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; DNA methylation; Lung cancer; DNA; Methylation; Cancer; Cancer research; Computational biology; Oncology; Internal medicine; Genetics; Gene; Gene expression; Biology","score_opus":0.05116896901006629,"score_gpt":0.46292772861565523,"score_spread":0.41175875960558894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99376726,0.0021796045,0.00023542177,0.0016840334,0.001083294,0.0004025191,0.000012928128,0.000010109078,0.00062483473],"genre_scores_gemma":[0.9982696,0.00024057807,0.000509236,0.00033273557,0.00032137695,0.000051388673,0.000007787829,0.000026545616,0.0002407464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758404,0.00053604646,0.0007392219,0.00019647893,0.00058302126,0.00036120886],"domain_scores_gemma":[0.9984386,0.00027094778,0.0007475729,0.00013419423,0.00028664852,0.00012203926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015700847,0.00013208383,0.00054692087,0.0005122261,0.00016387482,0.000015824167,0.00018806856,0.00006759473,0.0003786395],"category_scores_gemma":[0.00026211358,0.00011957126,0.00014717525,0.00037702968,0.000030642717,0.00013889778,0.00026981242,0.0009944018,0.0000019319714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076964684,0.0005184507,0.927536,0.0005540233,0.00019487081,0.0005976006,0.0038457222,0.0010816654,0.0078292955,0.0000022961406,0.0010087756,0.056061655],"study_design_scores_gemma":[0.003849364,0.0020294718,0.9799814,0.00048848573,0.0004959236,0.00018843892,0.0035362677,0.0015603394,0.003531941,0.00014267968,0.0039516184,0.00024402673],"about_ca_topic_score_codex":0.0002460819,"about_ca_topic_score_gemma":0.00024539395,"teacher_disagreement_score":0.05581763,"about_ca_system_score_codex":0.0026390126,"about_ca_system_score_gemma":0.00060213817,"threshold_uncertainty_score":0.6900926},"labels":[],"label_agreement":null},{"id":"W4294940204","doi":"10.1016/j.jtho.2022.07.663","title":"EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Chemotherapy; Internal medicine; Oncology; Immunotherapy; Cancer","score_opus":0.010292224125193981,"score_gpt":0.33288584980094604,"score_spread":0.32259362567575206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920113,0.0006280753,0.0001249492,0.006172454,0.0003293458,0.00047915545,0.000012785574,0.000009858298,0.00023208495],"genre_scores_gemma":[0.99473673,0.0002059286,0.0020914262,0.0023273353,0.00005436525,0.000018726938,0.000012278195,0.00003966049,0.0005135445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977415,0.00026939422,0.000802943,0.00016902435,0.00074478594,0.00027231523],"domain_scores_gemma":[0.99759734,0.00017010329,0.0016654318,0.0002162632,0.0002881372,0.00006271449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010238681,0.00019352845,0.00094224705,0.00032798774,0.00007214923,0.000007080851,0.00017971957,0.000108217464,0.00046226082],"category_scores_gemma":[0.000027096994,0.00013146353,0.00016764627,0.00040431932,0.00007929942,0.00014633388,0.000022225004,0.00052224344,7.419666e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14586043,0.0027003174,0.72688663,0.000039276412,0.0014629898,0.00006372572,0.0012565708,0.00033473727,0.0055898763,0.0000048650654,0.0007078214,0.11509275],"study_design_scores_gemma":[0.025719265,0.01811551,0.9454902,0.00014546754,0.0001445539,0.00009064734,0.001235039,0.0000070474675,0.0013254087,0.000044502445,0.0075011784,0.00018118459],"about_ca_topic_score_codex":0.00005612966,"about_ca_topic_score_gemma":0.000096905685,"teacher_disagreement_score":0.21860357,"about_ca_system_score_codex":0.002010378,"about_ca_system_score_gemma":0.00060264004,"threshold_uncertainty_score":0.53609276},"labels":[],"label_agreement":null},{"id":"W4294940241","doi":"10.1016/j.jtho.2022.07.592","title":"EP08.01-020 Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"TIGIT; Medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; Cancer research; Lung; Cancer; A549 cell; Immunotherapy","score_opus":0.029756570005303486,"score_gpt":0.40368168482379607,"score_spread":0.3739251148184926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98738855,0.0042388877,0.00006718605,0.0026343018,0.0028444545,0.000899217,0.00008159308,0.000013125303,0.0018326718],"genre_scores_gemma":[0.99525714,0.0019133072,0.0006093445,0.0009262981,0.00077217096,0.000040735802,0.00001642809,0.000046707915,0.00041787548],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966375,0.0002437783,0.0016500412,0.00029265822,0.00060772867,0.0005682663],"domain_scores_gemma":[0.9973484,0.0002507087,0.0016684736,0.00032127355,0.00019629224,0.00021484247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022152548,0.0002857056,0.0014209104,0.000694484,0.00012666704,0.00001763561,0.00041384413,0.00023282664,0.0022822125],"category_scores_gemma":[0.00006761969,0.00024471758,0.00053414213,0.0006595171,0.00015397492,0.00018184642,0.00013409027,0.0011465233,0.000003125997],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5798568,0.008001749,0.011390154,0.0006152627,0.0010055938,0.0030727808,0.003445499,0.00035983452,0.18690377,0.000004809934,0.012111225,0.19323249],"study_design_scores_gemma":[0.53427327,0.059691012,0.021197788,0.001257988,0.0026650745,0.0039842855,0.007054245,0.0016736275,0.08780952,0.00009297674,0.27906942,0.0012307814],"about_ca_topic_score_codex":0.0003698536,"about_ca_topic_score_gemma":0.00013256882,"teacher_disagreement_score":0.26695818,"about_ca_system_score_codex":0.0014224134,"about_ca_system_score_gemma":0.0024282336,"threshold_uncertainty_score":0.9986298},"labels":[],"label_agreement":null},{"id":"W4294940874","doi":"10.1016/j.jtho.2022.07.974","title":"EP14.04-001 Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Cancer Care South East; Northeast Cancer Centre; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Cascade; Internal medicine; Cancer; Lung cancer; Database","score_opus":0.0379800896193987,"score_gpt":0.4213255832223028,"score_spread":0.3833454936029041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696595,0.002893455,0.0000013269236,0.008243676,0.00016336427,0.00059830066,0.00026340265,0.00000244014,0.00086805923],"genre_scores_gemma":[0.99738556,0.00057899975,0.00023902506,0.0007098586,0.000061396844,0.0000640199,0.000016463207,0.00001544236,0.0009292583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983416,0.0003542501,0.0004066605,0.00014638642,0.00043234587,0.0003187179],"domain_scores_gemma":[0.9987297,0.00030093186,0.00036898997,0.00020660697,0.00019584547,0.00019793391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078313425,0.0001377989,0.0005720568,0.00039249993,0.00016956394,0.000009811404,0.00018805546,0.000043832326,0.00023251443],"category_scores_gemma":[0.000099127166,0.00007565774,0.000058411388,0.00027477226,0.00012670667,0.000065500666,0.00009657504,0.0005303412,3.9890995e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016667593,0.0009779634,0.97104055,0.00014200706,0.00041174545,0.00069881626,0.0027913887,0.00009734086,0.00004582926,0.0000073565716,0.0017401439,0.02038013],"study_design_scores_gemma":[0.006250999,0.007524089,0.9187404,0.0001001238,0.00073833106,0.00010234461,0.0034302117,0.00010421115,0.00015449211,0.0000055427668,0.06271513,0.0001341433],"about_ca_topic_score_codex":0.038493052,"about_ca_topic_score_gemma":0.28099874,"teacher_disagreement_score":0.24250568,"about_ca_system_score_codex":0.0024663927,"about_ca_system_score_gemma":0.00196733,"threshold_uncertainty_score":0.9679097},"labels":[],"label_agreement":null},{"id":"W4294940921","doi":"10.1016/j.jtho.2022.07.1102","title":"EP16.03-041 Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Phenotype; Lung cancer; Cancer; Cancer research; Genetics; Oncology; Internal medicine; Gene; Biology","score_opus":0.023290813400804286,"score_gpt":0.3686907576693265,"score_spread":0.3453999442685222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868423,0.0025554071,0.004646847,0.0035733075,0.00073857536,0.00020436713,0.000036528665,0.0000043855,0.0013982804],"genre_scores_gemma":[0.9912903,0.0001912797,0.005783152,0.0015102458,0.0003237115,0.00007523338,0.000011856816,0.000020814161,0.00079344376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985809,0.00024581986,0.00050496677,0.00021997372,0.00017788965,0.0002704631],"domain_scores_gemma":[0.9991415,0.000027633301,0.00037363954,0.00018898328,0.00016251215,0.00010574589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005924407,0.000121792174,0.0002511752,0.00018720728,0.00017853457,0.000017303944,0.00031226862,0.00009717124,0.00014317896],"category_scores_gemma":[0.0000464548,0.00012531772,0.000096100324,0.0003145915,0.000030208203,0.000016563023,0.00014945722,0.00029646204,0.000002066123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033749777,0.00012826631,0.0012967833,0.000032871467,0.00005524301,0.000040312625,0.00047337677,0.021371603,0.9540465,0.000044764955,0.006212763,0.015960002],"study_design_scores_gemma":[0.0024747858,0.004616051,0.02435494,0.00037850224,0.00044364732,0.0008317941,0.006538444,0.0010397263,0.60326755,0.00093056815,0.35375407,0.0013699273],"about_ca_topic_score_codex":0.000045410503,"about_ca_topic_score_gemma":0.00007534265,"teacher_disagreement_score":0.35077897,"about_ca_system_score_codex":0.0012998695,"about_ca_system_score_gemma":0.0010441567,"threshold_uncertainty_score":0.51103085},"labels":[],"label_agreement":null},{"id":"W4294940939","doi":"10.1016/j.jtho.2022.07.795","title":"EP08.02-112 Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.027287879768799372,"score_gpt":0.4541691762571138,"score_spread":0.4268812964883144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294940939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900867,0.001288389,0.000012445381,0.0048827976,0.0005165177,0.0010090672,0.000093631446,0.000003645464,0.0021068407],"genre_scores_gemma":[0.9961598,0.00010356268,0.0007459221,0.00022590617,0.00009694762,0.0001222234,0.000009706718,0.000020456195,0.0025155041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857044,0.00014281164,0.0005327,0.00016710383,0.00025910483,0.0003278233],"domain_scores_gemma":[0.99872947,0.00014666884,0.0005151301,0.00018342599,0.00012944256,0.0002958371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030677684,0.00017216102,0.00069239683,0.0005610703,0.000116078976,0.000010602031,0.000111930734,0.0000748699,0.00035330773],"category_scores_gemma":[0.000028792665,0.000111487716,0.0002263946,0.00022478291,0.000036372985,0.000061441475,0.000021165279,0.00024849368,0.0000020274372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0042552976,0.004962297,0.8357605,0.00013619462,0.0009090058,0.0027392835,0.0064904885,0.0044582607,0.000918421,0.000006949199,0.0021554467,0.1372079],"study_design_scores_gemma":[0.010756977,0.046029504,0.8766473,0.0003724675,0.0023009463,0.0008631294,0.0016878335,0.0012356538,0.0024829397,0.00006855427,0.057251815,0.00030288118],"about_ca_topic_score_codex":0.09027759,"about_ca_topic_score_gemma":0.11972503,"teacher_disagreement_score":0.13690501,"about_ca_system_score_codex":0.010591564,"about_ca_system_score_gemma":0.0112243015,"threshold_uncertainty_score":0.9943811},"labels":[],"label_agreement":null},{"id":"W4294941248","doi":"10.1016/j.jtho.2022.07.914","title":"EP11.03-001 Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Grading (engineering); Adenocarcinoma; Cycling; Lung; Pathology; Oncology; Internal medicine; Cancer; Biology","score_opus":0.0332168022923368,"score_gpt":0.40056620857272,"score_spread":0.3673494062803832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294941248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926154,0.0022911052,0.00019834416,0.0037521138,0.00021271927,0.0001443976,0.00000464991,0.000009648893,0.0007715915],"genre_scores_gemma":[0.9983742,0.000064518434,0.0005886621,0.0003359178,0.00020047389,0.000017853687,0.0000056230247,0.00001567823,0.0003970201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851024,0.00019434573,0.00060270214,0.00019653169,0.00026596914,0.00023022402],"domain_scores_gemma":[0.99872655,0.00035575964,0.00052254973,0.00013408164,0.00007752404,0.00018351186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052855443,0.0001385136,0.0005629527,0.00013124858,0.00009627048,0.000005892256,0.000151604,0.00014899204,0.00072848226],"category_scores_gemma":[0.00003961233,0.00010294404,0.000069110974,0.00019422975,0.00017447522,0.00006971985,0.000101371705,0.001066427,0.0000010932972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053466046,0.0014819345,0.85680234,0.00035708369,0.00015346704,0.0030733799,0.00037322674,0.0005333372,0.121834114,0.0000687511,0.0017273265,0.008248448],"study_design_scores_gemma":[0.008647336,0.0037908854,0.91073453,0.00072307524,0.0010412446,0.012016616,0.0008906553,0.002724751,0.037133873,0.0010638158,0.020693129,0.00054005993],"about_ca_topic_score_codex":0.0000049622395,"about_ca_topic_score_gemma":7.190536e-7,"teacher_disagreement_score":0.08470024,"about_ca_system_score_codex":0.00032487328,"about_ca_system_score_gemma":0.000110533765,"threshold_uncertainty_score":0.797637},"labels":[],"label_agreement":null},{"id":"W4294941295","doi":"10.1016/j.jtho.2022.07.696","title":"EP08.02-014 Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cohort; Osimertinib; Line (geometry); East Asia; First line; Demography; Internal medicine; Geography; Archaeology; China","score_opus":0.03542274332694116,"score_gpt":0.47209933260513326,"score_spread":0.4366765892781921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294941295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520161,0.00013797403,0.000011426067,0.031919528,0.0005784387,0.00043745458,0.00015092673,0.000009389175,0.014738739],"genre_scores_gemma":[0.99535286,0.000026081294,0.0006263821,0.0010573793,0.00026097993,0.000033822795,0.000016510423,0.00002611321,0.002599867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982389,0.000295913,0.000613588,0.00017604411,0.00035396233,0.00032154238],"domain_scores_gemma":[0.9981943,0.00015188569,0.00050893245,0.00026745233,0.00022942777,0.00064804446],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009344673,0.00015573,0.0006200113,0.0008307637,0.00018441529,0.000007807151,0.00016763501,0.00006666543,0.00095243857],"category_scores_gemma":[0.00021932342,0.00012201653,0.000256823,0.00058582524,0.000049324444,0.000055638884,0.00003436085,0.00045757604,0.000013495083],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10934977,0.0040779277,0.54174304,0.00013915691,0.0049823085,0.011260299,0.009153813,0.017047293,0.0037722448,0.00012710327,0.08315194,0.2151951],"study_design_scores_gemma":[0.002167541,0.025147628,0.8194852,0.00018963193,0.0011322389,0.0017356813,0.00094433984,0.00006085275,0.00023780414,0.0000679416,0.148663,0.00016813728],"about_ca_topic_score_codex":0.013626339,"about_ca_topic_score_gemma":0.030386062,"teacher_disagreement_score":0.27774218,"about_ca_system_score_codex":0.0036805654,"about_ca_system_score_gemma":0.0049887984,"threshold_uncertainty_score":0.99996084},"labels":[],"label_agreement":null},{"id":"W4294941528","doi":"10.1016/j.jtho.2022.07.781","title":"EP08.02-098 Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Oncology; Platinum; Internal medicine; First line; Phase (matter); Cancer; Immunotherapy","score_opus":0.057165156627755155,"score_gpt":0.4736893181085445,"score_spread":0.4165241614807893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294941528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445313,0.0006887049,0.00014137056,0.0031456735,0.00011095386,0.00046607113,0.000028125,0.000008395142,0.00095754885],"genre_scores_gemma":[0.99857867,0.0000665006,0.00071046455,0.00020699292,0.00013623244,0.00004963084,0.000006852052,0.00001696762,0.00022768106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793756,0.00025373272,0.0009839073,0.00020717081,0.0003852532,0.00023234668],"domain_scores_gemma":[0.99837565,0.00041856675,0.0006374113,0.00021113841,0.00012393027,0.00023332171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093771867,0.0001588578,0.0008039007,0.00023219785,0.000121047626,0.0000071048603,0.0001897703,0.000058496127,0.0005785193],"category_scores_gemma":[0.00020398876,0.0001390611,0.00010490697,0.0004492246,0.00011480886,0.00007506144,0.00010218756,0.00089318695,0.0000017618867],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063637376,0.07913863,0.015933445,0.002035774,0.0023927195,0.011501425,0.014754611,0.0062346,0.21724021,0.00036540598,0.0048396895,0.5819261],"study_design_scores_gemma":[0.2345676,0.17749119,0.04438426,0.0010248837,0.014891882,0.08153818,0.06897756,0.030734867,0.09982962,0.0070695314,0.2370207,0.0024697247],"about_ca_topic_score_codex":0.00001789364,"about_ca_topic_score_gemma":0.0000194313,"teacher_disagreement_score":0.5794564,"about_ca_system_score_codex":0.00037753483,"about_ca_system_score_gemma":0.00030610384,"threshold_uncertainty_score":0.63343805},"labels":[],"label_agreement":null},{"id":"W4294942468","doi":"10.1016/j.jtho.2022.07.662","title":"EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Immunotherapy; Internal medicine; Association (psychology); Cancer; Psychotherapist","score_opus":0.01063937803010871,"score_gpt":0.3284517726679701,"score_spread":0.3178123946378614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973687,0.00032355217,0.000045527886,0.0015422206,0.000060936556,0.00053540646,0.000006682283,0.000005798661,0.00011119692],"genre_scores_gemma":[0.9974551,0.00020375906,0.0015145178,0.0005539392,0.00001023603,0.000022287515,0.000011604798,0.000025085716,0.00020346713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840987,0.00024291589,0.000565403,0.00014255721,0.00045669655,0.00018255359],"domain_scores_gemma":[0.99845463,0.00013993328,0.0010540534,0.00011531264,0.0001971006,0.00003899265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073712616,0.00015197882,0.0007185491,0.00036359404,0.000042431904,0.000006097104,0.00007727929,0.000080420556,0.00012360603],"category_scores_gemma":[0.000020719088,0.000090429676,0.00004535647,0.0004235415,0.000059310158,0.0001415683,0.000010750211,0.00032256552,9.7800026e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17236066,0.0020863935,0.76457214,0.000027091337,0.0005039212,0.00006442107,0.0013937379,0.000060119317,0.0011775205,0.0000017016876,0.000041128467,0.05771114],"study_design_scores_gemma":[0.040239893,0.022293894,0.9344412,0.00010664718,0.000080997954,0.00009499358,0.001197738,0.00002059753,0.0005754657,0.000010958122,0.00082273415,0.00011488165],"about_ca_topic_score_codex":0.00008131507,"about_ca_topic_score_gemma":0.00021703543,"teacher_disagreement_score":0.16986904,"about_ca_system_score_codex":0.0012846021,"about_ca_system_score_gemma":0.00033811873,"threshold_uncertainty_score":0.3687615},"labels":[],"label_agreement":null},{"id":"W4294942898","doi":"10.1016/j.jtho.2022.07.411","title":"EP03.01-016 The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Cancer Care South East; Northeast Cancer Centre","funders":"","keywords":"Medicine; Cascade; Database; Lung cancer; Oncology","score_opus":0.08650866978257099,"score_gpt":0.47472910042043553,"score_spread":0.38822043063786454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.699655,0.029232908,0.0003331318,0.25092345,0.0054718805,0.0024169507,0.003652225,0.000046574638,0.008267894],"genre_scores_gemma":[0.985408,0.003198253,0.003851681,0.002370362,0.0013764129,0.00013753414,0.000081118094,0.000023740822,0.0035529106],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968699,0.00076520897,0.00074962736,0.00030390275,0.0008689695,0.000442366],"domain_scores_gemma":[0.9967232,0.0010092199,0.0006916468,0.00037988115,0.0007760987,0.0004199723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025657176,0.00018434471,0.0005070909,0.00043547308,0.0009867068,0.000045275097,0.0004682134,0.000076975106,0.00046961848],"category_scores_gemma":[0.0012365459,0.0001226002,0.0001243503,0.00083392905,0.00025069682,0.00024503472,0.00025408345,0.0013439025,0.0000092900855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034317918,0.0013824401,0.076314405,0.00054847787,0.0021459355,0.012850144,0.015308899,0.013166779,0.01600356,0.00028284386,0.79659176,0.03108684],"study_design_scores_gemma":[0.0075907954,0.0023650534,0.114267066,0.0013252549,0.0019462346,0.00072392594,0.0050352234,0.010381916,0.003676487,0.000071682574,0.8520986,0.0005177873],"about_ca_topic_score_codex":0.26979864,"about_ca_topic_score_gemma":0.8359297,"teacher_disagreement_score":0.56613106,"about_ca_system_score_codex":0.008932278,"about_ca_system_score_gemma":0.018282898,"threshold_uncertainty_score":0.9948723},"labels":[],"label_agreement":null},{"id":"W4294942902","doi":"10.1016/j.jtho.2022.07.786","title":"EP08.02-103 Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Internal medicine; Cancer research; Oncology","score_opus":0.02479497650447135,"score_gpt":0.4094396244081332,"score_spread":0.3846446479036618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98435354,0.00012633912,0.00007324671,0.0021612663,0.0010502993,0.00078664307,0.00011088998,0.000012582511,0.011325179],"genre_scores_gemma":[0.9931774,0.00001106363,0.0023110714,0.0008474371,0.00049243536,0.0001745796,0.00018125233,0.000027715045,0.0027770149],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862415,0.00011566589,0.0004959524,0.00019633319,0.00028760062,0.00028028066],"domain_scores_gemma":[0.99849707,0.000074673604,0.00051440665,0.00015858182,0.00043687286,0.00031841008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002333012,0.00014731902,0.00037894206,0.00040441143,0.000325142,0.000019520925,0.00009804019,0.00006190843,0.0005720645],"category_scores_gemma":[0.00005126908,0.00011385908,0.00009881659,0.00033820144,0.000050738763,0.00017615671,0.000020311234,0.00025157913,0.0000022367853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009638155,0.0034946895,0.4166807,0.00020609474,0.0021642507,0.0015613004,0.026225206,0.0019049338,0.0047692126,0.00028678734,0.117252864,0.4158158],"study_design_scores_gemma":[0.01698571,0.038775995,0.11233384,0.00028915663,0.0026596612,0.0015004369,0.010088383,0.0011002532,0.008509756,0.00025830997,0.80674136,0.00075716904],"about_ca_topic_score_codex":0.0031589945,"about_ca_topic_score_gemma":0.05617013,"teacher_disagreement_score":0.6894885,"about_ca_system_score_codex":0.002233056,"about_ca_system_score_gemma":0.0019425771,"threshold_uncertainty_score":0.9610523},"labels":[],"label_agreement":null},{"id":"W4294942906","doi":"10.1016/j.jtho.2022.07.747","title":"EP08.02-065 Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Systemic therapy; Cancer; Oncology; Internal medicine; Cancer research; Breast cancer","score_opus":0.031064456675271628,"score_gpt":0.4757297295253387,"score_spread":0.4446652728500671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97461987,0.0019194116,0.0000732722,0.021214072,0.00086630863,0.00043949095,0.00003069672,0.000011808772,0.0008250994],"genre_scores_gemma":[0.9949601,0.00022384583,0.0008553201,0.001668843,0.00017128022,0.00012956515,0.000007174377,0.00002048428,0.0019633411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982749,0.0005448869,0.0005435471,0.00014138891,0.0002937166,0.0002015167],"domain_scores_gemma":[0.9989054,0.00024797602,0.00035256692,0.00016527122,0.00018121909,0.00014755057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096517784,0.00011092773,0.00047254874,0.0005539361,0.00013290496,0.000010266517,0.00013730505,0.000057394896,0.0004883545],"category_scores_gemma":[0.00008730869,0.00008903032,0.00012062781,0.0005306966,0.00002956119,0.00007978992,0.000041523715,0.0003956398,0.00001221286],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05283193,0.005166604,0.12683056,0.0001560957,0.0016285138,0.0056078946,0.024640273,0.027669827,0.15370491,0.00012831196,0.020171637,0.58146346],"study_design_scores_gemma":[0.016235916,0.029738395,0.2953226,0.0006826579,0.0012213564,0.010763251,0.020771895,0.0002479813,0.006898109,0.00048850593,0.61706764,0.0005616788],"about_ca_topic_score_codex":0.00007987463,"about_ca_topic_score_gemma":0.000042752716,"teacher_disagreement_score":0.596896,"about_ca_system_score_codex":0.0021749495,"about_ca_system_score_gemma":0.0014570266,"threshold_uncertainty_score":0.56874174},"labels":[],"label_agreement":null},{"id":"W4294942918","doi":"10.1016/j.jtho.2022.07.632","title":"EP08.01-060 Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Term (time); Internal medicine; Cancer","score_opus":0.03262936974105671,"score_gpt":0.43071347476088573,"score_spread":0.39808410501982905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294942918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965808,0.0017749933,0.00009819339,0.00068612036,0.00028081538,0.00026836927,0.00023048287,0.0000043405453,0.00007592811],"genre_scores_gemma":[0.99811524,0.00043099318,0.0007451847,0.00025549644,0.000042214964,0.0000119539745,0.00024259542,0.000019009549,0.00013728773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983541,0.0002714157,0.0005444785,0.0002125057,0.0004483895,0.0001691074],"domain_scores_gemma":[0.9985662,0.00013266767,0.00065708644,0.00039510854,0.00016783363,0.00008109062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005652091,0.00014118667,0.00088976545,0.00043454795,0.000078491816,0.000015474554,0.00022764501,0.00004849455,0.00016149662],"category_scores_gemma":[0.00002630136,0.00009295467,0.00009912453,0.0005260317,0.00007951674,0.00037065224,0.00007391289,0.00026798705,1.02137506e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047761295,0.0016723259,0.9015667,0.000012392123,0.0042895493,0.00011839881,0.0016973051,0.00026728582,0.00013836137,0.0000036230776,0.00002060065,0.08543737],"study_design_scores_gemma":[0.0046851565,0.0037748043,0.98820066,0.000024468378,0.0017855426,0.000025378966,0.00078268105,0.000077228724,0.000024887968,0.000010288386,0.0005187386,0.000090175556],"about_ca_topic_score_codex":0.00050363975,"about_ca_topic_score_gemma":0.0015282197,"teacher_disagreement_score":0.08663399,"about_ca_system_score_codex":0.00060929864,"about_ca_system_score_gemma":0.00094796583,"threshold_uncertainty_score":0.37905815},"labels":[],"label_agreement":null},{"id":"W4294943489","doi":"10.1016/j.jtho.2022.07.497","title":"EP05.02-015 Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-small-Cell Lung Cancer: Optimizing Outcomes throughout the Trajectory of Care","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de l'Outaouais; McGill University Health Centre","funders":"","keywords":"Prehabilitation; Medicine; Trajectory; Lung cancer; Oncology; Neoadjuvant therapy; Cancer; Physical therapy; Internal medicine","score_opus":0.019104570904725796,"score_gpt":0.41924495152498137,"score_spread":0.4001403806202556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294943489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96087134,0.025091559,0.00089300866,0.009448502,0.0014463586,0.0018490152,0.00006201643,0.000011386115,0.00032683366],"genre_scores_gemma":[0.9837734,0.001914374,0.01244491,0.0009522738,0.00021238194,0.000539314,0.000011293523,0.00003577258,0.00011624749],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826473,0.00022167961,0.0007100743,0.00020490996,0.00034987577,0.00024871968],"domain_scores_gemma":[0.99746454,0.00079322065,0.0009116216,0.00025593612,0.00048663677,0.00008803935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006158642,0.00018777404,0.0008158756,0.00012094511,0.0001871596,0.000008139218,0.0002264373,0.000077037825,0.000086206834],"category_scores_gemma":[0.000051173116,0.00011670618,0.00046622675,0.00015229096,0.00007457027,0.00008267848,0.00004963695,0.00036146704,2.7748527e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016341686,0.0035659925,0.1670395,0.0016861116,0.0021767048,0.0001378594,0.04321107,0.06819328,0.0058698137,0.000043461027,0.0048470404,0.6868875],"study_design_scores_gemma":[0.0745123,0.16127889,0.36941674,0.0026528328,0.011134305,0.00073458813,0.15389663,0.0056360313,0.088189535,0.00054541184,0.13045299,0.0015497503],"about_ca_topic_score_codex":0.000069304995,"about_ca_topic_score_gemma":0.00008225065,"teacher_disagreement_score":0.6853377,"about_ca_system_score_codex":0.0018866681,"about_ca_system_score_gemma":0.0014209737,"threshold_uncertainty_score":0.49335715},"labels":[],"label_agreement":null},{"id":"W4294943817","doi":"10.1016/j.jtho.2022.07.444","title":"EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Liquid biopsy; Lung cancer; Biopsy; Quality of life (healthcare); Radiology; Oncology; Cancer; Internal medicine; Nursing","score_opus":0.016887253659731618,"score_gpt":0.3682457377969757,"score_spread":0.35135848413724413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294943817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247795,0.004965454,0.00027066155,0.00059216755,0.00077739934,0.00054860703,0.00031654988,0.0000016253977,0.0000495719],"genre_scores_gemma":[0.99792457,0.00072392524,0.0008484637,0.00028241266,0.00008874624,0.00004475039,0.000045388297,0.000027192142,0.000014545037],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974013,0.00037184704,0.0014794238,0.0002218025,0.00019751764,0.00032810264],"domain_scores_gemma":[0.9963595,0.00027788916,0.0026035674,0.00027332568,0.0003483831,0.00013730198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010847492,0.00017917802,0.0006649705,0.00013908747,0.00010507721,0.000005353447,0.000342238,0.00014214347,0.00003141449],"category_scores_gemma":[0.00035332292,0.00014415776,0.00036819646,0.00021013869,0.000077797245,0.000006990869,0.00023044854,0.00028867114,1.3367121e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096983105,0.005720533,0.16417958,0.0013125258,0.0014193221,0.000023726354,0.004962619,0.18207735,0.5178473,0.000055693105,0.00465756,0.020760654],"study_design_scores_gemma":[0.042375036,0.35258448,0.29524434,0.0010253815,0.0009938675,0.00023731613,0.010005988,0.0018605129,0.28142595,0.00051792257,0.011070066,0.0026591294],"about_ca_topic_score_codex":0.0005265723,"about_ca_topic_score_gemma":0.00026300515,"teacher_disagreement_score":0.34686396,"about_ca_system_score_codex":0.00058119587,"about_ca_system_score_gemma":0.0027915572,"threshold_uncertainty_score":0.58785826},"labels":[],"label_agreement":null},{"id":"W4294943844","doi":"10.1016/j.jtho.2022.07.376","title":"EP02.03-020 Patient Outcomes Following Salvage Lung Cancer Surgery Post Definitive Chemotherapy or Radiation","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Salvage surgery; Lung cancer; Chemotherapy; Radiation therapy; Surgery; Salvage therapy; General surgery; Oncology","score_opus":0.024652266170639682,"score_gpt":0.4134501269992294,"score_spread":0.3887978608285897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294943844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96269226,0.0039994367,0.000016635382,0.030024666,0.002452729,0.000350768,0.000037173268,0.000015542,0.0004107637],"genre_scores_gemma":[0.98861605,0.0009714731,0.00044279097,0.009381569,0.00022668506,0.00011223027,0.000018319657,0.000033013937,0.0001978832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981732,0.00027146417,0.0006478549,0.00018052962,0.0004648893,0.00026206454],"domain_scores_gemma":[0.9979755,0.0008090735,0.000760099,0.0001426837,0.0001551037,0.00015752247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005689539,0.0001718425,0.00082507427,0.0002648684,0.00016989995,0.000013719977,0.000083315186,0.00007459574,0.0016496754],"category_scores_gemma":[0.00016867794,0.000119143595,0.00050963415,0.00023386786,0.000024540062,0.00010643841,0.00004352037,0.00036578617,0.0000054049647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034762155,0.0013523584,0.6338635,0.00007287484,0.0018697422,0.0026950825,0.0022274107,0.00009345145,0.00016814248,0.000010791769,0.02280137,0.33136907],"study_design_scores_gemma":[0.006362859,0.008372766,0.8259756,0.0004828847,0.0031565125,0.0013278731,0.0033887806,0.00009978433,0.0030140167,0.00007018086,0.14728074,0.00046802565],"about_ca_topic_score_codex":0.000117906704,"about_ca_topic_score_gemma":0.000052152078,"teacher_disagreement_score":0.33090103,"about_ca_system_score_codex":0.0032598746,"about_ca_system_score_gemma":0.001416563,"threshold_uncertainty_score":0.9992629},"labels":[],"label_agreement":null},{"id":"W4294944328","doi":"10.1016/j.jtho.2022.07.439","title":"EP04.01-027 Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Sunnybrook Hospital; University of Manitoba; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Psychological intervention; Oncology; Internal medicine; Nursing","score_opus":0.023397391806014443,"score_gpt":0.39345710066277606,"score_spread":0.3700597088567616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293865,0.0069080396,0.00060880056,0.008140903,0.0002878944,0.00043774137,0.00003516511,0.0000074289023,0.0006353573],"genre_scores_gemma":[0.9949505,0.0008843493,0.0013107419,0.00078935426,0.00010613289,0.00012872645,0.000009398761,0.000016104232,0.0018047402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816805,0.0004846708,0.000676725,0.00020808056,0.0002267022,0.00023574126],"domain_scores_gemma":[0.9986144,0.00033274782,0.00063396624,0.0001677708,0.000086746244,0.0001644123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017327351,0.00013587304,0.0007377854,0.00063331303,0.000091735885,0.000015284848,0.00012426301,0.000063295345,0.00071823713],"category_scores_gemma":[0.000066378925,0.000112049565,0.00039438024,0.0005047818,0.000039406048,0.00006348205,0.000116867115,0.00049587915,8.3543335e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080193067,0.0019616087,0.94581413,0.0005734295,0.0014467175,0.0019083878,0.000988118,0.0015606735,0.00008009004,0.0000074331274,0.0047404394,0.040117055],"study_design_scores_gemma":[0.006939422,0.013626374,0.880889,0.0009398776,0.014474573,0.00029471077,0.004704444,0.0070152264,0.0005154103,0.00007962591,0.07012801,0.00039330407],"about_ca_topic_score_codex":0.0005205801,"about_ca_topic_score_gemma":0.0043647327,"teacher_disagreement_score":0.06538757,"about_ca_system_score_codex":0.0022927176,"about_ca_system_score_gemma":0.0007981949,"threshold_uncertainty_score":0.78641933},"labels":[],"label_agreement":null},{"id":"W4294944332","doi":"10.1016/j.jtho.2022.07.065","title":"OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Radon; Medicine; Radon exposure; Environmental health; Oncology; Lung cancer; Nuclear physics","score_opus":0.027540709912356583,"score_gpt":0.405678416901278,"score_spread":0.3781377069889214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944332","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949697,0.0012470767,0.000100621466,0.0025454988,0.0001748099,0.00035252262,0.000003127965,0.0000052200476,0.0006013978],"genre_scores_gemma":[0.99835175,0.00019888816,0.0008652565,0.00038038963,0.000039819126,0.000007831707,0.0000020741968,0.00001463125,0.00013935298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788845,0.0008244123,0.00072717585,0.0001456161,0.00027025669,0.0001440777],"domain_scores_gemma":[0.99903536,0.00012205684,0.0004564663,0.00013710978,0.00017496766,0.000074016345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013278128,0.00009408876,0.00041219298,0.0005712413,0.00004366957,0.000010209037,0.00013250487,0.000028943981,0.00009643541],"category_scores_gemma":[0.0005854931,0.00008656475,0.000031658954,0.00080733636,0.00004447026,0.00015600177,0.000090778936,0.0005612413,0.0000016344826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037173163,0.0045045386,0.717082,0.00029163974,0.00015039154,0.0072985846,0.0076255254,0.0066556167,0.09606231,0.000047336966,0.000644651,0.15592007],"study_design_scores_gemma":[0.004563369,0.0063238805,0.97358185,0.00025307282,0.00026134186,0.002080641,0.0013013197,0.005453616,0.0037781443,0.000035154368,0.0022221592,0.0001454418],"about_ca_topic_score_codex":0.000021281403,"about_ca_topic_score_gemma":0.000006586259,"teacher_disagreement_score":0.25649986,"about_ca_system_score_codex":0.00014909898,"about_ca_system_score_gemma":0.0003880721,"threshold_uncertainty_score":0.35300082},"labels":[],"label_agreement":null},{"id":"W4294944338","doi":"10.1016/j.jtho.2022.07.328","title":"EP02.01-001 Plasma Cell-Free DNA as a Point-of-Care Wellbeing Biomarker for Early-Stage Non-Small Cell Lung Cancer Patients","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Nurses in Oncology; Vancouver General Hospital; Vancouver Coastal Health","funders":"","keywords":"Medicine; Biomarker; Stage (stratigraphy); Oncology; Cell-free fetal DNA; Point of care; Lung cancer; Cell; Internal medicine; Lung; Cancer research; Pathology; Genetics","score_opus":0.01482640344656877,"score_gpt":0.3437613392606132,"score_spread":0.3289349358140444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98653346,0.0017530713,0.00017441997,0.0010587255,0.003799693,0.0007799473,0.00023260713,0.000014331333,0.0056537623],"genre_scores_gemma":[0.9944711,0.00014013189,0.0009128357,0.00063604745,0.00041322326,0.00010113262,0.000039235812,0.00006910207,0.003217205],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99754494,0.00024032801,0.00088647683,0.00029305616,0.0005662057,0.00046898276],"domain_scores_gemma":[0.9971836,0.00032675988,0.0011991854,0.00036741263,0.0006429963,0.00028002073],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006977346,0.00025579587,0.0008587423,0.00040390497,0.00018747886,0.000016841615,0.00048462686,0.00019363826,0.0011100151],"category_scores_gemma":[0.00009763622,0.0002341162,0.00047123161,0.0003180143,0.0000965247,0.00011351298,0.00029728765,0.0006764133,0.000004075313],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08029523,0.008169861,0.43989822,0.012806003,0.0020695596,0.0027638848,0.06367729,0.00067446014,0.052998263,0.0000538202,0.15044947,0.18614395],"study_design_scores_gemma":[0.037831817,0.042381123,0.057916995,0.0012588046,0.005269135,0.0005352151,0.042498417,0.0013858385,0.10428161,0.0002326926,0.7048672,0.0015411788],"about_ca_topic_score_codex":0.00042688783,"about_ca_topic_score_gemma":0.00046631484,"teacher_disagreement_score":0.55441767,"about_ca_system_score_codex":0.0012235946,"about_ca_system_score_gemma":0.0011744102,"threshold_uncertainty_score":0.9998031},"labels":[],"label_agreement":null},{"id":"W4294944568","doi":"10.1016/j.jtho.2022.07.206","title":"P1.15-10 Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Pulmonary disease; Immunotherapy; Internal medicine; Oncology; Population; Intensive care medicine; Disease; Lung; Cancer; Environmental health","score_opus":0.013554324106417243,"score_gpt":0.362537698635397,"score_spread":0.34898337452897976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918552,0.0039839437,0.000025012961,0.0014949801,0.0014455426,0.0010866128,0.00007171334,0.000005212457,0.000031760646],"genre_scores_gemma":[0.99858236,0.000049295664,0.00014962403,0.0006092906,0.00020525104,0.00020704605,0.000032165164,0.000028291703,0.00013667344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980674,0.00032003087,0.0007272667,0.00019075189,0.00042405666,0.0002705443],"domain_scores_gemma":[0.9985717,0.00024458303,0.00072358246,0.00017068947,0.00017401113,0.000115449744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055206596,0.00015181625,0.0005014379,0.00025350167,0.00017382066,0.000007493223,0.00018258524,0.00003751955,0.0007360194],"category_scores_gemma":[0.00006004069,0.00013784986,0.00016555327,0.00031916326,0.000018438912,0.00008167666,0.000028899454,0.0003606533,7.492036e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034405448,0.0008109526,0.7743969,0.000080319034,0.0002234907,0.00019528327,0.00021645939,0.0017666684,0.00022974605,2.807526e-7,0.0005019086,0.18717255],"study_design_scores_gemma":[0.004889188,0.0023410954,0.9841899,0.00009591143,0.00018815484,0.000023442866,0.00080060307,0.0019851027,0.000024015633,0.000016704005,0.0053051324,0.0001407101],"about_ca_topic_score_codex":0.136319,"about_ca_topic_score_gemma":0.32023582,"teacher_disagreement_score":0.20979305,"about_ca_system_score_codex":0.015022735,"about_ca_system_score_gemma":0.0090029845,"threshold_uncertainty_score":0.99661505},"labels":[],"label_agreement":null},{"id":"W4294944611","doi":"10.1016/j.jtho.2022.07.095","title":"MA04.05 T3 Defining Features Influence Long Term Survival after Resection of T3N0M0 NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Term (time); Resection; Oncology; Internal medicine; Surgery; Astronomy","score_opus":0.01781791556818545,"score_gpt":0.399707538790182,"score_spread":0.38188962322199654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016154,0.00423502,0.000016895621,0.0029772224,0.0012420082,0.00015359235,0.0000126912855,0.000007896482,0.0011931382],"genre_scores_gemma":[0.9979934,0.0003001338,0.00063905993,0.0004560756,0.00025817927,0.0000342243,0.0000048476827,0.000017466169,0.00029657508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840236,0.00026941072,0.0005137228,0.00015375746,0.00045749056,0.00020324596],"domain_scores_gemma":[0.9986486,0.00022489345,0.0006014425,0.00018504789,0.00022381337,0.0001162384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073915714,0.0001222424,0.0005281726,0.000249357,0.00008989547,0.000009560126,0.00012351545,0.000087363216,0.00032606325],"category_scores_gemma":[0.00011177549,0.00009603539,0.00019977166,0.00021921094,0.0000662955,0.00010325516,0.00010229795,0.0005577454,0.000003935765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012936466,0.001343477,0.8601989,0.0002522907,0.0007491077,0.0035240971,0.0011227037,0.00036580503,0.0018137504,0.00008433989,0.0030631297,0.11454593],"study_design_scores_gemma":[0.001457946,0.007673752,0.97890824,0.00028775117,0.0006332352,0.003080439,0.00033772457,0.0000024652047,0.002301964,0.000081481885,0.0051444937,0.00009052708],"about_ca_topic_score_codex":0.00006165039,"about_ca_topic_score_gemma":0.00014580581,"teacher_disagreement_score":0.11870932,"about_ca_system_score_codex":0.0010668213,"about_ca_system_score_gemma":0.0004669606,"threshold_uncertainty_score":0.39162093},"labels":[],"label_agreement":null},{"id":"W4294944612","doi":"10.1016/j.jtho.2022.07.467","title":"EP05.01-020 Unanticipated Radiation Re-planning for Stage III Non-small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Microsemi (Canada); Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Cancer; Oncology; Internal medicine","score_opus":0.03708926681296682,"score_gpt":0.43750032471918887,"score_spread":0.40041105790622206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837187,0.005180655,0.00083993067,0.00641792,0.0017924916,0.0007755572,0.00005229489,0.00001546386,0.001207006],"genre_scores_gemma":[0.99378896,0.000488627,0.0017752559,0.001216363,0.000635757,0.00021470839,0.00002913135,0.00003300783,0.0018182157],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985439,0.00013138408,0.00057760987,0.00018755494,0.00026016287,0.0002993916],"domain_scores_gemma":[0.99840325,0.0002518338,0.0008451946,0.00014837833,0.00018265043,0.00016868813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073203666,0.00014751498,0.0005938758,0.00021482137,0.00019369462,0.000013125496,0.00012580428,0.00008876456,0.00088724133],"category_scores_gemma":[0.000036885023,0.00012117192,0.00020746909,0.00018641619,0.000021879436,0.00006426867,0.00005064276,0.00039117888,0.0000020552284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023952002,0.005865315,0.45749626,0.0022883243,0.0033433912,0.0047641047,0.015704872,0.038151685,0.012569485,0.00006899207,0.26331797,0.1724776],"study_design_scores_gemma":[0.030450976,0.027559442,0.09864105,0.0010854725,0.009442911,0.0007998562,0.007660102,0.017551785,0.044374652,0.00011520333,0.7614911,0.0008274029],"about_ca_topic_score_codex":0.00013884746,"about_ca_topic_score_gemma":0.00004774847,"teacher_disagreement_score":0.49817318,"about_ca_system_score_codex":0.0022986245,"about_ca_system_score_gemma":0.0010145447,"threshold_uncertainty_score":0.9714671},"labels":[],"label_agreement":null},{"id":"W4294944712","doi":"10.1016/j.jtho.2022.07.441","title":"EP04.02-001 Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Cancer research","score_opus":0.013994358405730462,"score_gpt":0.33618110957336395,"score_spread":0.3221867511676335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294944712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943361,0.0021666097,0.00049738254,0.0006896246,0.0015851054,0.00026331464,0.00006633609,0.0000038081453,0.000391693],"genre_scores_gemma":[0.9974292,0.00033741645,0.00027038413,0.00037170982,0.0004703349,0.00003912112,0.000027596156,0.000029859859,0.0010243811],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981409,0.00039828496,0.00053663837,0.00025546504,0.00029816353,0.0003705997],"domain_scores_gemma":[0.99921894,0.00003987098,0.00031760504,0.00016250738,0.0001020525,0.00015899765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000541658,0.000189257,0.0003844638,0.00016013393,0.00011048148,0.000018662802,0.00037057034,0.00018759393,0.0006622372],"category_scores_gemma":[0.00002512946,0.0001779925,0.00019616834,0.00012670978,0.000038891427,0.0000069953535,0.00016703273,0.0006348199,0.0000045295496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002959161,0.0019698122,0.06501235,0.00012431025,0.00030107104,0.0024058023,0.0009366541,0.0075698695,0.8905389,0.00000642907,0.0020260816,0.026149578],"study_design_scores_gemma":[0.028343076,0.04655516,0.25734645,0.00028363342,0.0023087086,0.01304758,0.009439753,0.004140048,0.4135145,0.0004579158,0.2205302,0.0040329657],"about_ca_topic_score_codex":0.00020698282,"about_ca_topic_score_gemma":0.00025425488,"teacher_disagreement_score":0.47702438,"about_ca_system_score_codex":0.000177242,"about_ca_system_score_gemma":0.00078224397,"threshold_uncertainty_score":0.72583234},"labels":[],"label_agreement":null},{"id":"W4295169097","doi":"10.1016/j.jtho.2022.07.706","title":"EP08.02-024 Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Lung cancer; Brain metastasis; Lung; Metastasis; Cancer; Radiology; Systemic therapy; Oncology; Internal medicine; Breast cancer","score_opus":0.09092921533131355,"score_gpt":0.5389758959957797,"score_spread":0.4480466806644661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295169097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96722376,0.018050011,0.0001605018,0.013288843,0.0003618763,0.00059649127,0.0001645482,0.000006248519,0.00014771058],"genre_scores_gemma":[0.9934302,0.0019702225,0.0033706236,0.00042691658,0.0003335698,0.00009470869,0.000032027623,0.000029147599,0.000312557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99336797,0.0032277165,0.0014898869,0.00036285192,0.0011507043,0.00040084697],"domain_scores_gemma":[0.9949606,0.0023123298,0.0014670414,0.00056140294,0.00045894494,0.00023968637],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009474675,0.00020089309,0.0019017601,0.0010942728,0.000112733454,0.000014534913,0.00032623045,0.00014436185,0.0012982383],"category_scores_gemma":[0.0004010854,0.00013518236,0.00055883167,0.0018619872,0.00018169501,0.000073295916,0.000121080455,0.0013187961,0.0000015218815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10871125,0.008473522,0.46342295,0.0005179251,0.046091955,0.019739095,0.0034797967,0.0061629065,0.004674924,0.00012050256,0.04774351,0.29086164],"study_design_scores_gemma":[0.09173853,0.112167686,0.3972157,0.004558085,0.05753281,0.0147640705,0.028071355,0.004358125,0.0074373265,0.00272277,0.27734432,0.0020892366],"about_ca_topic_score_codex":0.0017169991,"about_ca_topic_score_gemma":0.00060215977,"teacher_disagreement_score":0.2887724,"about_ca_system_score_codex":0.0012237398,"about_ca_system_score_gemma":0.0018706113,"threshold_uncertainty_score":0.9996147},"labels":[],"label_agreement":null},{"id":"W4295169106","doi":"10.1016/j.jtho.2022.07.567","title":"EP07.03-002 Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Thymoma; Medicine; Thymic carcinoma; University hospital; General surgery; Oncology; Internal medicine; Pathology","score_opus":0.027037470659930216,"score_gpt":0.3521810237968701,"score_spread":0.3251435531369399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295169106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191576,0.00021771243,0.000074916396,0.0052853995,0.00053173775,0.00030387976,0.00007526919,0.000014937641,0.0015803698],"genre_scores_gemma":[0.9937252,0.000060680104,0.0024373734,0.00018060114,0.0002102239,0.000009730279,0.000023026023,0.000017379663,0.003335813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880713,0.00017236188,0.00036106937,0.00021435556,0.00023054265,0.00021451464],"domain_scores_gemma":[0.9987099,0.00025164345,0.00045444202,0.00022777433,0.00015288212,0.00020333195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033243932,0.00012044188,0.0004699967,0.00026228247,0.00023710681,0.000013266945,0.00023058472,0.00007329271,0.0005634994],"category_scores_gemma":[0.00006452598,0.00011615317,0.00016110722,0.0002489791,0.00014642785,0.000099162295,0.0001237778,0.00036944318,0.000005450644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042923294,0.0077041937,0.51456344,0.00022056449,0.0015150948,0.008722242,0.04209371,0.00003424671,0.03574626,0.012623982,0.09903236,0.23482062],"study_design_scores_gemma":[0.0035157942,0.0073732594,0.7464497,0.0000351092,0.00044744014,0.0004938235,0.013497951,0.00044276836,0.00031401863,0.0009859634,0.22623217,0.0002119835],"about_ca_topic_score_codex":0.00012540058,"about_ca_topic_score_gemma":0.00004906284,"teacher_disagreement_score":0.23460864,"about_ca_system_score_codex":0.0004116215,"about_ca_system_score_gemma":0.00038048255,"threshold_uncertainty_score":0.6169923},"labels":[],"label_agreement":null},{"id":"W4295169256","doi":"10.1016/j.jtho.2022.07.695","title":"EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Oncology; Internal medicine; ROS1; Cancer; Adenocarcinoma","score_opus":0.013159745558069796,"score_gpt":0.4129073631286669,"score_spread":0.39974761757059707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295169256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913142,0.0011178621,0.000047529134,0.0042525236,0.0003763988,0.00059017295,0.000031841075,0.0000057404313,0.002263734],"genre_scores_gemma":[0.9988485,0.000060717306,0.00041216955,0.00030709224,0.000045429602,0.00003093675,0.000006731781,0.000011634997,0.0002767939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853736,0.0003463661,0.00051929755,0.00014831228,0.00027559744,0.00017306465],"domain_scores_gemma":[0.99873775,0.00027622134,0.00053515646,0.00015044093,0.00021212897,0.000088287845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045309454,0.0001134245,0.0004485475,0.00016380378,0.00013593615,0.000005212691,0.00010920444,0.00006503001,0.00019059243],"category_scores_gemma":[0.00021314803,0.00007454885,0.000106085856,0.00035318767,0.00011982055,0.000080181104,0.00011849871,0.00044504335,3.9475327e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052056783,0.0023505182,0.78582174,0.00014536934,0.00056399516,0.0007992239,0.0047856844,0.00028980445,0.0051318337,0.0000685154,0.0009934417,0.19384418],"study_design_scores_gemma":[0.0032431905,0.0024027033,0.9843613,0.00024267394,0.0008358162,0.0012941599,0.002340565,0.0006433369,0.0016806327,0.00032663535,0.0025391036,0.00008986465],"about_ca_topic_score_codex":0.00009626932,"about_ca_topic_score_gemma":0.00006142408,"teacher_disagreement_score":0.19853956,"about_ca_system_score_codex":0.00041000705,"about_ca_system_score_gemma":0.00062981545,"threshold_uncertainty_score":0.3040014},"labels":[],"label_agreement":null},{"id":"W4295297459","doi":"10.1016/j.jtho.2022.08.018","title":"Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Janssen Pharmaceuticals; Chugai Pharmaceutical; EMD Serono; Teijin Pharma; Daiichi-Sankyo; G1 Therapeutics; BeiGene; Mirati Therapeutics; Bristol-Myers Squibb; Society for Academic Continuing Medical Education; Johnson and Johnson; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; Takeda Pharmaceutical Company; AbbVie; Merck; Yuhan; Merck KGaA; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Roche; Novartis; GlaxoSmithKline Japan; Sanofi; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Alectinib; Ceritinib; Medicine; Crizotinib; Internal medicine; ALK inhibitor; Anaplastic lymphoma kinase; Lung cancer; Gastroenterology; Oncology; Clinical endpoint; Adverse effect; Confidence interval; Clinical trial","score_opus":0.015249162801495204,"score_gpt":0.43815073301899576,"score_spread":0.4229015702175006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295297459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939231,0.00031066994,0.000007174632,0.0013259845,0.00047779756,0.0020952497,0.00010604241,0.000007066817,0.0017468686],"genre_scores_gemma":[0.9976459,0.00004803975,0.0014939634,0.00023887398,0.0001336979,0.00018869297,0.000034769364,0.000035835434,0.00018020015],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99713993,0.00043992107,0.0012061276,0.00026390218,0.00064151204,0.00030860325],"domain_scores_gemma":[0.99706936,0.0005301038,0.0016535511,0.00019618958,0.00042192364,0.0001288847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005263749,0.00021160248,0.0011301176,0.0004457893,0.00006875034,0.000005681228,0.00016652228,0.000097904194,0.00023443223],"category_scores_gemma":[0.00027805436,0.00015412977,0.00014840292,0.0007427731,0.00013072988,0.00012912495,0.000049316935,0.0006337778,3.3885252e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6091863,0.012103653,0.11186277,0.00026719272,0.0009052635,0.00049937796,0.005824666,0.001744802,0.00042433952,0.000022860184,0.00036061535,0.25679815],"study_design_scores_gemma":[0.28966555,0.0852356,0.6099833,0.003239154,0.0013855196,0.00013012026,0.0019452733,0.00010406802,0.0050288877,0.000038507664,0.0028970337,0.0003469479],"about_ca_topic_score_codex":0.00014881878,"about_ca_topic_score_gemma":0.00019031306,"teacher_disagreement_score":0.49812055,"about_ca_system_score_codex":0.0010593677,"about_ca_system_score_gemma":0.0020597735,"threshold_uncertainty_score":0.62852293},"labels":[],"label_agreement":null},{"id":"W4296767437","doi":"10.1016/j.jtho.2022.07.163","title":"P1.02-02 Current Status, Challenges and Perspectives of Lung Cancer Screening in Low- and Middle-Income Countries","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Lung cancer; Low and middle income countries; Current (fluid); Environmental health; Oncology; Economic growth; Developing country; Economics","score_opus":0.04180035784515361,"score_gpt":0.41667608909820775,"score_spread":0.3748757312530541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296767437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68739146,0.30584583,0.000003455435,0.0062455586,0.0002326035,0.00014755716,0.000017384691,0.0000027563474,0.00011342645],"genre_scores_gemma":[0.8621814,0.13723284,0.00033166655,0.000057502944,0.00013473192,0.00002840835,8.683264e-7,0.000010207279,0.000022338101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880683,0.00016312898,0.0003995161,0.00016510776,0.00026319528,0.00020220906],"domain_scores_gemma":[0.99901295,0.00022323757,0.00042440533,0.000086265034,0.00013076454,0.00012240825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000502944,0.00011772207,0.00058588816,0.00025719154,0.000063638676,0.0000064115366,0.000053924596,0.000044467004,0.00011400698],"category_scores_gemma":[0.000041616786,0.0000936456,0.000061021336,0.00009079534,0.00011749787,0.000088709305,0.00009435079,0.00036532758,1.000896e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039313314,0.0012226874,0.74981225,0.0026368145,0.0007836198,0.00055682403,0.030186666,0.00011631535,0.000027440514,0.00042485225,0.00020103213,0.21010017],"study_design_scores_gemma":[0.003830555,0.003930231,0.9566956,0.0035944674,0.00072511536,0.0005790289,0.01831932,0.00018028205,0.00020481087,0.00015461323,0.011625968,0.00016001918],"about_ca_topic_score_codex":0.0000831182,"about_ca_topic_score_gemma":0.00022132308,"teacher_disagreement_score":0.20994015,"about_ca_system_score_codex":0.0008506573,"about_ca_system_score_gemma":0.0004050851,"threshold_uncertainty_score":0.38187566},"labels":[],"label_agreement":null},{"id":"W4296767458","doi":"10.1016/j.jtho.2022.07.165","title":"P1.02-04 Spatial Access to Lung Screening in British Columbia, Canada","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Proxy (statistics); Lung cancer screening; Lung cancer; Population; Demography; Environmental health; Oncology; Statistics","score_opus":0.052685091878755815,"score_gpt":0.42290365823285214,"score_spread":0.37021856635409633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296767458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990124,0.0006045618,0.00066780375,0.005872332,0.001121966,0.00024471938,0.000020201958,0.0000070490946,0.0013373739],"genre_scores_gemma":[0.9898582,0.000018442102,0.0017177154,0.007378032,0.0005199876,0.000015769661,0.0000047707686,0.00001560167,0.0004714578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977895,0.00022749302,0.0006712282,0.00018694311,0.00074755406,0.00037729758],"domain_scores_gemma":[0.9988476,0.00011408632,0.000393604,0.00013452605,0.00020215452,0.0003080006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010948281,0.00008400877,0.000571628,0.00014378836,0.00017682831,0.000090071364,0.00041076288,0.00006608044,0.0013700618],"category_scores_gemma":[0.00029242522,0.00012693813,0.000096026924,0.0004902304,0.000026660018,0.00018370205,0.00029239408,0.00085282,8.1865807e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008944243,0.00009624105,0.55518305,0.000031682754,0.000063196036,0.012658027,0.00014242876,0.0017410489,0.0001250841,6.32021e-7,0.1081654,0.3208988],"study_design_scores_gemma":[0.0012240665,0.0019390999,0.847537,0.00032459662,0.00014233624,0.009912485,0.0020657307,0.00041641234,0.000058735124,0.000045421493,0.13613868,0.00019546403],"about_ca_topic_score_codex":0.8944446,"about_ca_topic_score_gemma":0.9905926,"teacher_disagreement_score":0.32070336,"about_ca_system_score_codex":0.0018750015,"about_ca_system_score_gemma":0.0033993039,"threshold_uncertainty_score":0.99954283},"labels":[],"label_agreement":null},{"id":"W4296767489","doi":"10.1016/j.jtho.2022.07.1076","title":"EP16.03-015 Centrosome Amplification Is a Prognostic Indicator and Potential Therapeutic Vulnerability in Non-small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Centrosome; Vulnerability (computing); Lung cancer; Cancer research; Oncology; Cancer; Cell; Internal medicine; Cell cycle; Genetics; Computer security; Biology","score_opus":0.010276799665264697,"score_gpt":0.33089245385517296,"score_spread":0.3206156541899083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296767489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927505,0.004032184,0.0013641473,0.0010723441,0.00037715095,0.0003179039,0.000034678153,0.0000022746958,0.00004880561],"genre_scores_gemma":[0.9975285,0.00079745793,0.0005306128,0.00075127394,0.00020018818,0.00005157836,0.000018934556,0.000016887827,0.000104564795],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986281,0.0003103532,0.00043648607,0.0002516728,0.0001354363,0.00023798902],"domain_scores_gemma":[0.9991597,0.000027897111,0.00046265018,0.00017415863,0.00008355812,0.0000920448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006367374,0.00013003284,0.0002660918,0.000121291734,0.000104710394,0.00001694304,0.00023655692,0.00014799536,0.00007826607],"category_scores_gemma":[0.000024657815,0.00012301804,0.000093699055,0.00011163788,0.00006339594,0.0000067503365,0.0001577096,0.00040801635,9.895044e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086806196,0.00077060965,0.11617112,0.000117579024,0.00011360448,0.000039637667,0.00087868376,0.00052105234,0.85501724,0.0000064414617,0.0009849444,0.024511013],"study_design_scores_gemma":[0.008670361,0.010080569,0.5648093,0.00013530496,0.0016755294,0.0021515992,0.004904245,0.008028294,0.27253777,0.0010110027,0.12421929,0.001776726],"about_ca_topic_score_codex":0.000022047381,"about_ca_topic_score_gemma":0.00003169088,"teacher_disagreement_score":0.5824795,"about_ca_system_score_codex":0.00018771188,"about_ca_system_score_gemma":0.00042120024,"threshold_uncertainty_score":0.501653},"labels":[],"label_agreement":null},{"id":"W4296767782","doi":"10.1016/j.jtho.2022.07.340","title":"EP02.01-013 Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; KRAS; Oncology; Internal medicine; Lung cancer; Cancer; Colorectal cancer","score_opus":0.013307281357276716,"score_gpt":0.3684444308555025,"score_spread":0.3551371494982258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296767782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99761915,0.00022535554,0.000004744034,0.0008225935,0.00025594656,0.0006707281,0.000052386844,0.0000050895433,0.00034399188],"genre_scores_gemma":[0.99414366,0.00013195984,0.00027226834,0.00017332345,0.000030438865,0.00009870298,0.000018151275,0.000019165213,0.0051123034],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872583,0.00012941167,0.00047914634,0.00020384956,0.000223312,0.00023846797],"domain_scores_gemma":[0.9991936,0.000073158626,0.00041789442,0.00012303602,0.00007207011,0.00012023304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016002398,0.00017489454,0.00055465597,0.00037006475,0.000056390705,0.0000108849135,0.0000759721,0.000045329536,0.00032221377],"category_scores_gemma":[0.0000037154605,0.0001203205,0.0000588553,0.00016966723,0.000020036292,0.00008531428,0.00004371302,0.0003414391,6.8286164e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001939315,0.0016956945,0.975422,0.000094239906,0.00021317646,0.0006528111,0.006533873,0.00041187947,0.000008829427,2.3589335e-7,0.000020886497,0.013007021],"study_design_scores_gemma":[0.007314171,0.0043695015,0.98639226,0.00019146009,0.0007279428,0.000035409448,0.00039298343,0.000032846725,0.000031011306,0.0000036709562,0.00040323002,0.00010551519],"about_ca_topic_score_codex":0.03960309,"about_ca_topic_score_gemma":0.35050142,"teacher_disagreement_score":0.31089833,"about_ca_system_score_codex":0.006534642,"about_ca_system_score_gemma":0.0010529216,"threshold_uncertainty_score":0.9972791},"labels":[],"label_agreement":null},{"id":"W4296767992","doi":"10.1016/j.jtho.2022.07.432","title":"EP04.01-020 Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Center (category theory); Oncology; DNA sequencing; Internal medicine; Genetics; Gene","score_opus":0.0338510810791569,"score_gpt":0.3201060568664355,"score_spread":0.2862549757872786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296767992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987834,0.00016139659,0.00016773389,0.00018337724,0.00021771621,0.00013809088,0.00023155453,0.0000010517554,0.00011564037],"genre_scores_gemma":[0.9990015,0.000101640675,0.00034843013,0.00015353718,0.00020927678,0.0000016656643,0.00013094027,0.000010392302,0.00004263375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991773,0.0002308375,0.00020759105,0.00012700209,0.00013708285,0.00012021354],"domain_scores_gemma":[0.9990714,0.000107477885,0.00048435587,0.00016421083,0.00011181743,0.000060733397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015486345,0.00010794692,0.00021164697,0.00004472299,0.00011389067,0.000010661081,0.00016691514,0.000037370264,0.00007633142],"category_scores_gemma":[0.000046443252,0.00006907141,0.00014882168,0.00006685821,0.00005098027,0.0000075624994,0.00006488972,0.00012421912,5.718133e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013234733,0.0035935496,0.56069183,0.00001908015,0.0038925773,0.00023513904,0.0021483514,0.09119168,0.21130866,0.000030649266,0.01418735,0.09946639],"study_design_scores_gemma":[0.01445506,0.089956045,0.7187934,0.00009626069,0.0021871952,0.00014698198,0.003377583,0.0018664794,0.052634165,0.00009838824,0.115522936,0.00086550246],"about_ca_topic_score_codex":0.0005136806,"about_ca_topic_score_gemma":0.00057147647,"teacher_disagreement_score":0.1586745,"about_ca_system_score_codex":0.0007384566,"about_ca_system_score_gemma":0.0004725315,"threshold_uncertainty_score":0.28166503},"labels":[],"label_agreement":null},{"id":"W4296768436","doi":"10.1016/j.jtho.2022.07.300","title":"EP01.04-005 Quantitative Characteristics in Global CT Lung Cancer Screening Populations Using the ELIC Distributed Database and Computation Environment","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Medicine; Computation; Lung cancer; Lung cancer screening; Internal medicine; Algorithm; Computer science","score_opus":0.0748100778827526,"score_gpt":0.4739621894827811,"score_spread":0.3991521116000285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796379,0.0027457082,0.0103219,0.0063373465,0.0003113148,0.00026831182,0.00036359756,0.0000033548056,0.000010517443],"genre_scores_gemma":[0.9893156,0.00032512177,0.009856337,0.00027258764,0.0000917795,0.000021067583,0.00010706547,0.0000072564353,0.000003146712],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885535,0.00025447487,0.00040787825,0.000118740325,0.00022691638,0.00013661612],"domain_scores_gemma":[0.9991901,0.00013296552,0.00048820395,0.00007941863,0.000038410864,0.00007091891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004380254,0.00009157759,0.0003117106,0.000068023895,0.00020520078,0.000012250647,0.000053444706,0.000019016172,0.000067582914],"category_scores_gemma":[0.000040000217,0.0000672938,0.00005122508,0.00015823856,0.000057958077,0.00007902614,0.00008608128,0.00025434955,2.388683e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013243097,0.000855461,0.88683945,0.00006382153,0.00045916293,0.0009889954,0.000629978,0.029128622,0.00022622844,0.00022516797,0.0007098369,0.078548945],"study_design_scores_gemma":[0.001678719,0.00093948666,0.9221652,0.00022329112,0.0013469751,0.0012942401,0.0013253852,0.06732436,0.000029350267,0.00011359928,0.0034452165,0.0001141726],"about_ca_topic_score_codex":0.0002647826,"about_ca_topic_score_gemma":0.000091535585,"teacher_disagreement_score":0.07843477,"about_ca_system_score_codex":0.0019993288,"about_ca_system_score_gemma":0.00021412785,"threshold_uncertainty_score":0.52281755},"labels":[],"label_agreement":null},{"id":"W4296768440","doi":"10.1016/j.jtho.2022.07.516","title":"EP06.01-001 The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Retrospective cohort study; Cohort; Cancer; Incidence (geometry); Pandemic; Internal medicine; Cohort study; Coronavirus disease 2019 (COVID-19); Disease; Infectious disease (medical specialty)","score_opus":0.120985244039211,"score_gpt":0.5265197362578306,"score_spread":0.40553449221861954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7060755,0.04972353,5.3270475e-7,0.24284065,0.00019785861,0.00086377125,0.00019784561,0.000002871169,0.000097424636],"genre_scores_gemma":[0.90134203,0.089461744,0.0000053778435,0.008723656,0.00022911833,0.000060468286,0.0000042691845,0.000013772285,0.0001595518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780667,0.0006248473,0.0006369855,0.00016926153,0.00041018234,0.0003520684],"domain_scores_gemma":[0.9967585,0.0011335752,0.0010055488,0.00025385545,0.00020666659,0.00064182404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001453301,0.00017479167,0.0009030863,0.00022430683,0.00028027836,0.0000034009063,0.00017619762,0.00009806892,0.002327041],"category_scores_gemma":[0.0010855283,0.00008789763,0.00029094232,0.00036933576,0.00015743783,0.00004517205,0.000058261183,0.0006610691,0.0000011764805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003787592,0.00051613036,0.8385374,0.00088828255,0.0009890363,0.0007165554,0.0049989363,0.000052212923,0.00009605597,0.00007932324,0.11573683,0.03360168],"study_design_scores_gemma":[0.002241496,0.0149885975,0.7487009,0.0014337776,0.0020686544,0.0025142974,0.0007664127,0.00005006428,0.00010527332,0.00011493581,0.22685857,0.00015699757],"about_ca_topic_score_codex":0.06292559,"about_ca_topic_score_gemma":0.05179472,"teacher_disagreement_score":0.234117,"about_ca_system_score_codex":0.014274069,"about_ca_system_score_gemma":0.0070320074,"threshold_uncertainty_score":0.9985972},"labels":[],"label_agreement":null},{"id":"W4296768674","doi":"10.1016/j.jtho.2022.07.023","title":"OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; KRAS; Oncology; Mutation; Internal medicine; Lung cancer; Cancer; non-small cell lung cancer (NSCLC); Cancer research; Genetics; Colorectal cancer; Gene","score_opus":0.017092201985731224,"score_gpt":0.44098012343178916,"score_spread":0.4238879214460579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514496,0.00025859012,0.00053668563,0.0013992016,0.00030374495,0.0018879164,0.000022096157,0.000008698823,0.00043808878],"genre_scores_gemma":[0.99597317,0.000014249071,0.0022521468,0.0008477603,0.00010348553,0.00027202815,0.000013640882,0.000037563896,0.00048596182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982846,0.0002494961,0.00047600566,0.00023086435,0.0005122729,0.00024677214],"domain_scores_gemma":[0.99867535,0.000061038896,0.00052226026,0.00017155186,0.00039404084,0.00017573443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048184334,0.0001837432,0.0005260785,0.00040623284,0.00013013385,0.000014383918,0.00011929652,0.000034001514,0.00027559078],"category_scores_gemma":[0.00001176455,0.00012377708,0.000059067333,0.00047118214,0.000023499808,0.000110026194,0.000024180834,0.00036968445,0.0000026189816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057967555,0.026530785,0.6971195,0.000100171295,0.0016062756,0.0023964066,0.042624764,0.020752646,0.00053403823,0.0000012516393,0.000985055,0.14938155],"study_design_scores_gemma":[0.117951795,0.178939,0.67064553,0.0004289446,0.005686175,0.00038921105,0.019078858,0.0011898532,0.00089573424,0.000024797546,0.004205074,0.00056503754],"about_ca_topic_score_codex":0.00024622958,"about_ca_topic_score_gemma":0.00037200577,"teacher_disagreement_score":0.15240821,"about_ca_system_score_codex":0.0017736765,"about_ca_system_score_gemma":0.0015580276,"threshold_uncertainty_score":0.5047483},"labels":[],"label_agreement":null},{"id":"W4296768782","doi":"10.1016/j.jtho.2022.07.436","title":"EP04.01-024 Influence of Lung Diagnostic Assessment Program on Health Resource Utilization in Lung Cancer in Southeastern Ontario, Canada","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Lung; Cancer; Resource (disambiguation); Intensive care medicine; Oncology; Internal medicine","score_opus":0.052227258032432014,"score_gpt":0.46868522307284255,"score_spread":0.41645796504041055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910325,0.0013573954,0.00002223269,0.0062187565,0.00027118172,0.00054092606,0.00001398758,0.000004972038,0.000538041],"genre_scores_gemma":[0.9974608,0.000080830054,0.00040581246,0.001834523,0.00006650667,0.000061308194,0.0000060995653,0.00001196193,0.00007219524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974529,0.00042465547,0.0009070788,0.00017484881,0.00071476196,0.00032575484],"domain_scores_gemma":[0.9984537,0.00029636332,0.000821849,0.00014428205,0.00012808015,0.0001557218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013607222,0.00012439035,0.0005977965,0.00028738694,0.00006160302,0.00000663154,0.00018636083,0.00005893817,0.00018142891],"category_scores_gemma":[0.00020925661,0.00011449697,0.000058334088,0.0004388259,0.00003472277,0.00007778886,0.00007604153,0.00095201493,1.2377085e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015496084,0.0004745252,0.84248763,0.00019493549,0.000043994198,0.00084296305,0.0017734121,0.075866565,0.000031910764,0.00001520563,0.0019266093,0.07479263],"study_design_scores_gemma":[0.0010549604,0.0033634051,0.97364926,0.0012129965,0.000073287374,0.00024390448,0.0022327227,0.0023695168,0.000025531459,0.000023375076,0.01565067,0.000100353944],"about_ca_topic_score_codex":0.61467206,"about_ca_topic_score_gemma":0.94896376,"teacher_disagreement_score":0.33429167,"about_ca_system_score_codex":0.0077151186,"about_ca_system_score_gemma":0.010621552,"threshold_uncertainty_score":0.9960941},"labels":[],"label_agreement":null},{"id":"W4296768816","doi":"10.1016/j.jtho.2022.07.140","title":"MA11.07 The ELIC Distributed Database and Computation Environment for Analyses of Lung Cancer Screening LDCTs Across the World","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Medicine; Computation; Lung cancer; Database; Internal medicine; Computer science; Programming language","score_opus":0.04923301866737189,"score_gpt":0.4950152684430194,"score_spread":0.4457822497756475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84171295,0.0053194724,0.102596946,0.049467504,0.0003739044,0.00037965443,0.00011375546,0.000005197832,0.0000306227],"genre_scores_gemma":[0.99082106,0.00021046016,0.0074615395,0.0011093498,0.00025142665,0.000019584497,0.000035738078,0.000011143282,0.00007971808],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99880207,0.00026120737,0.000400078,0.000098233984,0.00027889735,0.0001595361],"domain_scores_gemma":[0.99840367,0.0007473458,0.0006076116,0.00010918147,0.000059434915,0.00007274382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018816164,0.00007672226,0.00031204862,0.00006612017,0.00034774432,0.000012744159,0.00014434449,0.000020235495,0.000075893986],"category_scores_gemma":[0.00020915532,0.00004267185,0.00009601212,0.00014112068,0.00019218982,0.000043586828,0.00013772375,0.0005647922,1.2303155e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004465485,0.00047532166,0.03191195,0.00027860334,0.0016152548,0.00019974736,0.002330201,0.1084256,0.016344737,0.000072587056,0.026712812,0.8071677],"study_design_scores_gemma":[0.004667185,0.002445164,0.12447978,0.00035927485,0.0040583746,0.0019266789,0.00498663,0.5064735,0.0016789403,0.00028698245,0.34837636,0.0002611292],"about_ca_topic_score_codex":0.000053645108,"about_ca_topic_score_gemma":0.000011108984,"teacher_disagreement_score":0.8069066,"about_ca_system_score_codex":0.0001349205,"about_ca_system_score_gemma":0.000103643804,"threshold_uncertainty_score":0.26746032},"labels":[],"label_agreement":null},{"id":"W4296768820","doi":"10.1016/j.jtho.2022.07.145","title":"MA12.05 Economic Impact of Delaying Care with Single-Gene Testing Versus Next-Generation Sequencing in Non-small Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Cancer; Lung cancer; DNA sequencing; Oncology; Gene; Internal medicine; Computational biology; Intensive care medicine; Genetics","score_opus":0.048923743558009575,"score_gpt":0.3496273623518438,"score_spread":0.3007036187938342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296768820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99566984,0.0028032186,0.00031014215,0.00003295933,0.0006673996,0.00013539848,0.00005403817,0.0000014551466,0.0003255543],"genre_scores_gemma":[0.99452376,0.00017200588,0.0046514603,0.00005575407,0.0005122247,0.000014252836,0.00003471466,0.00002465774,0.000011167996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989751,0.00009578524,0.00044159775,0.00018375152,0.000086225635,0.00021752322],"domain_scores_gemma":[0.99886715,0.000078868885,0.000671479,0.00014163533,0.00016795212,0.00007291652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030340423,0.00013530458,0.0002929531,0.00013596585,0.00008365449,0.000018388531,0.00018695164,0.00009047171,0.00002017451],"category_scores_gemma":[0.00004328779,0.00012947687,0.00011056525,0.00010374984,0.000029603316,0.000009695755,0.000118237,0.00023135531,1.8529902e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008011159,0.000029915165,0.0092606535,0.000027582308,0.000060610197,0.000050668703,0.00033308766,0.38965952,0.5908132,4.1606964e-7,0.00011058235,0.008852609],"study_design_scores_gemma":[0.0069826664,0.029651055,0.0049716034,0.00017565857,0.00069259614,0.001018885,0.0067495476,0.040713847,0.9061492,0.000014406074,0.0019556254,0.0009248962],"about_ca_topic_score_codex":0.0007837152,"about_ca_topic_score_gemma":0.00148684,"teacher_disagreement_score":0.34894568,"about_ca_system_score_codex":0.0030579926,"about_ca_system_score_gemma":0.0030010475,"threshold_uncertainty_score":0.7996544},"labels":[],"label_agreement":null},{"id":"W4296769182","doi":"10.1016/j.jtho.2022.07.483","title":"EP05.02-001 Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Durvalumab; Consolidation (business); Cohort; Stage (stratigraphy); Oncology; Internal medicine; Cancer","score_opus":0.03072913150715149,"score_gpt":0.38827196383054247,"score_spread":0.35754283232339096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296769182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97346544,0.00016292545,0.00012669218,0.008977234,0.00092720264,0.0013136067,0.00012354947,0.000013600081,0.014889768],"genre_scores_gemma":[0.9709119,0.00008940473,0.0012327555,0.00034428152,0.000273105,0.00007647648,0.000060237122,0.000021769396,0.026990065],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983298,0.0001570563,0.00065815006,0.00016515572,0.00034427264,0.00034552073],"domain_scores_gemma":[0.9983544,0.00019418105,0.00072604406,0.0002104862,0.00026638736,0.00024851994],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000908272,0.0001469982,0.0007496741,0.0007598633,0.00016640457,0.000014095652,0.00015911709,0.00006183313,0.0014976799],"category_scores_gemma":[0.00006295209,0.00012669725,0.00022333738,0.00037847916,0.0000545986,0.000103124374,0.000044074477,0.00024799496,0.0000029205712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020165987,0.0024124463,0.60275555,0.00051367027,0.0049764984,0.0022042796,0.0030970154,0.001033808,0.00196924,0.0029409907,0.15950996,0.19842057],"study_design_scores_gemma":[0.010098236,0.014466982,0.15282643,0.00006479981,0.0024080079,0.00031170787,0.0026532419,0.00018694847,0.00069602765,0.00016692768,0.81590486,0.00021583827],"about_ca_topic_score_codex":0.03890023,"about_ca_topic_score_gemma":0.11228389,"teacher_disagreement_score":0.6563949,"about_ca_system_score_codex":0.002523652,"about_ca_system_score_gemma":0.0018297258,"threshold_uncertainty_score":0.9994151},"labels":[],"label_agreement":null},{"id":"W4296769186","doi":"10.1016/j.jtho.2022.07.119","title":"MA08.03 Breathe Anew: Designing and Testing the Feasibility of a Novel Intervention for Lung Cancer Survivorship","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Survivorship curve; Intervention (counseling); Lung cancer; Cancer survivorship; Cancer; Intensive care medicine; Gerontology; Oncology; Nursing; Internal medicine","score_opus":0.11899659534999765,"score_gpt":0.4577595962230828,"score_spread":0.3387630008730852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296769186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851559,0.0031793301,0.0072525125,0.0025876416,0.0011330072,0.00043429778,0.000033583932,0.000007380822,0.00021637567],"genre_scores_gemma":[0.9967401,0.000024651388,0.0024576832,0.00025471378,0.00026760015,0.000044964137,0.0000021460412,0.000015324807,0.00019278844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985878,0.0003398941,0.00052524486,0.00013772602,0.00023918414,0.00017018865],"domain_scores_gemma":[0.9976915,0.0009808822,0.0007240823,0.00014099141,0.0003882082,0.00007433539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003330301,0.000100627956,0.0004314833,0.000109746274,0.00015168544,0.000009858566,0.00014204788,0.000059663787,0.0000774623],"category_scores_gemma":[0.00046575555,0.00006873546,0.00019809364,0.00023644138,0.00008368643,0.00006205653,0.00008886327,0.00041461186,4.2577376e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014462068,0.0016321662,0.5457332,0.0021508296,0.0006934893,0.00009852857,0.012084182,0.0008900663,0.05235746,0.00012828989,0.0017366515,0.36803305],"study_design_scores_gemma":[0.034859106,0.06718025,0.6227095,0.0058871456,0.01282906,0.026560903,0.117225386,0.05253513,0.02342805,0.0050652316,0.029915897,0.0018043168],"about_ca_topic_score_codex":0.00089894497,"about_ca_topic_score_gemma":0.0011492115,"teacher_disagreement_score":0.36622873,"about_ca_system_score_codex":0.0004473557,"about_ca_system_score_gemma":0.00036011025,"threshold_uncertainty_score":0.28029507},"labels":[],"label_agreement":null},{"id":"W4296769725","doi":"10.1016/j.jtho.2022.07.075","title":"OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Lung cancer; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.02972234667860972,"score_gpt":0.46124054949718124,"score_spread":0.4315182028185715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296769725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845871,0.012690736,0.00007408096,0.0015987173,0.0004351765,0.00025611202,0.00014112685,0.0000053545277,0.00021160505],"genre_scores_gemma":[0.99646324,0.0007553056,0.0005393518,0.00056181976,0.00008962302,0.000025079866,0.0000080109985,0.00002119931,0.0015363808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977713,0.0002158762,0.0010802733,0.00018344396,0.00046391157,0.00028520037],"domain_scores_gemma":[0.99678504,0.00026314467,0.0020012585,0.00027628188,0.0005760474,0.00009820803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001204543,0.0001991724,0.0017903507,0.00045173286,0.00011814805,0.0000053040944,0.00024873822,0.00008478525,0.001083668],"category_scores_gemma":[0.000031494837,0.00013797279,0.00063900417,0.0009691054,0.00024535172,0.00007314436,0.00009203299,0.0004433028,2.821274e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12556069,0.008479797,0.43067992,0.0016696505,0.12578988,0.0014088664,0.024708204,0.0032017084,0.17392644,0.0000033814952,0.007956633,0.09661484],"study_design_scores_gemma":[0.074090816,0.040951595,0.58915216,0.0007280893,0.11413486,0.0015970785,0.07586609,0.0021843063,0.0794407,0.000023523902,0.020851888,0.0009788646],"about_ca_topic_score_codex":0.00011125768,"about_ca_topic_score_gemma":0.0005031296,"teacher_disagreement_score":0.15847227,"about_ca_system_score_codex":0.0006004954,"about_ca_system_score_gemma":0.0010828297,"threshold_uncertainty_score":0.9998295},"labels":[],"label_agreement":null},{"id":"W4296770023","doi":"10.1016/j.jtho.2022.07.137","title":"MA11.03 Updated Cost-Effectiveness Analysis of Lung Cancer Screening for Australia, Capturing Differences in the Impact of NELSON and NLST Outcomes","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Computed tomography; Medical physics; Cost effectiveness; Intensive care medicine; Radiology; Oncology; Risk analysis (engineering)","score_opus":0.0890455945612762,"score_gpt":0.5072080661065618,"score_spread":0.4181624715452856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296770023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974361,0.00080380664,0.00009267471,0.0009369493,0.00011354771,0.0005050474,0.000091569425,0.0000015006257,0.00001881355],"genre_scores_gemma":[0.99951094,0.00010539184,0.00017681373,0.00003953038,0.00003130139,0.00009826938,0.000010063506,0.0000064002306,0.00002126688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998735,0.00033498186,0.00045155815,0.000114064394,0.00021190335,0.00015248376],"domain_scores_gemma":[0.9983949,0.0006888357,0.0006327515,0.000106260406,0.00012532283,0.000051938176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096412544,0.00011022127,0.0009522789,0.00039615994,0.00005105451,0.0000062513727,0.0001091945,0.0000476603,0.00013137571],"category_scores_gemma":[0.000046634737,0.00006181488,0.00034197257,0.00042659888,0.000051273895,0.00005065531,0.000035935493,0.00021124988,2.3134094e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018166419,0.0004565231,0.97968674,0.00010315042,0.004375723,0.000048357466,0.0009238775,0.0040789256,0.00027911668,0.000008018963,0.00011168132,0.008111272],"study_design_scores_gemma":[0.0015562029,0.0019177132,0.989087,0.000110007284,0.0047261664,0.00004166373,0.0007997972,0.001206876,0.0004367401,0.000019636818,0.00004692849,0.000051304225],"about_ca_topic_score_codex":0.0024295105,"about_ca_topic_score_gemma":0.00040099307,"teacher_disagreement_score":0.009400251,"about_ca_system_score_codex":0.0007171638,"about_ca_system_score_gemma":0.00018150565,"threshold_uncertainty_score":0.36727092},"labels":[],"label_agreement":null},{"id":"W4296770063","doi":"10.1016/j.jtho.2022.07.177","title":"P1.09-02 Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Oncology; Mutation; Internal medicine; Genetics; Gene","score_opus":0.0507382076439071,"score_gpt":0.4930215019475437,"score_spread":0.44228329430363655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296770063","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969646,0.00031586885,0.00020090291,0.0011235754,0.0005886156,0.0003337219,0.000046243604,0.000005264388,0.00042122215],"genre_scores_gemma":[0.9943648,0.0008460306,0.0039382176,0.00017819545,0.000122025194,0.000031139123,0.00003327655,0.000015273172,0.00047105772],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99812573,0.0003429569,0.0010099686,0.00015200763,0.00021471767,0.00015458801],"domain_scores_gemma":[0.9983045,0.00038802365,0.00095987663,0.0001225679,0.00011276849,0.000112251655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065476884,0.00011567198,0.00073181227,0.0003743668,0.000053028067,0.0000057354773,0.00005578391,0.000037044738,0.00010528207],"category_scores_gemma":[0.00009790046,0.000095092975,0.00012975033,0.00019672452,0.0000423321,0.00008818173,0.000035221085,0.0002741751,9.296606e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017059499,0.0015145218,0.20185399,0.00007085074,0.0004204159,0.001561983,0.0015973336,0.00010085278,0.0002275018,0.000034436423,0.000040311865,0.79087186],"study_design_scores_gemma":[0.0053060325,0.012305725,0.9694175,0.00021511235,0.0016085482,0.00090669317,0.0022162627,0.00021446006,0.00015310245,0.00019581147,0.0073499875,0.000110723784],"about_ca_topic_score_codex":0.000098688,"about_ca_topic_score_gemma":0.00019007965,"teacher_disagreement_score":0.7907611,"about_ca_system_score_codex":0.00087807036,"about_ca_system_score_gemma":0.00049768836,"threshold_uncertainty_score":0.3877779},"labels":[],"label_agreement":null},{"id":"W4296770892","doi":"10.1016/j.jtho.2022.07.861","title":"EP08.03-005 HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Radiation therapy; Disease; Lung; Targeted therapy; Lung disease; Oncology; Cancer research; Internal medicine; Radiology; Cancer","score_opus":0.021945224871566443,"score_gpt":0.4285558895482716,"score_spread":0.40661066467670515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296770892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787523,0.009625966,0.000059622966,0.009717895,0.00045320473,0.0010012662,0.00003887645,0.000024087012,0.00032675243],"genre_scores_gemma":[0.99284965,0.00075674127,0.0032441649,0.0020820855,0.0002659227,0.00017027793,0.000045657904,0.000054869844,0.0005306196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770623,0.00045823999,0.0006984987,0.00027972378,0.00046364334,0.00039365102],"domain_scores_gemma":[0.9983827,0.00014622904,0.0006872169,0.00023777854,0.00022340662,0.00032270025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046295737,0.00024781632,0.0009028846,0.00063741615,0.00011717815,0.000016572683,0.00018889362,0.00008410378,0.0008958394],"category_scores_gemma":[0.00007370758,0.00016044953,0.00013670673,0.0007406257,0.00011762674,0.00013887724,0.00003189803,0.00070415565,0.0000014532396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19477744,0.007623609,0.5940852,0.000112190704,0.0019455288,0.0496885,0.011138155,0.004277057,0.004998565,0.000029594225,0.0035931193,0.12773101],"study_design_scores_gemma":[0.072724804,0.039516207,0.7913717,0.0012864199,0.002163977,0.011779422,0.010243912,0.007771402,0.0020472608,0.00023732056,0.059810672,0.0010469223],"about_ca_topic_score_codex":0.00012969717,"about_ca_topic_score_gemma":0.0001688699,"teacher_disagreement_score":0.19728644,"about_ca_system_score_codex":0.0021057993,"about_ca_system_score_gemma":0.002959933,"threshold_uncertainty_score":0.98088133},"labels":[],"label_agreement":null},{"id":"W4296771023","doi":"10.1016/j.jtho.2022.07.168","title":"P1.04-02 Optimizing Screening Frequency and Interval Using a Deep Learning Algorithm","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Foundation","funders":"","keywords":"Medicine; Interval (graph theory); Algorithm; Artificial intelligence; Computer science; Combinatorics; Mathematics","score_opus":0.035100967260158523,"score_gpt":0.4074330508526935,"score_spread":0.37233208359253495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296771023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9584822,0.0087529905,0.027092565,0.003426159,0.00097076147,0.00023423372,0.000004652165,0.000025545787,0.0010109061],"genre_scores_gemma":[0.7529904,0.00029883193,0.24575192,0.00042988392,0.00040148152,0.000009572618,0.0000031936793,0.00002487803,0.00008979359],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99855804,0.00028131896,0.00046563242,0.00016861649,0.0002882296,0.00023817188],"domain_scores_gemma":[0.998941,0.00015884027,0.0005252553,0.000092589944,0.00011321199,0.00016910693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008016418,0.00013196166,0.00053608604,0.00024308704,0.00026156983,0.000021640859,0.00008911883,0.00006379493,0.00030502048],"category_scores_gemma":[0.00006735212,0.000112403024,0.00015710169,0.00016378009,0.00005265894,0.00012435748,0.00014817626,0.00078591733,9.839713e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056641304,0.00041767603,0.024045503,0.00006310385,0.0005749267,0.0032513926,0.0016254093,0.0024519945,0.0012091346,0.000015109598,0.00016737288,0.96561193],"study_design_scores_gemma":[0.031382207,0.10559923,0.087354064,0.00467501,0.016604815,0.24142848,0.062007666,0.27292717,0.007510213,0.0019906256,0.16606607,0.0024544573],"about_ca_topic_score_codex":0.00005730004,"about_ca_topic_score_gemma":0.0000064906003,"teacher_disagreement_score":0.96315753,"about_ca_system_score_codex":0.0011286165,"about_ca_system_score_gemma":0.00023057498,"threshold_uncertainty_score":0.45836622},"labels":[],"label_agreement":null},{"id":"W4296771554","doi":"10.1016/j.jtho.2022.07.146","title":"MA12.07 Defining Morphologic Features of Invasion in Pulmonarynon-Mucinousadenocarcinoma with Lepidic Growth","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine","score_opus":0.02144649575499608,"score_gpt":0.35346731404130355,"score_spread":0.3320208182863075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296771554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836434,0.005602144,0.000010285803,0.0064464826,0.00027878647,0.00023686921,0.000007036895,0.000007391686,0.0037676182],"genre_scores_gemma":[0.996026,0.0004627473,0.002522121,0.00069475267,0.00009098837,0.000031636897,0.000008364831,0.00002008967,0.00014332579],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822146,0.00030753633,0.0005809839,0.00020314152,0.00043401643,0.00025288592],"domain_scores_gemma":[0.99855393,0.00027142197,0.00071896624,0.00018210024,0.00015497505,0.00011862803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008249875,0.00015631093,0.00077722623,0.00043114027,0.000077614844,0.0000048871448,0.00017332086,0.000093523864,0.0002811952],"category_scores_gemma":[0.00007804565,0.00010715746,0.00014601286,0.00036241327,0.00008268374,0.000076577504,0.00010684539,0.0006766017,0.000004213354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008429295,0.0027689321,0.92336386,0.00023327165,0.00028270643,0.01555575,0.0009912897,0.0002915537,0.0015610827,0.00024060192,0.003692487,0.04258919],"study_design_scores_gemma":[0.003383063,0.02498624,0.94068515,0.00037487026,0.0005961086,0.021444513,0.0018402189,0.0000133389685,0.004087083,0.0005312611,0.0019017644,0.00015637306],"about_ca_topic_score_codex":0.00012195437,"about_ca_topic_score_gemma":0.000058487003,"teacher_disagreement_score":0.04243282,"about_ca_system_score_codex":0.0012500208,"about_ca_system_score_gemma":0.0006986229,"threshold_uncertainty_score":0.43697542},"labels":[],"label_agreement":null},{"id":"W4296771556","doi":"10.1016/j.jtho.2022.07.388","title":"EP02.04-003 A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Retrospective cohort study; Overall survival; Epidermal growth factor receptor; Erlotinib; Cancer","score_opus":0.03243683485617222,"score_gpt":0.4700560418111188,"score_spread":0.4376192069549466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296771556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99066526,0.0002518105,0.00003312954,0.004768166,0.0009773661,0.00038330886,0.00011354988,0.000008476844,0.0027989529],"genre_scores_gemma":[0.9982223,0.000009605178,0.0006826958,0.0006088562,0.000052580428,0.000021920898,0.00003519502,0.000019829436,0.0003470525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997601,0.00054088136,0.00089788873,0.00017468345,0.00056272023,0.00022283953],"domain_scores_gemma":[0.9980336,0.0004522483,0.0009921367,0.00016475045,0.00024286294,0.00011444516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069838366,0.00015804377,0.0011200426,0.00044192644,0.00008982367,0.0000056090907,0.0001342736,0.00006215421,0.00034412896],"category_scores_gemma":[0.00045263788,0.000120787285,0.00021868196,0.00038105703,0.00006796325,0.00007713393,0.00006223447,0.00055245357,0.000004441817],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048643006,0.0073580346,0.9444988,0.00003582869,0.0009274525,0.00030941278,0.0029120503,0.00053667685,0.00034397998,0.00013810117,0.0034552235,0.034620162],"study_design_scores_gemma":[0.008389846,0.020433081,0.95355064,0.000099788216,0.0010368784,0.000098022625,0.004370186,0.00007345525,0.0011158589,0.00034392916,0.010324374,0.00016395596],"about_ca_topic_score_codex":0.00010346073,"about_ca_topic_score_gemma":0.00007590204,"teacher_disagreement_score":0.03445621,"about_ca_system_score_codex":0.0014240367,"about_ca_system_score_gemma":0.0005196678,"threshold_uncertainty_score":0.49255624},"labels":[],"label_agreement":null},{"id":"W4296771720","doi":"10.1016/j.jtho.2022.07.647","title":"EP08.01-075 Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital","funders":"","keywords":"Medicine; Oncology; Baseline (sea); Internal medicine; Line (geometry); Expression (computer science)","score_opus":0.016534481846255555,"score_gpt":0.369993945903954,"score_spread":0.35345946405769846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296771720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157214,0.0022091784,0.00022084641,0.0053339945,0.0002706132,0.00032054426,0.000027279239,0.0000045814477,0.000040791947],"genre_scores_gemma":[0.9968803,0.0008489844,0.0015781489,0.00043517316,0.00007411143,0.000019773204,0.000020719204,0.000014594433,0.00012818615],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99843794,0.00033236018,0.00058122416,0.00014000249,0.00036722794,0.00014125727],"domain_scores_gemma":[0.9986249,0.00037564954,0.0006033165,0.00018362845,0.00011812664,0.00009438514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010950998,0.00011690573,0.00039957045,0.00022303451,0.00009033778,0.000006026946,0.000100153884,0.000044278913,0.00012720963],"category_scores_gemma":[0.00011429618,0.000069355985,0.00007885375,0.00026588695,0.00008764036,0.00006603671,0.0000484342,0.00023612144,9.046082e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.116199225,0.0014344541,0.013821501,0.000039441093,0.0001817371,0.00086675823,0.0009166896,0.0010391795,0.02789827,0.000015239117,0.0009175643,0.8366699],"study_design_scores_gemma":[0.052554194,0.04964163,0.7348069,0.0022585536,0.0015035017,0.0024204091,0.0069630533,0.0013560461,0.021867113,0.0011567317,0.12496932,0.0005025444],"about_ca_topic_score_codex":0.00012162992,"about_ca_topic_score_gemma":0.00013820123,"teacher_disagreement_score":0.8361674,"about_ca_system_score_codex":0.0007126719,"about_ca_system_score_gemma":0.0004733245,"threshold_uncertainty_score":0.2828255},"labels":[],"label_agreement":null},{"id":"W4296772522","doi":"10.1016/j.jtho.2022.07.039","title":"OA06.07 Stereotactic Ablative Radiotherapy Before Resection to AvoId Delay for Early-Stage LunG Cancer or OligomEts","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Western University; CancerCare Manitoba","funders":"","keywords":"SABR volatility model; Medicine; Radiation therapy; Lung cancer; Malignancy; Surgery; Ablative case; Biopsy; Radiology; Oncology; Internal medicine","score_opus":0.033500588284974125,"score_gpt":0.4561405973794779,"score_spread":0.4226400090945037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296772522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786012,0.0018186208,0.0007874537,0.015231513,0.0019621025,0.0011704364,0.00006946559,0.000014600536,0.00034459776],"genre_scores_gemma":[0.9857584,0.0004879727,0.0037924037,0.0022588668,0.0009196688,0.00040539197,0.0000055439896,0.000047162503,0.006324591],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834764,0.00022670368,0.00051667145,0.0002255963,0.0003708443,0.00031256262],"domain_scores_gemma":[0.9983979,0.00031958276,0.00056318217,0.0001833212,0.00029528918,0.00024076301],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075216393,0.00016786453,0.00063446455,0.0003580144,0.00020506405,0.000018989951,0.00013642365,0.00008688842,0.0016193243],"category_scores_gemma":[0.00009257141,0.000118586446,0.0002281098,0.00032954558,0.000029195771,0.00013086322,0.000046572426,0.00043102488,0.0000033837239],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19896317,0.0066179624,0.28706855,0.0016455379,0.015233186,0.0058839405,0.046712223,0.0061529903,0.003731977,0.00016459994,0.100543775,0.3272821],"study_design_scores_gemma":[0.01347679,0.10872216,0.1285355,0.00070663803,0.0032261766,0.0038391962,0.0029454657,0.0011861755,0.00495123,0.00016630236,0.73173344,0.0005109172],"about_ca_topic_score_codex":0.00017392071,"about_ca_topic_score_gemma":0.00046226245,"teacher_disagreement_score":0.6311897,"about_ca_system_score_codex":0.0056659263,"about_ca_system_score_gemma":0.000904685,"threshold_uncertainty_score":0.9992933},"labels":[],"label_agreement":null},{"id":"W4296773182","doi":"10.1016/j.jtho.2022.07.148","title":"MA12.09 Frequency and Detectability of Uncommon EGFR Mutations in NSCLC","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Oncology; Internal medicine; Cancer research","score_opus":0.020488858053774588,"score_gpt":0.4347767627322449,"score_spread":0.4142879046784703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296773182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121815,0.001251783,0.00007038065,0.003710606,0.0002485863,0.00017870391,0.000016544749,0.000003771333,0.0033014577],"genre_scores_gemma":[0.99605626,0.000030844916,0.003621295,0.00012503771,0.00004232948,0.000015309697,0.000004537649,0.0000065167023,0.00009786116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99901867,0.00018326561,0.00044916428,0.00008524265,0.00016188201,0.000101800186],"domain_scores_gemma":[0.9992145,0.00016806433,0.0003260169,0.000101671925,0.00011789992,0.00007185923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046586295,0.000062237574,0.00033110744,0.00021942011,0.000061343184,0.0000025990219,0.00005804039,0.00004119685,0.00022433263],"category_scores_gemma":[0.00010313599,0.00005147075,0.00006832079,0.00022721614,0.00007125204,0.000065043314,0.00003262492,0.00029290302,6.580442e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019063171,0.0029323075,0.45694518,0.00022915997,0.00045522157,0.0010597516,0.0078277225,0.00045175958,0.014643552,0.00044101212,0.00045403524,0.512654],"study_design_scores_gemma":[0.0067044077,0.014084066,0.9301816,0.00017309401,0.0017036144,0.0047344407,0.011278723,0.00018657753,0.0029493987,0.015278518,0.012504678,0.00022083469],"about_ca_topic_score_codex":0.00013016231,"about_ca_topic_score_gemma":0.00016675149,"teacher_disagreement_score":0.5124332,"about_ca_system_score_codex":0.0006440592,"about_ca_system_score_gemma":0.00062791613,"threshold_uncertainty_score":0.2456285},"labels":[],"label_agreement":null},{"id":"W4296773600","doi":"10.1016/j.jtho.2022.07.753","title":"EP08.02-071 Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Medicine; Cohort; Oncology; Mutant; Radiation therapy; Internal medicine; Outcome (game theory); Epidermal growth factor receptor; Cancer; Gene; Erlotinib; Genetics","score_opus":0.035874043687401165,"score_gpt":0.4584005283914657,"score_spread":0.42252648470406456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296773600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766289,0.0008748054,0.000006909895,0.016742488,0.00045870437,0.0005667455,0.000059071677,0.0000050827866,0.004657279],"genre_scores_gemma":[0.9967762,0.00026239298,0.00041790135,0.0018592749,0.000084683394,0.000050170675,0.00003291745,0.000018117056,0.00049829006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978925,0.0004539029,0.0009498722,0.00014836795,0.00029265642,0.00026269618],"domain_scores_gemma":[0.9987044,0.0002596306,0.0005825682,0.00015985515,0.00010569037,0.0001878725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014267575,0.00012575058,0.00069524086,0.0012221384,0.00006305006,0.0000058229566,0.00012431885,0.00005735866,0.000537684],"category_scores_gemma":[0.00014941896,0.00010424482,0.00014038048,0.0007040609,0.000043679993,0.00009520808,0.00001966454,0.00041564734,0.0000020418477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016567166,0.0008651489,0.8394574,0.000026342643,0.00048165652,0.0014616007,0.0019588089,0.000649097,0.0010519786,0.0002617853,0.001623981,0.15050548],"study_design_scores_gemma":[0.0046897186,0.003409622,0.91465104,0.00006600426,0.00045174873,0.0005398348,0.0010423481,0.00009250653,0.0008623019,0.00033136422,0.07372528,0.00013821921],"about_ca_topic_score_codex":0.048040893,"about_ca_topic_score_gemma":0.10841448,"teacher_disagreement_score":0.15036726,"about_ca_system_score_codex":0.0026092748,"about_ca_system_score_gemma":0.0022680208,"threshold_uncertainty_score":0.95829827},"labels":[],"label_agreement":null},{"id":"W4298008223","doi":"10.1016/j.jtho.2022.09.109","title":"Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee","year":2022,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Pharmaceuticals; Johnson and Johnson; Ribon Therapeutics; Boehringer Ingelheim; International Association for the Study of Lung Cancer; Novartis; Daiichi Sankyo Europe; Sanofi; Merck; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Immunotherapy; Biomarker; Lung cancer; Oncology; Companion diagnostic; Cancer; Tumor microenvironment; Cancer immunotherapy; Adjuvant; Biomarker discovery; Internal medicine; Immunohistochemistry; Immunology; Proteomics","score_opus":0.04654945551221298,"score_gpt":0.47204737299830063,"score_spread":0.4254979174860877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298008223","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023079813,0.9799171,0.00012416091,0.0066277236,0.0049351486,0.0049565644,0.0010245477,0.0000064109277,0.00010033731],"genre_scores_gemma":[0.0014017702,0.99426526,0.00011662378,0.000500917,0.0011921099,0.0022325714,0.00004273288,0.00005644923,0.00019153877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99643207,0.0009747778,0.0014866412,0.00031329895,0.0005109994,0.00028219604],"domain_scores_gemma":[0.9882317,0.006815742,0.003977058,0.00030135308,0.0006380189,0.000036085054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036849172,0.00031434238,0.0019514156,0.00032679908,0.00018903486,0.000021452048,0.0008138094,0.00034828525,0.00041543072],"category_scores_gemma":[0.0005067338,0.00018009782,0.0010185104,0.00040492727,0.00011634197,0.000076950106,0.000090338464,0.00097422383,8.189687e-8],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022298919,0.001051009,0.0049921437,0.0007221031,0.023610042,0.000030097386,0.007500928,0.000024338211,0.000032909997,0.000007433256,0.015466271,0.9242638],"study_design_scores_gemma":[0.006242168,0.0033701153,0.00493492,0.002251059,0.00828775,0.00008378089,0.011366943,0.00024885577,0.000005161876,0.000053811393,0.96295977,0.0001956453],"about_ca_topic_score_codex":0.001980516,"about_ca_topic_score_gemma":0.0017921982,"teacher_disagreement_score":0.9474935,"about_ca_system_score_codex":0.009460801,"about_ca_system_score_gemma":0.0025890602,"threshold_uncertainty_score":0.99434173},"labels":[],"label_agreement":null},{"id":"W4298394429","doi":"10.1016/j.jtho.2022.07.1150","title":"There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor","year":2022,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Programmed cell death 1; Programmed cell death; Ligand (biochemistry); Programmed instruction; Apoptosis; Cancer research; Receptor; Internal medicine; Biochemistry; PD-L1; Cancer; Immunotherapy; Biology","score_opus":0.03218937784012032,"score_gpt":0.39145727128409524,"score_spread":0.3592678934439749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298394429","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19697206,0.010954505,0.00037514014,0.006988378,0.77371716,0.008850058,0.0006682343,0.00015922118,0.0013152661],"genre_scores_gemma":[0.013295139,0.0010741294,0.023575854,0.0016990973,0.94220954,0.0012991966,0.00064640434,0.000555939,0.015644714],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949618,0.0005456595,0.0016785208,0.0006357939,0.0013290017,0.0008492335],"domain_scores_gemma":[0.9947931,0.000548686,0.0026393367,0.0006374266,0.0010034717,0.0003779518],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002999374,0.00067956606,0.0020202524,0.00056747237,0.00024954817,0.00011741029,0.0006975895,0.0017410392,0.0007831953],"category_scores_gemma":[0.00038200087,0.00052858697,0.0011357325,0.00041250608,0.00016806189,0.00019090963,0.00010789571,0.0023082588,0.0000053361446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06462437,0.0024999352,0.00013835152,0.00092417427,0.0012527768,0.0005110498,0.0008189741,5.9148033e-7,0.01477658,0.0000023940302,0.7476118,0.16683897],"study_design_scores_gemma":[0.008339242,0.02801237,0.00004554418,0.00041097868,0.0014014107,0.00025021716,0.0008661027,0.000010149639,0.012353365,0.0001365034,0.94766587,0.00050825614],"about_ca_topic_score_codex":0.00014074772,"about_ca_topic_score_gemma":0.000060204013,"teacher_disagreement_score":0.20005403,"about_ca_system_score_codex":0.0017259634,"about_ca_system_score_gemma":0.004505511,"threshold_uncertainty_score":0.99999344},"labels":[],"label_agreement":null},{"id":"W4307461028","doi":"10.1016/j.jtho.2022.08.012","title":"Breathing Life Into Lung Cancer Screening Trials","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Teachable moment; Medicine; Lung cancer screening; Lung cancer; Smoking cessation; Scopus; National Lung Screening Trial; Cancer; Internal medicine; Family medicine; Oncology; MEDLINE; Pathology; Psychotherapist","score_opus":0.06584141598154884,"score_gpt":0.4812590484309963,"score_spread":0.41541763244944746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307461028","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038555698,0.030777533,0.0002122651,0.9583959,0.0047961455,0.0006440017,0.00004885782,0.000026202815,0.0012435409],"genre_scores_gemma":[0.0060067433,0.007163923,0.008950774,0.93676466,0.037809342,0.00025544802,0.000116388976,0.00016338221,0.002769344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99509126,0.0013039326,0.001843242,0.00036911725,0.0009436331,0.0004487975],"domain_scores_gemma":[0.9940927,0.0016532659,0.0032507253,0.00035797962,0.00037056356,0.00027474944],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032768077,0.00040552721,0.003132354,0.00061354577,0.00016250313,0.000045760407,0.00033025967,0.0008190478,0.004803969],"category_scores_gemma":[0.00087566645,0.00029430684,0.0011137918,0.00024169372,0.000069777096,0.00012363282,0.00015471199,0.004134909,0.000006181732],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016101858,0.00019365862,0.0020028946,0.0007465354,0.0038743608,0.013930785,0.00054497545,0.00006177445,0.000016432852,0.0000014734724,0.88198715,0.09502975],"study_design_scores_gemma":[0.0018891288,0.0023686606,0.00038206656,0.0015013795,0.008607408,0.0023587726,0.0001435098,0.00003529887,0.000072675364,0.00004623573,0.9823604,0.00023443685],"about_ca_topic_score_codex":0.00047669487,"about_ca_topic_score_gemma":0.000028950606,"teacher_disagreement_score":0.10037325,"about_ca_system_score_codex":0.004631151,"about_ca_system_score_gemma":0.0031929004,"threshold_uncertainty_score":0.9999509},"labels":[],"label_agreement":null},{"id":"W4308346460","doi":"10.1016/j.jtho.2022.10.016","title":"Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Ottawa; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Queen's University; McMaster University; Ottawa Hospital; Kingston General Hospital","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Ministry of Health, Ontario","keywords":"Medicine","score_opus":0.025651845585269867,"score_gpt":0.3936130777860882,"score_spread":0.36796123220081833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308346460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022827075,0.99438184,0.0000021993515,0.000052191896,0.00022676488,0.002834953,0.000087646134,0.000006548803,0.00012516642],"genre_scores_gemma":[0.0003881055,0.99885726,0.000116444724,0.00005613288,0.00014767722,0.00010953208,0.00007263323,0.000052440537,0.00019976731],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99475574,0.0014623469,0.002671279,0.00024563447,0.0006425721,0.00022245006],"domain_scores_gemma":[0.9926587,0.00060477445,0.0058475565,0.00038489964,0.0002882481,0.00021586448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014925586,0.00040292603,0.0074886843,0.00042025902,0.00006061183,0.000009984702,0.00023820986,0.00020032465,0.00021634408],"category_scores_gemma":[0.00029831153,0.00021712571,0.0006663271,0.0003791212,0.00008026711,0.00006606866,0.000064002634,0.000572711,0.000007802565],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030690277,0.00045452753,0.00010341893,0.7783354,0.00144897,0.0007545788,0.0000591861,6.960429e-8,6.8991504e-8,0.000009316833,0.00012419448,0.21840337],"study_design_scores_gemma":[0.0013443858,0.0049894145,0.00004292219,0.6599415,0.027319299,0.019492697,0.00003833773,4.4966936e-7,1.7479147e-7,0.0000059607014,0.28664878,0.00017606362],"about_ca_topic_score_codex":0.0000035962867,"about_ca_topic_score_gemma":3.8429846e-7,"teacher_disagreement_score":0.28652456,"about_ca_system_score_codex":0.00063553033,"about_ca_system_score_gemma":0.0011709108,"threshold_uncertainty_score":0.88541293},"labels":[],"label_agreement":null},{"id":"W4308949531","doi":"10.1016/j.jtho.2022.10.020","title":"Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institutes of Health; Financiadora de Estudos e Projetos; Instituto Nacional do Câncer, Ministério da Saúde; Princess Margaret Cancer Foundation; Hospital de Câncer de Barretos; World Health Organization","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Comorbidity; Respiratory system; Cancer; Intensive care medicine","score_opus":0.029445574051269824,"score_gpt":0.41141295684300444,"score_spread":0.3819673827917346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308949531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9566212,0.018294973,0.000033139804,0.02349962,0.0009292407,0.00017586185,0.00014922902,0.000005694076,0.00029101325],"genre_scores_gemma":[0.9939444,0.001525343,0.0001329656,0.0036649595,0.00048191278,0.0000592433,0.000006536009,0.000009749698,0.00017490353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871284,0.00027648528,0.00034940633,0.00016026125,0.00037486298,0.00012614152],"domain_scores_gemma":[0.99882436,0.00043367193,0.0003036523,0.00014253575,0.00016364251,0.00013216918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076003076,0.00010339853,0.0006088332,0.00028358624,0.00013654337,0.000029999352,0.00012682125,0.00003482491,0.00043243184],"category_scores_gemma":[0.00006476472,0.00006862233,0.00014053697,0.00029601387,0.0000766343,0.000050546874,0.00016756619,0.00025358537,3.3534926e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016352566,0.00020228147,0.922868,0.000016087437,0.011936366,0.00033271994,0.0020854664,0.00030184377,0.0004745306,0.00006295248,0.01609044,0.04399403],"study_design_scores_gemma":[0.0018060484,0.00074845686,0.8308016,0.000044004522,0.010460636,0.000093137554,0.002847183,0.000081525046,0.00025412336,0.000032494907,0.1527294,0.00010139423],"about_ca_topic_score_codex":0.00091167877,"about_ca_topic_score_gemma":0.00071350683,"teacher_disagreement_score":0.13663897,"about_ca_system_score_codex":0.0005822385,"about_ca_system_score_gemma":0.00035400872,"threshold_uncertainty_score":0.47348252},"labels":[],"label_agreement":null},{"id":"W4311086668","doi":"10.1016/j.jtho.2022.11.026","title":"Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth: A Proposal by the International Association for the Study of Lung Cancer Pathology Committee","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"Vrije Universiteit Amsterdam; International Association for the Study of Lung Cancer","keywords":"Medicine; Adenocarcinoma; Lung cancer; Pathology; Cancer; Lung; Stage (stratigraphy); Surgical pathology; Internal medicine; Biology","score_opus":0.017450133141719004,"score_gpt":0.3621248262123062,"score_spread":0.3446746930705872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311086668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710368,0.0065156496,0.000011556965,0.020846069,0.00047894302,0.000907245,0.000038056914,0.0000028296345,0.0001628718],"genre_scores_gemma":[0.9985689,0.00027777717,0.00019690055,0.00043580798,0.00009257358,0.00030790863,0.000009571026,0.00001229854,0.00009827384],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829924,0.0004335097,0.00051914685,0.00014582515,0.00044606396,0.00015622185],"domain_scores_gemma":[0.9971912,0.0011174442,0.0012314164,0.00013841939,0.00029369298,0.000027815067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016121074,0.00010722633,0.000482875,0.0001450014,0.00011736814,0.000005244496,0.00027509537,0.000068545276,0.000043602373],"category_scores_gemma":[0.00017641317,0.0000547465,0.00010013787,0.00019801274,0.00005790589,0.000044702298,0.00011013419,0.00048533894,9.589884e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045402157,0.0029320663,0.970419,0.000058112233,0.000654381,0.0003667312,0.0024897188,0.00034936395,0.00070908945,0.000040660107,0.006741889,0.010698792],"study_design_scores_gemma":[0.0040019453,0.0137124825,0.9703798,0.00011319955,0.001295688,0.0017152845,0.006806549,0.0001691006,0.0011564968,0.00011306572,0.00045960417,0.000076766075],"about_ca_topic_score_codex":0.00038184505,"about_ca_topic_score_gemma":0.0005282638,"teacher_disagreement_score":0.027532112,"about_ca_system_score_codex":0.0014886855,"about_ca_system_score_gemma":0.00051751017,"threshold_uncertainty_score":0.38928607},"labels":[],"label_agreement":null},{"id":"W4311903085","doi":"10.1016/j.jtho.2022.12.003","title":"Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; AstraZeneca; Eli Lilly and Company; Terry Fox Foundation; Bristol-Myers Squibb; Amgen","keywords":"Cancer research; Erlotinib; Medicine; Transcriptome; Population; Stromal cell; Lung cancer; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer; Epidermal growth factor receptor; Biology; Internal medicine; Receptor; Gene expression; Gene; Genetics","score_opus":0.016672958439172384,"score_gpt":0.2832375687837212,"score_spread":0.2665646103445488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311903085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934376,0.0035267307,0.002267699,0.0002577952,0.00017919698,0.00017744547,0.000052691565,0.0000036445485,0.00009721152],"genre_scores_gemma":[0.9963169,0.000093827024,0.0032284746,0.00019179871,0.000036716094,0.000007781357,0.00005477682,0.000021792424,0.000047895064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800473,0.0004726349,0.00074886467,0.00027083728,0.00024799487,0.00025494338],"domain_scores_gemma":[0.9989205,0.000038478593,0.00062555016,0.00015892254,0.0001499378,0.00010659865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045612323,0.00018985131,0.00058708736,0.00045420794,0.00009488136,0.000015552485,0.00022381623,0.000138258,0.000014516926],"category_scores_gemma":[0.000020494412,0.00018897346,0.00033054195,0.0003407048,0.000101959595,0.00001586492,0.00005629854,0.00034577042,6.573747e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031139217,0.0005593912,0.0074145775,0.000064721935,0.00039808635,0.000068358626,0.0052367654,0.052559797,0.9262007,0.0000018490236,0.0001307542,0.004251091],"study_design_scores_gemma":[0.013574753,0.021563169,0.06473956,0.00018284524,0.0080081355,0.0012969056,0.050124202,0.18358445,0.65381706,0.00024502946,0.0010113613,0.0018525606],"about_ca_topic_score_codex":0.00007041721,"about_ca_topic_score_gemma":0.00019657459,"teacher_disagreement_score":0.27238366,"about_ca_system_score_codex":0.00017514848,"about_ca_system_score_gemma":0.00021202887,"threshold_uncertainty_score":0.77061135},"labels":[],"label_agreement":null},{"id":"W4312114419","doi":"10.1016/j.jtho.2022.10.010","title":"Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations","year":2022,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Osimertinib; Medicine; Bevacizumab; Oncology; Internal medicine; Lung cancer; Progression-free survival; Randomized controlled trial; Pneumonitis; Epidermal growth factor receptor; Cancer; Lung; Overall survival; Chemotherapy; Erlotinib","score_opus":0.02327696652951689,"score_gpt":0.3954120527013132,"score_spread":0.3721350861717963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312114419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5087571,0.0059064645,0.0074868733,0.44968992,0.007420192,0.012048087,0.0023497974,0.00018713651,0.0061544008],"genre_scores_gemma":[0.69031763,0.0006714074,0.11852204,0.15685575,0.010272925,0.0021540592,0.007648685,0.0014549319,0.012102552],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972111,0.00021750938,0.001011455,0.00036885508,0.00072864705,0.00046244598],"domain_scores_gemma":[0.99556935,0.0007678097,0.002183249,0.00037829377,0.0009421265,0.00015919901],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024598715,0.00043578868,0.0014508188,0.00061431795,0.00021468921,0.000022198474,0.0002566783,0.00039153956,0.0004541797],"category_scores_gemma":[0.00009341762,0.00029990688,0.00032588307,0.00042935624,0.00019565318,0.00015388038,0.000027447326,0.0012487583,0.0000018717327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3455884,0.006355275,0.010700142,0.0024658032,0.038721975,0.007837002,0.010139352,0.0047412827,0.00038090293,0.00002691128,0.36344734,0.20959562],"study_design_scores_gemma":[0.056517612,0.07100003,0.003484534,0.0008581102,0.017332781,0.0006725139,0.00060268864,0.00015100079,0.00044790705,0.000016368183,0.84827906,0.0006374076],"about_ca_topic_score_codex":0.000071454575,"about_ca_topic_score_gemma":0.000023905099,"teacher_disagreement_score":0.48483172,"about_ca_system_score_codex":0.0024137206,"about_ca_system_score_gemma":0.0029787116,"threshold_uncertainty_score":0.9999453},"labels":[],"label_agreement":null},{"id":"W4318301860","doi":"10.1016/j.jtho.2022.09.125","title":"OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Internal medicine; Oncology; Lung cancer; Placebo; Cancer; Erlotinib; Epidermal growth factor receptor; Pathology; Gefitinib","score_opus":0.02533324856646252,"score_gpt":0.4374827494442849,"score_spread":0.4121495008778224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318301860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847977,0.0011644018,0.000040293915,0.0070175473,0.0011711656,0.00069184636,0.00015560347,0.00007069966,0.00489072],"genre_scores_gemma":[0.9875875,0.0010124467,0.0010388087,0.00046986126,0.00034751237,0.000044827786,0.00023987975,0.00005547827,0.009203655],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99715644,0.00026576323,0.0012876792,0.00033518474,0.0003789702,0.00057594985],"domain_scores_gemma":[0.99760354,0.0002465076,0.0009495892,0.00030665644,0.00056860613,0.00032507852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087082054,0.00026139748,0.0008951766,0.0008132909,0.000105208,0.000024088346,0.00022432153,0.00027334376,0.00025177465],"category_scores_gemma":[0.00020493453,0.00020366709,0.00017706788,0.0014428699,0.00007311822,0.00015677523,0.00007643483,0.0007851358,0.000053420375],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06627414,0.0057459865,0.12100875,0.0016123406,0.0043720286,0.050098218,0.026403971,0.012740641,0.15518034,0.000027918148,0.2824728,0.27406287],"study_design_scores_gemma":[0.056828413,0.013046102,0.61894196,0.0031066064,0.0057020206,0.0012192269,0.008725133,0.01785284,0.05594395,0.00016187869,0.21719305,0.0012788124],"about_ca_topic_score_codex":0.0006318878,"about_ca_topic_score_gemma":0.0007141151,"teacher_disagreement_score":0.4979332,"about_ca_system_score_codex":0.0013747535,"about_ca_system_score_gemma":0.0023232088,"threshold_uncertainty_score":0.8305303},"labels":[],"label_agreement":null},{"id":"W4318956414","doi":"10.1016/j.jtho.2023.01.083","title":"Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Jiangsu Hengrui Medicine","keywords":"Medicine; Pemetrexed; Carboplatin; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Progression-free survival; Chemotherapy; Phases of clinical research; Surgery; Clinical trial; Cisplatin","score_opus":0.12983751900397322,"score_gpt":0.4863944786987144,"score_spread":0.35655695969474116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318956414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680337,0.0029702466,0.00043596263,0.023441633,0.00011814952,0.004688345,0.00024093874,0.00003282508,0.000038211954],"genre_scores_gemma":[0.9860563,0.00034994597,0.012453465,0.0005708481,0.00005569259,0.00009823015,0.000118566,0.00006389802,0.00023301663],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9959422,0.000886321,0.0017199765,0.00051419623,0.00044977493,0.00048753785],"domain_scores_gemma":[0.9938285,0.0028318618,0.001965845,0.0003775214,0.000383252,0.0006130721],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027120125,0.00045242594,0.0025302542,0.00041740257,0.00024889727,0.000038116057,0.00015935767,0.00011429033,0.00003154044],"category_scores_gemma":[0.00093627215,0.00028352102,0.00011840445,0.0005586755,0.00023133997,0.00016118569,0.0001215797,0.0002747001,0.0000013874595],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40588835,0.06053844,0.002177528,0.00072934764,0.0070738336,0.0026151694,0.0063866316,0.0008892812,0.00087984925,0.00005739601,0.0007408681,0.5120233],"study_design_scores_gemma":[0.4066119,0.56094515,0.010332043,0.000892844,0.003714368,0.0019995046,0.009153521,0.0012391494,0.0005867392,0.000048425736,0.0039841766,0.00049220945],"about_ca_topic_score_codex":0.0011127678,"about_ca_topic_score_gemma":0.0027526384,"teacher_disagreement_score":0.5115311,"about_ca_system_score_codex":0.0006762091,"about_ca_system_score_gemma":0.0012322392,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W4319660271","doi":"10.1016/j.jtho.2023.01.088","title":"IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sun Yat-sen University Cancer Center; National Cancer Institute; Arthrex GmbH; Genentech; AIO-Studien; Université Hassan II de Casablanca; Centro de Investigación Biomédica en Red de Cáncer; Tokyo Women's Medical University; Shanghai Chest Hospital; Universitätsspital Zürich; Hyogo College of Medicine; Astellas Pharma; Medizinische Universität Wien; Universidad de Navarra; Universiteit Gent; Yale University; University of Toronto; Seoul National University; Universitair Ziekenhuis Gent; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Universität Wien; Shionogi; Sun Yat-sen University; Mount Sinai Health System; Imperial College London; Dalhousie University; Aix-Marseille Université; University of Chicago; International Association for the Study of Lung Cancer; University of Texas Southwestern Medical Center; Memorial Sloan-Kettering Cancer Center; Samsung; University of Leicester; Boehringer Ingelheim; Ohio State University; University of Aberdeen; Pfizer; York University; Universidade de São Paulo; AstraZeneca; Eli Lilly and Company; Technische Universität München; Ankara Universitesi","keywords":"Medicine; Lung cancer staging; Ninth; Lung cancer; Cancer; Oncology; Medical physics; Internal medicine","score_opus":0.06003635021639952,"score_gpt":0.4951274116895153,"score_spread":0.43509106147311577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319660271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78109837,0.0026124574,0.00012982043,0.21193539,0.001482534,0.0016340868,0.00009683324,0.0000090405265,0.0010014707],"genre_scores_gemma":[0.99425894,0.0031905721,0.00019381783,0.0012646236,0.000674078,0.0001348051,0.000010413114,0.000012373967,0.00026036002],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99843407,0.00018937941,0.0006326654,0.000114727074,0.00044908826,0.0001800546],"domain_scores_gemma":[0.998171,0.00040559354,0.0007535295,0.00034807404,0.00026326545,0.000058578233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012663365,0.000104561914,0.00035731654,0.00020712923,0.00009244681,0.000010547904,0.00028179787,0.00006292994,0.000097846896],"category_scores_gemma":[0.0002657216,0.000046329213,0.0001308287,0.0010361176,0.00006599006,0.00012641631,0.000074437936,0.00035467578,0.0000011851816],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012213133,0.0005839212,0.1883306,0.00086332805,0.0005786789,0.000051599396,0.018424885,0.001020458,0.0028051196,0.0005057867,0.56347984,0.22213449],"study_design_scores_gemma":[0.0018049348,0.00089916534,0.8858886,0.005275061,0.0019329949,0.00008590773,0.006214154,0.0022379765,0.0036117183,0.00007949913,0.09183025,0.00013974107],"about_ca_topic_score_codex":0.0009903648,"about_ca_topic_score_gemma":0.0011355364,"teacher_disagreement_score":0.697558,"about_ca_system_score_codex":0.0008986002,"about_ca_system_score_gemma":0.0017451361,"threshold_uncertainty_score":0.30957964},"labels":[],"label_agreement":null},{"id":"W4319939127","doi":"10.1016/j.jtho.2023.01.091","title":"Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; National Human Genome Research Institute; NIHR Imperial Biomedical Research Centre; Genentech; G1 Therapeutics; Bayer HealthCare; Jazz Pharmaceuticals; Royal College of Physicians and Surgeons of Canada; Canadian Institutes of Health Research; Associazione Italiana per la Ricerca sul Cancro; GlaxoSmithKline; Northwell Health; Imperial College London; Pfizer; Moderna; Boston Pharmaceuticals; Imperial Experimental Cancer Medicine Centre; Eisai; Wellcome Trust; Relay Therapeutics; Amgen; ViiV Healthcare; Bristol-Myers Squibb; AstraZeneca; National Institute for Health and Care Research; Falk Foundation","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Oncology; Blockade; Progression-free survival; Chemotherapy; Gastroenterology; Cancer; Immunotherapy; Receptor","score_opus":0.047569612600812425,"score_gpt":0.43930395670906125,"score_spread":0.3917343441082488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319939127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947232,0.002580966,0.000021980113,0.0017167563,0.0005711536,0.00021031576,0.000003453383,0.000015815325,0.00015637375],"genre_scores_gemma":[0.9940868,0.0047669555,0.0007123109,0.00017886139,0.00014545232,0.000001922318,0.0000031774164,0.00001989613,0.000084615596],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984006,0.00011878218,0.0009500521,0.00014352455,0.00014610947,0.00024088676],"domain_scores_gemma":[0.99815655,0.0006689284,0.00084870646,0.00015808195,0.000093335235,0.00007438341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001502125,0.00014302971,0.0007664549,0.00042262062,0.000038625367,0.0000057834413,0.00011938235,0.00018175459,0.00006911652],"category_scores_gemma":[0.0003668428,0.0001049549,0.00020943905,0.00042906145,0.00013119828,0.00008125441,0.00003438615,0.00039429293,0.0000022142701],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029513655,0.0004507925,0.16476142,0.00012623494,0.00018882786,0.00031221635,0.002116013,0.00008825978,0.25807,0.0000010974697,0.000120508805,0.54425097],"study_design_scores_gemma":[0.0073776827,0.0053611915,0.96994215,0.0003816831,0.00009389966,0.0005810144,0.0013913327,0.00007363555,0.009684932,0.00007014552,0.0049157715,0.000126566],"about_ca_topic_score_codex":0.000019123505,"about_ca_topic_score_gemma":0.00002258895,"teacher_disagreement_score":0.8051807,"about_ca_system_score_codex":0.00024729507,"about_ca_system_score_gemma":0.00022251262,"threshold_uncertainty_score":0.42799366},"labels":[],"label_agreement":null},{"id":"W4321794008","doi":"10.1016/j.jtho.2023.02.003","title":"Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; BC Cancer Agency; Saskatchewan Cancer Agency; CancerCare Manitoba; Alberta Cancer Foundation; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; Canadian Cancer Society; University Health Network","funders":"EMD Serono; Merck Canada; Servier; Canadian Cancer Society; Ipsen; BeiGene; Les Laboratories Pierre Fabre; Astellas Pharma; Novocure; Eisai; Jazz Pharmaceuticals; Merck KGaA; Sanofi; GlaxoSmithKline; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Mesothelioma; Pemetrexed; Confidence interval; Internal medicine; Lung cancer; Interim analysis; Interim; Oncology; Clinical trial; Cancer; Chemotherapy; Immunotherapy; Pathology","score_opus":0.028848081565407222,"score_gpt":0.4260797057055907,"score_spread":0.3972316241401834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321794008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971417,0.00023647731,0.000005264122,0.00069591944,0.0003523183,0.0013429243,0.00008038184,0.000008290286,0.00013669823],"genre_scores_gemma":[0.99914813,0.00007483553,0.0001686734,0.00021072368,0.00010770575,0.00007393248,0.000059412,0.000023342442,0.00013326334],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99670637,0.00070757157,0.0015375586,0.00020473203,0.0005578343,0.00028594056],"domain_scores_gemma":[0.9974593,0.00041722896,0.001451707,0.00017761056,0.00015839312,0.0003357646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001918995,0.0001815803,0.0017122225,0.000707119,0.00004649218,0.000006790642,0.00011403737,0.000090892274,0.00023582409],"category_scores_gemma":[0.00074068125,0.0001156424,0.00021732306,0.00044116972,0.00011236211,0.00013525902,0.000029712188,0.00021680226,0.0000036633257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5835361,0.0050002225,0.35996848,0.000088355846,0.0008115306,0.005177687,0.00092479197,0.0003536696,0.00037749464,0.0000065832446,0.00056526804,0.043189812],"study_design_scores_gemma":[0.2802271,0.009275144,0.7067073,0.00029067943,0.0011225368,0.00023335022,0.0009405069,0.00005627242,0.00012774541,0.00007272738,0.0008031514,0.0001435067],"about_ca_topic_score_codex":0.005115549,"about_ca_topic_score_gemma":0.0117025105,"teacher_disagreement_score":0.3467388,"about_ca_system_score_codex":0.00059966394,"about_ca_system_score_gemma":0.0008227719,"threshold_uncertainty_score":0.77332145},"labels":[],"label_agreement":null},{"id":"W4328053701","doi":"10.1016/j.jtho.2023.03.016","title":"Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Ignyta; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; EMD Serono; Foundation Medicine; Galecto; BeiGene; Mirati Therapeutics; AstraZeneca; Novocure; Jazz Pharmaceuticals; Merck KGaA; Revolution Medicines; Regeneron Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Amgen; Agenzia Italiana del Farmaco, Ministero della Salute; PharmaMar; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Open label; Exon; Cohort; Oncology; Internal medicine; Cancer research; Clinical trial; Gene; Genetics","score_opus":0.08658018113189056,"score_gpt":0.5278038491763837,"score_spread":0.4412236680444931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328053701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891481,0.00049153116,0.00010080724,0.003174956,0.0017972201,0.002562219,0.000049168368,0.000046351666,0.002629662],"genre_scores_gemma":[0.98852783,0.0006687183,0.0061691916,0.0002894841,0.0007700083,0.00030663848,0.00011980876,0.000057902696,0.0030904054],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9975103,0.0002871289,0.0011117874,0.0003291994,0.0003242188,0.00043736753],"domain_scores_gemma":[0.99802786,0.0004064523,0.0007088704,0.00026911253,0.00028984682,0.00029787046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007164503,0.00026697095,0.00097536005,0.000679782,0.0001370038,0.000064617656,0.0002273093,0.00018086846,0.0001473541],"category_scores_gemma":[0.0003806358,0.00020708694,0.00016673461,0.00064818515,0.000081598766,0.00040195318,0.00007184137,0.0003609287,0.000079676494],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20799783,0.041067287,0.04335821,0.0001706984,0.0050417176,0.017365633,0.00889174,0.0003065861,0.01037385,0.00006218303,0.004407038,0.6609572],"study_design_scores_gemma":[0.80107516,0.05596287,0.034308784,0.0013624928,0.00824916,0.0015404418,0.0061975433,0.006356949,0.0031054618,0.00025979057,0.08082802,0.00075335946],"about_ca_topic_score_codex":0.00026818257,"about_ca_topic_score_gemma":0.00020454229,"teacher_disagreement_score":0.6602039,"about_ca_system_score_codex":0.0016647921,"about_ca_system_score_gemma":0.0012624821,"threshold_uncertainty_score":0.84447604},"labels":[],"label_agreement":null},{"id":"W4362579322","doi":"10.1016/s1556-0864(23)00346-5","title":"91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Osimertinib; Stage (stratigraphy); Internal medicine; Clinical endpoint; Regimen; Lung cancer; Oncology; Adjuvant; non-small cell lung cancer (NSCLC); Cancer; Surgery; Adenocarcinoma; Randomized controlled trial","score_opus":0.030936763858233893,"score_gpt":0.46906767792065146,"score_spread":0.43813091406241755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362579322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918979,0.00040277495,0.0000138778605,0.002391147,0.000534511,0.00088125333,0.000070590024,0.000021633794,0.0037863068],"genre_scores_gemma":[0.98806936,0.0010043253,0.00028522318,0.00016717601,0.00017851056,0.00009717841,0.000006646424,0.000022332672,0.0101692565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984337,0.00014755702,0.00057425007,0.0002436971,0.00023480988,0.00036598023],"domain_scores_gemma":[0.9989658,0.00014565072,0.00035038652,0.00019958623,0.00012365321,0.0002149043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036113625,0.00020822481,0.00076159654,0.00036110624,0.0000778361,0.000026797998,0.000097272,0.000089335306,0.00009975177],"category_scores_gemma":[0.000021174175,0.00014413515,0.00012560711,0.00045192515,0.000030260479,0.000102354774,0.000059100857,0.00021959232,0.000008255282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078009075,0.0015566366,0.9760897,0.000086160806,0.00057356304,0.0028069294,0.003644545,0.00008484698,0.00006738392,0.000003094896,0.0006291563,0.013677902],"study_design_scores_gemma":[0.00548495,0.004402437,0.98397785,0.00015960778,0.0010698049,0.000056190165,0.0030649211,0.00009853033,0.00011137715,0.000016963222,0.001444425,0.00011296555],"about_ca_topic_score_codex":0.009712506,"about_ca_topic_score_gemma":0.029664678,"teacher_disagreement_score":0.019952172,"about_ca_system_score_codex":0.0021318607,"about_ca_system_score_gemma":0.0008745867,"threshold_uncertainty_score":0.9968819},"labels":[],"label_agreement":null},{"id":"W4362585394","doi":"10.1016/s1556-0864(23)00273-3","title":"19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Osimertinib; Afatinib; Erlotinib; Gefitinib; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer","score_opus":0.026347402457045813,"score_gpt":0.4532249383955534,"score_spread":0.4268775359385076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362585394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958191,0.0002289851,0.000093107206,0.0008729048,0.00046801224,0.00046474655,0.00010019729,0.000054889595,0.0018980738],"genre_scores_gemma":[0.995575,0.0004063312,0.0009133271,0.00020420195,0.00021932287,0.0000753708,0.00042007002,0.00002733332,0.0021590104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800247,0.0001918886,0.0008681314,0.0002627952,0.00034902993,0.00032570204],"domain_scores_gemma":[0.9981278,0.000120254525,0.000730999,0.00026565738,0.00048106356,0.00027418943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027286334,0.00022260888,0.0009151628,0.00091779017,0.00009381752,0.000017412964,0.00007843424,0.000130848,0.0002881831],"category_scores_gemma":[0.00007365037,0.00016303347,0.00050449965,0.001555483,0.00008378515,0.00022088499,0.000024363959,0.00019220673,0.000042519063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003300792,0.0015856671,0.9026138,0.000036735866,0.0056811,0.0012597181,0.00063152873,0.00048202966,0.000161049,0.0000017900987,0.0005677023,0.08367807],"study_design_scores_gemma":[0.0040832288,0.0025504427,0.9751445,0.00009412694,0.012843157,0.000017420418,0.00015039167,0.00041758045,0.00030630943,0.000050301984,0.0042140526,0.00012847701],"about_ca_topic_score_codex":0.00046457557,"about_ca_topic_score_gemma":0.0015270292,"teacher_disagreement_score":0.0835496,"about_ca_system_score_codex":0.0013745582,"about_ca_system_score_gemma":0.00032610595,"threshold_uncertainty_score":0.66483116},"labels":[],"label_agreement":null},{"id":"W4362585841","doi":"10.1016/s1556-0864(23)00351-9","title":"96P Characteristics of patients with resectable non-metastatic non-small cell lung cancer treated with or without neoadjuvant therapy in Europe and Canada: A real-world survey","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Vinorelbine; Carboplatin; Gemcitabine; Radiation therapy; Internal medicine; Oncology; Cisplatin; Lung cancer; Cancer; Chemotherapy; Surgery","score_opus":0.023797419697673516,"score_gpt":0.3826993075989642,"score_spread":0.3589018879012907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362585841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99831504,0.00009674641,0.000015848054,0.00026297243,0.0001167926,0.0006052109,0.00013817944,0.0000052766363,0.0004439257],"genre_scores_gemma":[0.99584085,0.0009533624,0.0006185967,0.00011835869,0.00004377677,0.000025638217,0.00006817257,0.000035720313,0.0022955062],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864155,0.00015035919,0.0005157939,0.00016888879,0.0002590624,0.00026433505],"domain_scores_gemma":[0.99804145,0.00021909036,0.0006594063,0.00014304531,0.00077712175,0.00015987552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003576427,0.00017593954,0.00080904114,0.00031764226,0.000045729954,0.000010312148,0.000077867786,0.000038802922,0.000030298705],"category_scores_gemma":[0.00004379199,0.00009705592,0.000020892421,0.0008494082,0.00005898593,0.00006990365,0.000018700503,0.00023175855,4.019401e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010831081,0.000426638,0.9778795,0.00017289592,0.00037497535,0.0008503783,0.0006054007,0.00005263844,0.00015401884,1.479553e-7,0.00097451836,0.007677802],"study_design_scores_gemma":[0.005594131,0.0048857653,0.98705256,0.00047190845,0.00048794865,0.000032693446,0.00016477464,0.000248996,0.0002579761,3.6506688e-7,0.0006971705,0.00010572918],"about_ca_topic_score_codex":0.26370275,"about_ca_topic_score_gemma":0.70284027,"teacher_disagreement_score":0.43913752,"about_ca_system_score_codex":0.000550524,"about_ca_system_score_gemma":0.00497823,"threshold_uncertainty_score":0.88311666},"labels":[],"label_agreement":null},{"id":"W4362586002","doi":"10.1016/s1556-0864(23)00258-7","title":"40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Docetaxel; Medicine; Common Terminology Criteria for Adverse Events; Visual analogue scale; Quality of life (healthcare); Internal medicine; Clinical endpoint; Adverse effect; Physical therapy; Oncology; Clinical trial; Cancer","score_opus":0.08041390054959867,"score_gpt":0.48994981325527814,"score_spread":0.40953591270567946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362586002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98823977,0.00033570605,0.000047441692,0.005433025,0.0034656064,0.0007257244,0.000024392575,0.000039822018,0.0016885062],"genre_scores_gemma":[0.9983967,0.000071953145,0.0002806372,0.00040621468,0.00040545274,0.00003367316,0.00011160907,0.00002296636,0.00027081987],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977759,0.00023051605,0.0010949688,0.00019517813,0.00039129477,0.00031213852],"domain_scores_gemma":[0.99762964,0.0008342844,0.00088015746,0.0002512931,0.00023288238,0.00017176878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053431944,0.00019352495,0.00089824386,0.00026242933,0.00011642703,0.000027245333,0.00015706864,0.0001429575,0.00019091909],"category_scores_gemma":[0.0004616864,0.000117416464,0.0002427199,0.0004989191,0.00008677929,0.0001352839,0.000051408857,0.00047350588,0.000036330206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6789397,0.0057050334,0.08393708,0.000036044235,0.0062322957,0.009359106,0.010345858,0.000612182,0.0019420371,0.000024646757,0.023599619,0.1792664],"study_design_scores_gemma":[0.6969844,0.014824064,0.2204336,0.00048018357,0.0067269485,0.0006114696,0.010560205,0.0019404752,0.0006606631,0.0003786344,0.0459117,0.00048766294],"about_ca_topic_score_codex":0.00052616367,"about_ca_topic_score_gemma":0.0003532126,"teacher_disagreement_score":0.17877872,"about_ca_system_score_codex":0.00064201985,"about_ca_system_score_gemma":0.0009211342,"threshold_uncertainty_score":0.47881043},"labels":[],"label_agreement":null},{"id":"W4362586968","doi":"10.1016/s1556-0864(23)00338-6","title":"84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Regeneron Pharmaceuticals; Genentech; F-star Therapeutics; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Daiichi-Sankyo; G1 Therapeutics; Amgen; LUNGevity Foundation; Mesothelioma Applied Research Foundation","keywords":"Medicine; Internal medicine; Oncology; Complete response; Neoadjuvant therapy; Nivolumab; Gastroenterology; Chemotherapy; Surgery; Cancer; Breast cancer; Immunotherapy","score_opus":0.034453478235764695,"score_gpt":0.4077052869778547,"score_spread":0.37325180874208996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362586968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96763396,0.0021256965,0.00082607794,0.024421254,0.0023958518,0.00061840087,0.00007771473,0.00008310091,0.0018179439],"genre_scores_gemma":[0.9466248,0.0064681363,0.019953834,0.009704233,0.0043958146,0.000085170825,0.00019882392,0.00021780246,0.012351365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978496,0.00011888152,0.00092758005,0.00025877613,0.00035216878,0.00049301964],"domain_scores_gemma":[0.9980196,0.00036144545,0.0007896236,0.0003185306,0.0003259027,0.00018491833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015079689,0.00022440967,0.0008939385,0.00033395295,0.00012696326,0.000037368995,0.0002871141,0.00028844483,0.00090876286],"category_scores_gemma":[0.00014519779,0.00017545669,0.00042747604,0.0004747625,0.00011297134,0.00018251434,0.000044765948,0.00042445553,0.00007868449],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07888693,0.00035215085,0.00085058087,0.0001244747,0.0011609048,0.00044794075,0.0008770187,0.000022696635,0.16391425,0.000019861678,0.18470739,0.5686358],"study_design_scores_gemma":[0.016905028,0.0053346767,0.012136522,0.0005792655,0.0004001572,0.0007653116,0.0007578203,0.00073438976,0.04829816,0.0013824011,0.91236836,0.00033792542],"about_ca_topic_score_codex":0.000106306084,"about_ca_topic_score_gemma":0.00005805761,"teacher_disagreement_score":0.72766095,"about_ca_system_score_codex":0.00044814017,"about_ca_system_score_gemma":0.00069763325,"threshold_uncertainty_score":0.99503165},"labels":[],"label_agreement":null},{"id":"W4362587019","doi":"10.1016/s1556-0864(23)00423-9","title":"169P Phase I dose escalation trial combining olaparib and thoracic radiation therapy in extensive-stage small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"PharmaMar; Castle Biosciences; Daiichi Sankyo Europe; Exelixis; ViewRay; Novocure; Elekta; Varian Medical Systems; Pfizer; Eli Lilly and Company; AstraZeneca; Accuray; LUNGevity Foundation; MedImmune; Mesothelioma Applied Research Foundation","keywords":"Medicine; Olaparib; Atezolizumab; Internal medicine; Oncology; Dysgeusia; Lung cancer; Adverse effect; Radiation therapy; Urology; Cancer; Gastroenterology; Nivolumab; Immunotherapy","score_opus":0.07487591896206015,"score_gpt":0.50855599154978,"score_spread":0.4336800725877199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362587019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98638463,0.0061185914,0.000073039744,0.005144874,0.00092201703,0.0009203047,0.000008493908,0.000027033011,0.00040099662],"genre_scores_gemma":[0.9854091,0.012367697,0.00032850562,0.00033666138,0.000769076,0.00005804333,0.000010463821,0.000028556042,0.0006919105],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978498,0.00046251013,0.0006950481,0.00022529518,0.0003926551,0.0003746597],"domain_scores_gemma":[0.998141,0.0005794945,0.0005877678,0.00014742558,0.00036090804,0.0001834186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021005906,0.0001702316,0.00072439486,0.00065398385,0.000104396524,0.000029717303,0.00010697371,0.00017401869,0.00006658629],"category_scores_gemma":[0.00047797372,0.00013522618,0.000111559864,0.00060628075,0.000102528385,0.00019849565,0.00006502087,0.00070123025,0.000004623061],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15205327,0.0011514365,0.034163237,0.00045248712,0.00037368704,0.0014072036,0.005962276,0.0003825821,0.022943437,0.000013004316,0.0046171625,0.7764802],"study_design_scores_gemma":[0.4341041,0.05211706,0.3801237,0.0020548229,0.0015142229,0.0005281356,0.0075738495,0.03866141,0.023203539,0.0006369672,0.058315,0.001167155],"about_ca_topic_score_codex":0.00007839344,"about_ca_topic_score_gemma":0.00007626551,"teacher_disagreement_score":0.7753131,"about_ca_system_score_codex":0.0007301938,"about_ca_system_score_gemma":0.00079756085,"threshold_uncertainty_score":0.55143636},"labels":[],"label_agreement":null},{"id":"W4362587340","doi":"10.1016/s1556-0864(23)00287-3","title":"33P Real-world experience of MET TKI-induced peripheral edema","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Merck KGaA","keywords":"Medicine; Peripheral edema; Crizotinib; Internal medicine; Adverse effect; Lung cancer","score_opus":0.06843871937804583,"score_gpt":0.4807378052308676,"score_spread":0.4122990858528218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362587340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98663,0.0002533424,0.000007944585,0.0045674606,0.0009713742,0.00015398009,0.0000037513876,0.000018232904,0.007393886],"genre_scores_gemma":[0.99574906,0.0006944809,0.0013169072,0.00031034302,0.0004995345,0.00001975862,0.0000025983695,0.000016704713,0.0013906459],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99855125,0.00010729328,0.0006376102,0.00014338958,0.00032524337,0.00023522504],"domain_scores_gemma":[0.9986342,0.0002027045,0.0005436584,0.00020364972,0.00023112733,0.00018463888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004724043,0.00012522553,0.0007302826,0.00031725268,0.0000416257,0.0000072405664,0.00012335085,0.00009212188,0.00044903439],"category_scores_gemma":[0.00010667691,0.000091731454,0.00024893048,0.00048323572,0.00007447663,0.00008184429,0.000047210982,0.00021560835,0.000019193556],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00547771,0.0027193162,0.1888063,0.0003153871,0.0012850842,0.005893026,0.010619364,0.0000855842,0.06653303,0.00080424396,0.037870742,0.6795902],"study_design_scores_gemma":[0.005421657,0.019004548,0.69104874,0.0009487847,0.001426789,0.0020834995,0.0068795937,0.00013618567,0.12277056,0.0007960418,0.14909983,0.00038378857],"about_ca_topic_score_codex":0.00017122293,"about_ca_topic_score_gemma":0.00022084579,"teacher_disagreement_score":0.67920643,"about_ca_system_score_codex":0.000491342,"about_ca_system_score_gemma":0.0004559895,"threshold_uncertainty_score":0.49166116},"labels":[],"label_agreement":null},{"id":"W4362587522","doi":"10.1016/s1556-0864(23)00269-1","title":"15MO Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"Loxo Oncology; Bavarian Nordic; Eli Lilly and Company; Bayer HealthCare; Incyte; Amgen","keywords":"Medicine; Trk receptor; Internal medicine; Lung cancer; Cancer; Oncology; Adverse effect; Cohort; Confidence interval; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Surgery; Clinical trial; Neurotrophin; Receptor; Phases of clinical research","score_opus":0.012531395940251905,"score_gpt":0.4192306762341641,"score_spread":0.4066992802939122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362587522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874383,0.00015729222,0.000019506648,0.00040553455,0.00005317369,0.0003805848,0.000023741191,0.000012871473,0.0002034528],"genre_scores_gemma":[0.9990159,0.00012083726,0.0004527073,0.00004513393,0.00003454347,0.000012852213,0.000113779286,0.000014695168,0.00018955053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989755,0.00011082228,0.00037571148,0.00015745481,0.00022367576,0.00015683498],"domain_scores_gemma":[0.9989033,0.000059711998,0.00042617923,0.00012300178,0.0003581289,0.00012972105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021165042,0.000116892035,0.000621931,0.00066111836,0.00004066856,0.0000068980657,0.000047656977,0.00008135063,0.00010944339],"category_scores_gemma":[0.000016297974,0.00006941585,0.000048873262,0.0013940453,0.00005935941,0.00011229784,0.000013018556,0.00016416417,5.4784516e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051254765,0.00073674094,0.9695843,0.000029780485,0.0021043688,0.00019009346,0.0007089929,0.00064216356,0.00016541792,6.4309296e-7,0.0001709187,0.020541117],"study_design_scores_gemma":[0.0045806826,0.0035538783,0.9836634,0.00013359576,0.0067725377,0.000022513901,0.00023185993,0.00041060886,0.00021895175,0.0000015068445,0.0003407962,0.00006969898],"about_ca_topic_score_codex":0.00023059527,"about_ca_topic_score_gemma":0.0006522706,"teacher_disagreement_score":0.020471416,"about_ca_system_score_codex":0.00026986442,"about_ca_system_score_gemma":0.00036795167,"threshold_uncertainty_score":0.2830696},"labels":[],"label_agreement":null},{"id":"W4362588616","doi":"10.1016/s1556-0864(23)00335-0","title":"81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Crizotinib; Cancer research; Lung cancer; Metastasis; Cancer; Oncology; Internal medicine","score_opus":0.010319327326104393,"score_gpt":0.4090416303925772,"score_spread":0.39872230306647277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362588616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959095,0.00011433334,0.000031326796,0.0014174539,0.00045751984,0.0012141413,0.00003194341,0.000024981173,0.00079881016],"genre_scores_gemma":[0.99877954,0.000018299224,0.00025522555,0.00031828147,0.00024238584,0.00007915343,0.000026988746,0.00003343815,0.00024669876],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99801725,0.00027400863,0.00062294357,0.00026347497,0.00044490345,0.00037740413],"domain_scores_gemma":[0.9981242,0.0003313921,0.00059331313,0.00019922048,0.00056782307,0.00018405021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000397101,0.00023321254,0.0006818581,0.0004411226,0.00021820041,0.000018485329,0.00013814459,0.00008306404,0.000021260437],"category_scores_gemma":[0.00023723797,0.00013785248,0.00010494409,0.0009707638,0.000108693755,0.00023372693,0.000066111934,0.0003053844,0.000011795951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07370186,0.045964215,0.14101668,0.0001033281,0.003582113,0.010075508,0.046855878,0.0014638951,0.0009591478,0.000024470191,0.0051773577,0.6710755],"study_design_scores_gemma":[0.05535603,0.16793343,0.75097036,0.0008309199,0.0023351319,0.000497849,0.01691598,0.00024013002,0.0016033,0.00016295208,0.0027958238,0.0003580949],"about_ca_topic_score_codex":0.00003743705,"about_ca_topic_score_gemma":0.00019824665,"teacher_disagreement_score":0.6707175,"about_ca_system_score_codex":0.001249474,"about_ca_system_score_gemma":0.0012513102,"threshold_uncertainty_score":0.56214607},"labels":[],"label_agreement":null},{"id":"W4362588741","doi":"10.1016/s1556-0864(23)00424-0","title":"170P Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; GlaxoSmithKline; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Etoposide; Internal medicine; Phases of clinical research; Oncology; Chemotherapy; Cancer; Nivolumab","score_opus":0.06322569750506297,"score_gpt":0.45745489743307094,"score_spread":0.394229199928008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362588741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942628,0.0004271935,0.000071642935,0.0015737796,0.0006487197,0.0022137705,0.00038961766,0.000040225113,0.00037226622],"genre_scores_gemma":[0.9946352,0.00014325399,0.0033005432,0.0001242876,0.0005125378,0.000079504105,0.00007204344,0.000064208245,0.0010684173],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99594915,0.00035596555,0.0014574567,0.0004817034,0.0011477064,0.0006080088],"domain_scores_gemma":[0.99353,0.0018304107,0.0017255713,0.0005182477,0.0021189307,0.00027685263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013774812,0.0003278341,0.0014854758,0.00046031576,0.00019261373,0.000019383446,0.00033600998,0.00017567177,0.000034269906],"category_scores_gemma":[0.0031783644,0.00023787367,0.00021933012,0.00065853156,0.00029728448,0.00023179493,0.00023406687,0.0006511461,0.000008747964],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6172427,0.047474347,0.038504753,0.0012318426,0.0045164735,0.0070609385,0.029645473,0.00047946375,0.009351549,0.000007958653,0.04422413,0.20026036],"study_design_scores_gemma":[0.10814382,0.51848054,0.31899607,0.0028746221,0.0028482436,0.00022549198,0.02475178,0.00087026024,0.006490413,0.00018965549,0.015478934,0.0006501751],"about_ca_topic_score_codex":0.00009425232,"about_ca_topic_score_gemma":0.00011491566,"teacher_disagreement_score":0.5090989,"about_ca_system_score_codex":0.00071608333,"about_ca_system_score_gemma":0.00082010106,"threshold_uncertainty_score":0.97002065},"labels":[],"label_agreement":null},{"id":"W4362591319","doi":"10.1016/s1556-0864(23)00257-5","title":"30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Array BioPharma; Apollomics; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Rash; Chemotherapy; Lung cancer; Oncology; Population; Immunotherapy; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Progressive disease; Cancer","score_opus":0.008698202301313506,"score_gpt":0.37683261051435096,"score_spread":0.36813440821303745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362591319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966037,0.00008099024,0.00008125154,0.0017886432,0.00038192788,0.0006420872,0.00006426412,0.000030231615,0.0003268679],"genre_scores_gemma":[0.99821895,0.000058987483,0.0008404974,0.00016160781,0.00007474775,0.0000074734385,0.000052049698,0.000031428244,0.0005542707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983686,0.00017813951,0.00064362935,0.00018970743,0.00036453587,0.0002553695],"domain_scores_gemma":[0.99790657,0.00041594164,0.0005909023,0.00018358431,0.00060558703,0.0002974073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041018985,0.00017156354,0.00060733233,0.00044744485,0.00007557039,0.000009404089,0.00009732615,0.00011171457,0.00006374046],"category_scores_gemma":[0.00038476274,0.00011861336,0.000080694925,0.00044475612,0.00012665293,0.00014578587,0.00005700128,0.00022350217,0.000010600508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081662275,0.001012944,0.784532,0.00011908236,0.0009488854,0.0009983664,0.0036301126,0.00034669836,0.0041051274,0.000002328538,0.0004262513,0.122215934],"study_design_scores_gemma":[0.0071002594,0.012286757,0.9773059,0.00050148496,0.0007227095,0.00014272697,0.00040072264,0.000008231857,0.00061499444,0.000004029306,0.00080869696,0.000103495135],"about_ca_topic_score_codex":0.000010481265,"about_ca_topic_score_gemma":0.000026198519,"teacher_disagreement_score":0.1927739,"about_ca_system_score_codex":0.00037653552,"about_ca_system_score_gemma":0.0005291333,"threshold_uncertainty_score":0.48369125},"labels":[],"label_agreement":null},{"id":"W4362591364","doi":"10.1016/s1556-0864(23)00281-2","title":"27P Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Hazard ratio; Cohort; Proportional hazards model; Osimertinib; Epidermal growth factor receptor; Cancer; Confidence interval; Erlotinib","score_opus":0.020234847810806592,"score_gpt":0.39046488949458946,"score_spread":0.3702300416837829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362591364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955448,0.0002867109,0.00002425554,0.002567237,0.00034487137,0.0006414727,0.000048184873,0.000010163072,0.00053230283],"genre_scores_gemma":[0.9966991,0.0019276957,0.0006674244,0.000225263,0.000110977075,0.000084683845,0.00003276455,0.000026359929,0.00022574009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878037,0.0001895597,0.00036385204,0.00018818515,0.000244496,0.0002335138],"domain_scores_gemma":[0.9988167,0.00023136781,0.0004479319,0.00009889305,0.00033178608,0.000073307325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016921821,0.00016763384,0.00039108438,0.00038748284,0.00007712854,0.000018586601,0.000094069124,0.00004958967,0.00003762554],"category_scores_gemma":[0.000026707225,0.0000949748,0.000034685596,0.0006971858,0.00007949795,0.00024513388,0.000018189878,0.00032699268,0.0000020935063],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065074395,0.00053958775,0.9665551,0.00009016803,0.00031940083,0.00017347856,0.0074957367,0.0014440024,0.00084560236,0.0000065181684,0.00017539387,0.015847558],"study_design_scores_gemma":[0.008661113,0.002554727,0.9850982,0.00034289522,0.0003235052,0.000007481844,0.0012074411,0.0001339807,0.000807838,0.000007217554,0.00073971524,0.00011588823],"about_ca_topic_score_codex":0.0005772518,"about_ca_topic_score_gemma":0.0035862874,"teacher_disagreement_score":0.018543083,"about_ca_system_score_codex":0.0005261616,"about_ca_system_score_gemma":0.0004910687,"threshold_uncertainty_score":0.387296},"labels":[],"label_agreement":null},{"id":"W4367840052","doi":"10.1016/j.jtho.2023.04.019","title":"Malignant Superior Vena Cava Syndrome: A Scoping Review","year":2023,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Central Venous Catheters and Hemodialysis","field":"Health Professions","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Queen's University; International Association for the Study of Lung Cancer; AstraZeneca; Pfizer","keywords":"Medicine; Superior vena cava syndrome; Malignancy; Radiology; Thrombus; Intensive care medicine; Inferior vena cava; Radiation therapy; Superior vena cava; Surgery; Internal medicine","score_opus":0.18489654926976307,"score_gpt":0.5683513018716707,"score_spread":0.38345475260190764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367840052","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003986602,0.99231666,0.000016861544,0.00086873194,0.003714301,0.0024726011,0.000053278207,0.000041647185,0.0004760525],"genre_scores_gemma":[0.0000017773324,0.99579173,0.00036141468,0.0007884682,0.0010784906,0.00016032292,0.000030477608,0.00012788149,0.0016594401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990824,0.0032359103,0.004133871,0.000379399,0.00048054365,0.0009462699],"domain_scores_gemma":[0.99210316,0.0017913516,0.004783552,0.00053187006,0.00037367456,0.00041641944],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005106797,0.0004988301,0.00747767,0.0006155991,0.0004388551,0.000014368594,0.00077570655,0.0009826696,0.0011645554],"category_scores_gemma":[0.0007671226,0.00034114317,0.0020439667,0.0008166801,0.00008228902,0.00011186734,0.00029065862,0.0027339973,0.0015092157],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025052717,0.000085249536,0.0000031539796,0.35119274,0.00039075,0.0019216381,0.00019170453,1.2424773e-7,2.1121885e-7,0.0000065317226,0.008298464,0.6378844],"study_design_scores_gemma":[0.00007901584,0.00037144544,0.0000018746704,0.47054738,0.0033450278,0.001467391,0.00006220973,2.3156879e-7,3.1919736e-8,0.000016625707,0.5239393,0.00016948691],"about_ca_topic_score_codex":0.000025538191,"about_ca_topic_score_gemma":0.000076524666,"teacher_disagreement_score":0.63771486,"about_ca_system_score_codex":0.0015713057,"about_ca_system_score_gemma":0.007897481,"threshold_uncertainty_score":0.99990404},"labels":[],"label_agreement":null},{"id":"W4372233746","doi":"10.1016/j.jtho.2023.05.001","title":"Mosaic Chromosomal Alterations Are Associated With Increased Lung Cancer Risk: Insight From the INTEGRAL-ILCCO Cohort Analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genomic variations and chromosomal abnormalities","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto; University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Georgia Clinical and Translational Science Alliance; Vanderbilt University Medical Center; Vanderbilt University; National Natural Science Foundation of China; Cancer Prevention and Research Institute of Texas; World Health Organization","keywords":"Medicine; Lung cancer; Cohort; Oncology; Mosaic; Cancer; Cohort study; Internal medicine","score_opus":0.009847879666239833,"score_gpt":0.3129631681548498,"score_spread":0.30311528848860997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4372233746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965295,0.0007423192,0.00055596896,0.0010905836,0.00025344387,0.0001335184,0.0005135818,0.000011860768,0.00016921062],"genre_scores_gemma":[0.997493,0.0005238833,0.00024889692,0.00028842792,0.00052632793,0.000031854015,0.0005190141,0.00001751833,0.0003510494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983806,0.00050409825,0.00046804213,0.00020508746,0.00020718345,0.00023500185],"domain_scores_gemma":[0.9981841,0.00017900621,0.0008927128,0.0002606946,0.00038844728,0.00009503954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005981221,0.0001651734,0.00041659144,0.00014878738,0.00026021927,0.000051901032,0.0003056116,0.00019091673,0.00016071941],"category_scores_gemma":[0.00025508268,0.00010459823,0.00023143012,0.0006918285,0.00009826109,0.000014923572,0.00008322987,0.00030808867,0.0000044274225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026588308,0.00013905662,0.97219366,0.000005222521,0.005962793,0.0000635632,0.00058660685,0.005630526,0.0062351534,0.000012277364,0.008046299,0.0008589725],"study_design_scores_gemma":[0.0005645064,0.00047285465,0.9772298,0.00005114494,0.003804823,0.00003725007,0.00096470234,0.0019478237,0.005101824,0.00006728898,0.0095426915,0.00021532665],"about_ca_topic_score_codex":0.0006511504,"about_ca_topic_score_gemma":0.004788951,"teacher_disagreement_score":0.005036118,"about_ca_system_score_codex":0.00016317185,"about_ca_system_score_gemma":0.00047890554,"threshold_uncertainty_score":0.4265392},"labels":[],"label_agreement":null},{"id":"W4376272496","doi":"10.1016/j.jtho.2023.05.007","title":"Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Marie-Josée and Henry R. Kravis Center for Molecular Oncology; Loxo Oncology; National Cancer Institute; National Institutes of Health; Royal College of Physicians and Surgeons of Canada; Helsinn; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Trametinib; Mdm2; Medicine; Cancer research; Adenocarcinoma; Lung cancer; Targeted therapy; MAPK/ERK pathway; MEK inhibitor; Cancer; Oncology; Internal medicine; Kinase; Gene; Biology; Genetics","score_opus":0.017626076959057865,"score_gpt":0.3820243639162987,"score_spread":0.3643982869572408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376272496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99636817,0.0012160308,0.00032549922,0.0012439729,0.00009294138,0.00065806165,0.000008996893,0.000007551113,0.00007879532],"genre_scores_gemma":[0.99863416,0.00083243754,0.00036686208,0.00007743371,0.000021884425,0.000029515342,0.000011220153,0.0000125947545,0.000013912777],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991457,0.000106200685,0.00029628546,0.00014272884,0.0001923397,0.000116731426],"domain_scores_gemma":[0.99901426,0.00013347983,0.00043354733,0.00007171304,0.00026244586,0.00008455285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017454031,0.00010929768,0.00036049658,0.00030130573,0.000041927295,0.0000075408516,0.000029085095,0.00006892391,0.0000046501377],"category_scores_gemma":[0.000012943922,0.00007215533,0.000032496395,0.0002739087,0.0001225398,0.00016658287,0.000012790521,0.00015032267,2.9407798e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007896749,0.0014794694,0.33716428,0.00034871013,0.0016131393,0.00043163355,0.04515628,0.0005674477,0.02108082,0.0002867405,0.0005119704,0.5834628],"study_design_scores_gemma":[0.019497667,0.03060421,0.90473306,0.0010073618,0.0014759728,0.00097170303,0.009305412,0.0041334135,0.026763106,0.0007687153,0.00045351198,0.00028583806],"about_ca_topic_score_codex":0.000033660373,"about_ca_topic_score_gemma":0.000019433743,"teacher_disagreement_score":0.5831769,"about_ca_system_score_codex":0.00029796464,"about_ca_system_score_gemma":0.0002614887,"threshold_uncertainty_score":0.2942409},"labels":[],"label_agreement":null},{"id":"W4377018147","doi":"10.1016/j.jtho.2023.03.009","title":"“Brief Report: Canadian Cancer Trials Group IND.227”: Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma","year":2023,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pembrolizumab; Unpacking; Mesothelioma; Oncology; Clinical trial; Internal medicine; Cancer; Pathology; Immunotherapy","score_opus":0.09913421175890003,"score_gpt":0.45830352301487987,"score_spread":0.35916931125597984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377018147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66284114,0.0021383276,0.000019546955,0.32805547,0.0054821833,0.00078140234,0.00032519142,0.000012956197,0.0003437412],"genre_scores_gemma":[0.85908854,0.0014698431,0.00058414397,0.12565963,0.01068648,0.000058606718,0.00038178635,0.00014605136,0.0019249464],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99351764,0.0014211739,0.0032832867,0.0003767342,0.0008703026,0.0005308386],"domain_scores_gemma":[0.9944721,0.0010510864,0.003616569,0.00037529698,0.00017378986,0.0003111507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033743668,0.00034126887,0.0020951862,0.00068317656,0.00008194114,0.00001977777,0.00036307183,0.00080367073,0.00039454194],"category_scores_gemma":[0.00138555,0.00021881468,0.0009502513,0.00031422783,0.0003185421,0.00010030081,0.000096972275,0.0018635689,0.000012926023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016314432,0.0012405454,0.071094684,0.0008772409,0.0025289364,0.15449089,0.00036137254,0.0007961458,0.0033981886,0.00001154566,0.5861984,0.16268761],"study_design_scores_gemma":[0.0041606394,0.0039217845,0.39235437,0.0021522718,0.003304191,0.008231529,0.00037672356,0.00004991967,0.00023595741,0.00046053782,0.5842963,0.00045579168],"about_ca_topic_score_codex":0.005626054,"about_ca_topic_score_gemma":0.011467127,"teacher_disagreement_score":0.32125968,"about_ca_system_score_codex":0.0016250474,"about_ca_system_score_gemma":0.0024328718,"threshold_uncertainty_score":0.89230037},"labels":[],"label_agreement":null},{"id":"W4377018442","doi":"10.1016/j.jtho.2023.03.003","title":"Response to a Letter Received Entitled: “‘Brief Report: Canadian Cancer Trials Group IND.227’: Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma”","year":2023,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; University of Alberta; Queen's University; Alberta Health Services","funders":"Canadian Cancer Society","keywords":"Medicine; Pembrolizumab; Mesothelioma; Oncology; Lung cancer; Internal medicine; Clinical trial; Cancer; Surgery; Pathology; Immunotherapy","score_opus":0.08669132187558784,"score_gpt":0.4493201992237101,"score_spread":0.3626288773481222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377018442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58422816,0.000413845,0.000017380442,0.4114346,0.0029704503,0.00064057985,0.00019977972,0.000008246828,0.00008697131],"genre_scores_gemma":[0.609376,0.00045866158,0.0010376117,0.37601614,0.008438658,0.00010448916,0.00023828838,0.0001676599,0.004162449],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924313,0.0027154386,0.0029681034,0.0004390601,0.00088770955,0.0005583835],"domain_scores_gemma":[0.9948879,0.0015167639,0.0025904677,0.0004432026,0.00019023854,0.000371459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005419746,0.000351236,0.0018972595,0.000979099,0.00008034992,0.000026778904,0.00038382068,0.0006984084,0.00070489163],"category_scores_gemma":[0.00267469,0.0002346765,0.0008304728,0.0003876281,0.00021757596,0.000093978124,0.00011775824,0.0015800575,0.000034853834],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05363585,0.0005551619,0.016414512,0.00025878573,0.0011088992,0.071625754,0.00037986672,0.00042390486,0.014877962,9.4979566e-7,0.81089705,0.02982132],"study_design_scores_gemma":[0.0026892417,0.002853426,0.23476207,0.0014316025,0.0011857314,0.0024781802,0.00016659137,0.000012999968,0.0003146381,0.00009184869,0.7537086,0.00030507438],"about_ca_topic_score_codex":0.0037615171,"about_ca_topic_score_gemma":0.008731405,"teacher_disagreement_score":0.21834756,"about_ca_system_score_codex":0.0019018004,"about_ca_system_score_gemma":0.0020035987,"threshold_uncertainty_score":0.956983},"labels":[],"label_agreement":null},{"id":"W4377944155","doi":"10.1016/j.jtho.2023.05.015","title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Astellas Pharma; Yuhan; BeiGene; G1 Therapeutics; Pfizer; Genentech; American Association for Cancer Research; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Osimertinib; Tolerability; Placebo; Internal medicine; Adverse effect; Oncology; Surgery; Cancer; Adenocarcinoma; Pathology","score_opus":0.05695210664319922,"score_gpt":0.4782207666485358,"score_spread":0.4212686600053366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377944155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884947,0.00014200971,0.00009163416,0.009538143,0.00018037621,0.0010994648,0.0004002841,0.000014557334,0.00003881589],"genre_scores_gemma":[0.998825,0.0000262103,0.00050493295,0.00027455686,0.00002894637,0.000009844276,0.00027694734,0.000015391643,0.000038144724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963289,0.0006067436,0.0020841153,0.0002315283,0.0005076257,0.00024107288],"domain_scores_gemma":[0.9965527,0.00063274003,0.001664766,0.000328319,0.0005799246,0.00024154622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018491326,0.00017027289,0.0017576177,0.00048784533,0.00006648204,0.000007841121,0.00014644559,0.00012225761,0.00018301414],"category_scores_gemma":[0.0006590938,0.0000977918,0.00018732635,0.0018320688,0.00012468733,0.000084903164,0.00006818272,0.00032533138,0.0000018658949],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1406263,0.0022604184,0.8361096,0.00003891026,0.0042375736,0.000026913756,0.002326023,0.0003392834,0.000121828154,0.000007362071,0.0003565049,0.013549307],"study_design_scores_gemma":[0.05796281,0.007699741,0.9315937,0.000088156645,0.0014441026,0.000001024763,0.00080966123,0.00012969505,0.000043440108,0.000060402548,0.00008838951,0.00007886971],"about_ca_topic_score_codex":0.0036816527,"about_ca_topic_score_gemma":0.003964938,"teacher_disagreement_score":0.09548413,"about_ca_system_score_codex":0.0003587933,"about_ca_system_score_gemma":0.0010354916,"threshold_uncertainty_score":0.55655825},"labels":[],"label_agreement":null},{"id":"W4378528212","doi":"10.1016/j.jtho.2023.05.019","title":"Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Human Genome Research Institute; Canadian Institutes of Health Research; Genentech; Bristol-Myers Squibb; AstraZeneca; Foghorn Therapeutics; Revolution Medicines; National Cancer Institute; Royal College of Physicians and Surgeons of Canada; Gilead Sciences; GlaxoSmithKline; G1 Therapeutics; V Foundation for Cancer Research; Pfizer; Amgen","keywords":"Medicine; Aneuploidy; Oncology; Immunotherapy; Internal medicine; Biomarker; Lung cancer; Cancer; Chromosome; Cancer research; Gene; Genetics; Biology","score_opus":0.016763935468031836,"score_gpt":0.36924656841797476,"score_spread":0.3524826329499429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378528212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929268,0.004196194,0.0000011072044,0.0022672596,0.00025161754,0.0002702573,0.000008788621,0.000007814353,0.000070178015],"genre_scores_gemma":[0.9966142,0.0028844555,0.00012540811,0.00009275819,0.00016087359,0.0000035707765,0.000003863528,0.000022016942,0.00009284272],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983033,0.00013493397,0.0009200104,0.00016930971,0.0002088679,0.00026357747],"domain_scores_gemma":[0.9988498,0.00018748819,0.00062002183,0.00018173449,0.000041360032,0.00011961083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010426032,0.00017922295,0.0007970652,0.00042627077,0.000033920714,0.00000841408,0.000089873254,0.00012086615,0.0000882503],"category_scores_gemma":[0.00008779703,0.00013048569,0.00024011955,0.00028236676,0.00026666958,0.00007222648,0.0000669767,0.00040743785,0.0000057909238],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019782634,0.00096938014,0.010873319,0.00014677987,0.00030928547,0.0010858647,0.0007705508,0.000016099028,0.9045266,0.0000010312323,0.00014113505,0.06137732],"study_design_scores_gemma":[0.0057918383,0.010312857,0.9085272,0.00067319366,0.00010481141,0.0026348978,0.00025745927,0.000020534886,0.07076609,0.000020395883,0.0007723246,0.000118430034],"about_ca_topic_score_codex":0.00006702482,"about_ca_topic_score_gemma":0.000005748779,"teacher_disagreement_score":0.8976539,"about_ca_system_score_codex":0.0004774798,"about_ca_system_score_gemma":0.00021313743,"threshold_uncertainty_score":0.53210515},"labels":[],"label_agreement":null},{"id":"W4379194035","doi":"10.1016/j.jtho.2023.05.024","title":"Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee","year":2023,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Brock University","funders":"","keywords":"Medicine; Lung cancer; Cancer; Lung; Lung cancer screening; Environmental health; Intensive care medicine; Oncology; Internal medicine","score_opus":0.08659866855007405,"score_gpt":0.5076850822236345,"score_spread":0.4210864136735605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379194035","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001240451,0.9898592,0.00044151454,0.006368643,0.0006366139,0.0013516338,0.00007691633,0.0000058177097,0.000019156465],"genre_scores_gemma":[0.0009315333,0.9977572,0.00011495219,0.0006218914,0.00023183238,0.00011610685,0.000002391122,0.000015740807,0.0002083799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977841,0.0006146676,0.00089590217,0.0001574198,0.0003635856,0.000184367],"domain_scores_gemma":[0.9962842,0.00078149536,0.002698616,0.00008358665,0.00006537553,0.00008673732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035443055,0.0001489924,0.0009300681,0.00007900398,0.00019350003,0.000015902244,0.00020157006,0.0001963878,0.000039039693],"category_scores_gemma":[0.00036527152,0.00010196538,0.00012152818,0.00022004591,0.000052268024,0.00018699652,0.00011119091,0.00047354988,5.734665e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005819048,0.000055117984,0.0014121075,0.005602697,0.00035615533,0.0000011762962,0.00034324432,0.000025986055,0.0000010911727,5.426361e-7,0.012977931,0.97916573],"study_design_scores_gemma":[0.00039666716,0.00074636366,0.0092005385,0.012722796,0.0034008927,0.000035431265,0.00016027859,0.00056207844,7.848568e-7,0.000014412553,0.97261655,0.00014321876],"about_ca_topic_score_codex":0.0012328863,"about_ca_topic_score_gemma":0.0013119053,"teacher_disagreement_score":0.97902256,"about_ca_system_score_codex":0.00154553,"about_ca_system_score_gemma":0.00013543194,"threshold_uncertainty_score":0.41580275},"labels":[],"label_agreement":null},{"id":"W4379741884","doi":"10.1016/j.jtho.2023.05.021","title":"Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Universitair Medisch Centrum Groningen; Yuhan; BeiGene; Chugai Pharmaceutical; CMC Microsystems; Amgen; Pfizer; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; Hazard ratio; Internal medicine; Confidence interval; Biomarker; Oncology; Tyrosine-kinase inhibitor; Progression-free survival; Gastroenterology; Overall survival; Cancer; Lung cancer; Genetics; Biology","score_opus":0.007478386264094088,"score_gpt":0.31431894572788743,"score_spread":0.30684055946379335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379741884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988976,0.00017479155,0.00010181702,0.00009826687,0.00013841933,0.00017363353,0.00004743229,0.0000022250663,0.00036583078],"genre_scores_gemma":[0.9985428,0.00014163145,0.0010895762,0.000046446134,0.00008262307,0.0000033946856,0.000040380433,0.000017881022,0.000035279925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991278,0.00006189907,0.00036946862,0.00016072117,0.00009879237,0.00018133057],"domain_scores_gemma":[0.99904865,0.00013036761,0.0004587378,0.00011690171,0.0001707698,0.00007457395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015077803,0.00012345736,0.00031716083,0.00012847703,0.000030746156,0.000008653378,0.00008539627,0.000086073065,0.0000023461107],"category_scores_gemma":[0.00011862119,0.0001029171,0.000063187974,0.00015350881,0.000080004385,0.0000077921895,0.00005560657,0.00009621699,8.514129e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007310462,0.000934381,0.5146347,0.00005379552,0.00036218407,0.0002582462,0.0010296925,0.0034858664,0.02377752,0.000088396635,0.000071554496,0.4479932],"study_design_scores_gemma":[0.0049609747,0.009581125,0.9769759,0.00012371813,0.00011574009,0.00005777743,0.00034837486,0.0003040161,0.0067706164,0.00007601624,0.0004926789,0.00019305921],"about_ca_topic_score_codex":0.000021168193,"about_ca_topic_score_gemma":0.00009271759,"teacher_disagreement_score":0.4623412,"about_ca_system_score_codex":0.00013491939,"about_ca_system_score_gemma":0.00020157828,"threshold_uncertainty_score":0.41968375},"labels":[],"label_agreement":null},{"id":"W4381850584","doi":"10.1016/j.jtho.2023.06.011","title":"European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"ETOP IBCSG Partners Foundation; Swiss Cancer Research Foundation; Sanofi; Amgen; Pfizer; Genentech; Invitae; Eli Lilly and Company","keywords":"Medicine; Mesothelioma; Database; Hazard ratio; Epidemiology; Internal medicine; Cohort; Malignancy; Confidence interval; Cardiothoracic surgery; Surgery; Oncology; Pathology","score_opus":0.12428115780297341,"score_gpt":0.416139082080753,"score_spread":0.29185792427777957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381850584","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853409,0.0023708441,0.0002325537,0.0052229506,0.0004411682,0.00045574942,0.0037174774,0.000020060228,0.002198282],"genre_scores_gemma":[0.99365497,0.0029917737,0.0011361889,0.0009894414,0.00034481936,0.0000032159344,0.0006711125,0.000072840296,0.00013564272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9845394,0.010473721,0.003119566,0.00055911456,0.00084278523,0.00046544385],"domain_scores_gemma":[0.9865116,0.005761366,0.005045005,0.0020996965,0.00027695426,0.00030541237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01937326,0.00041396244,0.0024698263,0.0005487397,0.00019651331,0.0000076217807,0.0015888058,0.00013457677,0.00019308506],"category_scores_gemma":[0.0032051643,0.00021233705,0.0013456712,0.0017189815,0.0024289084,0.00028399826,0.0024059752,0.0007345899,0.00001480267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018940128,0.003452176,0.7417169,0.0020528908,0.01792058,0.00058131584,0.0040257783,0.0013482142,0.07731437,0.00030890273,0.0362613,0.096077405],"study_design_scores_gemma":[0.0011051791,0.0004265533,0.9785659,0.00064198754,0.009696186,0.00021682128,0.0019989393,0.0028676158,0.0025081744,0.0001651507,0.0015967073,0.00021084123],"about_ca_topic_score_codex":0.0003621235,"about_ca_topic_score_gemma":0.00012474669,"teacher_disagreement_score":0.2368489,"about_ca_system_score_codex":0.00013757418,"about_ca_system_score_gemma":0.0005865591,"threshold_uncertainty_score":0.8949414},"labels":[],"label_agreement":null},{"id":"W4383340852","doi":"10.1016/j.jtho.2023.07.004","title":"Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Northeast Cancer Centre; Public Health Ontario; Ontario Institute for Cancer Research; Champlain Regional College; Lakeridge Health; Ottawa Hospital; McMaster University; Brock University; Health Sciences North; University of Toronto; Cancer Care Ontario","funders":"Ontario Ministry of Health and Long-Term Care; Ministry of Health, Ontario","keywords":"Medicine; Lung cancer screening; Smoking cessation; Computed tomography; Lung cancer; Environmental health; Radiology; Oncology; Pathology","score_opus":0.026399883530358666,"score_gpt":0.38024527231973426,"score_spread":0.3538453887893756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383340852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858138,0.00048721136,0.000092428425,0.011235193,0.0015519053,0.00024767022,0.000012884301,0.000011645544,0.00054724695],"genre_scores_gemma":[0.9975896,0.000065061315,0.0014203802,0.00046298667,0.00027128565,0.000011927679,0.000010244154,0.00001323082,0.00015526799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983475,0.00015073802,0.0007103466,0.00014613607,0.00044669525,0.00019855265],"domain_scores_gemma":[0.99801785,0.0003158883,0.00096457324,0.00018538932,0.0004062261,0.00011005025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062921,0.00013144499,0.0004678886,0.00020280486,0.00011037434,0.000011265068,0.00016871569,0.000071281145,0.000039989995],"category_scores_gemma":[0.00013081907,0.00008162726,0.00015260978,0.00061504537,0.000055960274,0.00006886558,0.00006565796,0.00043044885,1.5934559e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003474667,0.0004842582,0.8170081,0.00035010665,0.0015526834,0.00042518263,0.004598061,0.0029336514,0.0010728005,0.000027099892,0.053706035,0.11436739],"study_design_scores_gemma":[0.0035120747,0.0017158721,0.9711398,0.0028838178,0.0009706239,0.00011681026,0.0008043983,0.001372317,0.0060400646,0.00006736873,0.011246195,0.00013067314],"about_ca_topic_score_codex":0.70862347,"about_ca_topic_score_gemma":0.939428,"teacher_disagreement_score":0.23080449,"about_ca_system_score_codex":0.0025006307,"about_ca_system_score_gemma":0.002770352,"threshold_uncertainty_score":0.6539062},"labels":[],"label_agreement":null},{"id":"W4385163930","doi":"10.1016/j.jtho.2023.07.019","title":"Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer","year":2023,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Siemens Medical Solutions USA; National Cancer Institute; American Association of Physicists in Medicine; World Health Organization; Janssen Pharmaceuticals; AstraZeneca","keywords":"Medicine; Lung cancer screening; Lung cancer; National Lung Screening Trial; Cancer; Cancer screening; Medical physics; Intensive care medicine; Radiology; Oncology; Internal medicine","score_opus":0.062146716919035665,"score_gpt":0.4993126743981248,"score_spread":0.43716595747908915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385163930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030243609,0.9738403,0.00016697258,0.012782706,0.0046420936,0.0036324402,0.0018950183,0.000008324341,0.000007798986],"genre_scores_gemma":[0.000625679,0.9895389,0.00044760015,0.00016081773,0.0077413344,0.0012937823,0.00009658235,0.000040687206,0.000054593627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980016,0.00021919349,0.0007733167,0.00033337495,0.00047748146,0.00019506011],"domain_scores_gemma":[0.9936218,0.00365532,0.0017982598,0.00019503232,0.00063732004,0.00009223254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078509044,0.0002729662,0.0015270029,0.00023077571,0.00014245574,0.000043357526,0.00032896176,0.00017914533,0.000039069408],"category_scores_gemma":[0.00016782213,0.00014150454,0.00060983823,0.00031512903,0.000022599093,0.000042169475,0.00008795924,0.00051222974,2.8145942e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097069936,0.0006616846,0.010601658,0.0009134104,0.0145032685,0.000008615219,0.0033711675,0.00006035774,2.1749275e-7,0.000009814662,0.06240903,0.9064901],"study_design_scores_gemma":[0.0025248183,0.002019641,0.021465199,0.016480226,0.021616358,0.000005104969,0.0043607615,0.0005268459,0.0000011863099,0.000019130426,0.93080425,0.00017650075],"about_ca_topic_score_codex":0.00081389816,"about_ca_topic_score_gemma":0.0017064865,"teacher_disagreement_score":0.9063136,"about_ca_system_score_codex":0.0022498295,"about_ca_system_score_gemma":0.0006428377,"threshold_uncertainty_score":0.5883226},"labels":[],"label_agreement":null},{"id":"W4385481435","doi":"10.1016/j.jtho.2023.07.023","title":"Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Arena Pharmaceuticals; Da Volterra; GlaxoSmithKline; CMC Microsystems; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Crizotinib; Medicine; ALK inhibitor; Internal medicine; Mutation; Cancer research; Progression-free survival; Oncology; Overall survival; Lung cancer; Biology; Genetics; Gene","score_opus":0.01836020434151036,"score_gpt":0.42185335904802235,"score_spread":0.403493154706512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385481435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610317,0.000058503512,0.00017520759,0.001222978,0.00010249058,0.00090195343,0.000018300656,0.000009326821,0.0014080782],"genre_scores_gemma":[0.9921376,0.000047870515,0.0072065736,0.000081700906,0.00003450856,0.000028284232,0.000053502983,0.000020517471,0.00038942177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988999,0.000105609004,0.00044708682,0.0001750937,0.00019499986,0.00017736209],"domain_scores_gemma":[0.99869967,0.00030264028,0.00038701104,0.000107037005,0.0003815453,0.00012211826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014507874,0.00014220449,0.0005144927,0.0004980338,0.00004135952,0.0000066470066,0.00003840624,0.0000770648,0.000017363356],"category_scores_gemma":[0.00015333078,0.000085490625,0.000028139644,0.00092774385,0.00005893129,0.00016125744,0.000013171259,0.00015004158,0.000004669767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058305275,0.002972081,0.66300726,0.0000713739,0.00090826076,0.0015987607,0.024757447,0.0067842086,0.00043374742,0.00005646256,0.00007661588,0.2410285],"study_design_scores_gemma":[0.01426226,0.02032559,0.9609737,0.0007011435,0.0007091675,0.0001765748,0.0017792053,0.00020354659,0.00016008249,0.00004116309,0.00055854156,0.000109073524],"about_ca_topic_score_codex":0.00008285988,"about_ca_topic_score_gemma":0.0005314522,"teacher_disagreement_score":0.2979664,"about_ca_system_score_codex":0.0005704893,"about_ca_system_score_gemma":0.00074495946,"threshold_uncertainty_score":0.34862062},"labels":[],"label_agreement":null},{"id":"W4385766844","doi":"10.1016/j.jtho.2023.08.011","title":"Current and Future Treatment Options in the Management of Stage III NSCLC","year":2023,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Chemoimmunotherapy; Immunotherapy; Radiation therapy; Stage (stratigraphy); Oncology; Adjuvant; Internal medicine; Intensive care medicine; Medical physics; Cancer","score_opus":0.08948134540317854,"score_gpt":0.5103368223487551,"score_spread":0.42085547694557657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385766844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003981274,0.9952748,0.0000027956594,0.0017340895,0.0008439601,0.0010757054,0.00003465232,0.0000046399723,0.0006312272],"genre_scores_gemma":[0.00007706134,0.9983719,0.00037351632,0.000026656495,0.0006581916,0.00014603756,0.000020282785,0.000022196395,0.00030413913],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813545,0.00028357,0.00094667386,0.00018573203,0.00026554745,0.000183038],"domain_scores_gemma":[0.99838203,0.00022499509,0.0009593169,0.00027830596,0.00006623991,0.000089114954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006642647,0.00025603094,0.0018746927,0.00034718413,0.000034661083,0.000010356144,0.00015073345,0.00016446537,0.000040556864],"category_scores_gemma":[0.000004335684,0.00012485006,0.00049124815,0.00033677462,0.000054986867,0.000030159088,0.00004927486,0.00038843584,0.0000072338726],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010750253,0.0011271539,0.00003094809,0.012421115,0.0015154061,0.0011685682,0.0002918668,7.4853824e-7,1.6605869e-8,0.00033370408,0.0008040519,0.9821989],"study_design_scores_gemma":[0.0010601021,0.0020318385,0.000719351,0.016833937,0.008329772,0.0005063228,0.00064298854,5.0508163e-7,2.2298383e-7,0.000029656889,0.9697668,0.00007849168],"about_ca_topic_score_codex":0.000011655281,"about_ca_topic_score_gemma":0.00003417263,"teacher_disagreement_score":0.98212045,"about_ca_system_score_codex":0.0013419179,"about_ca_system_score_gemma":0.00047598482,"threshold_uncertainty_score":0.5091238},"labels":[],"label_agreement":null},{"id":"W4385778685","doi":"10.1016/j.jtho.2023.08.005","title":"The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"National Cancer Institute; Samsung; Genentech; Hyogo College of Medicine; Technische Universität München; Universiteit Gent; Universitair Ziekenhuis Gent; Seoul National University; International Association for the Study of Lung Cancer; University of Aberdeen; Shanghai Chest Hospital; University of Chicago; Mount Sinai Health System; Dalhousie University; Cancer Research UK; Aix-Marseille Université; National Institutes of Health; Ohio State University; University of Leicester; Memorial Sloan-Kettering Cancer Center; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Yale University; AstraZeneca","keywords":"Medicine; Mesothelioma; Cohort; Internal medicine; Proportional hazards model; Lung cancer; Confidence interval; Prognostic variable; Oncology; Cancer; Surgery; Pathology","score_opus":0.04606238352754886,"score_gpt":0.43720076104137023,"score_spread":0.39113837751382136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385778685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960744,0.0002498957,0.000035047135,0.0023172451,0.00048302006,0.00073175237,0.000059867318,0.00000758586,0.00004120628],"genre_scores_gemma":[0.99937713,0.0001140294,0.000050407423,0.000042960324,0.00012591248,0.00004530073,0.000018572611,0.000014222911,0.00021148361],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837595,0.00013073451,0.000679926,0.00010252739,0.0005344012,0.0001764627],"domain_scores_gemma":[0.9979734,0.00093409984,0.0007400787,0.00008856026,0.00022837117,0.000035515415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009745912,0.00010103387,0.00031371388,0.00027229718,0.000083777115,0.000011708449,0.00021501482,0.000056214958,0.000019923848],"category_scores_gemma":[0.00049969193,0.00005540208,0.00012813936,0.00033277628,0.000039214934,0.00010317419,0.000061560175,0.00017873265,4.4451687e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025434843,0.0005805763,0.9742746,0.000056785506,0.0006435417,0.00001569919,0.0020319803,0.014276136,0.001950754,0.000011671432,0.0007123794,0.0029023897],"study_design_scores_gemma":[0.0018166031,0.0011383806,0.8267747,0.00014139121,0.0006491542,0.000013304068,0.010130171,0.15821116,0.0006218247,0.00011473687,0.00031056989,0.000077989556],"about_ca_topic_score_codex":0.00017487248,"about_ca_topic_score_gemma":0.00018541761,"teacher_disagreement_score":0.14749989,"about_ca_system_score_codex":0.000512087,"about_ca_system_score_gemma":0.00026979775,"threshold_uncertainty_score":0.22592314},"labels":[],"label_agreement":null},{"id":"W4385782360","doi":"10.1016/j.jtho.2023.08.010","title":"Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Alectinib; Crizotinib; Medicine; Ceritinib; Internal medicine; Hazard ratio; Clinical endpoint; ALK inhibitor; Confidence interval; Adverse effect; Oncology; Gastroenterology; Randomized controlled trial; Lung cancer","score_opus":0.045490594610487586,"score_gpt":0.5245308825252416,"score_spread":0.479040287914754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385782360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855985,0.00022447518,0.00000813355,0.006596902,0.0016991236,0.0007962623,0.00010345326,0.000018411885,0.004954743],"genre_scores_gemma":[0.9980113,0.00007260873,0.00055468216,0.00018364695,0.0005725571,0.000053613767,0.00005472758,0.000020533917,0.0004763425],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980898,0.00025700047,0.00082983956,0.00020039234,0.0003785402,0.000244462],"domain_scores_gemma":[0.9980581,0.0005806326,0.0006770108,0.00017665407,0.00025613193,0.00025147153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065046,0.00014585834,0.0005416172,0.0004276168,0.000042332093,0.000008334276,0.00008262209,0.000114297014,0.0000519194],"category_scores_gemma":[0.0008626056,0.00010500461,0.00020222935,0.00045929156,0.0000897138,0.00009965925,0.000028115559,0.00033984578,0.000020014051],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7527484,0.0033611385,0.00041045496,0.00005383914,0.00027780927,0.0029080464,0.0014684545,0.000026689295,0.0004172985,0.000011582995,0.0029677458,0.2353485],"study_design_scores_gemma":[0.7281039,0.13964139,0.06729313,0.0042782817,0.003980848,0.00023473553,0.0019631784,0.0003146712,0.008914949,0.0004914619,0.04432395,0.00045950848],"about_ca_topic_score_codex":0.000013236124,"about_ca_topic_score_gemma":0.000019488698,"teacher_disagreement_score":0.23488899,"about_ca_system_score_codex":0.00036275043,"about_ca_system_score_gemma":0.0010526743,"threshold_uncertainty_score":0.42819637},"labels":[],"label_agreement":null},{"id":"W4385879651","doi":"10.1016/j.jtho.2023.08.016","title":"The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"Genentech; Helsinn; National Institutes of Health; Seagen; BeiGene; Clovis Oncology; International Association for the Study of Lung Cancer; Prevent Cancer Foundation; Bristol-Myers Squibb; AstraZeneca; Pfizer; Bristol-Myers Squibb Foundation","keywords":"Medicine; Deep learning; Lung cancer screening; Lung cancer; Nodule (geology); Artificial intelligence; Lung; Radiology; Metric (unit); Medical physics; Machine learning; Computer science; Oncology; Internal medicine","score_opus":0.06454970764709275,"score_gpt":0.4731338047066496,"score_spread":0.4085840970595569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385879651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529965,0.0032907266,0.0017490003,0.03816414,0.001250308,0.0018212354,0.0000057418765,0.000011448119,0.00071089604],"genre_scores_gemma":[0.9983165,0.0009038766,0.00012282966,0.00014605501,0.00016347665,0.00015030363,0.000001752579,0.000010373513,0.00018477615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998727,0.0002484436,0.00038381238,0.000100218895,0.0004230823,0.0001174484],"domain_scores_gemma":[0.996229,0.0016257968,0.00089678314,0.00004991449,0.00116491,0.000033575016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026925872,0.00007519494,0.00025705853,0.000074639305,0.00030227817,0.00009052515,0.00011621793,0.0000311019,0.000009087696],"category_scores_gemma":[0.0008105181,0.000042293042,0.00005661707,0.000069857546,0.000028210588,0.00013708726,0.00006688375,0.00019726074,3.8257764e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025706508,0.00054352684,0.85324615,0.0000543452,0.003969757,0.000022065478,0.020226821,0.0008331342,0.00046671744,0.00025774378,0.0036815845,0.11412748],"study_design_scores_gemma":[0.008808466,0.0060784863,0.8493958,0.00060294574,0.0035358581,0.00003914692,0.051666245,0.05098551,0.0011052917,0.00019774078,0.027421549,0.00016294331],"about_ca_topic_score_codex":0.00015976421,"about_ca_topic_score_gemma":0.00079640193,"teacher_disagreement_score":0.113964535,"about_ca_system_score_codex":0.0014188361,"about_ca_system_score_gemma":0.00026040763,"threshold_uncertainty_score":0.3710207},"labels":[],"label_agreement":null},{"id":"W4385975562","doi":"10.1016/j.jtho.2023.06.003","title":"Re: Response to Letter to the Editor “Respiratory and Cardiometabolic Comorbidities and Stage I-III Non-Small Cell Lung Cancer (NSCLC) Survival: A Pooled Analysis From the International Lung Cancer Consortium”","year":2023,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Alcohol Consumption and Health Effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Confounding; Cancer; Internal medicine; Oncology; Alcohol consumption; Gerontology","score_opus":0.06285758854492626,"score_gpt":0.4377553196072428,"score_spread":0.3748977310623165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385975562","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34253755,0.0072407406,0.00018636344,0.6368274,0.011755341,0.0008930475,0.00047778198,0.000020132935,0.00006162699],"genre_scores_gemma":[0.03397423,0.002234594,0.0001667675,0.89021343,0.06850583,0.0002981879,0.000035527682,0.000099306926,0.0044721058],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953951,0.0017299182,0.0009966277,0.00048694323,0.00088891695,0.00050248066],"domain_scores_gemma":[0.99341196,0.004056221,0.0010274965,0.0005024168,0.00065404555,0.00034784104],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003863899,0.00040770252,0.0016303865,0.0010514266,0.00024830192,0.00012838996,0.00052055455,0.00062467146,0.00039827972],"category_scores_gemma":[0.0005539182,0.00025375097,0.00035823698,0.00067206426,0.00019749683,0.00007727164,0.00030601138,0.0026674294,0.000013022173],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037340976,0.00002363792,0.023256017,0.00023212058,0.0038775054,0.0007650357,0.0024693022,0.0000824346,0.00058897067,2.7185163e-7,0.9629316,0.0020390141],"study_design_scores_gemma":[0.0011361464,0.00025747757,0.09554327,0.0003941531,0.0071957265,0.000015759038,0.00047163272,0.00017000863,0.00005216112,8.016312e-7,0.89453185,0.00023100131],"about_ca_topic_score_codex":0.0019252752,"about_ca_topic_score_gemma":0.003906525,"teacher_disagreement_score":0.30856332,"about_ca_system_score_codex":0.0008055108,"about_ca_system_score_gemma":0.0017856663,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W4386171730","doi":"10.1016/j.jtho.2023.08.024","title":"The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Centro de Investigación Biomédica en Red de Cáncer; Tokyo Women's Medical University; Shanghai Chest Hospital; Peking University; Universiteit Antwerpen; Chugai Pharmaceutical; Technische Universität München; Universiteit Gent; Astellas Pharma; Eisai; Universitair Ziekenhuis Gent; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Universität Wien; Alexion Pharmaceuticals; University of Toronto; Seoul National University; Mount Sinai Health System; Imperial College London; Universitätsspital Zürich; Hyogo College of Medicine; Sungkyunkwan University; Medizinische Universität Wien; Universidad de Navarra; Postgraduate Institute of Medical Education and Research, Chandigarh; National Cancer Institute; NSW Health Pathology; University of Chicago; Varian Medical Systems; International Association for the Study of Lung Cancer; University of Texas Southwestern Medical Center; Memorial Sloan-Kettering Cancer Center; Queen's University; Ohio State University; University of Aberdeen; Pfizer; York University; Samsung; Bristol-Myers Squibb; Universidade de São Paulo; AstraZeneca","keywords":"Medicine; Stage (stratigraphy); Thymic carcinoma; Cancer; Lung cancer; Ninth; Pathology; Internal medicine; Radiology; Thymoma","score_opus":0.04120699176233089,"score_gpt":0.4220916081816088,"score_spread":0.3808846164192779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386171730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93617225,0.00030405883,0.0038036522,0.050339334,0.0032279196,0.0059093735,0.00020939847,0.0000081533535,0.000025875575],"genre_scores_gemma":[0.9975718,0.00012259751,0.00024437858,0.00009850384,0.0010622706,0.00061636895,0.000008269459,0.000023627319,0.00025216275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997721,0.00023706588,0.0010415093,0.00013875315,0.00062747713,0.0002341565],"domain_scores_gemma":[0.991051,0.0046615954,0.0028692721,0.00026703812,0.0011276333,0.000023437784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055237394,0.00013180697,0.00041799084,0.00010989948,0.00047054965,0.0000252469,0.0005844895,0.00006392815,0.0000056555677],"category_scores_gemma":[0.0010399267,0.000050050832,0.0003580583,0.00023279146,0.00013954361,0.00007064005,0.000084774794,0.0002802936,1.357926e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050691348,0.004937718,0.18032148,0.0021305457,0.013124128,0.000015897582,0.04720586,0.005961675,0.24125592,0.019490186,0.05585513,0.37901008],"study_design_scores_gemma":[0.009200339,0.0068732454,0.59921354,0.0012254635,0.0058775423,0.00014425624,0.07001965,0.2448275,0.028029623,0.0038733955,0.030433921,0.00028152217],"about_ca_topic_score_codex":0.00012329874,"about_ca_topic_score_gemma":0.0003440257,"teacher_disagreement_score":0.41889206,"about_ca_system_score_codex":0.00039904262,"about_ca_system_score_gemma":0.00086929835,"threshold_uncertainty_score":0.3619135},"labels":[],"label_agreement":null},{"id":"W4386571007","doi":"10.1016/j.jtho.2023.09.001","title":"The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic Epithelial Tumors for the Forthcoming Ninth Edition of the TNM Classification of Malignant Tumors","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Yonsei University College of Medicine; College of Medicine, Seoul National University; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Centre Hospitalier Universitaire de Rennes; Ministry of Health of the Russian Federation; Shanghai Pulmonary Hospital; Szegedi Tudományegyetem; Institut de Cancérologie de Lorraine; Tokyo Women's Medical University; Shanghai Chest Hospital; Institut Gustave-Roussy; Peking University; Universiteit Gent; KU Leuven; Astellas Pharma; Samsung; Yonsei University; Eisai; Health Science Center, University of Tennessee; Universitair Ziekenhuis Gent; Soochow University; Universiteit Antwerpen; Seoul National University Hospital; Fudan University; Universität Wien; Universidade de São Paulo; Hyogo College of Medicine; Sungkyunkwan University; Bristol-Myers Squibb; Semmelweis Egyetem; Università di Pisa; Kanazawa University; Technische Universität München; Ankara Universitesi; Chugai Pharmaceutical; Hospices Civils de Lyon; Comprehensive Cancer Center, City of Hope; Aix-Marseille Université; University of Toronto; Imperial College London; AstraZeneca; University of Aberdeen; International Association for the Study of Lung Cancer; Mount Sinai Health System; University of Chicago; Yale University; NSW Health Pathology; University of North Carolina at Chapel Hill; Harvard University; Seoul National University; Alexion Pharmaceuticals; China Medical University; University of Leicester; Ohio State University; Kindai University; Memorial Sloan-Kettering Cancer Center; Varian Medical Systems; Università degli Studi di Padova; Centro de Investigación Biomédica en Red de Cáncer; Massachusetts General Hospital; Pfizer; Universidad de Navarra; York University; Universitätsspital Zürich; Medizinische Universität Wien; Postgraduate Institute of Medical Education and Research, Chandigarh; Brigham and Women's Hospital","keywords":"Medicine; Lymph node; Malignancy; Stage (stratigraphy); Cancer; Lung cancer; TNM staging system; Thymic carcinoma; Oncology; Internal medicine; Pathology; Neoplasm staging","score_opus":0.040838363366005825,"score_gpt":0.4198397274603377,"score_spread":0.3790013640943319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386571007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595471,0.00024695456,0.0028813253,0.0202717,0.007566146,0.007943705,0.0014915612,0.000012011365,0.000039509338],"genre_scores_gemma":[0.9952232,0.00023757132,0.00021903739,0.00014752368,0.0014421877,0.0021322602,0.000035796085,0.000060163162,0.00050224253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946756,0.00047909393,0.0024499982,0.00037367776,0.0015959766,0.0004256828],"domain_scores_gemma":[0.9821701,0.0060451743,0.008405579,0.0005117381,0.0028262888,0.00004108603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075792954,0.00032638366,0.00087072526,0.0003171821,0.00054374355,0.00006305327,0.0017870251,0.00014716419,0.000025099085],"category_scores_gemma":[0.0018118974,0.00015381511,0.000803554,0.0004301355,0.00017167369,0.0002143797,0.00029540816,0.0004456118,1.2985117e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016005343,0.004901029,0.8243623,0.0011715353,0.013847644,0.0000045766724,0.020438055,0.0065348675,0.074870065,0.004757347,0.009420736,0.023686493],"study_design_scores_gemma":[0.010222843,0.0023290874,0.7773836,0.001790007,0.003985548,0.000025074469,0.03724053,0.15604252,0.0076191803,0.0008701367,0.002229732,0.00026171195],"about_ca_topic_score_codex":0.000681442,"about_ca_topic_score_gemma":0.002176045,"teacher_disagreement_score":0.14950766,"about_ca_system_score_codex":0.0021922432,"about_ca_system_score_gemma":0.0013584811,"threshold_uncertainty_score":0.6272398},"labels":[],"label_agreement":null},{"id":"W4386571070","doi":"10.1016/j.jtho.2023.09.002","title":"The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Yonsei University College of Medicine; Samsung; Szegedi Tudományegyetem; Institut de Cancérologie de Lorraine; Università di Pisa; National Cancer Institute; Hospices Civils de Lyon; Medizinische Universität Wien; Universidad de Navarra; Universiteit Gent; Centro de Investigación Biomédica en Red de Cáncer; Seoul National University Hospital; KU Leuven; Memorial Sloan-Kettering Cancer Center; Università degli Studi di Padova; Queen's University; Universitätsspital Zürich; Sungkyunkwan University; Alexion Pharmaceuticals; Seoul National University; Universitair Ziekenhuis Gent; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Universität Wien; College of Medicine, Seoul National University; Institut Gustave-Roussy; Semmelweis Egyetem; University of Chicago; Mount Sinai Health System; Astellas Pharma; Eisai; Chugai Pharmaceutical; Technische Universität München; Ankara Universitesi; Varian Medical Systems; Pfizer; Yonsei University; Ministry of Health of the Russian Federation; University of Aberdeen; International Association for the Study of Lung Cancer; Aix-Marseille Université; Universidade de São Paulo; AstraZeneca; Centre Hospitalier Universitaire de Rennes; Eli Lilly and Company","keywords":"Medicine; Stage (stratigraphy); Thymic carcinoma; Ninth; Lung cancer; Internal medicine; Cancer; Thymus Neoplasm; Oncology; Lung; Pathology; Thymoma","score_opus":0.051302062665964696,"score_gpt":0.43146747730782165,"score_spread":0.38016541464185694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386571070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96098906,0.00013553754,0.0054781074,0.025502205,0.0019998357,0.005564559,0.00028102464,0.000010230829,0.000039430062],"genre_scores_gemma":[0.99730927,0.000103739694,0.0004004163,0.000049503233,0.0007822974,0.0007165033,0.00001724295,0.00002717619,0.00059383706],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975271,0.00023556758,0.0012064544,0.00016801941,0.00062494614,0.00023787157],"domain_scores_gemma":[0.99176264,0.0028415413,0.003652896,0.00027394283,0.0014412331,0.000027730763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053184815,0.00013724089,0.00043956775,0.00017348779,0.00036455743,0.000025739702,0.00049572805,0.00009639126,0.000005331183],"category_scores_gemma":[0.0014411072,0.00006218826,0.00033281863,0.00032128725,0.00012328613,0.000107287255,0.00005923028,0.00026172766,1.2995329e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03540723,0.00355922,0.22085026,0.0023549872,0.0061272555,0.000007856929,0.033823494,0.0022251967,0.33251426,0.02494572,0.022420233,0.3157643],"study_design_scores_gemma":[0.007534444,0.0061434866,0.6690555,0.0010842293,0.003341656,0.0000531509,0.07351494,0.19116504,0.028459806,0.0029926233,0.016396169,0.00025891722],"about_ca_topic_score_codex":0.0000819291,"about_ca_topic_score_gemma":0.00030663342,"teacher_disagreement_score":0.4482053,"about_ca_system_score_codex":0.0005110386,"about_ca_system_score_gemma":0.0012192447,"threshold_uncertainty_score":0.28039178},"labels":[],"label_agreement":null},{"id":"W4386607127","doi":"10.1016/j.jtho.2023.07.008","title":"The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors","year":2023,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute; Yonsei University College of Medicine; College of Medicine, Seoul National University; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Shanghai Pulmonary Hospital; Szegedi Tudományegyetem; Tokyo Women's Medical University; Shanghai Chest Hospital; Peking University; Università di Pisa; China Medical University; Universiteit Gent; KU Leuven; Queen's University; Astellas Pharma; Samsung; Yonsei University; Eisai; Health Science Center, University of Tennessee; Universitair Ziekenhuis Gent; Soochow University; Universiteit Antwerpen; Seoul National University Hospital; Fudan University; Universität Wien; Universidade de São Paulo; Hyogo College of Medicine; Sungkyunkwan University; Bristol-Myers Squibb; Semmelweis Egyetem; Kanazawa University; Technische Universität München; Ankara Universitesi; Chugai Pharmaceutical; Comprehensive Cancer Center, City of Hope; Aix-Marseille Université; University of Toronto; Imperial College London; AstraZeneca; University of Aberdeen; International Association for the Study of Lung Cancer; Mount Sinai Health System; University of Chicago; Yale University; NSW Health Pathology; Harvard University; Memorial Sloan-Kettering Cancer Center; Varian Medical Systems; Seoul National University; Alexion Pharmaceuticals; Ohio State University; Kindai University; University of Texas Southwestern Medical Center; Università degli Studi di Padova; Centro de Investigación Biomédica en Red de Cáncer; Massachusetts General Hospital; Merck; University of Leicester; Universitätsspital Zürich; Medizinische Universität Wien; York University; Universidad de Navarra; Université Hassan II de Casablanca; Postgraduate Institute of Medical Education and Research, Chandigarh; Brigham and Women's Hospital; Pfizer","keywords":"Medicine; Ninth; Lung cancer staging; Lung cancer; Oncology; General surgery","score_opus":0.13118339460393943,"score_gpt":0.49425661474988786,"score_spread":0.36307322014594845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386607127","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57489353,0.3954271,0.00022329637,0.0044341157,0.008776615,0.01421442,0.0018866915,0.000014990185,0.00012924691],"genre_scores_gemma":[0.3793999,0.61870474,0.00015082366,0.000063880776,0.0012084214,0.0001225467,0.000050155482,0.00008041427,0.00021910538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99439836,0.0010208763,0.0028799486,0.0001996253,0.0012339609,0.00026723705],"domain_scores_gemma":[0.9839196,0.0016400141,0.0126533285,0.00069256645,0.0010541601,0.00004033429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060208966,0.0002636399,0.0015620211,0.00021312073,0.00022619616,0.000016098447,0.0012596062,0.00017167086,0.000011238609],"category_scores_gemma":[0.0017147799,0.00010276933,0.0009211613,0.00064591167,0.00018705902,0.0001713973,0.0003292307,0.0007139381,9.3964836e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013542388,0.0011120023,0.017649194,0.020728191,0.0026432467,0.0000054421093,0.0058203004,0.00011134899,0.0014889388,0.0013450575,0.001054656,0.9466874],"study_design_scores_gemma":[0.0075619454,0.0064194957,0.23372842,0.3209335,0.037795335,0.00066919986,0.03724222,0.007794415,0.0057441136,0.0006836233,0.3404199,0.0010078334],"about_ca_topic_score_codex":0.00031533767,"about_ca_topic_score_gemma":0.0003451192,"teacher_disagreement_score":0.94567955,"about_ca_system_score_codex":0.00073858036,"about_ca_system_score_gemma":0.0021890868,"threshold_uncertainty_score":0.41908115},"labels":[],"label_agreement":null},{"id":"W4386640941","doi":"10.1016/j.jtho.2023.07.017","title":"International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"EMD Serono; Genentech; Eisai; Ministerio de Ciencia e Innovación; Daiichi-Sankyo; Parker Institute for Cancer Immunotherapy; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Yale University; Daiichi Sankyo Europe; Sanofi; Arrowhead Pharmaceuticals; GlaxoSmithKline; Amgen; Pfizer; Society for Immunotherapy of Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Neoadjuvant therapy; Adenocarcinoma; Concordance; Lung; Confidence interval; Internal medicine; H&E stain; Cancer; Oncology; Radiology; Pathology; Breast cancer; Immunohistochemistry","score_opus":0.048208536762571565,"score_gpt":0.5102898653406654,"score_spread":0.46208132857809386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386640941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295646,0.00067215745,0.0000036078345,0.003614786,0.0006967945,0.0020022832,0.000024517023,0.0000036408014,0.000025734704],"genre_scores_gemma":[0.9983883,0.0008824291,0.000083417195,0.000043263168,0.000091591246,0.00044680017,0.0000018972366,0.000010138363,0.000052156618],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968979,0.0010059187,0.0011211017,0.000307463,0.00050635386,0.00016128644],"domain_scores_gemma":[0.996058,0.0015298564,0.0013197579,0.0004073065,0.0006549286,0.000030136793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008666831,0.00010754228,0.00072163664,0.00040256497,0.000019465617,0.0000038048338,0.00016611945,0.000087072614,0.00003772577],"category_scores_gemma":[0.0010811232,0.00006694779,0.00011179854,0.00053397845,0.000031646425,0.000059074744,0.00005524518,0.0002721012,4.709403e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02762764,0.0059081414,0.9426052,0.00006771859,0.00079454214,0.00016773447,0.0090947235,0.0025983949,0.0011647203,5.520354e-7,0.00030274029,0.009667888],"study_design_scores_gemma":[0.007078635,0.011159918,0.9735502,0.0002103135,0.00030904537,0.00000568822,0.0061652567,0.0009240027,0.0004516094,0.000013811893,0.00008663015,0.000044863275],"about_ca_topic_score_codex":0.0011363922,"about_ca_topic_score_gemma":0.0036345106,"teacher_disagreement_score":0.030945022,"about_ca_system_score_codex":0.004249451,"about_ca_system_score_gemma":0.0008754913,"threshold_uncertainty_score":0.99957305},"labels":[],"label_agreement":null},{"id":"W4386759693","doi":"10.1016/j.jtho.2023.09.275","title":"Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; EMD Serono; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Invitae; Yale University; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pathology; Lung; Cell; Basal cell; Oncology; Internal medicine; Genetics; Biology","score_opus":0.0333078621977281,"score_gpt":0.4383378436677831,"score_spread":0.40502998147005503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386759693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948645,0.00071791565,0.00015781967,0.0019122084,0.00065125007,0.00032197678,0.000028274433,0.000007149681,0.0013389104],"genre_scores_gemma":[0.99764246,0.00008845264,0.001319528,0.00029096255,0.00008825567,0.0000054523175,0.0000043972695,0.0000137712,0.00054674415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998599,0.00016159726,0.00061325374,0.00012238525,0.000321627,0.00018217067],"domain_scores_gemma":[0.9982632,0.00021386215,0.00086307107,0.00021131747,0.00036452874,0.00008401586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029067323,0.000113880975,0.00052703114,0.00020456126,0.000057475263,0.0000039533993,0.00016191545,0.00010232485,0.000095862815],"category_scores_gemma":[0.000026271246,0.000070686656,0.000234155,0.00023733445,0.000109362096,0.000039451155,0.00010182822,0.00032940228,0.0000041078347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009056693,0.001757363,0.7022274,0.00090311386,0.0009601621,0.0011038473,0.0086035365,0.005347401,0.25051892,0.000046299785,0.006561226,0.021065054],"study_design_scores_gemma":[0.002589335,0.0017793367,0.9701118,0.00010521762,0.00137904,0.00039829232,0.0040617017,0.0012682043,0.015528181,0.000088180466,0.0026059996,0.0000846982],"about_ca_topic_score_codex":0.00007431605,"about_ca_topic_score_gemma":0.0000067954934,"teacher_disagreement_score":0.2678844,"about_ca_system_score_codex":0.00060108455,"about_ca_system_score_gemma":0.0008586316,"threshold_uncertainty_score":0.28825182},"labels":[],"label_agreement":null},{"id":"W4386759972","doi":"10.1016/j.jtho.2023.09.277","title":"Completeness of Resection and Long-Term Survival of Patients Undergoing Resection for Pathologic T3 NSCLC: An International Association for the Study of Lung Cancer Analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"National Cancer Institute; Université Hassan II de Casablanca; Tokyo Women's Medical University; Shanghai Chest Hospital; Universitätsspital Zürich; Hyogo College of Medicine; Ankara Universitesi; Technische Universität München; Medizinische Universität Wien; Universidad de Navarra; Yale University; Seoul National University; University of Toronto; Universitair Ziekenhuis Gent; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Universität Wien; AstraZeneca; Universidade de São Paulo; Mount Sinai Health System; Imperial College London; Harvard Medical School; University of Chicago; Universiteit Gent; Aix-Marseille Université; Memorial Sloan-Kettering Cancer Center; Samsung; Bristol-Myers Squibb; University of Leicester; Ohio State University; University of Aberdeen; International Association for the Study of Lung Cancer; York University","keywords":"Medicine; Lung cancer; Resection; Completeness (order theory); Oncology; Lung; Radiology; Internal medicine; Surgery","score_opus":0.06153186868906752,"score_gpt":0.4719571852242516,"score_spread":0.4104253165351841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386759972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973467,0.00013524693,0.0004790812,0.0004534887,0.00084059563,0.0006683376,0.00005897868,0.0000032710816,0.000014282115],"genre_scores_gemma":[0.9991225,0.00048168717,0.000091040136,0.000009645364,0.00015131303,0.00006549189,0.000037708407,0.0000074498425,0.00003314683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869454,0.00021850126,0.00055969966,0.00011966896,0.00030976575,0.00009781675],"domain_scores_gemma":[0.9962028,0.0012884556,0.0012856979,0.000099477926,0.0010928459,0.000030680112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001551663,0.00006987787,0.00049320067,0.00033925512,0.000060180395,0.0000061875453,0.00007774157,0.00007685712,0.000007799793],"category_scores_gemma":[0.00037038483,0.00004655898,0.000155887,0.00033996726,0.000025791414,0.000093862,0.000026426722,0.00008094862,2.5583912e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059945,0.0012192772,0.97860366,0.00026221864,0.003181404,0.000003665153,0.0006304274,0.00094070676,0.00026586917,0.000011407768,0.000048342004,0.008838532],"study_design_scores_gemma":[0.0032176697,0.009615765,0.9806285,0.00012170965,0.0038755038,0.0000027875633,0.00073805905,0.001214332,0.0004943379,0.000042466578,0.000015175369,0.000033711665],"about_ca_topic_score_codex":0.00008354265,"about_ca_topic_score_gemma":0.0029093656,"teacher_disagreement_score":0.00880482,"about_ca_system_score_codex":0.000682611,"about_ca_system_score_gemma":0.00012749118,"threshold_uncertainty_score":0.18986201},"labels":[],"label_agreement":null},{"id":"W4387107309","doi":"10.1016/j.jtho.2023.09.1447","title":"The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Shanghai Chest Hospital; Health Science Center, University of Tennessee; Shanghai Pulmonary Hospital; Peking University; Universiteit Antwerpen; Chugai Pharmaceutical; Technische Universität München; Universidad de Navarra; Universiteit Gent; Soochow University; Astellas Pharma; Eisai; Universitair Ziekenhuis Gent; Centro de Investigación Biomédica en Red de Cáncer; Fudan University; European Society for Medical Oncology; University of Toronto; Yale University; Alexion Pharmaceuticals; Seoul National University; Mount Sinai Health System; Imperial College London; Kanazawa University; Massachusetts General Hospital; University of Aberdeen; Kindai University; Comprehensive Cancer Center, City of Hope; University of Chicago; National Cancer Institute; NSW Health Pathology; Queen's University; Harvard University; Ohio State University; Varian Medical Systems; University of Texas Southwestern Medical Center; Memorial Sloan-Kettering Cancer Center; Merck; Samsung; China Medical University; Bristol-Myers Squibb; AstraZeneca; Hyogo College of Medicine; Sungkyunkwan University; Brigham and Women's Hospital; Pfizer","keywords":"Thymic carcinoma; Medicine; Thymoma; Stage (stratigraphy); Lymph node; Lung cancer; Cancer; TNM staging system; Oncology; Internal medicine; Neuroendocrine tumors; Carcinoma; Pathology; Staging system","score_opus":0.04521514920252677,"score_gpt":0.41961270619920343,"score_spread":0.37439755699667665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387107309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94326144,0.00043279183,0.0016694875,0.04697953,0.001742208,0.005735389,0.00014793646,0.000005836559,0.000025372614],"genre_scores_gemma":[0.99791086,0.00026030204,0.00009128698,0.00012080533,0.0007186437,0.00059038546,0.0000062354543,0.00002153709,0.00027991994],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976849,0.00035612748,0.0010083411,0.00013868227,0.0005903484,0.00022163065],"domain_scores_gemma":[0.98921645,0.0068941778,0.0027005787,0.0002681642,0.0008986967,0.000021924428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007331813,0.00013577209,0.00045778797,0.0001102233,0.00059855497,0.000034312867,0.00057423266,0.00006907852,0.0000035351557],"category_scores_gemma":[0.0013364607,0.000045651286,0.00029953299,0.00025209776,0.00026482134,0.00007644805,0.00010226176,0.0002828219,8.587948e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07688545,0.0031181057,0.25545081,0.0019944154,0.014690742,0.000010579035,0.078303754,0.0028955352,0.11122946,0.026465429,0.030084496,0.3988712],"study_design_scores_gemma":[0.013968824,0.0036386286,0.67491,0.0012211587,0.0054433164,0.00013015875,0.06885184,0.1998049,0.010948131,0.0056611085,0.015186686,0.0002352453],"about_ca_topic_score_codex":0.00015691515,"about_ca_topic_score_gemma":0.000233212,"teacher_disagreement_score":0.41945916,"about_ca_system_score_codex":0.0002373661,"about_ca_system_score_gemma":0.00042670086,"threshold_uncertainty_score":0.46036613},"labels":[],"label_agreement":null},{"id":"W4387807147","doi":"10.1016/j.jtho.2023.10.012","title":"The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; National Institutes of Health; AIO-Studien; Instituto Nacional do Câncer, Ministério da Saúde; Shanghai Chest Hospital; Soochow University; AstraZeneca; Universidade de São Paulo; International Association for the Study of Lung Cancer; University of Ulsan; Ankara Universitesi; Aix-Marseille Université; Yale University; University of Toronto; Bristol-Myers Squibb; University of Leicester; Cleveland Clinic; Université Hassan II de Casablanca; Memorial Sloan-Kettering Cancer Center; Queen's University; Keio University; Boehringer Ingelheim; Ohio State University; National Cancer Institute; Arthrex GmbH; Gilead Sciences; Eli Lilly and Company; Pfizer; LUNGevity Foundation","keywords":"Medicine; Ninth; Lung cancer staging; Lung cancer; Medical physics; Association (psychology); Oncology; General surgery; Internal medicine","score_opus":0.05987978039435571,"score_gpt":0.48590111155296856,"score_spread":0.42602133115861285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387807147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82332635,0.00651232,0.003061455,0.13670436,0.007534425,0.022296231,0.0005167715,0.00001163778,0.000036463185],"genre_scores_gemma":[0.99072516,0.0028708111,0.00018709814,0.00028692064,0.0011170174,0.004541746,0.0000096126205,0.000029290517,0.00023234669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755025,0.00031683114,0.0010145879,0.00019801974,0.0006417458,0.00027857805],"domain_scores_gemma":[0.99089444,0.0049298615,0.0026316391,0.00032137422,0.0012015641,0.000021117723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049443627,0.00016619584,0.00047545097,0.00011344198,0.00051233516,0.00003720413,0.0006218729,0.00010544513,0.0000052880177],"category_scores_gemma":[0.0011123107,0.00006179779,0.00041890368,0.0004119752,0.00009061664,0.00012960832,0.00007091515,0.0002717389,1.4098356e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006410703,0.0012548612,0.64173627,0.0019376314,0.004713579,8.93403e-7,0.020217288,0.005049441,0.001972032,0.00075613154,0.13986465,0.17608652],"study_design_scores_gemma":[0.015279934,0.0045145643,0.49149904,0.006925046,0.016725903,0.000017173754,0.05124389,0.32638037,0.015053637,0.0007059333,0.07125477,0.0003997116],"about_ca_topic_score_codex":0.00065255136,"about_ca_topic_score_gemma":0.0037444613,"teacher_disagreement_score":0.32133093,"about_ca_system_score_codex":0.0024934632,"about_ca_system_score_gemma":0.0012836177,"threshold_uncertainty_score":0.65203196},"labels":[],"label_agreement":null},{"id":"W4388044214","doi":"10.1016/j.jtho.2023.09.563","title":"P2.07-05 Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Organ transplantation; Lung cancer; Transplantation; Oncology; Solid organ; Lung transplantation; Cancer; PD-L1; Immune system; Clinical trial; Internal medicine; Intensive care medicine; Immunology; Immunotherapy","score_opus":0.018188234456912557,"score_gpt":0.40165788514028,"score_spread":0.38346965068336747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97125643,0.0026837527,0.000033095253,0.024237331,0.0012778194,0.0002022243,0.000012394011,0.000028686261,0.00026823932],"genre_scores_gemma":[0.9928818,0.0040049353,0.00047205927,0.000992559,0.00043301846,0.000023362645,0.000015831582,0.000029748478,0.0011466856],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99807405,0.00011752761,0.0010288989,0.00016294084,0.0002700824,0.00034648867],"domain_scores_gemma":[0.99887365,0.000071606984,0.0005480164,0.00018052214,0.00023386446,0.00009234197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011386644,0.00016184966,0.0005855603,0.0004941344,0.00004409888,0.000013740026,0.00014838556,0.0002426077,0.0008055993],"category_scores_gemma":[0.000049403992,0.00013198149,0.00018972527,0.0010885112,0.00011703199,0.00011253546,0.00002143733,0.0005870064,0.000015915612],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10974649,0.00077386596,0.06359845,0.001626664,0.0018707478,0.022179184,0.009030134,0.00011803516,0.616485,0.000005517369,0.025496919,0.14906897],"study_design_scores_gemma":[0.013371443,0.0029724746,0.76186806,0.0033198555,0.0010386223,0.009633644,0.0025800327,0.00045306273,0.13908297,0.00009361233,0.0650042,0.0005820075],"about_ca_topic_score_codex":0.00012875911,"about_ca_topic_score_gemma":0.00016561957,"teacher_disagreement_score":0.6982696,"about_ca_system_score_codex":0.00066534284,"about_ca_system_score_gemma":0.0009073055,"threshold_uncertainty_score":0.8820748},"labels":[],"label_agreement":null},{"id":"W4388044236","doi":"10.1016/j.jtho.2023.09.683","title":"P2.20-02 Thymomatous Myasthenia Gravis after Total Thymectomy at a Tertiary-Care Surgical Centre: a 20-Year Retrospective Review","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec","funders":"","keywords":"Thymectomy; Medicine; Myasthenia gravis; Thymoma; Incidence (geometry); Internal medicine; Surgery","score_opus":0.010239476263248394,"score_gpt":0.35157553870855873,"score_spread":0.34133606244531034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95716715,0.021627853,0.0000052649584,0.015602551,0.0012037414,0.0007388475,0.000075060634,0.00010127883,0.0034782472],"genre_scores_gemma":[0.984067,0.0052399323,0.0006792325,0.0014171525,0.0017248227,0.00003804875,0.00006211673,0.00010547589,0.006666195],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961642,0.00051115017,0.0012347528,0.00046568486,0.000871371,0.00075281184],"domain_scores_gemma":[0.99727255,0.00020797014,0.0007586633,0.00051787624,0.0006610762,0.0005818491],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010326732,0.00042102076,0.0016884258,0.00040498198,0.0001362486,0.0000304249,0.000289326,0.00036485726,0.002171079],"category_scores_gemma":[0.00022165035,0.0003020673,0.0008867326,0.00075617735,0.00017634987,0.00015074234,0.0002656381,0.0009776315,0.00082848594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022527289,0.0021683974,0.41404077,0.0062563797,0.0023892345,0.13649596,0.008436205,0.000008084147,0.003743039,0.00028887342,0.2607385,0.14290728],"study_design_scores_gemma":[0.0064681866,0.005432253,0.26413983,0.007203009,0.002382674,0.054722346,0.0014948162,0.00004496293,0.00085385516,0.0006582148,0.655746,0.00085389806],"about_ca_topic_score_codex":0.000006446878,"about_ca_topic_score_gemma":0.000041077892,"teacher_disagreement_score":0.39500746,"about_ca_system_score_codex":0.0009159715,"about_ca_system_score_gemma":0.0004122804,"threshold_uncertainty_score":0.99994946},"labels":[],"label_agreement":null},{"id":"W4388044269","doi":"10.1016/j.jtho.2023.09.442","title":"P1.24-05 The Association of Acinar Pattern with Clinicopathological, Molecular Features, and Prognosis in Lung Adenocarcinoma Patients","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Association (psychology); Adenocarcinoma; Internal medicine; Lung; Oncology; Pathology; Gastroenterology; Cancer","score_opus":0.013412591279382905,"score_gpt":0.37337698946869763,"score_spread":0.35996439818931475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98296726,0.000532901,0.00011320551,0.015812594,0.0002338345,0.00020736884,0.0000017139633,0.000008358043,0.00012277611],"genre_scores_gemma":[0.9978478,0.00027096274,0.00082226587,0.0008536528,0.00009853193,0.0000054480897,0.000004572795,0.000012837174,0.000083916675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846697,0.00037753346,0.0004766936,0.0001274578,0.0003535797,0.00019774442],"domain_scores_gemma":[0.99855125,0.00040100716,0.0006970646,0.0000919224,0.0001730069,0.000085740685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019275997,0.00009560458,0.00046623684,0.00018750141,0.000038602964,0.000011452093,0.00011435235,0.00015063668,0.000007146494],"category_scores_gemma":[0.0010605067,0.000053404325,0.00007479516,0.00029030562,0.00008969088,0.000047892387,0.000057664685,0.0008651576,0.0000010892145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003606769,0.00020740335,0.918923,0.00008211449,0.000057109824,0.0008688909,0.00045232213,0.000034435423,0.00035624127,0.000004523118,0.0027625116,0.07589074],"study_design_scores_gemma":[0.0014177004,0.0025077553,0.99301916,0.00023281931,0.00023836,0.0005257987,0.00023386827,0.0006236326,0.00015158534,0.000058912556,0.00093480415,0.00005557425],"about_ca_topic_score_codex":0.000008880969,"about_ca_topic_score_gemma":0.000004919873,"teacher_disagreement_score":0.07583517,"about_ca_system_score_codex":0.00014894654,"about_ca_system_score_gemma":0.00011345134,"threshold_uncertainty_score":0.37587273},"labels":[],"label_agreement":null},{"id":"W4388044284","doi":"10.1016/j.jtho.2023.09.202","title":"MA12.09 Identification of Tumor-Specific Single-Nucleotide Variants and Intratumor Heterogeneity in LUADs by Full Length ScRNAseq","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Disease; Cancer; Lung; Pathology; Environmental health","score_opus":0.023507253848727646,"score_gpt":0.3475292296127313,"score_spread":0.32402197576400366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961548,0.0018643189,0.00076728995,0.00058430247,0.00037023006,0.000102940816,0.00003435787,0.000004336352,0.00011746249],"genre_scores_gemma":[0.99803764,0.001155362,0.00035698613,0.00006328626,0.00019495597,0.000006700786,0.000030616917,0.000015825144,0.00013861251],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985562,0.00020085706,0.00069186144,0.00021810493,0.00014194626,0.00019100869],"domain_scores_gemma":[0.99886227,0.000029196619,0.0006180019,0.00022956816,0.00017802097,0.00008291857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009385061,0.00011351933,0.00027754396,0.00016907464,0.000043899454,0.000022611557,0.00020845316,0.00012509109,0.000012279319],"category_scores_gemma":[0.00008082384,0.00010740863,0.000074563635,0.00024171176,0.00012042749,0.000016359561,0.00006228434,0.00016376887,0.0000058092596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003727867,0.00019600306,0.0008708394,0.000021295993,0.00003621635,0.000024990477,0.000051444476,0.00009057419,0.9560061,0.000016792374,0.005065863,0.037247084],"study_design_scores_gemma":[0.0012807366,0.002126542,0.074012205,0.00007622913,0.00008487799,0.000658552,0.0006404997,0.00037201954,0.8600059,0.00043603007,0.059951857,0.00035451044],"about_ca_topic_score_codex":0.0000062969666,"about_ca_topic_score_gemma":0.00003251673,"teacher_disagreement_score":0.09600017,"about_ca_system_score_codex":0.00007007762,"about_ca_system_score_gemma":0.00012256426,"threshold_uncertainty_score":0.4379997},"labels":[],"label_agreement":null},{"id":"W4388044331","doi":"10.1016/j.jtho.2023.09.138","title":"MA04.05 Transcriptomic Features as Determinant of Therapy Response in Neuroendocrine-Transformed Adenocarcinomas Following TKI","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Phenotype; Adenocarcinoma; Cancer research; Transcriptome; Neuroendocrine tumors; Transformation (genetics); Immunohistochemistry; Neuroendocrine carcinoma; Tyrosine kinase; Tyrosine-kinase inhibitor; Proto-Oncogene Proteins c-kit; Malignant transformation; Oncology; Pathology; Internal medicine; Cancer; Gene; Receptor; Biology; Gene expression; Genetics","score_opus":0.035223752110640084,"score_gpt":0.44039107809777917,"score_spread":0.40516732598713906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839087,0.0016909656,0.0000059716303,0.012592033,0.00082582905,0.00057585357,0.0000055664814,0.000035893532,0.0003591593],"genre_scores_gemma":[0.995973,0.001747519,0.00042385486,0.00049830374,0.00015657209,0.000019680152,0.0000022704178,0.000057169924,0.0011216566],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962451,0.0009048766,0.0010949492,0.00028432894,0.0007397083,0.0007310664],"domain_scores_gemma":[0.99776804,0.0010505441,0.00039897353,0.00031221283,0.00016423641,0.00030598798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011394701,0.00026182277,0.0011318325,0.0015150867,0.000053426913,0.000014353173,0.00041548655,0.000035103378,0.00005605409],"category_scores_gemma":[0.0010315102,0.00020182875,0.00053225557,0.0009716835,0.00016660988,0.0002646624,0.000044498927,0.0010815057,0.000017292563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09221637,0.00055122026,0.0115171345,0.00022860075,0.0001666525,0.22603056,0.00088365836,0.000050857157,0.60336757,0.000013832113,0.0017623364,0.063211225],"study_design_scores_gemma":[0.0112529835,0.033267546,0.41734463,0.00069159525,0.0002466997,0.07965661,0.0023910934,0.000063264415,0.41741776,0.0010017407,0.03630545,0.0003606249],"about_ca_topic_score_codex":0.000038847316,"about_ca_topic_score_gemma":0.00007251272,"teacher_disagreement_score":0.4058275,"about_ca_system_score_codex":0.0002468778,"about_ca_system_score_gemma":0.0009910869,"threshold_uncertainty_score":0.82303375},"labels":[],"label_agreement":null},{"id":"W4388044837","doi":"10.1016/j.jtho.2023.09.102","title":"OA20.05 The International Association for the Study of Lung Cancer Grading System for Recurrence and Lung Cancer-Specific Survival","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Health, University of Sydney; McGill University; McGill University Health Centre; Cancer Research Institute","keywords":"Medicine; Lung cancer; Grading (engineering); Adenocarcinoma; Oncology; Lung; Internal medicine; Cohort; Survival analysis; Cancer","score_opus":0.055785272823305775,"score_gpt":0.4637681040774561,"score_spread":0.40798283125415036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044837","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581257,0.0065000327,0.00021711334,0.025558947,0.007691076,0.0017291226,0.0000847733,0.000011947279,0.00008127599],"genre_scores_gemma":[0.9947558,0.0032579468,0.00006723641,0.000064798965,0.001145319,0.00046208588,0.0000034123182,0.000012878737,0.00023049428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880946,0.00010752455,0.00045211747,0.00013284394,0.00033393505,0.0001640941],"domain_scores_gemma":[0.99650604,0.0019924848,0.00082649384,0.00010566522,0.00052400026,0.00004533023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017790345,0.00009459312,0.00039361615,0.000095326264,0.00015249151,0.000024383846,0.00016555889,0.00006194887,0.000009939343],"category_scores_gemma":[0.00016066374,0.00005092435,0.00012225306,0.00017257823,0.000024809602,0.00005993224,0.000036791374,0.00015846541,1.8103478e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022915015,0.0006253906,0.79223305,0.0007154758,0.0045907423,0.00003352795,0.0051845084,0.0005616045,0.00031707017,0.00035918446,0.071523026,0.12156491],"study_design_scores_gemma":[0.016717771,0.007905333,0.77229214,0.0035403222,0.011779022,0.00020155139,0.0353315,0.030407827,0.001863871,0.00017099727,0.11939324,0.0003964466],"about_ca_topic_score_codex":0.00013488109,"about_ca_topic_score_gemma":0.0005271326,"teacher_disagreement_score":0.121168464,"about_ca_system_score_codex":0.0022226728,"about_ca_system_score_gemma":0.00028608795,"threshold_uncertainty_score":0.5812212},"labels":[],"label_agreement":null},{"id":"W4388044943","doi":"10.1016/j.jtho.2023.09.837","title":"EP04.01-07 Optimal Predictors for Lung Cancer Using High-Resolution CT","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Lung cancer; Radiology; Computed tomography; Lung; High-resolution computed tomography; Cancer; Lung cancer screening; High resolution; Oncology; Internal medicine","score_opus":0.02849388548504429,"score_gpt":0.4465862031673295,"score_spread":0.4180923176822852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388044943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96010405,0.0007946921,0.02483008,0.011040056,0.0027919754,0.00024795855,0.000009149936,0.00004753814,0.00013452659],"genre_scores_gemma":[0.9475634,0.00042923508,0.047014944,0.00086697825,0.003271334,0.000014628313,0.000018456132,0.000055433025,0.000765553],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998472,0.00012111329,0.00056510686,0.00015916543,0.0003100837,0.00037253654],"domain_scores_gemma":[0.9986474,0.00029757278,0.00050472934,0.00011585182,0.00018739521,0.00024703055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015323764,0.00013086022,0.00055087387,0.00034582271,0.0001229991,0.000016953889,0.00013933344,0.000105764375,0.00013177666],"category_scores_gemma":[0.0007072168,0.00010344542,0.00020509836,0.0002656292,0.00010385664,0.000113640745,0.000048446942,0.0006326442,0.000004411254],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006562028,0.0007116138,0.06361335,0.0014148154,0.0020809115,0.0038016252,0.0015402002,0.18870386,0.051723212,0.00033770618,0.21323474,0.46627596],"study_design_scores_gemma":[0.002844582,0.0017084236,0.020154726,0.0007032645,0.0015966035,0.002664453,0.00028986583,0.8640884,0.0008004473,0.00017605103,0.10475318,0.00022001423],"about_ca_topic_score_codex":0.000074935786,"about_ca_topic_score_gemma":0.0000035613878,"teacher_disagreement_score":0.6753845,"about_ca_system_score_codex":0.00053821335,"about_ca_system_score_gemma":0.00058383646,"threshold_uncertainty_score":0.42183816},"labels":[],"label_agreement":null},{"id":"W4388045013","doi":"10.1016/j.jtho.2023.09.674","title":"P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Dosing; Jazz; Lung cancer; Intensive care medicine; Internal medicine; Acoustics","score_opus":0.023414895978585516,"score_gpt":0.4081311427605147,"score_spread":0.38471624678192917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246144,0.0016882803,0.000051767158,0.0021235452,0.00018859177,0.00043838966,0.00004074743,0.000030364867,0.0029768692],"genre_scores_gemma":[0.99060875,0.005228792,0.0010546268,0.00007658456,0.0002148471,0.000014150443,0.000030386564,0.000034476663,0.0027373768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765027,0.00023999515,0.0008321012,0.000268665,0.0005711136,0.00043784748],"domain_scores_gemma":[0.99720615,0.00041426055,0.00089864276,0.00023868102,0.000979146,0.00026309676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078088924,0.00022044902,0.0012366554,0.0012519355,0.00012434003,0.000010117421,0.00015916106,0.00011446438,0.00015438731],"category_scores_gemma":[0.00015293965,0.0001531963,0.00019594195,0.0022700694,0.00018713076,0.00011093566,0.00016744253,0.000511755,0.0000022479032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013243402,0.00037917466,0.9596079,0.00063655875,0.0035273212,0.00042629952,0.00086669263,0.0005082324,0.0006793139,0.0000018917802,0.0064811185,0.013642095],"study_design_scores_gemma":[0.0025889506,0.0043704123,0.98133427,0.00051848515,0.006522468,0.000023601064,0.00027302327,0.0007796844,0.000947916,0.000006213019,0.0024812194,0.00015374129],"about_ca_topic_score_codex":0.00083893153,"about_ca_topic_score_gemma":0.0018790449,"teacher_disagreement_score":0.021726387,"about_ca_system_score_codex":0.00074381975,"about_ca_system_score_gemma":0.00050053856,"threshold_uncertainty_score":0.6247164},"labels":[],"label_agreement":null},{"id":"W4388045045","doi":"10.1016/j.jtho.2023.09.160","title":"MA07.05 Canadian Lung Cancer Patient-Reported Fear and Anxiety: Current State and Ongoing Needs","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Concordia University","funders":"","keywords":"Medicine; Anxiety; Lung cancer; Current (fluid); Clinical psychology; Intensive care medicine; Psychiatry; Oncology","score_opus":0.023235991286798537,"score_gpt":0.3937404075620426,"score_spread":0.37050441627524405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836269,0.0073954966,0.000009735339,0.0061330153,0.002105284,0.0001592648,0.000019542184,0.000013385771,0.0005373857],"genre_scores_gemma":[0.99187607,0.006773939,0.000050978935,0.0005818833,0.00031730536,0.0000075484804,0.000004810519,0.00002013697,0.00036733385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881345,0.000086617,0.00041941722,0.00013585103,0.00022096049,0.00032368014],"domain_scores_gemma":[0.99873435,0.00006247065,0.0003156412,0.000107978725,0.00023890553,0.00054067356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004811404,0.00012504103,0.00040950518,0.00053877605,0.00008777533,0.000024289566,0.000049243332,0.00008465214,0.00007447601],"category_scores_gemma":[0.000072514384,0.00010516742,0.00006775305,0.00042493062,0.000065715096,0.00009249602,0.000042263346,0.0004341349,0.0000027050082],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003610671,0.000024567342,0.14838901,0.00017657848,0.0001544909,0.00075346715,0.0045721247,0.000012707004,0.0003731383,0.0000033256404,0.010074673,0.8351049],"study_design_scores_gemma":[0.0015243953,0.0013550641,0.31677577,0.0008591268,0.00091406197,0.0041875513,0.0045387177,0.0007080068,0.00049487996,0.0001513513,0.66815734,0.00033375403],"about_ca_topic_score_codex":0.012781591,"about_ca_topic_score_gemma":0.09592897,"teacher_disagreement_score":0.8347711,"about_ca_system_score_codex":0.00049509696,"about_ca_system_score_gemma":0.0013096485,"threshold_uncertainty_score":0.99379236},"labels":[],"label_agreement":null},{"id":"W4388045093","doi":"10.1016/j.jtho.2023.09.1307","title":"EP12.03-02 Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Docetaxel; KRAS; Oncology; Internal medicine; Tyrosine kinase; Cancer; Cancer research; Colorectal cancer","score_opus":0.07706149515622752,"score_gpt":0.4463946891866546,"score_spread":0.3693331940304271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712311,0.009232766,0.000044702378,0.0129839415,0.0014548405,0.000781323,0.00041549993,0.00008280083,0.0037730278],"genre_scores_gemma":[0.9865237,0.0069525656,0.0024875314,0.000963984,0.00064657483,0.00006250092,0.00013488131,0.000028893302,0.0021994025],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978424,0.00019415372,0.0006651526,0.00035114563,0.00042265773,0.0005245357],"domain_scores_gemma":[0.9971958,0.00043273316,0.00039918497,0.0003116404,0.00042869404,0.0012319903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049343775,0.00029144305,0.00084589655,0.0006145579,0.00027697408,0.000022234812,0.00020946926,0.000095327116,0.0004952289],"category_scores_gemma":[0.00084419997,0.00021126837,0.0002784494,0.00069814833,0.00019654538,0.00032088393,0.00008688018,0.00042766138,0.00014011153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026422286,0.0017253152,0.34684002,0.00042734956,0.0029049572,0.06101634,0.002117993,0.0008665736,0.0032478394,0.00012321054,0.059724577,0.49458352],"study_design_scores_gemma":[0.0044204397,0.002573885,0.87529683,0.002502624,0.0025813293,0.0004109056,0.00059149455,0.0011010672,0.00045828393,0.000103513405,0.10953991,0.0004196901],"about_ca_topic_score_codex":0.036394726,"about_ca_topic_score_gemma":0.23504893,"teacher_disagreement_score":0.5284568,"about_ca_system_score_codex":0.0024875249,"about_ca_system_score_gemma":0.0047426973,"threshold_uncertainty_score":0.970022},"labels":[],"label_agreement":null},{"id":"W4388045239","doi":"10.1016/j.jtho.2023.09.110","title":"OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Docetaxel; Oncology; Internal medicine; Nivolumab; Lung cancer; Cancer; Immune checkpoint; Immune system; Immunotherapy; Immunology","score_opus":0.031110110736264452,"score_gpt":0.4162212888867883,"score_spread":0.3851111781505238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855414,0.0050749127,0.000021850938,0.0075208633,0.00076531543,0.0008115945,0.000005668775,0.0000089562955,0.0002494538],"genre_scores_gemma":[0.9968072,0.001669987,0.000247932,0.000760426,0.00021992094,0.000052162453,0.0000026790858,0.000020663534,0.00021900686],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976299,0.00048814763,0.0010615911,0.00019745702,0.00028615515,0.00033679462],"domain_scores_gemma":[0.9986939,0.00040313043,0.0005064226,0.00022117412,0.00009035018,0.00008501683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032720896,0.00018950361,0.0007335671,0.00054523133,0.000059220067,0.000026037476,0.0002240874,0.00012509835,0.00007962375],"category_scores_gemma":[0.00008223439,0.00012458205,0.00016964026,0.0007745849,0.00008733421,0.00010465928,0.000059866885,0.00080989767,0.0000031249338],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07271644,0.013321803,0.17811163,0.0014123762,0.0014387398,0.021508306,0.078899585,0.00013369675,0.19997478,0.0000054544735,0.012585706,0.4198915],"study_design_scores_gemma":[0.077977635,0.043435503,0.649929,0.0020274343,0.0025020458,0.00397008,0.1708037,0.003491262,0.025380963,0.0002928105,0.019245163,0.00094442215],"about_ca_topic_score_codex":0.0006809953,"about_ca_topic_score_gemma":0.0014921238,"teacher_disagreement_score":0.47181734,"about_ca_system_score_codex":0.00036328277,"about_ca_system_score_gemma":0.0005852472,"threshold_uncertainty_score":0.50803083},"labels":[],"label_agreement":null},{"id":"W4388045246","doi":"10.1016/j.jtho.2023.09.1110","title":"EP08.04-01 Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Durvalumab; Pneumonitis; Lung cancer; Radiation therapy; Intensive care medicine; Cancer; Oncology; Internal medicine; Lung; Immunotherapy; Pembrolizumab","score_opus":0.01501962528952766,"score_gpt":0.3577376444077282,"score_spread":0.34271801911820055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997685,0.00043432004,0.00000416783,0.00076519535,0.00024143199,0.00034761245,0.00003703506,0.000008967095,0.00047628474],"genre_scores_gemma":[0.99784845,0.0013723446,0.0001351089,0.0001452635,0.000042252013,0.000013562225,0.000007735162,0.000018815275,0.00041644863],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870855,0.00013360975,0.00059387495,0.00013548763,0.00021363226,0.00021483484],"domain_scores_gemma":[0.99872845,0.0002167578,0.00063338573,0.00009635194,0.00022739898,0.000097623466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038062688,0.00014632022,0.0007056606,0.0003939615,0.000029035005,0.000005849178,0.00008159172,0.00012992077,0.00007002244],"category_scores_gemma":[0.000036428544,0.00009862205,0.000091430076,0.00040771195,0.00016026633,0.00007665524,0.000022252108,0.0002561963,9.000767e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067821634,0.00034934093,0.9710846,0.00016095718,0.00043828125,0.00029232557,0.0018506334,0.000009651113,0.0033467729,2.437574e-7,0.00047476348,0.015210246],"study_design_scores_gemma":[0.0059776516,0.0038776172,0.98248273,0.00042306646,0.00035240877,0.00008901198,0.0006717708,0.000071743816,0.005481734,0.0000033705937,0.0004741151,0.000094789924],"about_ca_topic_score_codex":0.00024100133,"about_ca_topic_score_gemma":0.00028568262,"teacher_disagreement_score":0.015115457,"about_ca_system_score_codex":0.00030984718,"about_ca_system_score_gemma":0.00036835286,"threshold_uncertainty_score":0.40216905},"labels":[],"label_agreement":null},{"id":"W4388045325","doi":"10.1016/j.jtho.2023.09.530","title":"P2.05-03 Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cohort; Lung cancer; Oncology; Immune system; Cancer; Internal medicine; Immunology","score_opus":0.03197573877820174,"score_gpt":0.3882890751755947,"score_spread":0.35631333639739293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922353,0.00241872,0.000017820352,0.0027095072,0.0011153957,0.0004575686,0.000020473834,0.000015513742,0.0010096804],"genre_scores_gemma":[0.9960479,0.0015083232,0.00017114998,0.0001766327,0.00013959322,0.000015485773,0.000021912767,0.000023537494,0.001895428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978163,0.00039412425,0.0010385865,0.00016305975,0.0003143329,0.00027356224],"domain_scores_gemma":[0.9980923,0.00042031577,0.0010913945,0.00011180516,0.00017006647,0.00011409784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003397137,0.00015513583,0.00083892606,0.00040831196,0.00004850424,0.000005563801,0.000104671664,0.00020960986,0.00006708933],"category_scores_gemma":[0.00011919941,0.00013068301,0.00020412693,0.0005303935,0.000039990446,0.00012855495,0.00003997224,0.00052813836,0.000008587861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026695433,0.0001527945,0.9783288,0.0001806274,0.0014027333,0.0004682912,0.0008686497,0.000020802976,0.0059270496,4.9807295e-7,0.0018303915,0.008149774],"study_design_scores_gemma":[0.005264881,0.00082819065,0.98816544,0.00039083036,0.00079549866,0.000067603454,0.0006902228,0.00023166696,0.0007823515,0.00003844206,0.0026136802,0.00013122367],"about_ca_topic_score_codex":0.00037629667,"about_ca_topic_score_gemma":0.000100586825,"teacher_disagreement_score":0.009836565,"about_ca_system_score_codex":0.0010447252,"about_ca_system_score_gemma":0.0009035477,"threshold_uncertainty_score":0.5329098},"labels":[],"label_agreement":null},{"id":"W4388045630","doi":"10.1016/j.jtho.2023.09.1237","title":"EP12.01-22 Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Health Services; Alberta Health; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Durvalumab; Oncology; Internal medicine; Osimertinib; Cohort; Lactate dehydrogenase; Cancer; Pembrolizumab; Immunotherapy; Adenocarcinoma","score_opus":0.05905623566364579,"score_gpt":0.43789601614458035,"score_spread":0.3788397804809346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947318,0.0010879065,0.00001769374,0.0021350482,0.0001907828,0.0004784375,0.000007844244,0.000007426842,0.0013430782],"genre_scores_gemma":[0.9990165,0.0005239595,0.00019758921,0.00004818689,0.00005445599,0.000024871943,0.000003524741,0.000008260003,0.00012264392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847776,0.0003685372,0.000533968,0.000109149245,0.00037602612,0.0001345369],"domain_scores_gemma":[0.9985529,0.00028082944,0.0005774064,0.00010103407,0.00044235506,0.00004548107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001694755,0.00009277763,0.00040868623,0.0001939345,0.000059452614,0.000005285114,0.000053206128,0.00008199623,0.000024090963],"category_scores_gemma":[0.001194454,0.00005637813,0.000080741214,0.0003781416,0.00010040693,0.000059675163,0.000045654993,0.00020632545,0.0000019888644],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041163764,0.0006174946,0.5006705,0.00009921447,0.0004967861,0.000058891943,0.0032658547,0.0039408477,0.002618253,0.000027988732,0.0009015944,0.4831862],"study_design_scores_gemma":[0.0034629263,0.002047631,0.92935187,0.00028249845,0.0018398426,0.00011902227,0.00088983396,0.05928181,0.0011871461,0.0012659117,0.00020110645,0.000070384944],"about_ca_topic_score_codex":0.00003279379,"about_ca_topic_score_gemma":0.000109778965,"teacher_disagreement_score":0.4831158,"about_ca_system_score_codex":0.0003034301,"about_ca_system_score_gemma":0.0004564396,"threshold_uncertainty_score":0.22990334},"labels":[],"label_agreement":null},{"id":"W4388045689","doi":"10.1016/j.jtho.2023.09.139","title":"MA04.06 Epigenomic Drug Effect on Osimertinib-Induced Drug Tolerant Persister in a Lung Cancer Patient-Derived Xenograft Model","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Medicine; Drug; Lung cancer; Epigenomics; Pharmacology; Cancer research; Oncology; Cancer; Internal medicine; Erlotinib; Genetics; Gene; Biology","score_opus":0.022681278175334493,"score_gpt":0.4259955665913915,"score_spread":0.403314288416057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915267,0.00075158174,0.000016053718,0.007862997,0.0007218806,0.0006019171,0.000019527013,0.000028369286,0.0008450246],"genre_scores_gemma":[0.99735945,0.00013533526,0.0002945564,0.00103995,0.00020161195,0.000079129015,0.000015465685,0.000038437764,0.0008360345],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99822396,0.00023570651,0.0006343873,0.00023429227,0.00028674843,0.0003849307],"domain_scores_gemma":[0.9988346,0.00021151554,0.00042591468,0.00019155856,0.00013485622,0.00020155025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046046916,0.00021580195,0.00070982677,0.00051688997,0.00009025291,0.000015910287,0.00011910421,0.00011254342,0.00007497517],"category_scores_gemma":[0.000052999047,0.00015636218,0.00027037974,0.00033150142,0.000038184102,0.00010734828,0.000039594175,0.00046493163,0.000036178208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01854788,0.0031992237,0.058087375,0.0010625058,0.0037165065,0.0058087087,0.08299598,0.04462433,0.21626918,0.0000209799,0.042367518,0.5232998],"study_design_scores_gemma":[0.076485746,0.04648913,0.27732038,0.012280998,0.022348909,0.002627963,0.02266416,0.25626016,0.22753893,0.0007954843,0.05133664,0.0038514964],"about_ca_topic_score_codex":0.00012767663,"about_ca_topic_score_gemma":0.00012738418,"teacher_disagreement_score":0.51944834,"about_ca_system_score_codex":0.0013417779,"about_ca_system_score_gemma":0.0007758339,"threshold_uncertainty_score":0.63762647},"labels":[],"label_agreement":null},{"id":"W4388045801","doi":"10.1016/j.jtho.2023.09.463","title":"P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Oncology; Internal medicine; Lung cancer; Epidermal growth factor receptor; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Cancer research; Cancer; Gefitinib; Erlotinib","score_opus":0.0543660129831342,"score_gpt":0.48905417034100224,"score_spread":0.43468815735786803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447674,0.00031087047,0.000029543406,0.0022643565,0.00049623573,0.00083894166,0.00006526672,0.000038430964,0.0014795954],"genre_scores_gemma":[0.99704915,0.00006137915,0.00087591994,0.00014579177,0.00015947885,0.000026697535,0.000046729838,0.00003460684,0.001600251],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974065,0.0003393045,0.0011788335,0.00023515927,0.00046687239,0.0003733536],"domain_scores_gemma":[0.998033,0.00021112764,0.00083362067,0.00026280593,0.00044376546,0.00021570062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082981406,0.00019851685,0.0010178335,0.0008224398,0.00015279141,0.000007971474,0.00018529994,0.00013706574,0.00042598112],"category_scores_gemma":[0.0003008602,0.00015256264,0.0001524126,0.0011131691,0.00008854243,0.00012604914,0.00011540401,0.0005119654,0.000018823222],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074810885,0.103462085,0.07058539,0.0007958299,0.008608474,0.03193931,0.124270886,0.0026519909,0.17875132,0.0001636932,0.036178965,0.36778116],"study_design_scores_gemma":[0.14319105,0.3312059,0.32096985,0.0016430123,0.0051540285,0.0012484638,0.07216822,0.0032338935,0.012454872,0.0005781669,0.10719118,0.00096135575],"about_ca_topic_score_codex":0.00018244475,"about_ca_topic_score_gemma":0.00019189357,"teacher_disagreement_score":0.3668198,"about_ca_system_score_codex":0.0005044302,"about_ca_system_score_gemma":0.00088414544,"threshold_uncertainty_score":0.62213236},"labels":[],"label_agreement":null},{"id":"W4388045850","doi":"10.1016/j.jtho.2023.09.374","title":"P1.18-05 Te Oranga Pūkahukahu: Developing an Indigenous Māori Led Approach to Lung Cancer Screening","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cultural Competency in Health Care","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Indigenous; Lung cancer; Oncology; Internal medicine; Traditional medicine","score_opus":0.11591020131286209,"score_gpt":0.5205031149850439,"score_spread":0.40459291367218175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727032,0.0010033217,0.0015302589,0.0141065745,0.004189432,0.000746362,0.000012750849,0.00015692407,0.005551132],"genre_scores_gemma":[0.9598642,0.0005047245,0.032255948,0.0025611757,0.0036725735,0.000056984863,0.000010008907,0.000042903495,0.0010314692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961835,0.0010690087,0.0008065372,0.00029810073,0.0007823175,0.0008605077],"domain_scores_gemma":[0.9974679,0.00035698464,0.00066275365,0.00018120088,0.0007916144,0.00053955783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037826984,0.0001982267,0.0006217546,0.00046272072,0.001080456,0.00010100891,0.0008307289,0.0003047303,0.000104602404],"category_scores_gemma":[0.0006321562,0.0001709315,0.00014943445,0.0017583134,0.0001255973,0.0005235202,0.00012557098,0.0007172686,0.000023128045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000631494,0.00016544743,0.01804819,0.0002773158,0.00022786962,0.00047560627,0.24293047,0.002864571,0.0007378027,0.0012816702,0.022660408,0.70969915],"study_design_scores_gemma":[0.0010797182,0.0018702267,0.060817655,0.0008819234,0.00037118766,0.0004406072,0.1780949,0.0009380341,0.00041911268,0.0018419041,0.75190765,0.001337113],"about_ca_topic_score_codex":0.0025189081,"about_ca_topic_score_gemma":0.0062266127,"teacher_disagreement_score":0.7292472,"about_ca_system_score_codex":0.0017725803,"about_ca_system_score_gemma":0.0029112578,"threshold_uncertainty_score":0.83101034},"labels":[],"label_agreement":null},{"id":"W4388045859","doi":"10.1016/j.jtho.2023.09.964","title":"EP07.01-18 Adjuvant Chemotherapy is Less Effective in Non Small Cell Lung Cancer Patients Rated Undernourished by CONUT Score","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Adjuvant; Chemotherapy; Adjuvant chemotherapy; Oncology; Lung cancer; Pathological; Internal medicine; Stage (stratigraphy); Adjuvant therapy; Cancer","score_opus":0.020621743187618384,"score_gpt":0.39073186612675725,"score_spread":0.37011012293913886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388045859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98973095,0.0018943468,0.000021168002,0.00582056,0.0008919306,0.00093940203,0.00003734563,0.000019255083,0.000645056],"genre_scores_gemma":[0.994372,0.0028471807,0.00009066027,0.0017101896,0.00022607506,0.00010315944,0.000028249138,0.000043652606,0.0005788092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982875,0.0001892556,0.00058752054,0.00027249788,0.000285992,0.00037724403],"domain_scores_gemma":[0.99847734,0.00025654738,0.00059390167,0.00016258885,0.00030688147,0.00020271234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043328208,0.00023409005,0.0008960844,0.0002845644,0.000049710823,0.000015119599,0.00013546953,0.00023057447,0.0002317747],"category_scores_gemma":[0.00003383993,0.00017514377,0.00017342281,0.00046610515,0.00005514224,0.00007748405,0.000036313417,0.0004521941,0.000016173908],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030926517,0.0023761797,0.7623327,0.00036323816,0.00060081447,0.00069070543,0.0018695656,0.000070961905,0.0023164642,5.1930334e-7,0.13340694,0.09287925],"study_design_scores_gemma":[0.016700154,0.0059510623,0.91536975,0.0013460487,0.0008439005,0.00004878764,0.00050826353,0.00066659437,0.05110903,0.000046637997,0.00711458,0.00029518042],"about_ca_topic_score_codex":0.00034054313,"about_ca_topic_score_gemma":0.00021053098,"teacher_disagreement_score":0.15303706,"about_ca_system_score_codex":0.0023590655,"about_ca_system_score_gemma":0.0005269127,"threshold_uncertainty_score":0.7142155},"labels":[],"label_agreement":null},{"id":"W4388046092","doi":"10.1016/j.jtho.2023.09.384","title":"P1.20-04 Predictability of Actionable Mutations in NSCLC using Attention-Based Multiple-Instance Learning on H&amp;E Images","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Genetics, Bioinformatics, and Biomedical Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Predictability; Computational biology; Statistics","score_opus":0.04108748019479128,"score_gpt":0.4169937837799288,"score_spread":0.3759063035851375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388046092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930582,0.00010136506,0.0052836356,0.0007224623,0.00030692326,0.00014323082,0.000024444822,0.0000064254746,0.00035330333],"genre_scores_gemma":[0.9936966,0.00012615352,0.0055773626,0.000072029,0.0001434459,0.000004400987,0.00006235707,0.000010992451,0.00030667966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982928,0.0002578581,0.00066191633,0.00014999579,0.00036195118,0.00027549587],"domain_scores_gemma":[0.99864537,0.00025913498,0.00044503825,0.0001632355,0.0003722365,0.00011496545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014422672,0.00010728398,0.00026859128,0.0003160436,0.000081424885,0.000012653305,0.00020348863,0.00021029529,0.00002645257],"category_scores_gemma":[0.0019728704,0.00009401816,0.00014159993,0.00033584505,0.00023666628,0.000011706642,0.00006340942,0.0003577392,0.000008873163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001882215,0.00065115886,0.08194404,0.00028951262,0.00010188279,0.000029817711,0.0002160732,0.033767283,0.83106333,0.0000034459938,0.0014976108,0.048553605],"study_design_scores_gemma":[0.0080141965,0.013939847,0.35667583,0.001122061,0.00024669597,0.00021113708,0.006675503,0.078953736,0.41715527,0.0007971831,0.115192354,0.0010161855],"about_ca_topic_score_codex":0.000016013812,"about_ca_topic_score_gemma":0.00009335443,"teacher_disagreement_score":0.4139081,"about_ca_system_score_codex":0.00012160527,"about_ca_system_score_gemma":0.00060584245,"threshold_uncertainty_score":0.38339493},"labels":[],"label_agreement":null},{"id":"W4388071532","doi":"10.1016/j.jtho.2023.09.1386","title":"EP14.02-03 Open Versus Video-Assisted and Robotic-Assisted Thymectomy for the Treatment of Thymic Neoplasms","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Thymectomy; Internal medicine; Myasthenia gravis","score_opus":0.08920789242136437,"score_gpt":0.45072847002338995,"score_spread":0.3615205776020256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388071532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813293,0.0015760862,0.00018818618,0.012711026,0.0016188308,0.0011426525,0.000017690005,0.000021186497,0.0013949929],"genre_scores_gemma":[0.9914531,0.0013274471,0.004392481,0.00017514003,0.00041614758,0.000056081775,0.000013755425,0.000039525094,0.0021263359],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99835527,0.00018222962,0.00071966613,0.00019937145,0.00023733014,0.0003061595],"domain_scores_gemma":[0.9967719,0.0017419013,0.0007085033,0.0003107606,0.00028012248,0.00018684147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085369736,0.00019882544,0.000983217,0.00023465078,0.00014587585,0.000038438026,0.0002894614,0.0001725087,0.00008336465],"category_scores_gemma":[0.00022547293,0.00011210726,0.00029874407,0.0003642944,0.00014278757,0.00009293801,0.00008146473,0.00018268135,0.00001500615],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036259938,0.0018462153,0.0040091155,0.00020666418,0.0024746873,0.0008695073,0.0016362523,0.00009234144,0.0095583685,0.0004396216,0.008758093,0.9338492],"study_design_scores_gemma":[0.03876018,0.080375284,0.43589833,0.00062193413,0.007034806,0.0072129807,0.004458699,0.0027928234,0.008353349,0.0011282198,0.41287047,0.0004929423],"about_ca_topic_score_codex":0.000051319526,"about_ca_topic_score_gemma":0.00011085095,"teacher_disagreement_score":0.9333562,"about_ca_system_score_codex":0.00025258027,"about_ca_system_score_gemma":0.0005116282,"threshold_uncertainty_score":0.45716012},"labels":[],"label_agreement":null},{"id":"W4388073436","doi":"10.1016/j.jtho.2023.09.074","title":"OA13.05 Strategies to Increase Acceptance of Referral to Smoking Cessation at an Ontario Regional Cancer Centre","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"NOSM University","funders":"","keywords":"Medicine; Referral; Smoking cessation; Cancer; Ambulatory; Family medicine; Health care; Environmental health; Physical therapy; Internal medicine","score_opus":0.1533006514784096,"score_gpt":0.4841759818464853,"score_spread":0.3308753303680757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388073436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98686755,0.00012374757,0.000092966766,0.010419265,0.0005308693,0.0001564816,0.000007983158,0.00001726859,0.001783886],"genre_scores_gemma":[0.99351585,0.000048737264,0.002337794,0.0020013778,0.00052043283,0.0000057977163,0.000010586186,0.000012968751,0.0015464689],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983032,0.00011873562,0.0005630709,0.00018705153,0.00053319806,0.00029479386],"domain_scores_gemma":[0.9984063,0.000073871306,0.00044972936,0.00017391646,0.00053242047,0.00036377914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007339817,0.00012876,0.00048341282,0.00029680607,0.000074783246,0.000018504074,0.000208036,0.00013167027,0.0005147901],"category_scores_gemma":[0.00012327087,0.00010960986,0.00010718693,0.0004677712,0.00004109537,0.00035611627,0.00008323539,0.00031234187,0.000012681549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02580665,0.00035257742,0.5474078,0.00021727284,0.00044416974,0.002199669,0.023171024,0.013774087,0.037089933,0.0004167673,0.1369542,0.21216583],"study_design_scores_gemma":[0.00090557314,0.003161979,0.8869635,0.00076001853,0.00028813083,0.0006235703,0.0072721476,0.00007114475,0.0022900377,0.00036067318,0.09710697,0.0001962787],"about_ca_topic_score_codex":0.011268238,"about_ca_topic_score_gemma":0.1345645,"teacher_disagreement_score":0.33955565,"about_ca_system_score_codex":0.0018136638,"about_ca_system_score_gemma":0.0015483412,"threshold_uncertainty_score":0.9953158},"labels":[],"label_agreement":null},{"id":"W4388073618","doi":"10.1016/j.jtho.2023.09.068","title":"OA12.03 An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aN0 NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Centre Hospitalier de l’Université de Montréal; Surrey Memorial Hospital; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Lung cancer; Alliance; Resection; Oncology; Internal medicine; Surgery","score_opus":0.04256322022190188,"score_gpt":0.444273668073886,"score_spread":0.4017104478519841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388073618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323034,0.001389202,0.000027228602,0.0017485658,0.0023997703,0.0006532838,0.0002902182,0.000006220492,0.0002551388],"genre_scores_gemma":[0.99712795,0.0015716311,0.00031059387,0.00012720925,0.0006055978,0.00004725069,0.000044222455,0.00001928895,0.00014623502],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.997856,0.00034746566,0.001011358,0.00021845555,0.00034807733,0.00021863899],"domain_scores_gemma":[0.9965835,0.0007677672,0.0015874062,0.0003588125,0.00058402866,0.00011847415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011308618,0.00015579356,0.0012671826,0.00029471953,0.00005223584,0.000005594764,0.00020669881,0.00019927943,0.00021420476],"category_scores_gemma":[0.00021025352,0.00010359989,0.0006862141,0.0008044198,0.00012469362,0.00011130905,0.00004546093,0.00022600192,8.81307e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7082049,0.004146363,0.106469356,0.0014770327,0.03328469,0.0001524096,0.0020901908,0.0048926957,0.050406326,0.000085110885,0.020237353,0.06855355],"study_design_scores_gemma":[0.084665224,0.025293306,0.72647905,0.0010339417,0.04140718,0.000014996985,0.00089682546,0.002470568,0.11051192,0.00031430018,0.006621142,0.00029151668],"about_ca_topic_score_codex":0.0005333826,"about_ca_topic_score_gemma":0.003400187,"teacher_disagreement_score":0.6235397,"about_ca_system_score_codex":0.0011703139,"about_ca_system_score_gemma":0.0010234484,"threshold_uncertainty_score":0.4224681},"labels":[],"label_agreement":null},{"id":"W4388074293","doi":"10.1016/j.jtho.2023.09.904","title":"EP06.03-12 Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2)","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Medicine; Exon; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.03609877914508521,"score_gpt":0.4449655504943838,"score_spread":0.4088667713492986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388074293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901326,0.00018923482,0.000013410549,0.0078492975,0.00031414366,0.00024340808,0.000055628214,0.00001211685,0.0011902137],"genre_scores_gemma":[0.9943837,0.0025009136,0.00039226923,0.0002022444,0.000116768286,0.00001679327,0.000026813474,0.000016237791,0.0023442819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99888635,0.000087615765,0.0005737428,0.00013765391,0.00013346376,0.00018115132],"domain_scores_gemma":[0.9990678,0.00020136968,0.0003743597,0.000114835144,0.00009482124,0.0001468539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021523992,0.00013823435,0.00068541727,0.0004346964,0.00004509734,0.000009998355,0.000039472416,0.00008308768,0.000049396633],"category_scores_gemma":[0.000053720258,0.000097219134,0.00008292082,0.00018106875,0.00006835504,0.000090314505,0.000028300583,0.00014607534,0.0000049487608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004520851,0.0005757681,0.87058735,0.00008158533,0.000366531,0.00053789176,0.00153771,0.0000024544954,0.00041354317,0.000029084062,0.00026984402,0.12514614],"study_design_scores_gemma":[0.00204779,0.0019210189,0.9887124,0.00019047935,0.00057857414,0.00017886923,0.00066501996,0.000034325894,0.00019661392,0.00010817291,0.005295751,0.000071022725],"about_ca_topic_score_codex":0.000648778,"about_ca_topic_score_gemma":0.0031707543,"teacher_disagreement_score":0.12507512,"about_ca_system_score_codex":0.00043674058,"about_ca_system_score_gemma":0.00027323316,"threshold_uncertainty_score":0.39644814},"labels":[],"label_agreement":null},{"id":"W4388075765","doi":"10.1016/j.jtho.2023.09.1306","title":"EP12.03-01 Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Immunotherapy; Oncology; Lung cancer; Internal medicine; Targeted therapy; Tyrosine kinase; Cancer; Receptor","score_opus":0.010908201547530218,"score_gpt":0.3845963050386493,"score_spread":0.3736881034911191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388075765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723965,0.0003299187,0.000072470815,0.0012379437,0.00042656664,0.00046222255,0.000008517782,0.000016997283,0.00020573245],"genre_scores_gemma":[0.9970705,0.00021404772,0.001872642,0.00038158623,0.00004605727,0.00001559767,0.000030698848,0.000026960295,0.00034189125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987746,0.00014487037,0.00042365398,0.00015548343,0.0002830601,0.00021833443],"domain_scores_gemma":[0.99906677,0.00020500265,0.00036322387,0.000104434526,0.00016395333,0.00009658867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003117812,0.00015337457,0.00050295517,0.00037960266,0.00008705597,0.000006091699,0.00006444158,0.00009424392,0.000047161328],"category_scores_gemma":[0.000057329446,0.000103772356,0.0001404921,0.00035732845,0.000035514946,0.00023293006,0.000014978734,0.00022236984,0.000009648603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002499292,0.00054984755,0.8915658,0.00000940665,0.0013000531,0.00047517678,0.003805845,0.00006613626,0.0004618702,0.000002116827,0.00007105358,0.09919338],"study_design_scores_gemma":[0.009335152,0.0027482677,0.98589486,0.00018812272,0.00025167636,0.000047165573,0.00078075595,0.000025275613,0.00020758546,0.00008754694,0.00033174298,0.00010184576],"about_ca_topic_score_codex":0.000036625603,"about_ca_topic_score_gemma":0.000031006897,"teacher_disagreement_score":0.09909153,"about_ca_system_score_codex":0.00049041066,"about_ca_system_score_gemma":0.00035187425,"threshold_uncertainty_score":0.4231714},"labels":[],"label_agreement":null},{"id":"W4388081523","doi":"10.1016/j.jtho.2023.09.089","title":"OA17.04 Long-Term Outcomes by Radiation Technique for Locally-Advanced Non-small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Oncology; Lung cancer; Radiation therapy; Radiation oncology; Internal medicine; Term (time)","score_opus":0.020553289864807534,"score_gpt":0.4300251242203998,"score_spread":0.40947183435559226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388081523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584956,0.002679183,0.0018409225,0.007072477,0.0007950481,0.0012838318,0.00018667427,0.000032206994,0.0002600988],"genre_scores_gemma":[0.9887343,0.004762597,0.0036552697,0.0009849429,0.0002059247,0.0005327061,0.00016573415,0.000049575316,0.00090896746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977795,0.00014084371,0.0010692463,0.00031694362,0.000302494,0.00039095685],"domain_scores_gemma":[0.9969765,0.0006810152,0.0014117393,0.00030214037,0.00039120333,0.0002373812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095032237,0.00024390448,0.0016993613,0.00086521346,0.00007956529,0.000009335724,0.0002087737,0.00035452546,0.00021689679],"category_scores_gemma":[0.00011964238,0.00019747727,0.00074141455,0.0008505533,0.00009769639,0.00010881796,0.000078076395,0.0003565511,0.00000466615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033037884,0.00097503944,0.6476865,0.00048029018,0.008114844,0.0005253351,0.0005813038,0.0006979005,0.0098406,0.0000049974756,0.02087805,0.30691135],"study_design_scores_gemma":[0.0071546035,0.0062810755,0.9300451,0.0004909436,0.014089715,0.00016742207,0.0001598354,0.0006096153,0.024925595,0.000044065164,0.01573978,0.0002922024],"about_ca_topic_score_codex":0.000068192545,"about_ca_topic_score_gemma":0.00062887644,"teacher_disagreement_score":0.30661917,"about_ca_system_score_codex":0.0039060495,"about_ca_system_score_gemma":0.0012678141,"threshold_uncertainty_score":0.9999178},"labels":[],"label_agreement":null},{"id":"W4388082881","doi":"10.1016/j.jtho.2023.09.103","title":"OA20.06 Quantification of Pathologically Assessed Lymph Node Area in Lung Cancer Resection Using Deep Learning","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Lymph node; Resection; Radiology; Lung; Pathology; Surgery; Internal medicine","score_opus":0.049478014994205864,"score_gpt":0.4589445164315564,"score_spread":0.4094665014373506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388082881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776119,0.00054209994,0.017727355,0.00311116,0.00053252775,0.00011045076,6.001842e-7,0.000023251405,0.00034064092],"genre_scores_gemma":[0.9925355,0.00074432284,0.006127765,0.00016395473,0.00026636536,0.000004415465,0.000007542285,0.000019580093,0.0001305969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980452,0.0004464943,0.0007685436,0.00016723866,0.00032750738,0.0002450247],"domain_scores_gemma":[0.99823993,0.00037311434,0.0008580037,0.00011554825,0.00030630917,0.00010706255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027914513,0.00010738761,0.00056353846,0.0005898433,0.00006775046,0.000013012278,0.00012288422,0.00019347106,0.000062800216],"category_scores_gemma":[0.0020796824,0.00008641141,0.00012051249,0.0006782521,0.00009259596,0.000106362946,0.000040942487,0.00087359943,0.0000025331967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009205977,0.00025576563,0.5501186,0.00033593518,0.00008729633,0.0008021734,0.0006124179,0.06995255,0.27870744,0.000022705079,0.00018949033,0.097995006],"study_design_scores_gemma":[0.0011408704,0.00039588704,0.53834325,0.0007753644,0.00022645923,0.0008037788,0.0006523734,0.45517322,0.0013203042,0.0001226772,0.0009390705,0.00010677912],"about_ca_topic_score_codex":0.000076108416,"about_ca_topic_score_gemma":0.000013207104,"teacher_disagreement_score":0.38522068,"about_ca_system_score_codex":0.00045603325,"about_ca_system_score_gemma":0.0003636835,"threshold_uncertainty_score":0.37954032},"labels":[],"label_agreement":null},{"id":"W4388084017","doi":"10.1016/j.jtho.2023.09.057","title":"OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Defence Medical Centre","funders":"","keywords":"Durvalumab; Medicine; Pemetrexed; Tremelimumab; Lung cancer; Epidermal growth factor receptor; Chemotherapy; Oncology; Tolerability; Internal medicine; Cisplatin; Pembrolizumab; Cancer; Immunotherapy; Adverse effect","score_opus":0.01720813783629397,"score_gpt":0.43329567382724554,"score_spread":0.41608753599095155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388084017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99115133,0.00081410474,0.000008535153,0.006537357,0.0004103677,0.00039008685,0.000003561571,0.000014658845,0.00066998054],"genre_scores_gemma":[0.9979206,0.00090055435,0.00069312577,0.00019434556,0.00013384793,0.0000065986374,0.000004931933,0.000021303405,0.00012473957],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99867815,0.00011333861,0.00057228503,0.00016998094,0.0002631891,0.00020304682],"domain_scores_gemma":[0.99905956,0.00023406102,0.0003760464,0.00011172846,0.000088560926,0.00013002005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006577648,0.00014017173,0.0005662134,0.00038414242,0.000064498294,0.000008450867,0.00005201525,0.00014036767,0.000017589196],"category_scores_gemma":[0.00014437866,0.00009905334,0.00009753616,0.0003419534,0.00009820825,0.00008933453,0.00003045427,0.00025915002,0.0000023458801],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070310505,0.00097274076,0.0277728,0.00017675046,0.000394335,0.0013169076,0.0059587,0.000029786599,0.013430433,0.000032720258,0.00030624907,0.94257754],"study_design_scores_gemma":[0.033025958,0.017934179,0.8912944,0.005443463,0.0012851058,0.0012830124,0.0056879446,0.00031444916,0.01697358,0.00042215656,0.02595336,0.00038235646],"about_ca_topic_score_codex":0.000015178902,"about_ca_topic_score_gemma":0.0000146774755,"teacher_disagreement_score":0.9421952,"about_ca_system_score_codex":0.00035973088,"about_ca_system_score_gemma":0.00030655568,"threshold_uncertainty_score":0.4039278},"labels":[],"label_agreement":null},{"id":"W4388084924","doi":"10.1016/j.jtho.2023.09.184","title":"MA10.06 CARMA-BROS: CAncers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Sunnybrook Health Science Centre","funders":"","keywords":"Observational study; Medicine; Real world data; Randomized controlled trial; Key (lock); Lung cancer; Intensive care medicine; Real world evidence; Data science; Oncology; Internal medicine; Computer science","score_opus":0.07094954310253289,"score_gpt":0.48963835149952933,"score_spread":0.41868880839699646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388084924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799213,0.00020762654,0.00018292373,0.01052315,0.0005138698,0.00062622386,0.00003594983,0.00004453026,0.00794445],"genre_scores_gemma":[0.9884008,0.000114293434,0.0028960195,0.0010053412,0.00039512102,0.00006645982,0.000084603766,0.00003269249,0.007004669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984741,0.0001485602,0.0005093146,0.00018803164,0.00043905553,0.00024091794],"domain_scores_gemma":[0.99850106,0.000140338,0.00038334407,0.00020350894,0.00053259725,0.00023917377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034255028,0.00015606536,0.00045495346,0.00038665262,0.0001503207,0.000024575445,0.00010989591,0.00006100247,0.00020347927],"category_scores_gemma":[0.00006439126,0.00011353678,0.00011358835,0.00077773863,0.00006092565,0.00014898238,0.000027489627,0.00029117338,0.000029156758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058217878,0.004377855,0.7011578,0.00041556184,0.008688606,0.023560937,0.013741901,0.030829139,0.008962777,0.0013832169,0.1457422,0.05531821],"study_design_scores_gemma":[0.00980791,0.013740484,0.7957339,0.0006004348,0.0060535264,0.0016980008,0.011426028,0.00090810034,0.0014214391,0.0005399953,0.15754138,0.0005287716],"about_ca_topic_score_codex":0.00028263207,"about_ca_topic_score_gemma":0.0008338927,"teacher_disagreement_score":0.09457612,"about_ca_system_score_codex":0.0011389853,"about_ca_system_score_gemma":0.002950382,"threshold_uncertainty_score":0.5233851},"labels":[],"label_agreement":null},{"id":"W4388085326","doi":"10.1016/j.jtho.2023.09.1414","title":"EP16.01-02 A Brief History of Lung Cancer in Canada: Care, Contributions and Challenges","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lung cancer; Family medicine; Intensive care medicine; Oncology","score_opus":0.02771504861242737,"score_gpt":0.42068840654527523,"score_spread":0.3929733579328479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388085326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77247494,0.19544475,0.00000917379,0.025125913,0.0015382401,0.00028388432,0.00010310874,0.000008976619,0.0050110295],"genre_scores_gemma":[0.9853679,0.01365642,0.00007196596,0.00019301978,0.00012072394,0.000014685012,0.000005030643,0.000008091328,0.00056216767],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99923575,0.000063809195,0.00032720508,0.00008230482,0.00014299803,0.00014794347],"domain_scores_gemma":[0.9991944,0.00012032907,0.0002561475,0.00007335982,0.00024445428,0.00011132027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017121683,0.00006832183,0.0003962547,0.00018593676,0.000018444118,0.0000010347451,0.000041155192,0.00006307836,0.000065098524],"category_scores_gemma":[0.00007269063,0.000055551543,0.000044589648,0.000109677705,0.000049886643,0.000044411616,0.000016956601,0.0001733132,3.8466123e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019237675,0.00054550165,0.11644778,0.0018802356,0.001936617,0.0043406473,0.02391595,0.00043670528,0.0016267872,0.00079053047,0.082795076,0.7633604],"study_design_scores_gemma":[0.0034127792,0.0009954105,0.52216184,0.0005872441,0.001310475,0.00044392742,0.00644839,0.0002155769,0.00022537363,0.000077328674,0.463994,0.00012765215],"about_ca_topic_score_codex":0.16518226,"about_ca_topic_score_gemma":0.57928514,"teacher_disagreement_score":0.76323277,"about_ca_system_score_codex":0.0069815773,"about_ca_system_score_gemma":0.0097889,"threshold_uncertainty_score":0.99683046},"labels":[],"label_agreement":null},{"id":"W4388086006","doi":"10.1016/j.jtho.2023.09.050","title":"OA07.05 Pre-Recruitment as a Strategy to Address “Near-Miss” Cases in Risk-Based Lung Cancer Screening Selection: An Analysis of ILST Data","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Selection (genetic algorithm); Lung cancer; Lung cancer screening; Cancer; Oncology; Intensive care medicine; Internal medicine; Artificial intelligence","score_opus":0.14681349070373162,"score_gpt":0.5369034721690236,"score_spread":0.39008998146529195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388086006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944897,0.0008194942,0.00014720186,0.003379329,0.00024453463,0.00062029256,0.00019139593,0.000020131587,0.00008787196],"genre_scores_gemma":[0.9963982,0.00046599068,0.0021626381,0.0003601045,0.00023368183,0.00010964576,0.00010668175,0.000021690292,0.00014132983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775493,0.0003656607,0.0007756282,0.00035103093,0.00044050853,0.00031224193],"domain_scores_gemma":[0.9978565,0.00036221548,0.00071323116,0.00043553233,0.00032098146,0.00031155316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011834323,0.00018171362,0.0009758565,0.0008881988,0.00008226161,0.000028393253,0.0002618496,0.00013264913,0.0004269359],"category_scores_gemma":[0.00022769217,0.00014409734,0.0001857833,0.0019538312,0.000048191698,0.00017115212,0.00007764918,0.00033076396,0.0000030157264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050575407,0.001637538,0.61962664,0.00017035705,0.004781678,0.0018309723,0.00080972514,0.16796575,0.0002984676,0.0000042719334,0.0065686023,0.19124845],"study_design_scores_gemma":[0.0032159244,0.013236824,0.87359047,0.0009805644,0.015943635,0.00025344055,0.0011046629,0.077543035,0.0035603018,0.000008092951,0.010294629,0.00026844017],"about_ca_topic_score_codex":0.005887689,"about_ca_topic_score_gemma":0.01552548,"teacher_disagreement_score":0.2539638,"about_ca_system_score_codex":0.0011317905,"about_ca_system_score_gemma":0.0014152144,"threshold_uncertainty_score":0.89004636},"labels":[],"label_agreement":null},{"id":"W4388086806","doi":"10.1016/j.jtho.2023.09.1368","title":"EP13.07-08 Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Conventional PCI; Radiation therapy; Immunotherapy; Magnetic resonance imaging; Oncology; Radiology; Internal medicine; Cancer","score_opus":0.05251884460915777,"score_gpt":0.4249657968331807,"score_spread":0.3724469522240229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388086806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98787004,0.0006128464,0.000029115596,0.010192741,0.0005664611,0.0004474172,0.00002893074,0.000016651067,0.0002358266],"genre_scores_gemma":[0.99222326,0.005045163,0.0017198705,0.0004653757,0.00016914202,0.000015003397,0.000024290935,0.00003246651,0.00030543984],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982603,0.00030112235,0.00058293226,0.00013611952,0.00038696584,0.0003325481],"domain_scores_gemma":[0.9973626,0.0007972846,0.0006391335,0.00020509269,0.0007815729,0.00021429455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009632094,0.00013307636,0.00052752526,0.0007283024,0.00012921459,0.000019584908,0.000121245306,0.00011077347,0.0002109038],"category_scores_gemma":[0.0006665881,0.000096588534,0.00010019619,0.0006198046,0.00017774687,0.00017762808,0.00002012987,0.00040169843,0.0000137731],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002174759,0.0001486491,0.4813075,0.000033431304,0.0006421336,0.00008498762,0.0012116625,0.000069268004,0.00018432805,0.0000046155787,0.026967527,0.48717114],"study_design_scores_gemma":[0.0026504907,0.0030036627,0.9074612,0.0003129577,0.00007049339,0.00004738619,0.00033708767,0.00006021172,0.0002996508,0.000044615215,0.08561379,0.000098434684],"about_ca_topic_score_codex":0.004695266,"about_ca_topic_score_gemma":0.008260102,"teacher_disagreement_score":0.4870727,"about_ca_system_score_codex":0.0009964608,"about_ca_system_score_gemma":0.001428882,"threshold_uncertainty_score":0.7097869},"labels":[],"label_agreement":null},{"id":"W4388087864","doi":"10.1016/j.jtho.2023.09.1258","title":"EP12.01-42 Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Tyrosine kinase; Cohort; Oncology; Lung cancer; Internal medicine; Term (time); Cohort study; Receptor","score_opus":0.010391728192855738,"score_gpt":0.3569277036322689,"score_spread":0.34653597543941317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388087864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98942226,0.0005074694,0.000070736394,0.0047244984,0.00039467303,0.0009223438,0.00008382069,0.000034950113,0.0038392625],"genre_scores_gemma":[0.9948808,0.00021733828,0.00047201273,0.00050898985,0.00033242686,0.00007491953,0.00013609027,0.00006269426,0.00331471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834794,0.00011083425,0.00046101087,0.00027088093,0.00030162052,0.0005076987],"domain_scores_gemma":[0.99792445,0.0001087912,0.00047476793,0.00021181825,0.00062089745,0.0006592692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027410054,0.00028375583,0.0007404887,0.0005859379,0.00016537443,0.00003232219,0.000119360855,0.00017459532,0.000117688054],"category_scores_gemma":[0.000016327804,0.00018617707,0.000112182715,0.00079532544,0.00012325989,0.00013570872,0.000020223746,0.0004041482,0.000013775685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032447532,0.00049144117,0.9725373,0.00015574155,0.0013938725,0.011151754,0.0011182248,0.00018635236,0.0007712269,0.000003928638,0.0029357548,0.0060096825],"study_design_scores_gemma":[0.0060050273,0.008105918,0.971811,0.0012389893,0.004669427,0.001066324,0.0006456091,0.00016483424,0.0050545386,0.0000029586224,0.0009357487,0.00029965307],"about_ca_topic_score_codex":0.036829907,"about_ca_topic_score_gemma":0.16351907,"teacher_disagreement_score":0.12668917,"about_ca_system_score_codex":0.002178017,"about_ca_system_score_gemma":0.0035578911,"threshold_uncertainty_score":0.9695839},"labels":[],"label_agreement":null},{"id":"W4388089347","doi":"10.1016/j.jtho.2023.09.029","title":"OA02.04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Mesothelioma; Oncology; Internal medicine; Pathology; Immunotherapy; Cancer","score_opus":0.037208090002457006,"score_gpt":0.44261272126127515,"score_spread":0.40540463125881815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388089347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280804,0.0004037026,0.00027485692,0.003959177,0.00054411025,0.0014726414,0.00012259246,0.00002312848,0.00039175042],"genre_scores_gemma":[0.99609226,0.00014433808,0.0020680022,0.00040206645,0.0005306089,0.000053083208,0.00007701466,0.000029558563,0.0006030685],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977288,0.0002564038,0.0010842622,0.00020575241,0.00043821812,0.0002865258],"domain_scores_gemma":[0.9977503,0.00090267946,0.0006462905,0.0001647547,0.00018239566,0.00035359827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010004658,0.00020824811,0.0015590991,0.00048688333,0.00007303252,0.000012355496,0.00013374546,0.00012430722,0.00016600004],"category_scores_gemma":[0.00057201897,0.00015345972,0.00042889704,0.00028054175,0.00023387479,0.00010438442,0.00006223107,0.00016481325,0.000015670534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.962777,0.0011745122,0.00016249092,0.0001798136,0.00038551673,0.0001642109,0.00025168216,0.00008443847,0.0061646383,0.00006182754,0.0046647796,0.0239291],"study_design_scores_gemma":[0.9646885,0.012618973,0.0058448175,0.0001603618,0.0015583456,0.00084796443,0.00026751106,0.0016324214,0.001540169,0.000939539,0.009717217,0.0001842251],"about_ca_topic_score_codex":0.000011296266,"about_ca_topic_score_gemma":0.000004002568,"teacher_disagreement_score":0.023744876,"about_ca_system_score_codex":0.00017111222,"about_ca_system_score_gemma":0.00029707435,"threshold_uncertainty_score":0.6257906},"labels":[],"label_agreement":null},{"id":"W4388089682","doi":"10.1016/j.jtho.2023.09.036","title":"OA04.03 Australian Registry and Biobank of Thoracic Cancers (AURORA) - A Multi-Site Research Platform and Longitudinal Cohort Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Richmond Hospital","funders":"","keywords":"Biobank; Medicine; Cohort; Cohort study; Oncology; Internal medicine; Bioinformatics","score_opus":0.14110587915907563,"score_gpt":0.5260127781645711,"score_spread":0.3849068990054955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388089682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940607,0.0010842882,0.0000029525481,0.0033565792,0.0004339451,0.00072756526,0.000028042721,0.000016728041,0.00028921093],"genre_scores_gemma":[0.99558276,0.0020841858,0.00093828683,0.0000453987,0.0003006421,0.000036841207,0.000007444621,0.000025351523,0.0009790999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766994,0.0002250588,0.00068837515,0.00035529872,0.0006357619,0.00042556698],"domain_scores_gemma":[0.9979889,0.00035342184,0.0005035699,0.00032098187,0.00048844254,0.00034472768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027671459,0.00019736243,0.00090091926,0.000572891,0.00013965004,0.000031219035,0.0001369367,0.00018943963,0.000053838983],"category_scores_gemma":[0.00021617748,0.00014729759,0.00010823559,0.0006323025,0.00038101827,0.00014718279,0.0001358633,0.00067015266,0.000014075681],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002098517,0.00081364013,0.95671636,0.00036450478,0.00076864514,0.0026698306,0.0011812437,0.0000100455445,0.0004556918,0.000006073329,0.0074168304,0.02749864],"study_design_scores_gemma":[0.0018278366,0.0073300414,0.9794146,0.00051827694,0.00088572985,0.0011208508,0.003244811,0.000047349586,0.0008858929,0.00004526366,0.0045583164,0.000121057834],"about_ca_topic_score_codex":0.000713213,"about_ca_topic_score_gemma":0.00088996434,"teacher_disagreement_score":0.027377583,"about_ca_system_score_codex":0.0010540022,"about_ca_system_score_gemma":0.0007340469,"threshold_uncertainty_score":0.6006621},"labels":[],"label_agreement":null},{"id":"W4388092012","doi":"10.1016/j.jtho.2023.09.232","title":"MA16.06 Real-world Survival with CRT+durvalumab for Unresectable, Stage III NSCLC in Canada: the RELEVANCE Study","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Chemoradiotherapy; Stage (stratigraphy); Internal medicine; Retrospective cohort study; Observational study; Overall survival; Population; Oncology; Cancer; Nivolumab","score_opus":0.03726675609655791,"score_gpt":0.4474466065650997,"score_spread":0.4101798504685418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388092012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464304,0.00019047176,0.00008484003,0.008196409,0.0007066072,0.001131621,0.000032928237,0.000014002863,0.005000053],"genre_scores_gemma":[0.98597205,0.00013616709,0.00045911002,0.0002574756,0.00026047134,0.000080323516,0.000010846015,0.0000272523,0.012796324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983551,0.00020348874,0.0005270313,0.00017091578,0.00040680828,0.00033664762],"domain_scores_gemma":[0.9981282,0.0008102238,0.00040935085,0.00023234809,0.0002988659,0.00012106194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010365006,0.00013919835,0.00056627794,0.00023032055,0.0001239207,0.000012892211,0.00016484108,0.000040401726,0.0000465748],"category_scores_gemma":[0.0001529945,0.00007930461,0.00006465107,0.00071632315,0.000046601188,0.00008670716,0.000031772794,0.0003463226,0.000003131794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023812354,0.0027565754,0.7831953,0.00035422677,0.0031390183,0.009891934,0.008266113,0.0059452197,0.00030484097,0.0005238518,0.055455077,0.10635546],"study_design_scores_gemma":[0.011357064,0.0068610576,0.8665654,0.0002719486,0.0012468911,0.00021213976,0.026385173,0.00038644086,0.00010255885,0.000159379,0.08624431,0.00020763482],"about_ca_topic_score_codex":0.25950354,"about_ca_topic_score_gemma":0.9455598,"teacher_disagreement_score":0.68605626,"about_ca_system_score_codex":0.0023515671,"about_ca_system_score_gemma":0.006887269,"threshold_uncertainty_score":0.99874276},"labels":[],"label_agreement":null},{"id":"W4388751886","doi":"10.1016/j.jtho.2023.11.013","title":"Perspective on Management of Low-Dose Computed Tomography Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening. From the International Association for the Study of Lung Cancer Early Detection and Screening Committee","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"International Association for the Study of Lung Cancer; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer screening; Lung cancer; Intensive care medicine; Regimen; Cancer; Radiation treatment planning; Computed tomography; Medical physics; Radiology; Oncology; Radiation therapy; Internal medicine","score_opus":0.0262822230873918,"score_gpt":0.3973777489302208,"score_spread":0.371095525842829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388751886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98604316,0.00079863926,0.002516123,0.007198946,0.0009770705,0.0022105398,0.00019318599,0.000018720295,0.00004363117],"genre_scores_gemma":[0.9977475,0.00026775105,0.0009279456,0.00024757034,0.00035300927,0.00037324248,0.000017239785,0.000022583652,0.00004316714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832684,0.0001555948,0.000544343,0.000246766,0.00052780926,0.00019865907],"domain_scores_gemma":[0.9956098,0.0023400201,0.0009521757,0.00016630464,0.00087211764,0.000059563787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090896623,0.00017693573,0.0004771329,0.00045988345,0.00024870384,0.000034093096,0.00021794673,0.00009834524,0.000010481304],"category_scores_gemma":[0.000074361444,0.000116797964,0.00027097279,0.00060945813,0.000059890008,0.00008851779,0.00006707207,0.00027501083,9.861866e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012201878,0.0040015527,0.7518206,0.0004076463,0.024773097,0.0000380819,0.013819416,0.009514703,0.0005916174,0.00023610481,0.009679996,0.17291528],"study_design_scores_gemma":[0.0060522025,0.003297098,0.9589179,0.0012723528,0.0024952064,0.0000026137288,0.0049200593,0.021785753,0.000889923,0.000053727454,0.00021443302,0.000098697434],"about_ca_topic_score_codex":0.00083837623,"about_ca_topic_score_gemma":0.0007098169,"teacher_disagreement_score":0.2070973,"about_ca_system_score_codex":0.0010127312,"about_ca_system_score_gemma":0.00007195351,"threshold_uncertainty_score":0.47628826},"labels":[],"label_agreement":null},{"id":"W4389091914","doi":"10.1016/j.jtho.2023.11.014","title":"Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Lung Foundation Australia; Eli Lilly and Company","keywords":"Medicine; Nivolumab; Ipilimumab; Mesothelioma; Internal medicine; Common Terminology Criteria for Adverse Events; Regimen; Surgery; Oncology; Adverse effect; Immunotherapy; Cancer; Pathology","score_opus":0.02709821514766123,"score_gpt":0.40735124332229766,"score_spread":0.3802530281746364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389091914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953028,0.00021658315,0.000008723324,0.0024485858,0.00025296505,0.00010608702,0.000008004648,0.000008731399,0.0016474961],"genre_scores_gemma":[0.9981006,0.0005031977,0.0002338827,0.000122043064,0.00007201209,0.0000020974235,0.000018250483,0.000010143466,0.00093778444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998799,0.00012214803,0.00058707653,0.000097083175,0.00027623473,0.00011843795],"domain_scores_gemma":[0.9991204,0.0001847014,0.00046068188,0.00009589966,0.000060020553,0.000078277764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007599064,0.000079511374,0.00041102822,0.00042185045,0.000023678334,0.000004041632,0.000054759847,0.000061695806,0.000085947504],"category_scores_gemma":[0.00009829843,0.00006457546,0.00008547117,0.0003592269,0.00010778232,0.00009199854,0.00002983582,0.00014310979,0.000003625155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003482716,0.0009582945,0.9297833,0.000098007644,0.00011102007,0.0015311708,0.00024408812,0.000028241879,0.025639879,0.0002124254,0.00073455716,0.03717632],"study_design_scores_gemma":[0.0013026666,0.0009496994,0.9921483,0.0000758592,0.00005261674,0.00048265734,0.00014566154,0.000087330336,0.0017071486,0.0010155927,0.0019794574,0.00005300958],"about_ca_topic_score_codex":0.00007645164,"about_ca_topic_score_gemma":0.0000858086,"teacher_disagreement_score":0.062365018,"about_ca_system_score_codex":0.00017834625,"about_ca_system_score_gemma":0.00012293515,"threshold_uncertainty_score":0.26333112},"labels":[],"label_agreement":null},{"id":"W4389454770","doi":"10.1016/j.jtho.2023.12.006","title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Arthrex GmbH; Samsung; National Institutes of Health; Lilly Deutschland; Shanghai Chest Hospital; AIO-Studien; Tokyo Women's Medical University; Peking University; Università degli Studi di Torino; Medizinische Universität Wien; Universitätsspital Zürich; Universidade de São Paulo; Hyogo College of Medicine; Shanghai Jiao Tong University; Sichuan University; Universiteit Gent; Seoul National University Hospital; Gazi Üniversitesi; Universität Wien; Istanbul Üniversitesi-Cerrahpasa; AstraZeneca; International Association for the Study of Lung Cancer; University of Aberdeen; Mount Sinai Health System; University of Toronto; Imperial College London; Bristol-Myers Squibb; Université Laval; Universitair Ziekenhuis Antwerpen; Technische Universität München; Ankara Universitesi; Aix-Marseille Université; York University; Cleveland Clinic; Universidad de Navarra; Postgraduate Institute of Medical Education and Research, Chandigarh; University of Leicester; University of Chicago; Universitair Ziekenhuis Gent; NYU Langone Medical Center; Boehringer Ingelheim; Ohio State University; Massachusetts General Hospital; Queen's University; University of Ulsan; University of Texas Southwestern Medical Center; Seoul National University; Yale University; Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company; Celgene","keywords":"Medicine; Lung cancer; Ninth; Univariate analysis; Proportional hazards model; Cancer; Internal medicine; Lung; Oncology; Radiology; Multivariate analysis","score_opus":0.06101873963389433,"score_gpt":0.49172908936091125,"score_spread":0.43071034972701694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389454770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7915624,0.0061334874,0.0008315562,0.17868342,0.0072629126,0.0149970725,0.00043377638,0.000010895663,0.000084498395],"genre_scores_gemma":[0.99115855,0.0029631283,0.00007597718,0.0003366577,0.0009884074,0.004147032,0.000006063823,0.000025267775,0.00029893455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975176,0.00034991556,0.0009899139,0.00018241756,0.000693264,0.00026691213],"domain_scores_gemma":[0.99182934,0.0042574694,0.0024448521,0.00034859474,0.0010969982,0.00002274352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041566594,0.00015774756,0.00044316184,0.00011339932,0.0005151292,0.000035487992,0.000648661,0.00009894599,0.000011653005],"category_scores_gemma":[0.0010551222,0.00005720636,0.0003722093,0.00050070137,0.00010762662,0.0001215069,0.0000843884,0.00033793098,2.612009e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028036009,0.0012186037,0.74491984,0.0010455716,0.0045457836,0.000001260311,0.021893395,0.0039817924,0.0019332737,0.0008425977,0.13125423,0.08556007],"study_design_scores_gemma":[0.0072656437,0.0018009141,0.7882509,0.0041416045,0.01067171,0.000013119656,0.04092108,0.1100505,0.005258236,0.0004464697,0.030936562,0.00024325939],"about_ca_topic_score_codex":0.00085921295,"about_ca_topic_score_gemma":0.004663246,"teacher_disagreement_score":0.19959615,"about_ca_system_score_codex":0.0023051852,"about_ca_system_score_gemma":0.0014064995,"threshold_uncertainty_score":0.6027979},"labels":[],"label_agreement":null},{"id":"W4390233924","doi":"10.1016/j.jtho.2023.12.019","title":"Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Brigham and Women's Hospital","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.1175471607756235,"score_gpt":0.4995437960313276,"score_spread":0.3819966352557041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390233924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908494,0.0017041797,0.00023852568,0.0064179064,0.00024069232,0.00020192648,0.0000044525236,0.000008779069,0.00033418843],"genre_scores_gemma":[0.99573374,0.0011578588,0.002381397,0.00012655671,0.00017677846,0.0000068153176,0.0000013789813,0.000013462715,0.00040203342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984749,0.00026922446,0.0005692209,0.00012569485,0.00034487018,0.00021609287],"domain_scores_gemma":[0.998707,0.00043941342,0.00035433492,0.0001358391,0.00026585712,0.000097566786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025857938,0.00007333527,0.00037720904,0.00039658343,0.000023990728,0.000005776755,0.00013670178,0.00011997427,0.00008841545],"category_scores_gemma":[0.00057396386,0.000059166865,0.00004670106,0.00045248045,0.00011889488,0.00005459976,0.000048577003,0.0004503523,0.000012778438],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022177557,0.00036378021,0.19252247,0.0015515883,0.0001157937,0.00036397303,0.0020200484,0.00009482312,0.12095847,0.00020761267,0.002808324,0.67677534],"study_design_scores_gemma":[0.0010035242,0.0019490313,0.97917503,0.00067311176,0.0000975778,0.0003628668,0.0005820303,0.00044817076,0.008912178,0.0017063227,0.005002045,0.00008810234],"about_ca_topic_score_codex":0.00003133106,"about_ca_topic_score_gemma":0.0000102761505,"teacher_disagreement_score":0.78665257,"about_ca_system_score_codex":0.00023612202,"about_ca_system_score_gemma":0.00049962563,"threshold_uncertainty_score":0.24127547},"labels":[],"label_agreement":null},{"id":"W4390372702","doi":"10.1016/j.jtho.2023.12.023","title":"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Eisai","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Placebo; Adverse effect; Oncology; Randomized controlled trial; Nivolumab; Gastroenterology; Immunotherapy; Cancer; Pathology","score_opus":0.09940783536830322,"score_gpt":0.4412411812161992,"score_spread":0.341833345847896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390372702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98736197,0.00038028613,0.00245589,0.0019313127,0.0003865913,0.0072920634,0.000025049163,0.000040274826,0.00012655686],"genre_scores_gemma":[0.99003655,0.00020283426,0.0067249876,0.00014831583,0.00048679762,0.0006250451,0.000065393346,0.000075244985,0.0016348269],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966384,0.00023275753,0.0016586753,0.00031969443,0.0006788002,0.00047164602],"domain_scores_gemma":[0.99537617,0.00055344,0.0027717105,0.00026139358,0.00081005396,0.00022720477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028481458,0.0003540041,0.0022300777,0.0005083963,0.00014434294,0.000026590225,0.00018204108,0.00013881388,0.00009892907],"category_scores_gemma":[0.00021157657,0.00018634654,0.00047717214,0.0007007689,0.00042862844,0.00016885975,0.000031350504,0.0003594536,0.000003498507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9630945,0.0023484514,0.00040462738,0.000994362,0.0014739922,0.00060240226,0.0006512986,0.000041545543,0.0037026843,0.0000044906637,0.00038165273,0.026300024],"study_design_scores_gemma":[0.90559393,0.061641354,0.000051427713,0.00081775215,0.0034723186,0.0034070348,0.00052728225,0.0005129936,0.020845702,0.000026280624,0.0028780021,0.00022589219],"about_ca_topic_score_codex":0.000039841598,"about_ca_topic_score_gemma":0.00035528681,"teacher_disagreement_score":0.059292905,"about_ca_system_score_codex":0.00034642348,"about_ca_system_score_gemma":0.001963886,"threshold_uncertainty_score":0.75989914},"labels":[],"label_agreement":null},{"id":"W4391180278","doi":"10.1016/j.jtho.2024.01.012","title":"Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute on Aging; University of California, Irvine; EMD Serono; Genentech; European Society for Medical Oncology; G1 Therapeutics; Seagen; Relay Therapeutics; University of California, San Francisco; NGM Biopharmaceuticals; Cancer Research Institute; AstraZeneca; Novocure; ViewRay; Celldex Therapeutics; Ipsen; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; International Association for the Study of Lung Cancer; Mirati Therapeutics; Association of American Medical Colleges; GlaxoSmithKline; Pfizer; American Association for Cancer Research; Amgen; American Society of Clinical Oncology; Eli Lilly and Company; Bristol-Myers Squibb; Hope Foundation; Sociedad Española de Oncología Médica; Society for Immunotherapy of Cancer; LUNGevity Foundation; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Conquer Cancer Foundation; Sanofi","keywords":"Durvalumab; Medicine; Osimertinib; Common Terminology Criteria for Adverse Events; Retrospective cohort study; Clinical endpoint; Internal medicine; Oncology; Proportional hazards model; Hazard ratio; Cohort; Adverse effect; Confidence interval; Adenocarcinoma; Cancer; Randomized controlled trial; Nivolumab","score_opus":0.035401231696182124,"score_gpt":0.45020228678219587,"score_spread":0.4148010550860137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391180278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990373,0.0009455103,0.00014562036,0.0015784227,0.004685189,0.0011034303,0.000016292286,0.00002511653,0.0011274106],"genre_scores_gemma":[0.99875826,0.00010732281,0.00034756938,0.000071859075,0.00039493464,0.000108785214,0.00003656073,0.000022848839,0.00015188458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998206,0.00020073466,0.00069126894,0.0002633377,0.00041468817,0.00022397874],"domain_scores_gemma":[0.9987245,0.00026428452,0.00032756533,0.00014914993,0.0004230742,0.000111421556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007103253,0.00016628492,0.00050818076,0.00034198753,0.00004794634,0.00004920541,0.00006735997,0.00012001476,0.00022982278],"category_scores_gemma":[0.00035714102,0.0001352965,0.000120925084,0.00043214083,0.000046861118,0.00037096895,0.000024728013,0.00041183687,0.000028696288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050125737,0.0043091783,0.83301276,0.00021064807,0.003185932,0.0021745185,0.009140204,0.00020934353,0.0019830689,0.000105750376,0.0010257355,0.0945171],"study_design_scores_gemma":[0.017598534,0.008300828,0.95982426,0.00037795314,0.002768449,0.00008570696,0.002243822,0.0031654078,0.0008895281,0.00003058633,0.0045367163,0.00017820689],"about_ca_topic_score_codex":0.0000891222,"about_ca_topic_score_gemma":0.00021928913,"teacher_disagreement_score":0.12681147,"about_ca_system_score_codex":0.0037535245,"about_ca_system_score_gemma":0.0008396634,"threshold_uncertainty_score":0.9815336},"labels":[],"label_agreement":null},{"id":"W4391520930","doi":"10.1016/j.jtho.2024.01.019","title":"The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Arthrex GmbH; Hyogo College of Medicine; Technische Universität München; National Cancer Institute; University of Toronto; Universidade de São Paulo; Seoul National University; National Institutes of Health; Ohio State University; University of Leicester; Instituto Nacional do Câncer, Ministério da Saúde; National Health and Medical Research Council; Aix-Marseille Université; Université Hassan II de Casablanca; Memorial Sloan-Kettering Cancer Center; International Association for the Study of Lung Cancer; Yale University; AstraZeneca; Shanghai Chest Hospital; Mount Sinai Health System; Ankara Universitesi; Boehringer Ingelheim","keywords":"Medicine; Ninth; Lung cancer; Lung cancer staging; Oncology; Medical physics; Internal medicine; Radiology; General surgery","score_opus":0.04901646013149777,"score_gpt":0.4822981308164227,"score_spread":0.43328167068492496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391520930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72193545,0.029729506,0.008610243,0.19537328,0.013710872,0.029812748,0.0007473492,0.0000147727,0.00006575838],"genre_scores_gemma":[0.99084926,0.003040419,0.000246309,0.0002768394,0.00133497,0.0039958707,0.0000067258775,0.00002995876,0.00021963345],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99764335,0.00029105155,0.0010008585,0.00020897183,0.00060593686,0.00024981514],"domain_scores_gemma":[0.99188244,0.0048551243,0.0018940964,0.00029621518,0.0010518384,0.00002025452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044336333,0.00017017976,0.0004527606,0.00010403376,0.00042125615,0.00005644428,0.00056957244,0.000105563224,0.000006801062],"category_scores_gemma":[0.0008061043,0.00006151795,0.00044948191,0.00031941623,0.000091196445,0.00014998441,0.00005953002,0.00031093368,1.0420005e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007690441,0.001741677,0.4299102,0.004275256,0.008154149,0.0000015961501,0.029603036,0.004182298,0.0026503655,0.0019635619,0.16585463,0.34397277],"study_design_scores_gemma":[0.013484802,0.005739523,0.2150015,0.014381313,0.027621798,0.0000355236,0.04627876,0.50404584,0.019489907,0.0010137052,0.15241309,0.00049424503],"about_ca_topic_score_codex":0.0006073677,"about_ca_topic_score_gemma":0.0032521938,"teacher_disagreement_score":0.49986356,"about_ca_system_score_codex":0.0029570747,"about_ca_system_score_gemma":0.0015586157,"threshold_uncertainty_score":0.77326477},"labels":[],"label_agreement":null},{"id":"W4391671405","doi":"10.1016/j.jtho.2024.01.018","title":"The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Medical Research Council; University of Texas MD Anderson Cancer Center; Samsung; Genentech; National Institutes of Health; Centro de Investigación Biomédica en Red de Cáncer; Tokyo Women's Medical University; Universitätsspital Zürich; Postgraduate Institute of Medical Education and Research, Chandigarh; Universidad de Navarra; Medizinische Universität Wien; National and Kapodistrian University of Athens; Universiteit Gent; Universiteit Antwerpen; Queen's University; DeGregorio Family Foundation; Universitair Ziekenhuis Gent; Universität Wien; National Health and Medical Research Council; AstraZeneca; Universidade de São Paulo; University of Toronto; Seoul National University; International Association for the Study of Lung Cancer; University of Aberdeen; Cancer Research UK; York University; University of Chicago; Memorial Sloan-Kettering Cancer Center; Istanbul Üniversitesi-Cerrahpasa; Imperial College London","keywords":"Medicine; Mesothelioma; Ninth; Stage (stratigraphy); Lung cancer; Lung cancer staging; Internal medicine; Oncology; General surgery; Pathology","score_opus":0.05008928426726776,"score_gpt":0.46859865282777124,"score_spread":0.41850936856050347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391671405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768597,0.00060642295,0.000109123306,0.020027239,0.00083262526,0.0011759538,0.00020829203,0.0000035659366,0.00017706973],"genre_scores_gemma":[0.9989272,0.00017499168,0.00008142676,0.00021463414,0.00028998105,0.00009785946,0.000017647259,0.000008947175,0.00018735153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981288,0.00020213127,0.00073258945,0.00009936485,0.0007198324,0.00011731147],"domain_scores_gemma":[0.9974095,0.0013677529,0.0007641401,0.00019568998,0.00023596395,0.000026939246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001806249,0.00009153722,0.00023287114,0.00018327168,0.0001221042,0.000021004282,0.0003617173,0.0000453778,0.00003252494],"category_scores_gemma":[0.0006621588,0.000039242983,0.00015100927,0.0004139509,0.00007303932,0.00017046777,0.00007604811,0.00022095714,4.842216e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013871294,0.004141232,0.67350733,0.0009910604,0.0026502472,0.000026448755,0.029940573,0.0018571768,0.056733716,0.0021758454,0.05853886,0.15556619],"study_design_scores_gemma":[0.0010789229,0.0011730511,0.9646118,0.00062422716,0.0008568838,0.000037394308,0.015050465,0.0060051647,0.0018742321,0.0001562974,0.008460131,0.000071422335],"about_ca_topic_score_codex":0.00009035568,"about_ca_topic_score_gemma":0.00018781502,"teacher_disagreement_score":0.29110444,"about_ca_system_score_codex":0.00049165613,"about_ca_system_score_gemma":0.00034215653,"threshold_uncertainty_score":0.16002823},"labels":[],"label_agreement":null},{"id":"W4392368785","doi":"10.1016/j.jtho.2024.02.011","title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":325,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Sun Yat-sen University Cancer Center; Boehringer Ingelheim; Centro de Investigación Médica Aplicada, Universidad de Navarra; University of Sydney; University of Colorado Colorado Springs; National Cancer Institute; Arthrex GmbH; AIO-Studien; Instituto Nacional do Câncer, Ministério da Saúde; Shanghai Chest Hospital; Peking University; AstraZeneca; Institut National Du Cancer; All-India Institute of Medical Sciences; Technische Universität München; Shanghai Jiao Tong University; University of Queensland; Instituto Nacional de Cancerología; Seoul National University Bundang Hospital; Columbus State University; Université Laval; International Association for the Study of Lung Cancer; Massachusetts General Hospital; Guangdong Provincial People's Hospital; Icahn School of Medicine at Mount Sinai","keywords":"Medicine; Ninth; Lung cancer; Stage (stratigraphy); Lung cancer staging; Lung; TNM staging system; Oncology; Internal medicine; Cancer; Neoplasm staging","score_opus":0.04133279433252079,"score_gpt":0.48126900068855855,"score_spread":0.43993620635603775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392368785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8832099,0.012418584,0.002211107,0.08219099,0.0065591983,0.01279876,0.00051383977,0.0000096030335,0.00008804269],"genre_scores_gemma":[0.9938256,0.0023030897,0.00016816119,0.00022407975,0.0011026262,0.002010536,0.00000763762,0.00002775208,0.0003305028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975019,0.00031799125,0.0010446087,0.00021408613,0.0006845014,0.00023687675],"domain_scores_gemma":[0.9939751,0.0027709075,0.0019900508,0.00028509658,0.0009563909,0.00002247169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037749936,0.00016544411,0.00047048103,0.00012324775,0.00028038232,0.00004825017,0.0004807241,0.00011260751,0.00001387243],"category_scores_gemma":[0.00055020256,0.000066744586,0.0003663878,0.00034368224,0.000078009274,0.00017050737,0.000068709975,0.0003511707,1.843929e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060922992,0.0023036238,0.642332,0.0052256742,0.006389456,0.0000046130367,0.03209848,0.003293823,0.0038639272,0.0024787511,0.07777062,0.21814671],"study_design_scores_gemma":[0.014642183,0.0054399087,0.47097936,0.01772378,0.020433227,0.000037747828,0.045913514,0.29389822,0.019365665,0.0009275403,0.11006816,0.00057068875],"about_ca_topic_score_codex":0.0006293125,"about_ca_topic_score_gemma":0.003454427,"teacher_disagreement_score":0.2906044,"about_ca_system_score_codex":0.0031509118,"about_ca_system_score_gemma":0.0014278997,"threshold_uncertainty_score":0.8239525},"labels":[],"label_agreement":null},{"id":"W4392931790","doi":"10.1016/j.jtho.2024.03.015","title":"The International Association for the Study of Lung Cancer (IASLC) Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Sun Yat-sen University Cancer Center; University of Sydney; University of Colorado Colorado Springs; National Cancer Institute; Arthrex GmbH; Instituto Nacional do Câncer, Ministério da Saúde; Shanghai Chest Hospital; Peking University; All-India Institute of Medical Sciences; Technische Universität München; Shanghai Jiao Tong University; University of Queensland; Instituto Nacional de Cancerología; Chartered Institute of Management Accountants; Seoul National University Bundang Hospital; Columbus State University; Université Laval; Massachusetts General Hospital; Institut National Du Cancer; Memorial Sloan-Kettering Cancer Center; International Association for the Study of Lung Cancer; Guangdong Provincial People's Hospital; Icahn School of Medicine at Mount Sinai; B.P. Koirala Institute of Health Sciences; Boehringer Ingelheim","keywords":"Medicine; Lung cancer; Lymphovascular invasion; Adenocarcinoma; Stage (stratigraphy); Univariate analysis; Cancer; Oncology; Internal medicine; Radiology; Pathology; Multivariate analysis; Metastasis","score_opus":0.053307338811694305,"score_gpt":0.4766270188299929,"score_spread":0.4233196800182986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392931790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9265303,0.004547333,0.0016408744,0.06105796,0.0025614633,0.0032260944,0.00034779377,0.0000068545332,0.0000813509],"genre_scores_gemma":[0.9949472,0.0026194458,0.00030765595,0.00026416077,0.00042647883,0.001261883,0.00002280785,0.00001420442,0.00013617343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974497,0.0005131576,0.0010583871,0.00025482287,0.0005247133,0.0001992153],"domain_scores_gemma":[0.9945115,0.0019711573,0.0022782462,0.00026257883,0.0009542845,0.000022258218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030576573,0.00016330543,0.00066903536,0.0003030762,0.00013933143,0.000025531996,0.0003717155,0.00010838631,0.000035394285],"category_scores_gemma":[0.0007423755,0.00007777544,0.00032639256,0.0008913052,0.000081881044,0.000167095,0.00005533288,0.00028315105,3.464629e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061755935,0.0027603165,0.78925234,0.0012926433,0.013591551,0.000008824367,0.04504785,0.009563643,0.0055871285,0.0009204311,0.04083606,0.08496363],"study_design_scores_gemma":[0.005213416,0.0071738,0.7849293,0.0026561317,0.036832567,0.000020011066,0.048278004,0.07685509,0.01123869,0.0002750174,0.026167119,0.00036086192],"about_ca_topic_score_codex":0.0029065562,"about_ca_topic_score_gemma":0.007667231,"teacher_disagreement_score":0.084602766,"about_ca_system_score_codex":0.0040087285,"about_ca_system_score_gemma":0.0009997913,"threshold_uncertainty_score":0.9998147},"labels":[],"label_agreement":null},{"id":"W4393028916","doi":"10.1016/j.jtho.2024.03.007","title":"The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the “T” Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"Medical Research Council; National Cancer Institute; National Institutes of Health; National Health and Medical Research Council; International Association for the Study of Lung Cancer; AstraZeneca","keywords":"Medicine; Ninth; Mesothelioma; Lung cancer; Oncology; Lung cancer staging; Internal medicine; General surgery; Pathology","score_opus":0.04901031727455116,"score_gpt":0.4572199415845698,"score_spread":0.4082096243100186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393028916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642042,0.0012088063,0.0007693469,0.027619667,0.0017704823,0.0040968983,0.00025968775,0.000004115991,0.00006678062],"genre_scores_gemma":[0.9984806,0.00012223041,0.00021645435,0.00014944389,0.00039929064,0.00039042096,0.000007354409,0.000014266692,0.0002199277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824095,0.00023960652,0.0007435325,0.000112673304,0.0005301412,0.00013311765],"domain_scores_gemma":[0.99606687,0.002362218,0.001063242,0.00017427788,0.00031706112,0.000016330807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024149688,0.0000975369,0.00024927346,0.000113031485,0.0002161016,0.00002357662,0.00040035066,0.000060685805,0.000007637426],"category_scores_gemma":[0.0009781721,0.00003752871,0.00030343904,0.0002580614,0.00010355357,0.000116217256,0.00004899385,0.0001777116,6.057795e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013587035,0.004156539,0.65874887,0.0023368665,0.0039158594,0.000003862969,0.022022216,0.0014323926,0.057648562,0.0058193197,0.055741154,0.17458735],"study_design_scores_gemma":[0.0030229625,0.0027581886,0.8913603,0.0018272587,0.0035776962,0.000044141452,0.028284919,0.033788208,0.009382031,0.0029176124,0.022877207,0.0001595044],"about_ca_topic_score_codex":0.000041232313,"about_ca_topic_score_gemma":0.00014114083,"teacher_disagreement_score":0.23261143,"about_ca_system_score_codex":0.0005140616,"about_ca_system_score_gemma":0.0004246132,"threshold_uncertainty_score":0.16621007},"labels":[],"label_agreement":null},{"id":"W4393385810","doi":"10.1016/j.jtho.2024.03.021","title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; University of Leicester; Samsung; Centro de Investigación Biomédica en Red de Cáncer; Hyogo College of Medicine; Ankara Universitesi; Technische Universität München; Universidad de Navarra; Yale University; Seoul National University; University of Toronto; Universitair Ziekenhuis Gent; Universidade de São Paulo; International Association for the Study of Lung Cancer; University of Aberdeen; Shanghai Chest Hospital; University of Chicago; Mount Sinai Health System; Universiteit Gent; Aix-Marseille Université; Queen's University; Ohio State University; Université Hassan II de Casablanca; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Ninth; Lung cancer; Lung cancer staging; Residual; Resection; Oncology; General surgery; Internal medicine; Medical physics; Surgery","score_opus":0.04075036373933873,"score_gpt":0.4683856223978124,"score_spread":0.4276352586584737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393385810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93540657,0.009848558,0.0018083139,0.03895202,0.004798165,0.008628626,0.00050831254,0.000007236884,0.000042183277],"genre_scores_gemma":[0.99484205,0.0017366075,0.00016694651,0.00006140423,0.0010250524,0.0018906478,0.000008072494,0.000029049994,0.00024018249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971628,0.00030681313,0.0013330415,0.0002247648,0.0007765915,0.00019598434],"domain_scores_gemma":[0.99153316,0.0027034264,0.0032914192,0.0003432053,0.0021055753,0.000023226135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033123048,0.00016239508,0.00050074555,0.00015031402,0.00024921872,0.000027370219,0.00037880137,0.00011707612,0.000014807668],"category_scores_gemma":[0.00076315674,0.0000703867,0.00038844545,0.00036883727,0.00013652473,0.00017464726,0.000068079105,0.00029349115,1.7299177e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02525987,0.0023759445,0.6571541,0.008441807,0.010483827,0.0000016201343,0.018175716,0.0026004722,0.036021627,0.0013547647,0.0698166,0.16831368],"study_design_scores_gemma":[0.0051345774,0.003537437,0.7733192,0.009354531,0.01406177,0.000016138258,0.010715315,0.099248126,0.06995126,0.00033039105,0.014105529,0.00022571474],"about_ca_topic_score_codex":0.00058710173,"about_ca_topic_score_gemma":0.0027715384,"teacher_disagreement_score":0.16808796,"about_ca_system_score_codex":0.0023344348,"about_ca_system_score_gemma":0.0015672552,"threshold_uncertainty_score":0.6104466},"labels":[],"label_agreement":null},{"id":"W4396767610","doi":"10.1016/j.jtho.2024.05.002","title":"The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Medical Research Council; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Genentech; National Institutes of Health; Université Hassan II de Casablanca; Soochow University; Ankara Universitesi; Technische Universität München; Yale University; Seoul National University; University of Toronto; Universitair Ziekenhuis Gent; National Health and Medical Research Council; AstraZeneca; Universidade de São Paulo; Temple University; Instituto Nacional do Câncer, Ministério da Saúde; Shanghai Chest Hospital; University of Chicago; Keio University; Mount Sinai Health System; Universiteit Gent; Cancer Research UK; Aix-Marseille Université; Memorial Sloan-Kettering Cancer Center; Queen's University; Samsung; University of Leicester; Ohio State University; University of Aberdeen; International Association for the Study of Lung Cancer","keywords":"Medicine; Stage (stratigraphy); Oncology; Lung cancer staging; Ninth; Lung cancer; Mesothelioma; Internal medicine; Radiology; Pathology","score_opus":0.03770783584872624,"score_gpt":0.4404436575184863,"score_spread":0.4027358216697601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396767610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662998,0.0007976095,0.0010095692,0.026174182,0.0014817573,0.0039011177,0.00028571743,0.000005335447,0.000044925702],"genre_scores_gemma":[0.9983345,0.000101458,0.00030634433,0.00016778555,0.0005119706,0.0002313342,0.0000148514355,0.000019452662,0.00031229574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785393,0.0002722428,0.0008663918,0.00015099281,0.00068502256,0.00017138761],"domain_scores_gemma":[0.99585015,0.0022198774,0.0013868866,0.00019682509,0.00032670193,0.000019585334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002774734,0.0001281749,0.00029925868,0.00012938153,0.00023932991,0.00003361713,0.00046562872,0.00007700172,0.00000843402],"category_scores_gemma":[0.00074930163,0.00005211322,0.00034237653,0.00026656006,0.00012058539,0.00017596809,0.0000720933,0.00023951581,8.313884e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029552583,0.004712499,0.62221736,0.0042187255,0.0040051113,0.000009348473,0.031553846,0.002512508,0.06558767,0.010227631,0.034367874,0.19103484],"study_design_scores_gemma":[0.004655258,0.0040189624,0.8476968,0.0018631907,0.0029773074,0.00005716096,0.031541497,0.07021163,0.008761423,0.0025919941,0.025401505,0.00022329092],"about_ca_topic_score_codex":0.000067686764,"about_ca_topic_score_gemma":0.00020116399,"teacher_disagreement_score":0.22547941,"about_ca_system_score_codex":0.0006334535,"about_ca_system_score_gemma":0.0004725254,"threshold_uncertainty_score":0.21251155},"labels":[],"label_agreement":null},{"id":"W4396767635","doi":"10.1016/j.jtho.2024.05.003","title":"The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the “N” Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Health and Medical Research Council; Tokyo Women's Medical University; Universitätsspital Zürich; Medizinische Universität Wien; National Institutes of Health; Queen's University; National Cancer Institute; University of Toronto; Postgraduate Institute of Medical Education and Research, Chandigarh; Cleveland Clinic; Universidad de Navarra; Imperial College London; Centro de Investigación Biomédica en Red de Cáncer; York University; Medical Research Council; Universität Wien; Memorial Sloan-Kettering Cancer Center; Universidade de São Paulo; International Association for the Study of Lung Cancer","keywords":"Medicine; Ninth; Mesothelioma; Lung cancer; Lung cancer staging; Oncology; Internal medicine; General surgery; Pathology","score_opus":0.04862773196924563,"score_gpt":0.4519639182085068,"score_spread":0.40333618623926115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396767635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93643075,0.0020940432,0.0022302899,0.050797433,0.0028125062,0.0053269714,0.00022925809,0.000007675987,0.00007109104],"genre_scores_gemma":[0.99764067,0.00015103817,0.00017764347,0.00024083542,0.0007260071,0.00074522005,0.00000948263,0.000016841963,0.00029225185],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834794,0.00019675618,0.000645954,0.00012144361,0.0005293476,0.00015855924],"domain_scores_gemma":[0.99514604,0.003599397,0.0008091345,0.00015529276,0.00027282548,0.000017322849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027877656,0.000107342705,0.00022057406,0.00011286403,0.00028363807,0.00004573049,0.0003986378,0.00006140204,0.00000768416],"category_scores_gemma":[0.00069188257,0.00004056972,0.00025611953,0.00021578472,0.000098141674,0.00013715707,0.000038470862,0.00019693434,1.2163375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021329392,0.0038121918,0.52764183,0.0015049644,0.005904117,0.000008615676,0.029123046,0.002123585,0.02529772,0.0055799796,0.07872086,0.2989537],"study_design_scores_gemma":[0.0037309502,0.0034301118,0.78417075,0.0008278233,0.004391088,0.00007045448,0.05065331,0.09359202,0.004893307,0.0032041671,0.050836917,0.00019912049],"about_ca_topic_score_codex":0.000060634768,"about_ca_topic_score_gemma":0.00024793815,"teacher_disagreement_score":0.2987546,"about_ca_system_score_codex":0.000633822,"about_ca_system_score_gemma":0.00039616608,"threshold_uncertainty_score":0.21815434},"labels":[],"label_agreement":null},{"id":"W4399761443","doi":"10.1016/j.jtho.2024.06.010","title":"Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; McGill University Health Centre","funders":"University of Leeds; Instituto Nacional de Cancerología; AstraZeneca","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Multidisciplinary approach; Cancer; Neoadjuvant therapy; Intensive care medicine; Population; Oncology; Internal medicine","score_opus":0.04385408277842607,"score_gpt":0.4678092149429926,"score_spread":0.42395513216456654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399761443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9214992,0.0065039406,0.00011878149,0.067791484,0.0021105432,0.0014113215,0.00043612163,0.000006083819,0.00012253162],"genre_scores_gemma":[0.9951593,0.0016231738,0.00056709093,0.00023458751,0.0005465017,0.00028380044,0.000015791029,0.000013976596,0.0015557231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990457,0.000090721434,0.0004090588,0.00012837272,0.000206744,0.00011939575],"domain_scores_gemma":[0.995743,0.0033446182,0.00041783112,0.00010591641,0.0003462261,0.000042424686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071123,0.00008874845,0.00031099335,0.00006225957,0.00010934486,0.00003933354,0.000094849885,0.000058141566,0.00006551458],"category_scores_gemma":[0.00021162705,0.000044570133,0.000118774515,0.000072480565,0.000023360042,0.000053417178,0.000027002612,0.00014519182,3.6674743e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061205216,0.002525468,0.47527006,0.00010665451,0.018309623,0.00007458086,0.010140798,0.00010558266,0.0005421061,0.00014830014,0.1322186,0.3544377],"study_design_scores_gemma":[0.01812201,0.016766092,0.5914989,0.0016413282,0.021124389,0.00008883037,0.0127552105,0.007906998,0.0018574161,0.00073378626,0.32726905,0.00023596792],"about_ca_topic_score_codex":0.00085697154,"about_ca_topic_score_gemma":0.0014008558,"teacher_disagreement_score":0.35420173,"about_ca_system_score_codex":0.0012101461,"about_ca_system_score_gemma":0.00037773937,"threshold_uncertainty_score":0.316449},"labels":[],"label_agreement":null},{"id":"W4400452226","doi":"10.1016/j.jtho.2024.05.344","title":"PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Jazz; Lung cancer; Internal medicine; Acoustics","score_opus":0.03104700443746073,"score_gpt":0.42867154048630385,"score_spread":0.3976245360488431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358195,0.0019145401,0.00006606498,0.0025722126,0.000432107,0.0003828852,0.00004285696,0.000020266289,0.0009870919],"genre_scores_gemma":[0.99402755,0.0016975054,0.001966578,0.000111116984,0.00021013431,0.00001644783,0.000025261645,0.000033811888,0.0019116183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975032,0.0002706846,0.00092942663,0.0002717518,0.0006170589,0.00040785348],"domain_scores_gemma":[0.99785393,0.00029923918,0.00051992526,0.00025404323,0.00086534774,0.00020748324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070055196,0.0002095269,0.0011883661,0.0019576026,0.00003565728,0.00002120843,0.00018618508,0.00011615977,0.0003258471],"category_scores_gemma":[0.00014361733,0.00014219194,0.00024770395,0.0030712988,0.00012158475,0.00020147339,0.000103169106,0.0008112542,0.0000029488692],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048453016,0.0006618479,0.9605159,0.0006423912,0.0039331256,0.00080904807,0.00069939345,0.0006839357,0.0005051052,0.0000074919703,0.016845023,0.009851416],"study_design_scores_gemma":[0.0023781734,0.003282562,0.9639598,0.0009203082,0.0067348727,0.000018072518,0.00014158865,0.0016948808,0.0015156243,0.000012125127,0.019125897,0.00021605394],"about_ca_topic_score_codex":0.0017663077,"about_ca_topic_score_gemma":0.009856332,"teacher_disagreement_score":0.009635362,"about_ca_system_score_codex":0.0014432479,"about_ca_system_score_gemma":0.0010923839,"threshold_uncertainty_score":0.5798419},"labels":[],"label_agreement":null},{"id":"W4400452265","doi":"10.1016/j.jtho.2024.05.332","title":"PP01.105 Early Detection of Non-Small Cell Lung Cancer using Electronic Health Record Data","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Medicine; Electronic health record; Lung cancer; Health records; Oncology; Health care","score_opus":0.04065701268092965,"score_gpt":0.4495400011999616,"score_spread":0.408882988519032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612032,0.030792467,0.002299883,0.0034631453,0.0017404746,0.00029467343,0.000019652578,0.000012132275,0.00017432864],"genre_scores_gemma":[0.98929703,0.006954023,0.0024913407,0.00023911709,0.0008172249,0.0000070588135,0.0000046979303,0.000027381227,0.00016213268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99854875,0.00011647521,0.00060774706,0.00022164683,0.00020020838,0.00030517564],"domain_scores_gemma":[0.9987737,0.0001205291,0.00052327046,0.00028438523,0.00015160206,0.00014653945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078093266,0.00012954682,0.00058163697,0.00023576307,0.0000449663,0.000016137712,0.00015884804,0.000111870715,0.000072804185],"category_scores_gemma":[0.000019730469,0.000098504795,0.00013381538,0.00025474234,0.000029058468,0.00014570606,0.000058408135,0.00049229746,0.0000032269768],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016365822,0.0008901872,0.031492203,0.0025045692,0.001350874,0.00048683686,0.0010277026,0.0001335797,0.020739576,0.00000857887,0.0056746514,0.9340547],"study_design_scores_gemma":[0.012935188,0.08433051,0.1496426,0.02315425,0.023918439,0.00877022,0.0016183365,0.078062825,0.19690908,0.00063485984,0.41849658,0.0015271051],"about_ca_topic_score_codex":0.001149944,"about_ca_topic_score_gemma":0.0010238405,"teacher_disagreement_score":0.93252754,"about_ca_system_score_codex":0.003086888,"about_ca_system_score_gemma":0.0033499699,"threshold_uncertainty_score":0.80721045},"labels":[],"label_agreement":null},{"id":"W4400452630","doi":"10.1016/j.jtho.2024.05.355","title":"PP01.132 Auto-Segmentation of Lung Tumors Using Deep Learning Engines","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Science North","funders":"","keywords":"Medicine; Segmentation; Artificial intelligence; Lung; Deep learning; Radiology; Internal medicine; Computer science","score_opus":0.01693927514831196,"score_gpt":0.42149560159889343,"score_spread":0.4045563264505815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93572396,0.004140643,0.05527769,0.0025661858,0.0013216999,0.000100438185,4.5591523e-7,0.000032984866,0.00083597173],"genre_scores_gemma":[0.96696603,0.00020098253,0.031629696,0.00016731033,0.00072901626,9.119741e-7,0.0000030524618,0.000028125427,0.0002748652],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985374,0.00018291434,0.0006585174,0.00012359276,0.00030589695,0.00019166918],"domain_scores_gemma":[0.9989148,0.0002953086,0.00040523373,0.00007524948,0.00016785582,0.0001416006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013169231,0.000114504495,0.00050051673,0.0004295522,0.00005200921,0.000023222445,0.00009562582,0.00009913787,0.00014474092],"category_scores_gemma":[0.0006293481,0.00008932651,0.0001812546,0.00027208196,0.0000901216,0.00014865803,0.000032250024,0.0009644405,0.000003812432],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047438,0.00018812207,0.015189402,0.0011999388,0.00047172373,0.002291031,0.0027391117,0.012394091,0.18082815,0.00016711983,0.00072362216,0.7833333],"study_design_scores_gemma":[0.0009555129,0.0017249399,0.008164391,0.0022467847,0.0012793541,0.010127689,0.001292999,0.9437196,0.006191318,0.0003028211,0.023791406,0.00020314503],"about_ca_topic_score_codex":0.000013285351,"about_ca_topic_score_gemma":5.949709e-7,"teacher_disagreement_score":0.93132555,"about_ca_system_score_codex":0.00028992846,"about_ca_system_score_gemma":0.00035740592,"threshold_uncertainty_score":0.4190068},"labels":[],"label_agreement":null},{"id":"W4400452669","doi":"10.1016/j.jtho.2024.05.270","title":"PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Exon; Oncology; Chemotherapy; Internal medicine; Genetics; Gene","score_opus":0.06063335095721781,"score_gpt":0.4938462651588927,"score_spread":0.43321291420167485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9544617,0.0042315493,0.0032682996,0.030599955,0.001992885,0.0022624012,0.00008025992,0.00010146573,0.0030015146],"genre_scores_gemma":[0.9703709,0.00056966575,0.021624692,0.000781001,0.0019806097,0.00036367858,0.000081808095,0.00007615708,0.0041515236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982668,0.000070307564,0.0007742027,0.0002951928,0.00025645902,0.0003370407],"domain_scores_gemma":[0.9981224,0.0005675432,0.00046843203,0.00020961632,0.00036871375,0.00026328614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032633758,0.00027737502,0.0007496613,0.0002909879,0.00018849071,0.000044163047,0.000094631934,0.0001471899,0.00014127702],"category_scores_gemma":[0.00019598818,0.00017586522,0.00032101994,0.00038671365,0.00007228967,0.00020232043,0.000011228801,0.00025704238,0.000015484438],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21111329,0.0054487325,0.00012539921,0.00019157905,0.0018470623,0.0010455054,0.0018476808,0.00042729705,0.0035329172,0.000053638167,0.001890392,0.7724765],"study_design_scores_gemma":[0.20368542,0.19213313,0.00031420158,0.0015311155,0.0054539153,0.0033619252,0.0007436148,0.0014494384,0.006972439,0.0007132327,0.5832508,0.00039073426],"about_ca_topic_score_codex":0.00002825982,"about_ca_topic_score_gemma":0.00009780921,"teacher_disagreement_score":0.7720858,"about_ca_system_score_codex":0.0012889489,"about_ca_system_score_gemma":0.0016387862,"threshold_uncertainty_score":0.7171576},"labels":[],"label_agreement":null},{"id":"W4400452750","doi":"10.1016/j.jtho.2024.05.257","title":"PP01.10 Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Centre for Social Innovation","funders":"","keywords":"Medicine; Oncology; Internal medicine; Real world data; Data science","score_opus":0.022406640428778324,"score_gpt":0.42191355811423026,"score_spread":0.39950691768545193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937044,0.0002810096,0.00032965816,0.004129551,0.0007672002,0.00015592677,0.000023650122,0.00001019554,0.0005984335],"genre_scores_gemma":[0.9910449,0.000055017637,0.007994464,0.0005414618,0.000100395926,6.8960435e-7,0.000050876402,0.00003007784,0.00018212787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807376,0.00015424233,0.0008340826,0.00020599883,0.00046941979,0.00026248235],"domain_scores_gemma":[0.99839115,0.00038961112,0.00047992176,0.00028858,0.0002624492,0.00018830934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007188837,0.00015133541,0.0007925555,0.0004192581,0.000026103711,0.000013084012,0.0002699609,0.00006403175,0.00014747308],"category_scores_gemma":[0.0005601395,0.00010271846,0.000053034957,0.00050911406,0.00007889971,0.00023435085,0.00007863283,0.0010100938,0.0000010680164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026164285,0.00036170942,0.69204456,0.00033790283,0.0005126564,0.0036180639,0.00021342754,0.0021007813,0.0013073889,0.00001435766,0.0033675265,0.2935052],"study_design_scores_gemma":[0.0031518561,0.0011019987,0.9155604,0.0016996049,0.0007453573,0.00039084835,0.00026804683,0.048910264,0.00015751312,0.000052507374,0.027724044,0.00023752228],"about_ca_topic_score_codex":0.084661126,"about_ca_topic_score_gemma":0.13946193,"teacher_disagreement_score":0.29326767,"about_ca_system_score_codex":0.0013632374,"about_ca_system_score_gemma":0.0050048064,"threshold_uncertainty_score":0.9214342},"labels":[],"label_agreement":null},{"id":"W4400452878","doi":"10.1016/j.jtho.2024.05.265","title":"PP01.19 Comparison of A.I. Models in Lung Cancer Staging and Subtyping","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Milton District Hospital","funders":"","keywords":"Subtyping; Medicine; Lung cancer; Lung; Oncology; Internal medicine; Programming language","score_opus":0.0329563464470569,"score_gpt":0.4839581926622077,"score_spread":0.45100184621515077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94759643,0.026009843,0.013908354,0.01068102,0.0006474991,0.00008441452,8.832777e-7,0.00000996156,0.0010616127],"genre_scores_gemma":[0.99416137,0.0010345145,0.004120379,0.00030687056,0.00024842663,0.0000015340092,5.606904e-7,0.000014389669,0.00011197492],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99885005,0.00010367616,0.0005760795,0.000113022,0.00019258639,0.00016456994],"domain_scores_gemma":[0.99923617,0.00025512007,0.0002327363,0.00006473201,0.00007635204,0.00013490919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011189111,0.00008311984,0.0005625186,0.0003781315,0.000021922704,0.000015070325,0.00007142166,0.00008414436,0.000039164363],"category_scores_gemma":[0.00017708445,0.00006489355,0.00006976,0.00018992656,0.00008617294,0.00012288378,0.000036954796,0.00090113725,2.9701684e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073504733,0.00020944283,0.257001,0.001914691,0.00025782303,0.0010486662,0.006633578,0.015161109,0.0062762955,0.0004399988,0.0029332496,0.7073891],"study_design_scores_gemma":[0.00068024057,0.00035686765,0.012350803,0.002226143,0.00028127735,0.00059980695,0.0008105654,0.97346914,0.0002991746,0.00095750886,0.007879368,0.00008913577],"about_ca_topic_score_codex":0.000102496895,"about_ca_topic_score_gemma":0.000012394565,"teacher_disagreement_score":0.958308,"about_ca_system_score_codex":0.0002417442,"about_ca_system_score_gemma":0.00038537357,"threshold_uncertainty_score":0.39150432},"labels":[],"label_agreement":null},{"id":"W4400452973","doi":"10.1016/j.jtho.2024.05.150","title":"PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; ROS1; Trident; Oncology; Internal medicine; Phase (matter); Adenocarcinoma; Cancer","score_opus":0.014774741149493426,"score_gpt":0.4350643118021281,"score_spread":0.4202895706526347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400452973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987688,0.0012996081,0.00018819624,0.0061931736,0.0026437037,0.0007624583,0.0000973438,0.000017782173,0.0011097073],"genre_scores_gemma":[0.99709713,0.00007606756,0.0006911602,0.0006050919,0.0009689339,0.000023331104,0.000078535544,0.000025950454,0.00043380895],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99828684,0.00023547927,0.0006594231,0.00022458995,0.00037735444,0.00021632912],"domain_scores_gemma":[0.99855185,0.0005060825,0.00039008856,0.00018338342,0.00023099702,0.0001375736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043554784,0.00016858801,0.0005085758,0.00019039416,0.0000928436,0.000052771255,0.00011321818,0.00011831123,0.00027375575],"category_scores_gemma":[0.00019323397,0.000090024354,0.00017417317,0.00033166746,0.00008024546,0.00019819921,0.000033212596,0.0005609815,0.000025556918],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25817335,0.0058839903,0.012983539,0.000034522152,0.0020519095,0.004688821,0.0048663253,0.000029325287,0.0003704784,0.00004404194,0.016785843,0.69408786],"study_design_scores_gemma":[0.4980418,0.10528941,0.21733908,0.005178199,0.01493413,0.0023121287,0.0047398526,0.00052223547,0.0035468312,0.0013876782,0.14570044,0.0010082133],"about_ca_topic_score_codex":0.00009953106,"about_ca_topic_score_gemma":0.00009779981,"teacher_disagreement_score":0.69307965,"about_ca_system_score_codex":0.0006719622,"about_ca_system_score_gemma":0.0010116214,"threshold_uncertainty_score":0.36710867},"labels":[],"label_agreement":null},{"id":"W4400942690","doi":"10.1016/j.jtho.2024.07.014","title":"Second Primary Lung Cancer – An Emerging Issue in Lung Cancer Survivors","year":2024,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"NIHR Cambridge Biomedical Research Centre; Manchester Biomedical Research Centre; Carlsbergfondet; Cancer Research UK; CRUK Lung Cancer Centre of Excellence; National Institute for Health and Care Research; Kræftens Bekæmpelse","keywords":"Medicine; Lung cancer; Adenocarcinoma; Oncology; Cancer; Disease; Lung; Intensive care medicine; Internal medicine","score_opus":0.04147310049022,"score_gpt":0.5087677598220591,"score_spread":0.4672946593318391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400942690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001803191,0.98680663,0.0000025463555,0.0022193792,0.006121821,0.00094410253,0.00009741596,0.000021613327,0.0019832894],"genre_scores_gemma":[0.00014723223,0.9921173,0.0002594862,0.00056402734,0.0034877772,0.0003183767,0.000039224837,0.00012956592,0.0029370042],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628896,0.000482479,0.0017160403,0.0005276,0.00045370066,0.0005312196],"domain_scores_gemma":[0.99744827,0.00024645505,0.0013413231,0.0003707583,0.00022406514,0.00036910857],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010883914,0.0005915992,0.0041410993,0.00094792235,0.000052314637,0.000043177704,0.0003169753,0.00062492245,0.0025349234],"category_scores_gemma":[0.00003242939,0.0003990537,0.0008301442,0.00064893457,0.000065957145,0.00020570759,0.00011262215,0.0017534661,0.000016458749],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00016273957,0.00046984432,0.0018758366,0.06890466,0.0024271542,0.003526249,0.00049221714,0.000011107924,0.0000010397013,0.0000050406156,0.029390963,0.89273316],"study_design_scores_gemma":[0.0004956837,0.0005705943,0.00038192482,0.056466997,0.015554491,0.0009369073,0.000058713005,0.000036108162,0.000003234265,0.000007944116,0.92517954,0.00030785825],"about_ca_topic_score_codex":0.0007099037,"about_ca_topic_score_gemma":0.00689565,"teacher_disagreement_score":0.8957886,"about_ca_system_score_codex":0.010373154,"about_ca_system_score_gemma":0.005854826,"threshold_uncertainty_score":0.99984616},"labels":[],"label_agreement":null},{"id":"W4401305916","doi":"10.1016/j.jtho.2024.07.022","title":"From the International Association for the Study of Lung Cancer Early Detection and Screening Committee: Terminology Issues in Screening and Early Detection of Lung Cancer—International Association for the Study of Lung Cancer Early Detection and Screening Committee Expert Group Recommendations","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of British Columbia","funders":"","keywords":"Terminology; Medicine; Lung cancer screening; Lung cancer; Cancer detection; Medical physics; Cancer; Pathology; Internal medicine; Linguistics","score_opus":0.034001882129973675,"score_gpt":0.42717205431829963,"score_spread":0.39317017218832595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401305916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971072,0.009177668,0.00603105,0.009719477,0.0018350334,0.0020358085,0.00010833293,0.000014190276,0.000006394003],"genre_scores_gemma":[0.9946942,0.0030032913,0.00037306704,0.00008106277,0.00095429417,0.0007874771,0.0000058832834,0.0000313095,0.00006945177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99750954,0.00041669907,0.0009912377,0.00032163007,0.0005305314,0.00023034596],"domain_scores_gemma":[0.9939123,0.003577934,0.0016075725,0.00015622795,0.0006952293,0.000050751936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019688723,0.00021993449,0.0006115067,0.00034079488,0.0003422676,0.00010822933,0.00020883985,0.00020429496,0.000015213501],"category_scores_gemma":[0.00035253767,0.00014846619,0.00013917517,0.0002700998,0.000064490094,0.00041903034,0.00010770517,0.0005321326,2.4507452e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018481947,0.0003726647,0.7202361,0.00006435053,0.0039742813,0.0000029731018,0.012850011,0.0002274509,0.0023515904,0.0000030851302,0.00024154954,0.25782773],"study_design_scores_gemma":[0.0047093504,0.0026722238,0.94374686,0.0008035625,0.002757062,0.000013768468,0.008318694,0.034129698,0.001559206,0.000029337165,0.0011293384,0.0001308995],"about_ca_topic_score_codex":0.031549964,"about_ca_topic_score_gemma":0.042095084,"teacher_disagreement_score":0.25769684,"about_ca_system_score_codex":0.0014761582,"about_ca_system_score_gemma":0.00009868274,"threshold_uncertainty_score":0.9753842},"labels":[],"label_agreement":null},{"id":"W4401843367","doi":"10.1016/j.jtho.2024.08.017","title":"Erratum to “Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813–819]”","year":2024,"lang":"en","type":"erratum","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; BC Cancer Agency; Saskatchewan Cancer Agency; CancerCare Manitoba; Alberta Cancer Foundation; Juravinski Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Mesothelioma; Randomized controlled trial; General surgery; Cancer; Pathology; Immunotherapy","score_opus":0.025424632798650978,"score_gpt":0.41981402393723655,"score_spread":0.39438939113858557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401843367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563956,0.0053561637,0.000019027455,0.0017010277,0.029566959,0.0038898122,0.0006254504,0.000013662122,0.002432265],"genre_scores_gemma":[0.97537583,0.0008633,0.0013176429,0.0011366019,0.0042676856,0.0002709619,0.00041337684,0.0002261629,0.016128462],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.987841,0.0026168427,0.0061179847,0.0007054127,0.0018840373,0.0008347228],"domain_scores_gemma":[0.98700863,0.0007510269,0.00839581,0.00055975886,0.0019913584,0.0012934179],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005637563,0.000884496,0.0076241535,0.0030746215,0.000146832,0.00003786725,0.0006307184,0.0009037593,0.00096548325],"category_scores_gemma":[0.0037068476,0.0005857222,0.0011252916,0.00089675543,0.0003777556,0.00032082348,0.0002091668,0.0025997232,0.000012323193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6360303,0.012388894,0.0060743256,0.00079630304,0.0040257503,0.016932506,0.001743543,0.00017698648,0.00017760166,0.0000027703454,0.28371006,0.037940964],"study_design_scores_gemma":[0.36936277,0.19219501,0.050886184,0.011491685,0.024718734,0.00582688,0.0033618591,0.00009284537,0.00016231589,0.000389791,0.33987674,0.0016351878],"about_ca_topic_score_codex":0.0038609449,"about_ca_topic_score_gemma":0.018560076,"teacher_disagreement_score":0.26666754,"about_ca_system_score_codex":0.0038363421,"about_ca_system_score_gemma":0.010483154,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W4402396951","doi":"10.1016/j.jtho.2024.09.1379","title":"Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Durvalumab; Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; Stage (stratigraphy); Oncology; Internal medicine; Lung cancer; Cancer; Immunotherapy; Nivolumab","score_opus":0.03071190997090472,"score_gpt":0.4315908156606996,"score_spread":0.4008789056897949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402396951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860831,0.0020638555,0.00035819982,0.0060221558,0.0020514552,0.00046027475,0.000032050048,0.000024810837,0.0029040969],"genre_scores_gemma":[0.99493545,0.000210223,0.0014202001,0.00027493786,0.00056262943,0.000037677102,0.00008179199,0.000022824945,0.002454269],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986549,0.00012452435,0.0005731821,0.00018245567,0.00026534955,0.00019959071],"domain_scores_gemma":[0.9988854,0.00032208374,0.00027502602,0.00011175664,0.00029213753,0.00011358357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044320693,0.00014199749,0.00037413125,0.00040008934,0.000047658486,0.00004556589,0.000049363203,0.00015679224,0.00030106225],"category_scores_gemma":[0.00025042973,0.00010702981,0.00009817786,0.0005113352,0.000049397106,0.0004954912,0.000019056333,0.00031505674,0.000017322878],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11778024,0.0034195995,0.02017554,0.0011793515,0.0023190724,0.014274218,0.01543605,0.0013371594,0.03409814,0.0006986505,0.013718523,0.7755635],"study_design_scores_gemma":[0.06863309,0.037663117,0.38337472,0.008031466,0.009376838,0.0027389391,0.011467185,0.013533496,0.11376972,0.00075489323,0.34911883,0.0015377111],"about_ca_topic_score_codex":0.000115878174,"about_ca_topic_score_gemma":0.00023827927,"teacher_disagreement_score":0.77402574,"about_ca_system_score_codex":0.0018391167,"about_ca_system_score_gemma":0.0013600877,"threshold_uncertainty_score":0.4809226},"labels":[],"label_agreement":null},{"id":"W4402462708","doi":"10.1016/j.jtho.2024.09.1386","title":"Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Genentech; National Institutes of Health; G1 Therapeutics; Incyte; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; RefleXion Medical; Varian Medical Systems; Novocure; Janssen Pharmaceuticals; Gilead Sciences; ViewRay; Sanofi; Bristol-Myers Squibb; AstraZeneca; Cardinal Health; Amgen; Pfizer","keywords":"Medicine; Lung cancer; Executive summary; Cancer; Radium; Oncology; Internal medicine; Intensive care medicine","score_opus":0.03897251142006592,"score_gpt":0.4273829651469691,"score_spread":0.3884104537269032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402462708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8899616,0.02432163,0.00830468,0.07292523,0.0028696053,0.0014322393,0.00010116613,0.000012923684,0.00007091288],"genre_scores_gemma":[0.96232283,0.019827515,0.014346846,0.0017862641,0.0012910462,0.00013941234,0.000008842761,0.000028397126,0.0002488565],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99852896,0.00008336255,0.000685933,0.00019544015,0.00020543115,0.00030086507],"domain_scores_gemma":[0.9985472,0.0004833452,0.00039196404,0.0002241582,0.00026658757,0.000086741486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050021807,0.00015760049,0.0004824678,0.000041199066,0.000051626,0.000042216478,0.00020410163,0.000058639765,0.00004993102],"category_scores_gemma":[0.000019733076,0.00008066914,0.0003160251,0.0002719131,0.0001116035,0.00007599287,0.000030043035,0.00024104465,7.292559e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005411124,0.002260836,0.10609181,0.003747773,0.009384128,0.00061792525,0.015390226,0.005994883,0.0037898743,0.0001140301,0.21055241,0.63664496],"study_design_scores_gemma":[0.0069682533,0.0029433272,0.7117032,0.00718492,0.014651302,0.00017269627,0.00994401,0.057322696,0.010998457,0.00028565532,0.177347,0.00047849288],"about_ca_topic_score_codex":0.0007734254,"about_ca_topic_score_gemma":0.0002444638,"teacher_disagreement_score":0.63616645,"about_ca_system_score_codex":0.0009406045,"about_ca_system_score_gemma":0.0005623232,"threshold_uncertainty_score":0.3289592},"labels":[],"label_agreement":null},{"id":"W4402696032","doi":"10.1016/j.jtho.2024.09.1433","title":"American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy","year":2024,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Cancer Institute","keywords":"Medicine; Radium; Cardiac toxicity; Radiation therapy; General surgery; Toxicity; Medical physics; Radiology; Intensive care medicine; Internal medicine; Radiochemistry","score_opus":0.046843676585891024,"score_gpt":0.4575526007934569,"score_spread":0.4107089242075659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402696032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018285438,0.9765352,0.00062811765,0.0007704516,0.001780989,0.0016269507,0.000042366548,0.000047247348,0.00028325338],"genre_scores_gemma":[0.00093717215,0.98515314,0.009652766,0.0006827997,0.0018308725,0.000091334274,0.000030025141,0.000113490925,0.0015083959],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966311,0.000850953,0.001145831,0.00051797065,0.0004911612,0.00036299205],"domain_scores_gemma":[0.99800324,0.00016421852,0.0010142921,0.0004143573,0.00014240098,0.00026151343],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015564659,0.0005637611,0.0032725758,0.00044492297,0.000067663124,0.00011808317,0.00016340226,0.00056064397,0.00004026157],"category_scores_gemma":[0.000031903408,0.0004123007,0.0021556136,0.00046309739,0.00022836137,0.00018601796,0.000069709735,0.0013296016,0.000013508925],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087946944,0.00026032762,0.0000034963116,0.01472116,0.0036149614,0.00035145006,0.00035759888,5.096439e-7,0.00024586654,0.000011048774,0.0028437322,0.9767104],"study_design_scores_gemma":[0.00038458055,0.0025833442,0.00008591314,0.015442795,0.010002945,0.001348212,0.00014710252,0.000013229163,0.00029325348,0.0000869103,0.9692382,0.0003734864],"about_ca_topic_score_codex":0.0000049231007,"about_ca_topic_score_gemma":0.000001792215,"teacher_disagreement_score":0.9763369,"about_ca_system_score_codex":0.0013674533,"about_ca_system_score_gemma":0.00044439794,"threshold_uncertainty_score":0.99983287},"labels":[],"label_agreement":null},{"id":"W4402945763","doi":"10.1016/j.jtho.2024.09.1437","title":"Accelerated Hypofractionated Radiotherapy for Locally Advanced NSCLC: A Systematic Review From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","year":2024,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Radiation therapy; Lung cancer; Cancer; Medical physics; Oncology; Lung; Radiology; Internal medicine","score_opus":0.04011297784104611,"score_gpt":0.48929692830712485,"score_spread":0.44918395046607873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402945763","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011217023,0.96640545,0.0002843115,0.017536215,0.0028503684,0.012585408,0.00019332909,0.00002189674,0.000010826935],"genre_scores_gemma":[0.00047032614,0.99130374,0.00045089176,0.000688848,0.0006472143,0.0060377056,0.000084995,0.00006530737,0.00025095936],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964772,0.000395776,0.0020883896,0.0003141345,0.0005070408,0.0002174837],"domain_scores_gemma":[0.9887919,0.004444701,0.004970335,0.00039609647,0.0013461817,0.000050799255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017214011,0.0003655908,0.0033109016,0.00028708574,0.0001104424,0.000034667017,0.00055911636,0.00036997578,0.000038287646],"category_scores_gemma":[0.0013416234,0.0001754142,0.00086161465,0.0005961915,0.000032703505,0.00013191746,0.000040670482,0.00065941573,0.0000015722],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007490472,0.00082151504,0.00008729282,0.15248062,0.018814651,0.0000159315,0.00015355491,0.000032591404,0.0000043823243,0.0000170657,0.01378274,0.8130406],"study_design_scores_gemma":[0.0032136994,0.0024853812,0.000050902596,0.30979165,0.06899142,0.00010514377,0.00029810314,0.00027699737,0.000009011543,0.000044828554,0.6145479,0.00018495622],"about_ca_topic_score_codex":0.000026766946,"about_ca_topic_score_gemma":0.000075804106,"teacher_disagreement_score":0.81285566,"about_ca_system_score_codex":0.0061002458,"about_ca_system_score_gemma":0.0015877234,"threshold_uncertainty_score":0.9977152},"labels":[],"label_agreement":null},{"id":"W4403410086","doi":"10.1016/j.jtho.2024.09.382","title":"P2.04A.02 Using an AI Transformer Model to Identify Incidental Pulmonary Nodules (IPN) For Lung Cancer Early Detection","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Lunenfeld-Tanenbaum Research Institute; Systems, Applications & Products in Data Processing (Canada); Vancouver Coastal Health; BC Cancer Foundation; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Lung cancer; Radiology; Lung; Pathology; Internal medicine","score_opus":0.04657705576548796,"score_gpt":0.49225369755070747,"score_spread":0.4456766417852195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95903057,0.002791343,0.03225652,0.003469435,0.0017450778,0.0005587854,0.00003549908,0.00002492051,0.000087877735],"genre_scores_gemma":[0.99362427,0.00029237787,0.0039659585,0.0006882441,0.0011478686,0.000078964666,0.000004494123,0.00004504676,0.00015277571],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986005,0.00005612566,0.0005243436,0.00025324803,0.0002867617,0.00027904124],"domain_scores_gemma":[0.999143,0.00007233957,0.00014743864,0.00012422453,0.00024890056,0.00026410766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042589675,0.00017498665,0.00047232353,0.00035265106,0.0001012347,0.000059919777,0.00009743562,0.00017034568,0.000060019698],"category_scores_gemma":[0.000018767374,0.00013617944,0.00028981792,0.00019985856,0.00003306826,0.00049393455,0.000014523297,0.0003162689,0.00000369331],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006071347,0.0017366027,0.00942216,0.0012225627,0.0014117628,0.0014487781,0.00348589,0.011696061,0.16279176,0.000035663787,0.0016859479,0.7989915],"study_design_scores_gemma":[0.004582791,0.02026486,0.07457212,0.0058263973,0.014172168,0.011499292,0.0013258762,0.6859515,0.16775002,0.0018710823,0.01110893,0.0010749946],"about_ca_topic_score_codex":0.00021725321,"about_ca_topic_score_gemma":0.00046328324,"teacher_disagreement_score":0.7979165,"about_ca_system_score_codex":0.002623795,"about_ca_system_score_gemma":0.0005134457,"threshold_uncertainty_score":0.68611324},"labels":[],"label_agreement":null},{"id":"W4403410089","doi":"10.1016/j.jtho.2024.09.322","title":"P1.06C.05 The Impact of Lymphovascular Invasion as Prognostic Factor on Long-Term Survival in More Than 3500 Resected NSCLC Patients","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Lymphovascular invasion; Oncology; Internal medicine; Term (time); Overall survival; Cancer; Metastasis","score_opus":0.03662981427040972,"score_gpt":0.4182928472195161,"score_spread":0.38166303294910636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955946,0.0011675986,0.000013890161,0.00085724733,0.0010706285,0.0005154994,0.00002370627,0.000013273444,0.00074352144],"genre_scores_gemma":[0.9989351,0.00033540276,0.00004629889,0.00020105383,0.00029980665,0.000006449721,0.000027058119,0.000031233012,0.00011756883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976598,0.0004587812,0.00076853496,0.0002229651,0.00058002566,0.00030986304],"domain_scores_gemma":[0.9982023,0.0006856133,0.0003764879,0.00029629256,0.00025661394,0.0001826759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076919596,0.00021741574,0.00074168656,0.00048174488,0.000042882355,0.000022944021,0.00025646258,0.00022312309,0.00040565286],"category_scores_gemma":[0.00063633715,0.000121975514,0.00049095723,0.00042890623,0.00012603575,0.00017095444,0.00006405389,0.000750312,0.000015251064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0091698775,0.0011424072,0.7178114,0.00041932895,0.00096998503,0.002471262,0.0023449787,0.00013907686,0.0064797625,0.000005853868,0.0011780065,0.25786805],"study_design_scores_gemma":[0.002111007,0.007880761,0.9859286,0.0009702004,0.00021972483,0.00044932493,0.00016086562,0.00014778203,0.0016044361,0.000033489792,0.00037970167,0.00011409635],"about_ca_topic_score_codex":0.00016362025,"about_ca_topic_score_gemma":0.00009309672,"teacher_disagreement_score":0.26811722,"about_ca_system_score_codex":0.001274354,"about_ca_system_score_gemma":0.0020159106,"threshold_uncertainty_score":0.4974017},"labels":[],"label_agreement":null},{"id":"W4403410103","doi":"10.1016/j.jtho.2024.09.436","title":"P2.10A.01 Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Phases of clinical research; Clinical trial","score_opus":0.03779296339728983,"score_gpt":0.4926715589626017,"score_spread":0.45487859556531185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993418,0.0022868493,0.00002492805,0.0009139165,0.0008862337,0.0020354292,0.000010302443,0.000010775759,0.0004135837],"genre_scores_gemma":[0.99820083,0.00007649623,0.0008081509,0.000041347248,0.00059993495,0.000094972806,0.0000033277609,0.00005481551,0.00012011964],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99644125,0.0005868917,0.0012436571,0.00034529142,0.0008647906,0.0005181336],"domain_scores_gemma":[0.9984167,0.00029467806,0.0005313253,0.00027388718,0.0002864713,0.00019693302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019152014,0.00023233463,0.0010675378,0.000854197,0.000033654724,0.00004090348,0.00030047525,0.00020253958,0.00019226894],"category_scores_gemma":[0.00013066197,0.00016787443,0.00011332644,0.00079122203,0.00013140039,0.00017775717,0.00011060539,0.0014444325,0.0000028269026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16625808,0.021455947,0.61944497,0.0016374525,0.00031491922,0.0041041686,0.008068467,0.00024734272,0.0008068045,8.67467e-7,0.0014512533,0.1762097],"study_design_scores_gemma":[0.41893727,0.162346,0.37505463,0.01615471,0.0018669382,0.00018299434,0.008276855,0.004283561,0.005738144,0.00005187083,0.0062059234,0.0009011121],"about_ca_topic_score_codex":0.00024857395,"about_ca_topic_score_gemma":0.00066863024,"teacher_disagreement_score":0.25267917,"about_ca_system_score_codex":0.0013596526,"about_ca_system_score_gemma":0.0023116532,"threshold_uncertainty_score":0.68457204},"labels":[],"label_agreement":null},{"id":"W4403410124","doi":"10.1016/j.jtho.2024.09.632","title":"P3.12D.10 Phase 1b Study of AMG 193, An MTA-Cooperative PRMT5i, Alone and in Combination with Other Therapies in MTAP-deleted NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Phase (matter); Internal medicine","score_opus":0.01572690049500855,"score_gpt":0.38711162080502,"score_spread":0.37138472031001146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961959,0.002398315,0.00038758322,0.00047563037,0.00012565852,0.00032426568,0.0000049759255,0.000003760585,0.000083879386],"genre_scores_gemma":[0.9991988,0.00012912044,0.0003539528,0.000039655934,0.000100546335,0.000011199096,0.000011425414,0.000019886802,0.00013541189],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872303,0.00037041714,0.00044277014,0.00020107973,0.00013638147,0.00012629757],"domain_scores_gemma":[0.9993668,0.00003405685,0.00024526127,0.00012354009,0.00018663582,0.00004366721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057311653,0.00012761545,0.00031782477,0.0002645885,0.000021512233,0.000018734943,0.0000904016,0.00017004664,0.000025211491],"category_scores_gemma":[0.00002942637,0.00010018945,0.00003147937,0.00026059154,0.000083181876,0.000026979675,0.000024561074,0.00020754807,5.393504e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013865451,0.006370114,0.0031327452,0.00006738313,0.0004701011,0.00013454672,0.007247523,0.0031928695,0.7656989,0.00001970087,0.0002929373,0.19950773],"study_design_scores_gemma":[0.080988504,0.27009884,0.10487493,0.0017198154,0.0011205967,0.0020992274,0.029854247,0.020654468,0.4389927,0.001025307,0.046590015,0.0019813192],"about_ca_topic_score_codex":0.000056650544,"about_ca_topic_score_gemma":0.0021864963,"teacher_disagreement_score":0.32670617,"about_ca_system_score_codex":0.000099138604,"about_ca_system_score_gemma":0.00023057364,"threshold_uncertainty_score":0.40856072},"labels":[],"label_agreement":null},{"id":"W4403410155","doi":"10.1016/j.jtho.2024.09.546","title":"P3.03H.01 Tumour Educated Platelets Display a Distinct RNA Content Profile Across Metastatic Patterns in NSCLC.","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Medicine; Oncology; Platelet; Internal medicine","score_opus":0.036810013516444175,"score_gpt":0.43994512838387484,"score_spread":0.40313511486743064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767507,0.0013673952,0.0027210426,0.016261086,0.0019720797,0.00027635114,0.000018746552,0.00003196315,0.00060068216],"genre_scores_gemma":[0.995483,0.000121671554,0.00201781,0.0007574188,0.0006205327,0.000013687306,0.00001985438,0.000044607357,0.0009214183],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99757975,0.0002979842,0.0009793016,0.00025965614,0.00038996505,0.00049333536],"domain_scores_gemma":[0.9984831,0.000501621,0.00037725622,0.00015483385,0.00013843371,0.00034471333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019924338,0.00022008909,0.0008751724,0.00030375484,0.00006098682,0.00007176078,0.00021227954,0.00011275926,0.0003022277],"category_scores_gemma":[0.0009252557,0.00015194294,0.00023737198,0.0003127987,0.0001305974,0.00015441392,0.000074360054,0.001723818,0.00004281293],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028242376,0.0016124301,0.03506467,0.0015095255,0.000793536,0.041748438,0.004973545,0.00009945759,0.03875429,0.000096081065,0.008893656,0.8636301],"study_design_scores_gemma":[0.012130774,0.0127809895,0.58097583,0.016807573,0.0030045107,0.09359528,0.009600873,0.13020346,0.007805195,0.0012225442,0.1303194,0.0015535316],"about_ca_topic_score_codex":0.000121936646,"about_ca_topic_score_gemma":0.00006773615,"teacher_disagreement_score":0.8620766,"about_ca_system_score_codex":0.000473131,"about_ca_system_score_gemma":0.00066559203,"threshold_uncertainty_score":0.74892277},"labels":[],"label_agreement":null},{"id":"W4403410227","doi":"10.1016/j.jtho.2024.09.271","title":"P1.03C.01 A Landscape of the Driver Alterations in 920 Brazilian Lung Cancer Patients","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.1388976117405197,"score_gpt":0.49907912096083507,"score_spread":0.36018150922031533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9458438,0.005245913,0.0003211839,0.041443955,0.00373295,0.0003432297,0.00014743951,0.0000072824155,0.0029142387],"genre_scores_gemma":[0.995634,0.00024491225,0.00060287,0.002433125,0.0004798014,0.000020501506,0.0000036208528,0.000017314702,0.0005638508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99585557,0.0004144363,0.0032198941,0.00019375657,0.000100029014,0.00021632716],"domain_scores_gemma":[0.9969067,0.00067769,0.0020263346,0.00019928513,0.000102747596,0.00008726808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061854,0.00010823682,0.000748888,0.0004585184,0.00006920892,0.000039261944,0.00030443916,0.00014734904,0.00063158147],"category_scores_gemma":[0.0009453778,0.00009554423,0.000180715,0.00033043174,0.000059462403,0.00039292505,0.000052015,0.0003653358,0.00006389388],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013165857,0.0005208378,0.827674,0.00090935925,0.00031107283,0.000013607785,0.010027965,0.0020971647,0.000023868988,0.011685677,0.13952187,0.0070829284],"study_design_scores_gemma":[0.001540878,0.000605864,0.7126493,0.0013622092,0.000107009495,0.00005214387,0.0012380311,0.028623337,0.00006417437,0.01188273,0.24145481,0.00041955055],"about_ca_topic_score_codex":0.00022575409,"about_ca_topic_score_gemma":0.00088745594,"teacher_disagreement_score":0.11502472,"about_ca_system_score_codex":0.00084819144,"about_ca_system_score_gemma":0.0006076993,"threshold_uncertainty_score":0.6915374},"labels":[],"label_agreement":null},{"id":"W4403410249","doi":"10.1016/j.jtho.2024.09.441","title":"P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Cancer research","score_opus":0.021139339467213112,"score_gpt":0.4677583966244069,"score_spread":0.44661905715719374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797312,0.0026104404,0.0052558235,0.0082284035,0.00046368103,0.002194874,0.00005126884,0.00006741683,0.001396895],"genre_scores_gemma":[0.98232824,0.00019748206,0.009912035,0.0010612287,0.000711199,0.00020561527,0.00003168041,0.00008585572,0.0054666437],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986028,0.00009458513,0.0005762796,0.00025889245,0.00018961761,0.00027781306],"domain_scores_gemma":[0.998835,0.00017061172,0.00031151532,0.00022289054,0.00027850037,0.0001814499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030518242,0.00022403199,0.0006564323,0.0002746005,0.00012070097,0.00005196223,0.00010847541,0.00009762003,0.00022347433],"category_scores_gemma":[0.000029799843,0.00014526876,0.000202427,0.00024197433,0.000057767542,0.00019488894,0.000009078701,0.00024805707,0.000018546121],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045439858,0.015227165,0.0058822474,0.00055749196,0.011391356,0.0020615472,0.020989519,0.0006006161,0.033863164,0.00019466762,0.025819913,0.83797246],"study_design_scores_gemma":[0.058941107,0.09743243,0.0075536217,0.0012146599,0.012014073,0.003210847,0.003791549,0.0011237564,0.0054517104,0.00043726657,0.80819607,0.00063292694],"about_ca_topic_score_codex":0.000018882021,"about_ca_topic_score_gemma":0.000083771294,"teacher_disagreement_score":0.8373395,"about_ca_system_score_codex":0.000914674,"about_ca_system_score_gemma":0.0011080452,"threshold_uncertainty_score":0.5923888},"labels":[],"label_agreement":null},{"id":"W4403410272","doi":"10.1016/j.jtho.2024.09.462","title":"P2.11A.12 Machine Learning-Based Clinicogenomic Prediction of Response to PD-(L)1 Inhibition in KRAS Altered Non-Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; KRAS; Lung cancer; Oncology; Cancer research; Internal medicine; Cancer; Colorectal cancer","score_opus":0.023557788308013142,"score_gpt":0.43049473602326505,"score_spread":0.4069369477152519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98829055,0.0022862088,0.0020823292,0.005087685,0.0013458285,0.00044963867,0.00006836321,0.000017665132,0.000371711],"genre_scores_gemma":[0.99640656,0.0002222722,0.0016259574,0.0003715436,0.0004761292,0.00003381586,0.000024981862,0.00002824291,0.0008105148],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983742,0.0002980333,0.0007756547,0.00018680237,0.0001772888,0.00018799285],"domain_scores_gemma":[0.9988701,0.00030990638,0.00036928977,0.000115603274,0.00018091411,0.00015419828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010684502,0.0001337632,0.00046003523,0.000646116,0.000036652615,0.000012414363,0.00004986858,0.00014987012,0.00015029966],"category_scores_gemma":[0.00012576232,0.00010907219,0.00016244286,0.00029147216,0.000034133147,0.00008232682,0.0000206338,0.0004973403,0.000009234086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07505622,0.0036907457,0.23019414,0.0026781752,0.0013695378,0.0039560464,0.0127886,0.06988199,0.44884905,0.000008491428,0.009750061,0.14177695],"study_design_scores_gemma":[0.024723368,0.045325894,0.5134597,0.010483453,0.009126638,0.0013408855,0.0018972862,0.09173274,0.12511316,0.00016695853,0.17586777,0.00076216855],"about_ca_topic_score_codex":0.00014101321,"about_ca_topic_score_gemma":0.00021668147,"teacher_disagreement_score":0.3237359,"about_ca_system_score_codex":0.001305743,"about_ca_system_score_gemma":0.0019104938,"threshold_uncertainty_score":0.44478348},"labels":[],"label_agreement":null},{"id":"W4403410304","doi":"10.1016/j.jtho.2024.09.054","title":"OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Pooled analysis; Meta-analysis; Adenocarcinoma; Cancer","score_opus":0.03214442016209941,"score_gpt":0.48421321979866294,"score_spread":0.45206879963656355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96465564,0.004197576,0.015553229,0.012833355,0.0006342062,0.00065343647,0.00037574026,0.00003327397,0.0010635626],"genre_scores_gemma":[0.96738464,0.0000510037,0.030010981,0.00078245415,0.00030215658,0.000025904199,0.00007919775,0.000028159757,0.0013355248],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9985652,0.00013571675,0.0006370648,0.00020256592,0.0002638085,0.00019566208],"domain_scores_gemma":[0.99791956,0.0008943901,0.0004872758,0.00018538667,0.00034524742,0.00016814198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005025001,0.00016494136,0.0010837724,0.0006016284,0.000046100464,0.00002236306,0.000100237296,0.00007888457,0.00041050045],"category_scores_gemma":[0.00018600194,0.00009160459,0.00038149318,0.0007314112,0.0000861948,0.00013185556,0.00001649303,0.00018596047,0.000003753466],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0394494,0.0032468475,0.035243757,0.0006976203,0.1740151,0.0033536502,0.008040608,0.0019665626,0.020945124,0.0005167214,0.019168487,0.6933561],"study_design_scores_gemma":[0.023919707,0.03792103,0.036010884,0.0031404924,0.6288041,0.002007104,0.007242199,0.013002408,0.030916505,0.0017356796,0.21440123,0.00089867803],"about_ca_topic_score_codex":0.00017846405,"about_ca_topic_score_gemma":0.0005670862,"teacher_disagreement_score":0.69245744,"about_ca_system_score_codex":0.00029042488,"about_ca_system_score_gemma":0.001423196,"threshold_uncertainty_score":0.44946918},"labels":[],"label_agreement":null},{"id":"W4403410305","doi":"10.1016/j.jtho.2024.09.178","title":"MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Taiwan University; National Taiwan University Hospital; Saint Petersburg State University; University of Ulsan; Seoul National University Hospital; Moffitt Cancer Center; Seoul National University; Ankara Yıldırım Beyazıt Üniversitesi; McGill University","keywords":"Medicine; Pembrolizumab; Olaparib; Oncology; Internal medicine; Maintenance therapy; Cancer; Immunotherapy; Chemotherapy; Poly ADP ribose polymerase; Polymerase","score_opus":0.06445639390388534,"score_gpt":0.49051155205626484,"score_spread":0.4260551581523795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9158279,0.014619011,0.03056724,0.02731428,0.005262736,0.0036984426,0.000121687495,0.00015651828,0.0024322174],"genre_scores_gemma":[0.9864096,0.0014179327,0.0042982167,0.0024553237,0.0017523037,0.00024821193,0.000016930448,0.00010747749,0.0032939992],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965575,0.00034917588,0.0014404817,0.0004486191,0.0006194239,0.0005848253],"domain_scores_gemma":[0.9967828,0.0010118813,0.0007141491,0.0004240943,0.00071140006,0.00035569046],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020680558,0.0003937583,0.0013913296,0.0005745504,0.00016553904,0.00007476632,0.000335807,0.00018602524,0.0010274152],"category_scores_gemma":[0.00033084885,0.00029206538,0.0005703659,0.00046760074,0.00018723572,0.00027010535,0.00004067001,0.00090673834,0.00015621644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15095344,0.01490695,0.00019376999,0.001043974,0.0047753695,0.013592611,0.008006507,0.00073948904,0.0089221,0.0005728237,0.1028652,0.69342774],"study_design_scores_gemma":[0.07910844,0.09422105,0.00035330607,0.0013233367,0.0023504477,0.019213142,0.003020162,0.00454684,0.006524789,0.005793597,0.7828508,0.00069411634],"about_ca_topic_score_codex":0.000023876477,"about_ca_topic_score_gemma":0.000035185,"teacher_disagreement_score":0.69273365,"about_ca_system_score_codex":0.0014390053,"about_ca_system_score_gemma":0.0021213559,"threshold_uncertainty_score":0.99995315},"labels":[],"label_agreement":null},{"id":"W4403410313","doi":"10.1016/j.jtho.2024.09.247","title":"P1.01A.02 Monitoring Inflammatory Response Secondary to Air Pollution Exposure Through Volatile Organic Compounds","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"","keywords":"Medicine; Inflammatory response; Environmental chemistry; Air pollution; Pollution; Environmental health; Toxicology; Immunology; Inflammation; Organic chemistry","score_opus":0.035574332715132335,"score_gpt":0.403330660468024,"score_spread":0.3677563277528917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9671768,0.0006170327,0.0014925906,0.02661562,0.0023376073,0.00015275102,0.0000059763493,0.00004890335,0.0015527458],"genre_scores_gemma":[0.98959666,0.000057644014,0.005644908,0.003110394,0.00073607836,0.0000033636552,6.86856e-7,0.000023913375,0.0008263231],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975897,0.0006917691,0.0007216544,0.00020494935,0.0004017146,0.00039017986],"domain_scores_gemma":[0.99877316,0.0003830771,0.00028360172,0.00019481368,0.000029818728,0.0003355174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027776007,0.00015945644,0.0003476807,0.00013514335,0.00020090994,0.000039979437,0.00028619333,0.00023232898,0.0011295131],"category_scores_gemma":[0.0002490157,0.00013946038,0.000104949606,0.00038768264,0.000117948286,0.00074996747,0.00016015656,0.00077795755,0.0005248392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012475579,0.0005996161,0.038013883,0.00053446845,0.00024009873,0.0023186062,0.04504859,0.0045600557,0.20562644,0.00012620418,0.28898633,0.40147012],"study_design_scores_gemma":[0.00030328883,0.0030243502,0.33357802,0.00028073622,0.000053968637,0.0009401071,0.0013783067,0.00010363933,0.007297899,0.0014735778,0.6513201,0.00024599742],"about_ca_topic_score_codex":0.000027825452,"about_ca_topic_score_gemma":0.000061247345,"teacher_disagreement_score":0.40122414,"about_ca_system_score_codex":0.0018038407,"about_ca_system_score_gemma":0.0005955361,"threshold_uncertainty_score":0.9997836},"labels":[],"label_agreement":null},{"id":"W4403410318","doi":"10.1016/j.jtho.2024.09.115","title":"MA03.11 Postoperative Complications Compromised Disease-Free and Recurrence-Free Survival in CALGB 140503 Trial Patients","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Surrey Memorial Hospital; University of British Columbia; Université du Québec","funders":"","keywords":"Medicine; Surgery; Oncology; Internal medicine","score_opus":0.045954771209030215,"score_gpt":0.4177748041736524,"score_spread":0.3718200329646222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97973,0.001310749,0.00003978734,0.013027871,0.0017474324,0.0008726801,0.000087505716,0.000017616712,0.0031663666],"genre_scores_gemma":[0.99810183,0.00016184349,0.0009041358,0.00026787503,0.00022625289,0.00004848417,0.000024949713,0.00001923526,0.0002453716],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980882,0.00034050198,0.00068474334,0.00026956276,0.00038479237,0.00023224275],"domain_scores_gemma":[0.9982502,0.0005851553,0.0002104728,0.00030442394,0.0002854922,0.00036427562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045775235,0.000180992,0.0006823427,0.00028180712,0.000056907065,0.000033580036,0.00022818321,0.00012054901,0.00014896395],"category_scores_gemma":[0.00074476877,0.00013558762,0.00015901563,0.0003488788,0.00016119574,0.00014562017,0.0001542521,0.0004799378,0.000013028246],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.275837,0.008165683,0.33340386,0.00045112794,0.0008786367,0.0057637496,0.0020742184,0.000023979435,0.00025432667,0.001338101,0.019179093,0.35263023],"study_design_scores_gemma":[0.050581876,0.009918639,0.88917565,0.0006846247,0.0005806677,0.00027596447,0.00015109447,0.0004941753,0.000042915046,0.0030219678,0.04482615,0.0002462745],"about_ca_topic_score_codex":0.000032282347,"about_ca_topic_score_gemma":0.00017606806,"teacher_disagreement_score":0.55577177,"about_ca_system_score_codex":0.0007180034,"about_ca_system_score_gemma":0.00070012663,"threshold_uncertainty_score":0.55291027},"labels":[],"label_agreement":null},{"id":"W4403410372","doi":"10.1016/j.jtho.2024.09.073","title":"OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Medicine; Pembrolizumab; KRAS; Oncology; Chemotherapy; Internal medicine; Cancer; Immunotherapy","score_opus":0.010375457593587985,"score_gpt":0.3512811453665129,"score_spread":0.3409056877729249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992229,0.0027030085,0.000060785733,0.0036855582,0.00019631813,0.00060296885,0.000010174676,0.000013254535,0.0004989712],"genre_scores_gemma":[0.9958404,0.0024961529,0.0010961381,0.00024747566,0.00009500187,0.0000083850955,0.0000068333156,0.000034172415,0.00017545147],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99854827,0.00008141659,0.0006353192,0.00021823439,0.0002881017,0.00022867593],"domain_scores_gemma":[0.9989628,0.0001954807,0.00038802615,0.000176096,0.0001601172,0.00011745066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028966911,0.00023094016,0.0008014714,0.0002851683,0.000035962017,0.000011571001,0.000080946695,0.00012928712,0.00012619547],"category_scores_gemma":[0.000023015786,0.00013045814,0.00010638517,0.0003474629,0.00018008178,0.00011595022,0.00001233249,0.00025991286,0.0000017667146],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29632673,0.0019141732,0.021042265,0.00020187155,0.0010288658,0.00064308994,0.0015300558,0.000063847016,0.0025520008,0.0000102546355,0.0000450029,0.67464185],"study_design_scores_gemma":[0.09414659,0.15412593,0.6512111,0.004524064,0.0010926864,0.0029527075,0.0005866097,0.00008683207,0.012483115,0.00007911908,0.07824323,0.00046802466],"about_ca_topic_score_codex":0.000044396536,"about_ca_topic_score_gemma":0.00012310962,"teacher_disagreement_score":0.67417383,"about_ca_system_score_codex":0.0007173044,"about_ca_system_score_gemma":0.00068661326,"threshold_uncertainty_score":0.53199285},"labels":[],"label_agreement":null},{"id":"W4403410377","doi":"10.1016/j.jtho.2024.09.074","title":"OA14.05 KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Samsung; Genentech; Humanitas Research Hospital; Universitair Ziekenhuis Antwerpen; Jewish General Hospital; Maastricht Universitair Medisch Centrum; Peter MacCallum Cancer Centre; Sungkyunkwan University; University of Manchester; Victoria University; University of Melbourne; Ottawa Hospital Research Institute; Monash University; Università degli Studi di Milano; Hospital de Câncer de Barretos; Seoul National University; Seoul National University Bundang Hospital; McGill University; Yale Cancer Center; Yale University","keywords":"Medicine; KRAS; Lung cancer; Oncology; Internal medicine; Phases of clinical research; Cancer; Cancer research; Clinical trial; Colorectal cancer","score_opus":0.012720449771520044,"score_gpt":0.3825332284158667,"score_spread":0.36981277864434664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578655,0.00042282732,0.00013090749,0.0016407066,0.00046992078,0.0005799443,0.00016559461,0.00003436788,0.000769164],"genre_scores_gemma":[0.997007,0.000046236437,0.0010730727,0.00048787033,0.00059836864,0.000021084341,0.0001115176,0.00004281376,0.0006120384],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971803,0.00027057633,0.001234048,0.00043927206,0.0005146623,0.00036115613],"domain_scores_gemma":[0.99817896,0.00017298493,0.00062858965,0.00025901737,0.00043954415,0.00032088914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006202036,0.00029777657,0.0009579488,0.0007186692,0.000059006517,0.000045348777,0.00015467337,0.00018621118,0.0003074792],"category_scores_gemma":[0.00009938712,0.0002126596,0.00022306632,0.00081072794,0.00006527612,0.00025734297,0.0000590684,0.00097608607,0.000025483067],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15317428,0.06410472,0.13649935,0.0008288669,0.005373203,0.047847662,0.02467127,0.0015332353,0.0886946,0.0000033965823,0.07121373,0.4060557],"study_design_scores_gemma":[0.36458603,0.15464422,0.22286701,0.03710051,0.020272937,0.0011201202,0.026572121,0.026338903,0.09037347,0.00010138471,0.05216476,0.0038585388],"about_ca_topic_score_codex":0.00016646233,"about_ca_topic_score_gemma":0.0005116167,"teacher_disagreement_score":0.40219715,"about_ca_system_score_codex":0.0008042652,"about_ca_system_score_gemma":0.00094165443,"threshold_uncertainty_score":0.8672006},"labels":[],"label_agreement":null},{"id":"W4403410382","doi":"10.1016/j.jtho.2024.09.051","title":"OA08.06 Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Docetaxel; Regimen; Internal medicine; Oncology; Pharmacology; Chemotherapy","score_opus":0.012242057141337833,"score_gpt":0.3590807503979023,"score_spread":0.34683869325656447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792493,0.00090723945,0.00024203233,0.008225151,0.0009428099,0.00048003645,0.000012886355,0.000023589282,0.0012413375],"genre_scores_gemma":[0.99526143,0.00007819315,0.0017832211,0.001821902,0.0003913565,0.000012157187,0.0000074412997,0.000045723293,0.00059858145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99777126,0.00019487822,0.0008171947,0.00031000315,0.00046593387,0.00044073781],"domain_scores_gemma":[0.99854696,0.00026036118,0.00038750228,0.0002581491,0.000302175,0.0002448552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011049282,0.00025986566,0.000870239,0.0008812856,0.000062865714,0.000053077194,0.00020882374,0.00021236105,0.00015034332],"category_scores_gemma":[0.00014595734,0.000186491,0.00020749068,0.0008151901,0.00011608229,0.00024286854,0.000053430736,0.0007412773,0.000035785088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32243586,0.0019281412,0.1356562,0.0006615011,0.0024474694,0.008204652,0.010002338,0.00019164245,0.026780581,0.000062839084,0.025759574,0.4658692],"study_design_scores_gemma":[0.010949142,0.028814506,0.778042,0.0039750156,0.00055656856,0.0017384483,0.0022096334,0.000083295,0.0031496647,0.000061444254,0.16990946,0.000510816],"about_ca_topic_score_codex":0.000051302235,"about_ca_topic_score_gemma":0.00014346343,"teacher_disagreement_score":0.6423858,"about_ca_system_score_codex":0.0014226851,"about_ca_system_score_gemma":0.001345749,"threshold_uncertainty_score":0.7604883},"labels":[],"label_agreement":null},{"id":"W4403410406","doi":"10.1016/j.jtho.2024.09.026","title":"OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Samsung; Université de Versailles Saint-Quentin-en-Yvelines; Sir Run Run Shaw Hospital; Faculty of Medicine, Prince of Songkla University; Deutsches Zentrum für Lungenforschung; College of Medicine, Seoul National University; Seoul National University Bundang Hospital; Prince of Songkla University; Institut Gustave-Roussy; Yonsei University College of Medicine; McGill University; Baskent Üniversitesi; Shanghai Jiao Tong University; Royal Marsden NHS Foundation Trust; Kindai University; Zhejiang University; Sungkyunkwan University; Yonsei University; Deutsches Krebsforschungszentrum; Capital Medical University; Seoul National University; Zhengzhou University; City of Hope; Kanazawa University; Nationales Centrum für Tumorerkrankungen Heidelberg; Universitätsklinikum Heidelberg; Hospital de Câncer de Barretos; Shanghai Chest Hospital","keywords":"Osimertinib; Medicine; Oncology; Mutant; First line; Second line; Internal medicine; Line (geometry); Epidermal growth factor receptor; Genetics; Cancer; Biology","score_opus":0.022268470418228156,"score_gpt":0.42492215481743734,"score_spread":0.4026536843992092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808855,0.0028019345,0.00009022108,0.010191701,0.002956963,0.0009148204,0.000018967872,0.0000207299,0.0021191475],"genre_scores_gemma":[0.99662024,0.00022232221,0.0005590139,0.0003944878,0.00027611706,0.000030108955,0.000004271637,0.00003491359,0.0018585471],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99770594,0.00021684945,0.0011020823,0.00024859337,0.0004279756,0.00029856194],"domain_scores_gemma":[0.99842715,0.0003442467,0.0005154811,0.00032745057,0.000251695,0.00013398484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066702964,0.00021669354,0.0008439189,0.00030664698,0.00007469327,0.000019229303,0.00023594528,0.00014224894,0.00021356219],"category_scores_gemma":[0.0002712511,0.00012803431,0.00031436345,0.0005827325,0.00009825044,0.00015866179,0.00009035594,0.00060795475,0.000021115939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04037343,0.010600518,0.10488137,0.001244019,0.0060397033,0.010484193,0.039374925,0.002529644,0.014906808,0.00020977615,0.0057193814,0.76363623],"study_design_scores_gemma":[0.07460857,0.058830157,0.53361714,0.009439331,0.019791842,0.0077190516,0.025270889,0.0036577217,0.0219933,0.0021460073,0.24156629,0.0013596811],"about_ca_topic_score_codex":0.00006359917,"about_ca_topic_score_gemma":0.00052481546,"teacher_disagreement_score":0.76227653,"about_ca_system_score_codex":0.0009584733,"about_ca_system_score_gemma":0.0013456651,"threshold_uncertainty_score":0.52210873},"labels":[],"label_agreement":null},{"id":"W4403410420","doi":"10.1016/j.jtho.2024.09.045","title":"OA07.04 Optimising Care of Older Patients with Lung Cancer - An Innovative Nurse-led Model of Care","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton University","funders":"","keywords":"Medicine; Lung cancer; Nursing; Intensive care medicine; Oncology","score_opus":0.15415617274211388,"score_gpt":0.511821861129548,"score_spread":0.35766568838743407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806633,0.00857439,0.004509358,0.0026250607,0.001043148,0.00044152452,0.00045225775,0.000011186924,0.0016797874],"genre_scores_gemma":[0.98594844,0.00007710188,0.013059083,0.0005451881,0.0002303484,0.000015976959,0.0000222766,0.000037689137,0.000063901396],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99544376,0.00027308203,0.0035821474,0.00029086103,0.00015486084,0.00025527307],"domain_scores_gemma":[0.99401265,0.00034419753,0.0040320745,0.00025695987,0.0012270258,0.00012710536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032507696,0.00017815376,0.0013989374,0.00067722995,0.00006629677,0.000027902646,0.00027729425,0.00020869878,0.00013661769],"category_scores_gemma":[0.000375453,0.00017543555,0.00012611265,0.00039784206,0.000110011046,0.00064516364,0.0000285778,0.0003542393,0.000006548823],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018346328,0.0011337356,0.41736224,0.013590833,0.002038037,0.000028150422,0.30882275,0.18447103,0.00009256275,0.014313744,0.0064408523,0.04987144],"study_design_scores_gemma":[0.014038796,0.017046485,0.30036485,0.017357199,0.0014324219,0.00011321836,0.20001362,0.4188649,0.001644503,0.0068925843,0.018693916,0.0035374947],"about_ca_topic_score_codex":0.00015255406,"about_ca_topic_score_gemma":0.000121225756,"teacher_disagreement_score":0.2343939,"about_ca_system_score_codex":0.0015639198,"about_ca_system_score_gemma":0.0013838792,"threshold_uncertainty_score":0.7154054},"labels":[],"label_agreement":null},{"id":"W4403410433","doi":"10.1016/j.jtho.2024.09.019","title":"PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of California, Davis; University of Texas MD Anderson Cancer Center; Institut Gustave-Roussy; Chinese Academy of Medical Sciences; Comprehensive Cancer Center, University of California, Davis; Zhengzhou University; Kanazawa University; Kindai University; Harbin Medical University","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.025264826565226155,"score_gpt":0.4676684770420523,"score_spread":0.4424036504768261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876873,0.0030221986,0.00027683785,0.003582708,0.0004523442,0.0012299012,0.000028653909,0.000021884878,0.003698173],"genre_scores_gemma":[0.9958338,0.00009831799,0.0031493814,0.00014851235,0.00011198001,0.000078705576,0.000007004547,0.000022645963,0.0005496086],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979341,0.00035542226,0.0009262807,0.00021419453,0.00034554183,0.00022446761],"domain_scores_gemma":[0.9983032,0.00052371324,0.0005299352,0.00018559366,0.0003123082,0.00014528802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067103066,0.00018943996,0.0011125705,0.00027369,0.000053168093,0.000015965796,0.000102335354,0.000082210034,0.000179446],"category_scores_gemma":[0.00015932352,0.00011825624,0.00019908462,0.0005113693,0.00013144755,0.00017352193,0.00003419514,0.0002760607,0.000015079366],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42717686,0.011538518,0.032679886,0.0005070232,0.008491397,0.011463542,0.062154137,0.0053558038,0.0030092048,0.00035793008,0.0012100884,0.4360556],"study_design_scores_gemma":[0.7707937,0.028524233,0.120125584,0.0030764956,0.015271045,0.0063485815,0.04012526,0.0012817783,0.0009390873,0.0031090905,0.009719647,0.0006855376],"about_ca_topic_score_codex":0.00013579556,"about_ca_topic_score_gemma":0.0005970713,"teacher_disagreement_score":0.43537006,"about_ca_system_score_codex":0.0010890369,"about_ca_system_score_gemma":0.0010337859,"threshold_uncertainty_score":0.48223495},"labels":[],"label_agreement":null},{"id":"W4403410443","doi":"10.1016/j.jtho.2024.09.013","title":"PL02.07 Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC","year":2024,"lang":"fr","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Adjuvant; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.03654236561430961,"score_gpt":0.42623399955929653,"score_spread":0.3896916339449869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88726276,0.07547149,0.0047846516,0.023011634,0.006844298,0.0005574379,0.00004543703,0.000016674134,0.0020055869],"genre_scores_gemma":[0.9717456,0.016237276,0.0078066094,0.00080809736,0.0014177032,0.000004155728,0.0000070887013,0.000077371835,0.0018960957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99583584,0.00039688378,0.001786374,0.0005029613,0.00068508,0.00079286547],"domain_scores_gemma":[0.9968027,0.0013614038,0.0007371375,0.0002701723,0.00021751296,0.0006111107],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004428469,0.00038978673,0.0016724741,0.00070597045,0.000100508856,0.000072768766,0.0002873171,0.00024950822,0.00041053636],"category_scores_gemma":[0.0019449507,0.00032838114,0.00020102962,0.0005348797,0.0007592074,0.00032893848,0.00029236736,0.0023811408,0.000013946551],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041445973,0.001904124,0.012428828,0.0023346012,0.0008902368,0.007228556,0.002942964,0.001133479,0.018559778,0.00064534764,0.004829747,0.94295776],"study_design_scores_gemma":[0.021662077,0.0066584293,0.2559138,0.030567221,0.0029266854,0.030917779,0.0018110208,0.19618559,0.0008549117,0.00045782223,0.45122325,0.0008214079],"about_ca_topic_score_codex":0.00045115952,"about_ca_topic_score_gemma":0.000053913598,"teacher_disagreement_score":0.94213635,"about_ca_system_score_codex":0.00065149873,"about_ca_system_score_gemma":0.0012119656,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W4403410455","doi":"10.1016/j.jtho.2024.09.016","title":"PL02.14 Triaging ILST Screening Participants at Program Entry: Comparative Performance of PanCan versus LungRADSv1.1 Protocol","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Transplantation: Methods and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health; Brock University","funders":"","keywords":"Medicine; Protocol (science); Pathology; Alternative medicine","score_opus":0.1746941991570953,"score_gpt":0.5622088168261614,"score_spread":0.38751461766906614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840405,0.00032305048,0.0007314582,0.0012263592,0.0010482122,0.010523843,0.000008456765,0.000049456572,0.0020486426],"genre_scores_gemma":[0.9494652,0.000053199605,0.04783692,0.00006267742,0.0004606743,0.0017768857,0.0000050911244,0.000020052372,0.00031929556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785036,0.00033130447,0.0009084237,0.00017589166,0.00038474836,0.0003492732],"domain_scores_gemma":[0.99827623,0.00064490864,0.00051526155,0.00013624725,0.00022304775,0.00020429287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013393441,0.00017675641,0.0008638428,0.00025312,0.00007891487,0.000023223833,0.00012586024,0.00012401269,0.00012235518],"category_scores_gemma":[0.00010128914,0.00012520191,0.0002293066,0.00033438046,0.00014067817,0.00018941957,0.000024812078,0.00051407766,0.000008119193],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059698712,0.0008116161,0.07662159,0.0026807436,0.0013970952,0.0010291435,0.006598672,0.00015359836,0.0071557635,0.00009134796,0.0011424586,0.84261924],"study_design_scores_gemma":[0.028818946,0.05087384,0.32463902,0.008950021,0.0062559014,0.0041950024,0.004075586,0.018683475,0.1471414,0.000097870216,0.40539595,0.0008729885],"about_ca_topic_score_codex":0.0000065087092,"about_ca_topic_score_gemma":0.000019853045,"teacher_disagreement_score":0.8417463,"about_ca_system_score_codex":0.00023816177,"about_ca_system_score_gemma":0.00043620294,"threshold_uncertainty_score":0.5105586},"labels":[],"label_agreement":null},{"id":"W4403419530","doi":"10.1016/j.jtho.2024.09.770","title":"P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"NOSM University; Thunder Bay Regional Health Sciences Centre; Université Laval; Ottawa Hospital; Institut universitaire de cardiologie et de pneumologie de Québec; Western University","funders":"","keywords":"Medicine; Observational study; Lung cancer; Database; Environmental health; Internal medicine","score_opus":0.08874857220178278,"score_gpt":0.5242819123374549,"score_spread":0.43553334013567213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97205824,0.0030032468,0.00004295646,0.01865164,0.0014369972,0.0029141922,0.00017705881,0.000044385895,0.0016713138],"genre_scores_gemma":[0.9969463,0.00012552044,0.000641421,0.0005171017,0.0004974887,0.00019382237,0.000043327407,0.00003420987,0.001000826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715114,0.00051792385,0.0010051104,0.00038439178,0.0004849629,0.00045648846],"domain_scores_gemma":[0.9980927,0.0002545935,0.0004326949,0.00026863575,0.00043684925,0.0005145229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013184793,0.00022418443,0.0008034199,0.0011859101,0.00015523286,0.00008014826,0.0001625006,0.00007206388,0.0001325034],"category_scores_gemma":[0.000087794484,0.00017587142,0.0001223553,0.0011432313,0.000035401976,0.00037317377,0.00004140536,0.00063872983,0.000011866303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00071732036,0.0033232197,0.95048606,0.00037928953,0.0017653838,0.005259786,0.012755385,0.00006371663,0.000012258366,0.00019430059,0.005183022,0.019860232],"study_design_scores_gemma":[0.0037255134,0.002347756,0.95142025,0.0009964319,0.0013664932,0.00025930873,0.031808045,0.0013980098,0.0000028177715,0.0000115511,0.0065131932,0.00015064015],"about_ca_topic_score_codex":0.26743752,"about_ca_topic_score_gemma":0.8895696,"teacher_disagreement_score":0.62213206,"about_ca_system_score_codex":0.010567092,"about_ca_system_score_gemma":0.007867995,"threshold_uncertainty_score":0.9977565},"labels":[],"label_agreement":null},{"id":"W4403419557","doi":"10.1016/j.jtho.2024.09.772","title":"P4.17E.01 Navigating from Target to Treatment: Early Impact of the Lung Precision Oncology Navigation Program (LPOP)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Precision oncology; Oncology; Lung; Medical physics; Internal medicine; Cancer","score_opus":0.02041583549095195,"score_gpt":0.5138545463403726,"score_spread":0.4934387108494207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834411,0.0060529755,0.0018695495,0.003935076,0.0028123911,0.00087731297,0.00003433017,0.000044904282,0.0009323508],"genre_scores_gemma":[0.9439071,0.0003984533,0.053143922,0.0002636347,0.0018760535,0.000034776855,0.00001825881,0.000042461237,0.00031538118],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975646,0.00053483655,0.00096726883,0.0002728247,0.00032566342,0.0003347705],"domain_scores_gemma":[0.9973316,0.0011439017,0.0007383584,0.00030258403,0.00025688607,0.00022667354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084724085,0.00024640944,0.00095708796,0.00015967507,0.00011798757,0.000020356192,0.00024065575,0.00046448663,0.00020763806],"category_scores_gemma":[0.00022915556,0.00013532114,0.00059270643,0.00051793084,0.0002286049,0.000221403,0.00005610897,0.00096712844,0.000014145037],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00392234,0.0010946667,0.022297919,0.0000679174,0.0009961409,0.00079681753,0.004519731,0.000628019,0.020863568,0.000022517457,0.0016177521,0.94317263],"study_design_scores_gemma":[0.008789077,0.17641705,0.27706397,0.009215965,0.004087234,0.013246758,0.0013879891,0.010254814,0.039957874,0.010115546,0.44854525,0.00091848965],"about_ca_topic_score_codex":0.00010075067,"about_ca_topic_score_gemma":0.000015795204,"teacher_disagreement_score":0.9422541,"about_ca_system_score_codex":0.0027765045,"about_ca_system_score_gemma":0.0015176941,"threshold_uncertainty_score":0.72604626},"labels":[],"label_agreement":null},{"id":"W4403419591","doi":"10.1016/j.jtho.2024.09.568","title":"P3.03I.18 Optimizing Delivery of Anti-Cancer Therapeutics in Lung Adenocarcinoma Using Ultrasound-Induced Cavitation of Microbubbles","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Microbubbles; Cavitation; Ultrasound; Adenocarcinoma; Lung cancer; Lung; Cancer; Radiology; Oncology; Internal medicine; Acoustics","score_opus":0.04420606049517691,"score_gpt":0.3782773754094116,"score_spread":0.3340713149142347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98558044,0.010638977,0.003010559,0.00007519726,0.00040622836,0.0000969013,0.000012889226,0.000017675191,0.00016111178],"genre_scores_gemma":[0.9869339,0.0015306077,0.011339022,0.000023900944,0.00012872729,0.000003210388,0.0000020964446,0.000029500161,0.000009052894],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989271,0.000068415415,0.00062457594,0.00009480285,0.00012300101,0.0001620735],"domain_scores_gemma":[0.99916315,0.00034466028,0.00020891328,0.000101493504,0.00014516468,0.0000366179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031288186,0.0001203109,0.00039138505,0.00034801732,0.000024292924,0.000017215572,0.000156432,0.00015360373,0.000031650332],"category_scores_gemma":[0.000011909813,0.00011155772,0.00011777663,0.00034119404,0.000046245957,0.00018708971,0.000011522407,0.00031120077,9.169859e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035292895,0.00006144688,0.0037248044,0.00027068803,0.00018083758,0.0000123507,0.0012999153,0.037481718,0.94556093,0.000026708649,0.00004003194,0.01130529],"study_design_scores_gemma":[0.00084981445,0.000501046,0.022406422,0.0016212029,0.0012021642,0.0009397463,0.00355695,0.08388817,0.88211757,0.00040327347,0.0019666443,0.0005469871],"about_ca_topic_score_codex":0.000040117367,"about_ca_topic_score_gemma":0.00003362644,"teacher_disagreement_score":0.06344334,"about_ca_system_score_codex":0.00028880345,"about_ca_system_score_gemma":0.00021793964,"threshold_uncertainty_score":0.4549192},"labels":[],"label_agreement":null},{"id":"W4403419630","doi":"10.1016/j.jtho.2024.09.585","title":"P3.06D.10 Concordance of Liquid Biopsy and Tissue Biopsy for the Detection of EGFR Mutation in Stage III NSCLC in the United States","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Concordance; Medicine; Stage (stratigraphy); Biopsy; Liquid biopsy; Oncology; Pathology; Internal medicine; Cancer","score_opus":0.02240898837132275,"score_gpt":0.43630960504835115,"score_spread":0.4139006166770284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98740065,0.0034022022,0.0043764496,0.0039563454,0.00027591386,0.00044019235,0.000026746155,0.0000038718767,0.000117639225],"genre_scores_gemma":[0.99836206,0.00043036664,0.0007748963,0.00009646382,0.00007451678,0.000024621768,0.000011943469,0.000008492856,0.00021663474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991111,0.000119602344,0.00046959965,0.00008246793,0.00011905376,0.00009814488],"domain_scores_gemma":[0.99867845,0.00072647474,0.00030310472,0.00008434139,0.00018196851,0.000025659667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007246343,0.0000745729,0.00026502123,0.00032016038,0.000029787147,0.000008688107,0.00006399822,0.000067765715,0.000020007077],"category_scores_gemma":[0.00010491347,0.000040601353,0.000047830406,0.00045078283,0.00010984057,0.00007969173,0.000009345502,0.0001716301,4.3518526e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024715299,0.0013963312,0.0028285747,0.0019119648,0.0011677286,0.001199798,0.04639503,0.0025998575,0.20085001,0.00086648227,0.00042053897,0.7156484],"study_design_scores_gemma":[0.029528024,0.08770543,0.15855232,0.0062323846,0.0076832506,0.012272338,0.14856368,0.046058066,0.22928584,0.005145915,0.26814163,0.0008311073],"about_ca_topic_score_codex":0.00037655723,"about_ca_topic_score_gemma":0.00022902199,"teacher_disagreement_score":0.7148173,"about_ca_system_score_codex":0.00017545246,"about_ca_system_score_gemma":0.0002467034,"threshold_uncertainty_score":0.16556752},"labels":[],"label_agreement":null},{"id":"W4403419632","doi":"10.1016/j.jtho.2024.09.517","title":"P2.16F.03 Development of a Patient-Friendly Lung Cancer Lexicon","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Lexicon; Lung cancer; Radiology; Oncology; Natural language processing","score_opus":0.017917203542575238,"score_gpt":0.46574949764445367,"score_spread":0.4478322941018784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97121924,0.014245219,0.00071844045,0.0044758082,0.002054307,0.00024950507,0.000012120348,0.000018052311,0.007007334],"genre_scores_gemma":[0.9833118,0.00021405009,0.014908749,0.00022247552,0.0002498915,0.000019916033,0.000004782791,0.000017533162,0.001050817],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998873,0.000043492288,0.0005792476,0.00011390859,0.0002321407,0.00015818584],"domain_scores_gemma":[0.9991912,0.000071010894,0.00028672733,0.000090439935,0.00023821654,0.00012235233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019726442,0.00010296198,0.00037760325,0.00023059666,0.000042721495,0.000010093646,0.00006331068,0.00008714309,0.0003570598],"category_scores_gemma":[0.00003430809,0.000070961214,0.00012526123,0.00019305915,0.000043910306,0.0001017893,0.00002472704,0.00021594287,0.000010345143],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007804838,0.00056475337,0.004068215,0.00061085937,0.0017893671,0.00081637566,0.010013198,0.000057531157,0.0052360627,0.00023457572,0.011179151,0.96464944],"study_design_scores_gemma":[0.0020122773,0.0047836616,0.012199932,0.0028632202,0.0038418823,0.00178618,0.0027528224,0.00037470084,0.035923593,0.00038120092,0.93281436,0.0002661794],"about_ca_topic_score_codex":0.000017715267,"about_ca_topic_score_gemma":0.000031936772,"teacher_disagreement_score":0.96438324,"about_ca_system_score_codex":0.0008752075,"about_ca_system_score_gemma":0.0034154535,"threshold_uncertainty_score":0.60588676},"labels":[],"label_agreement":null},{"id":"W4403419651","doi":"10.1016/j.jtho.2024.09.529","title":"P3.01D.02 Lung Cancer Incidence Trends by Histology and Sociodemographic Characteristics in the US from 2000-2019","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation","funders":"","keywords":"Medicine; Lung cancer; Histology; Incidence (geometry); Cancer; Internal medicine; Oncology","score_opus":0.03185678087537261,"score_gpt":0.4331647542080402,"score_spread":0.40130797333266754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91189146,0.06605862,0.00016817087,0.020121265,0.0010480185,0.00008276398,0.000047329184,0.000012256031,0.00057012984],"genre_scores_gemma":[0.99020964,0.00474825,0.0005140726,0.0034726753,0.0006628249,0.000008783315,0.000011956606,0.000014454792,0.00035732647],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982395,0.00026748198,0.00064785697,0.00021923386,0.00033109746,0.0002948178],"domain_scores_gemma":[0.99888575,0.0003983669,0.00033150372,0.00015268331,0.0001059964,0.00012572871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010588263,0.00016309904,0.0006339358,0.00031243794,0.000063804226,0.0000392146,0.00023591726,0.00025843582,0.0002540778],"category_scores_gemma":[0.000092298265,0.000109982786,0.00013507123,0.00042524928,0.00021270895,0.00018320075,0.000044475415,0.001001583,0.000003941211],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016127465,0.00013566228,0.3182054,0.00012748384,0.00029434377,0.0043137874,0.0040419395,0.0000068753043,0.0033596465,0.000056477664,0.13652469,0.531321],"study_design_scores_gemma":[0.0011317737,0.002591265,0.6933951,0.001471263,0.0016847542,0.0063199783,0.0011276444,0.0028491032,0.00012666117,0.0006773706,0.2882669,0.00035821757],"about_ca_topic_score_codex":0.00084141054,"about_ca_topic_score_gemma":0.000435673,"teacher_disagreement_score":0.53096277,"about_ca_system_score_codex":0.0005982203,"about_ca_system_score_gemma":0.0006672086,"threshold_uncertainty_score":0.4484968},"labels":[],"label_agreement":null},{"id":"W4403419652","doi":"10.1016/j.jtho.2024.09.543","title":"P3.02G.02 Integrin-Linked Kinase Facilitates Drug Tolerant Persister Cell Survival and EMT in Response to EGFR Targeted Therapy","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation","funders":"","keywords":"Medicine; Drug; Cancer research; Pharmacology; Multidrug tolerance; Oncology; Biology; Genetics; Bacteria","score_opus":0.05558787460023284,"score_gpt":0.4507780967487866,"score_spread":0.39519022214855376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483537,0.00965274,0.0000675079,0.039317522,0.0011755496,0.0004518677,0.00001797146,0.000024377463,0.0009387471],"genre_scores_gemma":[0.9915355,0.00087090925,0.0017823023,0.0007882294,0.0003650119,0.000018790675,0.0000026704354,0.000041565097,0.0045950483],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641645,0.0013456809,0.0008042099,0.00035545416,0.00057503843,0.00050314295],"domain_scores_gemma":[0.99738425,0.0014147958,0.0001244218,0.00026488173,0.0003367539,0.00047491462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005264318,0.00023779544,0.00081400713,0.00092464057,0.00004972296,0.000066733235,0.00025073215,0.00021466843,0.00059422373],"category_scores_gemma":[0.0005852527,0.00017456766,0.00020174214,0.000555692,0.00017148156,0.00013728217,0.000103039965,0.0014601168,0.000081176346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1166575,0.0013069689,0.009421679,0.0010562602,0.0003798688,0.018574048,0.04553066,0.00012024292,0.3950599,0.000016818956,0.027576435,0.38429958],"study_design_scores_gemma":[0.0059272414,0.020388005,0.06639586,0.0020257153,0.00019605315,0.0023384015,0.018160848,0.0015483059,0.02618737,0.00033359858,0.8558507,0.00064788316],"about_ca_topic_score_codex":0.0001211878,"about_ca_topic_score_gemma":0.00014143158,"teacher_disagreement_score":0.8282743,"about_ca_system_score_codex":0.0010450686,"about_ca_system_score_gemma":0.0013649683,"threshold_uncertainty_score":0.71186626},"labels":[],"label_agreement":null},{"id":"W4403419720","doi":"10.1016/j.jtho.2024.09.744","title":"P4.14C.03 Real-World Prognostic &amp; Predictive Implications of EORTC &amp; MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Place Centre; Surrey Memorial Hospital","funders":"","keywords":"Medicine; Mesothelioma; Immunotherapy; Chemotherapy; Oncology; Internal medicine; Pathology; Cancer","score_opus":0.03087979366233211,"score_gpt":0.4162864778492585,"score_spread":0.38540668418692636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895914,0.0028295936,0.000459972,0.0056622387,0.00017098259,0.00054613384,0.00010092198,0.000015364454,0.0006233728],"genre_scores_gemma":[0.9924687,0.0015107059,0.004754407,0.00034856866,0.00022264641,0.00005397909,0.000039275626,0.00002865231,0.00057303195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988451,0.0000701611,0.0005684962,0.00017129217,0.0001753998,0.00016952636],"domain_scores_gemma":[0.99891126,0.00050116784,0.00025921254,0.00013367413,0.000084727486,0.00010998425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034847046,0.00013584856,0.0004282346,0.0003899418,0.00003779977,0.00001243086,0.00009113185,0.00008425437,0.0001463419],"category_scores_gemma":[0.000084557265,0.00010285777,0.00015903491,0.00024651838,0.00018917922,0.000118460935,0.000019262385,0.00018466778,0.000005550652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011094588,0.001614202,0.8575988,0.0005722803,0.00067579554,0.000045129138,0.0011810466,0.00008388082,0.034441147,0.00055527815,0.0038552936,0.08828258],"study_design_scores_gemma":[0.0011961582,0.0014786564,0.9722455,0.00039254964,0.0002419621,0.00028687075,0.00006653011,0.00007840464,0.0006794062,0.0050019887,0.018238025,0.00009395437],"about_ca_topic_score_codex":0.000037026985,"about_ca_topic_score_gemma":0.00015851717,"teacher_disagreement_score":0.11464672,"about_ca_system_score_codex":0.00025292308,"about_ca_system_score_gemma":0.0002653934,"threshold_uncertainty_score":0.4194418},"labels":[],"label_agreement":null},{"id":"W4403419783","doi":"10.1016/j.jtho.2024.09.445","title":"P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lions Gate Hospital; Grand River Hospital; Lakeridge Health; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Osimertinib; Medicine; Pemetrexed; Lung cancer; Oncology; Prospective cohort study; Internal medicine; Cohort; Cancer; Chemotherapy; Epidermal growth factor receptor; Cisplatin; Erlotinib","score_opus":0.008008396597811867,"score_gpt":0.4372606523799116,"score_spread":0.4292522557820997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951262,0.0011277695,0.000010657363,0.00036245215,0.0004494157,0.0022937327,0.000017573971,0.000017844475,0.00059436937],"genre_scores_gemma":[0.9987485,0.00002658303,0.000647853,0.00005544031,0.00008617202,0.00021007788,0.000010859315,0.000030843625,0.00018371789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983448,0.00012901647,0.0006101346,0.00025768872,0.00045101176,0.00020734346],"domain_scores_gemma":[0.9988352,0.00014857251,0.00041640393,0.00014569725,0.0003486257,0.00010550901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027155058,0.00018344312,0.0006359069,0.0004013816,0.000031216972,0.000010674599,0.00006564479,0.00008290841,0.00013803778],"category_scores_gemma":[0.00008419692,0.000110261804,0.000088376655,0.00053251325,0.000058909023,0.00014004836,0.000022059221,0.00040129904,0.000003208532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019646833,0.004583713,0.8732061,0.00012183902,0.0011429192,0.0006377484,0.0029889555,0.00018833311,0.000089087705,0.0000015450169,0.00010025155,0.0972927],"study_design_scores_gemma":[0.0076048058,0.013947976,0.97378385,0.001813345,0.0015702271,0.000023211953,0.00034900816,0.000099181016,0.00052855443,0.000007975698,0.00017045299,0.00010138832],"about_ca_topic_score_codex":0.00003261948,"about_ca_topic_score_gemma":0.000067267756,"teacher_disagreement_score":0.100577794,"about_ca_system_score_codex":0.0011735152,"about_ca_system_score_gemma":0.0006929976,"threshold_uncertainty_score":0.4496346},"labels":[],"label_agreement":null},{"id":"W4403419790","doi":"10.1016/j.jtho.2024.09.671","title":"P4.04D.03 Lung Cancer in Those Who Never Smoked Study (luCNeSS) - Preliminary Analysis","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Lung cancer; Oncology","score_opus":0.025359377388269672,"score_gpt":0.4667775935709027,"score_spread":0.44141821618263305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9576493,0.031249652,0.0000471051,0.008435612,0.0011644438,0.0005195857,0.000011327916,0.00002114381,0.00090183783],"genre_scores_gemma":[0.9952373,0.0023134213,0.00022527073,0.00047462824,0.00056301634,0.000087154964,0.0000032875962,0.000027792003,0.0010681554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979243,0.00029203077,0.0007740814,0.00031163878,0.00040438733,0.0002935319],"domain_scores_gemma":[0.99875563,0.00030782277,0.00028547863,0.00026513173,0.00019345638,0.00019249998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009069802,0.00021194795,0.0010949692,0.00092890736,0.000042742544,0.000036906997,0.00014915498,0.00015908838,0.0006948724],"category_scores_gemma":[0.000053681317,0.00014653263,0.00040578804,0.0012071258,0.000047347105,0.0002548701,0.000064645035,0.0005673089,0.000010974934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003972539,0.0043469802,0.7462066,0.00042647767,0.0108104665,0.020106139,0.004644128,0.0013445668,0.000067274384,0.000028411006,0.011625818,0.19642064],"study_design_scores_gemma":[0.0018524925,0.004856477,0.9588778,0.0012351715,0.019267865,0.00029878388,0.00088419724,0.0028599377,0.00019220187,0.000072470786,0.009423184,0.00017942638],"about_ca_topic_score_codex":0.0003376286,"about_ca_topic_score_gemma":0.00080260186,"teacher_disagreement_score":0.21267124,"about_ca_system_score_codex":0.0022496926,"about_ca_system_score_gemma":0.00091906,"threshold_uncertainty_score":0.76083654},"labels":[],"label_agreement":null},{"id":"W4403419811","doi":"10.1016/j.jtho.2024.09.442","title":"P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Platinum; Oncology; Internal medicine; Pharmacology","score_opus":0.03753390002305056,"score_gpt":0.48300030210332506,"score_spread":0.4454664020802745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96883094,0.0006552966,0.013046706,0.014323844,0.00027061105,0.0021449898,0.000020446361,0.00014055347,0.0005666137],"genre_scores_gemma":[0.969625,0.0002895667,0.02793998,0.0006915317,0.00035605545,0.00014409733,0.000023248487,0.00005807243,0.0008724609],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977575,0.00012970691,0.0011814205,0.00028047903,0.0003381688,0.00031272383],"domain_scores_gemma":[0.9979381,0.00041498707,0.00060879585,0.0003337978,0.0004315946,0.0002727271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010407614,0.00022454002,0.0010315694,0.00030566976,0.000061282415,0.000021067268,0.00025476154,0.00017667352,0.00030189953],"category_scores_gemma":[0.00022600191,0.00016161418,0.00025748994,0.00041947767,0.00011297387,0.00011465774,0.00003219514,0.0005592237,0.000009324926],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01840678,0.011044769,0.00046617177,0.00070759165,0.0011760565,0.00068957324,0.0028629694,0.00002864816,0.13621022,0.00012328428,0.06148184,0.7668021],"study_design_scores_gemma":[0.056364603,0.11795446,0.001520799,0.003631022,0.0051053055,0.0038785404,0.0032586,0.014845565,0.12381095,0.002170021,0.6665644,0.00089571514],"about_ca_topic_score_codex":0.000015530639,"about_ca_topic_score_gemma":0.0000050747867,"teacher_disagreement_score":0.7659064,"about_ca_system_score_codex":0.0002879996,"about_ca_system_score_gemma":0.00045810954,"threshold_uncertainty_score":0.6590435},"labels":[],"label_agreement":null},{"id":"W4403419862","doi":"10.1016/j.jtho.2024.09.396","title":"P2.04B.08 Terminology in Lung Cancer Screening and Early Detection - IASLC Early Detection and Screening Committee Recommendations","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Medicine; Terminology; Lung cancer screening; Lung cancer; Cancer detection; Medical physics; Cancer; Oncology; Internal medicine; Linguistics","score_opus":0.031085773406783694,"score_gpt":0.41409903726729885,"score_spread":0.38301326386051515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976193,0.008325224,0.004414589,0.009834118,0.0008283035,0.0002522276,0.0000049579053,0.000026194572,0.0001213481],"genre_scores_gemma":[0.9947482,0.0018437292,0.0026508092,0.00017336324,0.0004147978,0.00004169833,0.0000012515503,0.000022683229,0.00010348631],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987224,0.00018209002,0.0004996994,0.00023045675,0.00013527229,0.00023009899],"domain_scores_gemma":[0.9991082,0.00031530144,0.00024126696,0.00009638635,0.00010290767,0.00013593407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053015887,0.00015209564,0.00045380383,0.0005655113,0.00011560995,0.000057521305,0.00004755091,0.00019958722,0.000043418444],"category_scores_gemma":[0.000057077134,0.00012727999,0.00008468043,0.0002531162,0.000078189536,0.00029560042,0.000046785568,0.0006355157,0.0000013085813],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005785901,0.00008433161,0.16345787,0.00013593867,0.00031642508,0.000366136,0.00096270145,0.000011909447,0.0019064044,0.000006423203,0.0001815855,0.8319917],"study_design_scores_gemma":[0.0019887714,0.003445829,0.96888345,0.0016593881,0.0010977186,0.0027376395,0.00046566958,0.002684789,0.0033642557,0.00013903875,0.013353858,0.00017960931],"about_ca_topic_score_codex":0.0006853503,"about_ca_topic_score_gemma":0.0013128372,"teacher_disagreement_score":0.8318121,"about_ca_system_score_codex":0.0005869386,"about_ca_system_score_gemma":0.00012183239,"threshold_uncertainty_score":0.5190327},"labels":[],"label_agreement":null},{"id":"W4403419864","doi":"10.1016/j.jtho.2024.09.400","title":"P2.04B.12 Respiratory Function as a Prognostic Factor for Lung Cancer in Screening and General Populations","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Sinai Health System","funders":"","keywords":"Medicine; Lung cancer; Lung function; Respiratory system; Cancer; Lung cancer screening; Internal medicine; Oncology; Intensive care medicine; Lung","score_opus":0.06728156085199953,"score_gpt":0.481915451720024,"score_spread":0.41463389086802444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97489893,0.016069863,0.0015309067,0.0056829434,0.0011588287,0.0004772481,0.000020699958,0.000013869632,0.00014672396],"genre_scores_gemma":[0.9947649,0.00024710395,0.0032112857,0.0005332634,0.00088396826,0.000090914065,0.0000033022454,0.000018151852,0.0002470861],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991685,0.00005880708,0.00035106987,0.00014198964,0.00012740759,0.0001522181],"domain_scores_gemma":[0.9994177,0.00017734707,0.00013950995,0.000059057944,0.00010128011,0.0001050907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002602541,0.00009503551,0.0002984005,0.00025681301,0.000044144108,0.00002332848,0.0000269306,0.00010108286,0.00009490644],"category_scores_gemma":[0.00009706013,0.00007019903,0.000096594544,0.0001171518,0.000023465305,0.00012265073,0.000013412338,0.0002089236,8.206408e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014575426,0.00024052641,0.519569,0.00047787966,0.00044912586,0.0003986112,0.0005541671,0.00026865306,0.0008042507,0.00026432384,0.0037988368,0.47171712],"study_design_scores_gemma":[0.0019841378,0.004831599,0.9248619,0.0017430895,0.0017605518,0.00041340681,0.00013708111,0.00478125,0.0002911309,0.00040899112,0.05864664,0.00014021434],"about_ca_topic_score_codex":0.000056180295,"about_ca_topic_score_gemma":0.00039210377,"teacher_disagreement_score":0.4715769,"about_ca_system_score_codex":0.00070362457,"about_ca_system_score_gemma":0.00049299403,"threshold_uncertainty_score":0.28626332},"labels":[],"label_agreement":null},{"id":"W4403419865","doi":"10.1016/j.jtho.2024.09.379","title":"P1.13A.10 Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Southlake Regional Health Center","funders":"","keywords":"Medicine; Jazz; Lung cancer; Oncology; Acoustics","score_opus":0.04138748019909001,"score_gpt":0.49237024254741807,"score_spread":0.45098276234832807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755593,0.012685791,0.000051725012,0.0053467206,0.0007756651,0.0015702432,0.000029306688,0.000022286818,0.0039589843],"genre_scores_gemma":[0.99239945,0.002530547,0.0012790941,0.000050859027,0.0005744996,0.00006971952,0.0000018251787,0.00003735524,0.0030566177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775016,0.0003002893,0.00094762706,0.00027154773,0.00034243806,0.0003879643],"domain_scores_gemma":[0.9976619,0.0012496222,0.00035995184,0.00016599458,0.0003881154,0.00017444944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023402264,0.00018919796,0.000949204,0.000695128,0.000055804885,0.000014502583,0.00014734197,0.00010174956,0.00015263601],"category_scores_gemma":[0.0007060518,0.00014018116,0.00014273201,0.00058478984,0.00009997925,0.000078086116,0.000112543166,0.0006863215,0.0000011365162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049577214,0.006344879,0.5158027,0.014771683,0.0051808134,0.004409943,0.027155405,0.0003728737,0.022979422,0.00020882895,0.10004827,0.253148],"study_design_scores_gemma":[0.026250927,0.03039337,0.71891874,0.00736183,0.005729807,0.00049457524,0.008091978,0.0030082278,0.007625159,0.0003144469,0.1910182,0.00079275237],"about_ca_topic_score_codex":0.0002536333,"about_ca_topic_score_gemma":0.0033287934,"teacher_disagreement_score":0.25235525,"about_ca_system_score_codex":0.00091401,"about_ca_system_score_gemma":0.0013190489,"threshold_uncertainty_score":0.5716422},"labels":[],"label_agreement":null},{"id":"W4403419874","doi":"10.1016/j.jtho.2024.09.390","title":"P2.04B.02 Eight Year Outcomes of a Multidisciplinary Lung Cancer Screening Program at a Large Community Centre in Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multidisciplinary approach; Lung cancer; Family medicine; Lung cancer screening; Gerontology; Oncology","score_opus":0.02532880449946669,"score_gpt":0.43962534135977194,"score_spread":0.41429653686030526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835417,0.0057862136,0.0000087406115,0.009149794,0.00065098976,0.0003724912,0.00006702745,0.00001021841,0.0004128057],"genre_scores_gemma":[0.9972399,0.0004938062,0.0016056024,0.00015854329,0.00011578554,0.000026120286,0.000011034912,0.000020378338,0.00032886962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847186,0.00025149825,0.00056919217,0.000119261254,0.00029840993,0.0002897765],"domain_scores_gemma":[0.99888843,0.00035673834,0.0002765628,0.00018374358,0.00013179054,0.00016272851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000524085,0.00014707925,0.0007058098,0.00017345959,0.00006711689,0.000007897853,0.00012709718,0.000091353824,0.00025870884],"category_scores_gemma":[0.000047137488,0.00010122971,0.00017445866,0.00023121819,0.000039590097,0.00007031252,0.00013219804,0.00063159555,0.0000015573814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005700782,0.0010473082,0.9383479,0.00055613584,0.000749868,0.0017927368,0.0016342953,0.000054833552,0.000033646786,0.000011269997,0.0063193315,0.048882622],"study_design_scores_gemma":[0.0022674035,0.0011118065,0.97186667,0.0023644108,0.00094309065,0.00021115999,0.0025031334,0.0016346573,0.00052784674,0.000020456107,0.01641557,0.00013379616],"about_ca_topic_score_codex":0.15201385,"about_ca_topic_score_gemma":0.82463896,"teacher_disagreement_score":0.6726251,"about_ca_system_score_codex":0.0048451154,"about_ca_system_score_gemma":0.002421804,"threshold_uncertainty_score":0.9989751},"labels":[],"label_agreement":null},{"id":"W4403419936","doi":"10.1016/j.jtho.2024.09.249","title":"P1.01A.04 Point-of-care Nicotine Replacement for the Treatment of Nicotine Addiction in a Provincial Cancer System","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Nicotinic Acetylcholine Receptors Study","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living North; Abbotsford Veterinary Clinic","funders":"","keywords":"Medicine; Nicotine Addiction; Addiction; Nicotine; Psychiatry","score_opus":0.013879421634245392,"score_gpt":0.3860590978516977,"score_spread":0.3721796762174523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615056,0.032214347,0.0013738397,0.0010654946,0.002446677,0.0010352336,0.00009196726,0.0000080569225,0.0002588085],"genre_scores_gemma":[0.9951506,0.0020918185,0.0010517952,0.000025105652,0.0012171594,0.00010045559,0.000019230498,0.000026818485,0.00031696667],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998314,0.0001749477,0.00090088113,0.00022823137,0.00017570987,0.00020621542],"domain_scores_gemma":[0.998612,0.0001467403,0.00065738143,0.0002344751,0.00029879113,0.000050620536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006608745,0.00016899861,0.00051126495,0.00012396945,0.000037347585,0.000008200853,0.00020107646,0.00018556062,0.000024537587],"category_scores_gemma":[0.00008756459,0.000108624525,0.00030700388,0.00015437225,0.00006899827,0.000007230573,0.00005340223,0.00013958415,8.5486073e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018417582,0.0025663378,0.008456201,0.0015650622,0.0026468218,0.000010849542,0.0037458728,0.0014071378,0.29907414,0.00017426653,0.011475259,0.6504605],"study_design_scores_gemma":[0.0035346174,0.028344171,0.0005647583,0.0007145613,0.0011284776,0.0002104139,0.0046493886,0.00079934194,0.62286377,0.000009223304,0.33694455,0.00023673552],"about_ca_topic_score_codex":0.00007454597,"about_ca_topic_score_gemma":0.00061674224,"teacher_disagreement_score":0.65022373,"about_ca_system_score_codex":0.00055974093,"about_ca_system_score_gemma":0.00088344386,"threshold_uncertainty_score":0.44295797},"labels":[],"label_agreement":null},{"id":"W4403419938","doi":"10.1016/j.jtho.2024.09.318","title":"P1.06C.01 Evaluation of Small Pulmonary Pathology Specimen Management in the Province of Quebec, Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Pathology; General surgery","score_opus":0.03183670408013367,"score_gpt":0.39455220807013325,"score_spread":0.3627155039899996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663556,0.006775878,0.00002847401,0.015378204,0.0007742002,0.0006694314,0.0000069647863,0.000002930021,0.010008301],"genre_scores_gemma":[0.9980006,0.0005563665,0.0005985023,0.00027634963,0.00016314378,0.0000253395,0.0000043501814,0.000008691468,0.0003666641],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99826694,0.00037780538,0.00059819594,0.00012880303,0.0004888406,0.00013944796],"domain_scores_gemma":[0.99903953,0.00022526641,0.00034199018,0.00018336241,0.0001672985,0.000042562617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018400686,0.000094763134,0.00040426047,0.00017963556,0.000012616879,0.0000045328084,0.00013918785,0.00006709263,0.00010592821],"category_scores_gemma":[0.00003939021,0.00005767854,0.000092855764,0.0001844005,0.000054756758,0.00004103415,0.000031971445,0.00021328231,0.0000012072429],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001171334,0.0016663967,0.009524057,0.0011476326,0.00080981693,0.016123462,0.0008272253,0.00036527368,0.00046747125,0.0006393356,0.016640438,0.95061755],"study_design_scores_gemma":[0.0036501116,0.005009309,0.8738831,0.0028213852,0.0074672443,0.0045034313,0.004490097,0.0018438096,0.005007593,0.0030931646,0.08795695,0.00027376643],"about_ca_topic_score_codex":0.016735274,"about_ca_topic_score_gemma":0.39269787,"teacher_disagreement_score":0.9503438,"about_ca_system_score_codex":0.0018809449,"about_ca_system_score_gemma":0.0026376925,"threshold_uncertainty_score":0.9898124},"labels":[],"label_agreement":null},{"id":"W4403419964","doi":"10.1016/j.jtho.2024.09.239","title":"MA18.13 Comparison of Sybil with Brock and PLCOm2012 Models Among Screening Participants with Positive and Negative Baseline Screens","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of Calgary; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Baseline (sea); Internal medicine; Oncology","score_opus":0.34706785144121965,"score_gpt":0.51292398023692,"score_spread":0.16585612879570033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90865546,0.0054134903,0.07768201,0.0069297096,0.00013666852,0.00032241765,0.00011533079,0.000011988547,0.0007328978],"genre_scores_gemma":[0.9768869,0.0001427281,0.022028109,0.00059619616,0.0001810191,0.0000091566535,0.0000038394105,0.000026611118,0.0001254258],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9960936,0.00051986775,0.0026411251,0.000307363,0.000121133446,0.0003169187],"domain_scores_gemma":[0.9945606,0.0022254414,0.002595218,0.00015082059,0.00020336169,0.00026456645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068587437,0.00018290953,0.0014527459,0.00042148677,0.0001018868,0.00006236049,0.000121223864,0.00014424219,0.00004079454],"category_scores_gemma":[0.0005523674,0.00015946924,0.0000594965,0.00019250387,0.00027336672,0.0008224343,0.000049490303,0.00040029828,0.000007791781],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044730147,0.0008710856,0.8500276,0.0024280937,0.0029777288,0.00016806569,0.035904355,0.040073156,0.00005179258,0.015651338,0.009124793,0.038248956],"study_design_scores_gemma":[0.0031937223,0.008543442,0.31362218,0.0039411355,0.00057738175,0.0007336831,0.028241105,0.623902,0.00022255666,0.012840258,0.0032865044,0.00089598884],"about_ca_topic_score_codex":0.0004700281,"about_ca_topic_score_gemma":0.00089204515,"teacher_disagreement_score":0.58382887,"about_ca_system_score_codex":0.00020277852,"about_ca_system_score_gemma":0.00023840123,"threshold_uncertainty_score":0.65029675},"labels":[],"label_agreement":null},{"id":"W4403419975","doi":"10.1016/j.jtho.2024.09.232","title":"MA18.04 Evaluating Early-Stage Lung Cancer Survival Based on Age and Morbidity to Inform the Upper Age Limit for Screening","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Age limit; Stage (stratigraphy); Limit (mathematics); Lung cancer; Lung cancer screening; Cancer; Oncology; Intensive care medicine; Internal medicine; Demography","score_opus":0.11010469702422217,"score_gpt":0.49935282911796214,"score_spread":0.38924813209374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692557,0.0015909319,0.002144082,0.02260938,0.00095402735,0.0011243477,0.00008557297,0.000026823627,0.0022091407],"genre_scores_gemma":[0.9901237,0.00008653693,0.0048431833,0.0011259036,0.0013080606,0.00008342215,0.000009667895,0.00005377423,0.0023657584],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997607,0.0002780597,0.0005437319,0.0002817939,0.0008117389,0.0004777008],"domain_scores_gemma":[0.99740607,0.0013948793,0.00020164899,0.00026515184,0.0003459013,0.00038637288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029187507,0.00020977344,0.00054365187,0.0003749178,0.00021596055,0.000102396814,0.00023310797,0.00014742215,0.00038225143],"category_scores_gemma":[0.0008587634,0.00013983421,0.00025955413,0.00037794342,0.00015596977,0.00017860773,0.00013223081,0.0008806081,0.000006898217],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015220708,0.00039259793,0.030712167,0.003139187,0.00096895226,0.00716285,0.0022817028,0.0048014927,0.0051999213,0.00047202228,0.0057284464,0.92392],"study_design_scores_gemma":[0.0028545319,0.0048917076,0.730406,0.0020289745,0.0012674985,0.00030137648,0.001387326,0.17097668,0.0006167812,0.00028359285,0.08459663,0.00038888707],"about_ca_topic_score_codex":0.00011626278,"about_ca_topic_score_gemma":0.000106954496,"teacher_disagreement_score":0.92353106,"about_ca_system_score_codex":0.0010259423,"about_ca_system_score_gemma":0.0012334827,"threshold_uncertainty_score":0.5702274},"labels":[],"label_agreement":null},{"id":"W4403419979","doi":"10.1016/j.jtho.2024.09.143","title":"MA07.06 Eradicating Drug Tolerant Persisters (DTPs) In EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) By Targeting TROP2","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Drug; Cancer research; Oncology; Internal medicine; Pharmacology","score_opus":0.0115437669861495,"score_gpt":0.3983043843750104,"score_spread":0.3867606173888609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96127677,0.02096066,0.00052221766,0.0101148905,0.0009048775,0.0003834181,0.000023457796,0.000026486177,0.005787212],"genre_scores_gemma":[0.99213415,0.0005025242,0.004375813,0.0009841819,0.00043909688,0.000030536066,0.00003427164,0.00003675698,0.0014626619],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982732,0.00017934668,0.00070198084,0.00024457855,0.00025583987,0.0003450485],"domain_scores_gemma":[0.9990463,0.00019111726,0.0003437828,0.00011323644,0.00013316858,0.0001723956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006610589,0.00019198793,0.00053660246,0.0003445343,0.00007756849,0.000047250604,0.00014276402,0.00012307591,0.00015937652],"category_scores_gemma":[0.000037301954,0.00014773595,0.00020639162,0.00035346785,0.000041929194,0.00014751221,0.00001976352,0.00064233603,0.000010568621],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026756304,0.0036855936,0.06273706,0.0045777922,0.0028540532,0.01800919,0.11472597,0.0025949108,0.1612436,0.000030810064,0.3408706,0.2859948],"study_design_scores_gemma":[0.029549304,0.011260258,0.039731957,0.020214925,0.02528601,0.0093237525,0.09682438,0.09296944,0.037826553,0.0002573552,0.63386524,0.002890809],"about_ca_topic_score_codex":0.0002048743,"about_ca_topic_score_gemma":0.000037145026,"teacher_disagreement_score":0.29299468,"about_ca_system_score_codex":0.0015002695,"about_ca_system_score_gemma":0.001083493,"threshold_uncertainty_score":0.6024497},"labels":[],"label_agreement":null},{"id":"W4403420001","doi":"10.1016/j.jtho.2024.09.065","title":"OA12.03 Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Osimertinib; Medicine; Oncology; Internal medicine; Stage (stratigraphy); Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.03484657134441829,"score_gpt":0.47502015657193275,"score_spread":0.4401735852275145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98063076,0.0034104188,0.00014986451,0.00890375,0.0012102113,0.00074439886,0.0001489064,0.000026597305,0.0047751158],"genre_scores_gemma":[0.99621713,0.0001278046,0.00036853465,0.0011784113,0.00026775466,0.000053197284,0.00002638261,0.000029956835,0.0017308494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979246,0.00038542453,0.00083089294,0.00023595875,0.00033168888,0.00029143185],"domain_scores_gemma":[0.99811596,0.0010547509,0.00026180406,0.00022233803,0.0002031226,0.00014202524],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007897239,0.0002059701,0.00069481804,0.00023766958,0.000087498396,0.000052051513,0.00014750536,0.00012294161,0.0012927578],"category_scores_gemma":[0.00020398242,0.000114661365,0.00019941732,0.0004063301,0.00008290984,0.00021198491,0.00005497261,0.0007222477,0.000060495695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05438434,0.018469727,0.43923667,0.00017464058,0.012181261,0.048996657,0.07077058,0.0002135593,0.0017052228,0.00016377679,0.010618526,0.34308502],"study_design_scores_gemma":[0.035998438,0.016574735,0.7872416,0.0013653652,0.0077554644,0.0007234162,0.047006257,0.00042435387,0.00074631127,0.0007143372,0.100920156,0.00052956474],"about_ca_topic_score_codex":0.0004832693,"about_ca_topic_score_gemma":0.00069051195,"teacher_disagreement_score":0.34800494,"about_ca_system_score_codex":0.000823725,"about_ca_system_score_gemma":0.001067438,"threshold_uncertainty_score":0.9996202},"labels":[],"label_agreement":null},{"id":"W4403420021","doi":"10.1016/j.jtho.2024.09.107","title":"MA02.12 UC Screen California: A Statewide Participatory Informatics Approach to Lung Cancer Screening","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lung cancer; Informatics; Citizen journalism; Lung cancer screening; Health informatics; Medical physics; Oncology; Nursing; World Wide Web; Public health","score_opus":0.17388628085946942,"score_gpt":0.5420492569862319,"score_spread":0.3681629761267624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83834,0.007786078,0.042455107,0.063635364,0.024021424,0.0024950441,0.000081153834,0.00018982928,0.020996004],"genre_scores_gemma":[0.9204995,0.00084961375,0.067625284,0.0026089898,0.0076756272,0.0004326856,0.000006394468,0.000049537866,0.0002523812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720365,0.00057654706,0.0009087878,0.000117223484,0.00064073456,0.00055306783],"domain_scores_gemma":[0.99700797,0.0015171843,0.00045810573,0.00011020846,0.00033586723,0.0005706944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004673573,0.00012390141,0.00039423397,0.0003539547,0.0003226351,0.00010650197,0.00033693397,0.0002352275,0.00014154406],"category_scores_gemma":[0.0020744994,0.00011168791,0.00013383935,0.0006469322,0.00016726524,0.00044252392,0.00005280169,0.0006258785,0.000037943588],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025049195,0.00018612378,0.018458368,0.00047118487,0.00025444877,0.00004080648,0.24184012,0.0011408214,0.000022740669,0.0011250083,0.044301204,0.69190866],"study_design_scores_gemma":[0.00014856066,0.0002550489,0.005578241,0.0004155361,0.00033037568,0.000027848884,0.035253935,0.0027734677,0.000030753756,0.00042443452,0.95454276,0.00021903492],"about_ca_topic_score_codex":0.0019591989,"about_ca_topic_score_gemma":0.0011705043,"teacher_disagreement_score":0.91024154,"about_ca_system_score_codex":0.0015598882,"about_ca_system_score_gemma":0.0036858167,"threshold_uncertainty_score":0.65384805},"labels":[],"label_agreement":null},{"id":"W4403420022","doi":"10.1016/j.jtho.2024.09.075","title":"OA14.06 Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Jewish General Hospital","funders":"Samsung; Genentech; Humanitas Research Hospital; Universitair Ziekenhuis Antwerpen; Jewish General Hospital; Maastricht Universitair Medisch Centrum; Peter MacCallum Cancer Centre; Sungkyunkwan University; University of Manchester; Victoria University; University of Melbourne; Ottawa Hospital Research Institute; Monash University; Università degli Studi di Milano; Hospital de Câncer de Barretos; Seoul National University; Seoul National University Bundang Hospital; McGill University; Yale Cancer Center; Yale University","keywords":"Medicine; Atezolizumab; Term (time); Oncology; KRAS; Internal medicine; Pembrolizumab; Cancer; Immunotherapy; Colorectal cancer","score_opus":0.019908694389413197,"score_gpt":0.3534978687197636,"score_spread":0.3335891743303504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943557,0.001696519,0.0000400232,0.0020255793,0.0005606524,0.00056635716,0.000011523813,0.000015262356,0.0007284325],"genre_scores_gemma":[0.9988295,0.00025261016,0.0002732427,0.00013049481,0.000102796235,0.000020489293,0.000043620705,0.000023781511,0.00032348055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858886,0.00014867018,0.00047860632,0.0002378986,0.00030567724,0.00024029966],"domain_scores_gemma":[0.99904364,0.00020911796,0.00024726236,0.00012515421,0.0001921291,0.00018270052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018039982,0.00022843007,0.00062096195,0.0003456124,0.000051146013,0.00004871748,0.00005258232,0.00013362242,0.00003774727],"category_scores_gemma":[0.000029948078,0.00014169102,0.00013335,0.0001914694,0.00007184759,0.00018081482,0.000029619196,0.00015254934,0.00001872344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00334883,0.005360389,0.61012197,0.00008030771,0.00072935247,0.0035042835,0.0012825009,0.0000026034097,0.000085356805,0.000058949638,0.00022314997,0.37520233],"study_design_scores_gemma":[0.010609184,0.022158159,0.9623788,0.0009019437,0.0010359364,0.00068703276,0.000096409836,0.000021277845,0.0013445317,0.000064284024,0.00057574065,0.00012669222],"about_ca_topic_score_codex":0.000032747652,"about_ca_topic_score_gemma":0.000077738165,"teacher_disagreement_score":0.37507564,"about_ca_system_score_codex":0.00263291,"about_ca_system_score_gemma":0.00034952635,"threshold_uncertainty_score":0.68849677},"labels":[],"label_agreement":null},{"id":"W4403420028","doi":"10.1016/j.jtho.2024.09.106","title":"MA02.11 Validation of the Sybil Deep Learning Lung Cancer Risk Prediction Model in Three Independent Screening Studies","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Artificial Intelligence in Healthcare","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; University of Calgary; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Lung cancer; Artificial intelligence; Oncology","score_opus":0.18419420653255297,"score_gpt":0.5764971891287354,"score_spread":0.3923029825961824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645765,0.0077025597,0.019689351,0.003690892,0.0036488732,0.0005065519,0.000012616125,0.00002544017,0.00014725297],"genre_scores_gemma":[0.99596244,0.0019674674,0.0010998372,0.00009265408,0.00061674917,0.00005196406,9.1409686e-7,0.000023226763,0.0001847581],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9957319,0.001765196,0.0015487415,0.0001845834,0.00043752242,0.00033205788],"domain_scores_gemma":[0.9963389,0.0014380435,0.0013095341,0.00015409826,0.00068793655,0.00007146353],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0045689046,0.00012881462,0.00045592137,0.00031780865,0.00043901635,0.000008092542,0.00024940798,0.00032999166,0.00008023336],"category_scores_gemma":[0.0013788113,0.00008770192,0.00013145887,0.00042874797,0.00009636658,0.00027657038,0.00016877607,0.002509096,0.000004660107],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022201308,0.000032683205,0.6226184,0.00053898693,0.000103464794,0.000015888932,0.016339242,0.28462642,0.00019197617,0.00014461963,0.00023770588,0.074928634],"study_design_scores_gemma":[0.00015989372,0.00032920655,0.048620604,0.0040280563,0.0003469797,0.000024408117,0.028283479,0.90917724,0.00079998694,0.0073088966,0.00080105476,0.0001201953],"about_ca_topic_score_codex":0.001048556,"about_ca_topic_score_gemma":0.0129060345,"teacher_disagreement_score":0.6245508,"about_ca_system_score_codex":0.0014087411,"about_ca_system_score_gemma":0.0010557226,"threshold_uncertainty_score":0.99979216},"labels":[],"label_agreement":null},{"id":"W4403420029","doi":"10.1016/j.jtho.2024.09.131","title":"MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; ROS1; Internal medicine; Lung cancer; Oncology; Cancer; Safety profile; Intensive care medicine; Adenocarcinoma; Adverse effect","score_opus":0.009353308013044336,"score_gpt":0.39624856093847466,"score_spread":0.3868952529254303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930538,0.0022225878,0.00002395933,0.0013886768,0.00050338375,0.00075714913,0.000026278998,0.000005801603,0.0020183402],"genre_scores_gemma":[0.99900013,0.00013410386,0.0003658228,0.000089994064,0.000120518,0.000013187968,0.0000027456986,0.000011888998,0.00026160007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898523,0.00009336041,0.00042823673,0.00014300388,0.00019743993,0.00015272337],"domain_scores_gemma":[0.99927133,0.000121192745,0.00024970894,0.00011688404,0.00015640327,0.000084487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030049778,0.0001202389,0.00041231455,0.00010586131,0.000063394546,0.000012185678,0.00008138786,0.00006266221,0.000039002844],"category_scores_gemma":[0.000024178787,0.000064176274,0.000055984994,0.0003122982,0.00006112708,0.00006495226,0.000041098494,0.00026797855,8.3613133e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038461655,0.0020862648,0.9089877,0.00014550891,0.0006084965,0.00022920746,0.0039423904,0.00012529091,0.000015377966,0.0000057981497,0.00038352708,0.07962428],"study_design_scores_gemma":[0.0064592725,0.009841637,0.97609234,0.00041397582,0.0018961397,0.00008742926,0.0014190739,0.00008459761,0.00005148127,0.000012365699,0.0035686463,0.00007305514],"about_ca_topic_score_codex":0.00013041626,"about_ca_topic_score_gemma":0.00030264448,"teacher_disagreement_score":0.07955123,"about_ca_system_score_codex":0.0006392596,"about_ca_system_score_gemma":0.0007184067,"threshold_uncertainty_score":0.26170325},"labels":[],"label_agreement":null},{"id":"W4403420033","doi":"10.1016/j.jtho.2024.09.114","title":"MA03.10 Association of Surgical Margin Distance, Locoregional Recurrence, and Survival Among Patients Undergoing Sublobar Resection in CALGB140503","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Surrey Memorial Hospital; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Duke Cancer Institute; University of Toronto; Moffitt Cancer Center","keywords":"Medicine; Margin (machine learning); Resection; Resection margin; Surgical margin; Surgical resection; Radiology; Surgery","score_opus":0.016458662850336286,"score_gpt":0.3485987047057015,"score_spread":0.33214004185536516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937539,0.00069188414,0.00003317134,0.0012529142,0.0007945787,0.00011562241,0.000007529907,0.0000065182035,0.0033439002],"genre_scores_gemma":[0.9981044,0.00035933382,0.00008433653,0.000013850249,0.00028710847,0.0000023120774,0.00001082577,0.000008782018,0.0011290485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984641,0.00023172739,0.0005744672,0.00014952171,0.0004015816,0.00017859964],"domain_scores_gemma":[0.9986557,0.0005547138,0.0003473519,0.000051270537,0.00028114306,0.00010985163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010975999,0.000100749305,0.00044993527,0.0003342361,0.000027634405,0.000014728349,0.000051280553,0.00017735247,0.00008583424],"category_scores_gemma":[0.00027286969,0.00007998518,0.00012473488,0.00041057804,0.00008009549,0.00015319273,0.00003504922,0.0004813681,0.0000025292222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034095335,0.00029556462,0.9689239,0.0003265858,0.0000851593,0.00070267735,0.00017228573,0.0000073683473,0.00007466955,0.00026236643,0.0024206731,0.023319203],"study_design_scores_gemma":[0.0014421912,0.0030335214,0.973952,0.00086830463,0.00015133277,0.00027188493,0.00019604963,0.0005276948,0.00009815113,0.00079314277,0.018563846,0.000101863894],"about_ca_topic_score_codex":0.000023313207,"about_ca_topic_score_gemma":0.00070251286,"teacher_disagreement_score":0.02321734,"about_ca_system_score_codex":0.0006942352,"about_ca_system_score_gemma":0.00034015227,"threshold_uncertainty_score":0.3261701},"labels":[],"label_agreement":null},{"id":"W4403420038","doi":"10.1016/j.jtho.2024.09.094","title":"MA01.07 Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) -/+ Metformin in Locally Advanced NSCLC.","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Medicine; Metformin; Oncology; Chemoradiotherapy; Internal medicine; Term (time); Phases of clinical research; Clinical trial; Overall survival; Astronomy","score_opus":0.03301604970201223,"score_gpt":0.49432315396629145,"score_spread":0.46130710426427923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97741175,0.016149295,0.0013396912,0.0014257733,0.0020042874,0.0010447203,0.000026966285,0.000012025349,0.0005855166],"genre_scores_gemma":[0.9933346,0.004573379,0.00087391125,0.00016140571,0.00046119024,0.000041394127,0.000030517065,0.000024169238,0.0004994443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966678,0.0004925245,0.001934715,0.00023898197,0.00038428736,0.0002817006],"domain_scores_gemma":[0.9971543,0.0010151648,0.0011677992,0.0001920684,0.00029143892,0.000179259],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022034687,0.00024963787,0.00358698,0.0014620099,0.000023542176,0.0000070833466,0.00018769021,0.00022811472,0.0015014231],"category_scores_gemma":[0.00017527604,0.000178871,0.0012154557,0.0010791788,0.00029776327,0.00013626768,0.000029765155,0.00048887904,0.000002497964],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6132578,0.004615423,0.0001947118,0.00021621193,0.006783899,0.00084583357,0.0008995233,0.00007682095,0.0150561845,0.00002942388,0.0003212928,0.35770285],"study_design_scores_gemma":[0.92278224,0.02601755,0.00027118716,0.000545134,0.021012682,0.00038180492,0.00011671708,0.0019938122,0.021569934,0.00006620315,0.0050400035,0.00020272234],"about_ca_topic_score_codex":0.00002105447,"about_ca_topic_score_gemma":0.000066763685,"teacher_disagreement_score":0.35750014,"about_ca_system_score_codex":0.0005872313,"about_ca_system_score_gemma":0.0011238541,"threshold_uncertainty_score":0.99941134},"labels":[],"label_agreement":null},{"id":"W4403420091","doi":"10.1016/j.jtho.2024.09.202","title":"MA14.07 Access Disparities to Lung Cancer Radiotherapy Across Brazil: An Observational Analysis","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Women's cancer prevention and management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Observational study; Lung cancer; Radiation therapy; Oncology; Environmental health; Internal medicine","score_opus":0.07618007202488287,"score_gpt":0.5605112306430764,"score_spread":0.48433115861819354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8934636,0.004652274,0.03805792,0.060412683,0.0022591723,0.00034147105,0.00003738478,0.000053253138,0.0007222368],"genre_scores_gemma":[0.96378577,0.0014600263,0.006630263,0.013687313,0.0017734468,0.00006458675,0.000024691279,0.000036791287,0.0125371395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843466,0.0001353975,0.00056228956,0.00021543348,0.00038900814,0.00026321062],"domain_scores_gemma":[0.9990325,0.000081698236,0.00021471488,0.00018294905,0.00022822154,0.00025991912],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009307397,0.00013679297,0.00057145354,0.00047215994,0.00007430987,0.00015190494,0.00025449935,0.00009210603,0.0023167038],"category_scores_gemma":[0.000030079278,0.00010963088,0.00030663924,0.00086655305,0.0000498907,0.0004831727,0.000070595364,0.00028761834,0.0000057165958],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041317395,0.001033491,0.1620434,0.0012514394,0.014684219,0.0012855898,0.0046471646,0.011595584,0.0024897074,0.0018981022,0.14682758,0.648112],"study_design_scores_gemma":[0.00095873023,0.0012524261,0.48710373,0.00034826229,0.003348967,0.00018535736,0.0006156712,0.008279482,0.00028629642,0.00035260618,0.4970087,0.0002597739],"about_ca_topic_score_codex":0.00006930258,"about_ca_topic_score_gemma":0.00030565955,"teacher_disagreement_score":0.64785224,"about_ca_system_score_codex":0.0008799719,"about_ca_system_score_gemma":0.00043116938,"threshold_uncertainty_score":0.9985953},"labels":[],"label_agreement":null},{"id":"W4403420098","doi":"10.1016/j.jtho.2024.09.222","title":"MA17.03 30 Years of International Real World Outcomes in Patients with Limited Disease Small Cell Lung Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Lunenfeld-Tanenbaum Research Institute; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Disease; Lung disease; Intensive care medicine; Oncology; Internal medicine; Lung","score_opus":0.023121765768051753,"score_gpt":0.4367275228555888,"score_spread":0.41360575708753705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913227,0.001180301,0.000011038377,0.00375213,0.0007952439,0.00024426766,0.000033417735,0.000009533986,0.0026514004],"genre_scores_gemma":[0.9965711,0.00094557967,0.0006464995,0.00015481147,0.00021693925,0.000014161541,0.000005137679,0.000019967683,0.0014258078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986406,0.00009259083,0.00043937197,0.00014118777,0.00048740287,0.00019887213],"domain_scores_gemma":[0.99892724,0.0002366051,0.00022375816,0.00011271337,0.0003385348,0.00016113713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034429604,0.0001037845,0.00045207003,0.0006135044,0.000012611065,0.00001194331,0.00015516207,0.000043989425,0.00021926561],"category_scores_gemma":[0.00014220821,0.0000724786,0.000105134735,0.00029336588,0.00009054571,0.00009032615,0.000081399114,0.00044653824,0.0000048243683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033876637,0.0005020575,0.96209645,0.00035662972,0.00049690605,0.00089513254,0.00042375518,0.00006378556,0.00005074775,0.000008271616,0.0022296088,0.029489018],"study_design_scores_gemma":[0.001516971,0.0007486587,0.9889949,0.00072154193,0.00030807793,0.00000472728,0.00006270939,0.00023207263,0.00005335445,0.00001619858,0.007273428,0.000067352],"about_ca_topic_score_codex":0.000119822784,"about_ca_topic_score_gemma":0.00030794073,"teacher_disagreement_score":0.029421667,"about_ca_system_score_codex":0.0010276517,"about_ca_system_score_gemma":0.00092534715,"threshold_uncertainty_score":0.29555914},"labels":[],"label_agreement":null},{"id":"W4403420103","doi":"10.1016/j.jtho.2024.09.195","title":"MA13.08 PM2.5 Exposure Impact on Never-Smoking Lung Cancer Patients","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation","funders":"","keywords":"Medicine; Lung cancer; Environmental health; Oncology","score_opus":0.032056909508572165,"score_gpt":0.45337236338505615,"score_spread":0.421315453876484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98411703,0.0008124456,0.00016337264,0.009139125,0.002079716,0.0001439816,0.000018622944,0.00002101145,0.0035046667],"genre_scores_gemma":[0.99422324,0.00019232908,0.00042291163,0.0041893837,0.00046688828,0.0000036416575,0.0000016848264,0.000019671934,0.0004802329],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980513,0.00028983454,0.00056208775,0.00018589287,0.0004891041,0.00042179585],"domain_scores_gemma":[0.99888825,0.00025605885,0.00035555437,0.00013123901,0.00002912342,0.0003397776],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001135435,0.00016633868,0.00035165664,0.00011691471,0.0001236813,0.000043450662,0.00025051212,0.00019836724,0.0038462253],"category_scores_gemma":[0.00010403482,0.000114941184,0.00017337393,0.0002577816,0.000085091284,0.0005657615,0.000082703664,0.0007057594,0.00015487461],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010206936,0.00052994915,0.1719068,0.00018749859,0.00016790071,0.00035071006,0.0029821456,0.0072806748,0.000223476,0.000051522733,0.22684117,0.58845747],"study_design_scores_gemma":[0.000593122,0.005494696,0.78278536,0.00057767483,0.00019923023,0.00017384156,0.000163931,0.0017904389,0.00037863984,0.00079807744,0.20673162,0.0003133654],"about_ca_topic_score_codex":0.00016305034,"about_ca_topic_score_gemma":0.00004925904,"teacher_disagreement_score":0.6108786,"about_ca_system_score_codex":0.0023776311,"about_ca_system_score_gemma":0.0002765001,"threshold_uncertainty_score":0.9970644},"labels":[],"label_agreement":null},{"id":"W4403420106","doi":"10.1016/j.jtho.2024.09.186","title":"MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Mutation; Cancer research; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.00967764361359079,"score_gpt":0.39723011494927507,"score_spread":0.38755247133568427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932751,0.0029238334,0.0002166821,0.0014012187,0.00022431006,0.0003327574,0.000028368047,0.000024547657,0.0015731561],"genre_scores_gemma":[0.9956092,0.00029833752,0.0032430561,0.0001766581,0.00008215501,0.000011953787,0.000058606583,0.000022381244,0.0004976202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987391,0.00008236104,0.0005462823,0.00017212726,0.00029582667,0.00016427506],"domain_scores_gemma":[0.99866736,0.00013681165,0.00040153853,0.00011741671,0.00053499034,0.00014188634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020000675,0.00014475547,0.00044530779,0.00025717684,0.000072624156,0.000020670186,0.000057933852,0.00010494912,0.00006636243],"category_scores_gemma":[0.000080239835,0.00009941442,0.00007806747,0.00030165806,0.00017938082,0.00032834866,0.000013137497,0.0002654634,0.000007882741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060597644,0.0014918367,0.5891847,0.0008256599,0.0018650953,0.00080357934,0.0041419277,0.0003196139,0.0051629776,0.00015304498,0.003312506,0.38667932],"study_design_scores_gemma":[0.0036929306,0.0051989458,0.9688086,0.0011253688,0.0014426336,0.00033923305,0.0008305078,0.00016307762,0.0020637785,0.00027821297,0.015893713,0.00016298446],"about_ca_topic_score_codex":0.000016542974,"about_ca_topic_score_gemma":0.000023061375,"teacher_disagreement_score":0.38651633,"about_ca_system_score_codex":0.0002711036,"about_ca_system_score_gemma":0.00046786305,"threshold_uncertainty_score":0.40540022},"labels":[],"label_agreement":null},{"id":"W4403420134","doi":"10.1016/j.jtho.2024.09.194","title":"MA13.07 Practical Implementation of Outdoor Air Pollution Exposure Measurement for Lung Cancer Risk Assessment","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation","funders":"","keywords":"Medicine; Lung cancer; Environmental health; Air pollution; Risk assessment; Oncology","score_opus":0.09178597401204766,"score_gpt":0.5411242641945728,"score_spread":0.44933829018252514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59019256,0.0019059955,0.20997724,0.19168736,0.0036002372,0.0013924874,0.00016487346,0.000033482545,0.0010457519],"genre_scores_gemma":[0.96817815,0.00029561014,0.029784434,0.0013293235,0.00031375609,0.000028136894,0.0000019790334,0.000012215047,0.000056399316],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977052,0.0004319163,0.0007968799,0.00015635962,0.0006299002,0.00027973184],"domain_scores_gemma":[0.9986348,0.00019637583,0.0007906328,0.0000981261,0.000106584615,0.00017348035],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048371493,0.00010929588,0.00030602995,0.0000826126,0.00011051867,0.000017086586,0.00010969367,0.00012412408,0.0011623102],"category_scores_gemma":[0.00017832687,0.00008681505,0.0001349931,0.00013895103,0.00007486658,0.0004332403,0.000046265093,0.00034872844,0.000008975413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001118481,0.0005940899,0.041172646,0.0007660023,0.000400209,0.000046582238,0.0032650768,0.0038575544,0.0048296433,0.0006571883,0.16892506,0.77436745],"study_design_scores_gemma":[0.0018227239,0.008245641,0.64487827,0.00042830437,0.0015616243,0.00025154356,0.0048459764,0.0094180945,0.006458664,0.0032887547,0.318415,0.00038540002],"about_ca_topic_score_codex":0.00032681503,"about_ca_topic_score_gemma":0.0006554899,"teacher_disagreement_score":0.77398205,"about_ca_system_score_codex":0.0025726,"about_ca_system_score_gemma":0.00091960403,"threshold_uncertainty_score":0.99975073},"labels":[],"label_agreement":null},{"id":"W4403420185","doi":"10.1016/j.jtho.2024.09.022","title":"OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"","keywords":"Medicine; Pembrolizumab; Perioperative; Stage (stratigraphy); Oncology; Internal medicine; Association (psychology); Surgery; Cancer; Immunotherapy","score_opus":0.029266082196785063,"score_gpt":0.4199902217130759,"score_spread":0.3907241395162908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995007,0.0011332226,0.0001164704,0.002218867,0.0003048921,0.00066710316,0.000010241328,0.000004761808,0.00053745566],"genre_scores_gemma":[0.9984073,0.00015858865,0.00042175458,0.00013655148,0.00012753853,0.000020595257,0.0000018709312,0.000011824874,0.0007139487],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99826175,0.00047679216,0.0006445102,0.00012672877,0.0003420243,0.00014818786],"domain_scores_gemma":[0.99833935,0.0005111369,0.0006983603,0.00013743792,0.00028602252,0.000027714297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022380678,0.00011505578,0.0005613989,0.00022999845,0.00004014048,0.00001398461,0.00013661386,0.00014852067,0.000040908453],"category_scores_gemma":[0.00018827255,0.000056731675,0.00015164295,0.00031820164,0.00006877605,0.000098694785,0.000015474237,0.00037475454,4.8036105e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26271138,0.008473851,0.18083416,0.0014516893,0.0028417585,0.0034023286,0.16525011,0.000186226,0.122091636,0.0001319095,0.0026250577,0.24999991],"study_design_scores_gemma":[0.02940671,0.15964317,0.68841565,0.0033951337,0.0020283635,0.0017954218,0.08041399,0.00061697536,0.013329681,0.00015037374,0.02040703,0.00039749377],"about_ca_topic_score_codex":0.000048270023,"about_ca_topic_score_gemma":0.0001537315,"teacher_disagreement_score":0.5075815,"about_ca_system_score_codex":0.00040102084,"about_ca_system_score_gemma":0.000422843,"threshold_uncertainty_score":0.23134504},"labels":[],"label_agreement":null},{"id":"W4403420330","doi":"10.1016/j.jtho.2024.09.672","title":"P4.04D.04 Efficiency of the Annual CT Screening Interval for Those at a Lower Risk of Lung Cancer - A CISNET Comparative Modelling Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; Statistics Canada","funders":"","keywords":"Medicine; Lung cancer; Interval (graph theory); Oncology; Internal medicine; Demography; Combinatorics; Mathematics","score_opus":0.05605480677570732,"score_gpt":0.47006224444371625,"score_spread":0.4140074376680089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839109,0.0079841735,0.0050026295,0.0008428507,0.0010593708,0.0009009655,0.00014619935,0.0000068070995,0.00014608777],"genre_scores_gemma":[0.9974847,0.00031160898,0.0016534508,0.00004895769,0.00026131095,0.000049573864,0.0000013351215,0.00001769561,0.00017139653],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99830586,0.00024145779,0.0007115884,0.00019567677,0.00034569707,0.0001997385],"domain_scores_gemma":[0.9979464,0.00058567344,0.0007556,0.00018651561,0.00043995416,0.000085875436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009711602,0.00016236026,0.00086735585,0.00015739161,0.00007382161,0.000009756863,0.00017547564,0.00005571444,0.000055851637],"category_scores_gemma":[0.00005205902,0.00009137937,0.00042869043,0.00024310724,0.000109859975,0.00009095822,0.000095899835,0.00034142192,5.704692e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058532774,0.027431222,0.41496032,0.0033150925,0.023549687,0.001467783,0.117503084,0.15861516,0.0012476215,0.00017305219,0.03670395,0.15650025],"study_design_scores_gemma":[0.03182838,0.1131764,0.08389911,0.021305928,0.045067646,0.0017791059,0.030236766,0.61562014,0.024554137,0.00037335145,0.031152634,0.0010064029],"about_ca_topic_score_codex":0.00015803718,"about_ca_topic_score_gemma":0.00020590161,"teacher_disagreement_score":0.457005,"about_ca_system_score_codex":0.0007307926,"about_ca_system_score_gemma":0.0005129448,"threshold_uncertainty_score":0.37263423},"labels":[],"label_agreement":null},{"id":"W4403420351","doi":"10.1016/j.jtho.2024.09.673","title":"P4.04D.05 Family History is an Independent Predictor of Lung Cancer Detection in Women in a Predominantly Caucasian Screening Cohort","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cohort; Lung cancer; Family history; Oncology; Internal medicine; Demography","score_opus":0.04899048642876321,"score_gpt":0.41475334472150366,"score_spread":0.36576285829274047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98583937,0.010599718,0.00049028103,0.0006071084,0.0013218304,0.0003184943,0.000009282317,0.000015081409,0.0007988532],"genre_scores_gemma":[0.9976069,0.0005220921,0.0006590251,0.0004815446,0.0004276899,0.00004030975,0.000001139697,0.000024068708,0.0002372758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751455,0.00023594097,0.0009947462,0.00027302612,0.0005566583,0.00042508414],"domain_scores_gemma":[0.9988466,0.00008349241,0.00043151848,0.00017096824,0.00021209651,0.00025536015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023705175,0.00017173638,0.00079001806,0.00083497283,0.000021493395,0.000012088046,0.00017939898,0.00028413816,0.00014449854],"category_scores_gemma":[0.00013281638,0.00015225334,0.00013350383,0.0004130558,0.00008836681,0.0004308461,0.00004522801,0.00092235976,0.0000011442238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014122432,0.00048065916,0.49262273,0.00084535714,0.00051985803,0.0065913727,0.022433884,0.00058231945,0.034097157,0.0000114138775,0.0035527055,0.42414013],"study_design_scores_gemma":[0.0020575896,0.00487664,0.9516133,0.0036269373,0.0004580349,0.0019854188,0.0049864845,0.009672511,0.002182387,0.000096935706,0.018192729,0.00025104394],"about_ca_topic_score_codex":0.0020165055,"about_ca_topic_score_gemma":0.0020355496,"teacher_disagreement_score":0.45899057,"about_ca_system_score_codex":0.006899947,"about_ca_system_score_gemma":0.001978926,"threshold_uncertainty_score":0.99691236},"labels":[],"label_agreement":null},{"id":"W4403420370","doi":"10.1016/j.jtho.2024.09.633","title":"P3.12D.11 Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Protein arginine methyltransferase 5; Pharmacology; Maximum tolerated dose; Phase (matter); Oncology; Internal medicine; Adverse effect; Methyltransferase; Genetics","score_opus":0.02022742145511315,"score_gpt":0.41595685252052705,"score_spread":0.3957294310654139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403420370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524105,0.0020508745,0.0005960104,0.00042590813,0.0011350405,0.00041011034,0.000011927761,0.000010122277,0.000118937074],"genre_scores_gemma":[0.9982326,0.00017188251,0.0005143061,0.00005750873,0.0007696184,0.0000121724,0.00003578445,0.00003441338,0.00017172888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976194,0.0005791757,0.0009269507,0.00035247358,0.0002794487,0.00024254614],"domain_scores_gemma":[0.9987415,0.000047299785,0.00043681829,0.0002811031,0.00036917458,0.00012408737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009013421,0.00021317333,0.00049730303,0.00034950316,0.000047847734,0.000026785076,0.00022118178,0.0003769517,0.000041076404],"category_scores_gemma":[0.00010207396,0.0001842423,0.00013872533,0.00041907548,0.000088041794,0.0000359424,0.000083122126,0.00039390547,0.0000035099313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003310496,0.0024982996,0.00034759042,0.000044442495,0.0001849112,0.00019122772,0.001692627,0.005484571,0.85357475,0.0000069283556,0.001657662,0.13100648],"study_design_scores_gemma":[0.01492782,0.098661244,0.009826114,0.0008398607,0.00088189257,0.0014401354,0.00883277,0.010463733,0.79413074,0.00020426135,0.058699008,0.0010923919],"about_ca_topic_score_codex":0.00006746669,"about_ca_topic_score_gemma":0.0010596158,"teacher_disagreement_score":0.12991409,"about_ca_system_score_codex":0.0002267932,"about_ca_system_score_gemma":0.0007959119,"threshold_uncertainty_score":0.7513183},"labels":[],"label_agreement":null},{"id":"W4403464744","doi":"10.1016/j.jtho.2024.09.1234","title":"EP.12E.02 Landscape, Management &amp; Outcome of Real-World Fusion-positive Non-Small Cell Lung Cancer (NSCLC)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Outcome (game theory); Oncology; Lung cancer; Internal medicine","score_opus":0.021849918105674923,"score_gpt":0.44467539721926386,"score_spread":0.4228254791135889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403464744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74127656,0.008880914,0.0021989378,0.009292815,0.0038791043,0.0010216909,0.00009353734,0.000043208238,0.23331322],"genre_scores_gemma":[0.94536304,0.002342913,0.008019535,0.0005173566,0.00061223796,0.00003627643,0.000022164068,0.00003913292,0.043047357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985296,0.000072162264,0.00070304505,0.00019257618,0.0002672881,0.00023529993],"domain_scores_gemma":[0.9988391,0.00016095396,0.00039556777,0.00018242137,0.00025279418,0.0001691671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003441299,0.00017106769,0.00059672375,0.00050284824,0.000056075594,0.000018554698,0.00012166371,0.000097586155,0.0006499654],"category_scores_gemma":[0.000010487365,0.0001210063,0.00025580882,0.00038047708,0.00004401135,0.00008775588,0.0000615358,0.00033889237,0.000026489557],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043167467,0.003658209,0.38938922,0.0073567294,0.010865773,0.008187047,0.011318914,0.0009035837,0.006375661,0.0010490586,0.15364835,0.4029307],"study_design_scores_gemma":[0.009466814,0.0055088354,0.5227906,0.008438385,0.035144053,0.0013797879,0.0031196112,0.0014499296,0.00693844,0.00061208615,0.40422964,0.00092179363],"about_ca_topic_score_codex":0.00019740021,"about_ca_topic_score_gemma":0.00039632502,"teacher_disagreement_score":0.40200892,"about_ca_system_score_codex":0.00070122746,"about_ca_system_score_gemma":0.0005236734,"threshold_uncertainty_score":0.7116666},"labels":[],"label_agreement":null},{"id":"W4403464845","doi":"10.1016/j.jtho.2024.09.990","title":"EP.07B.01 Definitions of Local Control after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer Reported in the Literature","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Radiation therapy; Lung; Stereotactic radiation therapy; Radiology; Oncology; Medical physics; Radiosurgery; Internal medicine","score_opus":0.02603393613679156,"score_gpt":0.42181846854414634,"score_spread":0.3957845324073548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403464845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9454623,0.036570657,0.0005312678,0.015499495,0.00082567177,0.000801407,0.00009066336,0.000007718555,0.00021084928],"genre_scores_gemma":[0.99253166,0.0054679494,0.00012805362,0.0010874117,0.00041598108,0.0002508732,0.000010942444,0.000015915306,0.0000911983],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987712,0.00017226304,0.00057277514,0.00013024753,0.00019711013,0.00015641855],"domain_scores_gemma":[0.9986886,0.0005621812,0.00034663395,0.00014863165,0.0001964713,0.000057518955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060858816,0.000114283815,0.0004151089,0.00020674926,0.000026621694,0.00003296896,0.00006319728,0.00013256869,0.00010631766],"category_scores_gemma":[0.000048034766,0.00006493086,0.00023104143,0.00023581197,0.0000460254,0.00013204177,0.000004854819,0.00033750472,8.25167e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04559841,0.006726508,0.5205238,0.003581357,0.010014075,0.017411992,0.026488015,0.00026652263,0.0015922987,0.0015690961,0.021997135,0.34423077],"study_design_scores_gemma":[0.009411961,0.008673552,0.9136114,0.003360953,0.0034631765,0.0018759735,0.0005620342,0.0011644902,0.0012563205,0.0009310449,0.05547178,0.0002173309],"about_ca_topic_score_codex":0.000045902456,"about_ca_topic_score_gemma":0.00007621945,"teacher_disagreement_score":0.39308757,"about_ca_system_score_codex":0.0006073552,"about_ca_system_score_gemma":0.00054484454,"threshold_uncertainty_score":0.26478034},"labels":[],"label_agreement":null},{"id":"W4403464924","doi":"10.1016/j.jtho.2024.09.1286","title":"EP.13D.12 International Consortium Real-World Outcomes in Extensive Disease Small Cell Lung Cancer Compared to IMPOWER133 And CASPIAN","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Medicine; Lung cancer; Disease; Internal medicine; Oncology; Intensive care medicine","score_opus":0.04067733677870837,"score_gpt":0.4912064786779988,"score_spread":0.45052914189929044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403464924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91408545,0.006118595,0.000063173,0.07324481,0.0022005432,0.00053404464,0.00005375055,0.00002052572,0.0036791232],"genre_scores_gemma":[0.9881122,0.0017331305,0.0009278996,0.0018364465,0.0005260647,0.00004223799,0.0000035142093,0.000025146443,0.0067933705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982954,0.00014583662,0.00060272525,0.0002533092,0.00037402948,0.00032866278],"domain_scores_gemma":[0.9984234,0.00038357405,0.00018845302,0.0001421622,0.00038568405,0.00047675337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005758452,0.00017061364,0.0006887043,0.0007493009,0.00004401864,0.000042864292,0.00016307773,0.00005725033,0.00019062532],"category_scores_gemma":[0.00036750454,0.00012785222,0.00012835607,0.0002418481,0.00013379248,0.000112569694,0.0001800072,0.00057392294,0.000007455678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004949126,0.00037729042,0.9120856,0.0007534795,0.0008640845,0.013110228,0.0026381735,0.00013346913,0.0019292987,0.00007805865,0.04220797,0.0208732],"study_design_scores_gemma":[0.0015348152,0.0006345961,0.9319696,0.001034851,0.00053339376,0.00024764807,0.0007605198,0.0010167295,0.00025479234,0.0001363768,0.06168573,0.00019096198],"about_ca_topic_score_codex":0.00053170143,"about_ca_topic_score_gemma":0.004059654,"teacher_disagreement_score":0.074026756,"about_ca_system_score_codex":0.0016268608,"about_ca_system_score_gemma":0.0011980956,"threshold_uncertainty_score":0.52136624},"labels":[],"label_agreement":null},{"id":"W4403464952","doi":"10.1016/j.jtho.2024.09.1052","title":"EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Niagara Health System; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Oncology; Volume (thermodynamics); Radiology","score_opus":0.0093149249322927,"score_gpt":0.36574370777628645,"score_spread":0.35642878284399376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403464952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741612,0.020580122,0.00023749837,0.003802506,0.00041477222,0.00030913678,0.000006776283,0.000028353941,0.00045959992],"genre_scores_gemma":[0.9959686,0.0011147573,0.0021748834,0.00017605635,0.0002870875,0.000008644905,0.000007306563,0.000042076623,0.00022062201],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980157,0.0005098786,0.0006632847,0.00021904254,0.00031078456,0.00028132446],"domain_scores_gemma":[0.9986572,0.00046717422,0.00032711148,0.00012439364,0.00017403362,0.00025006678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012953068,0.00019853302,0.0010940444,0.0005314967,0.000025766565,0.000029919362,0.00011256402,0.00013038817,0.000046876386],"category_scores_gemma":[0.0005654181,0.00013478445,0.000140462,0.00059501483,0.0002585627,0.00009798968,0.000023270484,0.0010665224,0.0000020379828],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036421039,0.0012212171,0.32701766,0.0013974734,0.0027179816,0.008616523,0.0027212573,0.00044519024,0.058053937,0.00043531798,0.004442921,0.5892884],"study_design_scores_gemma":[0.005204069,0.0059167435,0.8186645,0.0031399573,0.0023563039,0.008974664,0.0004236555,0.059209045,0.001521323,0.00010322894,0.09410405,0.0003824447],"about_ca_topic_score_codex":0.00007391749,"about_ca_topic_score_gemma":0.0000036891895,"teacher_disagreement_score":0.588906,"about_ca_system_score_codex":0.00018038055,"about_ca_system_score_gemma":0.0007141766,"threshold_uncertainty_score":0.549635},"labels":[],"label_agreement":null},{"id":"W4403464980","doi":"10.1016/j.jtho.2024.09.1276","title":"EP.13D.02 Low to Intermediate Grade Lung Neuroendocrine Tumours. A Single Centre Real World Experience","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung; Neuroendocrine carcinoma; Internal medicine; Carcinoma","score_opus":0.030797917699859206,"score_gpt":0.440437006569477,"score_spread":0.40963908886961775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403464980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593535,0.0009812712,0.000080157944,0.033662613,0.0027873707,0.00044331842,0.000009337501,0.000096774755,0.0025856579],"genre_scores_gemma":[0.98659676,0.00032949852,0.001761772,0.0010640479,0.0014938378,0.000016096885,0.0000031309798,0.00006737228,0.008667507],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967376,0.00032537666,0.0008957438,0.00043101894,0.0007542924,0.0008559584],"domain_scores_gemma":[0.99770665,0.0005197149,0.00027740124,0.00032975923,0.0002688939,0.00089757773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002668719,0.00029070594,0.000805682,0.0010933568,0.000066343324,0.00008975448,0.00044974702,0.000014664724,0.00040531534],"category_scores_gemma":[0.00084005675,0.00022892146,0.0002811897,0.00097480335,0.00020884242,0.0003919524,0.00025746724,0.0012233233,0.00009896223],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058721188,0.0018472073,0.012008521,0.0010944288,0.00022384142,0.619209,0.0019343853,0.00009942175,0.10953437,0.00015454086,0.09229883,0.15572333],"study_design_scores_gemma":[0.0032197514,0.018413141,0.02108577,0.0045737815,0.0007601629,0.1578066,0.00433562,0.0015207872,0.23032938,0.0007609553,0.55623496,0.00095907954],"about_ca_topic_score_codex":0.00001727963,"about_ca_topic_score_gemma":0.00013486062,"teacher_disagreement_score":0.46393615,"about_ca_system_score_codex":0.00074108364,"about_ca_system_score_gemma":0.00050777436,"threshold_uncertainty_score":0.9335146},"labels":[],"label_agreement":null},{"id":"W4403469663","doi":"10.1016/j.jtho.2024.09.1416","title":"MA19.12 Identification of Novel Therapeutic Targets for SOX2 Driven Lung Squamous Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Identification (biology); Basal cell; SOX2; Lung; Cancer research; Squamous-cell carcinoma of the lung; Oncology; Internal medicine; Gene; Genetics","score_opus":0.029353119897125114,"score_gpt":0.43755416756908666,"score_spread":0.4082010476719615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403469663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88811046,0.022316836,0.07156822,0.009464259,0.00396292,0.0012671624,0.00011605763,0.000035919045,0.0031581735],"genre_scores_gemma":[0.99323004,0.000047548692,0.004388524,0.00014963714,0.00035339105,0.00002112066,0.000018591318,0.000022109398,0.0017690283],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99898344,0.00003566799,0.0005495135,0.0001253463,0.00016170404,0.00014435496],"domain_scores_gemma":[0.9989404,0.0001969418,0.00037929983,0.00012401293,0.00027953365,0.00007977435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030873698,0.00009649882,0.00033065947,0.00021658312,0.00004331522,0.000014542827,0.00008268093,0.0001018377,0.00005550013],"category_scores_gemma":[0.00003755222,0.00007138986,0.0002064577,0.00011084391,0.000044127613,0.00010384473,0.000011522543,0.00015661145,0.0000040524324],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038721452,0.005517162,0.011042913,0.004747026,0.001976634,0.00062563084,0.0139056705,0.0010482561,0.61631936,0.0016520662,0.024299894,0.31499326],"study_design_scores_gemma":[0.022602223,0.028097762,0.16521005,0.001097766,0.035610646,0.006286879,0.007887256,0.08394806,0.29542154,0.0042115157,0.3485481,0.0010781683],"about_ca_topic_score_codex":0.000007922019,"about_ca_topic_score_gemma":0.000006392893,"teacher_disagreement_score":0.32424822,"about_ca_system_score_codex":0.0004145682,"about_ca_system_score_gemma":0.0007128447,"threshold_uncertainty_score":0.2911194},"labels":[],"label_agreement":null},{"id":"W4403469667","doi":"10.1016/j.jtho.2024.09.1334","title":"EP.15A.03 Lung Cancer Multidisciplinary Teams in China Show Multi-faceted Similarities and Differences Compared to Europe and Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multidisciplinary approach; China; Lung cancer; Multidisciplinary team; Cancer; Oncology; Nursing; Internal medicine; Archaeology; Geography; Social science","score_opus":0.01993595768275572,"score_gpt":0.4400025074029032,"score_spread":0.42006654972014745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403469667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96013266,0.02319624,0.00033757914,0.014372882,0.0014452946,0.00024661436,0.000021977421,0.000013132465,0.0002336151],"genre_scores_gemma":[0.98547834,0.004576361,0.007646752,0.0008154854,0.00039964897,0.000010956364,0.0000018613349,0.000020586373,0.0010500363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871945,0.0001991214,0.0004503769,0.00021873863,0.00015976255,0.00025254936],"domain_scores_gemma":[0.99906784,0.00040647254,0.00013955853,0.00008603203,0.00008593004,0.00021418334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036993297,0.00017475453,0.00069539016,0.00022842099,0.00009087849,0.000017904587,0.00010748622,0.00014124377,0.00006266756],"category_scores_gemma":[0.000101921534,0.00012336383,0.00003639135,0.00019044521,0.00021799907,0.00011928872,0.00006711938,0.0006707868,4.069602e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045941453,0.00048751384,0.7933388,0.0010577975,0.00059839815,0.009848886,0.008394232,0.0005231243,0.005112227,0.000046483212,0.011416883,0.16458152],"study_design_scores_gemma":[0.0015335166,0.0013143842,0.9600265,0.0010627212,0.0002095838,0.002109782,0.0015738342,0.011208501,0.000121364414,0.00007061941,0.020550298,0.0002189083],"about_ca_topic_score_codex":0.00800758,"about_ca_topic_score_gemma":0.18500598,"teacher_disagreement_score":0.1769984,"about_ca_system_score_codex":0.00057564804,"about_ca_system_score_gemma":0.0012630079,"threshold_uncertainty_score":0.99859816},"labels":[],"label_agreement":null},{"id":"W4403469838","doi":"10.1016/j.jtho.2024.09.1091","title":"EP.08F.12 Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia, Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Regimen; Stage (stratigraphy); Oncology; Chemotherapy; Toxicity; Internal medicine","score_opus":0.012771940947720743,"score_gpt":0.3541036949186663,"score_spread":0.34133175397094556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403469838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766785,0.006770372,0.000058367612,0.014870072,0.00064160174,0.000431445,0.00006189134,0.000010762039,0.00047698763],"genre_scores_gemma":[0.9897045,0.0013765498,0.0009558717,0.0019732376,0.00019219672,0.000023295037,0.00000770905,0.000028370747,0.005738293],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987583,0.000071753595,0.00046098084,0.0002074204,0.00021263999,0.00028886768],"domain_scores_gemma":[0.9989937,0.0004501477,0.00018168802,0.00010490793,0.00009074467,0.00017880161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055401155,0.00010790858,0.0006997965,0.00006827823,0.00006235014,0.00009551797,0.00006140099,0.00011563049,0.00010371624],"category_scores_gemma":[0.000072562376,0.00011993349,0.00010343649,0.00010965623,0.000045398447,0.00010485083,0.000018960367,0.0002691659,2.888777e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010765688,0.0008915263,0.2510094,0.00069710275,0.0013085025,0.0072808587,0.0005902495,0.000008623299,0.0017467518,0.000014458186,0.49539128,0.23998469],"study_design_scores_gemma":[0.016756052,0.006506371,0.23221062,0.0028007505,0.0009887781,0.0059843,0.0024208506,0.0004881406,0.004562854,0.00034617685,0.726372,0.00056307396],"about_ca_topic_score_codex":0.33452085,"about_ca_topic_score_gemma":0.895793,"teacher_disagreement_score":0.56127214,"about_ca_system_score_codex":0.0022693546,"about_ca_system_score_gemma":0.0014787255,"threshold_uncertainty_score":0.66991067},"labels":[],"label_agreement":null},{"id":"W4403470104","doi":"10.1016/j.jtho.2024.09.1014","title":"EP.07D.01 Regional Longitudinal Evaluation of Treatment Patterns in Early-Stage Non-Small Cell Lung Cancer (ELEVATE)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Global Affairs Canada","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine","score_opus":0.06135978248095595,"score_gpt":0.4795673355762905,"score_spread":0.4182075530953345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403470104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014527,0.004859784,0.0002960407,0.0020396246,0.00075614924,0.00048682277,0.000032786615,0.000007263546,0.001376275],"genre_scores_gemma":[0.9960899,0.0010548286,0.00060963636,0.00007178167,0.00038164714,0.00006150031,0.00001547936,0.000020850995,0.0016944027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851036,0.00014390022,0.00058757665,0.00018917467,0.00036676062,0.00020223967],"domain_scores_gemma":[0.9989319,0.00012051733,0.00034226466,0.00013359768,0.00035540454,0.000116313815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062107574,0.00015378905,0.00047238538,0.00037921238,0.000029013614,0.000014441213,0.00007080828,0.000121602636,0.00043456696],"category_scores_gemma":[0.000018215811,0.00011015989,0.00019482375,0.00022243339,0.000037719514,0.00011687047,0.000015287702,0.00023068792,0.0000056711933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016718742,0.0020909484,0.7801673,0.00095793355,0.001847143,0.0017961364,0.009578423,0.0035612555,0.0035393282,0.000042537587,0.0016840028,0.19306314],"study_design_scores_gemma":[0.006836905,0.00737038,0.9438848,0.002180225,0.008457158,0.000588371,0.0012007923,0.009897434,0.0059190933,0.00014293003,0.013270399,0.0002515473],"about_ca_topic_score_codex":0.001007684,"about_ca_topic_score_gemma":0.00086267054,"teacher_disagreement_score":0.1928116,"about_ca_system_score_codex":0.0032566625,"about_ca_system_score_gemma":0.002930892,"threshold_uncertainty_score":0.8516059},"labels":[],"label_agreement":null},{"id":"W4403470214","doi":"10.1016/j.jtho.2024.09.847","title":"EP.04A.08 Leveraging the Quebec Lung Cancer Screening Program to Create a Collaborative Biobanking Project for Research Purposes","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Santé Montérégie; Cegep de Sept Iles; Centre Hospitalier Universitaire de Sherbrooke; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Biobank; Medicine; Lung cancer; Medical physics; Oncology; Bioinformatics","score_opus":0.14816285181750524,"score_gpt":0.5037264546389447,"score_spread":0.3555636028214395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403470214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6451817,0.10338705,0.042361088,0.16387925,0.008332837,0.006817975,0.0006518465,0.00013946442,0.029248806],"genre_scores_gemma":[0.9720456,0.0018868902,0.013148867,0.0015166306,0.002952151,0.00082120573,0.000004146306,0.00009431984,0.007530191],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997722,0.00014414347,0.0010152938,0.00036936946,0.00011167658,0.0006374795],"domain_scores_gemma":[0.99779624,0.000643723,0.0005722022,0.00020208086,0.00065277895,0.00013295251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061977305,0.0001915812,0.0006813888,0.0008143453,0.0003573902,0.0004892019,0.00049863075,0.00017472632,0.00009688798],"category_scores_gemma":[0.00077270984,0.0001538296,0.00022858486,0.0009675797,0.00016452478,0.0005980338,0.00011464427,0.0006640712,0.000026210708],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010462662,0.00015506678,0.0025616018,0.00023744063,0.0006885153,0.000070034126,0.0106789265,0.0010736907,0.00007609475,0.016978495,0.1257127,0.8407212],"study_design_scores_gemma":[0.00035924753,0.0009680171,0.0015544437,0.00046275827,0.000076971286,0.00004603752,0.0018152675,0.0050271535,0.00021552182,0.0048222165,0.9844226,0.00022974456],"about_ca_topic_score_codex":0.0019447652,"about_ca_topic_score_gemma":0.0024554878,"teacher_disagreement_score":0.85870993,"about_ca_system_score_codex":0.0015033109,"about_ca_system_score_gemma":0.0017026115,"threshold_uncertainty_score":0.62729895},"labels":[],"label_agreement":null},{"id":"W4403470219","doi":"10.1016/j.jtho.2024.09.843","title":"EP.04A.04 Real-World Data of LDCT Lung Cancer Screening Implementation in a Public Healthcare System: Quebec Three 3-Year Experience","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Santé Montérégie; Institut National d'Excellence en Santé et en Services Sociaux; Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; Ministère de la Santé et des Services Sociaux (Québec); Centre Hospitalier de l’Université de Montréal; Université du Québec","funders":"","keywords":"Medicine; Health care; Lung cancer; Healthcare system; Public healthcare; Medical emergency; Public health; Nursing; Oncology; Economic growth","score_opus":0.10943881882961612,"score_gpt":0.5318634153411272,"score_spread":0.4224245965115111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403470219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9307845,0.009301657,0.00056414516,0.056415346,0.001376417,0.00070300716,0.000121922094,0.000030376876,0.00070258044],"genre_scores_gemma":[0.9954057,0.0013820168,0.0022772367,0.00025079568,0.00048040657,0.000057951525,0.00003745041,0.000022066977,0.00008642368],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978946,0.00018785823,0.00094035274,0.00028543753,0.00040050442,0.00029128042],"domain_scores_gemma":[0.9984464,0.00021141784,0.00056459237,0.00036453363,0.00024041727,0.00017264229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009974902,0.00014487517,0.00066800136,0.00051185384,0.000043136246,0.00003722349,0.00025506667,0.0000721605,0.00014499565],"category_scores_gemma":[0.00004127064,0.000110212284,0.000102005324,0.000611428,0.00007133983,0.0003995301,0.00011439683,0.0003295832,0.0000017559819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007281467,0.00022475807,0.5961866,0.0018569111,0.0005136865,0.00096234365,0.0023363936,0.00001433156,0.00011374952,0.0010032064,0.009921619,0.3861383],"study_design_scores_gemma":[0.0047174073,0.0041603297,0.8672495,0.016505754,0.0021737805,0.001004183,0.04045061,0.004603021,0.0012226009,0.00008541182,0.057365462,0.0004619514],"about_ca_topic_score_codex":0.041040212,"about_ca_topic_score_gemma":0.35852656,"teacher_disagreement_score":0.38567632,"about_ca_system_score_codex":0.0031663654,"about_ca_system_score_gemma":0.0020924387,"threshold_uncertainty_score":0.96534556},"labels":[],"label_agreement":null},{"id":"W4403470652","doi":"10.1016/j.jtho.2024.09.855","title":"EP.04A.16 Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Cancer; Oncology; Internal medicine","score_opus":0.11117997188148754,"score_gpt":0.4346286186289383,"score_spread":0.3234486467474508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403470652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55484074,0.019089768,0.42024007,0.00079276704,0.0020066458,0.0008608603,0.00018336614,0.000012262889,0.0019734981],"genre_scores_gemma":[0.99375975,0.0005226967,0.004786764,0.00009342653,0.0005454423,0.0001008146,0.0000018116574,0.000037510254,0.0001518117],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99809283,0.00008193992,0.0011862969,0.00028833235,0.00004867063,0.0003019586],"domain_scores_gemma":[0.9981273,0.0004860555,0.00085182476,0.0001541109,0.00026815193,0.000112582034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029569634,0.00018298846,0.0010648669,0.00047574515,0.00007107469,0.000049335915,0.00028572982,0.0001799563,0.0000969335],"category_scores_gemma":[0.00026807748,0.00018199124,0.00033569348,0.00020688084,0.00007390314,0.00051951385,0.00005592364,0.0003799898,0.000005459087],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019991506,0.0027296245,0.069811665,0.0026451563,0.0071721575,0.0001939605,0.006353387,0.20863858,0.00030911659,0.19855674,0.0051521077,0.478446],"study_design_scores_gemma":[0.005342908,0.010004433,0.011743535,0.0025214686,0.000951236,0.00011983137,0.004730513,0.81159586,0.0008253949,0.0912235,0.059745017,0.001196291],"about_ca_topic_score_codex":0.00023229454,"about_ca_topic_score_gemma":0.00010603577,"teacher_disagreement_score":0.6029573,"about_ca_system_score_codex":0.0008317272,"about_ca_system_score_gemma":0.0004391546,"threshold_uncertainty_score":0.74213874},"labels":[],"label_agreement":null},{"id":"W4403473591","doi":"10.1016/j.jtho.2024.09.1011","title":"EP.07C.15 Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer - A Retrospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Oncology; Retrospective cohort study; Chemotherapy; Internal medicine; Cohort; Lung cancer; Neoadjuvant therapy; Cancer; Breast cancer","score_opus":0.014091477278933964,"score_gpt":0.3929191152399555,"score_spread":0.37882763796102153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403473591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666491,0.022913104,0.00009054123,0.0030384685,0.002271879,0.0011064359,0.000008238638,0.00002551571,0.0038966865],"genre_scores_gemma":[0.9898715,0.004115199,0.0005265995,0.00061209383,0.00071381306,0.000064061474,0.0000021334192,0.00005629667,0.0040382794],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975499,0.00024948103,0.0009800055,0.00035283042,0.00043924194,0.0004285773],"domain_scores_gemma":[0.99871826,0.00016270287,0.00040719422,0.0002986957,0.000284622,0.00012850986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023755098,0.00025693924,0.0010480271,0.0005864968,0.00006661583,0.000053143616,0.00024699507,0.00024071372,0.00091023283],"category_scores_gemma":[0.000043200613,0.00019578064,0.00031034613,0.0007778375,0.000091985065,0.00016575737,0.000046957517,0.0011528417,0.000009348532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028593292,0.0025674368,0.79064,0.00041039745,0.002229432,0.0048663765,0.008138279,0.00003743671,0.07289926,0.0000034751083,0.02013429,0.06948032],"study_design_scores_gemma":[0.0072873263,0.009967876,0.9355164,0.0013777015,0.0008667019,0.0011176488,0.0028809973,0.00071204326,0.007996001,0.000084363135,0.03183999,0.0003529639],"about_ca_topic_score_codex":0.0010079154,"about_ca_topic_score_gemma":0.0006922813,"teacher_disagreement_score":0.14487639,"about_ca_system_score_codex":0.0028857163,"about_ca_system_score_gemma":0.0016439483,"threshold_uncertainty_score":0.99664116},"labels":[],"label_agreement":null},{"id":"W4403474065","doi":"10.1016/j.jtho.2024.09.1241","title":"EP.12G.02 Real-World Biomarker Testing and Treatment Patterns for Locally Advanced and Metastatic Non-Small Cell Lung Cancer in Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Biomarker; Cancer; Lung cancer; Oncology; Internal medicine","score_opus":0.030085991116694237,"score_gpt":0.42683102300074255,"score_spread":0.3967450318840483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403474065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989264,0.0056015146,0.00050257903,0.0027200473,0.00048628266,0.0006240665,0.00008068063,0.000006002878,0.0007148316],"genre_scores_gemma":[0.9896126,0.001332657,0.0077439295,0.0002080444,0.000097327335,0.00008561468,0.000004970241,0.000022522145,0.00089234335],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999069,0.000042205167,0.00040573883,0.0001756188,0.000094918265,0.0002125558],"domain_scores_gemma":[0.9989284,0.0005511585,0.00018005997,0.00006811449,0.0001115418,0.00016070915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016205257,0.00014478921,0.00044498735,0.00020669351,0.00004222737,0.00001818126,0.000032260723,0.00003122966,0.000025122441],"category_scores_gemma":[0.0000314933,0.00010065636,0.000046882586,0.00016979285,0.000021985317,0.00007152932,0.000014297375,0.000117292664,1.5850735e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006058788,0.00017786455,0.18004069,0.00084501324,0.00064473104,0.001919579,0.0007594554,0.0002554048,0.0013243279,0.0000054554903,0.0004400264,0.8129816],"study_design_scores_gemma":[0.0137849,0.008274815,0.8871831,0.0056329127,0.010240376,0.0018213277,0.0034591907,0.04494574,0.0030289243,0.00026726673,0.020744674,0.0006167557],"about_ca_topic_score_codex":0.18692315,"about_ca_topic_score_gemma":0.7568886,"teacher_disagreement_score":0.8123648,"about_ca_system_score_codex":0.002453821,"about_ca_system_score_gemma":0.004191842,"threshold_uncertainty_score":0.8184912},"labels":[],"label_agreement":null},{"id":"W4403475202","doi":"10.1016/j.jtho.2024.09.1006","title":"EP.07C.09 Neoadjuvant Chemoimmunotherapy (CIT) In Resectable Non-Small Cell Lung Cancer (NSCLC): Real-World Treatment Patterns and Surgical Outcomes","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Chemoimmunotherapy; Oncology; Internal medicine; Lung cancer; Neoadjuvant therapy; Cancer; Immunotherapy","score_opus":0.022836530559022867,"score_gpt":0.4208567042374991,"score_spread":0.39802017367847625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403475202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96832156,0.015933206,0.000012904743,0.010863001,0.0009815638,0.00052060845,0.000021679985,0.00001989544,0.0033255734],"genre_scores_gemma":[0.956293,0.037021615,0.00044013897,0.0002751744,0.0004945315,0.00009982125,0.0000061207465,0.00004644999,0.0053231795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981573,0.00013238656,0.00073507277,0.00032454124,0.00024603895,0.0004046131],"domain_scores_gemma":[0.99878746,0.00042578133,0.00025243795,0.00022477363,0.00009268131,0.00021685282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045951435,0.00029094043,0.0010991705,0.00043758732,0.000049087485,0.000050521965,0.000103907616,0.00016309008,0.00037977507],"category_scores_gemma":[0.0000076909755,0.00018449647,0.0002779726,0.00025985148,0.000049796934,0.000106275555,0.000038653212,0.00042752852,0.0000067350493],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019384056,0.0015066218,0.82951033,0.00046277212,0.00088762975,0.009443673,0.0015297781,0.000035214613,0.0003210619,0.000020420224,0.0017527502,0.15259136],"study_design_scores_gemma":[0.011426889,0.0067811115,0.8812736,0.0032861438,0.001755419,0.001190593,0.0004009042,0.00065644755,0.006866323,0.00006978429,0.08590445,0.00038829082],"about_ca_topic_score_codex":0.0040774806,"about_ca_topic_score_gemma":0.006214435,"teacher_disagreement_score":0.15220307,"about_ca_system_score_codex":0.0033480085,"about_ca_system_score_gemma":0.00095322414,"threshold_uncertainty_score":0.87549263},"labels":[],"label_agreement":null},{"id":"W4403476460","doi":"10.1016/j.jtho.2024.09.812","title":"EP.02G.01 Differentiation and Metabolic Phenotypes of Lung Squamous Cell Carcinoma Organoids are Modified by the Tumor Microenvironments","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto","funders":"","keywords":"Organoid; Medicine; Phenotype; Basal cell; Lung; Cancer research; Carcinoma; Pathology; Oncology; Internal medicine; Cell biology; Biology; Biochemistry; Gene","score_opus":0.01035010994945471,"score_gpt":0.3426637841896223,"score_spread":0.33231367424016756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738859,0.022476686,0.0003356448,0.0020975,0.0004024232,0.00020452666,0.000031212665,0.0000064561623,0.00055968034],"genre_scores_gemma":[0.9979343,0.00024329287,0.00025165887,0.00019600836,0.00015925708,0.0000064731794,0.0000100218185,0.000018440089,0.0011805646],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99910945,0.0000989624,0.0003625037,0.00012097024,0.00017511174,0.00013302904],"domain_scores_gemma":[0.9993203,0.00011201737,0.00031402506,0.0001132709,0.000057778034,0.00008258351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015392496,0.00011527555,0.00036374983,0.000109328575,0.00005895547,0.000016918457,0.00007166571,0.000062065694,0.00009922808],"category_scores_gemma":[0.0000240625,0.00006834816,0.00009298794,0.00010514745,0.00007714304,0.00007744511,0.000028109538,0.00020938419,0.000003906545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00378197,0.0046540205,0.2223088,0.0027565616,0.0029401965,0.0014532546,0.015451533,0.00017146493,0.54562545,0.00037125516,0.049284294,0.15120119],"study_design_scores_gemma":[0.0060091172,0.0036575494,0.7507049,0.00032093926,0.0152289625,0.002369775,0.003180632,0.0021187507,0.17477056,0.0006205473,0.040639848,0.00037841615],"about_ca_topic_score_codex":0.000025204987,"about_ca_topic_score_gemma":0.000004960605,"teacher_disagreement_score":0.52839607,"about_ca_system_score_codex":0.00018448039,"about_ca_system_score_gemma":0.00016478918,"threshold_uncertainty_score":0.27871573},"labels":[],"label_agreement":null},{"id":"W4403476474","doi":"10.1016/j.jtho.2024.09.867","title":"EP.04C.05 Projected Impact of the Age of Initiation for Lung Cancer Screening on Health Outcomes and Healthcare Resources in Canada","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Statistics Canada; Canadian Partnership Against Cancer","funders":"","keywords":"Medicine; Health care; Lung cancer; Cancer; Environmental health; Family medicine; Gerontology; Oncology; Internal medicine; Economic growth","score_opus":0.09995205240839945,"score_gpt":0.5149463896689005,"score_spread":0.41499433726050106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736014,0.005157762,0.000079225014,0.020379314,0.0002949611,0.00038098652,0.00005170916,0.000002763222,0.000051851654],"genre_scores_gemma":[0.9978314,0.00022623516,0.0006340323,0.0011627487,0.00010758497,0.000007180901,0.0000027295528,0.000009040195,0.000019050967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985899,0.00018345153,0.0006409155,0.00010110179,0.00029232266,0.00019230852],"domain_scores_gemma":[0.9987492,0.00033961935,0.0005457167,0.00008633962,0.00019751301,0.000081637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007665343,0.00009251277,0.0005669205,0.00019185484,0.000038640315,0.000006197505,0.00008706829,0.00006487677,0.000007668163],"category_scores_gemma":[0.0002564883,0.000054860957,0.00012380414,0.0002873497,0.000037840146,0.00006878795,0.000021389831,0.00034190755,1.2030843e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028265119,0.000042299376,0.84407157,0.0012767955,0.00024471738,0.00014465484,0.0029205484,0.00082828867,0.00038139586,0.000031788837,0.004368397,0.14286307],"study_design_scores_gemma":[0.0007178486,0.0026788153,0.9885106,0.0035132156,0.000113368835,0.00018152932,0.0015494023,0.0014246001,0.00021071118,0.000056678637,0.0009847519,0.00005845152],"about_ca_topic_score_codex":0.45489985,"about_ca_topic_score_gemma":0.63746977,"teacher_disagreement_score":0.1825699,"about_ca_system_score_codex":0.0017551094,"about_ca_system_score_gemma":0.0061983154,"threshold_uncertainty_score":0.9994356},"labels":[],"label_agreement":null},{"id":"W4403476484","doi":"10.1016/j.jtho.2024.09.1025","title":"EP.07E.03 TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Adenocarcinoma; Internal medicine; Lung; Cancer research; Gastroenterology; Cancer; Biology","score_opus":0.02168329886991565,"score_gpt":0.46473034816603187,"score_spread":0.4430470492961162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836643,0.008306645,0.00037259088,0.0017565897,0.0006511781,0.0003446941,0.00015748193,0.000020626452,0.0047258995],"genre_scores_gemma":[0.9955592,0.0006391663,0.0024892516,0.0001002403,0.00016297359,0.00001532424,0.00004152073,0.000021320908,0.0009709898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99820495,0.00029427136,0.0008215423,0.00018646127,0.0002705893,0.00022221763],"domain_scores_gemma":[0.9982703,0.00057565846,0.0004984596,0.00016861822,0.0002930264,0.00019397496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070329045,0.00015009932,0.0005522708,0.0006285759,0.00005317532,0.000018871133,0.00011413226,0.00013739336,0.00036627523],"category_scores_gemma":[0.00044734898,0.00011626274,0.00017807625,0.0005709715,0.00012404576,0.0002099001,0.000023003477,0.0005845883,0.000028461878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004300725,0.0023598778,0.68845737,0.0016044823,0.003014726,0.013709269,0.012637291,0.00103121,0.0045397403,0.00071233633,0.012081289,0.25555167],"study_design_scores_gemma":[0.006463268,0.007948389,0.9133765,0.0030880633,0.008322814,0.004654747,0.0057518855,0.0056701936,0.0053674695,0.0019036768,0.03696097,0.0004919906],"about_ca_topic_score_codex":0.00023288546,"about_ca_topic_score_gemma":0.00008121026,"teacher_disagreement_score":0.2550597,"about_ca_system_score_codex":0.0008830814,"about_ca_system_score_gemma":0.0019530138,"threshold_uncertainty_score":0.4741057},"labels":[],"label_agreement":null},{"id":"W4403476809","doi":"10.1016/j.jtho.2024.09.1046","title":"EP.07H.01 Analysis of Variables Predicting pCR and irAEs in Resectable NSCLC Receiving Neoadjuvant Immunotherapy with Chemotherapy (Pre-PLaN)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Immunotherapy; Cancer","score_opus":0.02000279258121889,"score_gpt":0.39625647121501384,"score_spread":0.37625367863379494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968396,0.003237722,0.016682973,0.01010556,0.00008673688,0.00023995516,0.0000070150354,0.00004354815,0.0012005],"genre_scores_gemma":[0.9471546,0.0024408842,0.049626675,0.00034158316,0.00014342969,0.000012998524,0.0000050933136,0.000023187553,0.00025157694],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99853814,0.000116983305,0.00068738125,0.00018820417,0.00026374005,0.00020557972],"domain_scores_gemma":[0.9987163,0.0004932405,0.00034798947,0.00020098452,0.00013169531,0.000109792156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016457865,0.00012679253,0.00076325866,0.0006962877,0.00003884858,0.000025514955,0.00013488044,0.0001380589,0.000177171],"category_scores_gemma":[0.0001284527,0.0000856618,0.00011014564,0.0010391125,0.00013350374,0.0001178652,0.00002568112,0.00056275935,3.76095e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005333656,0.0010899727,0.15845293,0.0007318017,0.0045917267,0.0007526238,0.005559611,0.00022406333,0.16635182,0.00059720845,0.0051141116,0.6512005],"study_design_scores_gemma":[0.010181995,0.020248396,0.44043383,0.020411968,0.01391884,0.010014682,0.0055072047,0.21218288,0.057211176,0.008405166,0.20006937,0.0014144795],"about_ca_topic_score_codex":0.00014973801,"about_ca_topic_score_gemma":0.000041188203,"teacher_disagreement_score":0.649786,"about_ca_system_score_codex":0.0001389326,"about_ca_system_score_gemma":0.00030798174,"threshold_uncertainty_score":0.34931868},"labels":[],"label_agreement":null},{"id":"W4403476923","doi":"10.1016/j.jtho.2024.09.1129","title":"EP.11A.18 LUMINATE 101-Maccabi: Real-World Study of Treatment Patterns and Clinical Outcomes in Patients with Mnsclc in an Israeli HMO","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Internal medicine; Oncology","score_opus":0.03434235135987941,"score_gpt":0.44970433460091186,"score_spread":0.41536198324103246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403476923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99803334,0.0001421625,0.000003706394,0.0005456978,0.00048482226,0.00048209156,0.000027890499,0.000007863019,0.00027239998],"genre_scores_gemma":[0.99918085,0.00019900656,0.0001263998,0.00008778487,0.00015753847,0.000008565196,0.000008285733,0.000022315162,0.0002092416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977904,0.00039716568,0.0010914624,0.00025792586,0.0002450323,0.00021801777],"domain_scores_gemma":[0.9988984,0.00023144155,0.0003282857,0.0001896596,0.00014769776,0.00020451254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005940282,0.0001889482,0.0010060257,0.0005385396,0.000020023415,0.000016158769,0.00010150234,0.00011435704,0.00005554727],"category_scores_gemma":[0.000044774246,0.00012049663,0.00015497138,0.00021057273,0.000084640444,0.00018164676,0.000045048833,0.0003969249,0.0000019941556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017886788,0.010218713,0.92823106,0.00013085986,0.00025319954,0.0017886558,0.0007974936,0.0000055877913,0.000008336636,0.000007893465,0.000036876998,0.040634543],"study_design_scores_gemma":[0.004173734,0.100204915,0.89265656,0.00065173995,0.00059434277,0.00004101322,0.0012040777,0.0001279741,0.0000045695256,0.000021168073,0.00022393101,0.00009598344],"about_ca_topic_score_codex":0.0008161095,"about_ca_topic_score_gemma":0.0035754838,"teacher_disagreement_score":0.089986205,"about_ca_system_score_codex":0.0005464535,"about_ca_system_score_gemma":0.0003216169,"threshold_uncertainty_score":0.491371},"labels":[],"label_agreement":null},{"id":"W4403477077","doi":"10.1016/j.jtho.2024.09.1021","title":"EP.07D.09 A Global Study to Evaluate Access and Dynamics of Multidisciplinary Teams Care and Biomarker Testing in Early-Stage NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Biomedical and Engineering Education","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Multidisciplinary approach; Stage (stratigraphy); Biomarker; Oncology; Intensive care medicine; Internal medicine","score_opus":0.028923456044831104,"score_gpt":0.4161884152633165,"score_spread":0.3872649592184854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403477077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956056,0.0014498516,0.0012904516,0.00033868977,0.00084517465,0.00015005216,0.000012746887,0.000026957025,0.00028048814],"genre_scores_gemma":[0.99669397,0.00003758865,0.003153428,0.0000045027373,0.00007630875,0.000004732955,0.0000012657096,0.000012857761,0.000015375426],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991715,0.000053137108,0.0003688057,0.000115154304,0.00014021044,0.00015120086],"domain_scores_gemma":[0.99954194,0.00014335061,0.00005035846,0.000068862595,0.00007304725,0.00012244134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005290463,0.00010727855,0.00025985015,0.00022487462,0.000018284856,0.00003501538,0.000119053584,0.000083621984,0.0000042700976],"category_scores_gemma":[0.00010902846,0.00008925582,0.000025275462,0.00045763157,0.000034961187,0.00014752467,0.00010392299,0.0002254168,9.3915367e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001659416,0.0002533591,0.11438208,0.0017637188,0.00015107827,0.00030422237,0.008313499,0.009207099,0.0011867244,0.0000131539655,0.00013063347,0.8641285],"study_design_scores_gemma":[0.00047817748,0.0014394396,0.8267687,0.00080089364,0.00013423372,0.0002509759,0.0052241897,0.16415642,0.0000525996,0.00025654037,0.0002321414,0.00020565825],"about_ca_topic_score_codex":0.00006410143,"about_ca_topic_score_gemma":0.00019281608,"teacher_disagreement_score":0.86392283,"about_ca_system_score_codex":0.00036200677,"about_ca_system_score_gemma":0.00009640178,"threshold_uncertainty_score":0.36397466},"labels":[],"label_agreement":null},{"id":"W4403477242","doi":"10.1016/j.jtho.2024.09.849","title":"EP.04A.10 Creating Safe Connections: Usability Testing of an Intervention Co-designed to Increase Equitable Access to Lung Cancer Screening","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Partnership Against Cancer; Women's College Hospital","funders":"","keywords":"Medicine; Usability; Intervention (counseling); Lung cancer; Lung cancer screening; Intensive care medicine; Oncology; Nursing; Human–computer interaction","score_opus":0.1400372449938826,"score_gpt":0.608264659570967,"score_spread":0.4682274145770844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403477242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9128001,0.00026467492,0.07177241,0.004015258,0.0014149181,0.0011231502,0.00007357221,0.000061148516,0.008474769],"genre_scores_gemma":[0.9434845,0.000011045291,0.05108538,0.003690217,0.00080993073,0.00015053141,0.000013859581,0.000024012805,0.0007305581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99264455,0.0024647526,0.003667788,0.00027648843,0.00036808246,0.00057831727],"domain_scores_gemma":[0.99183244,0.0038172214,0.0016884115,0.0002953644,0.001786399,0.000580179],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016160667,0.00018070046,0.00068393524,0.0006224529,0.0007317032,0.00009759219,0.00047533377,0.0002521972,0.0036069853],"category_scores_gemma":[0.010518169,0.00015084779,0.00014088344,0.0010739741,0.000050377177,0.0032749672,0.00027078151,0.0009856941,0.00004039466],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045575215,0.00058246846,0.11458807,0.0074481424,0.00015702036,0.0000297105,0.014474294,0.0031789185,0.002166774,0.00014364558,0.022746725,0.8299267],"study_design_scores_gemma":[0.0040494157,0.012468273,0.3053046,0.044055417,0.0009795595,0.00027578516,0.040285736,0.19664773,0.005099457,0.00213681,0.38721257,0.0014846477],"about_ca_topic_score_codex":0.0019575101,"about_ca_topic_score_gemma":0.0005724863,"teacher_disagreement_score":0.82844204,"about_ca_system_score_codex":0.0013334277,"about_ca_system_score_gemma":0.0019053151,"threshold_uncertainty_score":0.9978167},"labels":[],"label_agreement":null},{"id":"W4403904602","doi":"10.1016/j.jtho.2024.10.012","title":"Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Santé Montérégie","funders":"","keywords":"Pembrolizumab; Medicine; Chemotherapy; Olaparib; Oncology; Internal medicine; Lung cancer; Cancer; Immunotherapy; Polymerase; Poly ADP ribose polymerase","score_opus":0.06185208516748933,"score_gpt":0.4462156689385008,"score_spread":0.38436358377101143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403904602","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7419662,0.0044333413,0.17635967,0.066283904,0.0032270271,0.0040881317,0.00013741391,0.00027285828,0.00323147],"genre_scores_gemma":[0.9511127,0.00040015485,0.032437183,0.005715871,0.0011155285,0.00021360788,0.000009825128,0.0001531395,0.008841988],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693257,0.00020528631,0.0010109677,0.0004913512,0.0006895508,0.0006703052],"domain_scores_gemma":[0.9967111,0.0010260926,0.0006106117,0.0004579456,0.00070756424,0.0004866931],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013305057,0.00043436929,0.001550721,0.0007227251,0.00014626386,0.00008196007,0.00034428458,0.00021336661,0.0005455441],"category_scores_gemma":[0.00033583466,0.00027237294,0.00037592402,0.0006732287,0.00020994966,0.00028942732,0.00003566649,0.00074059697,0.00003917619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71217036,0.0012487475,0.00027579747,0.002149624,0.002201168,0.005525945,0.0062007094,0.0012254885,0.013015009,0.0006150485,0.05880611,0.19656597],"study_design_scores_gemma":[0.04591653,0.049976207,0.0009705753,0.00394719,0.0019025456,0.04168373,0.00125188,0.005316142,0.021871023,0.0017457796,0.82458216,0.0008362204],"about_ca_topic_score_codex":0.000012235376,"about_ca_topic_score_gemma":0.00014530156,"teacher_disagreement_score":0.7657761,"about_ca_system_score_codex":0.0019827527,"about_ca_system_score_gemma":0.0030133538,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W4404028640","doi":"10.1016/j.jtho.2024.08.014","title":"The Game is Afoot – Seeking Early-Stage Lung Cancer Circulating Tumor DNA","year":2024,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Oncology; Biology","score_opus":0.010272673217119908,"score_gpt":0.37655134457398576,"score_spread":0.36627867135686587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404028640","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07519875,0.03853194,0.00024759935,0.0013207177,0.88274854,0.00025393395,0.00042556142,0.000009553368,0.001263423],"genre_scores_gemma":[0.06925355,0.010459923,0.00025830467,0.00046636752,0.91544724,0.00003352482,0.000052210093,0.00014677459,0.003882108],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975094,0.0001707573,0.0009119899,0.00041733411,0.0005022187,0.0004883083],"domain_scores_gemma":[0.9968285,0.00060461136,0.0013472352,0.00042029927,0.0006277767,0.00017161018],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011447258,0.00036111352,0.00063654396,0.00012049848,0.00017348163,0.00021338835,0.000698926,0.0008473706,0.000044701505],"category_scores_gemma":[0.0010251788,0.00027581636,0.00048523647,0.00013089112,0.0001429301,0.0000063896136,0.00037223412,0.0014169939,0.00000848465],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041149868,0.000035946992,0.0000806326,0.00021489678,0.0006185975,0.0003584126,0.00022632771,0.00014348298,0.012356185,0.000010312165,0.9716115,0.013932187],"study_design_scores_gemma":[0.00026067978,0.0006216519,0.00003695374,0.00030295225,0.00051900046,0.00009298466,0.00009383049,0.00016490006,0.0027646183,0.00011914,0.9947194,0.00030389754],"about_ca_topic_score_codex":0.000107938,"about_ca_topic_score_gemma":0.00030351584,"teacher_disagreement_score":0.032698717,"about_ca_system_score_codex":0.00052118656,"about_ca_system_score_gemma":0.0032916325,"threshold_uncertainty_score":0.9999694},"labels":[],"label_agreement":null},{"id":"W4404028660","doi":"10.1016/j.jtho.2024.08.003","title":"Lung Cancer in Romania","year":2024,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Lung; Cancer; Oncology; Internal medicine","score_opus":0.012665282480370877,"score_gpt":0.45279717454456014,"score_spread":0.4401318920641893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404028660","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035523123,0.04479561,0.0000022237514,0.0074105654,0.9397739,0.0002688061,0.000075141346,0.000012713262,0.004108689],"genre_scores_gemma":[0.008813951,0.01574431,0.00031688402,0.00017935528,0.9709107,0.000058298156,0.000023396393,0.00007245943,0.003880618],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787354,0.00011614112,0.0008344373,0.000264154,0.0006302571,0.00028148628],"domain_scores_gemma":[0.998114,0.0005239317,0.0006213671,0.00019726827,0.00036779584,0.00017562143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006446578,0.0002625883,0.0013204992,0.00050578936,0.000018501994,0.000025653439,0.00017041848,0.00092892034,0.00043192512],"category_scores_gemma":[0.00022428914,0.00018480697,0.00034963072,0.00022714658,0.000044700813,0.000060896935,0.00006276592,0.0019633882,0.000029311976],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010555018,0.00043364408,0.0011013101,0.0011802454,0.0009159694,0.007892753,0.0002205675,0.0000063370817,0.0000119694605,0.000007699389,0.9491678,0.038006205],"study_design_scores_gemma":[0.0010949251,0.0017475392,0.0008252968,0.004761607,0.002982167,0.00022622907,0.00003529908,0.000019657458,0.00003349997,0.00008248894,0.9880549,0.00013643237],"about_ca_topic_score_codex":0.0001698175,"about_ca_topic_score_gemma":0.000739278,"teacher_disagreement_score":0.03888706,"about_ca_system_score_codex":0.006592928,"about_ca_system_score_gemma":0.0046250094,"threshold_uncertainty_score":0.9972206},"labels":[],"label_agreement":null},{"id":"W4404136502","doi":"10.1016/j.jtho.2024.10.026","title":"The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Santé Montérégie; McGill University; St Mary's Hospital Centre","funders":"Daiichi Sankyo Europe; EMD Serono; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; G1 Therapeutics; Pfizer; Coherus Biosciences; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Pemetrexed; Oncology; Maintenance therapy; Olaparib; Internal medicine; Lung cancer; Cancer; Chemotherapy; Immunotherapy; Polymerase; Cisplatin","score_opus":0.06874955987987083,"score_gpt":0.4853731063338285,"score_spread":0.4166235464539577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404136502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96047986,0.015673755,0.003924836,0.007925557,0.0063020946,0.0030260154,0.00007427239,0.000080868675,0.0025127504],"genre_scores_gemma":[0.9936911,0.0016748887,0.0012338659,0.0005094268,0.000958036,0.00023625247,0.00001034549,0.00009997465,0.0015861497],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99552715,0.00065918796,0.0017741016,0.0004464083,0.00092384376,0.0006692885],"domain_scores_gemma":[0.9938868,0.0029136888,0.0012319213,0.00061583536,0.0010502038,0.00030149272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023811585,0.00043201845,0.001551406,0.00057803787,0.00027433323,0.00008530201,0.0005640869,0.00019226904,0.0002515031],"category_scores_gemma":[0.0006694691,0.00027966098,0.0006698534,0.0007209768,0.00036876663,0.00024548548,0.00006278792,0.0009760945,0.000029851419],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48293552,0.00588885,0.000027973136,0.0005283436,0.005499627,0.002555674,0.008287445,0.0006561445,0.008717488,0.00097320415,0.041451354,0.44247836],"study_design_scores_gemma":[0.29914093,0.17141874,0.00034892463,0.0012353085,0.004606744,0.0090484535,0.021009086,0.008012732,0.011027592,0.0033304607,0.46991742,0.00090361736],"about_ca_topic_score_codex":0.000053752374,"about_ca_topic_score_gemma":0.0000819884,"teacher_disagreement_score":0.44157475,"about_ca_system_score_codex":0.0019828312,"about_ca_system_score_gemma":0.0036518485,"threshold_uncertainty_score":0.99996555},"labels":[],"label_agreement":null},{"id":"W4404634272","doi":"10.1016/j.jtho.2024.11.016","title":"Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee","year":2024,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Institut universitaire de cardiologie et de pneumologie de Québec; Sunnybrook Health Science Centre","funders":"Chugai Pharmaceutical; Genentech; Taipei Veterans General Hospital; Daiichi-Sankyo; University of Glasgow; Cancer Research UK; Novocure; Regeneron Pharmaceuticals; EMD Serono; International Association for the Study of Lung Cancer; Daiichi Sankyo Europe; Sanofi; G1 Therapeutics; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pathological; Pathology; Lung; Molecular pathology; Adenocarcinoma; Internal medicine; Cancer","score_opus":0.05737388833707415,"score_gpt":0.4541069086072013,"score_spread":0.3967330202701272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404634272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036387235,0.94570667,0.00011280699,0.013838819,0.0010032877,0.00182266,0.0010761631,0.000009060707,0.000043291002],"genre_scores_gemma":[0.08293186,0.9127853,0.0012451557,0.0012224539,0.0006232207,0.0007875783,0.00033535552,0.000041441243,0.00002764943],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718165,0.0009827247,0.0010104218,0.0003231753,0.00034453216,0.00015751114],"domain_scores_gemma":[0.99086165,0.006814563,0.0017139228,0.00024635688,0.00030601685,0.000057472098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008329796,0.00029988147,0.001570195,0.00014021638,0.0001605042,0.00006335737,0.00018795014,0.00021289107,0.00009779261],"category_scores_gemma":[0.00029187356,0.00013698552,0.0003354669,0.00012546589,0.000070837355,0.000057919653,0.00010838191,0.0007006735,6.611401e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012039281,0.003456287,0.02807402,0.0016618448,0.03032904,0.0017424665,0.0022167887,0.000027564996,0.000016668215,0.000104957515,0.04322581,0.88794065],"study_design_scores_gemma":[0.010469948,0.017160181,0.071893275,0.03765326,0.3549566,0.0025025734,0.0055549187,0.0007535784,0.00009035539,0.0018647497,0.49596637,0.0011342053],"about_ca_topic_score_codex":0.00008279864,"about_ca_topic_score_gemma":0.000174416,"teacher_disagreement_score":0.8868064,"about_ca_system_score_codex":0.0013113446,"about_ca_system_score_gemma":0.0006058265,"threshold_uncertainty_score":0.55861074},"labels":[],"label_agreement":null},{"id":"W4405024813","doi":"10.1016/j.jtho.2024.12.003","title":"The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Cancer Center, University of Colorado","keywords":"Medicine; Lung cancer; Clinical trial; Toxicity; Oncology; Medical physics; Intensive care medicine; Internal medicine","score_opus":0.7585637976775719,"score_gpt":0.7404548057998633,"score_spread":0.018108991877708536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405024813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164706,0.0018205527,0.0000355517,0.0051128035,0.0007105791,0.0005949101,0.000017712073,0.000005274004,0.00005557484],"genre_scores_gemma":[0.9937583,0.003287395,0.0020525085,0.00018687097,0.00032409694,0.0000117606405,7.89457e-7,0.000017633289,0.00036059693],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98965293,0.0030689635,0.006060046,0.00026151235,0.00070770434,0.00024882084],"domain_scores_gemma":[0.8714606,0.12109137,0.0058497246,0.0003292399,0.0007802184,0.00048881816],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.049181648,0.00013195966,0.00161232,0.00023655347,0.000051693114,0.000029392586,0.00015292586,0.000452383,0.000042771884],"category_scores_gemma":[0.2879418,0.00006983972,0.00034563497,0.0003690421,0.0007871829,0.00014596398,0.00011668054,0.0020470712,4.128945e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06281181,0.004499687,0.42128468,0.0009707236,0.0032615066,0.0042168605,0.0026160742,0.000021406257,0.052734636,0.00017519233,0.0010194847,0.44638795],"study_design_scores_gemma":[0.0445658,0.10305634,0.6238469,0.020601474,0.007948147,0.0021453935,0.0018708793,0.005144432,0.17829931,0.00813142,0.0037951486,0.000594794],"about_ca_topic_score_codex":0.00016390419,"about_ca_topic_score_gemma":0.00032098204,"teacher_disagreement_score":0.44579315,"about_ca_system_score_codex":0.00046191923,"about_ca_system_score_gemma":0.0049159797,"threshold_uncertainty_score":0.97906756},"labels":[],"label_agreement":null},{"id":"W4405075816","doi":"10.1016/j.jtho.2024.09.1432","title":"Second Primary Lung Cancer—Potential Areas of Ambiguity","year":2024,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"NIHR Cambridge Biomedical Research Centre; Manchester Biomedical Research Centre; CRUK Lung Cancer Centre of Excellence; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Lung cancer; Primary (astronomy); Primary cancer; Ambiguity; Lung; Cancer; Internal medicine","score_opus":0.01776658952501849,"score_gpt":0.40407411271481475,"score_spread":0.3863075231897963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405075816","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0627865,0.034388155,0.00002792409,0.88312685,0.009473701,0.00057553535,0.00025734812,0.000023512444,0.009340505],"genre_scores_gemma":[0.10312119,0.011475746,0.00205067,0.81131536,0.04594655,0.0001313589,0.00028044515,0.0002839511,0.025394728],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99737424,0.00018549376,0.0011212742,0.00031783935,0.0006466109,0.00035452962],"domain_scores_gemma":[0.99740815,0.00017786256,0.0014289629,0.0003339895,0.0004974022,0.00015364279],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046688283,0.00034187443,0.0018283101,0.00043765016,0.000033428656,0.000021190974,0.0002420089,0.0009671696,0.0017868332],"category_scores_gemma":[0.00003464129,0.00024699082,0.0008070229,0.00017606426,0.00014134464,0.00007447305,0.00010327745,0.0025719563,0.00001490223],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073527975,0.0003485613,0.0016009616,0.0055031106,0.0031146046,0.01653914,0.00012092261,0.0000060082666,0.00013761352,0.0000020226023,0.9421712,0.029720537],"study_design_scores_gemma":[0.0010560054,0.0021357634,0.007608319,0.0031739026,0.008815954,0.0037266184,0.000016975804,0.000013442987,0.00092687807,0.00015241587,0.972171,0.00020271272],"about_ca_topic_score_codex":0.000057426558,"about_ca_topic_score_gemma":0.000047975565,"teacher_disagreement_score":0.07181146,"about_ca_system_score_codex":0.0034488905,"about_ca_system_score_gemma":0.0030517725,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W4405075871","doi":"10.1016/j.jtho.2024.09.1436","title":"Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?","year":2024,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Chemoimmunotherapy; Medicine; Neoadjuvant therapy; Internal medicine; Oncology; Chemotherapy; Cancer; Cyclophosphamide; Breast cancer","score_opus":0.022420839682061752,"score_gpt":0.3727624608484775,"score_spread":0.3503416211664157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405075871","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009327519,0.09626941,0.000009661641,0.8910666,0.0018394731,0.00035470584,0.00003604059,0.000017301458,0.0010792834],"genre_scores_gemma":[0.004964288,0.04179743,0.0026516223,0.93420285,0.008637247,0.00008118495,0.000021026697,0.00015160188,0.007492781],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978136,0.00018735736,0.00079838245,0.00037196532,0.00046604263,0.00036267855],"domain_scores_gemma":[0.998285,0.00030802665,0.0006623095,0.0003566663,0.00023884268,0.00014916688],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00042619498,0.00039904317,0.0013711788,0.00045132922,0.000036836,0.00008320439,0.00017608052,0.0009264819,0.0007900304],"category_scores_gemma":[0.000039816226,0.0002660109,0.00041972732,0.00010604391,0.0001553,0.00009887375,0.00009405286,0.0025399807,0.000050237984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012349647,0.0001668572,0.00045085442,0.0010508157,0.0013542246,0.03847555,0.00087936036,1.4471986e-7,0.000055231973,0.0000023177363,0.86905926,0.087270394],"study_design_scores_gemma":[0.0010981697,0.0032316104,0.00074885954,0.004087406,0.0022802006,0.0065469323,0.00007279211,9.556109e-7,0.00019876755,0.0010864784,0.9804325,0.00021532785],"about_ca_topic_score_codex":0.00003262275,"about_ca_topic_score_gemma":0.00002282014,"teacher_disagreement_score":0.111373216,"about_ca_system_score_codex":0.0013206365,"about_ca_system_score_gemma":0.0007844872,"threshold_uncertainty_score":0.9999792},"labels":[],"label_agreement":null},{"id":"W4405356035","doi":"10.1016/j.jtho.2024.12.007","title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor Classification for Lung Cancer—Results from an International Survey Among Pathologists and Thoracic Surgeons","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Centro de Investigación Biomédica en Red de Cáncer; Tokyo Women's Medical University; Shanghai Chest Hospital; Peking University; Postgraduate Institute of Medical Education and Research, Chandigarh; Universidad de Navarra; Medizinische Universität Wien; Universiteit Gent; Universitair Ziekenhuis Gent; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Universität Wien; Universidade de São Paulo; University of Toronto; Seoul National University; International Association for the Study of Lung Cancer; University of Aberdeen; Mount Sinai Health System; Imperial College London; York University; Universitätsspital Zürich; Hyogo College of Medicine; Technische Universität München; National Cancer Institute; NSW Health Pathology; University of Chicago; Universiteit Antwerpen; Queen's University; Ohio State University; Samsung; University of Leicester; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Lung cancer; Cancer; Lung cancer screening; Family medicine; General surgery; Radiology; Oncology; Internal medicine","score_opus":0.036247223853377475,"score_gpt":0.4691930443833626,"score_spread":0.43294582052998515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405356035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800922,0.0035183511,0.0013618039,0.009837867,0.0019437664,0.0021869997,0.001026656,0.000009658842,0.000022644232],"genre_scores_gemma":[0.99577373,0.0024338053,0.0001282535,0.00007943728,0.0004151847,0.0009913808,0.00006771766,0.00002031859,0.00009018128],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794686,0.00034404756,0.0008260307,0.0002956223,0.00043198914,0.00015545229],"domain_scores_gemma":[0.99422634,0.0030177776,0.0015185395,0.00019808259,0.0009966813,0.00004260655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002793809,0.00014837625,0.00036136652,0.00013422273,0.00017987168,0.00008831366,0.00026052623,0.00009403289,0.0000043902633],"category_scores_gemma":[0.000710046,0.00008171539,0.000100846424,0.00017974604,0.00010471865,0.00024852782,0.00006686237,0.0002472916,1.7660998e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034121973,0.00030442348,0.90457207,0.00016190526,0.0016264776,0.000002398004,0.004800864,0.0004441106,0.00045220644,0.00004890571,0.001623687,0.08255076],"study_design_scores_gemma":[0.0011341062,0.00033106768,0.8288849,0.00049962546,0.0015155891,0.000005924517,0.0013712946,0.16523573,0.0004621165,0.00004859515,0.00044062603,0.00007042862],"about_ca_topic_score_codex":0.004606629,"about_ca_topic_score_gemma":0.018632147,"teacher_disagreement_score":0.16479161,"about_ca_system_score_codex":0.001598985,"about_ca_system_score_gemma":0.00071683567,"threshold_uncertainty_score":0.99927527},"labels":[],"label_agreement":null},{"id":"W4405893790","doi":"10.1016/j.jtho.2024.12.025","title":"Brief Report: Evaluating Early Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Brock University; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Cancer; Lung cancer screening; Lung; Limit (mathematics); Age limit; Oncology; Internal medicine; Radiology; Demography","score_opus":0.06286693751730724,"score_gpt":0.4863441203504161,"score_spread":0.42347718283310887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405893790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97760904,0.007599626,0.0003099971,0.010563599,0.002649362,0.0009117346,0.00009735615,0.00001507021,0.00024421274],"genre_scores_gemma":[0.9940362,0.0008544318,0.00065385207,0.0006064386,0.0010831469,0.00026036717,0.00002342032,0.000054633045,0.0024275207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759156,0.00021715919,0.0008891959,0.00032640106,0.0005701384,0.0004055404],"domain_scores_gemma":[0.9980834,0.0006038816,0.0005908618,0.00023682979,0.0003372892,0.00014775187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015709804,0.00021382708,0.0006493988,0.00018570133,0.00012115245,0.000059134527,0.00013817188,0.00014618276,0.00045265356],"category_scores_gemma":[0.00018769923,0.00013480637,0.00030913387,0.00020135492,0.000048326205,0.00016308983,0.000092019036,0.00049193506,0.0000010328404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013494797,0.0002294072,0.887564,0.0004931032,0.0008686003,0.0017069718,0.0012222837,0.00046259337,0.000061912455,0.000007793442,0.0033008126,0.10273302],"study_design_scores_gemma":[0.0028427304,0.0018209476,0.9713904,0.0030781757,0.001999,0.00014810992,0.00018771598,0.0036449505,0.00039643256,0.000013303887,0.014292222,0.00018598187],"about_ca_topic_score_codex":0.001346793,"about_ca_topic_score_gemma":0.0030474039,"teacher_disagreement_score":0.10254704,"about_ca_system_score_codex":0.0033921544,"about_ca_system_score_gemma":0.00078851345,"threshold_uncertainty_score":0.88703656},"labels":[],"label_agreement":null},{"id":"W4406175284","doi":"10.1016/j.jtho.2024.10.010","title":"Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy","year":2025,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Chemoimmunotherapy; Medicine; Adjuvant; Complete response; Immunotherapy; Neoadjuvant therapy; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.02937301994842129,"score_gpt":0.3933514504140159,"score_spread":0.36397843046559464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406175284","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57597005,0.0032725928,0.00016719502,0.020804487,0.39648005,0.002480057,0.0005240384,0.000061309496,0.00024018262],"genre_scores_gemma":[0.2764957,0.012091715,0.031007366,0.06891323,0.5891745,0.0006957531,0.0015440044,0.0014216009,0.018656118],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99324757,0.0011998364,0.0022704203,0.00066067284,0.0018439543,0.00077754736],"domain_scores_gemma":[0.9933522,0.002212338,0.0019969,0.00091066695,0.0012861075,0.00024181475],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0045740013,0.00080745784,0.0032792115,0.0016904973,0.000113127324,0.00006374516,0.0008490428,0.0017107045,0.00025392382],"category_scores_gemma":[0.00091931265,0.00057532714,0.00067970285,0.00095381466,0.00027511516,0.0001450254,0.000109056324,0.0029345325,0.000008812668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5820737,0.0015667581,0.0011639904,0.0001621411,0.00097526226,0.0013176508,0.0010534724,0.00001162951,0.013854468,6.5723793e-7,0.30032703,0.09749327],"study_design_scores_gemma":[0.022906085,0.027652021,0.040080976,0.0021032314,0.00033916638,0.00011810498,0.00017874864,0.0000027346891,0.0005527679,0.0000104026385,0.9054993,0.00055647315],"about_ca_topic_score_codex":0.00009590001,"about_ca_topic_score_gemma":0.000092361304,"teacher_disagreement_score":0.6051723,"about_ca_system_score_codex":0.002913457,"about_ca_system_score_gemma":0.0046731806,"threshold_uncertainty_score":0.9996698},"labels":[],"label_agreement":null},{"id":"W4406175496","doi":"10.1016/j.jtho.2024.10.007","title":"Response to the Letters to the Editor by Jing Peng and Colleagues and by Lauren C Leiman Regarding the Manuscript “Terminology Issues in Screening and Early Detection of Lung Cancer—International Association for the Study of Lung Cancer Early Detection and Screening Committee Expert Group Recommendations”","year":2025,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of British Columbia","funders":"","keywords":"Medicine; Terminology; Lung cancer; Traditional medicine; Oncology; Linguistics; Philosophy","score_opus":0.020626243261912352,"score_gpt":0.38691332481776197,"score_spread":0.3662870815558496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406175496","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49387813,0.0064319535,0.0006328825,0.4961716,0.0015572633,0.0012665752,0.000055244633,0.000004029618,0.000002335352],"genre_scores_gemma":[0.9657444,0.0039461306,0.00038523335,0.024389254,0.0043215286,0.00079213944,0.000008350217,0.000036980284,0.00037597664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975628,0.00090584374,0.00065991154,0.00029247405,0.00035261942,0.00022634333],"domain_scores_gemma":[0.99562484,0.002928267,0.00096017536,0.00017443614,0.0002685103,0.000043776825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023524335,0.00021849488,0.00060858164,0.0003094912,0.00040413046,0.0000982427,0.00020541598,0.00022562259,0.000003163367],"category_scores_gemma":[0.0003782485,0.00012254673,0.00007591427,0.00018269503,0.000078330246,0.00015295348,0.0001394049,0.0007889231,1.7298516e-8],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005753147,0.00010956426,0.11503797,0.00013128361,0.0022490846,0.000015103682,0.011803945,0.00003988401,0.004030903,4.2989214e-7,0.74061257,0.12021613],"study_design_scores_gemma":[0.0052902573,0.004599338,0.30658433,0.0026734471,0.0031399294,0.00009877976,0.008276821,0.0011724659,0.0016568825,0.00000632303,0.66617894,0.0003225082],"about_ca_topic_score_codex":0.004971282,"about_ca_topic_score_gemma":0.0053267092,"teacher_disagreement_score":0.47186628,"about_ca_system_score_codex":0.0007904354,"about_ca_system_score_gemma":0.00006217529,"threshold_uncertainty_score":0.75151247},"labels":[],"label_agreement":null},{"id":"W4406176356","doi":"10.1016/j.jtho.2024.12.014","title":"A Perspective on the MARS2 Trial","year":2025,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Universität Zürich","keywords":"Medicine; Perspective (graphical); Intensive care medicine; Artificial intelligence","score_opus":0.017157883154784743,"score_gpt":0.4309508875259864,"score_spread":0.4137930043712017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406176356","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070624123,0.0010852431,0.0000060007137,0.019663466,0.9328285,0.00058045005,0.00012970704,0.000009830519,0.03863442],"genre_scores_gemma":[0.004329047,0.0005371365,0.00019361603,0.0013517312,0.9713096,0.000022982598,0.000047521225,0.00002498535,0.022183383],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980258,0.00029573648,0.00050594145,0.00017961752,0.0008317838,0.00016117412],"domain_scores_gemma":[0.9962053,0.0024811544,0.0006734989,0.00021343751,0.00030336255,0.00012330111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006447972,0.00020067501,0.00070365815,0.00019914297,0.00007823703,0.000014763367,0.00023639835,0.00054194225,0.0005593987],"category_scores_gemma":[0.0028334213,0.000112358786,0.0004856828,0.000109948916,0.00014649666,0.000035057416,0.000064654596,0.0014844231,0.000061004725],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.153,0.00082575635,0.000015211567,0.000047071342,0.00040115602,0.00026087047,0.00005301664,0.0000023822215,0.000007727781,0.00016122429,0.8408875,0.0043380912],"study_design_scores_gemma":[0.0071439976,0.008292245,0.0004413269,0.00040489034,0.0013033648,0.000041348234,0.00034457247,0.0000016169224,0.00001829276,0.001359332,0.9805571,0.00009194757],"about_ca_topic_score_codex":0.000013256802,"about_ca_topic_score_gemma":0.0000037033335,"teacher_disagreement_score":0.145856,"about_ca_system_score_codex":0.0019152617,"about_ca_system_score_gemma":0.0020788468,"threshold_uncertainty_score":0.64491624},"labels":[],"label_agreement":null},{"id":"W4406194079","doi":"10.1016/j.jtho.2025.01.003","title":"Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; Fondation ARC pour la Recherche sur le Cancer; Automotive Research Center; Association pour la Recherche sur le Cancer","keywords":"Medicine; Post-hoc analysis; Post hoc; Internal medicine; National Lung Screening Trial; Oncology; Lung cancer screening; Lung cancer","score_opus":0.07753598499017345,"score_gpt":0.5084820087533316,"score_spread":0.43094602376315816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406194079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699194,0.0052674566,0.0000071928357,0.0066325595,0.0002020352,0.00029518866,0.00018715105,0.0000014490686,0.00041499868],"genre_scores_gemma":[0.99771553,0.0018197794,0.00006164393,0.0002494621,0.00007385153,0.000009717649,0.0000023378198,0.0000051923707,0.00006246263],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980988,0.00046728025,0.0009209324,0.000100839614,0.0002967312,0.00011541646],"domain_scores_gemma":[0.9960754,0.0014696721,0.001625977,0.00027720176,0.00049935177,0.00005239094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016469153,0.00012083264,0.0014211038,0.00029223133,0.000043976583,0.0000052392684,0.00014729817,0.00009128231,0.00015312363],"category_scores_gemma":[0.0004698953,0.000052905998,0.00078657747,0.0005172087,0.00018735594,0.000033706314,0.00005088701,0.0001892603,3.7909295e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005771291,0.00086376956,0.9311595,0.00021411748,0.026994739,0.000010864396,0.0008754917,0.0016380476,0.0007371703,0.00040082235,0.0022861615,0.029048055],"study_design_scores_gemma":[0.0011223155,0.0026490204,0.97269595,0.0007421858,0.01777918,0.000010387772,0.00034428862,0.00015427798,0.0043153833,0.00004604838,0.00010362767,0.000037313104],"about_ca_topic_score_codex":0.0010583177,"about_ca_topic_score_gemma":0.00069974037,"teacher_disagreement_score":0.0415365,"about_ca_system_score_codex":0.0003411951,"about_ca_system_score_gemma":0.0006838336,"threshold_uncertainty_score":0.2157444},"labels":[],"label_agreement":null},{"id":"W4406787938","doi":"10.1016/j.jtho.2025.01.013","title":"The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"International Association for the Study of Lung Cancer; Sanofi; AstraZeneca","keywords":"Medicine; Ninth; Neuroendocrine carcinoma; Lung cancer staging; Lung cancer; Oncology; General surgery; Carcinoma; Internal medicine","score_opus":0.04515490801387808,"score_gpt":0.4892663703647838,"score_spread":0.44411146235090576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406787938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.818698,0.0063066096,0.0015889723,0.16070539,0.0018248963,0.010521217,0.00027032223,0.0000036465692,0.00008095659],"genre_scores_gemma":[0.9969486,0.0015338723,0.00009787371,0.00021579956,0.00040137733,0.0006302492,0.0000038394696,0.000013849974,0.00015452578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973908,0.00058828836,0.000891769,0.00017119144,0.0007225324,0.00023538971],"domain_scores_gemma":[0.99042964,0.006075024,0.0018993824,0.00040044743,0.0011812736,0.000014261084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048487713,0.00013420156,0.00039472253,0.00011862174,0.000553312,0.000025384144,0.00077256555,0.00003493864,0.0000021496592],"category_scores_gemma":[0.002378751,0.000046382243,0.00018919441,0.00039524658,0.00027613447,0.00013773417,0.00027078684,0.0004866378,3.4231158e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009494308,0.0008602192,0.8231345,0.0025860323,0.0022111302,0.0000034480568,0.012559165,0.0010317647,0.009320285,0.0013704157,0.022473825,0.114954956],"study_design_scores_gemma":[0.0050818133,0.0014597244,0.7457052,0.0024624555,0.004171706,0.00003745501,0.0583719,0.16145973,0.007778577,0.0005398878,0.012784671,0.00014688143],"about_ca_topic_score_codex":0.0005382042,"about_ca_topic_score_gemma":0.0010788507,"teacher_disagreement_score":0.17825063,"about_ca_system_score_codex":0.0006728671,"about_ca_system_score_gemma":0.0012968669,"threshold_uncertainty_score":0.4255685},"labels":[],"label_agreement":null},{"id":"W4406788044","doi":"10.1016/j.jtho.2025.01.019","title":"Lung Cancer Screening Program Quality Indicators—Review and Recommendations: An International Association for the Study of Lung Cancer Delphi Process Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Brock University","funders":"","keywords":"Medicine; Lung cancer; Delphi method; Cancer; Lung cancer screening; Delphi; Association (psychology); Family medicine; Oncology; Internal medicine; Statistics","score_opus":0.05574040129432883,"score_gpt":0.5817868306503707,"score_spread":0.526046429356042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406788044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337321,0.021913417,0.000115410025,0.038961273,0.00072488596,0.004433175,0.00003196477,0.000011274253,0.000076519675],"genre_scores_gemma":[0.9876196,0.009311605,0.00047289368,0.0007182746,0.00020087708,0.0015718417,0.0000067331403,0.000009121712,0.00008907544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983272,0.000305017,0.0007702336,0.00017072703,0.0002995026,0.00012730194],"domain_scores_gemma":[0.9972237,0.0005011095,0.0013069547,0.0001329844,0.0007748131,0.0000604797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020989124,0.00011079889,0.0005774036,0.00017427682,0.000118704105,0.00002149578,0.00016338592,0.00006308844,0.000049350794],"category_scores_gemma":[0.00031612517,0.000070330345,0.00008034697,0.00029994218,0.000021915634,0.00016613248,0.00003976039,0.00023012771,3.018294e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041820103,0.003975064,0.698724,0.00056759414,0.0028337773,0.000002489416,0.0015812136,0.000019587698,0.0000011462203,0.0000071702875,0.0016683188,0.29020146],"study_design_scores_gemma":[0.0043832404,0.0040065604,0.96172225,0.0018410726,0.011516505,0.000007939877,0.0065933033,0.0004677353,0.000031205276,0.000020237616,0.009310634,0.0000993299],"about_ca_topic_score_codex":0.0002747416,"about_ca_topic_score_gemma":0.0012466143,"teacher_disagreement_score":0.29010212,"about_ca_system_score_codex":0.0011644423,"about_ca_system_score_gemma":0.00056139287,"threshold_uncertainty_score":0.3044976},"labels":[],"label_agreement":null},{"id":"W4406873201","doi":"10.1016/j.jtho.2025.01.016","title":"Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut Du Cancer de Montréal; Terry Fox Research Institute; Ministry of Scientific Research, Egypt; Fondation du CHUM; Society for Immunotherapy of Cancer; American Society of Clinical Oncology; Melanoma Research Alliance","keywords":"Medicine; STK11; Lung cancer; Immunotherapy; Chemotherapy; Oncology; Gene; SMARCA4; Internal medicine; Cancer research; Cancer; Gene expression; Genetics; Biology","score_opus":0.009004910959578238,"score_gpt":0.3621549340082238,"score_spread":0.35315002304864557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406873201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938919,0.0030053267,0.0011643588,0.0016348971,0.000057849433,0.00015185127,0.000003896646,0.0000016746436,0.00008826606],"genre_scores_gemma":[0.9923774,0.0026138194,0.0042424076,0.00046069108,0.00003418059,0.000004860157,0.000001978538,0.000008701708,0.00025598466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999105,0.00019450703,0.00035117645,0.00012245687,0.00012146077,0.00010540069],"domain_scores_gemma":[0.9988568,0.000119101875,0.00068013446,0.00012473352,0.00020018805,0.000019087767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087001343,0.00010727267,0.0004175747,0.00007274357,0.00003168422,0.000007766447,0.000103204904,0.00018075276,0.000003332419],"category_scores_gemma":[0.00006306783,0.000055552166,0.000044465105,0.000100054735,0.00012684075,0.0000054766015,0.000020536672,0.00016833712,2.6567934e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017815618,0.00035150684,0.55782765,0.00009113437,0.00053524383,0.000012275398,0.00067487505,0.0002879875,0.28532302,0.000008842433,0.00047702962,0.13659482],"study_design_scores_gemma":[0.010947868,0.013882683,0.67864704,0.00039883013,0.00039195534,0.0006775915,0.001662949,0.000236787,0.28977016,0.00022874026,0.002811096,0.00034428187],"about_ca_topic_score_codex":0.000022697688,"about_ca_topic_score_gemma":0.0002068963,"teacher_disagreement_score":0.13625053,"about_ca_system_score_codex":0.00005056744,"about_ca_system_score_gemma":0.0002655283,"threshold_uncertainty_score":0.22653516},"labels":[],"label_agreement":null},{"id":"W4408144083","doi":"10.1016/j.jtho.2024.12.018","title":"Enlarging the Reach of Screening and Early Detection of Lung Cancer","year":2025,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Lung; Oncology; Internal medicine","score_opus":0.012505348428065841,"score_gpt":0.41538758001692977,"score_spread":0.40288223158886394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408144083","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21305953,0.05854634,0.0005804946,0.0040048347,0.72181666,0.00075240794,0.00007873889,0.000010916998,0.001150099],"genre_scores_gemma":[0.5893249,0.015493943,0.0011760538,0.000070643895,0.39303148,0.00004103596,0.000007161119,0.000039536622,0.0008152839],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99833417,0.00017975034,0.0007306549,0.00014801348,0.00046047234,0.00014694237],"domain_scores_gemma":[0.9963101,0.0011712803,0.0015695847,0.00017828553,0.0007054543,0.000065308945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092736585,0.00015960156,0.001006169,0.0002683172,0.000052040323,0.000008362491,0.00012343856,0.00045268575,0.000015351021],"category_scores_gemma":[0.00042636675,0.00009888812,0.00023209621,0.00016367881,0.000099593126,0.000052647712,0.00005928907,0.00086584664,7.177976e-8],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052564,0.00043661895,0.021757597,0.0029525545,0.0042273114,0.00018618186,0.0012794789,0.000030205101,0.0014039974,0.000007689501,0.4430012,0.51946074],"study_design_scores_gemma":[0.004009036,0.0063463002,0.032811448,0.012029888,0.014022673,0.00017708115,0.00040802825,0.00008055919,0.011264903,0.00006378457,0.9185592,0.00022711615],"about_ca_topic_score_codex":0.0005807937,"about_ca_topic_score_gemma":0.00013442789,"teacher_disagreement_score":0.51923364,"about_ca_system_score_codex":0.0006515558,"about_ca_system_score_gemma":0.0011683619,"threshold_uncertainty_score":0.40325403},"labels":[],"label_agreement":null},{"id":"W4408144109","doi":"10.1016/j.jtho.2024.12.021","title":"Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links","year":2025,"lang":"en","type":"editorial","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Medicine; Biomarker; Disease; Biomarker discovery; Oncology; Internal medicine; Proteomics; Gene; Genetics","score_opus":0.07089036606738772,"score_gpt":0.5033168943564978,"score_spread":0.4324265282891101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408144109","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012371887,0.020306032,0.010166847,0.07415873,0.8765535,0.0103717055,0.0023305162,0.00016257627,0.004712951],"genre_scores_gemma":[0.0023771147,0.0035164247,0.021871487,0.0014575437,0.95194274,0.00051694445,0.00027037077,0.00021014892,0.017837204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99635106,0.00040084356,0.00094065187,0.00045347805,0.0012597849,0.000594196],"domain_scores_gemma":[0.9909472,0.0036260167,0.0012633818,0.0004042253,0.0032453574,0.00051383296],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014007074,0.00045675886,0.0018725814,0.00063079136,0.00021270446,0.000065411514,0.0004363414,0.0009919812,0.00007139021],"category_scores_gemma":[0.0036607978,0.0002672649,0.00042720334,0.00033730207,0.0004894713,0.000119557735,0.00017027899,0.002482314,0.0000020330624],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15498425,0.0005810346,0.00014856647,0.0029055034,0.004489651,0.0011825574,0.0003960737,0.00000262791,0.000137272,8.426038e-7,0.771718,0.06345359],"study_design_scores_gemma":[0.005729765,0.011566403,0.0010971585,0.0048875157,0.006220151,0.00012005408,0.00022865576,0.00023668284,0.000034566714,0.00015676861,0.96947575,0.00024654763],"about_ca_topic_score_codex":0.00001301313,"about_ca_topic_score_gemma":0.000038587794,"teacher_disagreement_score":0.1977577,"about_ca_system_score_codex":0.0021880758,"about_ca_system_score_gemma":0.020145154,"threshold_uncertainty_score":0.99997795},"labels":[],"label_agreement":null},{"id":"W4408599782","doi":"10.1016/j.jtho.2025.02.016","title":"Corrigendum to ‘OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs’ [Journal of Thoracic Oncology Vol. 19 No. 10S (2024) S28]","year":2025,"lang":"en","type":"erratum","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Oncology; Internal medicine; Pooled analysis; Cancer; Meta-analysis; Adenocarcinoma","score_opus":0.03426890095538612,"score_gpt":0.46778001545292425,"score_spread":0.4335111144975381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408599782","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12062914,0.07410341,0.13796724,0.11150594,0.43938726,0.020250643,0.021454565,0.00027392348,0.074427895],"genre_scores_gemma":[0.05710537,0.0021938535,0.18222569,0.017122809,0.015180846,0.0003834954,0.0026824358,0.00046316348,0.72264236],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99270993,0.0011048878,0.0035417422,0.00070850353,0.0011476082,0.0007873444],"domain_scores_gemma":[0.9828743,0.001799179,0.007405128,0.000777651,0.006242334,0.000901463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00244522,0.00087375974,0.0066431197,0.0037133396,0.00019275436,0.000052502255,0.00082257367,0.0009511861,0.0016512455],"category_scores_gemma":[0.0033092354,0.0005639675,0.001717075,0.0022283609,0.00032611287,0.00026521125,0.00015199263,0.001999455,0.000012268839],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041161627,0.0023660115,0.0020191018,0.0006546699,0.06086968,0.0017647913,0.0014421559,0.00034233677,0.00051774766,0.000014739403,0.81049436,0.078352794],"study_design_scores_gemma":[0.006195892,0.027709045,0.0015457663,0.002309648,0.16989262,0.0008549496,0.001986873,0.0003392245,0.0005962972,0.00012479324,0.7879248,0.00052007806],"about_ca_topic_score_codex":0.0006355085,"about_ca_topic_score_gemma":0.0036430443,"teacher_disagreement_score":0.64821446,"about_ca_system_score_codex":0.0026974136,"about_ca_system_score_gemma":0.020548236,"threshold_uncertainty_score":0.9996812},"labels":[],"label_agreement":null},{"id":"W4408978899","doi":"10.1016/s1556-0864(25)00213-8","title":"18P: Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Chugai Pharmaceutical; Daiichi Sankyo Europe; Gilead Sciences; LEO Pharma; Aptitude Health; Astellas Pharma; Eisai; Sanofi; Apollomics; Ribon Therapeutics; Ipsen; International Association for the Study of Lung Cancer; BeiGene; Les Laboratories Pierre Fabre; Helsinn; Puma Biotechnology; Regeneron Pharmaceuticals; EMD Serono; Mersana Therapeutics; Amgen; Helsinn Therapeutics; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.011245000987077146,"score_gpt":0.37667599156252296,"score_spread":0.3654309905754458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408978899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438304,0.00009559758,0.0014920939,0.0020818624,0.0000692994,0.0014201003,0.0000074054196,0.000019635758,0.00043099181],"genre_scores_gemma":[0.9853535,0.000021132084,0.014022932,0.00033366148,0.000034812463,0.000037504673,0.000015723279,0.000012006808,0.00016868868],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99813604,0.00030154674,0.0008449311,0.00019218698,0.00032225932,0.00020303766],"domain_scores_gemma":[0.99809533,0.000115101975,0.0009350897,0.00039421962,0.0003710553,0.00008919071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000587546,0.0001512779,0.0008843818,0.0004680833,0.00006337497,0.000010856797,0.00027867855,0.00015818105,0.000048978578],"category_scores_gemma":[0.00020822271,0.00009022743,0.00021749266,0.0015192486,0.00017259459,0.00007889298,0.00004938463,0.000519599,4.2104713e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23935343,0.009381317,0.34249803,0.00021254315,0.0031316201,0.00007668811,0.00057043706,0.00038303586,0.03372349,0.00011850616,0.003358617,0.3671923],"study_design_scores_gemma":[0.15138249,0.021353692,0.6985461,0.0048436583,0.014771316,0.00005310108,0.00030178274,0.004297811,0.07578265,0.0006212975,0.02729794,0.0007481747],"about_ca_topic_score_codex":0.00006628396,"about_ca_topic_score_gemma":0.000033236563,"teacher_disagreement_score":0.3664441,"about_ca_system_score_codex":0.0003599882,"about_ca_system_score_gemma":0.0005638829,"threshold_uncertainty_score":0.36793682},"labels":[],"label_agreement":null},{"id":"W4408978958","doi":"10.1016/s1556-0864(25)00197-2","title":"2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Oncology; Disease; Adenocarcinoma; Cancer","score_opus":0.016857338226273035,"score_gpt":0.4293698245302836,"score_spread":0.41251248630401055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408978958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934731,0.0012993467,0.00019272587,0.0025947257,0.00029468167,0.00085039146,0.000018716111,0.000014401264,0.0012619174],"genre_scores_gemma":[0.99463797,0.00012732277,0.0036997658,0.00078425364,0.00006712776,0.0000647754,0.000031665913,0.00001980412,0.00056733517],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984884,0.00015153167,0.000533514,0.00029262475,0.00028820534,0.00024571235],"domain_scores_gemma":[0.9985347,0.00027539473,0.00052013155,0.00019924989,0.00021918479,0.00025133768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022308798,0.00020352738,0.0005351012,0.0003179448,0.00011725316,0.000027525073,0.00007526573,0.000107948756,0.000025334606],"category_scores_gemma":[0.0003917635,0.00012989982,0.00008335502,0.0002410521,0.00007966992,0.00025287998,0.000041478037,0.00029114794,0.0000019044875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061881687,0.0038190149,0.21949874,0.00041970174,0.00080425147,0.00051195716,0.0022009134,0.000058659065,0.0013463775,0.00031981326,0.0009994878,0.7081394],"study_design_scores_gemma":[0.02223082,0.009121317,0.93188834,0.006516011,0.0023100325,0.000078249024,0.0015496023,0.0000662531,0.0014501418,0.0009822245,0.02345152,0.00035550262],"about_ca_topic_score_codex":0.000009350913,"about_ca_topic_score_gemma":0.000012621967,"teacher_disagreement_score":0.7123896,"about_ca_system_score_codex":0.00048758608,"about_ca_system_score_gemma":0.0005919962,"threshold_uncertainty_score":0.5297161},"labels":[],"label_agreement":null},{"id":"W4408978961","doi":"10.1016/s1556-0864(25)00195-9","title":"LBA2: Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Crizotinib; Medicine; ROS1; Lung cancer; Oncology; Internal medicine; Matching (statistics); Cancer; Adenocarcinoma; Pathology","score_opus":0.01945353136888187,"score_gpt":0.43611796631393235,"score_spread":0.41666443494505045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408978961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629497,0.0040560034,0.0011678822,0.00588948,0.0020342157,0.00080764625,0.000036151796,0.000029127928,0.023029823],"genre_scores_gemma":[0.99037385,0.00031478732,0.0039081355,0.0013270002,0.00031886643,0.00005936344,0.000018668263,0.00003287929,0.0036464364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977599,0.00027425817,0.0009856158,0.00030032205,0.00025589898,0.00042401717],"domain_scores_gemma":[0.99799293,0.0004125115,0.00080477155,0.00020889258,0.0003843756,0.00019650457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005421437,0.00027596796,0.0012098243,0.0007385958,0.00012683148,0.000034547847,0.00019648358,0.00027957195,0.00014792576],"category_scores_gemma":[0.00009185329,0.0002268916,0.00024887527,0.0006915016,0.00008131638,0.0001343233,0.00007074918,0.00093425123,0.00000916748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015361095,0.007403069,0.6582764,0.0014808205,0.0032900998,0.00356692,0.025906282,0.0016234831,0.012552999,0.000090940965,0.030608933,0.23983897],"study_design_scores_gemma":[0.020103151,0.007521042,0.87323534,0.006842923,0.008907567,0.001030898,0.010148505,0.0018893564,0.041308828,0.00035655615,0.027836075,0.0008197807],"about_ca_topic_score_codex":0.0006405796,"about_ca_topic_score_gemma":0.0012718564,"teacher_disagreement_score":0.23901919,"about_ca_system_score_codex":0.0019241864,"about_ca_system_score_gemma":0.0023191548,"threshold_uncertainty_score":0.9252371},"labels":[],"label_agreement":null},{"id":"W4408978966","doi":"10.1016/s1556-0864(25)00205-9","title":"10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"LG Chem; Plexxikon; European Society for Medical Oncology; Astellas Pharma; EQRx; G1 Therapeutics; MacroGenics; ECOG-ACRIN Cancer Research Group; International Association for the Study of Lung Cancer; BeiGene; Mirati Therapeutics; LAM Therapeutics; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Yonsei University; Pfizer; Incyte; American College of Radiology Imaging Network; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; American Society of Clinical Oncology; Mersana Therapeutics; Yuhan; Daiichi Sankyo Europe; LEO Pharma; Servier; Gilead Sciences; Sanofi; Amgen","keywords":"Medicine; Adverse effect; Mutant; Dermatology; Oncology; Internal medicine; Genetics","score_opus":0.02016522738120987,"score_gpt":0.3796947738518141,"score_spread":0.35952954647060426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408978966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926241,0.00037653366,0.00008447985,0.003909263,0.0003993559,0.0013060779,0.000007195186,0.000011230773,0.0012817362],"genre_scores_gemma":[0.9983426,0.000105414285,0.000541706,0.00030732274,0.000056185003,0.000052271804,0.0000015217802,0.000013930479,0.0005790606],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9980389,0.00024369966,0.000910887,0.00021740595,0.000287157,0.00030199075],"domain_scores_gemma":[0.9983249,0.00024077843,0.00075545243,0.00019996129,0.00039305355,0.0000858722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037199561,0.00022299237,0.0011062054,0.0002470944,0.00011552087,0.0000042151473,0.00020571491,0.00013011089,0.000017366268],"category_scores_gemma":[0.0002742949,0.0001250187,0.00017776088,0.00072883914,0.00007370517,0.000111987574,0.000121145385,0.0003642884,0.0000011986083],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71508795,0.0023178111,0.21406518,0.00044515438,0.0013362583,0.0009899948,0.002104741,0.0060519944,0.0009719601,0.000020287185,0.00013102533,0.056477625],"study_design_scores_gemma":[0.22236885,0.033356372,0.7023586,0.008456321,0.0031101732,0.0015062311,0.0027328522,0.0011618974,0.020953692,0.0004586679,0.002920128,0.0006162254],"about_ca_topic_score_codex":0.00010528144,"about_ca_topic_score_gemma":0.0011545281,"teacher_disagreement_score":0.4927191,"about_ca_system_score_codex":0.00076574896,"about_ca_system_score_gemma":0.000702822,"threshold_uncertainty_score":0.50981146},"labels":[],"label_agreement":null},{"id":"W4408979201","doi":"10.1016/s1556-0864(25)00220-5","title":"25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Tremelimumab; Oncology; Chemotherapy; Cohort; Internal medicine; Phase (matter); China; Cancer; Immunotherapy","score_opus":0.036060204868246334,"score_gpt":0.4327114401567048,"score_spread":0.39665123528845847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9462226,0.0027226144,0.0034041468,0.04294094,0.00079784176,0.0024151676,0.00013540167,0.000034146276,0.0013271222],"genre_scores_gemma":[0.97937226,0.0029260556,0.00626335,0.0034692269,0.00056108297,0.00010435363,0.00007544093,0.000048433474,0.0071797855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99754864,0.00023439355,0.0011547229,0.0003462265,0.0003663767,0.0003496587],"domain_scores_gemma":[0.99715257,0.000882569,0.0010345596,0.0004915357,0.00030146708,0.00013728645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012099063,0.0003507106,0.001343342,0.00018852527,0.00023214998,0.000037756825,0.00026541945,0.00015129986,0.00020006752],"category_scores_gemma":[0.00020213333,0.00016826847,0.0004109025,0.0003548836,0.00021255015,0.000103169456,0.000018498497,0.00031010914,0.0000027281874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5745711,0.001985366,0.00015986922,0.000038169495,0.00434178,0.0002538695,0.0017023383,0.000035263405,0.0017622206,0.000008574694,0.0028706468,0.4122708],"study_design_scores_gemma":[0.4329488,0.11989191,0.016301828,0.0020436803,0.011218412,0.0034662252,0.003196841,0.003400772,0.02013099,0.0007701332,0.38597533,0.00065506337],"about_ca_topic_score_codex":0.00071476004,"about_ca_topic_score_gemma":0.0011286158,"teacher_disagreement_score":0.41161576,"about_ca_system_score_codex":0.001328297,"about_ca_system_score_gemma":0.0024303594,"threshold_uncertainty_score":0.6861789},"labels":[],"label_agreement":null},{"id":"W4408979288","doi":"10.1016/s1556-0864(25)00277-1","title":"82P: A retrospective real-world evidence study of MTAP status and clinical outcomes in patients with advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retrospective cohort study; Real world evidence; Lung cancer; Intensive care medicine; Oncology; Internal medicine","score_opus":0.021060984740557398,"score_gpt":0.48835200343156415,"score_spread":0.46729101869100675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967059,0.00063110836,0.00002602136,0.00048257725,0.0003826919,0.00084803085,0.000006856714,0.000003678572,0.00091315864],"genre_scores_gemma":[0.9967889,0.0008135932,0.0015448772,0.00014138928,0.00003152178,0.00002216001,9.06605e-7,0.00000949638,0.0006471247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853426,0.00015377536,0.0007400786,0.00019166006,0.00020232187,0.00017789377],"domain_scores_gemma":[0.9982189,0.00035916784,0.0006745275,0.00015553836,0.00048412516,0.00010775814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035547817,0.00012415355,0.00083028834,0.00031246463,0.000033212542,0.00000579765,0.000070225404,0.00006458124,0.000014676414],"category_scores_gemma":[0.00014759135,0.00008082131,0.00006883292,0.00033903346,0.00006476402,0.00011728487,0.000041199157,0.00035232224,1.8422736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040107872,0.0031769613,0.9746334,0.00010809249,0.0005927072,0.00006618421,0.0013397823,0.000039189523,0.000008705229,0.0000035345245,0.00006864287,0.015952023],"study_design_scores_gemma":[0.0076727113,0.009405972,0.9792799,0.00076605397,0.001538769,0.0000014684823,0.0011514255,0.000013115537,0.000023022678,0.000017222157,0.00007041897,0.000059971946],"about_ca_topic_score_codex":0.0006272853,"about_ca_topic_score_gemma":0.0048380382,"teacher_disagreement_score":0.015892051,"about_ca_system_score_codex":0.00095757894,"about_ca_system_score_gemma":0.0011232729,"threshold_uncertainty_score":0.32957974},"labels":[],"label_agreement":null},{"id":"W4408979329","doi":"10.1016/s1556-0864(25)00291-6","title":"96P: Enhanced anti-tumor activity of zelenectide pevedotin in patients (pts) with non-small cell lung cancer (NSCLC) with NECTIN4 gene amplification (amp)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; EMD Serono; Sierra Oncology; European Society for Medical Oncology; Seagen; Pfizer; Moderna; Ipsen; Cholangiocarcinoma Foundation; BeiGene; Tizona Therapeutics; Astellas Pharma; Mereo BioPharma; Celldex Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Foghorn Therapeutics; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Merck KGaA; Exelixis; Sanofi; Amgen; G1 Therapeutics; Celgene","keywords":"Medicine; Lung cancer; Oncology; Cancer research; Gene; Internal medicine; Gene duplication; Genetics; Biology","score_opus":0.011364263231682112,"score_gpt":0.342964824284787,"score_spread":0.33160056105310487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922146,0.0000727124,0.0033318324,0.0003282133,0.00006791989,0.00016888806,0.000020619183,0.000010914932,0.003784303],"genre_scores_gemma":[0.99678415,0.00004988418,0.0023570927,0.000051316594,0.00010117866,0.000052584073,0.000009700584,0.000019063607,0.0005750302],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864835,0.000051274907,0.0005734115,0.00028109815,0.00019412453,0.00025175794],"domain_scores_gemma":[0.9976553,0.0002338028,0.0012687445,0.00033140468,0.00042483467,0.00008594428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024604856,0.00019865541,0.00054605043,0.0001186821,0.00007603356,0.000014234484,0.00031085016,0.00015427664,0.000098591685],"category_scores_gemma":[0.00006225365,0.00016481144,0.00008032693,0.0004310674,0.00008205655,0.00010506812,0.000049732003,0.0005542022,0.0000012164521],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017320473,0.0013837934,0.08937614,0.00043740208,0.00009836928,0.000007879155,0.00022436774,0.0009471937,0.8950476,0.000002401474,0.0001416983,0.010601115],"study_design_scores_gemma":[0.0015182958,0.00015879211,0.04454926,0.0003730388,0.00018748785,0.00001679368,0.00014598957,0.000085594766,0.9521733,0.000015955478,0.00062076387,0.00015475786],"about_ca_topic_score_codex":0.000094493604,"about_ca_topic_score_gemma":0.00026357293,"teacher_disagreement_score":0.057125673,"about_ca_system_score_codex":0.0004771443,"about_ca_system_score_gemma":0.00078503584,"threshold_uncertainty_score":0.6720816},"labels":[],"label_agreement":null},{"id":"W4408979331","doi":"10.1016/s1556-0864(25)00290-4","title":"95P: Adagrasib (ADA) plus cetuximab (CETUX) in patients (pts) with advanced KRASG12C-mutated non-small cell lung cancer (NSCLC) from KRYSTAL-1","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Basilea Pharmaceutica; Astellas Pharma; Eisai; Castle Biosciences; Pfizer; Moderna; Boston Pharmaceuticals; Agios Pharmaceuticals; Eisai Canada; BeiGene; Mirati Therapeutics; Clovis Oncology; Les Laboratories Pierre Fabre; Loxo Oncology; Astex Pharmaceuticals; Bayer HealthCare; Exelixis; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; Servier; Gilead Sciences; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Internal medicine; Cancer; Colorectal cancer","score_opus":0.008133498182003375,"score_gpt":0.38217835053725147,"score_spread":0.3740448523552481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98411,0.002389658,0.0011958649,0.0019422007,0.0009993914,0.0008244565,0.000059696322,0.000020764775,0.008457987],"genre_scores_gemma":[0.99063694,0.0003151489,0.0063212155,0.0009195941,0.00014847533,0.000055867145,0.00005321197,0.000036878468,0.0015126448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980371,0.00012270537,0.00077817915,0.00032136595,0.00034031726,0.00040034685],"domain_scores_gemma":[0.9981342,0.00016508852,0.00067772553,0.0002617096,0.0005568088,0.0002044758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001819182,0.00028119422,0.00093989266,0.00044931672,0.00008888084,0.000022114942,0.00019455333,0.00021087435,0.00014927887],"category_scores_gemma":[0.000047981855,0.0002059148,0.00014345154,0.00055420946,0.00006519333,0.00019360133,0.00005303396,0.0005936827,0.000005269019],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030401295,0.0070760637,0.63023716,0.00077072025,0.0030283006,0.0024684665,0.0060262606,0.0041581574,0.004808361,0.000026897462,0.00934228,0.30165604],"study_design_scores_gemma":[0.08294789,0.012655345,0.8437296,0.005621847,0.008187992,0.00012310842,0.004168954,0.0018659442,0.010258674,0.00030843634,0.029235113,0.0008970981],"about_ca_topic_score_codex":0.0004283602,"about_ca_topic_score_gemma":0.00074772263,"teacher_disagreement_score":0.30075893,"about_ca_system_score_codex":0.0025404934,"about_ca_system_score_gemma":0.0030933511,"threshold_uncertainty_score":0.83969617},"labels":[],"label_agreement":null},{"id":"W4408979333","doi":"10.1016/s1556-0864(25)00287-4","title":"92P: Real-world treatment sequencing and outcomes in ALK-positive metastatic non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.023817211696568166,"score_gpt":0.45924516566625434,"score_spread":0.4354279539696862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706835,0.002276294,0.00022454147,0.005475434,0.00044495508,0.00050909683,0.000016536522,0.000006695081,0.020362915],"genre_scores_gemma":[0.9822006,0.0014350777,0.0058329664,0.00072471215,0.00006689434,0.000047831134,0.0000044775634,0.000012525466,0.009674883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998977,0.00010233476,0.00047347666,0.00015082503,0.00009862825,0.00019773442],"domain_scores_gemma":[0.9990868,0.0002676216,0.00029889937,0.000102444115,0.00013607099,0.000108193555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021063114,0.00015278524,0.0006924576,0.000460746,0.000054121534,0.000012946101,0.000048527938,0.0000535225,0.000034355715],"category_scores_gemma":[0.000022418417,0.00010301318,0.00011053228,0.00024279168,0.000042550844,0.00007769895,0.000020769821,0.0001850578,0.0000010578534],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014040946,0.0013526299,0.7945377,0.00048386672,0.0033064983,0.0033693002,0.0086926045,0.00060359994,0.0034062678,0.00015099162,0.0010043907,0.18168806],"study_design_scores_gemma":[0.014690473,0.0055719875,0.9288105,0.002085985,0.015320765,0.0004674127,0.0057948604,0.0015547612,0.014870685,0.00065841945,0.009780001,0.00039418656],"about_ca_topic_score_codex":0.0021369073,"about_ca_topic_score_gemma":0.0040329047,"teacher_disagreement_score":0.18129387,"about_ca_system_score_codex":0.00404541,"about_ca_system_score_gemma":0.0021593433,"threshold_uncertainty_score":0.99977785},"labels":[],"label_agreement":null},{"id":"W4408979372","doi":"10.1016/s1556-0864(25)00289-8","title":"94P: Long-term efficacy of lorlatinib vs alectinib in patients with and without brain/central nervous system metastases: Matching-adjusted indirect comparisons","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer","keywords":"Medicine; Alectinib; Term (time); Matching (statistics); Internal medicine; Pathology","score_opus":0.02180832016412709,"score_gpt":0.3703625508632149,"score_spread":0.3485542306990878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960561,0.0006517818,0.00083703373,0.0010277705,0.00034140862,0.00074269896,0.000027795875,0.000016685135,0.00029874506],"genre_scores_gemma":[0.9941908,0.000018608223,0.005363782,0.00022858406,0.000060373433,0.000006752698,0.00002852852,0.000022274824,0.00008026942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741954,0.00060397293,0.0010231356,0.0002472631,0.00034509884,0.0003610153],"domain_scores_gemma":[0.9977514,0.00054232584,0.0010011166,0.00024288657,0.0002504402,0.00021182516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082642346,0.00025980728,0.0015373605,0.0005516894,0.00006375675,0.000018883886,0.00013264059,0.00014325553,0.000025162744],"category_scores_gemma":[0.00016972217,0.00017765611,0.00016062388,0.00046236656,0.00014545883,0.000099499426,0.00006216327,0.0005192258,0.0000012099675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014790554,0.002215643,0.93742454,0.00074190606,0.0013378426,0.00042373547,0.00059188146,0.00012795383,0.000037173344,0.000052835625,0.00041461212,0.041841343],"study_design_scores_gemma":[0.010990442,0.005554327,0.97821355,0.0017253945,0.0018058552,0.0005221418,0.00046880817,0.000053488428,0.00026635884,0.000007150082,0.0002680715,0.00012442429],"about_ca_topic_score_codex":0.00005603504,"about_ca_topic_score_gemma":0.00016647122,"teacher_disagreement_score":0.041716922,"about_ca_system_score_codex":0.00040861813,"about_ca_system_score_gemma":0.00051364343,"threshold_uncertainty_score":0.7244606},"labels":[],"label_agreement":null},{"id":"W4408979470","doi":"10.1016/s1556-0864(25)00319-3","title":"124TiP: TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Osimertinib; non-small cell lung cancer (NSCLC); Chemotherapy; Platinum; Oncology; Internal medicine; Cancer research; Lung cancer; Cancer; Adenocarcinoma; A549 cell","score_opus":0.012009612388934202,"score_gpt":0.4170762565770559,"score_spread":0.40506664418812166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356574,0.00083098724,0.00047112835,0.0014091452,0.00022021605,0.0033338198,0.000039757088,0.000015276039,0.000113928734],"genre_scores_gemma":[0.99609894,0.0001445823,0.0027029456,0.0005154762,0.000036113943,0.00019393516,0.000031047257,0.0000412153,0.00023573832],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975147,0.00021160864,0.001110146,0.0004011796,0.0004154119,0.00034691763],"domain_scores_gemma":[0.9975584,0.00020804761,0.0011412959,0.00029884963,0.0004505317,0.0003428407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024461412,0.00033886314,0.0010920144,0.00048099877,0.000108665874,0.000021198535,0.00016103212,0.00008921926,0.000071683746],"category_scores_gemma":[0.00008515168,0.00021009146,0.000086272215,0.000565668,0.000096205775,0.00017101143,0.000047401205,0.0004006585,5.2990987e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30159456,0.029286264,0.2639589,0.0008298361,0.0017673629,0.0008675062,0.0045910147,0.00055882015,0.0008028904,0.0000024421406,0.00037055387,0.39536986],"study_design_scores_gemma":[0.40891948,0.09304943,0.4605335,0.009484367,0.010583143,0.00005823691,0.0048007183,0.0036373558,0.006242974,0.000047845835,0.0018425297,0.000800414],"about_ca_topic_score_codex":0.00004699328,"about_ca_topic_score_gemma":0.00013041236,"teacher_disagreement_score":0.39456943,"about_ca_system_score_codex":0.00056452275,"about_ca_system_score_gemma":0.0025021816,"threshold_uncertainty_score":0.8567281},"labels":[],"label_agreement":null},{"id":"W4408979494","doi":"10.1016/s1556-0864(25)00299-0","title":"104P: MOMENT disease registry: Patient characteristics and treatment patterns from interim enrollment analysis of patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring METexon 14 (METex14) skipping treated with systemic therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Interim analysis; Interim; Oncology; Internal medicine; Lung cancer; Systemic therapy; Disease; Cancer; Clinical trial","score_opus":0.01092587723108532,"score_gpt":0.35502823836852576,"score_spread":0.3441023611374404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979494","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440664,0.0020527462,0.0016815037,0.00025632532,0.00021075236,0.0009484365,0.00033410877,0.000010304176,0.00009915586],"genre_scores_gemma":[0.99621356,0.0021438978,0.0010023145,0.00012511197,0.000046280587,0.00015970189,0.00013280369,0.000025114598,0.0001512396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826086,0.00012307735,0.000765745,0.00033028077,0.00027828073,0.00024176048],"domain_scores_gemma":[0.9975856,0.00010082501,0.0012717067,0.0003081105,0.00049749477,0.00023625331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008988929,0.00031343996,0.0011715284,0.0004957949,0.00007440682,0.000026052685,0.00009118008,0.00007662803,0.00003867022],"category_scores_gemma":[0.000010414571,0.00019184113,0.0001797098,0.0003638615,0.00004867515,0.00009328319,0.000030665513,0.00014768868,1.601752e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010738495,0.0021378794,0.8136059,0.00026269807,0.011645548,0.00024298133,0.0022102874,0.0004637388,0.001719525,9.047937e-7,0.000017039401,0.15695497],"study_design_scores_gemma":[0.00993587,0.0098919775,0.9421528,0.0030250615,0.026975283,0.000008799188,0.0010743224,0.0011238066,0.0047897277,0.0000012650514,0.0007730964,0.00024801935],"about_ca_topic_score_codex":0.00039706702,"about_ca_topic_score_gemma":0.000081796345,"teacher_disagreement_score":0.15670696,"about_ca_system_score_codex":0.001957784,"about_ca_system_score_gemma":0.0006778269,"threshold_uncertainty_score":0.7823054},"labels":[],"label_agreement":null},{"id":"W4408979500","doi":"10.1016/s1556-0864(25)00307-7","title":"112P: The role of socioeconomic status (SES) in non-small cell lung carcinoma (non-adenocarcinoma) outcomes: A two-decade perspective from Brazil","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Rajiv Gandhi Cancer Institute and Research Centre; Cambridge University Hospitals; University of Cambridge","keywords":"Medicine; Socioeconomic status; Perspective (graphical); Adenocarcinoma; Oncology; Lung; Internal medicine; Environmental health; Cancer; Population","score_opus":0.021840903671220827,"score_gpt":0.4027028249609113,"score_spread":0.3808619212896905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97188693,0.008543075,0.00021421372,0.0047639627,0.0005128667,0.0003706132,0.000018411074,0.0000061755645,0.013683757],"genre_scores_gemma":[0.99563336,0.00014057345,0.0018878334,0.001749839,0.00028068433,0.000010878522,0.000002428088,0.000018322171,0.000276059],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977497,0.0002344104,0.0010109339,0.00028529653,0.00025576612,0.0004639334],"domain_scores_gemma":[0.99760556,0.00061128044,0.00087206997,0.0003536792,0.00038997654,0.00016742513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090843404,0.00023587479,0.0011186729,0.00039262057,0.00008197839,0.000021241909,0.00045603182,0.00024000167,0.00012282208],"category_scores_gemma":[0.00017197237,0.0001713713,0.00038405796,0.00024377523,0.00018776297,0.00015473786,0.00014742093,0.0010822704,0.000013447974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019018799,0.00022295384,0.9768941,0.000052846277,0.00027570082,0.00031424497,0.006883724,0.00018503839,0.0045584547,0.00012301635,0.0012228319,0.0073652244],"study_design_scores_gemma":[0.0029582735,0.0010127297,0.9364983,0.0002523102,0.00068546593,0.00011180155,0.04742548,0.000816095,0.006187665,0.0027708856,0.0011281471,0.00015286068],"about_ca_topic_score_codex":0.004564159,"about_ca_topic_score_gemma":0.001012812,"teacher_disagreement_score":0.040541753,"about_ca_system_score_codex":0.0021921217,"about_ca_system_score_gemma":0.002310348,"threshold_uncertainty_score":0.6988319},"labels":[],"label_agreement":null},{"id":"W4408979510","doi":"10.1016/s1556-0864(25)00298-9","title":"103P: Enhancing survival prediction in advanced non-small cell lung cancer (aNSCLC): A comparison of artificial intelligence (AI) derived prognostication and RECIST assessments in MYSTIC phase III trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Glycemic Index Laboratories; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology","score_opus":0.030698747181751845,"score_gpt":0.4878925963278135,"score_spread":0.45719384914606165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8516096,0.00050494284,0.14495698,0.00091837754,0.0011675932,0.00058894465,0.0000019122147,0.000004949865,0.00024668447],"genre_scores_gemma":[0.9918885,0.00020474431,0.007540484,0.00008111162,0.00018923765,0.000028449924,0.0000058502396,0.000009596701,0.00005201638],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99774826,0.00027386475,0.0013566727,0.00019731437,0.00022017107,0.000203729],"domain_scores_gemma":[0.9983013,0.00057699427,0.00071901904,0.00010004765,0.00020704078,0.000095548996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017029278,0.00012449954,0.0007743706,0.00047854293,0.000038726324,0.000014478631,0.00010675671,0.00014235202,0.00002188136],"category_scores_gemma":[0.0009952119,0.00011287013,0.000060785256,0.0003761084,0.00008076353,0.00010225921,0.000037097587,0.0008825177,1.9559882e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049044617,0.0024000825,0.06384927,0.0005353257,0.00008590341,0.00008356107,0.0016434188,0.0028377192,0.13780887,0.000024421997,0.00005653283,0.74163026],"study_design_scores_gemma":[0.049050998,0.008318807,0.049715567,0.005711347,0.0011926306,0.000068644964,0.004197615,0.82156974,0.05886897,0.0006044096,0.000406861,0.00029442905],"about_ca_topic_score_codex":0.000097502576,"about_ca_topic_score_gemma":0.00023282018,"teacher_disagreement_score":0.818732,"about_ca_system_score_codex":0.00043113573,"about_ca_system_score_gemma":0.00085464545,"threshold_uncertainty_score":0.46027103},"labels":[],"label_agreement":null},{"id":"W4408979538","doi":"10.1016/s1556-0864(25)00317-x","title":"122TiP: TROPION-Lung10: Phase III study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig in non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); BC Cancer Agency","funders":"Innovent Biologics; Novocure; Regeneron Pharmaceuticals; Yuhan; Gilead Sciences; EQRx; BeiGene; Mirati Therapeutics; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Cancer research; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); A549 cell","score_opus":0.011069265108833071,"score_gpt":0.4012138063917119,"score_spread":0.39014454128287884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907887,0.0017359096,0.0039915796,0.00070093665,0.00046015217,0.0016216896,0.00003443916,0.000011639583,0.00065498316],"genre_scores_gemma":[0.9892105,0.0003859232,0.008730245,0.00018839585,0.00011099841,0.00018323779,0.00002142071,0.000032921398,0.0011363627],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978946,0.0001816491,0.0009678425,0.0003646009,0.00026730943,0.00032401955],"domain_scores_gemma":[0.9980222,0.00020037376,0.0008834532,0.00032042692,0.0003790657,0.00019447775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027023157,0.00028985325,0.0010139918,0.0006550223,0.00018994336,0.000028207976,0.00015791577,0.00010596122,0.000069234295],"category_scores_gemma":[0.000034733457,0.0002160353,0.00008444925,0.0004229223,0.00009141909,0.00030211452,0.000068616886,0.0004716712,0.0000011243592],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07537432,0.046778522,0.31904933,0.0030862878,0.0048286603,0.0028607186,0.03274366,0.029945286,0.3396533,0.00008094017,0.005275613,0.14032334],"study_design_scores_gemma":[0.35945436,0.05815271,0.3542678,0.009067258,0.028249633,0.0025099628,0.060198035,0.010234532,0.10564773,0.00054029207,0.00961711,0.002060581],"about_ca_topic_score_codex":0.00045679274,"about_ca_topic_score_gemma":0.0009981456,"teacher_disagreement_score":0.28408003,"about_ca_system_score_codex":0.0009316374,"about_ca_system_score_gemma":0.0019084946,"threshold_uncertainty_score":0.88096637},"labels":[],"label_agreement":null},{"id":"W4408979626","doi":"10.1016/s1556-0864(25)00323-5","title":"128TiP: ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Docetaxel; Oncology; Internal medicine; Open label; Randomized controlled trial; Chemotherapy; Immunotherapy; Cancer","score_opus":0.019421263798491486,"score_gpt":0.39840942607270036,"score_spread":0.3789881622742089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905021,0.0013826042,0.00073805096,0.0010823649,0.0006732731,0.004412983,0.000026379732,0.000008146975,0.0011740514],"genre_scores_gemma":[0.99472046,0.0004961041,0.0037156788,0.0004442996,0.000071515846,0.0003161196,0.000019986677,0.000026517739,0.00018931561],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99562955,0.00073333643,0.0021804718,0.00040532846,0.0005924438,0.000458857],"domain_scores_gemma":[0.99635255,0.00032779147,0.0021694282,0.0003188493,0.00068065024,0.00015072999],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023651195,0.0003922975,0.0025518325,0.00063183805,0.000070628164,0.000048504895,0.0004481209,0.00022216268,0.00008541934],"category_scores_gemma":[0.00020826487,0.00026320422,0.00020995323,0.0012705554,0.00036746822,0.00039763676,0.00010756778,0.0006249822,6.8640435e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9615209,0.012636343,0.00312066,0.00043674916,0.00067509344,0.00017892118,0.0015427909,0.000043143766,0.002723138,0.000014549359,0.0002345781,0.016873142],"study_design_scores_gemma":[0.97082895,0.014756488,0.0041495464,0.0026137829,0.0010606479,0.000072473056,0.0008445533,0.00077751296,0.0042655068,0.00005208119,0.00030838716,0.00027006617],"about_ca_topic_score_codex":0.0008458757,"about_ca_topic_score_gemma":0.00091023534,"teacher_disagreement_score":0.016603075,"about_ca_system_score_codex":0.0018943447,"about_ca_system_score_gemma":0.0033842584,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W4408979645","doi":"10.1016/s1556-0864(25)00311-9","title":"116P: Predicting overall survival (OS) differences and treatment duration from longitudinal ai-driven imaging-based prognostication (IPRO) and first-line (1L) treatment status among patients with advanced non-small cell lung cancer (aNSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Glycemic Index Laboratories; University of Calgary","funders":"Deutsche Krebshilfe","keywords":"Medicine; Oncology; Internal medicine; Overall survival; Lung cancer","score_opus":0.00943801842358994,"score_gpt":0.33754746496335103,"score_spread":0.3281094465397611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870536,0.0011494763,0.0072619705,0.0033845713,0.00034721784,0.0006692735,0.000023013741,0.000016891725,0.0000939953],"genre_scores_gemma":[0.9935466,0.0008490496,0.0051194755,0.00013871721,0.00017557177,0.000048010148,0.00004857775,0.000018145076,0.000055873275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856716,0.000121814155,0.00051503454,0.0003070267,0.0002218826,0.00026705462],"domain_scores_gemma":[0.9983902,0.0004204573,0.00058054633,0.00012328988,0.00026866377,0.0002168332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016980528,0.00023820346,0.0006002593,0.00018197474,0.00014094032,0.000048088554,0.000058314232,0.00008171002,0.000015826134],"category_scores_gemma":[0.00013582752,0.00015638978,0.0000616231,0.00010045007,0.00013953382,0.00015398252,0.00002413332,0.00029440143,1.5169562e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016472841,0.00063486834,0.87625515,0.00009987711,0.00023534363,0.000059945552,0.00051601883,0.00088486186,0.00022652258,0.0000015935586,0.000014346527,0.11942419],"study_design_scores_gemma":[0.006521738,0.0030240533,0.8884927,0.00068136596,0.0012306811,0.000008034449,0.000095533425,0.09931295,0.00025644412,0.00001871419,0.00024506403,0.00011269833],"about_ca_topic_score_codex":0.0007212334,"about_ca_topic_score_gemma":0.00056629465,"teacher_disagreement_score":0.11931149,"about_ca_system_score_codex":0.0006797864,"about_ca_system_score_gemma":0.0005020695,"threshold_uncertainty_score":0.637739},"labels":[],"label_agreement":null},{"id":"W4408979716","doi":"10.1016/s1556-0864(25)00330-2","title":"LBA3: Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Ottawa Hospital","funders":"Daiichi Sankyo Europe; National Cancer Institute; Sanofi K.K.; Bayer Yakuhin; Eli Lilly Japan; MSD K.K.; Chugai Pharmaceutical; Novartis Pharma; Ipsen; European Society for Medical Oncology; Pfizer Japan; Chinese Society of Clinical Oncology; Sociedad Española de Oncología Médica; Shionogi; Astellas Pharma; Eisai; Daiichi-Sankyo; Seagen; Yuhan; Astellas Foundation for Research on Metabolic Disorders; Taiho Pharmaceutical; Boehringer Ingelheim Japan; Pfizer; Incyte; AstraZeneca; Associazione Italiana di Oncologia Medica; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; American Society of Clinical Oncology; Otsuka Pharmaceutical; International Association for the Study of Lung Cancer; BeiGene; Sanofi; Amgen","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Placebo; Oncology; Internal medicine; Pathology; Cancer; Alternative medicine; Immunotherapy; Nivolumab","score_opus":0.052118191684946344,"score_gpt":0.47605230371866325,"score_spread":0.4239341120337169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890917,0.006821522,0.000005134504,0.0021399846,0.00007391785,0.0011639189,0.000007722264,0.0000030450303,0.00069303886],"genre_scores_gemma":[0.9981766,0.0012166172,0.00011818752,0.00013932453,0.00003947936,0.000030953648,0.0000029723337,0.0000075960784,0.00026826694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724054,0.0009981116,0.00086105394,0.00016537409,0.00048766896,0.0002472342],"domain_scores_gemma":[0.9981743,0.000746519,0.0004506135,0.00026269117,0.00027330877,0.00009254823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025990536,0.00013785178,0.00080053613,0.00064507837,0.000037068607,0.000008458516,0.00020533064,0.00011160062,0.000059728067],"category_scores_gemma":[0.00036468875,0.00008418913,0.00008485261,0.00061306637,0.00015701853,0.000079314625,0.00005743605,0.0006868734,4.047077e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2864133,0.029529266,0.52408147,0.0005052052,0.0012719871,0.009876015,0.019994482,0.00006468643,0.022503102,0.00014355415,0.0012732137,0.10434368],"study_design_scores_gemma":[0.113709494,0.1045406,0.7486631,0.00075561996,0.00035673802,0.00038441,0.016435305,0.00012409597,0.013435573,0.00056765816,0.00087300723,0.00015438233],"about_ca_topic_score_codex":0.00050800125,"about_ca_topic_score_gemma":0.0016835305,"teacher_disagreement_score":0.22458163,"about_ca_system_score_codex":0.0004113716,"about_ca_system_score_gemma":0.000958624,"threshold_uncertainty_score":0.3433133},"labels":[],"label_agreement":null},{"id":"W4408979741","doi":"10.1016/s1556-0864(25)00329-6","title":"134TiP: Evaluation of an additional cohort of patients with non-small cell lung cancer (NSCLC) in the phase I/II duravelo-1 study of zelenectide pevedotin (BT8009), a bicycle toxin conjugate","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Sierra Oncology; Ipsen; Daiichi Sankyo Europe; Servier; Genentech; Institut Gustave-Roussy; European Society for Medical Oncology; Basilea Pharmaceutica; Eisai; Incyte; Boston Pharmaceuticals; Seagen; Agios Pharmaceuticals; Eisai Canada; Cholangiocarcinoma Foundation; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Celldex Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; Bayer HealthCare; Sanofi; Exelixis; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Merck KGaA; Celgene; Amgen","keywords":"Medicine; Conjugate; Oncology; Lung cancer; Cohort; Internal medicine; Toxin; Microbiology","score_opus":0.017534328091956403,"score_gpt":0.43620637209627355,"score_spread":0.4186720440043171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664766,0.00018475782,0.000034690165,0.00031719246,0.00016730723,0.0013925701,0.00021004412,0.0000019354932,0.0010438173],"genre_scores_gemma":[0.99884635,0.00001697942,0.000719554,0.00011281046,0.0000499078,0.000100394456,0.00007556004,0.0000095595315,0.00006889087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979647,0.00037745354,0.0007992187,0.00014765916,0.00057773275,0.00013327101],"domain_scores_gemma":[0.9971662,0.0002335919,0.0010416798,0.00018662577,0.0013194233,0.000052453554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010406094,0.0001253357,0.0005635692,0.0003301813,0.000055229568,0.0000037418527,0.00013645148,0.000069856134,0.00033019012],"category_scores_gemma":[0.000113725575,0.0000797145,0.00007464671,0.0003856002,0.00006820705,0.000102403064,0.000023653705,0.00020434438,1.9952375e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01286025,0.04752024,0.82045233,0.00044535863,0.0024471402,0.000082478844,0.014730532,0.0032246935,0.004508078,0.000010356405,0.0021993914,0.09151917],"study_design_scores_gemma":[0.018183738,0.013943134,0.9527505,0.00051332475,0.004254401,0.000016195036,0.004135336,0.0008699913,0.0050489204,0.000046149282,0.00015987098,0.00007844735],"about_ca_topic_score_codex":0.00026012864,"about_ca_topic_score_gemma":0.0008103778,"teacher_disagreement_score":0.13229819,"about_ca_system_score_codex":0.00042497957,"about_ca_system_score_gemma":0.0021781176,"threshold_uncertainty_score":0.38638872},"labels":[],"label_agreement":null},{"id":"W4408979751","doi":"10.1016/s1556-0864(25)00328-4","title":"133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; Sumitomo Dainippon Pharma Oncology; Sun Pharma; Chinese Society of Clinical Oncology; PharmaMar; European Society for Medical Oncology; Coherus Biosciences; Seagen; Pfizer; Biogen; Incyte; International Association for the Study of Lung Cancer; BeiGene; Mirati Therapeutics; Les Laboratories Pierre Fabre; AstraZeneca; Associazione Italiana di Oncologia Medica; Novocure; Ipsen; Jazz Pharmaceuticals; Revolution Medicines; Regeneron Pharmaceuticals; G1 Therapeutics; Jounce Therapeutics; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Sanofi; Cilag; Cardinal Health; Amgen; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Lung cancer; First line treatment; Internal medicine; Lung; Cancer; Chemotherapy; Immunotherapy","score_opus":0.026725202347766104,"score_gpt":0.41932747852948,"score_spread":0.3926022761817139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979751","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730908,0.016399099,0.0011897469,0.0013098634,0.0010786231,0.0060023586,0.00022766025,0.000018853449,0.00068296917],"genre_scores_gemma":[0.98403084,0.0059310654,0.005448578,0.00008638275,0.00019562924,0.0014987789,0.0000515358,0.00008214826,0.0026750658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949289,0.0005245951,0.0025915918,0.0006399095,0.0007075425,0.00060744665],"domain_scores_gemma":[0.99280685,0.001454759,0.0035128077,0.00068391656,0.001145489,0.0003961956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004983169,0.000821956,0.0047671264,0.0008244903,0.00021065115,0.000022640106,0.00030873253,0.00013805478,0.00055661285],"category_scores_gemma":[0.000080585356,0.0005114185,0.00089951913,0.0007315046,0.0002513189,0.00016401078,0.00007204422,0.00028377405,0.0000023631771],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81719124,0.080395274,0.0031871507,0.0037050904,0.029092124,0.003839752,0.023737092,0.01814141,0.0060300874,0.0000091424545,0.00051058736,0.0141610745],"study_design_scores_gemma":[0.7437079,0.07086215,0.00055032584,0.0020618285,0.08426051,0.0001957267,0.005329756,0.0031422793,0.088549845,0.00003135153,0.0008621511,0.00044619082],"about_ca_topic_score_codex":0.008093057,"about_ca_topic_score_gemma":0.0025448012,"teacher_disagreement_score":0.08251976,"about_ca_system_score_codex":0.0027974735,"about_ca_system_score_gemma":0.004700488,"threshold_uncertainty_score":0.99973375},"labels":[],"label_agreement":null},{"id":"W4408979978","doi":"10.1016/s1556-0864(25)00334-x","title":"138P: Outcomes by treatment (tx) cycles (cyc) with perioperative nivolumab (NIVO) in patients (pts) with resectable NSCLC from CheckMate 77 T study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Nivolumab; Perioperative; Oncology; Internal medicine; Surgery; Cancer; Immunotherapy","score_opus":0.013623294942393761,"score_gpt":0.3809814202040986,"score_spread":0.3673581252617048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935449,0.0008379819,0.000026302821,0.0025076966,0.00024297061,0.0007884919,0.000022582246,0.000011992731,0.0020171234],"genre_scores_gemma":[0.9950521,0.00014064745,0.0007585837,0.00050055457,0.000047506535,0.00003444921,0.000012330414,0.000022256474,0.0034315651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981792,0.0002926039,0.00064492156,0.0002656429,0.00033165878,0.00028597194],"domain_scores_gemma":[0.9988413,0.00014345336,0.0004220678,0.00025279948,0.00024879145,0.0000915834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003432978,0.0002615018,0.0009770511,0.00028764503,0.000098415,0.000032982818,0.00015441782,0.00012520247,0.00017732619],"category_scores_gemma":[0.000034976598,0.00014790302,0.00011127189,0.000336314,0.00012862482,0.00016271895,0.000029934714,0.0003250867,0.000003334564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08285118,0.005897842,0.80186003,0.000020291947,0.0020694875,0.00033916766,0.0036944714,0.000017494614,0.0015256559,0.0000012205337,0.0009844713,0.100738674],"study_design_scores_gemma":[0.036058947,0.04223633,0.8956613,0.0005026718,0.00070404983,0.00004752088,0.008344861,0.000019322648,0.0028091127,0.000010598703,0.013383349,0.00022192014],"about_ca_topic_score_codex":0.0016713925,"about_ca_topic_score_gemma":0.0031549097,"teacher_disagreement_score":0.10051675,"about_ca_system_score_codex":0.0016224646,"about_ca_system_score_gemma":0.0007741998,"threshold_uncertainty_score":0.603131},"labels":[],"label_agreement":null},{"id":"W4408979982","doi":"10.1016/s1556-0864(25)00335-1","title":"139P: Global qualitative assessment of factors affecting multidisciplinary team (MDT) care in early-stage NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Interprofessional Education and Collaboration","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Multidisciplinary team; Stage (stratigraphy); Multidisciplinary approach; Oncology; Nursing","score_opus":0.05049572239586323,"score_gpt":0.6236455360274624,"score_spread":0.5731498136315992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408979982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703909,0.00018030712,0.0008571148,0.0019747566,0.003970264,0.00047169544,0.000032820135,0.000009613849,0.022112539],"genre_scores_gemma":[0.9937924,0.000012042398,0.0043609166,0.0001990336,0.000129367,0.00001824246,0.000010815106,0.000007977431,0.0014691923],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99480987,0.0032851873,0.0012067565,0.00015649,0.0002760472,0.0002656423],"domain_scores_gemma":[0.9956863,0.0016135859,0.0014012532,0.00014311753,0.0010699474,0.00008582354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002072414,0.00014192978,0.00055473886,0.00034827006,0.0002729929,0.000005959157,0.00021656601,0.0003119406,0.00013257831],"category_scores_gemma":[0.00067882385,0.00011218866,0.00011509675,0.00065818586,0.00006673375,0.00020547706,0.00012699474,0.0010093113,0.0000058236524],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002246646,0.0007611193,0.6966327,0.0007246227,0.0001282356,0.000020880798,0.28172934,0.00016971842,0.0011113889,0.0038028667,0.0024441993,0.010228286],"study_design_scores_gemma":[0.00059358357,0.00057261076,0.5091032,0.0008707163,0.000033892666,0.0000011854175,0.48690483,0.00005600186,0.00012721292,0.00049437804,0.0011737667,0.00006866382],"about_ca_topic_score_codex":0.0002780995,"about_ca_topic_score_gemma":0.001727572,"teacher_disagreement_score":0.20517547,"about_ca_system_score_codex":0.0025072794,"about_ca_system_score_gemma":0.007116478,"threshold_uncertainty_score":0.99851227},"labels":[],"label_agreement":null},{"id":"W4408980189","doi":"10.1016/s1556-0864(25)00348-x","title":"154P: Prognostic significance of T cell subtypes in the tumour microenvironment for recurrence following curative-intent resection in early-stage NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Coastal Health Research Institute; University of British Columbia; University of British Columbia Hospital; Vancouver General Hospital","funders":"Cancer Research Institute","keywords":"Medicine; Stage (stratigraphy); Oncology; Resection; Surgical resection; Internal medicine; Surgery","score_opus":0.02709275367169702,"score_gpt":0.3813607072995867,"score_spread":0.3542679536278897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991873,0.0020231225,0.00093234313,0.0035765893,0.00052059727,0.0007581728,0.0000036152794,0.0000017579823,0.0003108048],"genre_scores_gemma":[0.99790406,0.00034155417,0.0011542026,0.0002399182,0.000045349687,0.00003967937,0.0000012669994,0.0000057329867,0.000268214],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986037,0.00028492333,0.0006448749,0.00012814577,0.0001654204,0.00017295782],"domain_scores_gemma":[0.9988611,0.0005035869,0.00043570236,0.00010972509,0.000066396555,0.000023487743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016645213,0.00009558184,0.00037204442,0.0002512149,0.000032312957,0.000007626051,0.00015661075,0.000083144485,0.000009863196],"category_scores_gemma":[0.00021774299,0.00006509493,0.00018129827,0.00030835893,0.00008138751,0.00007119599,0.000016311755,0.00033653385,5.2215034e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038510203,0.002064084,0.17536499,0.0006767269,0.0002230722,0.0003196833,0.005810786,0.00008632427,0.71731615,0.000030763553,0.0010834252,0.05851378],"study_design_scores_gemma":[0.0068997582,0.0114124445,0.6895608,0.0029995972,0.00034792782,0.00010797205,0.011330937,0.00017697141,0.25751606,0.00037766137,0.019065691,0.00020421567],"about_ca_topic_score_codex":0.00008578771,"about_ca_topic_score_gemma":0.00021619248,"teacher_disagreement_score":0.5141958,"about_ca_system_score_codex":0.00042754077,"about_ca_system_score_gemma":0.0003252143,"threshold_uncertainty_score":0.26544943},"labels":[],"label_agreement":null},{"id":"W4408980242","doi":"10.1016/s1556-0864(25)00372-7","title":"178TiP: Bronchoalveolar lavage (BAL) to accelerate time to molecular diagnosis in early-stage lung cancer (AToM-001)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Bronchoalveolar lavage; Medicine; Stage (stratigraphy); Lung cancer; Oncology; Pathology; Lung; Internal medicine","score_opus":0.012561701430277671,"score_gpt":0.41313046033247014,"score_spread":0.40056875890219246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94929874,0.0035595475,0.00014899965,0.041977283,0.0006182025,0.00083521084,0.000028583381,0.000018868983,0.0035145862],"genre_scores_gemma":[0.9769511,0.0009372282,0.0024505365,0.013205045,0.0002755938,0.00033220323,0.000005304039,0.000041060717,0.0058019264],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978901,0.00020245691,0.00076117844,0.00034145443,0.00034204146,0.00046273763],"domain_scores_gemma":[0.99845004,0.00021711472,0.00027638357,0.00032389312,0.00031114023,0.00042142067],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005988978,0.00025778517,0.0009587088,0.0007016607,0.0000551584,0.00004219624,0.00026735576,0.00020595228,0.0013437179],"category_scores_gemma":[0.00013714436,0.0002130919,0.00021528812,0.0006424681,0.000031564057,0.00013140652,0.00013934661,0.0004745315,0.0001410391],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045944583,0.0037055626,0.56428266,0.0005629705,0.0019299759,0.008133088,0.0016420241,0.0020014837,0.0067617814,0.0001101098,0.22255926,0.18371662],"study_design_scores_gemma":[0.0047235657,0.0041601863,0.30848053,0.0027213285,0.0014571344,0.00009367185,0.000113543894,0.00010112409,0.048465297,0.00007075625,0.62919563,0.0004171882],"about_ca_topic_score_codex":0.0005534593,"about_ca_topic_score_gemma":0.0003937853,"teacher_disagreement_score":0.40663642,"about_ca_system_score_codex":0.0029117798,"about_ca_system_score_gemma":0.000830127,"threshold_uncertainty_score":0.9995692},"labels":[],"label_agreement":null},{"id":"W4408980253","doi":"10.1016/s1556-0864(25)00379-x","title":"LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Chemoradiotherapy; Oncology; Internal medicine; Stage (stratigraphy); non-small cell lung cancer (NSCLC); Lung cancer; Overall survival; Cancer; Epidermal growth factor receptor; A549 cell; Erlotinib","score_opus":0.010945723136319701,"score_gpt":0.37819552117808153,"score_spread":0.36724979804176183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993258,0.0012598003,0.0003486367,0.0014119506,0.00047298378,0.001263444,0.00014781751,0.000015787575,0.001821569],"genre_scores_gemma":[0.9958096,0.00020512422,0.0004847526,0.0014784975,0.00012832884,0.00012458452,0.000104755556,0.000038078066,0.0016262581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99728394,0.00048025057,0.0009131719,0.0004094113,0.00047078764,0.00044245852],"domain_scores_gemma":[0.99763465,0.00036834076,0.0007684326,0.000384622,0.00068059005,0.00016338316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005664866,0.00034578424,0.001283345,0.00053070654,0.00013320253,0.000062987674,0.00029081333,0.00018326608,0.0007914493],"category_scores_gemma":[0.000036016485,0.00021265421,0.00024166108,0.0014397486,0.000089778136,0.00018014082,0.00006409305,0.00070040545,0.000003690403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017311154,0.003937513,0.9591684,0.000036508656,0.008419543,0.00049216603,0.004943537,0.00096145464,0.00022903235,0.0000023251118,0.0010358582,0.003462514],"study_design_scores_gemma":[0.020985663,0.0028307566,0.9598367,0.0002703848,0.010144627,0.000004014489,0.0030180113,0.00061014766,0.00057936384,0.000012057189,0.0014720986,0.0002361429],"about_ca_topic_score_codex":0.0043157204,"about_ca_topic_score_gemma":0.00709317,"teacher_disagreement_score":0.0036745078,"about_ca_system_score_codex":0.0016030449,"about_ca_system_score_gemma":0.0016106234,"threshold_uncertainty_score":0.8671787},"labels":[],"label_agreement":null},{"id":"W4408980259","doi":"10.1016/s1556-0864(25)00357-0","title":"163P: Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thermo Fisher Scientific (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.021169923163706268,"score_gpt":0.43500369100691866,"score_spread":0.4138337678432124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98364985,0.00042725928,0.00036515217,0.008539924,0.0008616557,0.0009516346,0.000015626669,0.0000029735436,0.005185914],"genre_scores_gemma":[0.99766666,0.000036148576,0.00096089527,0.0004559677,0.00012562209,0.00003198595,0.0000095278765,0.000006992478,0.00070618663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864244,0.00025023427,0.0007109804,0.00010852534,0.00017054525,0.00011727028],"domain_scores_gemma":[0.99905705,0.00016052918,0.00034791956,0.00014452972,0.00023357062,0.00005642617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007592454,0.00008284173,0.0003820977,0.00018976057,0.000044976878,0.0000053554295,0.00008757468,0.000049065697,0.000057754194],"category_scores_gemma":[0.00010550267,0.000050594113,0.00012568921,0.00025995684,0.000020303234,0.00005329221,0.000014233129,0.00018749599,8.6453935e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022279283,0.0019576962,0.87172276,0.00028129702,0.000370408,0.00008478039,0.0055211713,0.0057728672,0.00086110336,0.000045038607,0.0029303683,0.08817324],"study_design_scores_gemma":[0.01093028,0.0013452675,0.97875506,0.00020096535,0.0006817265,0.0000064446835,0.0005495826,0.000079353784,0.00067135243,0.00008190234,0.0066417805,0.000056293822],"about_ca_topic_score_codex":0.00046500732,"about_ca_topic_score_gemma":0.0015654004,"teacher_disagreement_score":0.10703231,"about_ca_system_score_codex":0.0005375566,"about_ca_system_score_gemma":0.0006931155,"threshold_uncertainty_score":0.20631681},"labels":[],"label_agreement":null},{"id":"W4408980301","doi":"10.1016/s1556-0864(25)00353-3","title":"159P: Patient and clinician preferences for adjuvant treatment in early-stage non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Medicine; Stage (stratigraphy); Adjuvant; Oncology; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Lung","score_opus":0.028447219294535725,"score_gpt":0.45288004761676903,"score_spread":0.4244328283222333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987935,0.004721149,0.00020314594,0.0020436996,0.00067802373,0.0008494206,0.00003272375,0.0000045687375,0.0035322658],"genre_scores_gemma":[0.99235696,0.0015105058,0.002902703,0.00043768735,0.00011791539,0.00012892245,0.000004586512,0.00000954205,0.0025311892],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99899197,0.000059487975,0.00051829644,0.00015937496,0.00008039876,0.00019049946],"domain_scores_gemma":[0.99910086,0.00019643393,0.00034606998,0.00009818044,0.00015639838,0.00010205428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001679946,0.00012903236,0.00052220613,0.00022482107,0.000052113475,0.000012049175,0.000051911327,0.00010989857,0.000024522617],"category_scores_gemma":[0.000027592614,0.00008666536,0.000111287365,0.00011329901,0.000037627615,0.00005481755,0.000019204634,0.0001421435,6.1836084e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022943192,0.0013235772,0.35157505,0.00029505807,0.0005363178,0.00017118368,0.0052002664,0.00007041069,0.0003129467,0.000019406723,0.00080574665,0.63739574],"study_design_scores_gemma":[0.01793903,0.026788102,0.81136864,0.0021569498,0.005910406,0.00007362936,0.0065760026,0.0010610886,0.008072057,0.00050622347,0.11918342,0.00036442958],"about_ca_topic_score_codex":0.00038376116,"about_ca_topic_score_gemma":0.00096333394,"teacher_disagreement_score":0.6370313,"about_ca_system_score_codex":0.00074256235,"about_ca_system_score_gemma":0.0013676897,"threshold_uncertainty_score":0.35341105},"labels":[],"label_agreement":null},{"id":"W4408980795","doi":"10.1016/s1556-0864(25)00395-8","title":"201P: Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Osimertinib; Chemoradiotherapy; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer; Radiology; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.011183346550844117,"score_gpt":0.3971920526254999,"score_spread":0.38600870607465576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240834,0.001787643,0.00011374862,0.0015406541,0.0006481631,0.0026634363,0.00005536375,0.000020116207,0.000762522],"genre_scores_gemma":[0.99608237,0.000092787064,0.0010807101,0.0013371109,0.00007968795,0.000344203,0.00003506941,0.00004523845,0.0009028476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974055,0.00028602095,0.0010086836,0.00037515975,0.00051143323,0.0004131812],"domain_scores_gemma":[0.99738514,0.00026247045,0.0011518965,0.00035960178,0.0006879946,0.00015292133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003788969,0.00034492696,0.0010390581,0.00027211514,0.00014654544,0.000050975523,0.00020333429,0.00018163444,0.00020473886],"category_scores_gemma":[0.00006232809,0.00018746943,0.00014194984,0.000528342,0.00010239139,0.00019144508,0.00006753822,0.00065748976,0.0000021462547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014739204,0.003945145,0.9534156,0.00005644832,0.0016335957,0.00043023334,0.0060233013,0.000058165748,0.00016968168,5.147927e-7,0.00058833364,0.018939817],"study_design_scores_gemma":[0.019756433,0.004041005,0.9681073,0.000977625,0.00202472,0.000008775201,0.002690619,0.000084839,0.0011145457,0.000009559553,0.0009843094,0.0002002566],"about_ca_topic_score_codex":0.001011861,"about_ca_topic_score_gemma":0.00096115103,"teacher_disagreement_score":0.01873956,"about_ca_system_score_codex":0.0011240375,"about_ca_system_score_gemma":0.0017540255,"threshold_uncertainty_score":0.76447815},"labels":[],"label_agreement":null},{"id":"W4408980834","doi":"10.1016/s1556-0864(25)00386-7","title":"192P: Differential effect of proton pump inhibitors (PPIs) and antibiotics (ATB) on clinical outcomes from immunotherapy or placebo in patients with locally advanced, unresectable NSCLC who have not progressed following chemoradiation therapy (cCTRT): A post-hoc analysis of the PACIFIC trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Placebo; Immunotherapy; Internal medicine; Oncology; Antibiotics; Chemoradiotherapy; Chemotherapy; Cancer; Pathology; Alternative medicine","score_opus":0.01471447977675807,"score_gpt":0.3835884075308421,"score_spread":0.36887392775408406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408980834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950258,0.00030552558,0.000033626144,0.00083747075,0.00066675106,0.0030632168,0.000026172584,0.000005816722,0.000035636098],"genre_scores_gemma":[0.9991466,0.00032240088,0.0001663876,0.00017627308,0.0000721217,0.000016406348,0.000016219165,0.00002137699,0.00006224882],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9965644,0.0008900237,0.0014983019,0.0002733719,0.00054270495,0.00023120754],"domain_scores_gemma":[0.99651015,0.0012924392,0.001565699,0.00033933745,0.00023259148,0.00005975995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014747382,0.00027015808,0.0018393587,0.0005811279,0.00007352155,0.000022312417,0.00021016822,0.00030165876,0.000032331893],"category_scores_gemma":[0.0003066867,0.00013778164,0.0006472583,0.0008458956,0.00023680831,0.00011367313,0.000033235407,0.0005018795,9.828349e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5042197,0.0010020642,0.38308284,0.00004987173,0.0031631726,0.0000092659,0.00019814706,0.000012853133,0.003552093,3.4399562e-7,0.00000781458,0.10470185],"study_design_scores_gemma":[0.1669585,0.05429251,0.7370738,0.0010015481,0.001575722,0.0000020369134,0.00022747587,0.00017280517,0.03834588,0.0000036604656,0.00018766958,0.00015844245],"about_ca_topic_score_codex":0.000054925567,"about_ca_topic_score_gemma":0.00009117115,"teacher_disagreement_score":0.3539909,"about_ca_system_score_codex":0.00025102834,"about_ca_system_score_gemma":0.0005459163,"threshold_uncertainty_score":0.5618572},"labels":[],"label_agreement":null},{"id":"W4408981050","doi":"10.1016/s1556-0864(25)00423-x","title":"230P: A retrospective analysis on patterns of surveillance after curative intent treatment for unresectable stage III non-small cell lung cancer (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; BC Cancer Agency","funders":"Sanofi; Pfizer; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Stage (stratigraphy); Oncology; Retrospective cohort study; Internal medicine; Lung cancer; Lung; Radiology","score_opus":0.016564479674886976,"score_gpt":0.4334877923987314,"score_spread":0.4169233127238444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408981050","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98012805,0.0014133311,0.011682747,0.0019582047,0.0005382571,0.0009379991,0.00036468092,0.0000066941575,0.002970044],"genre_scores_gemma":[0.9887913,0.00049754995,0.0008930436,0.00028648713,0.00011458646,0.00019771881,0.000019565854,0.000013782205,0.009185989],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868166,0.00010039764,0.0005798094,0.00023356671,0.00017054772,0.00023403755],"domain_scores_gemma":[0.99802107,0.00024248312,0.0006660299,0.00021262164,0.0007549702,0.000102844766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025217969,0.0001906031,0.0009974192,0.00050609134,0.000057814705,0.000011039218,0.000087570435,0.00010511979,0.00017103058],"category_scores_gemma":[0.000043908112,0.00012890421,0.00047077643,0.00044214443,0.000038619197,0.000058059824,0.000022869976,0.00017469093,6.259439e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012409318,0.0024375662,0.9490239,0.00034828015,0.012921869,0.00021823494,0.004244841,0.0010714557,0.0010710414,0.00004885207,0.0009545133,0.015250141],"study_design_scores_gemma":[0.012026532,0.015209236,0.9205903,0.00096265535,0.016522694,0.000017936642,0.0031803274,0.0014796493,0.021374112,0.000075840435,0.008284933,0.00027579968],"about_ca_topic_score_codex":0.00043871233,"about_ca_topic_score_gemma":0.0018735698,"teacher_disagreement_score":0.028433604,"about_ca_system_score_codex":0.0027046078,"about_ca_system_score_gemma":0.0010715077,"threshold_uncertainty_score":0.7072455},"labels":[],"label_agreement":null},{"id":"W4408981120","doi":"10.1016/s1556-0864(25)00425-3","title":"232P: How socioeconomic status (SES) shapes lung adenocarcinoma diagnosis and survival in Brazil: A population-based analysis","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Socioeconomic status; Adenocarcinoma; Lung; Population; Demography; Oncology; Internal medicine; Environmental health; Cancer","score_opus":0.037791706419667746,"score_gpt":0.43029050613996966,"score_spread":0.39249879972030194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408981120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97964704,0.0046994747,0.0005806803,0.014341785,0.00021616723,0.00013960463,0.000008176265,0.000008273481,0.0003587825],"genre_scores_gemma":[0.9963137,0.0002853866,0.0016915797,0.001472326,0.00012904704,0.000009215021,0.000008227694,0.000007818863,0.00008269806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854374,0.00022225974,0.0005548378,0.00020247606,0.00019117938,0.00028551577],"domain_scores_gemma":[0.99859375,0.0005367575,0.0004309062,0.0001156257,0.00016414847,0.00015882749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083719444,0.00013844998,0.0008656517,0.0009027101,0.00006271919,0.000039094088,0.00011132751,0.00017442885,0.00014060986],"category_scores_gemma":[0.00030676986,0.000123406,0.00023876062,0.0005195298,0.000059748287,0.00017916725,0.00003737049,0.0003823385,0.0000014008741],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085441425,0.00008119409,0.9677344,0.00006739867,0.00047537635,0.00020025324,0.00012460703,0.0007688559,0.000032533495,0.000046416237,0.00079568184,0.028818868],"study_design_scores_gemma":[0.0009628377,0.00044238416,0.9903917,0.00013881503,0.0016920768,0.000032278844,0.00063828507,0.004314907,0.000047612688,0.00015754266,0.0010892457,0.000092367096],"about_ca_topic_score_codex":0.0006313202,"about_ca_topic_score_gemma":0.002319135,"teacher_disagreement_score":0.028726501,"about_ca_system_score_codex":0.00095214136,"about_ca_system_score_gemma":0.0006565124,"threshold_uncertainty_score":0.50323504},"labels":[],"label_agreement":null},{"id":"W4408981555","doi":"10.1016/s1556-0864(25)00491-5","title":"299P: First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Etoposide; Oncology; Biomarker; Stage (stratigraphy); Internal medicine; Cancer; Nivolumab; Chemotherapy","score_opus":0.12809308711444112,"score_gpt":0.5083823957932491,"score_spread":0.38028930867880795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408981555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9622663,0.017677946,0.0003051093,0.016448086,0.0007445481,0.00041541926,0.000083884086,0.000021737396,0.0020369282],"genre_scores_gemma":[0.9867748,0.005155589,0.004196937,0.0008666837,0.0003753433,0.000024893825,0.000015401703,0.000026315087,0.0025640272],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99668926,0.00047362235,0.0013172519,0.0004626309,0.0005580045,0.0004992521],"domain_scores_gemma":[0.9964034,0.0014470996,0.0007718656,0.0004081938,0.0007462729,0.00022314949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016384287,0.0003039686,0.0013371856,0.00070956553,0.00018120145,0.00003489294,0.00026165115,0.0002448695,0.00006255943],"category_scores_gemma":[0.0034264273,0.00024082964,0.00019243658,0.0007710986,0.0005220168,0.0002948718,0.00028340405,0.0009298907,0.000009343761],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12937206,0.0031844229,0.13482222,0.0022116045,0.0048371297,0.033227604,0.00739826,0.0007321423,0.077971354,0.00011153232,0.11582963,0.49030206],"study_design_scores_gemma":[0.015593232,0.004519731,0.8750621,0.004667902,0.0010764145,0.0004906822,0.00425074,0.0016586216,0.014191177,0.0009834835,0.076997966,0.0005079424],"about_ca_topic_score_codex":0.00029007837,"about_ca_topic_score_gemma":0.0015548139,"teacher_disagreement_score":0.7402399,"about_ca_system_score_codex":0.0009179626,"about_ca_system_score_gemma":0.0011365669,"threshold_uncertainty_score":0.98207474},"labels":[],"label_agreement":null},{"id":"W4408981570","doi":"10.1016/s1556-0864(25)00489-7","title":"297MO: Patterns of disease progression with durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Results from ADRIATIC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Durvalumab; Medicine; Oncology; Stage (stratigraphy); Chemoradiotherapy; Internal medicine; Disease; Cancer; Lung cancer; Immunotherapy","score_opus":0.022631747890215565,"score_gpt":0.4437401101460588,"score_spread":0.42110836225584325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408981570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97220755,0.016862305,0.00023599449,0.008703509,0.00055796094,0.000873915,0.00018697034,0.000012638813,0.00035914656],"genre_scores_gemma":[0.99332523,0.0036821668,0.001101143,0.0004412082,0.00030561906,0.00010753858,0.000014937963,0.00002841983,0.0009937459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733216,0.00037095352,0.0010014122,0.0003296946,0.0005713639,0.00039441502],"domain_scores_gemma":[0.99764985,0.00043370968,0.000853467,0.00034711405,0.00044821636,0.00026766324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071631663,0.00025029058,0.0010898123,0.00043792874,0.000040097613,0.000017338889,0.00024598115,0.00013391189,0.00014310652],"category_scores_gemma":[0.00027574316,0.00016714328,0.0001657118,0.00037666722,0.0001547902,0.00009368262,0.00011057737,0.0007233716,0.0000010186945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09212701,0.0024559544,0.78872746,0.0031003484,0.0011246374,0.002582164,0.0030227795,0.00014238003,0.0027504794,0.0000056803538,0.0026987703,0.10126236],"study_design_scores_gemma":[0.028206695,0.005249263,0.91685,0.017811337,0.0017893672,0.000030012252,0.0011014877,0.0021265221,0.010295388,0.00003195972,0.016091645,0.0004163333],"about_ca_topic_score_codex":0.00025887002,"about_ca_topic_score_gemma":0.00067926134,"teacher_disagreement_score":0.12812255,"about_ca_system_score_codex":0.0013425275,"about_ca_system_score_gemma":0.002233568,"threshold_uncertainty_score":0.68159056},"labels":[],"label_agreement":null},{"id":"W4408989062","doi":"10.1016/s1556-0864(25)00538-6","title":"346P: Multi-omics approach to identify factors underlying antibiotics (ABX)-mediated immunosuppression in a prospective trial of cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"ABX test; Medicine; Immunosuppression; Immunotherapy; Omics; Cancer; Cancer immunotherapy; Oncology; Immunology; Internal medicine; Bioinformatics","score_opus":0.05866612740197183,"score_gpt":0.47835019139768215,"score_spread":0.41968406399571034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408989062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918672,0.0027280264,0.0014302145,0.0008077096,0.0017692916,0.001079158,0.000013395445,0.0000167362,0.0002882642],"genre_scores_gemma":[0.9933379,0.0018182738,0.0042060814,0.00029209835,0.00009058165,0.000006706285,0.0000059435197,0.000030395162,0.00021197172],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99774015,0.00025041215,0.0012237849,0.00021824909,0.00028924705,0.00027817473],"domain_scores_gemma":[0.9982686,0.00027030558,0.0008353081,0.00023416693,0.0003154758,0.00007612397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010022171,0.00021224878,0.0010066387,0.00078994717,0.00005026815,0.000019344145,0.0002573926,0.0003254065,0.000021459024],"category_scores_gemma":[0.00024441862,0.00015933112,0.0003044803,0.00078062207,0.00014074067,0.00011963874,0.000052870393,0.0005738388,5.351216e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28699505,0.0030103382,0.05395821,0.00022452457,0.0011132458,0.00003237158,0.004237361,0.00010588647,0.59606606,0.000010613151,0.0002564609,0.053989865],"study_design_scores_gemma":[0.09685722,0.0061757723,0.7552941,0.0017918905,0.000383669,0.00007244211,0.00719005,0.0003901835,0.12723976,0.00011388955,0.004148264,0.00034274173],"about_ca_topic_score_codex":0.00031882085,"about_ca_topic_score_gemma":0.00007818727,"teacher_disagreement_score":0.7013359,"about_ca_system_score_codex":0.0010308992,"about_ca_system_score_gemma":0.0010581553,"threshold_uncertainty_score":0.6497334},"labels":[],"label_agreement":null},{"id":"W4408996213","doi":"10.1016/s1556-0864(25)00631-8","title":"439P: Standardization of endpoints in early NSCLC randomized clinical trials (RCTs): The DATECAN initiative","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Standardization; Randomized controlled trial; Oncology; Internal medicine; Clinical endpoint; Medical physics; Intensive care medicine","score_opus":0.1275065917859283,"score_gpt":0.5891366432201496,"score_spread":0.4616300514342213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408996213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94978666,0.0025052947,0.0064461282,0.022906542,0.003181567,0.001621435,0.00002737749,0.000008782001,0.013516183],"genre_scores_gemma":[0.9958897,0.0014235075,0.0007072145,0.0011855128,0.00039311606,0.000019150873,0.00000548539,0.0000075753337,0.00036873532],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9901428,0.0071000503,0.0022705162,0.00012467039,0.00020786414,0.00015408198],"domain_scores_gemma":[0.988276,0.0093456535,0.001742488,0.00013991178,0.00042263477,0.00007330868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0216573,0.00011971479,0.0022362901,0.00036157633,0.000032289165,0.000007084029,0.00014119143,0.0001987612,0.00022948401],"category_scores_gemma":[0.006338358,0.000067038614,0.0004902548,0.00034929442,0.00032605557,0.00007936281,0.00004073756,0.0005651017,0.0000025378931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72630125,0.0016995576,0.013073141,0.00008887294,0.0025355462,0.00029054348,0.0019965773,0.000044603854,0.0014560074,0.00053551776,0.009520277,0.24245813],"study_design_scores_gemma":[0.77890736,0.01520022,0.069687665,0.0015721445,0.013069495,0.00039483534,0.0020090248,0.00039645153,0.024746744,0.012797527,0.08090431,0.0003142227],"about_ca_topic_score_codex":0.00002390262,"about_ca_topic_score_gemma":0.000053366482,"teacher_disagreement_score":0.24214391,"about_ca_system_score_codex":0.000285158,"about_ca_system_score_gemma":0.0015542046,"threshold_uncertainty_score":0.75880647},"labels":[],"label_agreement":null},{"id":"W4409001910","doi":"10.1016/s1556-0864(25)00537-4","title":"345TiP: A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homologue 3 (B7-H3) protein-targeted antibody-drug conjugate (ADC), in combination with standard of care (SoC), in patients with advanced solid tumours, including lung cancers","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Merck Sharp and Dohme; Gilead Sciences","keywords":"Medicine; Conjugate; Standard of care; Antibody-drug conjugate; Antibody; Drug; Cancer research; Pharmacology; Oncology; Internal medicine; Monoclonal antibody; Immunology; Mathematical analysis","score_opus":0.008450471555992288,"score_gpt":0.4182881550432056,"score_spread":0.40983768348721333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409001910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584526,0.00057042536,0.00025214622,0.0004219231,0.00020353906,0.0025045164,0.000050245482,0.000010734216,0.00014122513],"genre_scores_gemma":[0.9979545,0.000044297616,0.0017277736,0.00004531489,0.00001916123,0.00006513349,0.00008621371,0.000023838384,0.000033757267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997537,0.000319684,0.0010900942,0.00027045322,0.00051507517,0.00026769485],"domain_scores_gemma":[0.9969837,0.00010979665,0.0013524636,0.00020831879,0.001246356,0.00009935326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004342404,0.00023702555,0.0011322257,0.0008286055,0.00008298352,0.000008928599,0.00012357786,0.00011210118,0.000011901189],"category_scores_gemma":[0.00011381621,0.00017334495,0.00007027175,0.00085550075,0.0001206407,0.0002882798,0.000045889905,0.00039440495,1.2735096e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06431705,0.008159057,0.861156,0.0008073746,0.0007654082,0.0004983461,0.022776516,0.0059019304,0.0040523256,0.00002581695,0.00005766656,0.031482525],"study_design_scores_gemma":[0.10142998,0.06623428,0.78389573,0.007031682,0.001793951,0.000033840035,0.028350953,0.00054637494,0.010130611,0.00009847859,0.00010830552,0.0003457833],"about_ca_topic_score_codex":0.0004370985,"about_ca_topic_score_gemma":0.0022541792,"teacher_disagreement_score":0.077260226,"about_ca_system_score_codex":0.0027546145,"about_ca_system_score_gemma":0.0019060689,"threshold_uncertainty_score":0.7203221},"labels":[],"label_agreement":null},{"id":"W4409100134","doi":"10.1016/j.jtho.2025.03.017","title":"PP01.09 Integrin-Linked Kinase Drives Drug-Tolerant Persister Cell Survival and EMT in Response to EGFR Inhibition in Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cancer research; Adenocarcinoma; Drug; Lung; Integrin; Oncology; Internal medicine; Pharmacology; Receptor; Cancer","score_opus":0.016480987100267738,"score_gpt":0.3701956390421829,"score_spread":0.35371465194191515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409100134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751537,0.0019733177,0.00035500113,0.020824967,0.0007322349,0.00031497085,0.0000028924405,0.0000062877393,0.0006366493],"genre_scores_gemma":[0.9961098,0.00017579562,0.0012768848,0.0012496139,0.00014955243,0.000009659946,0.0000014016141,0.000014100808,0.0010131878],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982116,0.0005139744,0.0006310339,0.00021428996,0.0001814402,0.00024761687],"domain_scores_gemma":[0.99904114,0.00030987684,0.0002086705,0.00014728098,0.00013889854,0.00015413885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001689713,0.00015499869,0.0006471651,0.0009410555,0.000034064786,0.000018467486,0.00007398884,0.00016546415,0.00006626187],"category_scores_gemma":[0.00012822563,0.0001320444,0.00011089378,0.00038666857,0.000062390725,0.00009685999,0.00006090336,0.00062297133,0.0000031219736],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18294263,0.0025779954,0.068997815,0.0008290057,0.00021570876,0.012946593,0.027660785,0.00019209478,0.5641891,0.00057147234,0.0026362136,0.13624063],"study_design_scores_gemma":[0.02164087,0.00888336,0.8617543,0.0040227594,0.00046122217,0.0014096348,0.026119836,0.0010871963,0.04739629,0.001951063,0.024649698,0.0006237596],"about_ca_topic_score_codex":0.00006905611,"about_ca_topic_score_gemma":0.00055010646,"teacher_disagreement_score":0.7927565,"about_ca_system_score_codex":0.00080645503,"about_ca_system_score_gemma":0.00052382104,"threshold_uncertainty_score":0.53846145},"labels":[],"label_agreement":null},{"id":"W4409100187","doi":"10.1016/j.jtho.2025.03.010","title":"PP01.02 Potentiating ERK Hyperactivation by Targeting the Proteostasis Network","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Proteostasis; Hyperactivation; MAPK/ERK pathway; Cell biology; Cancer research; Signal transduction","score_opus":0.010774236517717962,"score_gpt":0.35915867104817606,"score_spread":0.3483844345304581,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409100187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94224423,0.0166895,0.025057007,0.010337114,0.0017289178,0.00030616173,0.000008717874,0.0000075401454,0.0036208308],"genre_scores_gemma":[0.9908581,0.00054477877,0.0045893434,0.001946856,0.0012435707,0.000012895551,0.000014955565,0.000013170718,0.0007763331],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99890655,0.00023345512,0.00040651482,0.00013660682,0.00011375164,0.00020312217],"domain_scores_gemma":[0.99898034,0.00006962147,0.0005324253,0.00013579556,0.000245418,0.000036413778],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009498587,0.0001031769,0.00019412584,0.00003350957,0.0002212713,0.000024340075,0.00022737263,0.00016337186,0.000026601914],"category_scores_gemma":[0.0002449797,0.000070460395,0.00014013199,0.00017305909,0.000049893675,0.000007902341,0.00008365899,0.00019499914,0.0000016308495],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005832205,0.000109370405,0.0051611117,0.00002834741,0.0003344912,0.000007756135,0.000058887264,0.0012643689,0.5033903,0.000057349338,0.27954566,0.2094591],"study_design_scores_gemma":[0.0002536597,0.00045467162,0.0015584213,0.00006175473,0.00013437278,0.00005618243,0.000378783,0.00010563918,0.1596037,0.00026763076,0.8370004,0.0001247267],"about_ca_topic_score_codex":0.000009599445,"about_ca_topic_score_gemma":0.0000045395077,"teacher_disagreement_score":0.55745476,"about_ca_system_score_codex":0.00006276391,"about_ca_system_score_gemma":0.00026420288,"threshold_uncertainty_score":0.28732914},"labels":[],"label_agreement":null},{"id":"W4409100229","doi":"10.1016/j.jtho.2025.03.028","title":"PP01.25 Exploring the Impact of Socioeconomic and Geographic Factors on Immunotherapy Discontinuation and Success in Northern Ontario: A Retrospective, Single-Center Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Microscopic Colitis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Thunder Bay Regional Health Sciences Centre; NOSM University","funders":"","keywords":"Medicine; Discontinuation; Socioeconomic status; Retrospective cohort study; Center (category theory); Cohort; Single Center; Demography; Family medicine; Environmental health; Internal medicine; Population","score_opus":0.02359291979178708,"score_gpt":0.37518631821363624,"score_spread":0.35159339842184917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409100229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981675,0.00020413368,0.000007579132,0.00045103056,0.00025275658,0.00063668244,0.0000028354236,0.000003296056,0.00027419705],"genre_scores_gemma":[0.9996847,0.00008879949,0.000023104438,0.000034175304,0.000034747296,0.000012785165,0.0000010766354,0.0000093759245,0.00011126782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885017,0.00018435708,0.00054714835,0.00015763266,0.000108291904,0.00015238077],"domain_scores_gemma":[0.9990856,0.00017864814,0.0004232719,0.00015759954,0.000111975445,0.00004288205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007171816,0.00013381621,0.0006313445,0.00035619974,0.00005279133,0.000022751774,0.000091683,0.000066397515,0.000040684605],"category_scores_gemma":[0.00005870091,0.000086143555,0.00011730112,0.00010681856,0.00011880933,0.00013044158,0.000040387953,0.00042210886,2.1698766e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011538634,0.0008932426,0.9827632,0.000012468061,0.00043278685,0.000018750006,0.0046108887,0.0000042833785,0.001303619,0.0000045223505,0.000010097405,0.008792305],"study_design_scores_gemma":[0.0019211526,0.0040046563,0.99221355,0.00015701,0.000105100604,0.000033814133,0.0012468082,0.0000035494072,0.00012596612,0.00007622063,0.00005681465,0.000055350334],"about_ca_topic_score_codex":0.007494271,"about_ca_topic_score_gemma":0.12026791,"teacher_disagreement_score":0.11277364,"about_ca_system_score_codex":0.0012503505,"about_ca_system_score_gemma":0.00027874697,"threshold_uncertainty_score":0.99911493},"labels":[],"label_agreement":null},{"id":"W4409100763","doi":"10.1016/j.jtho.2025.03.022","title":"PP01.15 Transcriptional Changes Associated with Tolerance to EGFR Tyrosine Kinase Inhibitors in Mutant EGFR Lung Cancer PDX Models","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Mutant; Lung cancer; Tyrosine kinase; Cancer research; Receptor tyrosine kinase; Oncology; Internal medicine; Receptor; Genetics; Gene; Biology","score_opus":0.020283172524426497,"score_gpt":0.4167645258222943,"score_spread":0.39648135329786777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409100763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402911,0.006763137,0.001286787,0.047666468,0.0010548844,0.0005888272,0.00005803551,0.000018997405,0.0022717356],"genre_scores_gemma":[0.9936757,0.00030558626,0.0011664546,0.0029512213,0.0002603175,0.00007645282,0.000012196028,0.00001808138,0.0015339939],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986747,0.000097752505,0.00046362917,0.00019474416,0.00028751732,0.0002816837],"domain_scores_gemma":[0.9989538,0.00008734067,0.00026676463,0.000110844936,0.00041584158,0.00016540241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003174101,0.00017122655,0.0005920375,0.00044625654,0.00006856383,0.000015132286,0.00009545843,0.00014248332,0.00008490483],"category_scores_gemma":[0.00005695589,0.00012529551,0.000088808454,0.0006251683,0.00005522339,0.00014590134,0.000015381578,0.00034529195,0.0000011913942],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033592008,0.011828762,0.13578536,0.0012659762,0.0068260687,0.007938228,0.023991596,0.092372246,0.11901222,0.0027669258,0.041209456,0.52341115],"study_design_scores_gemma":[0.057616316,0.025123766,0.5961383,0.03451465,0.015710201,0.001822016,0.006872982,0.026331704,0.05371657,0.0036155514,0.17629534,0.0022425917],"about_ca_topic_score_codex":0.0001540313,"about_ca_topic_score_gemma":0.002366994,"teacher_disagreement_score":0.52116853,"about_ca_system_score_codex":0.0022163775,"about_ca_system_score_gemma":0.0013807964,"threshold_uncertainty_score":0.579575},"labels":[],"label_agreement":null},{"id":"W4410221591","doi":"10.1016/j.jtho.2025.05.004","title":"Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee","year":2025,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Radiation therapy; Stage (stratigraphy); Internal medicine; Cancer","score_opus":0.019342984038893108,"score_gpt":0.4126641653599286,"score_spread":0.3933211813210355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410221591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005454235,0.9856698,0.00001840508,0.011221612,0.0002836468,0.0017864829,0.000031635016,0.000008046287,0.00043495258],"genre_scores_gemma":[0.00025341992,0.99514383,0.0014598386,0.0022115314,0.00021575518,0.0001775075,0.000030561678,0.000040062096,0.0004674788],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99681026,0.00083099084,0.0014413063,0.0002735706,0.00036553762,0.00027834508],"domain_scores_gemma":[0.9966548,0.0011148751,0.001326392,0.00051721797,0.00026457835,0.00012212625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010955746,0.000407973,0.0044351737,0.00033418668,0.000049844024,0.00001513571,0.0004084982,0.00021236717,0.00034825844],"category_scores_gemma":[0.00011201658,0.00020074315,0.0005567718,0.0007333366,0.00007055637,0.000062083855,0.000055662662,0.0007545545,0.000004811669],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011359095,0.0006975168,0.0010748912,0.010749153,0.002604033,0.000195631,0.0006450941,0.0000036711492,0.0000045061315,0.000012979739,0.01932899,0.96354765],"study_design_scores_gemma":[0.0013504082,0.0029940512,0.00036743173,0.15233123,0.0033712522,0.000098978366,0.00017508713,6.5851765e-7,0.000013901061,0.000019903946,0.83913267,0.00014441137],"about_ca_topic_score_codex":0.00014499926,"about_ca_topic_score_gemma":0.00027033465,"teacher_disagreement_score":0.9634032,"about_ca_system_score_codex":0.0010303659,"about_ca_system_score_gemma":0.0018666777,"threshold_uncertainty_score":0.8186068},"labels":[],"label_agreement":null},{"id":"W4410421568","doi":"10.1016/j.jtho.2025.05.012","title":"Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Chugai Pharmaceutical; Janssen Research and Development; EMD Serono; Manchester Clinical Research Facility; Genentech; LG Chem; Grifols; Pfizer Japan; Sociedad Española de Oncología Médica; Otsuka Pharmaceutical; Astellas Pharma; Eisai; Curtin University of Technology; Clovis Oncology; National Institute for Health and Care Research; BeiGene; Mirati Therapeutics; Revolution Medicines; Kissei; Johnson and Johnson; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Array BioPharma; Manchester Biomedical Research Centre; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Sanofi; Amgen; G1 Therapeutics; Jounce Therapeutics; Bayer Yakuhin; Celgene; AstraZeneca; Ignyta; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Exon; Lung cancer; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Mutation; Cancer research; Genetics; Gene; Biology","score_opus":0.0415045479709282,"score_gpt":0.47087504440988687,"score_spread":0.42937049643895864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410421568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915254,0.0010379516,0.00014401037,0.005867472,0.00021387341,0.00045507945,0.000017576596,0.0000072058233,0.00073139224],"genre_scores_gemma":[0.99615777,0.000106224106,0.0029642251,0.00048037473,0.00007609645,0.000026094822,0.000008996757,0.00000740339,0.00017282972],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99880934,0.00020122515,0.00050660863,0.0001534299,0.00016443591,0.00016497848],"domain_scores_gemma":[0.9987056,0.00061319635,0.00031201055,0.00015283393,0.00015224675,0.000064105065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050574593,0.00009840945,0.00038229697,0.00015255401,0.000073339426,0.000018446193,0.00007634125,0.000049505663,0.00000863936],"category_scores_gemma":[0.00038518925,0.00005745057,0.000036053072,0.00028548008,0.00006989283,0.00012069443,0.000026447715,0.00026131925,9.009999e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025254142,0.0034354443,0.1953306,0.00004483812,0.002124017,0.0028825426,0.03277503,0.00086803327,0.0009012679,0.00006755955,0.00088818715,0.73542833],"study_design_scores_gemma":[0.014104483,0.005082078,0.9505758,0.0007217841,0.0020328474,0.00015829434,0.022673,0.000091370035,0.00022307022,0.00040042424,0.0038492377,0.000087585286],"about_ca_topic_score_codex":0.00017012536,"about_ca_topic_score_gemma":0.00089487224,"teacher_disagreement_score":0.7552452,"about_ca_system_score_codex":0.00026272997,"about_ca_system_score_gemma":0.0005840788,"threshold_uncertainty_score":0.23427661},"labels":[],"label_agreement":null},{"id":"W4410708263","doi":"10.1016/j.jtho.2025.05.014","title":"Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology and International Association for the Study of Lung Cancer Clinical Practice Guideline","year":2025,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Clinical Practice; Internal medicine; Oncology; Pulmonology; Bronchoscopy; Radiology; Pathology; Family medicine","score_opus":0.13117758278693623,"score_gpt":0.5820721562242435,"score_spread":0.4508945734373072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410708263","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029003134,0.95626247,0.0013285736,0.007969391,0.001542283,0.00310548,0.00075392553,0.000006024105,0.000028741933],"genre_scores_gemma":[0.008926562,0.97323036,0.016973823,0.00022881168,0.00036779736,0.0001356035,0.00006708413,0.000017653667,0.000052322262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640596,0.00072908803,0.0022690513,0.00025102517,0.00020293555,0.00014196079],"domain_scores_gemma":[0.9644004,0.0256582,0.007608235,0.0001231322,0.0021537526,0.000056250694],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0025405146,0.0001802444,0.0021290518,0.00025106556,0.00005236573,0.000008787747,0.00012318122,0.0002617492,0.0000075299413],"category_scores_gemma":[0.010404472,0.00012411043,0.00024808053,0.00017149639,0.00013746289,0.0000919581,0.00009671609,0.00028476823,1.7975301e-8],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015372452,0.001425202,0.09250683,0.003605859,0.0062278733,0.0000024981443,0.00016275905,0.0000033006331,0.0000023975754,0.000015997297,0.0015593683,0.89295065],"study_design_scores_gemma":[0.008159171,0.019017488,0.11932535,0.008449622,0.034161035,0.00017622954,0.0017913937,0.0007410592,0.0000029572245,0.000095666706,0.80787104,0.00020897192],"about_ca_topic_score_codex":0.00033930995,"about_ca_topic_score_gemma":0.00023951328,"teacher_disagreement_score":0.8927417,"about_ca_system_score_codex":0.0010082,"about_ca_system_score_gemma":0.00076469855,"threshold_uncertainty_score":0.9979313},"labels":[],"label_agreement":null},{"id":"W4410708315","doi":"10.1016/j.jtho.2025.05.016","title":"Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Incorporated; Merck Sharp and Dohme; Eisai Canada; Eisai; Merck; Eli Lilly and Company","keywords":"Medicine; Pemetrexed; Pembrolizumab; Oncology; Lenvatinib; Lung cancer; Internal medicine; Atezolizumab; Nivolumab; Cancer; Chemotherapy; Immunotherapy; Cisplatin","score_opus":0.04779553451295115,"score_gpt":0.4649378753724637,"score_spread":0.4171423408595126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410708315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97935474,0.007071299,0.0021564201,0.007826606,0.00081936264,0.0017855074,0.00002170495,0.000021265909,0.00094309234],"genre_scores_gemma":[0.99162924,0.0009887961,0.0029829706,0.001958699,0.0002928981,0.000076231125,0.000007856759,0.000030323014,0.002032991],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99785,0.0002189771,0.001057916,0.00026375585,0.0002918376,0.00031751592],"domain_scores_gemma":[0.99763155,0.000887563,0.00072148634,0.0002518984,0.0003702204,0.000137301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001496612,0.00026156465,0.0010833693,0.0005369784,0.00018185207,0.000034899993,0.00018409234,0.00013336314,0.00019225672],"category_scores_gemma":[0.00038615667,0.00019208888,0.0003018846,0.0004129095,0.00015473469,0.000122051206,0.000039668717,0.00040325584,0.0000028757142],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2104396,0.005113285,0.0013144097,0.00025805947,0.0022769198,0.00047120635,0.0022666561,0.000017517428,0.0053946017,0.000030816096,0.006612649,0.7658043],"study_design_scores_gemma":[0.30925307,0.20735767,0.015339289,0.0011003288,0.005086113,0.0061832773,0.013629876,0.0019100956,0.00846167,0.0019980045,0.4287861,0.00089451845],"about_ca_topic_score_codex":0.0000674577,"about_ca_topic_score_gemma":0.000143048,"teacher_disagreement_score":0.76490974,"about_ca_system_score_codex":0.00038371186,"about_ca_system_score_gemma":0.0011555848,"threshold_uncertainty_score":0.7833157},"labels":[],"label_agreement":null},{"id":"W4410773123","doi":"10.1016/j.jtho.2025.05.017","title":"Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor–Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"West China Hospital, Sichuan University; Sichuan University","keywords":"Medicine; Milestone; Refractory (planetary science); Pregnancy; Fetus; Pharmacokinetics; Obstetrics; Pediatrics; Oncology; Internal medicine","score_opus":0.010454245963589662,"score_gpt":0.3527189224648989,"score_spread":0.3422646765013092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410773123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928123,0.0041396823,0.0004360348,0.001188136,0.00008976176,0.000758614,0.00003336598,0.000012913205,0.0005292052],"genre_scores_gemma":[0.993846,0.00021966625,0.005571755,0.00017386365,0.000031219897,0.00003469595,0.000020118763,0.000019851263,0.00008280154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986216,0.00011872222,0.00057194364,0.00023047617,0.000206521,0.00025075482],"domain_scores_gemma":[0.9989071,0.000087676824,0.00047299635,0.00008547399,0.00021779073,0.00022895132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008925607,0.00023178392,0.0006124253,0.0003263075,0.0001387942,0.000027829497,0.000033457243,0.00007524266,0.000004842951],"category_scores_gemma":[0.00000917657,0.00014086695,0.000022398435,0.00026043082,0.00014142018,0.00015412312,0.000028088503,0.0003007854,1.9950157e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011820164,0.0011506033,0.82559305,0.00085300993,0.00131291,0.0037621656,0.0032812601,0.00020026547,0.00012139829,0.000035468045,0.000022504033,0.15184717],"study_design_scores_gemma":[0.011154246,0.0087381955,0.9590023,0.007812562,0.0025533424,0.0065417537,0.0018987543,0.00017349969,0.0012252071,0.0000017029955,0.00067737594,0.00022102037],"about_ca_topic_score_codex":0.00011579242,"about_ca_topic_score_gemma":0.00025568475,"teacher_disagreement_score":0.15162615,"about_ca_system_score_codex":0.0005698872,"about_ca_system_score_gemma":0.00053694024,"threshold_uncertainty_score":0.57443875},"labels":[],"label_agreement":null},{"id":"W4410979871","doi":"10.1016/j.jtho.2025.05.020","title":"LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Eisai Canada; Eisai; MSD","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Chemotherapy; Platinum; Internal medicine; PD-L1; Immunotherapy; Cancer; Hepatocellular carcinoma; Sorafenib","score_opus":0.05813767730453691,"score_gpt":0.3986231119463125,"score_spread":0.3404854346417756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410979871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806815,0.0039441166,0.0034326797,0.0054224893,0.00085161545,0.005080484,0.000042558815,0.000102491314,0.00044207275],"genre_scores_gemma":[0.9472289,0.00038885273,0.045982894,0.00169281,0.0004563417,0.00058992085,0.000052575342,0.00012770631,0.003479962],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995383,0.0004473093,0.0016754611,0.0006844789,0.000690682,0.001119045],"domain_scores_gemma":[0.99625826,0.0003757339,0.0016547455,0.00064049434,0.0006449402,0.00042583048],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019528858,0.000706348,0.0021176925,0.00066102215,0.00029972175,0.00024260879,0.000568048,0.00053669413,0.00018642028],"category_scores_gemma":[0.0001300819,0.0005030554,0.00076067663,0.00068828516,0.00037413248,0.00039270154,0.000073610165,0.0008849551,0.000005649431],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30749452,0.006307545,0.0064134984,0.0036577347,0.0023951724,0.0019178797,0.0037156693,0.000025713995,0.12876175,0.000018493207,0.0025548649,0.53673714],"study_design_scores_gemma":[0.11608797,0.05006564,0.020766538,0.0033695449,0.004303855,0.0026676925,0.004464914,0.0023331244,0.55679166,0.0005597987,0.23673303,0.0018562111],"about_ca_topic_score_codex":0.00008005095,"about_ca_topic_score_gemma":0.00010011286,"teacher_disagreement_score":0.53488094,"about_ca_system_score_codex":0.0010004669,"about_ca_system_score_gemma":0.0044740303,"threshold_uncertainty_score":0.9997421},"labels":[],"label_agreement":null},{"id":"W4410991379","doi":"10.1016/j.jtho.2025.05.024","title":"Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC","year":2025,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"National Cancer Institute; National Institutes of Health; International Association for the Study of Lung Cancer; Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Medicine; Lung cancer; Translational research; Cancer; Lung; Oncology; Internal medicine; Pathology","score_opus":0.16763353826312452,"score_gpt":0.5744941225693704,"score_spread":0.40686058430624583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410991379","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007018067,0.9915569,0.000004743165,0.004612888,0.00022172894,0.0005619048,0.000010069214,0.0000021738394,0.0023277942],"genre_scores_gemma":[0.0014769008,0.9976484,0.00029202667,0.00008115686,0.00033070898,0.00006269837,0.0000017500397,0.000015821664,0.00009054835],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99749917,0.0008078133,0.0007641189,0.0003118003,0.00035587087,0.00026120726],"domain_scores_gemma":[0.9981905,0.0010624917,0.00034577682,0.00010250213,0.00020364136,0.00009507642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019104348,0.00021062304,0.0018690643,0.0013576518,0.00005144384,0.00001999908,0.0001055253,0.0003003246,0.00007739153],"category_scores_gemma":[0.00015053859,0.00015489875,0.00017587356,0.00075654435,0.00014824196,0.00014713095,0.00004437361,0.0014694261,3.721271e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004131718,0.00018024875,0.0010507284,0.022647494,0.00007627079,0.00012008849,0.00037024796,0.0000022253923,5.015583e-7,0.00015929498,0.00013428285,0.97484547],"study_design_scores_gemma":[0.000962433,0.0009082358,0.0029982019,0.17667714,0.0008178251,0.00023609835,0.00055082253,0.00001856937,0.0000016401098,0.00030280312,0.8163489,0.00017733923],"about_ca_topic_score_codex":0.000031907777,"about_ca_topic_score_gemma":0.00027403803,"teacher_disagreement_score":0.9746681,"about_ca_system_score_codex":0.0007325697,"about_ca_system_score_gemma":0.0022891134,"threshold_uncertainty_score":0.6384007},"labels":[],"label_agreement":null},{"id":"W4411101071","doi":"10.1016/j.jtho.2025.03.040","title":"A Response to the Letter to the Editor: “Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?”","year":2025,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Brock University","funders":"","keywords":"Medicine; Lung cancer; Quality (philosophy); Oncology; Medical physics","score_opus":0.15005539168065474,"score_gpt":0.4897160353564105,"score_spread":0.33966064367575577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411101071","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023393525,0.0014812264,0.004123621,0.95741856,0.011460799,0.0016082973,0.00012991801,0.000017311582,0.00036675957],"genre_scores_gemma":[0.020657497,0.00009581257,0.0020535078,0.88735765,0.08482528,0.00030842848,0.000007486694,0.000044049295,0.004650284],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946079,0.0014841683,0.0012714198,0.00042683393,0.001407485,0.0008021566],"domain_scores_gemma":[0.9945071,0.0023044671,0.0012292364,0.00090727396,0.000837428,0.00021454178],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0096648745,0.00044199356,0.0011394364,0.00047318503,0.0005813115,0.00013512603,0.0018309255,0.0008329588,0.00013758555],"category_scores_gemma":[0.0022330792,0.00020300994,0.0006289601,0.0008632947,0.00020196698,0.00016850952,0.0003597684,0.004410978,0.000011596113],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008988473,0.000018533417,0.00040247064,0.00015669067,0.00042435195,0.00011511052,0.0012031783,0.0002031972,0.000046163135,0.0000014806858,0.87583023,0.112610094],"study_design_scores_gemma":[0.00046550724,0.0014598253,0.010848449,0.0010234597,0.00097349,0.00026138983,0.0004477466,0.00008775875,0.00014565444,0.0000071468344,0.98405033,0.00022925796],"about_ca_topic_score_codex":0.00016367125,"about_ca_topic_score_gemma":0.00014246683,"teacher_disagreement_score":0.11238084,"about_ca_system_score_codex":0.0013191741,"about_ca_system_score_gemma":0.0034138123,"threshold_uncertainty_score":0.9978859},"labels":[],"label_agreement":null},{"id":"W4411312400","doi":"10.1016/j.jtho.2025.06.005","title":"Genomic Profiles of Pathogenic and Moderate-Penetrance Germline Variants Associated With Risk of Early-Onset Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Capital Commission; Japan Science and Technology Agency; Japan Society for the Promotion of Science; Università degli Studi del Piemonte Orientale; World Education Services; Japan Agency for Medical Research and Development; National Cancer Center; Japan Society for the Promotion of Science London; Core Research for Evolutional Science and Technology; National Cancer Coalition","keywords":"Penetrance; Medicine; Germline; Adenocarcinoma; Germline mutation; Genetics; Oncology; Internal medicine; Gene; Mutation; Cancer; Biology; Phenotype","score_opus":0.01195021980601712,"score_gpt":0.37216109097231664,"score_spread":0.3602108711662995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411312400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993432,0.0046729804,0.0005579086,0.00048658604,0.0001237149,0.00028302532,0.00009927173,0.0000045098327,0.00034002162],"genre_scores_gemma":[0.9965134,0.00042847783,0.0026059025,0.00007706477,0.000035826557,0.0000062913387,0.000008513018,0.000011305977,0.0003132203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886805,0.00017418546,0.0005469754,0.00012576341,0.00014390907,0.0001411461],"domain_scores_gemma":[0.99830675,0.00022293224,0.00086734403,0.00012945285,0.0003995963,0.000073907504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039437704,0.00011343176,0.0006466252,0.00020761705,0.00004773219,0.000005288659,0.00007184112,0.00011682987,0.000020839912],"category_scores_gemma":[0.00014757874,0.00007940921,0.00008444314,0.00020462344,0.00011082738,0.00006432294,0.000020518322,0.00022540278,2.989931e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004719783,0.00064278464,0.968828,0.00020082945,0.002478319,0.00020281629,0.0009493658,0.00015024094,0.0070496867,0.000025105763,0.00023527822,0.014517767],"study_design_scores_gemma":[0.0026144008,0.0024653825,0.9880062,0.00043954895,0.003031597,0.00022954257,0.00012306329,0.00045903912,0.0022956152,0.0002432059,0.00003318965,0.00005926747],"about_ca_topic_score_codex":0.000058580452,"about_ca_topic_score_gemma":0.000037643225,"teacher_disagreement_score":0.019178124,"about_ca_system_score_codex":0.00021951702,"about_ca_system_score_gemma":0.0010714894,"threshold_uncertainty_score":0.32382137},"labels":[],"label_agreement":null},{"id":"W4412042216","doi":"10.1016/j.jtho.2025.04.006","title":"A Response to the Letter to the Editor: “Decision Trees and Random Forests: Nonlinear and Nonparametric Alternatives to Logistic Regression in Biological Data Analysis”","year":2025,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Artificial Intelligence in Healthcare","field":"Health Professions","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Logistic regression; Random forest; Nonparametric statistics; Decision tree; Medicine; Statistics; Nonparametric regression; Econometrics; Machine learning; Mathematics; Computer science","score_opus":0.22447510982785124,"score_gpt":0.5833782056270076,"score_spread":0.35890309579915636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412042216","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12036184,0.00092995766,0.008953541,0.8609977,0.006663552,0.0018069801,0.00025085342,0.0000109634375,0.00002462145],"genre_scores_gemma":[0.053556588,0.0008505556,0.01121014,0.8899071,0.04322773,0.00020133656,0.00006413426,0.000047689315,0.0009347279],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98579675,0.009900966,0.0021211526,0.0007777959,0.0006889784,0.0007143868],"domain_scores_gemma":[0.95344275,0.043291062,0.0011546612,0.0012568582,0.0005795611,0.00027508946],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013757979,0.0003881264,0.0015599636,0.0023012038,0.0005996223,0.000061512415,0.0020258822,0.0012661244,0.000065159686],"category_scores_gemma":[0.033591177,0.00018179866,0.00015526288,0.0022063602,0.00021425955,0.00011931409,0.0018869162,0.005379313,0.000056827193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013748524,0.00004837528,0.010499016,0.00005645276,0.0001456919,0.0004251645,0.0021848648,0.0004193085,0.000014307836,0.0000013437613,0.9207708,0.051686153],"study_design_scores_gemma":[0.00028146253,0.0013143118,0.012617766,0.001089584,0.00031156465,0.00002698333,0.0013208722,0.0014940299,0.000004399392,0.00032184587,0.981025,0.00019217379],"about_ca_topic_score_codex":0.0004761983,"about_ca_topic_score_gemma":0.010801125,"teacher_disagreement_score":0.06680526,"about_ca_system_score_codex":0.0006052759,"about_ca_system_score_gemma":0.0008111344,"threshold_uncertainty_score":0.99691534},"labels":[],"label_agreement":null},{"id":"W4412076815","doi":"10.1016/j.jtho.2025.07.009","title":"Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer","year":2025,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"Foundation Medicine; Loxo Oncology; Novartis Pharma; EMD Serono; Genentech; PharmaMar; European Society for Medical Oncology; Eisai; Bayer HealthCare; Relay Therapeutics; Boston Pharmaceuticals; Janssen Scientific Affairs; Takeda Oncology; Mirati Therapeutics; Teva Pharmaceutical Industries; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Associazione Italiana per la Ricerca sul Cancro; Eli Lilly and Company; National Comprehensive Cancer Network; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Celgene; BeiGene; International Association for the Study of Lung Cancer; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; American Society of Clinical Oncology; Bristol-Myers Squibb; Ariad Pharmaceuticals; Amgen; Incyte; Pfizer; LUNGevity Foundation","keywords":"Medicine; Statement (logic); Lung cancer; Association (psychology); Cancer; Family medicine; Oncology; Internal medicine; Epistemology","score_opus":0.03954637161951112,"score_gpt":0.5335992569666205,"score_spread":0.49405288534710934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412076815","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012632709,0.98622423,0.00010234424,0.006845171,0.0023748006,0.0024410835,0.00041018956,0.0000035697856,0.00033533768],"genre_scores_gemma":[0.0014672137,0.99543446,0.0003649857,0.0005554413,0.0006038516,0.0004570413,0.000041535466,0.00002077663,0.0010547093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99803513,0.00029533013,0.0010036189,0.0001358296,0.00040599535,0.00012408767],"domain_scores_gemma":[0.9941553,0.0024629468,0.0024471907,0.00018682377,0.0007092086,0.00003852624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008700335,0.00016315687,0.0011238146,0.000111932946,0.0000728478,0.000018508645,0.00027148132,0.00009851238,0.000053946314],"category_scores_gemma":[0.0005346956,0.000077302306,0.0004383718,0.00014146097,0.000026009675,0.000018328294,0.00005333867,0.0003422611,5.222608e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046143244,0.0010347402,0.0007027738,0.001806641,0.021019895,0.0001266548,0.0010431188,0.00006116567,0.000002722503,0.000022550237,0.035314877,0.9384034],"study_design_scores_gemma":[0.0013875671,0.0007860432,0.00020775096,0.0044538197,0.033486754,0.000033020722,0.0011424847,0.000033854703,0.0000039402657,0.000032393546,0.95837075,0.00006161312],"about_ca_topic_score_codex":0.00023389861,"about_ca_topic_score_gemma":0.0001607796,"teacher_disagreement_score":0.9383418,"about_ca_system_score_codex":0.002424587,"about_ca_system_score_gemma":0.003580912,"threshold_uncertainty_score":0.6352384},"labels":[],"label_agreement":null},{"id":"W4412558988","doi":"10.1016/j.jtho.2025.07.115","title":"Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Roche","keywords":"Medicine; Post hoc; Post-hoc analysis; Platinum; Phase (matter); Internal medicine; Oncology","score_opus":0.028948815020603615,"score_gpt":0.4481591844504088,"score_spread":0.4192103694298052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412558988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033797,0.000860706,0.00014032883,0.0066791703,0.0007119776,0.00049738394,0.00001069584,0.000005208579,0.00075655855],"genre_scores_gemma":[0.9986269,0.00006382877,0.00026892783,0.0006782347,0.00016821793,0.000005094721,0.0000107190035,0.000005842122,0.00017225138],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99782383,0.00037011906,0.0012890351,0.00015153184,0.00024572597,0.00011978255],"domain_scores_gemma":[0.9978073,0.0004888778,0.0009969096,0.00032770558,0.00034140304,0.000037767746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024875705,0.00010276357,0.0005771498,0.00017604811,0.000039519375,0.0000090567155,0.0001591448,0.000116805124,0.00013475402],"category_scores_gemma":[0.00056430325,0.000066045824,0.00016157638,0.00037715174,0.000105298976,0.00008442845,0.000040597562,0.00037243657,6.344153e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15150705,0.007864297,0.1875158,0.000073858784,0.0012522109,0.0017232565,0.0063549457,0.000018720773,0.09321089,0.000008663163,0.005575111,0.5448952],"study_design_scores_gemma":[0.035882816,0.014728277,0.87973374,0.00076706905,0.001126851,0.0010448229,0.011562689,0.000058531437,0.032867238,0.0006256235,0.021413667,0.00018869633],"about_ca_topic_score_codex":0.00061938044,"about_ca_topic_score_gemma":0.00039347223,"teacher_disagreement_score":0.69221795,"about_ca_system_score_codex":0.00032181822,"about_ca_system_score_gemma":0.00089347834,"threshold_uncertainty_score":0.26932707},"labels":[],"label_agreement":null},{"id":"W4413821196","doi":"10.1016/j.jtho.2025.07.070","title":"PP01.21: Evaluating the Accuracy &amp; Reproducibility of ChatGPT Models in Answering Patient’s Lung Cancer Queries","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Artificial Intelligence in Healthcare and Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Trillium Health Centre; University of Toronto","funders":"","keywords":"Medicine; Reproducibility; Lung cancer; Cancer; Oncology; Medical physics; Internal medicine; Statistics","score_opus":0.24562882393743035,"score_gpt":0.594969846062767,"score_spread":0.3493410221253367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413821196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704552,0.0043717357,0.0007561329,0.021926092,0.0015819942,0.00038252235,0.0000014695864,0.000005473146,0.00051934563],"genre_scores_gemma":[0.99642235,0.0006239084,0.001869815,0.00064215297,0.00026664315,0.000023878043,0.0000011032482,0.0000068145137,0.00014335608],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99767655,0.00040611302,0.0012255576,0.00025465968,0.0002391,0.00019801308],"domain_scores_gemma":[0.9969036,0.0008821972,0.00079048285,0.00054489565,0.0008222308,0.000056590427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045971554,0.000092248054,0.00044496622,0.00020717023,0.00008161234,0.000008354012,0.00014045797,0.00011979238,0.00007048596],"category_scores_gemma":[0.0056072767,0.000063463645,0.00010042962,0.00040384853,0.00011303178,0.000195213,0.00005111502,0.00051397906,8.1070476e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019976518,0.0003237439,0.07047609,0.00044242546,0.00007102167,0.000007977075,0.019561186,0.0057991263,0.0049714027,0.000102368685,0.0007859865,0.895461],"study_design_scores_gemma":[0.0012609474,0.013453524,0.27934915,0.016746044,0.0029594076,0.0009356141,0.11782586,0.121284686,0.3039055,0.10534252,0.03576219,0.0011745705],"about_ca_topic_score_codex":0.0013410405,"about_ca_topic_score_gemma":0.0008762157,"teacher_disagreement_score":0.89428645,"about_ca_system_score_codex":0.00058111805,"about_ca_system_score_gemma":0.0020231784,"threshold_uncertainty_score":0.6712839},"labels":[],"label_agreement":null},{"id":"W4414056345","doi":"10.1016/j.jtho.2025.06.025","title":"The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; National Institutes of Health; AIO-Studien; International Association for the Study of Lung Cancer; AstraZeneca","keywords":"Lung cancer staging; Lung cancer; Stage (stratigraphy); Overall survival; Ninth; Neoplasm staging; Cancer staging; Tumor stage","score_opus":0.049976963296787524,"score_gpt":0.5594834934295361,"score_spread":0.5095065301327486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414056345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910281,0.00026966634,0.00039218485,0.006132491,0.0006780254,0.0009590126,0.000111425405,0.0000013732074,0.00042774135],"genre_scores_gemma":[0.99952483,0.00010107632,0.00004040446,0.0000971624,0.00011134597,0.000061599516,0.000012932752,0.000005666806,0.000044985096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984444,0.00040346396,0.00062287296,0.000081169856,0.00033801043,0.0001101268],"domain_scores_gemma":[0.99710786,0.0013664638,0.0009294601,0.00017426287,0.00040943455,0.000012488769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013271912,0.0000826891,0.00029570516,0.00021563431,0.0001041529,0.000016039656,0.00021105168,0.000036724952,0.0000071039217],"category_scores_gemma":[0.00047098225,0.000036647445,0.00014551039,0.0003228573,0.000047920304,0.00009734509,0.00004797231,0.00028036957,1.8239485e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059515466,0.005069377,0.8535335,0.00012383699,0.0064474423,0.0000264814,0.015154412,0.06933848,0.012734617,0.0009972344,0.003167739,0.027455334],"study_design_scores_gemma":[0.0071617463,0.0021790026,0.9446378,0.0010268269,0.0022700452,0.0000073622487,0.01516394,0.018636895,0.008023905,0.00048750325,0.00030824935,0.00009677115],"about_ca_topic_score_codex":0.0027033812,"about_ca_topic_score_gemma":0.002467782,"teacher_disagreement_score":0.091104254,"about_ca_system_score_codex":0.0011331846,"about_ca_system_score_gemma":0.0011238365,"threshold_uncertainty_score":0.40867218},"labels":[],"label_agreement":null},{"id":"W4414056362","doi":"10.1016/j.jtho.2025.07.002","title":"The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"AstraZeneca Korea; International Association for the Study of Lung Cancer; World Health Organization; AstraZeneca","keywords":"Lung cancer staging; Lung cancer; Ninth; Stage (stratigraphy); Staging system; Neoplasm staging; Cancer staging","score_opus":0.03478700356993017,"score_gpt":0.4993600233458144,"score_spread":0.4645730197758843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414056362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96771014,0.0014368305,0.00007852276,0.026998539,0.0015101765,0.0017654686,0.00006133401,0.0000025643342,0.00043643347],"genre_scores_gemma":[0.9976957,0.0013406345,0.000013181639,0.00022214957,0.0003354859,0.0002872307,0.0000030278486,0.000009320161,0.00009326679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979031,0.00046175177,0.0007155354,0.00012317582,0.0006000417,0.00019638751],"domain_scores_gemma":[0.9946356,0.002556847,0.001882373,0.0002598178,0.00064920343,0.000016176462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027426102,0.00011948381,0.00033662355,0.00014536458,0.00020707304,0.000028377912,0.00037367348,0.000065340326,0.000012492963],"category_scores_gemma":[0.00046768205,0.000044122597,0.00021576483,0.00038408485,0.0000719091,0.000083660685,0.000048306832,0.00042771664,2.2620421e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014273338,0.0009453015,0.93368006,0.00009359077,0.0021228802,0.0000015821089,0.0093775075,0.0033422492,0.0003410772,0.00021865913,0.009527309,0.038922448],"study_design_scores_gemma":[0.0018418229,0.000837618,0.97424716,0.0007818452,0.0013820867,0.0000026275247,0.012663786,0.0059970785,0.00085861405,0.00010621608,0.001237061,0.000044085216],"about_ca_topic_score_codex":0.002533758,"about_ca_topic_score_gemma":0.0017418326,"teacher_disagreement_score":0.040567096,"about_ca_system_score_codex":0.004178577,"about_ca_system_score_gemma":0.0014511945,"threshold_uncertainty_score":0.9996442},"labels":[],"label_agreement":null},{"id":"W4414082877","doi":"10.1016/j.jtho.2025.07.117","title":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Chugai Pharmaceutical; Johnson and Johnson; University of California, Irvine; Daiichi Sankyo Europe; Gilead Sciences; LEO Pharma; Genentech; Grifols; GlaxoSmithKline; Orient Europharma; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; G1 Therapeutics; Revolution Medicines; Merck KGaA; BeiGene; Mirati Therapeutics; Sanofi; Amgen; Pfizer; AstraZeneca; Bristol-Myers Squibb","keywords":"Randomized controlled trial; Incidence (geometry); Regimen; MEDLINE; Clinical trial","score_opus":0.010068541213104881,"score_gpt":0.43336797958588713,"score_spread":0.4232994383727823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414082877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8958225,0.0021726117,0.00578358,0.016093533,0.0026409097,0.008161096,0.0000069802927,0.00003517094,0.06928358],"genre_scores_gemma":[0.99466985,0.00041634266,0.0030767086,0.00082208205,0.000073777715,0.00037523,0.0000060535194,0.000009589264,0.0005503346],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973804,0.0006610421,0.0011299427,0.00019294221,0.0003439846,0.00029172195],"domain_scores_gemma":[0.9975048,0.0009386699,0.0008707588,0.00020347616,0.00039570327,0.000086643886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011009038,0.00021851009,0.0020433995,0.0002088451,0.0000963912,0.000024365048,0.00016850552,0.00012083209,0.00004592101],"category_scores_gemma":[0.00044996457,0.000106738706,0.00030946382,0.00055998814,0.00020091729,0.0000897363,0.00003557627,0.00031243076,0.0000034873767],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9396294,0.00051480596,0.000053576117,0.00005132631,0.0027058749,0.00068761123,0.00020087985,0.00023959299,0.00004163514,0.00063186506,0.00032311733,0.05492032],"study_design_scores_gemma":[0.9844423,0.0045593185,0.00030646005,0.00042004124,0.0044040815,0.00013529847,0.0014008336,0.00007450932,0.000325383,0.0005212384,0.0033159088,0.00009460624],"about_ca_topic_score_codex":0.000008628261,"about_ca_topic_score_gemma":0.00008771149,"teacher_disagreement_score":0.098847345,"about_ca_system_score_codex":0.0012452278,"about_ca_system_score_gemma":0.0011296116,"threshold_uncertainty_score":0.4352678},"labels":[],"label_agreement":null},{"id":"W4414804117","doi":"10.1016/j.jtho.2025.07.003","title":"A Response to the Letter to the Editor: “Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups”","year":2025,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Research and Development","keywords":"MEDLINE; Complete response; Clinical trial; Text mining","score_opus":0.012445314026864236,"score_gpt":0.39968048449831395,"score_spread":0.38723517047144973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414804117","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05174716,0.0006930015,0.00016938621,0.9352707,0.009398422,0.0013238754,0.00006688059,0.0000195218,0.001311036],"genre_scores_gemma":[0.028513987,0.00004864233,0.0018683888,0.9156153,0.028563801,0.00015254001,0.000025156989,0.000083757,0.025128417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946039,0.0021857482,0.001275699,0.00047166832,0.00077911967,0.0006838919],"domain_scores_gemma":[0.99159145,0.0060962853,0.0007674849,0.00088972633,0.00046997677,0.0001850782],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0049770437,0.00044401447,0.0011902452,0.0010746516,0.00024533234,0.000100601974,0.00085907185,0.0007328033,0.00013743936],"category_scores_gemma":[0.0030418064,0.00024488062,0.00046695877,0.000831595,0.00009190946,0.00009837991,0.00023885998,0.0036107525,0.00009661362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036004648,0.00017574494,0.00004665989,0.000058147205,0.0005690112,0.0028061375,0.0032261787,0.00022194153,0.00084286917,0.0000021787037,0.9375693,0.01847716],"study_design_scores_gemma":[0.0014272269,0.0030681638,0.0023295903,0.001432081,0.001265271,0.0008067745,0.00036932802,0.000011043924,0.00020038574,0.000030270954,0.9888465,0.00021337271],"about_ca_topic_score_codex":0.00008105758,"about_ca_topic_score_gemma":0.00015342605,"teacher_disagreement_score":0.051277168,"about_ca_system_score_codex":0.0026832293,"about_ca_system_score_gemma":0.001986067,"threshold_uncertainty_score":0.998688},"labels":[],"label_agreement":null},{"id":"W4414812153","doi":"10.1016/j.jtho.2025.09.1761","title":"A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Fondation Institut Universitaire de Cardiologie et de Pneumologie de Québec; International Association for the Study of Lung Cancer","keywords":"Grading (engineering); Basal cell; Surgical pathology; Carcinoma; Anatomical pathology; Clinical pathology","score_opus":0.028279747975245302,"score_gpt":0.3872157380709278,"score_spread":0.3589359900956825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414812153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870062,0.0032560749,0.00040135617,0.0059357253,0.0012806926,0.0015537527,0.00003637076,0.0000069613034,0.000522868],"genre_scores_gemma":[0.9986024,0.000016144431,0.00042673043,0.00038507447,0.00011804681,0.00012869481,0.0000033709998,0.000010408496,0.00030915294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818337,0.0005408615,0.0006689906,0.0001685247,0.00023286912,0.00020538263],"domain_scores_gemma":[0.99720764,0.0012414674,0.0006849537,0.00031020615,0.00049100537,0.00006469857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086650334,0.0001553535,0.0006613215,0.00014177927,0.00023388817,0.00000963996,0.0003000361,0.00012796049,0.0000065783333],"category_scores_gemma":[0.00036446523,0.00007485115,0.00029362243,0.0002656106,0.00017320355,0.000035838937,0.00009299084,0.00035966362,7.1639886e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006664848,0.011720823,0.851748,0.0023037884,0.00153387,0.0013705413,0.0066583925,0.00016518692,0.0106309485,0.00055120303,0.10044949,0.006202936],"study_design_scores_gemma":[0.037341036,0.02163963,0.79847586,0.0016174661,0.011166954,0.004695576,0.027803559,0.00081860134,0.08482381,0.00018593488,0.011066812,0.0003647626],"about_ca_topic_score_codex":0.00008198216,"about_ca_topic_score_gemma":0.00019770817,"teacher_disagreement_score":0.08938268,"about_ca_system_score_codex":0.0014124054,"about_ca_system_score_gemma":0.0012639725,"threshold_uncertainty_score":0.36933908},"labels":[],"label_agreement":null},{"id":"W4415519091","doi":"10.1016/j.jtho.2025.09.967","title":"P3.13.31 Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates From Jazz EMERGE 402","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Southlake Regional Health Center","funders":"","keywords":"Jazz; Lung cancer; MEDLINE; Small Cell Lung Carcinoma","score_opus":0.021141748485960583,"score_gpt":0.45212914127192616,"score_spread":0.4309873927859656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712113,0.014227494,0.001077769,0.0064838785,0.0012788239,0.0010726429,0.00011287865,0.000016695736,0.0045185033],"genre_scores_gemma":[0.9842672,0.009358506,0.0032438138,0.00027536447,0.00068630854,0.00009888152,0.000012266543,0.000031301053,0.0020263987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810225,0.00029917175,0.00074064924,0.00025916315,0.00024858897,0.00035016082],"domain_scores_gemma":[0.99643457,0.0018493278,0.0005535876,0.00020245151,0.0008016801,0.00015836798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012587175,0.00020327233,0.0011807346,0.00043970565,0.00010155158,0.000009835752,0.00019671088,0.00014987239,0.00008609744],"category_scores_gemma":[0.00045708535,0.00015322979,0.00020074703,0.00041304983,0.00018316934,0.00008596373,0.00016399493,0.0004929819,6.9367314e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06692396,0.0012009287,0.60905844,0.008837553,0.0052977307,0.00031559763,0.0013559067,0.00017776666,0.09083074,0.00019673051,0.07437579,0.14142887],"study_design_scores_gemma":[0.010509905,0.004389582,0.8382198,0.0039150515,0.00370755,0.00003920318,0.0005487027,0.0008358882,0.07279522,0.001216479,0.06348638,0.00033618484],"about_ca_topic_score_codex":0.001167437,"about_ca_topic_score_gemma":0.0025279124,"teacher_disagreement_score":0.22916143,"about_ca_system_score_codex":0.0009099294,"about_ca_system_score_gemma":0.001187414,"threshold_uncertainty_score":0.62485296},"labels":[],"label_agreement":null},{"id":"W4415519186","doi":"10.1016/j.jtho.2025.09.777","title":"P3.01.31 Physical Characterization of PM2.5 - Effects on Cellular Uptake, Dispersion, and Lung Cell Interactions","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Particulates; Air pollutants; Cardiorespiratory fitness; Pollutant; Lung; Air pollution; Human lung","score_opus":0.00975056239527517,"score_gpt":0.3556595281928383,"score_spread":0.34590896579756314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930075,0.000121770296,0.00084826443,0.0018264635,0.00095561007,0.0001658896,0.0000022050262,0.0000071654963,0.0030651796],"genre_scores_gemma":[0.99690366,0.00006199149,0.00017802764,0.00078368373,0.0003727461,0.0000018466915,0.0000064941837,0.000007888797,0.0016836494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991278,0.00014494648,0.00037871368,0.0001030597,0.00014642494,0.00009902136],"domain_scores_gemma":[0.99902606,0.000186438,0.00039041758,0.00010451115,0.00020951821,0.00008307991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022344517,0.000097093274,0.00039798516,0.0003200467,0.000058017085,0.0000073309466,0.000052594198,0.00009697875,0.000030817944],"category_scores_gemma":[0.00007991072,0.0000730136,0.00012506518,0.00017545403,0.000055504446,0.00010140482,0.000024894895,0.00034872786,0.000006739193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014559608,0.0007384483,0.0010503152,0.00040703506,0.000107404805,0.000117918666,0.00041303245,0.000019080384,0.93887657,0.00006354198,0.0017472268,0.05500344],"study_design_scores_gemma":[0.0024944593,0.0034371873,0.051538542,0.0012358914,0.0011672669,0.00017503007,0.00034625348,0.0032609897,0.88473934,0.000051619314,0.05137985,0.00017355764],"about_ca_topic_score_codex":6.4823365e-7,"about_ca_topic_score_gemma":2.5921986e-7,"teacher_disagreement_score":0.05482988,"about_ca_system_score_codex":0.00013504835,"about_ca_system_score_gemma":0.00019327977,"threshold_uncertainty_score":0.29774082},"labels":[],"label_agreement":null},{"id":"W4415519187","doi":"10.1016/j.jtho.2025.09.1320","title":"EP.06.26 Resectable Lung Cancer With KRAS Mutation May Have Less Lymphatic Metastasis","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lung cancer; KRAS; Mutation; Metastasis; Lymphatic system","score_opus":0.024917900625227966,"score_gpt":0.4756826160250965,"score_spread":0.4507647153998685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9252872,0.014583023,0.006998407,0.029380962,0.0011341848,0.00081449765,0.000025065434,0.000044464938,0.02173222],"genre_scores_gemma":[0.97987145,0.00042037255,0.0067118597,0.0010450579,0.00021454348,0.000055711935,0.000009245838,0.000025225469,0.011646508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876267,0.00014221869,0.00045190795,0.00015688551,0.00026062533,0.00022567238],"domain_scores_gemma":[0.9985892,0.00016992113,0.00044174585,0.00015677403,0.00051955925,0.00012281121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034935505,0.00014158181,0.0005393615,0.0003550009,0.00011497676,0.000024728255,0.00009258469,0.00009849893,0.00016836813],"category_scores_gemma":[0.000079888414,0.00009447485,0.00011155227,0.00033532784,0.000070468246,0.00018046853,0.000020419102,0.00019636628,0.000004829903],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009103347,0.002374295,0.15909266,0.0019792276,0.012346561,0.0046884203,0.0057523553,0.0038614993,0.0021162643,0.0007271063,0.05504669,0.7429116],"study_design_scores_gemma":[0.04471359,0.017248778,0.2316785,0.010357054,0.08689322,0.013409665,0.038315084,0.00644144,0.0497508,0.0037718972,0.4958821,0.0015378819],"about_ca_topic_score_codex":0.00022848134,"about_ca_topic_score_gemma":0.00041717765,"teacher_disagreement_score":0.7413737,"about_ca_system_score_codex":0.0013861213,"about_ca_system_score_gemma":0.0023545858,"threshold_uncertainty_score":0.4176934},"labels":[],"label_agreement":null},{"id":"W4415519238","doi":"10.1016/j.jtho.2025.09.070","title":"OA12.02 CCTG IND227, a Randomized Trial of Chemotherapy + Pembrolizumab in Advanced Pleural Mesothelioma: Updated Analyses","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre; CancerCare Manitoba; Queen's University; Spinal Cord Injury BC; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Pembrolizumab; Chemotherapy; Randomized controlled trial; MEDLINE; Standard of care","score_opus":0.022106800547685927,"score_gpt":0.4488452117313857,"score_spread":0.42673841118369976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276495,0.0013469895,0.00010029032,0.002831476,0.00036084163,0.0005220075,0.000009071487,0.000007467152,0.0020568897],"genre_scores_gemma":[0.99691355,0.00035135064,0.0013560643,0.0005859593,0.000111122834,0.000015513931,0.00001666642,0.00001107886,0.00063871674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979276,0.00038406512,0.0010739904,0.00014146988,0.00030147634,0.0001713721],"domain_scores_gemma":[0.99856204,0.0003959227,0.0006924694,0.00014710918,0.00010621315,0.0000962215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067045185,0.00015387988,0.0013593415,0.0005943293,0.00002457555,0.000005108991,0.00013754435,0.0001381975,0.0003447182],"category_scores_gemma":[0.0003498383,0.00010795822,0.0004356816,0.0004073804,0.00019638926,0.000106498956,0.000031827785,0.00025557677,0.000004256332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95838636,0.0017421066,0.0032520664,0.000063822066,0.0005056168,0.00011368862,0.00009614813,0.00012600549,0.0077878935,0.000043073956,0.00054006744,0.02734313],"study_design_scores_gemma":[0.9289459,0.0028963177,0.052861307,0.00026304412,0.0010336223,0.00012882624,0.00023882676,0.00031093747,0.009947365,0.0014151316,0.0018342846,0.00012445162],"about_ca_topic_score_codex":0.000021342026,"about_ca_topic_score_gemma":0.000008984059,"teacher_disagreement_score":0.04960924,"about_ca_system_score_codex":0.00028536015,"about_ca_system_score_gemma":0.0004307511,"threshold_uncertainty_score":0.44024086},"labels":[],"label_agreement":null},{"id":"W4415519239","doi":"10.1016/j.jtho.2025.09.079","title":"OA14.03 Functional Characterization of Osimertinib-Induced Drug Tolerant Persisters in Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Adenocarcinoma; Lung; Epidermal growth factor receptor; Drug resistance; Tyrosine kinase; Drug; Tyrosine-kinase inhibitor; Population; Gefitinib","score_opus":0.02178682906306032,"score_gpt":0.4020771405004481,"score_spread":0.3802903114373878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925763,0.00042947673,0.00021745315,0.007045395,0.00094091083,0.00020149731,0.000005851205,0.0000049295713,0.001896831],"genre_scores_gemma":[0.997984,0.0000346259,0.00033022492,0.00061196,0.00012650713,0.0000075512075,0.000021075646,0.000007414323,0.0008766554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99893963,0.000095420786,0.00057105726,0.000107942156,0.00016083271,0.00012509528],"domain_scores_gemma":[0.99909776,0.00009097056,0.0004063942,0.000098025164,0.00024412975,0.00006270062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026236248,0.000090681904,0.0004107767,0.00040580556,0.0000347858,0.000005601969,0.000059267804,0.00008552786,0.00011188081],"category_scores_gemma":[0.00006273303,0.000072773706,0.0001319358,0.0002706319,0.00003344709,0.000109526634,0.000016885637,0.00020704311,0.000002828031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076387455,0.0024351436,0.50902885,0.00066349865,0.0016525912,0.000518507,0.006327286,0.00012568441,0.34198084,0.0002702147,0.0025078114,0.1268508],"study_design_scores_gemma":[0.002365118,0.0007068784,0.9809892,0.00043480098,0.00094079063,0.00021226658,0.0009397355,0.00030296238,0.009883502,0.00003925542,0.0031161525,0.00006932949],"about_ca_topic_score_codex":0.00002015042,"about_ca_topic_score_gemma":0.000010484364,"teacher_disagreement_score":0.47196034,"about_ca_system_score_codex":0.000541935,"about_ca_system_score_gemma":0.00088346074,"threshold_uncertainty_score":0.29676256},"labels":[],"label_agreement":null},{"id":"W4415519279","doi":"10.1016/j.jtho.2025.09.773","title":"P3.01.27 Environmental Carcinogenesis in Lung Cancer: Sodium Arsenite-Induced PML Dysregulation and LINE-1 Activation","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Arsenic contamination and mitigation","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Carcinogenesis; Lung; Sodium; Lung cancer; Human lung","score_opus":0.012202564218799998,"score_gpt":0.3456327530756301,"score_spread":0.33343018885683007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418306,0.000110905865,0.0005269916,0.0032816343,0.00034579835,0.00016905255,0.000002113556,0.000005496767,0.001374927],"genre_scores_gemma":[0.9979685,0.00012858561,0.00036244688,0.00030762478,0.000056763012,0.0000071027484,0.0000045163715,0.000006351713,0.0011580978],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998949,0.00015968508,0.00040718625,0.0001572248,0.00018720719,0.00013972036],"domain_scores_gemma":[0.99938816,0.000103641716,0.00035581618,0.00008221402,0.000010689473,0.000059489143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041277317,0.00009972062,0.00020061099,0.00017074523,0.000085028005,0.000009939712,0.00008846006,0.00013304705,0.00041502476],"category_scores_gemma":[0.000040108273,0.0000960534,0.000044622404,0.0001777924,0.00006951469,0.0002655084,0.00009788882,0.00016001922,0.0000063962243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034299114,0.00011759229,0.1959593,0.000016443282,0.000020685618,0.000013856,0.0009398244,0.0006337164,0.35786384,0.00002169992,0.00048859505,0.44358146],"study_design_scores_gemma":[0.0008411087,0.00024055343,0.8998679,0.000060558494,0.00008772301,0.000044629553,0.0005900173,0.007947996,0.08434199,0.00022923105,0.005610402,0.00013786736],"about_ca_topic_score_codex":0.000080633086,"about_ca_topic_score_gemma":0.00048614148,"teacher_disagreement_score":0.7039086,"about_ca_system_score_codex":0.0017140349,"about_ca_system_score_gemma":0.00006262221,"threshold_uncertainty_score":0.45442298},"labels":[],"label_agreement":null},{"id":"W4415519280","doi":"10.1016/j.jtho.2025.09.124","title":"MA04.04 Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Pembrolizumab; NODAL; Perioperative; Cancer; Squamous cell cancer","score_opus":0.016777693247040492,"score_gpt":0.4030823295487934,"score_spread":0.38630463630175293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98143286,0.0024859936,0.000032948188,0.009975531,0.0007727676,0.00078435417,0.00001334879,0.0000051627003,0.004497037],"genre_scores_gemma":[0.99352944,0.0007438085,0.00020388704,0.0032918563,0.000097072305,0.000046573645,0.0000022236113,0.000016278467,0.0020688905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768233,0.00054481707,0.00086630933,0.0002160295,0.0002964192,0.00039407166],"domain_scores_gemma":[0.9988809,0.0002957364,0.00035524118,0.00023744153,0.00015705235,0.00007358465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001292474,0.00021711887,0.00080890907,0.00039882993,0.0000675735,0.00003319059,0.00030810913,0.00017310686,0.00019722396],"category_scores_gemma":[0.00007771227,0.00013416613,0.00018929833,0.00052928866,0.00011129528,0.00009320216,0.000051147475,0.00089729356,0.00000454433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033915777,0.0046110773,0.8364337,0.00012690047,0.00054513087,0.0010702026,0.022023516,0.00005177447,0.012034125,0.0000078708845,0.008107476,0.08107244],"study_design_scores_gemma":[0.016718172,0.0047580027,0.91446275,0.00026484687,0.00026540132,0.0000770598,0.028930563,0.00003691613,0.0012312217,0.000018283887,0.03304931,0.0001874886],"about_ca_topic_score_codex":0.0011939221,"about_ca_topic_score_gemma":0.0033679705,"teacher_disagreement_score":0.08088495,"about_ca_system_score_codex":0.0010800414,"about_ca_system_score_gemma":0.0014336384,"threshold_uncertainty_score":0.5471136},"labels":[],"label_agreement":null},{"id":"W4415519518","doi":"10.1016/j.jtho.2025.09.1419","title":"EP.07.38 Immune Checkpoint Inhibitors May Not Fully Mitigate the Adverse Prognostic Impact of PD-L1 Expression in Early Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lung cancer; Adverse effect; Immune system; Immune checkpoint; Expression (computer science); Immunotherapy","score_opus":0.01477407890474573,"score_gpt":0.4031859119925588,"score_spread":0.3884118330878131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838642,0.007221729,0.000024177729,0.006560752,0.0009114264,0.0005033813,0.000010119054,0.00000787335,0.0008963574],"genre_scores_gemma":[0.99753094,0.00065168494,0.00026695474,0.00026103802,0.00023447469,0.000023265065,0.0000017675038,0.00001728137,0.0010126213],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976514,0.00031882356,0.0012491631,0.00016421375,0.00030270516,0.00031366805],"domain_scores_gemma":[0.9980454,0.0002972248,0.0010283942,0.00025648504,0.00027958083,0.000092902286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014340265,0.00020003534,0.00073435856,0.00039215194,0.00006242756,0.000010901654,0.0002433539,0.00022685205,0.0005970456],"category_scores_gemma":[0.00025930363,0.00011723704,0.00058796874,0.00048718095,0.00023284923,0.00014074214,0.00007243481,0.0006984879,0.0000038600947],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068709806,0.00084062957,0.09867285,0.0004534522,0.0011830265,0.00050263695,0.002482357,0.0002165921,0.74552166,0.0000050228064,0.0038745073,0.07753748],"study_design_scores_gemma":[0.0040787067,0.0031604418,0.84091485,0.0035980535,0.0004738354,0.00031389846,0.00066845724,0.00011857261,0.1425441,0.000036611298,0.003940189,0.00015227549],"about_ca_topic_score_codex":0.00041126323,"about_ca_topic_score_gemma":0.000040755007,"teacher_disagreement_score":0.742242,"about_ca_system_score_codex":0.0010190763,"about_ca_system_score_gemma":0.0016680268,"threshold_uncertainty_score":0.65372306},"labels":[],"label_agreement":null},{"id":"W4415519549","doi":"10.1016/j.jtho.2025.09.151","title":"MA07.04 Integration of a Molecular Prognostic Classifier Enhances Conventional Staging of Lung Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Lung cancer; Adenocarcinoma; Classifier (UML); Lung cancer staging; Lung; Staging system","score_opus":0.015559868621601056,"score_gpt":0.3827336553168892,"score_spread":0.3671737866952881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523785,0.0038806505,0.041635275,0.0005819488,0.00031277395,0.000110713874,0.000010331669,0.0000013524,0.0010884595],"genre_scores_gemma":[0.9964379,0.0001914474,0.0027489578,0.000079805905,0.00007085806,0.000008904899,0.000012938817,0.00000584951,0.00044332852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998966,0.00014034579,0.0005391212,0.00012104156,0.00013151199,0.000101993166],"domain_scores_gemma":[0.99866337,0.00004311735,0.00061924517,0.00014439134,0.0004969766,0.000032883658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039400213,0.000082611485,0.00024625467,0.00014521556,0.000026346965,0.0000063079265,0.00017924151,0.00012867607,0.000032088716],"category_scores_gemma":[0.00017508322,0.00007131282,0.00014877872,0.00014116085,0.000121413155,0.000008153232,0.000039249528,0.00012609788,3.3456152e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036667884,0.0001699436,0.011148273,0.00009107526,0.00017898617,0.000006010178,0.00004979979,0.00006857445,0.9656182,0.0010051819,0.0008945581,0.020402748],"study_design_scores_gemma":[0.0004238441,0.0007909806,0.04136687,0.00020279526,0.00021382658,0.000038532715,0.0003912664,0.00020987677,0.95102036,0.00064051326,0.0046137585,0.000087361615],"about_ca_topic_score_codex":0.00000444898,"about_ca_topic_score_gemma":0.0000053840145,"teacher_disagreement_score":0.044059414,"about_ca_system_score_codex":0.000049806556,"about_ca_system_score_gemma":0.00053025485,"threshold_uncertainty_score":0.29080525},"labels":[],"label_agreement":null},{"id":"W4415519633","doi":"10.1016/j.jtho.2025.09.1398","title":"EP.07.17 Patient Characteristics, Surgical Outcomes, and Treatment Decisions in Early-Stage Resected NSCLC in Canada","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; McGill University Health Centre; Vancouver Coastal Health","funders":"","keywords":"MEDLINE; Resection; Carcinoma; Neoplasm staging; Surgical resection","score_opus":0.025628159799364083,"score_gpt":0.37783466427138207,"score_spread":0.352206504472018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901807,0.00030634878,0.000011091264,0.006892403,0.0006173805,0.00026287316,0.000010510432,0.000003430981,0.0017152735],"genre_scores_gemma":[0.9958525,0.0006507473,0.0002853436,0.00049188035,0.000049529037,0.000007517278,0.00000502567,0.0000068575982,0.0026506225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984131,0.00013940493,0.0008052139,0.00015362278,0.00023124956,0.0002574211],"domain_scores_gemma":[0.9987913,0.0005459081,0.00028310705,0.00015258146,0.00008967152,0.00013746542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030714244,0.00014121532,0.00079484144,0.0005139371,0.000028254239,0.000012168481,0.00008707055,0.00008240319,0.00009312081],"category_scores_gemma":[0.00028488133,0.000101681755,0.0000799154,0.0003094834,0.000034553814,0.00005010024,0.00006934115,0.0003238974,0.0000014257239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015867505,0.00023609414,0.76076895,0.00001255538,0.000086699605,0.0052698078,0.0001503946,0.0000068347185,0.000007694152,0.00002525266,0.0015310231,0.23031794],"study_design_scores_gemma":[0.0027718826,0.00090212404,0.9094032,0.00015387924,0.000097620024,0.00007940241,0.00037849892,0.000039647253,0.000016566886,0.00002600809,0.08606884,0.00006230788],"about_ca_topic_score_codex":0.11510319,"about_ca_topic_score_gemma":0.5611795,"teacher_disagreement_score":0.44607633,"about_ca_system_score_codex":0.0026780828,"about_ca_system_score_gemma":0.0017604639,"threshold_uncertainty_score":0.8907894},"labels":[],"label_agreement":null},{"id":"W4415519656","doi":"10.1016/j.jtho.2025.09.1186","title":"EP.01.02 Long-Term Survival After Curative Surgery for Stage I-III NSCLC Patients in British Columbia, 2005-2021: A Population-Based Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Stage (stratigraphy); Overall survival; Survival rate; Neoplasm staging; MEDLINE","score_opus":0.022967112837508106,"score_gpt":0.38045981068222423,"score_spread":0.3574926978447161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545133,0.00031601853,0.0003124727,0.000618854,0.0017961496,0.0011953005,0.00008535545,0.0000082821125,0.00021622566],"genre_scores_gemma":[0.99562305,0.000042104075,0.0003433965,0.0010867178,0.00021450956,0.00008299671,0.00008524252,0.000022158649,0.0024998067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974011,0.0004412484,0.0011868351,0.00027711075,0.00032489348,0.00036877714],"domain_scores_gemma":[0.99759525,0.0010021795,0.0006232661,0.00019345901,0.00042387308,0.00016198901],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011621953,0.00015084533,0.001099351,0.00036266726,0.00008511858,0.00006928239,0.00012751618,0.00018418729,0.0011012942],"category_scores_gemma":[0.00045119846,0.00019311352,0.00029507373,0.0002931022,0.000049972263,0.00023594646,0.000037572576,0.00045149916,0.000002015706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005159543,0.0017456837,0.8977745,0.00016141441,0.00022202513,0.0007578036,0.00017574303,0.000021979506,0.000010138164,2.0123791e-7,0.0026417675,0.09132916],"study_design_scores_gemma":[0.005990704,0.0014834226,0.9889479,0.00042278302,0.00024601055,0.000014830388,0.00046762795,0.000059222148,0.000010606985,0.000013324996,0.0021931091,0.00015040334],"about_ca_topic_score_codex":0.0027054604,"about_ca_topic_score_gemma":0.16528471,"teacher_disagreement_score":0.16257925,"about_ca_system_score_codex":0.0012151202,"about_ca_system_score_gemma":0.0019195986,"threshold_uncertainty_score":0.9998118},"labels":[],"label_agreement":null},{"id":"W4415519671","doi":"10.1016/j.jtho.2025.09.466","title":"P1.17.81 Unveiling the Natural History of Lung Cancer by Sex, Histology, and Nodule Type Using Mathematical Modeling","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Natural history; Lung cancer; Nodule (geology); Solitary pulmonary nodule; Lung","score_opus":0.027339318885115416,"score_gpt":0.4543247194899735,"score_spread":0.42698540060485807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.914356,0.06977553,0.0036334395,0.0048273923,0.0015946246,0.00024173978,0.000004449562,0.000009130682,0.0055577066],"genre_scores_gemma":[0.9873053,0.00029516342,0.00409766,0.0006344058,0.00011648219,0.0000032244366,0.0000018238119,0.0000103017965,0.0075356616],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991985,0.00007078571,0.00039948756,0.00009445466,0.00011170233,0.00012505127],"domain_scores_gemma":[0.999225,0.00014075602,0.0002724193,0.00010333139,0.00020868608,0.000049780516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029160862,0.00008807488,0.00041126835,0.000113618844,0.00005446824,0.000003392495,0.00007032331,0.00009596259,0.00009255763],"category_scores_gemma":[0.00008830002,0.0000555661,0.00007153827,0.000089835354,0.00013247029,0.000056052293,0.000030476429,0.00030028308,3.5931967e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011728013,0.0043287515,0.028454626,0.005270405,0.0140970005,0.001097305,0.03341799,0.020295253,0.1253249,0.0034014652,0.30084783,0.45173648],"study_design_scores_gemma":[0.005515024,0.0021459972,0.00070408505,0.0024050174,0.014794316,0.0032458776,0.0033002864,0.78788155,0.0019208663,0.0024985976,0.17515977,0.00042860452],"about_ca_topic_score_codex":0.000052660922,"about_ca_topic_score_gemma":0.000010016126,"teacher_disagreement_score":0.7675863,"about_ca_system_score_codex":0.0015609945,"about_ca_system_score_gemma":0.0013633744,"threshold_uncertainty_score":0.40819466},"labels":[],"label_agreement":null},{"id":"W4415519672","doi":"10.1016/j.jtho.2025.09.1188","title":"EP.01.04 Features, Demographics and Treatment Profiles of Primary Lung Cancer Cases in Nigeria: The Largest Single Centre Report in West Africa","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Lung cancer; Incidence (geometry); Demographics; Cancer; Cancer registry; Cancer incidence","score_opus":0.019567081256498742,"score_gpt":0.4042042607077438,"score_spread":0.38463717945124504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95619136,0.02392516,0.000007985443,0.015691927,0.0003729412,0.00049901486,0.000024034598,0.0000047318417,0.0032828392],"genre_scores_gemma":[0.99539804,0.0020809933,0.0006845627,0.00018506893,0.00008829213,0.00002814164,0.000011619733,0.000008837411,0.001514432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891615,0.00013048349,0.0005182736,0.0001336197,0.00012970093,0.00017175051],"domain_scores_gemma":[0.99899524,0.00027924322,0.00040257422,0.00013645957,0.00012915155,0.00005730388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028260518,0.000119200406,0.0005139515,0.00029548476,0.000046627083,0.000008619518,0.000054831104,0.00011770384,0.000020832238],"category_scores_gemma":[0.00011721888,0.00007029067,0.00008368314,0.00036713967,0.00009901779,0.00005880869,0.000024693203,0.00021654867,9.056055e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012501918,0.0018821891,0.9270807,0.00019710859,0.0005583642,0.0057483856,0.0021902414,0.00004422585,0.000981701,0.000052065625,0.0025503377,0.05746448],"study_design_scores_gemma":[0.0031334888,0.0015890746,0.93956786,0.0011441817,0.0014716248,0.0027550848,0.002307559,0.000014236346,0.0009863443,0.000103838735,0.046816815,0.000109892026],"about_ca_topic_score_codex":0.00033142616,"about_ca_topic_score_gemma":0.0064629107,"teacher_disagreement_score":0.057354588,"about_ca_system_score_codex":0.0010058957,"about_ca_system_score_gemma":0.001283692,"threshold_uncertainty_score":0.3606456},"labels":[],"label_agreement":null},{"id":"W4415519676","doi":"10.1016/j.jtho.2025.09.1719","title":"EP.17.17 Availability of PD-L1 and Ngs Results at Initial Medical Oncology Consultation in Patients With Non-Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Lung cancer; MEDLINE; Clinical Oncology; Molecular oncology; Medical record","score_opus":0.012982544570741121,"score_gpt":0.3968592815292485,"score_spread":0.3838767369585074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855482,0.0008454599,0.000021005975,0.00683988,0.00045179657,0.0005409617,0.000033741464,0.0000040071877,0.0057149436],"genre_scores_gemma":[0.996946,0.00056336937,0.0008956015,0.0008969121,0.000105818486,0.000031884847,0.000016413664,0.000009352161,0.00053464714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99798095,0.00023707164,0.0009749913,0.00024537824,0.00034134038,0.00022023762],"domain_scores_gemma":[0.9974019,0.0008878093,0.00078537525,0.00015539465,0.00057675753,0.0001927616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008894338,0.00015543094,0.0008373641,0.00024070339,0.000042152464,0.000004681566,0.00009637854,0.0003038274,0.00017848788],"category_scores_gemma":[0.0004135137,0.00010823559,0.000072276016,0.00022764485,0.000243275,0.00006430799,0.000075565964,0.00042185446,0.0000011980279],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03162937,0.0030810726,0.8977267,0.00051472284,0.00035167133,0.0003852239,0.0016679331,0.00003247911,0.00006861799,0.0000046395116,0.014822188,0.049715348],"study_design_scores_gemma":[0.023006532,0.007401062,0.95633256,0.0012191096,0.0009756596,0.00006334119,0.00023446375,0.00011890002,0.0018128539,0.000026923364,0.008698908,0.00010969563],"about_ca_topic_score_codex":0.00021722958,"about_ca_topic_score_gemma":0.0020326388,"teacher_disagreement_score":0.058605812,"about_ca_system_score_codex":0.002126654,"about_ca_system_score_gemma":0.0024333985,"threshold_uncertainty_score":0.5561126},"labels":[],"label_agreement":null},{"id":"W4415519720","doi":"10.1016/j.jtho.2025.09.427","title":"P1.17.42 Canadian Consensus Recommendations for Multi-Disciplinary Team Meetings in Lung Cancer Care","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advances in Oncology and Radiotherapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; University of Saskatchewan; Royal Jubilee Hospital; Hôpital Charles-Le Moyne; Centre Hospitalier de l’Université de Montréal; CancerCare Manitoba","funders":"","keywords":"Lung cancer; Health care; MEDLINE; Patient care; Patient-centered care; Primary care; Clinical Practice","score_opus":0.038363153139809536,"score_gpt":0.5312015454847575,"score_spread":0.492838392344948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519720","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41872847,0.06085119,0.0072701164,0.45365417,0.01832985,0.0033627476,0.00028147563,0.00006209889,0.037459865],"genre_scores_gemma":[0.59139955,0.004182834,0.3622522,0.022518044,0.0023107347,0.00024896034,0.00005695684,0.000076816046,0.016953917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986473,0.00015433528,0.00062347815,0.00017086382,0.00007350477,0.00033056],"domain_scores_gemma":[0.99838763,0.000569305,0.00036558596,0.00013397756,0.0003575074,0.0001859857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000608142,0.00013563126,0.00059429987,0.0005984208,0.00018904879,0.0000052977125,0.00015249033,0.0003207044,0.00013292117],"category_scores_gemma":[0.00031749872,0.00011451412,0.00013993071,0.00027564145,0.00015902705,0.000053578176,0.000022761704,0.0005981965,7.8423716e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059097353,0.0007473406,0.12967053,0.0006468742,0.0007401935,0.0007860685,0.007908237,0.00084126694,0.0010077478,0.00028612863,0.41471934,0.43673652],"study_design_scores_gemma":[0.0047645383,0.0014038531,0.015687749,0.0009947387,0.00048091233,0.00064670807,0.0069325673,0.001888293,0.00029467436,0.00035962666,0.9663572,0.00018913904],"about_ca_topic_score_codex":0.0012823628,"about_ca_topic_score_gemma":0.07865219,"teacher_disagreement_score":0.5516378,"about_ca_system_score_codex":0.0028588886,"about_ca_system_score_gemma":0.004023438,"threshold_uncertainty_score":0.93816},"labels":[],"label_agreement":null},{"id":"W4415519733","doi":"10.1016/j.jtho.2025.09.1459","title":"EP.08.22 Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Cohort; Hazard ratio; Stage (stratigraphy); Osimertinib; Overall survival; Cohort study","score_opus":0.02482755089397919,"score_gpt":0.45152699523988427,"score_spread":0.42669944434590507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938704,0.00016976934,0.0003727625,0.0016519021,0.0003879481,0.00040098687,0.000023446464,0.000008951657,0.0031138533],"genre_scores_gemma":[0.99416375,0.00014302251,0.0010461432,0.00048086554,0.00006765799,0.000010447638,0.000013268374,0.000014024202,0.0040608025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985728,0.00014481833,0.00066252565,0.00019569989,0.00019269595,0.00023142218],"domain_scores_gemma":[0.99871635,0.00042206133,0.00039301167,0.00016329995,0.00015174446,0.00015351926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000293793,0.00016588267,0.0007369691,0.0002929579,0.00006951355,0.00002120899,0.000070275135,0.000120718956,0.00007236491],"category_scores_gemma":[0.00010381093,0.00010041707,0.00012425239,0.00015112403,0.00006871169,0.00010785095,0.000037476868,0.00025849874,0.0000022129693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019677002,0.0016947709,0.9522445,0.00004690243,0.00093083305,0.00029165347,0.0007805146,0.000017067023,0.0000024608153,0.000031103842,0.00008650555,0.041905988],"study_design_scores_gemma":[0.012548679,0.0069995695,0.975249,0.00035215498,0.001129617,0.00002602172,0.0015566727,0.000015169736,0.000038351904,0.000056420264,0.0019405746,0.000087788816],"about_ca_topic_score_codex":0.00017910103,"about_ca_topic_score_gemma":0.0010990263,"teacher_disagreement_score":0.0418182,"about_ca_system_score_codex":0.00086328696,"about_ca_system_score_gemma":0.0010629344,"threshold_uncertainty_score":0.40948895},"labels":[],"label_agreement":null},{"id":"W4415519759","doi":"10.1016/j.jtho.2025.09.780","title":"P3.01.34 Associating Pollution-Related Anthracotic Pigments Within Normal Lung Tissue With Lung Cancer Characteristics","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Lung cancer; Pigment; Lung; Cancer; Adenocarcinoma","score_opus":0.01776922916270728,"score_gpt":0.41457993951310435,"score_spread":0.39681071035039706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96917677,0.0003985442,0.0047869496,0.01962047,0.0017389146,0.00029732526,0.000019047464,0.000024618446,0.003937341],"genre_scores_gemma":[0.98940265,0.00012760764,0.00417085,0.0038370416,0.00016245522,0.000005710042,0.0000032440066,0.000015126954,0.0022753198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755085,0.00040982553,0.00095352496,0.00018595379,0.00042735567,0.00047249015],"domain_scores_gemma":[0.99786097,0.00019014429,0.0015096155,0.00013924141,0.00006245848,0.00023756137],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017306008,0.00017701792,0.00052100857,0.000116717696,0.00035163687,0.000034265544,0.0002738225,0.00024604748,0.0010097085],"category_scores_gemma":[0.00027726425,0.00014358095,0.00005835612,0.00043479344,0.00017691219,0.000400092,0.00011637788,0.000741922,0.000024660947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002293678,0.0010014315,0.68329585,0.0005187394,0.0006895857,0.00050637533,0.0074421247,0.008918252,0.0037901103,0.0002391106,0.033636466,0.25766832],"study_design_scores_gemma":[0.001712244,0.0018991096,0.9525433,0.0011440145,0.00083683967,0.00031047425,0.001041155,0.019789722,0.0012973559,0.00027396588,0.018661158,0.0004906154],"about_ca_topic_score_codex":0.00031428252,"about_ca_topic_score_gemma":0.00036134652,"teacher_disagreement_score":0.26924753,"about_ca_system_score_codex":0.0026948643,"about_ca_system_score_gemma":0.0005726789,"threshold_uncertainty_score":0.9999035},"labels":[],"label_agreement":null},{"id":"W4415519763","doi":"10.1016/j.jtho.2025.09.045","title":"OA05.04 A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC: ZEAL-1L","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Pembrolizumab; Maintenance therapy; Phases of clinical research; Antibody therapy; Phase (matter)","score_opus":0.028295237195804103,"score_gpt":0.45493130491482714,"score_spread":0.426636067719023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759851,0.007630679,0.005095289,0.005089845,0.0013742463,0.0032145593,0.000013397954,0.000016879421,0.0015799849],"genre_scores_gemma":[0.99009615,0.002101979,0.0032842394,0.0016968048,0.0001509111,0.00015418892,0.0000044706367,0.000028032999,0.0024831947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99686116,0.00057748856,0.0016278712,0.0002442345,0.00034589416,0.00034332505],"domain_scores_gemma":[0.9961633,0.0012000527,0.0015068979,0.00032921796,0.0006861857,0.000114357485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026483142,0.0002569794,0.0022075016,0.000495034,0.000087563705,0.000014554063,0.0002792521,0.00012678279,0.00013860097],"category_scores_gemma":[0.0006833327,0.00017447163,0.0007261213,0.00043166766,0.00026950668,0.00012262318,0.000030067851,0.00037315703,0.0000017880803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70469725,0.0032994829,0.000033733504,0.00014706363,0.0020429178,0.00013907904,0.0012834988,0.000022654835,0.008206297,0.000052283256,0.0029213582,0.2771544],"study_design_scores_gemma":[0.91002643,0.035739373,0.00032252102,0.00073088985,0.0017205368,0.0007838745,0.004994239,0.00029917926,0.005588886,0.0020928462,0.037489932,0.00021130264],"about_ca_topic_score_codex":0.000048417787,"about_ca_topic_score_gemma":0.000024293011,"teacher_disagreement_score":0.2769431,"about_ca_system_score_codex":0.0004918112,"about_ca_system_score_gemma":0.0017035389,"threshold_uncertainty_score":0.71147466},"labels":[],"label_agreement":null},{"id":"W4415519772","doi":"10.1016/j.jtho.2025.09.770","title":"P3.01.24 Economic Burden of Radon Attributable Non-Small Cell Lung Cancer: A Cost Analysis","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Radon; Lung cancer; Radon exposure; Cancer; Inhalation; Radon gas; Lung; Public health","score_opus":0.02288915085702791,"score_gpt":0.34045896403988735,"score_spread":0.31756981318285943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90479714,0.021200083,0.018379489,0.0038881327,0.0037372888,0.0004125388,0.00042288544,0.00001234815,0.047150124],"genre_scores_gemma":[0.98799455,0.005285369,0.0017391213,0.0003600675,0.0005187073,0.000019030445,0.000007280373,0.000023771441,0.0040520937],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972078,0.000045512883,0.0019341123,0.00033498192,0.000035084686,0.0004424893],"domain_scores_gemma":[0.9962971,0.00019263194,0.00284085,0.00035940204,0.00014754041,0.0001624623],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00142348,0.00023169766,0.0019380532,0.00122402,0.00008613121,0.000051538133,0.00060076715,0.00032137756,0.0009654777],"category_scores_gemma":[0.00007854526,0.00025560602,0.0006481227,0.00049711956,0.000106889725,0.0003450713,0.00011175421,0.00042949262,0.00006147886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028681702,0.0007897821,0.643011,0.00083476043,0.0075691496,0.000089370726,0.0019816197,0.12715954,0.0005522274,0.011101397,0.10965154,0.094391465],"study_design_scores_gemma":[0.004381877,0.001484834,0.069751754,0.0002953756,0.0034617928,0.000039007144,0.00076391135,0.04525596,0.0046048723,0.010207673,0.8586353,0.0011176395],"about_ca_topic_score_codex":0.0017794304,"about_ca_topic_score_gemma":0.00046815837,"teacher_disagreement_score":0.74898374,"about_ca_system_score_codex":0.0015976115,"about_ca_system_score_gemma":0.00086030853,"threshold_uncertainty_score":0.9999896},"labels":[],"label_agreement":null},{"id":"W4415519791","doi":"10.1016/j.jtho.2025.09.032","title":"OA02.02 Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Osimertinib; Chemotherapy; Pathological; Disease; Stage (stratigraphy); Neoadjuvant therapy","score_opus":0.01204574346857208,"score_gpt":0.4340913452839231,"score_spread":0.42204560181535106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9492192,0.0075528235,0.0014137704,0.03537227,0.0004221072,0.00033375964,0.000029865836,0.000016733542,0.005639453],"genre_scores_gemma":[0.9909682,0.00036820996,0.0034980362,0.003088552,0.00017823587,0.000018507799,0.000043452263,0.00001865123,0.0018181234],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981725,0.00021767606,0.00074978214,0.00026130202,0.00030759015,0.00029113755],"domain_scores_gemma":[0.99856293,0.00020718163,0.000396123,0.00033335725,0.00025208376,0.00024833396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038531073,0.00018087517,0.0008412478,0.0008211449,0.00006422585,0.000024727178,0.00017421995,0.00014618404,0.00038516268],"category_scores_gemma":[0.00020301018,0.00014107779,0.00033285542,0.0011062757,0.00007118503,0.00011360723,0.000038602062,0.0003973881,0.000007916099],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037575796,0.006083879,0.293057,0.00018344366,0.021527968,0.014593881,0.0030772146,0.003781289,0.026172196,0.00045738535,0.025663855,0.5678261],"study_design_scores_gemma":[0.01696862,0.0029446052,0.8319701,0.0010739934,0.02637309,0.00010394401,0.0018337547,0.0015361226,0.014773601,0.0060162684,0.09589239,0.000513523],"about_ca_topic_score_codex":0.00043583583,"about_ca_topic_score_gemma":0.00020119877,"teacher_disagreement_score":0.5673126,"about_ca_system_score_codex":0.00071743364,"about_ca_system_score_gemma":0.001684116,"threshold_uncertainty_score":0.57529855},"labels":[],"label_agreement":null},{"id":"W4415519832","doi":"10.1016/j.jtho.2025.09.1251","title":"EP.04.07 Participant and Provider Experiences in an Indigenous Focused Trial of Lung Cancer Screening in Aotearoa New Zealand","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"","keywords":"Aotearoa; Lung cancer screening; Indigenous; Primary care; Cancer screening; Participant observation; Qualitative research; Primary health care","score_opus":0.229222428152147,"score_gpt":0.5902705651990189,"score_spread":0.3610481370468719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871217,0.00053496764,0.0002004999,0.01112106,0.00043693106,0.00055363565,0.000001026091,0.0000034068298,0.000026747759],"genre_scores_gemma":[0.99350125,0.00016898755,0.005157112,0.0005945117,0.00027437223,0.000022480386,0.0000013929796,0.000007759792,0.00027212437],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99729633,0.0004291201,0.0016787216,0.00015111253,0.00022483774,0.0002199009],"domain_scores_gemma":[0.9978263,0.00090994476,0.0008720011,0.000108367225,0.00015025225,0.00013314401],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024671217,0.00009456064,0.00064698735,0.00035324434,0.000021823967,0.000013675524,0.00009301503,0.0001359091,0.00008108925],"category_scores_gemma":[0.002190527,0.0000753133,0.00005410246,0.0002816348,0.000071941686,0.0002934376,0.00004092008,0.00043166455,2.2613408e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08804726,0.0008261176,0.3295416,0.000088539826,0.00012741107,0.00022196148,0.031547584,0.0001215087,0.0012060312,0.000002888384,0.0011196194,0.5471495],"study_design_scores_gemma":[0.19787873,0.028270494,0.67750263,0.0026473347,0.0024680414,0.00037066758,0.06400986,0.0053056898,0.0038900552,0.0018976072,0.015232984,0.00052587735],"about_ca_topic_score_codex":0.002606438,"about_ca_topic_score_gemma":0.004263834,"teacher_disagreement_score":0.5466236,"about_ca_system_score_codex":0.00014808522,"about_ca_system_score_gemma":0.001902091,"threshold_uncertainty_score":0.3940172},"labels":[],"label_agreement":null},{"id":"W4415519843","doi":"10.1016/j.jtho.2025.09.033","title":"OA02.03 Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Trinity College","funders":"","keywords":"Nivolumab; Overall survival; Chemotherapy; Phases of clinical research; Neoadjuvant therapy","score_opus":0.021321537285763765,"score_gpt":0.43101578009003844,"score_spread":0.4096942428042747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97534764,0.0012906906,0.000068257956,0.019529471,0.0006142589,0.0006558283,0.0000070568867,0.000013207295,0.002473619],"genre_scores_gemma":[0.994352,0.00043966385,0.00015885929,0.002585637,0.0001597414,0.000016909938,0.0000039483994,0.000020125037,0.0022631404],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755454,0.0005414877,0.0008588619,0.0002259122,0.00048348898,0.0003357105],"domain_scores_gemma":[0.9985824,0.00038429143,0.0004769546,0.00032488606,0.00014773093,0.000083706895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023224533,0.00024047968,0.0010824071,0.00024224569,0.000079712256,0.00003587273,0.00034801904,0.00016026897,0.00022192848],"category_scores_gemma":[0.000047800524,0.00012840243,0.00024335414,0.00038114973,0.00015613779,0.00010422742,0.000029299683,0.0006774239,0.000003868186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32914728,0.023236396,0.1661891,0.00018312731,0.0043120836,0.008900373,0.0076575866,0.00002908166,0.0073315823,0.000058705074,0.030175926,0.4227788],"study_design_scores_gemma":[0.18936177,0.043623626,0.24953254,0.0006310803,0.0013031324,0.0041464847,0.012705197,0.00018089749,0.0021017212,0.00019134043,0.49555826,0.0006639665],"about_ca_topic_score_codex":0.00015762693,"about_ca_topic_score_gemma":0.00018607627,"teacher_disagreement_score":0.46538234,"about_ca_system_score_codex":0.0006064766,"about_ca_system_score_gemma":0.0007867931,"threshold_uncertainty_score":0.5236099},"labels":[],"label_agreement":null},{"id":"W4415519856","doi":"10.1016/j.jtho.2025.09.109","title":"MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; KRAS; MEDLINE; Immunotherapy; PD-L1","score_opus":0.018901264307362615,"score_gpt":0.3817211829039664,"score_spread":0.3628199185966038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817583,0.0073684365,0.000077057965,0.0071635647,0.0005037707,0.00033965346,0.00005559333,0.00000928679,0.002724354],"genre_scores_gemma":[0.99317175,0.0044960664,0.001002308,0.0006427821,0.00018476315,0.0000023709617,0.000012777483,0.000015675725,0.0004715226],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975844,0.0002919792,0.0013245655,0.00027215588,0.00024499622,0.0002819289],"domain_scores_gemma":[0.9979209,0.0007970092,0.0007348288,0.00025499603,0.00015363347,0.00013867908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012189191,0.00021274196,0.0010789804,0.00044879396,0.000055232627,0.000015531275,0.0001583457,0.0003150674,0.00008498976],"category_scores_gemma":[0.0003764489,0.00016595244,0.000135944,0.00038424818,0.00031965296,0.00010217872,0.00007819201,0.00056150235,0.0000017336256],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41830412,0.001191733,0.013633637,0.00030929074,0.0011458735,0.001412561,0.0031231092,0.00003488777,0.084752604,0.000054715085,0.004408732,0.47162873],"study_design_scores_gemma":[0.08073179,0.0071168165,0.7993732,0.0033611334,0.0011271451,0.001955498,0.0022661937,0.00031118406,0.012243372,0.00067238306,0.09040718,0.00043407216],"about_ca_topic_score_codex":0.00037115105,"about_ca_topic_score_gemma":0.00032217553,"teacher_disagreement_score":0.7857396,"about_ca_system_score_codex":0.00055309274,"about_ca_system_score_gemma":0.0010064207,"threshold_uncertainty_score":0.6767344},"labels":[],"label_agreement":null},{"id":"W4415519869","doi":"10.1016/j.jtho.2025.09.024","title":"PL03.16 Spread Through Airspaces (STAS) and Prognosis in the Phase III JCOG0802/WJOG4607L Trial of Segmentectomy vs Lobectomy in NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Sunnybrook Health Science Centre","funders":"","keywords":"Overall survival; Adenocarcinoma; Clinical endpoint; Survival analysis; Survival rate; Clinical trial","score_opus":0.027623149689362664,"score_gpt":0.4214906107438245,"score_spread":0.3938674610544618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9737935,0.0019466411,0.00006141266,0.017907986,0.00035274556,0.0007462755,0.000003449113,0.0000060219886,0.005181953],"genre_scores_gemma":[0.99820715,0.00032137716,0.00035324224,0.00063288683,0.0002398966,0.000027552524,0.0000018209306,0.000008325818,0.00020775186],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979561,0.00042963735,0.0008619849,0.00018791984,0.00030059562,0.0002637866],"domain_scores_gemma":[0.9985857,0.00055205886,0.00050058187,0.0001410507,0.00015358653,0.00006702895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014525579,0.000174404,0.0009481129,0.00043366413,0.00004091843,0.000014955214,0.0002014711,0.00017642301,0.00004305997],"category_scores_gemma":[0.0003198247,0.00010912311,0.00019108354,0.00068457535,0.00019073376,0.00014463962,0.00008059981,0.0006571384,9.3176425e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5522,0.010356324,0.07927618,0.0008180986,0.0005274855,0.0029654335,0.007785817,0.000008849612,0.008345014,0.00052041735,0.00914628,0.32805008],"study_design_scores_gemma":[0.52661663,0.104405366,0.12312189,0.005688357,0.0032708345,0.0042873872,0.029771058,0.0003122858,0.052638944,0.007023036,0.14199181,0.00087242154],"about_ca_topic_score_codex":0.00015472567,"about_ca_topic_score_gemma":0.0004948887,"teacher_disagreement_score":0.32717764,"about_ca_system_score_codex":0.0002547102,"about_ca_system_score_gemma":0.00052962784,"threshold_uncertainty_score":0.44499114},"labels":[],"label_agreement":null},{"id":"W4415519914","doi":"10.1016/j.jtho.2025.09.230","title":"P1.04.40 Improving Lung Cancer Risk Prediction in Asbestos Exposed Individuals: The AQC Ensemble Model","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Asbestos; Lung cancer; Risk assessment; Risk model; Relative risk; Cancer; Risk factor","score_opus":0.0178473844707739,"score_gpt":0.38145821913820377,"score_spread":0.3636108346674299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103177,0.0026018643,0.0016709024,0.0025525007,0.00045756518,0.00025964918,0.00003521258,0.000009648952,0.001380906],"genre_scores_gemma":[0.9962489,0.00045081935,0.0011499808,0.00084476016,0.00020038713,0.00002669708,0.000006732571,0.000009772093,0.0010619225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873936,0.00015611234,0.00052188506,0.00013393516,0.0002699172,0.00017878768],"domain_scores_gemma":[0.9991513,0.00017759844,0.0003988632,0.00013101479,0.000053827174,0.00008741256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006385663,0.00011208322,0.00030834466,0.00020404678,0.00009833505,0.000011246651,0.00012289673,0.00012564378,0.00008909463],"category_scores_gemma":[0.0001590548,0.00007315116,0.000121757796,0.00017380719,0.00007372085,0.0001418751,0.000058065463,0.00047502047,0.0000034524278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023270275,0.00065560313,0.7890965,0.00012980957,0.0002343295,0.000060977407,0.00048643618,0.01477349,0.005401719,0.000037373895,0.0057240953,0.18107265],"study_design_scores_gemma":[0.0014522708,0.0006224419,0.94207036,0.00035847284,0.0011970549,0.000090531925,0.00046347806,0.04883304,0.0014967908,0.0011295892,0.0021897587,0.000096205134],"about_ca_topic_score_codex":0.000077005214,"about_ca_topic_score_gemma":0.00006778746,"teacher_disagreement_score":0.18097645,"about_ca_system_score_codex":0.0006483086,"about_ca_system_score_gemma":0.0006104076,"threshold_uncertainty_score":0.2983018},"labels":[],"label_agreement":null},{"id":"W4415519940","doi":"10.1016/j.jtho.2025.09.1179","title":"PT2.17.01 Point-Of-Care Rapid Tissue Diagnosis at Primary Consultation: Optimizing TIME to Treatment in the Neoadjuvant Era","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Ultrasound in Clinical Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Neoadjuvant therapy; Primary (astronomy); MEDLINE; Primary treatment","score_opus":0.02963761668171187,"score_gpt":0.4331168645433704,"score_spread":0.4034792478616585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8040362,0.0048030484,0.00080552074,0.1473264,0.0004583126,0.002015356,0.000043901586,0.000024575034,0.040486686],"genre_scores_gemma":[0.81555027,0.0028580625,0.15102896,0.02020803,0.0008640665,0.00057689624,0.00009798344,0.000052077303,0.008763639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981014,0.00028910008,0.001007403,0.00018346558,0.00022736349,0.00019126464],"domain_scores_gemma":[0.993786,0.004997868,0.00046256854,0.00030773235,0.00033021971,0.00011562445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076544005,0.000143657,0.00073969545,0.0002395504,0.00007577115,0.000011250194,0.00023777303,0.00016576704,0.0008381684],"category_scores_gemma":[0.0008806814,0.000092807066,0.00016955392,0.00047608954,0.00012036646,0.000060143015,0.000057291338,0.00035254593,0.00008994036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037213622,0.00258418,0.0061988463,0.00017891284,0.00037856892,0.000257739,0.007587923,0.00039263556,0.01012187,0.000086474174,0.037890013,0.9306015],"study_design_scores_gemma":[0.0045115296,0.013124891,0.06693276,0.0008539776,0.0013913475,0.00084261433,0.0036805097,0.0000454964,0.0126859,0.00049994723,0.89520425,0.00022679391],"about_ca_topic_score_codex":0.000011937795,"about_ca_topic_score_gemma":0.000025045001,"teacher_disagreement_score":0.9303747,"about_ca_system_score_codex":0.0010179164,"about_ca_system_score_gemma":0.00059399736,"threshold_uncertainty_score":0.9177356},"labels":[],"label_agreement":null},{"id":"W4415519990","doi":"10.1016/j.jtho.2025.09.134","title":"MA05.05 Analysis of Longitudinal Low-Dose CT Sybil Scores in Two Canadian Cohorts","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Foundation","funders":"","keywords":"Longitudinal study; Computed tomography; Lung cancer; MEDLINE; Longitudinal data; Risk assessment","score_opus":0.022232344339234735,"score_gpt":0.41199378929333486,"score_spread":0.38976144495410014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415519990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98888534,0.0050790366,0.000021207683,0.0019466168,0.00078598125,0.00017249145,0.00001312163,0.000004852225,0.0030913672],"genre_scores_gemma":[0.9983411,0.00051714375,0.00018890177,0.00044477795,0.00011192373,0.0000037856441,0.0000074571644,0.000008509073,0.0003764063],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979795,0.00022572723,0.0010686431,0.0001776327,0.0002668205,0.00028163174],"domain_scores_gemma":[0.9982741,0.00024075435,0.0005722296,0.00024347265,0.0003325859,0.00033686773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096674036,0.00013951902,0.0012257225,0.0025037844,0.000040136783,0.000010477616,0.0001722521,0.000112191025,0.00027658913],"category_scores_gemma":[0.000361671,0.000104389015,0.00042473339,0.0016014059,0.0001161797,0.000063015716,0.000029500814,0.0003694143,0.00000432418],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012970836,0.00053243234,0.95186263,0.00015420595,0.0033067197,0.0028675494,0.00015200526,0.0011199624,0.0010295844,0.00006494049,0.004809587,0.032803282],"study_design_scores_gemma":[0.0014521339,0.000407923,0.985868,0.0021199454,0.0067131487,0.00054573256,0.0004990872,0.0006804127,0.0005750384,0.00006792226,0.00097254047,0.000098110955],"about_ca_topic_score_codex":0.017099343,"about_ca_topic_score_gemma":0.057084378,"teacher_disagreement_score":0.039985035,"about_ca_system_score_codex":0.00077357225,"about_ca_system_score_gemma":0.0022697845,"threshold_uncertainty_score":0.98944587},"labels":[],"label_agreement":null},{"id":"W4415520086","doi":"10.1016/j.jtho.2025.09.1000","title":"P3.16.07 Canadian Action Plan for Lung Cancer - Patient Perspective","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Lung cancer; Action (physics); Plan (archaeology); Action plan; MEDLINE","score_opus":0.02601026845966635,"score_gpt":0.4957272293236868,"score_spread":0.4697169608640204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7666584,0.009942938,0.004238382,0.1259585,0.008445738,0.001958082,0.00019833275,0.000028421031,0.08257118],"genre_scores_gemma":[0.9931064,0.00016930613,0.0015448357,0.0020436044,0.00036862263,0.00005586352,0.000009420779,0.00000951928,0.002692383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937576,0.000034486606,0.00023793854,0.00009667459,0.000085542015,0.00016957236],"domain_scores_gemma":[0.99900216,0.00007200758,0.00020030014,0.0000712776,0.00049125333,0.00016297725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010546726,0.00007750047,0.00025954974,0.0002879009,0.00010789594,0.000009025765,0.000043146167,0.00009501177,0.00016177577],"category_scores_gemma":[0.00007073163,0.000059197093,0.00010974444,0.00011963222,0.0000254588,0.000067277906,0.000006166715,0.00016748522,0.0000015687018],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053805215,0.0007441994,0.018197622,0.0002821379,0.00361335,0.00033068805,0.0066647646,0.00033802536,0.00092831836,0.0020102554,0.21863581,0.7428743],"study_design_scores_gemma":[0.00396547,0.0054761395,0.026984936,0.00065377454,0.00541424,0.00056015793,0.017389424,0.0005648206,0.0021848062,0.0017631612,0.93483335,0.00020971682],"about_ca_topic_score_codex":0.016204912,"about_ca_topic_score_gemma":0.050620247,"teacher_disagreement_score":0.7426646,"about_ca_system_score_codex":0.006381906,"about_ca_system_score_gemma":0.0039076377,"threshold_uncertainty_score":0.9974324},"labels":[],"label_agreement":null},{"id":"W4415520109","doi":"10.1016/j.jtho.2025.09.1224","title":"EP.02.09 Deciphering CD47-Mediated Platelet-Tumor Crosstalk and Its Role in NSCLC Metastasis","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Crosstalk; CD47; Metastasis; Lung cancer; Immune system; Cancer cell; Cancer metastasis","score_opus":0.014690313319337381,"score_gpt":0.3492633528900643,"score_spread":0.3345730395707269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96699,0.029387984,0.00010638984,0.0008853889,0.0015500719,0.00014219903,0.000009799519,0.000013791536,0.00091435696],"genre_scores_gemma":[0.99841464,0.00053609366,0.00025126294,0.00018324873,0.00004098476,0.000006873236,0.000009709,0.0000121747435,0.0005449909],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811655,0.000449106,0.00083456596,0.00019344008,0.000048660626,0.00035766975],"domain_scores_gemma":[0.9986399,0.0005012852,0.0005328545,0.00013434602,0.00016017396,0.000031482177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010219474,0.00018221563,0.0007067333,0.00042577277,0.000115910116,0.00002399952,0.00022610361,0.00029821618,0.00018196175],"category_scores_gemma":[0.00044395725,0.00015507311,0.00012488572,0.0003313547,0.00011887964,0.00026344962,0.00012563617,0.00056892587,0.00003730679],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018068458,0.00032032808,0.0017848824,0.000043162723,0.0004125112,0.00012703726,0.00044785807,0.00010639883,0.7197963,0.000193865,0.000855321,0.2741055],"study_design_scores_gemma":[0.006370695,0.0017616465,0.09058157,0.0006320659,0.0004049182,0.002107448,0.0017553951,0.00039347695,0.6381423,0.0014463327,0.25589553,0.0005086105],"about_ca_topic_score_codex":0.000020571038,"about_ca_topic_score_gemma":0.000045414505,"teacher_disagreement_score":0.27359688,"about_ca_system_score_codex":0.00022135745,"about_ca_system_score_gemma":0.00028085752,"threshold_uncertainty_score":0.6323698},"labels":[],"label_agreement":null},{"id":"W4415520146","doi":"10.1016/j.jtho.2025.09.1122","title":"PT1.04.04 Biomarker-Based Eligibility for Lung Cancer Screening - Validation of Protein-Based INTEGRAL-Risk Model in the LC3 Consortium","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Lung cancer screening; Lung cancer; MEDLINE; Cancer","score_opus":0.032491435333927156,"score_gpt":0.46536927765584163,"score_spread":0.43287784232191445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6591815,0.0005580889,0.3194482,0.019798698,0.0001919823,0.00061164994,0.000010207641,0.00000762719,0.00019205816],"genre_scores_gemma":[0.9514067,0.000029453853,0.04691115,0.0014242014,0.00008878244,0.0000567827,0.000008803102,0.000013158774,0.000060933136],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9978009,0.000535259,0.0009342756,0.00018758571,0.0003038454,0.00023817075],"domain_scores_gemma":[0.99736243,0.0009758201,0.00092005625,0.00023428885,0.00042550845,0.0000818649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049578035,0.00014461177,0.00062928157,0.00043077298,0.00007873771,0.000016402095,0.00024811813,0.00015899079,0.000020470181],"category_scores_gemma":[0.00290171,0.00009447509,0.00024969957,0.00038259255,0.0001994171,0.0000629192,0.000020737862,0.00084424677,1.07676335e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015133525,0.0017374569,0.20790674,0.0023295777,0.0005719247,0.00012887619,0.0007850903,0.18060401,0.04026064,0.00028921946,0.0047564837,0.54549646],"study_design_scores_gemma":[0.0030078855,0.0006075936,0.010459044,0.0012945053,0.0006190127,0.000022044873,0.00019724878,0.97162545,0.009998579,0.00081977405,0.0012533937,0.00009549116],"about_ca_topic_score_codex":0.00018389887,"about_ca_topic_score_gemma":0.00002855454,"teacher_disagreement_score":0.7910214,"about_ca_system_score_codex":0.00031215054,"about_ca_system_score_gemma":0.0015987189,"threshold_uncertainty_score":0.38525823},"labels":[],"label_agreement":null},{"id":"W4415520171","doi":"10.1016/j.jtho.2025.09.112","title":"MA03.01 Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; St Joseph's Health Centre; Toronto East General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Stage (stratigraphy); Neoplasm staging; MEDLINE; Carcinoma","score_opus":0.011144662150878143,"score_gpt":0.40401976473193674,"score_spread":0.3928751025810586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707856,0.00040309096,0.007864434,0.0077255885,0.0010705321,0.0001614576,9.3812645e-7,0.000014537341,0.011973814],"genre_scores_gemma":[0.9920499,0.00014962666,0.0033348727,0.0014027507,0.00029130286,0.0000024601304,0.0000014075796,0.000011972913,0.002755715],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99861884,0.0002443515,0.00054873695,0.00014554724,0.00019503637,0.00024751527],"domain_scores_gemma":[0.9988527,0.00035733468,0.0003234512,0.00012418408,0.00021899705,0.0001233025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015783616,0.00010627337,0.0005059802,0.0005341977,0.00005318212,0.000016012344,0.000092960465,0.00015715137,0.00004934905],"category_scores_gemma":[0.0014993806,0.00008530408,0.00010303075,0.0004473246,0.000098730736,0.00010203514,0.00003262902,0.0012255975,0.000004118727],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030619747,0.00033390915,0.003512103,0.00015495674,0.0001397829,0.0017487754,0.0004109521,0.00013432663,0.29349416,0.00008381811,0.0011600786,0.69576514],"study_design_scores_gemma":[0.015708407,0.0120853735,0.3666528,0.003911721,0.0014833388,0.008373222,0.010361047,0.022302354,0.26981205,0.0056207096,0.28287387,0.0008151374],"about_ca_topic_score_codex":0.00011274934,"about_ca_topic_score_gemma":0.00008496252,"teacher_disagreement_score":0.69495004,"about_ca_system_score_codex":0.0004394171,"about_ca_system_score_gemma":0.0005567354,"threshold_uncertainty_score":0.5324679},"labels":[],"label_agreement":null},{"id":"W4415520173","doi":"10.1016/j.jtho.2025.09.786","title":"P3.01.40 10 Years Post Implementation of a Smoking Cessation (SC) Program in Regional Cancer Centres in Ontario, Canada:Successes and Ongoing Challenges","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Referral; Cancer; Ambulatory; Smoking cessation; Champion; Tobacco use; Health care","score_opus":0.06490567424576012,"score_gpt":0.45359271488340824,"score_spread":0.38868704063764814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98390967,0.004887931,0.000002716105,0.010493352,0.00015769605,0.00017053788,0.000002111258,0.0000025255713,0.00037347284],"genre_scores_gemma":[0.9977652,0.0012502149,0.00053046,0.00035511333,0.000051404288,0.000009663675,0.0000040282407,0.000003929648,0.000030000878],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988991,0.00008288666,0.0004925184,0.000111116904,0.00024855256,0.00016581456],"domain_scores_gemma":[0.9992063,0.000112983,0.00037999352,0.000052694733,0.00019834723,0.00004969353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042533237,0.00007564105,0.00033337373,0.0002895356,0.000019629477,0.0000082916595,0.00006977028,0.00007508506,0.00012550839],"category_scores_gemma":[0.00006938603,0.00006975223,0.000031414285,0.00018884553,0.000035570094,0.00014568945,0.000027016058,0.00026206256,3.7427217e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010701779,0.000070204966,0.45687187,0.000099045414,0.000055408465,0.00017689017,0.0014987375,0.00006820828,0.00018684569,0.00005683239,0.00044096517,0.5394048],"study_design_scores_gemma":[0.00094403006,0.00060794066,0.97247124,0.00089850405,0.00007982256,0.000065259286,0.0063717957,0.000018954377,0.00029319912,0.00009395921,0.018103776,0.00005149381],"about_ca_topic_score_codex":0.9017682,"about_ca_topic_score_gemma":0.99752,"teacher_disagreement_score":0.5393533,"about_ca_system_score_codex":0.0019197892,"about_ca_system_score_gemma":0.0041437745,"threshold_uncertainty_score":0.7350878},"labels":[],"label_agreement":null},{"id":"W4415520176","doi":"10.1016/j.jtho.2025.09.908","title":"P3.12.46 Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Randomized controlled trial; MEDLINE; Standard of care; Clinical trial","score_opus":0.011785634787195635,"score_gpt":0.39852840324071354,"score_spread":0.3867427684535179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8845259,0.003630317,0.0012137471,0.02192543,0.00073940697,0.0009177489,0.000007697465,0.000025179192,0.08701458],"genre_scores_gemma":[0.99269843,0.001147423,0.0032998999,0.0019540295,0.00006184617,0.000052320243,0.0000017619882,0.000008992815,0.0007752684],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982788,0.00017283203,0.00063690805,0.00022391338,0.00033203262,0.00035552811],"domain_scores_gemma":[0.9988404,0.00017271859,0.00042589684,0.0002192184,0.0002617412,0.00008006187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041678516,0.00022539927,0.00089389505,0.00015455771,0.00012539417,0.00001794874,0.00020360354,0.00010180053,0.00004064286],"category_scores_gemma":[0.00008187075,0.000120928235,0.00012837698,0.0005194909,0.0001829732,0.00008189493,0.00010842745,0.00035865416,0.0000040738787],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.087413035,0.0008934641,0.038938247,0.00032449205,0.001456768,0.003392717,0.00071406184,0.00013792084,0.00022505409,0.00049221586,0.004517243,0.8614948],"study_design_scores_gemma":[0.024761828,0.029205149,0.6445888,0.003426178,0.0029677402,0.002592143,0.011467445,0.000068472385,0.0056244284,0.0029850458,0.2717619,0.0005508683],"about_ca_topic_score_codex":0.0000138241285,"about_ca_topic_score_gemma":0.0006484069,"teacher_disagreement_score":0.8609439,"about_ca_system_score_codex":0.0013136038,"about_ca_system_score_gemma":0.00044405824,"threshold_uncertainty_score":0.49313104},"labels":[],"label_agreement":null},{"id":"W4415520187","doi":"10.1016/j.jtho.2025.09.066","title":"OA11.02 Molecular Alterations and Survival: Analyses from IASLC 9th Edition Staging Database","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"MEDLINE; Neoplasm staging","score_opus":0.054472339431632544,"score_gpt":0.48501806305376977,"score_spread":0.4305457236221372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642152,0.0067403913,0.011268308,0.011224052,0.0014785251,0.00015766725,0.000059801987,0.000013712376,0.004842311],"genre_scores_gemma":[0.9921111,0.0008696508,0.0054971646,0.0007480398,0.00031895222,0.0000063842426,0.00003530741,0.0000068571057,0.00040657446],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991451,0.00012345765,0.00033116812,0.00013070859,0.00015340946,0.00011613798],"domain_scores_gemma":[0.99917775,0.00021463475,0.00019870627,0.00011485141,0.00021670184,0.00007736772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023356565,0.000100819154,0.00044164306,0.00020721441,0.00009945928,0.00002026127,0.000046108984,0.000050934384,0.00008368719],"category_scores_gemma":[0.00015995331,0.00007489859,0.00008535362,0.0001690347,0.00006386998,0.000110399465,0.000053905158,0.00019645596,0.0000015812376],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008645922,0.0026267644,0.08131203,0.00039540106,0.009145606,0.0055589727,0.0029937048,0.0002004462,0.19336613,0.00091239274,0.05340149,0.64144117],"study_design_scores_gemma":[0.0138186235,0.011984276,0.5091421,0.0027111764,0.020159269,0.0008437098,0.013421168,0.0019395854,0.11003717,0.009579358,0.30543393,0.00092965516],"about_ca_topic_score_codex":0.000104820916,"about_ca_topic_score_gemma":0.00013227384,"teacher_disagreement_score":0.6405115,"about_ca_system_score_codex":0.000207811,"about_ca_system_score_gemma":0.0002581615,"threshold_uncertainty_score":0.30542758},"labels":[],"label_agreement":null},{"id":"W4415520210","doi":"10.1016/j.jtho.2025.09.927","title":"P3.12.65 First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; MEDLINE; Disease; Neoplasm staging","score_opus":0.03006908009901295,"score_gpt":0.49352239960862987,"score_spread":0.46345331950961693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9471732,0.0029257615,0.0006649531,0.034584682,0.0026342906,0.00070466724,0.000027290685,0.000045874676,0.0112393005],"genre_scores_gemma":[0.983191,0.00084096607,0.0048375023,0.00310779,0.00017904473,0.000023642146,0.00004961086,0.000030998846,0.0077394494],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99702424,0.000245635,0.0017598972,0.00029661818,0.00029417462,0.00037943033],"domain_scores_gemma":[0.9971673,0.0010682517,0.0008914231,0.00028353525,0.0003538028,0.00023572032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008813826,0.00025811308,0.001279957,0.00041330757,0.00013168517,0.000025563215,0.00020422363,0.00031623343,0.00021692186],"category_scores_gemma":[0.00113212,0.00018965846,0.00035319795,0.00055592484,0.00012399908,0.0001682795,0.000056539153,0.0007899331,0.000027782711],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008998849,0.0028298306,0.3485351,0.00010257212,0.0014699035,0.0008837566,0.00037011912,0.00017813306,0.00084761134,0.000029440707,0.027717974,0.6080367],"study_design_scores_gemma":[0.029876703,0.010825004,0.5979483,0.0011546215,0.0035398917,0.00043833183,0.001087985,0.00057723676,0.0019748649,0.0009816671,0.35109282,0.0005025809],"about_ca_topic_score_codex":0.000073626325,"about_ca_topic_score_gemma":0.00047792934,"teacher_disagreement_score":0.6075341,"about_ca_system_score_codex":0.00077344227,"about_ca_system_score_gemma":0.0011334877,"threshold_uncertainty_score":0.7734048},"labels":[],"label_agreement":null},{"id":"W4415520233","doi":"10.1016/j.jtho.2025.09.1690","title":"EP.15.15 Lived Experiences and Needs of People Living Long-Term With Metastatic Non-Small Cell Cancer: A Qualitative Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Lived experience; Qualitative research; Living cell; Qualitative analysis; MEDLINE","score_opus":0.04319561719198481,"score_gpt":0.3822965163513275,"score_spread":0.3391008991593427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854629,0.0069496464,0.0029137055,0.00035762726,0.00054620416,0.0002954085,0.000014345883,0.0000040963932,0.0034560605],"genre_scores_gemma":[0.9967506,0.00083744485,0.0011363479,0.00016330408,0.00008153252,0.000041499843,3.3104368e-7,0.000014372496,0.0009745929],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9982582,0.000115446834,0.0011228061,0.00019450152,0.000042635234,0.00026644723],"domain_scores_gemma":[0.99719954,0.0005017612,0.0018492029,0.00016184156,0.00017738076,0.000110257424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014150223,0.00018621351,0.0011860566,0.00057952735,0.000085147854,0.000046426074,0.0002866907,0.00008527406,0.00018276079],"category_scores_gemma":[0.00016177405,0.00016689215,0.00011262838,0.00036109454,0.00015830054,0.0003325483,0.000084033585,0.00026028848,0.0000048923293],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008232335,0.0009816835,0.39614075,0.0002919095,0.000543509,0.000032761953,0.58641523,0.00010912478,0.000044688455,0.00035844275,0.00022549125,0.014033201],"study_design_scores_gemma":[0.002191288,0.006412701,0.3819996,0.00053042884,0.00032586727,0.000052863063,0.60558945,0.00015798227,0.00037508956,0.0014258164,0.00049752643,0.00044138802],"about_ca_topic_score_codex":0.00044164757,"about_ca_topic_score_gemma":0.00065924856,"teacher_disagreement_score":0.019174222,"about_ca_system_score_codex":0.00023153926,"about_ca_system_score_gemma":0.0004100364,"threshold_uncertainty_score":0.68056643},"labels":[],"label_agreement":null},{"id":"W4415520243","doi":"10.1016/j.jtho.2025.09.1205","title":"EP.01.21 Mapping Persistent and Irreversible Arsenic Effects on Lung Epithelium Using Integrated Transcriptome and Methylome Analysis","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Arsenic contamination and mitigation","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Arsenic; Transcriptome; Epigenetics; DNA methylation; Methylation; Biotransformation; Lung cancer; Lung","score_opus":0.014018389795169223,"score_gpt":0.3375435488054643,"score_spread":0.32352515901029505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98624176,0.00044068226,0.009856651,0.0018055597,0.0002708749,0.00012361474,0.0000016558104,0.000007000396,0.0012522315],"genre_scores_gemma":[0.9948874,0.000107629145,0.0036769756,0.00046376706,0.000020326539,0.0000013972584,0.0000013468956,0.000004596279,0.0008365734],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99886817,0.00030715982,0.00033870785,0.00017471147,0.00015998138,0.00015130117],"domain_scores_gemma":[0.99930394,0.00023802684,0.00025053148,0.00008347505,0.000029137414,0.00009491948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000800879,0.000113366936,0.00035858923,0.00042756446,0.00012189173,0.000023093215,0.00009125228,0.000103519735,0.00013689573],"category_scores_gemma":[0.000084303305,0.00009531631,0.00016085348,0.00064577983,0.000109551474,0.00016975861,0.00004739485,0.00023837978,0.0000027317321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050643465,0.00023911142,0.033916645,0.00015812357,0.0016414508,0.00013777985,0.0051507317,0.0020134966,0.37970555,0.00012227008,0.0006673487,0.57574105],"study_design_scores_gemma":[0.0048299176,0.0029430708,0.7040131,0.0009711903,0.014165868,0.00071324053,0.017917644,0.1671274,0.032218073,0.00141591,0.052614387,0.0010702084],"about_ca_topic_score_codex":0.00003571493,"about_ca_topic_score_gemma":0.000050202187,"teacher_disagreement_score":0.67009646,"about_ca_system_score_codex":0.00053436734,"about_ca_system_score_gemma":0.00004990893,"threshold_uncertainty_score":0.38868865},"labels":[],"label_agreement":null},{"id":"W4415520288","doi":"10.1016/j.jtho.2025.09.1118","title":"PT1.03.06 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Acquired resistance; Osimertinib; Tyrosine-kinase inhibitor; Tyrosine kinase; Kinase","score_opus":0.016036992200530342,"score_gpt":0.40690262097484164,"score_spread":0.3908656287743113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86622995,0.0020616737,0.06498224,0.056498203,0.0014284456,0.0009405448,0.00028949467,0.00006127927,0.007508156],"genre_scores_gemma":[0.96755266,0.00011160933,0.02433314,0.0019800093,0.00013439314,0.000015220071,0.00011135363,0.000019137167,0.0057425],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977711,0.00016256282,0.001172814,0.00027800532,0.00034507117,0.0002704667],"domain_scores_gemma":[0.9976197,0.00026801368,0.00086785114,0.00039848132,0.000626556,0.0002194208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042740945,0.00020744062,0.0012807901,0.0007554634,0.00009577432,0.000015859952,0.00024568956,0.00020152067,0.00044241213],"category_scores_gemma":[0.00025095633,0.00016251109,0.00038424323,0.0013934774,0.000063940664,0.0000959827,0.00007704179,0.00016574681,0.00001985977],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18154654,0.013501353,0.0677263,0.0013591362,0.12767752,0.0062160953,0.013562548,0.012282688,0.16716811,0.004717683,0.20805681,0.19618522],"study_design_scores_gemma":[0.026382726,0.011586629,0.25400087,0.0025851193,0.11353005,0.00019106673,0.0035171479,0.0028213968,0.17541666,0.016044173,0.39281604,0.0011081106],"about_ca_topic_score_codex":0.00015714661,"about_ca_topic_score_gemma":0.00080459646,"teacher_disagreement_score":0.1950771,"about_ca_system_score_codex":0.00076008606,"about_ca_system_score_gemma":0.00096229557,"threshold_uncertainty_score":0.662701},"labels":[],"label_agreement":null},{"id":"W4415520301","doi":"10.1016/j.jtho.2025.09.060","title":"OA09.03 Real-World Assessment of TROP2-NMR by Quantitative Continuous Scoring (QCS) in Non-Small Cell Lung Carcinoma (NSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Advanced NMR Techniques and Applications","field":"Chemistry","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Immunohistochemistry; Biomarker; Cell; Lung; Lung cancer; Carcinoma","score_opus":0.019840236797512942,"score_gpt":0.4216739074429083,"score_spread":0.4018336706453953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8574255,0.00041526658,0.021936372,0.0005537614,0.00006567314,0.00019560504,0.000024527071,0.000018553292,0.11936471],"genre_scores_gemma":[0.93761426,0.00022414098,0.06047094,0.00009304475,0.000062724546,0.000037534894,0.000007706409,0.000016727146,0.0014729508],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982698,0.00010001477,0.00095571054,0.00022207505,0.00018159555,0.00027079476],"domain_scores_gemma":[0.9979347,0.00045501054,0.0010301071,0.00027543594,0.00023413474,0.000070597736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005707894,0.00017855098,0.00068434724,0.00030054248,0.000054944037,0.000014652428,0.00044242686,0.00016608932,0.00006116086],"category_scores_gemma":[0.000041918272,0.00016998334,0.00016103598,0.00038764786,0.000075294665,0.00010370918,0.00007660938,0.0006863463,0.0000011330419],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080954627,0.0031519106,0.14426027,0.0013593646,0.00018248198,0.0004325555,0.001327872,0.00075251807,0.78591037,0.009529311,0.012459859,0.03982391],"study_design_scores_gemma":[0.0065590325,0.0033274756,0.07091912,0.0032809216,0.0012916743,0.00022749155,0.01559943,0.008988242,0.80202925,0.0126188,0.07367837,0.0014802059],"about_ca_topic_score_codex":0.00011642187,"about_ca_topic_score_gemma":0.00010397326,"teacher_disagreement_score":0.11789176,"about_ca_system_score_codex":0.00055562134,"about_ca_system_score_gemma":0.00037494415,"threshold_uncertainty_score":0.693172},"labels":[],"label_agreement":null},{"id":"W4415520343","doi":"10.1016/j.jtho.2025.09.1208","title":"EP.01.24 Determinants Influencing Smoking Cessation Implementation in an Oncology Setting: Canadian Healthcare Provider Perspectives","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Partnership Against Cancer; Cancer Care Ontario; Centre for Addiction and Mental Health","funders":"","keywords":"Smoking cessation; Health care; MEDLINE; Healthcare system","score_opus":0.040477379282662235,"score_gpt":0.42061812987970076,"score_spread":0.38014075059703856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98085743,0.0024882376,0.00018122974,0.010297799,0.0013619256,0.00023483965,0.000034048746,0.000007227649,0.004537238],"genre_scores_gemma":[0.9967872,0.00024024217,0.0009342695,0.001663931,0.00025644188,0.000013094168,0.000004289074,0.000015212278,0.000085309766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781173,0.00012574586,0.0013208376,0.00027255813,0.00003564154,0.00043346186],"domain_scores_gemma":[0.99802506,0.00009907368,0.0013477384,0.0001521216,0.00018052485,0.00019546672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018216112,0.00014690118,0.00064440205,0.0011825571,0.00014229803,0.00006402139,0.00025443084,0.00028934883,0.00012720285],"category_scores_gemma":[0.00026240732,0.00017005211,0.000109396664,0.00028792938,0.000060563583,0.00094813196,0.000032964515,0.00048422694,0.000008315469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019374004,0.00009689442,0.66160214,0.000066733344,0.00005727633,0.00007493155,0.009842239,0.00025330752,0.00002866482,0.007758128,0.0007207934,0.31930515],"study_design_scores_gemma":[0.0016004527,0.0016138573,0.852529,0.00016717642,0.000045954614,0.000089573354,0.025929937,0.00071978814,0.0002113445,0.03185418,0.08486753,0.00037120536],"about_ca_topic_score_codex":0.029898025,"about_ca_topic_score_gemma":0.3016981,"teacher_disagreement_score":0.31893396,"about_ca_system_score_codex":0.005244209,"about_ca_system_score_gemma":0.0022055097,"threshold_uncertainty_score":0.9985745},"labels":[],"label_agreement":null},{"id":"W4415520360","doi":"10.1016/j.jtho.2025.09.135","title":"MA05.06 Integrating Circulating Protein Biomarkers in Nodule Malignancy Prediction Model Based on Five International Lung Cancer Screening Cohorts","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Malignancy; Lung cancer screening; Lung cancer; Nodule (geology); Cancer; Lung; Biomarker","score_opus":0.011904925806043175,"score_gpt":0.3964103218691319,"score_spread":0.3845053960630887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.769272,0.00033128005,0.20598876,0.017304506,0.0009152264,0.0004426519,0.000007440725,0.000027084294,0.005711026],"genre_scores_gemma":[0.948642,0.000022397136,0.049326893,0.00131635,0.00027157803,0.000026477222,0.000012569473,0.000018612553,0.00036309907],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99817574,0.00018964766,0.0007938664,0.000223874,0.00037889992,0.00023797748],"domain_scores_gemma":[0.99877524,0.0001863968,0.0005604375,0.00012269306,0.0002483679,0.00010687935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015870656,0.0001530193,0.00047204737,0.0007302133,0.00007981742,0.00002770832,0.0001630117,0.0001600544,0.000049725462],"category_scores_gemma":[0.0012027622,0.000129083,0.00014234848,0.00030948393,0.00006525614,0.0001303675,0.00004326507,0.0010576915,4.816877e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019721582,0.0004533079,0.27982315,0.0003446624,0.0005862208,0.00084774353,0.0005645317,0.25362137,0.022627262,0.00018233267,0.0027371403,0.43624014],"study_design_scores_gemma":[0.0014114047,0.00020570647,0.017426835,0.004835374,0.00014891585,0.00010532955,0.00022181546,0.97454214,0.00039906192,0.00014670382,0.0004722306,0.00008447345],"about_ca_topic_score_codex":0.00008766372,"about_ca_topic_score_gemma":0.000015083522,"teacher_disagreement_score":0.7209208,"about_ca_system_score_codex":0.000848361,"about_ca_system_score_gemma":0.00067502214,"threshold_uncertainty_score":0.5263852},"labels":[],"label_agreement":null},{"id":"W4415520390","doi":"10.1016/j.jtho.2025.09.223","title":"P1.04.33 Sybil Pilot for Incidental Pulmonary Nodules","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"MEDLINE; Lung; Neoplasm staging; Respiratory disease; Coronavirus disease 2019 (COVID-19)","score_opus":0.02772517064012228,"score_gpt":0.43801997786254365,"score_spread":0.4102948072224214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9601479,0.0040739696,0.00052825955,0.021741949,0.0025011126,0.0005873965,0.000022640283,0.000020395575,0.010376374],"genre_scores_gemma":[0.9912104,0.00049390615,0.0040290616,0.0016796087,0.0006291874,0.00004214781,0.000007704866,0.000014294903,0.001893662],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888444,0.000066319655,0.000511674,0.00015569766,0.00017364923,0.00020819865],"domain_scores_gemma":[0.99881214,0.00033763296,0.00032693485,0.00016344895,0.00023435372,0.00012548715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042965147,0.00013004836,0.00056593877,0.00022964196,0.000072135546,0.000012504251,0.00012289942,0.00010369172,0.000082797014],"category_scores_gemma":[0.00013168281,0.00009419032,0.000235415,0.00014063068,0.00006494574,0.00008326238,0.000046792902,0.00021972883,0.000010422006],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015209835,0.008303403,0.09675561,0.0008861415,0.0017187156,0.002560769,0.00022528178,0.000036521033,0.004763581,0.0010646948,0.09576247,0.772713],"study_design_scores_gemma":[0.009755726,0.035505123,0.35422945,0.002508408,0.005418659,0.0075615756,0.0010565169,0.000273619,0.021985484,0.0071910354,0.554102,0.0004123977],"about_ca_topic_score_codex":0.000021934897,"about_ca_topic_score_gemma":0.000040880135,"teacher_disagreement_score":0.7723006,"about_ca_system_score_codex":0.0011963353,"about_ca_system_score_gemma":0.00051443925,"threshold_uncertainty_score":0.38409698},"labels":[],"label_agreement":null},{"id":"W4415520426","doi":"10.1016/j.jtho.2025.09.015","title":"PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Osimertinib; Overall survival; Chemotherapy; Progression-free survival; Survival rate","score_opus":0.033442603702206385,"score_gpt":0.4544711842950624,"score_spread":0.421028580592856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9342776,0.004225814,0.0012482689,0.042726796,0.0029047607,0.0007013897,0.000012156834,0.000039218725,0.013864014],"genre_scores_gemma":[0.9832964,0.0023954066,0.0051669343,0.002889113,0.0005628765,0.00003975516,0.000021790049,0.00004558887,0.0055821515],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979452,0.00013948181,0.00095750997,0.00027232172,0.00029756827,0.00038793526],"domain_scores_gemma":[0.99827987,0.00044134047,0.00056187925,0.0002727813,0.00028088174,0.00016323211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004655164,0.00026712962,0.0009019919,0.0004312029,0.00009488698,0.000019665316,0.00020439002,0.00022936917,0.00027668377],"category_scores_gemma":[0.00016004166,0.00021384985,0.00028076392,0.000421568,0.00008881345,0.00017977107,0.000027576109,0.00054223504,0.000014768479],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086054765,0.0035891572,0.017380876,0.00016890599,0.0021313925,0.00077595323,0.0020846666,0.0014790619,0.005437076,0.0003039041,0.008335848,0.87225837],"study_design_scores_gemma":[0.09086288,0.013874043,0.1223162,0.0013541674,0.0016897827,0.0003025165,0.0010396258,0.00093817763,0.008895185,0.0016600873,0.75644654,0.000620792],"about_ca_topic_score_codex":0.000053230946,"about_ca_topic_score_gemma":0.00015511135,"teacher_disagreement_score":0.8716376,"about_ca_system_score_codex":0.0009727272,"about_ca_system_score_gemma":0.001123316,"threshold_uncertainty_score":0.8720544},"labels":[],"label_agreement":null},{"id":"W4415520472","doi":"10.1016/j.jtho.2025.09.355","title":"P1.11.55 Identifying Patients Cured From Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Anti-PD-(L)1 Therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Lung cancer; Cancer; Respiratory disease; Chemotherapy; Cell","score_opus":0.022508638690742617,"score_gpt":0.4370143230663238,"score_spread":0.4145056843755812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675823,0.0055438904,0.0018580488,0.0022501347,0.0012752429,0.0005477422,0.000037045542,0.0000137980305,0.0017158587],"genre_scores_gemma":[0.9876168,0.0010655968,0.008728981,0.0010196602,0.00020125485,0.000036069654,0.000028273966,0.000028113822,0.0012752905],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857277,0.00012074419,0.00056472054,0.00021382424,0.00026623477,0.00026168575],"domain_scores_gemma":[0.9984017,0.00015635288,0.00064324745,0.00019952476,0.00045214704,0.00014705064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016162016,0.00020394292,0.0007003745,0.00029184335,0.000114950424,0.000034428747,0.00015509035,0.00009495204,0.00021062848],"category_scores_gemma":[0.000024649578,0.00013479716,0.00016540963,0.00030839175,0.000047837053,0.00015885851,0.000029066907,0.00031497626,0.00000592923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041645532,0.0040868795,0.7950952,0.00054229045,0.005902944,0.0010802853,0.0076010185,0.0003482952,0.007597581,0.000023196255,0.01744446,0.15611328],"study_design_scores_gemma":[0.029379098,0.0033791363,0.8618703,0.0029477212,0.014943526,0.00014068867,0.0039907577,0.0005845647,0.022639344,0.00048285743,0.05904566,0.000596376],"about_ca_topic_score_codex":0.000351783,"about_ca_topic_score_gemma":0.00018964957,"teacher_disagreement_score":0.15551691,"about_ca_system_score_codex":0.0006183385,"about_ca_system_score_gemma":0.0014419138,"threshold_uncertainty_score":0.54968685},"labels":[],"label_agreement":null},{"id":"W4415520519","doi":"10.1016/j.jtho.2025.09.1659","title":"EP.14.15 Patterns of Failure and Long-Term Outcomes in Patients With Thymoma Treated With Surgery and Radiation Therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Toronto General Hospital; Ted Rogers Centre for Heart Research; Princess Margaret Cancer Centre","funders":"","keywords":"Thymoma; Radiation therapy; Thymus Neoplasm; Thymectomy; MEDLINE","score_opus":0.013144159763879662,"score_gpt":0.33726309071799315,"score_spread":0.3241189309541135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99753195,0.00054756214,0.000040595747,0.0015480197,0.00005993638,0.00022725217,0.0000054792918,0.0000037384777,0.00003546903],"genre_scores_gemma":[0.9992213,0.00025893652,0.00015804353,0.00019862183,0.000025115041,0.0000029125092,0.000007427927,0.0000104694545,0.00011713986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999027,0.00012474917,0.000427049,0.000118558346,0.00016862221,0.00013403676],"domain_scores_gemma":[0.99899554,0.00021992132,0.00041959743,0.00010619392,0.00018329383,0.00007544043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028098538,0.00013044836,0.0007244354,0.00039184495,0.000022438955,0.0000096945205,0.000041269253,0.0001087665,0.000023568344],"category_scores_gemma":[0.000036987898,0.00007385696,0.000047815978,0.0001562365,0.00006200105,0.00009581697,0.000013197389,0.00019515214,1.6175868e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004279067,0.00040983368,0.8959542,0.00008505627,0.00022352728,0.00017800821,0.00015726406,5.349863e-7,0.00004696625,0.0000057867205,0.000050773273,0.098609],"study_design_scores_gemma":[0.0038457243,0.0029958307,0.9918614,0.00038912205,0.00014146364,0.00014833738,0.0000708803,0.0000025307233,0.00032182064,0.000016567361,0.00014107644,0.00006527223],"about_ca_topic_score_codex":0.000019273708,"about_ca_topic_score_gemma":0.0001115082,"teacher_disagreement_score":0.098543726,"about_ca_system_score_codex":0.00006128904,"about_ca_system_score_gemma":0.00015501089,"threshold_uncertainty_score":0.30117995},"labels":[],"label_agreement":null},{"id":"W4415520521","doi":"10.1016/j.jtho.2025.09.700","title":"P2.10.06 Docetaxel in NSCLC: A Multi-Centre Real World Evidence Analysis in the Immunotherapy Era","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Docetaxel; Immunotherapy; Lung cancer; Real world evidence; Standard of care; Second line; Chemotherapy; Nivolumab","score_opus":0.057748108346006,"score_gpt":0.5180295112931637,"score_spread":0.46028140294715764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86633927,0.019432997,0.00027483588,0.10672128,0.0003041998,0.00074320444,0.000003744754,0.000013412654,0.006167084],"genre_scores_gemma":[0.98333937,0.0061765793,0.0019912026,0.0015557891,0.00017016944,0.000021352958,0.0000013655894,0.0000097237435,0.006734428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710906,0.00094760564,0.0008447214,0.00020942045,0.00049369765,0.00039550808],"domain_scores_gemma":[0.9974943,0.0013680314,0.00037557987,0.00034589978,0.00034483479,0.00007138437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034620776,0.00016022156,0.000956823,0.0017127134,0.000062823194,0.000028144092,0.0004506526,0.00010124535,0.00020976426],"category_scores_gemma":[0.0009991986,0.00009818886,0.00031065027,0.0031296967,0.00016780068,0.0001590634,0.000087051674,0.0011217288,0.0000122104375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0114731975,0.0022466676,0.7811423,0.00026543566,0.003390215,0.0028623682,0.0072041634,0.00029503103,0.002435186,0.00008527613,0.020937378,0.1676628],"study_design_scores_gemma":[0.003519474,0.00070157147,0.96157366,0.0012251879,0.00094335165,0.00006803559,0.0024980102,0.00055271725,0.00017791284,0.00016184915,0.028455349,0.0001228652],"about_ca_topic_score_codex":0.000615823,"about_ca_topic_score_gemma":0.010486451,"teacher_disagreement_score":0.1804314,"about_ca_system_score_codex":0.0014390128,"about_ca_system_score_gemma":0.0011728343,"threshold_uncertainty_score":0.5851686},"labels":[],"label_agreement":null},{"id":"W4415520534","doi":"10.1016/j.jtho.2025.09.261","title":"P1.07.18 Peri-Operative Immune Cell Profiling in Lung Cancer Resection: A Longitudinal Study","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Lung cancer; Immune system; Profiling (computer programming); Longitudinal study; Respiratory disease","score_opus":0.039609317922157015,"score_gpt":0.47541152227669464,"score_spread":0.43580220435453765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771832,0.012890506,0.00012412839,0.0032408354,0.0016433015,0.0006200422,0.0000020971042,0.000008905845,0.0042869393],"genre_scores_gemma":[0.99484867,0.00068838015,0.00074682094,0.00029672746,0.00034706198,0.000042990105,0.0000010190397,0.000012503367,0.0030158393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981653,0.00032243622,0.0008396675,0.00019948295,0.00023209071,0.00024100984],"domain_scores_gemma":[0.9989467,0.00012087158,0.00039104902,0.00017061816,0.00030977806,0.000060937404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013571567,0.00015509731,0.00066163647,0.0004586703,0.00010093969,0.000022316255,0.0001477611,0.00014591352,0.00060218683],"category_scores_gemma":[0.000070936374,0.00011920636,0.00017683089,0.0005781569,0.00008717464,0.00013209782,0.00004999609,0.00073113764,0.000002288811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.091454305,0.0046117897,0.72907066,0.00065952743,0.0017093082,0.0021707048,0.0057737753,0.00017601899,0.09176736,0.000014349246,0.0043953247,0.06819688],"study_design_scores_gemma":[0.017136797,0.014868095,0.87431717,0.0019715305,0.0012839205,0.0009875231,0.019544592,0.0005220686,0.055779602,0.000055447264,0.013148295,0.00038497397],"about_ca_topic_score_codex":0.0002614938,"about_ca_topic_score_gemma":0.00045629952,"teacher_disagreement_score":0.1452465,"about_ca_system_score_codex":0.0013677938,"about_ca_system_score_gemma":0.0014438519,"threshold_uncertainty_score":0.65935236},"labels":[],"label_agreement":null},{"id":"W4415520630","doi":"10.1016/j.jtho.2025.09.092","title":"OA18.01 Improving Lung Cancer Outcomes Through Policy a Global Perspective on Risk Reduction, Early Detection, Care and Survivorship","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Survivorship curve; Lung cancer; Perspective (graphical); Limiting; Cancer survivorship; Cancer; Treatment of lung cancer","score_opus":0.01446618360121207,"score_gpt":0.44637190470259963,"score_spread":0.4319057211013876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686973,0.008244679,0.00019476177,0.016512666,0.0016320848,0.0003414846,0.000024641757,0.000022013983,0.0043303617],"genre_scores_gemma":[0.9961747,0.001699021,0.00060355465,0.00054218475,0.0007169144,0.000030383826,6.156414e-7,0.000012235136,0.00022037044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987052,0.00020399451,0.0003941502,0.0002523338,0.00021007312,0.00023425969],"domain_scores_gemma":[0.9984812,0.00014472983,0.00046250352,0.00017096312,0.00062062015,0.00011999458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002463547,0.00018414625,0.00057223975,0.00019892861,0.00017702155,0.00002896747,0.000075692216,0.0001704379,0.000019377936],"category_scores_gemma":[0.0003220301,0.00013367219,0.00019132136,0.0003840432,0.00009601339,0.00013263737,0.00003722069,0.00040309504,0.0000013470183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028991431,0.0004506071,0.7719646,0.000254958,0.0016930336,0.000120206016,0.0058167167,0.0000462899,0.00009819868,0.0010986279,0.00091865234,0.21463898],"study_design_scores_gemma":[0.002949124,0.0043315277,0.9720966,0.0005448771,0.0026516074,0.00041211193,0.00968269,0.000015770454,0.0021617543,0.0024090928,0.002570565,0.00017424693],"about_ca_topic_score_codex":0.01722708,"about_ca_topic_score_gemma":0.0035487728,"teacher_disagreement_score":0.21446474,"about_ca_system_score_codex":0.009006427,"about_ca_system_score_gemma":0.0012548912,"threshold_uncertainty_score":0.9947978},"labels":[],"label_agreement":null},{"id":"W4415520663","doi":"10.1016/j.jtho.2025.09.924","title":"P3.12.62 First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; Cohort; Chemotherapy; Cohort study; MEDLINE","score_opus":0.01191241342935816,"score_gpt":0.4269445142671295,"score_spread":0.4150321008377713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.815547,0.0039067646,0.029646521,0.0756457,0.0062306197,0.005256948,0.00015787904,0.00015413787,0.06345442],"genre_scores_gemma":[0.9691461,0.0005916236,0.018109286,0.004053972,0.00061336055,0.00012533253,0.000119196746,0.000058267073,0.00718287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980417,0.000057615744,0.00096998113,0.0002733773,0.00027433582,0.0003830037],"domain_scores_gemma":[0.99782985,0.0003413271,0.00075703766,0.00026895275,0.00059790234,0.00020493237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048364073,0.00026729165,0.0009769456,0.00036286472,0.00018556682,0.000023596747,0.0001773825,0.00025274965,0.00016958486],"category_scores_gemma":[0.00023890274,0.00020655761,0.00028346968,0.00042420675,0.000095841904,0.0001573307,0.000022455119,0.00037774706,0.000007572486],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023909463,0.002220759,0.025042007,0.000492068,0.0047347755,0.000405187,0.0014089273,0.00038085965,0.008894159,0.0001132183,0.028587807,0.9038108],"study_design_scores_gemma":[0.039387304,0.014750937,0.11073937,0.0018734284,0.007105077,0.0010361341,0.0015897236,0.0024957592,0.017082093,0.0013391653,0.8019657,0.0006353074],"about_ca_topic_score_codex":0.00002010919,"about_ca_topic_score_gemma":0.00010344721,"teacher_disagreement_score":0.9031755,"about_ca_system_score_codex":0.0009914336,"about_ca_system_score_gemma":0.0013035217,"threshold_uncertainty_score":0.8423175},"labels":[],"label_agreement":null},{"id":"W4415520740","doi":"10.1016/j.jtho.2025.09.093","title":"OA18.02 Emerging Disparities in Lung Cancer Burden in the Americas: A GLOBOCAN-Based Projection to 2050","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Juravinski Cancer Centre","funders":"","keywords":"Lung cancer; Projection (relational algebra); MEDLINE; Cancer","score_opus":0.02002968837523213,"score_gpt":0.46115214015315986,"score_spread":0.44112245177792775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83864915,0.0030603535,0.00016378026,0.15492466,0.00073273096,0.0005918017,0.000003363679,0.000006878102,0.0018672937],"genre_scores_gemma":[0.9938688,0.00054211204,0.00063879706,0.004285992,0.00027581333,0.00017041915,0.0000017007065,0.0000074834606,0.00020885872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987682,0.00022645394,0.00044722127,0.0001378655,0.00020193287,0.0002183183],"domain_scores_gemma":[0.99927604,0.00023035677,0.00020022028,0.00013146386,0.000108244654,0.000053681084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006439734,0.00011077231,0.0004427642,0.00044344144,0.000038741004,0.0000169954,0.000119714045,0.000073378586,0.000041250227],"category_scores_gemma":[0.000118776596,0.00007041669,0.00009519911,0.00067180506,0.00003783538,0.000056669436,0.000020430925,0.00033138058,0.0000013378573],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003567296,0.0013189603,0.6451714,0.00053730095,0.00032246075,0.0010933215,0.0038579616,0.004522067,0.00028268446,0.00008819688,0.028447283,0.31079108],"study_design_scores_gemma":[0.0046229726,0.0035999287,0.8691863,0.004536813,0.0011010034,0.00022256174,0.0054540783,0.0032717267,0.00090793683,0.0002060033,0.10664747,0.00024324114],"about_ca_topic_score_codex":0.0039489833,"about_ca_topic_score_gemma":0.003938277,"teacher_disagreement_score":0.31054783,"about_ca_system_score_codex":0.0023150246,"about_ca_system_score_gemma":0.0007688951,"threshold_uncertainty_score":0.6053709},"labels":[],"label_agreement":null},{"id":"W4415520743","doi":"10.1016/j.jtho.2025.09.226","title":"P1.04.36 LungFlagTM Risk Prediction Validation on Canadian Ever Smokers Pre-Classified as High Risk for Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Identification (biology); Risk assessment; Population; Cancer; MEDLINE","score_opus":0.01826823492911851,"score_gpt":0.41088959826601695,"score_spread":0.39262136333689845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415520743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98101556,0.0012882543,0.00087352603,0.007866596,0.0029629236,0.0013976514,0.0004655825,0.000028138975,0.004101794],"genre_scores_gemma":[0.99022126,0.0010246483,0.0008000213,0.0005822438,0.0011462985,0.00012866082,0.000070706104,0.00004159917,0.0059845853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99720144,0.0005321774,0.0007666756,0.0003793049,0.0005493323,0.00057108287],"domain_scores_gemma":[0.9969356,0.00055608636,0.000744013,0.00034413987,0.0008035802,0.0006165578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001331184,0.00024330648,0.000625255,0.00097342336,0.0003120633,0.000034655688,0.00024489066,0.00039412858,0.00067635276],"category_scores_gemma":[0.0011220855,0.00021318546,0.00029969896,0.00046154816,0.00015275224,0.00022242172,0.000043124375,0.0011031242,0.000010545482],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030595131,0.00090865913,0.33449548,0.0011215472,0.0032085795,0.0004981983,0.0006735052,0.0054495987,0.0010425999,0.00048549377,0.12094026,0.50058097],"study_design_scores_gemma":[0.0042532017,0.0020662346,0.91262025,0.00065809913,0.0033271736,0.00013922423,0.00043320458,0.012375607,0.0022442478,0.0018732854,0.059779435,0.00023004094],"about_ca_topic_score_codex":0.029636707,"about_ca_topic_score_gemma":0.011892879,"teacher_disagreement_score":0.57812476,"about_ca_system_score_codex":0.0074970536,"about_ca_system_score_gemma":0.007243076,"threshold_uncertainty_score":0.99838495},"labels":[],"label_agreement":null},{"id":"W4415768344","doi":"10.1016/j.jtho.2025.10.006","title":"Corrigendum to “The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423–1440]”","year":2025,"lang":"en","type":"erratum","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lung cancer; Overall survival; Lung cancer staging; Ninth; Association (psychology); Neoplasm staging; Staging system","score_opus":0.062171978940883284,"score_gpt":0.5373235145508077,"score_spread":0.47515153560992446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415768344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8415262,0.003855564,0.0031498477,0.030364448,0.098992504,0.010118639,0.004565501,0.000012633995,0.0074146274],"genre_scores_gemma":[0.99103904,0.0004788264,0.0002293271,0.0004244483,0.0028791123,0.00016114813,0.00024826603,0.00004358702,0.004496271],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9950096,0.0013943884,0.002009246,0.00023140294,0.0010569972,0.0002983902],"domain_scores_gemma":[0.98997474,0.0014455607,0.004935709,0.0004114896,0.003173004,0.000059524726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033589648,0.0003036337,0.0013084149,0.0009747197,0.00014739018,0.000033991266,0.0007595919,0.0002561038,0.00008667301],"category_scores_gemma":[0.0020216245,0.00015305358,0.00053146126,0.0007518531,0.00010257694,0.00018970123,0.00016179317,0.0015626258,2.6958628e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016522564,0.009074511,0.06575578,0.0006157588,0.014776902,0.00018913054,0.018007204,0.046106406,0.002937343,0.00006731145,0.80160826,0.0243388],"study_design_scores_gemma":[0.038042597,0.0658179,0.52936244,0.027311748,0.049098544,0.0004047383,0.067633554,0.05015266,0.009041101,0.00077448145,0.16051972,0.0018404986],"about_ca_topic_score_codex":0.0034464072,"about_ca_topic_score_gemma":0.006796782,"teacher_disagreement_score":0.64108855,"about_ca_system_score_codex":0.0043204604,"about_ca_system_score_gemma":0.0072688274,"threshold_uncertainty_score":0.99950176},"labels":[],"label_agreement":null},{"id":"W4416293381","doi":"10.1016/j.jtho.2025.11.006","title":"Radiotherapy for Unresectable Locally Advanced NSCLC: A Practical Multidisciplinary Approach to Challenging Scenarios From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"EMD Serono; Genentech; Novocure; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Varian Medical Systems; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Multidisciplinary approach; Radiation therapy; Lung cancer; Radiation oncology; MEDLINE","score_opus":0.022180875779264555,"score_gpt":0.44923389785405643,"score_spread":0.4270530220747919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416293381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5374653,0.017478297,0.07583203,0.35923043,0.0026725456,0.0070206285,0.000055955545,0.000026197578,0.00021862386],"genre_scores_gemma":[0.9798484,0.0015729512,0.015569138,0.0009268575,0.00044226274,0.0013805715,0.000008732784,0.000020257405,0.00023085969],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986219,0.000110167995,0.00056011876,0.00021453472,0.00028408924,0.00020919902],"domain_scores_gemma":[0.99563795,0.002721042,0.0007323819,0.00022148046,0.0006419989,0.000045161556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009546304,0.00013504377,0.0005077703,0.00019450505,0.00017536011,0.000017175593,0.00026465877,0.0001482945,0.000009923771],"category_scores_gemma":[0.0008027439,0.00007950757,0.00015418603,0.00028435435,0.000029078632,0.0001107327,0.000058036643,0.00030323348,1.4069366e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036334842,0.009728465,0.17284448,0.00022174389,0.010342538,0.000017668655,0.007040679,0.036946584,0.003378918,0.000607691,0.0256288,0.6969076],"study_design_scores_gemma":[0.09079094,0.033231992,0.33807397,0.0029696405,0.012519097,0.00012878426,0.05143031,0.21360713,0.009953147,0.0020076574,0.24444959,0.00083774456],"about_ca_topic_score_codex":0.00004737335,"about_ca_topic_score_gemma":0.00017568463,"teacher_disagreement_score":0.69606984,"about_ca_system_score_codex":0.0025781544,"about_ca_system_score_gemma":0.00064170914,"threshold_uncertainty_score":0.6741784},"labels":[],"label_agreement":null},{"id":"W4416808481","doi":"10.1016/j.jtho.2025.11.018","title":"Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Health Services","funders":"National Cancer Institute; National Institutes of Health; Eli Lilly and Company","keywords":"Pembrolizumab; KRAS; Immunotherapy; Adverse effect; PD-L1","score_opus":0.009457525746142717,"score_gpt":0.35428404019241183,"score_spread":0.3448265144462691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416808481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974279,0.0007497353,0.00005002959,0.00084882404,0.00007725182,0.00044586087,0.0000041025687,0.0000017783085,0.00039451715],"genre_scores_gemma":[0.99861795,0.0005455875,0.0007302058,0.00004711073,0.0000070027145,0.000004491371,0.0000041161024,0.0000061731766,0.00003735714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989646,0.0001076162,0.000568827,0.00009826697,0.00015089731,0.000109796936],"domain_scores_gemma":[0.9990367,0.0001463083,0.00051531265,0.000097548305,0.00017189093,0.00003221924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022103144,0.00010358163,0.00061297714,0.00036718947,0.0000124515045,0.0000017366028,0.000045116412,0.000077069184,0.0000122519095],"category_scores_gemma":[0.000029644903,0.00006392817,0.00004160743,0.00034265826,0.00012260381,0.00006222773,0.000008164804,0.00011019033,6.109047e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3012947,0.0035292963,0.24425296,0.00012505837,0.00025821067,0.00007848817,0.0008493267,0.00004448281,0.0041640755,0.00002165287,0.0000058383816,0.4453759],"study_design_scores_gemma":[0.04704072,0.023596939,0.92144376,0.0009054685,0.00015924242,0.000053222324,0.00031628713,0.000015276108,0.005540214,0.000030494346,0.00084264093,0.000055712666],"about_ca_topic_score_codex":0.00004032988,"about_ca_topic_score_gemma":0.00019018736,"teacher_disagreement_score":0.67719084,"about_ca_system_score_codex":0.0005299524,"about_ca_system_score_gemma":0.00042960417,"threshold_uncertainty_score":0.26069152},"labels":[],"label_agreement":null},{"id":"W4416938018","doi":"10.1016/j.jtho.2025.08.019","title":"Lung Cancer in the Philippines","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"","score_opus":0.019340485766420723,"score_gpt":0.4725469026357729,"score_spread":0.4532064168693522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416938018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79138416,0.013802765,0.000036606263,0.1806042,0.0012771846,0.00026408586,0.0000023801317,0.000004396418,0.012624202],"genre_scores_gemma":[0.99303573,0.0019278239,0.0002047316,0.0038677834,0.0003359446,0.000024963581,3.9285825e-7,0.000003613357,0.00059901114],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9992976,0.00010018325,0.0002948217,0.00006839091,0.00012558338,0.00011341915],"domain_scores_gemma":[0.9994075,0.00019148513,0.0001530166,0.000111079,0.00010585859,0.000031072886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004479831,0.0000646258,0.00030135384,0.00015261027,0.000028719749,0.000007059155,0.0001040156,0.00006148218,0.00016921143],"category_scores_gemma":[0.000058338515,0.00003381173,0.00009810741,0.0002311211,0.000033404693,0.000036744685,0.000015254613,0.00022933818,0.00000152905],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013449155,0.0013301721,0.45641944,0.00028789084,0.0005743079,0.0011490727,0.0011586989,0.00008490215,0.000284614,0.00051460945,0.07474385,0.4621075],"study_design_scores_gemma":[0.002670663,0.0013190579,0.69758916,0.0013649489,0.0015100884,0.0006138894,0.000786776,0.00013608247,0.0014188209,0.0008789377,0.29162556,0.00008603778],"about_ca_topic_score_codex":0.000039970302,"about_ca_topic_score_gemma":0.00025122808,"teacher_disagreement_score":0.46202147,"about_ca_system_score_codex":0.0006792917,"about_ca_system_score_gemma":0.00055866246,"threshold_uncertainty_score":0.18527465},"labels":[],"label_agreement":null},{"id":"W4416938027","doi":"10.1016/j.jtho.2025.06.009","title":"Managing Thymic Malignancies in 2025: Migrating from Masaoka to TNM","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Thymic carcinoma; Thymoma; Thymus Neoplasm; MEDLINE","score_opus":0.0202594955382733,"score_gpt":0.4044778867678985,"score_spread":0.3842183912296252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416938027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9593766,0.0014915869,0.0011225974,0.029067127,0.0007827204,0.0001635255,0.0000030886376,0.000010165855,0.00798264],"genre_scores_gemma":[0.98037773,0.00010910988,0.013280017,0.003496157,0.00031540194,0.000005042896,0.0000021370179,0.00001255352,0.002401869],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985551,0.00014148832,0.00069214706,0.00016361006,0.00018816246,0.00025948556],"domain_scores_gemma":[0.99906194,0.00022095731,0.00026800996,0.0001817864,0.00013905102,0.0001282361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007291412,0.00013120574,0.00063737336,0.00056434615,0.000042653453,0.000019439265,0.00018110183,0.00012749802,0.0001707261],"category_scores_gemma":[0.00025308385,0.000104508275,0.00013791237,0.00041417647,0.00003222162,0.00007249466,0.00008257268,0.0004421015,0.00003098769],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003997442,0.0006374364,0.13515507,0.00024230374,0.00037336402,0.0051042745,0.003358656,0.00016236781,0.08188652,0.0012538049,0.022746388,0.7450824],"study_design_scores_gemma":[0.0045199385,0.00416231,0.6115735,0.006604233,0.0009052902,0.0014105549,0.009646969,0.0010103296,0.024590049,0.027866565,0.30715865,0.0005515956],"about_ca_topic_score_codex":0.00011479845,"about_ca_topic_score_gemma":0.00024199074,"teacher_disagreement_score":0.7445308,"about_ca_system_score_codex":0.00029261824,"about_ca_system_score_gemma":0.00035238202,"threshold_uncertainty_score":0.42617238},"labels":[],"label_agreement":null},{"id":"W4417123826","doi":"10.1016/j.jtho.2025.12.002","title":"The Risk of Cardiovascular Adverse Outcomes in Patients With Thymoma or Thymic Carcinoma Receiving Cancer Therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Princess Margaret Cancer Centre; University Health Network; Toronto General Hospital; University of Toronto; Ted Rogers Centre for Heart Research","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Canadian Cancer Society","keywords":"Thymic carcinoma; Thymoma; Adverse effect; Radiation therapy; Cancer; Carcinoma","score_opus":0.013623869266441598,"score_gpt":0.3538197015409972,"score_spread":0.3401958322745556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417123826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99191326,0.0054303827,0.000041901334,0.0011906379,0.00055447576,0.00038113038,0.000007037676,0.000004667101,0.00047652377],"genre_scores_gemma":[0.99649054,0.0022500113,0.0004530287,0.00018354133,0.000077268196,0.000011650461,7.495191e-7,0.000016401022,0.0005167927],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807924,0.0004253482,0.0006956195,0.00015221574,0.0003982983,0.0002492669],"domain_scores_gemma":[0.99809813,0.00042222542,0.0006128802,0.0003747339,0.00041679628,0.00007525541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012410403,0.0001677895,0.0009883714,0.00025893087,0.00008782446,0.0000070310234,0.00023227633,0.0001279846,0.000045032753],"category_scores_gemma":[0.00025614272,0.000076099066,0.00039622202,0.00036432676,0.00012779699,0.00007321257,0.000041609794,0.00049950293,0.0000010855052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007758298,0.0003073973,0.8083786,0.000035289024,0.0015925223,0.00010765778,0.000311015,0.000091088215,0.000016653486,0.000011040352,0.00015475108,0.1812357],"study_design_scores_gemma":[0.0044752033,0.0022351185,0.9769914,0.0002622636,0.00068581663,0.000041558913,0.0004122568,0.000019381081,0.00024081198,0.00008009261,0.01447956,0.00007652867],"about_ca_topic_score_codex":0.00024908697,"about_ca_topic_score_gemma":0.00027804964,"teacher_disagreement_score":0.18115917,"about_ca_system_score_codex":0.00028396983,"about_ca_system_score_gemma":0.0007910823,"threshold_uncertainty_score":0.310323},"labels":[],"label_agreement":null},{"id":"W4417259921","doi":"10.1016/j.jtho.2025.12.004","title":"High-Penetrance Rare Variants Underlying Familial Lung Cancer Risk: Insights From Genetic Epidemiology of Lung Cancer Consortium","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre","funders":"National Institute of Environmental Health Sciences; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; Texas A and M University Health Science Center; World Health Organization","keywords":"Lung cancer; Genetic epidemiology; Genetic variants; Epidemiology; Glycosylation; Personalized medicine; Genetic testing; Genetic predisposition","score_opus":0.032396372872059334,"score_gpt":0.4625969334342655,"score_spread":0.4302005605622062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417259921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92747045,0.058532733,0.0061163614,0.0030245772,0.003722012,0.00043246362,0.00014737267,0.00001401056,0.0005400516],"genre_scores_gemma":[0.98171467,0.007082379,0.009006143,0.0011118879,0.00050602265,0.000050253246,0.000013006407,0.00002169923,0.00049393275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973896,0.00053353555,0.0012486803,0.00030767178,0.00019637638,0.00032413873],"domain_scores_gemma":[0.9967422,0.0009154838,0.0014039823,0.00026864544,0.00049360964,0.00017608619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030574616,0.00022970875,0.0013036388,0.0003154192,0.00013176842,0.000005186665,0.00020270997,0.00030533815,0.00030899406],"category_scores_gemma":[0.0003368613,0.00017595272,0.00022548404,0.0003259039,0.00018262427,0.00011288773,0.00004612307,0.00055143266,0.0000014513329],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002977822,0.0005573755,0.87290406,0.00044323778,0.005438441,0.00042238555,0.0012015725,0.007833626,0.0043624225,0.0003876128,0.004775927,0.09869549],"study_design_scores_gemma":[0.0036532762,0.0005738937,0.97997886,0.001188009,0.0063609034,0.000051694777,0.00022817015,0.0026041525,0.0009967949,0.0017095738,0.0024890304,0.00016565026],"about_ca_topic_score_codex":0.0040629352,"about_ca_topic_score_gemma":0.0010611474,"teacher_disagreement_score":0.10707476,"about_ca_system_score_codex":0.0011322876,"about_ca_system_score_gemma":0.0028677653,"threshold_uncertainty_score":0.71751434},"labels":[],"label_agreement":null},{"id":"W851077011","doi":"10.1097/jto.0000000000000548","title":"Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Surrogate endpoint; Medicine; Hazard ratio; Progression-free survival; Internal medicine; Confidence interval; Proportional hazards model; Oncology; Lung cancer; Clinical endpoint; Randomized controlled trial; Overall survival","score_opus":0.13755274537181256,"score_gpt":0.5236198700037795,"score_spread":0.38606712463196696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W851077011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97799283,0.005824744,0.0002253712,0.0099321185,0.002618905,0.0021127055,0.00006541632,0.000011270128,0.001216621],"genre_scores_gemma":[0.9926916,0.00087809656,0.0039730924,0.00014360885,0.0014918719,0.00016220276,0.000013372911,0.00004405321,0.0006021216],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955513,0.00086429797,0.0011022297,0.00028190823,0.0017259961,0.00047428376],"domain_scores_gemma":[0.9925045,0.0012112049,0.001130903,0.00033199115,0.004498362,0.00032303212],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01122653,0.0002300311,0.0012098822,0.00041258318,0.00005799048,0.000013940808,0.00030478358,0.00021137286,0.00016023283],"category_scores_gemma":[0.009334052,0.00017232086,0.0002548654,0.00025822263,0.000163958,0.00016726047,0.0002210274,0.0005647795,0.0000020356345],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31147522,0.0104587665,0.23009667,0.0069651366,0.0043019606,0.002778366,0.019044474,0.020755729,0.02617701,0.00023016978,0.03285134,0.33486518],"study_design_scores_gemma":[0.4246332,0.08392717,0.16901818,0.010910638,0.01324373,0.0009935342,0.01838726,0.12862319,0.06597743,0.010184395,0.071535975,0.002565292],"about_ca_topic_score_codex":0.0006510303,"about_ca_topic_score_gemma":0.003592091,"teacher_disagreement_score":0.3322999,"about_ca_system_score_codex":0.0021460499,"about_ca_system_score_gemma":0.00464625,"threshold_uncertainty_score":0.99901074},"labels":[],"label_agreement":null},{"id":"W946845951","doi":"10.1097/jto.0000000000000600","title":"Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer","year":2015,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Sanofi","keywords":"Medicine; Stage (stratigraphy); Radiation therapy; Lung cancer; Resection; Stereotactic radiotherapy; Radiology; Radiosurgery; Surgery; Oncology","score_opus":0.02596155408691999,"score_gpt":0.41772536037149,"score_spread":0.39176380628457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W946845951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389106,0.0011754974,0.000014711381,0.0029758231,0.001312329,0.00038326796,0.0000049482187,0.0000074130307,0.00023497363],"genre_scores_gemma":[0.9981889,0.00025614985,0.0004639286,0.00042296943,0.0002221521,0.000052144223,0.0000025753666,0.000024242374,0.00036691662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987483,0.00014647936,0.00037899674,0.00015087568,0.0003581681,0.00021720637],"domain_scores_gemma":[0.99881285,0.0001287009,0.00037052116,0.00015896007,0.000328613,0.0002003497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002661768,0.00014762719,0.00051738345,0.0002682615,0.000018892548,0.000015783722,0.000061211045,0.00011582878,0.0001496305],"category_scores_gemma":[0.000050101666,0.00009228317,0.000086928434,0.00019084977,0.000035644905,0.00019798,0.000013935965,0.00030794894,0.0000024859594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03365476,0.0011781832,0.9566132,0.000050369166,0.00062442856,0.0005033643,0.0009549403,0.000029091469,0.0000040613663,9.723933e-7,0.0008951551,0.0054914844],"study_design_scores_gemma":[0.015965058,0.006877632,0.9724031,0.0002667926,0.00043400805,0.000027926011,0.00009904824,0.000033134176,0.000063295796,0.0000020921439,0.0037359362,0.000091981376],"about_ca_topic_score_codex":0.00022214843,"about_ca_topic_score_gemma":0.00061827037,"teacher_disagreement_score":0.017689701,"about_ca_system_score_codex":0.0030671626,"about_ca_system_score_gemma":0.00044888468,"threshold_uncertainty_score":0.8020524},"labels":[],"label_agreement":null}]}